

SCORE OVER LENGTH SEARCHES

Attached is a score over length search. This search was developed to overcome limitations in most standard search systems which favor large sequences with high scoring, but lesser overall identity over smaller sequences with higher overall identity. This search is especially useful for relatively small nucleic acid or polypeptide target sequences (antisense, fragments, probes, primers, RNAi, epitopes, haptens, etc.) claimed functionally via a form of hybridization and/or identity language and having defined upper and lower polynucleotide and or polypeptide length limits.

The score over length search is performed by first running the query sequence using examiner-specified identity and polynucleotide or protein length limit parameters, and saving 65,000 hits and 0 alignments from each desired database. The resulting output is reformatted using a Microsoft Word macro and is imported into Excel. The summary table data are then sorted by the ratio of score of each hit sequence divided by its length and the accession numbers for all hits below the examiner's desired score over length parameters are deleted. The remaining accession numbers are used to pull the corresponding sequences from the databases into subdatabases enriched for good hits and the query sequence is re-run against these subdatabases to yield the final results.

The score over length cutoff for this search is 75.90.

Examiner Please Note: This cover sheet should be included when submitting results to be scanned.

THIS PAGE BLANK (USTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 26, 2004, 15:58:56 ; Search time 32 Seconds
(without alignments)
3.507 Million cell updates/sec

Title: US-09-923-515-3
Perfect score: 7200
Sequence: 1 ctggagattgggacacactt.....acgcacactgcacatgc 7200

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 493 seqs, 7793 residues

Total number of hits satisfying chosen parameters: 986

Minimum DB seq length: 12
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 505 summaries

Database : rge3.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	30	0.4	30	1	AR063732
2	30	0.4	30	1	AR063733
3	30	0.4	30	1	AR063733
4	30	0.4	30	1	AR063733
5	26	0.4	26	1	AR278865
6	26	0.4	26	1	AR278865
7	24	0.3	24	1	BD272249
8	23	0.3	23	1	BD081422
9	23	0.3	23	1	BD081422
10	23	0.3	23	1	BD081422
11	20	0.3	20	1	AR613070
12	20	0.3	20	1	AR278868
13	20	0.3	20	1	BD130529
14	19	0.3	19	1	AR39505
15	19	0.3	19	1	AR278867
16	19	0.3	19	1	AR278867
17	19	0.3	19	1	AR278867
18	18	0.3	18	1	AR613071
19	17	0.2	17	1	AR613071
20	16	0.2	16	1	AR481848
21	16	0.2	16	1	BD105834
22	16	0.2	16	1	BD105834
23	16	0.2	16	1	BD105834
24	16	0.2	16	1	BD105834
25	16	0.2	16	1	BD105834
26	16	0.2	16	1	BD105834
27	16	0.2	16	1	BD105834
28	15	0.2	15	1	AR060430
29	15	0.2	15	1	AR774015
30	15	0.2	15	1	AR298638
31	15	0.2	15	1	AR298638
32	15	0.2	15	1	AR298638
33	15	0.2	15	1	AR298638

107	13.8	0.2	17	1	CO617714	ACCESSION:CO617714
108	13.8	0.2	17	1	CO623033	ACCESSION:CO623033
109	13.8	0.2	17	1	AR401816	ACCESSION:AR401816
110	13.8	0.2	17	1	AR458776	ACCESSION:AR458776
111	13.8	0.2	17	1	AR458777	ACCESSION:AR458777
112	13.8	0.2	17	1	AR464096	ACCESSION:AR464096
113	13.8	0.2	17	1	AR464894	ACCESSION:AR464894
114	13.8	0.2	17	1	AR744399	ACCESSION:AR744399
115	13.8	0.2	17	1	AX744402	ACCESSION:AX744402
116	13.8	0.2	17	1	AX744403	ACCESSION:AX744403
117	13.8	0.2	17	1	AX759739	ACCESSION:AX759739
118	13.8	0.2	17	1	AX926745	ACCESSION:AX926745
119	13.8	0.2	17	1	BD067316	ACCESSION:BD067316
120	13.8	0.2	18	1	AR096845	ACCESSION:AR096845
121	13.4	0.2	15	1	AR97683	ACCESSION:AR97683
122	13.4	0.2	15	1	135050	ACCESSION:135050
123	13.4	0.2	15	1	135051	ACCESSION:135051
124	13.4	0.2	15	1	135052	ACCESSION:135052
125	13.4	0.2	15	1	135053	ACCESSION:135053
126	13.4	0.2	15	1	135055	ACCESSION:135055
127	13.4	0.2	15	1	135056	ACCESSION:135056
128	13.4	0.2	15	1	135067	ACCESSION:135067
129	13.4	0.2	15	1	135077	ACCESSION:135077
130	13.4	0.2	15	1	135089	ACCESSION:135089
131	13.4	0.2	15	1	135092	ACCESSION:135092
132	13.4	0.2	15	1	135097	ACCESSION:135097
133	13.4	0.2	15	1	135105	ACCESSION:135105
134	13.4	0.2	15	1	135197	ACCESSION:135197
135	13.4	0.2	15	1	135198	ACCESSION:135198
136	13.4	0.2	15	1	135199	ACCESSION:135199
137	13.4	0.2	15	1	135209	ACCESSION:135209
138	13.4	0.2	15	1	135210	ACCESSION:135210
139	13.4	0.2	15	1	135211	ACCESSION:135211
140	13.4	0.2	15	1	135212	ACCESSION:135212
141	13.4	0.2	15	1	135221	ACCESSION:135221
142	13.4	0.2	15	1	135222	ACCESSION:135222
143	13.4	0.2	15	1	135223	ACCESSION:135223
144	13.4	0.2	15	1	135224	ACCESSION:135224
145	13.4	0.2	15	1	135225	ACCESSION:135225
146	13.4	0.2	15	1	135229	ACCESSION:135229
147	13.4	0.2	15	1	135239	ACCESSION:135239
148	13.4	0.2	15	1	135240	ACCESSION:135240
149	13.4	0.2	15	1	135245	ACCESSION:135245
150	13.4	0.2	15	1	135246	ACCESSION:135246
151	13.4	0.2	15	1	135247	ACCESSION:135247
152	13.4	0.2	15	1	135255	ACCESSION:135255
153	13.4	0.2	15	1	135260	ACCESSION:135260
154	13.4	0.2	15	1	135261	ACCESSION:135261
155	13.4	0.2	16	1	AR317132	ACCESSION:AR317132
156	13.4	0.2	16	1	AR755229	ACCESSION:AR755229
157	13.4	0.2	17	1	AR339894	ACCESSION:AR339894
158	13.4	0.2	17	1	BD231502	ACCESSION:BD231502
159	13.4	0.2	17	1	AR349822	ACCESSION:AR349822
160	13.4	0.2	17	1	AX218292	ACCESSION:AX218292
161	13.4	0.2	17	1	AX727254	ACCESSION:AX727254
162	13.4	0.2	17	1	AX729966	ACCESSION:AX729966
163	13.2	0.2	20	1	AR731513	ACCESSION:AR731513
164	13.2	0.2	20	1	AR278868	ACCESSION:AR278868
165	13	0.2	15	1	AR130529	ACCESSION:AR130529
166	13	0.2	15			

C 253	12.8	0.2	17	1	AX736701	ACCESSION:AX736701	C 326	11.8	0.2	15	1	BD132342	ACCESSION:BD132342
C 254	12.8	0.2	17	1	AX738145	ACCESSION:AX738145	C 327	11.4	0.2	13	1	AR235781	ACCESSION:AR235781
C 255	12.8	0.2	17	1	AX738306	ACCESSION:AX738306	C 328	11.4	0.2	13	1	AX151058	ACCESSION:AX151058
C 256	12.8	0.2	17	1	AX738436	ACCESSION:AX738436	C 329	11.4	0.2	13	1	AX419854	ACCESSION:AX419854
C 257	12.8	0.2	17	1	AX744398	ACCESSION:AX744398	C 330	11.4	0.2	14	1	A06948	ACCESSION:A06948
C 258	12.8	0.2	17	1	AX744404	ACCESSION:AX744404	C 331	11.4	0.2	14	1	A21463	ACCESSION:A21463
C 259	12.8	0.2	17	1	AX757649	ACCESSION:AX757649	C 332	11.4	0.2	14	1	A40528	ACCESSION:A40528
C 260	12.8	0.2	17	1	AX762032	ACCESSION:AX762032	C 333	11.4	0.2	14	1	A88057	ACCESSION:A88057
C 261	12.4	0.2	14	1	AR053108	ACCESSION:AR053108	C 334	11.4	0.2	14	1	A89491	ACCESSION:A89491
C 262	12.4	0.2	15	1	AR062170	ACCESSION:AR062170	C 335	11.4	0.2	14	1	A90024	ACCESSION:A90024
C 263	12.4	0.2	15	1	AR135146	ACCESSION:AR135146	C 336	11.4	0.2	14	1	AR118971	ACCESSION:AR118971
C 264	12.4	0.2	15	1	BD184387	ACCESSION:BD184387	C 337	11.4	0.2	14	1	AR178312	ACCESSION:AR178312
C 265	12.4	0.2	15	1	135088	ACCESSION:135088	C 338	11.4	0.2	14	1	AR178313	ACCESSION:AR178313
C 266	12.4	0.2	15	1	135229	ACCESSION:135229	C 339	11.4	0.2	14	1	BD209366	ACCESSION:BD209366
C 267	12.4	0.2	15	1	135242	ACCESSION:135242	C 340	11.4	0.2	14	1	BD232808	ACCESSION:BD232808
C 268	12.4	0.2	15	1	135244	ACCESSION:135244	C 341	11.4	0.2	14	1	AR300261	ACCESSION:AR300261
C 269	12.4	0.2	15	1	135266	ACCESSION:135266	C 342	11.4	0.2	14	1	AX016242	ACCESSION:AX016242
C 270	12.4	0.2	15	1	AR180179	ACCESSION:AR180179	C 343	11.4	0.2	14	1	AX030103	ACCESSION:AX030103
C 271	12.4	0.2	15	1	AR180697	ACCESSION:AR180697	C 344	11.4	0.2	14	1	AX316424	ACCESSION:AX316424
C 272	12.4	0.2	15	1	AX107826	ACCESSION:AX107826	C 345	11.4	0.2	14	1	AX323394	ACCESSION:AX323394
C 273	12.4	0.2	15	1	AX107827	ACCESSION:AX107827	C 346	11.4	0.2	14	1	AX323395	ACCESSION:AX323395
C 274	12.4	0.2	15	1	AX119564	ACCESSION:AX119564	C 347	11.4	0.2	14	1	BD065570	ACCESSION:BD065570
C 275	12.4	0.2	15	1	AX742534	ACCESSION:AX742534	C 348	11.4	0.2	14	1	BD067004	ACCESSION:BD067004
C 276	12.4	0.2	15	1	BD005887	ACCESSION:BD005887	C 349	11.4	0.2	14	1	BD135020	ACCESSION:BD135020
C 277	12.4	0.2	15	1	BD005888	ACCESSION:BD005888	C 350	11.4	0.2	15	1	A32711	ACCESSION:A32711
C 278	12.4	0.2	16	1	BD233229	ACCESSION:BD233229	C 351	11.4	0.2	15	1	A88231	ACCESSION:A88231
C 279	12.4	0.2	16	1	CO808615	ACCESSION:CO808615	C 352	11.4	0.2	15	1	A90198	ACCESSION:A90198
C 280	12.4	0.2	16	1	AR328298	ACCESSION:AR328298	C 353	11.4	0.2	15	1	AR019424	ACCESSION:AR019424
C 281	12.4	0.2	16	1	AX007783	ACCESSION:AX007783	C 354	11.4	0.2	15	1	AR024030	ACCESSION:AR024030
C 282	12.4	0.2	16	1	AX814334	ACCESSION:AX814334	C 355	11.4	0.2	15	1	AR029145	ACCESSION:AR029145
C 283	12.4	0.2	16	1	BD104579	ACCESSION:BD104579	C 356	11.4	0.2	15	1	AR029148	ACCESSION:AR029148
C 284	12.4	0.2	16	1	AR063735	ACCESSION:AR063735	C 357	11.4	0.2	15	1	AR030938	ACCESSION:AR030938
C 285	12.4	0.2	12	1	130098	ACCESSION:130098	C 358	11.4	0.2	15	1	AR030939	ACCESSION:AR030939
C 286	12.4	0.2	13	1	AR019431	ACCESSION:AR019431	C 359	11.4	0.2	15	1	AR030940	ACCESSION:AR030940
C 287	12.4	0.2	13	1	AR156387	ACCESSION:AR156387	C 360	11.4	0.2	15	1	AR030941	ACCESSION:AR030941
C 288	12.4	0.2	15	1	AR003153	ACCESSION:AR003153	C 361	11.4	0.2	15	1	AR030942	ACCESSION:AR030942
C 289	12.4	0.2	15	1	AR003246	ACCESSION:AR003246	C 362	11.4	0.2	15	1	AR033422	ACCESSION:AR033422
C 290	12.4	0.2	15	1	AR009111	ACCESSION:AR009111	C 363	11.4	0.2	15	1	AR033480	ACCESSION:AR033480
C 291	12.4	0.2	15	1	AR011400	ACCESSION:AR011400	C 364	11.4	0.2	15	1	AR036529	ACCESSION:AR036529
C 292	12.4	0.2	15	1	AR028084	ACCESSION:AR028084	C 365	11.4	0.2	15	1	AR036532	ACCESSION:AR036532
C 293	12.4	0.2	15	1	AR041240	ACCESSION:AR041240	C 366	11.4	0.2	15	1	AR056504	ACCESSION:AR056504
C 294	12.4	0.2	15	1	AR052800	ACCESSION:AR052800	C 367	11.4	0.2	15	1	AR056536	ACCESSION:AR056536
C 295	12.4	0.2	15	1	AR127918	ACCESSION:AR127918	C 368	11.4	0.2	15	1	AR082988	ACCESSION:AR082988
C 296	12.4	0.2	15	1	AR175199	ACCESSION:AR175199	C 369	11.4	0.2	15	1	AR096062	ACCESSION:AR096062
C 297	12.4	0.2	15	1	BD208610	ACCESSION:BD208610	C 370	11.4	0.2	15	1	AR096065	ACCESSION:AR096065
C 298	12.4	0.2	15	1	118038	ACCESSION:118038	C 371	11.4	0.2	15	1	AR113244	ACCESSION:AR113244
C 299	12.4	0.2	15	1	135068	ACCESSION:135068	C 372	11.4	0.2	15	1	AR113302	ACCESSION:AR113302
C 300	12.4	0.2	15	1	AR180461	ACCESSION:AR180461	C 373	11.4	0.2	15	1	AR114262	ACCESSION:AR114262
C 301	12.4	0.2	15	1	AR288113	ACCESSION:AR288113	C 374	11.4	0.2	15	1	AR114294	ACCESSION:AR114294
C 302	12.4	0.2	15	1	AR408262	ACCESSION:AR408262	C 375	11.4	0.2	15	1	AR116342	ACCESSION:AR116342
C 303	12.4	0.2	15	1	AK636712	ACCESSION:AK636712	C 376	11.4	0.2	15	1	AR133220	ACCESSION:AR133220
C 304	12.4	0.2	15	1	BD000643	ACCESSION:BD000643	C 377	11.4	0.2	15	1	AR133221	ACCESSION:AR133221
C 305	12.4	0.2	15	1	BD017683	ACCESSION:BD017683	C 378	11.4	0.2	15	1	AR133222	ACCESSION:AR133222
C 306	12.4	0.2	15	1	BD017688	ACCESSION:BD017688	C 379	11.4	0.2	15	1	AR133223	ACCESSION:AR133223
C 307	12.4	0.2	16	1	AR279393	ACCESSION:AR279393	C 380	11.4	0.2	15	1	AR133250	ACCESSION:AR133250
C 308	12.4	0.2	16	1	AR279396	ACCESSION:AR279396	C 381	11.4	0.2	15	1	AR133251	ACCESSION:AR133251
C 309	12.4	0.2	16	1	AX139231	ACCESSION:AX139231	C 382	11.4	0.2	15	1	AR133686	ACCESSION:AR133686
C 310	12.4	0.2	16	1	BD007209	ACCESSION:BD007209	C 383	11.4	0.2	15	1	AR156380	ACCESSION:AR156380
C 311	12.4	0.2	16	1	BD007212	ACCESSION:BD007212	C 384	11.4	0.2	15	1	AR174819	ACCESSION:AR174819
C 312	12.4	0.2	16	1	BD013515	ACCESSION:BD013515	C 385	11.4	0.2	15	1	AR174822	ACCESSION:AR174822
C 313	11.8	0.2	15	1	A15244	ACCESSION:A15244	C 386	11.4	0.2	15	1	AR174826	ACCESSION:AR174826
C 314	11.8	0.2	15	1	A16459	ACCESSION:A16459	C 387	11.4	0.2	15	1	BD176030	ACCESSION:BD176030
C 315	11.8	0.2	15	1	AR041366	ACCESSION:AR041366	C 388	11.4	0.2	15	1	BD184560	ACCESSION:BD184560
C 316	11.8	0.2	15	1	135061	ACCESSION:135061	C 389	11.4	0.2	15	1	BD207155	ACCESSION:BD207155
C 317	11.8	0.2	15	1	135086	ACCESSION:135086	C 390	11.4	0.2	15	1	BD207213	ACCESSION:BD207213
C 318	11.8	0.2	15	1	135087	ACCESSION:135087	C 391	11.4	0.2	15	1	BD233228	ACCESSION:BD233228
C 319	11.8	0.2	15	1	135108	ACCESSION:135108	C 392	11.4	0.2	15	1	119571	ACCESSION:119571
C 320	11.8	0.2	15	1	135241	ACCESSION:135241	C 393	11.4	0.2	15	1	121595	ACCESSION:121595
C 321	11.8	0.2	15	1	AR479048	ACCESSION:AR479048	C 394	11.4	0.2	15	1	129017	ACCESSION:129017
C 322	11.8	0.2	15	1	AX328777	ACCESSION:AX328777	C 395	11.4	0.2	15	1	132400	ACCESSION:132400
C 323	11.8	0.2	15	1	AX586988	ACCESSION:AX586988	C 396	11.4	0.2	15	1	135091	ACCESSION:135091
C 324	11.8	0.2	15	1	AX636791	ACCESSION:AX636791	C 397	11.4	0.2	15	1	135252	ACCESSION:135252
C 325	11.8	0.2	15	1	AX708801	ACCESSION:AX708801	C 398	11.4	0.2	15	1	136653	ACCESSION:136653

C 399	11.4	0.2	15	1	138652	ACCESSION:138652
C 400	11.4	0.2	15	1	138666	ACCESSION:138666
C 401	11.4	0.2	15	1	140402	ACCESSION:140402
C 402	11.4	0.2	15	1	144778	ACCESSION:144778
C 403	11.4	0.2	15	1	157651	ACCESSION:157651
C 404	11.4	0.2	15	1	157709	ACCESSION:157709
C 405	11.4	0.2	15	1	159729	ACCESSION:159724
C 406	11.4	0.2	15	1	163133	ACCESSION:163133
C 407	11.4	0.2	15	1	166639	ACCESSION:166639
C 408	11.4	0.2	15	1	166640	ACCESSION:166640
C 409	11.4	0.2	15	1	184256	ACCESSION:184256
C 410	11.4	0.2	15	1	196095	ACCESSION:196095
C 411	11.4	0.2	15	1	AR182826	ACCESSION:AR1828
C 412	11.4	0.2	15	1	AR212825	ACCESSION:AR2122
C 413	11.4	0.2	15	1	AR212298	ACCESSION:AR2122
C 414	11.4	0.2	15	1	AR242023	ACCESSION:AR2420
C 415	11.4	0.2	15	1	AR242024	ACCESSION:AR2420
C 416	11.4	0.2	15	1	AR270973	ACCESSION:AR2709
C 417	11.4	0.2	15	1	AR285770	ACCESSION:AR2857
C 418	11.4	0.2	15	1	AR349204	ACCESSION:AR3492
C 419	11.4	0.2	15	1	AR397781	ACCESSION:AR3977
C 420	11.4	0.2	15	1	AR429171	ACCESSION:AR4291
C 421	11.4	0.2	15	1	AR429172	ACCESSION:AR4291
C 422	11.4	0.2	15	1	AR429173	ACCESSION:AR4291
C 423	11.4	0.2	15	1	AR429174	ACCESSION:AR4291
C 424	11.4	0.2	15	1	AR429175	ACCESSION:AR4291
C 425	11.4	0.2	15	1	AR442656	ACCESSION:AR4426
C 426	11.4	0.2	15	1	AR482043	ACCESSION:AR4820
C 427	11.4	0.2	15	1	AX007782	ACCESSION:AX0077
C 428	11.4	0.2	15	1	AX377178	ACCESSION:AX3771
C 429	11.4	0.2	15	1	AX463385	ACCESSION:AX4632
C 430	11.4	0.2	15	1	AX468705	ACCESSION:AX4687
C 431	11.4	0.2	15	1	AX492919	ACCESSION:AX4929
C 432	11.4	0.2	15	1	AX633508	ACCESSION:AX6335
C 433	11.4	0.2	15	1	AX633555	ACCESSION:AX6335
C 434	11.4	0.2	15	1	AX742207	ACCESSION:AX7422
C 435	11.4	0.2	15	1	BD014073	ACCESSION:BD0140
C 436	11.4	0.2	15	1	BD014112	ACCESSION:BD0141
C 437	11.4	0.2	15	1	BD065744	ACCESSION:BD0657
C 438	11.4	0.2	15	1	BD070457	ACCESSION:BD0704
C 439	11.4	0.2	15	1	BD141534	ACCESSION:BD1415
C 440	11.4	0.2	15	1	BD144266	ACCESSION:BD1415
C 441	11.4	0.2	26	1	AR278865	ACCESSION:BD1415
C 442	11.4	0.2	26	1	BD130526	ACCESSION:AR2788
C 443	11.2	0.2	16	1	AX139231	ACCESSION:BD1305
C 444	11.2	0.2	16	1	BD013515	ACCESSION:AX1392
C 445	11.2	0.2	12	1	A07188	ACCESSION:BD0135
C 446	11.1	0.2	12	1	AR636407	ACCESSION:A07188
C 447	11.1	0.2	12	1	165474	ACCESSION:AR6364
C 448	11.1	0.2	13	1	171091	ACCESSION:165474
C 449	11.1	0.2	13	1	BD013873	ACCESSION:171091
C 450	11.1	0.2	13	1	A87915	ACCESSION:BD0138
C 451	11.1	0.2	14	1	A89882	ACCESSION:A87915
C 452	11.1	0.2	14	1	BD201857	ACCESSION:A89882
C 453	11.1	0.2	14	1	BD066428	ACCESSION:BD2018
C 454	11.1	0.2	15	1	BD006643	ACCESSION:BD0642
C 455	11.1	0.2	15	1	BD017683	ACCESSION:BD0066
C 456	11.1	0.2	15	1	BD017688	ACCESSION:BD0176
C 457	11.1	0.2	21	1	AX535508	ACCESSION:BD0176
C 458	10.8	0.2				

C 472	10.8	0.2	14	1	AX316422	ACCESSION:AX316422
C 473	10.8	0.1	14	1	AX71850	ACCESSION:AX71850
C 474	10.8	0.2	14	1	BD065571	ACCESSION:BD065571
C 475	10.8	0.1	14	1	BD065819	ACCESSION:BD065819
C 476	10.8	0.2	14	1	BD066566	ACCESSION:BD066566
C 477	10.8	0.2	14	1	BD069011	ACCESSION:BD069011
C 478	10.4	0.1	12	1	A26031	ACCESSION:A26031
C 479	10.4	0.1	12	1	AR178315	ACCESSION:AR178315
C 480	10.4	0.1	12	1	BD232406	ACCESSION:BD232406
C 481	10.4	0.1	12	1	CQ766108	ACCESSION:CQ766108
C 482	10.4	0.1	12	1	CQ766133	ACCESSION:CQ766133
C 483	10.4	0.1	12	1	CQ766279	ACCESSION:CQ766279
C 484	10.4	0.1	12	1	CQ766475	ACCESSION:CQ766475
C 485	10.4	0.1	12	1	CQ828053	ACCESSION:CQ828053
C 486	10.4	0.1	12	1	120196	ACCESSION:120196
C 487	10.4	0.1	12	1	171434	ACCESSION:171434
C 488	10.4	0.1	12	1	AR235827	ACCESSION:AR235827
C 489	10.4	0.1	12	1	AX011023	ACCESSION:AX011023
C 490	10.4	0.1	12	1	AX151104	ACCESSION:AX151104
C 491	10.4	0.1	12	1	AX323397	ACCESSION:AX323397
C 492	10.4	0.1	12	1	AX721931	ACCESSION:AX721931
C 493	10.4	0.1	13	1	AR019426	ACCESSION:AR019426
C 494	10.4	0.1	13	1	AR156382	ACCESSION:AR156382
C 495	10.4	0.1	13	1	BD235146	ACCESSION:BD235146
C 496	10.4	0.1	13	1	CQ794371	ACCESSION:CQ794371
C 497	10.4	0.1	13	1	AX310643	ACCESSION:AX310643
C 498	10.4	0.1	13	1	AX098817	ACCESSION:AX098817
C 499	10.4	0.1	13	1	AX098918	ACCESSION:AX098918
C 500	10.4	0.1	13	1	AX137018	ACCESSION:AX137018
C 501	10.4	0.1	13	1	AX551709	ACCESSION:AX551709
C 502	10.4	0.1	13	1	AX555912	ACCESSION:AX555912
C 503	10.4	0.1	13	1	BD086465	ACCESSION:BD086465
C 504	10.4	0.1	13	1	BD086508	ACCESSION:BD086508
C 505	10.4	0.1	13	1	BD086527	ACCESSION:BD086527

ALIGNMENTS

[illegible]

```

ACCESSION   AR063733
VERSION     AR063733.1
KEYWORDS    GI:5993041
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 30)
AUTHORS     Foulkes,J.Gordon., Liechtfried,F.E., Pieler,C., Stephenson,J.R. and
            Case,C.C.
TITLE       Methods of determining chemicals that modulate expression of genes
            associated with cardiovascular disease
JOURNAL     Patent: US 5846720-A 18 08-DEC-1998;
FEATURES    Location/Qualifiers
            1..30
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.4%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.87;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 47 TGAACATAAGAGAGTGTCTTCTACTTC 76
Db 1 TGAACATAAGAGAGTGTCTTCTACTTC 30

RESULT 3
LOCUS       130095             30 bp      DNA      linear      PAT 06-FEB-1997
DEFINITION  Sequence 17 from patent US 5580722.
ACCESSION   130095
VERSION     130095.1
KEYWORDS    GI:1820866
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 30)
AUTHORS     Foulkes,J.Gordon., Liechtfried,F.E., Pieler,C., Stephenson,J.R. and
            Case,C.C.
TITLE       Methods of determining chemicals that modulate transcriptionally
            expression of genes associated with cardiovascular disease
JOURNAL     Patent: US 5580722-A 17 03-DEC-1996;
FEATURES    Location/Qualifiers
            1..30
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.4%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.87;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 80 TATTTTGAATCGACGACCTGAGCAA 109
Db 1 TATTTTGAATCGACGACCTGAGCAA 30

RESULT 4
LOCUS       130096             30 bp      DNA      linear      PAT 06-FEB-1997
DEFINITION  Sequence 18 from patent US 5580722.
ACCESSION   130096
VERSION     130096.1
KEYWORDS    GI:1820887
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 30)
AUTHORS     Foulkes,J.Gordon., Liechtfried,F.E., Pieler,C., Stephenson,J.R. and
            Case,C.C.
TITLE       Methods of determining chemicals that modulate transcriptionally
            expression of genes associated with cardiovascular disease
JOURNAL     Patent: US 5580722-A 18 03-DEC-1996;
FEATURES    Location/Qualifiers

```

```

source      1..30
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.4%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.87;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 47 TGAACATAAGAGAGTGTCTTCTACTTC 76
Db 1 TGAACATAAGAGAGTGTCTTCTACTTC 30

RESULT 5
LOCUS       AR278865/c        26 bp      DNA      linear      PAT 10-APR-2003
DEFINITION  Sequence 3 from patent US 6512161.
ACCESSION   AR278865
VERSION     AR278865.1
KEYWORDS    GI:29713382
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 26)
AUTHORS     Rouy,D., Duverger,N., Emmanuel,F., Deneffe,P., Houdebine,L.-M.,
            Viglietta,C., Rubin,E.M. and Hughes,S.D.
TITLE       Transgenic rabbit that expresses a functional human lipoprotein (a)
JOURNAL     Patent: US 6512161-A 3 28-JAN-2003;
FEATURES    Location/Qualifiers
            1..26
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.4%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 523 GGAAGACCTGCCAGCTGTGCATC 548
Db 26 GGAAGACCTGCCAGCTGTGCATC 1

RESULT 6
LOCUS       BD130526/c        26 bp      DNA      linear      PAT 18-SEP-2002
DEFINITION  Transgenic rabbit expressing functional human lipoprotein (A).
ACCESSION   BD130526
VERSION     BD130526.1
KEYWORDS    GI:23225471
SOURCE      JP 2002500039-A/3.
ORGANISM    Homo sapiens (human)
            Homo sapiens
            Homo sapiens
            Bukayota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
            1 (bases 1 to 26)
REFERENCE   1 (bases 1 to 26)
AUTHORS     Rouy,D., Duverger,N., Emmanuel,F., Deneffe,P., Houdebine,L.M.,
            Viglietta,C., Rubin,E. and Hughes,S.D.
TITLE       Transgenic rabbit expressing functional human lipoprotein (A)
JOURNAL     Patent: JP 2002500039-A 3 08-JAN-2002;
COMMENT     AVENTIS PHARMACEUTICALS PRODUCTS INC
            OS Homo sapiens (human)
            PN JP 2002500039-A/3
            PD 08-JAN-2002
            PF 08-JAN-1999 JP 2000527627
            PR 08-JAN-1998 US 60/070727
            PI DIDIER ROUY,NICOLAS DUVERGER,FLORENCE EMMANUEL,PATRICE
            DENEFFE,
            PI LOUIS MARIE HOUEDBINE,CELINE VIGLIETTA,EDWARD RUBIN,STEVEN D
            HUGHES
            PC A01K67/027//C12N15/09,C12N15/00
            CC Transgenic rabbit expressing functional human lipoprotein (A)
            FH Key
            FT source
            1..26
            /organism="Homo sapiens (human)".

```

```

FEATURES
    source
        Location/Qualifiers
            1..26
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"

Query Match
    Best Local Similarity 100.0%; Score 26; DB 1; Length 26;
    Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy
    523 GGAAGACCTGCCAGCTGTGCATC 548
    |||
    26 GGAAGACCTGCCAGCTGTGCATC 1

RESULT 7
BD272249
LOCUS
DEFINITION
    BD272249 24 bp DNA linear PAT 17-JUL-2003
    Anti-angiogenesis plasmids and delivery systems, and methods of
    making and using the same.
ACCESSION
    BD272249.1 GI:33082017
VERSION
    JP 2002524036-A/11.
KEYWORDS
    Homo sapiens (human)
SOURCE
    Homo sapiens
ORGANISM
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
    1 (bases 1 to 24)
    Wang, M., Szymanski, P., Mehrens, D., Ralston, R. and Sullivan, S.
    Anti-angiogenesis plasmids and delivery systems, and methods of
    making and using the same
    Patent: JP 2002524036-A 11 06-AUG-2002;
    VALENTIS INC

COMMENT
    OS Homo sapiens (human)
    PN JP 2002524036-A/11
    PD 06-AUG-2002
    PR 20-JUL-1999 JP 2000562541
    PF 27-JUL-1998 US 60/094375
    PI MIN WANG, PAUL SZYMANSKI, DOROTHY MEHRENS, ROBERT RALSTON, SEAN
    PI SULLIVAN
    PC C12N15/09, A61K38/00, A61K47/18, A61K47/32, A61K47/44, A61K48/00,
    PC A61P35/00,
    PC C12N5/10, C12N15/00, C12N5/00, A61K37/02
    CC Human Angiostatin
    FH Key
    FT source
    Location/Qualifiers
        1..24
            /organism="Homo sapiens (human)"
            /db_xref="taxon:9606"

FEATURES
    source
        Location/Qualifiers
            1..24
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"

Query Match
    Best Local Similarity 100.0%; Score 24; DB 1; Length 24;
    Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy
    46 ATGGAATATAGAGAGCTTCTT 69
    |||
    1 ATGGAATATAGAGAGCTTCTT 24

RESULT 8
BD081422/c
LOCUS
DEFINITION
    BD081422 27 bp DNA linear PAT 27-AUG-2002
    Fused protein containing angiotensin component and utilization
    thereof in antitumor therapy.
ACCESSION
    BD081422.1 GI:22627025
VERSION
    JP 2001518304-A/65.
KEYWORDS
    Homo sapiens (human)
SOURCE
    Homo sapiens
ORGANISM
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```

```

REFERENCE
    AUTHORS
        Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
        1 (bases 1 to 27)
        Bolanowski, M.A., Caparon, M.H., Casperson, G.F., Gregory, S.A.,
        Klein, B.K. and McKeown, J.P.
    TITLE
        Fused protein containing angiotensin component and utilization
        thereof in antitumor therapy
    JOURNAL
        Patent: JP 2001518304-A 65 16-OCT-2001;
    COMMENT
        GD SEARLE AND CO
        OS Homo sapiens (human)
        PN JP 2001518304-A/65
        PD 16-OCT-2001
        PR 30-SEP-1998 JP 2000513958
        PF 01-OCT-1997 US 60/060609
        PI MARK A. BOLANOWSKI, MAIRE H. CAPARON, GERALD F. CASPERSON, SUSAN A
        PI GREGORY,
        PI BARBARA K. KLEIN, JOHN P. MCKEOWN
        PC C12N15/09, A61K38/00, A61K48/00, A61P9/10, A61P35/00, C07K14/52, PC
        PC C07K14/56,
        PC C07K14/78, C12N9/68, C12N15/00, A61K37/02
        CC Fused protein containing angiotensin component and utilization
        thereof in
        CC antitumor therapy
        CC Key
        FH Key
        FT source
        Location/Qualifiers
            1..27
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"

FEATURES
    source
        Location/Qualifiers
            1..27
                /organism="Homo sapiens (human)"

Oy
    Query Match
    Best Local Similarity 92.6%; Score 23.8; DB 1; Length 27;
    Matches 25; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db
    120 CCAGATTGCTACATGATGATGACA 146
    |||
    27 CCAGATTGCTACATGATGATGACA 1

RESULT 9
A39504/c
LOCUS
DEFINITION
    A39504 23 bp DNA linear PAT 05-MAR-1997
    Sequence 5 from Patent EP0609059.
ACCESSION
    A39504
VERSION
    A39504.1 GI:2295822
KEYWORDS
    unidentified
    SOURCE
        unidentified
        ORGANISM
            unidentified
            unclassified.
    REFERENCE
        1 (bases 1 to 23)
        Colucci, G. and Taramelli, R.
    AUTHORS
        Nucleotide probes
    TITLE
        Patent: EP 0609059-A 5 03-AUG-1994;
    JOURNAL
        CLONIT SPA (IT)
    COMMENT
        Other publication JP 6277098 941004.
    FEATURES
        Location/Qualifiers
            1..23
                /organism="unidentified"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32644"

Query Match
    Best Local Similarity 100.0%; Score 23; DB 1; Length 23;
    Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy
    219 TCAACATPATDGCACACAGAAA 241
    |||
    23 TCAACATPATDGCACACAGAAA 1

RESULT 10

```

125913/c
 LOCUS 125913 23 bp DNA linear PAT 07-OCT-1996
 DEFINITION Sequence 5 from patent US 5554509.
 ACCESSION 125913
 VERSION 125913.1 GI:1605783
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE
 1 (bases 1 to 23)
 Colucci, G. and Taramelli, R.
 Nucleotide probes and methods for determining Tag1 polymorphisms in
 the human Apo(a) gene
 JOURNAL Patent: US 5554509-A 5 10-SEP-1996;
 FEATURES
 SOURCE Location/Qualifiers
 1..23
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.3%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 7.6;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 219 TCAACATATATAGACACACAGAAA 241
 Db 23 TCAACATATATAGACACACAGAAA 1

RESULT 11
 LOCUS AX613070 24 bp DNA linear PAT 17-FEB-2003
 DEFINITION Sequence 4095 from Patent WO02072882.
 ACCESSION AX613070
 VERSION AX613070.1 GI:28408499
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE
 1
 Cullen, P. and Seedorf, U.
 Coronary chip
 JOURNAL Patent: WO 02072882-A 4095 19-SEP-2002;
 OGHAM GmbH (DE)
 FEATURES
 SOURCE Location/Qualifiers
 1..24
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.3%; Score 20.4; DB 1; Length 24;
 Best Local Similarity 95.5%; Pred. No. 23;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 327 TGTGAGGTGGAGTGTGCAAC 348
 Db 3 TGTGAGTGGAGTGTGCAAC 24

RESULT 12
 LOCUS AR278868/c 20 bp DNA linear PAT 10-APR-2003
 DEFINITION Sequence 6 from patent US 6512161.
 ACCESSION AR278868
 VERSION AR278868.1 GI:29713385
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE
 1 (bases 1 to 20)
 Rouy, D., Duverger, N., Emmanuel, F., Deneffe, P., Houdebine, L.-M.,
 Viglietta, C., Rubin, E. M. and Hughes, S. D.
 JOURNAL Transgenic rabbit that expresses a functional human lipoprotein (a)

JOURNAL Patent: US 6512161-A 6 28-JAN-2003;
 FEATURES Location/Qualifiers
 SOURCE 1..20
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 18;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 324 CGGTGTCAGTGGAGTACT 343
 Db 20 CGGTGTCAGTGGAGTACT 1

RESULT 13
 LOCUS BD130529/c 20 bp DNA linear PAT 18-SEP-2002
 DEFINITION Transgenic rabbit expressing functional human lipoprotein (A).
 ACCESSION BD130529
 VERSION BD130529.1 GI:23225474
 KEYWORDS UP 2002500039-A/6.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE
 1 (bases 1 to 20)
 Rouy, D., Duverger, N., Emmanuel, F., Deneffe, P., Houdebine, L.-M.,
 Viglietta, C., Rubin, E. and Hughes, S. D.
 Transgenic rabbit expressing functional human lipoprotein (A)
 JOURNAL Patent: JP 2002500039-A 6 08-JAN-2002;
 AVENTIS PHARMACEUTICALS PRODUCTS INC
 COMMENT OS Homo sapiens (human)
 FN JP 2002500039-A/6
 PD 08-JAN-2002
 PR 08-JAN-1999 JP 2000527627
 PR 08-JAN-1998 US 60/070727
 PI DIDIER ROUY, NICOLAS DUVERGER, FLORENCE EMMANUEL, PATRICE
 DENEFFE,
 PI LOUIS MARIE HOUEDBINE, CELINE VIGLIETTA, EDWARD RUBIN, STEVEN D
 HUGHES
 PC A01K67/027//C12N15/09, C12N15/00
 CC Transgenic rabbit expressing functional human lipoprotein (A)
 FH Key location/Qualifiers
 FT source 1..20
 /organism="Homo sapiens (human)".
 FEATURES
 SOURCE Location/Qualifiers
 1..20
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

Query Match 0.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 18;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 324 CGGTGTCAGTGGAGTACT 343
 Db 20 CGGTGTCAGTGGAGTACT 1

RESULT 14
 LOCUS A39505 19 bp DNA linear PAT 05-MAR-1997
 DEFINITION Sequence 6 from Patent EP0609059.
 ACCESSION A39505
 VERSION A39505.1 GI:2295823
 KEYWORDS
 SOURCE unidentified
 ORGANISM unidentified
 REFERENCE
 1 (bases 1 to 19)
 Colucci, G. and Taramelli, R.

TITLE Nucleotide probes
JOURNAL Patent: EP 0609059-A 6 03-AUG-1994;
CLONIT SPA (IT)
COMMENT Other publication JP 6277098 941004.
FEATURES Location/Qualifiers
source 1..19
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.3%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 98 CACCTGAGCAAGCCATGT 116
|||||
1 CACCTGAGCAAGCCATGT 19

RESULT 15
LOCUS 125914 19 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 6 from patent US 5554509.
ACCESSION 125914
VERSION 125914.1 GI:1605784
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Colucci G. and Taramelli R.
TITLE Nucleotide probes and methods for determining TagI polymorphisms in the human Apo(a) gene
JOURNAL Patent: US 5554509-A 6 10-SEP-1996;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.3%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 98 CACCTGAGCAAGCCATGT 116
|||||
1 CACCTGAGCAAGCCATGT 19

RESULT 16
LOCUS AR278867 19 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 5 from patent US 6512161.
ACCESSION AR278867
VERSION AR278867.1 GI:29713384
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Rouy D., Duverger N., Emmanuelli F., Deneffe P., Houdebine L.-M., Viglietta C., Rubin E. M. and Hughes S. D.
TITLE Transgenic rabbit that expresses a functional human lipoprotein (a)
JOURNAL Patent: US 6512161-A 5 28-JAN-2003;
FEATURES Location/Qualifiers
source 1..19
/organism="genomic DNA"
/mol_type="genomic DNA"

Query Match 0.3%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 99 ACCTGAGCAAGCCATGTG 117

Db
|||||
1 ACCTGAGCAAGCCATGTG 19

RESULT 17
LOCUS BD130528 19 bp DNA linear PAT 18-SEP-2002
DEFINITION Transgenic rabbit expressing functional human lipoprotein (A).
ACCESSION BD130528
VERSION BD130528.1 GI:23225473
KEYWORDS JP 2002500039-A/5.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Rouy D., Duverger N., Emmanuelli F., Deneffe P., Houdebine L.-M., Viglietta C., Rubin E. and Hughes S. D.
TITLE Transgenic rabbit expressing functional human lipoprotein (A)
JOURNAL Patent: JP 2002500039-A 5 08-JAN-2002;
COMMENT AVENTIS PHARMACEUTICALS PRODUCTS INC
OS Homo sapiens (human)
PN JP 2002500039-A/5
PD 08-JAN-2002
PF 08-JAN-1999 JP 2000527627
PR 08-JAN-1998 US 60/070727
PI DIDIER ROUY, NICOLAS DUVERGER, FLORENCE EMMANUEL, PATRICE DENEFFE,
PI LOUIS MARIE HOUEBINE, CELINE VIGLIETTA, EDWARD RUBIN, STEVEN D
PI HUGHES
PC A01K67/027//C12N15/09, C12N15/00
CC Transgenic rabbit expressing functional human lipoprotein (A)
FH Key
FT source 1..19
/organism="Homo sapiens (human)"

FEATURES
source 1..19
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.3%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 99 ACCTGAGCAAGCCATGTG 117
|||||
1 ACCTGAGCAAGCCATGTG 19

RESULT 18
LOCUS AX613071 24 bp DNA linear PAT 17-FEB-2003
DEFINITION Sequence 4096 from Patent WO02072882.
ACCESSION AX613071
VERSION AX613071.1 GI:28408500
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 19)
AUTHORS Cullen P. and Seedorf U.
TITLE Coronary chip
JOURNAL Patent: WO 02072882-A 4096 19-SEP-2002;
FEATURES Location/Qualifiers
source 1..24
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.3%; Score 18.8; DB 1; Length 24;

Best Local Similarity 90.9%; Pred. No. 42;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 327 TGTGAGTGGAGTCTGCAAC 348
Db 3 TGTGAGTGGAGTCTGCAAC 24

RESULT 19
LOCUS 189346/c 17 bp DNA linear PAT 10-AUG-1998
DEFINITION Sequence 3 from patent US 5721138.
ACCESSION 189346
VERSION 189346.1 GI:3409286
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Lawn, R. Mark.
TITLE Apolipoprotein(A) promoter and regulatory sequence constructs and
JOURNAL Methods of use
FEATURES Location/Qualifiers
source 1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 GAAGTGTTCTCTACT 74
Db 17 GAAGTGTTCTCTACT 1

RESULT 20
LOCUS AR481848 18 bp DNA linear PAT 14-MAY-2004
DEFINITION Sequence 10 from patent US 6699838.
ACCESSION AR481848
VERSION AR481848.1 GI:47243564
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Davidson, D. J.
TITLE Antiangiogenic peptides
JOURNAL Patent: US 6699838-A 10 02-MAR-2004;
FEATURES Location/Qualifiers
source 1. .18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 58;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 118 GTCCAGATTGCTACCAT 135
Db 1 GTCCAGATTGCTACCAT 18

RESULT 21
LOCUS BD105834 18 bp DNA linear PAT 18-SEP-2002
DEFINITION Novel antiangiogenic peptides, polynucleotides encoding same and
ACCESSION BD105834
VERSION BD105834.1 GI:23200652
KEYWORDS JP 2002502235-A/8.

SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 18)
AUTHORS Davidson, D. J., Wang, J. and Gubbins, E. J.
TITLE Novel antiangiogenic peptides, polynucleotides encoding same and
JOURNAL methods for inhibiting angiogenesis
PATENT: JP 2002502235-A 8 22-JAN-2002;
COMMENT ABBOTT LABORATORIES
PN JP 2002502235-A/8
PD 22-JAN-2002
PR 05-MAY-1997 JP 1997540162
PR 03-MAY-1996 US 08/643219
PI DONALD J DAVIDSON, JIEYI WANG, EARL J GUBBINS
PC AG1K
CC Strandedness: Single;
CC Topology: Linear;
FH Key
FEATURES Location/Qualifiers
source 1. .18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 58;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 118 GTCCAGATTGCTACCAT 135
Db 1 GTCCAGATTGCTACCAT 18

RESULT 22
LOCUS A07672 21 bp DNA linear PAT 24-JUN-1993
DEFINITION Oligonucleotide for mutagenesis.
ACCESSION A07672
VERSION A07672.1 GI:413163
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 21)
AUTHORS Brinkmann, U., Matthes, R. and Stern, A.
TITLE Procedure for the expression of a recombinant gene
JOURNAL Patent: EP 0388963-A 8 26-SEP-1990;
FEATURES Location/Qualifiers
source 1. .21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 85;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 268 AACTACTGCGAATCCAGAT 288
Db 1 AACTACTGCGAATCCAGAT 21

RESULT 23
LOCUS I35369 16 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 337 from patent US 5599706.
ACCESSION I35369
VERSION I35369.1 GI:2088337
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS

REFERENCE 1 (bases 1 to 16)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 337 04-FEB-1997;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 374 GCAGTCCGTCGCGCC 389
Db 1 GCAGTCCGTCGCGCC 16

RESULT 24

LOCUS I35370 16 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 338 from patent US 5599706.
ACCESSION I35370
VERSION I35370.1 GI:2088338
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 16)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 338 04-FEB-1997;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 377 CTGCCGTGCGCCTCC 392
Db 1 CTGCCGTGCGCCTCC 16

RESULT 25

LOCUS I35371 16 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 339 from patent US 5599706.
ACCESSION I35371
VERSION I35371.1 GI:2088339
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 16)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 339 04-FEB-1997;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 436 GCACCGACTGAGCAA 451
Db 1 GCACCGACTGAGCAA 16

RESULT 26
LOCUS I35408 16 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 376 from patent US 5599706.
ACCESSION I35408
VERSION I35408.1 GI:2088376
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 16)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 376 04-FEB-1997;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 436 GCACCGACTGAGCAA 451
Db 1 GCACCGACTGAGCAA 16

RESULT 27

LOCUS I35412 16 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 380 from patent US 5599706.
ACCESSION I35412
VERSION I35412.1 GI:2088380
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 16)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 380 04-FEB-1997;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 436 GCACCGACTGAGCAA 451
Db 1 GCACCGACTGAGCAA 16

RESULT 28

LOCUS AR060430 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 3 from patent US 5840673.
ACCESSION AR060430
VERSION AR060430.1 GI:5986880
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
AUTHORS Buckbinder,L.R., Kley,N. and Seizinger,B.R.
TITLE Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment
JOURNAL Patent: US 5840673-A 3 24-NOV-1998;
FEATURES Location/Qualifiers

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.2%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 181 GGAAGACCTGCCAGCTT 199
DB 2 GCGAAGACCTGCCAGCTT 20

RESULT 29
AX774015/c 20 bp DNA linear PAT 09-JUL-2003
DEFINITION Sequence 16 from Patent WO03046161.
ACCESSION AX774015
VERSION AX774015.1 GI:32485841
KEYWORDS
SOURCE
ORGANISM
ARTIFICAL SEQUENCES.
REFERENCE
1 Hosfeld,D.K., Fiedler,W., Gehling,U. and Loges,S.
METHOD for carrying out the ex vivo expansion and ex vivo
differentiation of multipotent stem cells
Patent: WO 03046161-A 16 05-JUN-2003;
LOCATION/Qualifiers
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/Note="innerer vwf antisense-Primer"

Query Match
Best Local Similarity 0.2%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 104 AGCAAGCCATGTGTCCTCA 122
DB 19 AGCAAGCCATGTGTCCTCA 1

RESULT 30
AR298638 21 bp DNA linear PAT 12-JUN-2003
LOCUS AR298638/c
DEFINITION Sequence 10373 from patent US 6537751.
ACCESSION AR298638
VERSION AR298638.1 GI:31685922
KEYWORDS
SOURCE
ORGANISM
ARTIFICAL SEQUENCES.
REFERENCE
1 Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
disequilibrium map of the human genome
Patent: US 6537751-A 10373 25-MAR-2003;
LOCATION/Qualifiers
1. .21
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.2%; Score 15.8; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 CCACAGAAACTACCCCAA 251
DB 21 CCACAGAAACTACCCACA 3

```

```

RESULT 31
AX353508 21 bp DNA linear PAT 06-FEB-2002
LOCUS AX353508
DEFINITION Sequence 40 from Patent WO0204636.
ACCESSION AX353508
VERSION AX353508.1 GI:18618583
KEYWORDS
SOURCE
ORGANISM
ARTIFICAL SEQUENCES.
REFERENCE
1 van Roy,F., Goossens,S., Janssens,B. and Vanpouche,G.
TITLE Novel g(a) expressed in heart and testis
Patent: WO 0204636-A 40 17-JAN-2002;
LOCATION/Qualifiers
1. .21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/Note="splice donor 17"

Query Match
Best Local Similarity 0.2%; Score 15.8; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 327 TGTACGTGGAGTACTGC 345
DB 2 TGTACGTGGAGTACTGC 20

RESULT 32
AR328939 17 bp RNA linear PAT 17-AUG-2003
LOCUS AR328939
DEFINITION Sequence 6341 from patent US 6566127.
ACCESSION AR328939
VERSION AR328939.1 GI:33714747
KEYWORDS
SOURCE
ORGANISM
ARTIFICAL SEQUENCES.
REFERENCE
1 Payco,P., Meswigen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of disease or conditions
related to levels of vascular endothelial growth factor receptor
Patent: US 6566127-A 6341 20-MAY-2003;
LOCATION/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match
Best Local Similarity 0.2%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 104 AGCAAGCCATGTGTC 120
DB 1 AGCAAGCCATGTGTC 17

RESULT 33
AX254709/c 19 bp DNA linear PAT 10-OCT-2001
LOCUS AX254709
DEFINITION Sequence 3 from Patent WO0171030.
ACCESSION AX254709
VERSION AX254709.1 GI:16074376
KEYWORDS
SOURCE
ORGANISM
ARTIFICAL SEQUENCES.
REFERENCE
1

```

AUTHORS Satsangi, J.G., Welsh, K.N., Halder, N.D. and Chapman, R.G.
 TITLE Genetic determinant for chronic inflammatory disease
 JOURNAL Patent: WO 0171030-A 3 27-SRP-2001;
 ISIS INNOVATION LIMITED (GB)
 FEATURES Location/Qualifiers

source 1..19
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Oligonucleotide primer"

Query Match 0.2%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 94;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 285 AGATGCTGTGCAGCTC 301
 |||||
 17 AGAGCTGTGGCAGCTC 1

Db 17 AGAGCTGTGGCAGCTC 1

RESULT 34
 ARI26742 20 bp DNA linear PAT 16-MAY-2001
 LOCUS Sequence 171 from patent US 6180353.
 DEFINITION ARI26742
 ACCESSION ARI26742
 VERSION ARI26742.1 GI:1411335
 KEYWORDS
 SOURCE Unknown.

REFERENCE Unclassified.
 1 (bases 1 to 20)
 AUTHORS Dean, N.M. and Cowsett, L.M.
 TITLE Antisense modulation of daxx expression
 JOURNAL Patent: US 6180353-A 171 30-JAN-2001;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.2%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 73 CTTCTTATTTTGAATC 92
 |||||
 1 CTTCTTCTCCGAAATC 20

Db 1 CTTCTTCTCCGAAATC 20

RESULT 35
 ARI36424 20 bp DNA linear PAT 16-JUN-2001
 LOCUS Sequence 19 from patent US 6136604.
 DEFINITION ARI36424
 ACCESSION ARI36424
 VERSION ARI36424.1 GI:14477096
 KEYWORDS
 SOURCE Unknown.

REFERENCE Unclassified.
 1 (bases 1 to 20)
 AUTHORS Monia, B.P. and Wyatt, J.
 TITLE Antisense inhibition of methionine aminopeptidase 2 expression
 JOURNAL Patent: US 6136604-A 19 24-OCT-2000;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.2%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 66 TCTTCACTTCTTTATTC 85
 |||||

Db 1 TCTTCTTCTTTTCTTC 20

RESULT 36
 ARI39790 20 bp DNA linear PAT 16-JUN-2001
 LOCUS Sequence 35 from patent US 6207412.
 DEFINITION ARI39790
 ACCESSION ARI39790
 VERSION ARI39790.1 GI:14482286
 KEYWORDS
 SOURCE Unknown.

REFERENCE Unclassified.
 1 (bases 1 to 20)
 AUTHORS Weng, Z. and Witte, O.N.
 TITLE Identification of a G protein-coupled receptor transcriptionally
 regulated by protein tyrosine kinase signaling in hematopoietic
 cells
 JOURNAL Patent: US 6207412-A 35 27-MAR-2001;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.2%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 190 TGCCAGCTTGTCATCTAT 209
 |||||
 1 TGCCACTGTGGTCATCTAT 20

Db 1 TGCCACTGTGGTCATCTAT 20

RESULT 37
 ARI58621 20 bp DNA linear PAT 17-OCT-2001
 LOCUS Sequence 243 from patent US 6251588.
 DEFINITION ARI58621
 ACCESSION ARI58621
 VERSION ARI58621.1 GI:16220725
 KEYWORDS
 SOURCE Unknown.

REFERENCE Unclassified.
 1 (bases 1 to 20)
 AUTHORS Shannon, K.W., Wolber, P.K., Delenstarr, G.C., Webb, P.G. and
 Kincaid, R.H.
 TITLE Method for evaluating oligonucleotide probe sequences
 JOURNAL Patent: US 6251588-A 243 26-JUN-2001;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.2%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 284 CAGATGCTGTGCAGCTCT 303
 |||||

Db 1 CAGATGCTGTGCAGCTCT 20

RESULT 38
 ARI59140 20 bp DNA linear PAT 17-OCT-2001
 LOCUS Sequence 762 from patent US 6251588.
 DEFINITION ARI59140
 ACCESSION ARI59140
 VERSION ARI59140.1 GI:16221707
 KEYWORDS
 SOURCE Unknown.

REFERENCE Unclassified.
 1 (bases 1 to 20)
 Query Match 0.2%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

RESULT 43
LOCUS 135039 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 7 from patent US 5599706.
ACCESSION 135039
VERSION 135039.1 GI:2088007
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 7 04-FEB-1997;
FEATURES
source Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 120 CCAGATTGCTACCA 134
Db 1 CCAGATTGCTACCA 15
|||||

RESULT 44
LOCUS 135040 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 8 from patent US 5599706.
ACCESSION 135040
VERSION 135040.1 GI:2088008
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 8 04-FEB-1997;
FEATURES
source Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 144 ACAGATTATCGAGG 158
Db 1 ACAGATTATCGAGG 15
|||||

RESULT 45
LOCUS 135041 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 9 from patent US 5599706.
ACCESSION 135041
VERSION 135041.1 GI:2088009
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 9 04-FEB-1997;
FEATURES
source Location/Qualifiers

source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 147 GAGTTATCGAGCAC 161
Db 1 GAGTTATCGAGCAC 15
|||||

RESULT 46
LOCUS 135042 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 10 from patent US 5599706.
ACCESSION 135042
VERSION 135042.1 GI:2088010
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 10 04-FEB-1997;
FEATURES
source Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 192 CCAAGCTTGTCATC 206
Db 1 CCAAGCTTGTCATC 15
|||||

RESULT 47
LOCUS 135043 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 11 from patent US 5599706.
ACCESSION 135043
VERSION 135043.1 GI:2088011
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 11 04-FEB-1997;
FEATURES
source Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 355 CAATGCTCAGACGA 369
Db 1 CAATGCTCAGACGA 15
|||||

RESULT 48
LOCUS 135044 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 12 from patent US 5599706.

ACCESSION 135044
VERSION 135044.1 GI:2088012
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 12 04-FEB-1997;
FEATURES
source
1. 15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 393 GACTGTACCCCGGT 407
DB 1 GACTGTACCCCGGT 15

RESULT 49
135045 15 bp DNA linear PAT 13-MAY-1997
LOCUS Sequence 13 from patent US 559706.
DEFINITION 135045
ACCESSION 135045
VERSION 135045.1 GI:2088013
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 13 04-FEB-1997;
FEATURES
source
1. 15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 401 CCCCGTTCCAGCC 415
DB 1 CCCCGTTCCAGCC 15

RESULT 50
135046 15 bp DNA linear PAT 13-MAY-1997
LOCUS Sequence 14 from patent US 559706.
DEFINITION 135046
ACCESSION 135046
VERSION 135046.1 GI:2088014
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 14 04-FEB-1997;
FEATURES
source
1. 15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 402 CCCCGTTCCAGCCT 416
DB 1 CCCCGTTCCAGCCT 15

RESULT 51
135047 15 bp DNA linear PAT 13-MAY-1997
LOCUS Sequence 15 from patent US 559706.
DEFINITION 135047
ACCESSION 135047
VERSION 135047.1 GI:2088015
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 15 04-FEB-1997;
FEATURES
source
1. 15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 410 CAAGCTAGAGGCTC 424
DB 1 CAAGCTAGAGGCTC 15

RESULT 52
135048 15 bp DNA linear PAT 13-MAY-1997
LOCUS Sequence 16 from patent US 559706.
DEFINITION 135048
ACCESSION 135048
VERSION 135048.1 GI:2088016
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 16 04-FEB-1997;
FEATURES
source
1. 15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 474 CCATGGTAATGACA 488
DB 1 CCATGGTAATGACA 15

RESULT 53
135049 15 bp DNA linear PAT 13-MAY-1997
LOCUS Sequence 17 from patent US 559706.
DEFINITION 135049
ACCESSION 135049
VERSION 135049.1 GI:2088017
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 17 04-FEB-1997;
FEATURES
source
1. 15
/organism="unknown"
/mol_type="unassigned DNA"

REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 17 04-FEB-1997;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 564 GCATGCTCGACCC 578
|||||
Db 1 GCATGCTCGACCC 15

RESULT 54
LOCUS 135200 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 168 from patent US 5599706.
ACCESSION 135200
VERSION 135200.1 GI:2088168
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 168 04-FEB-1997;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 401 CCCGGTTCAGCC 415
|||||
Db 1 CCCGGTTCAGCC 15

RESULT 55
LOCUS 135201 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 169 from patent US 5599706.
ACCESSION 135201
VERSION 135201.1 GI:2088169
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 169 04-FEB-1997;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 417 AGAGGCTCTTCGA 431
|||||
Db 1 AGAGGCTCTTCGA 15

RESULT 56
LOCUS 135202 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 170 from patent US 5599706.
ACCESSION 135202
VERSION 135202.1 GI:2088170
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 170 04-FEB-1997;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 420 GGCTCCTTCGACA 434
|||||
Db 1 GGCTCCTTCGACA 15

RESULT 57
LOCUS 135203 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 171 from patent US 5599706.
ACCESSION 135203
VERSION 135203.1 GI:2088171
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 171 04-FEB-1997;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 420 GGCTCCTTCGACA 434
|||||
Db 1 GGCTCCTTCGACA 15

RESULT 58
LOCUS 135204 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 172 from patent US 5599706.
ACCESSION 135204
VERSION 135204.1 GI:2088172
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 172 04-FEB-1997;
FEATURES Location/Qualifiers
source 1..15

Query Match	0.2%;	Score 15;	DB 1;	Length 15;	
Best Local Similarity	100.0%;	Pred. No. 68;			
Matches 15;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;	
Oy	420	GGCTCCTTCGGAACA	434		
Db	1	GGCTCCTTCGGAACA	15		
RESULT 59					
LOCUS	135205		15 bp	DNA	linear
DEFINITION	Sequence 173 from patent US 5599706.				PAT 13-MAY-1997
ACCESSION	135205				
VERSION	135205.1	GI:2088173			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 15)				
TITLE	Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.				
JOURNAL	Ribozymes targeted to apo(a) mRNA				
FEATURES	Patent: US 5599706-A 173 04-FEB-1997;				
	Location/Qualifiers				
source	1..15				
	/organism="unknown"				
	/mol_type="unassigned DNA"				
Query Match	0.2%;	Score 15;	DB 1;	Length 15;	
Best Local Similarity	100.0%;	Pred. No. 68;			
Matches 15;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;	
Oy	420	GGCTCCTTCGGAACA	434		
Db	1	GGCTCCTTCGGAACA	15		
RESULT 60					
LOCUS	135206		15 bp	DNA	linear
DEFINITION	Sequence 174 from patent US 5599706.				PAT 13-MAY-1997
ACCESSION	135206				
VERSION	135206.1	GI:2088174			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 15)				
TITLE	Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.				
JOURNAL	Ribozymes targeted to apo(a) mRNA				
FEATURES	Patent: US 5599706-A 174 04-FEB-1997;				
	Location/Qualifiers				
source	1..15				
	/organism="unknown"				
	/mol_type="unassigned DNA"				
Query Match	0.2%;	Score 15;	DB 1;	Length 15;	
Best Local Similarity	100.0%;	Pred. No. 68;			
Matches 15;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;	
Oy	421	GCTCCTTCGGAACA	435		
Db	1	GCTCCTTCGGAACA	15		
RESULT 61					
LOCUS	135207		15 bp	DNA	linear
DEFINITION	Sequence 175 from patent US 5599706.				PAT 13-MAY-1997
ACCESSION	135207				

```

VERSION      135207.1  GI:2088175
KEYWORDS
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 15)
AUTHORS      Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE        Ribozymes targeted to apo(a) mRNA
JOURNAL      Patent: US 559706-A 175 04-FEB-1997;
FEATURES
            Location/Qualifiers
                1..15
                    /organism="unknown"
                    /mol_type="unassigned DNA"

Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      144  ACAGATTATCGAGG 158
        |||||||||
        1 ACAGATTATCGAGG 15

RESULT 62
LOCUS      135208                15 bp      DNA                linear      PAT 13-MAY-1997
DEFINITION Sequence 176 from patent US 559706.
ACCESSION  135208
VERSION    135208.1  GI:2088176
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE   1 (bases 1 to 15)
AUTHORS     Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE       Ribozymes targeted to apo(a) mRNA
JOURNAL     Patent: US 559706-A 175 04-FEB-1997;
FEATURES
            Location/Qualifiers
                1..15
                    /organism="unknown"
                    /mol_type="unassigned DNA"

Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      147  GAGTTATCGAGGCAC 161
        |||||||||
        1 GAGTTATCGAGGCAC 15

Db
1 GAGTTATCGAGGCAC 15

RESULT 63
LOCUS      135220                15 bp      DNA                linear      PAT 13-MAY-1997
DEFINITION Sequence 188 from patent US 559706.
ACCESSION  135220
VERSION    135220.1  GI:2088188
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE   1 (bases 1 to 15)
AUTHORS     Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE       Ribozymes targeted to apo(a) mRNA
JOURNAL     Patent: US 559706-A 188 04-FEB-1997;
FEATURES
            Location/Qualifiers
                1..15
                    /organism="unknown"
                    /mol_type="unassigned DNA"

Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      151  GAGTTATCGAGGCAC 161
        |||||||||
        1 GAGTTATCGAGGCAC 15

Db
1 GAGTTATCGAGGCAC 15

```

QY 499 GGCACTACTCCACC 513
 |||||
 TITLE
 JOURNAL
 Patent: US 559706-A 196 04-FEB-1997;
 FEATURES
 Location/Qualifiers
 1. .15
 /organism="unknown"
 /mol_type="unassigned DNA"

RESULT 64
 LOCUS 135226 15 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 194 from patent US 559706.
 ACCESSION 135226
 VERSION 135226.1 GI:2088194
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
 AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
 TITLE Ribozymes targeted to apo(a) mRNA
 JOURNAL Patent: US 559706-A 194 04-FEB-1997;
 FEATURES
 Location/Qualifiers
 1. .15
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 68;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 564 GCATAGTCGACCCC 578
 |||||
 Db 1 GCATAGTCGACCCC 15

RESULT 65
 LOCUS 135227 15 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 195 from patent US 559706.
 ACCESSION 135227
 VERSION 135227.1 GI:2088195
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
 AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
 TITLE Ribozymes targeted to apo(a) mRNA
 JOURNAL Patent: US 559706-A 195 04-FEB-1997;
 FEATURES
 Location/Qualifiers
 1. .15
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 68;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 564 GCATAGTCGACCCC 578
 |||||
 Db 1 GCATAGTCGACCCC 15

RESULT 66
 LOCUS 135228 15 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 196 from patent US 559706.
 ACCESSION 135228
 VERSION 135228.1 GI:2088196
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)

AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
 TITLE Ribozymes targeted to apo(a) mRNA
 JOURNAL Patent: US 559706-A 196 04-FEB-1997;
 FEATURES
 Location/Qualifiers
 1. .15
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 68;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 564 GCATAGTCGACCCC 578
 |||||
 Db 1 GCATAGTCGACCCC 15

RESULT 67
 LOCUS 135230 15 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 198 from patent US 559706.
 ACCESSION 135230
 VERSION 135230.1 GI:2088198
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
 AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
 TITLE Ribozymes targeted to apo(a) mRNA
 JOURNAL Patent: US 559706-A 198 04-FEB-1997;
 FEATURES
 Location/Qualifiers
 1. .15
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 68;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 276 CAGGAATCCAGATGC 290
 |||||
 Db 1 CAGGAATCCAGATGC 15

RESULT 68
 LOCUS 135231 15 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 199 from patent US 559706.
 ACCESSION 135231
 VERSION 135231.1 GI:2088199
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
 AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
 TITLE Ribozymes targeted to apo(a) mRNA
 JOURNAL Patent: US 559706-A 199 04-FEB-1997;
 FEATURES
 Location/Qualifiers
 1. .15
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.2%; Score 15; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 68;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 276 CAGGAATCCAGATGC 290
 |||||
 Db 1 CAGGAATCCAGATGC 15

```
RESULT 69
LOCUS 135232
DEFINITION Sequence 200 from patent US 5599706.
ACCESSION 135232
VERSION 135232.1 GI:2088200
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
  TITLE
  Ribozymes targeted to apo(a) mRNA
  JOURNAL
  Patent: US 5599706-A 200 04-FEB-1997;
  location/Qualifiers
  1. .15
  /organism="unknown"
  /mol_type="unassigned DNA"

Query Match
  0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 276 CAGGAATCCAGATGC 290
      |||||||
      1 CAGGAATCCAGATGC 15

Db

RESULT 70
LOCUS 135233
DEFINITION Sequence 201 from patent US 5599706.
ACCESSION 135233
VERSION 135233.1 GI:2088201
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
  AUTHORS
  Ribozymes targeted to apo(a) mRNA
  TITLE
  Patent: US 5599706-A 201 04-FEB-1997;
  location/Qualifiers
  1. .15
  /organism="unknown"
  /mol_type="unassigned DNA"

Query Match
  0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 276 CAGGAATCCAGATGC 290
      |||||||
      1 CAGGAATCCAGATGC 15

Db

RESULT 71
LOCUS 135234
DEFINITION Sequence 202 from patent US 5599706.
ACCESSION 135234
VERSION 135234.1 GI:2088202
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
  TITLE
  Ribozymes targeted to apo(a) mRNA
  JOURNAL
  Patent: US 5599706-A 202 04-FEB-1997;
  location/Qualifiers
  1. .15
  /organism="unknown"
  /mol_type="unassigned DNA"

Query Match
  0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 276 CAGGAATCCAGATGC 290
      |||||||
      1 CAGGAATCCAGATGC 15

Db

RESULT 72
LOCUS 135256
DEFINITION Sequence 224 from patent US 5599706.
ACCESSION 135256
VERSION 135256.1 GI:2088224
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
  AUTHORS
  Ribozymes targeted to apo(a) mRNA
  TITLE
  Patent: US 5599706-A 224 04-FEB-1997;
  location/Qualifiers
  1. .15
  /organism="unknown"
  /mol_type="unassigned DNA"

Query Match
  0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 120 CCAGATTGCTACCA 134
      |||||||
      1 CCAGATTGCTACCA 15

Db

RESULT 73
LOCUS 135257
DEFINITION Sequence 225 from patent US 5599706.
ACCESSION 135257
VERSION 135257.1 GI:2088225
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
  AUTHORS
  Ribozymes targeted to apo(a) mRNA
  TITLE
  Patent: US 5599706-A 225 04-FEB-1997;
  location/Qualifiers
  1. .15
  /organism="unknown"
  /mol_type="unassigned DNA"

Query Match
  0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 120 CCAGATTGCTACCA 134
      |||||||
      1 CCAGATTGCTACCA 15

Db

RESULT 74
LOCUS 189347/c
DEFINITION Sequence 4 from patent US 5721138.
ACCESSION 189347
VERSION 189347.1 GI:3409287
```

```

/mol_type="unassigned DNA"

Query Match
  0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 276 CAGGAATCCAGATGC 290
      |||||||
      1 CAGGAATCCAGATGC 15

Db

RESULT 72
LOCUS 135256
DEFINITION Sequence 224 from patent US 5599706.
ACCESSION 135256
VERSION 135256.1 GI:2088224
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
  AUTHORS
  Ribozymes targeted to apo(a) mRNA
  TITLE
  Patent: US 5599706-A 224 04-FEB-1997;
  location/Qualifiers
  1. .15
  /organism="unknown"
  /mol_type="unassigned DNA"

Query Match
  0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 120 CCAGATTGCTACCA 134
      |||||||
      1 CCAGATTGCTACCA 15

Db

RESULT 73
LOCUS 135257
DEFINITION Sequence 225 from patent US 5599706.
ACCESSION 135257
VERSION 135257.1 GI:2088225
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
  AUTHORS
  Ribozymes targeted to apo(a) mRNA
  TITLE
  Patent: US 5599706-A 225 04-FEB-1997;
  location/Qualifiers
  1. .15
  /organism="unknown"
  /mol_type="unassigned DNA"

Query Match
  0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 120 CCAGATTGCTACCA 134
      |||||||
      1 CCAGATTGCTACCA 15

Db

RESULT 74
LOCUS 189347/c
DEFINITION Sequence 4 from patent US 5721138.
ACCESSION 189347
VERSION 189347.1 GI:3409287
```

KEYWORDS	Unknown.
SOURCE	Unknown.
ORGANISM	Unclassified.
REFERENCE	1 (bases 1 to 15)
AUTHORS	Lawn,R.Mark.
TITLE	Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
JOURNAL	Patent: US 5721138-A 4 24-FEB-1998;
FEATURES	Location/Qualifiers
source	1..15

Query Match	0.2%	Score 15;	DB 1;	Length 15;
Best Local Similarity	100.0%	Pre. No. 68;		
Matches	15;	Conservative 0;	Mismatches 0;	Gaps 0;
Qy	105	GCAAGCCATGTGTT	119	
Db	15	GCAAGCCATGTGTT	1	

RESULT 75					
AX734096	AX734096	17 bp	DNA	linear	PAT 08-MAY-2003
LOCUS					
DEFINITION	Sequence 5730 from Patent WO03025175.				
ACCESSION	AX734096				
VERSION	AX734096.1	GI:30513439			
KEYWORDS	.				
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				

REFERENCE
AUTHORS
TITLE
SEQUENCES INVOLVED IN PHENOMENA OF TUMOUR SUPPRESSION

1
Telerman, A., Amson, R. and Tuijinder M.
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
Eumetazoa; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.

JOURNAL Patent: WO 03025175-A 5730 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers

```
/organism="Homo sapiens"  
/mol_type="unassigned DNA"  
/db_xref="taxon:9606"
```

Query Match	0.2%	Score 15;	DB 1;	Length 17;
Best Local Similarity	100.0%;	Pred. No. 87;		
Matches	15;	Conservative	0;	Mismatches
			0;	Indels
				Gaps

OY	75	TCTTTATTCTGAA	89
D6	3	TCTTTATTCTGAA	17

RESULT 76	AX737374	AX737374	17 bp	DNA	linear	PAT 08-MAY-2003
LOCUS	AX737374					
DEFINITION	Sequence	2964	from Patent	WO03025177.		
ACCESSION	AX737374					
VERSION	AX737374.1		GI:30516662			
KEYWORDS	.					
SOURCE	Homo sapiens					
ORGANISM	Homo sapiens (human)					

1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE	AUTHORS	TITLE
1	Telerman, A., Amson, R. and Tuijinder, M.	Sequences involved in rheumatism of Tuzigw...

JOURNAL

source	1..17
location/Qualifiers	
FEATURES	
Molecular Engines Laboratories (FR)	

```
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
```

Query Match 0.2%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 0; Gaps 0;

OY	75	TCTTTTATTCTGAA	89
Db	3	TCTTTTATTCTGAA	17

RESULT	77				
LOCUS	AX762753				
DEFINITION	AX762753		17 bp	DNA	
ACCESSION	Sequence 6074 from Patent	WO03040369.		linear	PAT 25-JUN-2003
VERSION	AX762753.1	GI:32257369			
KEYWORDS	.				
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				

REFERENCE
AUTHORS
TITLE

1
Telerman, A., Amson, R. and Tuijnder, M.
Sequences involved in tumoral suppression, tumoral reversion,

JOURNAL
of
Medicines
Patent: WO 03040369-A 6074 15-MAY-2003;
Molecular Engines Laboratories (FR)

```
/organism="Homo sapiens"  
/mol_type="unassigned DNA"  
/db_xref="taxon:9606"
```

Query Match 0.2%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	75	TCTTTATTCTGAA	89
Db	3	TCTTTATTCTGAA	17

RESULT 78		
AX010205		
LOCUS	20 bp	DNA
AX010205		
DEFINITION	Sequence 9 from Patent WO960115.	linear
ACCSSION		PAT 06-SEP-2000

SOURCE ORGANISM
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1

Proteins and genes useful as tumor markers

VLAAMS INTERUNIV INST BIOTECH (BE); LEUVEN FRED VAN (BE)

source
1. :20
vocation/qualification

Source

```
/organism="Homo sapiens"  
/mol type="unassigned DNA"
```

misc feature

```
/note="splicing boundary: 1 - 10: intron ; 11 - 20: exon"
```

Query Match 0.2%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 515 CTGTACACGAGAGAA 529
|||||
2 CTGTACACGAGAGAA 16

Db

RESULT 79
AR082444 19 bp DNA linear PAT 31-AUG-2000
LOCUS AR082444
DEFINITION Sequence 3 from patent US 5972901.
ACCESSION AR082444
VERSION AR082444.1 GI:10009170
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 19)
AUTHORS Ferkol,T.W., Jr., Davis,P.B. and Ziady,A.-G.
TITLE Serpin enzyme complex receptor-mediated gene transfer
JOURNAL Patent: US 5972901-A 3 26-OCT-1999;
FEATURES
source 1. .19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 65 TTCTTCTACTCTTTTAT 82
|||||
2 TTCTTCTCTCTTTT 19

Db

RESULT 80
AR139000 19 bp DNA linear PAT 16-JUN-2001
LOCUS AR139000
DEFINITION Sequence 3 from patent US 6200801.
ACCESSION AR139000
VERSION AR139000.1 GI:14481345
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 19)
AUTHORS Ferkol,T.W., Jr., Davis,P.B. and Ziady,A.-G.
TITLE Serpin enzyme complex receptor-mediated gene transfer
JOURNAL Patent: US 6200801-A 3 13-MAR-2001;
FEATURES
source 1. .19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 65 TTCTTCTACTCTTTTAT 82
|||||
2 TTCTTCTCTCTTTT 19

Db

RESULT 81
I35372 16 bp DNA linear PAT 13-MAY-1997
LOCUS I35372
DEFINITION Sequence 340 from patent US 5599706.
ACCESSION I35372
VERSION I35372.1 GI:2088340
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 16)
AUTHORS Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 340 04-FEB-1997;
FEATURES
source 1. .16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 97;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 436 GCACCGCTGACGAAA 451
|||||
1 GCACCGCTGACGAGA 16

Db

RESULT 82
I35373 16 bp DNA linear PAT 13-MAY-1997
LOCUS I35373
DEFINITION Sequence 341 from patent US 5599706.
ACCESSION I35373
VERSION I35373.1 GI:2088341
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 16)
AUTHORS Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 341 04-FEB-1997;
FEATURES
source 1. .16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 97;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 293 TGGACGCTCTATTG 308
|||||
1 TGGACGCTCTATTG 16

Db

RESULT 83
I35406 16 bp DNA linear PAT 13-MAY-1997
LOCUS I35406
DEFINITION Sequence 374 from patent US 5599706.
ACCESSION I35406
VERSION I35406.1 GI:2088374
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 16)
AUTHORS Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 374 04-FEB-1997;
FEATURES
source 1. .16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 97;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 374 GGAATGCGCTGCGCC 389
|||||

Db 1 GGACTGCCGTGCACC 16

RESULT 84

LOCUS 135407 16 bp DNA linear PAT 13-MAY-1997

DEFINITION Sequence 375 from patent US 5599706.

ACCESSION 135407

VERSION 135407.1 GI:2088375

KEYWORDS

SOURCE unknown.

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 16)

AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.

TITLE Ribozymes targeted to apo(a) mRNA

JOURNAL Patent: US 5599706-A 375 04-FEB-1997;

FEATURES

source

1.16

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.2%; Score 14.4; DB 1; Length 16;

Best Local Similarity 93.8%; Pred. No. 97;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 377 CTGCGGTGCGCCCTCC 392

Db 1 CTGCGGTGCGACCTCC 16

RESULT 85

LOCUS 135409 16 bp DNA linear PAT 13-MAY-1997

DEFINITION Sequence 377 from patent US 5599706.

ACCESSION 135409

VERSION 135409.1 GI:2088377

KEYWORDS

SOURCE unknown.

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 16)

AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.

TITLE Ribozymes targeted to apo(a) mRNA

JOURNAL Patent: US 5599706-A 377 04-FEB-1997;

FEATURES

source

1.16

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.2%; Score 14.4; DB 1; Length 16;

Best Local Similarity 93.8%; Pred. No. 97;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 293 TGGCAGCTCCTTATTG 308

Db 1 TGGCAGCCCTTATTG 16

RESULT 86

LOCUS 135410 16 bp DNA linear PAT 13-MAY-1997

DEFINITION Sequence 378 from patent US 5599706.

ACCESSION 135410

VERSION 135410.1 GI:2088378

KEYWORDS

SOURCE unknown.

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 16)

AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.

TITLE Ribozymes targeted to apo(a) mRNA

JOURNAL Patent: US 5599706-A 378 04-FEB-1997;

FEATURES

source

Location/Qualifiers

1.16

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.2%; Score 14.4; DB 1; Length 16;

Best Local Similarity 93.8%; Pred. No. 97;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 293 TGGCAGCTCCTTATTG 308

Db 1 TGGCAGCCCTTATTG 16

RESULT 87

LOCUS 135413 16 bp DNA linear PAT 13-MAY-1997

DEFINITION Sequence 381 from patent US 5599706.

ACCESSION 135413

VERSION 135413.1 GI:2088381

KEYWORDS

SOURCE unknown.

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 16)

AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.

TITLE Ribozymes targeted to apo(a) mRNA

JOURNAL Patent: US 5599706-A 381 04-FEB-1997;

FEATURES

source

1.16

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.2%; Score 14.4; DB 1; Length 16;

Best Local Similarity 93.8%; Pred. No. 97;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 374 GGACTGCCGTGCGCC 389

Db 1 GGACTGCCGTGCACC 16

RESULT 88

LOCUS 135414 16 bp DNA linear PAT 13-MAY-1997

DEFINITION Sequence 382 from patent US 5599706.

ACCESSION 135414

VERSION 135414.1 GI:2088382

KEYWORDS

SOURCE unknown.

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 16)

AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.

TITLE Ribozymes targeted to apo(a) mRNA

JOURNAL Patent: US 5599706-A 382 04-FEB-1997;

FEATURES

source

1.16

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.2%; Score 14.4; DB 1; Length 16;

Best Local Similarity 93.8%; Pred. No. 97;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 374 GGACTGCCGTGCGCC 389

Db 1 GGACTGCCGTGCACC 16

RESULT 89

LOCUS 135415 16 bp DNA linear PAT 13-MAY-1997

DEFINITION	Sequence 366 from Patent WO03031621.
ACCESSION	AY7444401
VERSION	AY7444401.1
KEYWORDS	GI:30723068
SOURCE	
ORGANISM	Homo sapiens (human)
REFERENCE	Homo sapiens
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
JOURNAL	
FEATURES	
source	1. .17 /organism="Homo sapiens" /mol_type="genomic DNA" /db_xref="taxon:9606"
Query Match	0.2%; Score 14.4; DB 1; Length 17;
Best Local Similarity	93.8%; Pred. No. 1.1e+02;
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy	45 AATGAACATTAAGGA 60 1 AATGAGCATTAAGGA 16
Db	
RESULT 95	
AX756824	
LOCUS	AX756824 17 bp DNA linear PAT 25-JUN-2003
DEFINITION	Sequence 145 from Patent WO03040369.
ACCESSION	AX756824
VERSION	AX756824.1
KEYWORDS	GI:32251378
SOURCE	
ORGANISM	Homo sapiens (human)
REFERENCE	Homo sapiens
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
JOURNAL	
FEATURES	
source	1. .17 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"
Query Match	0.2%; Score 14.4; DB 1; Length 17;
Best Local Similarity	93.8%; Pred. No. 1.1e+02;
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy	281 ATCCAGATGCTGTGAC 296 2 ATCCATATGCTGTGAC 17
Db	
RESULT 96	
ARI00312/c	
LOCUS	ARI00312 18 bp DNA linear PAT 14-FEB-2001
DEFINITION	Sequence 43 from patent US 6080560.
ACCESSION	ARI00312
VERSION	ARI00312.1
KEYWORDS	GI:12810760
SOURCE	
ORGANISM	Unknown.
REFERENCE	Unknown.
AUTHORS	Unclassified.
1 (bases 1 to 18)	
Baker,B.F., Bennett,C.Frank., Butler,M.W. and Shanahan,W.R. Jr.	

FEATURES	source	1. .18	/organism="unknown"	/mol_type="unassigned DNA"
JOURNAL	Antisense oligonucleotide modulation of tumor necrosis factor- α (TNF- α) expression			
PATENT	US 6080580-A 4327-JUN-2000;			
DEFINITION	Location/Qualifiers			
LOCUS	1. .18			
Query Match	0.2%; Score 14.4; DB 1; Length 18;			
Best Local Similarity	93.8%; Pred. No. 1.2e+02;			
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;			
Db	430 GAACAGCAGCCGCTG 445			
LOCUS	16 GAACAGCAGCCGCTG 1			
DEFINITION	Sequence 43 from patent US 6228642.	18 bp	DNA	linear
ACCESSION	ARI49967			
VERSION	ARI49967			
KEYWORDS	ARI49967.1 GI:15114558			
SOURCE	Unknown.			
ORGANISM	Unclassified.			
REFERENCE	1 (bases 1 to 18)			
AUTHORS	Baker,B.F., Bennett,C.,Frank., Butler,M.M. and Shanahan,W.R. Jr.			
TITLE	Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF- α) expression			
JOURNAL	Patent: US 6228642-A 43 08-MAY-2001;			
FEATURES	Location/Qualifiers			
source	1. .18			
	/organism="unknown"			
	/mol_type="unassigned DNA"			
Query Match	0.2%; Score 14.4; DB 1; Length 18;			
Best Local Similarity	93.8%; Pred. No. 1.2e+02;			
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;			
Db	430 GAACAGCAGCCGCTG 445			
LOCUS	16 GAACAGCAGCCGCTG 1			
DEFINITION	Sequence 43 from patent US 6228642.	18 bp	DNA	linear
ACCESSION	ARI49967			
VERSION	ARI49967			
KEYWORDS	ARI49967.1 GI:15114558			
SOURCE	Unknown.			
ORGANISM	Unclassified.			
REFERENCE	1 (bases 1 to 18)			
AUTHORS	Baker,B.F., Bennett,C.,Frank., Butler,M.M. and Shanahan,W.R. Jr.			
TITLE	Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF- α) expression			
JOURNAL	Patent: US 6228642-A 43 08-MAY-2001;			
FEATURES	Location/Qualifiers			
source	1. .18			
	/organism="unknown"			
	/mol_type="unassigned DNA"			
Query Match	0.2%; Score 14.4; DB 1; Length 18;			
Best Local Similarity	93.8%; Pred. No. 1.2e+02;			
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;			
Db	430 GAACAGCAGCCGCTG 445			
LOCUS	16 GAACAGCAGCCGCTG 1			
DEFINITION	Sequence 43 from patent US 6228642.	18 bp	DNA	linear
ACCESSION	ARI49967			
VERSION	ARI49967			
KEYWORDS	ARI49967.1 GI:15114558			
SOURCE	Unknown.			
ORGANISM	Unclassified.			
REFERENCE	1 (bases 1 to 18)			
AUTHORS	Baker,B.F., Bennett,C.,Frank., Butler,M.M. and Jr,W.R. S.			
TITLE	Antisense oligonucleotide regulation of expression of tumor necrosis factor- α (TNF- α)			
JOURNAL	Patent: JP 2002526125-A 43 20-AUG-2002;			
FEATURES	Location/Qualifiers			
source	1 (bases 1 to 18)			
	/organism="unknown"			
	/mol_type="unassigned DNA"			
Query Match	0.2%; Score 14.4; DB 1; Length 18;			
Best Local Similarity	93.8%; Pred. No. 1.2e+02;			
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;			
Db	430 GAACAGCAGCCGCTG 445			
LOCUS	16 GAACAGCAGCCGCTG 1			
DEFINITION	Sequence 43 from patent US 6228642.	18 bp	DNA	linear
ACCESSION	ARI49967			
VERSION	ARI49967			
KEYWORDS	ARI49967.1 GI:15114558			
SOURCE	Unknown.			
ORGANISM	Unclassified.			
REFERENCE	1 (bases 1 to 18)			
AUTHORS	Baker,B.F., Bennett,C.,Frank., Butler,M.M. and Jr,W.R. S.			
TITLE	Antisense oligonucleotide regulation of expression of tumor necrosis factor- α (TNF- α)			
JOURNAL	Patent: JP 2002526125-A 43 20-AUG-2002;			
FEATURES	Location/Qualifiers			
source	1 (bases 1 to 18)			
	/organism="unknown"			
	/mol_type="unassigned DNA"			
Query Match	0.2%; Score 14.4; DB 1; Length 18;			
Best Local Similarity	93.8%; Pred. No. 1.2e+02;			

DEFINITION Sequence 383 from patent US 5599706.
ACCESSION I35415
VERSION I35415.1 GI:2088383
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 16)
AUTHORS Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 383 04-FEB-1997;
FEATURES
source
1. .16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 97;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 377 CTGCGTGGCGCTCC 392
Db 1 CTGCGTGGCGCTCC 16

RESULT 90
LOCUS AR286121 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 493 from patent US 6528640.
ACCESSION AR286121
VERSION AR286121.1 GI:29723717
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpelsky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 493 04-MAR-2003;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.2%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 167 CCACCCTGTCACAGG 182
Db 1 CCACCCTGTCACAGG 16

RESULT 91
LOCUS AR328940 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6342 from patent US 656127.
ACCESSION AR328940
VERSION AR328940.1 GI:33714748
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwigen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL Patent: US 656127-A 6342 20-MAY-2003;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.2%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 105 GCAGGCCATGTGTC 120
Db 1 GCAGGCCATGTGTC 16

RESULT 92
LOCUS AR398111 17 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 492 from patent US 6617438.
ACCESSION AR398111
VERSION AR398111.1 GI:40135657
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpelsky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 492 09-SEP-2003;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.2%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 167 CCACCCTGTCACAGG 182
Db 1 CCACCCTGTCACAGG 16

RESULT 93
LOCUS AX744400 17 bp DNA linear PAT 14-MAY-2003
DEFINITION Sequence 365 from Patent WO03031621.
ACCESSION AX744400
VERSION AX744400.1 GI:30723067
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Zhang,J.
TITLE A human G protein coupled receptor
JOURNAL Patent: WO 03031621-A 365 17-APR-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="Genomic DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 45 AATGAACATAGGAA 60
Db 2 AATGAACATAGGAA 17

RESULT 94
LOCUS AX744401 17 bp DNA linear PAT 14-MAY-2003

C07H21/02,
CC C07H21/04, C12N15/00

PC PCR primer
FH key Location/Qualifiers
FT source 1..18
FT Location/Qualifiers

1..18
/organism="Artificial Sequence"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 430 GAACAGCACCAGCTG 445
16 GAACAGCACCAGCTG 1

RESULT 99
AX451725

LOCUS AX451725 18 bp DNA linear PAT 03-JUL-2002
DEFINITION Sequence 14 from Patent WO0226944.
ACCESSION AX451725
VERSION AX451725.1 GI:21698629
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Brownlie, A.
TITLES Methods and compositions employing a stearyl-coa desaturase-hcds
JOURNAL Patent: WO 0226944-A 14 04-APR-2002;
Xenon Genetics, Inc. (CA)
LOCATION/Qualifiers

1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PCR Primer"

Query Match 0.2%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 26 CACTGCTGCCAGTCC 41
3 CACTGCTGCCAGTCC 18

RESULT 100
AX937537 19 bp DNA linear PAT 06-JAN-2004
LOCUS AX937537
DEFINITION Sequence 17 from Patent EP1361433.
ACCESSION AX937537
VERSION AX937537.1 GI:40713577
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Yanaei, Y.C., Yamamoto, S.C., Yamamoto, K.C. and Ikegami, H.C.
TITLES Method for estimating therapeutic efficacy of tumor necrosis factor
JOURNAL Patent: EP 1361433-A 17 12-NOV-2003;
(TNF)
KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUO (JP)

FEATURES
SOURCE
1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

/note="Oligonucleotide used as primer for PCR detection of
FAN mRNA"

Query Match 0.2%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 407 TTCCAGCCTAGAGGC 422
17 TTCCAGCCTAGAGGC 2

RESULT 101
LOCUS 135054 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 22 from patent US 5599706.
ACCESSION 135054
VERSION 135054.1 GI:2088022
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb, D.T., McSwiggen, J., Newton, R.S. and Ramharack, R.
TITLES Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 22 04-FEB-1997;
LOCATION/Qualifiers

1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 301 CCTATTGTTATAC 314
2 CCTATTGTTATAC 15

RESULT 102
LOCUS 135062 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 30 from patent US 5599706.
ACCESSION 135062
VERSION 135062.1 GI:2088030
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb, D.T., McSwiggen, J., Newton, R.S. and Ramharack, R.
TITLES Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 30 04-FEB-1997;
LOCATION/Qualifiers

1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 410 CAAGCCTAGAGGCT 423
1 CAAGCCTAGAGGCT 14

RESULT 103
LOCUS 135259 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 227 from patent US 5599706.
ACCESSION 135259

```

VERSION      135259.1   GI:2088227
KEYWORDS
SOURCE
ORGANISM
REFERENCE    1 (bases 1 to 15)
              Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
              Ribozymes targeted to apo(a) mRNA
              Patent: US 5599706-A 227 04-FEB-1997;
              Location/Qualifiers
              1..15
              /organism="unknown"
              /mol_type="unassigned DNA"
FEATURES
source

```

Query Match	0.2%	Score 14;	DB 1;	Length 15;
Best Local Similarity	100.0%	Pred. No. 99;		
Matches	14;	Conservative	0;	Mismatches 0;
				Indels 0;
				Gaps 0;
QY	197	CTTGTCATCTATG	210	
Db	2	CTTGTCATCTATG	15	

RESULT_104			
AX264296/c			
LOCUS	AX264296	17 bp	DNA
DEFINITION	Sequence 1687 from Patent WO0173002.		linear
ACCESSION	AX264296		
VERSION	AX264296.1	GI:16513095	
KEYWORDS	.		
SOURCE	Homo sapiens	(human)	
ORGANISM	Homo sapiens		

REFERENCE	1	Pharmacia; Solvay; Primates; Catarrhini; Hominae; Homo.
AUTHORS	Kniec, E. B., Gamper, H. B. and Rice, M. C.	
TITLE	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides	
JOURNAL	Patent: WO 0173002-A 1687 04-OCT-2001;	
UNIVERSITY	UNIVERSITY OF DELAWARE (US)	
FEATURES	Location/Qualifiers	
source	1..17	

```
/organism="Homo sapiens"  
/mol_type="unassigned DNA"  
/db_xref="taxon:9606"
```

Query Match	0.23;	Score 14;	DB 1;	Length 17;
Best Local Similarity	100.0%;	Pred. No. 1.3e+02;		
Matches 14;	Conservative 0;	Mismatches 0;	Indels 0.	Gap 0.

Oy 74 TTCTTTTATTTCG 87
|||||
Db 16 TTCTTTTATTTCG 3

RESULT 105		
AX264297		
LOCUS		
AX264297	17 bp	DNA
DEFINITION		
Sequence 1688 from Patent WO0171002.		linear
		PAT 26-OCT-2001

SOURCE ORGANISM	Homo sapiens (human) Homo sapiens
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single

JOURNAL Patent: WO 0173002-A 1688 04-OCT-2001,
UNIVERSITY OF DELAWARE (US)
FEATURES Location/Qualifiers

```
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
```

Query Match 0.2%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	74	TTCTTTTATTTCTG	87
Db	2	TTCTTTTATTTCTG	15

RESULT 106			
CO617713			
LOCUS	CO617713	17 bp	DNA
DEFINITION	Sequence 2453 from Patent WO0195524.		linear
			PAT 02-FEB-2004

SOURCE	Homo sapiens (human)
Genetic material	
Protein	
Mitochondrial DNA	
Nuclear DNA	
Chromosomes	
Plasma	
Saliva	
Urine	
Feces	
Sweat	
Tears	
Blood	
Spinal fluid	
Amniotic fluid	
Vaginal secretions	
Semen	
Egg cells	
Sperm cells	
Ovarian follicles	
Embryonic tissue	
Fetal membranes	
Placental tissue	
Cord blood	
Postnatal urine	
Postnatal feces	
Postnatal sweat	
Postnatal tears	
Postnatal blood	
Postnatal spinal fluid	
Postnatal amniotic fluid	
Postnatal vaginal secretions	
Postnatal semen	
Postnatal egg cells	
Postnatal sperm cells	
Postnatal ovarian follicles	
Postnatal embryonic tissue	
Postnatal fetal membranes	
Postnatal placental tissue	
Postnatal cord blood	

REFERENCE

1. Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS	Shu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE	Myosin-like gene expressed in human heart and muscle
JOURNAL	Patent: WO 019524-A 2453 06-DEC-2001; Aeonica, Inc. (US)

```
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"
```

Query Match	0.2%	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No. 1.4e+02;		
Matches 15; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0

QY	246	CCCAATGCTGGCTTGA	262
Db	1	CCAGATGCTGGCTGA	17

RESULT 107		
CO617714		
LOCUS	17 bp	DNA
CO617714		
DEFINITION	Sequence 2454 from Patent WO0195524.	linear
		PAT 02-FEB-2004

VERSION CQ617714.1 GI:41667932

SOURCE	ORGANISM
Homo sapiens (human)	Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.	Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

AUTHORS
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.

TITLE
Myosin-like gene expressed in human heart and muscle

JOURNAL
Patent: WO 0192524-A 2454 06-DEC-2001;

FEATURES	Location/Qualifiers
source	1-17

```

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

```

Query Match	0.2%	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No. 1.4e+02;		
Matches 15;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;

QY 247 CCAATGCTGCTGAT 263
 Db 1 CCAGATCTGCTGAT 17

RESULT 108
 LOCUS C0623033 17 bp DNA
 DEFINITION Sequence 7773 from Patent WO0192524.
 ACCSSION C0623033
 VERSION C0623033.1 GI:41673251
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens (human)
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Myosin-like gene expressed in human heart and muscle
 JOURNAL Patent: WO 0192524-A 7773 06-DEC-2001;
 FEATURES location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.24; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.24; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 323 CCGGTCTCAGTGGAG 339
 Db 1 CCAGTGTCCGATGGAG 17

RESULT 109
 LOCUS AR401816 17 bp DNA
 DEFINITION Sequence 156 from patent US 6623962.
 ACCSSION AR401816
 VERSION AR401816.1 GI:40149266
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Akhtar,S., Fell,P. and McSwigen,J.A.
 TITLE Enzymatic nucleic acid treatment of diseases of conditions related to levels of epidermal growth factor receptors
 JOURNAL Patent: US 6623962-A 156 23-SEP-2003;
 FEATURES location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.24; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.24; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 501 CACATCTCCACCACTG 517
 Db 1 CACATCTCTCTCTCTG 17

RESULT 110
 LOCUS AR458776 17 bp DNA
 DEFINITION Sequence 2453 from patent US 6686188.
 ACCSSION AR458776
 VERSION AR458776.1 GI:42693833
 KEYWORDS

SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 JOURNAL Patent: US 6686188-A 2453 03-FEB-2004;
 FEATURES location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.24; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.24; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 246 CCCAATGCTGCTGCA 262
 Db 1 CCAGATCTGCTGCA 17

RESULT 111
 LOCUS AR458777 17 bp DNA
 DEFINITION Sequence 2454 from patent US 6686188.
 ACCSSION AR458777
 VERSION AR458777.1 GI:42693834
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 JOURNAL Patent: US 6686188-A 2454 03-FEB-2004;
 FEATURES location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.24; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.24; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 247 CCAATGCTGCTGAT 263
 Db 1 CCAGATCTGCTGAT 17

RESULT 112
 LOCUS AR464096 17 bp DNA
 DEFINITION Sequence 7773 from patent US 6686188.
 ACCSSION AR464096
 VERSION AR464096.1 GI:42699153
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 JOURNAL Patent: US 6686188-A 7773 03-FEB-2004;
 FEATURES location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="genomic DNA"

AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
JOURNAL Patent: WO 03040369-A 3060 15-MAY-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 248 CAAATGCTGCTTGATC 264
DB 17 CAAAGCTCGCTTGATC 1

RESULT 118
AX926745/c 17 bp DNA linear PAT 19-DEC-2003
LOCUS Sequence 28 from Patent WO03085133.
DEFINITION AX926745
ACCESSION AX926745
VERSION AX926745.1 GI:40247085
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Negaraju, J.G.
TITLE Novel fiber-pcr primers and method of identifying genotyping diverse genomes of plant and animal systems including rice varieties, a kit thereof
JOURNAL Patent: WO 03085133-A 28 16-OCT-2003;
FEATURES Centre for DNA Fingerprinting and Diagnostics, Centre for the Department of Biotechnology, Ministry of Science & Technology (IN)
source Location/Qualifiers
1.17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="A novel FISSR-PCR primer for genotyping eukaryotes"

Query Match 0.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 62 TGGTTCCTTCTACTTCTT 78
DB 17 TAGTTCCTTCTTCTTCTT 1

RESULT 119
BD067316 17 bp RNA linear PAT 27-AUG-2002
LOCUS Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors.
ACCESSION BD067316
DEFINITION BD067316.1 GI:22612919
ACCESSION BD067316
VERSION BD067316.1 GI:22612919
KEYWORDS JP 2001511003-A/156.
SOURCE unclassified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar, S., Feli, P. and McSwiggen, J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 156 07-AUG-2001;
COMMENT RIBOZYME PHARMACEUTICALS INC, ASTON UNIV
OS Unidentified

PN JP 2001511003-A/156
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476-04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR, PATRICIA FELL, JAMES A MCSWIGGEN PC
C12N9/00, C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
CC levels of epidermal growth factor receptors
FH Key location/Qualifiers
FT source 1.17
/organism="Unidentified".
FEATURES Location/Qualifiers
1.17
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match 0.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 501 CACATCTCCACCACTG 517
DB 1 CACATCTCTCTCTCTG 17

RESULT 120
AR096845/c 18 bp DNA linear PAT 08-SEP-2000
LOCUS AR096845
DEFINITION Sequence 43 from patent US 6008344.
ACCESSION AR096845
VERSION AR096845.1 GI:10026010
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett, C. Frank, and Cowsett, L.M.
TITLE Antisense modulation of phospholipase A2 group IV expression
JOURNAL Patent: US 6008344-A 43 28-DEC-1999;
FEATURES Location/Qualifiers
1.18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 457 GGGGTGCGAGGTGCTA 473
DB 18 GGGCTGAAGGAGTGCTA 2

RESULT 121
A98763 15 bp DNA linear PAT 26-JAN-2000
LOCUS A98763
DEFINITION Sequence 1 from Patent WO9910362.
ACCESSION A98763
VERSION A98763.1 GI:6781785
KEYWORDS
SOURCE unclassified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 15)
AUTHORS Southern, E.M. and Shepnev, M.S.
TITLE BRANCHED DENDRIMERIC STRUCTURES
JOURNAL Patent: WO 9910362-A 1 04-MAR-1999;
COMMENT SOUTHERN EDWIN MELLOR (GB); ISIS INNOVATION (GE)
FEATURES Location/Qualifiers

source

1. .15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match

Best Local Similarity 0.2%; Score 13.4; DB 1; Length 15;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy

66 TCTTCTACTCTCTTT 80
|||||
1 TCTTCTCTCTTTT 15

Db

RESULT 122

LOCUS 135050 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 18 from patent US 5599706.
ACCESSION 135050
VERSION 135050.1 GI:2088018

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match

Best Local Similarity 0.2%; Score 13.4; DB 1; Length 15;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy

474 CCATGTAATGACGA 488
|||||
1 CCACGTAATGACGA 15

Db

RESULT 123

LOCUS 135051 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 19 from patent US 5599706.
ACCESSION 135051
VERSION 135051.1 GI:2088019

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match

Best Local Similarity 0.2%; Score 13.4; DB 1; Length 15;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy

282 TCCAGATGCTGTGGC 296
|||||
1 TCCAGATCTGTGGC 15

Db

RESULT 124

LOCUS 135052 15 bp DNA linear PAT 13-MAY-1997

DEFINITION Sequence 20 from patent US 5599706.
ACCESSION 135052
VERSION 135052.1 GI:2088020

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match

Best Local Similarity 0.2%; Score 13.4; DB 1; Length 15;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy

297 AGCTCTTATTGTTA 311
|||||
1 AGCCCTTATTGTTA 15

Db

RESULT 125

LOCUS 135053 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 21 from patent US 5599706.
ACCESSION 135053
VERSION 135053.1 GI:2088021

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match

Best Local Similarity 0.2%; Score 13.4; DB 1; Length 15;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy

298 GCTCCTTATTGTAT 312
|||||
1 GCCCCTTATTGTAT 15

Db

RESULT 126

LOCUS 135055 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 23 from patent US 5599706.
ACCESSION 135055
VERSION 135055.1 GI:2088023

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match

Best Local Similarity 0.2%; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 420 GGCTCCTTCGACAA 434
|||||

Db 1 GGCTCCTTCGACAA 15

RESULT 127

135056

LOCUS 135056 15 bp DNA linear PAT 13-MAY-1997

DEFINITION Sequence 24 from patent US 559706.

ACCESSION 135056

VERSION 135056.1 GI:2088024

KEYWORDS

SOURCE

ORGANISM

REFERENCE 1 (bases 1 to 15)

AUTHORS Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.

TITLE Ribozymes targeted to apo(a) mRNA

JOURNAL Patent: US 559706-A 24 04-FEB-1997;

FEATURES Location/Qualifiers

source 1..15

/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 421 GCTCCTTCGACAA 435
|||||

Db 1 GCTCCTTCGACAA 15

RESULT 128

135067

LOCUS 135067 15 bp DNA linear PAT 13-MAY-1997

DEFINITION Sequence 35 from patent US 559706.

ACCESSION 135067

VERSION 135067.1 GI:2088035

KEYWORDS

SOURCE

ORGANISM

REFERENCE 1 (bases 1 to 15)

AUTHORS Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.

TITLE Ribozymes targeted to apo(a) mRNA

JOURNAL Patent: US 559706-A 35 04-FEB-1997;

FEATURES Location/Qualifiers

source 1..15

/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 525 AAGAACTGCCAGC 539
|||||

Db 1 AAGAACTGCCAGC 15

RESULT 129

135077

LOCUS 135077 15 bp DNA linear PAT 13-MAY-1997

DEFINITION Sequence 45 from patent US 559706.

ACCESSION 135077

VERSION 135077.1 GI:2088045

KEYWORDS

SOURCE

ORGANISM

Unclassified.

REFERENCE 1 (bases 1 to 15)

AUTHORS Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.

TITLE Ribozymes targeted to apo(a) mRNA

JOURNAL Patent: US 559706-A 45 04-FEB-1997;

FEATURES Location/Qualifiers

source 1..15

/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 147 GAGTATCGAGGAC 161
|||||

Db 1 GAGTATCGAGGCTC 15

RESULT 130

135089

LOCUS 135089 15 bp DNA linear PAT 13-MAY-1997

DEFINITION Sequence 57 from patent US 559706.

ACCESSION 135089

VERSION 135089.1 GI:2088057

KEYWORDS

SOURCE

ORGANISM

REFERENCE 1 (bases 1 to 15)

AUTHORS Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.

TITLE Ribozymes targeted to apo(a) mRNA

JOURNAL Patent: US 559706-A 57 04-FEB-1997;

FEATURES Location/Qualifiers

source 1..15

/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 171 CACTGTACAGGAAG 185
|||||

Db 1 CACTGTACAGGAAG 15

RESULT 131

135092

LOCUS 135092 15 bp DNA linear PAT 13-MAY-1997

DEFINITION Sequence 60 from patent US 559706.

ACCESSION 135092

VERSION 135092.1 GI:2088060

KEYWORDS

SOURCE

ORGANISM

REFERENCE 1 (bases 1 to 15)

AUTHORS Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.

TITLE Ribozymes targeted to apo(a) mRNA

JOURNAL Patent: US 559706-A 60 04-FEB-1997;

FEATURES Location/Qualifiers

source 1..15

/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 168 CACCACGTGACAGG 182
|||||

Db 1 CACCACGTGACAGG 15

```
RESULT 132
LOCUS      135097
DEFINITION Sequence 65 from patent US 5599706.
ACCESSION  135097
VERSION    135097.1 GI:2088065
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 15)
AUTHORS   Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE     Ribozymes targeted to apo(a) mRNA
JOURNAL   Patent: US 5599706-A 65 04-FEB-1997;
FEATURES
source     1..15
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 15;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 548 CTATGATACACACT 562
Db 1 CTATGATACACACT 15

RESULT 133
LOCUS      135105
DEFINITION Sequence 73 from patent US 5599706.
ACCESSION  135105
VERSION    135105.1 GI:2088073
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 15)
AUTHORS   Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE     Ribozymes targeted to apo(a) mRNA
JOURNAL   Patent: US 5599706-A 73 04-FEB-1997;
FEATURES
source     1..15
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 15;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 500 GCACATCTCCACCA 514
Db 1 GCACATCTCCACCA 15

RESULT 134
LOCUS      135197
DEFINITION Sequence 165 from patent US 5599706.
ACCESSION  135197
VERSION    135197.1 GI:2088165
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 15)
AUTHORS   Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE     Ribozymes targeted to apo(a) mRNA
JOURNAL   Patent: US 5599706-A 165 04-FEB-1997;
FEATURES
Location/Qualifiers
```

```
source
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 15;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 377 CTGCCGTCGCCTC 391
Db 1 CTGCCGTCGCCTC 15

RESULT 135
LOCUS      135198
DEFINITION Sequence 166 from patent US 5599706.
ACCESSION  135198
VERSION    135198.1 GI:2088166
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 15)
AUTHORS   Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE     Ribozymes targeted to apo(a) mRNA
JOURNAL   Patent: US 5599706-A 166 04-FEB-1997;
FEATURES
source     1..15
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 15;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 377 CTGCCGTCGCCTC 391
Db 1 CTGCCGTCGCCTC 15

RESULT 136
LOCUS      135199
DEFINITION Sequence 167 from patent US 5599706.
ACCESSION  135199
VERSION    135199.1 GI:2088167
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 15)
AUTHORS   Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE     Ribozymes targeted to apo(a) mRNA
JOURNAL   Patent: US 5599706-A 167 04-FEB-1997;
FEATURES
source     1..15
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 15;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 377 CTGCCGTCGCCTC 391
Db 1 CTGCCGTCGCCTC 15

RESULT 137
LOCUS      135209
DEFINITION Sequence 177 from patent US 5599706.
```


ACCESSION 135209
VERSION 135209.1 GI:2088177
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 179 04-FEB-1997;
FEATURES
source
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 556 CCACACTCGCATGT 570
Db 1 CCACACTCTCATGT 15

RESULT 138
LOCUS 135210 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 178 from patent US 559706.
ACCESSION 135210
VERSION 135210.1 GI:2088178
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 178 04-FEB-1997;
FEATURES
source
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 556 CCACACTCGCATGT 570
Db 1 CCACACTCTCATGT 15

RESULT 139
LOCUS 135211 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 179 from patent US 559706.
ACCESSION 135211
VERSION 135211.1 GI:2088179
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 179 04-FEB-1997;
FEATURES
source
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 556 CCACACTCGCATGT 570
Db 1 CCACACTCTCATGT 15

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 417 AGAGGCTCCTCCGA 431
Db 1 AGAGGCTCCTCTGA 15

RESULT 140
LOCUS 135212 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 180 from patent US 559706.
ACCESSION 135212
VERSION 135212.1 GI:2088180
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 180 04-FEB-1997;
FEATURES
source
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 417 AGAGGCTCCTCCGA 431
Db 1 AGAGGCTCCTCTGA 15

RESULT 141
LOCUS 135221 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 189 from patent US 559706.
ACCESSION 135221
VERSION 135221.1 GI:2088189
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 189 04-FEB-1997;
FEATURES
source
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 170 CCACTGTCACAGAA 184
Db 1 CCACTGTTACAGAA 15

RESULT 142
LOCUS 135222 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 190 from patent US 559706.
ACCESSION 135222
VERSION 135222.1 GI:2088190
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 190 04-FEB-1997;
FEATURES
source
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

REFERENCE 1 (bases 1 to 15)
 AUTHORS Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
 TITLE Ribozymes targeted to apo(a) mRNA
 JOURNAL Patent: US 5599706-A 190 04-FEB-1997;
 FEATURES Location/Qualifiers
 source 1..15
 /mol_type="unassigned DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 170 CCACTGTCACAGGAA 184
 |||||
 1 CCACTGTCACAGGAA 15

RESULT 143
 135223

LOCUS 135223 15 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 191 from patent US 5599706.
 ACCESSION 135223
 VERSION 135223.1 GI:2088191
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 Unclassified.

REFERENCE 1 (bases 1 to 15)
 AUTHORS Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
 TITLE Ribozymes targeted to apo(a) mRNA
 JOURNAL Patent: US 5599706-A 191 04-FEB-1997;
 FEATURES Location/Qualifiers
 source 1..15
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 170 CCACTGTCACAGGAA 184
 |||||
 1 CCACTGTCACAGGAA 15

RESULT 144
 135224

LOCUS 135224 15 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 192 from patent US 5599706.
 ACCESSION 135224
 VERSION 135224.1 GI:2088192
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 Unclassified.

REFERENCE 1 (bases 1 to 15)
 AUTHORS Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
 TITLE Ribozymes targeted to apo(a) mRNA
 JOURNAL Patent: US 5599706-A 192 04-FEB-1997;
 FEATURES Location/Qualifiers
 source 1..15
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 170 CCACTGTCACAGGAA 184
 |||||
 1 CCACTGTCACAGGAA 15

RESULT 145
 135225

LOCUS 135225 15 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 193 from patent US 5599706.
 ACCESSION 135225
 VERSION 135225.1 GI:2088193
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 Unclassified.

REFERENCE 1 (bases 1 to 15)
 AUTHORS Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
 TITLE Ribozymes targeted to apo(a) mRNA
 JOURNAL Patent: US 5599706-A 193 04-FEB-1997;
 FEATURES Location/Qualifiers
 source 1..15
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 171 CACTGTCACAGAG 185
 |||||
 1 CACTGTCACAGAG 15

RESULT 146
 135239

LOCUS 135239 15 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 207 from patent US 5599706.
 ACCESSION 135239
 VERSION 135239.1 GI:2088207
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 Unclassified.

REFERENCE 1 (bases 1 to 15)
 AUTHORS Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
 TITLE Ribozymes targeted to apo(a) mRNA
 JOURNAL Patent: US 5599706-A 207 04-FEB-1997;
 FEATURES Location/Qualifiers
 source 1..15
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 124 GATGCTACCATGGT 138
 |||||
 1 GATGCTACCATGGT 15

RESULT 147
 135240

LOCUS 135240 15 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 208 from patent US 5599706.
 ACCESSION 135240
 VERSION 135240.1 GI:2088208
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 Unclassified.

REFERENCE 1 (bases 1 to 15)
 AUTHORS Stinchcomb,D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
 TITLE Ribozymes targeted to apo(a) mRNA
 JOURNAL Patent: US 5599706-A 208 04-FEB-1997;
 FEATURES Location/Qualifiers
 source 1..15

```

/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 147 GAGTATCGAGGCAC 161
Db 1 GAGTATCGAGGCTC 15

RESULT 148
LOCUS 135245 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 213 from patent US 5599706.
ACCESSION 135245
VERSION 135245.1 GI:2088213
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 213 04-FEB-1997;
FEATURES
SOURCE
1. .15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 199 TGGTCATCTATGACA 213
Db 1 TGGTCCTCTATGACA 15

RESULT 149
LOCUS 135246 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 214 from patent US 5599706.
ACCESSION 135246
VERSION 135246.1 GI:2088214
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 214 04-FEB-1997;
FEATURES
SOURCE
1. .15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 199 TGGTCATCTATGACA 213
Db 1 TGGTCCTCTATGACA 15

RESULT 150
LOCUS 135247 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 215 from patent US 5599706.
ACCESSION 135247
```

```

VERSION 135247.1 GI:2088215
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 215 04-FEB-1997;
FEATURES
SOURCE
1. .15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 201 GTCATCTATGACACC 215
Db 1 GTCCTCTATGACACC 15

RESULT 151
LOCUS 135255 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 223 from patent US 5599706.
ACCESSION 135255
VERSION 135255.1 GI:2088223
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 223 04-FEB-1997;
FEATURES
SOURCE
1. .15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 421 GCTCCTTCGACACA 435
Db 1 GCTCCTTCGACACA 15

RESULT 152
LOCUS 135260 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 228 from patent US 5599706.
ACCESSION 135260
VERSION 135260.1 GI:2088228
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 228 04-FEB-1997;
FEATURES
SOURCE
1. .15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 421 GCTCCTTCGACACA 435
Db 1 GCTCCTTCGACACA 15
```

QY 199 TGGTCATCATGACA 213
 Db 1 TGGTCATCATGATA 15

RESULT 153
 135261

LOCUS 135261 15 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 229 from patent US 5599706.
 ACCESSION 135261
 VERSION 135261.1 GI:2088229
 KEYWORDS

SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)
 AUTHORS Stinchcomb D.T., McSwigen,J., Newton,R.S. and Ramharack,R.
 TITLE Ribozymes targeted to apo(a) mRNA
 JOURNAL Patent: US 5599706-A 229 04-FEB-1997;
 FEATURES Location/Qualifiers
 1..15
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 201 GTCATCATGACACC 215
 Db 1 GTCATCATGATACC 15

RESULT 154
 AR231732

LOCUS AR231732 15 bp DNA linear PAT 20-DEC-2002
 DEFINITION Sequence 1 from patent US 6455071.
 ACCESSION AR231732
 VERSION AR231732.1 GI:27273073
 KEYWORDS

SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)
 AUTHORS Shepelinov,M.S. and Southern,E.M.
 TITLE Branched dendrimeric structures
 JOURNAL Patent: US 6455071-A 1 24-SEP-2002;
 FEATURES Location/Qualifiers
 1..15
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 66 TCTTCTCTCTTT 80
 Db 1 TCTTCTCTCTTT 15

RESULT 155
 AR215229/c

LOCUS AR215229 16 bp DNA linear PAT 10-APR-2003
 DEFINITION Sequence 34 from patent US 6506893.
 ACCESSION AR215229
 VERSION AR215229.1 GI:29708230
 KEYWORDS

SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 16)
 Unclassified.

AUTHORS El Solh,N. and Allignet,J.
 TITLE Polynucleotides and their use for detecting resistance to streptogramin A or to streptogramin B and related compounds
 JOURNAL Patent: US 6506893-A 34 14-UN-2003;
 FEATURES Location/Qualifiers
 1..16
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 16;
 Best Local Similarity 93.3%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 61 GTGGTTCTTCTACT 75
 Db 16 GTGGTTCTTCTACT 2

RESULT 156
 AR339894/c

LOCUS AR339894 16 bp DNA linear PAT 17-AUG-2003
 DEFINITION Sequence 39 from patent US 6570001.
 ACCESSION AR339894
 VERSION AR339894.1 GI:33731113
 KEYWORDS

SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 16)
 AUTHORS Solh,N.E. and Allignet,J.
 TITLE Polynucleotides and their use for detecting resistance to streptogramin A or to streptogramin B and related compounds
 JOURNAL Patent: US 6570001-A 39 27-MAY-2003;
 FEATURES Location/Qualifiers
 1..16
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 16;
 Best Local Similarity 93.3%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 61 GTGGTTCTTCTACT 75
 Db 16 GTGGTTCTTCTACT 2

RESULT 157
 BD231502/c

LOCUS BD231502 17 bp DNA linear PAT 17-JUL-2003
 DEFINITION Chromosome 17q-linked prostate cancer susceptibility gene.
 ACCESSION BD231502
 VERSION BD231502.1 GI:33041272
 KEYWORDS JP 2002529065-A/54.
 SOURCE Homo sapiens (human)

REFERENCE 1 (bases 1 to 17)
 AUTHORS Tavtigian,S.V., Teng,D.H.F., Simard,J. and Rommens,J.M.
 TITLE Chromosome 17q-linked prostate cancer susceptibility gene
 JOURNAL Patent: JP 2002529065-A 54 10-SEP-2002;
 MYRIAD GENETICS INC,THE HOSPITAL FOR SICK CHILDREN
 OS Homo sapiens (human)
 PN JP 2002529065-A/54

PD 10-SEP-2002
 PF 05-NOV-1999 JP 2000581041
 PR 06-NOV-1998 US 60/107468
 PI SPAN V TAVTIGIAN,DAVID H F TENG,JACQUES SIMARD,JOHANNA M PI
 ROMMENS

PC C12N15/09,A61K31/713,A61K38/00,A61K39/395,A61K45/00,A61K46/00,
 PC A61P35/00,
 PC

C07K14/47, C07K16/18, C07K16/44, C12N1/15, C12N1/19, C12N1/21, C12N5/ PC
10, C12P21/02, C12Q1/68, G01N33/15, G01N33/50, G01N33/53, G01N33/566,
PC G01N33/577
PC G01N37/00, C12N15/00, A61K37/02, C12N5/00
CC Chromosome 17q-linked prostate cancer susceptibility gene FH
Key Location/Qualifiers
FT source 1. .17
Location/Qualifiers
1. .17
/organism="Homo sapiens (human)"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 17 CTTTCTGACACTGC 31
15 CTTTCTGACTCTGC 1

RESULT 158
AR349822 17 bp DNA linear PAT 17-AUG-2003
LOCUS AR349822
DEFINITION Sequence 4 from patent US 6586197.
ACCESSION AR349822
VERSION AR349822.1 GI:33750710
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Adang, M. J. and Luo, K.
TITLE Methods and materials for identifying novel pesticide agents
JOURNAL Patent: US 6586197-A 4 01-JUL-2003;
FEATURES
source
Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 470 GCTACCATGTTAATG 484
3 GCTACCATGTTAATG 17

RESULT 159
AX218292/c 17 bp RNA linear PAT 07-SEP-2001
LOCUS AX218292
DEFINITION Sequence 3734 from Patent WO0159103.
ACCESSION AX218292
VERSION AX218292.1 GI:15528353
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., Meswigen, J. and Chowrira, B. M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 3734 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwigen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"

/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.2%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 70 CTTACTCTTTATT 84
15 CTTCTCTTTATT 1

RESULT 160
AX727254/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX727254
DEFINITION Sequence 4941 from Patent WO03025175.
ACCESSION AX727254
VERSION AX727254.1 GI:30506597
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
JOURNAL Patent: WO 03025175-A 4941 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.2%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 351 GACGCAATGCTCAGA 365
17 GACGCAATGCTCAGA 3

RESULT 161
AX729966 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX729966
DEFINITION Sequence 1600 from Patent WO03025175.
ACCESSION AX729966
VERSION AX729966.1 GI:30509309
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
JOURNAL Patent: WO 03025175-A 1600 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 218 ATCACATATATAGGA 232
 Db 2 ATCACATCATAGGA 16

RESULT 162
 LOCUS AX731513 17 bp DNA
 DEFINITION Sequence 3147 from Patent WO03025175.
 ACCESSION AX731513
 VERSION AX731513.1 GI:30510856
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
 AUTHORS Telemann, A., Amson, R. and Tuijthof, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour medicines
 JOURNAL Patent: WO 03025175-A 3147 27-MAR-2003;
 FEATURES Molecular Engines Laboratories (FR)
 source Location/Qualifiers
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match
 Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 75 TCTTTATTTCTGGA 99
 Db 3 TCTTTATTTCTGGA 17

RESULT 163
 LOCUS AR278668 20 bp DNA
 DEFINITION Sequence 6 from patent US 6512161.
 ACCESSION AR278668
 VERSION AR278668.1 GI:29713385
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE Unclassified.
 AUTHORS 1 (bases 1 to 20)
 TITLE Rouy, D., Duverger, N., Emmanuël, F., Deneffe, P., Houdebine, L.-M., Viglietta, C., Rubin, E. M. and Hughes, S. D.
 JOURNAL Transgenic rabbit that expresses a functional human lipoprotein (a)
 FEATURES Patent: US 6512161-A 6 28-JAN-2003;
 source Location/Qualifiers
 1..20
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match
 Best Local Similarity 83.3%; Score 13.2; DB 1; Length 20;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 338 AGTACTGCACCTGACGC 355
 Db 1 AGTACTGCCACCTGACAC 18

RESULT 164
 LOCUS BD130529 20 bp DNA
 DEFINITION Transgenic rabbit expressing functional human lipoprotein (A).
 ACCESSION BD130529
 VERSION BD130529.1 GI:23225474

KEYWORDS JP 200250039-A/6.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
 AUTHORS Rouy, D., Duverger, N., Emmanuël, F., Deneffe, P., Houdebine, L.-M., Viglietta, C., Rubin, E. and Hughes, S. D.
 TITLE Transgenic rabbit expressing functional human lipoprotein (A)
 JOURNAL Patent: JP 200250039-A 6 08-JAN-2002;
 COMMENT AVANTIS PHARMACEUTICALS PRODUCTS INC
 OS Homo sapiens (human)
 PN JP 200250039-A/6
 PD 08-JAN-2002
 PF 08-JAN-1999 JP 2000527627
 PR 08-JAN-1998 US 60/070727
 PI DIDIER ROUY, NICOLAS DUVERGER, FLORENCE EMMANUEL, PATRICE DENEFFE
 PT LOUIS MARIE HOUDEBINE, CELINE VIGLIETTA, EDWARD RUBIN, STEVEN D HUGHES
 PC A01K67/027//C12N15/09, C12N15/00
 CC Transgenic rabbit expressing functional human lipoprotein (A)
 FH Key Location/Qualifiers
 FT source 1..20
 /organism="Homo sapiens (human)".
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

Query Match
 Best Local Similarity 83.3%; Score 13.2; DB 1; Length 20;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 338 AGTACTGCACCTGACGC 355
 Db 1 AGTACTGCCACCTGACAC 18

RESULT 165
 LOCUS AR019429 15 bp DNA
 DEFINITION Sequence 17 from patent US 5783431.
 ACCESSION AR019429
 VERSION AR019429.1 GI:3974543
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE Unclassified.
 AUTHORS 1 (bases 1 to 15)
 TITLE Peterson, T. C., Foster, L. M. and Brian, P.
 JOURNAL Methods for generating and screening novel metabolic pathways
 FEATURES Patent: US 5783431-A 17 21-UTL-1998;
 source Location/Qualifiers
 1..15
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match
 Best Local Similarity 100.0%; Score 13; DB 1; Length 15;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCGG 326
 Db 2 CGAGGATCCCGG 14

RESULT 166
 LOCUS AR156385 15 bp DNA
 DEFINITION Sequence 14 from patent US 6242211.
 ACCESSION AR156385

VERSION AR156385.1 GI:15125089
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 15)
TITLE Peterson,T.C. and Brian,P.
JOURNAL Methods for generating and screening novel metabolic pathways
FEATURES
source
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 314 CGAGGATCCCGG 326
DB 2 CGAGGATCCCGG 14

RESULT 167
BD208609 15 bp RNA linear PAT 17-JUN-2003
LOCUS Enzymatic nucleic acid treatment of diseases or conditions related
DEFINITION to hepatitis C virus infection.
ACCESSION BD208609.1 GI:33018379
VERSION BD208609.1
KEYWORDS JP 2002512791-A/2199.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 15)
AUTHORS Blatt,L., McSwiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
JOURNAL to hepatitis C virus infection
PATENT: JP 2002512791-A 2199 08-MAY-2002;
RIBOZYME PHARMACEUTICALS INC
OS Hepatitis virus (hepatitis C virus)
PN JP 2002512791-A/2199
PD 08-MAY-2002
PR 26-APR-1998 JP 2000545991
PR 27-APR-1998 US 60/083217, 18-SEP-1998 US 60/100842 PR
25-FEB-1999 US 09/257608, 23-MAR-1999 US 09/274553 PI
LAMRENCE BLATT, JAMES A MCSWIGGEN, ELISABETH ROBERTS, PAMELA A PI
PAVCO.
PI DENNIS MACEJAK
PC C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions CC
related to
CC hepatitis C virus infection.
FH key Location/Qualifiers
FT source 1. .15
/organism="Hepatitis virus (hepatitis C FT
virus)"
location/Qualifiers
1. .15
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match 0.2%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 159 CACGACTCCACC 171
DB 3 CACGACTCCACC 15

RESULT 168
I35096 15 bp DNA linear PAT 13-MAY-1997
LOCUS Sequence 64 from patent US 5599706.
DEFINITION
ACCESSION I35096
VERSION I35096.1 GI:2088064
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 15)
TITLE Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
JOURNAL Ribozymes targeted to apo(a) mRNA
PATENT: US 5599706-A 64 04-FEB-1997;
FEATURES
source
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 402 CCCGTTCCAGC 414
DB 1 CCCGTTCCAGC 13

RESULT 169
I35248 15 bp DNA linear PAT 13-MAY-1997
LOCUS Sequence 216 from patent US 5599706.
DEFINITION
ACCESSION I35248
VERSION I35248.1 GI:2088216
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 216 04-FEB-1997;
FEATURES
source
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 579 AGAATCTACCA 591
DB 3 AGAATCTACCA 15

RESULT 170
I35249 15 bp DNA linear PAT 13-MAY-1997
LOCUS Sequence 217 from patent US 5599706.
DEFINITION
ACCESSION I35249
VERSION I35249.1 GI:2088217
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 15)
TITLE Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
JOURNAL Ribozymes targeted to apo(a) mRNA
PATENT: US 5599706-A 217 04-FEB-1997;
FEATURES
source
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

```

/organism="unknown"
/mol_type="unassigned DNA"

Query Match
  0.2%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 579 AGAATACTACCCA 591
DB 3 AGAATACTACCCA 15

RESULT 171
LOCUS AX217415 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 2857 from Patent WO0159103.
ACCESSION AX217415
VERSION AX217415.1 GI:15527476
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt, L., Mcawiggen, J. and Chowitra, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 2857 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
Mcswiggen, James (US) ; Chowitra, Bharat M. (US)
FEATURES
  source
    1..17
      location/Qualifiers
        /organism="synthetic construct"
        /mol_type="unassigned RNA"
        /db_xref="taxon:32630"
        /note="Nucleic Acid"

Query Match
  0.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 73 CTTCTTTTATTTC 85
DB 16 CTTCTTTTATTTC 4

RESULT 172
LOCUS AX613070 24 bp DNA linear PAT 17-FEB-2003
DEFINITION Sequence 4095 from Patent WO02072882.
ACCESSION AX613070
VERSION AX613070.1 GI:28408499
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Cullen, P. and Seedorf, U.
TITLE Coronary chip
JOURNAL Patent: WO 02072882-A 4095 19-SEP-2002;
OGHAM GmbH (DE)
FEATURES
  source
    1..24
      location/Qualifiers
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  0.2%; Score 13; DB 1; Length 24;
Best Local Similarity 76.2%; Pred. No. 3.1e+02;
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 333 GTGGAGTACTGCAACTGAC 353
DB 11 GTGGAGTACTGCAACTGAC 353

```

```

DB 24 GTTGCACTACTCCCATCTGAC 4

RESULT 173
LOCUS AX613071 24 bp DNA linear PAT 17-FEB-2003
DEFINITION Sequence 4096 from Patent WO02072882.
ACCESSION AX613071
VERSION AX613071.1 GI:28408500
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Cullen, P. and Seedorf, U.
TITLE Coronary chip
JOURNAL Patent: WO 02072882-A 4096 19-SEP-2002;
OGHAM GmbH (DE)
FEATURES
  source
    1..24
      location/Qualifiers
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  0.2%; Score 13; DB 1; Length 24;
Best Local Similarity 76.2%; Pred. No. 3.1e+02;
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 333 GTGGAGTACTGCAACTGAC 353
DB 24 GTTGCACTACTCCCATCTGAC 4

RESULT 174
LOCUS A89457 16 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 1605 from Patent WO9833904.
ACCESSION A89457
VERSION A89457.1 GI:6738027
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Brysch, W. and Schlingensiepen, K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 1605 06-AUG-1998;
BIOGHOSTIK GBS (DE); BRYSCH WOLFGANG (DE)
FEATURES
  source
    1..16
      location/Qualifiers
        /organism="unidentified"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32644"

Query Match
  0.2%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 158 GCACGTACTCCACGAC 173
DB 1 GCACGTACTCCATGAC 16

RESULT 175
LOCUS I15374 16 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 342 from patent US 5599706.
ACCESSION I15374
VERSION I15374.1 GI:2088342
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

```


Unclassified.
1 (bases 1 to 16)
REFERENCE Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
AUTHORS
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 342 04-FEB-1997;
FEATURES Location/Qualifiers
source 1.16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 270 CTACTGCGAGATCCA 285
Db 1 CTACTGCCGAATCCA 16

RESULT 176
LOCUS 135377 16 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 345 from patent US 559706.
ACCESSION 135377
VERSION 135377.1 GI:2088345
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 345 04-FEB-1997;
FEATURES Location/Qualifiers
source 1.16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 436 GCACCGACTGAGCAAA 451
Db 1 GCACGTGACTGAGGAAA 16

RESULT 177
LOCUS 135411 16 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 379 from patent US 559706.
ACCESSION 135411
VERSION 135411.1 GI:2088379
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 379 04-FEB-1997;
FEATURES Location/Qualifiers
source 1.16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 377 CTGCGGTGCGGCTCC 392
Db 1 CTGCGGTGCGGCTCC 16

RESULT 178
LOCUS 135416 16 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 384 from patent US 559706.
ACCESSION 135416
VERSION 135416.1 GI:2088384
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 384 04-FEB-1997;
FEATURES Location/Qualifiers
source 1.16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 270 CTACTGCGAGATCCA 285
Db 1 CTACTGCCGAATCCA 16

RESULT 179
LOCUS BD066970 16 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066970
VERSION BD066970.1 GI:22612573
KEYWORDS JP 2001511000-A/1605.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS Schlingensiepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 1605 07-AUG-2001;
COMMENT BIOGENOSTIK GESELLSCHAFT FUR BIOWOLKULARE DIAGNOSTIK MEH
OS Unknown
PN JP 2001511000-A/1605
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 BP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN, WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
FEATURES Location/Qualifiers
source 1.16
/organism="unknown"
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.2%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 158 GCACGTACTCCACCAC 173
Db 1 GCACGTACTCCAGCAC 16

RESULT 180
AR072504

```

LOCUS      AR072504      17 bp      DNA      linear      PAT 28-AUG-2000
DEFINITION Sequence 1 from patent US 5948616.
ACCESSION  AR072504
VERSION    AR072504.1  GI:9999268
KEYWORDS
SOURCE
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Chao,L. and Chao,J.
TITLE      Methods and compositions of correlating tissue kallikrein gene
           promoter polymorphisms with essential hypertension
JOURNAL    Patent: US 5948616-A 1 07-SEP-1999;
FEATURES
SOURCE
           1..17
           /organism="Unknown"
           /mol_type="unassigned DNA"

Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      273  CTGCAGGATCCAGAT 288
Db      1  CTGCAGGATCTAGTT 16

RESULT 181
LOCUS      AR105109      17 bp      DNA      linear      PAT 14-FEB-2001
DEFINITION Sequence 8 from patent US 6096505.
ACCESSION  AR105109
VERSION    AR105109.1  GI:12818706
KEYWORDS
SOURCE
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Selby,M., Thudium,K.B. and Dina,D.
TITLE      Noncloning technique for expressing a gene of interest
JOURNAL    Patent: US 6096505-A 8 01-AUG-2000;
FEATURES
SOURCE
           1..17
           /organism="Unknown"
           /mol_type="unassigned DNA"

Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      318  GGATCCGGGTCTCAGG 333
Db      17  GGATCCGAGAGTCAGG 2

RESULT 182
LOCUS      BD197397      17 bp      RNA      linear      PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning
           molecule participating in vasculogenic response.
ACCESSION  BD197397
VERSION    BD197397.1  GI:33007167
KEYWORDS  JP 2002509721-A/423.
SOURCE
ORGANISM   Homo sapiens (human)
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE      Method and reagent for treating diseases or conditions concerning
           molecule participating in vasculogenic response
JOURNAL    Patent: JP 2002509721-A 423 02-APR-2002;
FEATURES
SOURCE
           1..17
           /organism="Homo sapiens"
           /mol_type="genomic RNA"

COMMENT
OS      Homo sapiens (human)
PN      JP 2002509721-A/423
PD      02-APR-2002
PF      24-MAR-1999  JP 2000541291
PR      27-MAR-1998  US 60/079678
PI      PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI      JAMES A MCSWIGGEN
PC      C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
           A61P29/00,
           PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
           C12N5/00
CC      Method and reagent for treating diseases or conditions CC
           concerning molecule
CC      participating in vasculogenic response
FH      Key
FT      source
FT      1..17
           /organism="Homo sapiens (human)".
           Location/Qualifiers
           1..17
           /organism="Homo sapiens"
           /mol_type="genomic RNA"

FEATURES
SOURCE
           1..17
           /organism="Homo sapiens"
           /mol_type="genomic RNA"

Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      296  CAGCTCCTTATGTGTTA 311
Db      17  CCGCTCCTTATCGTTA 2

RESULT 183
LOCUS      BD197446      17 bp      RNA      linear      PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning
           molecule participating in vasculogenic response.
ACCESSION  BD197446
VERSION    BD197446.1  GI:33007216
KEYWORDS  JP 2002509721-A/472.
SOURCE
ORGANISM   Homo sapiens (human)
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE      Method and reagent for treating diseases or conditions concerning
           molecule participating in vasculogenic response
JOURNAL    Patent: JP 2002509721-A 472 02-APR-2002;
FEATURES
SOURCE
           1..17
           /organism="Homo sapiens"
           /mol_type="genomic RNA"
           /db_xref="taxon:9606"

FEATURES
SOURCE
           1..17
           /organism="Homo sapiens (human)".
           Location/Qualifiers
           1..17
           /organism="Homo sapiens"
           /mol_type="genomic RNA"

```

/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

498 AGGCACATCTCCACC 513
16 AGACACATACACACAC 1

Db

RESULT 184
BD198885/c
LOCUS
DEFINITION BD198885 17 bp RNA linear PAT 17-JUN-2003
Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.
ACCESSION BD198885
VERSION BD198885.1 GI:33008655
KEYWORDS JP 2002509721-A/1911.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswigen,J.A.
TITLE 1 (bases 1 to 17)
JOURNAL Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
Patent: JP 2002509721-A 1911 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/1911
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGEN
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
FT Location/Qualifiers
1..17
/organism="Homo sapiens (human)".
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

FEATURES
source

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

214 CCACATCAACATATA 229
16 CCACCTCAACATATAA 1

Db

RESULT 185
BD198936
LOCUS
DEFINITION BD198936 17 bp RNA linear PAT 17-JUN-2003
Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.
ACCESSION BD198936
VERSION BD198936.1 GI:33008706
KEYWORDS JP 2002509721-A/1962.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswigen,J.A.
TITLE 1 (bases 1 to 17)
JOURNAL Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
Patent: JP 2002509721-A 1962 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/1962
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGEN
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions concerning molecule
CC participating in vasculogenic response

REFERENCE
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE 1 (bases 1 to 17)
JOURNAL Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswigen,J.A.
Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
Patent: JP 2002509721-A 1962 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/1962
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGEN
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions concerning molecule
CC participating in vasculogenic response

FEATURES
source

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

68 TTCTACTCTTTTATT 83
2 TTCTATTCTTCTATT 17

Db

RESULT 186
BD198937
LOCUS
DEFINITION BD198937 17 bp RNA linear PAT 17-JUN-2003
Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.
ACCESSION BD198937
VERSION BD198937.1 GI:33008707
KEYWORDS JP 2002509721-A/1963.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE 1 (bases 1 to 17)
JOURNAL Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswigen,J.A.
Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
Patent: JP 2002509721-A 1963 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/1963
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGEN
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions concerning molecule
CC participating in vasculogenic response

FEATURES
source
FH Key Location/Qualifiers
FT source 1..17 /organism='Homo sapiens (human)'.
1..17 Location/Qualifiers
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 68 TTCTACTTCTTTATT 83
Db 1 TTCTATTCTTCTATT 16

RESULT 187
BD225508/c 17 bp DNA linear PAT 17-JUL-2003
LOCUS BD225508 Noncloning technique for expressing a gene of interest.
DEFINITION BD225508
ACCESSION BD225508.1 GI:33035278
VERSION JP 2002511257-A/8.
KEYWORDS JP 2002511257-A/8.
SOURCE synthetic construct
ORGANISM artificial construct
REFERENCE 1 (bases 1 to 17)
AUTHORS Selby, M., Thudium, K. and Dina, D.
TITLE Noncloning technique for expressing a gene of interest
JOURNAL Patent: JP 2002511257-A 8 16-APR-2002;
CHIRON CORP

COMMENT
OS Artificial Sequence
PN JP 2002511257-A/8
PD 16-APR-2002
PF 13-APR-1999 JP 2000543594
PR 14-APR-1998 US 60/081777
PI MARK SELBY, KENT THUDIUM, DINO DINA
PC C12N15/09, C12N5/10, C12P21/02//C07K14/07, C12N15/00, C12N5/00 CC
Description of Artificial Sequence: CMVp-pres2 RT-PCR primer CC 127

FEATURES
source
FH Key Location/Qualifiers
FT source 1..17 /organism='Artificial Sequence'.
1..17 Location/Qualifiers
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 318 GGATCCCGGTGTCAGG 333
Db 17 GGATCCGAGATCAGG 2

RESULT 188
BD241280 17 bp DNA linear PAT 17-JUL-2003
LOCUS BD241280 Methods and products related to genotyping and DNA analysis.
DEFINITION BD241280
ACCESSION BD241280.1 GI:33051050
VERSION JP 2002525127-A/227.
KEYWORDS JP 2002525127-A/227.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 17)
AUTHORS Landers, J.E., Jordan, B., Housman, D.E. and Charest, A.

TITLE Methods and products related to genotyping and DNA analysis
JOURNAL Patent: JP 2002525127-A 227 13-AUG-2002;
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT
OS Homo sapiens (human)
PN JP 2002525127-A/227
PD 13-AUG-2002
PF 24-SEP-1999 JP 2000572407
PR 25-SEP-1998 US 60/101757
PI JOHN E LANDERS, BARBARA JORDAN, DAVID E HOUSMAN, ALAIN CHAREST PC
C12N15/09, C12O1/68, G01N33/53, G01N33/566, G01N33/58, G01N37/00, PC
G01N37/00, PC
C12N15/00
CC Methods and products related to genotyping and DNA analysis FH

FEATURES
source
FH Key Location/Qualifiers
FT source 1..17 /organism='Homo sapiens (human)'.
1..17 Location/Qualifiers
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 208 ATGACACCCACATCAAC 223
Db 1 ATGACACCCACACCAAC 16

RESULT 189
BD257751/c 17 bp DNA linear PAT 17-JUL-2003
LOCUS BD257751 Regulation of repressor genes using nucleic acid molecules.
DEFINITION BD257751
ACCESSION BD257751.1 GI:33067521
VERSION JP 2002541795-A/5544.
KEYWORDS JP 2002541795-A/5544.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt, L., Zwick, M., Payco, P. and Mcswiggen, J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 5544 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC

COMMENT
OS Eukaryote
PN JP 2002541795-A/5544
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAYCO, JAMES MCSWIGGEN PC
C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02, PC
C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02
CC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH

FEATURES
source
FH Key Location/Qualifiers
FT source 1..17 /organism='Eukaryote'.
1..17 Location/Qualifiers
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 72 ACTCTTTTATTCG 87
 Db 17 AATCTTTATTTTG 2

RESULT 190
 LOCUS CO616418 17 bp DNA linear PAT 02-FEB-2004
 DEFINITION Sequence 1158 from Patent WO0192524.
 VERSION CO616418
 ACCESSION CO616418.1 GI:41666636
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens (human)
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Myosin-like gene expressed in human heart and muscle
 JOURNAL Patent: WO 0192524-A 1158 06-DEC-2001;
 Aeomica, Inc. (US)
 FEATURES location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 569 GTCCGACCCGAGATA 584
 Db 2 GACCGTCCCGAGATA 17

RESULT 191
 LOCUS CO616419 17 bp DNA linear PAT 02-FEB-2004
 DEFINITION Sequence 1159 from Patent WO0192524.
 VERSION CO616419
 ACCESSION CO616419.1 GI:41666637
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens (human)
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Myosin-like gene expressed in human heart and muscle
 JOURNAL Patent: WO 0192524-A 1159 06-DEC-2001;
 Aeomica, Inc. (US)
 FEATURES location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 569 GTCCGACCCGAGATA 584
 Db 1 GACCGTCCCGAGATA 16

RESULT 192
 LOCUS CO617712 17 bp DNA linear PAT 02-FEB-2004

DEFINITION Sequence 2452 from Patent WO0192524.
 LOCUS CO617712
 VERSION CO617712.1 GI:41667930
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens (human)
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Myosin-like gene expressed in human heart and muscle
 JOURNAL Patent: WO 0192524-A 2452 06-DEC-2001;
 Aeomica, Inc. (US)
 FEATURES location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 246 CCCAATGCTGCTTG 261
 Db 2 CCCAATGCTGCTTG 17

RESULT 193
 LOCUS CO617715 17 bp DNA linear PAT 02-FEB-2004
 DEFINITION Sequence 2455 from Patent WO0192524.
 VERSION CO617715
 ACCESSION CO617715.1 GI:41667933
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens (human)
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Myosin-like gene expressed in human heart and muscle
 JOURNAL Patent: WO 0192524-A 2455 06-DEC-2001;
 Aeomica, Inc. (US)
 FEATURES location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 248 CAAATGCTGCTGAT 263
 Db 1 CAAATGCTGCTGAT 16

RESULT 194
 LOCUS CO622788 17 bp DNA linear PAT 02-FEB-2004
 DEFINITION Sequence 7528 from Patent WO0192524.
 VERSION CO622788
 ACCESSION CO622788.1 GI:41673006
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens (human)
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1

AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Myosin-like gene expressed in human heart and muscle
 JOURNAL Patent: WO 0192524-A 7528 06-DEC-2001;
 Aeomica, Inc. (US)

FEATURES
 source location/Qualifiers
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 445 GAGCAAAAGCCTGGGG 460
 |||||
 2 GAGCAAAAGCCTGGGG 17

RESULT 195

LOCUS CQ622789 17 bp DNA linear PAT 02-FEB-2004
 DEFINITION Sequence 7529 from Patent WO0192524.
 ACCESSION CQ622789
 VERSION CQ622789.1 GI:41673007
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Myosin-like gene expressed in human heart and muscle
 JOURNAL Patent: WO 0192524-A 7529 06-DEC-2001;
 Aeomica, Inc. (US)

FEATURES
 source location/Qualifiers
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 445 GAGCAAAAGCCTGGGG 460
 |||||
 1 GAGCAAAAGCCTGGGG 16

RESULT 196
 LOCUS CQ622936 17 bp DNA linear PAT 02-FEB-2004
 DEFINITION Sequence 7676 from Patent WO0192524.
 ACCESSION CQ622936
 VERSION CQ622936.1 GI:41673154
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Myosin-like gene expressed in human heart and muscle
 JOURNAL Patent: WO 0192524-A 7676 06-DEC-2001;
 Aeomica, Inc. (US)

FEATURES
 source location/Qualifiers
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 65 TTCTTCTACTTCTTT 80
 |||||
 17 TTCTTCTGCTTCTTCT 2

RESULT 197
 LOCUS CQ622937 17 bp DNA linear PAT 02-FEB-2004
 DEFINITION Sequence 7677 from Patent WO0192524.
 ACCESSION CQ622937
 VERSION CQ622937.1 GI:41673155
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Myosin-like gene expressed in human heart and muscle
 JOURNAL Patent: WO 0192524-A 7677 06-DEC-2001;
 Aeomica, Inc. (US)

FEATURES
 source location/Qualifiers
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 65 TTCTTCTACTTCTTT 80
 |||||
 16 TTCTTCTGCTTCTTCT 1

RESULT 198
 LOCUS CQ623032 17 bp DNA linear PAT 02-FEB-2004
 DEFINITION Sequence 7772 from Patent WO0192524.
 ACCESSION CQ623032
 VERSION CQ623032.1 GI:41673250
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Myosin-like gene expressed in human heart and muscle
 JOURNAL Patent: WO 0192524-A 7772 06-DEC-2001;
 Aeomica, Inc. (US)

FEATURES
 source location/Qualifiers
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 323 CCGGTGTCAGGTGGGA 338
 |||||
 2 CCAAGTCCGAGTGGGA 17

RESULT 199
LOCUS CO623034 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7774 from Patent WO0192524.
ACCESSION CO623034
VERSION CO623034.1 GI:41673252
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7774 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 324 CGGTGTCAGGTGGAG 339
Db 1 CAGTGTCCGTTGGAG 16
RESULT 200
LOCUS CO623683 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8423 from Patent WO0192524.
ACCESSION CO623683
VERSION CO623683.1 GI:41673901
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8423 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 363 AGACGACGAAGGACT 378
Db 2 AGACGACGAAGGACT 17
RESULT 201
LOCUS CO623684 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8424 from Patent WO0192524.
ACCESSION CO623684
VERSION CO623684.1 GI:41673902
KEYWORDS

SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8424 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 363 AGACGACGAAGGACT 378
Db 1 AGACGACGAAGGACT 16
RESULT 202
LOCUS CO623952 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8692 from Patent WO0192524.
ACCESSION CO623952
VERSION CO623952.1 GI:41674170
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8692 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 264 CATGAACACTGCAGG 279
Db 2 CAAGAACACTGCAGG 17
RESULT 203
LOCUS CO623953 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8693 from Patent WO0192524.
ACCESSION CO623953
VERSION CO623953.1 GI:41674171
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8693 06-DEC-2001;

```

FEATURES
  source
    Aeomica, Inc. (US)
    Location/Qualifiers
      1..117
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  0.2%; Score 12.8; DB 1; Length 17;
  Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 264 CATGAAGTCTGCGAG 279
  |||||
  1 CAGAACAACACTGCAGG 16

RESULT 204
LOCUS C0625373 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10113 from Patent WO0192524.
ACCESSION C0625373
VERSION C0625373.1 GI:41675591
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
  1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
  Shannon,M.E.
  Myosin-like gene expressed in human heart and muscle
  Patent: WO 0192524-A 10113 06-DEC-2001;
  Aeomica, Inc. (US)
  Location/Qualifiers
    1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  0.2%; Score 12.8; DB 1; Length 17;
  Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 413 GCCTAGAGGCTCCTTC 428
  |||||
  17 GCCTAGAGGCTCCTTC 2

Db 17 GCCTAGAGGCTCCTTC 2

RESULT 205
LOCUS C0625374 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10114 from Patent WO0192524.
ACCESSION C0625374
VERSION C0625374.1 GI:41675592
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
  1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
  Shannon,M.E.
  Myosin-like gene expressed in human heart and muscle
  Patent: WO 0192524-A 10114 06-DEC-2001;
  Aeomica, Inc. (US)
  Location/Qualifiers
    1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  0.2%; Score 12.8; DB 1; Length 17;
  Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Query Match
  0.2%; Score 12.8; DB 1; Length 17;
  Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 413 GCCTAGAGGCTCCTTC 428
  |||||
  16 GCCTAGAGGCTCCTTC 1

Db 16 GCCTAGAGGCTCCTTC 1

RESULT 206
LOCUS I37621 17 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 634 from patent US 5612215.
ACCESSION I37621
VERSION I37621.1 GI:2085581
KEYWORDS
SOURCE Unknown.
ORGANISM
  Unclassified.
REFERENCE
  1 (bases 1 to 17)
  Draper,K.G., Pavco,P., McSwigen,J., Gustofson,J. and
  Stinchcomb,D.T.
  Stromelysin targeted ribozymes
  Patent: US 5612215-A 634 18-MAR-1997;
  Location/Qualifiers
    1..17
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  0.2%; Score 12.8; DB 1; Length 17;
  Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 63 GGTTCTTCTACTTCTT 78
  |||||
  2 GGTTTCTTCTTCTT 17

Db 2 GGTTTCTTCTTCTT 17

RESULT 207
LOCUS I94471 17 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 634 from patent US 5731295.
ACCESSION I94471
VERSION I94471.1 GI:3938941
KEYWORDS
SOURCE Unknown.
ORGANISM
  Unclassified.
REFERENCE
  1 (bases 1 to 17)
  Draper,K.G., Pavco,P., McSwigen,J., Gustofson,J. and
  Stinchcomb,D.T.
  Method of reducing stromelysin RNA via ribozymes
  Patent: US 5731295-A 634 24-MAR-1998;
  Location/Qualifiers
    1..17
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  0.2%; Score 12.8; DB 1; Length 17;
  Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 63 GGTTCTTCTACTTCTT 78
  |||||
  2 GGTTTCTTCTTCTT 17

Db 2 GGTTTCTTCTTCTT 17

RESULT 208
LOCUS AR187057 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 2545 from patent US 6346398.
ACCESSION AR187057
VERSION AR187057.1 GI:20233022
KEYWORDS
SOURCE Unknown.

```



```

ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL Patent: US 6346398-A 2545 12-FEB-2002;
FEATURES
    source
        location/Qualifiers
            1..17
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 69 TCTACTCTTTTATT 84
Db 2 TCTACTTTTATTTT 17

RESULT 209
LOCUS AR187058 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 2546 from patent US 6346398.
ACCESSION AR187058
VERSION AR187058.1 GI:20233023
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL Patent: US 6346398-A 2546 12-FEB-2002;
FEATURES
    source
        location/Qualifiers
            1..17
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 69 TCTACTCTTTTATT 84
Db 1 TCTACTTTTATTTT 16

RESULT 210
LOCUS AR323667 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 1069 from patent US 6566127.
ACCESSION AR323667
VERSION AR323667.1 GI:33709475
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL Patent: US 6566127-A 1069 20-MAY-2003;
FEATURES
    source
        location/Qualifiers
            1..17
                /organism="unknown"
                /mol_type="unassigned RNA"

Query Match
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 69 TCTACTCTTTTATT 84
Db 1 TCTACTTTTATTTT 16

RESULT 211
LOCUS AR323668 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 1070 from patent US 6566127.
ACCESSION AR323668
VERSION AR323668.1 GI:33709476
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL Patent: US 6566127-A 1070 20-MAY-2003;
FEATURES
    source
        location/Qualifiers
            1..17
                /organism="unknown"
                /mol_type="unassigned RNA"

Query Match
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 69 TCTACTCTTTTATT 84
Db 1 TCTACTTTTATTTT 16

RESULT 212
LOCUS AR329195/c 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6597 from patent US 6566127.
ACCESSION AR329195
VERSION AR329195.1 GI:33715003
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL Patent: US 6566127-A 6597 20-MAY-2003;
FEATURES
    source
        location/Qualifiers
            1..17
                /organism="unknown"
                /mol_type="unassigned RNA"

Query Match
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 52 CATAGGAGTGGTTC 67
Db 17 CATAGGAGTGGTTC 2

RESULT 213
LOCUS AR367731 17 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 1 from patent US 6376182.
ACCESSION AR367731
VERSION AR367731.1 GI:34601110
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

```

```

Qy 69 TCTACTCTTTTATT 84
Db 2 TCTACTTTTATTTT 17

RESULT 211
LOCUS AR323668 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 1070 from patent US 6566127.
ACCESSION AR323668
VERSION AR323668.1 GI:33709476
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL Patent: US 6566127-A 1070 20-MAY-2003;
FEATURES
    source
        location/Qualifiers
            1..17
                /organism="unknown"
                /mol_type="unassigned RNA"

Query Match
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 69 TCTACTCTTTTATT 84
Db 1 TCTACTTTTATTTT 16

RESULT 212
LOCUS AR329195/c 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6597 from patent US 6566127.
ACCESSION AR329195
VERSION AR329195.1 GI:33715003
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL Patent: US 6566127-A 6597 20-MAY-2003;
FEATURES
    source
        location/Qualifiers
            1..17
                /organism="unknown"
                /mol_type="unassigned RNA"

Query Match
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 52 CATAGGAGTGGTTC 67
Db 17 CATAGGAGTGGTTC 2

RESULT 213
LOCUS AR367731 17 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 1 from patent US 6376182.
ACCESSION AR367731
VERSION AR367731.1 GI:34601110
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

```

Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Chao,L., Chao,J. and Song,Q.
TITLE Methods and compositions for correlating tissue kallikrein gene promoter polymorphisms with treatment of essential hypertension
JOURNAL Patent: US 6376182-A 1 23-APR-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 273 CTCGAGGATCCAGAT 288
Db 1 CTCGAGGATCTAGTT 16

RESULT 214
AR457481 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 1158 from patent US 6686188.
DEFINITION AR457481
ACCESSION AR457481.1 GI:42692538
VERSION
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1158 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 569 GTCGACCCGAGATA 584
Db 2 GACGCTCCCGAGATA 17

RESULT 215
AR457482 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 1159 from patent US 6686188.
DEFINITION AR457482
ACCESSION AR457482
VERSION AR457482.1 GI:42692539
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1159 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 569 GTCGACCCGAGATA 584
Db 1 GACGCTCCCGAGATA 16

RESULT 216
AR458775 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 2452 from patent US 6686188.
DEFINITION AR458775
ACCESSION AR458775
VERSION AR458775.1 GI:42693832
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2452 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 246 CCCAATGCTGCTGG 261
Db 2 CCCAATGCTGCTGG 17

RESULT 217
AR458778 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 2455 from patent US 6686188.
DEFINITION AR458778
ACCESSION AR458778
VERSION AR458778.1 GI:42693835
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2455 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 248 CAAATGCTGCTGAT 263
Db 1 CAAATGCTGCTGAT 16

RESULT 218
AR463851 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 7528 from patent US 6686188.
DEFINITION AR463851
ACCESSION AR463851
VERSION AR463851.1 GI:42698908

KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7528 03-FEB-2004;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 445 GAGCAAGCGCTGGGG 460
Db 2 GAGCAAAAGCTTGGGG 17

RESULT 219
AR463852 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 7529 from patent US 6686188.
DEFINITION AR463852
ACCESSION AR463852
VERSION AR463852.1 GI:42698909
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7529 03-FEB-2004;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 445 GAGCAAGCGCTGGGG 460
Db 1 GAGCAAAAGCTTGGGG 16

RESULT 220
AR463999/c 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 7676 from patent US 6686188.
DEFINITION AR463999
ACCESSION AR463999
VERSION AR463999.1 GI:42699056
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7676 03-FEB-2004;
FEATURES Location/Qualifiers
1..17
/organism="unknown"

/mol_type="genomic DNA"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 65 TTCTTCTACTTCTTT 80
Db 17 TTCTTCTGCTTCTTCT 2

RESULT 221
AR464000/c 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 7677 from patent US 6686188.
DEFINITION AR464000
ACCESSION AR464000
VERSION AR464000.1 GI:42699057
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7677 03-FEB-2004;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 65 TTCTTCTACTTCTTT 80
Db 16 TTCTTCTGCTTCTTCT 1

RESULT 222
AR464095 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 7772 from patent US 6686188.
DEFINITION AR464095
ACCESSION AR464095
VERSION AR464095.1 GI:42699152
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7772 03-FEB-2004;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 323 CCGGTGTCAGTGGGA 338
Db 2 CCACTGCCGTGGGA 17

RESULT 223
AR464097

```

LOCUS      AR464097      17 bp      DNA      linear      PAT 20-FEB-2004
DEFINITION Sequence 7774 from patent US 6686188.
ACCESSION  AR464097
VERSION     AR464097.1  GI:42699154
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL     Patent: US 6686188-A 7774 03-FEB-2004;
FEATURES
source      1..17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      324  CGGTGTCAGTGGAG 339
Db      1  CAGTGTCCGTGGAG 16

RESULT 224
LOCUS      AR464746      17 bp      DNA      linear      PAT 20-FEB-2004
DEFINITION Sequence 8423 from patent US 6686188.
ACCESSION  AR464746
VERSION     AR464746.1  GI:42699803
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL     Patent: US 6686188-A 8423 03-FEB-2004;
FEATURES
source      1..17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      363  AGACGCAAGAGGACT 378
Db      2  AGACGCAAGAGTGCT 17

RESULT 225
LOCUS      AR464747      17 bp      DNA      linear      PAT 20-FEB-2004
DEFINITION Sequence 8424 from patent US 6686188.
ACCESSION  AR464747
VERSION     AR464747.1  GI:42699804
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle

```

```

JOURNAL     Patent: US 6686188-A 8424 03-FEB-2004;
FEATURES
source      1..17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      363  AGACGCAAGAGGACT 378
Db      1  AGACGCAAGAGTGCT 16

RESULT 226
LOCUS      AR465015      17 bp      DNA      linear      PAT 20-FEB-2004
DEFINITION Sequence 8692 from patent US 6686188.
ACCESSION  AR465015
VERSION     AR465015.1  GI:42700072
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL     Patent: US 6686188-A 8692 03-FEB-2004;
FEATURES
source      1..17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      264  CATGAACACTGCAGG 279
Db      2  CAAGAACAACCTGCAGG 17

RESULT 227
LOCUS      AR465016      17 bp      DNA      linear      PAT 20-FEB-2004
DEFINITION Sequence 8693 from patent US 6686188.
ACCESSION  AR465016
VERSION     AR465016.1  GI:42700073
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL     Patent: US 6686188-A 8693 03-FEB-2004;
FEATURES
source      1..17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      264  CATGAACACTGCAGG 279
Db      1  CAAGAACAACCTGCAGG 16

```

RESULT 228
AR466436/c 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR466436
DEFINITION Sequence 10113 from patent US 6686188.
ACCESSION AR466436
VERSION AR466436.1 GI:42701493
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10113 03-FEB-2004;
FEATURES
source 1. 17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 413 GCCTAGAGGCTCCTTC 428
Db 17 GCCTAGAGGCTCCTCC 2

RESULT 229
AR466437/c 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR466437
DEFINITION Sequence 10114 from patent US 6686188.
ACCESSION AR466437
VERSION AR466437.1 GI:42701494
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10114 03-FEB-2004;
FEATURES
source 1. 17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 413 GCCTAGAGGCTCCTTC 428
Db 16 GCCTAGAGGCTCCTCC 1

RESULT 230
AR482781 17 bp DNA linear PAT 14-MAY-2004
LOCUS AR482781
DEFINITION Sequence 227 from patent US 6703228.
ACCESSION AR482781
VERSION AR482781.1 GI:47245304
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
Unclassified.

AUTHORS Landers,J., Jordan,B., Housman,D.E. and Charest,A.
TITLE Methods and products related to genotyping and DNA analysis
JOURNAL Patent: US 6703228-A 227 09-MAR-2004;
FEATURES
source 1. 17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 208 ATGACACACACATCAAC 223
Db 1 ATGACACACACACACAC 16

RESULT 231
AX214883/c 17 bp RNA linear PAT 07-SEP-2001
LOCUS AX214883
DEFINITION Sequence 325 from Patent WO0159103.
ACCESSION AX214883
VERSION AX214883.1 GI:15524926
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Blatt,L., McSwiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 325 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source 1. 17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 73 CTTCCTTATTCTGA 88
Db 16 CTTCCTTATTCTGA 1

RESULT 232
AX215515/c 17 bp RNA linear PAT 07-SEP-2001
LOCUS AX215515
DEFINITION Sequence 957 from Patent WO0159103.
ACCESSION AX215515
VERSION AX215515.1 GI:15525558
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Blatt,L., McSwiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 957 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source 1. 17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 359 GCTCAGAGCGAGG 374
|||||
Db 16 GCTCAGATGAGCAGG 1

RESULT 233
AX216730/c
LOCUS AX216730 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 2172 from Patent W00159103.
ACCESSION AX216730
VERSION AX216730.1 GI:15526791
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 2172 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source location/Qualifiers
1. 17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 65 TTCTTCTACTTCTTT 80
|||||
Db 17 TTCTTCTATTTT 2

RESULT 234
AX217033
LOCUS AX217033 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 2475 from Patent W00159103.
ACCESSION AX217033
VERSION AX217033.1 GI:15527094
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. 17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Blatt, L., McSwiggen, J. and Chowrira, B. M.
Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
PATENT: WO 0159103-A 2475 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source location/Qualifiers
1. 17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 2 TGCAGTGGAGCTCCT 17

RESULT 235
AX421728
LOCUS AX421728 17 bp RNA linear PAT 18-JUN-2002
DEFINITION Sequence 64 from Patent W00188124.
ACCESSION AX421728
VERSION AX421728.1 GI:21525110
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. 17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Jarvis, T., von Carlwiltz, I., McSwiggen, J. A., McLaughlin, F. G. and
Randi, A. M.
Method and reagent for the inhibition of erg
PATENT: WO 0188124-A 64 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source location/Qualifiers
1. 17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 145 CAGAGTTATCGAGCA 160
|||||
Db 2 CAGAGTTATCGTCCA 17

RESULT 236
AX423741
LOCUS AX423741 17 bp RNA linear PAT 18-JUN-2002
DEFINITION Sequence 2077 from Patent W00188124.
ACCESSION AX423741
VERSION AX423741.1 GI:21527123
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. 17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
Jarvis, T., von Carlwiltz, I., McSwiggen, J. A., McLaughlin, F. G. and
Randi, A. M.
Method and reagent for the inhibition of erg
PATENT: WO 0188124-A 2077 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source location/Qualifiers
1. 17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 77 TTTTATTTTCGAATC 92
|||||
Db 17 TTTTGTTCGAATC 2

RESULT 237
AX475319/c
LOCUS AX475319 17 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 540 from Patent W00224750.
ACCESSION AX475319
VERSION AX475319.1 GI:22214604

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 542 28-MAR-2002;
Aeomica, Inc. (US)

FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 413 GCCTAGAGGCTCTTC 428
|||||
17 GCCTGAGAGCTCTGC 2

RESULT 238
AX475320/c 17 bp DNA linear PAT 12-AUG-2002
LOCUS
DEFINITION Sequence 541 from Patent WO0224750.
ACCESSION AX475320
VERSION AX475320.1 GI:22214605
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 541 28-MAR-2002;
Aeomica, Inc. (US)

FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 413 GCCTAGAGGCTCTTC 428
|||||
16 GCCTGAGAGCTCTGC 1

RESULT 239
AX475321/c 17 bp DNA linear PAT 12-AUG-2002
LOCUS
DEFINITION Sequence 542 from Patent WO0224750.
ACCESSION AX475321
VERSION AX475321.1 GI:22214606
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 542 28-MAR-2002;
Aeomica, Inc. (US)

FEATURES
Location/Qualifiers

source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 411 AAGCTTAGAGGCTCTT 426
|||||
17 ATGCCTGAGAGCTCTT 2

RESULT 240
AX475322/c 17 bp DNA linear PAT 12-AUG-2002
LOCUS
DEFINITION Sequence 543 from Patent WO0224750.
ACCESSION AX475322
VERSION AX475322.1 GI:22214607
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 543 28-MAR-2002;
Aeomica, Inc. (US)

FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 411 AAGCTTAGAGGCTCTT 426
|||||
16 ATGCCTGAGAGCTCTT 1

RESULT 241
AX531296/c 17 bp DNA linear PAT 22-NOV-2002
LOCUS
DEFINITION Sequence 805 from Patent EP1239051.
ACCESSION AX531296
VERSION AX531296.1 GI:25254378
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Shannon, M.
TITLE Human poxh-like protein 1
JOURNAL Patent: EP 1239051-A 805 11-SEP-2002;
Aeomica, Inc. (US)

FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 289 GCTGTGACAGCTCTT 304
|||||

Db 17 GCTGGGCGAGCTGCTT 2

RESULT 242
AX64893/c 17 bp DNA linear PAT 22-NOV-2002

LOCUS
DEFINITION Sequence 806 from Patent EP1239051.
ACCESSION AX531297
VERSION AX531297.1 GI:25254380
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
AUTHORS Shannon, M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 806 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
Source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 289 GCTGGGCGAGCTGCTT 304
Db 16 GCTGGGCGAGCTGCTT 1

RESULT 243
AX64893/c 17 bp DNA linear PAT 22-MAR-2003

LOCUS
DEFINITION Sequence 733 from Patent EP1273660.
ACCESSION AX64893
VERSION AX64893.1 GI:29151711
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
AUTHORS Gu, Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 733 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
Source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 168 CACCACTGTCACAGA 183
Db 17 CACCACTGTCACAGA 2

RESULT 244
AX64895/c 17 bp DNA linear PAT 22-MAR-2003

LOCUS
DEFINITION Sequence 735 from Patent EP1273660.
ACCESSION AX64895
VERSION AX64895.1 GI:29151713
KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
AUTHORS Gu, Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 735 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
Source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 167 CCACCACTGTCACAG 182
Db 16 CCACCACTGTCACAG 1

RESULT 245
AX64899 17 bp DNA linear PAT 22-MAR-2003

LOCUS
DEFINITION Sequence 739 from Patent EP1273660.
ACCESSION AX64899
VERSION AX64899.1 GI:29151717
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
AUTHORS Gu, Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 739 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
Source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 24 GACACTGCTGCGCAGT 39
Db 2 GACACTGCTGCGCAGT 17

RESULT 246
AX64890 17 bp DNA linear PAT 22-MAR-2003

LOCUS
DEFINITION Sequence 740 from Patent EP1273660.
ACCESSION AX64890
VERSION AX64890.1 GI:29151718
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
AUTHORS Gu, Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 740 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
Source Location/Qualifiers
1.17
/organism="Homo sapiens"


```

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 24 GACACTGCTGCCAGT 39
DB 1 GACAGTCTGCGCAAT 16

RESULT 247
AX674781 17 bp DNA linear PAT 27-MAR-2003
LOCUS Sequence 3226 from Patent WO03004526.
ACCESSION AX674781
VERSION AX674781.1 GI:29333129
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 3226 16-JAN-2003;
FEATURES Molecular Engines Laboratories (FR)
SOURCE Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 204 ATCTATGACACACAT 219
DB 2 ATCTTTACACACAT 17

RESULT 248
AX729139 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 773 from Patent WO03025175.
ACCESSION AX729139
VERSION AX729139.1 GI:30508482
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 773 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
SOURCE Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 579 AGAATACTACCCAAT 594
DB 17 AGAATCTACCAAT 2

RESULT 249
AX729776 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 1410 from Patent WO03025175.
ACCESSION AX729776
VERSION AX729776.1 GI:30509119
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 1410 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
SOURCE Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 77 TTTTATTCTGAATC 92
DB 16 TTTTATTCTGAGATC 1

RESULT 250
AX730568 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 2202 from Patent WO03025175.
ACCESSION AX730568
VERSION AX730568.1 GI:30509911
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 2202 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
SOURCE Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 307 TGTATACGAGGATC 322
DB 16 TGTATCTGAGATC 1

RESULT 251
AX732761

```

LOCUS AX732761 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 4395 from Patent WO03025175.
 ACCESSION AX732761
 VERSION AX732761.1 GI:30512104
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
 AUTHORS 1
 TITLE Telerman, A., Amson, R. and Tuijinder, M.
 FEATURES
 JOURNAL Sequences involved in phenomena of tumour suppression, tumour
 reversal, apoptosis and/or virus resistance and their use as
 medicines
 PATENT: WO 03025175-A 4395 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 FEATURES
 source location/Qualifiers
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 204 ATCTATGACACCAAT 219
 |||||
 Db 2 ATCTTTTACACCAAT 17
 |||||

RESULT 252
 LOCUS AX733540 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 5174 from Patent WO03025175.
 ACCESSION AX733540
 VERSION AX733540.1 GI:30512883
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
 AUTHORS 1
 TITLE Telerman, A., Amson, R. and Tuijinder, M.
 FEATURES
 JOURNAL Sequences involved in phenomena of tumour suppression, tumour
 reversal, apoptosis and/or virus resistance and their use as
 medicines
 PATENT: WO 03025175-A 5174 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 FEATURES
 source location/Qualifiers
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 515 CTGTACAGGAGAAC 530
 |||||
 Db 16 CTGTACAGGAGATC 1
 |||||

RESULT 253
 LOCUS AX736701 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 2291 from Patent WO03025177.
 ACCESSION AX736701
 VERSION AX736701.1 GI:30515989
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE
 AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 TITLE Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
 JOURNAL 1
 FEATURES
 JOURNAL Sequences involved in phenomena of tumour suppression, tumour
 reversal, apoptosis and/or resistance to viruses and the use
 thereof as medicaments
 PATENT: WO 03025177-A 2291 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 FEATURES
 source location/Qualifiers
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 237 AGAAACTACCCAAAT 252
 |||||
 Db 17 AGAAATTAACCCAGAT 2
 |||||

RESULT 254
 LOCUS AX738145 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 3735 from Patent WO03025177.
 ACCESSION AX738145
 VERSION AX738145.1 GI:30517433
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
 AUTHORS 1
 TITLE Telerman, A., Amson, R. and Tuijinder, M.
 FEATURES
 JOURNAL Sequences involved in phenomena of tumour suppression, tumour
 reversal, apoptosis and/or resistance to viruses and the use
 thereof as medicaments
 PATENT: WO 03025177-A 3735 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 FEATURES
 source location/Qualifiers
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 481 AATGACAGGATATC 496
 |||||
 Db 16 AATGACAGGATATC 1
 |||||

RESULT 255
 LOCUS AX738306 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 3896 from Patent WO03025177.
 ACCESSION AX738306
 VERSION AX738306.1 GI:30517594
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
 AUTHORS 1
 TITLE Telerman, A., Amson, R. and Tuijinder, M.
 FEATURES
 JOURNAL Sequences involved in phenomena of tumour suppression, tumour
 reversal, apoptosis and/or resistance to viruses and the use
 thereof as medicaments

JOURNAL Patent: WO 03025177-A 3896 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 261 GATCATGAACTACTGCTG 276
1 GATCAGAGCCTACTGCTG 16

RESULT 256
AX738436 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 4026 from Patent WO03025177.
DEFINITION AX738436
ACCESSION AX738436.1 GI:30517724
VERSION
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 4026 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 204 ATCTATGACACCAT 219
2 ATCTTTACACCAT 17

RESULT 257
AX744398 17 bp DNA linear PAT 14-MAY-2003
LOCUS Sequence 363 from Patent WO03031621.
DEFINITION AX744398
ACCESSION AX744398.1 GI:30723065
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Zhang, J.
TITLE A human G protein coupled receptor
JOURNAL Patent: WO 03031621-A 363 17-APR-2003;
Amerisham Biosciences (SV) Corp. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 43 AAATGGAACCTAAG 58
2 ATAATGAGCATAG 17

RESULT 258
AX744404 17 bp DNA linear PAT 14-MAY-2003
LOCUS Sequence 369 from Patent WO03031621.
DEFINITION AX744404
ACCESSION AX744404
VERSION AX744404.1 GI:30723071
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Zhang, J.
TITLE A human G protein coupled receptor
JOURNAL Patent: WO 03031621-A 369 17-APR-2003;
Amerisham Biosciences (SV) Corp. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 48 GGAACATPAGGAGT 63
1 GGAGCATPAGGAGT 16

RESULT 259
AX757649 17 bp DNA linear PAT 25-JUN-2003
LOCUS Sequence 970 from Patent WO03040369.
DEFINITION AX757649
ACCESSION AX757649
VERSION AX757649.1 GI:32252265
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 970 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 17 CTTTCTGACACGCT 32
17 CTTTCTGAAACTGAT 2

RESULT 260

```

AX762032
LOCUS AX762032 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 5353 from Patent WO03040369.
ACCESSION AX762032
VERSION AX762032.1 GI:32256648
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Euteria; Primates; Catarrhini; Homnidae; Homo.
TITLE Tejerana, A., Amson, R. and Tuijinder, M.
Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
Patent: WO 03040369-A 5353 15-MAY-2003;
JOURNAL Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.2%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db
261 GATCAGGACTACTGC 276
1 GATCAGGACTACTGC 16

RESULT 261
LOCUS AR053108 14 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 14 from patent US 5834183.
ACCESSION AR053108
VERSION AR053108.1 GI:5977970
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 14)
TITLE Orr, H.T., Ranum, L.P.W., Chung, M.-Y. and Zoghbi, H.Y.
Gene sequence for spinocerebellar ataxia type 1 and method for
diagnosis
Patent: US 5834183-A 14 10-NOV-1998;
JOURNAL Location/Qualifiers
FEATURES
source
1..14
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.2%; Score 12.4; DB 1; Length 14;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy
327 TGTGAGGTGGAGT 340
1 TGTGAGGTGGAGT 14

Db
1 TGTGAGGTGGAGT 14

RESULT 262
LOCUS AR062170 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 7 from patent US 5843701.
ACCESSION AR062170
VERSION AR062170.1 GI:5989861
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 15)
TITLE Gold, L., Tuerk, C., Pribnow, D. and Smith, J. Drew.

```

```

TITLE Systematic polypeptide evolution by reverse translation
JOURNAL Patent: US 5843701-A 7 01-DEC-1998;
FEATURES
source
Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.2%; Score 12.4; DB 1; Length 15;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy
467 AGTGCTACCATGTT 480
14 AGTGCTACCATGTT 1

Db
14 AGTGCTACCATGTT 1

RESULT 263
LOCUS AR135146 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 6 from patent US 6194550.
ACCESSION AR135146
VERSION AR135146.1 GI:14124051
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 15)
TITLE Gold, L., Tuerk, C., Pribnow, D. and Smith, J. Drew.
Systematic polypeptide evolution by reverse translation
Patent: US 6194550-A 6 27-FEB-2001;
JOURNAL Location/Qualifiers
FEATURES
source
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.2%; Score 12.4; DB 1; Length 15;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy
467 AGTGCTACCATGTT 480
14 AGTGCTACCATGTT 1

Db
14 AGTGCTACCATGTT 1

RESULT 264
LOCUS BD184387 15 bp DNA linear PAT 17-JUN-2003
DEFINITION Method and detector for identifying subtypes of human papilloma
viruses.
ACCESSION BD184387
VERSION BD184387.1 GI:31876587
KEYWORDS JP 2002360271-A/366.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 15)
AUTHORS Ling, C., Lin, R., Yoo, Z., Huang, X., Lee, B., Lee, S., Lin, Y.,
Huang, C., Heu, H., Shi, C., Yeh, C., Cao, Y. and Pan, C.
Method and detector for identifying subtypes of human papilloma
Patent: JP 2002360271-A 366 17-DEC-2002;
JOURNAL KING CAR FOOD INDUSTRIAL CO LTD
COMMENT OS Artificial Sequence
PN JP 2002360271-A/366
PD 17-DEC-2002
PF 28-NOV-2001 JP 2001362595
PR 04-MAY-2001 TW 90110785
PI CHING-YEE LING, RUEY-WEN LIN, ZHOU-MENG YOO, XIN-HSIUAN HUANG, BOW-
PI HAENG LEE,
PI SHENG-HSIUNG LEE, YI-JU LIN, CI-CHUNG HUANG, HAN-CHANG HSU, CHA-
PI WEN SHI,
PI CHIH-XIN YEH, YI-FENG CAO, CHIH-LONG PAN
PI C12N15/09, C12N15/09, C12M1/34, C12Q1/04, C12Q1/42, C12Q1/68 PC
, C12Q1/70, G01N21/64,

```

PC G01N33/53, G01N33/574, G01N33/58, G01N37/00// (C12M1/34, C12R1:93),
PC (C12O1/70, C12R1:93), C12N15/00, C12N15/00
CC Oligonucleotide M5901 for identifying HPV 59. FH Key
Location/Qualifiers
FT source 1. .15
/organism='Artificial Sequence'.
1. .15
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'

Query Match 0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 65 TTCTTCTACTTCTT 78
|||||
1 TTCTACTACTTCTT 14

Db 1 TTCTACTACTTCTT 14

RESULT 265
135088 135088 15 bp DNA linear PAT 13-MAY-1997
LOCUS Sequence 56 from patent US 5599706.
DEFINITION 135088
ACCESSION 135088
VERSION 135088.1 GI:2088056
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 56 04-FEB-1997;
FEATURES
source 1. .15
/organism='unknown'
/mol_type='unassigned DNA'

Query Match 0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 503 CATCTCCACCACCT 516
|||||
2 CATCTCCACCACCT 15

Db 2 CATCTCCACCACCT 15

RESULT 266
135229 135229 15 bp DNA linear PAT 13-MAY-1997
LOCUS Sequence 197 from patent US 5599706.
DEFINITION 135229
ACCESSION 135229
VERSION 135229.1 GI:2088197
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 197 04-FEB-1997;
FEATURES
source 1. .15
/organism='unknown'
/mol_type='unassigned DNA'

Query Match 0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 239 AAAACTACCCAAT 252

Db 2 AAAACTACCCAAT 15
|||||

RESULT 267
135242 135242 15 bp DNA linear PAT 13-MAY-1997
LOCUS Sequence 210 from patent US 5599706.
DEFINITION 135242
ACCESSION 135242
VERSION 135242.1 GI:2088210
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 210 04-FEB-1997;
FEATURES
source 1. .15
/organism='unknown'
/mol_type='unassigned DNA'

Query Match 0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 503 CATCTCCACCACCT 516
|||||
2 CATCTCCACCACCT 15

Db 2 CATCTCCACCACCT 15

RESULT 268
135244 135244 15 bp DNA linear PAT 13-MAY-1997
LOCUS Sequence 212 from patent US 5599706.
DEFINITION 135244
ACCESSION 135244
VERSION 135244.1 GI:2088212
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 212 04-FEB-1997;
FEATURES
source 1. .15
/organism='unknown'
/mol_type='unassigned DNA'

Query Match 0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 197 CTTGGTCATCTATG 210
|||||
2 CTTGGTCCTCTATG 15

Db 2 CTTGGTCCTCTATG 15

RESULT 269
135266 135266 15 bp DNA linear PAT 13-MAY-1997
LOCUS Sequence 234 from patent US 5599706.
DEFINITION 135266
ACCESSION 135266
VERSION 135266.1 GI:2088234
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA

JOURNAL	Patent: US 5599706-A 234 04-FEB-1997;
FEATURES	Location/Qualifiers
source	1. .15

Query Match	0.2%;	Score 12.4;	DB 1;	Length 15;
Best Local Similarity	92.9%;	Pred. No. 1.8e+02;		
Matches 13;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;

RESTULT 270			
AR180179	AR180179	15 bp DNA	linear PAT 20-APR-2002
LOCUS			
DEFINITION	Sequence 247 from patent US 6333152.		
ACCESSION	AR180179		
VERSION	AR180179.1 GI:20222212		
KEYWORDS			

Query Match	0.2%	Score 12.4	DB 1	Length 15
Best Local Similarity	92.9%	Pred. No. 1.8e+02		
Matches	13	Conservative	0	Mismatches 1
				Indels 0
				Gaps 0
133	CATGGTGTATGACA	146		
1	CATGGTGTGTGACA	14		
db				
QY				

RESULT 271			
ARI180697			
LOCUS	15 bp	DNA	
DEFINITION	Sequence 765 from patent US 6339152.	linear	PAT 20-APR-2002
ACCESSION	ARI180697		
VERSION	ARI180697.1		
KEYWORDS	GI:20222730		
	Unknown.		

Query Match	0.28;	Score 12.4;	DB 1;	Length 15;
Best Local Similarity	92.9%;	Pred. No. 1.8e+02;		
Matches 13;	Conservative	0;	Mismatches 1;	Indels 0; Gaps 0;
133 CATGGTGTATGAGACA	146			
1 CATGGTGTATGAGACA	14			
b				

RESULT 272
AX107826/C

LOCUS	15 bp	DNA	linear	PAT 30-APR-2001
DEFINITION	Sequence 1 from Patent WO0125287.			
ACCESSION	AX107826			
VERSION	AX107826.1	GI:13923224		
KEYWORDS				

Query Match	0.2%	Score 12.4;	DB 1;	Length 15;
Best Local Similarity	92.9%;	Pred. No. 1.8e+02;		
Matches 13;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0

RESULTS	273						
AX107827							
LOCUS	AX107827	15 bp	DNA				
DEFINITION	Sequence 2 from Patent WO0125287.						
ACCESSION	AX107827						
VERSION	AX107827.1	GI:13923225					
KEYWORDS	.						
SOURCE	synthetic construct						
ORGANISM	synthetic construct						
	artificial sequences.						
REFERENCE	1						
AUTHORS	Freitag, R. and Garret-Flaudy, F.						
TITLE	Affinity macroligands						
JOURNAL	Patent: WO 0125287-A 2 12-APR-2001;						
	ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH)						
FEATURES	Location/Qualifiers						
source	1..15						

```

Query Match          0.2%;   Score 12.4;   DB 1;   Length 15;
Best Local Similarity 92.9%;   Pred. No. 1.8e+02;
Matches 13;   Conservative 0;   Mismatches 1;   Indels 0;   Gaps 0;

QY      65 TTCTTCTACTCTT 78
      |||||  |||||
      1 TTCTTCTTCTCTT 14
      |||||
      db

```

RESULT 274					
AX119564					
LOCUS	AX119564	15 bp	DNA	linear	PAT 11-MAY-2001
DEFINITION	Sequence 221 from Patent WO0129251.				
ACCESSION	AX119564				
VERSION	AX119564.1	GI:14036483			
KEYWORDS	.				
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
REFERENCE	1				
AUTHORS	Messiaen,L. and Callens,T.				

TITLE Improved mutation analysis of the nfi gene
JOURNAL Patent: WO 0129251-A 221 26-APR-2001;
FEATURES
SOURCE
Location/Qualifiers
1. .15
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 77 TTTATTTCGAAA 90
|||||
2 TTTATTTCGAGA 15

RESULT 275
LOCUS AX742534 15 bp DNA linear PAT 12-MAY-2003
DEFINITION Sequence 337 from Patent EP1302550.
ACCESSION AX742534
VERSION AX742534.1 GI:30576502
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
AUTHORS 1
Lin,C.Y., Lin,R.W., You,C.M., Huang,H.H., Lee,B.H., Lee,H.H.,
Lin,Y.J., Fan,C.C., Hsu,H.C., Shih,C.W., Yeh,C.H., Kao,Y.F.,
Pan,C.L. and Chan,P.
Method and detector for identifying subtypes of human papilloma
viruses
Patent: EP 1302550-A 317 16-APR-2003;
JOURNAL King Car Food Industrial Co., Ltd. (TW)
FEATURES
SOURCE
1. .15
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide for Identifying HPV 59"

Query Match 0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 65 TTCTTCTACTTCTT 78
|||||
1 TTCTTCTACTTCTT 14

RESULT 276
LOCUS BD005887/c 15 bp DNA linear PAT 31-JAN-2002
DEFINITION Novel probes for the detection of Mycobacteria.
ACCESSION BD005887
VERSION BD005887.1 GI:18634258
KEYWORDS JP 2001501825-A/98.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS 1 (bases 1 to 15)
Stender,H., Lund,K. and Mollerup,T.A.
TITLE Novel probes for the detection of Mycobacteria
Patent: JP 2001501825-A 98 13-FEB-2001;
JOURNAL DAKO AS
COMMENT OS Unidentified
PN JP 2001501825-A/98
PD 13-FEB-2001
PF 03-OCT-1997 JP 1998517095
PR 04-OCT-1996 DK 1096/96,18-OCT-1996 DK 1156/96 PR
05-MAY-1997 DK 0512/97

PI HENRIK STENDER, KAARE LUND, TINA ANDRESEN MOLLERUP PC
CI201/68, C07K14/00
CC Strandedness: Single;
CC Topology: Linear;
FH Key
FT source
FT Location/Qualifiers
1. .15
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 182 GAAGACCTGCCAA 195
|||||
14 GAAGACCTGCCAA 1

RESULT 277
LOCUS BD005888 15 bp DNA linear PAT 31-JAN-2002
DEFINITION Novel probes for the detection of Mycobacteria.
ACCESSION BD005888
VERSION BD005888.1 GI:18634259
KEYWORDS JP 2001501825-A/99.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS 1 (bases 1 to 15)
Stender,H., Lund,K. and Mollerup,T.A.
TITLE Novel probes for the detection of Mycobacteria
Patent: JP 2001501825-A 99 13-FEB-2001;
JOURNAL DAKO AS
COMMENT OS Unidentified
PN JP 2001501825-A/99
PD 13-FEB-2001
PF 03-OCT-1997 JP 1998517095
PR 04-OCT-1996 DK 1096/96,18-OCT-1996 DK 1156/96 PR
05-MAY-1997 DK 0512/97
PI HENRIK STENDER, KAARE LUND, TINA ANDRESEN MOLLERUP PC
CI201/68, C07K14/00
CC Strandedness: Single;
CC Topology: Linear;
FH Key
FT source
FT Location/Qualifiers
1. .15
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 524 GAAGACCTGCCAA 537
|||||
14 GAAGACCTGCCAA 1

RESULT 278
LOCUS BD233229 16 bp DNA linear PAT 17-JUL-2003
DEFINITION Method of detecting mutation selected by drug in HIV protease gene.
ACCESSION BD233229
VERSION BD233229.1 GI:33042999
KEYWORDS JP 2002518065-A/325.
SOURCE Aids-associated retrovirus

ORGANISM Aids-associated retrovirus
 Viruses; Retroid viruses; Retroviridae.
 REFERENCE 1 (bases 1 to 16)
 AUTHORS Stuyver, L.
 TITLE Method of detecting mutation selected by drug in HIV protease gene
 JOURNAL Patent: JP 2002518065-A 325 25-JUN-2002;
 INNOGENETICS NV
 COMMENT OS Aids-associated retrovirus
 PN JP 2002518065-A/325
 PD 25-JUN-2002
 PR 22-JUN-1998 JP 2000556068
 PR 24-JUN-1998 EP 98870143.9
 PI LIEVEN STUYVER
 PC C12N15/09, C12Q1/68, C12Q1/70, C12N15/00
 CC Method of detecting mutation selected by drug in HIV protease
 FT source
 FT Key gene location/Qualifiers
 FT 1.16 /organism="Aids-associated retrovirus".
 FT Location/Qualifiers
 FT 1.16 /organism="Aids-associated retrovirus"
 FT /mol_type="genomic DNA"
 FT /db_xref="taxon:11966"

Query Match 0.2%; Score 12.4; DB 1; Length 16;
 Best Local Similarity 92.9%; Pred. No. 2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 219 TCACATATATAGGA 232
 |||||
 Db 3 TCACATATATGGA 16

RESULT 279
 CQ808615 16 bp DNA linear PAT 10-MAY-2004
 LOCUS Sequence 2065 from Patent WO2004035803.
 DEFINITION CQ808615
 ACCESSION CQ808615.1 GI:47114009
 VERSION
 KEYWORDS
 SOURCE
 ORGANISM
 synthetic construct
 synthetic construct
 artificial sequences.
 REFERENCE 1
 AUTHORS Fockens, J., Harbeck, N., Koenig, T., Maier, S., Martens, J., Model, F.,
 Nimmrich, I., Rujan, T., Schmitt, A., Schmitt, M., Look, M.P. and
 Marx, A.
 TITLE Method and nucleic acids for the improved treatment of breast cell
 JOURNAL proliferative disorders
 Patent: WO 2004035803-A 2065 29-APR-2004;
 Epigenomics AG (DE)
 FEATURES
 source
 1.16
 Location/Qualifiers
 1.16 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Detection oligonucleotide for PRKCD"

Query Match 0.2%; Score 12.4; DB 1; Length 16;
 Best Local Similarity 92.9%; Pred. No. 2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 142 GGACAGAGTTATCG 155
 |||||
 Db 1 GGACGAGATTATCG 14

RESULT 280
 AR328298 16 bp RNA linear PAT 17-AUG-2003
 LOCUS AR328298
 DEFINITION Sequence 5700 from patent US 656127.
 ACCESSION AR328298

VERSION AR328298.1 GI:33714106
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 16)
 AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
 TITLE Method and reagent for the treatment of diseases or conditions
 JOURNAL related to levels of vascular endothelial growth factor receptor
 Patent: US 656127-A 5700 20-MAY-2003;
 FEATURES
 source
 1.16
 Location/Qualifiers
 1.16 /organism="unknown"
 /mol_type="unassigned RNA"

Query Match 0.2%; Score 12.4; DB 1; Length 16;
 Best Local Similarity 92.9%; Pred. No. 2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 198 TTGGTCATCTATGA 211
 |||||
 Db 16 TTGGACATCTATGA 3

RESULT 281
 AX007783 16 bp DNA linear PAT 06-SEP-2000
 LOCUS AX007783
 DEFINITION Sequence 325 from Patent WO9967428.
 ACCESSION AX007783
 VERSION AX007783.1 GI:9995480
 KEYWORDS
 SOURCE
 ORGANISM
 Aids-associated retrovirus
 Aids-associated retrovirus
 Viruses; Retroid viruses; Retroviridae.
 REFERENCE 1
 AUTHORS Stuyver, L.
 TITLE Method for detection of drug-selected mutations in the hiv protease
 JOURNAL gene
 Patent: WO 9967428-A 325 29-DEC-1999;
 INNOGENETICS NV (BE); STUYVER LIEVEN (BE)
 FEATURES
 source
 1.16
 Location/Qualifiers
 1.16 /organism="Aids-associated retrovirus"
 /mol_type="unassigned DNA"
 /db_xref="taxon:11966"

Query Match 0.2%; Score 12.4; DB 1; Length 16;
 Best Local Similarity 92.9%; Pred. No. 2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 219 TCACATATATAGGA 232
 |||||
 Db 3 TCACATATATGGA 16

RESULT 282
 AX814334 16 bp DNA linear PAT 05-DEC-2003
 LOCUS AX814334
 DEFINITION Sequence 3 from Patent WO03065044.
 ACCESSION AX814334
 VERSION AX814334.1 GI:39103570
 KEYWORDS
 SOURCE
 ORGANISM
 Homo sapiens (human)
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
 REFERENCE 1
 AUTHORS Golz, S., Brueggemeier, U. and Geerts, A.
 TITLE Diagnostics and therapeutics for diseases associated with gpr72
 JOURNAL Patent: WO 03065044-A 3 07-AUG-2003;
 Bayer Aktiengesellschaft (DE)
 FEATURES
 source
 1.16
 Location/Qualifiers
 1.16


```

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.2%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      379 GCGCTCGCGCTCC 392
Db      15 GCGGTAGCGCTCC 2

RESULT 283
BD104579/c      16 bp  DNA      linear  PAT 27-AUG-2002
LOCUS      BD104579
DEFINITION  Kit and method for determining HLA type.
ACCESSION  BD104579.1 GI:22650153
VERSION     WO 0192572-A/683.
KEYWORDS    synthetic construct
SOURCE      synthetic construct
ORGANISM    artificial sequences.
REFERENCE   1 (bases 1 to 16)
AUTHORS     Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
            Nishida,M.
TITLE       Kit and method for determining HLA type
JOURNAL     Patent: WO 0192572-A 683 06-DEC-2001;
            NISSHINBO INDUSTRIES INC.,SYSTEM RESEARCH INC.,HIDETOSHI INOKO, TAEKO
            KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, SHOGO MORIYA, MICHIO
            NISHIDA
COMMENT     OS Artificial Sequence
            PN WO 0192572-A/683
            PD 06-DEC-2001
            PF 01-JUN-2001 WO 2001JP004662
            PR 01-JUN-2000 JP 00P 164798
            PI HIDETOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIYUKI
            MATSUMURA,
            PI SHOGO MORIYA, MICHIO NISHIDA
            PC C1201/68,C12M1/00,C12N15/09,G01N33/53
            CC Description of Artificial Sequence:capture
            FH Key Location/Qualifiers
            FT source 1..16
            /organism='Artificial Sequence'.
FEATURES
    source
        1..16
            /location/Qualifiers
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"

Query Match      0.2%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      158 GCACGTACTCCAC 171
Db      14 GCACGTACTCTCC 1

RESULT 284
AR063735
LOCUS      AR063735
DEFINITION Sequence 20 from patent US 5846720.
ACCESSION  AR063735
VERSION     AR063735.1 GI:5993043
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 12)
AUTHORS     Foulkes,J.Gordon., Liechtfried,F.E., Pieler,C., Stephenson,J.R. and
            Case,C.C.
TITLE       Methods of determining chemicals that modulate expression of genes

```

```

associated with cardiovascular disease
JOURNAL     Patent: US 5846720-A 20 08-DEC-1998;
FEATURES
    source
        1..12
            /location/Qualifiers
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.2%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      33 GGCAGTCCCAA 44
Db      1 GGCAGTCCCAA 12

RESULT 285
I30098
LOCUS      I30098
DEFINITION Sequence 20 from patent US 5580722.
ACCESSION  I30098
VERSION     I30098.1 GI:1820889
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 12)
AUTHORS     Foulkes,J.Gordon., Liechtfried,F.E., Pieler,C., Stephenson,J.R. and
            Case,C.C.
TITLE       Methods of determining chemicals that modulate transcriptionally
            expression of genes associated with cardiovascular disease
            Patent: US 5580722-A 20 03-DEC-1996;
            Location/Qualifiers
            1..12
            /organism="unknown"
            /mol_type="unassigned DNA"

JOURNAL     Patent: US 5580722-A 20 03-DEC-1996;
FEATURES
    source
        1..12
            /location/Qualifiers
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.2%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      33 GGCAGTCCCAA 44
Db      1 GGCAGTCCCAA 12

RESULT 286
AR019431/c
LOCUS      AR019431
DEFINITION Sequence 19 from patent US 5783431.
ACCESSION  AR019431
VERSION     AR019431.1 GI:3974545
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 13)
AUTHORS     Peterson,T.C., Foster,L.M. and Brian,P.
TITLE       Methods for generating and screening novel metabolic pathways
            Patent: US 5783431-A 19 21-JUL-1998;
            Location/Qualifiers
            1..13
            /location/Qualifiers
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.2%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      315 GAGGATCCCGG 326
Db      13 GAGGATCCCGG 2

```

```

RESULT 287
ARI56387/c 13 bp DNA PAT 08-AUG-2001
LOCUS
DEFINITION Sequence 16 from patent US 6242211.
ACCESSION ARI56387
VERSION ARI56387.1 GI:15125091
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 13)
  Unclassified.
AUTHORS Peterson,T.C. and Brian,P.
TITLE Methods for generating and screening novel metabolic pathways
JOURNAL Patent: US 6242211-A 16 05-JUN-2001;
FEATURES
  1..13
    Location/Qualifiers
    source
      /organism="unknown"
      /mol_type="unassigned DNA"

```

```

Query Match
Best Local Similarity 0.2%; Score 12; DB 1; Length 13;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

OY 315 CGAGGATCCCG 326
Db 13 CGAGGATCCCG 2

```

```

RESULT 288
AR003153/c 15 bp DNA PAT 04-DEC-1998
LOCUS
DEFINITION Sequence 87 from patent US 5744140.
ACCESSION AR003153
VERSION AR003153.1 GI:3964412
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Unclassified.
AUTHORS Paoletti,E. and Pincus,S.Elliott.
TITLE Flavivirus recombinant poxvirus vaccine
JOURNAL Patent: US 5744140-A 87 28-APR-1998;
FEATURES
  1..15
    Location/Qualifiers
    source
      /organism="unknown"
      /mol_type="unassigned DNA"

```

```

Query Match
Best Local Similarity 0.2%; Score 12; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

OY 314 CGAGGATCCCG 325
Db 12 CGAGGATCCCG 1

```

```

RESULT 289
AR003246/c 15 bp DNA PAT 04-DEC-1998
LOCUS
DEFINITION Sequence 87 from patent US 5744141.
ACCESSION AR003246
VERSION AR003246.1 GI:3964505
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Unclassified.
AUTHORS Paoletti,E. and Pincus,S.Elliott.
TITLE Flavivirus recombinant poxvirus immunological composition
JOURNAL Patent: US 5744141-A 87 28-APR-1998;
FEATURES
  1..15
    Location/Qualifiers
    source

```

```

/organism="unknown"
/mol_type="unassigned DNA"

```

```

Query Match
Best Local Similarity 0.2%; Score 12; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

OY 314 CGAGGATCCCG 325
Db 12 CGAGGATCCCG 1

```

```

RESULT 290
AR009111/c 15 bp DNA PAT 04-DEC-1998
LOCUS
DEFINITION Sequence 108 from patent US 5756102.
ACCESSION AR009111
VERSION AR009111.1 GI:3967916
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Unclassified.
AUTHORS Paoletti,E., Tartaglia,J. and Taylor,J.
TITLE Poxvirus-canine distemper virus (CDV) recombinants and compositions
JOURNAL and methods employing the recombinants
FEATURES Patent: US 5756102-A 108 26-MAY-1998;
  1..15
    Location/Qualifiers
    source
      /organism="unknown"
      /mol_type="unassigned DNA"

```

```

Query Match
Best Local Similarity 0.2%; Score 12; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

OY 314 CGAGGATCCCG 325
Db 12 CGAGGATCCCG 1

```

```

RESULT 291
AR011400/c 15 bp DNA PAT 04-DEC-1998
LOCUS
DEFINITION Sequence 273 from patent US 5762938.
ACCESSION AR011400
VERSION AR011400.1 GI:3969390
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 15)
  Unclassified.
AUTHORS Paoletti,E., Perkins,M.E., Taylor,J., Tartaglia,J., Norton,E.K.,
  Riviere,M., de Taisne,C., Lindbach,K.J., Johnson,G.P., Pincus,S.E.,
  Cox,W.I., Audommet,J.-C., Francis, and Gettig,R.Robert.
TITLE Modified recombinant vaccinia virus and expression vectors thereof
JOURNAL Patent: US 5762938-A 273 09-JUN-1998;
FEATURES
  1..15
    Location/Qualifiers
    source
      /organism="unknown"
      /mol_type="unassigned DNA"

```

```

Query Match
Best Local Similarity 0.2%; Score 12; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

OY 314 CGAGGATCCCG 325
Db 12 CGAGGATCCCG 1

```

```

RESULT 292
AR028084/c

```

```

LOCUS       AR028084                      15 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION   Sequence 48 from patent US 5858373.
ACCESSION   AR028084
VERSION     AR028084.1  GI:5940057
KEYWORDS    .
SOURCE      .
ORGANISM    .
REFERENCE   1 (bases 1 to 15)
AUTHORS     Paoletti,E. and Gettig,R.
TITLE       Recombinant poxvirus-feline infectious peritonitis virus,
            compositions thereof and methods for making and using them
JOURNAL     Patent: US 5858373-A 48 12-JAN-1999;
            Location/Qualifiers
FEATURES
  source     1..15
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      314 CGAGGATCCCG 325
Db      12 CGAGGATCCCG 1

RESULT 293
AR041240/c                      15 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION   Sequence 30 from patent US 5811300.
ACCESSION   AR041240
VERSION     AR041240.1  GI:5961736
KEYWORDS    .
SOURCE      .
ORGANISM    .
REFERENCE   1 (bases 1 to 15)
AUTHORS     Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwigen,J.
TITLE       TNF- $\alpha$ . ribozymes
JOURNAL     Patent: US 5811300-A 30 22-SEP-1998;
            Location/Qualifiers
FEATURES
  source     1..15
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      430 GAACAGCACC 441
Db      12 GAACAGCACC 1

RESULT 294
AR052800/c                      15 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION   Sequence 137 from patent US 5833975.
ACCESSION   AR052800
VERSION     AR052800.1  GI:5977662
KEYWORDS    .
SOURCE      .
ORGANISM    .
REFERENCE   1 (bases 1 to 15)
AUTHORS     Paoletti,E., Tartaglia,J. and Cox,W.I.
TITLE       DNA sequence
JOURNAL     Patent: US 5833975-A 137 10-NOV-1998;
            Location/Qualifiers
FEATURES
  source     1..15
             /organism="unknown"

```

```

/mol_type="unassigned DNA"

Query Match      0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      314 CGAGGATCCCG 325
Db      12 CGAGGATCCCG 1

RESULT 295
AR127918/c                      15 bp      DNA      linear      PAT 16-MAY-2001
DEFINITION   Sequence 68 from patent US 6183752.
ACCESSION   AR127918
VERSION     AR127918.1  GI:1411580
KEYWORDS    .
SOURCE      .
ORGANISM    .
REFERENCE   1 (bases 1 to 15)
AUTHORS     Epstein,S.E., Finkel,T., Speir,E., Zhou,Y.Fu., Zhu,J., Erdile,L.
            and Pincus,S.
TITLE       Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
JOURNAL     Patent: US 6183752-A 68 06-FEB-2001;
            Location/Qualifiers
FEATURES
  source     1..15
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      314 CGAGGATCCCG 325
Db      12 CGAGGATCCCG 1

RESULT 296
AR175199/c                      15 bp      DNA      linear      PAT 17-DEC-2001
DEFINITION   Sequence 108 from patent US 6309647.
ACCESSION   AR175199
VERSION     AR175199.1  GI:17916498
KEYWORDS    .
SOURCE      .
ORGANISM    .
REFERENCE   1 (bases 1 to 15)
AUTHORS     Paoletti,E., Tartaglia,J., Taylor,J. and Gettig,R.
TITLE       Poxvirus--canine distemper virus (CDV) or measles virus
            recombinants and compositions and methods employing the
            recombinants
JOURNAL     Patent: US 6309647-A 108 30-OCT-2001;
            Location/Qualifiers
FEATURES
  source     1..15
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      314 CGAGGATCCCG 325
Db      12 CGAGGATCCCG 1

RESULT 297
BD208610                      15 bp      RNA      linear      PAT 17-JUL-2003
LOCUS       BD208610

```

DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection.

ACCESSION BD208610
VERSION BD208610.1 GI:33018380
KEYWORDS JP 2002512791-A/2200.
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 15)
AUTHORS Blatt, L., McSwiggen, J. A., Roberts, E., Pavco, P. A. and Macejak, D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
JOURNAL Patent: JP 2002512791-A 2200 08-MAY-2002;
RIBOZYME PHARMACEUTICALS INC

COMMENT OS Hepatitis virus (hepatitis C virus)
PN JP 2002512791-A/2200
PD 08-MAY-2002
PF 26-APR-1999 JP 2000545991
PR 27-APR-1998 US 60/083217, 18-SEP-1998 US 60/100842 PR
25-FEB-1999 US 09/257608, 23-MAR-1999 US 09/274553 PI
LAWRENCE BLATT, JAMES A MCSWIGGEN, ELISABETH ROBERTS, PAMELA A PI
PAVCO,

PI DENNIS MACEJAK
PC C12N9/00, A61K31/7105, A61K38/21, A61K48/00, A61P31/12, C12N15/09,
PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions CC
CC related to
FH hepatitis C virus infection.
FT Key Location/Qualifiers
FT source 1. .15
FT virus', /organism='Hepatitis virus (hepatitis C FT

FEATURES
source
1. .15
Location/Qualifiers
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 100.0%; Score 12; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 160 ACGTACTCCACC 171
|||||
Db 1 ACGTACTCCACC 12

RESULT 298
LOCUS 118038
DEFINITION Sequence 273 from patent US 5494807.
ACCESSION 118038
VERSION 118038.1 GI:1598393
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)
AUTHORS Paolletti, E., Perkus, M. E., Taylor, J., Tartaglia, J., Norton, E. K.,
Riviere, M., de Taisne, C., Limbach, K. J., Johnson, G. F., Pincus, S. E.,
Cox, W. I., Audonnet, J.-C. F. and Gettys, R. R.
TITLE NYVAC vaccinia virus recombinants comprising heterologous inserts
JOURNAL Patent: US 5494807-A 273 27-FEB-1996;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
|||||
Db 12 CGAGGATCCCG 1

RESULT 299
LOCUS 135068
DEFINITION Sequence 36 from patent US 5599706.
ACCESSION 135068
VERSION 135068.1 GI:2088036
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb, D. T., McSwiggen, J., Newton, R. S. and Ramharack, R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 36 04-FEB-1997;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 564 GCATAGTCGAC 575
|||||
Db 4 GCATAGTCGAC 15

RESULT 300
LOCUS AR180461/c
DEFINITION Sequence 529 from patent US 6333152.
ACCESSION AR180461
VERSION AR180461.1 GI:20222494
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)
AUTHORS Vogelstein, B., Kinzler, K. W., Zhang, L. and Zhou, W.
TITLE Gene expression profiles in normal and cancer cells
JOURNAL Patent: US 6333152-A 529 25-DEC-2001;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 104 AGCAAGCCATG 115
|||||
Db 12 AGCAAGCCATG 1

RESULT 301
LOCUS AR288113/c
DEFINITION Sequence 137 from patent US 6537594.
ACCESSION AR288113
VERSION AR288113.1 GI:31675392
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)
AUTHORS Paolletti, E., Tartaglia, J. and Cox, W. I.

TITLE Vaccina virus comprising cytokine and/or tumor associated antigen
 JOURNAL Genes
 FEATURES Patent: US 6537594-A 137 25-MAR-2003;
 SOURCE Location/Qualifiers
 1. .15
 /organism="unknown"
 /mol_type="mRNA"

Query Match 0.2%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 314 CGAGGATCCCG 325
 12 CGAGGATCCCG 1

Db 12 CGAGGATCCCG 1

RESULT 302
 AR408262/c
 LOCUS AR408262 15 bp DNA linear PAT 18-DEC-2003
 DEFINITION Sequence 91 from patent US 6632438.
 ACCESSION AR408262
 VERSION AR408262.1 GI:40159408
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)
 AUTHORS Paoletti,E., Pincus,S.E., Cox,W.I. and Kauffmann,E.K.
 TITLE Recombinant poxvirus cytomegalovirus, compositions, and uses
 JOURNAL Patent: US 6632438-A 91 14-OCT-2003;
 FEATURES Location/Qualifiers
 1. .15
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.2%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 314 CGAGGATCCCG 325
 12 CGAGGATCCCG 1

Db 12 CGAGGATCCCG 1

RESULT 303
 AX636712/c
 LOCUS AX636712 15 bp RNA linear PAT 21-FEB-2003
 DEFINITION Sequence 3851 from Patent EP1260586.
 ACCESSION AX636712
 VERSION AX636712.1 GI:28472326
 KEYWORDS
 SOURCE unidentified
 ORGANISM unidentified
 unclassified.

REFERENCE 1
 AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A.,
 Kapelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
 Mcwiesgen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
 Swedler,D., Thompson,J.D., Tracz,D., Ueman,N., Wincott,F.E. and
 Wolf,T.
 TITLE Method and reagent for inhibiting the expression of disease related
 genes
 JOURNAL Patent: EP 1260586-A 3851 27-NOV-2002;
 FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)
 SOURCE Location/Qualifiers
 1. .15
 /organism="unidentified"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32644"

Query Match 0.2%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2e+02;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 430 GAACAGCACCG 441
 12 GAACAGCACCG 1

Db 12 GAACAGCACCG 1

RESULT 304
 BD000643
 LOCUS BD000643 15 bp DNA linear PAT 31-JAN-2002
 DEFINITION Probe used for the method for detecting nucleic acid.
 ACCESSION BD000643
 VERSION BD000643.1 GI:18623756
 KEYWORDS JP 2000342288-A/2.
 SOURCE unidentified
 ORGANISM unidentified
 unclassified.

REFERENCE 1 (bases 1 to 15)
 AUTHORS Nagai,K. and Kamibara,H.
 TITLE Probe used for the method for detecting nucleic acid
 JOURNAL Patent: JP 2000342288-A 2 12-DEC-2000;
 COMMENT HITACHI LTD
 OS Unidentified
 PN JP 2000342288-A/2
 PD 12-DEC-2000
 PF 08-MAY-2000 JP 2000135040
 PR

PI KEIICHI NAGAI,HIDEKI KAMIBARA
 PC C12N15/09,C12Q1/68,G01N31/78,G01N33/53,G01N33/542,
 PC G01N33/566,
 PC C12N15/00
 CC Strandedness: Single;
 CC Topology: Linear;
 FH Key
 FT source
 FT 1. .15
 /organism="unidentified".
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

Query Match 0.2%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 190 TGCCAGCTTGG 201
 3 TGCCAGCTTGG 14

Db 3 TGCCAGCTTGG 14

RESULT 305
 BD017683
 LOCUS BD017683 15 bp DNA linear PAT 27-AUG-2002
 DEFINITION Probe for using in detection method of nucleic acid.
 ACCESSION BD017683
 VERSION BD017683.1 GI:22558959
 KEYWORDS JP 2001245683-A/2.
 SOURCE unidentified
 ORGANISM unidentified
 unclassified.

REFERENCE 1 (bases 1 to 15)
 AUTHORS Nagai,K. and Kamibara,H.
 TITLE Probe for using in detection method of nucleic acid
 JOURNAL Patent: JP 2001245683-A 2 11-SEP-2001;
 COMMENT HITACHI LTD
 OS M13 phage
 PN JP 2001245683-A/2
 PD 11-SEP-2001
 PF 01-FEB-2001 JP 2001026140
 PI KEIICHI NAGAI,HIDEKI KAMIBARA
 PC C12N15/09,C12Q1/68,G01N33/53,G01N33/542,G01N33/566,C12N15/00
 CC Strandedness: Single;

CC Topology: Linear;
CC Probe for using in detection method of nucleic acid FH Key
FT source 1..15
Location/Qualifiers
FT Location/Qualifiers
1..15
/organism="M13 phage".
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match

Best Local Similarity 0.2%; Score 12; DB 1; Length 15;
Matches 12; Conservativity 0; Mismatches 0; Indels 0; Gaps 0;

QY 190 TGCCAGCTTGG 201
|||||
Db 3 TGCCAGCTTGG 14

RESULT 306

BD017688 15 bp DNA linear PAT 27-AUG-2002
LOCUS Method for detecting nucleic acid.
DEFINITION BD017688
ACCESSION BD017688.1 GI:22558864
VERSION JP 2001245699-A/2.
KEYWORDS unclassified
SOURCE unclassified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 15)
AUTHORS Nagai,K. and Kambarata,H.
TITLE Method for detecting nucleic acid
JOURNAL Patent: JP 2001245699-A 2 11-SEP-2001;
HITACHI LTD

COMMENT
OS M13 phage
PN JP 2001245699-A/2
PD 11-SEP-2001
PF 01-FEB-2001 JP 2001026141
PI KEIICHI NAGAI,HIDEKI KAMBARA
PC C12Q1/68,C12N15/09,G01N33/53,G01N33/542,G01N33/566/(C12N15/09, PC
C12R1.92),
CC C12N15/00,C12N15/00,C12R1.92)
CC Strandedness: Single;
CC Topology: Linear;
CC Method for detecting nucleic acid
FH Key Location/Qualifiers
FT source 1..15
/organism="M13 phage".

FEATURES
source 1..15
Location/Qualifiers
/organism="unclassified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservativity 0; Mismatches 0; Indels 0; Gaps 0;

QY 190 TGCCAGCTTGG 201
|||||
Db 3 TGCCAGCTTGG 14

RESULT 307
AR279393/c 16 bp DNA linear PAT 10-APR-2003
LOCUS Sequence 37 from patent US 6514699.
DEFINITION AR279393
ACCESSION AR279393
VERSION AR279393.1 GI:29714145
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS O'Neill,R.A., Chen,J.-K., Chiesa,C. and Fry,G.
TITLE Multiplex polynucleotide capture methods and compositions
JOURNAL Patent: US 6514699-A 37 04-FEB-2003;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservativity 0; Mismatches 0; Indels 0; Gaps 0;

QY 125 ATTGCTACCATG 136
|||||
Db 15 ATTGCTACCATG 4

RESULT 308
AR279396 16 bp DNA linear PAT 10-APR-2003
LOCUS Sequence 40 from patent US 6514699.
DEFINITION AR279396
ACCESSION AR279396
VERSION AR279396.1 GI:29714148
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS O'Neill,R.A., Chen,J.-K., Chiesa,C. and Fry,G.
TITLE Multiplex polynucleotide capture methods and compositions
JOURNAL Patent: US 6514699-A 40 04-FEB-2003;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservativity 0; Mismatches 0; Indels 0; Gaps 0;

QY 125 ATTGCTACCATG 136
|||||
Db 15 ATTGCTACCATG 4

RESULT 309
AX139231 16 bp DNA linear PAT 30-MAY-2001
LOCUS Sequence 79 from Patent EP1076099.
DEFINITION AX139231
ACCESSION AX139231
VERSION AX139231.1 GI:14274904
KEYWORDS
SOURCE Mycobacterium tuberculosis
ORGANISM Mycobacterium tuberculosis
Mycobacterium tuberculosis
Bacteria; Actinobacteria; Actinomycetales;
Corynebacterineae; Mycobacteriaceae; Mycobacterium; Mycobacterium
tuberculosis complex.

REFERENCE 1
AUTHORS Suzuki,Y., Nishida,M. and Takenishi,S.
TITLE Kit for diagnosis of tubercle bacilli
JOURNAL Patent: EP 1076099-A 79 14-FEB-2001;
NISHINBO INDUSTRIES, INC. (JP) ; System Research Incorporation
(JP)

FEATURES
source 1..16
Location/Qualifiers
/organism="Mycobacterium tuberculosis"
/mol_type="unassigned DNA"
/db_xref="taxon:1773"
/note="capture"

Query Match 0.2%; Score 12; DB 1; Length 16;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 182 GAAGGACCTGCC 193
 |||||
 4 GAAGGACCTGCC 15

RESULT 310
 BD007209/c

LOCUS BD007209 16 bp DNA linear PAT 31-JAN-2002
 DEFINITION Method and composition for capturing multiple polynucleotide.
 ACCESION BD007209
 VERSION BD007209.1 GI:18635580
 KEYWORDS JP 2001503973-A/37.
 SOURCE unidentified
 ORGANISM unidentified
 unclassified.

REFERENCE 1 (bases 1 to 16)

AUTHORS O'Neill, R.A., Chen, J.C., Chiesa, C. and Fry, G.
 TITLE Method and composition for capturing multiple polynucleotide
 JOURNAL Patent: JP 2001503973-A 37 27-MAR-2001;
 THE PERKIN ELMAR CORP
 OS Unidentified
 PN JP 2001503973-A/37
 PD 27-MAR-2001
 PF 02-OCT-1997 JP 1998516839
 PR 04-OCT-1996 US 60/027832, 12-JUN-1997 US 08/873437 PT
 ROGER A O'NEILL, JAR CAIN CHEN, CLAUDIA CHIESA, GEORGE FRY PC
 C12Q1/68, C12N15/09, C12N15/00
 CC Strandedness: Single;
 CC Topology: Linear;
 FH Key
 FT source

FEATURES
 source 1. .16
 Location/Qualifiers
 FT 1. .16
 /organism="Unidentified".
 /location="Genomic DNA"
 /db_xref="taxon:32644"

Query Match 0.2%; Score 12; DB 1; Length 16;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 125 ATTGCTACCATG 136
 |||||
 15 ATTGCTACCATG 4

RESULT 311
 BD007212/c
 LOCUS BD007212 16 bp DNA linear PAT 31-JAN-2002
 DEFINITION Method and composition for capturing multiple polynucleotide.
 ACCESION BD007212
 VERSION BD007212.1 GI:18635583
 KEYWORDS JP 2001503973-A/40.
 SOURCE unidentified
 ORGANISM unidentified
 unclassified.

REFERENCE 1 (bases 1 to 16)
 AUTHORS O'Neill, R.A., Chen, J.C., Chiesa, C. and Fry, G.
 TITLE Method and composition for capturing multiple polynucleotide.
 JOURNAL Patent: JP 2001503973-A 40 27-MAR-2001;
 THE PERKIN ELMAR CORP
 OS Unidentified
 PN JP 2001503973-A/40
 PD 27-MAR-2001
 PF 02-OCT-1997 JP 1998516839
 PR 04-OCT-1996 US 60/027832, 12-JUN-1997 US 08/873437 PT
 ROGER A O'NEILL, JAR CAIN CHEN, CLAUDIA CHIESA, GEORGE FRY PC
 C12Q1/68, C12N15/09, C12N15/00

CC Strandedness: Single;
 CC Topology: Linear;
 FH Key
 FT source 1. .16
 Location/Qualifiers
 FT 1. .16
 /organism="Unidentified".
 /location="Genomic DNA"
 /db_xref="taxon:32644"

Query Match 0.2%; Score 12; DB 1; Length 16;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 125 ATTGCTACCATG 136
 |||||
 15 ATTGCTACCATG 4

RESULT 312

BD013515
 LOCUS BD013515 16 bp DNA linear PAT 27-AUG-2002
 DEFINITION Diagnosis kit of tubercle bacillus.
 ACCESION BD013515
 VERSION BD013515.1 GI:22553829
 KEYWORDS JP 2001103981-A/79
 SOURCE Mycobacterium tuberculosis
 ORGANISM Mycobacterium tuberculosis
 Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales;
 Corynebacterineae; Mycobacteriaceae; Mycobacterium; Mycobacterium
 tuberculosis complex.

REFERENCE 1 (bases 1 to 16)
 AUTHORS Suzuki, S., Nishida, M. and Takenishi, S.
 TITLE Diagnosis kit of tubercle bacillus
 JOURNAL Patent: JP 2001103981-A 79 17-APR-2001;
 NISHINBO IND INC, SYSTEM RESEARCH CO LTD
 OS Mycobacterium tuberculosis
 PN JP 2001103981-A/79
 PD 17-APR-2001
 PF 26-JUL-2000 JP 2000225985
 PI SADAHIRO SUZUKI, MICHIO NISHIDA, SOICHIRO TAKENISHI PC
 C12N15/09, C12N15/09, C12M1/00, C12Q1/68, C12Q1/68, C12R1/32, PC
 C12Q1/68, C12R1/325, C12Q1/68, C12R1/33, C12N15/00, C12N15/00 CC
 capture

FEATURES
 source 1. .16
 Location/Qualifiers
 FT 1. .16
 /organism="Mycobacterium tuberculosis".
 /location="Genomic DNA"
 /db_xref="taxon:1773"

Query Match 0.2%; Score 12; DB 1; Length 16;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 182 GAAGGACCTGCC 193
 |||||
 4 GAAGGACCTGCC 15

RESULT 313

A15244
 LOCUS A15244 15 bp DNA linear PAT 22-MAR-1994
 DEFINITION Oligonucleotide AH16.
 ACCESION A15244
 VERSION A15244.1 GI:512692
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 artificial sequences.

```

REFERENCE      1 (bases 1 to 15)
AUTHORS        Ueda,I., Niwa,M., Saito,Y., Yamada,H. and Ishii,Y.
TITLE          A process for the production of alpha-human atrial natriuretic
JOURNAL        Polypeptide
                Patent: EP 0206769-A 17 30-DEC-1986;
                FUJISAWA PHARMACEUTICAL CO., LTD
FEATURES        Location/Qualifiers
SOURCE          1..15
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"

Query Match    0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db            480 TAATGACAGAGTTA 494
              |||||
              1 TAACGGAAGAGTTA 15

RESULT 314
LOCUS          A16459                      15 bp    DNA          linear    PAT 17-MAR-1994
DEFINITION     oligonucleotide A16.
ACCESSION      A16459
VERSION        A16459.1 GI:489866
KEYWORDS       .
SOURCE         synthetic construct
ORGANISM       artificial sequences.
REFERENCE      1 (bases 1 to 15)
AUTHORS        Ueda,I., Niwa,M., Saito,Y., Yamada,H. and Ishii,Y.
TITLE          A process for the production of alpha-human atrial natriuretic
JOURNAL        polypeptide
                Patent: EP 0440311-A 34 07-AUG-1991;
                FUJISAWA PHARMACEUTICAL CO., LTD
FEATURES        Location/Qualifiers
SOURCE          1..15
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"

Query Match    0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db            480 TAATGACAGAGTTA 494
              |||||
              1 TAACGGAAGAGTTA 15

RESULT 315
LOCUS          AR041366                      15 bp    DNA          linear    PAT 29-SEP-1999
DEFINITION     Sequence 156 from patent US 5813300.
ACCESSION      AR041366
VERSION        AR041366.1 GI:5961862
KEYWORDS       .
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 15)
AUTHORS        Sullivan,S., Draper,K., Kisch,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE          TNP-.alpha. ribozymes
JOURNAL        Patent: US 5813300-A 156 22-SEP-1998;
FEATURES        Location/Qualifiers
SOURCE          1..15
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match    0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db            480 TAATGACAGAGTTA 494
              |||||
              1 TAACGGAAGAGTTA 15

```

```

Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy            31 CTGGCCGCTCCCAA 45
              |||||
              15 CTGGCAGAACCAA 1

Db            15 CTGGCAGAACCAA 1

RESULT 316
LOCUS          I35061                      15 bp    DNA          linear    PAT 13-MAY-1997
DEFINITION     Sequence 29 from patent US 5599706.
ACCESSION      I35061
VERSION        I35061.1 GI:2088029
KEYWORDS       .
SOURCE         Unknown.
ORGANISM       Unknown.
REFERENCE      1 (bases 1 to 15)
AUTHORS        Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE          Ribozymes targeted to apo(a) mRNA
JOURNAL        Patent: US 5599706-A 29 04-FEB-1997;
FEATURES        Location/Qualifiers
SOURCE          1..15
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match    0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db            355 CAATGCTCAGAGCA 369
              |||||
              1 CAATGCTCAGATCA 15

RESULT 317
LOCUS          I35086                      15 bp    DNA          linear    PAT 13-MAY-1997
DEFINITION     Sequence 54 from patent US 5599706.
ACCESSION      I35086
VERSION        I35086.1 GI:2088054
KEYWORDS       .
SOURCE         Unknown.
ORGANISM       Unknown.
REFERENCE      1 (bases 1 to 15)
AUTHORS        Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE          Ribozymes targeted to apo(a) mRNA
JOURNAL        Patent: US 5599706-A 54 04-FEB-1997;
FEATURES        Location/Qualifiers
SOURCE          1..15
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match    0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db            496 CGAGGCACATCTCC 510
              |||||
              1 CGAGGCTCATCTCC 15

RESULT 318
LOCUS          I35087                      15 bp    DNA          linear    PAT 13-MAY-1997
DEFINITION     Sequence 55 from patent US 5599706.
ACCESSION      I35087
VERSION        I35087.1 GI:2088055
KEYWORDS       .
SOURCE         Unknown.
ORGANISM       Unknown.
REFERENCE      1 (bases 1 to 15)
AUTHORS        Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE          Ribozymes targeted to apo(a) mRNA
JOURNAL        Patent: US 5599706-A 55 04-FEB-1997;
FEATURES        Location/Qualifiers
SOURCE          1..15
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match    0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db            496 CGAGGCACATCTCC 510
              |||||
              1 CGAGGCTCATCTCC 15

```



```

REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 55 04-FEB-1997;
FEATURES
    SOURCE
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
Best Local Similarity 86.7%; Pred. No. 2.2e+02; Length 15;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 500 GCACATCTCCACCA 514
Db 1 GCTCATCTCCACCA 15

RESULT 319
LOCUS 135108 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 76 from patent US 559706.
ACCESSION 135108
VERSION 135108.1 GI:2088076
KEYWORDS
SOURCE
ORGANISM
    UNKNOWN.
    Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 76 04-FEB-1997;
FEATURES
    SOURCE
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
Best Local Similarity 86.7%; Pred. No. 2.2e+02; Length 15;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 355 CAATGCTCAGACCA 369
Db 1 CGATGCTCAGACCA 15

RESULT 320
LOCUS 135241 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 209 from patent US 559706.
ACCESSION 135241
VERSION 135241.1 GI:2088209
KEYWORDS
SOURCE
ORGANISM
    UNKNOWN.
    Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 559706-A 209 04-FEB-1997;
FEATURES
    SOURCE
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
Best Local Similarity 86.7%; Pred. No. 2.2e+02; Length 15;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 496 CGAGGCACATCTCC 510
Db 1 CGAGGCATCTCTCC 15

```

```

RESULT 321
LOCUS AR479048/c 15 bp DNA linear PAT 14-MAY-2004
DEFINITION Sequence 15 from patent US 669691.
ACCESSION AR479048
VERSION AR479048.1 GI:47237973
KEYWORDS
SOURCE
ORGANISM
    UNKNOWN.
    Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Inan,M., Meagher,M.M. and Benson,A.K.
TITLE Alcohol oxidase 1 regulatory nucleotide sequences for heterologous
JOURNAL gene expression in yeast
    Patent: US 669691-A 15 02-MAR-2004;
FEATURES
    SOURCE
        /organism="unknown"
        /mol_type="genomic DNA"

Query Match
Best Local Similarity 86.7%; Pred. No. 2.2e+02; Length 15;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 549 TATGACACCACTC 563
Db 15 TTGACCCACACTC 1

RESULT 322
LOCUS AX328777/c 15 bp DNA linear PAT 08-JAN-2002
DEFINITION Sequence 274 from Patent EP1164203.
ACCESSION AX328777
VERSION AX328777.1 GI:18101976
KEYWORDS
SOURCE
ORGANISM
    UNIDENTIFIED.
    Unclassified.
REFERENCE 1
AUTHORS Koeester,H., Little,D.P., Braun,A., Jurinke,C., van den Boom,D.,
Xiang,G., Lough,D.M., Ruppert,A. and Hillenkamp,F.
TITLE Dna diagnostics based on mass spectrometry
JOURNAL Patent: EP 1164203-A 274 19-DEC-2001;
FEATURES
    SOURCE
        /organism="unidentified"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32644"

Query Match
Best Local Similarity 86.7%; Pred. No. 2.2e+02; Length 15;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 321 TCCCGGTCTCAGTGC 335
Db 15 TCCAGAGTCTCAGTGC 1

RESULT 323
LOCUS AX586988 15 bp DNA linear PAT 10-JAN-2003
DEFINITION Sequence 10 from Patent WO02072883.
ACCESSION AX586988
VERSION AX586988.1 GI:27655863
KEYWORDS
SOURCE
ORGANISM
    Fusobacterium nucleatum subsp. nucleatum
    Bacteria; Fusobacteria; Fusobacteriales; Fusobacteriaceae;
    Fusobacterium.
REFERENCE 1

```

AUTHORS Roetger, A.
 TITLE Nucleotide carrier for diagnosing and treating oral diseases
 JOURNAL Patent: WO 02072883-A 10 19-SEP-2002;
 ROETGER, Antje (DE)
 FEATURES Location/Qualifiers
 source 1..15

/organism="Fusobacterium nucleatum subsp. nucleatum"
 /mol_type="unassigned DNA"
 /sub_species="nucleatum"
 /db_xref="taxon:76856"

Query Match
 Best Local Similarity 0.2%; Score 11.8; DB 1; Length 15;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 105 GCAAGCCATGTGTT 119
 |||||
 Db 1 GCAAGCCGTGAGT 15

RESULT 324
 AX636791/c 15 bp DNA linear PAT 21-FEB-2003
 LOCUS Sequence 3930 from Patent EP1260586.
 DEFINITION AX636791
 ACCESSION AX636791
 VERSION AX636791.1 GI:28472405
 KEYWORDS
 SOURCE unidentified
 ORGANISM unidentified
 REFERENCE unclassified.
 AUTHORS 1

Stinchcomb, D.T., Dudycz, L.W., Chowrita, B., Grimm, S., Dizenzo, A.,
 Karelsky, A., Draper, K.G., Kleich, K., Matulic-Adamic, J.,
 Mesziggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M.,
 Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and
 Woolf, T.
 TITLE Method and reagent for inhibiting the expression of disease related
 genes
 JOURNAL Patent: EP 1260586-A 3930 27-NOV-2002;
 RIBOZYME PHARMACEUTICALS, INC. (US)
 FEATURES Location/Qualifiers
 source 1..15
 /organism="unidentified"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32644"

Query Match
 Best Local Similarity 0.2%; Score 11.8; DB 1; Length 15;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 31 CTGGCAGTCCCAA 45
 |||||
 Db 15 CTGGCAGAACCAA 1

RESULT 325
 AX708801 15 bp DNA linear PAT 04-APR-2003
 LOCUS Sequence 17 from Patent WO02095071.
 DEFINITION AX708801
 ACCESSION AX708801
 VERSION AX708801.1 GI:29564528
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE artificial sequences.
 1

AUTHORS Piasterik, R.H.
 TITLE Means and methods for identifying genes and proteins involved in
 the prevention and/or repair of a replication error
 JOURNAL Patent: WO 02095071-A 17 28-NOV-2002;
 Koninklijke Nederlandse Akademie van Wetenschappen (NL)
 FEATURES Location/Qualifiers
 source 1..15

Query Match
 Best Local Similarity 0.2%; Score 11.8; DB 1; Length 15;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 144 ACAAGTATTCAGG 158
 |||||
 Db 1 AAAAGTTTCAGG 15

RESULT 326
 BD132342/c 15 bp DNA linear PAT 18-SEP-2002
 LOCUS DNA diagnosis method based on mass spectrometry.
 DEFINITION BD132342
 ACCESSION BD132342.1 GI:23227287
 VERSION BD132342
 KEYWORDS JP 2002507883-A/274.
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE artificial sequences.
 1 (bases 1 to 15)

AUTHORS Koster, H., Little, D.P., Braun, A., Lough, D.M., Xiang, G.,
 Boom, D.V.D., Jurinke, C. and Rupert, A.
 TITLE DNA diagnosis method based on mass spectrometry
 JOURNAL Patent: JP 2002507883-A 274 12-MAR-2002;
 SEQUENOM INC
 COMMENT
 PN JP 2002507883-A/274
 PD 12-MAR-2002
 PR 06-NOV-1997 JP 1998521832
 PR 06-NOV-1996 US 08/744481, 06-NOV-1996 US 08/746036 PR
 06-NOV-1996 US 08/746055, 06-NOV-1996 US 08/744590 PR
 23-JAN-1997 US 08/786988, 23-JAN-1997 US 08/787639 PR
 19-SEP-1997 US 08/933792, 08-OCT-1997 US 08/947801 PI
 KOSTER, DANIEL P LITTLE, ANDREAS BRAUN, DAVID M LOUGH, PI GUOBING
 XIANG,
 PI DIRK VAN DEN BOOM, CHRISTIAN JURINKE, ANDREAS RUPERT PC
 CI201/68, C07H21/00, C07P9/24
 CC Strandedness: Single;
 CC Topology: Unknown;
 FH Key

FEATURES Location/Qualifiers
 source 1..15
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

Query Match
 Best Local Similarity 0.2%; Score 11.8; DB 1; Length 15;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 321 TCCCGGTCTCAGTG 335
 |||||
 Db 15 TCCAGAGTCTCAGTG 1

RESULT 327
 AR235781/c 13 bp DNA linear PAT 20-DEC-2002
 LOCUS Sequence 2 from patent US 6461837.
 DEFINITION AR235781
 ACCESSION AR235781
 VERSION AR235781.1 GI:27279104
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE Unclassified.
 1 (bases 1 to 13)
 AUTHORS Yaver, D.S. and Bellini, D.A.
 TITLE Methods for producing a polypeptide using a consensus translational
 initiator sequence

JOURNAL Patent: US 6461837-A 2 08-OCT-2002;
FEATURES Location/Qualifiers
source 1..13
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 133 CATGCTGATGAGC 145
13 CATGCTGAGAGC 1

RESULT 328
AX151058 13 bp DNA linear PAT 23-JUN-2001
LOCUS
DEFINITION Sequence 2 from Patent WO0140489.
ACCESSION AX151058
VERSION AX151058.1 GI:14533260
KEYWORDS
SOURCE
ORGANISM
Aspergillus oryzae
Aspergillus oryzae
Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; Aspergillus.
Yaver, D.S. and Bellini, D.A.
METHODS for producing a polypeptide using a consensus translational
initiator sequence
Patent: WO 0140489-A 2 07-JUN-2001;
JOURNAL NOVO NORDISK BIOTECH, INC. (US)
FEATURES Location/Qualifiers
source 1..13
/organism="Aspergillus oryzae"
/mol_type="unassigned DNA"
/db_xref="taxon:5062"

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 133 CATGCTGATGAGC 145
13 CATGCTGAGAGC 1

RESULT 329
AX419854 13 bp DNA linear PAT 18-JUN-2002
LOCUS
DEFINITION Sequence 191 from Patent WO0198537.
ACCESSION AX419854
VERSION AX419854.1 GI:21524221
KEYWORDS
SOURCE
ORGANISM
synthetic construct
artificial sequences.
REFERENCE
AUTHORS
TITLE
JOURNAL
Lymichev, V., Allawi, H., Dong, F., Neri, B.P. and Vener, I.T.
Nucleic acid accessible hybridization sites
Patent: WO 0198537-A 191 27-DEC-2001;
JOURNAL THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES Location/Qualifiers
source 1..13
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 380 CCGTCGCCCTCC 392

DB 1 CCGTCACGCCCTCC 13

RESULT 330
A06948 14 bp DNA linear PAT 14-OCT-1993
LOCUS
DEFINITION Nucleotide sequence 6 from patent number EP0246864.
ACCESSION A06948
VERSION A06948.1 GI:489034
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
artificial sequences.
REFERENCE
AUTHORS
TITLE
JOURNAL
Carr, F.J.
Hybridisation probes
Patent: EP 0246864-A 6 25-NOV-1987;
JOURNAL IMPERIAL CHEMICAL INDUSTRIES PLC
FEATURES Location/Qualifiers
source 1..14
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 83 TTCTGAATCAGC 95
2 TTCTGAATGAGC 14

RESULT 331
A21463 14 bp DNA linear PAT 26-JUL-1994
LOCUS
DEFINITION oligonucleotide.
ACCESSION A21463
VERSION A21463.1 GI:579047
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
artificial sequences.
REFERENCE
AUTHORS
TITLE
JOURNAL
Charles, I.G. and Fairweather, N.F.
Bordetella vaccines
Patent: EP 0425082-A 9 02-MAY-1991;
JOURNAL THE WELLCOME FOUNDATION LIMITED
FEATURES Location/Qualifiers
source 1..14
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 415 CTAAGGCTCCTT 427
14 CTAAGGATCCTT 2

RESULT 332
A40528 14 bp DNA linear PAT 05-MAR-1997
LOCUS
DEFINITION Sequence 65 from Patent WO9425578.
ACCESSION A40528
VERSION A40528.1 GI:2296563
KEYWORDS
SOURCE
ORGANISM
unidentified

```

REFERENCE 1 unclassified.
AUTHORS 1 (bases 1 to 14)
TITLE ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE
JOURNAL EFFECTS OF TRANSFORMING GROWTH FACTOR--g(b) (TGF--g(b))
BIOGOSTIK GES (DE)
Patent: WO 9425578-A 65 10-NOV-1994;
FEATURES
SOURCE
1. .14
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 0.2%; Score 11.4; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 575 CCCCAGAACTA 587
Db 14 CCCCAGAACTA 2

RESULT 333
LOCUS A88057 14 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 205 from Patent WO9833904.
ACCESSION A88057.1 GI:6736627
VERSION A88057.1 GI:6736627
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 205 06-AUG-1998;
BIOGOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
SOURCE
1. .14
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 0.2%; Score 11.4; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 41 CCAAAATGGAACA 53
Db 13 CTAATAATGGAACA 1

RESULT 334
LOCUS A89491 14 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 1639 from Patent WO9833904.
ACCESSION A89491
VERSION A89491.1 GI:6738061
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 1639 06-AUG-1998;
BIOGOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
SOURCE
1. .14
/organism="unassigned DNA"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

```

```

Query Match
Best Local Similarity 0.2%; Score 11.4; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 113 ATGTGCTCCAGCA 125
Db 1 AGGTGCTCCAGCA 13

RESULT 335
LOCUS A90024 14 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 205 from Patent EP0856579.
ACCESSION A90024
VERSION A90024.1 GI:6738538
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 205 05-AUG-1998;
BIOGOSTIK GES (DE)
FEATURES
SOURCE
1. .14
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 0.2%; Score 11.4; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 41 CCAAAATGGAACA 53
Db 13 CTAATAATGGAACA 1

RESULT 336
LOCUS AR118971 14 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 97 from patent US 6150092.
ACCESSION AR118971
VERSION AR118971.1 GI:14100881
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 14)
AUTHORS Uchida,K., Uchida,T., Tanaka,Y., Matsuda,Y. and Kondo,S.
TITLE Antisense nucleic acid compound targeted to VEGF
JOURNAL Patent: US 6150092-A 97 21-NOV-2000;
BIOGOSTIK GES (DE)
FEATURES
SOURCE
1. .14
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.2%; Score 11.4; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 382 GTCGGGCTCCGA 394
Db 13 GTCGGGCTCCGA 1

RESULT 337
LOCUS AR178312 14 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 29 from patent US 6319672.
ACCESSION AR178312
VERSION AR178312.1 GI:20219450

```

KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 14)
TITLE Crouzet,J., Scherman,D., Wils,P., Blanche,F. and Cameron,B.
oligonucleotide
Purification of a triple helix formation with an immobilized
oligonucleotide
Patent: US 6319672-A 29 20-NOV-2001;
JOURNAL Location/Qualifiers
FEATURES
source 1..14
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 74 TTCTTTATTTCT 86
14 TTCTTTATTTCT 2

RESULT 338
ARI78313 14 bp DNA linear PAT 20-APR-2002
LOCUS
DEFINITION Sequence 30 from patent US 6319672.
ACCESSION ARI78313
VERSION ARI78313.1 GI:20219451
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 14)
TITLE Crouzet,J., Scherman,D., Wils,P., Blanche,F. and Cameron,B.
Purification of a triple helix formation with an immobilized
oligonucleotide
Patent: US 6319672-A 30 20-NOV-2001;
JOURNAL Location/Qualifiers
FEATURES
source 1..14
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 74 TTCTTTATTTCT 86
14 TTCTTTATTTCT 13

RESULT 339
BD209366/c 14 bp RNA linear PAT 17-JUN-2003
LOCUS
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
to hepatitis C virus infection.
ACCESSION BD209366
VERSION BD209366.1 GI:33019136
KEYWORDS JP 2002512791-A/2956.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS 1 (bases 1 to 14)
TITLE Blatt,L., McSwiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
Enzymatic nucleic acid treatment of diseases or conditions related
to hepatitis C virus infection
Patent: JP 2002512791-A 2956 08-MAY-2002;
JOURNAL RIBOZYME PHARMACEUTICALS INC
OS Hepatitis virus (hepatitis C virus)
PN JP 2002512791-A/2956
PF 26-APR-1999 JP 2000545991

PR 27-APR-1998 US 60/083217,18-SEP-1998 US 60/100842 PR
25-FEB-1999 US 09/257608,23-MAR-1999 US 09/274553 PI
LAWRENCE BLATT, JAMES A MCSWIGGEN, ELISABETH ROBERTS, PAMELA A PI
PAVCO, DENNIS MACEJAK
PI DENNIS MACEJAK
PC C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions
related to
hepatitis C virus infection.
CC hepatitis C virus infection.
FH key Location/Qualifiers
FT source 1..14
FT virus)'/organism="Hepatitis virus (hepatitis C FT

FEATURES
source 1..14
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 137 GTGATGACAGAG 149
14 GTGTTGACAGAG 2

RESULT 340
AR232808/c 14 bp DNA linear PAT 20-DEC-2002
LOCUS
DEFINITION Sequence 65 from patent US 6455689.
ACCESSION AR232808
VERSION AR232808.1 GI:27275146
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 14)
TITLE Schlingensiepen,G.-F., Brysch,W., Schlingensiepen,K.-H.,
Schlingensiepen,R. and Bogdan,U.
Antisense-oligonucleotides for transforming growth factor- β .
(TGF- β .)
Patent: US 6455689-A 65 24-SEP-2002;
JOURNAL Location/Qualifiers
FEATURES
source 1..14
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 575 CCCGAGATACTA 587
14 CCCGAGAGACTA 2

RESULT 341
AR300261/c 14 bp DNA linear PAT 12-JUN-2003
LOCUS
DEFINITION Sequence 63 from patent US 6537775.
ACCESSION AR300261
VERSION AR300261.1 GI:31687680
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 14)
TITLE Tournier-Laeserve,E., Joutel,A., Bousseer,M.-G. and Bach,J.-F.
Gene involved in cadasil, method of diagnosis and therapeutic

JOURNAL Application
Patent: US 6537775-A 63 25-MAR-2003;
FEATURES Location/Qualifiers
source 1..14
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 528 AACCTGCCAGCT 540
Db 13 AACCTACCAAGCT 1

RESULT 342 AX016242 14 bp DNA linear PAT 07-SEP-2000
LOCUS AX016242/c
DEFINITION Sequence 9 from Patent WO949067.
ACCESSION AX016242
VERSION AX016242.1 GI:10041819
KEYWORDS
SOURCE synthetic construct
ORGANISM artificial sequences.

REFERENCE 1
AUTHORS Wils,P., Ciolina,C. and Scherman,D.
TITLE Nucleic acid transfer vectors, compositions containing same and uses

JOURNAL Patent: WO 9949067-A 9 30-SEP-1999;
WILS PIERRE (FR); CIOLINA CAROLE (FR); SCHERMAN DANIEL (FR); RHONE
POULENC ROBER SA (FR)
FEATURES Location/Qualifiers
source 1..14
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="misc_binding"

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 74 TTCTTTATTCT 86
Db 14 TTCTTTTTTCT 2

RESULT 343 AX030103 14 bp DNA linear PAT 16-SEP-2000
LOCUS AX030103/c
DEFINITION Sequence 65 from Patent EP1008649.
ACCESSION AX030103
VERSION AX030103.1 GI:10190320
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1
AUTHORS Bogdahn,U., Brysch,W., Schlingensiepen,G.F., Schlingensiepen,K.H.
TITLE Antisense-oligonucleotides for the treatment of immunosuppressive
effects of transforming growth factor-beta (tgf-beta)
JOURNAL Patent: EP 1008649-A 65 14-JUN-2000;
BIOGNOSTIK GES (DE)
FEATURES Location/Qualifiers
source 1..14
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 575 CCCGAGATCTA 587
Db 14 CCCGAGAGACTA 2

RESULT 344 AX16424 14 bp DNA linear PAT 14-DEC-2001
LOCUS AX16424/c
DEFINITION Sequence 65 from Patent EP1160319.
ACCESSION AX16424
VERSION AX16424.1 GI:17899597
KEYWORDS
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1

JOURNAL Schlingensiepen,G.F., Brysch,W., Schlingensiepen,K.H.,
Schlingensiepen,R. and Bogdahn,U.
TITLE Antisense-oligonucleotides for the treatment of immunosuppressive
effects of transforming growth factor-beta (tgf-beta)
JOURNAL Patent: EP 1160319-A 65 05-DEC-2001;
BIOGNOSTIK GES/LSCHAFT FUER BIOMOLEKULARE DIAGNOSTIK mbH (DE)
FEATURES Location/Qualifiers
source 1..14
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/note="Description of unknown: unknown"

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 575 CCCGAGATCTA 587
Db 14 CCCGAGAGACTA 2

RESULT 345 AX233394 14 bp DNA linear PAT 07-JAN-2002
LOCUS AX233394/c
DEFINITION Sequence 29 from Patent WO0192511.
ACCESSION AX233394
VERSION AX233394.1 GI:18094156
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Cruzet,J., Scherman,D., Wils,P., Blanche,F. and Cameron,B.
TITLE Purification of a triple helix formation with an immobilized
oligonucleotide
JOURNAL Patent: WO 0192511-A 29 06-DEC-2001;
Aventis Pharma (FR)
FEATURES Location/Qualifiers
source 1..14
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="synthetic oligonucleotide"

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 74 TTCTTTATTCT 86
Db 14 TTCTTTTTTCT 2

```

RESULT 346
AX323395          14 bp   DNA       linear   PAT 07-JAN-2002
LOCUS             Sequence 30 from Patent WO0192511.
DEFINITION        AX323395
ACCESSION         AX323395
VERSION           AX323395.1 GI:18094157
KEYWORDS
SOURCE
ORGANISM          synthetic construct
                  artificial sequence.
REFERENCE
1
AUTHORS          Crouzet,V., Scherman,D., Wils,P., Blanche,F. and Cameron,B.
TITLE            Purification of a triple helix formation with an immobilized
                  oligonucleotide
JOURNAL          Patent: WO 0192511-A 30 06-DEC-2001;
                  Aventis Pharma (FR)
FEATURES
source            Location/Qualifiers
                  1..14
                  /organism="synthetic construct"
                  /mol_type="unassigned DNA"
                  /db_xref="taxon:32630"
                  /note="synthetic oligonucleotide"

Query Match      0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY              74 TTCTTTTATTTCCT 86
                  |||||
                  1 TTCTTTTTCCT 13

RESULT 347
BD065570/c        14 bp   DNA       linear   PAT 27-AUG-2002
LOCUS             An antisense oligonucleotide preparation method.
DEFINITION        BD065570
ACCESSION         BD065570
VERSION           BD065570.1 GI:22611173
KEYWORDS          JP 2001511000-A/205.
SOURCE            unidentified
ORGANISM          unidentified
                  unclassified.
REFERENCE
1 (bases 1 to 14)
AUTHORS          Schlingensiepen,K.H. and Brysch,W.
TITLE            An antisense oligonucleotide preparation method
JOURNAL          Patent: JP 2001511000-A 205 07-AUG-2001;
                  BIOLOGISTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT
OS              Unknown
PN              JP 2001511000-A/205
PD              07-AUG-2001
PF              30-JAN-1998 JP 1998532533
PI              31-JAN-1997 EP 97101531.8
PT              KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
PC              C12N15/11,C07H21/04,A61K31/70
CC              An antisense oligonucleotide preparation method FH Key
                  Location/Qualifiers
                  1..14
                  FT source
                  /organism="unknown".
                  Location/Qualifiers
                  1..14
                  /organism="unidentified"
                  /mol_type="genomic DNA"
                  /db_xref="taxon:32644"

Query Match      0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY              41 CCAAAATGGAACA 53
                  |||||
                  13 CTAATGGAACA 1

FEATURES
source            Location/Qualifiers
                  1..14
                  /organism="unidentified"
                  /mol_type="genomic DNA"
                  /db_xref="taxon:32644"

```

```

RESULT 348
BD067004          14 bp   DNA       linear   PAT 27-AUG-2002
LOCUS             BD067004
DEFINITION        An antisense oligonucleotide preparation method.
ACCESSION         BD067004
VERSION           BD067004.1 GI:22612607
KEYWORDS          JP 2001511000-A/1639.
SOURCE            unidentified
ORGANISM          unidentified
                  unclassified.
REFERENCE
1 (bases 1 to 14)
AUTHORS          Schlingensiepen,K.H. and Brysch,W.
TITLE            An antisense oligonucleotide preparation method
JOURNAL          Patent: JP 2001511000-A 1639 07-AUG-2001;
                  BIOLOGISTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT
OS              Unknown
PN              JP 2001511000-A/1639
PD              07-AUG-2001
PF              30-JAN-1998 JP 1998532533
PI              31-JAN-1997 EP 97101531.8
PT              KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
PC              C12N15/11,C07H21/04,A61K31/70
CC              An antisense oligonucleotide preparation method FH Key
                  Location/Qualifiers
                  1..14
                  FT source
                  /organism="unknown".
                  Location/Qualifiers
                  1..14
                  /organism="unidentified"
                  /mol_type="genomic DNA"
                  /db_xref="taxon:32644"

Query Match      0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY              113 ATGTGTCACAGA 125
                  |||||
                  1 AGTGTTCACAGA 13

RESULT 349
BD135020/c        14 bp   DNA       linear   PAT 18-SEP-2002
LOCUS             BD135020
DEFINITION        Vector having nucleic acid transferred thereinto, compositions
                  containing the vector and utilization thereof.
ACCESSION         BD135020
VERSION           BD135020.1 GI:23229965
KEYWORDS          JP 2002507429-A/9.
SOURCE            unidentified
ORGANISM          unidentified
                  unclassified.
REFERENCE
1 (bases 1 to 14)
AUTHORS          Storrin,C., Sherman,D. and Wille,P.
TITLE            Vector having nucleic acid transferred thereinto, compositions
                  containing the vector and utilization thereof
JOURNAL          Patent: JP 2002507429-A 9 12-MAR-2002;
                  AVENTIS PHARMA SA
COMMENT
OS              Unidentified
PN              JP 2002507429-A/9
PD              12-MAR-2002
PF              19-MAR-1999 JP 2000538027
PI              24-MAR-1998 FR 98/03573,18-MAY-1998 US 60/085 848 PI
PT              CAROL STORINA,DANIEL SHERMAN,PIERRE WILLS
PC              C12N15/09,A61K39/39,A61K48/00,C12N1/15,C12N1/19,C12N5/10,PC
                  C12N15/00,
                  PC C12N5/00
CC              Strandedness: Single;
                  CC Topology: Linear;
                  CC Vector having nucleic acid transferred thereinto, compositions
                  containing

```

CC the vector and utilization thereof
 FH Key Location/Qualifiers
 FT source 1..14
 FT /organism='Unidentified'.
 FEATURES
 source 1..14
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

Query Match 0.2%; Score 11.4; DB 1; Length 14;
 Best Local Similarity 92.3%; Pred. No. 2.2e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 74 TTCTTTATTTCT 86
 Db 14 TTCTTTATTTCT 2

RESULT 350
 A32711/c 15 bp DNA linear PAT 05-JUL-1996
 LOCUS Synthetic capture probe for HPV6 E7 gene.
 DEFINITION A32711
 ACCESSION A32711 GI:1567559
 VERSION A32711.1 GI:1567559
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1 (bases 1 to 15)
 AUTHORS
 TITLE METHOD FOR DETECTING A NUCLEOTIDE SEQUENCE BY SANDWICH
 JOURNAL HYBRIDIZATION
 FEATURES Patent: WO 9119812-A 11 26-DEC-1991;
 source Location/Qualifiers
 1..15
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 18 TTCTGACACTCG 30
 Db 13 TTCTGACACTCG 1

RESULT 351
 A88231/c 15 bp DNA linear PAT 22-JAN-2000
 LOCUS Sequence 379 from Patent WO9833904.
 DEFINITION A88231
 ACCESSION A88231 GI:6736801
 VERSION A88231.1 GI:6736801
 KEYWORDS
 SOURCE unidentified
 ORGANISM unidentified
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Brysch,W. and Schlingensiepen,K.
 TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
 JOURNAL Patent: WO 9833904-A 379 06-AUG-1998;
 BIOGOSTRIK GES (DE); BRYSCH WOLFGANG (DE)
 FEATURES Location/Qualifiers
 1..15
 /organism="unidentified"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32644"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 527 GAACCTGCCAGC 539
 Db 14 GAACCTGCCAGC 2

RESULT 352
 A90198/c 15 bp DNA linear PAT 22-JAN-2000
 LOCUS Sequence 379 from Patent EP0856579.
 DEFINITION A90198
 ACCESSION A90198 GI:6738712
 VERSION A90198.1 GI:6738712
 KEYWORDS
 SOURCE unidentified
 ORGANISM unidentified

REFERENCE 1 (bases 1 to 15)
 AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
 TITLE An antisense oligonucleotide preparation method
 JOURNAL Patent: EP 0856579-A 379 05-AUG-1998;
 BIOGOSTRIK GES (DE)
 FEATURES Location/Qualifiers
 1..15
 /organism="unidentified"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32644"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 527 GAACCTGCCAGC 539
 Db 14 GAACCTGCCAGC 2

RESULT 353
 AR019424 15 bp DNA linear PAT 05-DEC-1998
 LOCUS Sequence 12 from patent US 5783431.
 DEFINITION AR019424
 ACCESSION AR019424 GI:3974538
 VERSION AR019424.1 GI:3974538
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Peterson,T.C., Foster,L.M. and Brian,P.
 TITLE Methods for generating and screening novel metabolic pathways
 JOURNAL Patent: US 5783431-A 12 21-JUL-1998;
 FEATURES Location/Qualifiers
 1..15
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 314 CGAGGATCCCGG 326
 Db 2 CGAGGATCCCGG 14

RESULT 354
 AR024030/c 15 bp DNA linear PAT 05-DEC-1998
 LOCUS Sequence 18 from patent US 5795770.
 DEFINITION AR024030
 ACCESSION AR024030 GI:3977324
 VERSION AR024030.1 GI:3977324
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Gaber, R.F.
TITLE Genetically engineered eukaryotic organism capable of detecting the expression of heterologous ion channels and method to use the same
JOURNAL Patent: US 5795770-A 18 18-AUG-1998;
FEATURES
SOURCE 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 518 TCACAGAGAGAC 530
DB 15 TCACAGTAGAAC 3

RESULT 355
AR029145/c 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR029145
DEFINITION Sequence 21 from patent US 5859221.
ACCESSION AR029145
VERSION AR029145.1 GI:5941118
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Cook, P.Dan. and Kawasaki, A.Mamoru.
TITLE 2'-modified oligonucleotides
JOURNAL Patent: US 5859221-A 21 12-JAN-1999;
FEATURES
SOURCE 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
DB 13 ACTGCATAGTCG 1

RESULT 356
AR029148/c 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR029148
DEFINITION Sequence 24 from patent US 5859221.
ACCESSION AR029148
VERSION AR029148.1 GI:5941121
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Cook, P.Dan. and Kawasaki, A.Mamoru.
TITLE 2'-modified oligonucleotides
JOURNAL Patent: US 5859221-A 24 12-JAN-1999;
FEATURES
SOURCE 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
DB 13 ACTGCATAGTCG 1

DB 13 ACTGCATAGTCG 1

RESULT 357
AR030938/c 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR030938
DEFINITION Sequence 12 from patent US 5861493.
ACCESSION AR030938
VERSION AR030938.1 GI:5944152
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Cook, P.Dan., Sprinkle, R.H., Sprankle, K.G. and Ross, B.S.
TITLE Process for the synthesis of 2'-O-substituted pyrimidines
JOURNAL Patent: US 5861493-A 12 19-JAN-1999;
FEATURES
SOURCE 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
DB 13 ACTGCATAGTCG 1

RESULT 358
AR030939/c 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR030939
DEFINITION Sequence 13 from patent US 5861493.
ACCESSION AR030939
VERSION AR030939.1 GI:5944153
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Cook, P.Dan., Springer, R.H., Sprankle, K.G. and Ross, B.S.
TITLE Process for the synthesis of 2'-O-substituted pyrimidines
JOURNAL Patent: US 5861493-A 13 19-JAN-1999;
FEATURES
SOURCE 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
DB 13 ACTGCATAGTCG 1

RESULT 359
AR030940/c 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR030940
DEFINITION Sequence 14 from patent US 5861493.
ACCESSION AR030940
VERSION AR030940.1 GI:5944154
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Cook, P.Dan., Springer, R.H., Sprankle, K.G. and Ross, B.S.
TITLE Process for the synthesis of 2'-O-substituted pyrimidines
JOURNAL Patent: US 5861493-A 14 19-JAN-1999;

FEATURES
source

Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.2%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTCGCATAGTCG 572
Db 13 ACTTGCAATAGTCG 1

RESULT 360
AR030941/c 15 bp DNA linear PAT 29-SEP-1999

DEFINITION
AR030941 Sequence 15 from patent US 5861493.
ACCESSION
AR030941
VERSION
AR030941.1 GI:5944155
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unclassified.

REFERENCE
1 (bases 1 to 15)
AUTHORS
Cook, P. Dan., Springer, R. H., Sprankle, K. G. and Ross, B. S.
TITLE
Process for the synthesis of 2'-O-substituted pyrimidines
JOURNAL
Patent: US 5861493-A 15 19-JAN-1999;
FEATURES
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.2%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTCGCATAGTCG 572
Db 13 ACTTGCAATAGTCG 1

RESULT 361
AR030942/c 15 bp DNA linear PAT 29-SEP-1999

DEFINITION
AR030942 Sequence 16 from patent US 5861493.
ACCESSION
AR030942
VERSION
AR030942.1 GI:5944156
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unclassified.

REFERENCE
1 (bases 1 to 15)
AUTHORS
Cook, P. Dan., Springer, R. H., Sprankle, K. G. and Ross, B. S.
TITLE
Process for the synthesis of 2'-O-substituted pyrimidines
JOURNAL
Patent: US 5861493-A 16 19-JAN-1999;
FEATURES
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.2%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTCGCATAGTCG 572
Db 13 ACTTGCAATAGTCG 1

RESULT 362
AR033422/c 15 bp DNA linear PAT 29-SEP-1999

DEFINITION
AR033422 Sequence 188 from patent US 5869253.
ACCESSION
AR033422
VERSION
AR033422.1 GI:5949027
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unclassified.

REFERENCE
1 (bases 1 to 15)
AUTHORS
Draper, K. G.
TITLE
Method and reagent for inhibiting hepatitis C virus replication
JOURNAL
Patent: US 5869253-A 188 09-FEB-1999;
FEATURES
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.2%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 36 CAGTCCCAATG 48
Db 15 CAGTCCCAATG 3

RESULT 363
AR033480/c 15 bp DNA linear PAT 29-SEP-1999

DEFINITION
AR033480 Sequence 246 from patent US 5869253.
ACCESSION
AR033480
VERSION
AR033480.1 GI:5949085
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unclassified.

REFERENCE
1 (bases 1 to 15)
AUTHORS
Draper, K. G.
TITLE
Method and reagent for inhibiting hepatitis C virus replication
JOURNAL
Patent: US 5869253-A 246 09-FEB-1999;
FEATURES
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

QY 137 GTGATGCACAGAG 149
Db 14 GTGTTGCACAGAG 2

RESULT 364
AR036529/c 15 bp DNA linear PAT 29-SEP-1999

DEFINITION
AR036529 Sequence 21 from patent US 5872232.
ACCESSION
AR036529
VERSION
AR036529.1 GI:5953197
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unclassified.

REFERENCE
1 (bases 1 to 15)
AUTHORS
Cook, P. Dan. and Kawasaki, A. Mamoru.
TITLE
2'-O-modified oligonucleotides
JOURNAL
Patent: US 5872232-A 21 16-FEB-1999;
FEATURES
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 365
AR036532/c 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR036532
DEFINITION Sequence 24 from patent US 5872232.
ACCESSION AR036532
VERSION AR036532.1 GI:5953200
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Cook, P. Dan. and Kawasaki, A. Mamoru.
TITLE 2'-O-modified oligonucleotides
JOURNAL Patent: US 5872232-A 24 16-FEB-1999;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 366
AR056504 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR056504
DEFINITION Sequence 708 from patent US 5837542.
ACCESSION AR056504
VERSION AR056504.1 GI:5982081
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm, S., Stinchcomb, D. T., McSwiggen, J., Sullivan, S. and Draper, K. G.
TITLE Inter cellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 708 17-NOV-1998;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 59 AAGTGGTTCTTCT 71
Db 1 AAGTGGTTCTTCT 13

RESULT 367
AR056536 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR056536
DEFINITION Sequence 740 from patent US 5837542.
ACCESSION AR056536
VERSION AR056536.1 GI:5982113
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm, S., Stinchcomb, D. T., McSwiggen, J., Sullivan, S. and Draper, K. G.
TITLE Inter cellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 740 17-NOV-1998;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 59 AAGTGGTTCTTCT 71
Db 1 AAGTGGTTCTTCT 13

RESULT 368
AR082988/c 15 bp DNA linear PAT 01-SEP-2000
LOCUS AR082988
DEFINITION Sequence 14 from patent US 5976798.
ACCESSION AR082988
VERSION AR082988.1 GI:10009778
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Parker, W. Davis., Herrin, C., Ghosh, S. and Faby, E. D.
TITLE Methods for detecting mitochondrial mutations diagnostic for Alzheimer's disease and methods for determining heteroplasmy of mitochondrial nucleic acid
JOURNAL Patent: US 5976798-A 14 02-NOV-1999;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 257 GCTTGATCATGAA 269
Db 15 GCGTGATCATGAA 3

RESULT 369
AR096062/c 15 bp DNA linear PAT 08-SEP-2000
LOCUS AR096062
DEFINITION Sequence 21 from patent US 6005087.
ACCESSION AR096062
VERSION AR096062.1 GI:10024522
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Cook, P. Dan. and Kawasaki, A. Mamoru.
TITLE 2'-modified oligonucleotides
JOURNAL Patent: US 6005087-A 21 21-DEC-1999;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTCGCATAGTCG 572
DB 13 ACTGCCAATGTCG 1

RESULT 370
AR096065/c 15 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 24 from patent US 6005087.
ACCESSION AR096065
VERSION AR096065.1 GI:10024528
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Cook, P.Dan. and Kawasaki, A.Mamoru.
TITLE 2'-modified oligonucleotides
JOURNAL Patent: US 6005087-A 24 21-DEC-1999;
FEATURES Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTCGCATAGTCG 572
DB 13 ACTGCCAATGTCG 1

RESULT 371
AR113244/c 15 bp DNA linear PAT 16-MAY-2001
LOCUS AR113244
DEFINITION Sequence 188 from patent US 6132966.
ACCESSION AR113244
VERSION AR113244.1 GI:14093566
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Draper, K.G.
TITLE Method and reagent for inhibiting hepatitis C virus replication
JOURNAL Patent: US 6132966-A 188 17-OCT-2000;
FEATURES Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 36 CAGTCCCAATG 48
DB 15 CAGTCCCAATG 3

RESULT 372
AR113302/c 15 bp DNA linear PAT 16-MAY-2001
LOCUS AR113302
DEFINITION Sequence 246 from patent US 6132966.
ACCESSION AR113302
VERSION AR113302.1 GI:14093624
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)

AUTHORS Draper, K.G.
TITLE Method and reagent for inhibiting hepatitis C virus replication
JOURNAL Patent: US 6132966-A 246 17-OCT-2000;
FEATURES Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 137 GTGATGACACAG 149
DB 14 GTGTTGACACAG 2

RESULT 373
AR114262 15 bp DNA linear PAT 16-MAY-2001
LOCUS AR114262
DEFINITION Sequence 708 from patent US 6132967.
ACCESSION AR114262
VERSION AR114262.1 GI:14094584
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm, S., Stinchcomb, D.T., McSwiggen, J., Sullivan, S. and Draper, K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 708 17-OCT-2000;
FEATURES Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 59 AAGTGTTCTTCT 71
DB 1 AAGTGTTCTTCT 13

RESULT 374
AR114294 15 bp DNA linear PAT 16-MAY-2001
LOCUS AR114294
DEFINITION Sequence 740 from patent US 6132967.
ACCESSION AR114294
VERSION AR114294.1 GI:14094616
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm, S., Stinchcomb, D.T., McSwiggen, J., Sullivan, S. and Draper, K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 740 17-OCT-2000;
FEATURES Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 59 AAGTGTTCTTCT 71

Db 1 |||||
1 AGGTGTTCTTCT 13

RESULT 375
ARI16342/c 15 bp DNA linear PAT 16-MAY-2001
LOCUS Sequence 30 from patent US 6133031.
DEFINITION ARI16342
ACCESSION ARI16342 GI:14096664
VERSION ARI16342.1
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 15)
TITLE Monta, B.P. and Gaarde, W.A.
JOURNAL Antisense inhibition of focal adhesion kinase expression
FEATURES Patent: US 6133031-A 30 17-OCT-2000;
1. .15 Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 293 TGGCAGCTCCTTA 305
|||
13 TGGCAGCTCCTTA 1

RESULT 376
ARI33220/c 15 bp DNA linear PAT 16-MAY-2001
LOCUS ARI33220
DEFINITION Sequence 1645 from patent US 6194150.
ACCESSION ARI33220
VERSION ARI33220.1 GI:14122125
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 15)
TITLE Stinchcomb, D.T., Jarvis, T. and McSwiggen, J.
JOURNAL Nucleic acid based inhibition of CD40
FEATURES Patent: US 6194150-A 1645 27-FEB-2001;
1. .15 Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 84 TCTGAATCAGCA 96
|||
13 TCTGAATCAGCA 1

RESULT 377
ARI33221/c 15 bp DNA linear PAT 16-MAY-2001
LOCUS ARI33221
DEFINITION Sequence 1646 from patent US 6194150.
ACCESSION ARI33221
VERSION ARI33221.1 GI:14122126
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 15)
TITLE Stinchcomb, D.T., Jarvis, T. and McSwiggen, J.
JOURNAL Nucleic acid based inhibition of CD40

JOURNAL Patent: US 6194150-A 1646 27-FEB-2001;
FEATURES Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 84 TCTGAATCAGCA 96
|||
13 TCTGAATCAGCA 1

RESULT 378
ARI33222/c 15 bp DNA linear PAT 16-MAY-2001
LOCUS ARI33222
DEFINITION Sequence 1647 from patent US 6194150.
ACCESSION ARI33222
VERSION ARI33222.1 GI:14122127
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 15)
TITLE Stinchcomb, D.T., Jarvis, T. and McSwiggen, J.
JOURNAL Nucleic acid based inhibition of CD40
FEATURES Patent: US 6194150-A 1647 27-FEB-2001;
1. .15 Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 84 TCTGAATCAGCA 96
|||
13 TCTGAATCAGCA 1

RESULT 379
ARI33223/c 15 bp DNA linear PAT 16-MAY-2001
LOCUS ARI33223
DEFINITION Sequence 1648 from patent US 6194150.
ACCESSION ARI33223
VERSION ARI33223.1 GI:14122128
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 15)
TITLE Stinchcomb, D.T., Jarvis, T. and McSwiggen, J.
JOURNAL Nucleic acid based inhibition of CD40
FEATURES Patent: US 6194150-A 1648 27-FEB-2001;
1. .15 Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 84 TCTGAATCAGCA 96
|||
13 TCTGAATCAGCA 1

RESULT 380
ARI33250/c

```

LOCUS       AR133250                               15 bp      DNA      linear      PAT 16-MAY-2001
DEFINITION   Sequence 1675 from patent US 6194150.
ACCESSION   AR133250
VERSION      AR133250.1  GI:14122155
KEYWORDS
SOURCE
ORGANISM     Unknown.
REFERENCE
  1 (bases 1 to 15)
  Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  Nucleic acid based inhibition of CD40
  JOURNAL
  Patent: US 6194150-A 1675 27-FEB-2001;
  Location/Qualifiers
    source
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  Best Local Similarity  0.2%; Score 11.4; DB 1; Length 15;
  Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      577 CCAGATACTACC 589
Db      14 CCAAAATACTACC 2

RESULT 381
LOCUS       AR133251                               15 bp      DNA      linear      PAT 16-MAY-2001
DEFINITION   Sequence 1676 from patent US 6194150.
ACCESSION   AR133251
VERSION      AR133251.1  GI:14122156
KEYWORDS
SOURCE
ORGANISM     Unknown.
REFERENCE
  1 (bases 1 to 15)
  Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  Nucleic acid based inhibition of CD40
  JOURNAL
  Patent: US 6194150-A 1676 27-FEB-2001;
  Location/Qualifiers
    source
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  Best Local Similarity  0.2%; Score 11.4; DB 1; Length 15;
  Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      577 CCAGATACTACC 589
Db      14 CCAAAATACTACC 2

RESULT 382
LOCUS       AR133686/c                             15 bp      DNA      linear      PAT 16-MAY-2001
DEFINITION   Sequence 2111 from patent US 6194150.
ACCESSION   AR133686
VERSION      AR133686.1  GI:14122591
KEYWORDS
SOURCE
ORGANISM     Unknown.
REFERENCE
  1 (bases 1 to 15)
  Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  Nucleic acid based inhibition of CD40
  JOURNAL
  Patent: US 6194150-A 2111 27-FEB-2001;
  Location/Qualifiers
    source
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  Best Local Similarity  0.2%; Score 11.4; DB 1; Length 15;
  Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      577 CCAGATACTACC 589
Db      14 CCAAAATACTACC 2

RESULT 383
LOCUS       AR156380                               15 bp      DNA      linear      PAT 08-AUG-2001
DEFINITION   Sequence 9 from patent US 6242211.
ACCESSION   AR156380
VERSION      AR156380.1  GI:15125084
KEYWORDS
SOURCE
ORGANISM     Unknown.
REFERENCE
  1 (bases 1 to 15)
  Peterson,T.C. and Brian,P.
  Methods for generating and screening novel metabolic pathways
  JOURNAL
  Patent: US 6242211-A 9 05-JUN-2001;
  Location/Qualifiers
    source
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  Best Local Similarity  0.2%; Score 11.4; DB 1; Length 15;
  Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      314 CGAGGATCCCG 326
Db      2 CGGGGATCCCG 14

RESULT 384
LOCUS       AR174819                               15 bp      DNA      linear      PAT 17-DEC-2001
DEFINITION   Sequence 1 from patent US 6307040.
ACCESSION   AR174819
VERSION      AR174819.1  GI:17915139
KEYWORDS
SOURCE
ORGANISM     Unknown.
REFERENCE
  1 (bases 1 to 15)
  Cook,P.Dan. and Kawasaki,A.M.
  Sugar modified oligonucleotides that detect and modulate gene
  expression
  JOURNAL
  Patent: US 6307040-A 1 23-OCT-2001;
  Location/Qualifiers
    source
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  Best Local Similarity  0.2%; Score 11.4; DB 1; Length 15;
  Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      560 ACTGCATAGTCG 572
Db      13 ACTGCATAGTCG 1

RESULT 385
LOCUS       AR174822/c                             15 bp      DNA      linear      PAT 17-DEC-2001
DEFINITION   Sequence 4 from patent US 6307040.
ACCESSION   AR174822
VERSION      AR174822.1  GI:17915142
KEYWORDS

```

```

SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 15)
AUTHORS     Cook,P.Dan. and Kawasaki,A.M.
TITLE       Sugar modified oligonucleotides that detect and modulate gene
            expression
JOURNAL     Patent: US 6307040-A 4 23-OCT-2001;
FEATURES    Location/Qualifiers
            source
              1..15
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      560 ACTGCATAGTCG 572
Db      13 ACTGCATAGTCG 1

RESULT 386
AR174826/c
LOCUS      AR174826      15 bp      DNA      linear      PAT 17-DEC-2001
DEFINITION Sequence 8 from patent US 6307040.
ACCESSION  AR174826
VERSION     AR174826.1 GI:17915146
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 15)
AUTHORS     Cook,P.Dan. and Kawasaki,A.M.
TITLE       Sugar modified oligonucleotides that detect and modulate gene
            expression
JOURNAL     Patent: US 6307040-A 8 23-OCT-2001;
FEATURES    Location/Qualifiers
            source
              1..15
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      560 ACTGCATAGTCG 572
Db      13 ACTGCATAGTCG 1

RESULT 387
BD176030
LOCUS      BD176030      15 bp      DNA      linear      PAT 18-MAR-2003
DEFINITION Method for production of recombinant protein.
ACCESSION  BD176030
VERSION     BD176030.1 GI:29121734
KEYWORDS    JP 2002272481-A/62.
SOURCE      synthetic construct
            synthetic construct
            artificial sequences.
REFERENCE   1 (bases 1 to 15)
AUTHORS     Ito,T., Tanaka,Y. and Kondo,M.
TITLE       Method for production of recombinant protein
JOURNAL     Patent: JP 2002272481-A 62 24-SEP-2002;
            TAKEDA CHEMICAL INDUSTRIES LTD
FEATURES    OS Artificial Sequence
            PN JP 2002272481-A/62
            PD 24-SEP-2002
            PF 25-JUL-2001 JP 2001224117
            PI TAKASHI ITO,YOKO TANAKA,MITSUYO KONDO
            PC C12N15/09,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12P21/02// PC
            AG1K38/00,

COMMENT

```

```

PC      A61P43/00, (C12P21/02,C12R1.01),C12N15/00,C12N5/00,A61K37/02 CC
        Synthetic DNA
        FH Key      Location/Qualifiers
        FT source      1..15
        FT      /organism='Artificial Sequence'.
FEATURES    Location/Qualifiers
            source
              1..15
              /organism="synthetic construct"
              /mol_type="genomic DNA"
              /db_xref="taxon:32630"

Query Match      0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      403 CCGGTTCCAGCC 415
Db      3 CCGGTTCCATGCC 15

RESULT 388
BD184560/c
LOCUS      BD184560      15 bp      DNA      linear      PAT 17-JUN-2003
DEFINITION Method and detector for identifying subtypes of human papilloma
            viruses.
ACCESSION  BD184560
VERSION     BD184560.1 GI:31876760
KEYWORDS    JP 2002360271-A/539.
SOURCE      synthetic construct
            synthetic construct
            artificial sequences.
REFERENCE   1 (bases 1 to 15)
AUTHORS     Liang,C., Lin,R., Yoo,Z., Huang,X., Lee,B., Lee,S., Lin,Y.,
            Huang,C., Hsu,H., Shi,C., Yeh,C., Cao,Y. and Pan,C.
TITLE       Method and detector for identifying subtypes of human papilloma
            virus
JOURNAL     Patent: JP 2002360271-A 539 17-DEC-2002;
            KING CAR FOOD INDUSTRIAL CO LTD
FEATURES    OS Artificial Sequence
            PN JP 2002360271-A/539
            PD 17-DEC-2002
            PF 28-NOV-2001 JP 2001362595
            PR 04-MAY-2001 TW 90110785
            PI CHING-YEE LING,RUEY-WEN LIN,ZHOU-MENG YOO,XIN-HSUAN HUANG,BOW-
            PI HAENG LEE,
            PI SHENG-HSIUNG LEE,YI-JU LIN,CI-CHUNG HUANG,HAN-CHANG HSU,CHA-
            PI WEN SHI,
            PI CHIH-XIN YEH,YI-FENG CAO,CHIH-LONG PAN
            PC C12N15/09,C12N15/09,C12M1/34,C12Q1/04,C12Q1/42,C12Q1/68 PC
            ,C12Q1/70,G01N21/64,
            PC G01N33/53,G01N33/574,G01N33/58,G01N37/00// (C12M1/34,C12R1.93),
            PC (C12Q1/70,C12R1.93),C12N15/00,C12N15/00
            CC Oligonucleotide M7203 for identifying HPV 72. FH Key
            Location/Qualifiers
            source
              1..15
              /organism='Artificial Sequence'.
            FT
            FT      Location/Qualifiers
            FT      1..15
            FT      /organism="synthetic construct"
            FT      /mol_type="genomic DNA"
            FT      /db_xref="taxon:32630"

Query Match      0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      286 GATGCTGTGGCAG 298
Db      13 GAGCGTGTGGCAG 1

RESULT 389
BD207155/c
LOCUS      BD207155      15 bp      RNA      linear      PAT 17-JUL-2003

```

DEFINITION	Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection.
ACCESSION	BD207155
VERSION	BD207155.1 GI:33016925
KEYWORDS	JP 2002512791-A/745.
SOURCE	unidentified
ORGANISM	unclassified
REFERENCE	1 (bases 1 to 15)
AUTHORS	Blatt,L., Mewswigen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE	Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
JOURNAL	Patent: JP 2002512791-A 745 08-MAY-2002;
COMMENT	RIBOZYME PHARMACEUTICALS INC OS Hepatitis virus (hepatitis C virus) PN JP 2002512791-A/745 PD 08-MAY-2002 PF 26-APR-1999 JP 2000545991 PR 27-APR-1998 US 60/083217,18-SRP-1998 US 60/100842 PR 25-FEB-1999 US 09/257608,23-MAR-1999 US 09/274553 PI * LAWRENCE BLATT,JAMES A MCSWIGEN,ELISABETH ROBERTS,PAMELA A PAVCO. PI DENNIS MACEJAK PC C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09, PC A61K37/66, PC C12N15/00 CC Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection. CC key Location/Qualifiers FT source 1..15 virus' /organism='Hepatitis virus (hepatitis C FT
FEATURES	source 1..15 Location/Qualifiers /organism="unidentified" /mol_type="genomic RNA" /db_xref="taxon:32644"
Query Match	0.2% Score 11.4; DB 1; Length 15; Best Local Similarity 92.3%; Pred. No.2.5e+02; Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY	36 CAGTCCCAATG 48
Db	15 CAGTCCCAAGTG 3
RESULT 390	
BD207213/C	
LOCUS	BD207213 15 bp RNA linear PAT 17-JUL-2003
DEFINITION	Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection.
ACCESSION	BD207213
VERSION	BD207213.1 GI:33016983
KEYWORDS	JP 2002512791-A/803.
SOURCE	unidentified
ORGANISM	unclassified
REFERENCE	1 (bases 1 to 15)
AUTHORS	Blatt,L., Mewswigen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE	Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
JOURNAL	Patent: JP 2002512791-A 803 08-MAY-2002;
COMMENT	RIBOZYME PHARMACEUTICALS INC OS Hepatitis virus (hepatitis C virus) PN JP 2002512791-A/803 PD 08-MAY-2002 PF 26-APR-1999 JP 2000545991 PR 27-APR-1998 US 60/083217,18-SRP-1998 US 60/100842 PR 25-FEB-1999 US 09/257608,23-MAR-1999 US 09/274553 PI LAWRENCE BLATT,JAMES A MCSWIGEN,ELISABETH ROBERTS,PAMELA A PAVCO,

[illegible]

VERSION I19571.1 GI:1599926
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Hoke, G. and Cook, P. D.
TITLE Oligonucleotides with substantially chirally pure phosphorothioate linkages
JOURNAL Patent: US 5506212-A 9 09-APR-1996;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 393
LOCUS I21595 15 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 7 from patent US 5521302.
ACCESSION I21595
VERSION I21595.1 GI:1601949
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Cook, P. D.
TITLE Process for preparing oligonucleotides having chiral phosphorus linkages
JOURNAL Patent: US 5521302-A 7 28-MAY-1996;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 394
LOCUS I29017 15 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 13 from patent US 5576302.
ACCESSION I29017
VERSION I29017.1 GI:1819808
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Cook, P. D. and Hoke, G.
TITLE Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
JOURNAL Patent: US 5576302-A 13 19-NOV-1996;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 395
LOCUS I32400 15 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 13 from patent US 5587361.
ACCESSION I32400
VERSION I32400.1 GI:1823191
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Cook, P. D. and Hoke, G.
TITLE Oligonucleotides having phosphorothioate linkages of high chiral purity
JOURNAL Patent: US 5587361-A 13 24-DEC-1996;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 396
LOCUS I35091 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 59 from patent US 5599706.
ACCESSION I35091
VERSION I35091.1 GI:2088059
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb, P. T., McSwiggen, J., Newton, R. S. and Ramharack, R.
TITLE Ribozymes targeted to apo(a) mRNA
JOURNAL Patent: US 5599706-A 59 04-FEB-1997;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 402 CCCGTTCCAAGC 414
Db 2 CCCAGTTCCAAGC 14

RESULT 397
LOCUS I35252 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 220 from patent US 5599706.
ACCESSION I35252
VERSION I35252.1 GI:2088220
KEYWORDS

```
SOURCE      UNKNOWN.
ORGANISM     UNKNOWN.
REFERENCE    1 (bases 1 to 15)
AUTHORS      Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE        Ribozymes targeted to apo(a) mRNA
JOURNAL      Patent: US 559706-A 220 04-FEB-1997;
FEATURES     Location/Qualifiers
             1..15
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy          402 CCCGATTCGAGC 414
Db          2 CCCAGTTCGAGC 14

RESULT 398
LOCUS       136653
DEFINITION  Sequence 13 from patent US 5607923.
ACCESSION   136653
VERSION     136653.1 GI:2086478
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 15)
AUTHORS      Cook,P.D. and Hoke,G.
TITLE        Oligonucleotides for modulating cytomegalovirus having
JOURNAL      phosphorothioate linkages of high chiral purity
FEATURES     Patent: US 5607923-A 13 04-MAR-1997;
             Location/Qualifiers
             1..15
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy          560 ACTCGCATAGTCG 572
Db          13 ACTTGCATAGTCG 1

RESULT 399
LOCUS       138652
DEFINITION  Sequence 12 from patent US 5614617.
ACCESSION   138652
VERSION     138652.1 GI:2084706
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 15)
AUTHORS      Cook,P.D. and Sanghvi,Y.S.
TITLE        Nuclease resistant, pyrimidine modified oligonucleotides that
JOURNAL      detect and modulate gene expression
FEATURES     Patent: US 5614617-A 12 25-MAR-1997;
             Location/Qualifiers
             1..15
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy          560 ACTCGCATAGTCG 572
Db          13 ACTTGCATAGTCG 1

RESULT 400
LOCUS       138666
DEFINITION  Sequence 26 from patent US 5614617.
ACCESSION   138666
VERSION     138666.1 GI:2084720
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 15)
AUTHORS      Cook,P.D. and Sanghvi,Y.S.
TITLE        Nuclease resistant, pyrimidine modified oligonucleotides that
JOURNAL      detect and modulate gene expression
FEATURES     Patent: US 5614617-A 26 25-MAR-1997;
             Location/Qualifiers
             1..15
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy          560 ACTCGCATAGTCG 572
Db          13 ACTTGCATAGTCG 1

RESULT 401
LOCUS       140402
DEFINITION  Sequence 13 from patent US 5620963.
ACCESSION   140402
VERSION     140402.1 GI:2082694
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 15)
AUTHORS      Cook,P.D. and Hoke,G.
TITLE        Oligonucleotides for modulating protein kinase C having
JOURNAL      phosphorothioate linkages of high chiral purity
FEATURES     Patent: US 5620963-A 13 15-APR-1997;
             Location/Qualifiers
             1..15
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy          560 ACTCGCATAGTCG 572
Db          13 ACTTGCATAGTCG 1

RESULT 402
LOCUS       144778
DEFINITION  Sequence 2 from patent US 5635488.
ACCESSION   144778
VERSION     144778.1 GI:2469491
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unknown.
```

Unclassified.

REFERENCE 1 (bases 1 to 15)

AUTHORS Cook, P.D. and Hoke, G.

TITLE Compounds having phosphorodithioate linkages of high chiral purity

JOURNAL Patent: US 5635488-A 2 03-JUN-1997;

FEATURES Location/Qualifiers

source

1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 2.5e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCGTAGTCG 572

Db 13 ACTTGCACTAGTCG 1

RESULT 403

LOCUS 157651/c

DEFINITION Sequence 188 from patent US 5610054.

ACCESSION 157651

VERSION 157651.1 GI:2482715

KEYWORDS

SOURCE Unknown.

ORGANISM

REFERENCE 1 (bases 1 to 15)

AUTHORS Draper, K.G.

TITLE Enzymatic RNA molecule targeted against Hepatitis C virus

JOURNAL Patent: US 5610054-A 198 11-MAR-1997;

FEATURES Location/Qualifiers

source

1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 2.5e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 36 CAGTCCCAAAATG 48

Db 15 CAGTCCCAAAATG 3

RESULT 404

LOCUS 157709/c

DEFINITION Sequence 246 from patent US 5610054.

ACCESSION 157709

VERSION 157709.1 GI:2482773

KEYWORDS

SOURCE Unknown.

ORGANISM

REFERENCE 1 (bases 1 to 15)

AUTHORS Draper, K.G.

TITLE Enzymatic RNA molecule targeted against Hepatitis C virus

JOURNAL Patent: US 5610054-A 246 11-MAR-1997;

FEATURES Location/Qualifiers

source

1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 2.5e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 137 GTGATGACAGAG 149

Db 14 GTGTTGACAGAG 2

RESULT 405

LOCUS 159724/c

DEFINITION Sequence 13 from patent US 5654284.

ACCESSION 159724

VERSION 159724.1 GI:2478356

KEYWORDS

SOURCE Unknown.

ORGANISM

REFERENCE 1 (bases 1 to 15)

AUTHORS Cook, P.Dan. and Hoke, G.

TITLE Oligonucleotides for modulating RAF kinase having phosphorothioate

JOURNAL linkages of high chiral purity

Patent: US 5654284-A 13 05-AUG-1997;

FEATURES Location/Qualifiers

source

1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 2.5e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCGTAGTCG 572

Db 13 ACTTGCACTAGTCG 1

RESULT 406

LOCUS 163133/c

DEFINITION Sequence 13 from patent US 5661134.

ACCESSION 163133

VERSION 163133.1 GI:2480841

KEYWORDS

SOURCE Unknown.

ORGANISM

REFERENCE 1 (bases 1 to 15)

AUTHORS Cook, P.Dan. and Hoke, G.

TITLE Oligonucleotides for modulating Ha-ras or Ki-ras having

JOURNAL phosphorothioate linkages of high chiral purity

Patent: US 5661134-A 13 26-AUG-1997;

FEATURES Location/Qualifiers

source

1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 2.5e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCGTAGTCG 572

Db 13 ACTTGCACTAGTCG 1

RESULT 407

LOCUS 166639/c

DEFINITION Sequence 1 from patent US 5670633.

ACCESSION 166639

VERSION 166639.1 GI:2724617

KEYWORDS

SOURCE Unknown.

ORGANISM

REFERENCE 1 (bases 1 to 15)

AUTHORS Cook, P.Dan. and Kawasaki, A.Mamoro.

TITLE Sugar modified oligonucleotides that detect and modulate gene

JOURNAL expression
Patent: US 5670633-A 1 23-SEP-1997;
FEATURES location/Qualifiers
source 1. .15
/mol_type="unknown"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 408
LOCUS 166640 15 bp DNA linear PAT 29-DEC-1997
DEFINITION Sequence 2 from patent US 5670633.
ACCESSION 166640
VERSION 166640.1 GI:2724618
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)
AUTHORS Cook,P.Dan. and Kawasaki,A.Mamoro.
TITLE Sugar modified oligonucleotides that detect and modulate gene expression
JOURNAL Patent: US 5670633-A 2 23-SEP-1997;
FEATURES location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 409
LOCUS 184256 15 bp DNA linear PAT 04-APR-1998
DEFINITION Sequence 27 from patent US 5695926.
ACCESSION 184256
VERSION 184256.1 GI:3021776
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)
AUTHORS Cros,P., Allibert,P., Maillet,F., Mabilat,C. and Mandrand,B.
TITLE Sandwich hybridization assays using very short capture probes
JOURNAL Patent: US 5695926-A 27 09-DEC-1997;
FEATURES location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 18 TTTCGACACTG 30
Db 13 TTTCGACACTG 1

RESULT 410
LOCUS 196095 15 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 14 from patent US 5734033.
ACCESSION 196095
VERSION 196095.1 GI:3940565
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)
AUTHORS Reed,J.
TITLE Antisense oligonucleotides inhibiting human bcl-2 gene expression
JOURNAL Patent: US 5734033-A 14 31-MAR-1998;
FEATURES location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 377 CTGCCGTCGGCC 389
Db 13 CTGCCGTCGGCC 1

RESULT 411
LOCUS AR182826 15 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 134 from patent US 6339066.
ACCESSION AR182826
VERSION AR182826.1 GI:20226033
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)
AUTHORS Bennett,C.,Frank., Dean,N.M., Cook,P.Dan. and Hoke,G.
TITLE Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate beta.I., beta.II., gamma., delta., EPSILON., zeta. and .eta. isoforms of human protein kinase C
JOURNAL Patent: US 6339066-A 134 15-JUN-2002;
FEATURES location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 412
LOCUS AR212295 15 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 21 from patent US 6399754.
ACCESSION AR212295
VERSION AR212295.1 GI:21515831
KEYWORDS
SOURCE Unknown.

REFERENCE 1 (bases 1 to 15)
AUTHORS Cook,P.Dan.
TITLE Sugar modified oligonucleotides

JOURNAL Patent: US 639754-A 21 04-JUN-2002;
FEATURES
SOURCE
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 560 ACTGCATAGTCG 572
|||
13 ACTGCATAGTCG 1

RESULT 413
AR212298/c AR212298 15 bp DNA linear PAT 20-JUN-2002
LOCUS
DEFINITION Sequence 24 from patent US 639754.
ACCESSION AR212298
VERSION AR212298.1 GI:21515835
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Cook,P.Dan.
TITLE Sugar modified oligonucleotides
JOURNAL Patent: US 639754-A 24 04-JUN-2002;
FEATURES Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 560 ACTGCATAGTCG 572
|||
13 ACTGCATAGTCG 1

RESULT 414
AR242023/c AR242023 15 bp DNA linear PAT 20-DEC-2002
LOCUS
DEFINITION Sequence 311 from patent US 6472154.
ACCESSION AR242023
VERSION AR242023.1 GI:27287835
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Garner,H.R., Wren,J.D., Minna,J.D. and Fondon,J.W. III.
JOURNAL Polymorphic repeats in human genes
FEATURES Patent: US 6472154-A 311 29-OCT-2002;
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 66 TCTTCTCTCTT 78
|||
14 TCTTCTCTCTT 2

RESULT 415
AR242024/c

LOCUS AR242024 15 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 312 from patent US 6472154.
ACCESSION AR242024
VERSION AR242024.1 GI:27287836
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Garner,H.R., Wren,J.D., Minna,J.D. and Fondon,J.W. III.
JOURNAL Polymorphic repeats in human genes
FEATURES Patent: US 6472154-A 312 29-OCT-2002;
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 66 TCTTCTCTCTT 78
|||
14 TCTTCTCTCTT 2

RESULT 416
AR270973/c AR270973 15 bp DNA linear PAT 10-APR-2003
LOCUS
DEFINITION Sequence 7 from patent US 6500945.
ACCESSION AR270973
VERSION AR270973.1 GI:29702232
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Cook,P.D.
TITLE Nucleotides having chiral phosphorus linkages
JOURNAL Patent: US 6500945-A 7 31-DEC-2002;
FEATURES Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 560 ACTGCATAGTCG 572
|||
13 ACTGCATAGTCG 1

RESULT 417
AR285770 AR285770 15 bp RNA linear PAT 10-APR-2003
LOCUS
DEFINITION Sequence 142 from patent US 6528640.
ACCESSION AR285770
VERSION AR285770.1 GI:29723364
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpelsky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
JOURNAL Synthetic ribonucleic acids with RNase activity
FEATURES Patent: US 6528640-A 142 04-MAR-2003;
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned RNA"

		/mol_type="genomic DNA"	
Query Match	0.2%;	Score 11.4;	DB 1; Length 15;
Best Local Similarity	92.3%;	Pred. No. 2.5e+02;	
Matches 12; Conservative	0;	Mismatches 1;	Indels 0; Gaps 0;
OY	560	ACTGCGATAGTCG	572
Db	13	ACTTGCATAGTCG	1
RESULT 423			
LOCUS	AR429174	15 bp	DNA
DEFINITION	Sequence 15 from patent US 6642367.		linear
ACCESSION	AR429174		PAT 18-DEC-2003
VERSION	AR429174.1		GI:40189301
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	Unclassified.		
AUTHORS	1 (bases 1 to 15)		
TITLE	Cook,P.D., Sanghvi,Y.S., Sprankle,K.G., Ross,B.S., Griffey,R.H. and		
JOURNAL	Process for the synthesis of 2'-O-substituted pyrimidines and		
FEATURES	oligomeric compounds therefrom		
source	Patent: US 6642367-A 15 04-NOV-2003;		
	Location/Qualifiers		
	1..15		
	/organism="unknown"		
	/mol_type="genomic DNA"		
OY 560 ACTGCGATAGTCG 572			
Query Match	0.2%;	Score 11.4;	DB 1; Length 15;
Best Local Similarity	92.3%;	Pred. No. 2.5e+02;	
Matches 12; Conservative	0;	Mismatches 1;	Indels 0; Gaps 0;
OY	560	ACTGCGATAGTCG	572
Db	13	ACTTGCATAGTCG	1
RESULT 424			
LOCUS	AR429175	15 bp	DNA
DEFINITION	Sequence 16 from patent US 6642367.		linear
ACCESSION	AR429175		PAT 18-DEC-2003
VERSION	AR429175.1		GI:40189302
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	Unclassified.		
AUTHORS	1 (bases 1 to 15)		
TITLE	Cook,P.D., Sanghvi,Y.S., Sprankle,K.G., Ross,B.S., Griffey,R.H. and		
JOURNAL	Process for the synthesis of 2'-O-substituted pyrimidines and		
FEATURES	oligomeric compounds therefrom		
source	Patent: US 6642367-A 16 04-NOV-2003;		
	Location/Qualifiers		
	1..15		
	/organism="unknown"		
	/mol_type="genomic DNA"		
OY 560 ACTGCGATAGTCG 572			
Query Match	0.2%;	Score 11.4;	DB 1; Length 15;
Best Local Similarity	92.3%;	Pred. No. 2.5e+02;	
Matches 12; Conservative	0;	Mismatches 1;	Indels 0; Gaps 0;
OY	560	ACTGCGATAGTCG	572
Db	13	ACTTGCATAGTCG	1
RESULT 425			
LOCUS	AR442656	15 bp	DNA
DEFINITION	Sequence 15 from patent US 6642367.		linear
ACCESSION	AR442656		PAT 18-DEC-2003
VERSION	AR442656.1		GI:40189303
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	Unclassified.		
AUTHORS	1 (bases 1 to 15)		
TITLE	Cook,P.D., Sanghvi,Y.S., Sprankle,K.G., Ross,B.S., Griffey,R.H. and		
JOURNAL	Process for the synthesis of 2'-O-substituted pyrimidines and		
FEATURES	oligomeric compounds therefrom		
source	Patent: US 6642367-A 15 04-NOV-2003;		
	Location/Qualifiers		
	1..15		
	/organism="unknown"		
	/mol_type="genomic DNA"		
OY 560 ACTGCGATAGTCG 572			
Query Match	0.2%;	Score 11.4;	DB 1; Length 15;
Best Local Similarity	92.3%;	Pred. No. 2.5e+02;	
Matches 12; Conservative	0;	Mismatches 1;	Indels 0; Gaps 0;
OY	560	ACTGCGATAGTCG	572
Db	13	ACTTGCATAGTCG	1
RESULT 426			
LOCUS	AR442657	15 bp	DNA
DEFINITION	Sequence 16 from patent US 6642367.		linear
ACCESSION	AR442657		PAT 18-DEC-2003
VERSION	AR442657.1		GI:40189304
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	Unclassified.		
AUTHORS	1 (bases 1 to 15)		
TITLE	Cook,P.D., Sanghvi,Y.S., Sprankle,K.G., Ross,B.S., Griffey,R.H. and		
JOURNAL	Process for the synthesis of 2'-O-substituted pyrimidines and		
FEATURES	oligomeric compounds therefrom		
source	Patent: US 6642367-A 16 04-NOV-2003;		
	Location/Qualifiers		
	1..15		
	/organism="unknown"		
	/mol_type="genomic DNA"		
OY 560 ACTGCGATAGTCG 572			
Query Match	0.2%;	Score 11.4;	DB 1; Length 15;
Best Local Similarity	92.3%;	Pred. No. 2.5e+02;	
Matches 12; Conservative	0;	Mismatches 1;	Indels 0; Gaps 0;
OY	560	ACTGCGATAGTCG	572
Db	13	ACTTGCATAGTCG	1
RESULT 427			
LOCUS	AR442658	15 bp	DNA
DEFINITION	Sequence 17 from patent US 6642367.		linear
ACCESSION	AR442658		PAT 18-DEC-2003
VERSION	AR442658.1		GI:40189305
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	Unclassified.		
AUTHORS	1 (bases 1 to 15)		
TITLE	Cook,P.D., Sanghvi,Y.S., Sprankle,K.G., Ross,B.S., Griffey,R.H. and		
JOURNAL	Process for the synthesis of 2'-O-substituted pyrimidines and		
FEATURES	oligomeric compounds therefrom		
source	Patent: US 6642367-A 17 04-NOV-2003;		
	Location/Qualifiers		
	1..15		
	/organism="unknown"		
	/mol_type="genomic DNA"		

LOCUS	AR442656	15 bp	DNA	linear	PAT 20-FEB-2004
DEFINITION	Sequence 5 from patent US 6670135.				
ACCESSION	AR442656				
VERSION	AR442656.1	GI:42669917			
KEYWORDS	.				
SOURCE	Unknown.				
ORGANISM	Unclassified.				
REFERENCE	1 (bases 1 to 15)				
AUTHORS	Spriggs,M.K.				
TITLE	Semaphorin polypeptides				
JOURNAL	Patent: US 6670135-A 5 30-DEC-2003;				
FEATURES	location/Qualifiers				
source	1..15				
	/organism="unknown"				
	/mol_type="genomic DNA"				
Query Match	0.2%; Score 11.4; DB 1;	Length 15;			
Best Local Similarity	92.3%; Pred. No. 2.5e+02;				
Matches	12; Conservative 0; Mismatches 1;	Indels 0; Gaps 0;			
OY	66 TCTTCTACTTCTT 78				
Db	1 TCTACTTCTT 13				
RESULT 426	AR482043	15 bp	DNA	linear	PAT 14-MAY-2004
LOCUS	AR482043/C				
DEFINITION	Sequence 7 from patent US 6699979.				
ACCESSION	AR482043				
VERSION	AR482043.1	GI:47243990			
KEYWORDS	.				
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 15)				
TITLE	Cook,P.D.				
JOURNAL	Oligonucleotides having chiral phosphorus linkages				
FEATURES	Patent: US 6699979-A 7 02-MAR-2004;				
source	location/Qualifiers				
	1..15				
	/organism="unknown"				
	/mol_type="genomic DNA"				
Query Match	0.2%; Score 11.4; DB 1;	Length 15;			
Best Local Similarity	92.3%; Pred. No. 2.5e+02;				
Matches	12; Conservative 0; Mismatches 1;	Indels 0; Gaps 0;			
OY	560 ACTGCATAGTCG 572				
Db	13 ACTGCATAGTCG 1				
RESULT 427	AX007782	15 bp	DNA	linear	PAT 06-SEP-2000
LOCUS	AX007782				
DEFINITION	Sequence 324 from Patent WO9967428.				
ACCESSION	AX007782				
VERSION	AX007782.1	GI:9995479			
KEYWORDS	.				
SOURCE	Aids-associated retrovirus				
ORGANISM	Aids-associated retrovirus				
REFERENCE	1				
AUTHORS	Stuyver,L.				
TITLE	Method for detection of drug-selected mutations in the hiv protease gene				
JOURNAL	Patent: WO 9967428-A 324 29-DEC-1999;				
FEATURES	INNOCENTIS NV (BE); STUYVER LIEVEN (BE)				
source	location/Qualifiers				
	1..15				
	/organism="Aids-associated retrovirus"				

/mol_type="unassigned DNA"
/db_xref="taxon:11966"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 219 TCAACATATATAGG 231
3 TCAACATATATTTGG 15

RESULT 428
AX377178/c

LOCUS AX377178 15 bp DNA linear PAT 18-MAR-2002
DEFINITION Sequence 23 from Patent WO0212342.
ACCESSION AX377178
VERSION AX377178.1 GI:19573468
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Kazami, A., Koshy, B. and Sanchis, A.
TITLE Haplotypes of the edg4 gene
JOURNAL Patent: WO 0212342-A 23 14-FEB-2002;
Genaisance Pharmaceuticals, Inc. (US)
FEATURES
source Location/Qualifiers
1.15
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 444 TGAGCAAGGCCT 456
13 TGAGCAGAGGCCT 1

RESULT 429
AX463285/c
LOCUS AX463285 15 bp DNA linear PAT 15-JUL-2002
DEFINITION Sequence 5 from Patent WO0250295.
ACCESSION AX463285
VERSION AX463285.1 GI:21886236
KEYWORDS
SOURCE Glycine max (soybean)
ORGANISM Glycine max

REFERENCE
AUTHORS Oulmasov, T., Wang, Q., Dubois, P. and Liang, J.
TITLE Arcelin-5 promoter and uses thereof
JOURNAL Patent: WO 0250295-A 5 27-JUN-2002;
RENESEN LLC (US)
FEATURES
source Location/Qualifiers
1.15
/organism="Glycine max"
/mol_type="unassigned DNA"
/db_xref="taxon:3847"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 63 GGTTCTTCTACTT 75
|||||||

Db 15 GGTTCTTCTTCTT 3

RESULT 430
AX468705/c
LOCUS AX468705 15 bp DNA linear PAT 16-JUL-2002
DEFINITION Sequence 21 from Patent WO0213799.
ACCESSION AX468705
VERSION AX468705.1 GI:21901475
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct

REFERENCE
AUTHORS Henry, J. L., Cahill, C. M. and Yashpal, K.
TITLE Oligonucleotides and other modulators of the nk-1 receptor pathway
JOURNAL Patent: WO 0213799-A 21 21-FEB-2002;
MCGILL UNIVERSITY (CA)
FEATURES
source Location/Qualifiers
1.15
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 38 GTCCCAAAATGGA 50
14 GCCCCAAATGGA 2

RESULT 431
AX492919/c
LOCUS AX492919 15 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 16 from Patent EP1227162.
ACCESSION AX492919
VERSION AX492919.1 GI:2338592
KEYWORDS
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus

REFERENCE
AUTHORS Berger, D. M., Nusebaumer, W. A., Fort, T. L. and Heiliger, T. J.
TITLE Sequences and methods for detection of Hepatitis B virus
JOURNAL Patent: EP 1227162-A 16 31-JUL-2002;
Becton, Dickinson and Company (US)
FEATURES
source Location/Qualifiers
1.15
/organism="Hepatitis B virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10407"

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 277 AGGAATCCAGATG 289
13 AGGAATCCTGATG 1

RESULT 432
AX633508
LOCUS AX633508 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 647 from Patent EP1260586.
ACCESSION AX633508
VERSION AX633508.1 GI:28469122
KEYWORDS
SOURCE unidentified


```

ORGANISM      unidentified
REFERENCE      unclassified.
AUTHORS        1
                Stinchcomb,D.T., Dudycz,L.W., Chowitra,B., Grimm,S., Dizenzo,A.,
                Karpelesky,A., Draper,K.G., Klisch,K., Matulic-Adamic,J.,
                Mswisigen,J.A., Modak,A., Pavco,P., Belgelman,L., Sullivan,S.M.,
                Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
                Wolf,T.
TITLE          Method and reagent for inhibiting the expression of disease related
                genes
JOURNAL        Patent: EP 1260586-A 647 27-NOV-2002;
FEATURES        RIBOZYME PHARMACEUTICALS, INC. (US)
SOURCE          location/Qualifiers
                1. .15
                /organism="unidentified"
                /mol_type="unassigned RNA"
                /db_xref="taxon:32644"

Query Match    0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY            59 AAGTGGTTCTTCT 71
Db            1 AGGTGGTTCTTCT 13

RESULT 433
AX633555      15 bp      RNA      linear      PAT 21-FEB-2003
LOCUS         Sequence 694 from Patent EP1260586.
DEFINITION    AX633555
ACCESSION     AX633555
VERSION       AX633555.1 GI:28469169
KEYWORDS      unidentified
SOURCE        unidentified
ORGANISM      unclassified.
REFERENCE      1
AUTHORS        Stinchcomb,D.T., Dudycz,L.W., Chowitra,B., Grimm,S., Dizenzo,A.,
                Karpelesky,A., Draper,K.G., Klisch,K., Matulic-Adamic,J.,
                Mswisigen,J.A., Modak,A., Pavco,P., Belgelman,L., Sullivan,S.M.,
                Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
                Wolf,T.
TITLE          Method and reagent for inhibiting the expression of disease related
                genes
JOURNAL        Patent: EP 1260586-A 694 27-NOV-2002;
FEATURES        RIBOZYME PHARMACEUTICALS, INC. (US)
SOURCE          location/Qualifiers
                1. .15
                /organism="unidentified"
                /mol_type="unassigned RNA"
                /db_xref="taxon:32644"

Query Match    0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY            59 AAGTGGTTCTTCT 71
Db            1 AGGTGGTTCTTCT 13

RESULT 434
AX742707/c    15 bp      DNA      linear      PAT 12-MAY-2003
LOCUS         Sequence 510 from Patent EP1302550.
DEFINITION    AX742707
ACCESSION     AX742707
VERSION       AX742707.1 GI:30576696
KEYWORDS      synthetic construct
SOURCE        synthetic construct
ORGANISM      artificial sequences.
REFERENCE      1

```

```

AUTHORS        Lin,C.Y., Lin,R.W., You,C.M., Huang,H.H., Lee,B.H., Lee,H.H.,
                Lin,Y.J., Fan,C.C., Hsu,H.C., Shih,C.W., Yeh,C.H., Kao,Y.F.,
                Pan,C.L. and Chan,P.
TITLE          Method and detector for identifying subtypes of human papilloma
                viruses
JOURNAL        Patent: EP 1302550-A 510 16-APR-2003;
FEATURES        King Car Food Industrial Co., Ltd. (TW)
SOURCE          location/Qualifiers
                1. .15
                /organism="synthetic construct"
                /mol_type="genomic DNA"
                /db_xref="taxon:32630"
                /note="Oligonucleotide for identifying HPV 72"

Query Match    0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY            286 GATGCTGTGCAG 298
Db            13 GACCTGTGCGAG 1

RESULT 435
BD014073/c    15 bp      DNA      linear      PAT 27-AUG-2002
LOCUS         Oligonucleotide having phosphorothioate bond with high chiral
DEFINITION    purity.
ACCESSION     BD014073
VERSION       BD014073.1 GI:22554402
KEYWORDS      JP 2001103987-A/13.
SOURCE        unidentified
ORGANISM      unidentified
REFERENCE      1 (bases 1 to 15)
AUTHORS        Cook,P.D. and Hawk,G.
TITLE          Oligonucleotide having phosphorothioate bond with high chiral
                purity
JOURNAL        Patent: JP 2001103987-A 13 17-APR-2001;
FEATURES        ISIS PHARMACEUTICALS INC
SOURCE          OS Unidentified
                PN JP 2001103987-A/13
                PD 17-APR-2001
                PF 31-AUG-2000 JP 2000262871
                PR 06-JUN-1995 US 08/471967 06-JUN-1995 US 08/467597 PR
                PR 06-JUN-1995 US 08/468447 06-JUN-1995 US 08/468569 PR
                PR 06-JUN-1995 US 08/466692 06-JUN-1995 US 08/471966 PR
                PR 06-JUN-1995 US 08/469851 06-JUN-1995 US 08/470129 PI PHILIP
                DAN COOK, GLENN HAWK
                PC C12N15/09,A61K31/7125,A61K48/00,A61P27/02,A61P29/00,A61P31/12,
                PC A61P31/18,
                PC A61P35/00,C07H21/00,C12N15/00
                CC Strandedness: Single;
                CC Topology: Linear;
                CC Oligonucleotide having phosphorothioate bond with high chiral
                purity
                FH Key location/Qualifiers
                FT source 1. .15
                /organism="unidentified".
                location/Qualifiers
                1. .15
                /organism="unidentified"
                /mol_type="genomic DNA"
                /db_xref="taxon:32644"

Query Match    0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY            560 ACTGCGATAGTCG 572
Db            13 ACTTGCATAGTCG 1

```

```

RESULT 436
BD014112/c
LOCUS BD014112 15 bp DNA linear PAT 27-AUG-2002
DEFINITION High-chimeric purity phosphorothioate bond-containing oligonucleotide.
ACCESSION BD014112
VERSION BD014112.1 GI:22554441
KEYWORDS JP 200114798-A/13.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 15)
AUTHORS Cook, P.D. and Hawk, G.
TITLE High-chimeric purity phosphorothioate bond-containing
JOURNAL Patent: JP 200114798-A 13 24-APR-2001;
ISIS PHARMACEUTICALS INC
COMMENT OS Unidentified
PN JP 200114798-A/13
PD 24-APR-2001
PR 31-AUG-2000 JP 2000262865
PR 06-JUN-1995 US 08/471967,06-JUN-1995 US 08/467597 PR
06-JUN-1995 US 08/468447,06-JUN-1995 US 08/468569 PR
06-JUN-1995 US 08/46692,06-JUN-1995 US 08/471966 PR
DAN COOK, GLENN HAWK 08/469851,06-JUN-1995 US 08/470129 PI PHILIP
PC C07H21/00,A61K31/7125,A61K48/00,A61P1/16,A61P27/02,A61P29/00,
PC A61P31/14,
PC A61P31/18,A61P35/00,C12N15/09,C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC High-chimeric purity phosphorothioate bond-containing CC
oligonucleotide
FH Key Location/Qualifiers
FT source 1..15
FT Location/Qualifiers
1..15
/mol_type="genomic DNA"
/db_xref="taxon:32644"

FEATURES
source
1..15
Location/Qualifiers
1..15
/organism="Unidentified".

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATGATCG 572
Db 13 ACTGCATGATCG 1

RESULT 437
BD065744/c
LOCUS BD065744 15 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD065744
VERSION BD065744.1 GI:22611347
KEYWORDS JP 2001511000-A/379.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 15)
AUTHORS Schlingensiepen, K.H. and Brysch, W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 379 07-AUG-2001;
BIOGENSTIK GESellschaft FÜR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT OS Unknown
PN JP 2001511000-A/379
PD 07-AUG-2001
PR 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN, WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70

```

```

CC An antisense oligonucleotide preparation method FH Key
FT Location/Qualifiers
FT source 1..15
FT Location/Qualifiers
1..15
/organism="Unknown".
/mol_type="genomic DNA"
/db_xref="taxon:32644"

FEATURES
source
1..15
Location/Qualifiers
1..15
/organism="Unidentified".

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 527 GAACCTGCACAGC 539
Db 14 GAACCTGCATGC 2

RESULT 438
BD070457/c
LOCUS BD070457 15 bp DNA linear PAT 27-AUG-2002
DEFINITION Methods for detecting mitochondrial mutations diagnostic for Alzheimer's disease and methods for determining heteroplasmy of mitochondrial nucleic acid.
ACCESSION BD070457
VERSION BD070457.1 GI:22616060
KEYWORDS JP 2001514500-A/14.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 15)
AUTHORS Parker, W.D., Herrnstadt, C., Ghosh, S. and Fahy, E.D.
TITLE Methods for detecting mitochondrial mutations diagnostic for Alzheimer's disease and methods for determining heteroplasmy of mitochondrial nucleic acid
JOURNAL Patent: JP 2001514500-A 14 11-SEP-2001;
MITOKOR
COMMENT OS Unidentified
PN JP 2001514500-A/14
PD 11-SEP-2001
PR 27-FEB-1998 JP 1998537738
PR 28-FEB-1997 US 08/810599
PI WILLIAM DAVIS PARKER, CORINNA HERRNSTADT, SOUMITRA GHOSH, EOIN D
PC C12O1/68,C07H21/04
CC Strandedness: Double;
CC Topology: Linear;
CC Methods for detecting mitochondrial mutations diagnostic for disease and methods for determining heteroplasmy of CC
mitochondrial nucleic acid
FH Key Location/Qualifiers
FT source 1..15
FT Location/Qualifiers
1..15
/organism="Unidentified".
/mol_type="genomic DNA"
/db_xref="taxon:32644"

FEATURES
source
1..15
Location/Qualifiers
1..15
/organism="Unidentified".

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 257 GCTTATCATGAA 269
Db 15 GCGTATCATGAA 3

RESULT 439
BD141534

```

```

LOCUS       BD141534               15 bp    DNA    linear    PAT 18-SEP-2002
DEFINITION  Method for production of recombinant protein.
ACCESSION   BD141534
VERSION     BD141534.1 GI:23236479
KEYWORDS    WO 0208417-A/62.
SOURCE      synthetic construct
            synthetic construct
            artificial sequences.
ORGANISM    1 (bases 1 to 15)
REFERENCE   1 (bases 1 to 15)
AUTHORS     Ito,T., Tanaka,Y. and Kondo,M.
TITLE       Method for production of recombinant protein
JOURNAL     Patent: WO 0208417-A 62 31-JAN-2002;
            TAKEDA CHEMICAL INDUSTRIES LTD,TAKASHI ITO,YOKO TANAKA, MITSUYO
            KONDO
COMMENT     OS Artificial Sequence
            PN WO 0208417-A/62
            PD 31-JAN-2002
            PR 25-JUL-2001 WO 2001JP006392
            PR 25-JUL-2000 JP 00P 229064
            PI TAKASHI ITO,YOKO TANAKA,MITSUYO KONDO
            PC C12N15/10,C12N1/21,C12P21/02,C12Q1/02
            CC Synthetic DNA
            FH Key
            FT source
            FT Location/Qualifiers
               1..15
               /organism='Artificial Sequence'.

FEATURES
source      1..15
            /location/Qualifiers
            /organism='synthetic construct'
            /mol_type='genomic DNA'
            /db_xref='taxon:32630'

Query Match      0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 403 CCGGTTCCAGCC 415
      |||||
      3 CCGGTTCCATGCC 15

RESULT 440
LOCUS       BD144266
DEFINITION  Preparation for forming triplex nucleic acid.
ACCESSION   BD144266
VERSION     BD144266.1 GI:27850024
KEYWORDS    JP 2002114797-A/1.
SOURCE      synthetic construct
            synthetic construct
            artificial sequences.
ORGANISM    1 (bases 1 to 15)
REFERENCE   1 (bases 1 to 15)
AUTHORS     Torigoe,H., Akaike,T. and Maruyama,A.
TITLE       Preparation for forming triplex nucleic acid
JOURNAL     Patent: JP 2002114797-A 1 16-APR-2002;
            ATSUSHI MARUYAMA
COMMENT     OS Artificial Sequence
            PN JP 2002114797-A/1
            PD 16-APR-2002
            PR 10-OCT-2000 JP 2000308897
            PI HIDEMINE TORIGOE,TOSHIHIRO AKAIKE,ATSUSHI MARUYAMA PC
            C07H1/04,C07H21/02,C08B31/12,C08G69/00,C08L77/00,C08L101/12, PC
            C12N15/09
            PC C12N15/00
            CC Preparation for forming triplex nucleic acid
            FH Key
            FT source
            FT Location/Qualifiers
               1..15
               /organism='Artificial Sequence'.

FEATURES
source      1..15
            /location/Qualifiers
            /organism='synthetic construct'
            /mol_type='genomic DNA'
            /db_xref='taxon:32630'

```

```

Query Match      0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 73 CTTCTTTTATTC 85
      |||||
      3 CTTCTTTCTTTC 15

RESULT 441
LOCUS       AR278865               26 bp    DNA    linear    PAT 10-APR-2003
DEFINITION  Sequence 3 from patent US 6512161.
ACCESSION   AR278865
VERSION     AR278865.1 GI:29713382
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 26)
AUTHORS     Rouy,D., Duvenger,N., Emmanuel,F., Deneffe,P., Houdebine,L.-M.,
            Viglietta,C., Rubin,E.M. and Hughes,S.D.
TITLE       Transgenic rabbit that expresses a functional human lipoprotein (a)
JOURNAL     Patent: US 6512161-A 3 28-JAN-2003;
            Location/Qualifiers
FEATURES
source      1..26
            /organism='unknown'
            /mol_type='genomic DNA'

Query Match      0.2%; Score 11.4; DB 1; Length 26;
Best Local Similarity 71.4%; Pred. No. 4.7e+02;
Matches 15; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 409 CCAAGCTTAGAGCTCTTCC 429
      |||||
      6 CCAAGCTTGGCAGGTTCTTCC 26

RESULT 442
LOCUS       BD130526               26 bp    DNA    linear    PAT 18-SEP-2002
DEFINITION  Transgenic rabbit expressing functional human lipoprotein (A).
ACCESSION   BD130526
VERSION     BD130526.1 GI:23225471
KEYWORDS    JP 2002500039-A/3.
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1 (bases 1 to 26)
AUTHORS     Rouy,D., Duvenger,N., Emmanuel,F., Deneffe,P., Houdebine,L.M.,
            Viglietta,C., Rubin,E. and Hughes,S.D.
TITLE       Transgenic rabbit expressing functional human lipoprotein (A)
JOURNAL     Patent: JP 2002500039-A 3 08-JAN-2002;
            AVENTIS PHARMACEUTICALS PRODUCTS INC
COMMENT     OS Homo sapiens (human)
            PN JP 2002500039-A/3
            PD 08-JAN-2002
            PR 08-JAN-1999 JP 2000527627
            PR 08-JAN-1998 US 60/070727
            PI DIDIER ROUY,NICOLAS DUVERGER,FLORENCE EMMANUEL,PATRICE
            DENEFFE.
            PI LOUIS MARIE HOUEDBINE,CELINE VIGLIETTA,EDWARD RUBIN,STEVEN D
            PI HUGHES
            PC A01K67/027//C12N15/09,C12N15/00
            CC Transgenic rabbit expressing functional human lipoprotein (A)
            FH Key
            FT source
            FT Location/Qualifiers
               1..26
               /organism='Homo sapiens (human)'.

FEATURES
source      1..26
            /location/Qualifiers
            /organism='Homo sapiens'
            /mol_type='genomic DNA'

```

/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.2%; Score 11.4; DB 1; Length 26;
Matches 15; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 409 CCAAGCCTAGAGCTCTTCC 429
DB 6 CCAAGCTTGCAAGTCTTCC 26

RESULT 443
AX139231/c 16 bp DNA linear PAT 30-MAY-2001

LOCUS AX139231
DEFINITION Sequence 79 from Patent EP1076099.
ACCESSION AX139231
VERSION AX139231.1 GI:14274904
KEYWORDS
SOURCE
ORGANISM Mycobacterium tuberculosis
Mycobacterium tuberculosis
Bacteria; Actinobacteria; Actinomycetales;
Corynebacterineae; Mycobacteriaceae; Mycobacterium; Mycobacterium
tuberculosis complex.

REFERENCE 1
AUTHORS Suzuki, Y., Nishida, M. and Takenishi, S.
TITLE Kit for diagnosis of tubercle bacilli
JOURNAL Patent: EP 1076099-A 79 14-FEB-2001;
NISHINO INDUSTRIES, INC. (JP) ; System Research Incorporation
(JP)

FEATURES
source Location/Qualifiers
1.16
/organism="Mycobacterium tuberculosis"
/mol_type="unassigned DNA"
/db_xref="taxon:1773"
/note="capture"

Query Match
Best Local Similarity 0.2%; Score 11.2; DB 1; Length 16;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 156 AGGACGATCTCCACC 171
DB 16 AGGACGATCTCCACC 1

RESULT 444
BD013515/c 16 bp DNA linear PAT 27-AUG-2002

LOCUS BD013515
DEFINITION Diagnosis kit of tubercle bacillus.
ACCESSION BD013515
VERSION BD013515.1 GI:22553829
KEYWORDS JP 2001103981-A/79.
SOURCE Mycobacterium tuberculosis
ORGANISM Mycobacterium tuberculosis
Bacteria; Actinobacteria; Actinomycetales;
Corynebacterineae; Mycobacteriaceae; Mycobacterium; Mycobacterium
tuberculosis complex.

REFERENCE 1 (bases 1 to 16)
AUTHORS Suzuki, S., Nishida, M. and Takenishi, S.
TITLE Diagnosis kit of tubercle bacillus
JOURNAL Patent: JP 2001103981-A 79 17-APR-2001;
NISHINO IND INC. SYSTEM RESEARCH CO LTD
OS Mycobacterium tuberculosis
PN JP 2001103981-A/79
PD 17-APR-2001
PR 26-JUL-2000 JP 2000225985
P1 SADHIKO SUZUKI, MICHIO NISHIDA, SOICHIRO TAKENISHI PC
C12N15/09, C12M15/09, C12M1/68, C12Q1/68, C12R1:32), PC
(C12Q1/68, C12R1:32), (C12Q1/68, C12R1:33), C12N15/00, C12N15/00 CC
capture
FH Key Location/Qualifiers
FT source 1.16
/organism="Mycobacterium tuberculosis".

FEATURES
source Location/Qualifiers
1.16
/organism="Mycobacterium tuberculosis"
/mol_type="genomic DNA"
/db_xref="taxon:1773"

Query Match
Best Local Similarity 0.2%; Score 11.2; DB 1; Length 16;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 156 AGGACGATCTCCACC 171
DB 16 AGGACGATCTCCACC 1

RESULT 445
A07188 12 bp DNA linear PAT 02-AUG-1993

LOCUS A07188
DEFINITION Oligonucleotide.
ACCESSION A07188
VERSION A07188.1 GI:411392
KEYWORDS
SOURCE
ORGANISM synthetic construct
artificial sequences.

REFERENCE 1 (bases 1 to 12)
AUTHORS Niwa, M., Satoh, S., Suzuki, S., Otsuka, K. and Kusunoki, C.
TITLE New tissue plasminogen activator
JOURNAL Patent: EP 0379890-A 10 01-AUG-1990;
FUJISAWA PHARMACEUTICAL CO., LTD

FEATURES
source Location/Qualifiers
1.12
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 0.2%; Score 11; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATGCC 324
DB 2 CGAGGATGCC 12

RESULT 446
AR363407/c 12 bp DNA linear PAT 03-SEP-2003

LOCUS AR363407
DEFINITION Sequence 61 from patent US 5212286.
ACCESSION AR363407
VERSION AR363407.1 GI:34424929
KEYWORDS
SOURCE
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 12)
AUTHORS Lewicki, J.A. and Scarborough, R.M. Jr.
TITLE Actrial Natriuretic/Vasodilator peptide compounds
JOURNAL Patent: US 5212286-A 61 18-MAY-1993;
location/Qualifiers
1.12
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.2%; Score 11; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 191 GCCAAGCTTGG 201
DB 11 GCCAAGCTTGG 1

```

RESULT 447
165474 LOCUS 165474 13 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 10 from patent US 5667994.
ACCESSION 165474
VERSION 165474.1 GI:2482044
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 13)
AUTHORS Dilly,K.Ann., Bustos,S.A., Rostkowski,C.Ann. and Berger,D.M.
TITLE Amplification and detection of mycobacterium avium complex species
JOURNAL Patent: US 5667994-A 10 16-SEP-1997;
FEATURES
source
    1. 13
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 385 GCGCCTCCGAC 395
Db 3 GCGCCTCCGAC 13

RESULT 448
171091 LOCUS 171091 13 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 7 from patent US 5681705.
ACCESSION 171091
VERSION 171091.1 GI:3007226
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 13)
AUTHORS Schram,J.L., Nadeau,J.G. and Dean,C.H.
TITLE Amplification and detection of mycobacterium avium complex species
JOURNAL Patent: US 5681705-A 7 28-OCT-1997;
FEATURES
source
    1. 13
    Location/Qualifiers
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 385 GCGCCTCCGAC 395
Db 3 GCGCCTCCGAC 13

RESULT 449
BD013873 LOCUS BD013873 13 bp DNA linear PAT 27-AUG-2002
DEFINITION Amplification and detection of Mycobacterium avium complex.
ACCESSION BD013873
VERSION BD013873.1 GI:22554202
KEYWORDS UP 2001103986-A/7.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 13)
AUTHORS Shureanu,J.L., Nadeau,J.G. and Dean,C.H.
TITLE Amplification and detection of Mycobacterium avium complex
JOURNAL Patent: JP 2001103986-A 7 17-APR-2001;
COMMENT OS Unidentified
PN JP 2001103986-A/7

```

```

PD 17-APR-2001
PF 28-AUG-2000 JP 2000256939
PR 28-AUG-1995 US 08/520194
PI JAMES L. SHURAMU, JAMES G. NADEAU, CHERYL H. DEAN
PC C12N15/09, C1201/68, G01N33/53, G01N33/566, G01N33/58//G01N33/569,
PC C12N15/00
CC Amplification and detection of Mycobacterium avium complex PH
Key Location/Qualifiers
FT source 1. 13
    /organism="unidentified".
    Location/Qualifiers
    1. 13
    /organism="unidentified"
    /mol_type="genomic DNA"
    /db_xref="taxon:32644"

Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 385 GCGCCTCCGAC 395
Db 3 GCGCCTCCGAC 13

RESULT 450
A87915 LOCUS A87915 14 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 63 from Patent WO9833904.
ACCESSION A87915
VERSION A87915.1 GI:6736485
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W. and Schlingsiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 63 06-AUG-1998;
FEATURES
source
    1. 14
    Location/Qualifiers
    /organism="unidentified"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32644"

Query Match 0.2%; Score 11; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 173 CTGTACACAGA 183
Db 2 CTGTACACAGA 12

RESULT 451
A89882 LOCUS A89882 14 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 63 from Patent EP0856579.
ACCESSION A89882
VERSION A89882.1 GI:6738396
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W.D. and Schlingsiepen,K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 63 05-AUG-1998;
FEATURES
source
    1. 14
    Location/Qualifiers
    /organism="unidentified"

```

/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 0.2%; Score 11; DB 1; Length 14;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 173 CTGTACACAGA 183
DB 2 CTGTACACAGA 12

RESULT 452
BD01857/c
LOCUS
DEFINITION 14 bp RNA linear PAT 17-JUL-2003
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response.
ACCESSION BD01857
VERSION BD201857.1 GI:33011627
KEYWORDS JP 2002509721-A/4883.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
JOURNAL Payco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Meswigen,J.A.
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response
Patent: JP 2002509721-A 4883 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PD JP 2002509721-A/4883
PF 02-APR-2002
PR 24-MAR-1999 JP 2000541291
PI 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
CC concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..14
FT Location/Qualifiers

FEATURES
source 1..14
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.2%; Score 11; DB 1; Length 14;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 84 TCTGAATCAG 94
DB 14 TCTGAATCAG 4

RESULT 453
BD065428
LOCUS 14 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD065428
VERSION BD065428.1 GI:22611031
KEYWORDS JP 2001511000-A/63.
SOURCE unidentified
ORGANISM unidentified
unclassified.

REFERENCE
AUTHORS 1 (bases 1 to 14)
TITLE Schlengersienpen,K.H. and Brysch,W.
JOURNAL An antisense oligonucleotide preparation method
BIOGESTIK GESSELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK MBH
OS Unknown
PN JP 2001511000-A/63
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSTIEPEN,WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
Location/Qualifiers

FEATURES
source 1..14
/organism="Unknown".
Location/Qualifiers
1..14
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 0.2%; Score 11; DB 1; Length 14;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 173 CTGTACACAGA 183
DB 2 CTGTACACAGA 12

RESULT 454
BD000643/c
LOCUS 15 bp DNA linear PAT 31-JAN-2002
DEFINITION Probe used for the method for detecting nucleic acid.
ACCESSION BD000643
VERSION BD000643.1 GI:18623756
KEYWORDS JP 2000342288-A/2.
SOURCE unidentified
ORGANISM unidentified
unclassified.

REFERENCE
AUTHORS 1 (bases 1 to 15)
TITLE Nagai,K. and Kamibara,H.
JOURNAL Probe used for the method for detecting nucleic acid
HITACHI LTD
OS Unidentified
PN JP 2000342288-A/2
PD 12-DEC-2000
PF 08-MAY-2000 JP 2000135040
PR
PI KEIICHI NAGAI,HIDEKI KAMIBARA
PC C12N15/09,C12Q1/68,G01N21/78,G01N33/53,G01N33/542,
PC G01N33/566,
PC C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers
FT source 1..15
FT Location/Qualifiers

FEATURES
source 1..15
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 0.2%; Score 11; DB 1; Length 15;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 191 GCCAGCTTGG 201
DB 15 GCCAGCTTGG 5

```

RESULT 455
BD017683/c      15 bp   DNA   linear   PAT 27-AUG-2002
LOCUS           Probe for using in detection method of nucleic acid.
ACCESSION       BD017683
VERSION         BD017683.1 GI:22558859
KEYWORDS        JP 2001245683-A/2.
SOURCE          unidentified
ORGANISM        unidentified
REFERENCE       1 (bases 1 to 15)
AUTHORS        Nagai, K. and Kamibara, H.
TITLE          Probe for using in detection method of nucleic acid
JOURNAL        Patent: JP 2001245683-A 2 11-SEP-2001;
               HITACHI LTD
COMMENT         OS   M13 phage
               PN   JP 2001245683-A/2
               PD   11-SEP-2001
               PF   01-FEB-2001 JP 2001026140
               PI   KEIICHI NAGAI, HIDEKI KAMIBARA
               PC   C12N15/09, C12Q1/68, G01N33/53, G01N33/542, G01N33/566, C12N15/00
               CC   Strandedness: Single;
               CC   Topology: Linear;
               CC   Probe for using in detection method of nucleic acid FH   Key
               CC   Location/Qualifiers
               FT   source
                   1..15
                   /organism="M13 phage".
                   location/Qualifiers
                   1..15
                   /organism="unidentified"
                   /mol_type="genomic DNA"
                   /db_xref="taxon:32644"

Query Match      0.2%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      191 GCCACGCTTG 201
Db      15 GCCACGCTTG 5

RESULT 456
BD017688/c      15 bp   DNA   linear   PAT 27-AUG-2002
LOCUS           Method for detecting nucleic acid.
ACCESSION       BD017688
VERSION         BD017688.1 GI:22558864
KEYWORDS        JP 2001245699-A/2.
SOURCE          unidentified
ORGANISM        unidentified
REFERENCE       1 (bases 1 to 15)
AUTHORS        Nagai, K. and Kamibara, H.
TITLE          Method for detecting nucleic acid
JOURNAL        Patent: JP 2001245699-A 2 11-SEP-2001;
               HITACHI LTD
COMMENT         OS   M13 phage
               PN   JP 2001245699-A/2
               PD   11-SEP-2001
               PF   01-FEB-2001 JP 2001026141
               PI   KEIICHI NAGAI, HIDEKI KAMIBARA
               PC   C12Q1/68, C12N15/09, G01N33/53, G01N33/542, G01N33/566, C12N15/09, PC
               CC   C12R1:92;
               CC   C12N15/00, (C12N15/00, C12R1:92)
               CC   Strandedness: Single;
               CC   Topology: Linear;
               CC   Method for detecting nucleic acid
               CC   Key
               FT   source
                   1..15

```

```

FEATURES
source          FT
               Location/Qualifiers
               1..15
               /organism="unidentified"
               /mol_type="genomic DNA"
               /db_xref="taxon:32644"

Query Match      0.2%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      191 GCCACGCTTG 201
Db      15 GCCACGCTTG 5

RESULT 457
AX353508/c      21 bp   DNA   linear   PAT 06-FEB-2002
LOCUS           Sequence 40 from Patent WO0204636.
ACCESSION       AX353508
VERSION         AX353508.1 GI:18618583
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Homo sapiens
REFERENCE       1
AUTHORS        van Roy, F., Goossens, S., Janssens, B. and Vampoucke, G.
TITLE          Novel _g(a) expressed in heart and testis
JOURNAL        Patent: WO 0204636-A 40 17-JAN-2002;
               Vlaams Interuniversitair Instituut voor Biotechnologie vzw. (BE)
FEATURES
source          Location/Qualifiers
               1..21
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
               /note="splice donor 17"

Query Match      0.2%; Score 11; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

OY      335 GGGAGTACTGCAACCTGAC 353
Db      21 GGCACTACTCAGACCTGAC 3

RESULT 458
A40526/c      14 bp   DNA   linear   PAT 05-MAR-1997
LOCUS           Sequence 63 from Patent WO9425578.
ACCESSION       A40526
VERSION         A40526.1 GI:2296561
KEYWORDS
SOURCE          unidentified
ORGANISM        unidentified
REFERENCE       1 (bases 1 to 14)
AUTHORS
TITLE          ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE
JOURNAL        EFFECTS OF TRANSFORMING GROWTH FACTOR--g(b) (TGF--g(b))
               Patent: WO 9425578-A 63 10-NOV-1994;
               BIOGENSTIK GBS (DE)
FEATURES
source          Location/Qualifiers
               1..14
               /organism="unidentified"
               /mol_type="unassigned DNA"
               /db_xref="taxon:32644"

Query Match      0.2%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      95 CAGACCTGAGCAA 108
Db      14 CAGATCCTGAGCAA 1

RESULT 459
A67803
LOCUS      A67803
DEFINITION Sequence 8 from Patent WO9743427.
ACCESSION  A67803
VERSION     A67803.1 GI:4756629
KEYWORDS
SOURCE      unidentified
ORGANISM    unidentified
REFERENCE    1 (bases 1 to 14)
AUTHORS      De,V.S., Schmidt,E.D., Van,H.G. and Hecht,V.F.
TITLE        PRODUCTION OF APOMICRIC SEED
JOURNAL      Patent: WO 9743427-A 8 20-NOV-1997;
              CIBA GEIGY AG (CH)
FEATURES
  source
    1..14
    /organism="unidentified"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32644"

Query Match
Best Local Similarity 0.2%; Score 10.8; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      74 TTCTTTATTTCTG 87
Db      1 TTTTITTTTCTG 14

RESULT 460
A88058/c
LOCUS      A88058
DEFINITION Sequence 206 from Patent WO9833904.
ACCESSION  A88058
VERSION     A88058.1 GI:6736628
KEYWORDS
SOURCE      unidentified
ORGANISM    unidentified
REFERENCE    1 (bases 1 to 14)
AUTHORS      Brysch,W. and Schlingensiepen,K.
TITLE        AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL      Patent: WO 9833904-A 206 06-AUG-1998;
              BIOGENOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
  source
    1..14
    /organism="unidentified"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32644"

Query Match
Best Local Similarity 0.2%; Score 10.8; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      67 CTCTACTCTCTTT 80
Db      14 CTTCGACTTTT 1

RESULT 461
A88306/c
LOCUS      A88306
DEFINITION Sequence 454 from Patent WO9833904.
ACCESSION  A88306
VERSION     A88306.1 GI:6736876
KEYWORDS
  source
    1..14
    /organism="unidentified"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32644"

```

```

SOURCE      unidentified
ORGANISM    unidentified
REFERENCE    1 (bases 1 to 14)
AUTHORS      Brysch,W. and Schlingensiepen,K.
TITLE        AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL      Patent: WO 9833904-A 454 06-AUG-1998;
              BIOGENOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
  source
    1..14
    /organism="unidentified"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32644"

Query Match
Best Local Similarity 0.1%; Score 10.8; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      71 TACTCTTTATTT 84
Db      14 TACTTTTGT 1

RESULT 462
A89053/c
LOCUS      A89053
DEFINITION Sequence 1201 from Patent WO9833904.
ACCESSION  A89053
VERSION     A89053.1 GI:6737623
KEYWORDS
SOURCE      unidentified
ORGANISM    unidentified
REFERENCE    1 (bases 1 to 14)
AUTHORS      Brysch,W. and Schlingensiepen,K.
TITLE        AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL      Patent: WO 9833904-A 1201 06-AUG-1998;
              BIOGENOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
  source
    1..14
    /organism="unidentified"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32644"

Query Match
Best Local Similarity 0.2%; Score 10.8; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      95 CAGACCTGAGCAA 108
Db      14 CAGATCCTGAGCAA 1

RESULT 463
A90025/c
LOCUS      A90025
DEFINITION Sequence 206 from Patent EP0856579.
ACCESSION  A90025
VERSION     A90025.1 GI:6738539
KEYWORDS
SOURCE      unidentified
ORGANISM    unidentified
REFERENCE    1 (bases 1 to 14)
AUTHORS      Brysch,W.D. and Schlingensiepen,K.D.
TITLE        An antisense oligonucleotide preparation method
JOURNAL      Patent: EP 0856579-A 206 05-AUG-1998;
              BIOGENOSTIK GES (DE)
FEATURES
  source
    1..14
    /organism="unidentified"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32644"

```


Query Match 0.2%; Score 10.8; DB 1; Length 14;
 Best Local Similarity 85.7%; Pred. No. 2.7e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 67 CTCTACTCTCTTT 80
 Db 14 CTCCTACTTTTTT 1

RESULT 464
 A90273/c
 LOCUS Sequence 454 from Patent EP0856579. 14 bp DNA linear PAT 22-JAN-2000
 DEFINITION A80273
 VERSION A90273.1 GI:6738787
 KEYWORDS
 SOURCE unidentified
 ORGANISM unidentified

REFERENCE 1 (bases 1 to 14)
 AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
 TITLE An antisense oligonucleotide preparation method
 JOURNAL Patent: EP 0856579-A 454 05-AUG-1998;
 BIOGNOSTIK GES (DE)

FEATURES
 source Location/Qualifiers
 1..14
 /organism="unidentified"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32644"

Query Match 0.1%; Score 10.8; DB 1; Length 14;
 Best Local Similarity 85.7%; Pred. No. 2.7e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 71 TACTCTTTTATTT 84
 Db 14 TACTTTTTTTGTT 1

RESULT 465
 ARI18996/c
 LOCUS Sequence 122 from patent US 6150092. 14 bp DNA linear PAT 16-MAY-2001
 DEFINITION ARI18996
 ACCESSION ARI18996
 VERSION ARI18996.1 GI:14100906
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 14)
 AUTHORS Uchida,K., Uchida,T., Tanaka,Y., Matsuda,Y. and Kondo,S.
 TITLE Antisense nucleic acid compound targeted to VEGF
 JOURNAL Patent: US 6150092-A 122 21-NOV-2000;
 FEATURES
 source Location/Qualifiers
 1..14
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.2%; Score 10.8; DB 1; Length 14;
 Best Local Similarity 85.7%; Pred. No. 2.7e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 52 CATAGAGAGTGT 65
 Db 14 CATCACAAGTGT 1

RESULT 466
 BD197839
 LOCUS 14 bp RNA linear PAT 17-JUL-2003
 DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.

ACCESSION BD197839
 VERSION BD197839.1 GI:33007609
 KEYWORDS JP 2002509721-A/865.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 14)
 AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswigen,J.A.
 TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
 JOURNAL Patent: JP 2002509721-A 865 02-APR-2002;
 RIBOZYME PHARMACEUTICALS INC

COMMENT OS Homo sapiens (human)
 PN JP 2002509721-A/865
 PD 02-APR-2002
 PF 24-MAR-1999 JP 2000541291
 PR 27-MAR-1998 US 60/079678
 PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
 PI JAMES A MCSWIGEN

FEATURES
 source Location/Qualifiers
 1..14
 /organism="Homo sapiens (human)"
 /mol_type="genomic RNA"
 /db_xref="taxon:9606"

Query Match 0.2%; Score 10.8; DB 1; Length 14;
 Best Local Similarity 85.7%; Pred. No. 2.7e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 281 ATCCAGATGCTGTG 294
 Db 1 ACCCAGATGATGTG 14

RESULT 467
 BD197860/c
 LOCUS 14 bp RNA linear PAT 17-JUL-2003
 DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.
 ACCESSION BD197860
 VERSION BD197860.1 GI:33007630
 KEYWORDS JP 2002509721-A/886.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 14)
 AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswigen,J.A.
 TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
 JOURNAL Patent: JP 2002509721-A 886 02-APR-2002;
 RIBOZYME PHARMACEUTICALS INC

COMMENT OS Homo sapiens (human)
 PN JP 2002509721-A/886
 PD 02-APR-2002
 PF 24-MAR-1999 JP 2000541291
 PR 27-MAR-1998 US 60/079678
 PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
 PI JAMES A MCSWIGEN

C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
 A61P29/00,
 PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
 C12N5/00
 CC Method and reagent for treating diseases or conditions CC
 CC concerning molecule
 CC participating in vasculogenic response
 FH Key Location/Qualifiers
 FT source 1..14
 /organism="Homo sapiens (human)"

A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00/A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
CC participating molecule
FH Key Location/Qualifiers
FT source 1..14
FT /organism='Homo sapiens (human)'.
location/Qualifiers
1..14
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'

Query Match 0.2%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 517 GTCACGAGGAGAAC 530
DB 14 GTCACGAGGAGAAC 1

RESULT 468
BD203602/c
LOCUS BD203602 14 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response.
ACCESSION BD203602
VERSION BD203602.1 GI:33013372
KEYWORDS JP 2002509721-A/6628.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 14)
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswigen,J.A.
TITLE Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response
JOURNAL Patent: JP 2002509721-A 6628 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Homo sapiens (human)
PN JP 2002509721-A/6628
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00/A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
CC participating molecule
FH Key Location/Qualifiers
FT source 1..14
FT /organism='Homo sapiens (human)'.
location/Qualifiers
1..14
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'

FEATURES
source
1..14
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'

Query Match 0.1%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 93 AGCAGCAGCTGAGC 106
DB 14 AGCAGCAGCTGAGC 1

RESULT 469
AR232806/c
LOCUS AR232806 14 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 63 from patent US 6455689.
ACCESSION AR232806
VERSION AR232806.1 GI:27275144
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 14)
AUTHORS Schlingensiepen,G.-F., Brysch,W., Schlingensiepen,K.-H.,
Schlingensiepen,R. and Bogdahn,U.
TITLE Antisense-oligonucleotides for transforming growth factor-.beta.
(TGF-.beta.)
JOURNAL Patent: US 6455689-A 63 24-SEP-2002;
FEATURES location/Qualifiers
source 1..14
/organism='unknown'
/mol_type='genomic DNA'

Query Match 0.2%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 95 CAGCAGCTGAGCAA 108
DB 14 CAGCAGCTGAGCAA 1

RESULT 470
AR403511/c
LOCUS AR403511 14 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 1851 from patent US 6623962.
ACCESSION AR403511
VERSION AR403511.1 GI:40150961
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 14)
AUTHORS Akhtar,S., Fell,P. and McSwigen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases of conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: US 6623962-A 1851 23-SEP-2003;
FEATURES location/Qualifiers
source 1..14
/organism='unknown'
/mol_type='genomic DNA'

Query Match 0.2%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 479 GTAATGAGCAGAGT 492
DB 14 GGAAGGAGCAGAGT 1

RESULT 471
AX030101/c
LOCUS AX030101 14 bp DNA linear PAT 16-SEP-2000
DEFINITION Sequence 63 from patent EP1008649.
ACCESSION AX030101
VERSION AX030101.1 GI:10190318
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1

AUTHORS Bogdahn,U., Brysch,W., Schlingensiepen,G.F., Schlingensiepen,K.H.
and Schlingensiepen,R.
TITLE Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-b2 (tgf-b2)
JOURNAL Patent: EP 1008649-A 63 14-JUN-2000;
BIOGENSTIK GES (DE)
FEATURES
source 1. .14
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.2%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 95 CAGCAGCTGAGCAA 108
DB 14 CAGATCCTGAGCAA 1

RESULT 472
AX316422 14 bp DNA linear PAT 14-DEC-2001
LOCUS Sequence 63 from Patent EP160319.
DEFINITION AX316422
ACCESSION AX316422
VERSION AX316422.1 GI:17899595
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS 1 Schlingensiepen,G.F., Brysch,W., Schlingensiepen,K.H.,
Schlingensiepen,R. and Bogdahn,U.
TITLE Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta (tgf-beta)
JOURNAL Patent: EP 1160319-A 63 05-DEC-2001;
BIOGENSTIK GESELLSCHAFT FUER BIOMOLEKULARE DIAGNOSTIK MBH (DE)
FEATURES
source 1. .14
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/note="Description of unknown: unknown"

Query Match 0.2%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 95 CAGCAGCTGAGCAA 108
DB 14 CAGATCCTGAGCAA 1

RESULT 473
AX571850 14 bp DNA linear PAT 29-MAY-2003
LOCUS Sequence 9 from Patent WO02077274.
DEFINITION AX571850
ACCESSION AX571850
VERSION AX571850.1 GI:26003984
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1 Blanche,F. and Cameron,B.
TITLE Methods for purifying and detecting double stranded dna target sequences by triple helix interaction
JOURNAL Patent: WO 02077274-A 9 03-OCT-2002;
Aventis Pharma S.A. (FR)
FEATURES
source 1. .14
Location/Qualifiers

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.1%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 65 TTCTTACTTCTT 78
DB 14 TTCTTCTTCTT 1

RESULT 474
BD065571 14 bp DNA linear PAT 27-AUG-2002
LOCUS An antisense oligonucleotide preparation method.
DEFINITION BD065571
ACCESSION BD065571
VERSION BD065571.1 GI:22611174
KEYWORDS JP 2001511000-A/206.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS 1 (bases 1 to 14)
TITLE Schlingensiepen,K.H. and Brysch,W.
JOURNAL An antisense oligonucleotide preparation method
Patent: JP 2001511000-A 206 07-AUG-2001;
BIOGENSTIK GESELLSCHAFT FUER BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT OS Unknown
PN JP 2001511000-A/206
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PI 31-JAN-1997 BP 97101531.8
PR KARL HERMANN SCHLINGENSIEPEN, MORGANG BRYSCH
PC C12N15/11, C07H21/04, A61K31/70
CC An antisense oligonucleotide preparation method FH Key
location/Qualifiers
FT source 1. .14
/organism="unknown".
location/Qualifiers
1. .14
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.2%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 67 CTCTACTTCTTT 80
DB 14 CTTCACCTTTT 1

RESULT 475
BD065819 14 bp DNA linear PAT 27-AUG-2002
LOCUS An antisense oligonucleotide preparation method.
DEFINITION BD065819
ACCESSION BD065819
VERSION BD065819.1 GI:22611422
KEYWORDS JP 2001511000-A/454.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS 1 (bases 1 to 14)
TITLE Schlingensiepen,K.H. and Brysch,W.
JOURNAL An antisense oligonucleotide preparation method
Patent: JP 2001511000-A 454 07-AUG-2001;
BIOGENSTIK GESELLSCHAFT FUER BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT OS Unknown
PN JP 2001511000-A/454
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533

ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 12)
AUTHORS Crouzet,J., Scherman,D., Wilc,P., Blanche,F. and Cameron,B.
TITLE Purification of a triple helix formation with an immobilized oligonucleotide
JOURNAL Patent: US 6319672-A 32-20-NOV-2001;
FEATURES
source
1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.1%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 75 TCCTTTATTTCT 86
Db 12 TCCTTTATTTCT 1

RESULT 480
BD232406/c 12 bp RNA linear PAT 17-JUL-2003
LOCUS Attenuated Influenza viruses.
DEFINITION BD232406
ACCESSION BD232406.1 GI:33042176
VERSION UP 2002513575-A/10.
KEYWORDS unclassified
SOURCE unclassified
ORGANISM unclassified.

REFERENCE 1 (bases 1 to 12)
AUTHORS Brownlee,G.G., Fodor,E., Palese,P. and Sastre,A.G.
TITLE Attenuated Influenza viruses
JOURNAL Patent: JP 2002513575-A 10 14-MAY-2002;
JOURNAL ISIS INNOVATION LTD
OS Modified Influenza A virus
PN JP 2002513575-A/10
PD 14-MAY-2002
PF 06-MAY-1999 JP 2000547239
PR 06-MAY-1998 GB 9809666.2
PI GEORGE GOW BROWNLEE, ERVIN FODOR, PETER PALESE, ADOLFO GARCIA PI
SASTRE
PC C12N15/09,A61K39/145,A61P31/16,C12N5/10,C12N7/00,C12N15/00, PC
C12N5/00
CC Attenuated influenza viruses
FH Key Location/Qualifiers
FT source 1..12
/organism="Modified Influenza A virus".
location/Qualifiers
1..12
/organism="unclassified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

FEATURES
source

Query Match 0.1%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 446 AGCAAGGCGCTG 457
Db 12 AGCAAGGCGCTG 1

RESULT 481
CQ766108 12 bp DNA linear PAT 03-MAR-2004
LOCUS Sequence 69 from Patent WO2004005547.
DEFINITION CQ766108
ACCESSION CQ766108
VERSION CQ766108.1 GI:44908368
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct

artificial sequences.

REFERENCE 1
AUTHORS Weinzierl,R.
TITLE Method
JOURNAL Patent: WO 2004005547-A 69 15-JAN-2004;
JOURNAL IMPERIAL COLLEGE INNOVATIONS LIMITED (GB)
FEATURES
source
1..12
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="HS consensus sequence"

Query Match 0.1%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 494 ATCGAGGCACAT 505
Db 1 ATCGAGGCACAT 12

RESULT 482
CQ766133/c 12 bp DNA linear PAT 03-MAR-2004
LOCUS CQ766133
DEFINITION Sequence 94 from Patent WO2004005547.
ACCESSION CQ766133
VERSION CQ766133.1 GI:44908393
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Weinzierl,R.
TITLE Method
JOURNAL Patent: WO 2004005547-A 94 15-JAN-2004;
JOURNAL IMPERIAL COLLEGE INNOVATIONS LIMITED (GB)
FEATURES
source
1..12
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="HS consensus sequence"

Query Match 0.1%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 247 CCAATGCTGAC 258
Db 12 CCAGATGCTGAC 1

RESULT 483
CQ766279/c 12 bp DNA linear PAT 03-MAR-2004
LOCUS CQ766279
DEFINITION Sequence 240 from Patent WO2004005547.
ACCESSION CQ766279
VERSION CQ766279.1 GI:44908539
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Weinzierl,R.
TITLE Method
JOURNAL Patent: WO 2004005547-A 240 15-JAN-2004;
JOURNAL IMPERIAL COLLEGE INNOVATIONS LIMITED (GB)
FEATURES
source
1..12
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

/note="HS motif"

Query Match 0.1%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 2.4e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 247 CCMAATGCTGCG 258
 Db 12 CCAGATGCTGCG 1

RESULT 484

CQ766475

LOCUS CQ766475 12 bp DNA linear PAT 03-MAR-2004
 DEFINITION Sequence 436 from Patent WO2004005547.
 ACCESSION CQ766475
 VERSION CQ766475.1 GI:44908735
 KEYWORDS
 SOURCE Synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1 artificial sequences.

AUTHORS Weinzierl, R.
 TITLE Method
 JOURNAL Patent: WO 2004005547-A 436 15-JAN-2004;
 FEATURES IMPERIAL COLLEGE INNOVATIONS LIMITED (GB)
 source Location/Qualifiers
 1. 12
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="HS motif"

Query Match 0.1%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 2.4e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 494 ATCGAGGACACT 505
 Db 1 ATCGAGGACACT 12

RESULT 485

CQ829053

LOCUS CQ829053 12 bp DNA linear PAT 05-JUL-2004
 DEFINITION Sequence 771 from Patent WO2004053120.
 ACCESSION CQ829053
 VERSION CQ829053.1 GI:49732536
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE 1 Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 AUTHORS Weihe, E., Bieller, A. and Schaefer, M.K.
 TITLE Regulatory elements in the 5' region of the vrl gene
 JOURNAL Patent: WO 2004053120-A 771 24-JUN-2004;
 FEATURES Gruenthal GmbH (DE)
 source Location/Qualifiers
 1. 12
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 /note="V\$IK2 01"

Query Match 0.1%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 2.4e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 369 AGAAGGACTGC 380
 Db 1 AGAAGGACTGC 12

RESULT 486

I20196

LOCUS I20196 12 bp DNA linear PAT 07-OCT-1996
 DEFINITION Sequence 11 from patent US 5514546.
 ACCESSION I20196
 VERSION I20196.1 GI:1600551
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 12)
 AUTHORS Kool, E.T.
 TITLE Stem-loop oligonucleotides containing parallel and antiparallel binding domains
 JOURNAL Patent: US 5514546-A 11 07-MAY-1996;
 FEATURES Location/Qualifiers
 1. 12
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.1%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 2.4e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 74 TTCTTTTATTC 85
 Db 1 TTCTTTTCTTC 12

RESULT 487

I71434

LOCUS I71434 12 bp DNA linear PAT 03-APR-1998
 DEFINITION Sequence 4 from patent US 5681932.
 ACCESSION I71434
 VERSION I71434.1 GI:3007569
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 12)
 AUTHORS Grinnell, B.W.
 TITLE Method of using eukaryotic expression vectors comprising the BK virus
 JOURNAL Patent: US 5681932-A 4 28-OCT-1997;
 FEATURES Location/Qualifiers
 1. 12
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.1%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 2.4e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 97 GCACCTGACCA 108
 Db 1 GCACCTGATCAA 12

RESULT 488

AR235827/C

LOCUS AR235827 12 bp DNA linear PAT 20-DEC-2002
 DEFINITION Sequence 48 from patent US 6461837.
 ACCESSION AR235827
 VERSION AR235827.1 GI:27279150
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 12)
 AUTHORS Yaver, D.S. and Bellini, D.A.
 TITLE Methods for producing a polypeptide using a consensus translational initiator sequence


```

AR019426/c
LOCUS AR019426 13 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 14 from patent US 5783431.
ACCESSION AR019426
VERSION AR019426.1 GI:3974540
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 13)
AUTHORS Peterson,T.C., Foster,L.M. and Brian,P.
TITLE Methods for generating and screening novel metabolic pathways
JOURNAL Patent: US 5783431-A 14 21-JUN-1998;
FEATURES
source
1. .13
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.1%; Score 10.4; DB 1; Length 13;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 315 GAGGATCCCGG 326
Db 13 GGGGATCCCGG 2

RESULT 494
LOCUS AR156382 13 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 11 from patent US 6242211.
ACCESSION AR156382
VERSION AR156382.1 GI:15125086
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 13)
AUTHORS Peterson,T.C. and Brian,P.
TITLE Methods for generating and screening novel metabolic pathways
JOURNAL Patent: US 6242211-A 11 05-JUN-2001;
FEATURES
source
1. .13
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.1%; Score 10.4; DB 1; Length 13;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 315 GAGGATCCCGG 326
Db 13 GGGGATCCCGG 2

RESULT 495
BD235146 13 bp RNA linear PAT 17-JUL-2003
LOCUS BD235146
DEFINITION Detection of non-viral organisms with SRP RNA.
ACCESSION BD235146
VERSION BD235146.1 GI:33044916
KEYWORDS JP 2002518026-A/25.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 13)
AUTHORS Boles,C.T., Weir,L. and Stone,B.B.
TITLE Detection of non-viral organisms with SRP RNA
JOURNAL Patent: JP 2002518026-A 25 25-JUN-2002;
COMMENT MOSAIC TECHNOLOGIES
OS Artificial Sequence
PN JP 2002518026-A/25
PD 25-JUN-2002

AR019426/c
PF 18-JUN-1999 JP 2000554886
PR 19-JUN-1998 US 60/090063
PI CHRISTIAN T BOLES,LAWRENCE WEIR,BENJAMIN B STONE PC
CI2N15/09,C07H21/04,C12O1/68,C12R1/93,C12N15/00 CC
Description of Artificial Sequence:complementary nucleic acid CC
PH Key Location/Qualifiers
FT source 1. .13
FT /organism='Artificial Sequence'.
FEATURES
source
1. .13
/mol_type="synthetic construct"
/mol_type="genomic RNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 0.1%; Score 10.4; DB 1; Length 13;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 185 GGACCTGCCAAG 196
Db 2 GGACCTGCCAAG 13

RESULT 496
LOCUS CQ794371 13 bp DNA linear PAT 19-APR-2004
DEFINITION Sequence 43 from Patent WO2004024949.
ACCESSION CQ794371
VERSION CQ794371.1 GI:46407006
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Fukayocsa; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
JOURNAL Method of rapid detection of mutations and nucleotide polymorphisms
using chemometrics
PATENT: WO 2004024949-A 43 25-MAR-2004;
FEATURES
source
1. .13
/mol_type="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.1%; Score 10.4; DB 1; Length 13;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 158 GCACGTACTCCA 169
Db 13 GCACGTACTCCA 2

RESULT 497
AR310643 13 bp DNA linear PAT 12-JUN-2003
LOCUS AR310643
DEFINITION Sequence 7 from patent US 6559125.
ACCESSION AR310643
VERSION AR310643.1 GI:31703746
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 13)
AUTHORS Deryan,P.B., Wurtz,N. and Chang,A.
TITLE Polyamide-alkylator conjugates and related products and method
JOURNAL Patent: US 6559125-A 7 06-MAY-2003;
FEATURES
source
1. .13
/mol_type="unknown"

```


/mol_type="genomic DNA"

Query Match 0.1%; Score 10.4; DB 1; Length 13;

Best Local Similarity 91.7%; Pred. No. 2.8e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 295 GCAGCTCCTTAT 306

DB 2 GCAGCTCCTTAT 13

RESULT 498

AX098817

LOCUS AX098817 13 bp DNA linear PAT 02-APR-2001

DEFINITION Sequence 124 from Patent WO0120025.

ACCESSION AX098817 GI:13538058

VERSION

KEYWORDS

SOURCE

ORGANISM synthetic construct

REFERENCE 1

AUTHORS Wojnowski, L. and Eiselt, R.

TITLE Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in

JOURNAL diagnostic and therapeutic applications

Patent: WO 0120025-A 124 22-MAR-2001;

Epidaurus Biotechnology AG (DE)

Location/Qualifiers

1. .13

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="artificial"

Query Match 0.1%; Score 10.4; DB 1; Length 13;

Best Local Similarity 91.7%; Pred. No. 2.8e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 480 TAATGCACAGAG 491

DB 1 TACTGCACAGAG 12

RESULT 499

AX098818/c

LOCUS AX098818 13 bp DNA linear PAT 02-APR-2001

DEFINITION Sequence 125 from Patent WO0120025.

ACCESSION AX098818

VERSION AX098818.1 GI:13538059

KEYWORDS

SOURCE

ORGANISM synthetic construct

REFERENCE 1

AUTHORS Wojnowski, L. and Eiselt, R.

TITLE Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in

JOURNAL diagnostic and therapeutic applications

Patent: WO 0120025-A 125 22-MAR-2001;

Epidaurus Biotechnology AG (DE)

Location/Qualifiers

1. .13

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="artificial"

Query Match 0.1%; Score 10.4; DB 1; Length 13;

Best Local Similarity 91.7%; Pred. No. 2.8e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 480 TAATGCACAGAG 491

DB 13 TACTGCACAGAG 2

RESULT 500

AX137018

LOCUS AX137018 13 bp DNA linear PAT 30-MAY-2001

DEFINITION Sequence 92 from Patent EP1088900.

ACCESSION AX137018

VERSION AX137018.1 GI:14273365

KEYWORDS

SOURCE

ORGANISM

REFERENCE 1

AUTHORS Huster, E., Wojnowski, L. and Eiselt, R.

TITLE Polymorphisms in the human cyp3a4, cyp3a7 and hpxr genes and their

JOURNAL use in diagnostic and therapeutic applications

Patent: EP 1088900-A 92 04-APR-2001;

Epidaurus Biotechnology AG (DE)

Location/Qualifiers

1. .13

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="DNA"

Query Match 0.1%; Score 10.4; DB 1; Length 13;

Best Local Similarity 91.7%; Pred. No. 2.8e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 480 TAATGCACAGAG 491

DB 1 TACTGCACAGAG 12

RESULT 501

AX137019/c

LOCUS AX137019 13 bp DNA linear PAT 30-MAY-2001

DEFINITION Sequence 93 from Patent EP1088900.

ACCESSION AX137019

VERSION AX137019.1 GI:14273366

KEYWORDS

SOURCE

ORGANISM

REFERENCE 1

AUTHORS Huster, E., Wojnowski, L. and Eiselt, R.

TITLE Polymorphisms in the human cyp3a4, cyp3a7 and hpxr genes and their

JOURNAL use in diagnostic and therapeutic applications

Patent: EP 1088900-A 93 04-APR-2001;

Epidaurus Biotechnology AG (DE)

Location/Qualifiers

1. .13

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="DNA"

Query Match 0.1%; Score 10.4; DB 1; Length 13;

Best Local Similarity 91.7%; Pred. No. 2.8e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 480 TAATGCACAGAG 491

DB 13 TACTGCACAGAG 2

RESULT 502

AX555912

LOCUS AX555912 13 bp DNA linear PAT 27-NOV-2002

DEFINITION Sequence 508 from Patent WO02070755.

ACCESSION AX555912

VERSION AX555912.1 GI:25899370

KEYWORDS

SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Lyamichchev,V.I., Kaiser,M.W. and Lyamichcheva,N.
TITLE Pen endonucleases
JOURNAL Patent: WO 0207075-A 508 12-SEP-2002;
Third Wave Technologies, Inc. (US)
FEATURES
source 1. .13
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.1%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 380 CCGTCGCGCTC 391
|||||
Db 1 CCGTCGCGCTC 12

RESULT 503
LOCUS BD086489 13 bp DNA linear PAT 27-AUG-2002
DEFINITION Tenascin antisense oligonucleotide for treating leukemia.
ACCESSION BD086489
VERSION BD086489.1 GI:22632099
KEYWORDS JP 2001523451-A/20.
SOURCE unclassified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 13)
AUTHORS Anuschirwan,P., Uhlmann,E. and Weiser,C.
TITLE Tenascin antisense oligonucleotide for treating leukemia
JOURNAL Patent: JP 2001523451-A 20 27-NOV-2001;
AVENTIS PHARMA DEUTSCHLAND GMBH
COMMENT OS Unclassified
PN JP 2001523451-A/20
PD 27-NOV-2001
PF 29-OCT-1998 JP 2000521185
PR 15-NOV-1997 DE 197 50 702.6
PI PEYMAN ANUSCHIRWAN,EUGEN UHLMANN,CAROLINE WEISER PC
CI2N15/09,A61K31/711,A61K48/00,A61P17/00,C12Q1/68,C12N15/00 CC
Strandedness: Single;
CC Topology: Linear;
CC Tenascin antisense oligonucleotide for treating leukemia FH
Key Location/Qualifiers
FT exon 1. .13.

FEATURES
source 1. .13
/organism="unclassified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.1%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 519 CACAGAGAGAC 530
|||||
Db 2 CACAGAGAGAC 13

RESULT 504
LOCUS BD086508 13 bp DNA linear PAT 27-AUG-2002
DEFINITION Tenascin antisense oligonucleotide for treating leukemia.
ACCESSION BD086508
VERSION BD086508.1 GI:22632118
KEYWORDS JP 2001523451-A/39.
SOURCE unclassified

ORGANISM unclassified
REFERENCE 1 (bases 1 to 13)
AUTHORS Anuschirwan,P., Uhlmann,E. and Weiser,C.
TITLE Tenascin antisense oligonucleotide for treating leukemia
JOURNAL Patent: JP 2001523451-A 39 27-NOV-2001;
AVENTIS PHARMA DEUTSCHLAND GMBH
COMMENT OS Unclassified
PN JP 2001523451-A/39
PD 27-NOV-2001
PF 29-OCT-1998 JP 2000521185
PR 15-NOV-1997 DE 197 50 702.6
PI PEYMAN ANUSCHIRWAN,EUGEN UHLMANN,CAROLINE WEISER PC
CI2N15/09,A61K31/711,A61K48/00,A61P17/00,C12Q1/68,C12N15/00 CC
Strandedness: Single;
CC Topology: Linear;
CC Tenascin antisense oligonucleotide for treating leukemia FH
Key Location/Qualifiers
FT exon 1. .13.

FEATURES
source 1. .13
/organism="unclassified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.1%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 519 CACAGAGAGAC 530
|||||

RESULT 505
LOCUS BD086527 13 bp DNA linear PAT 27-AUG-2002
DEFINITION Tenascin antisense oligonucleotide for treating leukemia.
ACCESSION BD086527
VERSION BD086527.1 GI:22632137
KEYWORDS JP 2001523451-A/58.
SOURCE unclassified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 13)
AUTHORS Anuschirwan,P., Uhlmann,E. and Weiser,C.
TITLE Tenascin antisense oligonucleotide for treating leukemia
JOURNAL Patent: JP 2001523451-A 58 27-NOV-2001;
AVENTIS PHARMA DEUTSCHLAND GMBH
COMMENT OS Unclassified
PN JP 2001523451-A/58
PD 27-NOV-2001
PF 29-OCT-1998 JP 2000521185
PR 15-NOV-1997 DE 197 50 702.6
PI PEYMAN ANUSCHIRWAN,EUGEN UHLMANN,CAROLINE WEISER PC
CI2N15/09,A61K31/711,A61K48/00,A61P17/00,C12Q1/68,C12N15/00 CC
Strandedness: Single;
CC Topology: Linear;
CC Tenascin antisense oligonucleotide for treating leukemia FH
Key Location/Qualifiers
FT exon 1. .13.

FEATURES
source 1. .13
/organism="unclassified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.1%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 519 CACAGAGAGAC 530
|||||

Db 2 CACGAAAGAAC 13

Search completed: October 26, 2004, 15:59:31
Job time : 34 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 27, 2004, 06:57:43 ; Search time 2 Seconds
(without alignments)
5.062 Million cell updates/sec

Title: US-09-923-515-3
Perfect score: 7200
Sequence: 1 ctgggattgggacacattc.....actgcaacctgacgaatgc 7200

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 45 seqs, 703 residues

Total number of hits satisfying chosen parameters: 90

Minimum DB seq length: 12
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 46 summaries

Database: rnp3.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	25	0.3	25	1	US-10-956-157-149069
2	25	0.3	25	1	US-10-956-157-149069
3	24	0.3	25	1	US-10-956-157-149069
4	20.2	0.3	25	1	US-10-956-157-149069
5	19.8	0.3	25	1	US-10-956-157-149069
6	19.2	0.3	25	1	US-10-956-157-149069
7	15.2	0.2	20	1	PCT-US04-32130-307
8	14.4	0.2	25	1	US-10-956-157-149069
9	14.4	0.2	25	1	US-10-956-157-149069
10	12.8	0.2	17	1	US-10-951-303-1070
11	12.8	0.2	17	1	US-10-951-303-1070
12	12.8	0.2	14	1	US-60-522-459-8962
13	11.8	0.2	15	1	US-09-686-1488-274
14	11.8	0.2	15	1	US-60-522-459-8962
15	11.8	0.2	15	1	US-60-522-459-8962
16	11.8	0.2	15	1	US-60-522-459-8962
17	11.4	0.2	13	1	US-60-522-459-8962
18	11.4	0.2	13	1	US-60-522-459-8962
19	11.4	0.2	14	1	US-60-522-459-8962
20	11.4	0.2	14	1	US-60-522-459-8962
21	11.4	0.2	14	1	US-60-522-459-8962
22	11.4	0.2	15	1	US-60-522-459-8962
23	11.4	0.2	15	1	US-60-522-459-8962
24	11.4	0.2	15	1	US-60-522-459-8962
25	11.4	0.2	15	1	US-60-522-459-8962
26	10.8	0.2	14	1	US-60-522-459-8962
27	10.8	0.2	14	1	US-60-522-459-8962
28	10.8	0.2	14	1	US-60-522-459-8962
29	10.8	0.2	14	1	US-60-522-459-8962
30	10.8	0.2	14	1	US-60-522-459-8962
31	10.8	0.2	14	1	US-60-522-459-8962
32	10.8	0.2	14	1	US-60-522-459-8962
33	10.8	0.2	14	1	US-60-522-459-8962

C	34	10.8	0.2	14	1	US-60-522-459-13337	Sequence 13337, A
C	35	10.8	0.2	14	1	US-60-522-459-14147	Sequence 14147, A
C	36	10.4	0.1	12	1	US-10-474-148-12	Sequence 12, Ap1
C	37	10.4	0.1	12	1	US-60-522-459-7565	Sequence 7565, Ap
C	38	10.4	0.1	12	1	US-60-522-459-7723	Sequence 7723, Ap
C	39	10.4	0.1	12	1	US-60-522-459-13687	Sequence 13687, A
C	40	10.4	0.1	13	1	US-60-522-459-1592	Sequence 1592, Ap
C	41	10.4	0.1	13	1	US-60-522-459-2582	Sequence 2582, Ap
C	42	10.4	0.1	13	1	US-60-522-459-2913	Sequence 2913, Ap
C	43	10.4	0.1	13	1	US-60-522-459-3952	Sequence 3952, Ap
C	44	10.4	0.1	13	1	US-60-522-459-5448	Sequence 5448, Ap
C	45	10.4	0.1	13	1	US-60-522-459-7234	Sequence 7234, Ap
C	46	10.4	0.1	13	1	US-60-522-459-13617	Sequence 13617, A

ALIGNMENTS

```
RESULT 1
US-10-956-157-149069
; Sequence 149069, Application US/10956157
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 149069
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
; US-10-956-157-149069
```

Query Match 0.3%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Cy 27 ACTGCTGGCCAGTCCCAAAATGGAA 51
Db 1 ACTGCTGGCCAGTCCCAAAATGGAA 25
```

```
RESULT 2
US-10-956-157-277052
; Sequence 277052, Application US/10956157
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 277052
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
; US-10-956-157-277052
```

Query Match 0.3%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Cy 62 TGGTCTTCTACTCTTTTATTCT 86
Db 1 TGGTCTTCTACTCTTTTATTCT 25
```

```
RESULT 3
US-10-956-157-197231
; Sequence 197231, Application US/10956157
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 197231
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-197231

Query Match
Best Local Similarity 0.3%; Score 24; DB 1; Length 25;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CTGGGATTGGGACACACTTTCTCG 24
DB 2 CTGGGATTGGGACACACTTTCTCG 25

RESULT 4
US-10-956-157-70926/c
; Sequence 70926, Application US/10956157
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 70926
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-70926

Query Match
Best Local Similarity 0.3%; Score 20.2; DB 1; Length 25;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 205 TCTATGACACACATCAACATATATA 229
DB 25 TGTATTCACCAATCAACAGATA 1

RESULT 5
US-10-956-157-70931/c
; Sequence 70931, Application US/10956157
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 70931
; LENGTH: 25
; TYPE: DNA
```

```
; ORGANISM: Probe Sequence
US-10-956-157-70931

Query Match
Best Local Similarity 0.3%; Score 19.8; DB 1; Length 25;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 207 TATGACACACATCAACATATATA 229
DB 24 TATTCACCAATCAACAGATA 2

RESULT 6
US-10-956-157-140292
; Sequence 140292, Application US/10956157
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 140292
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-140292

Query Match
Best Local Similarity 0.3%; Score 19.2; DB 1; Length 25;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 319 GATCCCGGTGTCAGTGGAGTAC 342
DB 2 GACCCACGTCAGGTGGAGTAC 25

RESULT 7
PCT-US04-32130-307/c
; Sequence 307, Application PC/TUS0432130
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Inghirami, Giorgio
; TITLE OF INVENTION: Antisense Oligonucleotide Modulation of STAT3 Expression
; FILE REFERENCE: ISPH-0883
; CURRENT APPLICATION NUMBER: PCT/US04/32130
; PRIOR FILING DATE: 2004-10-06
; PRIOR FILING DATE: 2004-02-06
; PRIOR APPLICATION NUMBER: 10/773,678
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 09/758,881
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: PCT/US00/09054
; PRIOR FILING DATE: 2000-04-06
; PRIOR APPLICATION NUMBER: 09/288,461
; PRIOR FILING DATE: 1999-04-08
; NUMBER OF SEQ ID NOS: 511
; SOFTWARE: PatentIn Ver. 2.1 and FastSeq Ver. 4.0
; SEQ ID NO 307
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
PCT-US04-32130-307

Query Match
Best Local Similarity 0.2%; Score 15.2; DB 1; Length 20;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 285 AGATGCTGCGCAGCTTCCTT 304

DB 20 AGATGCTGCGCAGCAGCCTT 1

RESULT 8
US-10-773-678-307/C

Sequence 307, Application US/10773678

GENERAL INFORMATION:

APPLICANT: Kariya, James G

TITLE OF INVENTION: Antisense Oligonucleotide Modulation of STAT3

TITLE OF INVENTION: Expression

FILE REFERENCE: ISPH-0828

CURRENT APPLICATION NUMBER: US/10/773,678

CURRENT FILING DATE: 2004-02-06

PRIOR APPLICATION NUMBER: 10/713,139

PRIOR FILING DATE: 2003-11-14

PRIOR APPLICATION NUMBER: 09/758,881

PRIOR FILING DATE: 2001-01-11

PRIOR APPLICATION NUMBER: PCT/US00/09054

PRIOR FILING DATE: 2000-04-06

PRIOR APPLICATION NUMBER: 09/288,461

PRIOR FILING DATE: 1999-04-08

NUMBER OF SEQ ID NOS: 402

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 307

LENGTH: 20

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Antisense oligonucleotide

US-10-773-678-307

Query Match
Best Local Similarity 85.0%; Score 15.2; DB 1; Length 20;
Pred. No. 3;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 285 AGATGCTGCGCAGCTTCCTT 304

DB 20 AGATGCTGCGCAGCAGCCTT 1

RESULT 9
US-10-956-157-140292/C

Sequence 140292, Application US/10956157

GENERAL INFORMATION:

APPLICANT: Wyeth

APPLICANT: Mounts, William

TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

FILE REFERENCE: 031896-043000 (AM 101081)

CURRENT APPLICATION NUMBER: US/10/956,157

CURRENT FILING DATE: 2004-10-04

NUMBER OF SEQ ID NOS: 319805

SOFTWARE: PatentIn version 3.2

SEQ ID NO 140292

LENGTH: 25

TYPE: DNA

ORGANISM: Probe Sequence

US-10-956-157-140292

Query Match
Best Local Similarity 0.2%; Score 14.4; DB 1; Length 25;
Pred. No. 8,1;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 339 GTACTGCACTGACCAATGCTC 362

DB 25 GTACTGCCACTGACGCTGGGCTC 2

RESULT 10

US-10-951-303-1069
Sequence 1069, Application US/10951303

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam

APPLICANT: McSwigen, Jim

APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related

FILE REFERENCE: MBH00-876-K (400/021)

CURRENT APPLICATION NUMBER: US/10/951,303

CURRENT FILING DATE: 2004-09-27

PRIOR APPLICATION NUMBER: US/09/685,664

PRIOR FILING DATE: 2000-10-10

PRIOR APPLICATION NUMBER: US 60/005,974

PRIOR FILING DATE: 1995-10-26

PRIOR APPLICATION NUMBER: US 08/584,040

PRIOR FILING DATE: 1996-01-08

PRIOR APPLICATION NUMBER: US 09/371,772

PRIOR FILING DATE: 1999-08-10

NUMBER OF SEQ ID NOS: 8231

SOFTWARE: PatentIn version 3.0

SEQ ID NO 1069

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-10-951-303-1069

Query Match
Best Local Similarity 0.2%; Score 12.8; DB 1; Length 17;
Pred. No. 8,4;
Matches 3; Conservative 11; Mismatches 2; Indels 0; Gaps 0;

QY 69 TCTACTTCTTTATT 84

DB 2 UCUCUUCUUUUUU 17

RESULT 11
US-10-951-303-1070

Sequence 1070, Application US/10951303

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam

APPLICANT: McSwigen, Jim

APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related

FILE REFERENCE: MBH00-876-K (400/021)

CURRENT APPLICATION NUMBER: US/10/951,303

CURRENT FILING DATE: 2004-09-27

PRIOR APPLICATION NUMBER: US/09/685,664

PRIOR FILING DATE: 2000-10-10

PRIOR APPLICATION NUMBER: US 60/005,974

PRIOR FILING DATE: 1995-10-26

PRIOR APPLICATION NUMBER: US 08/584,040

PRIOR FILING DATE: 1996-01-08

PRIOR APPLICATION NUMBER: US 09/371,772

PRIOR FILING DATE: 1999-08-10

NUMBER OF SEQ ID NOS: 8231

SOFTWARE: PatentIn version 3.0

SEQ ID NO 1070

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-10-951-303-1070

Query Match
Best Local Similarity 0.2%; Score 12.8; DB 1; Length 17;
Pred. No. 8,4;
Matches 3; Conservative 11; Mismatches 2; Indels 0; Gaps 0;

QY 69 TCTACTTCTTTATT 84

```
Db          1 UCUACUUUUUUUUUU 16
          |||:::|::|
RESULT 12
US-60-522-459-6316/c
; Sequence 6316, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6316
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-6316

Query Match          0.2%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 8.6;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY          92 CAGCAGCAGCTG 103
Db          13 CAGCAGCAGCTG 2

RESULT 13
US-09-686-148B-274/c
; Sequence 274, Application US/09686148B
; GENERAL INFORMATION:
; APPLICANT: KOSTER, Hubert
; LITTLE, Daniel P.
; BRAUN, Andreas
; LOUGH, David M.
; XIANG, Guobing
; VAN DEN BOOM, Dick
; JURINKE, Christian
; RUPPERT, Andreas
; TITLE OF INVENTION: DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY
; NUMBER OF SEQUENCES: 320
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P. C.
; STREET: 12930 El Camino Real
; CITY: San Diego
; STATE: CA
; COUNTRY: USA
; ZIP: 92130
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/686,148B
; FILING DATE: 10-Oct-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/297,576
; FILING DATE: 28-Jun-99
; APPLICATION NUMBER: 08/947,801
; FILING DATE: 08-Oct-97
; APPLICATION NUMBER: 08/933,792
; FILING DATE: 19-Sep-97
; APPLICATION NUMBER: 08/787,639
; FILING DATE: 23-Jan-97
; APPLICATION NUMBER: 08/786,988
; FILING DATE: 23-Jan-97
; APPLICATION NUMBER: 08/746,055

; FILING DATE: 06-Nov-96
; APPLICATION NUMBER: 08/746,036
; FILING DATE: 06-Nov-96
; APPLICATION NUMBER: 08/744,590
; FILING DATE: 06-Nov-96
; APPLICATION NUMBER: 08/744,481
; FILING DATE: 06-Nov-96
; ATTORNEY/AGENT INFORMATION:
; NAME: Seidman, Stephanie L.
; REGISTRATION NUMBER: 33,779
; REFERENCE/DOCKET NUMBER: 24736-2004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 858-450-8400
; TELEFAX: 858-450-8499
; INFORMATION FOR SEQ ID NO: 274:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: unknown
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: <Unknown>
; ORIGINAL SOURCE:
; SEQUENCE DESCRIPTION: SEQ ID NO: 274:
US-09-686-148B-274

Query Match          0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 11;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY          321 TCCCGGTGTCAGTG 335
Db          15 TCCAGAGTCAGTG 1

RESULT 14
US-60-522-459-8686
; Sequence 8686, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8686
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-8686

Query Match          0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 11;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY          172 ACTGTCTCAGGAGG 186
Db          1 AAUGUCACAGCAGG 15

RESULT 15
US-60-522-459-11208/c
; Sequence 11208, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; CURRENT APPLICATION NUMBER: US/60/522,459
```


; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11208
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-11208

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 11;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 77 TTTTATTTCTGAAT 91
DB 15 TTTTATTTCTTACT 1

RESULT 16
US-60-522-459-13311/C
; Sequence 13311, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13311
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
US-60-522-459-13311

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 11;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 153 TCGAGCGACCTACTC 167
DB 15 TCGAGCGACCTACTC 1

RESULT 17
US-60-522-459-8962
; Sequence 8962, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8962
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-8962

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 10;
Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 411 AAGCCTAGAGGCT 423
DB 1 AAGACUAGAGGCU 13

RESULT 18

US-60-522-459-12964
; Sequence 12964, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12964
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
US-60-522-459-12964

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 10;
Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 455 CTGGGCTGCAGCA 467
DB 1 CTGGGCTGCAGCA 13

RESULT 19
US-60-522-459-2774
; Sequence 2774, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2774
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-2774

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 12;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 458 GGGTGCAGGATG 470
DB 2 GGGAGCGAGAGUG 14

RESULT 20
US-60-522-459-10553
; Sequence 10553, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; TITLE OF INVENTION: VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10553
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-10553

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 76.9%; Pred. No. 12;

Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
Qy 174 TGTCACGAGG 186
Db 2 UGUCACGAGG 14

RESULT 21
US-60-522-459-13461/c
; Sequence 13461, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13461
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
US-60-522-459-13461

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 12;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 21 CTGACACCTGCTG 33
Db 13 CTGCGACCTGCTG 1

RESULT 22
US-60-522-459-2047
; Sequence 2047, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2047
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-2047

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 76.9%; Pred. No. 14;
Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 413 GCCTAGAGCTGC 425
Db 2 GCCUGAGGCTCC 14

RESULT 23
US-60-522-459-9790
; Sequence 9790, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 9790
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-9790

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 76.9%; Pred. No. 14;
Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 85 CTGAATCAGAG 97
Db 1 CUCACUCAGAG 13

RESULT 24
US-60-522-459-14062
; Sequence 14062, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14062
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
US-60-522-459-14062

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 46.2%; Pred. No. 14;
Matches 6; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 80 TATTCGAAATC 92
Db 2 UAUUCUACUAC 14

RESULT 25
US-60-522-459-2550
; Sequence 2550, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2550
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-2550

Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 177 CACAGGAAGA 187
Db 3 CACAGGAAGA 13

RESULT 26
US-60-522-459-1445/c
; Sequence 1445, Application US/60522459
; GENERAL INFORMATION:

```

; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 1445
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-1445

```

```

Query Match          0.2%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 17;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      171 CACTGTCACAGAA 184
Db      14 CACTGCTCAGAA 1

```

```

RESULT 27
US-60-522-459-2052/c
; Sequence 2052, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 2052
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-2052

```

```

Query Match          0.1%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 17;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      99 ACCTGACCAAGCC 112
Db      14 ACCTGAGCCAGGCC 1

```

```

RESULT 28
US-60-522-459-4834/c
; Sequence 4834, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 4834
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-4834

```

```

Query Match          0.2%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 17;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      30 GCTGCCAGTCCCA 43

```

```

Db      14 GCTGCCAGCCCA 1

```

```

RESULT 29
US-60-522-459-6125
; Sequence 6125, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 6125
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-6125

```

```

Query Match          0.1%; Score 10.8; DB 1; Length 14;
Best Local Similarity 50.0%; Pred. No. 17;
Matches 7; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      293 TGGCAGCTCCTTAT 306
Db      1 UGGCAGCUCGUUUU 14

```

```

RESULT 30
US-60-522-459-8720
; Sequence 8720, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 8720
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-8720

```

```

Query Match          0.1%; Score 10.8; DB 1; Length 14;
Best Local Similarity 71.4%; Pred. No. 17;
Matches 10; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      172 ACTGTCACAGAG 185
Db      1 AATGUCACAGCGG 14

```

```

RESULT 31
US-60-522-459-10339/c
; Sequence 10339, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 10339
; LENGTH: 14
; TYPE: RNA

```

ORGANISM: Human
US-60-522-459-10339

Query Match
Best Local Similarity 0.1%; Score 10.8; DB 1; Length 14;
Matches 12; Conservative 0; Pred. No. 17; Mismatches 2; Indels 0; Gaps 0;

QY 445 GAGCAAGGCTGG 458
DB 14 GAGCCAGGCTTGG 1

RESULT 32
US-60-522-459-10691/c
Sequence 10691, Application US/60522459
GENERAL INFORMATION:
APPLICANT: ROSETTA GENOMICS LTD
TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
FILE REFERENCE: 52904
CURRENT APPLICATION NUMBER: US/60/522,459
CURRENT FILING DATE: 2004-10-04
NUMBER OF SEQ ID NOS: 15575
SOFTWARE: PatentIn version 3.2
SEQ ID NO 10691
LENGTH: 14
TYPE: RNA
ORGANISM: Human
US-60-522-459-10691

Query Match
Best Local Similarity 0.2%; Score 10.8; DB 1; Length 14;
Matches 12; Conservative 0; Pred. No. 17; Mismatches 2; Indels 0; Gaps 0;

QY 570 TCGAGCCCGAAT 583
DB 14 TCAGACCCCTGAAT 1

RESULT 33
US-60-522-459-10956
Sequence 10956, Application US/60522459
GENERAL INFORMATION:
APPLICANT: ROSETTA GENOMICS LTD
TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
FILE REFERENCE: 52904
CURRENT APPLICATION NUMBER: US/60/522,459
CURRENT FILING DATE: 2004-10-04
NUMBER OF SEQ ID NOS: 15575
SOFTWARE: PatentIn version 3.2
SEQ ID NO 10956
LENGTH: 14
TYPE: RNA
ORGANISM: Human
US-60-522-459-10956

Query Match
Best Local Similarity 0.2%; Score 10.8; DB 1; Length 14;
Matches 11; Conservative 1; Pred. No. 17; Mismatches 2; Indels 0; Gaps 0;

QY 285 AGATGCTGGCAG 298
DB 1 AGAGGCTGAGGAG 14

RESULT 34
US-60-522-459-13237/c
Sequence 13237, Application US/60522459
GENERAL INFORMATION:
APPLICANT: ROSETTA GENOMICS LTD
TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
FILE REFERENCE: 52904
CURRENT APPLICATION NUMBER: US/60/522,459
CURRENT FILING DATE: 2004-10-04
NUMBER OF SEQ ID NOS: 15575
SOFTWARE: PatentIn version 3.2
SEQ ID NO 13237
LENGTH: 14
TYPE: RNA
ORGANISM: Human
US-60-522-459-13237

FILE REFERENCE: 52904

CURRENT APPLICATION NUMBER: US/60/522,459
CURRENT FILING DATE: 2004-10-04
NUMBER OF SEQ ID NOS: 15575
SOFTWARE: PatentIn version 3.2
SEQ ID NO 13237
LENGTH: 14
TYPE: RNA
ORGANISM: Human
US-60-522-459-13237

Query Match
Best Local Similarity 0.2%; Score 10.8; DB 1; Length 14;
Matches 12; Conservative 0; Pred. No. 17; Mismatches 2; Indels 0; Gaps 0;

QY 367 GCAGAGGAGCTGC 380
DB 14 GCAGCAGGAGCTGC 1

RESULT 35
US-60-522-459-14147/c
Sequence 14147, Application US/60522459
GENERAL INFORMATION:
APPLICANT: ROSETTA GENOMICS LTD
TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
FILE REFERENCE: 52904
CURRENT APPLICATION NUMBER: US/60/522,459
CURRENT FILING DATE: 2004-10-04
NUMBER OF SEQ ID NOS: 15575
SOFTWARE: PatentIn version 3.2
SEQ ID NO 14147
LENGTH: 14
TYPE: RNA
ORGANISM: Human
US-60-522-459-14147

Query Match
Best Local Similarity 0.2%; Score 10.8; DB 1; Length 14;
Matches 12; Conservative 0; Pred. No. 17; Mismatches 2; Indels 0; Gaps 0;

QY 362 CAGAGCAGAGG 375
DB 14 CAGCAGCAGAGG 1

RESULT 36
US-10-474-148-12
Sequence 12, Application US/10474148
GENERAL INFORMATION:
APPLICANT: ENSHEL, Jonathan
TITLE OF INVENTION: PHAGE DISPLAY VECTOR, PHAGES ENCODED THEREBY, AND METHODS OF USE
FILE REFERENCE: GERSHONI-4
CURRENT APPLICATION NUMBER: US/10/474,148
CURRENT FILING DATE: 2003-10-06
NUMBER OF SEQ ID NOS: 29
SOFTWARE: PatentIn version 3.0
SEQ ID NO 12
LENGTH: 12
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: synthetic
US-10-474-148-12

Query Match
Best Local Similarity 0.1%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Pred. No. 15; Mismatches 1; Indels 0; Gaps 0;

QY 21 CTGAGACTGCT 32
DB 1 CTGAGACTGCT 32

```
Db      1 CTGACCCCTGCT 12

RESULT 37
US-60-522-459-7565
; Sequence 7565, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 7565
; LENGTH: 12
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-7565

Query Match      0.1%; Score 10.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 15;
Matches 10; Conservative 1; Mismatches 0; Gaps 0;

Qy      48 GGAACATTAAGCA 59
Db      1 GGAATUUAAGCA 12

RESULT 38
US-60-522-459-7723
; Sequence 7723, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 7723
; LENGTH: 12
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-7723

Query Match      0.1%; Score 10.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 15;
Matches 10; Conservative 1; Mismatches 0; Gaps 0;

Qy      413 GCCTAGAGGCTC 424
Db      1 GCCUAGAGGCC 12

RESULT 39
US-60-522-459-13687
; Sequence 13687, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 13687
; LENGTH: 12
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
```

```
US-60-522-459-13687

Query Match      0.1%; Score 10.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 15;
Matches 10; Conservative 1; Mismatches 0; Gaps 0;

Qy      375 GACTGCCGTCGC 386
Db      1 GACTGCCGCGCC 12

RESULT 40
US-60-522-459-1592
; Sequence 1592, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 1592
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-1592

Query Match      0.1%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 18;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      185 GACCTGCCAAG 196
Db      1 GACACGCCAAG 12

RESULT 41
US-60-522-459-2582
; Sequence 2582, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 2582
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-2582

Query Match      0.1%; Score 10.4; DB 1; Length 13;
Best Local Similarity 25.0%; Pred. No. 18;
Matches 3; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

Qy      72 ACTCTTTATT 83
Db      2 ACUGUUUUUU 13

RESULT 42
US-60-522-459-2913
; Sequence 2913, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
```

```

; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2913
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-2913

```

```

Query Match
Best Local Similarity 0.1%; Score 10.4; DB 1; Length 13;
Matches 8; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      8 TGGACACACTT 19
Db      2 UGAAACACACU 13

```

```

RESULT 43
US-60-522-459-3952/c
; Sequence 3952, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3952
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-3952

```

```

Query Match
Best Local Similarity 0.1%; Score 10.4; DB 1; Length 13;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      40 CCCAAATGGA 51
Db      12 CCCAAATGAA 1

```

```

RESULT 44
US-60-522-459-5448
; Sequence 5448, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5448
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-5448

```

```

Query Match
Best Local Similarity 0.1%; Score 10.4; DB 1; Length 13;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      175 GTACACAGAGG 186
Db      1 GUACACAGGAGG 12

```

```

RESULT 45
US-60-522-459-7234/c
; Sequence 7234, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7234
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Human
US-60-522-459-7234

```

```

Query Match
Best Local Similarity 0.1%; Score 10.4; DB 1; Length 13;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      367 GCAGAGGACT 378
Db      12 GCAGAGGACT 1

```

```

RESULT 46
US-60-522-459-13617
; Sequence 13617, Application US/60522459
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND
; FILE REFERENCE: 52904
; CURRENT APPLICATION NUMBER: US/60/522,459
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 15575
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13617
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Human herpesvirus 4 [Epstein-Barr virus]
US-60-522-459-13617

```

```

Query Match
Best Local Similarity 0.1%; Score 10.4; DB 1; Length 13;
Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      452 GCCTGGGGTGC 463
Db      2 GCACUGGGGUC 13

```

```

Search completed: October 27, 2004, 06:57:47
Job time : 3 secs

```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 27, 2004, 06:59:52 : Search time 0.001 Seconds
(without alignments)
1094.400 Million cell updates/sec

Title: US-09-923-515-3

Perfect score: 7200

Sequence: 1 ccggagatcgagacacattt.....actgcacctgacgaatgc 7200

Scoring table: IDENTITY_NTC
Gapop 10.0 , Gapext 0.5

Searched: 6 seqs, 76 residues

Total number of hits satisfying chosen parameters: 12

Minimum DB seq length: 12
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 7 summaries

Database : rct3.seq*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
C 1	12	0.2	15	1	ACCESSION:CA851710
C 2	10.4	0.1	12	1	ACCESSION:BO591624
C 3	10.4	0.1	12	1	ACCESSION:CN752857
C 4	9.8	0.1	13	1	ACCESSION:CF291168
C 5	9.4	0.1	12	1	ACCESSION:CF331242
C 6	9.4	0.1	12	1	ACCESSION:CL437025
C 7	9	0.1	12	1	ACCESSION:CL437025

ALIGNMENTS

RESULT 1
CA851710/c 15 bp mRNA linear EST 01-AUG-2003
LOCUS D16F12.124.12.ab1 cDNA Peking library 2, 4 day SCN3 Glycine max
DEFINITION CDNA clone D16F12 5', mRNA sequence.
ACCESSION CA851710
VERSION CA851710.1 GI:33388503
KEYWORDS EST.
SOURCE Glycine max (soybean)
ORGANISM Glycine max

Alpharouf, N.W., Khan, R. and Matthews, B.F.
Analysis of expressed sequence tags from roots of resistant soybean
infected by the soybean cyst nematode
Unpublished (2002)
Contact: Alpharouf, N.W.
Soybean Genomics and Improvement Laboratory (SGIL)

Alpharouf, N.W., Khan, R. and Matthews, B.F.

Analysis of expressed sequence tags from roots of resistant soybean

infected by the soybean cyst nematode

Unpublished (2002)

Contact: Alpharouf, N.W.

Soybean Genomics and Improvement Laboratory (SGIL)

US Department of Agriculture (USDA), ARS, PSI
Bldg. 006, Rm 118, 10300 Baltimore Ave., Beltsville, MD 20705-2350,
USA
Tel: 301 504 5750
Fax: 301 504 5728
Email: alpharouf@ars.usda.gov.
Location/Qualifiers

FEATURES

source
1.15
/organism="Glycine max"
/mol_type="mRNA"
/cultivar="Peking"
/db_xref="taxon:3847"
/clone="D16F12"
/issue_type="Roots"
/dev_stage="Seedling"
/clone_lib="CDNA Peking library 2, 4 day SCN3"
/note="Vector: pBluescript SK-; CDNA clones from mRNA
extracted from Peking roots 2 and 4 days past invasion."

Query Match 0.2% Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 0.49;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 53 ATAGGAGAGTGG 64
Db 15 ATAGGAGAGTGG 4

RESULT 2
BO591624/c 12 bp mRNA linear EST 06-DEC-2002
LOCUS B012618-024-017-P07-SP6 MP12-ADIS-024-storage root Beta vulgaris

DEFINITION CDNA clone 024-017-P07 5-PRIME, mRNA sequence.
ACCESSION BO591624
VERSION BO591624.1 GI:26121207

KEYWORDS EST.
SOURCE Beta vulgaris
ORGANISM Beta vulgaris

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Caryophyllales; Amaranthaceae; Beta.

REFERENCE
AUTHORS Herwig, R., Schulz, B., Weisshaar, B., Hennig, S., Steinfach, M.,
Drungowski, M., Stahl, D., Wruck, W., Menze, A., O'Brien, J., Lehrach, H.
and Radelof, U.

Construction of a 'unigenes' cDNA clone set by oligonucleotide
fingerprinting allows access to 25 000 potential sugar beet genes
J. 32 (5), 845-857 (2002)

TITLE
JOURNAL MEDLINE
PUBMED
COMMENT

Contact: Weisshaar B
ADIS DNA core facility at MP12
Max-Planck-Institute for Plant Breeding Research
Carl-von-Linne Weg 10, 50829 Koeln, Germany
Fax: 00492215062851
Email: weisshaar@mp12-koeln.mpg.de
Insert Length: 12 Std Error: 0.00
Plate: 17 row: P column: 07
Seq primer: SP6; CATACGATTAGTGACACTATAG.
Location/Qualifiers

FEATURES

source
1.12
/organism="Beta vulgaris"
/mol_type="mRNA"
/cultivar="KWS2320 (double haploid, monogerm breeding
line)"
/db_xref="taxon:161934"
/clone="024-017-P07"
/issue_type="storage root"
/clone_lib="MP12-ADIS-024-storage root"
/note="Vector: pCMVSPORT6; Site 1: SalI; Site 2: NotI;
CDNA library from sugar beet, library provided by KWS

Kleinwanzlebener Saatnucht AG Einbeck, Germany, contact: b.schulz@kws.de; Cloning sites SalI-NotI, primer sites and orientation:
 SP6-SalI-CCAGCGTCGCG-5prime-cDNA-polyA-CC-NotI-T7; Note: Sequencing granted in the context of the GABI-BeeT project, local PI: Dr. Katharina Schneider, coordinator: Prof. Christian Jung; Sequence submissions managed by RZPD/GABI-Primary database: <http://gabi.rzpd.de>

Query Match
 Best Local Similarity 0.1%; Score 10.4; DB 1; Length 12;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 35 CCAGTCCCAAA 46
 12 CCATTCCCAAA 1

RESULT 3
 CN752857
 LOCUS
 DEFINITION CN752857 12 bp mRNA linear EST 19-MAY-2004
 APHL3D-VII-F11 APHL3D Acyrthosiphon pisum cDNA clone
 CN752857
 VERSION
 KEYWORDS
 SOURCE
 ORGANISM

Acyrthosiphon pisum (pea aphid)
 Acyrthosiphon pisum
 Bukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota; Neoptera; Paraneoptera; Hemiptera; Sternorrhyncha; Aphidiformes; Aphidoidea; Aphididae; Macrosiphini; Acyrthosiphon.
 1 (bases 1 to 12)
 Hunter, W., Martinez-Torres, D., Rahbe, Y., Sabater-Munoz, B., Stern, D., Tagu, D. and Wincker, P.
 An expressed sequence tags database for the pea aphid *Acyrthosiphon pisum*
 Unpublished (2004)
 Contact: D. Tagu
 INRA Rennes
 UMR BIO3P, BP 35327, F-35653 Le Rheu Cedex France
 Tel: +33.2.23.48.51.65
 Fax: +33.2.23.48.51.50
 Risk of contamination by bacterial sequences from obligatory (Buchnera) or facultative endosymbionts.
 PCR Primers
 FORWARD: GCCGATACCTGCTATAGCA
 Plate: VII row: F column: 11.
 Location/Qualifiers

FEATURES
 source
 1..12
 Location/Qualifiers

/organism="Acyrthosiphon pisum"
 /mol_type="mRNA"
 /cultivar="yr2"
 /db_xref="taxon:7029"
 /clone="APHL3DIVIIF11"
 /tissue_type="head"
 /dev_stage="third instar nymph (L3)"
 /lab_host="TOP10"
 /clone_lib="APHL3D"
 /note="Vector: pDNR-LIB; Site 1: SfiI; Site 2: SfiI; Sample name: APHL3D; Plant growth place: INRA-Rennes, UMR BIO3P, BP 35327, 35653 Le Rheu cedex, France; Soil date: 03/02/2003; Stress date: no stress; Harvesting: aphids inoculated on one-week old *Vicia faba* germinations under non sterile conditions; experimental condition: long photoperiod (16-hr light/8-hr dark at 18 c)"

Query Match
 Best Local Similarity 91.7%; Pred. No. 1.8;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 65 TTCTTCTCTTC 76
 |||||

Db 1 TTCTTCTCTTC 12

RESULT 4
 CF291168/c 13 bp mRNA linear EST 14-AUG-2003
 LOCUS
 DEFINITION 14RCOT--01-H20.g1 Rice root plasmid cDNA library (14RCOT) Oryza sativa (japonica cultivar-group) cDNA clone 14RCOT--01-H20, mRNA sequence.

ACCESSION
 VERSION
 KEYWORDS
 SOURCE
 ORGANISM

Oryza sativa (japonica cultivar-group)
 Oryza sativa (japonica cultivar-group)
 Bukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzaceae; Oryza.
 1 (bases 1 to 13)
 Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C., Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
 Large-scale Sequencing Analysis of Rice ESTs
 Unpublished (2003)
 Contact: Nahm B.H.
 Genomics and Genetics Institute, Greengene Biotech Inc.; Division of Bioscience and Bioinformatics, Yonsei University
 Yongsin, Kyeonggi, Korea
 Tel: 82 31 330 6193
 Fax: 82 31 321 6355
 Email: bhnahm@bio.com, bhnahm@bio.myonji.ac.kr.
 Location/Qualifiers

FEATURES
 source
 1..13
 Location/Qualifiers

/organism="Oryza sativa (japonica cultivar-group)"
 /mol_type="mRNA"
 /cultivar="Nackdong"
 /db_xref="taxon:39947"
 /clone="14RCOT--01-H20"
 /tissue_type="root"
 /dev_stage="14 days after germination"
 /lab_host="E.coli DH109"
 /clone_lib="Rice root plasmid cDNA library (14RCOT)"
 /note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match
 Best Local Similarity 0.1%; Score 9.8; DB 1; Length 13;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 74 TTCTTTATTTCT 86
 13 TTTTATTTT 1

RESULT 5
 CF331242/c 12 bp mRNA linear EST 18-AUG-2003
 LOCUS
 DEFINITION NACL--07-E15.g1 Rice callus plasmid cDNA library (NACL) Oryza sativa (japonica cultivar-group) cDNA clone NACL--07-E15, mRNA sequence.

ACCESSION
 VERSION
 KEYWORDS
 SOURCE
 ORGANISM

Oryza sativa (japonica cultivar-group)
 Oryza sativa (japonica cultivar-group)
 Bukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzaceae; Oryza.
 1 (bases 1 to 12)
 Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C., Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
 Large-scale Sequencing Analysis of Rice ESTs
 Unpublished (2003)
 Contact: Nahm B.H.

REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 COMMENT

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, Myongji University
Yongin, Kyonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES

source

1. 12
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="NACL--07-E15"
/issue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 30 days"
/lab_host="E.coli DH10B"
/clone_lib="Rice callus plasmid cDNA library (NACL)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.1%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 3.4;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 74 TTCTTTATTT 84
DB 11 TTTTATTT 1

RESULT 6
CL437025 12 bp DNA linear GSS 18-MAR-2004
LOCUS PST4343-NR.Seg MCB1 Mus musculus genomic clone PST4343-NR.Seg
DEFINITION similar to 9430020E02Rik, genomic survey sequence.
ACCESSION CL437025
VERSION CL437025.1 GI:45572407
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 12)
AUTHORS Hicks G.G.
TITLE www.EScellis.ca
JOURNAL Unpublished (2002)
COMMENT Mammalian Functional Genomics Centre
Manitoba Institute of Cell Biology, University of Manitoba
ON5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
Tel: 204 787 2133
Fax: 204 787 2190
Email: hicksg@cc.umanitoba.ca

U3NeosVI gene trap. Tag generated by plasmid rescue. Additional sequence information and target gene cloning can be generated. ES cell line harboring insertion mutation of target gene is available. Sequence analysis available from
http://140.193.242.7/esdb/public_search_frame.php?PST=PST4343-NR.Se

FEATURES

source

1. 12
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="129 sv"
/db_xref="taxon:10090"
/clone="PST4343-NR.Seg"
/sex="Male"
/cell_type="Embryonic stem cell"
/cell_line="D3H (J1 subclone)"
/clone_lib="MCB1"
/note="Vector: U3NeosVI"

Query Match 0.1%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 3.4;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 296 CAGCTCCTTAT 306
DB 1 CAGCTCCTTAT 11

RESULT 7
CL437025/c 12 bp DNA linear GSS 18-MAR-2004
LOCUS PST4343-NR.Seg MCB1 Mus musculus genomic clone PST4343-NR.Seg
DEFINITION similar to 9430020E02Rik, genomic survey sequence.
ACCESSION CL437025
VERSION CL437025.1 GI:45572407
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 12)
AUTHORS Hicks G.G.
TITLE www.EScellis.ca
JOURNAL Unpublished (2002)
COMMENT Mammalian Functional Genomics Centre
Manitoba Institute of Cell Biology, University of Manitoba
ON5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
Tel: 204 787 2133
Fax: 204 787 2190
Email: hicksg@cc.umanitoba.ca

U3NeosVI gene trap. Tag generated by plasmid rescue. Additional sequence information and target gene cloning can be generated. ES cell line harboring insertion mutation of target gene is available. Sequence analysis available from
http://140.193.242.7/esdb/public_search_frame.php?PST=PST4343-NR.Se

FEATURES

source

1. 12
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="129 sv"
/db_xref="taxon:10090"
/clone="PST4343-NR.Seg"
/sex="Male"
/cell_type="Embryonic stem cell"
/cell_line="D3H (J1 subclone)"
/clone_lib="MCB1"
/note="Vector: U3NeosVI"

Query Match 0.1%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.3;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 183 AAGGACCTG 191
DB 9 AAGGACCTG 1

Search completed: October 27, 2004, 06:59:53
Job time: 0.001 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 26, 2004, 16:20:46 ! Search time 30 Seconds
(without alignments)
3.582 Million cell updates/sec

Title: US-09-923-515-3

Perfect score: 7200
Sequence: 1 ctgggattgggacactt.....actgcaactcgcagcaatgc 7200

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 487 seqs, 7463 residues

Total number of hits satisfying chosen parameters: 974

Minimum DB seq length: 12
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 495 summaries

Database : rni3.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	30	0.4	30	1	US-07-832-905B-17
2	30	0.4	30	1	US-07-832-905B-18
3	30	0.4	30	1	US-08-700-757-17
4	30	0.4	30	1	US-08-700-757-18
5	26	0.4	26	1	US-09-227-701-3
6	23	0.3	23	1	US-08-185-301-5
7	20	0.3	20	1	US-09-227-701-6
8	19	0.3	19	1	US-08-185-301-6
9	19	0.3	19	1	US-09-227-701-5
10	17	0.2	17	1	US-08-441-370-3
11	16.4	0.2	18	1	US-08-851-350-10
12	16.4	0.2	18	1	US-08-924-287A-10
13	16.4	0.2	19	1	US-07-720-585A-2
14	16.4	0.2	19	1	US-07-720-585A-7
15	16.4	0.2	19	1	US-07-720-585A-8
16	16.4	0.2	19	1	US-07-720-585A-9
17	16	0.2	16	1	US-08-311-760A-337
18	16	0.2	16	1	US-08-311-760A-338
19	16	0.2	16	1	US-08-311-760A-339
20	16	0.2	16	1	US-08-311-760A-376
21	16	0.2	16	1	US-08-311-760A-380
22	16	0.2	16	1	US-08-774-310-337
23	16	0.2	16	1	US-08-774-310-338
24	16	0.2	16	1	US-08-774-310-339
25	16	0.2	16	1	US-08-774-310-376
26	16	0.2	16	1	US-08-774-310-380
27	15.8	0.2	20	1	US-08-713-052-3
28	15.8	0.2	21	1	US-09-422-978-10373
29	15.4	0.2	17	1	US-09-371-772B-6341
30	15.2	0.2	20	1	US-09-428-584-19
31	15.2	0.2	20	1	US-09-490-692-171
32	15.2	0.2	20	1	US-08-969-815-35
33	15.2	0.2	20	1	US-09-120-025-35

34	15.2	0.2	20	1	US-09-021-701-243	Sequence 243, App
35	15.2	0.2	20	1	US-09-021-701-762	Sequence 762, App
36	15.2	0.2	20	1	US-09-710-481-35	Sequence 35, App
37	15.2	0.2	20	1	US-09-553-875-35	Sequence 35, App
38	15.2	0.2	20	1	US-09-768-670-35	Sequence 35, App
39	15.2	0.2	20	1	US-09-544-398B-264	Sequence 264, App
40	15	0.2	15	1	US-08-311-760A-7	Sequence 7, App
41	15	0.2	15	1	US-08-311-760A-8	Sequence 8, App
42	15	0.2	15	1	US-08-311-760A-9	Sequence 9, App
43	15	0.2	15	1	US-08-311-760A-10	Sequence 10, App
44	15	0.2	15	1	US-08-311-760A-11	Sequence 11, App
45	15	0.2	15	1	US-08-311-760A-12	Sequence 12, App
46	15	0.2	15	1	US-08-311-760A-13	Sequence 13, App
47	15	0.2	15	1	US-08-311-760A-14	Sequence 14, App
48	15	0.2	15	1	US-08-311-760A-15	Sequence 15, App
49	15	0.2	15	1	US-08-311-760A-16	Sequence 16, App
50	15	0.2	15	1	US-08-311-760A-17	Sequence 17, App
51	15	0.2	15	1	US-08-311-760A-168	Sequence 168, App
52	15	0.2	15	1	US-08-311-760A-169	Sequence 169, App
53	15	0.2	15	1	US-08-311-760A-170	Sequence 170, App
54	15	0.2	15	1	US-08-311-760A-171	Sequence 171, App
55	15	0.2	15	1	US-08-311-760A-172	Sequence 172, App
56	15	0.2	15	1	US-08-311-760A-173	Sequence 173, App
57	15	0.2	15	1	US-08-311-760A-174	Sequence 174, App
58	15	0.2	15	1	US-08-311-760A-175	Sequence 175, App
59	15	0.2	15	1	US-08-311-760A-176	Sequence 176, App
60	15	0.2	15	1	US-08-311-760A-188	Sequence 188, App
61	15	0.2	15	1	US-08-311-760A-194	Sequence 194, App
62	15	0.2	15	1	US-08-311-760A-195	Sequence 195, App
63	15	0.2	15	1	US-08-311-760A-196	Sequence 196, App
64	15	0.2	15	1	US-08-311-760A-198	Sequence 198, App
65	15	0.2	15	1	US-08-311-760A-199	Sequence 199, App
66	15	0.2	15	1	US-08-311-760A-200	Sequence 200, App
67	15	0.2	15	1	US-08-311-760A-201	Sequence 201, App
68	15	0.2	15	1	US-08-311-760A-202	Sequence 202, App
69	15	0.2	15	1	US-08-311-760A-224	Sequence 224, App
70	15	0.2	15	1	US-08-311-760A-225	Sequence 225, App
71	15	0.2	15	1	US-08-441-370-4	Sequence 4, App
72	15	0.2	15	1	US-08-774-310-7	Sequence 7, App
73	15	0.2	15	1	US-08-774-310-8	Sequence 8, App
74	15	0.2	15	1	US-08-774-310-9	Sequence 9, App
75	15	0.2	15	1	US-08-774-310-10	Sequence 10, App
76	15	0.2	15	1	US-08-774-310-11	Sequence 11, App
77	15	0.2	15	1	US-08-774-310-12	Sequence 12, App
78	15	0.2	15	1	US-08-774-310-13	Sequence 13, App
79	15	0.2	15	1	US-08-774-310-14	Sequence 14, App
80	15	0.2	15	1	US-08-774-310-15	Sequence 15, App
81	15	0.2	15	1	US-08-774-310-16	Sequence 16, App
82	15	0.2	15	1	US-08-774-310-17	Sequence 17, App
83	15	0.2	15	1	US-08-774-310-168	Sequence 168, App
84	15	0.2	15	1	US-08-774-310-169	Sequence 169, App
85	15	0.2	15	1	US-08-774-310-170	Sequence 170, App
86	15	0.2	15	1	US-08-774-310-171	Sequence 171, App
87	15	0.2	15	1	US-08-774-310-172	Sequence 172, App
88	15	0.2	15	1	US-08-774-310-173	Sequence 173, App
89	15	0.2	15	1	US-08-774-310-174	Sequence 174, App
90	15	0.2	15	1	US-08-774-310-175	Sequence 175, App
91	15	0.2	15	1	US-08-774-310-176	Sequence 176, App
92	15	0.2	15	1	US-08-774-310-188	Sequence 188, App
93	15	0.2	15	1	US-08-774-310-194	Sequence 194, App
94	15	0.2	15	1	US-08-774-310-195	Sequence 195, App
95	15	0.2	15	1	US-08-774-310-196	Sequence 196, App
96	15	0.2	15	1	US-08-774-310-198	Sequence 198, App
97	15	0.2	15	1	US-08-774-310-199	Sequence 199, App
98	15	0.2	15	1	US-08-774-310-200	Sequence 200, App
99	15	0.2	15	1	US-08-774-310-201	Sequence 201, App
100	15	0.2	15	1	US-08-774-310-202	Sequence 202, App
101	15	0.2	15	1	US-08-774-310-224	Sequence 224, App
102	15	0.2	15	1	US-08-720-585A-1	Sequence 225, App
103	14.8	0.2	19	1	US-07-720-585A-4	Sequence 4, App
104	14.8	0.2	19	1	US-07-720-585A-5	Sequence 5, App
105	14.8	0.2	19	1	US-07-720-585A-6	Sequence 6, App
106	14.8	0.2	19	1	US-07-720-585A-6	Sequence 6, App

107	14.8	0.2	19	1	US-08-656-906-3	Sequence 3, Appl1	180	13.4	0.2	15	1	US-08-774-310-23	Sequence 23, Appl1
108	14.8	0.2	19	1	US-09-217-847-3	Sequence 3, Appl1	181	13.4	0.2	15	1	US-08-774-310-24	Sequence 24, Appl1
109	14.4	0.2	16	1	US-08-311-760A-340	Sequence 340, App	182	13.4	0.2	15	1	US-08-774-310-25	Sequence 35, Appl1
110	14.4	0.2	16	1	US-08-311-760A-341	Sequence 341, App	183	13.4	0.2	15	1	US-08-774-310-45	Sequence 45, Appl1
111	14.4	0.2	16	1	US-08-311-760A-374	Sequence 374, App	184	13.4	0.2	15	1	US-08-774-310-57	Sequence 57, Appl1
112	14.4	0.2	16	1	US-08-311-760A-375	Sequence 375, App	185	13.4	0.2	15	1	US-08-774-310-60	Sequence 60, Appl1
113	14.4	0.2	16	1	US-08-311-760A-377	Sequence 377, App	186	13.4	0.2	15	1	US-08-774-310-65	Sequence 65, Appl1
114	14.4	0.2	16	1	US-08-311-760A-378	Sequence 378, App	187	13.4	0.2	15	1	US-08-774-310-73	Sequence 73, Appl1
115	14.4	0.2	16	1	US-08-311-760A-381	Sequence 381, App	188	13.4	0.2	15	1	US-08-774-310-165	Sequence 165, App
116	14.4	0.2	16	1	US-08-311-760A-382	Sequence 382, App	189	13.4	0.2	15	1	US-08-774-310-166	Sequence 166, App
117	14.4	0.2	16	1	US-08-311-760A-383	Sequence 383, App	190	13.4	0.2	15	1	US-08-774-310-167	Sequence 167, App
118	14.4	0.2	16	1	US-08-774-310-340	Sequence 340, App	191	13.4	0.2	15	1	US-08-774-310-177	Sequence 177, App
119	14.4	0.2	16	1	US-08-774-310-341	Sequence 341, App	192	13.4	0.2	15	1	US-08-774-310-178	Sequence 178, App
120	14.4	0.2	16	1	US-08-774-310-374	Sequence 374, App	193	13.4	0.2	15	1	US-08-774-310-179	Sequence 179, App
121	14.4	0.2	16	1	US-08-774-310-375	Sequence 375, App	194	13.4	0.2	15	1	US-08-774-310-180	Sequence 180, App
122	14.4	0.2	16	1	US-08-774-310-377	Sequence 377, App	195	13.4	0.2	15	1	US-08-774-310-189	Sequence 189, App
123	14.4	0.2	16	1	US-08-774-310-378	Sequence 378, App	196	13.4	0.2	15	1	US-08-774-310-190	Sequence 190, App
124	14.4	0.2	16	1	US-08-774-310-381	Sequence 381, App	197	13.4	0.2	15	1	US-08-774-310-191	Sequence 191, App
125	14.4	0.2	16	1	US-08-774-310-382	Sequence 382, App	198	13.4	0.2	15	1	US-08-774-310-192	Sequence 192, App
126	14.4	0.2	16	1	US-08-774-310-383	Sequence 383, App	199	13.4	0.2	15	1	US-08-774-310-193	Sequence 193, App
127	14.4	0.2	17	1	US-09-477-432B-493	Sequence 493, App	200	13.4	0.2	15	1	US-08-774-310-207	Sequence 207, App
128	14.4	0.2	17	1	US-09-477-432B-493	Sequence 493, App	201	13.4	0.2	15	1	US-08-774-310-208	Sequence 208, App
129	14.4	0.2	17	1	US-09-476-387-492	Sequence 492, App	202	13.4	0.2	15	1	US-08-774-310-213	Sequence 213, App
C 130	14.4	0.2	17	1	US-09-166-186-43	Sequence 43, Appl1	203	13.4	0.2	15	1	US-08-774-310-214	Sequence 214, App
C 131	14.4	0.2	18	1	US-09-313-932-43	Sequence 43, Appl1	204	13.4	0.2	15	1	US-08-774-310-223	Sequence 223, App
132	14	0.2	15	1	US-08-311-760A-22	Sequence 22, Appl1	205	13.4	0.2	15	1	US-08-774-310-225	Sequence 225, App
133	14	0.2	15	1	US-08-311-760A-30	Sequence 30, Appl1	206	13.4	0.2	15	1	US-08-774-310-228	Sequence 228, App
134	14	0.2	15	1	US-08-311-760A-227	Sequence 227, App	207	13.4	0.2	15	1	US-08-774-310-229	Sequence 229, App
135	14	0.2	15	1	US-08-774-310-22	Sequence 22, App	208	13.4	0.2	15	1	US-09-486-453-1	Sequence 1, Appl1
136	14	0.2	15	1	US-08-774-310-30	Sequence 30, Appl1	209	13.4	0.2	16	1	US-09-446-301A-34	Sequence 34, Appl1
137	14	0.2	15	1	US-08-774-310-227	Sequence 227, App	C 210	13.4	0.2	16	1	US-09-099-932-39	Sequence 39, Appl1
138	13.8	0.2	17	1	US-08-985-162-156	Sequence 156, App	C 211	13.4	0.2	17	1	US-09-564-805-35	Sequence 55, Appl1
139	13.8	0.2	17	1	US-09-401-063-156	Sequence 156, App	212	13.4	0.2	17	1	US-09-657-931A-4	Sequence 4, Appl1
140	13.8	0.2	17	1	US-09-866-108A-2453	Sequence 2453, App	213	13.2	0.2	20	1	US-09-227-701-6	Sequence 6, Appl1
141	13.8	0.2	17	1	US-09-866-108A-2454	Sequence 2454, App	214	13	0.2	15	1	US-08-311-760A-44	Sequence 64, Appl1
142	13.8	0.2	17	1	US-09-866-108A-7773	Sequence 7773, App	215	13	0.2	15	1	US-08-311-760A-216	Sequence 216, App
C 143	13.8	0.2	18	1	US-02-255-893-43	Sequence 43, Appl1	216	13	0.2	15	1	US-08-311-760A-217	Sequence 217, App
144	13.4	0.2	15	1	US-08-311-760A-18	Sequence 18, Appl1	217	13	0.2	15	1	US-08-738-944-17	Sequence 17, App
145	13.4	0.2	15	1	US-08-311-760A-19	Sequence 19, Appl1	218	13	0.2	15	1	US-08-774-310-64	Sequence 64, Appl1
146	13.4	0.2	15	1	US-08-311-760A-20	Sequence 20, Appl1	219	13	0.2	15	1	US-08-774-310-216	Sequence 216, App
147	13.4	0.2	15	1	US-08-311-760A-21	Sequence 21, Appl1	220	13	0.2	15	1	US-08-774-310-217	Sequence 217, App
148	13.4	0.2	15	1	US-08-311-760A-23	Sequence 23, Appl1	221	13	0.2	15	1	US-09-263-352-14	Sequence 14, App
149	13.4	0.2	15	1	US-08-311-760A-24	Sequence 24, Appl1	222	12.8	0.2	16	1	US-08-311-760A-145	Sequence 342, App
150	13.4	0.2	15	1	US-08-311-760A-35	Sequence 35, Appl1	223	12.8	0.2	16	1	US-08-311-760A-379	Sequence 344, App
151	13.4	0.2	15	1	US-08-311-760A-45	Sequence 45, Appl1	224	12.8	0.2	16	1	US-08-311-760A-384	Sequence 345, App
152	13.4	0.2	15	1	US-08-311-760A-57	Sequence 57, Appl1	225	12.8	0.2	16	1	US-08-774-310-342	Sequence 346, App
153	13.4	0.2	15	1	US-08-311-760A-60	Sequence 60, Appl1	226	12.8	0.2	16	1	US-08-774-310-345	Sequence 347, App
154	13.4	0.2	15	1	US-08-311-760A-65	Sequence 65, Appl1	227	12.8	0.2	16	1	US-08-774-310-346	Sequence 348, App
155	13.4	0.2	15	1	US-08-311-760A-73	Sequence 73, Appl1	228	12.8	0.2	16	1	US-08-774-310-384	Sequence 349, App
156	13.4	0.2	15	1	US-08-311-760A-165	Sequence 165, App	229	12.8	0.2	17	1	US-08-435-634-634	Sequence 634, App
157	13.4	0.2	15	1	US-08-311-760A-166	Sequence 166, App	230	12.8	0.2	17	1	US-08-856-141-1	Sequence 1, Appl1
158	13.4	0.2	15	1	US-08-311-760A-167	Sequence 167, App	231	12.8	0.2	17	1	US-09-290-449-8	Sequence 8, Appl1
159	13.4	0.2	15	1	US-08-311-760A-177	Sequence 177, App	232	12.8	0.2	17	1	US-08-584-040-2545	Sequence 2545, App
160	13.4	0.2	15	1	US-08-311-760A-178	Sequence 178, App	C 233	12.8	0.2	17	1	US-08-584-040-2546	Sequence 2546, App
161	13.4	0.2	15	1	US-08-311-760A-179	Sequence 179, App	234	12.8	0.2	17	1	US-09-495-140-1	Sequence 1, Appl1
162	13.4	0.2	15	1	US-08-311-760A-180	Sequence 180, App	235	12.8	0.2	17	1	US-09-371-772B-1069	Sequence 1069, App
163	13.4	0.2	15	1	US-08-311-760A-189	Sequence 189, App	236	12.8	0.2	17	1	US-09-371-772B-6597	Sequence 6597, App
164	13.4	0.2	15	1	US-08-311-760A-190	Sequence 190, App	237	12.8	0.2	17	1	US-09-866-108A-1158	Sequence 1158, App
165	13.4	0.2	15	1	US-08-311-760A-191	Sequence 191, App	238	12.8	0.2	17	1	US-09-866-108A-2452	Sequence 2452, App
166	13.4	0.2	15	1	US-08-311-760A-192	Sequence 192, App	239	12.8	0.2	17	1	US-09-866-108A-2455	Sequence 2455, App
167	13.4	0.2	15	1	US-08-311-760A-193	Sequence 193, App	C 240	12.8	0.2	17	1	US-09-866-108A-7528	Sequence 7528, App
168	13.4	0.2	15	1	US-08-311-760A-207	Sequence 207, App	241	12.8	0.2	17	1	US-09-866-108A-7529	Sequence 7529, App
169	13.4	0.2	15	1	US-08-311-760A-208	Sequence 208, App	242	12.8	0.2	17	1	US-09-866-108A-7676	Sequence 7676, App
170	13.4	0.2	15	1	US-08-311-760A-213	Sequence 213, App	243	12.8	0.2	17	1	US-09-866-108A-7772	Sequence 7772, App
171	13.4	0.2	15	1	US-08-311-760A-214	Sequence 214, App	244	12.8	0.2	17	1	US-09-866-108A-8423	Sequence 8423, App
172	13.4	0.2	15	1	US-08-311-760A-215	Sequence 215, App	245	12.8	0.2	17	1	US-09-866-108A-8424	Sequence 8424, App
173	13.4	0.2	15	1	US-08-311-760A-223	Sequence 223, App	C 246	12.8	0.2	17	1	US-09-866-108A-8692	Sequence 8692, App
174	13.4	0.2	15	1	US-08-311-760A-228	Sequence 228, App	247	12.8	0.2	17	1		
175	13.4	0.2	15	1	US-08-311-760A-229	Sequence 229, App	248	12.8	0.2	17	1		
176	13.4	0.2	15	1	US-08-774-310-18	Sequence 18, Appl1	249	12.8	0.2	17	1		
177	13.4	0.2	15	1	US-08-774-310-19	Sequence 19, Appl1	250	12.8	0.2	17	1		
178	13.4	0.2	15	1	US-08-774-310-20	Sequence 20, Appl1	251	12.8	0.2	17	1		
179	13.4	0.2	15	1	US-08-774-310-21	Sequence 21, Appl1	252	12.8	0.2	17	1		

253	12.8	0.2	17	1	US-09-866-108A-8693	Sequence 8693, Ap	C 326	11.4	0.2	15	1	US-07-664-989B-118	Sequence 118, App
C 254	12.8	0.2	17	1	US-09-866-108A-10113	Sequence 10113, A	C 327	11.4	0.2	15	1	US-08-297-703-9	Sequence 9, App11
C 255	12.8	0.2	17	1	US-09-866-108A-10114	Sequence 10114, A	C 328	11.4	0.2	15	1	US-08-058-023-7	Sequence 7, App11
256	12.8	0.2	17	1	US-09-404-912-227	Sequence 227, App	C 329	11.4	0.2	15	1	US-08-468-447-13	Sequence 13, App1
257	12.8	0.2	17	1	US-10-059-877-1	Sequence 1, App11	C 330	11.4	0.2	15	1	US-08-469-851A-13	Sequence 59, App1
258	12.4	0.2	14	1	US-08-267-803B-14	Sequence 14, App1	C 331	11.4	0.2	15	1	US-08-311-760A-59	Sequence 220, App
259	12.4	0.2	15	1	US-08-311-760A-56	Sequence 56, App1	C 332	11.4	0.2	15	1	US-08-311-760A-220	Sequence 13, App1
260	12.4	0.2	15	1	US-08-311-760A-197	Sequence 197, App1	C 333	11.4	0.2	15	1	US-08-467-597A-13	Sequence 13, App1
261	12.4	0.2	15	1	US-08-311-760A-210	Sequence 210, App	C 334	11.4	0.2	15	1	US-08-182-968A-188	Sequence 188, App
262	12.4	0.2	15	1	US-08-311-760A-212	Sequence 212, App	C 335	11.4	0.2	15	1	US-08-182-968A-246	Sequence 246, App
263	12.4	0.2	15	1	US-08-311-760A-234	Sequence 234, App	C 336	11.4	0.2	15	1	US-07-971-978-12	Sequence 12, App1
C 264	12.4	0.2	15	1	US-07-829-461A-7	Sequence 7, App11	C 337	11.4	0.2	15	1	US-07-971-978-26	Sequence 26, App1
265	12.4	0.2	15	1	US-08-774-310-56	Sequence 56, App1	C 338	11.4	0.2	15	1	US-08-468-569A-13	Sequence 13, App1
266	12.4	0.2	15	1	US-08-774-310-197	Sequence 197, App	C 339	11.4	0.2	15	1	US-08-470-129-2	Sequence 2, App11
267	12.4	0.2	15	1	US-08-774-310-210	Sequence 210, App	C 340	11.4	0.2	15	1	US-08-466-692A-13	Sequence 13, App1
268	12.4	0.2	15	1	US-08-774-310-212	Sequence 212, App	C 341	11.4	0.2	15	1	US-08-471-966A-13	Sequence 13, App1
269	12.4	0.2	15	1	US-08-774-310-234	Sequence 234, App	C 342	11.4	0.2	15	1	US-08-471-966A-13	Sequence 13, App1
C 270	12.4	0.2	15	1	US-08-981-462-66	Sequence 66, App1	C 343	11.4	0.2	15	1	US-07-835-932A-1	Sequence 2, App11
C 271	12.4	0.2	15	1	US-08-956-182-32	Sequence 32, App1	C 344	11.4	0.2	15	1	US-08-255-892-27	Sequence 27, App1
C 272	12.4	0.2	15	1	US-09-197-649-6	Sequence 6, App11	C 345	11.4	0.2	15	1	US-08-217-082A-14	Sequence 14, App1
C 273	12.4	0.2	15	1	US-09-081-646-247	Sequence 247, App	C 346	11.4	0.2	15	1	US-08-475-467-12	Sequence 12, App1
274	12.4	0.2	15	1	US-09-081-646-765	Sequence 765, App	C 347	11.4	0.2	15	1	US-08-475-467-13	Sequence 13, App1
C 275	12.4	0.2	15	1	US-09-544-934B-98	Sequence 98, App1	C 348	11.4	0.2	15	1	US-08-475-467-15	Sequence 15, App1
C 276	12.4	0.2	15	1	US-09-544-934B-99	Sequence 99, App1	C 349	11.4	0.2	15	1	US-08-475-467-16	Sequence 16, App1
C 277	12.4	0.2	16	1	US-09-371-772B-5700	Sequence 5700, Ap	C 350	11.4	0.2	15	1	US-08-738-944-12	Sequence 12, App1
278	12	0.2	12	1	US-07-832-905B-20	Sequence 20, App1	C 351	11.4	0.2	15	1	US-08-738-944-12	Sequence 12, App1
279	12	0.2	12	1	US-08-700-757-20	Sequence 20, App1	C 352	11.4	0.2	15	1	US-08-795-788A-18	Sequence 18, App1
C 280	12	0.2	13	1	US-08-738-944-19	Sequence 19, App1	C 353	11.4	0.2	15	1	US-08-292-620A-708	Sequence 708, App
C 281	12	0.2	13	1	US-09-263-352-16	Sequence 16, App1	C 354	11.4	0.2	15	1	US-08-468-037A-21	Sequence 21, App1
C 282	12	0.2	15	1	US-08-105-483-273	Sequence 273, App	C 355	11.4	0.2	15	1	US-08-468-037A-24	Sequence 24, App1
C 283	12	0.2	15	1	US-08-311-760A-36	Sequence 36, App1	C 356	11.4	0.2	15	1	US-08-890-084-12	Sequence 12, App1
C 284	12	0.2	15	1	US-08-224-391-87	Sequence 87, App1	C 357	11.4	0.2	15	1	US-08-890-084-13	Sequence 13, App1
C 285	12	0.2	15	1	US-08-484-304-87	Sequence 87, App1	C 358	11.4	0.2	15	1	US-08-890-084-14	Sequence 14, App1
C 286	12	0.2	15	1	US-08-224-657-108	Sequence 108, App	C 359	11.4	0.2	15	1	US-08-890-084-15	Sequence 15, App1
C 287	12	0.2	15	1	US-08-709-209-273	Sequence 273, App	C 360	11.4	0.2	15	1	US-08-890-084-16	Sequence 16, App1
C 288	12	0.2	15	1	US-08-257-073-66	Sequence 66, App1	C 361	11.4	0.2	15	1	US-08-774-306A-168	Sequence 168, App
C 289	12	0.2	15	1	US-08-458-101-273	Sequence 273, App	C 362	11.4	0.2	15	1	US-08-774-306A-246	Sequence 246, App
C 290	12	0.2	15	1	US-08-311-486C-30	Sequence 30, App1	C 363	11.4	0.2	15	1	US-08-471-973A-21	Sequence 21, App1
C 291	12	0.2	15	1	US-08-184-009-137	Sequence 137, App	C 364	11.4	0.2	15	1	US-08-471-973A-24	Sequence 24, App1
C 292	12	0.2	15	1	US-08-356-398-48	Sequence 48, App1	C 365	11.4	0.2	15	1	US-08-585-684B-1645	Sequence 1645, App
C 293	12	0.2	15	1	US-08-774-310-36	Sequence 36, App1	C 366	11.4	0.2	15	1	US-08-585-684B-1646	Sequence 1646, App
C 294	12	0.2	15	1	US-08-458-356-137	Sequence 137, App	C 367	11.4	0.2	15	1	US-08-585-684B-1647	Sequence 1647, App
C 295	12	0.2	15	1	US-08-658-665-91	Sequence 91, App1	C 368	11.4	0.2	15	1	US-08-585-684B-1648	Sequence 1648, App
C 296	12	0.2	15	1	US-08-796-101-68	Sequence 68, App1	C 369	11.4	0.2	15	1	US-08-585-684B-1648	Sequence 1648, App
C 297	12	0.2	15	1	US-08-460-736-137	Sequence 137, App	C 370	11.4	0.2	15	1	US-08-585-684B-1675	Sequence 1675, App
C 298	12	0.2	15	1	US-09-085-273-91	Sequence 91, App1	C 371	11.4	0.2	15	1	US-08-585-684B-1676	Sequence 1676, App
C 299	12	0.2	15	1	US-09-354-138-108	Sequence 108, App	C 372	11.4	0.2	15	1	US-08-585-684B-2111	Sequence 2111, App
C 300	12	0.2	15	1	US-09-081-646-529	Sequence 529, App	C 373	11.4	0.2	15	1	US-08-774-310-220	Sequence 220, App
C 301	12	0.2	15	1	US-09-535-370-137	Sequence 137, App	C 374	11.4	0.2	15	1	US-08-810-599-14	Sequence 14, App1
C 302	12	0.2	15	1	US-09-916-963-91	Sequence 91, App1	C 375	11.4	0.2	15	1	US-09-035-357-21	Sequence 21, App1
C 303	12	0.2	15	1	US-09-663-667-137	Sequence 137, App	C 376	11.4	0.2	15	1	US-09-035-357-24	Sequence 24, App1
C 304	12	0.2	16	1	US-08-873-437-37	Sequence 37, App1	C 377	11.4	0.2	15	1	US-09-064-156A-188	Sequence 188, App
C 305	12	0.2	16	1	US-08-873-437-40	Sequence 40, App1	C 378	11.4	0.2	15	1	US-09-064-156A-246	Sequence 246, App
C 306	12	0.2	16	1	US-09-593-312-37	Sequence 37, App1	C 379	11.4	0.2	15	1	US-09-071-845-708	Sequence 708, App
C 307	12	0.2	16	1	US-09-593-312-40	Sequence 40, App1	C 380	11.4	0.2	15	1	US-09-071-845-740	Sequence 740, App
C 308	11.8	0.2	15	1	US-08-311-760A-29	Sequence 29, App1	C 381	11.4	0.2	15	1	US-09-373-310-30	Sequence 30, App1
309	11.8	0.2	15	1	US-08-311-760A-54	Sequence 54, App1	C 382	11.4	0.2	15	1	US-09-038-073-1645	Sequence 1645, App
310	11.8	0.2	15	1	US-08-311-760A-55	Sequence 55, App1	C 383	11.4	0.2	15	1	US-09-038-073-1646	Sequence 1646, App
311	11.8	0.2	15	1	US-08-311-760A-76	Sequence 76, App1	C 384	11.4	0.2	15	1	US-09-038-073-1647	Sequence 1647, App
312	11.8	0.2	15	1	US-08-311-760A-209	Sequence 209, App	C 385	11.4	0.2	15	1	US-09-038-073-1648	Sequence 1648, App
C 313	11.8	0.2	15	1	US-08-311-486C-156	Sequence 156, App	C 386	11.4	0.2	15	1	US-09-038-073-1675	Sequence 1675, App
314	11.8	0.2	15	1	US-08-774-310-29	Sequence 29, App1	C 387	11.4	0.2	15	1	US-09-038-073-1676	Sequence 1676, App
315	11.8	0.2	15	1	US-08-774-310-54	Sequence 54, App1	C 388	11.4	0.2	15	1	US-09-038-073-2111	Sequence 2111, App
316	11.8	0.2	15	1	US-08-774-310-55	Sequence 55, App1	C 389	11.4	0.2	15	1	US-08-894-899-12	Sequence 12, App1
317	11.8	0.2	15	1	US-08-774-310-76	Sequence 76, App1	C 390	11.4	0.2	15	1	US-08-894-899-13	Sequence 13, App1
318	11.8	0.2	15	1	US-08-774-310-209	Sequence 209, App	C 391	11.4	0.2	15	1	US-08-894-899-14	Sequence 14, App1
C 319	11.8	0.2	15	1	US-10-116-993A-15	Sequence 15, App1	C 392	11.4	0.2	15	1	US-08-894-899-15	Sequence 15, App1
C 320	11.4	0.2	13	1	US-09-717-847E-2	Sequence 2, App11	C 393	11.4	0.2	15	1	US-08-894-899-16	Sequence 16, App1
C 321	11.4	0.2	14	1	US-08-765-340-97	Sequence 97, App1	C 394	11.4	0.2	15	1	US-09-263-352-9	Sequence 9, App11
C 322	11.4	0.2	14	1	US-09-580-923-29	Sequence 29, App1	C 395	11.4	0.2	15	1	US-08-383-666A-3	Sequence 3, App11
C 323	11.4	0.2	14	1	US-09-580-923-30	Sequence 30, App1	C 396	11.4	0.2	15	1	US-08-936-166-1	Sequence 1, App11
C 324	11.4	0.2	14	1	US-08-535-249-65	Sequence 65, App1	C 397	11.4	0.2	15	1	US-08-936-166-4	Sequence 4, App11
C 325	11.4	0.2	14	1	US-09-230-652-63	Sequence 63, App1	C 398	11.4	0.2	15	1	US-08-936-166-4	Sequence 4, App11


```
/ INFORMATION FOR SEQ ID NO: 18:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 30 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
US-08-700-757-18
```

```
Query Match          0.4%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.86;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      47 TGAACATAGAGAGTGTCTTCTTACTTC 76
DB      1 TGAACATAGAGAGTGTCTTCTTACTTC 30
```

RESULT 5

```
US-09-227-701-3/c
/ Sequence 3, Application US/09227701
/ Patent No. 6512161
/ GENERAL INFORMATION:
/ APPLICANT: Rouy, Didier
/ APPLICANT: Duverger, Nicolas
/ APPLICANT: Emmanuel, Florence
/ APPLICANT: Denefle, Patrice
/ APPLICANT: Houdedine, Louis-Marie
/ APPLICANT: Viglietta, Celine
/ APPLICANT: Hughes, Steven D.
/ TITLE OF INVENTION: TRANSGENIC RABBIT THAT EXPRESSES A FUNCTIONAL HUMAN
/ FILE REFERENCE: 22841A USA
/ CURRENT APPLICATION NUMBER: US/09/227,701
/ CURRENT FILING DATE: 1999-01-08
/ EARLIER APPLICATION NUMBER: 60/070727
/ EARLIER FILING DATE: 1998-01-08
/ NUMBER OF SEQ ID NOS: 11
/ SOFTWARE: Patent In Ver. 2.0
/ SEQ ID NO 3
/ LENGTH: 26
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-227-701-3
```

```
Query Match          0.4%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      523 GGAAGAACTGCCAAGCTTGTCATC 548
DB      26 GGAAGAACTGCCAAGCTTGTCATC 1
```

RESULT 6

```
US-08-185-301-5/c
/ Sequence 5, Application US/08185301
/ Patent No. 5554509
/ GENERAL INFORMATION:
/ APPLICANT: COLUCCI, GIUSEPPE
/ APPLICANT: TARNELLI, ROBERTO
/ TITLE OF INVENTION: NUCLEOTIDE PROBES
/ NUMBER OF SEQUENCES: 6
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: OBLON, SPIVAK, MCLELLAND, MAIER & NEUSTADT, P.C.
/ STREET: 1755 S. Jefferson Davis Highway, Suite 400
/ CITY: Arlington
/ STATE: Virginia
/ COUNTRY: U.S.A.
/ ZIP: 2202
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
```

```
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/185,301
/ FILING DATE: 26-JAN 1994
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: GB 9301453.8
/ FILING DATE: 26-JAN-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Oblon, No. 5554509man F.
/ REGISTRATION NUMBER: 24,618
/ REFERENCE/DOCKET NUMBER: 769-281-0 PCT
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (703) 413-1000
/ TELEFAX: (703) 413-2220
/ TELEX: 248855 OPAT UR
/ INFORMATION FOR SEQ ID NO: 5:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 23 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
US-08-185-301-5
```

```
Query Match          0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 7.4;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      219 TCAACTATAGACCAAGGAAA 241
DB      23 TCAACTATAGACCAAGGAAA 1
```

```
RESULT 7
US-09-227-701-6/c
/ Sequence 6, Application US/09227701
/ Patent No. 6512161
/ GENERAL INFORMATION:
/ APPLICANT: Rouy, Didier
/ APPLICANT: Duverger, Nicolas
/ APPLICANT: Emmanuel, Florence
/ APPLICANT: Denefle, Patrice
/ APPLICANT: Houdedine, Louis-Marie
/ APPLICANT: Viglietta, Celine
/ APPLICANT: Hughes, Steven D.
/ TITLE OF INVENTION: TRANSGENIC RABBIT THAT EXPRESSES A FUNCTIONAL HUMAN
/ FILE REFERENCE: 22841A USA
/ CURRENT APPLICATION NUMBER: US/09/227,701
/ CURRENT FILING DATE: 1999-01-08
/ EARLIER APPLICATION NUMBER: 60/070727
/ EARLIER FILING DATE: 1998-01-08
/ NUMBER OF SEQ ID NOS: 11
/ SOFTWARE: Patent In Ver. 2.0
/ SEQ ID NO 6
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-227-701-6
```

```
Query Match          0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      324 CGGTGTAGGTGGAGTACT 343
DB      20 CGGTGTAGGTGGAGTACT 1
```


RESULT 8
US-08-185-301-6
Sequence 6, Application US/08185301
Patent No. 5554509
GENERAL INFORMATION:
APPLICANT: COLUCCI, GIUSEPPE
APPLICANT: TARMELLI, ROBERTO
TITLE OF INVENTION: NUCLEOTIDE PROBES
NUMBER OF SEQUENCES: 6
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
STREET: 1755 S. Jefferson Davis Highway, Suite 400
City: Arlington
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 2202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/185,301
FILING DATE: 26-JAN 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9301453.8
FILING DATE: 26-JAN-1993
ATTORNEY/AGENT INFORMATION:
NAME: OBLON, No. 5554509man F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 769-281-0 PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 413-3000
TELEFAX: (703) 413-2220
TELEX: 248855 OPAT UR
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-185-301-6
Query Match 0.3%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 98 CACCTGAGCAAGCCATGT 116
|||||
Db 1 CACCTGAGCAAGCCATGT 19

RESULT 9
US-09-227-701-5
Sequence 5, Application US/09227701
Patent No. 6512161
GENERAL INFORMATION:
APPLICANT: Rouy, Didier
APPLICANT: Duvergier, Nicolas
APPLICANT: Emmanuel, Florence
APPLICANT: Deneffe, Patrice
APPLICANT: Houdebine, Louis-Marie
APPLICANT: Viglietta, Celine
APPLICANT: Rubin, Edward M.
APPLICANT: Hughes, Steven D.
TITLE OF INVENTION: TRANSGENIC RABBIT THAT EXPRESSES A FUNCTIONAL HUMAN
TITLE OR INVENTION: LIPOPROTEIN(A)
FILE REFERENCE: 22841A USA
CURRENT APPLICATION NUMBER: US/09/227,701
CURRENT FILING DATE: 1999-01-08
EARLIER APPLICATION NUMBER: 60/070727

EARLIER FILING DATE: 1998-01-08
NUMBER OF SEQ ID NOS: 11
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 5
LENGTH: 19
TYPE: DNA
ORGANISM: Homo sapiens
US-09-227-701-5
Query Match 0.3%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 99 ACCTGAGCAAGCCATGT 117
|||||
Db 1 ACCTGAGCAAGCCATGT 19

RESULT 10
US-08-441-370-3/c
Sequence 3, Application US/08441370
Patent No. 5721138
GENERAL INFORMATION:
APPLICANT: Lawn, Richard M.
TITLE OF INVENTION: Apolipoprotein(A) Promoter and
TITLE OF INVENTION: Regulatory Sequence Constructs and Methods of Use
Patent No. 5721138
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: PENNIE & EDMONDS
STREET: 1155 Avenue of the Americas
City: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/441,370
FILING DATE:
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/991,849
FILING DATE: 15-DEC-1992
ATTORNEY/AGENT INFORMATION:
NAME: Cornuzzi, Laura A.
REGISTRATION NUMBER: 30,742
REFERENCE/DOCKET NUMBER: 7627-003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212 790-9090
TELEFAX: 212 869-8864/9741
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
US-08-441-370-3
Query Match 0.2%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 GAAGTGTCTTCTTACT 74
|||||
Db 17 GAAGTGTCTTCTTACT 1

RESULT 11
US-08-851-350-10
; Sequence 10, Application US/08851350
; Patent No. 6057122
; GENERAL INFORMATION:
; APPLICANT: Abbott Laboratories
; TITLE OF INVENTION: NOVEL ANTIANGIOGENIC PEPTIDES,
; TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING SAME AND METHODS
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Abbott Laboratories
; STREET: 100 Abbott Park Road
; CITY: Abbott Park
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/851,350
; FILING DATE: 05-MAY-1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Casuto, Dianne
; REGISTRATION NUMBER: 40,943
; REFERENCE/DOCKET NUMBER: 5940.US.P2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 847-938-3137
; TELEFAX: 847-938-2623
; TELEX:
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-851-350-10
Query Match 0.2%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 56;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 118 GTCGAGATTGCTACCAT 135
Db 1 GTCGAGAGCTGCTACCAT 18
RESULT 12
US-08-924-287A-10
; Sequence 10, Application US/08924287A
; Patent No. 6693838
; GENERAL INFORMATION:
; APPLICANT: Abbott Laboratories
; APPLICANT: Davidson, Donald J.
; TITLE OF INVENTION: NOVEL ANTIANGIOGENIC PEPTIDES,
; TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING SAME AND METHODS FOR INHIBITING
; FILE REFERENCE: 5940.US.P3
; CURRENT APPLICATION NUMBER: US/08/924,287A
; CURRENT FILING DATE: 1997-09-05
; PRIOR APPLICATION NUMBER: US 08/851,350
; PRIOR FILING DATE: 1997-05-05
; PRIOR APPLICATION NUMBER: US 08/832,087
; PRIOR FILING DATE: 1997-04-03
; PRIOR APPLICATION NUMBER: US 08/643,219
; PRIOR FILING DATE: 1996-05-03

; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: FASTSEQ for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Amplification Primer
US-08-924-287A-10
Query Match 0.2%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 56;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 118 GTCGAGATTGCTACCAT 135
Db 1 GTCGAGAGCTGCTACCAT 18
RESULT 13
US-07-720-585A-2/c
; Sequence 2, Application US/07720585A
; Patent No. 5216143
; GENERAL INFORMATION:
; APPLICANT: James J. Hogan
; APPLICANT: Philip W. Hammond
; TITLE OF INVENTION: NUCLEIC ACIDS PROBES
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version
; OPERATING SYSTEM: 3.30)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/720,585A
; FILING DATE: 19910628
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION NUMBER: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; NAME: J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 193/121
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
US-07-720-585A-2
Query Match 0.2%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 63;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 226 AATAGACACAGAAAC 243
 |||||
 Db 18 AATAGACACAGAAAC 1

RESULT 14
 US-07-720-585A-7
 ; Sequence 7, Application US/07720585A
 ; Patent No. 5216143
 ; GENERAL INFORMATION:
 ; APPLICANT: James J. Hogan
 ; APPLICANT: Philip W. Hammond
 ; TITLE OF INVENTION: NUCLEIC ACIDS PROBES
 ; TITLE OF INVENTION: TO MYCOBACTERIUM GORDONAE
 ; NUMBER OF SEQUENCES: 9
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 611 West Sixth Street
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: USA
 ; ZIP: 90017
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: Storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS (Version
 ; OPERATING SYSTEM: 3.30)
 ; SOFTWARE: WordPerfect (Version 5.1)
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/07/720,585A
 ; FILING DATE: 19910628
 ; CLASSIFICATION: 435
 ; PRIOR APPLICATION DATA:
 ; PRIOR APPLICATION DATA: including application
 ; PRIOR APPLICATION DATA: described below: none
 ; APPLICATION NUMBER:
 ; FILING DATE:
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard
 ; NAME: J.
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 193/121
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; INFORMATION FOR SEQ ID NO: 7:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 19
 ; TYPE: NUCLEIC ACID
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-07-720-585A-7

Query Match 0.2%; Score 16.4; DB 1; length 19;
 Best Local Similarity 94.4%; Pred. No. 63;
 Matches 1; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 226 AATAGACACAGAAAC 243
 |||||
 Db 2 AATAGACACAGAAAC 19

RESULT 15
 US-07-720-585A-8
 ; Sequence 8, Application US/07720585A
 ; Patent No. 5216143
 ; GENERAL INFORMATION:
 ; APPLICANT: James J. Hogan
 ; APPLICANT: Philip W. Hammond
 ; TITLE OF INVENTION: NUCLEIC ACIDS PROBES
 ; TITLE OF INVENTION: TO MYCOBACTERIUM GORDONAE

NUMBER OF SEQUENCES: 9
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Lyon & Lyon
 STREET: 611 West Sixth Street
 CITY: Los Angeles
 STATE: California
 COUNTRY: USA
 ZIP: 90017
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: Storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS (Version
 OPERATING SYSTEM: 3.30)
 SOFTWARE: WordPerfect (Version 5.1)
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/07/720,585A
 FILING DATE: 19910628
 CLASSIFICATION: 435
 PRIOR APPLICATION DATA:
 PRIOR APPLICATION DATA: including application
 PRIOR APPLICATION DATA: described below: none
 APPLICATION NUMBER:
 FILING DATE:
 ATTORNEY/AGENT INFORMATION:
 NAME: Warburg, Richard
 NAME: J.
 REGISTRATION NUMBER: 32,327
 REFERENCE/DOCKET NUMBER: 193/121
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEEX: 67-3510
 INFORMATION FOR SEQ ID NO: 8:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 19
 TYPE: NUCLEIC ACID
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-07-720-585A-8

Query Match 0.2%; Score 16.4; DB 1; length 19;
 Best Local Similarity 88.9%; Pred. No. 63;
 Matches 16; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 226 AATAGACACAGAAAC 243
 |||||
 Db 2 AATAGACACAGAAAC 19

RESULT 16
 US-07-720-585A-9/c
 ; Sequence 9, Application US/07720585A
 ; Patent No. 5216143
 ; GENERAL INFORMATION:
 ; APPLICANT: James J. Hogan
 ; APPLICANT: Philip W. Hammond
 ; TITLE OF INVENTION: NUCLEIC ACIDS PROBES
 ; TITLE OF INVENTION: TO MYCOBACTERIUM GORDONAE
 ; NUMBER OF SEQUENCES: 9
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 611 West Sixth Street
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: USA
 ; ZIP: 90017
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: Storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS (Version
 ; OPERATING SYSTEM: 3.30)

```
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/720,585A
FILING DATE: 19910628
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
APPLICATION NUMBER: described below:
FILING DATE: none
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
NAME: J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 193/121
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
US-07-720-585A-9

Query Match
Best Local Similarity 0.2%; Score 16.4; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 226 AATAGACACAGAAAC 243
DB 18 AATAGACACAGAAAC 1

RESULT 17
US-08-311-760A-337
Sequence 337, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESS: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
```

```
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 337:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-337

Query Match
Best Local Similarity 0.2%; Score 16; DB 1; Length 16;
Matches 14; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 374 GGACTGCGTCGCGCC 389
DB 1 GGACTGCGTCGCGCC 16

RESULT 18
US-08-311-760A-338
Sequence 338, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESS: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 338:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-338
```

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 51;
Matches 13; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 377 CTGCGGTGCGCGCTCC 392
1 CUGCCGCGCGCCGCC 16

Db 1 CUGCCGCGCGCCGCC 16

RESULT 19
US-08-311-760A-339
; Sequence 339, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF INVENTION: 392
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 339:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-760A-339

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 51;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 436 GCACCGACTGAGCAAA 451
1 GCACCGACTGAGCAAA 16

Db 1 GCACCGACTGAGCAAA 16

RESULT 20
US-08-311-760A-376
; Sequence 376, Application US/08311760A

; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF INVENTION: 392
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 376:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-760A-376

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 51;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 436 GCACCGACTGAGCAAA 451
1 GCACCGACTGAGCAAA 16

Db 1 GCACCGACTGAGCAAA 16

RESULT 21
US-08-311-760A-380
; Sequence 380, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF INVENTION: 392
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:

```

1 ADDRESS: Lyon & Lyon
2 STREET: 633 West Fifth Street
3 STREET: Suite 4700
4 City: Los Angeles
5 STATE: California
6 COUNTRY: U.S.A.
7 ZIP: 90071
8
9 COMPUTER READABLE FORM:
10 MEDIUM TYPE: 3.5" Diskette, 1.44 MB
11 MEDIUM TYPE: storage
12
13 OPERATING SYSTEM: IBM Compatible
14 SOFTWARE: FastSeq Version 1.5
15 CURRENT APPLICATION DATA:
16 APPLICATION NUMBER: US/08/311,760A
17 FILING DATE: September 23, 1994
18 PRIOR APPLICATION DATA:
19 APPLICATION NUMBER:
20 FILING DATE:
21 ATTORNEY/AGENT INFORMATION:
22 NAME: Warburg, Richard
23 REGISTRATION NUMBER: 32,327
24 REFERENCE/DOCKET NUMBER: 208/155
25 TELECOMMUNICATION INFORMATION:
26 TELEPHONE: (213) 489-1600
27 TELEFAX: (213) 955-0440
28
29 INFORMATION FOR SEQ ID NO: 380:
30 SEQUENCE CHARACTERISTICS:
31 LENGTH: 16 base pairs
32 TYPE: nucleic acid
33 STRANDEDNESS: single
34 TOPOLOGY: linear
35
36 US-08-311-760A-380
37
38
39 Query Match 0.2% Score 16; DB 1; Length 16;
40 Best Local Similarity 93.8%; Pred. No. 51;
41 Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0,
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
```

```

1 CURRENT APPLICATION DATA:
2 APPLICATION NUMBER: US/08/774,310
3 FILING DATE: December 23, 1996
4 PRIOR APPLICATION DATA:
5 APPLICATION NUMBER: 08/311,760
6 FILING DATE: September 23, 1994
7 ATTORNEY/AGENT INFORMATION:
8 NAME: Warburg, Richard
9 REGISTRATION NUMBER: 32,327
10 REFERENCE/DOCKET NUMBER: 223/229
11 TELECOMMUNICATION INFORMATION:
12 TELEPHONE: (213) 489-1600
13 TELEFAX: (213) 955-0440
14
15 INFORMATION FOR SEQ. ID NO: 337:
16 SEQUENCE CHARACTERISTICS:
17 LENGTH: 16 base pairs
18 TYPE: nucleic acid
19 STRANDEDNESS: single
20 TOPOLOGY: linear
21
22 US-08-774-310-337
23
24 Query Match 0.2%; Score 16; DB 1; Length 16;
25 Best Local Similarity 87.5%; Pred. No. 51;
26 Matches 14; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
27
28 QY 374 GGACTGCCGCTGCCGCC 389
29 ||||:||||:||||
30
31 DB 1 GGACUGCCGUGCGGCC 16
32
33 RESULT 23
34 US-08-774-310-338
35 Sequence 338, Application US/08774310
36 Patent No. 5877022
37 GENERAL INFORMATION:
38 APPLICANT: Stinchcomb, Daniel T.
39 APPLICANT: McSwiggen, James
40 APPLICANT: Newton, Roger S.
41 APPLICANT: Ramnarack, Randy
42 TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
43 TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
44 TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
45 TITLE OF INVENTION: INHIBITING APOLOPROTEIN
46 NUMBER OF INVENTION: 392
47 CORRESPONDENCE ADDRESS:
48 ADDRESSEE: Lyon & Lyon
49 STREET: 633 West Fifth Street
50 STREET: Suite 4700
51 CITY: Los Angeles
52 STATE: California
53 COUNTRY: U.S.A.
54 ZIP: 90071
55
56 COMPUTER READABLE FORM:
57 MEDIUM TYPE: 3.5" Diskette, 1.44 MB
58 MEDIUM TYPE: storage
59 COMPUTER: IBM Compatible
60 OPERATING SYSTEM: IBM P.C. DOS 5.0
61 SOFTWARE: FASTSEQ Version 1.5
62 CURRENT APPLICATION DATA:
63 APPLICATION NUMBER: US/08/774,310
64 FILING DATE: December 23, 1996
65 PRIOR APPLICATION DATA:
66 APPLICATION NUMBER: 08/311,760
67 FILING DATE: September 23, 1994
68 ATTORNEY/AGENT INFORMATION:
69 NAME: Warburg, Richard
70 REGISTRATION NUMBER: 32,327
71 REFERENCE/DOCKET NUMBER: 223/229
72 TELECOMMUNICATION INFORMATION:
73 TELEPHONE: (213) 489-1600
74 TELEFAX: (213) 955-0440

```

TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 338:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-338

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 51;
Matches 13; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Oy 377 CTGCGCTGCGGCGCC 392
Db 1 CUGCGGUGCGCGCCUCC 16

RESULT 24

US-08-774-310-339
Sequence 339, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 339:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-339

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 51;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Oy 436 GCACCGACTGACGCAA 451
Db 1 GCACCGACTGACGCAA 16

RESULT 25
US-08-774-310-376
Sequence 376, Application US/08774310
Patent No. 5877022

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 376:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-376

Query Match 0.2%; Score 16; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 51;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Oy 436 GCACCGACTGACGCAA 451
Db 1 GCACCGACTGACGCAA 16

RESULT 26
US-08-774-310-380
Sequence 380, Application US/08774310
Patent No. 5877022

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.

```

; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [Lp(a)] BY
; TITLE OF INVENTION: INHIBITING APOLOPOPROTEIN
; TITLE OF INVENTION:
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE: September 08/311,760
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 222/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 380:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-310-380

Query Match
Best Local Similarity 0.2%; Score 16; DB 1; Length 16;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 436 GCACCGACTGAGCAA 451
DB 1 GCACCGACTGAGCAA 16

RESULT 27
US-08-713-052-3
; Sequence 3: Application US/08713052
; Patent No. 5840673
; GENERAL INFORMATION:
; APPLICANT: Buckbinder, Leonard R.
; APPLICANT: Kley, Nikolai
; APPLICANT: Seizinger, Bernd
; TITLE OF INVENTION: Insulin-like Growth Factor Binding
; TITLE OF INVENTION: Protein 3 (IGF-BP3) in Treatment of P53-Related Tumors
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bristol-Myers Squibb Company
; STREET: P.O. Box 4000
; CITY: Princeton
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 08543-4000
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
```

```

; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/713,052
; FILING DATE: 12-SEP-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaul, Timothy J.
; REGISTRATION NUMBER: 33,111
; REFERENCE/DOCKET NUMBER: DC38a
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 252-5801
; TELEFAX: (609) 252-4526
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-713-052-3

Query Match
Best Local Similarity 0.2%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 181 GGAAGAGCTGCCAGCTT 199
DB 2 GGAAGAGCTGCCAGCTT 20

RESULT 28
US-09-422-978-10373/C
; Sequence 10373, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; EARLIER FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 10373
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..21
; OTHER INFORMATION: downstream amplification primer 99-11506 for SEQ 2508, in compleme
; US-09-422-978-10373

Query Match
Best Local Similarity 0.2%; Score 15.8; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 CCACGAAATTAACCCACA 251
DB 21 CCACGAAATTAACCCACA 3

RESULT 29
US-09-371-772B-6341
; Sequence 6341, Application US/09371772B
; Patent No. 6566127
```



```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MAB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6341
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-6341

Query Match      0.2%; Score 15.4; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 73;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy      104 AGCAAGCCATGTGTC 120
Db      1 AGCAGAGCCAGUGUGUC 17

RESULT 30
US-09-428-584-19
; Sequence 19, Application US/09428584
; Patent No. 6136604
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF METHIONINE AMINOPEPTIDASE 2 EXPRESSION
; FILE REFERENCE: RTS-0114
; CURRENT APPLICATION NUMBER: US/09/428,584
; CURRENT FILING DATE: 1999-10-27
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-428-584-19

Query Match      0.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1,1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      66 TCTTCTACTTCTTTATTC 85
Db      1 TCTTCTTCTCTTTTCTTC 20

RESULT 31
US-09-490-692-171
; Sequence 171, Application US/09490692
; Patent No. 6180353
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
; FILE REFERENCE: RTS-0120
; CURRENT APPLICATION NUMBER: US/09/490,692
; CURRENT FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 176
```

```
; SEQ ID NO 171
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-490-692-171

Query Match      0.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1,1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      73 CTCTTTTATTTCTGAATC 92
Db      1 CTCTTTTCTTCGGAATC 20

RESULT 32
US-08-969-815-35
; Sequence 35, Application US/08969815
; Patent No. 6207412
; GENERAL INFORMATION:
; APPLICANT: Witte, Owen N.
; TITLE OF INVENTION: IDENTIFICATION OF A G PROTEIN-COUPLED
; TITLE OF INVENTION: RECEPTOR TRANSCRIPTIONALLY REGULATED BY PROTEIN
; TITLE OF INVENTION: TYROSINE KINASE SIGNALING IN HEMATOPOIETIC CELLS
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson & Bear
; STREET: 620 Newport Center Drive, 16th Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/969,815
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Bartfeld, Neil S
; REGISTRATION NUMBER: 39,901
; REFERENCE/DOCKET NUMBER: UCLA015.001A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-235-8550
; TELEFAX: 619-235-0176
; TELEX:
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-969-815-35

Query Match      0.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1,1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      190 TGCCAGCTTGTCATCTAT 209
Db      1 TGCCACTCTGGGTCATCTAT 20

RESULT 33
```

US-09-120-025-35
Sequence 35, Application US/09120025
Patent No. 6214562
GENERAL INFORMATION:
APPLICANT: Weng, Zhiqiang.
APPLICANT: Wite, Owen N.
TITLE OF INVENTION: TRANSCRIPTIONALLY REGULATED G PROTEIN-COUPLED
RECEPTOR
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Knobe, Martens, Olson & Bear
STREET: 620 Newport Center Drive, 16th Floor
CITY: Newport Beach
STATE: CA
COUNTRY: U.S.A.
ZIP: 92660
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/120,025
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/969,815
FILING DATE: 13-NOV-1997
ATTORNEY/AGENT INFORMATION:
NAME: Bartfeld, Neil S
REGISTRATION NUMBER: 39,901
REFERENCE/DOCKET NUMBER: UCLA015.001CP1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-235-8550
TELEFAX: 619-235-0176
TELEX:
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-120-025-35
Query Match 0.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy 190 TGCACAGCTTGTCATCTAT 209
Db 1 TGCACACTCTGGGTCATCTAT 20
RESULT 34
US-09-021-701-243
Sequence 243, Application US/09021701
Patent No. 6251588
GENERAL INFORMATION:
APPLICANT: Shannon, Karen W.
APPLICANT: Wolber, Paul K.
APPLICANT: Delenstarr, Glenda C.
APPLICANT: Webb, Peter G.
APPLICANT: Kincaid, Robert H.
TITLE OF INVENTION: Methods for evaluating oligonucleotide
NUMBER OF SEQUENCES: 1165
CORRESPONDENCE ADDRESS:
ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard Company M/S 20
STREET: 3000 Hanover Street
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent'n Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/021,701
FILING DATE: 10-FEB-1998
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Choi, Wendy A.
REGISTRATION NUMBER: 36,697
REFERENCE/DOCKET NUMBER: 10971464-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-852-8063
TELEFAX: 650-236-2386
INFORMATION FOR SEQ ID NO: 243:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-09-021-701-243
Query Match 0.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy 284 CAGATGCTGGCAGCTCCT 303
Db 1 CAGATGTGCTCAGCTCCT 20
RESULT 35
US-09-021-701-762
Sequence 762, Application US/09021701
Patent No. 6251588
GENERAL INFORMATION:
APPLICANT: Shannon, Karen W.
APPLICANT: Wolber, Paul K.
APPLICANT: Delenstarr, Glenda C.
APPLICANT: Webb, Peter G.
APPLICANT: Kincaid, Robert H.
TITLE OF INVENTION: Methods for evaluating oligonucleotide
NUMBER OF SEQUENCES: 1165
CORRESPONDENCE ADDRESS:
ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard Company M/S 20
STREET: 3000 Hanover Street
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent'n Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/021,701
FILING DATE: 10-FEB-1998
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Choi, Wendy A.
REGISTRATION NUMBER: 36,697
REFERENCE/DOCKET NUMBER: 10971464-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-852-8063
TELEFAX: 650-236-2386
INFORMATION FOR SEQ ID NO: 762:


```

; COUNTRY: U.S.A.
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/768,670
; FILING DATE: 23-Jan-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/969,815
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Bartfeld, Neil S
; REGISTRATION NUMBER: 39,901
; REFERENCE/DOCKET NUMBER: UCLA015.001A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-235-0176
; TELEFAX: 619-235-8550
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 35:
US-09-768-670-35

```

```

Query Match
Best Local Similarity 0.2%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 190 TGCACACTGCTGCTACTAT 209
DB 1 TGCACACTGCTGCTACTAT 20

```

```

RESULT 39
US-09-544-398B-264/c
; Sequence 264, Application US/09544398B
; Patent No. 6770461
; GENERAL INFORMATION:
; APPLICANT: Canuli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of 11q13.3
; FILE REFERENCE: 032796-013
; CURRENT APPLICATION NUMBER: US/09/544,398B
; PRIOR FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: US 09/229,319
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US 60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 264
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-544-398B-264

```

```

Query Match
Best Local Similarity 0.2%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 324 CGGTGTGAGTGGAGTACT 343

```

```

DB 20 CGGTATCAGTGGAGTACT 1

```

```

RESULT 40
US-08-311-760A-7
; Sequence 7, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [Lp(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-311-760A-7

```

```

Query Match
Best Local Similarity 0.2%; Score 15; DB 1; Length 15;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 120 CCAGATTGCTACCA 134
DB 1 CCAGATUUGCUACCA 15

```

```

RESULT 41
US-08-311-760A-8
; Sequence 8, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES

```

```

1  TITLE OF INVENTION:  OR CONDITIONS RELATED TO LEVELS OF
2  TITLE OF INVENTION:  PLASMA LIPOPROTEIN (a) [LP(a)] BY
3  TITLE OF INVENTION:  INHIBITING APOB100PROTEIN
4  TITLE OF INVENTION:
5  NUMBER OF SEQUENCES:  392
6  CORRESPONDENCE ADDRESS:
7  ADDRESSEE:  Lyon & Lyon
8  STREET:  633 West Fifth Street
9  STREET:  Suite 4700
10 CITY:  Los Angeles
11 STATE:  California
12 COUNTRY:  U.S.A.
13 ZIP:  90071
14
15 COMPUTER READABLE FORM:
16 MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
17 MEDIUM TYPE:  storage
18 COMPUTER:  IBM Compatible
19 OPERATING SYSTEM:  IBM P.C. DOS 5.0
20 SOFTWARE:  PaetSEQ Version 1.5
21
22 CURRENT APPLICATION DATA:
23 APPLICATION NUMBER:  US/08/311,760A
24 FILING DATE:  September 23, 1994
25
26 PRIOR APPLICATION DATA:
27 APPLICATION NUMBER:
28 FILING DATE:
29
30 ATTORNEY/AGENT INFORMATION:
31 NAME:  Warburg, Richard
32 REGISTRATION NUMBER:  32,327
33 REFERENCE/DOCKET NUMBER:  208/155
34
35 TELECOMMUNICATION INFORMATION:
36 TELEPHONE:  (213) 489-1600
37 TELEFAX:  (213) 955-0440
38
39 TELE:  67-3510
40
41 INFORMATION FOR SEQ ID NO:  8:
42
43 SEQUENCE CHARACTERISTICS:
44 LENGTH:  15 base pairs
45 TYPE:  nucleic acid
46 STRANDEDNESS:  single
47
48 TOPOLOGY:  linear
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

```

```

Oy      144 ACAGAGTATTCGAGC 158
      |||||::|||
Db      1 ACAGAGUUAUCGAGC 15

Query Match Similarity 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0;

RESULT 42
US-08-311-760A-9
; Sequence 9, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: MCSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [Lp(a)] BY
; TITLE OF INVENTION: INHIBITING APO(L)PROTEIN
; TITLE OF INVENTION:
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

```

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: FastSeq Version 1.5
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/311,760A
 FILING DATE: September 23, 1994
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER:
 FILING DATE:
 ATTORNEY/AGENT INFORMATION:
 NAME: Warburg, Richard
 REGISTRATION NUMBER: 32,327
 REFERENCE/DOCKET NUMBER: 208/155
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 9:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 15 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-311-760A-9

```

Query Match          0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY      147 GAGTTATGAGGCAC 161
      |||:::|||||
Db      1 GAGUUAUCGAGGCAC 15

RESULT 43
US-08-311-760A-10
; Sequence 10, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Schlumberger, Dan T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramnarack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:

```

NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-10

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 65;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 192 CCAAGCTTGCTCATC 206
DB 1 CCAAGCTTGCTCATC 15

RESULT 44

US-08-311-760A-11
Sequence 11, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-311-760A-11

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 355 CAATGCTGAGACGCA 369
DB 1 CAATGCTGAGACGCA 15

RESULT 45

US-08-311-760A-12
Sequence 12, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-311-760A-12

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 65;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 393 GACTGTATCCCGGT 407
DB 1 GACTGTATCCCGGT 15

RESULT 46
US-08-311-760A-13

```
Sequence 13, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-13

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 401 CCGCGTTCACAGCC 415
Db 1 CCGCGGUCCAAGCC 15

RESULT 47
US-08-311-760A-14
Sequence 14, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
```

```
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-14

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 402 CCGCGTTCACAGCCT 416
Db 1 CCGCGGUCCAAGCCU 15

RESULT 48
US-08-311-760A-15
Sequence 15, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
```

SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-15

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 410 CAGGCTAAGAGCTC 424
Db 1 CAGGCCUAGAGGCTC 15

RESULT 49
US-08-311-760A-16
Sequence 16, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESS: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440
TELEFAX: 67-3510
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-16

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 474 CCATGTAATGAGCA 488
Db 1 CCAUGGUAAUGACA 15

RESULT 50
US-08-311-760A-17
Sequence 17, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESS: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-17

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Oy 564 GCATAGTCGACCCC 578
Db 1 GCAAGUCGACCCCC 15

RESULT 51
US-08-311-760A-168
Sequence 168, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 168:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-168

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Oy 401 CCCCCGTTCCAGCC 415
Db 1 CCCCCGTTCCAGCC 15

RESULT 52
US-08-311-760A-169
Sequence 169, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 169:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-169

APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 169:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-169

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Oy 417 AGAGGCTCCTCCGA 431
Db 1 AGAGGCTCCTCCGA 15

RESULT 53
US-08-311-760A-170
Sequence 170, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 170:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-170

```
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 170:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-170

Query Match
Best Local Similarity 0.2%; Score 15; DB 1; Length 15;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 420 GGCTCCTCCGACACA 434
Db 1 GGCTCCUCCGACACA 15

RESULT 54
US-08-311-760A-171
Sequence 171, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
```

```
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 171:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-171

Query Match
Best Local Similarity 0.2%; Score 15; DB 1; Length 15;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 420 GGCTCCTCCGACACA 434
Db 1 GGCTCCUCCGACACA 15

RESULT 55
US-08-311-760A-172
Sequence 172, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 172:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
```

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-172

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 420 GGCTCCTTCGACAA 434
Db 1 GGCTCCTTCGACAA 15

RESULT 56
US-08-311-760A-173
Sequence 173, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
TITLE OF INVENTION: RAMNARACK, RANDY
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF INVENTION: 392.
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 173:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-173

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 420 GGCTCCTTCGACAA 434
Db 1 GGCTCCTTCGACAA 15

RESULT 57
US-08-311-760A-174
Sequence 174, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
TITLE OF INVENTION: RAMNARACK, RANDY
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF INVENTION: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 174:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-174

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 421 GCTCCTTCGACAA 435
Db 1 GGCTCCTTCGACAA 15

RESULT 58
US-08-311-760A-175
Sequence 175, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
TITLE OF INVENTION: RAMNARACK, RANDY
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

;; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
;; TITLE OF INVENTION:
;; NUMBER OF SEQUENCES: 392
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: FastSeq Version 1.5
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/311,760A
;; FILING DATE: September 23, 1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER:
;; FILING DATE:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/155
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 175:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;;
US-08-311-760A-175
;
Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
;
QY 144 ACAGATTATCGAGC 158
DB 1 ACAGAGUUAUCGAGC 15
;
RESULT 59
US-08-311-760A-176
;; Sequence 176, Application US/08311760A
;; Patent No. 5599706
;; GENERAL INFORMATION:
;; APPLICANT: Stinchcomb, Dan T.
;; APPLICANT: McSwigen, James
;; APPLICANT: Newton, Roger S.
;; APPLICANT: Rambarack, Randy
;; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
;; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
;; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
;; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
;; NUMBER OF SEQUENCES: 392
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: FastSeq Version 1.5
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/311,760A
;; FILING DATE: September 23, 1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER:
;; FILING DATE:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/155
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 176:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;;
US-08-311-760A-176
;
Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
;
QY 147 GAGTTATCGAGC 161
DB 1 GAGUUAUCGAGC 15
;
RESULT 60
US-08-311-760A-188
;; Sequence 188, Application US/08311760A
;; Patent No. 5599706
;; GENERAL INFORMATION:
;; APPLICANT: Stinchcomb, Dan T.
;; APPLICANT: McSwigen, James
;; APPLICANT: Newton, Roger S.
;; APPLICANT: Rambarack, Randy
;; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
;; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
;; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
;; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
;; NUMBER OF SEQUENCES: 392
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: FastSeq Version 1.5
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/311,760A
;; FILING DATE: September 23, 1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER:
;; FILING DATE:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 188:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-188

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 499 GCACATACCTCCACC 513
Db 1 GGCACAUACUCCACC 15

RESULT 61
US-08-311-760A-194
Sequence 194, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Walburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 194:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-194

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 564 GCATAGTCGACCCC 578
Db 1 GCAUAGUCGACCCC 15

RESULT 62
US-08-311-760A-195
Sequence 195, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Walburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 195:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-195

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 564 GCATAGTCGACCCC 578
Db 1 GCAUAGUCGACCCC 15

RESULT 63
US-08-311-760A-196
Sequence 196, Application US/08311760A
Patent No. 5599706

```

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 196:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-196

Query Match          0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      564 GCATAGTCGAGACCC 578
Db      1  GCAUAGUGGAGACCC 15

RESULT 64
US-08-311-760A-198
Sequence 198, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
```

```

STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 198:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-198

Query Match          0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      276 CAGGATCCAGATGC 290
Db      1  CAGGAUCCAGAUCC 15

RESULT 65
US-08-311-760A-199
Sequence 199, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
```

```

; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TOPOLOGY: linear
US-08-311-760A-199

Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      276 CAGGAATCCAGATGC 290
Db      1 CAGGAATCCAGATGC 15

RESULT 66
US-08-311-760A-200
; Sequence 200, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TOPOLOGY: linear
US-08-311-760A-201
```

```

; INFORMATION FOR SEQ ID NO: 200:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-311-760A-200

Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      276 CAGGAATCCAGATGC 290
Db      1 CAGGAATCCAGATGC 15

RESULT 67
US-08-311-760A-201
; Sequence 201, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TOPOLOGY: linear
US-08-311-760A-201

Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      276 CAGGAATCCAGATGC 290
Db      1 CAGGAATCCAGATGC 15
```

Db 1 CAGGAUCCAGAUCC 15

RESULT 68

US-08-311-760A-202

Sequence 202, Application US/08311760A

Patent No. 5599706

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Dan T.

APPLICANT: McSwiggen, James

APPLICANT: Newton, Roger S.

APPLICANT: Ramharack, Randy

TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES

TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF

TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY

TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

NUMBER OF SEQUENCES: 392

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Suite 4700

STATE: Los Angeles

COUNTRY: California

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSeq Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/311,760A

FILING DATE: September 23, 1994

PRIOR APPLICATION DATA:

APPLICATION NUMBER:

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/155

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

INFORMATION FOR SEQ ID NO: 202:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-311-760A-202

Query Match 0.2%; Score 15; DB 1; Length 15;

Best Local Similarity 86.7%; Pred. No. 65;

Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 276 CAGGAATCCAGATCC 290

Db 1 CAGGAUCCAGAUCC 15

RESULT 69

US-08-311-760A-224

Sequence 224, Application US/08311760A

Patent No. 5599706

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Dan T.

APPLICANT: McSwiggen, James

APPLICANT: Newton, Roger S.

APPLICANT: Ramharack, Randy

TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES

TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF

TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY

TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

NUMBER OF SEQUENCES: 392

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Suite 4700

STATE: Los Angeles

COUNTRY: U.S.A.

TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES

TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF

TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY

TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

NUMBER OF SEQUENCES: 392

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Suite 4700

STATE: Los Angeles

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSeq Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/311,760A

FILING DATE: September 23, 1994

PRIOR APPLICATION DATA:

APPLICATION NUMBER:

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/155

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

INFORMATION FOR SEQ ID NO: 224:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-311-760A-224

Query Match 0.2%; Score 15; DB 1; Length 15;

Best Local Similarity 80.0%; Pred. No. 65;

Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 120 CCAGATTGCTACCA 134

Db 1 CCAGAUCCAGAUCC 15

RESULT 70

US-08-311-760A-225

Sequence 225, Application US/08311760A

Patent No. 5599706

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Dan T.

APPLICANT: McSwiggen, James

APPLICANT: Newton, Roger S.

APPLICANT: Ramharack, Randy

TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES

TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF

TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY

TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

NUMBER OF SEQUENCES: 392

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Suite 4700

STATE: Los Angeles

COUNTRY: U.S.A.


```

; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 225:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-760A-225

Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      120 CCAAGATTGCTACCA 134
Db      1 CCAAGATUGCUACCA 15

RESULT 71
US-08-441-370-4/c
; Sequence 4, Application US/08441370
; Patent No. 5721138
; GENERAL INFORMATION:
; APPLICANT: Lawm, Richard M.
; TITLE OF INVENTION: Apolipoprotein(A) Promoter and
; TITLE OF INVENTION: Regulatory Sequence Constructs and Methods of Use
; Patent No. 5721138
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PENNIE & EDMONDS
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10036-2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/441,370
; FILING DATE:
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/991,849
; FILING DATE: 15-DEC-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A.
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 7627-003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212 790-9090

```

```

; TELEFAX: 212 869-8864/9741
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; US-08-441-370-4

Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      105 GCAAGCCATGTGT 119
Db      15 GCAAGCCATGTGT 1

RESULT 72
US-08-774-310-7
; Sequence 7, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-310-7

Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;

```

Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 120 CCAGATTGCTACCA 134
|||||:|||||
Db 1 CCAGAGUUCGACCA 15

RESULT 73

US-08-774-310-8
; Sequence 8, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-774-310-8

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 144 ACAGAGTATCGAGG 158
|||||:|||||
Db 1 ACAGAGUUCGAGG 15

RESULT 74

US-08-774-310-9
; Sequence 9, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.

US-08-774-310-9

APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-774-310-9

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 147 GAGTTATCGAGGCAC 161
|||||:|||||
Db 1 GAGUUCGAGGCAC 15

US-08-774-310-10

RESULT 75

US-08-774-310-10

Sequence 10, Application US/08774310

Patent No. 5877022

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Daniel T.

APPLICANT: McSwigen, James

APPLICANT: Newton, Roger S.

APPLICANT: Ramharack, Randy

TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES

TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF

TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY

TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

NUMBER OF SEQUENCES: 392

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSeq Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/774,310

FILING DATE: December 23, 1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/311,760

FILING DATE: September 23, 1994

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 223/229

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 9:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-774-310-9

CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Waiburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-10

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 65;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 192 CCAAGCTTGTCATC 206
DB 1 CCAAGCTTGTCATC 15
RESULT 76
US-08-774-310-11
Sequence 11, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Waiburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-11

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 355 CAATGCTCAGACGCA 369
DB 1 CAATGCTCAGACGCA 15

RESULT 77
US-08-774-310-12
Sequence 12, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Waiburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-12

Query Match
Best Local Similarity 0.2%; Score 15; DB 1; Length 15;
Pred. No. 65;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 393 GACTGTACCCGGT 407
|||:|||||:
Db 1 GACUGUACCCGGU 15

RESULT 78

US-08-774-310-13
Sequence 13, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-13

Query Match
Best Local Similarity 0.2%; Score 15; DB 1; Length 15;
Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 401 CCCCAGTCCAGCC 415
|||||:|||||:
Db 1 CCCCAGTCCAGCC 15

RESULT 79

US-08-774-310-14
Sequence 14, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-14

Query Match
Best Local Similarity 0.2%; Score 15; DB 1; Length 15;
Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 402 CCCCAGTCCAGCC 416
|||||:|||||:
Db 1 CCCCAGTCCAGCC 15

RESULT 80

US-08-774-310-15
Sequence 15, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF

```

1      TITLE OF INVENTION:  PLASMA LIPOPROTEIN (a) [LP(a)] BY
2      TITLE OF INVENTION:  INHIBITING ABOLIPROTEIN
3      TITLE OF INVENTION:
4      NUMBER OF SEQUENCES:  392
5      CORRESPONDENCE ADDRESS:
6      ADDRESSEE:  Lyon & Lyon
7      STREET:  633 West Fifth Street
8      STREET:  Suite 4700
9      CITY:  Los Angeles
10     STATE:  California
11     COUNTRY:  U.S.A.
12     ZIP:  90071
13
14     COMPUTER READABLE FORM:
15     MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
16     MEDIUM TYPE:  storage
17     COMPUTER:  IBM Compatible
18     OPERATING SYSTEM:  IBM P.C. DOS 5.0
19     SOFTWARE:  FASTSEQ Version 1.5
20     CURRENT APPLICATION DATA:
21     APPLICATION NUMBER:  US/08/774,310
22     FILING DATE:  December 23, 1996
23     PRIOR APPLICATION DATA:
24     APPLICATION NUMBER:  08/311,760
25     FILING DATE:  September 23, 1994
26     ATTORNEY/AGENT INFORMATION:
27     NAME:  Waiburg, Richard
28     REGISTRATION NUMBER:  32,327
29     REFERENCE/DOCKET NUMBER:  223/229
30     TELECOMMUNICATION INFORMATION:
31     TELEPHONE:  (213) 489-1600
32     TELEFAX:  (213) 955-0440
33     TELEX:  67-3510
34
35     INFORMATION FOR SEQ ID NO:  15:
36     SEQUENCE CHARACTERISTICS:
37     LENGTH:  15 base pairs
38     TYPE:  nucleic acid
39     STRANDEDNESS:  single
40     TOPOLOGY:  linear
41
42     US-08-774-310-15
43
44     Query Match 0.2% Score 15; DB 1; Length 15;
45     Best Local Similarity 86.7%; Pred. No. 65;
46     Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
47
48     QY 410 CAGCGCTAGAGGCTC 424
49     |||||:|||||:|
50     Db 1 CAGCGCTAGAGGCTC 15
51
52     RESULT 81
53     US-08-774-310-16
54     Sequence 16, Application US/08774310
55     Patent No. 5877022
56
57     GENERAL INFORMATION:
58     APPLICANT:  Stinchcomb, Daniel T.
59     APPLICANT:  McSwigen, James
60     APPLICANT:  Newton, Roger S.
61     APPLICANT:  Rambarack, Randy
62
63     TITLE OF INVENTION:  RIBOZYME TREATMENT OF DISEASES
64     TITLE OF INVENTION:  OR CONDITIONS RELATED TO LEVELS OF
65     TITLE OF INVENTION:  PLASMA LIPOPROTEIN (a) [LP(a)] BY
66     TITLE OF INVENTION:  INHIBITING APOLIPOPROTEIN
67
68     NUMBER OF SEQUENCES:  392
69     CORRESPONDENCE ADDRESS:
70     ADDRESSEE:  Lyon & Lyon
71     STREET:  633 West Fifth Street
72     STREET:  Suite 4700
73     CITY:  Los Angeles
74     STATE:  California
75     COUNTRY:  U.S.A.
76     ZIP:  90071
77
78     COMPUTER READABLE FORM:

```

```

1 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
2 MEDIUM TYPE: storage
3 COMPUTER: IBM Compatible
4 OPERATING SYSTEM: IBM P.C. DOS 5.0
5 SOFTWARE: FastSeq Version 1.5
6 CURRENT APPLICATION DATA:
7 APPLICATION NUMBER: US/08/774,310
8 FILING DATE: December 23, 1996
9 PRIOR APPLICATION DATA:
10 APPLICATION NUMBER: 08/311,760
11 FILING DATE: September 23, 1994
12 ATTORNEY/AGENT INFORMATION:
13 REGISTRATION NUMBER: 32,327
14 REFERENCE/DOCKET NUMBER: 223/229
15 TELECOMMUNICATION INFORMATION:
16 TELEPHONE: (213) 489-1600
17 TELEFAX: (213) 955-0440
18 TELEX: 67-3510
19 INFORMATION FOR SEQ ID NO: 16:
20 SEQUENCE CHARACTERISTICS:
21 LENGTH: 15 base pairs
22 TYPE: nucleic acid
23 STRANDEDNESS: single
24 TOPOLOGY: linear
25 US-08-774-310-16
26
27 Query Match 0.2%; Score 15; DB 1; Length 15;
28 Best Local Similarity 80.0%; Pred.No. 65;
29 Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
30
31 QY 474 CCATGCTAATGACGA 488
32 |||:|||||
33 Db 1 CCAUGGUAUGGACA 15
34
35 RESULT 82
36 US-08-774-310-17
37 Sequence 17, Application US/08774310
38 Patent No. 5877022
39 GENERAL INFORMATION:
40 APPLICANT: Stinchcomb, Daniel T.
41 APPLICANT: McSwiggen, James
42 APPLICANT: Newton, Roger S.
43 APPLICANT: Ramharack, Randy
44 TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
45 TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
46 TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
47 TITLE OF INVENTION: INHIBITING APOLOPROTEIN
48 TITLE OF INVENTION:
49 NUMBER OF SEQUENCES: 392
50 CORRESPONDENCE ADDRESS:
51 ADDRESSEE: Lyon & Lyon
52 STREET: 633 West Fifth Street
53 STREET: Suite 4700
54 CITY: Los Angeles
55 STATE: California
56 COUNTRY: U.S.A.
57 ZIP: 90071
58
59 COMPUTER READABLE FORM:
60 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
61 MEDIUM TYPE: storage
62 COMPUTER: IBM Compatible
63 OPERATING SYSTEM: IBM P.C. DOS 5.0
64 SOFTWARE: FastSeq Version 1.5
65 CURRENT APPLICATION DATA:
66 APPLICATION NUMBER: US/08/774,310
67 FILING DATE: December 23, 1996
68 PRIOR APPLICATION DATA:
69 APPLICATION NUMBER: 08/311,760
70 FILING DATE: September 23, 1994
71 ATTORNEY/AGENT INFORMATION:
72 NAME: Wardburg, Richard

```

```

;
;   REGISTRATION NUMBER: 32,327
;   REFERENCE/DOCKET NUMBER: 223/229
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (213) 489-1600
;   TELEFAX: (213) 955-0440
;   TELETYPE: 67-3510
;   INFORMATION FOR SEQ ID NO: 17:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH: 15 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
;
US-08-774-310-17

Query Match          0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      564 GCATAGTCGACCC 578
Db      1 GCAUAGUCGACCC 15

RESULT 83
US-08-774-310-168
; Sequence 168, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
;   APPLICANT: Stinchcomb, Daniel T.
;   APPLICANT: McSwigen, James
;   APPLICANT: Newton, Roger S.
;   APPLICANT: Ramharack, Randy
;   TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
;   TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
;   TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
;   TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
;   NUMBER OF INVENTION: 392
;   CORRESPONDENCE ADDRESS:
;   ADDRESSEE: Lyon & Lyon
;   STREET: 633 West Fifth Street
;   STREET: Suite 4700
;   CITY: Los Angeles
;   STATE: California
;   COUNTRY: U.S.A.
;   ZIP: 90071
;   COMPUTER READABLE FORM:
;   MEDIUM TYPE: 3.5" Diskette, 1.44 MB
;   MEDIUM TYPE: storage
;   COMPUTER: IBM Compatible
;   OPERATING SYSTEM: IBM P.C. DOS 5.0
;   SOFTWARE: FastSeq Version 1.5
;   CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/08/774,310
;   FILING DATE: December 23, 1996
;   PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: 08/311,760
;   FILING DATE: September 23, 1994
;   ATTORNEY/AGENT INFORMATION:
;   NAME: Warburg, Richard
;   REGISTRATION NUMBER: 32,327
;   REFERENCE/DOCKET NUMBER: 223/229
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (213) 489-1600
;   TELEFAX: (213) 955-0440
;   TELETYPE: 67-3510
;   INFORMATION FOR SEQ ID NO: 168:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH: 15 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
;
US-08-774-310-168
```

```

Query Match          0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      401 CCCCCTTCACGCC 415
Db      1 CCCCCTTCACGCC 15

RESULT 84
US-08-774-310-169
; Sequence 169, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
;   APPLICANT: Stinchcomb, Daniel T.
;   APPLICANT: McSwigen, James
;   APPLICANT: Newton, Roger S.
;   APPLICANT: Ramharack, Randy
;   TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
;   TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
;   TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
;   TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
;   NUMBER OF INVENTION: 392
;   CORRESPONDENCE ADDRESS:
;   ADDRESSEE: Lyon & Lyon
;   STREET: 633 West Fifth Street
;   STREET: Suite 4700
;   CITY: Los Angeles
;   STATE: California
;   COUNTRY: U.S.A.
;   ZIP: 90071
;   COMPUTER READABLE FORM:
;   MEDIUM TYPE: 3.5" Diskette, 1.44 MB
;   MEDIUM TYPE: storage
;   COMPUTER: IBM Compatible
;   OPERATING SYSTEM: IBM P.C. DOS 5.0
;   SOFTWARE: FastSeq Version 1.5
;   CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/08/774,310
;   FILING DATE: December 23, 1996
;   PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: 08/311,760
;   FILING DATE: September 23, 1994
;   ATTORNEY/AGENT INFORMATION:
;   NAME: Warburg, Richard
;   REGISTRATION NUMBER: 32,327
;   REFERENCE/DOCKET NUMBER: 223/229
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (213) 489-1600
;   TELEFAX: (213) 955-0440
;   TELETYPE: 67-3510
;   INFORMATION FOR SEQ ID NO: 169:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH: 15 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
;
US-08-774-310-169

Query Match          0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      417 AGAGCTCTTCGCA 431
Db      1 AGAGCTCTTCGCA 15

RESULT 85
US-08-774-310-170
; Sequence 170, Application US/08774310
```

```

; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; TITLE OF INVENTION:
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 170:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-310-170

Query Match          0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy      420 GGCCTCTCCGACACA 434
Db      1 GGCCTCTCCGACACA 15

RESULT 86
US-08-774-310-171
; Sequence 171, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:

```

```

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 171:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-310-171

Query Match          0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy      420 GGCCTCTCCGACACA 434
Db      1 GGCCTCTCCGACACA 15

RESULT 87
US-08-774-310-172
; Sequence 172, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5

```

```

? TELER: 67-3510
? INFORMATION FOR SEQ ID NO: 173
? SEQUENCE CHARACTERISTICS:
? LENGTH: 15 base pairs
? TYPE: nucleic acid
? STRANDEDNESS: single
? TOPOLOGY: linear
?
US-08-774-310-173

Query Match          0.2% S
Best Local Similarity 80.0% P
Matches 12; Conservative 3;

QY      420 GGCCTCTCCCAACA 434
      |||::|::|::|
Db       1 GGCCTCTCCCAACA 15

RESULT 89
US-08-774-310-174

```

Query Match	0.2%	Score 15;	DB 1;	Length 15;
Best Local Similarity	80.0%	Pred. No. 65;		
Matches 12;	Conservative 3;	Mismatches 0;	Indels 0;	Gaps 0;

QY 420 GGCCTCTTCCGAACA 434
|||:|||||
Db 1 GGCUCCTUCCGAACA 15

RESULT 89

US-08-774-310-174

Sequence 1/4, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McGisgen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharrack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [Lp(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS: 392

Query Match	0.2%	Score 15;	DB 1;	Length 15;
Best Local Similarity	80.0%;	Pred. No. 65;		
Matches 12;	Conservative 3;	Mismatches 0;	Indels 0;	Gaps 0;


```
Oy      421 GCTCCTTCGACAA 435
Db      1 GCUCUCCGACAA 15

RESULT 90
US-08-774-310-175
; Sequence 175, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 175:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-310-175

Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Oy      144 ACAGATTATCGAGG 158
Db      1 ACAGAGUUAUCGAGG 15

RESULT 91
US-08-774-310-176
; Sequence 176, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.

APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Wardburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 176:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-176

Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Oy      147 GAGTTATCGAGGCAC 161
Db      1 GAGUUAUCGAGGCAC 15

RESULT 92
US-08-774-310-188
; Sequence 188, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
```

COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 188:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-188

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 499 GCACACTACTCCACC 513
Db 1 GCACACUACUCCACC 15

RESULT 93
US-08-774-310-194
Sequence 194, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760

FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 194:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-194

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 564 GCATAGTCGAGCC 578
Db 1 GCAUAGUCGAGCC 15

RESULT 94
US-08-774-310-195
Sequence 195, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 195:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-195

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 564 GCATAGCGAGACCC 578
DB 1 GCAUAGUGGAGACCC 15

RESULT 95

US-08-774-310-196
Sequence 196, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 196:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-196

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 564 GCATAGCGAGACCC 578
DB 1 GCAUAGUGGAGACCC 15

RESULT 96
US-08-774-310-198
Sequence 198, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 198:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-198

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 276 CAGGATCGAGATGC 290
DB 1 CAGGATCGAGATGC 15

RESULT 97
US-08-774-310-199
Sequence 199, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

```

; TITLE OF INVENTION:
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 199:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-774-310-199
;
Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      276 CAGGATCCAGATGC 290
Db      1 CAGGATCCAGATGC 15

RESULT 98
US-08-774-310-200
; Sequence 200, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 200:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-774-310-200
;
Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      276 CAGGATCCAGATGC 290
Db      1 CAGGATCCAGATGC 15

RESULT 99
US-08-774-310-201
; Sequence 201, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 200:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-774-310-200
;
Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      276 CAGGATCCAGATGC 290
Db      1 CAGGATCCAGATGC 15
```

```

; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 200:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-774-310-200
;
Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      276 CAGGATCCAGATGC 290
Db      1 CAGGATCCAGATGC 15

RESULT 99
US-08-774-310-201
; Sequence 201, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 200:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-774-310-200
;
Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      276 CAGGATCCAGATGC 290
Db      1 CAGGATCCAGATGC 15
```

TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 201:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-201

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 276 CAGGATCCAGATGC 290
Db 1 CAGGAUCCAGAUCC 15

RESULT 100
US-08-774-310-202
Sequence 202, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF INVENTION: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 202:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-202
Query Match 0.2%; Score 15; DB 1; Length 15;

Best Local Similarity 86.7%; Pred. No. 65;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY 276 CAGGATCCAGATGC 290
Db 1 CAGGAUCCAGAUCC 15

RESULT 101
US-08-774-310-224
Sequence 224, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF INVENTION: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 224:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-224
Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
OY 120 CAGGATGCTACCA 134
Db 1 CAGGAUCCUACCA 15
RESULT 102
US-08-774-310-225
Sequence 225, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:

```

; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: WordPerfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 225:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-774-310-225
;
; Query Match 0.2%; Score 15; DB 1; Length 15;
; Best Local Similarity 80.0%; Pred. No. 65;
; Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
;
; QY 120 CCAGATTGCTACCA 134
; Db 1 CCAGATUGGCA 15
;
; RESULT 103
; US-07-720-585A-1/C
; Sequence 1, Application US/07720585A
; Patent No. 5216143
; GENERAL INFORMATION:
; APPLICANT: James J. Hogan
; APPLICANT: Philip W. Hammond
; TITLE OF INVENTION: NUCLEIC ACIDS PROBES
; TITLE OF INVENTION: TO MYCOBACTERIUM GORDONAE
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version
; OPERATING SYSTEM: WordPerfect (Version 5.1)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/720,585A
; FILING DATE: 19910628
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: none
```

```

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version
; OPERATING SYSTEM: WordPerfect (Version 5.1)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/720,585A
; FILING DATE: 19910628
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: none
;
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 193/121
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-07-720-585A-1
;
; Query Match 0.2%; Score 14.8; DB 1; Length 19;
; Best Local Similarity 88.9%; Pred. No. 1.1e+02;
; Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
; QY 226 AATAGACCCAGAAAC 243
; Db 18 AATAGACCCAGAC 1
;
; RESULT 104
; US-07-720-585A-4
; Sequence 4, Application US/07720585A
; Patent No. 5216143
; GENERAL INFORMATION:
; APPLICANT: James J. Hogan
; APPLICANT: Philip W. Hammond
; TITLE OF INVENTION: NUCLEIC ACIDS PROBES
; TITLE OF INVENTION: TO MYCOBACTERIUM GORDONAE
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version
; OPERATING SYSTEM: WordPerfect (Version 5.1)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/720,585A
; FILING DATE: 19910628
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: none
```

FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
NAME: J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 193/121
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
US-07-720-585A-4

Query Match 0.2%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 226 AATGAGCCACAGAAAC 243
Db 2 AATGAGCCACAGAGAC 19

RESULT 105
US-07-720-585A-5
Sequence 5, Application US/07720585A
Patent No. 5216143
GENERAL INFORMATION:
APPLICANT: James J. Hogan
APPLICANT: Philip W. Hammond
TITLE OF INVENTION: NUCLEIC ACIDS PROBES
TITLE OF INVENTION: TO MYCOBACTERIUM GORDONAE
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 611 West Sixth Street
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS (Version
OPERATING SYSTEM: 3.30)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/720,585A
FILING DATE: 19910628
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
NAME: J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 193/121
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: NUCLEIC ACID

STRANDEDNESS: single
TOPOLOGY: linear
US-07-720-585A-5

Query Match 0.2%; Score 14.8; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 1.1e+02;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 226 AATGAGCCACAGAAAC 243
Db 2 AATGAGCCACAGAGAC 19

RESULT 106
US-07-720-585A-6/C
Sequence 6, Application US/07720585A
Patent No. 5216143
GENERAL INFORMATION:
APPLICANT: James J. Hogan
APPLICANT: Philip W. Hammond
TITLE OF INVENTION: NUCLEIC ACIDS PROBES
TITLE OF INVENTION: TO MYCOBACTERIUM GORDONAE
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 611 West Sixth Street
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS (Version
OPERATING SYSTEM: 3.30)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/720,585A
FILING DATE: 19910628
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
NAME: J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 193/121
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
US-07-720-585A-6

Query Match 0.2%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 226 AATGAGCCACAGAAAC 243
Db 18 AATGAGCCACAGAGAC 1

RESULT 107

US-08-656-906-3
Sequence 3, Application US/08656906
Patent No. 5972901
GENERAL INFORMATION:
APPLICANT: Petrol Jr., Thomas W.
APPLICANT: Davis, Pamela B.
APPLICANT: Ziaady, Assem-Galal
TITLE OF INVENTION: Serpin Enzyme Complex Receptor -
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESS: Medlen & Carroll
STREET: 220 Montgomery Street, Suite 2200
CITY: San Francisco
STATE: California
COUNTRY: United States Of America
ZIP: 94104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/656,906
FILING DATE: 03-JUN-1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/
FILING DATE: 03-JUN-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: WO WO 95/25809
FILING DATE: 23-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/216,534
FILING DATE: 23-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Ingolia, Diane E.
REGISTRATION NUMBER: 40,027
REFERENCE/DOCKET NUMBER: CASE-02280
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 705-8410
TELEFAX: (415) 397-8338
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-656-906-3

Query Match 0.2%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 65 TTCTTCTACTCTTTAT 82
Db 2 TTCTTCTCTCTTTT 19

RESULT 108
US-09-217-847-3
Sequence 3, Application US/09217847
Patent No. 6200801
GENERAL INFORMATION:
APPLICANT: Petrol Jr., Thomas W.
APPLICANT: Davis, Pamela B.
APPLICANT: Ziaady, Assem-Galal
TITLE OF INVENTION: Serpin Enzyme Complex Receptor -
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESS: Medlen & Carroll

STREET: 220 Montgomery Street, Suite 2200
CITY: San Francisco
STATE: California
COUNTRY: United States Of America
ZIP: 94104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/217,847
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/656,906
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: WO WO 95/25809
FILING DATE: 23-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/216,534
FILING DATE: 23-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Ingolia, Diane E.
REGISTRATION NUMBER: 40,027
REFERENCE/DOCKET NUMBER: CASE-02280
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 705-8410
TELEFAX: (415) 397-8338
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-217-847-3

Query Match 0.2%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 65 TTCTTCTACTCTTTAT 82
Db 2 TTCTTCTCTCTTTT 19

RESULT 109
US-08-311-760A-340
Sequence 340, Application US/08311760A
Patent No. 559706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESS: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb


```

MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 340:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-340

Query Match      0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 93;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy      436 GCACGACTGAGCAA 451
Db      1 GCACGACUGAGCAGA 16

RESULT 110
US-08-311-760A-341
Sequence 341, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 340:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-374
```

```

REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 341:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-341

Query Match      0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 62.5%; Pred. No. 93;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy      293 TGGCAGCTCCTTATG 308
Db      1 UGCAGCCCUUATUG 16

RESULT 111
US-08-311-760A-374
Sequence 374, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 374:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-374
```

Query Match 0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 93;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 374 GGACTGCCCTCGGCC 389
DB 1 GGACUCCCGCCGCCACC 16

RESULT 112
US-08-311-760A-375
; Sequence 375, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 375:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-760A-375

Query Match 0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 93;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 377 CTGCGCCGGCGCTCC 392
DB 1 CUGCGCCGCGCCACC 16

RESULT 113
US-08-311-760A-377
; Sequence 377, Application US/08311760A
; Patent No. 5599706

; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 377:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-760A-377

Query Match 0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 62.5%; Pred. No. 93;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 293 TGGCAGCTCTTATG 308
DB 1 UGGCAGCCCUUUG 16

RESULT 114
US-08-311-760A-378
; Sequence 378, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon

STREET: 633 West Filth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 378:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-378

Query Match 0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 62.5%; Pred. No. 93;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 293 TGGCAGCTCCTATTG 308
DB 1 UGCGAGCCCCUUAUG 16

RESULT 115
US-08-311-760A-381
Sequence 381, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF INVENTION: 392
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Filth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 381:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-381

Query Match 0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 62.5%; Pred. No. 93;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 293 TGGCAGCTCCTATTG 308
DB 1 UGCGAGCCCCUUAUG 16

RESULT 116
US-08-311-760A-382
Sequence 382, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF INVENTION: 392
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Filth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 382:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-382

Query Match 0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 93;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

374 GGAAGCCGCGCCGCC 389
1 GGAAGCCGCGCCGCC 16

RESULT 117

US-08-311-760A-383
Sequence 383, Application US/08311760A
Patent No. 5599706

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 383:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-383

Query Match 0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 93;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

377 CAGCGCTCGCGCTCC 392

DB 1 CAGCGCTCGCGCTCC 16

RESULT 118

US-08-774-310-340
Sequence 340, Application US/08774310
Patent No. 5877022

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 340:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-340

Query Match 0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 93;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

436 GCACCGACTGAGCAAA 451
1 GCACCGACTGAGCAAA 16

RESULT 119

US-08-774-310-341
Sequence 341, Application US/08774310
Patent No. 5877022

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy

```

; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 341:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-774-310-341
;
; Query Match 0.2%; Score 14.4; DB 1; Length 16;
; Best Local Similarity 62.5%; Pred. No. 93;
; Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
;
; QY 293 TGGCAGCTCCTTATG 308
; Db 1 UGGCAGCCCUUAVUG 16
;
; RESULT 120
; US-08-774-310-374
; Sequence 374, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
```

```

; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 374:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-774-310-374
;
; Query Match 0.2%; Score 14.4; DB 1; Length 16;
; Best Local Similarity 81.2%; Pred. No. 93;
; Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
;
; QY 374 GGACTGCCGTCGCGCC 389
; Db 1 GGACTGCCGTCGCGCC 16
;
; RESULT 121
; US-08-774-310-375
; Sequence 375, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
```

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 375:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-375

Query Match 0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 93;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 377 CTGCGCTCGCGCTTC 392
Db 1 UGCGCGCGCACCCUCC 16

RESULT 122
US-08-774-310-377
Sequence 377, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 377:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

TOPOLOGY: linear
US-08-774-310-377

Query Match 0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 62.5%; Pred. No. 93;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 293 TGGCAGCTCTTATTG 308
Db 1 UGCGAGCCCCCUUAVUG 16

RESULT 123
US-08-774-310-378
Sequence 378, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 378:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-378

Query Match 0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 62.5%; Pred. No. 93;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 293 TGGCAGCTCTTATTG 308
Db 1 UGCGAGCCCCCUUAVUG 16

RESULT 124

US-08-774-310-381
; Sequence 381, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 381:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-310-381
Query Match 0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 62.5%; Pred. No. 93;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
QY 293 TGGCAGCTCCTTATG 308
Db 1 UGGCAGCCCUUAVUG 16
RESULT 125
US-08-774-310-382
; Sequence 382, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 382:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-382
Query Match 0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 93;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 374 GGAATGCGCTGCGCC 389
Db 1 GGAUCGCGCGCGCACC 16
RESULT 126
US-08-774-310-383
; Sequence 383, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible

```
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Wardburg, Richard
REGISTRATION NUMBER: 32,327
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 383:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-383
```

```
Query Match      0.2%; Score 14.4; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 93;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      377 CTGCGCTGCGGCTCC 392
      1 CUGCCGUCGACACUCC 16
```

```
RESULT 127
US-09-474-432B-493
Sequence 493, Application US/09474432B
Patent No. 6528640
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Burgin, Alex
APPLICANT: Beaudry, Amber
APPLICANT: Karpelsky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, David
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
FILE REFERENCE: MHB00-831-B (247/276)
CURRENT APPLICATION NUMBER: US/09/474,432B
CURRENT FILING DATE: 1999-12-19
PRIOR APPLICATION NUMBER: US 60/064,866
PRIOR FILING DATE: 1997-11-05
PRIOR APPLICATION NUMBER: US 60/084,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: US 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: US 09/301,511
PRIOR FILING DATE: 1999-04-28
NUMBER OF SEQ ID NOS: 1526
SOFTWARE: PatentIn version 3.0
SEQ ID NO 493
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-474-432B-493
```

```
Query Match      0.2%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 11e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      167 CCACCACTGTCTCAGG 182
      1 CCACCCCTGUCACAGG 16
```

```
RESULT 128
US-09-371-772B-6342
Sequence 6342, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MHB00, 876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 6342
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-6342
```

```
Query Match      0.2%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 11e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      105 GCAGAGCCATGTGTC 120
      1 GCAGAGCCATGUGGUC 16
```

```
RESULT 129
US-09-476-387-492
Sequence 492, Application US/09476387
Patent No. 6617438
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Beaudry, Amber
APPLICANT: Karpelsky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, Dave
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide Triphosphate and their incorporation into Oligonucleot
FILE REFERENCE: MHB00-831-C (249/073)
CURRENT APPLICATION NUMBER: US/09/476,387
CURRENT FILING DATE: 2001-04-04
PRIOR APPLICATION NUMBER: 09/474,432
PRIOR FILING DATE: 1999-12-29
PRIOR APPLICATION NUMBER: 09/301,511
PRIOR FILING DATE: 1999-04-28
PRIOR APPLICATION NUMBER: 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: 60/083,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/064,866
PRIOR FILING DATE: 1997-11-05
NUMBER OF SEQ ID NOS: 1524
SOFTWARE: PatentIn version 3.0
SEQ ID NO 492
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-476-387-492
```

```
Query Match      0.2%; Score 14.4; DB 1; Length 17;
```


Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 167 CCACCACTGTCACAG 182
Db 1 CCACCCGUCACAG 16

RESULT 130

US-09-166-186-43/c
; Sequence 43, Application US/09166186A
; Patent No. 6080580
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda
; APPLICANT: Bennett, C. Frank
; APPLICANT: Butler, Madeline M.
; APPLICANT: Shanahan, William R.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TNF- α EXPRESSION
; FILE REFERENCE: ISPH-0322
; CURRENT APPLICATION NUMBER: US/09/166,186A
; CURRENT FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 250
; SEQ ID NO 43
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-09-166-186-43

Query Match 0.2%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 430 GAACAGCACCAGCTG 445
Db 16 GAACAGCACCAGCTG 1

RESULT 131

US-09-313-932-43/c
; Sequence 43, Application US/09313932A
; Patent No. 6228642
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda
; APPLICANT: Bennett, C. Frank
; APPLICANT: Butler, Madeline M.
; APPLICANT: Shanahan, William R.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TNF-
; FILE REFERENCE: ISPH-0356
; CURRENT APPLICATION NUMBER: US/09/313,932A
; CURRENT FILING DATE: 1999-05-18
; NUMBER OF SEQ ID NOS: 501
; SEQ ID NO 43
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-09-313-932-43

Query Match 0.2%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 430 GAACAGCACCAGCTG 445
Db 16 GAACAGCACCAGCTG 1

RESULT 132

US-08-311-760A-22

; Sequence 22, Application US/08311760A

; Patent No. 5599706
; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Dan T.

; APPLICANT: McSwiggen, James

; APPLICANT: Newton, Roger S.

; APPLICANT: Ramharack, Randy

; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES

; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF

; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY

; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

; NUMBER OF SEQUENCES: 392

; CORRESPONDENCE ADDRESS:

; ADDRESS: Lyon & Lyon

; STREET: 633 West Fifth Street

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: FASTSEQ Version 1.5

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/311,760A

; FILING DATE: September 23, 1994

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER:

; FILING DATE:

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 208/155

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 22:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-311-760A-22

QY 301 CCTATTGTATAC 314

Db 2 CCUUAUUGUUAUC 15

RESULT 133

US-08-311-760A-30
; Sequence 30, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Dan T.

; APPLICANT: McSwiggen, James

; APPLICANT: Newton, Roger S.

; APPLICANT: Ramharack, Randy

; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES

; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF

; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY

; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

; NUMBER OF SEQUENCES: 392

```
/
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/311,760A
/ FILING DATE: September 23, 1994
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/155
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 30:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
/ US-08-311-760A-30
/
/ Query Match
/ Best Local Similarity 0.2%; Score 14; DB 1; Length 15;
/ Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
/
/ QY 410 CAAGCTAGAGGCT 423
/ Db 1 CAAGCTAGAGGCT 14
/
/ RESULT 134
/ US-08-311-760A-227
/ Sequence 227, Application US/08311760A
/ Patent No. 5599706
/ GENERAL INFORMATION:
/ APPLICANT: Stinchcomb, Dan T.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Newton, Roger S.
/ APPLICANT: Ramharack, Randy
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
/ TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
/ TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
/ TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
/ NUMBER OF SEQUENCES: 392
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/774,310
/ FILING DATE: December 23, 1996
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/311,760
/ FILING DATE: September 23, 1994
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 223/229
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
```

```
/
/ SOFTWARE: FastSeq Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/311,760A
/ FILING DATE: September 23, 1994
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/155
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 227:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
/ US-08-311-760A-227
/
/ Query Match
/ Best Local Similarity 0.2%; Score 14; DB 1; Length 15;
/ Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
/
/ QY 197 CTGTGTCATCTATG 210
/ Db 2 CUGGUCACUCUAG 15
/
/ RESULT 135
/ US-08-774-310-22
/ Sequence 22, Application US/08774310
/ Patent No. 5877022
/ GENERAL INFORMATION:
/ APPLICANT: Stinchcomb, Daniel T.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Newton, Roger S.
/ APPLICANT: Ramharack, Randy
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
/ TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
/ TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
/ TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
/ NUMBER OF SEQUENCES: 392
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/774,310
/ FILING DATE: December 23, 1996
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/311,760
/ FILING DATE: September 23, 1994
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 223/229
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
```

TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-22

Query Match 0.2%; Score 14; DB 1; Length 15;
Best Local Similarity 50.0%; Pred. No. 94;
Matches 7; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

OY 301 CCTATTGTATAC 314
Db 2 CCUUAUUGUUAUC 15

RESULT 136
US-08-774-310-30
Sequence 30, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITTING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-30

Query Match 0.2%; Score 14; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 94;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 410 CAAGCTAGAGCT 423
Db 1 CAAGCTAGAGCT 14

RESULT 137
US-08-774-310-227
Sequence 227, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITTING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 227:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-227

Query Match 0.2%; Score 14; DB 1; Length 15;
Best Local Similarity 57.1%; Pred. No. 94;
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

OY 197 CTTGTCATCTATG 210
Db 2 CUUGUCUUAUC 15

RESULT 138
US-08-985-162-156
Sequence 156, Application US/08985162
Patent No. 6057156
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia

```

/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
/ TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
/ TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
/ TITLE OF INVENTION: FACTOR RECEPTORS
/ NUMBER OF SEQUENCES: 1877
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071-2066
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq for Windows 2.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/985,162
/ FILING DATE: 04 December 1997
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 60/036,476
/ FILING DATE: 31 January 1997
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 230/107
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 156:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
/ US-08-985-162-156
/
/ Query Match 0.2%; Score 13.8; DB 1; Length 17;
/ Best Local Similarity 70.6%; Pred. No. 1.3e+02;
/ Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
/
/ QY 501 CACATCTCCACACTG 517
/ Db 1 CACAACUCCUCCUCUG 17
/
/ RESULT 139
/ US-09-401-063-156
/ Sequence 156, Application US/09401063
/ Patent No. 6623962
/ GENERAL INFORMATION:
/ APPLICANT: Akhtar, Saghir
/ APPLICANT: Fell, Patricia
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
/ TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
/ TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
/ NUMBER OF SEQUENCES: 1877
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071-2066

```

```

/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq for Windows 2.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/401,063
/ FILING DATE:
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/985,162
/ FILING DATE: 04 December 1997
/ APPLICATION NUMBER: 60/036,476
/ FILING DATE: 31 January 1997
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 230/107
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 156:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
/ US-09-401-063-156
/
/ Query Match 0.2%; Score 13.8; DB 1; Length 17;
/ Best Local Similarity 70.6%; Pred. No. 1.3e+02;
/ Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
/
/ QY 501 CACATCTCCACACTG 517
/ Db 1 CACAACUCCUCCUCUG 17
/
/ RESULT 140
/ US-09-866-108A-2453
/ Sequence 2453, Application US/09866108A
/ Patent No. 6686188
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: Ji, Yonggang
/ APPLICANT: PENN, Sharon G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: A60MICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668

```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No.: 6686188
; SEQ ID NO 2453
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2453

Query Match      0.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      246 CCAATGCTGGCTTGA 262
Db      1 CCGAGATGCTGGCTGGA 17

RESULT 141
US-09-866-108A-2454
; Sequence 2454, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2454
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2454

Query Match      0.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      247 CCAATGCTGGCTTGA 263
```

```

Db      1 CCGATGCTGGCTGAT 17

RESULT 142
US-09-866-108A-7773
; Sequence 7773, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7773
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7773

Query Match      0.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      323 CCGGTGCTGGGAG 339
Db      1 CCGGTGCTGGGAG 17

RESULT 143
US-09-255-893-43/C
; Sequence 43, Application US/09255893A
; Patent No. 6008144
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPASE A2 GROUP IV EXPRESSION
; FILE REFERENCE: RTS-0055
; CURRENT APPLICATION NUMBER: US/09/255,893A
; CURRENT FILING DATE: 1999-02-23
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 43
; LENGTH: 18
```

TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-255-893-43

Query Match 0.2%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 457 GGGGCGAGAGTCTA 473
DB 18 GGGCGAAGAGTCTA 2

RESULT 144
US-08-311-760A-18
Sequence 18, Application US/08311760A
Patent No. 5599706

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEO Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:

FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-18

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 474 CCATGGTATGACA 488
DB 1 CCACGGUAAUGACA 15

RESULT 145
US-08-311-760A-19
Sequence 19, Application US/08311760A
Patent No. 5599706

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEO Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:

FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-19

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 282 TCCAGATGCTGTGGC 296
DB 1 UCCAGAUCCUGGCG 15

RESULT 146
US-08-311-760A-20
Sequence 20, Application US/08311760A
Patent No. 5599706

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF

```

; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITTING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-760A-20

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 1.2e+02;
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGCTCTTATTTGTTA 311
Db 1 AGCCCUAUGUUA 15

RESULT 147
US-08-311-760A-21
; Sequence 21, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITTING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:

```

```

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-760A-21

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 46.7%; Pred. No. 1.2e+02;
Matches 7; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 298 GCTCCTTATTTGTTAT 312
Db 1 GCCCUAUGUUAU 15

RESULT 148
US-08-311-760A-23
; Sequence 23, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITTING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard

```

REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-23

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 420 GGCTCTTCGACAA 434
DB 1 GGCTCTTCGACAA 15

RESULT 149
US-08-311-760A-24
Sequence 24, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-24

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 421 GCTCTTCGACAA 435
DB 1 GGCTCTTCGACAA 15

RESULT 150
US-08-311-760A-35
Sequence 35, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-35

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.2e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 525 AAGAACTGCGAAGC 539
DB 1 AAGAACTGCGAAGC 15

RESULT 151
US-08-311-760A-45
Sequence 45, Application US/08311760A

Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 45:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-45
Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 147 GAGTTATGAGGAC 161
Db 1 GAGTUAUGAGGAC 15
RESULT 152
US-08-311-760A-57
Sequence 57, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 57:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-57
Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 171 CACTGTACAGGAG 185
Db 1 CACUGUACAGGAG 15
RESULT 153
US-08-311-760A-60
Sequence 60, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5

;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/311,760A
;; FILING DATE: September 23, 1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER:
;; FILING DATE:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/155
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 60:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-311-760A-60

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 168 CACCACGTCACACG 182
Db 1 CACCACUACACACG 15

RESULT 154
US-08-311-760A-65
; Sequence 65, Application US/08311760A
; Patent No. 5599706

;; GENERAL INFORMATION:
;; APPLICANT: Stinchcomb, Dan T.
;; APPLICANT: McSwiggen, James
;; APPLICANT: Newton, Roger S.
;; APPLICANT: Ramharack, Randy
;; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
;; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
;; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
;; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
;; NUMBER OF SEQUENCES: 392
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; STREET: Suite 4700
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071

;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: FastSeq Version 1.5
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/311,760A
;; FILING DATE: September 23, 1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER:
;; FILING DATE:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/155
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440

;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 65:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-311-760A-65

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 548 CTATGACCCACACT 562
Db 1 CUATGATUCCACACU 15

RESULT 155
US-08-311-760A-73
; Sequence 73, Application US/08311760A
; Patent No. 5599706

;; GENERAL INFORMATION:
;; APPLICANT: Stinchcomb, Dan T.
;; APPLICANT: McSwiggen, James
;; APPLICANT: Newton, Roger S.
;; APPLICANT: Ramharack, Randy
;; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
;; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
;; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
;; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
;; NUMBER OF SEQUENCES: 392
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; STREET: Suite 4700
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071

;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: FastSeq Version 1.5
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/311,760A
;; FILING DATE: September 23, 1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER:
;; FILING DATE:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/155
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 73:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-311-760A-73

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 500 GCACATCTCCACCA 514
| | | | : | | | | |
Db 1 GCACATCTCCACCA 15

RESULT 156
US-08-311-760A-165
; Sequence 165, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 165:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-760A-165

Query Match 0.2%; Score 13.4; DB 1; length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 377 CTGCGGTGCGCCCTC 391
| : | | | : | | | | |
Db 1 CUGCCGUCGACCC 15

RESULT 157
US-08-311-760A-166
; Sequence 166, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.

; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 166:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-760A-166

Query Match 0.2%; Score 13.4; DB 1; length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 377 CTGCGGTGCGCCCTC 391
| : | | | : | | | | |
Db 1 CUGCCGUCGACCC 15

RESULT 158
US-08-311-760A-167
; Sequence 167, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California

COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 167:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-167

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 377 CCGCGTCGCGGCTC 391
DB 1 CCGCGGCGCACCCUC 15

RESULT 159
US-08-311-760A-177
Sequence 177, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:

FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 177:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-177

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 556 CCACACTCGCATGT 570
DB 1 CCACACUCUCAAGU 15

RESULT 160
US-08-311-760A-178
Sequence 178, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 178:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-178

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 556 CCACACCTCCGATAGT 570
|||||:|||||:
DB 1 CCACACCTCCCAUAGU 15

RESULT 161
US-08-311-760A-179
Sequence 179, Application US/08311760A

PATENT No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 179:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-179

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 417 AGAGGCTCCTCCGA 431
|||||:|||||:
DB 1 AGAGGCTCCUUCUGA 15

RESULT 162
US-08-311-760A-180
Sequence 180, Application US/08311760A

PATENT No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 180:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-180

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 417 AGAGGCTCCTCCGA 431
|||||:|||||:
DB 1 AGAGGCTCCUUCUGA 15

RESULT 163
US-08-311-760A-189
Sequence 189, Application US/08311760A

PATENT No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

```

/ TITLE OF INVENTION:
/ NUMBER OF SEQUENCES: 392
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 MB
/
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FASTSEQ Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/311,760A
/ FILING DATE: September 23, 1994
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/155
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 189:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
/ US-08-311-760A-189
/
Query Match          0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy      170 CCACTGTCACAGAA 184
Db      1 CCACUGUACAGAA 15
||||:|||||

RESULT 164
US-08-311-760A-190
/ Sequence 190, Application US/08311760A
/ Patent No. 5599706
/ GENERAL INFORMATION:
/ APPLICANT: Stinchcomb, Dan T.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Newton, Roger S.
/ APPLICANT: Ramharack, Randy
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
/ TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
/ TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
/ TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
/ NUMBER OF SEQUENCES: 392
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 MB
/
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FASTSEQ Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/311,760A
/ FILING DATE: September 23, 1994
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/155
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 190:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
/ US-08-311-760A-190
/
Query Match          0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy      170 CCACTGTCACAGAA 184
Db      1 CCACUGUACAGAA 15
||||:|||||

RESULT 165
US-08-311-760A-191
/ Sequence 191, Application US/08311760A
/ Patent No. 5599706
/ GENERAL INFORMATION:
/ APPLICANT: Stinchcomb, Dan T.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Newton, Roger S.
/ APPLICANT: Ramharack, Randy
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
/ TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
/ TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
/ TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
/ NUMBER OF SEQUENCES: 392
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 MB
/
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FASTSEQ Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/311,760A
/ FILING DATE: September 23, 1994
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/155
```

TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 191:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-191

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 170 CCACTGTCACAGAA 184
Db 1 CCACUGUACAGAA 15

RESULT 166
US-08-311-760A-192
Sequence 192, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 192:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-192

Query Match 0.2%; Score 13.4; DB 1; Length 15;

Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
Qy 170 CCACTGTCACAGAA 184
Db 1 CCACUGUACAGAA 15

RESULT 167
US-08-311-760A-193
Sequence 193, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 193:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-193

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 171 CACTGTCACAGAG 185
Db 1 CACUGUACAGAG 15

RESULT 168
US-08-311-760A-207
Sequence 207, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:

```

/ APPLICANT: Stinchcomb, Dan T.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Newton, Roger S.
/ APPLICANT: Ramharack, Randy
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
/ TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
/ TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
/ TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
/ NUMBER OF SEQUENCES: 392
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/311,760A
/ FILING DATE: September 23, 1994
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/155
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 207:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
/ US-08-311-760A-207
/
Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Oy 124 GATTGCTACCATGCT 138
Db 1 GACUGCUACCAUGGU 15

RESULT 169
US-08-311-760A-208
/ Sequence 208, Application US/08311760A
/ Patent No. 5599706
/ GENERAL INFORMATION:
/ APPLICANT: Stinchcomb, Dan T.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Newton, Roger S.
/ APPLICANT: Ramharack, Randy
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
/ TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
/ TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
/ TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
/ NUMBER OF SEQUENCES: 392
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
```

```

/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/311,760A
/ FILING DATE: September 23, 1994
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/155
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 208:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
/ US-08-311-760A-208
/
Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Oy 147 GAGTATCGAGGCAC 161
Db 1 GAGUUAUCGAGGCUC 15

RESULT 170
US-08-311-760A-213
/ Sequence 213, Application US/08311760A
/ Patent No. 5599706
/ GENERAL INFORMATION:
/ APPLICANT: Stinchcomb, Dan T.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Newton, Roger S.
/ APPLICANT: Ramharack, Randy
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
/ TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
/ TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
/ TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
/ NUMBER OF SEQUENCES: 392
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/311,760A
```



```

SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-214

Query Match          0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 1.2e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0

QY      199 TGCTCATCTATGACA 213
      :||:|:|:|:|:|
Db      1 UGCTCCTCUNAGACA 15

RESULT 172
US-08-311-760A-215
Sequence 215, Application US/08311760A
Patent No. 559706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [Lp(a)] BY
TITLE OF INVENTION: INHIBITING APOLOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESS: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 215:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-215

Query Match          0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0

QY      201 GTCTATATGACACC 215
      |:|:|:|:|:|:|

```

Db 1 GUCCUCUAGACACC 15

RESULT 173

US-08-311-760A-223

Sequence 223, Application US/08311760A

Patent No. 5599706

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Dan T.

APPLICANT: McSwigen, James

APPLICANT: Newton, Roger S.

APPLICANT: Ramharack, Randy

TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES

TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF

TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY

TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

NUMBER OF SEQUENCES: 392

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FASTSEQ Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/311,760A

FILING DATE: September 23, 1994

PRIOR APPLICATION DATA:

APPLICATION NUMBER:

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/155

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 223:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-311-760A-223

Query Match 0.2%; Score 13.4; DB 1; Length 15;

Best Local Similarity 73.3%; Pred. No. 1.2e+02;

Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 421 GCTCTCTCCGACAA 435

Db 1 GCCTCCTCCGACAA 15

RESULT 174

US-08-311-760A-228

Sequence 228, Application US/08311760A

Patent No. 5599706

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Dan T.

APPLICANT: McSwigen, James

APPLICANT: Newton, Roger S.

APPLICANT: Ramharack, Randy

TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES

TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF

TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY

TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

NUMBER OF SEQUENCES: 392

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FASTSEQ Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/311,760A

FILING DATE: September 23, 1994

PRIOR APPLICATION DATA:

APPLICATION NUMBER:

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/155

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 228:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-311-760A-228

TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF

TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY

TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

NUMBER OF SEQUENCES: 392

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FASTSEQ Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/311,760A

FILING DATE: September 23, 1994

PRIOR APPLICATION DATA:

APPLICATION NUMBER:

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/155

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 228:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-311-760A-228

Query Match 0.2%; Score 13.4; DB 1; Length 15;

Best Local Similarity 60.0%; Pred. No. 1.2e+02;

Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 199 TGTGATCTATGACA 213

Db 1 UGUCACUUGACAA 15

RESULT 175

US-08-311-760A-229

Sequence 229, Application US/08311760A

Patent No. 5599706

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Dan T.

APPLICANT: McSwigen, James

APPLICANT: Newton, Roger S.

APPLICANT: Ramharack, Randy

TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES

TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF

TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY

TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

NUMBER OF SEQUENCES: 392

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

```
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 229:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-229

Query Match      0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      201 GTCATCTATGACACC 215
DB      1 GUCACUUAUGAUAACC 15

RESULT 176
US-08-774-310-18
Sequence 18, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF INVENTION: 392
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
```

```
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-18

Query Match      0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      474 CCATGTAATGACA 488
DB      1 CCACGUAUGACA 15

RESULT 177
US-08-774-310-19
Sequence 19, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF INVENTION: 392
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 223/229
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
```

US-08-774-310-19

Query Match 0.2%; Score 13.4; DB 1; Length 15;

Best Local Similarity 66.7%; Pred. No. 1.2e+02;

Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 282 TCACAGTCTGTGTC 296

Db 1 UCCAGUCCUGGCGC 15

RESULT 178

US-08-774-310-20

; Sequence 20, Application US/08774310

; Patent No. 5877022

; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Daniel T.

; APPLICANT: McSwiggen, James

; APPLICANT: Newton, Roger S.

; APPLICANT: Ramharack, Randy

; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES

; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF

; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY

; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

; NUMBER OF SEQUENCES: 392

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; CITY: Suite 4700

; STATE: Los Angeles

; COUNTRY: U.S.A.

; ZIP: 90071

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: FastSeq Version 1.5

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/774,310

; FILING DATE: December 23, 1996

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/311,760

; FILING DATE: September 23, 1994

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 223/229

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 20:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; US-08-774-310-20

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 1.2e+02;
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGCTCCTATTGTAT 311

Db 1 AGCCCCUATUGUUA 15

RESULT 179
US-08-774-310-21

; Sequence 21, Application US/08774310

; Patent No. 5877022

; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Daniel T.

; APPLICANT: McSwiggen, James

; APPLICANT: Newton, Roger S.

; APPLICANT: Ramharack, Randy

; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES

; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF

; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY

; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

; NUMBER OF SEQUENCES: 392

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; CITY: Suite 4700

; STATE: Los Angeles

; COUNTRY: U.S.A.

; ZIP: 90071

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: FastSeq Version 1.5

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/774,310

; FILING DATE: December 23, 1996

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/311,760

; FILING DATE: September 23, 1994

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 223/229

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 21:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; US-08-774-310-21

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 46.7%; Pred. No. 1.2e+02;
Matches 7; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 298 GCTCCTATTGTAT 312

Db 1 GCCCCUATUGUUA 15

RESULT 180
US-08-774-310-23

; Sequence 23, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392

```

CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-23

Query Match          0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY      420 GGCTCTTCGACAA 434
Db      1 GGCTCTTCGACAA 15

RESULT 181
US-08-774-310-24
Sequence 24, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF INVENTION: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
```

```

SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-24

Query Match          0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY      421 GCTCTTCGACAA 435
Db      1 GGCTCTTCGACAA 15

RESULT 182
US-08-774-310-35
Sequence 35, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF INVENTION: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
```

TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-35

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.2e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 525 AAGAACCTGCACAGC 539
Db 1 AAGAACUUGCAAGC 15

RESULT 183
US-08-774-310-45
Sequence 45, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 45:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-45

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 147 GAGTATGACGAGC 161
Db 1 GAGUUAUGAGGCTC 15

RESULT 184
US-08-774-310-57
Sequence 57, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 57:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-57

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 171 CACTGTACAGAGAG 185
Db 1 CACUGUACAGAGAG 15

RESULT 185
US-08-774-310-60
Sequence 60, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James

APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 60:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-60
Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 168 CACCAGTGTACAGG 182
DB 1 CACCACUUCACAGG 15
RESULT 186
US-08-774-310-65
Sequence 65, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles

STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-65
Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 75.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 548 CTATGACCCACACT 562
DB 1 CUAUGAUCACACACU 15
RESULT 187
US-08-774-310-73
Sequence 73, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SRO ID NO: 73
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-73

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 500 GCACATCTCCACCA 514
Db 1 GCACATCTCCACCA 15

RESULT 188
US-08-774-310-165
Sequence 165, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SRO ID NO: 165
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-165

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 377 CTGCCGTCGCGCCCTC 391
Db 1 CTGCCGTCGCGCCCTC 15

RESULT 189
US-08-774-310-166
Sequence 166, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SRO ID NO: 166
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-166

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 377 CTGCCGTCGCGCCCTC 391
Db 1 CTGCCGTCGCGCCCTC 15


```
RESULT 190
US-08-774-310-167
; Sequence 167, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELETYPE: 67-3510
; INFORMATION FOR SEQ ID NO: 167:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-774-310-167

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 377 CTGCGCTGCGCCCTC 391
Db 1 CUGCGGUGCGACCCUC 15

RESULT 191
US-08-774-310-177
; Sequence 177, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
```

```
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; TITLE OF INVENTION:
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELETYPE: 67-3510
; INFORMATION FOR SEQ ID NO: 177:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-774-310-177

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 556 CCACACTGCGATAGT 570
Db 1 CCACACUCUCUAGU 15

RESULT 192
US-08-774-310-178
; Sequence 178, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
```

```

MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 178:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-176

Query Match
Best Local Similarity 0.2%; Score 13.4; DB 1; Length 15;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 556 CCACACTCGCATAGT 570
Db 1 CCACACUCCUAGU 15

RESULT 193
US-08-774-310-179
Sequence 179, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
```

```

REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 179:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-179

Query Match
Best Local Similarity 0.2%; Score 13.4; DB 1; Length 15;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 417 AGAGGCTCTCCGA 431
Db 1 AGAGGCTCTCCGA 15

RESULT 194
US-08-774-310-180
Sequence 180, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 180:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-180
```

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY 417 AGAGGCTCTTCCGA 431
|||||:|||||
Db 1 AGAGCUCUCUUGA 15

RESULT 195
US-08-774-310-189
; Sequence 189, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramnarack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 189:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-310-189

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 170 CCACTGTCACAGAA 184
|||||:|||||
Db 1 CCACUGUACAGAA 15

RESULT 196
US-08-774-310-190
; Sequence 190, Application US/08774310
; Patent No. 5877022

; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramnarack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 190:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-310-190

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 170 CCACTGTCACAGAA 184
|||||:|||||
Db 1 CCACUGUACAGAA 15

RESULT 197
US-08-774-310-191
; Sequence 191, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramnarack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon

INFORMATION FOR SEQ ID NO: 193:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-193

Query Match 0.2% Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 171 CACTGTCAAGAG 185
Db 1 CACGUAACAGAG 15

RESULT 200
US-08-774-310-207
Sequence 207, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF INVENTION:
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Wardburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 207:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-207

Query Match 0.2% Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
OY 124 GATTGTACATGCT 138

Db 1 CACGUAACAGAG 15

RESULT 201
US-08-774-310-208
Sequence 208, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF INVENTION:
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Wardburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 208:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-208

Query Match 0.2% Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY 147 GAGTTATCGAGCAGC 161
Db 1 CAGTUAACAGAGC 15

RESULT 202
US-08-774-310-213
Sequence 213, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy

```

; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 213:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-310-213

Query Match          0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 1.2e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy      199 TGTCATCTATGACA 213
Db      1 UGUCUCCUAGACA 15

RESULT 203
US-08-774-310-214
; Sequence 214, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
```

```

; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 214:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-310-214

Query Match          0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 1.2e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy      199 TGTCATCTATGACA 213
Db      1 UGUCUCCUAGACA 15

RESULT 204
US-08-774-310-215
; Sequence 215, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
```

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 215:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-215

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 201 GTCATCATGACACC 215
DB 1 GUCCUUAUGACACC 15

RESULT 205
US-08-774-310-223
Sequence 223, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 223:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

TOPOLOGY: linear
US-08-774-310-223

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 421 GTCCTTCGACAA 435
DB 1 GUCCUUAUGACAA 15

RESULT 206
US-08-774-310-228
Sequence 228, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 228:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-228

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 1.2e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 199 TGTCATCATGACA 213
DB 1 UGUCUUAUGACA 15

RESULT 207

```
US-08-774-310-229
; Sequence 229, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [Lp(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-9510
; INFORMATION FOR SEQ ID NO: 229:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-774-310-229

Query Match          0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy      201 GTGCTATGACACC 215
Db      1 GUCACUAGUADUACC 15

RESULT 208
US-09-486-453-1
; Sequence 1, Application US/09486453
; Patent No. 6435071
; GENERAL INFORMATION:
; APPLICANT: Shephard, Mikhail Sergeevich
; APPLICANT: Southern, Edwin Mellor
; TITLE OF INVENTION: Branched Dendrimeric Structures
; FILE REFERENCE: GFE-38
; CURRENT APPLICATION NUMBER: US/09/486,453
; PRIOR FILING DATE: 2000-02-25
; PRIOR APPLICATION NUMBER: GB 9718129.1
; PRIOR FILING DATE: 1997-08-27
; NUMBER OF SEQ ID NOS: 1
```

```
; SEQ ID NO 1
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
US-09-486-453-1

Query Match          0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      66 TCTTCTACTCTTT 80
Db      1 TCTTCTTCTCTTT 15

RESULT 209
US-09-446-301A-34/c
; Sequence 34, Application US/09446301A
; Patent No. 6506893
; GENERAL INFORMATION:
; APPLICANT: EL SOLH, NEVINE
; APPLICANT: ALLIGNET, JEANINE
; TITLE OF INVENTION: POLYNUCLEOTIDES AND THEIR USE FOR DETECTING RESISTANCE
; TITLE OF INVENTION: TO STREPTOGRAMIN A OR TO STREPTOGRAMIN B AND RELATED
; FILE REFERENCE: 03715-0059
; CURRENT APPLICATION NUMBER: US/09/446,301A
; CURRENT FILING DATE: 1999-12-20
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 34
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-446-301A-34

Query Match          0.2%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      61 GTGTTCTTCTACTT 75
Db      16 GTGTTCTTCTACTT 2

RESULT 210
US-09-099-932-39/c
; Sequence 39, Application US/09099932
; Patent No. 6570001
; GENERAL INFORMATION:
; APPLICANT: EL SOLH, NEVINE
; APPLICANT: ALLIGNET, JEANINE
; TITLE OF INVENTION: POLYNUCLEOTIDES AND THEIR USE FOR DETECTING RESISTANCE
; TITLE OF INVENTION: TO STREPTOGRAMIN A OR TO STREPTOGRAMIN B AND RELATED
; FILE REFERENCE: 03495-0173-00000
; CURRENT APPLICATION NUMBER: US/09/099,932
; CURRENT FILING DATE: 1998-06-19
; EARLIER APPLICATION NUMBER: 60/050,380
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 39
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-099-932-39
```


Query Match 0.2% Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 61 GTGGTTCTTCTACTT 75
|||||
Db 16 GTGGTTCTTCTACTT 2

RESULT 211
US-09-564-805-55/c
; Sequence 55, Application US/09564805
; Patent No. 6333403
; GENERAL INFORMATION:
; APPLICANT: Taviglian, Sean V.
; APPLICANT: Teng, David H.F.
; APPLICANT: Simard, Jacques
; APPLICANT: Rommens, Johanna M.
; APPLICANT: Myriad Genetics, Inc.
; TITLE OF INVENTION: Chromosome 17p-Linked Prostate Cancer Susceptibility
; TITLE OF INVENTION: Gene and a Paralog and Orthologous Genes
; FILE REFERENCE: 2318-258
; CURRENT APPLICATION NUMBER: US/09/564,805
; PRIOR FILING DATE: 2000-05-05
; PRIOR APPLICATION NUMBER: US 60/107,468
; PRIOR FILING DATE: 1998-11-06
; PRIOR APPLICATION NUMBER: 09/434,382
; PRIOR FILING DATE: 1999-11-05
; NUMBER OF SEQ ID NOS: 240
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 55
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-564-805-55

Query Match 0.2% Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 17 CTTTCTGCACACTGC 31
|||||
Db 15 CTTTCTGCACACTGC 1

RESULT 212
US-09-657-931A-4
; Sequence 4, Application US/09657931A
; Patent No. 6586197
; GENERAL INFORMATION:
; APPLICANT: ADANG, MICHAEL J
; APPLICANT: LUD, KE
; TITLE OF INVENTION: METHODS AND MATERIALS FOR IDENTIFYING NOVEL PESTICIDE AGENTS
; FILE REFERENCE: UGR-101X
; CURRENT APPLICATION NUMBER: US/09/657,931A
; CURRENT FILING DATE: 2000-09-07
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Manduca sexta
US-09-657-931A-4

Query Match 0.2% Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 470 GCTACCATGTATG 484
|||||
Db 3 GCTACCATGTATG 17

RESULT 213
US-09-227-701-6
; Sequence 6, Application US/09227701
; Patent No. 6512161
; GENERAL INFORMATION:
; APPLICANT: Rouy, Didier
; APPLICANT: Duverger, Nicolas
; APPLICANT: Emmanuel, Florence
; APPLICANT: Deneffe, Patrice
; APPLICANT: Houdebine, Louis-Marie
; APPLICANT: Viglietta, Celine
; APPLICANT: Rubin, Edward M.
; APPLICANT: Hughes, Steven D.
; TITLE OF INVENTION: TRANSGENIC RABBIT THAT EXPRESSES A FUNCTIONAL HUMAN
; TITLE OF INVENTION: LIPOPROTEIN(A)
; FILE REFERENCE: 22841A USA
; CURRENT APPLICATION NUMBER: US/09/227,701
; CURRENT FILING DATE: 1999-01-08
; EARLIER APPLICATION NUMBER: 60/070727
; EARLIER FILING DATE: 1998-01-08
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-227-701-6

Query Match 0.2% Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 338 AGTACTGCACCTGACGC 355
|||||
Db 1 AGTACTGCACCTGACGC 18

RESULT 214
US-08-311-760A-64
; Sequence 64, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramnarack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version, 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 64:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-64

Query Match 0.2%; Score 13; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.4e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 402 CCCGTTCCAGC 414
Db 1 CCCGTTCCAGC 13

RESULT 215
US-08-311-760A-216
Sequence 216, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 216:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

TOPOLOGY: linear
US-08-311-760A-216

Query Match 0.2%; Score 13; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.4e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 579 AGAATATCTACCA 591
Db 3 AGAATATCTACCA 15

RESULT 216
US-08-311-760A-217
Sequence 217, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 217:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-217

Query Match 0.2%; Score 13; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.4e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 579 AGAATATCTACCA 591
Db 3 AGAATATCTACCA 15

RESULT 217

```
US-08-738-944-17
; Sequence 17, Application US/08738944
; Patent No. 5783431
; GENERAL INFORMATION:
; APPLICANT: Peterson, et al.
; TITLE OF INVENTION: METHODS FOR GENERATING AND
; SCREENING NOVEL METABOLIC PATHWAYS
; NUMBER OF SEQUENCES: 51
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036/2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/738, 944
; FILING DATE: 24-OCT-1996
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/639,255
; FILING DATE: 24-APR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 8757-007
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-790-9090
; TELEFAX: 212-869-8864
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: Terminator
; LOCATION: 1...15
; OTHER INFORMATION:
; NAME/KEY: Other
; LOCATION: 5...6
; OTHER INFORMATION: Terminator site
; NAME/KEY: Other
; LOCATION: 1
; OTHER INFORMATION: Phosphate at nucleotide 1
; US-08-738-944-17

Query Match          0.2%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      314 CGAGGATCCCGC 326
      |||||
Db      2 CGAGGATCCCGC 14
```

```
RESULT 218
US-08-774-310-64
; Sequence 64, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramnarack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
```

```
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 64:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-310-64

Query Match          0.2%; Score 13; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.4e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      402 CCCGTTCCAGC 414
      |||||
Db      1 CCCGATCCAGC 13
```

```
RESULT 219
US-08-774-310-216
; Sequence 216, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramnarack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
```

```

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 216:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-774-310-216

Query Match      0.2% Score 13; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.4e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      579 AGAATACCTACCCA 591
Db      3 AGAATACCTACCCA 15

RESULT 220
US-08-774-310-217
; Sequence 217, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramnarack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:

```

```

; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 217:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-774-310-217

Query Match      0.2% Score 13; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.4e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      579 AGAATACCTACCCA 591
Db      3 AGAATACCTACCCA 15

RESULT 221
US-09-263-352-14
; Sequence 14, Application US/09263352
; Patent No. 6242211
; GENERAL INFORMATION:
; APPLICANT: Peterson, T.
; APPLICANT: Brian, P.
; TITLE OF INVENTION: METHODS FOR GENERATING AND SCREENING NOVEL METABOLIC
; FILE REFERENCE: 8757-010
; CURRENT APPLICATION NUMBER: US/09/263,352
; CURRENT FILING DATE: 1999-03-05
; EARLIER APPLICATION NUMBER: 08/986,186
; EARLIER FILING DATE: 1997-12-05
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 14
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: linker
;
US-09-263-352-14

Query Match      0.2% Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      314 CGAGGATCCCGG 326
Db      2 CGAGGATCCCGG 14

RESULT 222
US-08-311-760A-342
; Sequence 342, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramnarack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:

```

```

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELE: 67-3510
; INFORMATION FOR SEQ ID NO: 342:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-760A-342

Query Match 0.2%; Score 12.8; DB 1; Length 16;
Best Local Similarity 68.8%; Pred. No. 1.7e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 270 CTACTCGAGGATCCA 285
Db 1 GCACGCGGAAUCCA 16

RESULT 223
; US-08-311-760A-345
; Sequence 345, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELE: 67-3510
; INFORMATION FOR SEQ ID NO: 345:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-760A-345

Query Match 0.2%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 436 GCACGACTGAGCAA 451
Db 1 GCACGACUGAGGAAA 16

RESULT 224
; US-08-311-760A-379
; Sequence 379, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELE: 67-3510
; INFORMATION FOR SEQ ID NO: 345:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-760A-345
```

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELE: 67-3510
; INFORMATION FOR SEQ ID NO: 345:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-760A-345

Query Match 0.2%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 436 GCACGACTGAGCAA 451
Db 1 GCACGACUGAGGAAA 16

RESULT 224
; US-08-311-760A-379
; Sequence 379, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELE: 67-3510
; INFORMATION FOR SEQ ID NO: 345:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-760A-345
```

TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 379:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 16 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-311-760A-379

Query Match 0.2%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 68.8%; Pred. No. 1.7e+02;
 Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

OY 377 CTGCGTCGCGCCCTCC 392
 DB 1 CUCGACGCGCACCCUCC 16

RESULT 225

US-08-311-760A-384
 Sequence 384, Application US/08311760A
 Patent No. 5599706

GENERAL INFORMATION:
 APPLICANT: Stinchcomb, Dan T.
 APPLICANT: McSwigen, James
 APPLICANT: Newton, Roger S.
 APPLICANT: Ramharack, Randy
 TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
 TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
 TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
 TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
 NUMBER OF SEQUENCES: 392
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Lyon & Lyon
 STREET: 633 West Fifth Street
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: FastSeq Version 1.5
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/311,760A
 FILING DATE: September 23, 1994
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER:
 FILING DATE:

ATTORNEY/AGENT INFORMATION:
 NAME: Warburg, Richard
 REGISTRATION NUMBER: 32,327
 REFERENCE/DOCKET NUMBER: 208/155
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 384:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 16 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-311-760A-384

Query Match 0.2%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 68.8%; Pred. No. 1.7e+02;
 Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

OY 270 CTACTGCGAGAAATCCA 285
 DB 1 CUACUGCCGAAAUCCA 16

RESULT 226

US-08-774-310-342
 Sequence 342, Application US/08774310
 Patent No. 5877022

GENERAL INFORMATION:
 APPLICANT: Stinchcomb, Daniel T.
 APPLICANT: McSwigen, James
 APPLICANT: Newton, Roger S.
 APPLICANT: Ramharack, Randy
 TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
 TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
 TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
 TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
 NUMBER OF SEQUENCES: 392
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Lyon & Lyon
 STREET: 633 West Fifth Street
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: FastSeq Version 1.5
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/774,310
 FILING DATE: December 23, 1996
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER:
 FILING DATE: September 08/311,760

ATTORNEY/AGENT INFORMATION:
 NAME: Warburg, Richard
 REGISTRATION NUMBER: 32,327
 REFERENCE/DOCKET NUMBER: 223/229
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 342:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 16 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-774-310-342

Query Match 0.2%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 68.8%; Pred. No. 1.7e+02;
 Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

OY 270 CTACTGCGAGAAATCCA 285
 DB 1 CUACUGCCGAAAUCCA 16

RESULT 227

US-08-774-310-345
 Sequence 345, Application US/08774310
 Patent No. 5877022

GENERAL INFORMATION:
 APPLICANT: Stinchcomb, Daniel T.
 APPLICANT: McSwigen, James
 APPLICANT: Newton, Roger S.

APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Filth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Waiburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 345:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-345

Query Match 0.2%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 436 GCACGACTGAGCAA 451
Db 1 GCACGACGACGAGAA 16

RESULT 228
US-08-774-310-379
Sequence 379, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Filth Street
CITY: Los Angeles
STATE: California

COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Waiburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 379:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-379

Query Match 0.2%; Score 12.8; DB 1; Length 16;
Best Local Similarity 68.8%; Pred. No. 1.7e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 377 CTGCGTCGCGCCTCC 392
Db 1 CUGCAGUCGACCCUCC 16

RESULT 229
US-08-774-310-384
Sequence 384, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Filth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760

FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 384:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-384

Query Match 0.2%; Score 12.8; DB 1; Length 16;
Best Local Similarity 68.8%; Pred. No. 1.7e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 270 CTACTGAGAAATCA 285
Db 1 CUACUGCCGAATCCA 16

RESULT 230
US-08-390-850-634
Sequence 634, Application US/08390850
Patent No. 5612215
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5612215ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 634:
SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-634

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 31.2%; Pred. No. 1.9e+02;
Matches 5; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

QY 63 GGTCTCTACTCTT 78
Db 2 GGUUUUCUUAUUUU 17

RESULT 231
US-08-435-634-634
Sequence 634, Application US/08435634
Patent No. 5731295
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 634:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-634

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 31.2%; Pred. No. 1.9e+02;

Matches 5; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

Qy 63 GGTCTTCTACTCTT 78
|:::|:::|:::|
Db 2 GGUUUUCUUAUUUCU 17

RESULT 232
US-08-856-141-1
; Sequence 1, Application US/08856141
; Patent No. 5948616
; GENERAL INFORMATION:
; APPLICANT: CHAO, LEE
; APPLICANT: CHAO, JULIE
; TITLE OF INVENTION: METHODS AND COMPOSITIONS OF
; TITLE OF INVENTION: CORRELATING TISSUE KALLIKREIN GENE PROMOTER POLYMORPHISMS WITH
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NEEDLE & ROSENBERG, P. C.
; STREET: Suite 1200, 127 Peachtree Street, NE
; CITY: Atlanta
; STATE: GA
; COUNTRY: USA
; ZIP: 30303
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; APPLICATION NUMBER: US/08/856,141
; FILING DATE: 14-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Miller, Mary L
; REGISTRATION NUMBER: 39,303
; REFERENCE/DOCKET NUMBER: 19070.0045
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 404/688-0770
; TELEFAX: 404/688-9880
; TELEX:
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-856-141-1

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 273 CTCGAGAAATCCAGT 288
|:::|:::|:::|
Db 1 CTCGAGAAATCTAGT 16

RESULT 233
US-09-290-449-8/c
; Sequence 8, Application US/09290449A
; Patent No. 6096505
; GENERAL INFORMATION:
; APPLICANT: SELBY, Mark
; APPLICANT: THUDUM, Kent
; APPLICANT: DINI, Dino
; TITLE OF INVENTION: NONCLONING TECHNIQUE FOR EXPRESSING A GENE OF INTEREST
; FILE REFERENCE: 1448.002
; CURRENT APPLICATION NUMBER: US/09/290,449A

CURRENT FILING DATE: 1999-04-13
; EARLIER APPLICATION NUMBER: US 60/081,777
; EARLIER FILING DATE: 1998-04-14
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 8
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: CMPV-pres2
; US-09-290-449-8

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 318 GGATCCCGGTGTGAG 333
|:::|:::|:::|
Db 17 GGATCCAGATCTAG 2

RESULT 234
US-08-584-040-2545
; Sequence 2545, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2545:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

RESULT 238
US-09-371-772B-1070
; Sequence 1070, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggan, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1070
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1070

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 18.8%; Pred. No. 1.9e+02;
Matches 3; Conservative 11; Mismatches 2; Indels 0; Gaps 0;

QY 69 TCTACTCTCTTTATTT 84
Db 1 UCDAUUUUUUUUUUU 16

RESULT 239
US-09-371-772B-6597/C
; Sequence 6597, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggan, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6597
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6597

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 52 CATAGAGAGTGGTTC 67
Db 17 CATAGGAGAGTGGTTC 2

RESULT 240

US-09-866-108A-1158
; Sequence 1158, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1158
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1158

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 569 GTGGAGCCGAGATA 584
Db 2 GACGGTCCGAGATA 17

RESULT 241
US-09-866-108A-1159
; Sequence 1159, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6

```

; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2452
; TYPE: DNA
; LENGTH: 17
; ORGANISM: Homo sapiens
US-09-866-108A-1159

Query Match
Best Local Similarity 0.2%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 569 GTCGACCCGAGAT 584
DB 1 GACGGTCCCGAGATA 16

RESULT 242
US-09-866-108A-2452
; Sequence 2452, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2455
; TYPE: DNA
; LENGTH: 17
; ORGANISM: Homo sapiens
US-09-866-108A-2455
```

```

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2452
; TYPE: DNA
; LENGTH: 17
; ORGANISM: Homo sapiens
US-09-866-108A-2452

Query Match
Best Local Similarity 0.2%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 246 CCCAATGCTGGCTG 261
DB 2 CCCAGATGCTGGCTG 17

RESULT 243
US-09-866-108A-2455
; Sequence 2455, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2455
; TYPE: DNA
; LENGTH: 17
; ORGANISM: Homo sapiens
US-09-866-108A-2455

Query Match
Best Local Similarity 0.2%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 248 CAATGCTGGCTGAT 263
DB 1 CAGATGCTGGCTGAT 16
```

```
RESULT 244
US-09-866-108A-7528
; Sequence 7528, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AROMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7528
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7528

Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      445 GAGCAAGCCTGGGG 460
Db      2 GAGCAAAAGCTTGGGG 17

RESULT 245
US-09-866-108A-7529
; Sequence 7529, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AROMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
```

```
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30

RESULT 246
US-09-866-108A-7676/C
; Sequence 7676, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AROMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30

Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      445 GAGCAAGCCTGGGG 460
Db      1 GAGCAAAAGCTTGGGG 16
```

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 7676

LENGTH: 17
TYPE: DNA

ORGANISM: Homo sapiens
US-09-866-108A-7676

Query Match
Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
Pred. No. 1.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 65 TTCTTCTACTCTTTT 80
|||||
Db 17 TTCTTCTGCTTCTTCT 2

RESULT 247

US-09-866-108A-7677/C

Sequence 7677, Application US/09866108A

Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharon G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AECOMICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263,6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aecomica Sequence Listing Engine

Patent No. 6686188

SEQ ID NO 7677

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-7677

Query Match
Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
Pred. No. 1.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 65 TTCTTCTACTCTTTT 80
|||||
Db 16 TTCTTCTGCTTCTTCT 1

RESULT 248

US-09-866-108A-7772

Sequence 7772, Application US/09866108A

Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharon G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AECOMICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263,6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aecomica Sequence Listing Engine

Patent No. 6686188

SEQ ID NO 7772

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-7772

Query Match
Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
Pred. No. 1.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 323 CCGGTGTCAGTGGA 338
|||||
Db 2 CCGGTGTCAGTGGA 17

RESULT 249

US-09-866-108A-7774

Sequence 7774, Application US/09866108A

Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharon G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AECOMICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

```
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aeomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 7774
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-7774
```

```
Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      324 CGGTGTCAGTGGAG 339
Db      1 CAGGTCTCGGTGGAG 16
```

```
RESULT 250
US-09-866-108A-8423
;; Sequence 8423, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE.
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108A
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
```

```
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aeomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 8423
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-8423
```

```
Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      363 AGACGAGAGGAGT 378
Db      2 AGACGAGAGGAGTCT 17
```

```
RESULT 251
US-09-866-108A-8424
;; Sequence 8424, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108A
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aeomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 8424
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-8424
```

```
Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      363 AGACGAGAGGAGT 378
Db      1 AGACGAGAGGAGTCT 16
```

```
RESULT 252
US-09-866-108A-8692
; Sequence 8692, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8692
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8692

Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      264 CATGAACACTGCGAG 279
Db      2 CAAGAACACTGCGAG 17

RESULT 253
US-09-866-108A-8693
; Sequence 8693, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
```

```

; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8693
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8693

Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      264 CATGAACACTGCGAG 279
Db      1 CAAGAACACTGCGAG 16

RESULT 254
US-09-866-108A-10113/c
; Sequence 10113, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
```


QY 273 CTCGAGGATCCAGAT 288
Db 1 CTCGAGGATCTAGT 16

RESULT 258

US-08-267-803B-14
Sequence 14, Application US/08267803B
Patent No. 5834183
GENERAL INFORMATION:
APPLICANT: Orr, Harry T.
APPLICANT: Rannum, Laura P.W.
APPLICANT: Chung, Ming-Yi
APPLICANT: Zoghbi, Huda Y.
TITLE OF INVENTION: Gene Sequence for SpinoCerebellar Ataxia
Patent No. 5834183
TITLE OF INVENTION: Type 1 and Method for Diagnosis
NUMBER OF SEQUENCES: 85
CORRESPONDENCE ADDRESS:
ADDRESSEE: Mueling, Raasch, Gebhardt & Schwappach, P.A.
STREET: P.O. Box 581415
CITY: Minneapolis
STATE: MN
COUNTRY: USA
ZIP: 55458-1415
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/267,803B
FILING DATE: 28-JUN-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: McCormack, Myra H.
REGISTRATION NUMBER: 36,602
REFERENCE/DOCKET NUMBER: 110,00030120
TELECOMMUNICATION INFORMATION:
TELEPHONE: 612-305-1217
TELEFAX: 612-305-1228
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-267-803B-14

Query Match 0.2%; Score 12.4; DB 1; Length 14;

Best Local Similarity 92.9%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 327 TGTGAGGTGGAGT 340
Db 1 TGTGAGGTGGAGT 14

RESULT 259

US-08-311-760A-56
Sequence 56, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

NUMBER OF SEQUENCES: 392

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSeq Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/311,760A

FILING DATE: September 23, 1994

PRIOR APPLICATION DATA:

APPLICATION NUMBER:

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/155

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 56:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-311-760A-56

Query Match 0.2%; Score 12.4; DB 1; Length 15;

Best Local Similarity 71.4%; Pred. No. 1.7e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 503 CACTCTCCACCACT 516
Db 2 CACTCTCCACCACT 15

RESULT 260

US-08-311-760A-197
Sequence 197, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM compatible

```

; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 197:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-760A-197

Query Match          0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      239 AAAACTACCCAAAT 252
Db      2   AAAACUACCCAAU 15

RESULT 261
US-08-311-760A-210
; Sequence 210, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:

```

```

; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 210:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-760A-210

Query Match          0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 1.7e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      503 CATACTCCACCAC 516
Db      2   CAUUCUCCACCACU 15

RESULT 262
US-08-311-760A-212
; Sequence 212, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 212:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-760A-212

Query Match          0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 50.0%; Pred. No. 1.7e+02;

```



```
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 56:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-56

Query Match      0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 1.7e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      503 CATCTCCACCACCT 516
Db      2 CAUUCUCCACCACU 15

RESULT 266
US-08-774-310-197
Sequence 197, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
```

```
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 197:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-197

Query Match      0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      239 AAACCTACCAAT 252
Db      2 AAACGUAUCCAAU 15

RESULT 267
US-08-774-310-210
Sequence 210, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 210:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
```

US-08-774-310-210

Query Match 0.2%; Score 12.4; DB 1; Length 15;

Best Local Similarity 71.4%; Pred. No. 1.7e+02;

Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 503 CACTCCACCACT 516

DB 2 CAUUCUCCACACU 15

RESULT 268

US-08-774-310-212

Sequence 212, Application US/08774310

Patent No. 5877022

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Daniel T.

APPLICANT: McSwigen, James

APPLICANT: Ramharack, Randy S.

TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES

TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF

TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY

TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

NUMBER OF SEQUENCES: 392

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 MB

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSeq Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/774,310

FILING DATE: December 23, 1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/311,760

FILING DATE: September 23, 1994

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 223/229

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 212:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-774-310-212

Query Match 0.2%; Score 12.4; DB 1; Length 15;

Best Local Similarity 50.0%; Pred. No. 1.7e+02;

Matches 7; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 197 CTGCGATCATATG 210

DB 2 CUUGGUCUCUANG 15

RESULT 269

US-08-774-310-234

Sequence 234, Application US/08774310

Patent No. 5877022

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Daniel T.

APPLICANT: McSwigen, James

APPLICANT: Newton, Roger S.

APPLICANT: Ramharack, Randy

TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES

TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF

TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY

TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

NUMBER OF SEQUENCES: 392

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 MB

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSeq Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/774,310

FILING DATE: December 23, 1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/311,760

FILING DATE: September 23, 1994

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 223/229

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 234:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-774-310-234

Query Match 0.2%; Score 12.4; DB 1; Length 15;

Best Local Similarity 64.3%; Pred. No. 1.7e+02;

Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 193 CAAGCTTGTCATC 206

DB 2 CAUUCUGUCUAC 15

RESULT 270

US-08-981-462-66/C

Sequence 66, Application US/08981462

Patent No. 6054275

GENERAL INFORMATION:

APPLICANT: Morgan, Una

APPLICANT: Thompson, Richard C.A.

TITLE OF INVENTION: NOVEL DETECTION METHODS FOR

TITLE OF INVENTION: CRYPTOSPORIDIUM

NUMBER OF SEQUENCES: 68

CORRESPONDENCE ADDRESS:

ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun

STREET: 233 South Wacker Drive/6300 Sears Tower

CITY: Chicago

STATE: Illinois

```

; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/981,462
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/AU96/00387
; FILING DATE: 25-JUN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Cavley, Jr., Thomas A.
; REGISTRATION NUMBER: 40,944
; REFERENCE/DOCKET NUMBER: 28594/34423
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-981-462-66

Query Match          0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      65 TTCTTCTACTTCTT 78
Db      15 TTCTTCTTCTCTT 2

RESULT 271
US-08-956-182-32
; Sequence 32, Application US/08956182
; Patent No. 6100450
; GENERAL INFORMATION:
; APPLICANT: Thomas, Terry L.
; TITLE OF INVENTION: NOVEL SEED SPECIFIC PROMOTERS BASED ON
; TITLE OF INVENTION: ARABIDOPSIS GENES
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/956,182
; FILING DATE:
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 10701
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 32:
```

```

; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-956-182-32

Query Match          0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      520 ACAGAGAGAACTTG 533
Db      1 ACAGAGAGAACTTG 14

RESULT 272
US-09-197-649-6/c
; Sequence 6, Application US/09197649
; Patent No. 6194550
; GENERAL INFORMATION:
; APPLICANT: Gold, Larry
; APPLICANT: Tueck, Craig
; APPLICANT: Pribnow, David
; APPLICANT: Smith, Jonathan D.
; TITLE OF INVENTION: Systematic Polypeptide Evolution by Reverse Translation
; FILE REFERENCE: NEX02/CI-COR
; CURRENT APPLICATION NUMBER: US/09/197,649
; CURRENT FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: 07/829,461
; EARLIER FILING DATE: 1992-01-31
; EARLIER APPLICATION NUMBER: 07/739,055
; EARLIER FILING DATE: 1991-08-01
; EARLIER APPLICATION NUMBER: 07/561,968
; EARLIER FILING DATE: 1990-08-02
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 6
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Fragment
; OTHER INFORMATION: complementary to 3' fixed fragment of SEQ ID NO 5.
; US-09-197-649-6

Query Match          0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      467 AGTGCTACCATGCT 480
Db      14 AGTGCTGCATGCT 1

RESULT 273
US-09-081-646-247
; Sequence 247, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152ma1 and
; FILE REFERENCE: 01107,74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
```

```

; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 247
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-247

Query Match
Best Local Similarity 92.9%; Score 12.4; DB 1; Length 15;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 133 CATGCGTGGAGCA 146
Db 1 CATGCGTGGAGCA 14

RESULT 274
US-09-081-646-765
; Sequence 765, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; EARLIER FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 765
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-765

Query Match
Best Local Similarity 92.9%; Score 12.4; DB 1; Length 15;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 133 CATGCGTGGAGCA 146
Db 1 CATGCGTGGAGCA 14

RESULT 275
US-09-544-934B-98/C
; Sequence 98, Application US/09544934B
; Patent No. 6753421
; GENERAL INFORMATION:
; APPLICANT: Henrik Stender
; Kaare Lund
; Tina Anderson Hollerup
; TITLE OF INVENTION: No. 6753421el Process For The Detection of Mycobacteria
; NUMBER OF SEQUENCES: 123
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FINNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER
; STREET: 1300 I ST. NW
; CITY: Washington
; STATE: District of Columbia
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk 3.5 inch
; OPERATING SYSTEM: ASCII
; SOFTWARE: Microsoft Word
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/544,934B
```

```

; FILING DATE: 07-Apr-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/028,392
; FILING DATE: 15-Oct-96
; APPLICATION NUMBER: 60/029,595
; FILING DATE: 23-Oct-96
; APPLICATION NUMBER: 60/045,962
; FILING DATE: 08-May-97
; APPLICATION NUMBER: 08/943,777
; FILING DATE: 3-Oct-97
; ATTORNEY/AGENT INFORMATION:
; NAME: Anthony C. Tridico
; REGISTRATION NUMBER: 45,958
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4173
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 98:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 basepairs
; TYPE: nucleic acid basepairs
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 98:
US-09-544-934B-98

Query Match
Best Local Similarity 92.9%; Score 12.4; DB 1; Length 15;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 182 GAAGAGCCTGCCA 195
Db 14 GAAGAGCCTGCCA 1

RESULT 276
US-09-544-934B-99/C
; Sequence 99, Application US/09544934B
; Patent No. 6753421
; GENERAL INFORMATION:
; APPLICANT: Henrik Stender
; Kaare Lund
; Tina Anderson Hollerup
; TITLE OF INVENTION: No. 6753421el Process For The Detection of Mycobacteria
; NUMBER OF SEQUENCES: 123
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FINNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER
; STREET: 1300 I ST. NW
; CITY: Washington
; STATE: District of Columbia
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk 3.5 inch
; OPERATING SYSTEM: ASCII
; SOFTWARE: Microsoft Word
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/544,934B
; FILING DATE: 07-Apr-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/028,392
; FILING DATE: 15-Oct-96
; APPLICATION NUMBER: 60/029,595
; FILING DATE: 23-Oct-96
; APPLICATION NUMBER: 60/045,962
; FILING DATE: 08-May-97
; APPLICATION NUMBER: 08/943,777
; FILING DATE: 3-Oct-97
; ATTORNEY/AGENT INFORMATION:
; NAME: Anthony C. Tridico
; REGISTRATION NUMBER: 45,958
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4173
```


TELEFAX: (202) 408-4400
INFORMATION FOR SEQ ID NO: 99:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 basepairs
TYPE: nucleic acid basepairs
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 99:
US-09-544-934B-99

Query Match 0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 524 GAAGACCTGCCAA 537
DB 14 GAAGACCGGCCAA 1

RESULT 277
US-09-371-772B-5700/C
Sequence 5700, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MBH00, 876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 5700
LENGTH: 16
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-5700

Query Match 0.2%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 198 TTGTCATCTATGA 211
DB 16 TTGACATCTATGA 3

RESULT 278
US-07-832-905B-20
Sequence 20, Application US/07832905B
Patent No. 5580722
GENERAL INFORMATION:
APPLICANT: J. Gordon Foulkes, et al.
TITLE OF INVENTION: Methods of Transcriptionally
TITLE OF INVENTION: Modulating Expression of Genes Associated with Cardiovascular
TITLE OF INVENTION: Disease.
NUMBER OF SEQUENCES: 93
CORRESPONDENCE ADDRESSES:
ADDRESSEE: John P. White, Esq.
STREET: 30 Rockefeller Plaza
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10112
COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/832,905B
FILING DATE: 19920207
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 26134-H
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-977-9550
TELEFAX: 212-664-0525
TELEX: 422523 COOP UI
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-07-832-905B-20

Query Match 0.2%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 33 GGCCAGTCCCAA 44
DB 1 GGCCAGTCCCAA 12

RESULT 279
US-08-700-757-20
Sequence 20, Application US/08700757
Patent No. 5846720
GENERAL INFORMATION:
APPLICANT: J. Gordon Foulkes, et al.
TITLE OF INVENTION: METHODS OF DETERMINING CHEMICALS THAT MODULATE
TITLE OF INVENTION: EXPRESSION OF GENES ASSOCIATED WITH
TITLE OF INVENTION: CARDIOVASCULAR DISEASE
NUMBER OF SEQUENCES: 93
CORRESPONDENCE ADDRESSES:
ADDRESSEE: John P. White, Esq.
STREET: 1185 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/700,757
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 26134-HA
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-278-0400
TELEFAX: 212-391-0525
TELEX:
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-700-757-20

Query Match
Best Local Similarity 100.0%; Score 12; DB 1; Length 12;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 33 GGGCAGTCCCAA 44
DB 1 GGGCAGTCCCAA 12

RESULT 280

US-08-738-944-19/c
Sequence 19, Application US/08738944
Patent No. 5783431

GENERAL INFORMATION:

APPLICANT: Peterson, et al.

TITLE OF INVENTION: METHODS FOR GENERATING AND
SCREENING NOVEL METABOLIC PATHWAYS

NUMBER OF SEQUENCES: 51

CORRESPONDENCE ADDRESS:

ADDRESSEE: Pennie & Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: NY

COUNTRY: USA

ZIP: 10036/2711

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS

SOFTWARE: FASTSEQ Version 2.0

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/738,944

FILING DATE: 24-OCT-1996

CLASSIFICATION: 536

PRIOR APPLICATION DATA:
APPLICATION NUMBER: USSN 08/639,255

FILING DATE: 24-APR-1996

ATTORNEY/AGENT INFORMATION:
NAME: Coruzzi, Laura A

REGISTRATION NUMBER: 30,742

REFERENCE/DOCKET NUMBER: 8757-007

TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-780-9090

TELEFAX: 212-869-8864

INFORMATION FOR SEQ ID NO: 19:

SEQUENCE CHARACTERISTICS:

LENGTH: 13 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA

FEATURE:

NAME/KEY: Terminator

LOCATION: 1..13

OTHER INFORMATION:

NAME/KEY: Other

LOCATION: 10..11

OTHER INFORMATION: Terminator site

LOCATION: 1

OTHER INFORMATION: Phosphate at nucleotide 1

US-08-738-944-19

QY 315 GAGGATCCCGG 326

DB 13 GAGGATCCCGG 2

RESULT 281
US-09-263-352-16/c
Sequence 16, Application US/09263352
Patent No. 6242211

GENERAL INFORMATION:

APPLICANT: Peterson, T.

TITLE OF INVENTION: METHODS FOR GENERATING AND
SCREENING NOVEL METABOLIC

FILE REFERENCE: 8757-010

CURRENT APPLICATION NUMBER: US/09/263,352

CURRENT FILING DATE: 1999-03-05

EARLIER APPLICATION NUMBER: 08/986,186

NUMBER OF SEQ ID NOS: 41

SOFTWARE: Patentin Ver. 2.0

SEQ ID NO 16

LENGTH: 13

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: linker

US-09-263-352-16

QY 315 GAGGATCCCGG 326

DB 13 GAGGATCCCGG 2

RESULT 282
US-08-105-483-273/c
Sequence 273, Application US/08105483
Patent No. 5494807

GENERAL INFORMATION:

APPLICANT: Paoletti, Enzo

TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE

NUMBER OF SEQUENCES: 462

CORRESPONDENCE ADDRESS:

ADDRESSEE: Curtiss, Morris & Safford
STREET: 530 Fifth Avenue
CITY: New York
STATE: NY

COUNTRY: USA

ZIP: 10036

COMPUTER READABLE FORM:

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/105,483

FILING DATE: 12-AUG-1993

CLASSIFICATION: 424

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/847,951

FILING DATE: 06-MAR-1992

ATTORNEY/AGENT INFORMATION:

NAME: Frommer, William S.

REGISTRATION NUMBER: 25,506

REFERENCE/DOCKET NUMBER: 454310-2400

TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333

TELEFAX: (212) 840-0712

QY 315 GAGGATCCCGG 326

;; INFORMATION FOR SEQ ID NO: 273:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-08-105-483-273

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
Db 12 CGAGGATCCCG 1

RESULT 283
US-08-311-760A-36
; Sequence 36, Application US/08311760A
; Patent No. 559706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-311-760A-36

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 83.3%; Pred. No. 2e+02;
Matches 10; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 564 GCATAGTCGAC 575

Db 4 GCAUAGCGGAC 15

RESULT 284
US-08-224-391-87/c
; Sequence 87, Application US/08224391
; Patent No. 5744140
; GENERAL INFORMATION:
; APPLICANT: Paoletti, Enzo
; APPLICANT: Pincus, Steven E.
; TITLE OF INVENTION: FLAVIVIRUS RECOMBINANT POXVIRUS VACCINE
; NUMBER OF SEQUENCES: 93
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris & Safford
; ADDRESS: c/o William S. Frommer
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/224,391
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/729,800
; FILING DATE: 17-JUL-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Frommer, William S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2340
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 87:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-224-391-87

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
Db 12 CGAGGATCCCG 1

RESULT 285
US-08-484-304-87/c
; Sequence 87, Application US/08484304
; Patent No. 5744141
; GENERAL INFORMATION:
; APPLICANT: Paoletti, Enzo
; APPLICANT: Pincus, Steven E.
; TITLE OF INVENTION: FLAVIVIRUS RECOMBINANT POXVIRUS VACCINE
; NUMBER OF SEQUENCES: 93
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris & Safford
; ADDRESS: c/o William S. Frommer
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: New York
; COUNTRY: United States of America

```

;
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/484,304
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/224,391
; FILING DATE:
; APPLICATION NUMBER: US 07/729,800
; FILING DATE: 17-JUL-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Frommer, William S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2340
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 87:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-484-304-87

Query Match
Best Local Similarity 100.0%; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
DB 12 CGAGGATCCCG 1

RESULT 286
US-08-224-657-108/c
; Sequence 108, Application US/08224657
; Patent No. 5756102
; GENERAL INFORMATION:
; APPLICANT: Paoletti, Enzo
; APPLICANT: Tartaglia, James
; APPLICANT: Taylor, Jill
; TITLE OF INVENTION: POXVIRUS - CANINE DISTEMPER VIRUS (CDV)
; TITLE OF INVENTION: RECOMBINANTS AND COMPOSITIONS AND METHODS EMPLOYING THE
; NUMBER OF SEQUENCES: 122
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris & Safford, P.C.
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/224,657
; FILING DATE: 06-APR-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Frommer, William S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2550
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
```

```

;
; TELEFAX: (212) 840-0712
; TELEX: 425066 CURTMS
; INFORMATION FOR SEQ ID NO: 108:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
;
US-08-224-657-108

Query Match
Best Local Similarity 100.0%; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
DB 12 CGAGGATCCCG 1

RESULT 287
US-08-709-209-273/c
; Sequence 273, Application US/08709209
; Patent No. 5762938
; GENERAL INFORMATION:
; APPLICANT: Paoletti, Enzo
; TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
; TITLE OF INVENTION: STRAIN
; NUMBER OF SEQUENCES: 462
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris & Safford
; ADDRESSEE: c/o William S. Frommer
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/709,209
; FILING DATE: 21-AUG-1996
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/105,483
; FILING DATE: 12-AUG-1993
; APPLICATION NUMBER: US 07/847,951
; FILING DATE: 06-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Frommer, William S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2400
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 273:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-709-209-273

Query Match
Best Local Similarity 100.0%; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
DB 12 CGAGGATCCCG 1
```

RESULT 288
US-08-257-073-66/c
Sequence 66, Application US/08257073
Patent No. 5766597
GENERAL INFORMATION:
APPLICANT: Paolletti, Enzo
APPLICANT: de Taisne, Charles
APPLICANT: Tine, John A.
TITLE OF INVENTION: MALARIA RECOMBINANT POXVIRUS VACCINE
NUMBER OF SEQUENCES: 143
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Curtis, Morris & Safford, P.C.
STREET: 530 Fifth Avenue, 25th Floor
CITY: New York
STATE: New York
COUNTRY: UNITED STATES OF AMERICA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/257,073
FILING DATE: 09-JUN-1994
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2570
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
TELEX: 425066 CURTMS
INFORMATION FOR SEQ ID NO: 66:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-257-073-66

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
Db 12 CGAGGATCCCG 1

RESULT 289
US-08-458-101-273/c
Sequence 273, Application US/08458101
Patent No. 5766599
GENERAL INFORMATION:
APPLICANT: Paolletti, Enzo
APPLICANT: Perkins, Marion E.
APPLICANT: Taylor, Jill
APPLICANT: Tartaglia, James
APPLICANT: No. 5766599ton, Elizabeth K.
APPLICANT: Riviere, Michel

APPLICANT: de Taisne, Charles
APPLICANT: Limbach, Keith J.
APPLICANT: Johnson, Gerard P.
APPLICANT: Pincus, Steven E.
APPLICANT: Cox, William I.
APPLICANT: Audonnet, Jean-Christophe Francis
APPLICANT: Gettig, Russell Robert
TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
NUMBER OF SEQUENCES: 467
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Curtis, Morris & Safford
ADDRESSEE: c/o William S. Frommer
STREET: 530 Fifth Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/458,101
FILING DATE: 01-JUN-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2740
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 273:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-458-101-273

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
Db 12 CGAGGATCCCG 1

RESULT 290
US-08-311-486C-30/c
Sequence 30, Application US/08311486C
Patent No. 5811300
GENERAL INFORMATION:
APPLICANT: Sean Sullivan
APPLICANT: Kenneth Draper
APPLICANT: Kevin Kisich
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
RELATED TO LEVELS OF
TITLE OF INVENTION: TNF-
NUMBER OF SEQUENCES: 1157
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.

ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,486C
FILING DATE: September 23, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/166
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-486C-30

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 430 GACAGACGCG 441
DB 12 GACAGACGCG 1

RESULT 291
US-08-184-009-137/c
Sequence 137, Application US/08184009
Patent No. 5833975
GENERAL INFORMATION:
APPLICANT: Paoletti, Enzo
APPLICANT: Tartaglia, James
APPLICANT: Cox, William I.
TITLE OF INVENTION: RECOMBINANT VIRUS IMMUNOTHERAPY
NUMBER OF SEQUENCES: 217
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris & Safford
STREET: 530 Fifth Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/184,009
FILING DATE: 19-JAN-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2530

TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
TELEX: 425066CURTMS
INFORMATION FOR SEQ ID NO: 137:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-184-009-137

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
DB 12 CGAGGATCCCG 1

RESULT 292
US-08-566-398-48/c
Sequence 48, Application US/08566398
Patent No. 5858373
GENERAL INFORMATION:
APPLICANT: Paoletti, Enzo
APPLICANT: Gettig, Russell
TITLE OF INVENTION: RECOMBINANT POXVIRUS - FELINE INFECTIONS
TITLE OF INVENTION: PERTONITIS VIRUS, COMPOSITIONS THEREOF, AND METHODS FOR
NUMBER OF SEQUENCES: 63
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris & Safford, P.C.
STREET: 530 Fifth Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/566,398
FILING DATE: 01-DEC-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2880
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 48:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-566-398-48

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
DB 12 CGAGGATCCCG 1

```
RESULT 293
US-08-774-310-36
Sequence 36, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 36:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-36

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 83.3%; Pred. No. 2e+02;
Matches 10; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 564 GCATAGTCGAC 575
Db 4 GCAUAGUCGAC 15

RESULT 294
US-08-458-356-137/C
Sequence 137, Application US/08458356
Patent No. 594235
GENERAL INFORMATION:
APPLICANT: Paoletti, Enzo
APPLICANT: Tartaglia, James
APPLICANT: Cox, William I.
TITLE OF INVENTION: RECOMBINANT VIRUS IMMUNOTHERAPY
NUMBER OF SEQUENCES: 217
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris & Safford
```

```
STREET: 530 Fifth Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/458,356
FILING DATE: 02-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/184,009
FILING DATE: 19-JAN-1994
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2530
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
TELEX: 425066CURTMS
INFORMATION FOR SEQ ID NO: 137:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-458-356-137

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
Db 12 CGAGGATCCCG 1

RESULT 295
US-08-658-665-91/C
Sequence 91, Application US/08658665
Patent No. 5997878
GENERAL INFORMATION:
APPLICANT: Paoletti, Enzo
APPLICANT: Pincus, Steven E.
APPLICANT: Cox, William I.
APPLICANT: Kaufman, Elizabeth K.
TITLE OF INVENTION: Recombinant Poxvirus - Cytomegalovirus,
TITLE OF INVENTION: Compositions and Uses
NUMBER OF SEQUENCES: 190
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris & Safford, P.C.
STREET: 530 Fifth Avenue
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/658,665
FILING DATE: 05-JUN-1996
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Frommer Esq., William S.
```

REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2720.1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 91:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-658-665-91

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
DB 12 CGAGGATCCCG 1

RESULT 296
US-08-796-101-68/C
Sequence 68, Application US/08796101
Patent No. 6183752
GENERAL INFORMATION:
APPLICANT: EPSTEIN, STEPHEN E.
APPLICANT: FINKEL, TOREN
APPLICANT: SPEIR, EDITH
APPLICANT: ZHOU, YI FU
APPLICANT: ZHU, JIANHUI
APPLICANT: ERDILE, LORNE
APPLICANT: PINCUS, STEVEN
TITLE OF INVENTION: STENOSIS/ATHEROSCLEROSIS DIAGNOSIS,
TITLE OF INVENTION: PROPHYLAXIS AND THERAPY
NUMBER OF SEQUENCES: 184
CORRESPONDENCE ADDRESS:
ADDRESSEE: CURTIS, MORRIS & SAFFORD, P.C.
STREET: 530 FIFTH AVENUE
CITY: NEW YORK
STATE: NY
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/796,101
FILING DATE: 05-FEB-1997
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: KOMALSKI, THOMAS J.
REGISTRATION NUMBER: 32,147
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 764-5574
INFORMATION FOR SEQ ID NO: 68:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-796-101-68

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
DB 12 CGAGGATCCCG 1

RESULT 297
US-08-460-736-137/C
Sequence 137, Application US/08460736
Patent No. 6265189
GENERAL INFORMATION:
APPLICANT: Paoletti, Enzo
APPLICANT: Tartaglia, James
APPLICANT: Cox, William I.
TITLE OF INVENTION: RECOMBINANT VIRUS IMMUNOTHERAPY
NUMBER OF SEQUENCES: 217
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris & Safford
STREET: 530 Fifth Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/460,736
FILING DATE: 02-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/184,009
FILING DATE: 19-JAN-1994
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2530
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 137:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-460-736-137

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
DB 12 CGAGGATCCCG 1

RESULT 298
US-09-085-273-91/C
Sequence 91, Application US/09085273
Patent No. 6267965
GENERAL INFORMATION:
APPLICANT: Paoletti, Enzo
APPLICANT: Pincus, Steven E.
APPLICANT: Cox, William I.
APPLICANT: Kaufman, Elizabeth K.
TITLE OF INVENTION: RECOMBINANT POXVIRUS - CYTOMEGALOVIRUS,
TITLE OF INVENTION: COMPOSITIONS AND USES
NUMBER OF SEQUENCES: 176
CORRESPONDENCE ADDRESS:

ADDRESSEE: Curtiss, Morris & Safford
STREET: 530 Fifth Avenue
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/085,273
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/471,014
FILING DATE: 06-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Frommer Bag, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2720
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
FAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 91:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-085-273-91

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
DB 12 CGAGGATCCCG 1

RESULT 299
US-09-354-138-108/c
Sequence 108, Application US/09354138
GENERAL INFORMATION:
APPLICANT: Paoletti, Enzo
APPLICANT: Tartaglia, James
APPLICANT: Taylor, Jill
TITLE OF INVENTION: POXVIRUS - CANINE DISTEMPER VIRUS (CDV)
TITLE OF INVENTION: RECOMBINANTS AND COMPOSITIONS AND METHODS EMPLOYING THE
TITLE OF INVENTION: RECOMBINANTS
NUMBER OF SEQUENCES: 139
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtiss, Morris & Safford, P.C.
STREET: 530 Fifth Avenue, 25th Floor
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/354,138
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/472,379
FILING DATE: 07-JUN-1995
APPLICATION NUMBER: US 08/416,646
FILING DATE: 05-APR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/224,657
FILING DATE: 16-APR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/073,962
FILING DATE: 08-JUN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/776,867
FILING DATE: 23-OCT-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/621,614
FILING DATE: 30-NOV-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/938,283
FILING DATE: 31-AUG-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/105,483
FILING DATE: 12-AUG-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/847,951
FILING DATE: 06-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/713,967
FILING DATE: 11-JUN-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07,666,056
FILING DATE: 07-MAR-1991
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2860
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
FAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 108:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-09-354-138-108

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
DB 12 CGAGGATCCCG 1

RESULT 300
US-09-081-646-529/c
Sequence 529, Application US/09081646
Patent No. 6333152
GENERAL INFORMATION:
APPLICANT: Kinzler, Kenneth
APPLICANT: Vogelstein, Bert
APPLICANT: Zhang, Lin
TITLE OF INVENTION: Gene Expression Profiles in No. 6333152ma1 and
TITLE OF INVENTION: Cancer Cells
FILE REFERENCE: 01107,74664
CURRENT APPLICATION NUMBER: US/09/081,646
FILING DATE: 1998-05-20
EARLIER APPLICATION NUMBER: 60/047,352
FILING DATE: 1997-05-21
NUMBER OF SEQ ID NOS: 871

SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 529
LENGTH: 15
TYPE: DNA
ORGANISM: Homo sapiens
US-09-081-646-529

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 104 AGCAAGCCATG 115
|||
Db 12 AGCAAGCCATG 1

RESULT 301

US-09-535-370-137/c
Sequence 137, Application US/09535370
Patent No. 6537594
GENERAL INFORMATION:
APPLICANT: Paolletti, Enzo
Cox, William I.
Tartaglia, James
TITLE OF INVENTION: RECOMBINANT VIRUS IMMUNOTHERAPY
NUMBER OF SEQUENCES: 217
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Curtis, Morris & Safford
STREET: 530 Fifth Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/535,370
FILING DATE: 24-Mar-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/460,736
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2530
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
TELEX: 425066CURTMS
INFORMATION FOR SEQ ID NO: 137:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
SEQUENCE DESCRIPTION: SEQ ID NO: 137:
US-09-535-370-137

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
|||
Db 12 CGAGGATCCCG 1

RESULT 302

US-09-916-963-91/c
Sequence 91, Application US/0916963
Patent No. 6632438
GENERAL INFORMATION:
APPLICANT: Paolletti, Enzo
Pincus, Steven E.
Cox, William I.
Kauffman, Elizabeth K.

TITLE OF INVENTION: RECOMBINANT POXVIRUS - CYTOMEGALOVIRUS,
COMPOSITIONS AND USES
NUMBER OF SEQUENCES: 176
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Curtis, Morris & Safford
STREET: 530 Fifth Avenue
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10036

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/916,963
FILING DATE: 26-Jul-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/471,014
FILING DATE: 06-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Frommer Esq., William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2720
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712

INFORMATION FOR SEQ ID NO: 91:

SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 91:
US-09-916-963-91

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 CGAGGATCCCG 325
|||
Db 12 CGAGGATCCCG 1

RESULT 303

US-09-663-667-137/c
Sequence 137, Application US/09663667
Patent No. 6780407
GENERAL INFORMATION:
APPLICANT: Paolletti, Enzo
Cox, William I.
Tartaglia, James

TITLE OF INVENTION: RECOMBINANT VIRUS IMMUNOTHERAPY
NUMBER OF SEQUENCES: 217
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Curtis, Morris & Safford
STREET: 530 Fifth Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036

```
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC Compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/663,667
FILING DATE: 15-Sep-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/184,009
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2530
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
TELEX: 42506CURTMS
INFORMATION FOR SEQ ID NO: 137:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
SEQUENCE DESCRIPTION: SEQ ID NO: 137:
US-09-663-667-137

Query Match      0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      314 CGAGGATCCCG 325
Db      12 CGAGGATCCCG 1

RESULT 304
US-08-873-437-37/c
Sequence 37, Application US/08873437
Patent No. 6124092
GENERAL INFORMATION:
APPLICANT: O'Neill, Roger A.
APPLICANT: Chen, Jer-Kang
APPLICANT: Chiesa, Claudia
APPLICANT: Fry, George
TITLE OF INVENTION: Multiplex Polynucleotide Capture
TITLE OF INVENTION: Methods and Compositions
NUMBER OF SEQUENCES: 50
CORRESPONDENCE ADDRESS:
ADDRESSEE: PE Applied Biosystems
STREET: 850 Lincoln Centre Drive
CITY: Foster City
STATE: CA
COUNTRY: USA
ZIP: 94404
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/873,437
FILING DATE: 12-JUN-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/027,832
FILING DATE: 04-OCT-1996
ATTORNEY/AGENT INFORMATION:
NAME: Bortner, Scott R
REGISTRATION NUMBER: 34,298
REFERENCE/DOCKET NUMBER: 4294
```

```
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-638-6245
TELEFAX: 415-638-6071
INFORMATION FOR SEQ ID NO: 37:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-873-437-37

Query Match      0.2%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      125 ATTGCTACCATG 136
Db      15 ATTGCTACCATG 4

RESULT 305
US-08-873-437-40/c
Sequence 40, Application US/08873437
Patent No. 6124092
GENERAL INFORMATION:
APPLICANT: O'Neill, Roger A.
APPLICANT: Chen, Jer-Kang
APPLICANT: Chiesa, Claudia
APPLICANT: Fry, George
TITLE OF INVENTION: Multiplex Polynucleotide Capture
TITLE OF INVENTION: Methods and Compositions
NUMBER OF SEQUENCES: 50
CORRESPONDENCE ADDRESS:
ADDRESSEE: PE Applied Biosystems
STREET: 850 Lincoln Centre Drive
CITY: Foster City
STATE: CA
COUNTRY: USA
ZIP: 94404
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/873,437
FILING DATE: 12-JUN-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/027,832
FILING DATE: 04-OCT-1996
ATTORNEY/AGENT INFORMATION:
NAME: Bortner, Scott R
REGISTRATION NUMBER: 34,298
REFERENCE/DOCKET NUMBER: 4294
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-638-6245
TELEFAX: 415-638-6071
INFORMATION FOR SEQ ID NO: 40:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-873-437-40

Query Match      0.2%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      125 ATTGCTACCATG 136
Db      15 ATTGCTACCATG 4
```

```
RESULT 306
US-09-593-312-37/c
; Sequence 37, Application US/09593312
; Patent No. 6514699
; GENERAL INFORMATION:
; APPLICANT: O'Neill, Roger A.
; APPLICANT: Chen, Jer-Kang
; APPLICANT: Chiesia, Claudia
; APPLICANT: Fry, George
; TITLE OF INVENTION: Multiplex Polynucleotide Capture
; TITLE OF INVENTION: Methods and Compositions
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PE Applied Biosystems
; STREET: 850 Lincoln Centre Drive
; CITY: Foster City
; STATE: CA
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/593,312
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/873,437
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Bortner, Scott R.
; REGISTRATION NUMBER: 34,298
; REFERENCE/DOCKET NUMBER: 4294
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-638-6245
; TELEFAX: 415-638-6071
; INFORMATION FOR SEQ ID NO: 37:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-593-312-37

Query Match      0.2%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      125 ATTGCTACCATG 136
Db      15 ATTGCTACCATG 4

RESULT 307
US-09-593-312-40/c
; Sequence 40, Application US/09593312
; Patent No. 6514699
; GENERAL INFORMATION:
; APPLICANT: O'Neill, Roger A.
; APPLICANT: Chen, Jer-Kang
; APPLICANT: Chiesia, Claudia
; APPLICANT: Fry, George
; TITLE OF INVENTION: Multiplex Polynucleotide Capture
; TITLE OF INVENTION: Methods and Compositions
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PE Applied Biosystems
; STREET: 850 Lincoln Centre Drive
; CITY: Foster City
; STATE: CA
; COUNTRY: USA
```

```
ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/593,312
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/873,437
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Bortner, Scott R.
; REGISTRATION NUMBER: 34,298
; REFERENCE/DOCKET NUMBER: 4294
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-638-6245
; TELEFAX: 415-638-6071
; INFORMATION FOR SEQ ID NO: 40:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-593-312-40

Query Match      0.2%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      125 ATTGCTACCATG 136
Db      15 ATTGCTACCATG 4

RESULT 308
US-08-311-760A-29
; Sequence 29, Application US/08311760A
; Patent No. 5599706
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,760A
; FILING DATE: September 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
```

```

:
:   REGISTRATION NUMBER: 32,327
:   REFERENCE/DOCKET NUMBER: 208/155
:   TELECOMMUNICATION INFORMATION:
:   TELEPHONE: (213) 489-1600
:   TELEFAX: (213) 955-0440
:   TELEX: 67-3510
:   INFORMATION FOR SEQ ID NO: 29:
:   SEQUENCE CHARACTERISTICS:
:   LENGTH: 15 base pairs
:   TYPE: nucleic acid
:   STRANDEDNESS: single
:   TOPOLOGY: linear
:
US-08-311-760A-29

Query Match          0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 2.1e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

OY      355 CAATGCTCAGACGCA 369
Db      1 CGAGCUCACAGACCA 15

RESULT 309
US-08-311-760A-54
: Sequence 54, Application US/08311760A
: Patent No. 5599706
: GENERAL INFORMATION:
:   APPLICANT: Stinchcomb, Dan T.
:   APPLICANT: McSwiggen, James
:   APPLICANT: Newton, Roger S.
:   APPLICANT: Ramharack, Randy
:   TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
:   TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
:   TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
:   TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
:   NUMBER OF INVENTION:
:   NUMBER OF SEQUENCES: 392
:   CORRESPONDENCE ADDRESS:
:   ADDRESSEE: Lyon & Lyon
:   STREET: 633 West Fifth Street
:   STREET: Suite 4700
:   CITY: Los Angeles
:   STATE: California
:   COUNTRY: U.S.A.
:   ZIP: 90071
:   COMPUTER READABLE FORM:
:   MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
:   MEDIUM TYPE: storage
:   COMPUTER: IBM Compatible
:   OPERATING SYSTEM: IBM P.C. DOS 5.0
:   SOFTWARE: FastSeq Version 1.5
:   CURRENT APPLICATION DATA:
:   APPLICATION NUMBER: US/08/311,760A
:   FILING DATE: September 23, 1994
:   PRIOR APPLICATION DATA:
:   APPLICATION NUMBER:
:   FILING DATE:
:   ATTORNEY/AGENT INFORMATION:
:   NAME: Wardburg, Richard
:   REGISTRATION NUMBER: 32,327
:   REFERENCE/DOCKET NUMBER: 208/155
:   TELECOMMUNICATION INFORMATION:
:   TELEPHONE: (213) 489-1600
:   TELEFAX: (213) 955-0440
:   TELEX: 67-3510
:   INFORMATION FOR SEQ ID NO: 54:
:   SEQUENCE CHARACTERISTICS:
:   LENGTH: 15 base pairs
:   TYPE: nucleic acid
:   STRANDEDNESS: single
:   TOPOLOGY: linear
:
US-08-311-760A-54

Query Match          0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 2.1e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

OY      500 GCACATCTCAGACCA 514
Db      1 GCUCACUCACACCA 15

RESULT 311
US-08-311-760A-76
: Sequence 76, Application US/08311760A
```

```
/ Patent No. 5599706
/ GENERAL INFORMATION:
/ APPLICANT: Stinchcomb, Dan T.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Newton, Roger S.
/ APPLICANT: Ramnarack, Randy
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
/ TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
/ TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
/ TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
/ NUMBER OF SEQUENCES: 392
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Suite 4700
/ STATE: Los Angeles
/ COUNTRY: California
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FASTSEQ Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/311,760A
/ FILING DATE: September 23, 1994
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/155
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 76:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-311-760A-76

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 2.1e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Oy 355 CGATGCTCACAGCGA 369
Db 1 CGAUGCUCACAGACA 15

RESULT 312
US-08-311-760A-209
/ Sequence 209 Application US/08311760A
/ Patent No. 5599706
/ GENERAL INFORMATION:
/ APPLICANT: Stinchcomb, Dan T.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Newton, Roger S.
/ APPLICANT: Ramnarack, Randy
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
/ TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
/ TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
/ TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
/ NUMBER OF SEQUENCES: 392
/ CORRESPONDENCE ADDRESS:
```

```
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Suite 4700
/ STATE: Los Angeles
/ COUNTRY: California
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FASTSEQ Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/311,760A
/ FILING DATE: September 23, 1994
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/155
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 209:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-311-760A-209

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 2.1e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Oy 496 CGAGGCACATCTCC 510
Db 1 CGAGGCUCAUUCUC 15

RESULT 313
US-08-311-486C-156/C
/ Sequence 156 Application US/08311486C
/ Patent No. 5811300
/ GENERAL INFORMATION:
/ APPLICANT: Sean Sullivan
/ APPLICANT: Kenneth Draper
/ APPLICANT: Kevin Kisich
/ APPLICANT: Dan T. Stinchcomb
/ APPLICANT: James McSwiggen
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF
/ TITLE OF INVENTION: DISEASES OR CONDITIONS
/ TITLE OF INVENTION: RELATED TO LEVELS OF
/ TITLE OF INVENTION: TNF- $\alpha$ 
/ NUMBER OF SEQUENCES: 1157
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Suite 4700
/ STATE: Los Angeles
/ COUNTRY: California
/ ZIP: 90071-2066
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: Word Perfect 5.1
```

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,486C
FILING DATE: September 23, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/166
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 156:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-486C-156

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 31 CTGGCCAGTCCCAA 45
Db 15 CTGGCCAGAACCAA 1

RESULT 314
US-08-774-310-29
Sequence 29, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-29

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 2.1e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 355 CAATGCTCAGACGCA 369
Db 1 CGAUGCUCAGAUCA 15

RESULT 315
US-08-774-310-54
Sequence 54, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 54:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-54

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 2.1e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 496 CGAGCAGCATCTCC 510
DB 1 CGAGCAGCATCTCC 15

RESULT 316
US-08-774-310-55
; Sequence 55, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 55:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-310-55

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 2.1e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 500 GCACATCTCCACCA 514
DB 1 GCACATCTCCACCA 15

RESULT 317
US-08-774-310-76
; Sequence 76, Application US/08774310

; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 76:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-310-76

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 2.1e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 355 CAATGCTCAGACGA 369
DB 1 CGAGCAGCATCTCC 15

RESULT 318
US-08-774-310-209
; Sequence 209, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwigen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774.310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 209:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-209

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 2.1e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 496 CGAGGCACATCTCC 510
Db 1 CGAGGCACATCTCC 15

RESULT 319
US-10-116-993A-15/c
Sequence 15, Application US/10116993A
Patent No. 6699691
GENERAL INFORMATION:
APPLICANT: The Board of Regents of the University of Nebraska
TITLE OF INVENTION: ALCOHOL OXIDASE 1 REGULATORY NUCLEOTIDE SEQUENCES FOR
FILE REFERENCE: UNL 3071.1
CURRENT APPLICATION NUMBER: US/10/116,993A
CURRENT FILING DATE: 2002-04-05
NUMBER OF SEQ ID NOS: 29
SOFTWARE: PatentIn version 3.1
SEQ ID NO 15
LENGTH: 15
TYPE: DNA
ORGANISM: methylotrophic yeast
US-10-116-993A-15

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 549 TATGACACCACTC 563
Db 15 TTGACCCACACTC 1

RESULT 320

US-09-717-847E-2/c
Sequence 2, Application US/09717847E
Patent No. 6461837
GENERAL INFORMATION:
APPLICANT: Yaver, Debbie S.
APPLICANT: Bellini, Daniel Alan
TITLE OF INVENTION: Methods For Producing A Polypeptide
FILE REFERENCE: 5996 200-US
CURRENT APPLICATION NUMBER: US/09/717,847E
CURRENT FILING DATE: 2000-11-20
PRIOR APPLICATION NUMBER: 09/451,503
PRIOR FILING DATE: 1999-11-30
NUMBER OF SEQ ID NOS: 48
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 13
TYPE: DNA
ORGANISM: Aspergillus oryzae
US-09-717-847E-2

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 133 CATGCTGATGGAC 145
Db 13 CATGCTGATGGAC 1

RESULT 321
US-08-765-340-97/c
Sequence 97, Application US/08765340
Patent No. 6150092

GENERAL INFORMATION:
APPLICANT: UCHIDA, K.,
APPLICANT: UCHIDA, T.,
APPLICANT: TANAKA, Y.,
APPLICANT: MATSUDA, Y.,
APPLICANT: KONDO, S.,
TITLE OF INVENTION: AN ANTISENSE NUCLEIC ACID
NUMBER OF SEQUENCES: 185
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
STREET: 345 PARK AVENUE
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10154

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/765,340
FILING DATE: 23-DEC-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 145146/94
FILING DATE: 27-JUN-1994

PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 311130/94
FILING DATE: 21-NOV-1994
ATTORNEY/AGENT INFORMATION:
NAME: SERUNIAN, LESLIE
REGISTRATION NUMBER: 35,353
REFERENCE/DOCKET NUMBER: 1452-4005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 751-6849
TELEFAX: (212) 751-6849
INFORMATION FOR SEQ ID NO: 97:

```

; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "synthetic DNA"
US-08-765-340-97

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 382 GTGCGCGCTCCGA 394
Db 13 GTGCGCGCTCCGA 1

RESULT 322
US-09-580-923-29/c
; Sequence 29, Application US/09580923
; Patent No. 6319672
; GENERAL INFORMATION:
; APPLICANT: Crouzet, Joel
; APPLICANT: Scherman, Daniel
; APPLICANT: Wils, Pierre
; APPLICANT: Cameron, Beatrice
; APPLICANT: Blanche, Francis
; TITLE OF INVENTION: PURIFICATION OF A TRIPLE HELIX FORMATION WITH AN
; FILE REFERENCE: 03804.0138-01
; CURRENT APPLICATION NUMBER: US/09/580,923
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: 08/860,038
; PRIOR FILING DATE: 1997-06-09
; PRIOR APPLICATION NUMBER: PCT/FR95/01468
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
US-09-580-923-29

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 74 TTCTTTATTCT 86
Db 14 TTCTTTATTCT 2

RESULT 323
US-09-580-923-30
; Sequence 30, Application US/09580923
; Patent No. 6319672
; GENERAL INFORMATION:
; APPLICANT: Crouzet, Joel
; APPLICANT: Scherman, Daniel
; APPLICANT: Wils, Pierre
; APPLICANT: Cameron, Beatrice
; APPLICANT: Blanche, Francis
; TITLE OF INVENTION: PURIFICATION OF A TRIPLE HELIX FORMATION WITH AN
; FILE REFERENCE: 03804.0138-01
; CURRENT APPLICATION NUMBER: US/09/580,923
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: 08/860,038
```

```

; PRIOR FILING DATE: 1997-06-09
; PRIOR APPLICATION NUMBER: PCT/FR95/01468
; PRIOR FILING DATE: 1995-11-08
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 30
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
US-09-580-923-30

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 74 TTCTTTATTCT 86
Db 1 TTCTTTATTCT 13

RESULT 324
US-08-535-249-65/c
; Sequence 65, Application US/08535249
; Patent No. 6455689
; GENERAL INFORMATION:
; APPLICANT: Schlingensiepen, Georg-Ferdinand
; APPLICANT: Bysch, Wolfgang
; APPLICANT: Schlingensiepen, Karl-Hermann
; APPLICANT: Schlingensiepen, Reimar
; APPLICANT: Bogdahn, Ulrich
; TITLE OF INVENTION: Antisense-oligonucleotides for the treatment of
; TITLE OF INVENTION: Immuno-suppressive effect of transforming-growth-factor beta (1
; NUMBER OF SEQUENCES: 137
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Jacobson, Price, Holman & Stern
; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C.
; COUNTRY: U.S.A.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/535,249
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 93 107 089.0
; FILING DATE: 30-APR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 93 107 849.7
; FILING DATE: 13-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Player, William B.
; REGISTRATION NUMBER: 31,409
; REFERENCE/DOCKET NUMBER: 10577/P58418
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)638-6666
; TELEFAX: (202) 393-5350
; TELEX: RCA 248593 IDEA UR
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: YES
```

US-08-535-249-65

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 2.1e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 575 CCCCAGATACTA 587
14 CCCCAGAGACTA 2

RESULT 325

US-09-230-652-63/c
Sequence 63, Application US/09230652A
Patent No. 6537775
GENERAL INFORMATION:
APPLICANT: Joutel, Anne
APPLICANT: Bousser, Marie-Germaine
APPLICANT: Bach, Jean-Francois
TITLE OF INVENTION: GENE INVOLVED IN CADASIL, METHOD OF DIAGNOSIS AND
TITLE OF INVENTION: THERAPEUTIC APPLICATION
FILE REFERENCE: 03715.0048-00000
CURRENT FILING DATE: 1999-05-17
EARLIER APPLICATION NUMBER: FR 96 09733
EARLIER FILING DATE: 1996-08-01
EARLIER APPLICATION NUMBER: FR 97 04680
EARLIER FILING DATE: 1997-04-16
EARLIER APPLICATION NUMBER: PCT/FR97/01433
EARLIER FILING DATE: 1997-07-31
NUMBER OF SEQ ID NOS: 163
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 63
LENGTH: 14
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-230-652-63

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 2.1e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 528 AACCTGCCAAGCT 540
13 AACCTACCAAGCT 1

RESULT 326

US-07-664-989B-118/c
Sequence 118, Application US/07664989B
Patent No. 5223409
GENERAL INFORMATION:
APPLICANT: Ladner, Robert Charles
APPLICANT: Guterman, Sonia Kosow
APPLICANT: Roberts, Bruce Lindsay
APPLICANT: Markland, William
APPLICANT: Ley, Arthur Charles
APPLICANT: Kent, Rachel Baribault
TITLE OF INVENTION: Directed Evolution of No. 5223409e1
TITLE OF INVENTION: Binding Proteins
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Browdy and Neimark
STREET: 419 Seventh Street, N.W.
STREET: Suite 300
CITY: Washington,
STATE: DC
COUNTRY: USA
ZIP: 20004
COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WORDPERFECT 4.2

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/664,989B
FILING DATE: 19910301
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US89/03731
FILING DATE: 01-SEP-1989

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/487,063
FILING DATE: 02-MAR-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/240,160
FILING DATE: 02-SEP-1988

ATTORNEY/AGENT INFORMATION:
NAME: Cooper, Iver P.
REGISTRATION NUMBER: 28005
REFERENCE/DOCKET NUMBER: LADNER 7
TELEPHONE: 202-628-5197
TELEFAX: 202-737-3528

INFORMATION FOR SEQ ID NO: 118:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: double
TOPOLOGY: circular

MOLECULE TYPE: genomic DNA
US-07-664-989B-118

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 102 TGAGCAAGCCAT 114
13 TGACCAAGCCAT 1

RESULT 327

US-08-297-703-9/c
Sequence 9, Application US/08297703
Patent No. 5506212
GENERAL INFORMATION:
APPLICANT: Hake, Glenn
TITLE OF INVENTION: Stereoisomerically Pure
TITLE OF INVENTION: Phosphorothioate
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 10
CORRESPONDENCE ADDRESS:
ADDRESSEE: John W. Caldwell
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/297,703
FILING DATE:
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/777,007
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Caldwell, John W.

REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-0015
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-368-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
US-08-297-703-9

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
DB 13 ACTGCATAGTCG 1

RESULT 328
US-08-058-023-7/c
Sequence 7, Application US/08058023
Patent No. 5521302
GENERAL INFORMATION:
APPLICANT: Cook, Phillip D.
TITLE OF INVENTION: OLIGONUCLEOTIDES HAVING CHIRAL
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
ADDRESS: and No. 5521302xis
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 KB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/058,023
FILING DATE: 05-MAY-1993
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucchi
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-1053
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-058-023-7

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 560 ACTGCATAGTCG 572
DB 13 ACTGCATAGTCG 1

DB 13 ACTGCATAGTCG 1

RESULT 329
US-08-468-447-13/c
Sequence 13, Application US/08468447
Patent No. 5576302
GENERAL INFORMATION:
APPLICANT: Phillip Dan Cook and Glenn Hoke
TITLE OF INVENTION: Oligonucleotides for Modulating
Hepatitis C Virus Having Phosphorothioate Linkages of High Chirality
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5576302xis
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 KB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/468,447
FILING DATE: 06-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 297,703
FILING DATE: 29-AUG-1994
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucchi
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-2008
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-468-447-13

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
DB 13 ACTGCATAGTCG 1

RESULT 330
US-08-469-851A-13/c
Sequence 13, Application US/08469851A
Patent No. 5587361
GENERAL INFORMATION:
APPLICANT: Cook and Hoke
TITLE OF INVENTION: OLIGONUCLEOTIDES HAVING PHOSPHOROTHIOATE
LINKAGES OF HIGH CHIRAL PURITY
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5587361xis
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 KB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/469,851A
FILING DATE: 06-JUN-1995
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 297,703
FILING DATE: 29-AUG-1994
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucchi
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-2012
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-469-851A-13

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 560 ACTCGCATGTCG 572
DB 13 ACTGTCATGTCG 1

RESULT 331
US-08-311-760A-59
Sequence 59, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 59:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-59

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 76.9%; Pred. No. 2.4e+02;
Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 402 CCCGTTCCAAGC 414
DB 2 CCCAGUCCAAGC 14

RESULT 332
US-08-311-760A-220
Sequence 220, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwiggen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 220:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-311-760A-220

Query Match

Best Local Similarity 0.2%; Score 11.4; DB 1; Length 15;
Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 402 CCCGCTCCAGC 414

Db 2 CCCAGTCCAGC 14

RESULT 333

US-08-467-597A-13/c

/ Sequence 13, Application US/08467597A
/ Patent No. 5607923

/ GENERAL INFORMATION:

/ APPLICANT: Phillip Dan Cook and Glenn Hoke

/ TITLE OF INVENTION: Oligonucleotides For Modulating

/ TITLE OF INVENTION: Cytomegalovirus Having Phosphorothioate Linkages Of High Chire

/ NUMBER OF SEQUENCES: 16

/ CORRESPONDENCE ADDRESS:

/ ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5607923tris

/ STREET: One Liberty Place - 46th Floor

/ CITY: Philadelphia

/ STATE: PA

/ COUNTRY: U.S.A.

/ ZIP: 19103

/ COMPUTER READABLE FORM:

/ MEDIUM TYPE: 3.5 inch disk, 720 KB

/ COMPUTER: IBM PC compatible

/ OPERATING SYSTEM: PC-DOS/MS-DOS

/ SOFTWARE: WordPerfect 5.1

/ CURRENT APPLICATION DATA:

/ APPLICATION NUMBER: US/08/467,597A

/ FILING DATE: 06-JUN-1995

/ CLASSIFICATION: 514

/ PRIOR APPLICATION DATA:

/ APPLICATION NUMBER: 297,703

/ FILING DATE: 29-AUG-1994

/ ATTORNEY/AGENT INFORMATION:

/ NAME: Joseph Lucchi

/ REGISTRATION NUMBER: 33,307

/ REFERENCE/DOCKET NUMBER: ISIS-2007

/ TELECOMMUNICATION INFORMATION:

/ TELEPHONE: 215-568-3100

/ TELEFAX: 215-568-3439

/ INFORMATION FOR SEQ ID NO: 13:

/ SEQUENCE CHARACTERISTICS:

/ LENGTH: 15

/ TYPE: nucleic acid

/ STRANDEDNESS: single

/ TOPOLOGY: linear

/ MOLECULE TYPE: DNA (genomic)

US-08-467-597A-13

Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 2.4e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTCGCATAGTCG 572

Db 13 ACTTGATAGTCG 1

RESULT 334

US-08-182-968A-188/c

/ Sequence 188, Application US/08182968A

/ Patent No. 5610054

/ GENERAL INFORMATION:

/ APPLICANT: Draper, Kenneth G.

/ TITLE OF INVENTION: METHOD AND REAGENT FOR

/ CURRENT APPLICATION DATA:

/ APPLICATION NUMBER: US/08/182,968A

/ TITLE OF INVENTION: VIRUS REPLICATION

/ NUMBER OF SEQUENCES: 497

/ CORRESPONDENCE ADDRESS:

/ ADDRESS: Lyon & Lyon

/ STREET: 633 West Fifth Street

/ STREET: Suite 4700

/ CITY: Los Angeles

/ STATE: California

/ COUNTRY: U.S.A.

/ ZIP: 90071-2066

/ COMPUTER READABLE FORM:

/ MEDIUM TYPE: 3.5" Diskette, 1.44 MB

/ MEDIUM TYPE: storage

/ COMPUTER: IBM Compatible

/ OPERATING SYSTEM: IBM P.C. DOS 5.0

/ SOFTWARE: Word Perfect 5.1

/ CURRENT APPLICATION DATA:

/ APPLICATION NUMBER: US/08/182,968A

/ FILING DATE: 13-JANUARY-1994

/ PRIOR APPLICATION DATA:

/ APPLICATION NUMBER: 07/882,888

/ FILING DATE: 14-MAY-1992

/ ATTORNEY/AGENT INFORMATION:

/ NAME: Warburg, Richard J.

/ REGISTRATION NUMBER: 32,327

/ REFERENCE/DOCKET NUMBER: 205/277

/ TELECOMMUNICATION INFORMATION:

/ TELEPHONE: (213) 489-1600

/ TELEFAX: (213) 955-0440

/ TELETYPE: 67-3510

/ INFORMATION FOR SEQ ID NO: 188:

/ SEQUENCE CHARACTERISTICS:

/ LENGTH: 15

/ TYPE: nucleic acid

/ STRANDEDNESS: single

/ TOPOLOGY: linear

US-08-182-968A-188

Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 2.4e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 36 CAGTCCCAAGTG 48

Db 15 CAGTCCCAAGTG 3

RESULT 335

US-08-182-968A-246/c

/ Sequence 246, Application US/08182968A

/ Patent No. 5610054

/ GENERAL INFORMATION:

/ APPLICANT: Draper, Kenneth G.

/ TITLE OF INVENTION: METHOD AND REAGENT FOR

/ TITLE OF INVENTION: INHIBITING HEPATITIS C

/ NUMBER OF SEQUENCES: 497

/ CORRESPONDENCE ADDRESS:

/ ADDRESSEE: Lyon & Lyon

/ STREET: 633 West Fifth Street

/ STREET: Suite 4700

/ CITY: Los Angeles

/ STATE: California

/ COUNTRY: U.S.A.

/ ZIP: 90071-2066

/ COMPUTER READABLE FORM:

/ MEDIUM TYPE: 3.5" Diskette, 1.44 MB

/ MEDIUM TYPE: storage

/ COMPUTER: IBM Compatible

/ OPERATING SYSTEM: IBM P.C. DOS 5.0

/ SOFTWARE: Word Perfect 5.1

/ CURRENT APPLICATION DATA:

/ APPLICATION NUMBER: US/08/182,968A

```

; FILING DATE: 13-JANUARY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/882,888
; FILING DATE: 14-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 205/277
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEEX: 67-3510
; INFORMATION FOR SEQ ID NO: 246:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-182-968A-246

Query Match      0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      137 GTGATGCACAGAG 149
Db      14 GTGTTGCACAGAG 2

RESULT 336
US-07-971-978-12/c
; Sequence 12, Application US/07971978
; Patent No. 5614617
; GENERAL INFORMATION:
; APPLICANT: Cook and Sanghvi
; TITLE OF INVENTION: Nuclease Resistant, Pyrimidine
; TITLE OF INVENTION: Modified Oligonucleotides that Detect and Modulate
; TITLE OF INVENTION: Gene Expression
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and
; ADDRESSEE: No. 5614617r1s
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/971,978
; FILING DATE: February 18, 1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/558,806
; FILING DATE: July 27, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-0333
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)

```

```

; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 5
; OTHER INFORMATION: 6-aza-thymidine substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 7
; OTHER INFORMATION: 6-aza-thymidine substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 13
; OTHER INFORMATION: 6-aza-thymidine substitution
; US-07-971-978-12

Query Match      0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      560 ACTGCATAGTCG 572
Db      13 ACTGCATAGTCG 1

RESULT 337
US-07-971-978-26/c
; Sequence 26, Application US/07971978
; Patent No. 5614617
; GENERAL INFORMATION:
; APPLICANT: Cook and Sanghvi
; TITLE OF INVENTION: Nuclease Resistant, Pyrimidine
; TITLE OF INVENTION: Modified Oligonucleotides that Detect and Modulate
; TITLE OF INVENTION: Gene Expression
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and
; ADDRESSEE: No. 5614617r1s
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/971,978
; FILING DATE: February 18, 1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/558,806
; FILING DATE: July 27, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-0333
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 1
; OTHER INFORMATION: 6-aza-cytidine substitution
; NAME/KEY: Modified-site

```

LOCATION: 4
OTHER INFORMATION: 6-aza-cytidine substitution
FEATURE:
NAME/KEY: Modified-site
LOCATION: 9
OTHER INFORMATION: 6-aza-cytidine substitution
US-07-971-978-26

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
DB 13 ACTGCATAGTCG 1

RESULT 338
US-08-468-569A-13/C
Sequence 13, Application US/08468569A
GENERAL INFORMATION:
APPLICANT: Cook and Hoke
TITLE OF INVENTION: OLIGONUCLEOTIDES FOR MODULATING PROTEIN
TITLE OF INVENTION: KINASE C HAVING PHOSPHOROTHIOMATE LINKAGES
TITLE OF INVENTION: AND HIGH CHIRAL PURITY
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 56209631ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 Kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/468,569A
FILING DATE: 06-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 297,703
FILING DATE: 29-AUG-1994
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Luccl
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-2009
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-468-569A-13

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
DB 13 ACTGCATAGTCG 1

RESULT 339
US-08-470-129-2/C

Sequence 2, Application US/08470129
Patent No. 5635488
GENERAL INFORMATION:
APPLICANT: Phillip Dan Cook, Glenn Hoke
TITLE OF INVENTION: Compounds Having Phosphorothioate
TITLE OF INVENTION: Linkages Of High Chiral Purity
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5635488ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 Kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/470,129
FILING DATE: Herewith
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 297,703
FILING DATE: 29-AUG-1994
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Luccl
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-2013
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-470-129-2

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
DB 13 ACTGCATAGTCG 1

RESULT 340
US-08-466-692A-13/C
Sequence 13, Application US/08466692A
Patent No. 5654284
GENERAL INFORMATION:
APPLICANT: Cook and Hoke
TITLE OF INVENTION: OLIGONUCLEOTIDES FOR MODULATING RAP KINASE
TITLE OF INVENTION: HAVING PHOSPHOROTHIOMATE LINKAGES OF HIGH
TITLE OF INVENTION: CHIRAL PURITY
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5654284ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 Kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1


```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,692A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 297,703
; FILING DATE: 29-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-2010
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-466-692A-13

Query Match          0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      560 ACTGCATAGTCG 572
Db      13 ACTGCATAGTCG 1

RESULT 341
US-08-471-966A-13/c
; Sequence 13, Application US/08471966A
; Patent No. 5661134
; GENERAL INFORMATION:
; APPLICANT: Phillip Dan Cook and Glenn Hoke
; TITLE OF INVENTION: Oligonucleotides For Modulating Ha-ras or
; TITLE OF INVENTION: Ki-ras Having Phosphothioate Linkages Of High Chiral Purity
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5661134ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 KB
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/471,966A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 297,703
; FILING DATE: 29-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-2011
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```

```

; MOLECULE TYPE: DNA (genomic)
; US-08-471-966A-13

Query Match          0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      560 ACTGCATAGTCG 572
Db      13 ACTGCATAGTCG 1

RESULT 342
US-07-835-932A-1/c
; Sequence 1, Application US/07835932A
; Patent No. 5670633
; GENERAL INFORMATION:
; APPLICANT: Cook and Kawasaki
; TITLE OF INVENTION: Sugar Modified Oligonucleotides That
; TITLE OF INVENTION: Detect and Modulate Gene Expression
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Woodcock Washburn Kurtz
; ADDRESSEE: Mackiewicz & No. 5670633ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/835,932A
; FILING DATE: 19920305
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 566,977
; FILING DATE: AUGUST 13, 1990
; APPLICATION NUMBER: PCT/US91/05720
; FILING DATE: AUGUST 12, 1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0407
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: NUCLEIC
; STRANDEDNESS: single
; TOPOLOGY: linear
; ANTI-SENSE: Yes
; US-07-835-932A-1

Query Match          0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      560 ACTGCATAGTCG 572
Db      13 ACTGCATAGTCG 1

RESULT 343
US-07-835-932A-2/c
; Sequence 2, Application US/07835932A
; Patent No. 5670633
; GENERAL INFORMATION:
```

APPLICANT: Cook and Kawasaki
TITLE OF INVENTION: Sugar Modified Oligonucleotides That
TITLE OF INVENTION: Detect and Modulate Gene Expression
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz
ADDRESSEE: Mackiewicz & No. 5670633r1s
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/935,932A
FILING DATE: 19920305
CLASSIFICATION: 435
PRIOR APPLICATION NUMBER:
APPLICATION NUMBER: 566,977
FILING DATE: AUGUST 13, 1990
APPLICATION NUMBER: PCT/US91/05720
FILING DATE: AUGUST 12, 1991
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISIS-0407
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: NUCLEIC
STRANDEDNESS: single
TOPOLOGY: linear
ANTI-SENSE: yes
US-07-935-932A-2

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2,4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 560 ACTGCATGCTCG 572
Db 13 ACTGCATGCTCG 1

RESULT 344
US-08-255-892-27/c
Sequence 27, Application US/08255892
Patent No. 5695926
GENERAL INFORMATION:
APPLICANT: CROS, PHILIPPE
APPLICANT: ALBERT, PATRICE
APPLICANT: MALLET, FRANCOIS
APPLICANT: MARILLAT, CLAUDE
APPLICANT: MANDRAND, BERNARD
TITLE OF INVENTION: PROCEDURE FOR DETECTION OF A NUCLEOTIDE
TITLE OF INVENTION: SEQUENCE BY IMPLEMENTING THE SANDWICH HYBRIDIZATION
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: CUSHMAN, DARBY & CUSHMAN
STREET: 1100 NEW YORK AVENUE, N.W.
CITY: WASHINGTON
STATE: D.C.
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/255,892
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/834,543
FILING DATE: 11-FEB-1992
ATTORNEY/AGENT INFORMATION:
NAME: DEEVER, DONALD B.
REGISTRATION NUMBER: 23,048
REFERENCE/DOCKET NUMBER: 1032/94109
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-861-3000
TELEFAX: 202-822-0944
TELEX: 6714627 CUSH
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-255-892-27

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2,4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 18 TTTCGTGACACTG 30
Db 13 TTTCGTGACACTG 1

RESULT 345
US-08-217-082A-14/c
Sequence 14, Application US/08217082A
Patent No. 5734033
GENERAL INFORMATION:
APPLICANT: Reed, John
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES FOR INHIBITING THE
TITLE OF INVENTION: GROWTH OF CELLS EXPRESSING THE HUMAN BCL-2 GENE
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, WAIR & NEUSTADT,
ADDRESSEE: P.C.
STREET: 224 Airport Parkway
CITY: San Jose
STATE: California
COUNTRY: U.S.A.
ZIP: 95110
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/217,082A
FILING DATE: 24-MAR-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/840,716
FILING DATE: 21-FEB-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/288,692
FILING DATE: 22-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Fortney, Andrew D.
REGISTRATION NUMBER: 34,600
REFERENCE/DOCKET NUMBER: 3335-067-55 FWC

```
TELECOMMUNICATION INFORMATION:
TELEPHONE: (408) 436-2070
TELEFAX: (408) 436-2075
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: Synthetic DNA
ANTI-SENSE: YES
US-08-217-082A-14

Query Match      0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      377 CTGCGCGTGGCGCC 389
Db      13 CCGCGTGGCGCC 1

RESULT 346
US-08-475-467-12/c
Sequence 12, Application US/08475467
Patent No. 5760202
GENERAL INFORMATION:
APPLICANT: Cook, Philip Dan
APPLICANT: Sprankle, Kelly G.
APPLICANT: Rose, Bruce S.
APPLICANT: Springer, Robert, H.
TITLE OF INVENTION: Improved process for the
TITLE OF INVENTION: synthesis of 2'-O-substituted
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
ADDRESS: and No. 576020218
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 Kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/475,467
FILING DATE: herewith
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-1965
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-475-467-12

Query Match      0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      560 ACTGCGTAGTTCG 572
Db      13 ACTGCGTAGTTCG 1

RESULT 348
US-08-475-467-14/c
Sequence 14, Application US/08475467
Patent No. 5760202
GENERAL INFORMATION:
APPLICANT: Cook, Philip Dan
APPLICANT: Sprankle, Kelly G.
APPLICANT: Rose, Bruce S.
APPLICANT: Springer, Robert, H.
TITLE OF INVENTION: Improved process for the
TITLE OF INVENTION: synthesis of 2'-O-substituted
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
ADDRESS: and No. 576020218
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 Kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/475,467
FILING DATE: herewith
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-1965
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-475-467-13
```

```
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      560 ACTGCGTAGTTCG 572
Db      13 ACTGCGTAGTTCG 1

RESULT 347
US-08-475-467-13/c
Sequence 13, Application US/08475467
Patent No. 5760202
GENERAL INFORMATION:
APPLICANT: Cook, Philip Dan
APPLICANT: Sprankle, Kelly G.
APPLICANT: Rose, Bruce S.
APPLICANT: Springer, Robert, H.
TITLE OF INVENTION: Improved process for the
TITLE OF INVENTION: synthesis of 2'-O-substituted
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
ADDRESS: and No. 576020218
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 Kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/475,467
FILING DATE: herewith
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-1965
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-475-467-13

Query Match      0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      560 ACTGCGTAGTTCG 572
Db      13 ACTGCGTAGTTCG 1

RESULT 348
US-08-475-467-14/c
Sequence 14, Application US/08475467
Patent No. 5760202
GENERAL INFORMATION:
APPLICANT: Cook, Philip Dan
APPLICANT: Sprankle, Kelly G.
APPLICANT: Rose, Bruce S.
APPLICANT: Springer, Robert, H.
TITLE OF INVENTION: Improved process for the
TITLE OF INVENTION: synthesis of 2'-O-substituted
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
ADDRESS: and No. 576020218
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 Kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/475,467
FILING DATE: herewith
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-1965
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-475-467-13
```

```

; TITLE OF INVENTION: Improved process for the
; TITLE OF INVENTION: synthesis of 2'-O-substituted
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESSES:
; ADDRESSER: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 57602021s
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/475,467
; FILING DATE: herewith
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: John W. Caldwell
; REGISTRATION NUMBER: 28,937
; REFERENCE/DOCKET NUMBER: ISIS-1965
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3439
; TELEFAX: 215-568-3100
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-475-467-14

Query Match      0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      560 ACTGCATAGTCG 572
Db      13 ACTGCATAGTCG 1

RESULT 349
US-08-475-467-15/C
; Sequence 15, Application US/08475467
; Patent No. 5760202
; GENERAL INFORMATION:
; APPLICANT: Cook, Philip Dan
; APPLICANT: Sprankle, Kelly G.
; APPLICANT: Rose, Bruce S.
; APPLICANT: Springer, Robert, H.
; TITLE OF INVENTION: Improved process for the
; TITLE OF INVENTION: synthesis of 2'-O-substituted
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESSES:
; ADDRESSER: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 57602021s
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/475,467
; FILING DATE: herewith
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: John W. Caldwell
; REGISTRATION NUMBER: 28,937
; REFERENCE/DOCKET NUMBER: ISIS-1965
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3439
; TELEFAX: 215-568-3100
; INFORMATION FOR SEQ ID NO: 16:
```

```

; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/475,467
; FILING DATE: herewith
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: John W. Caldwell
; REGISTRATION NUMBER: 28,937
; REFERENCE/DOCKET NUMBER: ISIS-1965
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3439
; TELEFAX: 215-568-3100
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-475-467-15

Query Match      0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      560 ACTGCATAGTCG 572
Db      13 ACTGCATAGTCG 1

RESULT 350
US-08-475-467-16/C
; Sequence 16, Application US/08475467
; Patent No. 5760202
; GENERAL INFORMATION:
; APPLICANT: Cook, Philip Dan
; APPLICANT: Sprankle, Kelly G.
; APPLICANT: Rose, Bruce S.
; APPLICANT: Springer, Robert, H.
; TITLE OF INVENTION: Improved process for the
; TITLE OF INVENTION: synthesis of 2'-O-substituted
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESSES:
; ADDRESSER: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 57602021s
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/475,467
; FILING DATE: herewith
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: John W. Caldwell
; REGISTRATION NUMBER: 28,937
; REFERENCE/DOCKET NUMBER: ISIS-1965
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3439
; TELEFAX: 215-568-3100
; INFORMATION FOR SEQ ID NO: 16:
```

SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-475-467-16

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 560 ACTGCATAGTCG 572
13 ACTGCATAGTCG 1

RESULT 351
US-08-738-944-12
Sequence 12, Application US/08738944
Patent No. 5783431
GENERAL INFORMATION:
APPLICANT: Peterson, et al.
TITLE OF INVENTION: METHODS FOR GENERATING AND
NUMBER OF SEQUENCES: 51
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie & Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036/2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/738,944
FILING DATE: 24-OCT-1996
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: USSN 08/639,255
FILING DATE: 24-APR-1996
ATTORNEY/AGENT INFORMATION:
NAME: Coruzzi, Laura A
REGISTRATION NUMBER: 30,742
REFERENCE/DOCKET NUMBER: 8757-007
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-790-9090
TELEFAX: 212-869-8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
FEATURE:
NAME/KEY: Terminator for cDNA inserts
LOCATION: 1...15
OTHER INFORMATION:
NAME/KEY: Other
LOCATION: 5...6
OTHER INFORMATION: Terminator site
NAME/KEY: Other
LOCATION: 1
OTHER INFORMATION: Phosphate at nucleotide 1
US-08-738-944-12
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 314 CGAGGATCCCG 326
2 CGGGGATCCCG 14

RESULT 352
US-08-795-788-18/C
Sequence 18, Application US/08795788
Patent No. 5795770
GENERAL INFORMATION:
APPLICANT: GABER, RICHARD F.
TITLE OF INVENTION: GENETICALLY ENGINEERED EUKARYOTIC
TITLE OF INVENTION: ORGANISM CAPABLE OF DETECTING THE EXPRESSION OF
TITLE OF INVENTION: HETEROLOGOUS ION CHANNELS AND METHOD TO USE SAME
NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: TILTON, FALLOON, LUNGWUS & CHESTNUT
STREET: 100 SOUTH WACKER DRIVE, SUITE 960, HARTFORD
STREET: PLAZA
CITY: CHICAGO
STATE: ILLINOIS
COUNTRY: USA
ZIP: 60606-4002
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/795,788
FILING DATE: 05-FEB-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/923,094
FILING DATE: 31-JUL-1992
APPLICATION NUMBER: US 07/874,846
FILING DATE: 27-APR-1992
ATTORNEY/AGENT INFORMATION:
NAME: FENTRESS, SUSAN B.
REGISTRATION NUMBER: 31,327
REFERENCE/DOCKET NUMBER: NU-9211CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/456-8000
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
US-08-795-788-18
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 518 TCACAGAGAGAC 530
15 TCACAGTAGAGAC 3
Db 15 TCACAGTAGAGAC 3
RESULT 353
US-08-292-620A-708
Sequence 708, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McGwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper

```

/ TITLE OF INVENTION: RIBOZYME TREATMENT OF
/ TITLE OF INVENTION: DISEASES OR CONDITIONS
/ TITLE OF INVENTION: RELATED TO LEVELS OF
/ TITLE OF INVENTION: INTRACELLULAR ADHESION
/ TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
/ NUMBER OF SEQUENCES: 2390
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071-2066
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: Word Perfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/292,620A
/ FILING DATE: August 17, 1994
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ PRIOR APPLICATION DATA: including application
/ PRIOR APPLICATION DATA: described below:
/ APPLICATION NUMBER: 08/008,895
/ FILING DATE: January 19, 1993
/ APPLICATION NUMBER: 07/989,849
/ FILING DATE: December 7, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/149
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 708:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
US-08-292-620A-708

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 46.2%; Pred. No. 2.4e+02;
Matches 6; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 59 AAGTGTTCTTCT 71
DB 1 AGGUGUUCUUCU 13

RESULT 354
US-08-292-620A-740
/ Sequence 740, Application US/08292620A
/ Patent No. 5837542
/ GENERAL INFORMATION:
/ APPLICANT: Susan Grimm
/ APPLICANT: Dan T. Stinchcomb
/ APPLICANT: James McSwiggen
/ APPLICANT: Sean Sullivan
/ APPLICANT: Kenneth G. Draper
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF
/ TITLE OF INVENTION: DISEASES OR CONDITIONS
/ TITLE OF INVENTION: RELATED TO LEVELS OF
/ TITLE OF INVENTION: INTRACELLULAR ADHESION
/ TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
/ NUMBER OF SEQUENCES: 2390
/ CORRESPONDENCE ADDRESS:
```

```

/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071-2066
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: Word Perfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/292,620A
/ FILING DATE: August 17, 1994
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ PRIOR APPLICATION DATA: including application
/ PRIOR APPLICATION DATA: described below:
/ APPLICATION NUMBER: 08/008,895
/ FILING DATE: January 19, 1993
/ APPLICATION NUMBER: 07/989,849
/ FILING DATE: December 7, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/149
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 740:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
US-08-292-620A-740

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 46.2%; Pred. No. 2.4e+02;
Matches 6; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 59 AAGTGTTCTTCT 71
DB 1 AGGUGUUCUUCU 13

RESULT 355
US-08-468-037A-21/c
/ Sequence 21, Application US/08468037A
/ Patent No. 5859221
/ GENERAL INFORMATION:
/ APPLICANT: Phillip Dan Cook
/ APPLICANT: A. Kawasaki
/ TITLE OF INVENTION: 2'-Modified Oligonucleotides
/ NUMBER OF SEQUENCES: 37
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5859221iris
/ STREET: One Liberty Place - 46th Floor
/ CITY: Philadelphia
/ STATE: PA
/ COUNTRY: U.S.A.
/ ZIP: 19103
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5 inch disk, 720 Kb
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: WordPerfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/468,037A
/ FILING DATE: 06-JUN-1995
```

CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 835,932
FILING DATE: 05-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucci
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-2004
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-468-037A-21

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 356
US-08-468-037A-24/C
Sequence 24, Application US/08468037A
Patent No. 5859221
GENERAL INFORMATION:
APPLICANT: Phillip Dan Cook
APPLICANT: A. Kawasaki
TITLE OF INVENTION: 2'-Modified Oligonucleotides
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5859221ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 KB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/468,037A
FILING DATE: 06-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 835,932
FILING DATE: 05-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucci
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-2004
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-468-037A-24

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 357
US-08-890-084-12/C
Sequence 12, Application US/08890084
Patent No. 5861493
GENERAL INFORMATION:
APPLICANT: Cook, Phillip Dan
APPLICANT: Sprankle, Kelly G.
APPLICANT: Rose, Bruce S.
APPLICANT: Springer, Robert, H.
TITLE OF INVENTION: Improved process for the
SYNTHESIS OF 2'-O-SUBSTITUTED
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
and No. 5861493ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 KB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/890,084
FILING DATE:
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/475,467
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-1965
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-890-084-12

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 358
US-08-890-084-13/C
Sequence 13, Application US/08890084
Patent No. 5861493
GENERAL INFORMATION:
APPLICANT: Cook, Phillip Dan
APPLICANT: Sprankle, Kelly G.
APPLICANT: Rose, Bruce S.
APPLICANT: Springer, Robert, H.

```

; TITLE OF INVENTION: Improved process for the
; TITLE OF INVENTION: synthesis of 2'-O-substituted
; TITLE OF INVENTION: pyrimidines
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 5861493ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/890,084
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/475,467
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: John W. Caldwell
; REGISTRATION NUMBER: 28,937
; REFERENCE/DOCKET NUMBER: ISIS-1965
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-890-084-13

Query Match
Best Local Similarity 0.2%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 359
US-08-890-084-14/c
; Sequence 14, Application US/08890084
; Patent No. 5861493
; GENERAL INFORMATION:
; APPLICANT: Cook, Philip Dan
; APPLICANT: Sprankle, Kelly G.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Springer, Robert, H.
; TITLE OF INVENTION: Improved process for the
; TITLE OF INVENTION: synthesis of 2'-O-substituted
; TITLE OF INVENTION: pyrimidines
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 5861493ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/890,084
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/475,467
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: John W. Caldwell
; REGISTRATION NUMBER: 28,937
; REFERENCE/DOCKET NUMBER: ISIS-1965
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 15:
```

```

; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/890,084
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/475,467
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: John W. Caldwell
; REGISTRATION NUMBER: 28,937
; REFERENCE/DOCKET NUMBER: ISIS-1965
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-890-084-14

Query Match
Best Local Similarity 0.2%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 360
US-08-890-084-15/c
; Sequence 15, Application US/08890084
; Patent No. 5861493
; GENERAL INFORMATION:
; APPLICANT: Cook, Philip Dan
; APPLICANT: Sprankle, Kelly G.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Springer, Robert, H.
; TITLE OF INVENTION: Improved process for the
; TITLE OF INVENTION: synthesis of 2'-O-substituted
; TITLE OF INVENTION: pyrimidines
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 5861493ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/890,084
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/475,467
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: John W. Caldwell
; REGISTRATION NUMBER: 28,937
; REFERENCE/DOCKET NUMBER: ISIS-1965
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 15:
```


SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-890-084-15

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
DB 13 ACTGCATAGTCG 1

RESULT 361
US-08-890-084-16/c
Sequence 16, Application US/08890084
Patent No. 5861493
GENERAL INFORMATION:
APPLICANT: Cook, Philip Dan
APPLICANT: Sprinkle, Kelly G.
APPLICANT: Ross, Bruce S.
APPLICANT: Springer, Robert, H.
TITLE OF INVENTION: Improved process for the
TITLE OF INVENTION: synthesis of 2'-O-substituted
pyrimidines
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
ADDRESS: Woodcock Washburn Kurtz Mackiewicz
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 KB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/890,084
FILING DATE:
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/475,467
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-1965
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-890-084-16

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
DB 13 ACTGCATAGTCG 1

RESULT 362
US-08-774-306A-188/c
Sequence 246, Application US/08774306A
Patent No. 5869253
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 497
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,306A
FILING DATE: December 26, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/182,968
FILING DATE: January 13, 1994
APPLICATION NUMBER: 07/882,888
FILING DATE: May 14, 1992

ATTORNEY/AGENT INFORMATION:
NAME: Walburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/227
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 188:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-306A-188

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 36 CAGTCCCAATG 48
DB 15 CAGTCCCAATG 3

RESULT 363
US-08-774-306A-246/c
Sequence 246, Application US/08774306A
Patent No. 5869253
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 497
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

: COUNTRY: U.S.A.
: ZIP: 90071-2066
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
: MEDIUM TYPE: storage
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: IBM P.C. DOS 5.0
: SOFTWARE: Word Perfect 5.1
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/774,306A
: FILING DATE: December 26, 1996
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 08/182,968
: FILING DATE: January 13, 1994
: APPLICATION NUMBER: 07/882,888
: FILING DATE: May 14, 1992
: ATTORNEY/AGENT INFORMATION:
: NAME: Warburg, Richard J.
: REGISTRATION NUMBER: 32,327
: REFERENCE/DOCKET NUMBER: 223/227
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (213) 489-1600
: TELEFAX: (213) 955-0440
: TELETYPE: 67-3510
: INFORMATION FOR SEQ ID NO: 246:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 15
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: US-08-774-306A-246

```

```

Query Match          0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      137 GTGATGCACAGAG 149
DB      14 GTGTTGACAGAG 2

```

```

RESULT 364
US-08-471-973A-21/c
: Sequence 21, Application US/08471973A
: Patent No. 5872232
: GENERAL INFORMATION:
: APPLICANT: Phillip Dan Cook
: TITLE OF INVENTION: Sugar Modified Oligonucleotides
: NUMBER OF SEQUENCES: 37
: CORRESPONDENCE ADDRESS:
: ADDRESS: Woodcock Washburn Kurtz Mackiewicz and No. 5872232r1s
: STREET: One Liberty Place - 46th Floor
: CITY: Philadelphia
: STATE: PA
: COUNTRY: U.S.A.
: ZIP: 19103
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5 inch disk, 720 Kb
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: WordPerfect 5.1
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/471,973A
: FILING DATE: 06-JUN-1995
: CLASSIFICATION: 514
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 835,932
: FILING DATE: 05-MAR-1992
: ATTORNEY/AGENT INFORMATION:
: NAME: Joseph Lucchi
: REGISTRATION NUMBER: 33,307
: REFERENCE/DOCKET NUMBER: ISIS-2005

```

```

: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 215-568-3100
: TELEFAX: 215-568-3439
: INFORMATION FOR SEQ ID NO: 21:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 15 bases
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: US-08-471-973A-21

```

```

Query Match          0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      560 ACTGCATAGTCG 572
DB      13 ACTTGATAGTCG 1

```

```

RESULT 365
US-08-471-973A-24/c
: Sequence 24, Application US/08471973A
: Patent No. 5872232
: GENERAL INFORMATION:
: APPLICANT: Phillip Dan Cook
: TITLE OF INVENTION: Sugar Modified Oligonucleotides
: NUMBER OF SEQUENCES: 37
: CORRESPONDENCE ADDRESS:
: ADDRESS: Woodcock Washburn Kurtz Mackiewicz and No. 5872232r1s
: STREET: One Liberty Place - 46th Floor
: CITY: Philadelphia
: STATE: PA
: COUNTRY: U.S.A.
: ZIP: 19103
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5 inch disk, 720 Kb
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: WordPerfect 5.1
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/471,973A
: FILING DATE: 06-JUN-1995
: CLASSIFICATION: 514
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 835,932
: FILING DATE: 05-MAR-1992
: ATTORNEY/AGENT INFORMATION:
: NAME: Joseph Lucchi
: REGISTRATION NUMBER: 33,307
: REFERENCE/DOCKET NUMBER: ISIS-2005
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 215-568-3100
: TELEFAX: 215-568-3439
: INFORMATION FOR SEQ ID NO: 24:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 15 bases
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: US-08-471-973A-24

```

```

Query Match          0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      560 ACTGCATAGTCG 572
DB      13 ACTTGATAGTCG 1

```

```

RESULT 366

```

US-08-585-684B-1645/c
; Sequence 1645, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1645:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-1645

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 84 TCTGAATCAGCA 96
|||
Db 13 TCTGAGATCAGCA 1

RESULT 367
US-08-585-684B-1646/c
; Sequence 1646, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles

STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1646:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-1646

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 84 TCTGAATCAGCA 96
|||
Db 13 TCTGAGATCAGCA 1

RESULT 368
US-08-585-684B-1647/c
; Sequence 1647, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:

```

; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1647:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-1647

```

```

Query Match      0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      84 TCTGAATCAGCA 96
DB      13 TCTGATCAGCA 1

```

```

RESULT 369
US-08-585-684B-1648/c
; Sequence 1648, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESS: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1648:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-1648

```

```

Query Match      0.2%; Score 11.4; DB 1; Length 15;

```

```

Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      84 TCTGAATCAGCA 96
DB      13 TCTGATCAGCA 1

```

```

RESULT 370
US-08-585-684B-1675/c
; Sequence 1675, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESS: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1675:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-1675

```

```

Query Match      0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      577 CCAGAACTACC 589
DB      14 CCAAACTACTAC 2

```

```

RESULT 371
US-08-585-684B-1676/c
; Sequence 1676, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, James

```

TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1676:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-1676

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 577 CCAGAACTACC 589
DB 14 CCAAAATCTACC 2

RESULT 372
US-08-585-684B-2111/C
Sequence 2111, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2111:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-2111

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 231 GACCACAGAAAC 243
DB 15 GACCACAGACAAC 3

RESULT 373
US-08-774-310-59
Sequence 59, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ. ID NO: 59:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-59

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 76.9%; Pred. No. 2.4e+02;
Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 402 CCCGTTCCAGC 414
Db 2 CCCAGUCCAGC 14

RESULT 374
US-08-774-310-220
; Sequence 220, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISPHASIS
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ. ID NO: 220:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-310-220

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 76.9%; Pred. No. 2.4e+02;

Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
Qy 402 CCCGTTCCAGC 414
Db 2 CCCAGUCCAGC 14

RESULT 375
US-08-810-599-14/C
; Sequence 14, Application US/08810599
; Patent No. 5976798
; GENERAL INFORMATION:
; APPLICANT: PARKER, W. Davis
; APPLICANT: HERNSTADT, Corinna
; APPLICANT: GHOSH, Soumitra S.
; APPLICANT: FAHY, Boi
; TITLE OF INVENTION: Methods for Detecting Mitochondrial Mutations
; TITLE OF INVENTION: Diagnostic for Alzheimer's Disease and Methods for Determining
; TITLE OF INVENTION: of Mitochondrial Nucleic Acid
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: 1025 Connecticut Avenue, N.W., Suite 600
; CITY: Washington
; STATE: D.C.
; COUNTRY: US
; ZIP: 20036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.25" Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 6.1 for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/810,599
; FILING DATE: Concurrent Herewith
; CLASSIFICATION: 436
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/757,438
; FILING DATE: 27 No. 5976798 1996
; APPLICATION NUMBER: US 08/614,072
; FILING DATE: 12 Mar 1996
; APPLICATION NUMBER: US 08/536,036
; FILING DATE: 29 Sep 1995
; APPLICATION NUMBER: US 08/414,969
; FILING DATE: 31 Mar 1995
; APPLICATION NUMBER: US 08/413,740
; FILING DATE: 30 Mar 1995
; APPLICATION NUMBER: US 08/410,658
; FILING DATE: 24 MARCH 1995
; APPLICATION NUMBER: US 08/397,808
; FILING DATE: 3 Mar 1995
; APPLICATION NUMBER: US 08/219,842
; FILING DATE: 30 MARCH 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Toftennetti, Judith L.
; REGISTRATION NUMBER: 39,048
; REFERENCE/DOCKET NUMBER: 2105/17
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-429-1776
; TELEFAX: 202-429-0796
; INFORMATION FOR SEQ. ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; MOLECULE TYPE: linear
; TOPOLOGY: linear
; HYPOTHETICAL: No
; ANTI-SENSE: No
; US-08-810-599-14

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 257 GCTGATCATGAA 269

DB 15 GCGTGCATCATGAA 3

RESULT 376

US-09-035-357-21/C

Sequence 21, Application US/09035357

Patent No. 6005087

GENERAL INFORMATION:

APPLICANT: Phillip Dan Cook

APPLICANT: A. Kawasaki

TITLE OF INVENTION: 2'-Modified Oligonucleotides

NUMBER OF SEQUENCES: 37

CORRESPONDENCE ADDRESS:

ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6005087xis

STREET: One Liberty Place - 46th Floor

CITY: Philadelphia

STATE: PA

COUNTRY: U.S.A.

ZIP: 19103

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5 inch disk, 720 Kb

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: WordPerfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/035,357

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/468,037

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Joseph Lucci

REGISTRATION NUMBER: 33,307

REFERENCE/DOCKET NUMBER: ISIS-2004

TELECOMMUNICATION INFORMATION:

TELEPHONE: 215-568-3439

TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 21:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 bases

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-09-035-357-21

Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 2.4e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572

DB 13 ACTGCATAGTCG 1

RESULT 377

US-09-035-357-24/C

Sequence 24, Application US/09035357

Patent No. 6005087

GENERAL INFORMATION:

APPLICANT: Phillip Dan Cook

APPLICANT: A. Kawasaki

TITLE OF INVENTION: 2'-Modified Oligonucleotides

NUMBER OF SEQUENCES: 37

CORRESPONDENCE ADDRESS:

ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6005087xis

STREET: One Liberty Place - 46th Floor

CITY: Philadelphia

STATE: PA

COUNTRY: U.S.A.

ZIP: 19103

COUNTRY: U.S.A.

ZIP: 19103

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5 inch disk, 720 Kb

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: WordPerfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/035,357

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/468,037

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Joseph Lucci

REGISTRATION NUMBER: 33,307

REFERENCE/DOCKET NUMBER: ISIS-2004

TELECOMMUNICATION INFORMATION:

TELEPHONE: 215-568-3439

TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 24:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 bases

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-09-035-357-24

Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 2.4e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572

DB 13 ACTGCATAGTCG 1

RESULT 378

US-09-064-156A-188/C

Sequence 188, Application US/09064156A

Patent No. 6132966

GENERAL INFORMATION:

APPLICANT: Draper, Kenneth G.

TITLE OF INVENTION: METHOD AND REAGENT FOR

TITLE OF INVENTION: INHIBITING HEPATITIS C

NUMBER OF SEQUENCES: 498

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/064,156A

FILING DATE: April 21, 1998

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/774,306

FILING DATE: December 26, 1996

APPLICATION NUMBER: 08/182,968

FILING DATE: January 13, 1994

APPLICATION NUMBER: 07/882,888

FILING DATE: May 14, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 234/083
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 188:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-064-156A-188

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 36 CAGTCCCAAAATG 48
DB 15 CAGTCCCAAGATG 3

RESULT 379

US-09-064-156A-246/c
Sequence 246, Application US/09064156A
Patent No. 6132966
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 498
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/064,156A
FILING DATE: April 21, 1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/774,306
FILING DATE: December 26, 1996
APPLICATION NUMBER: 08/182,968
FILING DATE: January 13, 1994
APPLICATION NUMBER: 07/882,888
FILING DATE: May 14, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 234/083
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 246:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-064-156A-246

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 137 GTGATGACAGAG 149
DB 14 GTGTTGACAGAG 2

RESULT 380

US-09-071-845-708
Sequence 708, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 708:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-708

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 46.2%; Pred. No. 2.4e+02;
Matches 6; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 59 AAGTGTTCTTCT 71
|:|:|:|:|:|:|:

Db 1 AGUGGUCUCUCU 13

RESULT 381
US-09-071-845-740
Sequence 740, Application US/09071845
Patent No. 6132967

GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (1-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESS: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071.845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292.620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Waiburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 740:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-09-071-845-740

Query Match 0.2%, Score 11.4; DB 1; Length 15;
Best Local Similarity 46.2%; Pred. No. 2.4e+02;
Matches 6; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 59 AAGTGCTCTCTCT 71
|:|:|:|:|:|:|:
1 AGUGGUCUCUCU 13

Db 1 AGUGGUCUCUCU 13

RESULT 382
US-09-377-310-30/c
Sequence 30, Application US/09377310B
Patent No. 6133031

Db 1 AGUGGUCUCUCU 13

GENERAL INFORMATION:
APPLICANT: Monica, Brett P.
APPLICANT: Gaarde, William A.
TITLE OF INVENTION: Antisense Modulation of Focal Adhesion Kinase
EXPRESSION
FILE REFERENCE: ISPH-0389
CURRENT APPLICATION NUMBER: US/09/377.310B
CURRENT FILING DATE: 1999-08-19
NUMBER OF SEQ ID NOS: 43
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 30
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: antisense sequence

US-09-377-310-30

Query Match 0.2%, Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 293 TGGCAGCTCTCTTA 305
|:|:|:|:|:|:|:
13 TGGCAGCTCTCTTA 1

Db 13 TGGCAGCTCTCTTA 1

RESULT 383
US-09-038-073-1645/c
Sequence 1645, Application US/09038073
Patent No. 6194150

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESS: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038.073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Waiburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1645:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-09-038-073-1645

Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 2.4e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 84 TCTGAATCAGCA 96

Db 13 TCTGAGATCAGCA 1

RESULT 384

US-09-038-073-1646/c

; Sequence 1646, Application US/09038073

; Patent No. 6194150

; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Daniel T.

; APPLICANT: Jarvis, Thale

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE

; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE

; NUMBER OF SEQUENCES: 2751

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; STREET: Suite 4700

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; INFORMATION FOR SEQ ID NO: 1646:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; US-09-038-073-1646

; Query Match 0.2%; Score 11.4; DB 1; Length 15;

; Best Local Similarity 92.3%; Pred. No. 2.4e+02;

; Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

; QY 84 TCTGAATCAGCA 96

; Db 13 TCTGAGATCAGCA 1

; RESULT 385

; US-09-038-073-1647/c

; Sequence 1647, Application US/09038073

; Patent No. 6194150

; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Daniel T.

; APPLICANT: Jarvis, Thale

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE

; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE

; NUMBER OF SEQUENCES: 2751

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; STREET: Suite 4700

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071

; COMPUTER READABLE FORM:

; US-09-038-073-1647

; Sequence 1647, Application US/09038073

; Patent No. 6194150

; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Daniel T.

; APPLICANT: Jarvis, Thale

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE

; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE

; NUMBER OF SEQUENCES: 2751

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; STREET: Suite 4700

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071

; COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Wardburg, Richard
REGISTRATION NUMBER: 32,327
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1648:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1648

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 84 TCTGAATCAGCA 96
DB 13 TCTGAATCAGCA 1

RESULT 387
US-09-038-073-1675/C
Sequence 1675, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Wardburg, Richard
REGISTRATION NUMBER: 32,327
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1676:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1676

TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1675:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1675

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 577 CCAGATCTACC 589
DB 14 CCAGATCTACC 2

RESULT 388
US-09-038-073-1676/C
Sequence 1676, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Wardburg, Richard
REGISTRATION NUMBER: 32,327
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1676:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1676

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 577 CCAGATCTACC 589

Db 14 CCAAAATACTACC 2

RESULT 389

US-09-038-073-2111/c
; Sequence 2111, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038.073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2111:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-038-073-2111

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 231 GACCAAGAGAAAC 243
Db 15 GACCAAGAGAAC 3

RESULT 390

US-08-894-899-12/c
; Sequence 12, Application US/08894899
; Patent No. 622025
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Sanghvi, Yogesh S.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Griffey, Rich H.
; APPLICANT: Springer, Robert H.
; APPLICANT: Sprankle, Kelly G.
; TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidi

; TITLE OF INVENTION: Oligomeric Compounds Therefrom
; FILE REFERENCE: ISIS-2167
; CURRENT APPLICATION NUMBER: US/08/894,899
; CURRENT FILING DATE: 1998-01-07
; PRIOR APPLICATION NUMBER: PCT/US96/03174
; PRIOR FILING DATE: 1996-03-06
; PRIOR APPLICATION NUMBER: 08/475,467
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/398,901
; PRIOR FILING DATE: 1995-03-06
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 12
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: No. 622025e1 Sequence
US-08-894-899-12

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 391
US-08-894-899-13/c
; Sequence 13, Application US/08894899
; Patent No. 622025
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Sanghvi, Yogesh S.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Griffey, Rich H.
; APPLICANT: Springer, Robert H.
; APPLICANT: Sprankle, Kelly G.
; TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidi
; FILE REFERENCE: ISIS-2167
; CURRENT APPLICATION NUMBER: US/08/894,899
; CURRENT FILING DATE: 1998-01-07
; PRIOR APPLICATION NUMBER: PCT/US96/03174
; PRIOR FILING DATE: 1996-03-06
; PRIOR APPLICATION NUMBER: 08/475,467
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/398,901
; PRIOR FILING DATE: 1995-03-06
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 13
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: No. 622025e1 Sequence
US-08-894-899-13

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 392
US-08-894-899-14/c
; Sequence 14, Application US/08894899

Patent No. 6222025
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Sanghvi, Yogesh S.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Griffey, Rich H.
; APPLICANT: Springer, Robert H.
; APPLICANT: Sprankle, Kelly G.
; TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidin
; FILE REFERENCE: ISIS-2167
; CURRENT APPLICATION NUMBER: US/08/894, 899
; PRIOR FILING DATE: 1998-01-07
; PRIOR APPLICATION NUMBER: PCT/US96/03174
; PRIOR FILING DATE: 1996-03-06
; PRIOR APPLICATION NUMBER: 08/475,467
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/398,901
; PRIOR FILING DATE: 1995-03-06
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: No. 6222025e1 Sequence
US-08-894-899-14

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 393
US-08-894-899-15/c
; Sequence 15, Application US/08894899
; Patent No. 6222025
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Sanghvi, Yogesh S.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Griffey, Rich H.
; APPLICANT: Springer, Robert H.
; APPLICANT: Sprankle, Kelly G.
; TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidin
; FILE REFERENCE: ISIS-2167
; CURRENT APPLICATION NUMBER: US/08/894, 899
; PRIOR FILING DATE: 1998-01-07
; PRIOR APPLICATION NUMBER: PCT/US96/03174
; PRIOR FILING DATE: 1996-03-06
; PRIOR APPLICATION NUMBER: 08/475,467
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/398,901
; PRIOR FILING DATE: 1995-03-06
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 15
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: No. 6222025e1 Sequence
US-08-894-899-15

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 394
US-08-894-899-16/c
; Sequence 16, Application US/08894899
; Patent No. 6222025
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Sanghvi, Yogesh S.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Griffey, Rich H.
; APPLICANT: Springer, Robert H.
; TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidin
; FILE REFERENCE: ISIS-2167
; CURRENT APPLICATION NUMBER: US/08/894, 899
; PRIOR FILING DATE: 1998-01-07
; PRIOR APPLICATION NUMBER: PCT/US96/03174
; PRIOR FILING DATE: 1996-03-06
; PRIOR APPLICATION NUMBER: 08/475,467
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/398,901
; PRIOR FILING DATE: 1995-03-06
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 16
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: No. 6222025e1 Sequence
US-08-894-899-16

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 395
US-09-263-352-9
; Sequence 9, Application US/09263352
; Patent No. 6242211
; GENERAL INFORMATION:
; APPLICANT: Peterson, T.
; APPLICANT: Brian, P.
; TITLE OF INVENTION: METHODS FOR GENERATING AND SCREENING NOVEL METABOLIC
; FILE REFERENCE: 8757-010
; CURRENT APPLICATION NUMBER: US/09/263,352
; PRIOR FILING DATE: 1999-03-05
; EARLIER APPLICATION NUMBER: 08/986,186
; EARLIER FILING DATE: 1997-12-05
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 9
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: linker
US-09-263-352-9

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 314 CGAGGATCCCGG 326
 Db 2 CGGGGATCCCGG 14

RESULT 396
 US-08-383-66A-3/c
 ; Sequence 3, Application US/0838366A
 ; Patent No. 6262241
 ; GENERAL INFORMATION:
 ; APPLICANT: Cook et al.
 ; TITLE OF INVENTION: COMPOUNDS FOR DETECTING AND MODULATING
 ; TITLE OF INVENTION: RNA ACTIVITY AND GENE EXPRESSION
 ; NUMBER OF SEQUENCES: 21
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESS: Woodcock Washburn Kurtz Mackiewicz & No. 6262241ris LLP
 ; STREET: One Liberty Place - 46th Floor
 ; CITY: Philadelphia
 ; STATE: PA
 ; COUNTRY: U.S.A.
 ; ZIP: 19103
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5 inch disk, 1.44 MB
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Wordperfect 6.1
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/383,66A
 ; FILING DATE: 03-FEB-1995
 ; CLASSIFICATION: 435
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 07/854,634
 ; FILING DATE: 01-JUL-1992
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Joseph Lucci
 ; REGISTRATION NUMBER: 33,307
 ; REFERENCE/DOCKET NUMBER: 181S-1787
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 215-568-3100
 ; TELEFAX: 215-568-3439
 ; INFORMATION FOR SEQ ID NO: 3:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 15 bases
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-08-383-66A-3

Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 2.4e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 560 ACTGCATAGTCG 572
 Db 13 ACTGCATAGTCG 1

RESULT 397
 US-08-936-166-1/c
 ; Sequence 1, Application US/08936166A
 ; Patent No. 6307040
 ; GENERAL INFORMATION:
 ; APPLICANT: Cook, Phillip Dan
 ; APPLICANT: Kawasaki, Andrew M
 ; TITLE OF INVENTION: Sugar Modified Oligonucleotides That Detect And
 ; TITLE OF INVENTION: Modulate Gene Expression
 ; FILE REFERENCE: IS182708
 ; CURRENT APPLICATION NUMBER: US/08/936,166A
 ; CURRENT FILING DATE: 1997-09-23
 ; EARLIER APPLICATION NUMBER: 07/835,932
 ; EARLIER FILING DATE: 1992-03-05

; NUMBER OF SEQ ID NOS: 12
 ; SOFTWARE: Patentln Ver. 2.1
 ; SEQ ID NO 1
 ; LENGTH: 15
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: nucleoside
 ; US-08-936-166-1

Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 2.4e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
 Db 13 ACTGCATAGTCG 1

RESULT 398
 US-08-936-166-4/c
 ; Sequence 4, Application US/08936166A
 ; Patent No. 6307040
 ; GENERAL INFORMATION:
 ; APPLICANT: Cook, Phillip Dan
 ; APPLICANT: Kawasaki, Andrew M
 ; TITLE OF INVENTION: Sugar Modified Oligonucleotides That Detect And
 ; TITLE OF INVENTION: Modulate Gene Expression
 ; FILE REFERENCE: IS182708
 ; CURRENT APPLICATION NUMBER: US/08/936,166A
 ; CURRENT FILING DATE: 1997-09-23
 ; EARLIER APPLICATION NUMBER: 07/835,932
 ; EARLIER FILING DATE: 1992-03-05
 ; NUMBER OF SEQ ID NOS: 12
 ; SOFTWARE: Patentln Ver. 2.1
 ; SEQ ID NO 4
 ; LENGTH: 15
 ; TYPE: RNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: nucleoside
 ; OTHER INFORMATION: having a modified sugar moiety
 ; US-08-936-166-4

Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 2.4e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
 Db 13 ACTGCATAGTCG 1

RESULT 399
 US-08-936-166-8/c
 ; Sequence 8, Application US/08936166A
 ; Patent No. 6307040
 ; GENERAL INFORMATION:
 ; APPLICANT: Cook, Phillip Dan
 ; APPLICANT: Kawasaki, Andrew M
 ; TITLE OF INVENTION: Sugar Modified Oligonucleotides That Detect And
 ; TITLE OF INVENTION: Modulate Gene Expression
 ; FILE REFERENCE: IS182708
 ; CURRENT APPLICATION NUMBER: US/08/936,166A
 ; CURRENT FILING DATE: 1997-09-23
 ; EARLIER APPLICATION NUMBER: 07/835,932
 ; EARLIER FILING DATE: 1992-03-05
 ; NUMBER OF SEQ ID NOS: 12
 ; SOFTWARE: Patentln Ver. 2.1
 ; SEQ ID NO 8
 ; LENGTH: 15
 ; TYPE: RNA

ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: nucleoside
OTHER INFORMATION: having a modified sugar moiety
US-08-936-166-8

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 400
US-08-829-637A-134/c
Sequence 134, Application US/08829637A
Patent No. 6339066
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Phillip Dan Cook
APPLICANT: Nicholas Dean
APPLICANT: Glenn Hoke
TITLE OF INVENTION: OLIGONUCLEOTIDES WHICH HAVE
TITLE OF INVENTION: PHOSPHOROTHIATE LINKAGES OF HIGH CHIRAL PURITY AND
TITLE OF INVENTION: WHICH MODULATE a1, a11, 'k, n, AND ISOFORMS OF
TITLE OF INVENTION: PROTEIN KINASE C
NUMBER OF SEQUENCES: 136
CORRESPONDENCE ADDRESS:
ADDRESSEE: John W. Caldwell (28,937) Woodcock
ADDRESSEE: Washburn Kurtz Mackiewicz & No. 6339066r1s
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/829,637A
FILING DATE: herewith
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/481,066
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/470,129
FILING DATE: 06-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/469,851
FILING DATE: 06-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/468,569
FILING DATE: 06-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/089,996
FILING DATE: 09-JUL-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/058,023
FILING DATE: 05-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/777,007
FILING DATE: 16-OCT-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/777,760
FILING DATE: 15-OCT-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/852,852
FILING DATE: 16-MAR-1992

PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/00243
FILING DATE: 11-JAN-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/566,977
FILING DATE: 13-AUG-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/436,358
FILING DATE: 11-JAN-1990
ATTORNEY/AGENT INFORMATION:
NAME:
REGISTRATION NUMBER:
REFERENCE/DOCKET NUMBER: ISIS-
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 134:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
ANTI-SENSE: Yes
US-08-829-637A-134

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 401
US-09-135-202-21/c
Sequence 21, Application US/09135202
Patent No. 6399754
GENERAL INFORMATION:
APPLICANT: Phillip Dan Cook
APPLICANT: Andrew Kawasaki
TITLE OF INVENTION: Sugar Modified Oligonucleotides
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 6399754r1s
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 Kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/135,202
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/471,973
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucet
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-2005
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid

```
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-09-135-202-21

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 402
US-09-135-202-24/c
Sequence 24, Application US/09135202
Patent No. 6399754
GENERAL INFORMATION:
APPLICANT: Phillip Dan Cook
APPLICANT: Andrew Kawasaki
TITLE OF INVENTION: Sugar Modified Oligonucleotides
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:
ADDRESS: Woodcock Washburn Kurtz Mackiewicz and No. 6399754aris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 KB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/135,202
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/471,973
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucel
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-2005
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-135-202-24

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 403
US-09-475-947A-311/c
Sequence 311, Application US/09475947A
Patent No. 6472154
GENERAL INFORMATION:
APPLICANT: Garner, Harold R.
APPLICANT: Wren, Jonathan D.
APPLICANT: Minna, John D.
```

```
/ TITLE OF INVENTION: Polymorphic Repeats in Human Genes
/ FILE REFERENCE: UTS0667
/ CURRENT APPLICATION NUMBER: US/09/475,947A
/ CURRENT FILING DATE: 1999-12-31
/ NUMBER OF SEQ ID NOS: 346
/ SOFTWARE: Patentln Ver. 2.1
/ SEQ ID NO 311
/ LENGTH: 15
/ TYPE: DNA
/ ORGANISM: human
US-09-475-947A-311

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 66 TCTTCTCTCTCT 78
Db 14 TCTTCTCTCTCT 2

RESULT 404
US-09-475-947A-312/c
Sequence 312, Application US/09475947A
Patent No. 6472154
GENERAL INFORMATION:
APPLICANT: Garner, Harold R.
APPLICANT: Wren, Jonathan D.
APPLICANT: Minna, John D.
TITLE OF INVENTION: Polymorphic Repeats in Human Genes
FILE REFERENCE: UTS0667
CURRENT APPLICATION NUMBER: US/09/475,947A
CURRENT FILING DATE: 1999-12-31
NUMBER OF SEQ ID NOS: 346
SOFTWARE: Patentln Ver. 2.1
/ SEQ ID NO 312
/ LENGTH: 15
/ TYPE: DNA
/ ORGANISM: human
US-09-475-947A-312

Query Match
Best Local Similarity 92.3%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 66 TCTTCTCTCTCT 78
Db 14 TCTTCTCTCTCT 2

RESULT 405
US-09-784-917-7/c
Sequence 7, Application US/09784917
Patent No. 6500945
GENERAL INFORMATION:
APPLICANT: Cook, Phillip Dan
TITLE OF INVENTION: Oligonucleotides Having Chiral Phosphorus Linkages
FILE REFERENCE: ISIS4732
CURRENT APPLICATION NUMBER: US/09/784,917
CURRENT FILING DATE: 2002-05-07
PRIOR APPLICATION NUMBER: 09/208,533
PRIOR FILING DATE: 1998-12-09
PRIOR APPLICATION NUMBER: 08/635,009
PRIOR FILING DATE: 1996-04-19
PRIOR APPLICATION NUMBER: 08/058,023
PRIOR FILING DATE: 1993-05-05
PRIOR APPLICATION NUMBER: PCT/US91/00243
PRIOR FILING DATE: 1991-01-11
PRIOR APPLICATION NUMBER: 07/777,670
PRIOR FILING DATE: 1991-10-15
PRIOR APPLICATION NUMBER: 07/463,358
PRIOR FILING DATE: 1990-01-11
PRIOR APPLICATION NUMBER: 07/566,977
```


; PRIOR FILING DATE: 1990-08-13
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO: 7
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-784-917-7

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 406
US-09-474-432B-142
; Sequence 142, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MHHB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; PRIOR FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 142
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-142

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 76.9%; Pred. No. 2.4e+02;
Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 269 ACTACTGCAGGAA 281
Db 2 ACUCGUCGAGGAA 14

RESULT 407
US-09-389-283-21/c
; Sequence 21, Application US/09389283
; Patent No. 6531584
; GENERAL INFORMATION:
; APPLICANT: Phillip Dan Cook
; APPLICANT: A. Kawasaki
; TITLE OF INVENTION: 2'-Modified Oligonucleotides
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESSES:
; ADDRESS: Woodcock Washburn Kurtz Mackiewicz & No. 6531584 is
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia

STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 Kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/389,283
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/035,357
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucci
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-2004
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-389-283-21

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 408
US-09-389-283-24/c
; Sequence 24, Application US/09389283
; Patent No. 6531584
; GENERAL INFORMATION:
; APPLICANT: Phillip Dan Cook
; APPLICANT: A. Kawasaki
; TITLE OF INVENTION: 2'-Modified Oligonucleotides
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESSES:
; ADDRESS: Woodcock Washburn Kurtz Mackiewicz & No. 6531584 is
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 Kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/389,283
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/035,357
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucci
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-2004
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100

TELEFAX: 215-568-1439
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-389-283-24

Query Match

Best Local Similarity 0.2%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Pred. No. 2.4e+02;
Mismatches 1; Indels 0; Gaps 0;

Qy 560 ACTCGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 409

US-09-770-532-16/C
Sequence 16, Application US/09770532
Patent No. 6583279
GENERAL INFORMATION:
APPLICANT: Berger, Dolores M.
APPLICANT: Nusbaumer, William A.
APPLICANT: Fort, Thomas L.
APPLICANT: Hellyer, Tobin J.
TITLE OF INVENTION: Sequences and Methods for Detection of Hepatitis B
FILE REFERENCE: Seq/Mtds for Detection of HBV
CURRENT APPLICATION NUMBER: US/09/770,532
NUMBER OF SEQ ID NOS: 20
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 16
LENGTH: 15
TYPE: DNA
ORGANISM: Hepatitis B virus
US-09-770-532-16

Query Match

Best Local Similarity 0.2%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Pred. No. 2.4e+02;
Mismatches 1; Indels 0; Gaps 0;

Qy 277 AGGAATCCAGATG 289
Db 13 AGGAATCTGATG 1

RESULT 410

US-09-476-387-142
Sequence 142, Application US/09476387
Patent No. 6617438
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka Matulic
APPLICANT: Sweedler, Dave
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
FILE REFERENCE: MBH00-831-C (249/073)
CURRENT APPLICATION NUMBER: US/09/476,387
PRIOR FILING DATE: 2001-04-04
PRIOR APPLICATION NUMBER: 09/474,432
PRIOR FILING DATE: 1999-12-29
PRIOR APPLICATION NUMBER: 09/301,511
PRIOR FILING DATE: 1999-04-28
PRIOR APPLICATION NUMBER: 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: 60/083,727
PRIOR FILING DATE: 1998-04-29

PRIOR APPLICATION NUMBER: 60/064,866
PRIOR FILING DATE: 1997-11-05
NUMBER OF SEQ ID NOS: 1524
SOFTWARE: PatentIn version 3.0
SEQ ID NO 142
LENGTH: 15
TYPE: RNA
ORGANISM: Homo sapiens
US-09-476-387-142

Query Match

Best Local Similarity 0.2%; Score 11.4; DB 1; Length 15;
Matches 10; Conservative 2; Pred. No. 2.4e+02;
Mismatches 1; Indels 0; Gaps 0;

Qy 269 ACTACTGCAGGAA 281
Db 2 ACUGCUCAGAGAA 14

RESULT 411

US-09-747-009A-12/C
Sequence 12, Application US/09747009A
Patent No. 6642367
GENERAL INFORMATION:
APPLICANT: Cook, Phillip Dan
APPLICANT: Sanghvi, Yogesh S.
APPLICANT: Ross, Bruce S.
APPLICANT: Griffey, Rich H.
APPLICANT: Sprinkle, Robert H.
TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidine
FILE REFERENCE: ISIS-4684
CURRENT APPLICATION NUMBER: US/09/747,009A
CURRENT FILING DATE: 2000-12-22
PRIOR APPLICATION NUMBER: 08/894,899
PRIOR FILING DATE: 1998-01-07
PRIOR APPLICATION NUMBER: PCT/US96/03174
PRIOR FILING DATE: 1996-01-07
PRIOR APPLICATION NUMBER: 08/475,467
PRIOR FILING DATE: 1995-06-07
PRIOR APPLICATION NUMBER: 08/398,901
PRIOR FILING DATE: 1995-03-06
NUMBER OF SEQ ID NOS: 31
SOFTWARE: PatentIn version 3.1
SEQ ID NO 12
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: No. 6642367el Sequence
US-09-747-009A-12

Query Match

Best Local Similarity 0.2%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Pred. No. 2.4e+02;
Mismatches 1; Indels 0; Gaps 0;

Qy 560 ACTCGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 412

US-09-747-009A-13/C
Sequence 13, Application US/09747009A
Patent No. 6642367
GENERAL INFORMATION:
APPLICANT: Cook, Phillip Dan
APPLICANT: Sanghvi, Yogesh S.
APPLICANT: Ross, Bruce S.
APPLICANT: Griffey, Rich H.
APPLICANT: Sprinkle, Robert H.

QY	560	ACTGCATAGTCG	572
Db	13	ACTTGCATAGTCG	1

FILE REFERENCE: ISIS-4684
CURRENT APPLICATION NUMBER: US/09/7/747, 0092A
CURRENT FILING DATE: 2000-12-22
PRIOR APPLICATION NUMBER: 08/894, 899
PRIOR FILING DATE: 1998-01-07
PRIOR APPLICATION NUMBER: PCT/US96/03174
PRIOR FILING DATE: 1996-01-07
PRIOR APPLICATION NUMBER: 08/475, 467
PRIOR FILING DATE: 1995-06-07
PRIOR APPLICATION NUMBER: 08/398, 901
PRIOR FILING DATE: 1995-03-06
NUMBER OF SEQ ID NOS: 31
SOFTWARE: PatentIn version 3.1
SEQ ID NO 16
LENGTH: 15

TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: No. 6642367el Sequence
US-09-747-009A-16

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
DB 13 ACTGCATAGTCG 1

RESULT 416
US-09-689-012-5
Sequence 5, Application US/09689012
Patent No. 6670135
GENERAL INFORMATION:
APPLICANT: SPIRIGS, Melanie K.
TITLE OF INVENTION: NOVEL SEMAPHORIN POLYPEPTIDES
FILE REFERENCE: 2634-US
CURRENT APPLICATION NUMBER: US/09/689,012
CURRENT FILING DATE: 2000-10-12
PRIOR APPLICATION NUMBER: PCT/US99/09831
PRIOR FILING DATE: 1999-05-05
PRIOR APPLICATION NUMBER: US 60/085,497
PRIOR FILING DATE: 1998-05-14
NUMBER OF SEQ ID NOS: 10
SOFTWARE: Patent version 3.1
SEQ ID NO 5
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: PRIMER
US-09-689-012-5

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 66 TCTTCTACTTCTT 78
DB 1 TCTTCTACTTCTT 13

RESULT 417
US-10-150-696-7/c
Sequence 7, Application US/10150696
Patent No. 6699979
GENERAL INFORMATION:
APPLICANT: Cook, Phillip Dan
TITLE OF INVENTION: OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES
FILE REFERENCE: ISIS-5033
CURRENT APPLICATION NUMBER: US/10/150,696
CURRENT FILING DATE: 2002-05-17
PRIOR APPLICATION NUMBER: US 09/784,917
PRIOR FILING DATE: 2001-02-16
PRIOR APPLICATION NUMBER: US 09/208,533
PRIOR FILING DATE: 1998-12-09
PRIOR APPLICATION NUMBER: US 08/635,009
PRIOR FILING DATE: 1996-04-19
PRIOR APPLICATION NUMBER: US 08/058,023
PRIOR FILING DATE: 1993-05-05
PRIOR APPLICATION NUMBER: US 07/777,670
PRIOR FILING DATE: 1991-10-15
NUMBER OF SEQ ID NOS: 8
SOFTWARE: Patent version 3.2
SEQ ID NO 7
LENGTH: 15
TYPE: DNA

ORGANISM: Homo sapiens
US-10-150-696-7

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
DB 13 ACTGCATAGTCG 1

RESULT 418
PCT-US93-03942-16/c
Sequence 18, Application PC/TUS9303942
GENERAL INFORMATION:
APPLICANT: GABER, RICHARD F.
TITLE OF INVENTION: GENETICALLY ENGINEERED EUKARYOTIC
TITLE OF INVENTION: ORGANISM CAPABLE OF DETECTING THE EXPRESSION
TITLE OF INVENTION: OF HETEROLOGOUS ION CHANNELS AND METHOD TO
TITLE OF INVENTION: USE SAME
NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: TILTON, FALLON, LUNGKUS & CHESTNUT
STREET: 100 SOUTH WACKER DRIVE, SUITE 960, HARTFORD PLAZA
CITY: CHICAGO
STATE: ILLINOIS
COUNTRY: USA
ZIP: 60606-4002
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/03942
FILING DATE: 19930421
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/874,846
FILING DATE: 27-APR-1992
ATTORNEY/AGENT INFORMATION:
NAME: FENTRESS, SUSAN B.
REGISTRATION NUMBER: 31,327
REFERENCE/DOCKET NUMBER: NU-9211CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/456-8000
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
PCT-US93-03942-18

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 518 TCACGAGAAAGAC 530
DB 15 TCACGAGTAAGAC 3

RESULT 419
PCT-US96-08757A-13/c
Sequence 13, Application PC/TUS9608757A
GENERAL INFORMATION:
APPLICANT: ISIS Pharmaceuticals, Inc., et al.
TITLE OF INVENTION: Oligonucleotides Having Phosphorothioate
Linkages Of High Chiral Purity
NUMBER OF SEQUENCES: 17

;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & Norris
;; STREET: One Liberty Place - 46th Floor
;; CITY: Philadelphia
;; STATE: PA
;; COUNTRY: U.S.A.
;; ZIP: 19103
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5 inch disk, 720 KB
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: WordPerfect 6.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: PCT/US96/08757A
;; FILING DATE: 05-JUN-1996
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/471,967
;; FILING DATE: 06-JUN-1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/467,597
;; FILING DATE: 06-JUN-1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/468,447
;; FILING DATE: 06-JUN-1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/468,569
;; FILING DATE: 06-JUN-1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/466,692
;; FILING DATE: 06-JUN-1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/471,966
;; FILING DATE: 06-JUN-1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/469,851
;; FILING DATE: 06-JUN-1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/470,129
;; FILING DATE: 06-JUN-1995
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Joseph Lucchi
;; REGISTRATION NUMBER: 33,307
;; REFERENCE/DOCKET NUMBER: ISIS-2298
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 215-568-3100
;; TELEFAX: 215-568-3439
;; INFORMATION FOR SEQ ID NO: 13:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;; PCT-US96-08757A-13

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 420
US-09-227-701-3
; Sequence 3, Application US/09227701
; Patent No. 6512161
; GENERAL INFORMATION:
; APPLICANT: Rouy, Didier
; APPLICANT: Duverget, Nicolas
; APPLICANT: Emmanuel, Florence

;; APPLICANT: Deneffe, Patrice
;; APPLICANT: Houdeline, Louis-Marie
;; APPLICANT: Viglietta, Celine
;; APPLICANT: Rubin, Edward M.
;; APPLICANT: Hughes, Steven D.
;; TITLE OF INVENTION: TRANSGENIC RABBIT THAT EXPRESSES A FUNCTIONAL HUMAN
;; FILE REFERENCE: 22841A USA
;; CURRENT APPLICATION NUMBER: US/09/227,701
;; EARLIER APPLICATION NUMBER: 60/070727
;; EARLIER FILING DATE: 1998-01-08
;; NUMBER OF SEQ ID NOS: 11
;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO: 3
;; LENGTH: 26
;; TYPE: DNA
;; ORGANISM: Homo sapiens
;; US-09-227-701-3

Query Match 0.2%; Score 11.4; DB 1; Length 26;
Best Local Similarity 71.4%; Pred. No. 4.6e+02;
Matches 15; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Oy 409 CCAAGCTTAGAGCTCTTCC 429
Db 6 CCAAGCTTAGAGCTCTTCC 26

RESULT 421
5185259-1/c
; Patent No. 5185259
; APPLICANT: GOEDDEL, DAVID V.; KOHR, WILLIAM J.; PENNICK, DIANE;
; VEHAR, GORDON A.
; TITLE OF INVENTION: TRUNCATED HUMAN TISSUE PLASMINOGEN
; ACTIVATOR
; NUMBER OF SEQUENCES: 15
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/489,855
; FILING DATE: 02-MAR-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 12,694
; FILING DATE: 09-FEB-1987
; APPLICATION NUMBER: 483,052
; FILING DATE: 07-APR-1983
; APPLICATION NUMBER: 398,003
; FILING DATE: 14-JUL-1982
; APPLICATION NUMBER: 374,860
; FILING DATE: 05-MAY-1982
; SEQ ID NO: 1
; LENGTH: 14
; 5185259-1

Query Match 0.2%; Score 11.2; DB 1; Length 14;
Best Local Similarity 71.4%; Pred. No. 2.3e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Oy 334 TGGGAGTACTGCAA 347
Db 14 TGGGAGTACTGCGA 1

RESULT 422
5212286-61/c
; Patent No. 5212286
; APPLICANT: LEWICKI, JOHN A.; SCARBOROUGH, ROBERT M.
; TITLE OF INVENTION: ATRIAL NATRIURETIC/VASODILATOR
; PEPTIDE COMPOUNDS
; NUMBER OF SEQUENCES: 68
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/870,795
; FILING DATE: 05-JUN-1986
; PRIOR APPLICATION DATA:

APPLICATION NUMBER: 766,030
FILING DATE: 08-MAY-1985
APPLICATION NUMBER: 602,117
FILING DATE: 09-APR-1984
APPLICATION NUMBER: 616,488
FILING DATE: 01-JUN-1984
SEQ ID NO:61
LENGTH: 12
5212286-61

Query Match 0.2%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred.No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 191 GCCAGCTTGG 201
DB 11 GCCAGCTTGG 1

RESULT 423
US-08-608-584-10

Sequence 10, Application US/08608584
Patent No. 5667994
GENERAL INFORMATION:

APPLICANT: Dilly, Karen A.
APPLICANT: Bustos, Silvia A.
APPLICANT: Roszkowski, Christine A.
APPLICANT: Berger, Dolores
TITLE OF INVENTION: AMPLIFICATION AND DETECTION OF
NUMBER OF INVENTION: MYCOBACTERIUM AVIUM COMPLEX SPECIES
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSER: R. J. Rodrick, Becton Dickinson and Company
STREET: 1 Becton Drive
CITY: Franklin Lakes
STATE: NJ
COUNTRY: US
ZIP: 07417

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/608,584
FILING DATE:

CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Fugit, Donna R.
REGISTRATION NUMBER: 32,135
REFERENCE/DOCKET NUMBER: P-3550
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-608-584-10

Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred.No. 2.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 385 GCGCCTCCGAC 395
DB 3 GCGCCTCCGAC 13

RESULT 424
US-08-520-194-7

Sequence 7, Application US/08520194
Patent No. 5681705
GENERAL INFORMATION:

APPLICANT: Schram, James L.
APPLICANT: Nadeau, James G.
APPLICANT: Dean, Cheryl H.
TITLE OF INVENTION: AMPLIFICATION AND DETECTION OF
NUMBER OF INVENTION: MYCOBACTERIUM AVIUM COMPLEX SPECIES
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSER: Richard J. Rodrick, Becton Dickinson and
STREET: 1 Becton Drive
CITY: Franklin Lakes
STATE: NJ
COUNTRY: US
ZIP: 07417

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/520,194
FILING DATE:

CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Fugit, Donna R.
REGISTRATION NUMBER: P-3274
REFERENCE/DOCKET NUMBER: 32,135
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-520-194-7

Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred.No. 2.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 385 GCGCCTCCGAC 395
DB 3 GCGCCTCCGAC 13

RESULT 425
US-08-985-162-1851/C
Sequence 1851, Application US/08985162
Patent No. 6057156
GENERAL INFORMATION:

APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwigen, James
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:

Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred.No. 2.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1851:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-1851

Query Match 0.2%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 479 GTATGCACAGT 492
Db 14 GGAAGGACAGAGT 1

RESULT 426
US-08-765-340-122/c
Sequence 122, Application US/08765340
GENERAL INFORMATION:
APPLICANT: UCHIDA, K.
APPLICANT: UCHIDA, T.
APPLICANT: TANAKA, Y.
APPLICANT: MATSUDA, Y.
APPLICANT: KONDO, S.
TITLE OF INVENTION: AN ANTISENSE NUCLEIC ACID
TITLE OF INVENTION: COMPOUND
NUMBER OF SEQUENCES: 185
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORGAN & PINNEGAN, L.L.P.
STREET: 345 PARK AVENUE
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10154
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version
SOFTWARE: #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/765,340
FILING DATE: 23-DEC-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 145146/94
FILING DATE: 27-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 311130/94
FILING DATE: 21-NOV-1994
ATTORNEY/AGENT INFORMATION:
NAME: SERUNIAN, LESLIE
REGISTRATION NUMBER: 35,353
REFERENCE/DOCKET NUMBER: 1452-4005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 758-4800
TELEFAX: (212) 751-6849

INFORMATION FOR SEQ ID NO: 122:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "synthetic DNA"
US-08-765-340-122

Query Match 0.2%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 52 CATACAGAGTGT 65
Db 14 CATCAGAGTGT 1

RESULT 427
US-08-535-249-63/c
Sequence 63, Application US/08535249
GENERAL INFORMATION:
APPLICANT: Schlengersiepen, Georg-Ferdinand
APPLICANT: Brysch, Wolfgang
APPLICANT: Schlengersiepen, Karl-Hermann
APPLICANT: Schlengersiepen, Reimar
APPLICANT: Bogdahn, Ulrich
TITLE OF INVENTION: Antisense-oligonucleotides for the treatment of
TITLE OF INVENTION: Immuno-suppressive effect of transforming-growth-factor beta
NUMBER OF SEQUENCES: 137
CORRESPONDENCE ADDRESS:
ADDRESSEE: Jacobson, Price, Holman & Stern
STREET: 400 Seventh St. N.W.
CITY: Washington D.C.
COUNTRY: U.S.A.
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/535,249
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 93 107 089.0
FILING DATE: 30-APR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 93 107 849.7
FILING DATE: 13-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Player, William E.
REGISTRATION NUMBER: 31,409
REFERENCE/DOCKET NUMBER: 10577/P58418
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 638-6666
TELEFAX: (202) 393-5350
TELEX: RCA 248593 IDEA UR
INFORMATION FOR SEQ ID NO: 63:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: YES
US-08-535-249-63

Query Match 0.2%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.6e+02;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 95 CAGCAGCTGAGCAA 108
Db 14 CAGATCCTGAGCAA 1

RESULT 428
US-09-401-063-1851/c
; Sequence 1851, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1851:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-401-063-1851
Query Match 0.2%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 479 GTAATGACAGACT 492
Db 14 GGAAGGAGCAGACT 1

RESULT 429
US-09-384-327-4
; Sequence 4, Application US/09384327
; Patent No. RE37806
; GENERAL INFORMATION:

APPLICANT: Grinnell, Brian W.
TITLE OF INVENTION: METHOD FOR COMPLICATION OF HUMAN
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Eli Lilly and Company
STREET: Lilly Corporate Center/Parent Division
CITY: Indianapolis
STATE: IN
COUNTRY: US
ZIP: 46285
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/384,327
; FILING DATE: 16-Aug-1999
; CLASSIFICATION: <Unknown>
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/458,372
; FILING DATE: 02-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: No. RE37806man, Douglas K.
; REGISTRATION NUMBER: 33,267
; REFERENCE/DOCKET NUMBER: X-66061
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 317-276-2958
; TELEFAX: 317-277-1917
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-09-384-327-4

Query Match 0.1%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 97 GCACCTGATCAA 108
Db 1 GCACCTGATCAA 12

RESULT 430
US-08-115-497-11
; Sequence 11, Application US/08115497
; Patent No. 5514546
; GENERAL INFORMATION:
; APPLICANT: Kool, Eric T.
; TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/115,497
; FILING DATE:


```
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8771
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-115-497-11

Query Match      0.1%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      74 TTCTTTATTTC 85
        |||||
Db      1 TTCTTTCTTTC 12

RESULT 431
US-08-458-372-4
Sequence 4, Application US/08458372
Patent No. 5681932
GENERAL INFORMATION:
APPLICANT: Grinnell, Brian W.
TITLE OF INVENTION: METHOD FOR COMPLICATION OF HUMAN
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Eli Lilly and Company
STREET: Lilly Corporate Center/Patent Division
CITY: Indianapolis
STATE: IN
COUNTRY: US
ZIP: 46285
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/458,372
FILING DATE: 02-JUN-1993
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: No. 5681932man, Douglas K.
REGISTRATION NUMBER: 33,267
REFERENCE/DOCKET NUMBER: X-66061
TELECOMMUNICATION INFORMATION:
TELEPHONE: 317-276-1917
TELEFAX: 317-276-2958
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-458-372-4

Query Match      0.1%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      97 GCACCTGACGA 108
```

```
Db      1 GCACCTGACGA 12
        |||||
RESULT 432
US-08-466-670-11
Sequence 11, Application US/08466670
Patent No. 5808036
GENERAL INFORMATION:
APPLICANT: KOOL, Eric T.
TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/466,670
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/115,497
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8771
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-466-670-11

Query Match      0.1%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 2.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      74 TTCTTTATTTC 85
        |||||
Db      1 TTCTTTCTTTC 12

RESULT 433
US-08-508-761B-18
Sequence 18, Application US/08508761B
Patent No. 6027920
GENERAL INFORMATION:
APPLICANT: Jolliffe, Gwennael
APPLICANT: Guyonvarch, Armel
APPLICANT: Purification, Relano
APPLICANT: Duchiron, Francis
APPLICANT: Renaud, Michel
TITLE OF INVENTION: System for Protein Expression and
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:
ADDRESSEE: Jacobson, Price, Holman & Stern, PLLC
```

```

; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C.
; COUNTRY: U.S.A.
; ZIP: 20004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/508,761B
; FILING DATE: 31-JUL-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: FR 91/09652
; FILING DATE: 29-JUL-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: FR 91/09870
; FILING DATE: 02-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Player, William E.
; REGISTRATION NUMBER: 31,409
; REFERENCE/DOCKET NUMBER: P58525NA
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 638-6666
; TELEFAX: (202) 393-5350
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHEetical: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Corynebacterium Melaeseola
;
; US-08-508-761B-18
;
Query Match
Best Local Similarity 0.1%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
QY 474 CCATGGTATGG 485
DB 1 CCATGGCAATGG 12
;
RESULT 434
US-09-580-923-32/C
; Sequence 32, Application US/09580923
; Patent No. 6319672
; GENERAL INFORMATION:
; APPLICANT: Crouzet, Joel
; APPLICANT: Scherman, Daniel
; APPLICANT: Wils, Pierre
; APPLICANT: Cameron, Beatrice
; APPLICANT: Blanche, Francis
; TITLE OF INVENTION: PURIFICATION OF A TRIPLE HELIX FORMATION WITH AN
; FILE REFERENCE: 03804.0138-01
; CURRENT APPLICATION NUMBER: US/09/580,923
; PRIOR APPLICATION NUMBER: 2000-05-26
; PRIOR FILING DATE: 1997-06-09
; PRIOR APPLICATION NUMBER: PCT/FR95/01468
; PRIOR FILING DATE: 1995-11-08
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 32
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

```

; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: oligonucleotide
;
; US-09-580-923-32
;
Query Match
Best Local Similarity 0.1%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
QY 75 TCTTTATTCT 86
DB 12 TCTTTTCT 1
;
RESULT 435
US-09-717-847E-48/C
; Sequence 48, Application US/09717847E
; Patent No. 6461837
; GENERAL INFORMATION:
; APPLICANT: Yaver, Debbie S.
; APPLICANT: Bellini, Daniel Alan
; TITLE OF INVENTION: Methods For Producing A Polypeptide
; FILE REFERENCE: 5996.200-US
; CURRENT APPLICATION NUMBER: US/09/717,847E
; PRIOR APPLICATION NUMBER: 2000-11-20
; PRIOR FILING DATE: 1999-11-30
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 48
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Aspergillus oryzae
;
; US-09-717-847E-48
;
Query Match
Best Local Similarity 0.1%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
QY 133 CATGGGATGCA 144
DB 12 CATGGTGAAGA 1
;
RESULT 436
US-08-738-944-14/C
; Sequence 14, Application US/08738944
; Patent No. 5783431
; GENERAL INFORMATION:
; APPLICANT: Peterson, et al.
; TITLE OF INVENTION: METHODS FOR GENERATING AND
; NUMBER OF SEQUENCES: 51
; CORRESPONDENCE ADDRESS:
; STREET: Pennie & Edmonds
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036/2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/738,944
; FILING DATE: 24-OCT-1996
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/639,255
; FILING DATE: 24-APR-1996
; ATTORNEY/AGENT INFORMATION:
```

```

; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 8757-007
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-790-9090
; TELEFAX: 212-869-8864
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: Terminator for cDNA inserts
; LOCATION: 1...13
; OTHER INFORMATION:
; NAME/KEY: Other
; LOCATION: 10...11
; OTHER INFORMATION: Terminator site
; NAME/KEY: Other
; LOCATION: 1
; OTHER INFORMATION: Phosphate at nucleotide 1
; US-08-738-944-14

Query Match      0.1%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      315 GAGGATCCCGG 326
Db      13 GGGGATCCCGG 2

RESULT 437
US-09-263-352-11/c
; Sequence 11, Application US/09263352
; Patent No. 6242211
; GENERAL INFORMATION:
; APPLICANT: Peterson, T.
; APPLICANT: Brian, P.
; TITLE OF INVENTION: METHODS FOR GENERATING AND SCREENING NOVEL METABOLIC
; TITLE OF INVENTION: PATHWAYS
; FILE REFERENCE: 8757-010
; CURRENT APPLICATION NUMBER: US/09/263,352
; CURRENT FILING DATE: 1999-03-05
; EARLIER APPLICATION NUMBER: 08/986,186
; EARLIER FILING DATE: 1997-12-05
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 11
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Description of Artificial Sequence: linker
; US-09-263-352-11

Query Match      0.1%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      315 GAGGATCCCGG 326
Db      13 GGGGATCCCGG 2

RESULT 438
US-09-772-315-7
; Sequence 7, Application US/09772315
; Patent No. 6559125
; GENERAL INFORMATION:
```

```

; APPLICANT: DERYAN, Peter
; APPLICANT: WURTZ, Nicholas
; APPLICANT: CHANG, Aileen
; TITLE OF INVENTION: POLYAMIDE-ALKYLATOR CONJUGATES & RELATED PRODUCTS & METHODS
; FILE REFERENCE: GENESOF09/772315
; CURRENT APPLICATION NUMBER: US/09/772,315
; CURRENT FILING DATE: 2001-01-26
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 7
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Description of Artificial Sequence: Polyamide-Alkylator
; OTHER INFORMATION: Conjugate Target Sequence
; US-09-772-315-7

Query Match      0.1%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      295 GCAGCTCCTTAT 306
Db      2 GCAGCTGCTTAT 13

RESULT 439
US-07-832-905B-18/c
; Sequence 18, Application US/07832905B
; Patent No. 5580722
; GENERAL INFORMATION:
; APPLICANT: J. Gordon Foulkes, et al.
; TITLE OF INVENTION: Methods of transcriptionally
; TITLE OF INVENTION: Modulating Expression of Genes Associated with Cardiovascular
; TITLE OF INVENTION: Disease.
; NUMBER OF SEQUENCES: 93
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: John P. White, Esq.
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10112
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/832,905B
; FILING DATE: 19920207
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: White, John P.
; REGISTRATION NUMBER: 28,678
; REFERENCE/DOCKET NUMBER: 26134-H
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-977-9550
; TELEFAX: 212-664-0525
; TELEX: 423523 coop ui
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 30 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-07-832-905B-18

Query Match      0.1%; Score 10.4; DB 1; Length 30;
Best Local Similarity 60.7%; Pred. No. 4.9e+02;
```

Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 58 GAAGTGTTCTTCTACTCTTTATTC 85
Db 30 GAAGTAGAGACCACTTCCTTATGTC 3

RESULT 440
US-08-700-757-18/c
Sequence 18, Application US/08700757
Patent No. 5846720
GENERAL INFORMATION:
APPLICANT: J. Gordon Foulkes, et al.
TITLE OF INVENTION: METHODS OF DETERMINING CHEMICALS THAT MODULATE
TITLE OF INVENTION: EXPRESSION OF GENES ASSOCIATED WITH
TITLE OF INVENTION: CARDIOVASCULAR DISEASE
NUMBER OF SEQUENCES: 93
CORRESPONDENCE ADDRESS:
ADDRESSEE: John P. White, Esq.
STREET: 1185 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/700,757
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 26134-HA
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-278-0400
TELEFAX: 212-391-0525
TELEX:
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 30 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-700-757-18

Query Match 0.1%; Score 10.4; DB 1; Length 30;
Best Local Similarity 60.7%; Pred. No. 4.9e+02;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 58 GAAGTGTTCTTCTACTCTTTATTC 85
Db 30 GAAGTAGAGACCACTTCCTTATGTC 3

RESULT 441
5212286-61
Patent No. 5212286
APPLICANT: LEWICKI, JOHN A.; SCARBOROUGH, ROBERT M.
TITLE OF INVENTION: ATRIAL NATRIURETIC/VASODILATOR
PEPTIDE COMPOUNDS
NUMBER OF SEQUENCES: 68
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/870,795
FILING DATE: 05-JUN-1986
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 766,030
FILING DATE: 08-MAY-1985
APPLICATION NUMBER: 602,117

FILING DATE: 09-APR-1984
APPLICATION NUMBER: 616,488
FILING DATE: 01-JUN-1984
SEQ ID NO: 61
LENGTH: 12
5212286-61

Query Match 0.1%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 192 CCAAGCTTG 201
Db 1 CCAAGCTTG 10

RESULT 442
US-08-030-731A-3
Sequence 3, Application US/08030731A
Patent No. 5426036
GENERAL INFORMATION:
APPLICANT: Koller, Klaus-Peter
APPLICANT: Riess, Guenther Johannes
APPLICANT: Uhlmann, Eugen
APPLICANT: Wallmeier, Holger
TITLE OF INVENTION: Processes for the Preparation of Foreign
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
STREET: 1300 I Street, N.W., Suite 700
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/030,731A
FILING DATE: 12-MAR-1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/189,840
FILING DATE: 03-MAY-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/430,622
FILING DATE: 01-NOV-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/687,610
FILING DATE: 19-APR-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/735,757
FILING DATE: 29-JUL-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: DE P 37 14 866.4
FILING DATE: 05-MAY-1987
PRIOR APPLICATION DATA:
APPLICATION NUMBER: DE P 38 37 273.8
FILING DATE: 03-NOV-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: DE P 39 27 449.7
FILING DATE: 19-AUG-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: DE P 40 12 818.0
FILING DATE: 21-APR-1990
ATTORNEY/AGENT INFORMATION:
NAME: Kirschner Michael R.
REGISTRATION NUMBER: 34,851
REFERENCE/DOCKET NUMBER: 02481-0593-02000

TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-408-4000
TELEFAX: 202-408-4400
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: Other
DESCRIPTION: synthetic DNA
US-08-030-731A-3

Query Match 0.1%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 192 CCAAGCTTGG 201
DB 2 CCAAGCTTGG 11

RESULT 443
US-08-030-731A-3/c
Sequence 3, Application US/08030731A
Patent No. 5426036
GENERAL INFORMATION:
APPLICANT: Koller, Klaus-Peter
APPLICANT: Riese, Guenther Johannes
APPLICANT: Uhlmann, Eugen
APPLICANT: Wallmeier, Holger
TITLE OF INVENTION: Processes for the Preparation of Foreign
TITLE OF INVENTION: Proteins in Streptomyces
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
ADDRESS: Dunner
STREET: 1300 I Street, N.W., Suite 700
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/030,731A
FILING DATE: 12-MAR-1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/189,840
FILING DATE: 03-MAY-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/430,622
FILING DATE: 01-NOV-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/687,610
FILING DATE: 19-APR-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/735,757
FILING DATE: 29-JUL-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: DE P 37 14 866.4
FILING DATE: 05-MAY-1987
PRIOR APPLICATION DATA:
APPLICATION NUMBER: DE P 38 37 273.8
FILING DATE: 03-NOV-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: DE P 39 27 449.7
FILING DATE: 19-AUG-1989
PRIOR APPLICATION DATA:

APPLICATION NUMBER: DE P 40 12 818.0
FILING DATE: 21-APR-1990
ATTORNEY/AGENT INFORMATION:
NAME: Kirschner Michael K.
REGISTRATION NUMBER: 34,851
REFERENCE/DOCKET NUMBER: 02481-0593-02000
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-408-4000
TELEFAX: 202-408-4400
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: Other
DESCRIPTION: synthetic DNA
US-08-030-731A-3

Query Match 0.1%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 192 CCAAGCTTGG 201
DB 11 CCAAGCTTGG 2

RESULT 444
US-08-305-764C-4
Sequence 4, Application US/08305764C
Patent No. 5856090
GENERAL INFORMATION:
APPLICANT: Epstein, David M.
TITLE OF INVENTION: DNA METHYLASE LINKING REACTION
NUMBER OF SEQUENCES: 71
CORRESPONDENCE ADDRESS:
ADDRESSEE: THE SCRIPPS RESEARCH INSTITUTE
STREET: 10550 No. 5856090th Torrey Pines Road
CITY: La Jolla
STATE: California
COUNTRY: USA
ZIP: 92037
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/305,764C
FILING DATE: 09-SEP-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Fitting, Thomas
REGISTRATION NUMBER: 34,163
REFERENCE/DOCKET NUMBER: TSRI 440.0
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 784-2937
TELEFAX: (619) 784-9399
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-305-764C-4

Query Match 0.1%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 343 TGCACCTGA 352
Db 2 TGCACCTGA 11

RESULT 445
US-08-547-214-6
Sequence 6, Application US/08547214
Patent No. 5871697
GENERAL INFORMATION:
APPLICANT: Rothberg, Jonathan
APPLICANT: Deem, Michael
TITLE OF INVENTION: Method for the Determination and
TITLE OF INVENTION: Classification of DNA Sequences in a Sample without
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie and Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/547,214
FILING DATE: 24-OCT-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Mistrock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 7934-015-999
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)-790-9090
TELEFAX: (212)-869-8864
TELEX: 66441 PENNIE
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-547-214-6

Query Match 0.1%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 255 TGGCTTGATC 264
Db 3 TGGCTTGATC 12

RESULT 446
US-08-663-823B-6
Sequence 6, Application US/08663823B
Patent No. 5972693
GENERAL INFORMATION:
APPLICANT: Rothberg, Jonathan
APPLICANT: Deem, Michael
TITLE OF INVENTION: METHOD AND APPARATUS FOR IDENTIFYING,
TITLE OF INVENTION: CLASSIFYING, OR QUANTIFYING DNA SEQUENCES IN A SAMPLE
NUMBER OF SEQUENCES: 77
CORRESPONDENCE ADDRESS:

ADDRESSEE: Pennie and Edmonds LLP
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/663,823B
FILING DATE: 14-June-1996
CLASSIFICATION: 422
ATTORNEY/AGENT INFORMATION:
NAME: Mistrock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 7934-033
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 790-9090
TELEFAX: (212) 869-9741/8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-663-823B-6

Query Match 0.1%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 255 TGGCTTGATC 264
Db 3 TGGCTTGATC 12

RESULT 447
US-08-942-406-6
Sequence 6, Application US/08942406
Patent No. 6141657
GENERAL INFORMATION:
APPLICANT: Rothberg, Jonathan
APPLICANT: Deem, Michael
TITLE OF INVENTION: Method for the Determination and
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie and Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/942,406
FILING DATE: 01-Oct-1997
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/547,214
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Mistrock, S. Leslie
REGISTRATION NUMBER: 18,872

REFERENCE/DOCKET NUMBER: 7934-015-999
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)-790-9090
TELEFAX: (212)-869-8864
TELEX: 66441 PENNIE
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-08-942-406-6

Query Match 0.1%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 255 TGCGTTGATC 264
Db 3 TGCGTTGATC 12

RESULT 448
US-09-322-617-6
Sequence 6, Application US/09322617
Patent No. 6231812
GENERAL INFORMATION:
APPLICANT: Rothberg, Jonathan
APPLICANT: Deem, Michael
APPLICANT: Simpson, John
TITLE OF INVENTION: Method for the Determination and
TITLE OF INVENTION: Classification of DNA Sequences in a Sample Without
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie and Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/322,617
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/547,214
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Mifrock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 7934-015-999
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)-790-9090
TELEFAX: (212)-869-8864
TELEX: 66441 PENNIE
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-09-322-617-6

Query Match 0.1%; Score 10; DB 1; Length 12;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 255 TGCGTTGATC 264
Db 3 TGCGTTGATC 12

RESULT 449
US-08-676-444-12/C
Sequence 12, Application US/08676444A
Patent No. 6294325
GENERAL INFORMATION:
APPLICANT: Wetmur, James G.
TITLE OF INVENTION: CLONING AND EXPRESSION OF THERMOSTABLE
FILE REFERENCE: MS95-02
CURRENT APPLICATION NUMBER: US/08/676,444A
CURRENT FILING DATE: 1996-07-05
NUMBER OF SEQ ID NOS: 48
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 12
LENGTH: 12
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Oligonucleotide
US-08-676-444-12

Query Match 0.1%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 315 GAGGATCCC 324
Db 12 GAGGATCCC 3

RESULT 450
US-08-676-342A-35
Sequence 35, Application US/08676342A
Patent No. 6348313
GENERAL INFORMATION:
APPLICANT: SIBSON, DAVID R.
TITLE OF INVENTION: Sequencing of Nucleic Acids
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Millen, White, Zelano & Branigan, P.C.
STREET: 2200 Clarendon Blvd. Suite 1400
CITY: Arlington
STATE: VA
COUNTRY: US
ZIP: 22201
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MS-DOS text
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/676,342A
FILING DATE: 19-JUL-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB95/00109
FILING DATE: 20-JAN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9401200.2
FILING DATE: 21-JAN-1994
ATTORNEY/AGENT INFORMATION:
NAME: Lebovitz, Richard M.
REGISTRATION NUMBER: 37,067
REFERENCE/DOCKET NUMBER: HLB 4
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-243-6333

TELEFAX: 703-243-6410
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 bases
TYPE: nucleotides
STRANDEDNESS: single
TOPOLOGY: linear
US-08-676-342A-35

Query Match
Best Local Similarity 100.0%; Score 10; DB 1; Length 12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 191 GCCAGCTTG 200
Db 1 GCCAGCTTG 10

RESULT 451
US-09-203-231B-10
Sequence 10, Application US/09203231B
Patent No. 6355423
GENERAL INFORMATION:
APPLICANT: Rothberg, Jonathan M
APPLICANT: Mallur, Girish N
TITLE OF INVENTION: Methods and Devices for Measuring
TITLE OF INVENTION: Differential Gene Expression
FILE REFERENCE: 7934-052
CURRENT APPLICATION NUMBER: US/09/203,231B
PRIOR FILING DATE: 1998-12-02
PRIOR APPLICATION NUMBER: 60/105,305
NUMBER OF SEQ ID NOS: 88
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 10
LENGTH: 12
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer
US-09-203-231B-10

Query Match
Best Local Similarity 100.0%; Score 10; DB 1; Length 12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 255 TGGCTTGATC 264
Db 3 TGGCTTGATC 12

RESULT 452
US-09-751-561-6
Sequence 6, Application US/09751561
Patent No. 6418382
GENERAL INFORMATION:
APPLICANT: Rothberg, Jonathan
APPLICANT: Deem, Michael
APPLICANT: Simpson, John
TITLE OF INVENTION: Method for the Determination and
TITLE OF INVENTION: Classification of DNA Sequences in a Sample Without
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie and Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/751,561
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/547,214
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Mistrock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 7934-015-999
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)-790-9090
TELEFAX: (212)-869-8864
TELEX: 66441 PENNIE
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-09-751-561-6

Query Match
Best Local Similarity 100.0%; Score 10; DB 1; Length 12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 255 TGGCTTGATC 264
Db 3 TGGCTTGATC 12

RESULT 453
US-09-724-385-6
Sequence 6, Application US/09724385
Patent No. 6432361
GENERAL INFORMATION:
APPLICANT: Rothberg, Jonathan
APPLICANT: Deem, Michael
APPLICANT: Simpson, John
TITLE OF INVENTION: Method for the Determination and
TITLE OF INVENTION: Classification of DNA Sequences in a Sample Without
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie and Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/724,385
FILING DATE: 28-No. 6432361-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/322,617
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Mistrock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 7934-015-999
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)-790-9090
TELEFAX: (212)-869-8864
TELEX: 66441 PENNIE


```

; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 12 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-724-385-6

Query Match      0.1%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      255 TGGCTTGATC 264
Db      3 TGGCTTGATC 12

RESULT 454
US-09-757-528-6
; Sequence 6, Application US/09757528
; Patent No. 6453245
; GENERAL INFORMATION:
;   APPLICANT: Rothberg, Jonathan
;             Deem, Michael
;             Simpson, John
; TITLE OF INVENTION: Method for the Determination and
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie and Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036-2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/09/757,528
;   FILING DATE: 10-Jan-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: 08/547,214
;   FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
;   NAME: Mistrock, S. Leslie
;   REGISTRATION NUMBER: 18,872
; REFERENCE/DOCKET NUMBER: 7934-015-999
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (212) -790-9090
;   TELEFAX: (212) -869-8864
;   TELEX: 66441 PENNIE
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 12 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-757-528-6

Query Match      0.1%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      255 TGGCTTGATC 264
Db      3 TGGCTTGATC 12
```

```

RESULT 455, \
US-09-874-601-172
; Sequence 172, Application US/09874601
; Patent No. 6632057
; GENERAL INFORMATION:
;   APPLICANT: LEWIN, ALFRED S.
;   APPLICANT: SHAW, LYNN C.
;   APPLICANT: GRANT, MARIA B.
; TITLE OF INVENTION: ADENO-ASSOCIATED VIRUS-DELIVERED RIBOZYME COMPOSITIONS AND METHODS
; FILE REFERENCE: 4300, 014100
; CURRENT APPLICATION NUMBER: US/09/874,601
; PRIOR FILING DATE: 2001-05-01
; PRIOR APPLICATION NUMBER: 09/063,667
; PRIOR FILING DATE: 1998-04-21
; PRIOR APPLICATION NUMBER: 60/046,147
; PRIOR FILING DATE: 1997-05-09
; PRIOR APPLICATION NUMBER: 60/044,492
; PRIOR FILING DATE: 1997-04-21
; NUMBER OF SEQ ID NOS: 182
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 172
; LENGTH: 12
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: ()..()
; OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-09-874-601-172

Query Match      0.1%; Score 10; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      37 AGTCCAAA 46
Db      1 AGUCCAAA 10

RESULT 456
US-09-194-949A-20/C
; Sequence 20, Application US/09194949A
; Patent No. 6653125
; GENERAL INFORMATION:
;   APPLICANT: Merck & Co., Inc.
;   APPLICANT: Donnelly, John J.
;   APPLICANT: Fu, Tong-Ming
;   APPLICANT: Liu, Margaret A.
;   APPLICANT: Shiver, John W.
; TITLE OF INVENTION: SYNTHETIC HEPATITIS C GENES
; FILE REFERENCE: 19732YP
; CURRENT APPLICATION NUMBER: US/09/194,949A
; CURRENT FILING DATE: 2000-02-17
; PRIOR APPLICATION NUMBER: PCT/US97/09884
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/020,494
; PRIOR FILING DATE: 1996-06-11
; PRIOR APPLICATION NUMBER: 60/033,534
; PRIOR FILING DATE: 1996-12-20
; PRIOR APPLICATION NUMBER: 08/865,823
; PRIOR FILING DATE: 1997-05-30
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Modified Vector Sequence
US-09-194-949A-20
```

Query Match 0.1%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred No. 2.6e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 132 CCATGGTGAT 141
Db 10 CCATGGTGAT 1

RESULT 457
US-08-013-801-7/C
; Sequence 7, Application US/08013801
; Patent No. 5420019
; GENERAL INFORMATION:
; APPLICANT: Theofan, Georgia
; APPLICANT: Horwitz, Arnold
; APPLICANT: Burke, David
; APPLICANT: Baitalan, Malik
; APPLICANT: Grima, Lynn S
; TITLE OF INVENTION: Stable Bactericidal/Permeability-
; TITLE OF INVENTION: Increasing Protein Products and Pharmaceutical
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
; STREET: Two First National Plaza
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60603
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/013.801
; FILING DATE: 02 FEB 1993
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Meyers, Thomas C.
; REGISTRATION NUMBER: P-36,989
; REFERENCE/DOCKET NUMBER: 27129/30911
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/346-5750
; TELEFAX: 312/346-9740
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-013-801-7

Query Match 0.1%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred No. 3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 132 CCATGGTGATG 143
Db 13 CCATGGTGATG 2

RESULT 458
US-08-072-063-16/C
; Sequence 16, Application US/08072063
; Patent No. 5439807
; GENERAL INFORMATION:
; APPLICANT: Theofan, Georgia

APPLICANT: Grima, Lynn S
; APPLICANT: Horwitz, Arnold
; TITLE OF INVENTION: BPI-Immunoglobulin Fusion Proteins
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/072.063
; FILING DATE: 19930519
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Meyers Thomas C.
; REGISTRATION NUMBER: 36,989
; REFERENCE/DOCKET NUMBER: 30659
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-072-063-16

Query Match 0.1%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred No. 3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 132 CCATGGTGATG 143
Db 13 CCATGGTGATG 2

RESULT 459
US-08-212-132-7/C
; Sequence 7, Application US/08212132
; Patent No. 5447913
; GENERAL INFORMATION:
; APPLICANT: Little, Roger G.
; APPLICANT: Ammons, William Steve
; TITLE OF INVENTION: Therapeutic Uses of Bactericidal/Permeability-
; TITLE OF INVENTION: Increasing Protein Dimer Products
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/212.132
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:

NAME: Sharp, Jeffrey S.
REGISTRATION NUMBER: 31,879
REFERENCE/DOCKET NUMBER: 27129/31735
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-212-132-7

Query Match 0.1%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 132 CCATGCGATGG 143
DB 13 CCATGGYGGTGG 2

RESULT 460
US-08-064-693-16/C
Sequence 16, Application US/08064693
Patent No. 5643570
GENERAL INFORMATION:
APPLICANT: Theofan, Georgia
APPLICANT: Grinna, Lynn S
APPLICANT: Horwitz, Arnold
TITLE OF INVENTION: Bp1-Immunoglobulin Fusion Proteins
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
STREET: 6300 Sears Tower, 233 South Wacker
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/064,693
FILING DATE: 19930519
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Meyers Thomas C.
REGISTRATION NUMBER: 36,989
REFERENCE/DOCKET NUMBER: 30659
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-064-693-16

Query Match 0.1%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 132 CCATGCGATGG 143
DB 13 CCATGGYGGTGG 2

RESULT 461
US-08-430-417-7/C
Sequence 7, Application US/08430417
Patent No. 5674834
GENERAL INFORMATION:
APPLICANT: Theofan, Georgia
APPLICANT: Horwitz, Arnold
APPLICANT: Burke, David
APPLICANT: Baltaian, Manik
APPLICANT: Grinna, Lynn S.
TITLE OF INVENTION: Stable Bactericidal/Permeability-Increasing
TITLE OF INVENTION: Protein Products and Pharmaceutical Compositions Containing
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/430,417
FILING DATE:
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Meyers, Thomas C.
REGISTRATION NUMBER: P-36,989
REFERENCE/DOCKET NUMBER: 27129/30911
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-430-417-7

Query Match 0.1%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 132 CCATGCGATGG 143
DB 13 CCATGGYGGTGG 2

RESULT 462
US-08-470-366-7/C
Sequence 7, Application US/08470366
Patent No. 5703038
GENERAL INFORMATION:
APPLICANT: Little, Roger
APPLICANT: Ammons, Steve
TITLE OF INVENTION: Therapeutic Uses of Bactericidal/Permeability-
TITLE OF INVENTION: Increasing Protein Dimer Products
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun

```
/
/ STREET: 6300 Sears Tower, 233 South Wacker Drive
/ CITY: Chicago
/ STATE: Illinois
/ COUNTRY: United States of America
/ ZIP: 60606-6402
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/470,366
/ FILING DATE:
/ CLASSIFICATION: 514
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Sharp, Jeffrey S.
/ REGISTRATION NUMBER: 31,879
/ REFERENCE/DOCKET NUMBER: 27129/31735
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 312/474-6300
/ TELEFAX: 312/474-0448
/ TELEX: 25-3856
/ INFORMATION FOR SEQ ID NO: 7:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 13 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: CDNA
/
US-08-470-366-7

Query Match      0.1%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      132 CCATGCGATGCG 143
DB      13 CCATGGYGTGCG 2

RESULT 463
US-08-466-822-7/C
/ Sequence 7, Application US/08466822
/ Patent No. 5827816
/ GENERAL INFORMATION:
/ APPLICANT: Theofan, Georgia.
/ APPLICANT: Horwitz, Arnold
/ APPLICANT: Burke, David
/ APPLICANT: Balcaian, Manik
/ APPLICANT: Grima, Lynn S.
/ TITLE OF INVENTION: Stable Bactericidal/Permeability-Increasing
/ TITLE OF INVENTION: Protein Products and Pharmaceutical Compositions Containing
/ TITLE OF INVENTION: the Same
/ NUMBER OF SEQUENCES: 14
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
/ STREET: 6300 Sears Tower, 233 South Wacker Drive
/ CITY: Chicago
/ STATE: Illinois
/ COUNTRY: USA
/ ZIP: 60606-6402
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/466,822
/ FILING DATE:
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Meyers, Thomas C.
/ REGISTRATION NUMBER: P-36,989
```

```
/
/ REFERENCE/DOCKET NUMBER: 27129/30911
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 312/474-6300
/ TELEFAX: 312/474-0448
/ TELEX: 25-3856
/ INFORMATION FOR SEQ ID NO: 7:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 13 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: CDNA
/
US-08-466-822-7

Query Match      0.1%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      132 CCATGCGATGCG 143
DB      13 CCATGGYGTGCG 2

RESULT 464
US-08-704-504-7/C
/ Sequence 7, Application US/08704504
/ Patent No. 5856302
/ GENERAL INFORMATION:
/ APPLICANT: Little, Roger G.
/ APPLICANT: Ammons, William Steve
/ TITLE OF INVENTION: Therapeutic Uses of Bactericidal/Permeability-
/ TITLE OF INVENTION: Increasing Protein Dimer Products
/ NUMBER OF SEQUENCES: 11
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
/ STREET: 6300 Sears Tower, 233 South Wacker Drive
/ CITY: Chicago
/ STATE: Illinois
/ COUNTRY: United States of America
/ ZIP: 60606-6402
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/704,504
/ FILING DATE:
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/08/212,132
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Sharp, Jeffrey S.
/ REGISTRATION NUMBER: 31,879
/ REFERENCE/DOCKET NUMBER: 27129/31735
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 312/474-6300
/ TELEFAX: 312/474-0448
/ TELEX: 25-3856
/ INFORMATION FOR SEQ ID NO: 7:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 13 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: CDNA
/
US-08-704-504-7

Query Match      0.1%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
```

OY 132 CCATGGTGATGG 143
Db 13 CCATGGYGCTGG 2

RESULT 465

US-08-885-166-16/c
Sequence 16, Application US/08885366
Patent No. 6274348
GENERAL INFORMATION:
APPLICANT: Theofan, Georgia
APPLICANT: Grima, Lynn S
APPLICANT: Horwitz, Arnold
TITLE OF INVENTION: BPI-Immunoglobulin Fusion Proteins
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
ADDRESSEE: Borun
STREET: 6300 Sears Tower, 233 South Wacker
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/885,366
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/064,693
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Meyers Thomas C.
REGISTRATION NUMBER: 36,989
REFERENCE/DOCKET NUMBER: 30659
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-885-366-16

Query Match 0.1%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 132 CCATGGTGATGG 143
Db 13 CCATGGYGCTGG 2

RESULT 466

US-09-223-342-7/c
Sequence 7, Application US/09223342
Patent No. 6277821
GENERAL INFORMATION:
APPLICANT: Little, Roger G.
APPLICANT: Ammons, William Steve
TITLE OF INVENTION: Therapeutic Uses of Bactericidal/Permeability-
INCREASING PROTEIN DIMER PRODUCTS
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun

STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/223,342
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/704,504
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Sharp, Jeffrey S.
REGISTRATION NUMBER: 31,879
REFERENCE/DOCKET NUMBER: 27129/31735
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-09-223-342-7

Query Match 0.1%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 132 CCATGGTGATGG 143
Db 13 CCATGGYGCTGG 2

RESULT 467

US-09-425-034A-7/c
Sequence 7, Application US/09425034A
Patent No. 6433140
GENERAL INFORMATION:
APPLICANT: Theofan, Georgia
APPLICANT: Horwitz, Arnold
APPLICANT: Burke, David
APPLICANT: Baitalan, Manik
APPLICANT: Grima, Lynn S.
TITLE OF INVENTION: Stable Bactericidal/Permeability-Increasing
Protein Products and Pharmaceutical Compositions Containing
the Same
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Marshall, Gerstein & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/425,034A
FILING DATE: 19-Oct-1999
CLASSIFICATION: <Unknown>

ATTORNEY/AGENT INFORMATION:
NAME: Sharp, Jeffrey S.
REGISTRATION NUMBER: 31,879
REFERENCE/DOCKET NUMBER: 29715/35065A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
SEQUENCE DESCRIPTION: SEQ ID NO: 7:
US-09-425-034A-7

Query Match 0.1%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 132 CCATGATGATG 143
DB 13 CCATGGGATG 2

RESULT 468
US-08-479-660-14/c
Sequence 14, Application US/08479660
Patent No. 6475806
GENERAL INFORMATION:
APPLICANT: Benjamin, Howard
APPLICANT: Signer, Ethan
APPLICANT: Gefer, Malcolm
TITLE OF INVENTION: ANCHOR LIBRARIES AND IDENTIFICATION
TITLE OF INVENTION: OF PEPTIDE BINDING SEQUENCES
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
STREET: 600 Atlantic Avenue
CITY: Boston
STATE: Massachusetts
COUNTRY: USA
ZIP: 02210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/479,660
FILING DATE: 1995
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Greer, Helen
REGISTRATION NUMBER: 36,816
REFERENCE/DOCKET NUMBER: P0567/7000
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 720-3500
TELEFAX: (617) 720-2441
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-479-660-14

Query Match 0.1%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 CAGCAGCACC 101

DB 13 CAGCAGCACC 4

RESULT 469
US-09-874-601-67/c
Sequence 67, Application US/09874601
Patent No. 6632057
GENERAL INFORMATION:
APPLICANT: LEWIN, ALFRED S.
APPLICANT: SHAW, LYNN C.
APPLICANT: GRANT, MARIA B.
TITLE OF INVENTION: ADENO-ASSOCIATED VIRUS-DELIVERED RIBOZYME COMPOSITIONS AND METHODS
TITLE OF INVENTION: THE TREATMENT OF RETINAL DISEASES
FILE REFERENCE: 4300.014100
CURRENT APPLICATION NUMBER: US/09/874,601
CURRENT FILING DATE: 2001-05-01
PRIOR APPLICATION NUMBER: 09/063,667
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/046,147
PRIOR FILING DATE: 1997-05-09
PRIOR APPLICATION NUMBER: 60/044,492
PRIOR FILING DATE: 1997-04-21
NUMBER OF SEQ ID NOS: 182
SOFTWARE: PatentIn version 3.0
SEQ ID NO 67
LENGTH: 13
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
NAME/KEY: misc feature
LOCATION: (1..7)
OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-09-874-601-67

Query Match 0.1%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 37 AGTCCCAAAA 46
DB 13 AGTCCCAAAA 4

RESULT 470
PCT-US93-04754-16/c
Sequence 16, Application PC/TUS9304754
GENERAL INFORMATION:
APPLICANT: Theofan, Georgia
APPLICANT: Grima, Lynn S
APPLICANT: Horwitz, Arnold
TITLE OF INVENTION: Bp1-Immunoglobulin Fusion Proteins
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
STREET: 6300 Seare Tower, 233 South Wacker
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/04754
FILING DATE: 19930519
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Meyers Thomas C.
REGISTRATION NUMBER: 36,989

REFERENCE/DOCKET NUMBER: 30659
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
PCT-US93-04754-16

Query Match 0.1%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 132 CCATGTCGATGG 143
Db 13 CCATGGYGGTGG 2

RESULT 471
PCT-US94-01235-7/c
Sequence 7, Application PC/TUS9401235
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: Stable Bactericidal/Permeability-Increasing
TITLE OF INVENTION: Protein Products and Pharmaceutical Compositions Containing th
TITLE OF INVENTION: Same
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/01235
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Meyers, Thomas C.
REGISTRATION NUMBER: 36,989
REFERENCE/DOCKET NUMBER: 27129/30911
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
PCT-US94-01235-7

Query Match 0.1%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 132 CCATGTCGATGG 143
Db 13 CCATGGYGGTGG 2

RESULT 472
PCT-US95-03125-7/c
Sequence 14, Application PC/TUS9503125
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: Therapeutic Uses of Bactericidal/Permeability-
TITLE OF INVENTION: Increasing Protein Dimer Products
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/03125
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Sharp, Jeffrey S.
REGISTRATION NUMBER: 31,879
REFERENCE/DOCKET NUMBER: 27129/32528
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
PCT-US95-03125-7

Query Match 0.1%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 132 CCATGTCGATGG 143
Db 13 CCATGGYGGTGG 2

RESULT 473
PCT-US96-09383-14/c
Sequence 14, Application PC/TUS9609383
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: ANCHOR LIBRARIES AND IDENTIFICATION
TITLE OF INVENTION: PEPTIDE BINDING SEQUENCES
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
STREET: 600 Atlantic Avenue
CITY: Boston
STATE: Massachusetts
COUNTRY: USA
ZIP: 02210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/09383
FILING DATE:

```
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/479,660
FILING DATE: 07-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Greer, Helen
REGISTRATION NUMBER: 36,816
REFERENCE/DOCKET NUMBER: P0567/7000WO
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 720-3500
TELEFAX: (617) 720-2441
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
PCT-US96-09383-14

Query Match
Best Local Similarity 100.0%; Score 10; DB 1; Length 13;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 92 CAGCAGCACC 101
Db 13 CAGCAGCACC 4

RESULT 474
US-08-311-760A-10/c
Sequence 10, Application US/08311760A
Patent No. 559706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESS: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
```

```
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-10

Query Match
Best Local Similarity 100.0%; Score 10; DB 1; Length 15;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 192 CCAAGCTTG 201
Db 10 CCAAGCTTG 1

RESULT 475
US-08-774-310-10/c
Sequence 10, Application US/08774310
Patent No. 5877022
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: McSwigen, James
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESS: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 223/229
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-10

Query Match
Best Local Similarity 100.0%; Score 10; DB 1; Length 15;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 192 CCAAGCTTG 201
Db 10 CCAAGCTTG 1
```


RESULT 476
US-08-105-483-122
Sequence 122, Application US/08105483
Patent No. 5494807
GENERAL INFORMATION:
APPLICANT: Paoletti, Enzo
TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
TITLE OF INVENTION: STRAIN
NUMBER OF SEQUENCES: 462
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris & Safford
ADDRESSEE: c/o William S. Frommer
STREET: 530 Fifth Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/105.483
FILING DATE: 12-AUG-1993
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/847,951
FILING DATE: 06-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2400
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 122:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-105-483-122

Query Match 0.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 65 TTCTTCTACTTCT 77
|||||
Db 1 TTCTTCTCTTGT 13

RESULT 477
US-07-714-687-35
Sequence 35, Application US/07714687
Patent No. 5514375
GENERAL INFORMATION:
APPLICANT: Paoletti, Enzo
TITLE OF INVENTION: FLAVIVIRUS RECOMBINANT POXVIRUSVACCINE
TITLE OF INVENTION: 55
NUMBER OF SEQUENCES: 55
CORRESPONDENCE ADDRESS:
ADDRESSEE: William S. Frommer
STREET: 530 Fifth Avenue
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/714,687
FILING DATE: 19910613
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/567960
FILING DATE: 15-AUG-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/711429
FILING DATE: 06-JUN-1991
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2310
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
US-07-714-687-35

Query Match 0.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 65 TTCTTCTACTTCT 77
|||||
Db 1 TTCTTCTCTTGT 13

RESULT 478
US-08-203-534-4
Sequence 4, Application US/08203534
Patent No. 5518884
GENERAL INFORMATION:
APPLICANT: Spears, Patricia A.
TITLE OF INVENTION: NUCLEIC ACID SEQUENCES SPECIFIC FOR
TITLE OF INVENTION: MYCOBACTERIUM KANSASII
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: Richard J. Rodrick, Becton Dickinson and
ADDRESS: Company
STREET: 1 Becton Drive
CITY: Franklin Lakes
STATE: NJ
COUNTRY: US
ZIP: 07417
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/203,534
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Fugit, Donna R.
REGISTRATION NUMBER: 32,135
REFERENCE/DOCKET NUMBER: P-2658
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ORIGINAL SOURCE:
ORGANISM: Mycobacterium kansasii
US-08-203-534-4

Query Match 0.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 246 CCCAATGCTGGC 258
DB 1 CACAATGCTGGC 13

RESULT 479
US-08-224-391-35
Sequence 35, Application US/08224391
Patent No. 5744140
GENERAL INFORMATION:
APPLICANT: Paoletti, Enzo
APPLICANT: Pincus, Steven E.
TITLE OF INVENTION: FLAVIVIRUS RECOMBINANT POXVIRUS VACCINE
NUMBER OF SEQUENCES: 93
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris & Safford
ADDRESSEE: c/o William S. Frommer
STREET: 530 Fifth Avenue
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/224,391
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/729,800
FILING DATE: 17-JUL-1991
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2340
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-224-391-35

Query Match 0.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 65 TTCTTCTACTTCT 77
DB 1 TTCTTCTTCTTGT 13

RESULT 480
US-08-484-304-35
Sequence 35, Application US/08484304
Patent No. 5744141
GENERAL INFORMATION:

APPLICANT: Paoletti, Enzo
APPLICANT: Pincus, Steven E.
TITLE OF INVENTION: FLAVIVIRUS RECOMBINANT POXVIRUS VACCINE
NUMBER OF SEQUENCES: 93
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris & Safford
ADDRESSEE: c/o William S. Frommer
STREET: 530 Fifth Avenue
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,304
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/224,391
FILING DATE:
APPLICATION NUMBER: US 07/729,800
FILING DATE: 17-JUL-1991
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2340
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-484-304-35

Query Match 0.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 65 TTCTTCTACTTCT 77
DB 1 TTCTTCTTCTTGT 13

RESULT 481
US-08-709-209-122
Sequence 122, Application US/08709209
Patent No. 5762938
GENERAL INFORMATION:
APPLICANT: Paoletti, Enzo
TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
NUMBER OF SEQUENCES: 462
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris & Safford
ADDRESSEE: c/o William S. Frommer
STREET: 530 Fifth Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:

```
APPLICATION NUMBER: US/08/709,209
FILING DATE: 21-AUG-1996
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/105,483
FILING DATE: 12-AUG-1993
APPLICATION NUMBER: US 07/847,951
FILING DATE: 06-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2400
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 122:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-709-209-122

Query Match          0.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      65 TTCTTCTACTTCT 77
Db      1 TTCTTCTCTTGT 13

RESULT 482
US-08-458-101-122
Sequence 122, Application US/08458101
Patent No. 576559
GENERAL INFORMATION:
APPLICANT: Paolietti, Enzo
APPLICANT: Perkins, Marion E.
APPLICANT: Taylor, Jill
APPLICANT: Tartaglia, James
APPLICANT: No. 5766599ton, Elizabeth K.
APPLICANT: Riviere, Michel
APPLICANT: de Taiane, Charles
APPLICANT: Limbach, Keith J.
APPLICANT: Johnson, Gerard P.
APPLICANT: Pincus, Steven E.
APPLICANT: Cox, William I.
APPLICANT: Audonnet, Jean-Christophe Francis
APPLICANT: Gettig, Russell Robert
TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
TITLE OF INVENTION: STRAIN
NUMBER OF SEQUENCES: 467
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis, Morris & Safford
ADDRESS: C/O William S. Frommer
STREET: 530 Fifth Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: IBM PC compatible
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/458,101
FILING DATE: 01-JUN-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
```

```
REFERENCE/DOCKET NUMBER: 454310-2740
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 122:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-458-101-122

Query Match          0.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      65 TTCTTCTACTTCT 77
Db      1 TTCTTCTCTTGT 13

RESULT 483
US-08-705-937-12
Sequence 12, Application US/08705937
Patent No. 5981841
GENERAL INFORMATION:
APPLICANT: Santino, Colleen G.
APPLICANT: Conner, Timothy W.
TITLE OF INVENTION: EARLY SEED 5' REGULATORY SEQUENCE
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: Carmen Rodriguez, Paralegal, Arnold, White & Durkee
STREET: P.O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: IBM PC compatible
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/705,937
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Nicolas G. Barzoukas.
REGISTRATION NUMBER: 38,823
REFERENCE/DOCKET NUMBER: MOBT:018 (38-2(10694)A
NAME: Janelle D. Waack.
REGISTRATION NUMBER: 36,300
REFERENCE/DOCKET NUMBER: MOBT:018 (38-2(10694)A
NAME: Barbara S. Kitchell
REGISTRATION NUMBER: 33,928
REFERENCE/DOCKET NUMBER: MOBT:018 (38-2(10694)A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (713) 787-1400
TELEFAX: (713) 789-2679
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-705-937-12

Query Match          0.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      467 AGTGCTACATCG 479
```

Pb 1 AGATCTACCATG 13

RESULT 484

US-08-767-942A-42/c
; Sequence 42, Application US/08767942A
; Patent No. 6068982
; GENERAL INFORMATION:
; APPLICANT: Rolfe, Mark
; APPLICANT: Chiu, M. Isabel
; APPLICANT: Berlin, Vivian
; APPLICANT: Damagnez, Veronique
; APPLICANT: Draetta, Giulio
; APPLICANT: Guillaume, Cottarel
; TITLE OF INVENTION: UBICUITIN CONJUGATING ENZYMES
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FOLEY, HOAG & ELIOT LLP
; STREET: One Post Office Square
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109-2170
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; APPLICATION NUMBER: US/08/767,942A
; FILING DATE: 17-DEC-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Vincent, Matthew P.
; REGISTRATION NUMBER: 36,709
; REFERENCE/DOCKET NUMBER: MIV-029,04
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-832-1000
; TELEFAX: 617-832-7000
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-767-942A-42

Query Match 0.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 110 GCCATGTGTCGA 122
Db 13 GCCACGTGTCGA 1

RESULT 485

US-08-983-041-22
; Sequence 22, Application US/08983041A
; Patent No. 6114155
; GENERAL INFORMATION:
; APPLICANT: Statens Institutt for Folkehelse
; TITLE OF INVENTION: Internal Control and Method for Surveillance of GAP-LCR
; FILE REFERENCE: 23506 exams 3a-3c
; CURRENT APPLICATION NUMBER: US/08/983,041A
; CURRENT FILING DATE: 1998-01-15
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Hepatitis B virus

; FEATURE:
US-08-983-041-22

Query Match 0.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 111 CCATGTGTCGAG 123
Db 1 CCATGTGTCGAG 13

RESULT 486

US-09-316-447A-1
; Sequence 1, Application US/09316447A
; Patent No. 6287774
; GENERAL INFORMATION:
; APPLICANT: Nikiforov, Theo T.
; TITLE OF INVENTION: Assay Methods and Systems
; FILE REFERENCE: 09316447
; CURRENT APPLICATION NUMBER: US/09/316,447A
; CURRENT FILING DATE: 1999-02-21
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Peptide
US-09-316-447A-1

Query Match 0.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 499 GGCACTACTCCA 511
Db 1 GTCAACTACTCCA 13

RESULT 487
US-08-980-832-54/c
; Sequence 54, Application US/08980832B
; Patent No. 6291204
; GENERAL INFORMATION:
; APPLICANT: Pasamonies, Luis
; APPLICANT: Tsygankov, Yuri
; TITLE OF INVENTION: Improved Fermentative Carotenoid Production
; FILE REFERENCE: Improved Fermentative Carotenoid
; CURRENT APPLICATION NUMBER: US/08/980,832B
; CURRENT FILING DATE: 1997-12-01
; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 54
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Escherichia coli
US-08-980-832-54

Query Match 0.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 270 CTACTGCAGGAT 282
Db 13 CTACTGCAGGAT 1

RESULT 488

US-09-727-532A-1
; Sequence 1, Application US/09727532A

```
Patent No. 6436646
GENERAL INFORMATION:
APPLICANT: NikiForov, Theo T.
TITLE OF INVENTION: Kinase Assays Using Polycations
FILE REFERENCE: 100/07930
CURRENT APPLICATION NUMBER: US/09/727,532A
CURRENT FILING DATE: 2000-11-28
PRIOR APPLICATION NUMBER: US 09/316,447
PRIOR FILING DATE: 1999-05-21
PRIOR APPLICATION NUMBER: US 60/156,366
PRIOR FILING DATE: 1999-09-28
PRIOR APPLICATION NUMBER: US 60/139,562
PRIOR FILING DATE: 1999-06-16
NUMBER OF SEQ ID NOS: 19
SOFTWARE: PatentIn version 3.1
SEQ ID NO 1
LENGTH: 13
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: PNA probe
US-09-727-532A-1

Query Match          0.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      499 GGCACATCTCCA 511
DB      1 GTCMAATCTCCA 13

RESULT 489
US-09-717-847E-3/c
Sequence 3, Application US/09717847E
Patent No. 6461837
GENERAL INFORMATION:
APPLICANT: Yaver, Debbie S.
TITLE OF INVENTION: Methods For Producing A Polypeptide
FILE REFERENCE: 5996.200-US
CURRENT APPLICATION NUMBER: US/09/717,847E
CURRENT FILING DATE: 2000-11-20
PRIOR APPLICATION NUMBER: 09/451,503
PRIOR FILING DATE: 1999-11-30
NUMBER OF SEQ ID NOS: 48
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 3
LENGTH: 13
TYPE: DNA
ORGANISM: Aspergillus oryzae
US-09-717-847E-3

Query Match          0.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      133 CATGCTGATGAGC 145
DB      13 CATGCTGAGAGC 1

RESULT 490
US-09-717-847E-4/c
Sequence 4, Application US/09717847E
Patent No. 6461837
GENERAL INFORMATION:
APPLICANT: Yaver, Debbie S.
APPLICANT: Bellini, Daniel Alan
TITLE OF INVENTION: Methods For Producing A Polypeptide
FILE REFERENCE: 5996.200-US
FILE REFERENCE: 5996.200-US
```

```
CURRENT APPLICATION NUMBER: US/09/717,847E
CURRENT FILING DATE: 2000-11-20
PRIOR APPLICATION NUMBER: 09/451,503
PRIOR FILING DATE: 1999-11-30
NUMBER OF SEQ ID NOS: 48
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 4
LENGTH: 13
TYPE: DNA
ORGANISM: Aspergillus oryzae
US-09-717-847E-4

Query Match          0.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      133 CATGCTGATGAGC 145
DB      13 CATGCTGAGAGC 1

RESULT 491
US-09-569-193A-1
Sequence 1, Application US/09569193A
Patent No. 6472141
GENERAL INFORMATION:
APPLICANT: NikiForov, Theo T.
TITLE OF INVENTION: Kinase Assays Using Polycations
FILE REFERENCE: 100/07930
CURRENT APPLICATION NUMBER: US/09/569,193A
CURRENT FILING DATE: 2000-05-11
PRIOR APPLICATION NUMBER: US 09/316,447
PRIOR FILING DATE: 1999-05-21
PRIOR APPLICATION NUMBER: US 60/156,366
PRIOR FILING DATE: 1999-09-28
PRIOR APPLICATION NUMBER: US 60/139,562
PRIOR FILING DATE: 1999-06-16
NUMBER OF SEQ ID NOS: 19
SOFTWARE: PatentIn version 3.1
SEQ ID NO 1
LENGTH: 13
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: PNA probe
US-09-569-193A-1

Query Match          0.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      499 GGCACATCTCCA 511
DB      1 GTCMAATCTCCA 13

RESULT 492
US-09-920-923B-54/c
Sequence 54, Application US/09920923B
Patent No. 6677134
GENERAL INFORMATION:
APPLICANT: Pasamontes, Luis
APPLICANT: Teygankov, Yuri
TITLE OF INVENTION: Fermentative Carotenoid Production
FILE REFERENCE: 15464 US (C38435/125944)
CURRENT APPLICATION NUMBER: US/09/920,923B
CURRENT FILING DATE: 2001-08-02
PRIOR APPLICATION NUMBER: 08/980,832
PRIOR FILING DATE: 1997-12-01
NUMBER OF SEQ ID NOS: 66
SOFTWARE: PatentIn version 3.1
SEQ ID NO 54
LENGTH: 13
```

TYPE: RNA
ORGANISM: Escherichia coli
US-09-920-923B-54

Query Match
Best Local Similarity 84.6%; Score 9.8; DB 1; Length 13;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 270 CTAAGGAGGAT 282
Db 13 CTAAGGAGGAT 1

RESULT 493
US-10-057-812A-1
Sequence 1, Application US/10057812A
Patent No. 6689565
GENERAL INFORMATION:
APPLICANT: NIKIFOROV, THEO T.
TITLE OF INVENTION: Kinase Assays Using Polycations
FILE REFERENCE: 100/07930
CURRENT APPLICATION NUMBER: US/10/057,812A
PRIOR FILING DATE: 2002-01-24
PRIOR APPLICATION NUMBER: US/09/569,193
PRIOR FILING DATE: 2000-05-11
PRIOR APPLICATION NUMBER: US 09/316,447
PRIOR FILING DATE: 1999-05-21
PRIOR APPLICATION NUMBER: US 60/156,366
PRIOR FILING DATE: 1999-09-28
PRIOR APPLICATION NUMBER: US 60/139,562
PRIOR FILING DATE: 1999-06-16
NUMBER OF SEQ ID NOS: 19
SOFTWARE: Patentin version 3.1
SEQ ID NO 1
LENGTH: 13
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: PNA probe
US-10-057-812A-1

Query Match
Best Local Similarity 84.6%; Score 9.8; DB 1; Length 13;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 499 GGCACTACTCCA 511
Db 1 GTCAATACTCCA 13

RESULT 494
US-09-865-044-1
Sequence 1, Application US/09865044
Patent No. 6699655
GENERAL INFORMATION:
APPLICANT: NIKIFOROV, THEO T.
TITLE OF INVENTION: Assay Methods and Systems
FILE REFERENCE: 09316447
CURRENT APPLICATION NUMBER: US/09/865,044
PRIOR FILING DATE: 2001-05-24
PRIOR APPLICATION NUMBER: 09/316,447
PRIOR FILING DATE: 1999-05-21
NUMBER OF SEQ ID NOS: 6
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 1
LENGTH: 13
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Peptide
US-09-865-044-1

Query Match
Best Local Similarity 84.6%; Score 9.8; DB 1; Length 13;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 499 GGCACTACTCCA 511
Db 1 GTCAATACTCCA 13

RESULT 495
US-09-854-417A-2
Sequence 2, Application US/09854417A
Patent No. 6777184
GENERAL INFORMATION:
APPLICANT: NIKIFOROV, THEO T.
APPLICANT: JEONG, SANG
TITLE OF INVENTION: DETECTION OF NUCLEIC ACID HYBRIDIZATION BY FLUORESCENCE
FILE REFERENCE: 01-054210US
CURRENT APPLICATION NUMBER: US/09/854,417A
PRIOR FILING DATE: 2001-05-11
PRIOR APPLICATION NUMBER: 60/203,723
PRIOR FILING DATE: 2000-05-12
NUMBER OF SEQ ID NOS: 7
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 2
LENGTH: 13
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-09-854-417A-2

Query Match
Best Local Similarity 84.6%; Score 9.8; DB 1; Length 13;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 499 GGCACTACTCCA 511
Db 1 GTCAATACTCCA 13

Search completed: October 26, 2004, 16:21:19
Job time : 32 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 26, 2004, 16:13:19 ; Search time 50 Seconds
(without alignments)
3.538 Million cell updates/sec

Title: US-09-923-515-3

Perfect score: 7200

Sequence: 1 ctggagattgggacacattc.....actgcaactcagcgaatgc 7200

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 805 seqs, 12283 residues

Total number of hits satisfying chosen parameters: 1610

Minimum DB seq length: 12
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%

Database : rng3.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	30	0.4	30	1	AAT58420
2	30	0.4	30	1	AAT58419
3	30	0.4	30	1	AAV82531
4	30	0.4	30	1	AAV82530
5	26	0.4	26	1	AAV89305
6	25	0.3	25	1	ADO33413
7	24	0.3	24	1	AAZ50401
8	24	0.3	24	1	ADO33415
9	23.8	0.3	27	1	AAZ35370
10	23	0.3	23	1	AAO70748
11	22	0.3	22	1	AAH79116
12	22	0.3	22	1	AAH44009
13	20.2	0.3	26	1	AAH79105
14	20.2	0.3	26	1	ABQ76080
15	20.2	0.3	26	1	AAH44001
16	20	0.3	20	1	AAV89308
17	20	0.3	20	1	ACC47289
18	20	0.3	20	1	ACC47298
19	20	0.3	20	1	ACC47295
20	20	0.3	20	1	ACC47287
21	20	0.3	20	1	ACC47299
22	20	0.3	20	1	ACC47291
23	20	0.3	20	1	ACC47293
24	20	0.3	20	1	ACC47296
25	20	0.3	20	1	ACC47292
26	20	0.3	20	1	ACC47286
27	20	0.3	20	1	ACC47284
28	20	0.3	20	1	ACC47290
29	20	0.3	20	1	ACC47294
30	20	0.3	20	1	ACC47297
31	20	0.3	20	1	ACC47285
32	20	0.3	20	1	ACC47288
33	19	0.3	19	1	AAO70749

34	19	0.3	19	1	AAV89307	Primer K1P used i
35	18.4	0.3	20	1	ACC47300	Human apolipoprotei
36	18.4	0.3	20	1	ACC47301	Human apolipoprotei
37	18.4	0.3	20	1	ACC47304	Human apolipoprotei
38	18	0.2	18	1	ADO33414	PCR primer 2 used
39	17.4	0.2	20	1	ACC47309	Human apolipoprotei
40	17	0.2	17	1	AAV15097	Human apolipoprote
41	16.8	0.2	21	1	ABV98154	Human multidrug re
42	16.4	0.2	18	1	AAT93192	Primer for K1Ple
43	16.4	0.2	18	1	AAV52282	Human plasminogen
44	16.4	0.2	18	1	ADK23663	Human plasminogen
45	16.4	0.2	19	1	AAQ39588	Mycobacterium gord
46	16.4	0.2	19	1	AAQ39594	Mycobacterium gord
47	16.4	0.2	19	1	AAQ39595	Mycobacterium gord
48	16.4	0.2	19	1	AAQ39599	Mycobacterium gord
49	15.8	0.2	20	1	ACC80563	Flutropent stem c
50	15.8	0.2	20	1	ADK65736	Human vWF cDNA PCR
51	15.8	0.2	20	1	AD128399	Human neurotrophid
52	15.8	0.2	21	1	AAZ76017	Human blallelic ma
53	15.8	0.2	21	1	AAV62205	Per tyrosine kinas
54	15.8	0.2	21	1	ABK41507	Human CTNNA3 gene
55	15.4	0.2	19	1	ABK14648	Human matrix metal
56	15.4	0.2	20	1	ABK17704	Human vlokinae pl
57	15.4	0.2	20	1	ADO22862	Human interleukin
58	15.4	0.2	20	1	ADO22785	Human interleukin
59	15.2	0.2	20	1	AAV51877	Zea mays genome re
60	15.2	0.2	20	1	AAV58789	Primer HUN2AE+2A u
61	15.2	0.2	20	1	AAV73070	Human dactx inhibic
62	15.2	0.2	20	1	AAV67699	Oligonucleotide #1
63	15.2	0.2	20	1	AAH80279	Oligonucleotide hy
64	15.2	0.2	20	1	AAH80798	Oligonucleotide hy
65	15.2	0.2	20	1	ABA82239	maxi gene region
66	15.2	0.2	20	1	AAV17642	Human G protein-co
67	15.2	0.2	20	1	ABK23036	Human Znaxi. cDNA r
68	15.2	0.2	20	1	ACC47310	Human apolipoprotei
69	15.2	0.2	20	1	ACC45619	Human HMV STS mark
70	15.2	0.2	20	1	ABZ23255	PCR primer specif
71	15.2	0.2	20	1	ADK48521	Chicken lysozyme G
72	15.2	0.2	20	1	ADK89317	Sequence tagged si
73	15.2	0.2	20	1	ADK81170	HIV PRT antisense
74	15.2	0.2	20	1	ADK81689	HIV PRT antisense
75	15.2	0.2	20	1	ADJ78427	Human perlipin ta
76	15.2	0.2	20	1	ADJ78345	Human perlipin ch
77	15.2	0.2	20	1	ADL17774	PCR primer used to
78	15.2	0.2	20	1	ADK74226	Chimeric phosphoro
79	15.2	0.2	20	1	ADK75026	Chimeric phosphoro
80	15.2	0.2	20	1	ADK75027	Chimeric phosphoro
81	15	0.2	15	1	AAT37560	Apo(a) mRNA (nt. p
82	15	0.2	15	1	AAT37568	Apo(a) mRNA (nt. p
83	15	0.2	15	1	AAT37572	Apo(a) mRNA (nt. p
84	15	0.2	15	1	AAT37716	Apo(a) mRNA (nt. p
85	15	0.2	15	1	AAT37728	Apo(a) mRNA (nt. p
86	15	0.2	15	1	AAT37772	Apo(a) mRNA (nt. p
87	15	0.2	15	1	AAT37756	Apo(a) mRNA (nt. p
88	15	0.2	15	1	AAT37564	Apo(a) mRNA (nt. p
89	15	0.2	15	1	AAT37726	Apo(a) mRNA (nt. p
90	15	0.2	15	1	AAT37752	Apo(a) mRNA (nt. p
91	15	0.2	15	1	AAT37776	Apo(a) mRNA (nt. p
92	15	0.2	15	1	AAT37778	Apo(a) mRNA (nt. p
93	15	0.2	15	1	AAT37782	Apo(a) mRNA (nt. p
94	15	0.2	15	1	AAT37784	Apo(a) mRNA (nt. p
95	15	0.2	15	1	AAT37720	Apo(a) mRNA (nt. p
96	15	0.2	15	1	AAT37768	Apo(a) mRNA (nt. p
97	15	0.2	15	1	AAT37558	Apo(a) mRNA (nt. p
98	15	0.2	15	1	AAT37714	Apo(a) mRNA (nt. p
99	15	0.2	15	1	AAT37724	Apo(a) mRNA (nt. p
100	15	0.2	15	1	AAT37770	Apo(a) mRNA (nt. p
101	15	0.2	15	1	AAT37554	Apo(a) mRNA (nt. p
102	15	0.2	15	1	AAT37780	Apo(a) mRNA (nt. p
103	15	0.2	15	1	AAT37732	Apo(a) mRNA (nt. p
104	15	0.2	15	1	AAT37552	Apo(a) mRNA (nt. p
105	15	0.2	15	1	AAT37562	Apo(a) mRNA (nt. p
106	15	0.2	15	1	AAT37722	Apo(a) mRNA (nt. p

107	15	0.2	15	1	AAT37730	Apo(a) mRNA (nt. p
108	15	0.2	15	1	AAT37556	Apo(a) mRNA (nt. p
109	15	0.2	15	1	AAT37566	Apo(a) mRNA (nt. p
110	15	0.2	15	1	AAT37751	Apo(a) mRNA (nt. p
111	15	0.2	15	1	AAT37570	Apo(a) mRNA (nt. p
112	15	0.2	15	1	AAV15098	Human apolipoprote
113	15	0.2	17	1	ABT40093	Tumour suppression
114	15	0.2	17	1	ABD45751	Tumour suppression
115	15	0.2	17	1	ADT50461	Human tumour supp
116	15	0.2	19	1	AAQ39591	Mycobacterium gord
117	14.8	0.2	19	1	AAQ39592	Mycobacterium gord
118	14.8	0.2	19	1	AAQ39590	Mycobacterium gord
119	14.8	0.2	19	1	AAQ39587	Mycobacterium gord
120	14.8	0.2	19	1	ABT53411	Haemagglutination
121	14.8	0.2	19	1	ADN34436	Lower strand of cy
122	14.8	0.2	19	1	ADN34197	Upper strand of cy
123	14.4	0.2	17	1	AAA25065	Oestrogen receptor
124	14.4	0.2	17	1	ACA99849	G-protein coupled
125	14.4	0.2	17	1	ABZ64673	G-protein coupled
126	14.4	0.2	17	1	ADB39822	Human HER2 DNAzyme
127	14.4	0.2	17	1	ADL48869	Tumour suppression
128	14.4	0.2	17	1	ADL48143	Human IKK-gamma su
129	14.4	0.2	17	1	AAH40802	Human IKK-gamma su
130	14.4	0.2	18	1	AAH40802	Forward PCR primer
131	14.4	0.2	18	1	AAH40802	Human hscD5 cDNA a
132	14.4	0.2	18	1	ABT06163	Human light chain
133	14.4	0.2	18	1	ACD05030	Tumour necrosis fa
134	14.4	0.2	19	1	ADP71306	Protein tyrosine p
135	14.4	0.2	19	1	ADP71232	Human TNF s1NA O1
136	14.4	0.2	19	1	ADG34746	Human TNF s1NA O1
137	14.4	0.2	19	1	ADG34658	Human TNF s1NA O1
138	14.4	0.2	19	1	ADG09449	TYF-alpha-related
139	14.4	0.2	19	1	ADG027987	s1PAK1-0 targeted
140	14	0.2	15	1	AAT37582	Apo(a) mRNA (nt. p
141	14	0.2	15	1	AAT37598	Apo(a) mRNA (nt. p
142	14	0.2	15	1	AAA60130	Apo(a) mRNA (nt. p
143	14	0.2	15	1	AAA60130	Human APC gene var
144	14	0.2	17	1	ABA78841	APC mutation corre
145	14	0.2	17	1	ABA78842	Drug-tolerant gene
146	14	0.2	17	1	ADK71405	Human BGF-R target
147	13.8	0.2	18	1	AAV97376	Human GMPLP-1 17-m
148	13.8	0.2	17	1	ABN02462	Human GMPLP-1 17-m
149	13.8	0.2	17	1	ABN07781	Human GMPLP-1 17-m
150	13.8	0.2	17	1	ABN02461	Human GMPLP-1 17-m
151	13.8	0.2	17	1	AAH46306	Human ribozyme cle
152	13.8	0.2	17	1	ACN10466	WNV minus strand I
153	13.8	0.2	17	1	ACA99847	G-protein coupled
154	13.8	0.2	17	1	ACA99851	G-protein coupled
155	13.8	0.2	17	1	ACA99850	G-protein coupled
156	13.8	0.2	17	1	ADB47377	Tumour suppression
157	13.8	0.2	17	1	ADG04247	Human Na/H exchange
158	13.8	0.2	17	1	ADG69470	3' anchored (ISSR)
159	13.8	0.2	17	1	ADL47944	Human IKK-gamma su
160	13.8	0.2	18	1	AAZ56074	Human IKK-gamma su
161	13.8	0.2	18	1	ADP77875	Phospholipase A2 g
162	13.6	0.2	24	1	ADG33415	Human BBT clone an
163	13.6	0.2	24	1	ADG33415	FAH/TAMPA-labelled
164	13.4	0.2	15	1	AAT37574	Apo(a) mRNA (nt. p
165	13.4	0.2	15	1	AAT37749	Apo(a) mRNA (nt. p
166	13.4	0.2	15	1	AAT37710	Apo(a) mRNA (nt. p
167	13.4	0.2	15	1	AAT37584	Apo(a) mRNA (nt. p
168	13.4	0.2	15	1	AAT37628	Apo(a) mRNA (nt. p
169	13.4	0.2	15	1	AAT37762	Apo(a) mRNA (nt. p
170	13.4	0.2	15	1	AAT37579	Apo(a) mRNA (nt. p
171	13.4	0.2	15	1	AAT37578	Apo(a) mRNA (nt. p
172	13.4	0.2	15	1	AAT37578	Apo(a) mRNA (nt. p
173	13.4	0.2	15	1	AAT37580	Apo(a) mRNA (nt. p
174	13.4	0.2	15	1	AAT37712	Apo(a) mRNA (nt. p
175	13.4	0.2	15	1	AAT37760	Apo(a) mRNA (nt. p
176	13.4	0.2	15	1	AAT37573	Apo(a) mRNA (nt. p
177	13.4	0.2	15	1	AAT37605	Apo(a) mRNA (nt. p
178	13.4	0.2	15	1	AAT37740	Apo(a) mRNA (nt. p
179	13.4	0.2	15	1	AAT37764	Apo(a) mRNA (nt. p
180	13.4	0.2	15	1	AAT37714	Apo(a) mRNA (nt. p
181	13.4	0.2	15	1	AAT37736	Apo(a) mRNA (nt. p
182	13.4	0.2	15	1	AAT37608	Apo(a) mRNA (nt. p
183	13.4	0.2	15	1	AAT37589	Apo(a) mRNA (nt. p
184	13.4	0.2	15	1	AAT37738	Apo(a) mRNA (nt. p
185	13.4	0.2	15	1	AAT37738	Apo(a) mRNA (nt. p
186	13.4	0.2	15	1	AAT37759	Apo(a) mRNA (nt. p
187	13.4	0.2	15	1	AAT37759	Apo(a) mRNA (nt. p
188	13.4	0.2	15	1	AAT37717	Apo(a) mRNA (nt. p
189	13.4	0.2	15	1	AAT37734	Apo(a) mRNA (nt. p
190	13.4	0.2	15	1	AAT37758	Apo(a) mRNA (nt. p
191	13.4	0.2	15	1	AAT37719	Apo(a) mRNA (nt. p
192	13.4	0.2	15	1	AAT37731	Apo(a) mRNA (nt. p
193	13.4	0.2	15	1	AAT37761	Apo(a) mRNA (nt. p
194	13.4	0.2	15	1	AAT37766	Apo(a) mRNA (nt. p
195	13.4	0.2	15	1	AAT37576	Apo(a) mRNA (nt. p
196	13.4	0.2	17	1	AAH60234	Human hPC2 cDNA se
197	13.4	0.2	17	1	ABK03774	Human CD20 Ambery
198	13.4	0.2	17	1	ABK03774	Human prostate can
199	13.4	0.2	17	1	ABT35963	Tumour suppression
200	13.4	0.2	17	1	ABT35963	Tumour suppression
201	13.4	0.2	17	1	ABZ65103	Human HER2 DNAzyme
202	13.4	0.2	17	1	ACG67694	Murine oligonucleo
203	13.4	0.2	17	1	ADL48870	PCR primer MSIR re
204	13.4	0.2	17	1	ADL48870	Human IKK-gamma su
205	13.2	0.2	20	1	AAH89308	Primer k1r used i
206	13	0.2	13	1	ABH38632	Oligonucleotide SE
207	13	0.2	13	1	ABF92992	Oligonucleotide SE
208	13	0.2	13	1	ABF92992	Oligonucleotide SE
209	13	0.2	13	1	ABH38633	Oligonucleotide SE
210	13	0.2	15	1	AAT37737	Apo(a) mRNA (nt. p
211	13	0.2	15	1	AAT37587	Apo(a) mRNA (nt. p
212	13	0.2	15	1	AAT37735	Apo(a) mRNA (nt. p
213	13	0.2	15	1	AAH64031	Substrate for ham
214	13	0.2	15	1	ABX01084	Human APC gene var
215	13	0.2	15	1	ABX02857	Hepatitis C virus
216	13	0.2	17	1	ABZ62017	Human CD20 Hammer
217	13	0.2	17	1	ABZ62016	Human H-Ras DNAzm
218	13	0.2	17	1	ABZ63821	Human H-Ras DNAzm
219	13	0.2	17	1	ACD63821	HCV minus strand D
220	13	0.2	17	1	ACD63822	HCV DNAzyme subst
221	13	0.2	17	1	ADL83796	HCV minus strand D
222	13	0.2	17	1	ADL83796	HCV DNAzyme subst
223	13	0.2	17	1	ADL83796	HCV DNAzyme subst
224	13	0.2	17	1	ADL83796	HCV DNAzyme subst
225	13	0.2	17	1	ADL83796	HCV DNAzyme subst
226	12.8	0.2	16	1	ABE14002	Opineurin promote
227	12.8	0.2	17	1	AAH64002	Rabbit stromelysin
228	12.8	0.2	17	1	AAH64002	Human flt1 VEGF re
229	12.8	0.2	17	1	AAH17197	Axyl hydropocarbon
230	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
231	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
232	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
233	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
234	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
235	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
236	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
237	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
238	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
239	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
240	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
241	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
242	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
243	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
244	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
245	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
246	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
247	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
248	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
249	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
250	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
251	12.8	0.2	17	1	AAH17197	Human TIE-2 subst
252	12.8	0.2	17	1	AAH17197	Human TIE-2 subst

C 253	12.8	0.2	17	1	ABN07685	Human GDM/P-1 17-m	326	12.4	0.2	15	1	AAK31192	Tag sequence of a
C 254	12.8	0.2	17	1	ABN08431	Human GDM/P-1 17-m	327	12.4	0.2	15	1	AAK31710	Transcript tag seq
C 255	12.8	0.2	17	1	ABN10121	Human GDM/P-1 17-m	328	12.4	0.2	15	1	AAK5553	Arabidopsis seed-s
C 256	12.8	0.2	17	1	ABN07537	Human GDM/P-1 17-m	329	12.4	0.2	15	1	AAV64955	Mouse histone H2B
C 257	12.8	0.2	17	1	ABN07684	Human GDM/P-1 17-m	330	12.4	0.2	15	1	AAK60128	Human APC gene var
C 258	12.8	0.2	17	1	ABN01166	Human GDM/P-1 17-m	331	12.4	0.2	15	1	AAFS3634	IGF-1 oligonucleot
C 259	12.8	0.2	17	1	ABN02460	Human GDM/P-1 17-m	332	12.4	0.2	15	1	AAFS3633	IGF-1 oligonucleot
C 260	12.8	0.2	17	1	ABN02780	Human GDM/P-1 17-m	333	12.4	0.2	15	1	AAAF76909	DNA fragment. Syn
C 261	12.8	0.2	17	1	ABN08780	Human GDM/P-1 17-m	334	12.4	0.2	15	1	AAK97511	Human LCAT gene po
C 262	12.8	0.2	17	1	ABN07782	Human GDM/P-1 17-m	335	12.4	0.2	15	1	AA172774	Oligo #6 for cloni
C 263	12.8	0.2	17	1	ABN10122	Human GDM/P-1 17-m	336	12.4	0.2	15	1	ABK32146	Human colon cancer
C 264	12.8	0.2	17	1	ABN01167	Human GDM/P-1 17-m	337	12.4	0.2	15	1	ABK32664	Human colorectal a
C 265	12.8	0.2	17	1	ABN02463	Human GDM/P-1 17-m	338	12.4	0.2	15	1	ABX76573	M. avium 16S rRNA
C 266	12.8	0.2	17	1	ABN0536	Human GDM/P-1 17-m	339	12.4	0.2	15	1	ADCC4107	M. avium 16S rRNA
C 267	12.8	0.2	17	1	ABO63767	Human K10M1a porti	340	12.4	0.2	15	1	ADFC44009	Human papillomavir
C 268	12.8	0.2	17	1	ABO63764	Human K10M1a porti	341	12.4	0.2	15	1	ADFC44009	HPV S9 detecting p
C 269	12.8	0.2	17	1	ABO63766	Human K10M1a porti	342	12.4	0.2	16	1	AAZ97835	HIV-1 protease gen
C 270	12.8	0.2	17	1	ABO63765	Human K10M1a porti	343	12.4	0.2	16	1	ABL31194	Human HLA genotypi
C 271	12.8	0.2	17	1	AA143459	Human tissue kall	344	12.4	0.2	16	1	ADB99302	PCR primer Seq ID3
C 272	12.8	0.2	17	1	ABK19430	Human ERG Ambery	345	12.2	0.2	20	1	ACCA47295	Human apolipoprotei
C 273	12.8	0.2	17	1	ABK17417	Human ERG hamme	346	12	0.2	12	1	AB134086	Oligonucleotide pr
C 274	12.8	0.2	17	1	ABV90092	Human PDSHL1 scann	347	12	0.2	12	1	ABH80898	Oligonucleotide pr
C 275	12.8	0.2	17	1	ABV90093	Human PDSHL1 scann	348	12	0.2	12	1	AB148149	Oligonucleotide pr
C 276	12.8	0.2	17	1	AA519261	HIV env PCR primer	349	12	0.2	12	1	ABH80536	Oligonucleotide pr
C 277	12.8	0.2	17	1	ACN10465	WNV minus strand I	350	12	0.2	12	1	AB162899	Oligonucleotide pr
C 278	12.8	0.2	17	1	ACN10807	WNV minus strand I	351	12	0.2	13	1	ABH23673	Oligonucleotide SE
C 279	12.8	0.2	17	1	ACN12492	WNV minus strand Z	352	12	0.2	13	1	ABH23673	Oligonucleotide SE
C 280	12.8	0.2	17	1	ACN14377	WNV minus strand A	353	12	0.2	13	1	ABH49265	Oligonucleotide SE
C 281	12.8	0.2	17	1	ACN07170	WNV Amberzyme subs	354	12	0.2	13	1	ABF56286	Oligonucleotide SE
C 282	12.8	0.2	17	1	ACN07622	WNV minus strand H	355	12	0.2	13	1	ABH32287	Oligonucleotide SE
C 283	12.8	0.2	17	1	ACN06696	WNV Amberzyme subs	356	12	0.2	13	1	ABH23672	Oligonucleotide SE
C 284	12.8	0.2	17	1	ACN08143	WNV minus strand H	357	12	0.2	13	1	ABH32286	Oligonucleotide SE
C 285	12.8	0.2	17	1	ACN03095	WNV inozyme subste	358	12	0.2	13	1	ABH50727	Oligonucleotide SE
C 286	12.8	0.2	17	1	ACN05378	WNV DNAzyme subste	359	12	0.2	13	1	ABH49264	Oligonucleotide SE
C 287	12.8	0.2	17	1	ACN05378	WNV Amberzyme subs	360	12	0.2	13	1	ABH50726	Oligonucleotide SE
C 288	12.8	0.2	17	1	ACN08394	WNV minus strand H	361	12	0.2	13	1	ABH78850	Oligonucleotide SE
C 289	12.8	0.2	17	1	ACN09846	G-protein coupled	362	12	0.2	13	1	ABF56287	Oligonucleotide SE
C 290	12.8	0.2	17	1	ACN09852	G-protein coupled	363	12	0.2	15	1	AA55551	Human TNF-alpha ha
C 291	12.8	0.2	17	1	ABT3565	Tumour suppression	364	12	0.2	15	1	AA137610	Apo(a) mRNA (nt. p
C 292	12.8	0.2	17	1	ABT35136	Tumour suppression	365	12	0.2	15	1	AAK31474	Tag sequence of a
C 293	12.8	0.2	17	1	ABT35773	Tumour suppression	366	12	0.2	15	1	AAZ64032	Substrate for ham
C 294	12.8	0.2	17	1	ABT35937	Tumour suppression	367	12	0.2	15	1	AA169910	Probe #2. Enterob
C 295	12.8	0.2	17	1	ABT38758	Tumour suppression	368	12	0.2	15	1	AA167325	Human FKBP8 allele
C 296	12.8	0.2	17	1	ACA06465	NKRB sub-unit modu	369	12	0.2	15	1	AA167341	Human FKBP8 allele
C 297	12.8	0.2	17	1	ACA06466	NKRB sub-unit modu	370	12	0.2	15	1	AA167418	Human FKBP8 allele
C 298	12.8	0.2	17	1	ABZ60124	Human K-Ras DNAzym	371	12	0.2	15	1	AA169904	Probe #2. Enterob
C 299	12.8	0.2	17	1	ADB40647	Tumour suppression	372	12	0.2	15	1	AA169904	Nucleic acid detec
C 300	12.8	0.2	17	1	ADCC04246	Human Na/H exchang	373	12	0.2	15	1	AA169904	Human IL4R1alpha ge
C 301	12.8	0.2	17	1	ADCC04252	Human Na/H exchang	374	12	0.2	15	1	AA169904	Human IL4R1alpha ge
C 302	12.8	0.2	17	1	ADCC04253	Human Na/H exchang	375	12	0.2	15	1	AB108938	Oligonucleotide CP
C 303	12.8	0.2	17	1	ADCC04248	Tumour suppression	376	12	0.2	15	1	AB101163	Human AKR1B1 gene
C 304	12.8	0.2	17	1	ADB45030	Human Na/H exchang	377	12	0.2	15	1	AB157605	Human SCY24 ASO p
C 305	12.8	0.2	17	1	ADBE06477	HIV-1 ENV PCR prim	378	12	0.2	15	1	ABA97008	zfp36 allele-speci
C 306	12.8	0.2	17	1	ADFS5656	Human Kallikrein P	379	12	0.2	15	1	AA142374	Human G protein ga
C 307	12.8	0.2	17	1	ADIS1523	Human tumour suppr	380	12	0.2	15	1	AA145863	Human TNF alpha ge
C 308	12.8	0.2	17	1	ADIS1523	Human tumour suppr	381	12	0.2	15	1	ABK63975	Human BF gene alle
C 309	12.8	0.2	17	1	ADIS1393	Human tumour suppr	382	12	0.2	15	1	ABK32428	Human colon cancer
C 310	12.8	0.2	17	1	AD149788	Human tumour suppr	383	12	0.2	15	1	ABX01085	Hepatitis C virus
C 311	12.8	0.2	17	1	ACCS4459	Human tumour suppr	384	12	0.2	15	1	ABX10152	Human TIGR/Myocili
C 312	12.8	0.2	17	1	ADL48142	Human IKK-gamma su	385	12	0.2	15	1	ADM66138	Canarypox virus C3
C 313	12.8	0.2	17	1	ADL48142	Human IKK-gamma su	386	12	0.2	16	1	AA169508	wild-type capture
C 314	12.8	0.2	17	1	AD185077	Human apolipoprotei	387	12	0.2	20	1	AA169508	Human apolipoprotei
C 315	12.8	0.2	17	1	ABG90246	HCV DNAzyme subste	388	12	0.2	15	1	AA169508	Human TNF-alpha ha
C 316	12.6	0.2	13	1	ABG90246	Oligonucleotide SE	389	11.8	0.2	15	1	AA177611	Apo(a) mRNA (nt. p
C 317	12.6	0.2	15	1	AA167426	Human FXBP8 allele	390	11.8	0.2	15	1	AA177611	Apo(a) mRNA (nt. p
C 318	12.6	0.2	20	1	ACCA47292	Human apolipoprotei	391	11.8	0.2	15	1	AA177611	Apo(a) mRNA (nt. p
C 319	12.6	0.2	20	1	ACCA47290	Human apolipoprotei	392	11.8	0.2	15	1	AA177611	Apo(a) mRNA (nt. p
C 320	12.4	0.2	15	1	AAQ36858	PCR primer for 5'	393	11.8	0.2	15	1	AAV93756	Oligonucleotide SE
C 321	12.4	0.2	15	1	AA173571	Apo(a) mRNA (nt. p	394	11.8	0.2	15	1	AAV93756	Target sequence w/
C 322	12.4	0.2	15	1	AA173571	Apo(a) mRNA (nt. p	395	11.8	0.2	15	1	AAZ07074	peptide nucleic ac
C 323	12.4	0.2	15	1	AA1737723	Apo(a) mRNA (nt. p	396	11.8	0.2	15	1	AA1737723	IGF-1 oligonucleot
C 324	12.4	0.2	15	1	AA1737723	Apo(a) mRNA (nt. p	397	11.8	0.2	15	1	AA1737723	IGF-1 oligonucleot
C 325	12.4	0.2	15	1	AA1737727	Apo(a) mRNA (nt. p	398	11.8	0.2	15	1	AA1737727	IGF-1 oligonucleot

C 399	11.8	0.2	15	1	AAF53632	IGF-1 oligonucleot
C 400	11.8	0.2	15	1	AAF46987	IGFBP3 oligonucleo
C 401	11.8	0.2	15	1	AAF52990	IGF-1 oligonucleot
C 402	11.8	0.2	15	1	AAF50542	IGF-1 oligonucleot
C 403	11.8	0.2	15	1	AAF50839	IGF-1 oligonucleot
C 404	11.8	0.2	15	1	AAF50836	IGF-1 oligonucleot
C 405	11.8	0.2	15	1	AAF53631	IGF-1 oligonucleot
C 406	11.8	0.2	15	1	AAF53631	IGF-1 oligonucleot
C 407	11.8	0.2	15	1	AAF49121	IGF-1 oligonucleot
C 408	11.8	0.2	15	1	AAF49128	IGF-1 oligonucleot
C 409	11.8	0.2	15	1	AAF50837	IGFBP3 oligonucleo
C 410	11.8	0.2	15	1	AAF53635	IGF-1 oligonucleot
C 411	11.8	0.2	15	1	AAF69969	Human TNFRSF11B ge
C 412	11.8	0.2	15	1	ABX03881	F. nucleatum 16S r
C 413	11.8	0.2	15	1	AAF73827	Human SLC6A4 allel
C 414	11.8	0.2	15	1	ABK12188	Human Tachykinin R
C 415	11.8	0.2	15	1	ABK12188	Consensus sequence
C 416	11.8	0.2	15	1	AD081041	Cow prion protein
C 417	11.8	0.2	15	1	ABF33431	Oligonucleotide SE
C 418	11.6	0.2	13	1	ABH24411	Oligonucleotide SE
C 419	11.6	0.2	13	1	ABH24410	Oligonucleotide SE
C 420	11.6	0.2	13	1	ABF33430	Oligonucleotide SE
C 421	11.4	0.2	13	1	AAV11097	Human ribozyme tar
C 422	11.4	0.2	13	1	AAC65841	Consensus translat
C 423	11.4	0.2	13	1	ABC22089	Oligonucleotide SE
C 424	11.4	0.2	13	1	ABC09203	Oligonucleotide SE
C 425	11.4	0.2	13	1	ABC84204	Oligonucleotide SE
C 426	11.4	0.2	13	1	ABC84203	Oligonucleotide SE
C 427	11.4	0.2	13	1	ABC87898	Oligonucleotide SE
C 428	11.4	0.2	13	1	ABC09202	Oligonucleotide SE
C 429	11.4	0.2	13	1	ABF63776	Oligonucleotide SE
C 430	11.4	0.2	13	1	ABH62772	Oligonucleotide SE
C 431	11.4	0.2	13	1	ABC92901	Oligonucleotide SE
C 432	11.4	0.2	13	1	ABC20648	Oligonucleotide SE
C 433	11.4	0.2	13	1	ABC75630	Oligonucleotide SE
C 434	11.4	0.2	13	1	ABC75631	Oligonucleotide SE
C 435	11.4	0.2	13	1	ABC84205	Oligonucleotide SE
C 436	11.4	0.2	13	1	ABF31796	Oligonucleotide SE
C 437	11.4	0.2	13	1	ABF39371	Oligonucleotide SE
C 438	11.4	0.2	13	1	ABF99419	Oligonucleotide SE
C 439	11.4	0.2	13	1	ABH40717	Oligonucleotide SE
C 440	11.4	0.2	13	1	ABC22088	Oligonucleotide SE
C 441	11.4	0.2	13	1	ABC06060	Oligonucleotide SE
C 442	11.4	0.2	13	1	ABC55652	Oligonucleotide SE
C 443	11.4	0.2	13	1	ABF92995	Oligonucleotide SE
C 444	11.4	0.2	13	1	ABH21122	Oligonucleotide SE
C 445	11.4	0.2	13	1	ABF47023	Oligonucleotide SE
C 446	11.4	0.2	13	1	ABF64141	Oligonucleotide SE
C 447	11.4	0.2	13	1	ABH65196	Oligonucleotide SE
C 448	11.4	0.2	13	1	ABC35068	Oligonucleotide SE
C 449	11.4	0.2	13	1	ABH01372	Oligonucleotide SE
C 450	11.4	0.2	13	1	ABF76677	Oligonucleotide SE
C 451	11.4	0.2	13	1	ABF52447	Oligonucleotide SE
C 452	11.4	0.2	13	1	ABH29162	Oligonucleotide SE
C 453	11.4	0.2	13	1	ABC20649	Oligonucleotide SE
C 454	11.4	0.2	13	1	ABF44475	Oligonucleotide SE
C 455	11.4	0.2	13	1	ABH21123	Oligonucleotide SE
C 456	11.4	0.2	13	1	ABF47022	Oligonucleotide SE
C 457	11.4	0.2	13	1	ABH24304	Oligonucleotide SE
C 458	11.4	0.2	13	1	ABF52446	Oligonucleotide SE
C 459	11.4	0.2	13	1	ABH40716	Oligonucleotide SE
C 460	11.4	0.2	13	1	ABH65196	Oligonucleotide SE
C 461	11.4	0.2	13	1	ABH64140	Oligonucleotide SE
C 462	11.4	0.2	13	1	ABC50178	Oligonucleotide SE
C 463	11.4	0.2	13	1	ABC75563	Oligonucleotide SE
C 464	11.4	0.2	13	1	ABF08149	Oligonucleotide SE
C 465	11.4	0.2	13	1	ABF08149	Oligonucleotide SE
C 466	11.4	0.2	13	1	ABC75566	Oligonucleotide SE
C 467	11.4	0.2	13	1	ABF22616	Oligonucleotide SE
C 468	11.4	0.2	13	1	ABF22617	Oligonucleotide SE
C 469	11.4	0.2	13	1	ABF92997	Oligonucleotide SE
C 470	11.4	0.2	13	1	ABH24305	Oligonucleotide SE
C 471	11.4	0.2	13	1	ABH34644	Oligonucleotide SE
C 472	11.4	0.2	13	1	ABC53554	Oligonucleotide SE
C 473	11.4	0.2	13	1	ABC06061	Oligonucleotide SE
C 474	11.4	0.2	13	1	ABF12440	Oligonucleotide SE
C 475	11.4	0.2	13	1	ABF63777	Oligonucleotide SE
C 476	11.4	0.2	13	1	ABH43729	Oligonucleotide SE
C 477	11.4	0.2	13	1	ABF00547	Oligonucleotide SE
C 478	11.4	0.2	13	1	ABF00547	Oligonucleotide SE
C 479	11.4	0.2	13	1	ABC5653	Oligonucleotide SE
C 480	11.4	0.2	13	1	ABF44472	Oligonucleotide SE
C 481	11.4	0.2	13	1	ABF44472	Oligonucleotide SE
C 482	11.4	0.2	13	1	ABH01373	Oligonucleotide SE
C 483	11.4	0.2	13	1	ABH38635	Oligonucleotide SE
C 484	11.4	0.2	13	1	ABF65743	Oligonucleotide SE
C 485	11.4	0.2	13	1	ABC09229	Oligonucleotide SE
C 486	11.4	0.2	13	1	ABC47607	Oligonucleotide SE
C 487	11.4	0.2	13	1	ABF00460	Oligonucleotide SE
C 488	11.4	0.2	13	1	ABF12441	Oligonucleotide SE
C 489	11.4	0.2	13	1	ABF37567	Oligonucleotide SE
C 490	11.4	0.2	13	1	ABF33321	Oligonucleotide SE
C 491	11.4	0.2	13	1	ABF99418	Oligonucleotide SE
C 492	11.4	0.2	13	1	ABH34645	Oligonucleotide SE
C 493	11.4	0.2	13	1	ABH58626	Oligonucleotide SE
C 494	11.4	0.2	13	1	ABC45745	Oligonucleotide SE
C 495	11.4	0.2	13	1	ABC0928	Oligonucleotide SE
C 496	11.4	0.2	13	1	ABC77744	Oligonucleotide SE
C 497	11.4	0.2	13	1	ABF92994	Oligonucleotide SE
C 498	11.4	0.2	13	1	ABH29163	Oligonucleotide SE
C 499	11.4	0.2	13	1	ABH08913	Oligonucleotide SE
C 500	11.4	0.2	13	1	ABH38634	Oligonucleotide SE
C 501	11.4	0.2	13	1	ABC47606	Oligonucleotide SE
C 502	11.4	0.2	13	1	ABF00461	Oligonucleotide SE
C 503	11.4	0.2	13	1	ABF00546	Oligonucleotide SE
C 504	11.4	0.2	13	1	ABC38320	Oligonucleotide SE
C 505	11.4	0.2	13	1	ABF31797	Oligonucleotide SE
C 506	11.4	0.2	13	1	ABF44474	Oligonucleotide SE
C 507	11.4	0.2	13	1	ABH14748	Oligonucleotide SE
C 508	11.4	0.2	13	1	ABH65742	Oligonucleotide SE
C 509	11.4	0.2	13	1	ABH43728	Oligonucleotide SE
C 510	11.4	0.2	13	1	ABH62773	Oligonucleotide SE
C 511	11.4	0.2	13	1	ABC50179	Oligonucleotide SE
C 512	11.4	0.2	13	1	ABC50179	Oligonucleotide SE
C 513	11.4	0.2	13	1	ABH14749	Oligonucleotide SE
C 514	11.4	0.2	13	1	ABC45744	Oligonucleotide SE
C 515	11.4	0.2	13	1	ABC35069	Oligonucleotide SE
C 516	11.4	0.2	13	1	ABF39370	Oligonucleotide SE
C 517	11.4	0.2	13	1	ABF76676	Oligonucleotide SE
C 518	11.4	0.2	13	1	ABH65197	Oligonucleotide SE
C 519	11.4	0.2	13	1	ABF77745	Oligonucleotide SE
C 520	11.4	0.2	13	1	ABC53555	Oligonucleotide SE
C 521	11.4	0.2	13	1	ABF92996	Oligonucleotide SE
C 522	11.4	0.2	13	1	ABH08912	Oligonucleotide SE
C 523	11.4	0.2	13	1	ABC92900	Oligonucleotide SE
C 524	11.4	0.2	13	1	ABF78999	Oligonucleotide SE
C 525	11.4	0.2	13	1	ABF93320	Oligonucleotide SE
C 526	11.4	0.2	13	1	ABH46224	Oligonucleotide SE
C 527	11.4	0.2	13	1	ABH59502	Oligonucleotide SE
C 528	11.4	0.2	13	1	ABT17625	Aspergillus oryzae
C 529	11.4	0.2	14	1	AAO78416	Invasive detection
C 530	11.4	0.2	14	1	AAV11052	TGF-beta gene phos
C 531	11.4	0.2	14	1	AAV79148	Human ribozyme tar
C 532	11.4	0.2	14	1	AAV48616	Human VEGF cDNA an
C 533	11.4	0.2	14	1	AAV57062	junc gene antisens
C 534	11.4	0.2	14	1	AAZ59021	Human Notch3 gene
C 535	11.4	0.2	14	1	AAZ64788	Triple helix form
C 536	11.4	0.2	14	1	AAA26129	Substrate for hair
C 537	11.4	0.2	14	1	AAZ21101	Oestrogen receptor
C 538	11.4	0.2	14	1	ABX01625	Oligonucleotide co
C 539	11.4	0.2	14	1	ABX11625	Oligonucleotide us
C 540	11.4	0.2	14	1	ADBE4664	Hepatitis C virus
C 541	11.4	0.2	14	1	AAU51214	Yak milk protein g
C 542	11.4	0.2	14	1	ADNA1976	Adenovirus cap pro
C 543	11.4	0.2	14	1	ADNA1978	Oligonucleotide sequenc
C 544	11.4	0.2	15	1	AAQ22407	Sequence targeting
C 545	11.4	0.2	15	1	AAQ22407	12-mer homopurine
C 546	11.4	0.2	15	1	AAQ22407	Antisense sequence

C 545	11.4	0.2	15	1	AAQ22408	Antisense sequence
C 546	11.4	0.2	15	1	AAQ20399	Capture probe #1 f
C 547	11.4	0.2	15	1	AAQ41490	Target region for
C 548	11.4	0.2	15	1	AAQ85837	2'-O-alkylamino-co
C 549	11.4	0.2	15	1	AAQ101730	Peptide nucleic ac
C 550	11.4	0.2	15	1	AAQ52494	Mouse ICM hammer
C 551	11.4	0.2	15	1	AAQ52447	Mouse ICM hammer
C 552	11.4	0.2	15	1	AAQ37743	Apoc (a) mRNA (nt. p
C 553	11.4	0.2	15	1	AAQ37577	Apoc (a) mRNA (nt. p
C 554	11.4	0.2	15	1	AAQ38763	CD16 type I and II
C 555	11.4	0.2	15	1	AAQ66181	Mouse B7-2 hammet
C 556	11.4	0.2	15	1	AAQ66151	Mouse B7-2 hammet
C 557	11.4	0.2	15	1	AAQ66617	Human CD40 hammet
C 558	11.4	0.2	15	1	AAQ66153	Mouse B7-2 hammet
C 559	11.4	0.2	15	1	AAQ66152	Mouse B7-2 hammet
C 560	11.4	0.2	15	1	AAQ66152	Mouse B7-2 hammet
C 561	11.4	0.2	15	1	AAQ66154	Mouse B7-2 hammet
C 562	11.4	0.2	15	1	AAQ33482	Oligomeric compou
C 563	11.4	0.2	15	1	AAQ49219	Specific phospho
C 564	11.4	0.2	15	1	AAQ51082	Phosphorothioate o
C 565	11.4	0.2	15	1	AAQ53024	Cytochrome c oxida
C 566	11.4	0.2	15	1	AAQ48790	EtB-2 gene antis
C 567	11.4	0.2	15	1	AAQ19664	Human bcl-2 antis
C 568	11.4	0.2	15	1	AAQ15078	Nuclease resistant
C 569	11.4	0.2	15	1	AAQ15081	Nuclease resistant
C 570	11.4	0.2	15	1	AAQ73854	5-lipoxygenase DNA
C 571	11.4	0.2	15	1	AAQ05476	2'-modified oligon
C 572	11.4	0.2	15	1	AAQ05479	2'-deoxy-2'-methyl
C 573	11.4	0.2	15	1	AAQ62635	Substrate for HH r
C 574	11.4	0.2	15	1	AAQ62577	HIV-1 protease gen
C 575	11.4	0.2	15	1	AAQ297834	PCR primer for hum
C 576	11.4	0.2	15	1	AAQ40170	Polyribonucleotide
C 577	11.4	0.2	15	1	AAQ48137	Oligonucleotide SE
C 578	11.4	0.2	15	1	AAQ48140	Human APC gene var
C 579	11.4	0.2	15	1	AAQ60127	C-1027 gene cluste
C 580	11.4	0.2	15	1	AAQ63373	DNA tagging relate
C 581	11.4	0.2	15	1	AAQ95574	Human IGBR allele
C 582	11.4	0.2	15	1	AAQ92147	Complex PCR amplif
C 583	11.4	0.2	15	1	AAQ20784	Papillomavirus mod
C 584	11.4	0.2	15	1	AAQ15970	Papillomavirus mod
C 585	11.4	0.2	15	1	AAQ15973	Papillomavirus mod
C 586	11.4	0.2	15	1	AAQ15973	Papillomavirus mod
C 587	11.4	0.2	15	1	AAQ15974	Papillomavirus mod
C 588	11.4	0.2	15	1	AAQ15975	Papillomavirus mod
C 589	11.4	0.2	15	1	AAQ15972	Papillomavirus mod
C 590	11.4	0.2	15	1	AAQ15968	Papillomavirus mod
C 591	11.4	0.2	15	1	AAQ15967	Papillomavirus mod
C 592	11.4	0.2	15	1	AAQ15976	Papillomavirus mod
C 593	11.4	0.2	15	1	AAQ15908	Papillomavirus oli
C 594	11.4	0.2	15	1	AAQ15971	Papillomavirus mod
C 595	11.4	0.2	15	1	AAQ15977	Papillomavirus mod
C 596	11.4	0.2	15	1	AAQ46986	IGFBP3 oligonucleo
C 597	11.4	0.2	15	1	AAQ48776	IGFBP3 oligonucleo
C 598	11.4	0.2	15	1	AAQ50392	IGFBP3 oligonucleo
C 599	11.4	0.2	15	1	AAQ50383	IGFBP3 oligonucleo
C 600	11.4	0.2	15	1	AAQ51605	IGFBP3 oligonucleo
C 601	11.4	0.2	15	1	AAQ48775	IGFBP3 oligonucleo
C 602	11.4	0.2	15	1	AAQ53075	IGFBP3 oligonucleo
C 603	11.4	0.2	15	1	AAQ50544	IGFBP3 oligonucleo
C 604	11.4	0.2	15	1	AAQ51716	IGFBP3 oligonucleo
C 605	11.4	0.2	15	1	AAQ53076	IGFBP3 oligonucleo
C 606	11.4	0.2	15	1	AAQ46541	IGFBP3 oligonucleo
C 607	11.4	0.2	15	1	AAQ49445	IGFBP3 oligonucleo
C 608	11.4	0.2	15	1	AAQ50543	IGFBP3 oligonucleo
C 609	11.4	0.2	15	1	AAQ46539	IGFBP3 oligonucleo
C 610	11.4	0.2	15	1	AAQ50390	IGFBP3 oligonucleo
C 611	11.4	0.2	15	1	AAQ50391	IGFBP3 oligonucleo
C 612	11.4	0.2	15	1	AAQ51606	IGFBP3 oligonucleo
C 613	11.4	0.2	15	1	AAQ49446	IGFBP3 oligonucleo
C 614	11.4	0.2	15	1	AAQ46540	IGFBP3 oligonucleo
C 615	11.4	0.2	15	1	AAQ51604	IGFBP3 oligonucleo
C 616	11.4	0.2	15	1	AAQ49447	IGFBP3 oligonucleo
C 617	11.4	0.2	15	1	AAQ51715	IGFBP3 oligonucleo
C 618	11.4	0.2	15	1	AAQ46985	IGFBP3 oligonucleo
C 619	11.4	0.2	15	1	AAQ48777	IGFBP3 oligonucleo
C 620	11.4	0.2	15	1	AAQ98064	Human IGBR allele
C 621	11.4	0.2	15	1	AAQ98062	Human IGBR allele
C 622	11.4	0.2	15	1	AAQ81625	Human phospholipid
C 623	11.4	0.2	15	1	AAQ65562	Human focal adhesi
C 624	11.4	0.2	15	1	ABK46589	EDG4 gene, allele
C 625	11.4	0.2	15	1	ABK81899	Human CYP27A1 gene
C 626	11.4	0.2	15	1	AAQ95506	Human HSD3B2 gene
C 627	11.4	0.2	15	1	AAQ14439	ASO primer #2 to d
C 628	11.4	0.2	15	1	ABQ95809	Myeloid progenitor
C 629	11.4	0.2	15	1	ABQ90987	Human protein kina
C 630	11.4	0.2	15	1	ABN83920	GmDSV 5'UTR seque
C 631	11.4	0.2	15	1	ABQ96055	CYP8B1 allele-spec
C 632	11.4	0.2	15	1	ABQ96470	Human protective p
C 633	11.4	0.2	15	1	AAQ98359	Sugar-modified nuc
C 634	11.4	0.2	15	1	AAQ98362	Sugar-modified nuc
C 635	11.4	0.2	15	1	AAQ98366	Sugar-modified nuc
C 636	11.4	0.2	15	1	AAQ95678	Superoxide dismuta
C 637	11.4	0.2	15	1	AAQ19794	ASO primer #52 to
C 638	11.4	0.2	15	1	AAQ19818	ASO primer #76 to
C 639	11.4	0.2	15	1	ABK63849	Neurokinin 1 recep
C 640	11.4	0.2	15	1	AAQ43406	Human CYP3A5 gene
C 641	11.4	0.2	15	1	AAQ94637	Human PLTP gene al
C 642	11.4	0.2	15	1	ABX00486	Hepatitis C virus
C 643	11.4	0.2	15	1	ABX00428	Hepatitis C virus
C 644	11.4	0.2	15	1	AAQ15410	Human focal adhesi
C 645	11.4	0.2	15	1	AAQ95951	Human CLM1 gene a
C 646	11.4	0.2	15	1	ABQ54516	Hepatitis C virus
C 647	11.4	0.2	15	1	ABX79986	Hepatitis C virus
C 648	11.4	0.2	15	1	ABX79986	Hepatitis C virus
C 649	11.4	0.2	15	1	ACD56058	HBV enzymatic nucl
C 650	11.4	0.2	15	1	ACQ61367	2'-deoxy-2'-substi
C 651	11.4	0.2	15	1	ACQ61370	2'-deoxy-2'-substi
C 652	11.4	0.2	15	1	ADQ84280	Human papillomavir
C 653	11.4	0.2	15	1	ADQ44707	2'-Deoxy-2'-fluoro
C 654	11.4	0.2	15	1	ADQ44704	2'-Deoxy-2'-fluoro
C 655	11.4	0.2	15	1	ADQ44182	HPV 72 detecting p
C 656	11.4	0.2	15	1	ADQ12097	2'-modified oligon
C 657	11.4	0.2	15	1	ADQ12094	2'-modified oligon
C 658	11.4	0.2	15	1	ADQ50860	Human PKR substat
C 659	11.4	0.2	15	1	ADQ65819	Hepatitis B virus
C 660	11.4	0.2	15	1	ADQ49882	H. pylori strain J
C 661	11.4	0.2	15	1	AAQ89305	Primer used in RT-
C 662	11.4	0.2	15	1	AAQ89305	Sequence of probe
C 663	11.2	0.2	14	1	AAQ10002	Sequence of probe
C 664	11.2	0.2	16	1	AAQ95086	Wild-type capture
C 665	11.2	0.2	20	1	ADQ22785	Human interleukin
C 666	11.2	0.2	20	1	ADQ22785	Human interleukin
C 667	11	0.2	12	1	ABQ18569	Oligonucleotide pr
C 668	11	0.2	12	1	ABQ134799	Oligonucleotide pr
C 669	11	0.2	12	1	ABQ80895	Oligonucleotide pr
C 670	11	0.2	12	1	ABQ108552	Oligonucleotide pr
C 671	11	0.2	12	1	ABQ111770	Oligonucleotide pr
C 672	11	0.2	12	1	ABQ176195	Oligonucleotide pr
C 673	11	0.2	12	1	ABQ177608	Oligonucleotide pr
C 674	11	0.2	12	1	ABQ123040	Oligonucleotide pr
C 675	11	0.2	12	1	ABQ148148	Oligonucleotide pr
C 676	11	0.2	12	1	ABQ140077	Oligonucleotide pr
C 677	11	0.2	12	1	ABQ149928	Oligonucleotide pr
C 678	11	0.2	12	1	ABQ86381	Oligonucleotide pr
C 679	11	0.2	12	1	ABQ91845	Oligonucleotide pr
C 680	11	0.2	12	1	ABQ72726	Oligonucleotide pr
C 681	11	0.2	12	1	ABQ13618	Oligonucleotide pr
C 682	11	0.2	12	1	ABQ83544	Oligonucleotide pr
C 683	11	0.2	12	1	ABQ14477	Oligonucleotide pr
C 684	11	0.2	12	1	ABQ177034	Oligonucleotide pr
C 685	11	0.2	12	1	ABQ19608	Oligonucleotide pr
C 686	11	0.2	12	1	ABQ14428	Oligonucleotide pr
C 687	11	0.2	12	1	ABQ97425	Oligonucleotide pr
C 688	11	0.2	12	1	ABQ130266	Oligonucleotide pr
C 689	11	0.2	12	1	ABQ96681	Oligonucleotide pr
C 690	11	0.2	12	1	ABQ100737	Oligonucleotide pr

C 691	11	0.2	12	1	AB102148	Oligonucleotide pr
692	11	0.2	12	1	AB105650	Oligonucleotide pr
693	11	0.2	12	1	AB180923	Oligonucleotide pr
694	11	0.2	13	1	AA189579	Oligonucleotide pr
695	11	0.2	13	1	AA191810	Oligonucleotide pr
C 696	11	0.2	13	1	AA191810	Oligonucleotide pr
C 697	11	0.2	13	1	AA191810	Oligonucleotide pr
C 698	11	0.2	13	1	AB192566	Oligonucleotide pr
C 699	11	0.2	13	1	AB192566	Oligonucleotide pr
C 700	11	0.2	13	1	AB192566	Oligonucleotide pr
701	11	0.2	13	1	AB192566	Oligonucleotide pr
702	11	0.2	13	1	AB192566	Oligonucleotide pr
703	11	0.2	13	1	AB192566	Oligonucleotide pr
C 704	11	0.2	13	1	AB192566	Oligonucleotide pr
C 705	11	0.2	13	1	AB192566	Oligonucleotide pr
C 706	11	0.2	13	1	AB192566	Oligonucleotide pr
C 707	11	0.2	13	1	AB192566	Oligonucleotide pr
708	11	0.2	13	1	AB192566	Oligonucleotide pr
709	11	0.2	13	1	AB192566	Oligonucleotide pr
710	11	0.2	13	1	AB192566	Oligonucleotide pr
711	11	0.2	13	1	AB192566	Oligonucleotide pr
712	11	0.2	13	1	AB192566	Oligonucleotide pr
713	11	0.2	13	1	AB192566	Oligonucleotide pr
714	11	0.2	13	1	AB192566	Oligonucleotide pr
715	11	0.2	13	1	AB192566	Oligonucleotide pr
716	11	0.2	13	1	AB192566	Oligonucleotide pr
C 717	11	0.2	13	1	AB192566	Oligonucleotide pr
C 718	11	0.2	13	1	AB192566	Oligonucleotide pr
C 719	11	0.2	13	1	AB192566	Oligonucleotide pr
C 720	11	0.2	13	1	AB192566	Oligonucleotide pr
C 721	11	0.2	13	1	AB192566	Oligonucleotide pr
C 722	11	0.2	13	1	AB192566	Oligonucleotide pr
C 723	11	0.2	13	1	AB192566	Oligonucleotide pr
C 724	11	0.2	13	1	AB192566	Oligonucleotide pr
C 725	11	0.2	13	1	AB192566	Oligonucleotide pr
726	11	0.2	13	1	AB192566	Oligonucleotide pr
727	11	0.2	13	1	AB192566	Oligonucleotide pr
C 728	11	0.2	13	1	AB192566	Oligonucleotide pr
729	11	0.2	13	1	AB192566	Oligonucleotide pr
C 730	11	0.2	13	1	AB192566	Oligonucleotide pr
731	11	0.2	13	1	AB192566	Oligonucleotide pr
C 732	11	0.2	13	1	AB192566	Oligonucleotide pr
C 733	11	0.2	13	1	AB192566	Oligonucleotide pr
C 734	11	0.2	13	1	AB192566	Oligonucleotide pr
C 735	11	0.2	13	1	AB192566	Oligonucleotide pr
C 736	11	0.2	13	1	AB192566	Oligonucleotide pr
737	11	0.2	13	1	AB192566	Oligonucleotide pr
738	11	0.2	13	1	AB192566	Oligonucleotide pr
739	11	0.2	13	1	AB192566	Oligonucleotide pr
C 740	11	0.2	13	1	AB192566	Oligonucleotide pr
C 741	11	0.2	13	1	AB192566	Oligonucleotide pr
C 742	11	0.2	13	1	AB192566	Oligonucleotide pr
C 743	11	0.2	13	1	AB192566	Oligonucleotide pr
C 744	11	0.2	13	1	AB192566	Oligonucleotide pr
745	11	0.2	13	1	AB192566	Oligonucleotide pr
746	11	0.2	13	1	AB192566	Oligonucleotide pr
C 747	11	0.2	13	1	AB192566	Oligonucleotide pr
C 748	11	0.2	13	1	AB192566	Oligonucleotide pr
C 749	11	0.2	13	1	AB192566	Oligonucleotide pr
750	11	0.2	13	1	AB192566	Oligonucleotide pr
751	11	0.2	13	1	AB192566	Oligonucleotide pr
752	11	0.2	13	1	AB192566	Oligonucleotide pr
C 753	11	0.2	13	1	AB192566	Oligonucleotide pr
754	11	0.2	13	1	AB192566	Oligonucleotide pr
755	11	0.2	13	1	AB192566	Oligonucleotide pr
C 756	11	0.2	13	1	AB192566	Oligonucleotide pr
C 757	11	0.2	13	1	AB192566	Oligonucleotide pr
C 758	11	0.2	13	1	AB192566	Oligonucleotide pr
C 759	11	0.2	13	1	AB192566	Oligonucleotide pr
760	11	0.2	13	1	AB192566	Oligonucleotide pr
761	11	0.2	13	1	AB192566	Oligonucleotide pr
C 762	11	0.2	13	1	AB192566	Oligonucleotide pr
C 763	11	0.2	13	1	AB192566	Oligonucleotide pr

764	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 765	11	0.2	13	1	ABH03131	Oligonucleotide SE
766	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 767	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 768	11	0.2	13	1	ABH03131	Oligonucleotide SE
769	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 770	11	0.2	13	1	ABH03131	Oligonucleotide SE
771	11	0.2	13	1	ABH03131	Oligonucleotide SE
772	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 773	11	0.2	13	1	ABH03131	Oligonucleotide SE
774	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 775	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 776	11	0.2	13	1	ABH03131	Oligonucleotide SE
777	11	0.2	13	1	ABH03131	Oligonucleotide SE
778	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 779	11	0.2	13	1	ABH03131	Oligonucleotide SE
780	11	0.2	13	1	ABH03131	Oligonucleotide SE
781	11	0.2	13	1	ABH03131	Oligonucleotide SE
782	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 783	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 784	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 785	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 786	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 787	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 788	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 789	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 790	11	0.2	13	1	ABH03131	Oligonucleotide SE
791	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 792	11	0.2	13	1	ABH03131	Oligonucleotide SE
793	11	0.2	13	1	ABH03131	Oligonucleotide SE
794	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 795	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 796	11	0.2	13	1	ABH03131	Oligonucleotide SE
797	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 798	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 799	11	0.2	13	1	ABH03131	Oligonucleotide SE
800	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 801	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 802	11	0.2	13	1	ABH03131	Oligonucleotide SE
803	11	0.2	13	1	ABH03131	Oligonucleotide SE
804	11	0.2	13	1	ABH03131	Oligonucleotide SE
805	11	0.2	13	1	ABH03131	Oligonucleotide SE
806	11	0.2	13	1	ABH03131	Oligonucleotide SE
807	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 808	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 809	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 810	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 811	11	0.2	13	1	ABH03131	Oligonucleotide SE
812	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 813	11	0.2	13	1	ABH03131	Oligonucleotide SE
814	11	0.2	13	1	ABH03131	Oligonucleotide SE
C 815	11	0.2	13	1	ABH03131	Oligonucleotide SE

ALIGNMENTS

RESULT 1
ID AAT58420 standard; DNA, 30 Bp.
AAT58420;

AC AAT58420;
XX 25-MAR-2003 (revised)
DT 24-MAR-1997 (first entry)

DE Apolipoprotein A gene promoter probe, Apolipoprotein A-2.

KW mammalian expression shuttle vector; promoter-reporter gene fusion;
KW screen; identity; transcript; modulator; multi-cloning site;
KW beta-globin leader sequence; luciferase gene; gene expression;
KW cardiovascular disease; atherosclerosis; restenosis; thrombosis;
KW hypertension; ss.

```

XX OS Synthetic.
XX PN US5580722-A.
XX PD 03-DEC-1996.
XX PF 07-FEB-1992; 92US-00832905.
XX PR 18-JUL-1989; 89US-00382712.
XX PR 18-JUL-1990; 90US-00555196.
XX PA (ONCO-) ONCOGENE SCI INC.
XX PI Case CC, Stephenson JR, Pieler C, Liechtfried FE, Foulkes JG;
XX WPI; 1997-033562/03.
XX PT Screening assay for modulators of gene expression - relating to
XX PT cardiovascular diseases.
XX PS Example C1; Col 65-66; 93pp; English.
XX TS8419-61 are probes used in molecular cloning of cardiovascular gene
XX CC promoters and regulatory elements for insertion into a mammalian
XX CC expression shuttle vector. Mammalian expression shuttle vectors were
XX CC designed to allow the construction of promoter-reporter gene fusions to
XX CC be used in high-throughput screens to identify transcriptionally
XX CC modifying chemicals. The vectors can be used in a claimed screening assay
XX CC for modulators of gene expression relating to cardiovascular diseases,
XX CC e.g. atherosclerosis, restenosis, thrombosis or hypertension. T58419-21
XX CC are probes used to screen a human leukocyte genomic DNA library in EMBL-3
XX CC for the Apolipoprotein A gene promoter. (Updated on 25-MAR-2003 to
XX CC correct PF field.)
XX SQ Sequence 30 BP; 8 A; 5 C; 7 G; 10 T; 0 U; 0 Other;

Query Match 0.4%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 47 TGGACATAGAAGAGTGTCTTCTACTTC 76
Db 1 TGGACATAGAAGAGTGTCTTCTACTTC 30

RESULT 2
AAT58419
ID AAT58419 standard; DNA; 30 BP.
XX AC AAT58419;
XX DT 25-MAR-2003 (revised)
XX DT 24-MAR-1997 (first entry)
XX DE Apolipoprotein A gene promoter probe, Apoma-1.
XX KW mammalian expression shuttle vector; promoter-reporter gene fusion;
XX KW screen; identify; transcription; modulator; multi-cloning site;
XX KW beta-globin leader sequence; luciferase gene; gene expression;
XX KW cardiovascular disease; atherosclerosis; restenosis; thrombosis;
XX KW hypertension; ss.
XX OS Synthetic.
XX PN US5580722-A.
XX PD 03-DEC-1996.
XX PF 07-FEB-1992; 92US-00832905.
XX PR 18-JUL-1989; 89US-00382712.
XX PR 18-JUL-1990; 90US-00555196.

```

```

XX PA (ONCO-) ONCOGENE SCI INC.
XX PI Case CC, Stephenson JR, Pieler C, Liechtfried FE, Foulkes JG;
XX WPI; 1997-033562/03.
XX PT Screening assay for modulators of gene expression - relating to
XX PT cardiovascular diseases.
XX PS Example C1; Col 63-64; 93pp; English.
XX TS8419-61 are probes used in molecular cloning of cardiovascular gene
XX CC promoters and regulatory elements for insertion into a mammalian
XX CC expression shuttle vector. Mammalian expression shuttle vectors were
XX CC designed to allow the construction of promoter-reporter gene fusions to
XX CC be used in high-throughput screens to identify transcriptionally
XX CC modifying chemicals. The vectors can be used in a claimed screening assay
XX CC for modulators of gene expression relating to cardiovascular diseases,
XX CC e.g. atherosclerosis, restenosis, thrombosis or hypertension. T58419-21
XX CC are probes used to screen a human leukocyte genomic DNA library in EMBL-3
XX CC for the Apolipoprotein A gene promoter. Apoma-1 spans the coding regions
XX CC for the end of the apolipoprotein A prepeptide and its mature amino
XX CC terminus, thus crossing the region of plasminogen (>100 bp) which is
XX CC absent in apolipoprotein A. (Updated on 25-MAR-2003 to correct PF field.)
XX SQ Sequence 30 BP; 11 A; 7 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 80 TATTTGGAATCGACGACCTGAGCAA 109
Db 1 TATTTGGAATCGACGACCTGAGCAA 30

RESULT 3
AAV82531
ID AAV82531 standard; DNA; 30 BP.
XX AC AAV82531;
XX DT 20-MAR-2003 (revised)
XX DT 09-FEB-1999 (first entry)
XX DE Probe Apoma-2 used to screen for apolipoprotein (a) gene.
XX KW Apolipoprotein (a) gene; treatment; cardiovascular disease;
XX KW atherosclerosis; hypertension; restenosis; probe; ss.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN US5846720-A.
XX PD 08-DEC-1998.
XX PF 15-AUG-1996; 96US-00700757.
XX PR 18-JUL-1989; 89US-00382712.
XX PR 18-JUL-1990; 90US-00555196.
XX PR 18-JUL-1990; 90US-00504021.
XX PR 07-FEB-1992; 92US-00832905.
XX PA (ONCO-) ONCOGENE SCI INC.
XX PI Stephenson JR, Liechtfried FE, Pieler C, Case CC, Foulkes JG;
XX WPI; 1999-059041/05.
XX PT Screening assay using reporter gene construct - for modulators of genes
XX PT associated with cardiovascular diseases.

```

XX Disclosure; Col 30; 95pp; English.
 PS
 CC Oligonucleotide probes AAV82530-32 were used to screen a human leukocyte
 CC genomic DNA library for the apolipoprotein (a) gene. The probes
 CC correspond to the 5' end of the gene coding sequence. Apolipoprotein (a)
 CC is associated with the treatment of cardiovascular disease. The
 CC specification describes a method for determining if a test compound is
 CC capable of specifically transcriptionally modulating the expression of a
 CC gene encoding a protein of interest associated with the treatment of a
 CC cardiovascular disease. The cardiovascular disease may be
 CC atherosclerosis, hypertension or restenosis. The protein of interest may
 CC be involved in lipid transport or cellular uptake, in the uptake of
 CC modified lipoproteins, in lipid metabolism, in lipid oxidation, or in
 CC smooth muscle cell growth. Additional cardiovascular diseases include
 CC congestive heart failure, angina, ischemic heart disease, diabetes
 CC mellitus, non-insulin-dependent diabetes, thrombophlebitis, stroke,
 CC hypercholesterolemia, familial hypercholesterolemia, combined familial
 CC hypercholesterolemia, hyperglycaemia or diseases associated with calcium
 CC regulation or metabolism. (Updated on 20-MAR-2003 to correct PR field.)
 CC
 SQ Sequence 30 BP; 8 A; 5 C; 7 G; 10 T; 0 U; 0 Other;

Query Match 0.4%; Score 30; DB 1; Length 30;
 Best Local Similarity 100.0%; Pred. No. 1.2;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 47 TGAACATAGAGAGTGTCTTCTACTTC 76
 Db 1 TGAACATAGAGAGTGTCTTCTACTTC 30

RESULT 4
 AAV82530
 ID AAV82530 standard; DNA; 30 BP.
 AC AAV82530;
 XX
 DT 20-MAR-2003 (revised)
 DT 09-FEB-1999 (first entry)
 XX
 DE Probe Aposma-1 used to screen for apolipoprotein (a) gene.
 XX
 KM Apolipoprotein (a) gene; treatment; cardiovascular disease;
 KM atherosclerosis; hypertension; restenosis; probe; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 PN US5846720-A.
 XX
 PD 08-DEC-1998.
 XX
 PF 15-AUG-1996; 96US-00700757.
 XX
 PR 18-JUL-1989; 89US-00382712.
 PR 18-JUL-1990; 90US-00555196.
 PR 18-JUL-1990; 90MO-US004021.
 PR 07-FEB-1992; 92US-00832905.
 XX
 PA (ONCO-) ONCOGENE SCI INC.
 PI
 PI Stephenson JR, Liechtfried FE, Pieler C, Case CC, Foulkes JG;
 DR WPI; 1999-059041/05.
 XX
 PT Screening assay using reporter gene construct - for modulators of genes
 PT associated with cardiovascular diseases.
 XX
 PS Disclosure; Col 30; 95pp; English.
 XX
 CC Oligonucleotide probes AAV82530-32 were used to screen a human leukocyte
 CC genomic DNA library for the apolipoprotein (a) gene. The probes

CC correspond to the 5' end of the gene coding sequence. Apolipoprotein (a)
 CC is associated with the treatment of cardiovascular disease. The
 CC specification describes a method for determining if a test compound is
 CC capable of specifically transcriptionally modulating the expression of a
 CC gene encoding a protein of interest associated with the treatment of a
 CC cardiovascular disease. The cardiovascular disease may be
 CC atherosclerosis, hypertension or restenosis. The protein of interest may
 CC be involved in lipid transport or cellular uptake, in the uptake of
 CC modified lipoproteins, in lipid metabolism, in lipid oxidation, or in
 CC smooth muscle cell growth. Additional cardiovascular diseases include
 CC congestive heart failure, angina, ischemic heart disease, diabetes
 CC mellitus, non-insulin-dependent diabetes, thrombophlebitis, stroke,
 CC hypercholesterolemia, familial hypercholesterolemia, combined familial
 CC hypercholesterolemia, hyperglycaemia or diseases associated with calcium
 CC regulation or metabolism. (Updated on 20-MAR-2003 to correct PR field.)
 CC
 SQ Sequence 30 BP; 11 A; 7 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 30; DB 1; Length 30;
 Best Local Similarity 100.0%; Pred. No. 1.2;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 80 TATTCTGAAATCAGCAGCACTGAGCAAA 109
 Db 1 TATTCTGAAATCAGCAGCACTGAGCAAA 30

RESULT 5
 AAX89305/C
 ID AAX89305 standard; DNA; 26 BP.
 XX
 AC AAX89305;
 XX
 DT 21-SEP-1999 (first entry)
 XX
 DE Primer used in RT-PCR analysis of transgenic apo(a).
 XX
 KM Transgenic rabbit; apolipoprotein (a) / apolipoprotein B; lipoprotein;
 KM atherosclerotic lesion; cholesterol; vascular injury; restenosis; apob;
 KM RT-PCR; primer; ss.
 XX
 OS Synthetic.
 XX
 PN WO935241-A1.
 XX
 PD 15-JUL-1999.
 XX
 PF 08-JAN-1999; 99WO-US000401.
 XX
 PR 08-JAN-1998; 98US-0070727P.
 XX
 PA (RHON) RHON-POULENC RORER PHARM INC.
 PI
 PI Rouy D, Duverger N, Emmanuel F, Denefle P, Houdebine L,
 PI Viglietta C, Rubin E, Hughes SD;
 DR WPI; 1999-430386/36.
 XX
 PT A transgenic rabbit that expresses a functional human lipoprotein A.
 PT Example 3; Page 46; 73pp; English.
 PS
 XX The invention provides a transgenic rabbit, which has in its genomic DNA,
 CC sequences that encode apolipoprotein (a) and apolipoprotein B
 CC polypeptides, which are capable of combining to produce lipoprotein (a).
 CC The transgenic rabbit expresses a functional human lipoprotein (a). The
 CC rabbit develops human-like atherosclerotic lesions when fed a cholesterol
 CC rich diet. The transgenic rabbit is useful as a model for human diseases
 CC that are induced and/or exacerbated by lipoprotein (a) expression. The
 CC model can be used to identify inhibitors of lipoprotein (a) particle
 CC assembly and inhibitors of lipoprotein (a) associated diseases. The
 CC rabbit model is advantageous when compared to the mouse, due partly to
 CC its relatively larger size, enabling facile studies of vascular injury

CC and restenosis. In addition, while rabbits are similar to mice in lacking
 CC apo(a) and lipoprotein (a), their lipoprotein profile more closely mimics
 CC that of humans, with LDL as the predominant plasma lipoprotein. Sequences
 CC AA89305-308 represent primers used in the analysis of transgenic
 CC apo(a) and apoB

XX Sequence 26 BP; 5 A; 7 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 25; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 4.2;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 523 GGAGAACTGCAAGCTTGGTCATC 548

Db 26 GGAGAACTGCAAGCTTGGTCATC 1

RESULT 6
 ID ADO33413 standard; DNA; 25 BP.

XX ADO33413;

XX 12-AUG-2004 (first entry)

DE PCR primer 1 used to amplify human apolipoprotein(a) [Lp(a)] DNA.

XX apolipoprotein B; ApoB; cardiovascular; antiarteriosclerotic;
 XX antilipemic; antidiabetic; anorectic; cardiant; vasotrophic; hypotensive;
 XX anabolic; eating disorder; cytosolic; endocrine; vasotrophic;
 XX neuroprotective; nootropic; lipid; cholesterol metabolism;
 XX hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolemia;
 XX von Gierke's disease; lipodystrophy; Cushing's syndrome;
 XX sexual ateliotic dwarfism; hyperthyroidism; hypertension;
 XX anorexia nervosa; Werner's syndrome; hepatoma; multiple myeloma; uraemia;
 XX impotence; obstructive liver disease; Alzheimer's; dementia; diabetes;
 XX obesity; atherosclerosis; human; ss; PCR; primer; apolipoprotein(a);
 XX Lp(a).

XX Homo sapiens.

XX WO2004044181-A2.

XX 27-MAY-2004.

XX 13-NOV-2003; 2003WO-US036411.

XX 13-NOV-2002; 2002US-0426234P.

XX 15-MAY-2003; 2003WO-US015493.

XX (ISIS-) ISIS PHARM INC.

XX Crooke R, Graham M, Lemonidis-Tarbet K, Dobie KW;

XX WPI; 2004-420321/39.

PT Antisense oligonucleotide compound that inhibits expression of mRNA
 PT encoding human apolipoprotein B, useful for treating hyperlipidemia,
 PT diabetes, obesity, von Gierke's disease, lipodystrophies, Cushing's
 PT syndrome.

XX Example 57; SEQ ID NO 861; 483bp; English.

XX The invention relates to a novel antisense compound where the compound
 CC hybridises to and inhibits expression of mRNA encoding human
 CC apolipoprotein B (ApoB) after 16-24 hours by at least 30% in 80%
 CC confluent HepG2 cells in culture at a concentration of 150 nM. The
 CC compound of the invention demonstrates cardiovascular,
 CC antiarteriosclerotic, antilipemic, antidiabetic, anorectic, cardiant,
 CC vasotrophic, hypotensive, anabolic, eating disorder-related, cytosolic,
 CC endocrine, vasotrophic, neuroprotective and nootropic activities and may
 CC be useful for inhibiting the expression of apolipoprotein B in cells or
 CC tissues in vivo in order to address a condition associated with abnormal

CC lipid or cholesterol metabolism. The compound may be useful for
 CC decreasing circulating lipoprotein levels, triglyceride levels,
 CC cholesterol levels, lipid levels, fatty acid levels, acute phase
 CC reactants and chylomicrons and thus may be utilised during treatment of
 CC hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia,
 CC cardiovascular disorders, von Gierke's disease, lipodystrophy, Cushing's
 CC syndrome, sexual ateliotic dwarfism, hyperthyroidism, hypertension,
 CC anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,
 CC impotence, obstructive liver disease, Alzheimer's disease, dementia,
 CC diabetes, obesity and atherosclerosis. The current sequence is that of
 CC the PCR primer 1 of the invention which was used to amplify human
 CC apolipoprotein(a) [Lp(a)] DNA.

XX Sequence 25 BP; 6 A; 5 C; 6 G; 8 T; 0 U; 0 Other;

Query Match 0.3%; Score 25; DB 1; Length 25;
 Best Local Similarity 100.0%; Pred. No. 5.7;
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 296 CAGCTCTATTGTTATACGAGGA 320

Db 1 CAGCTCTATTGTTATACGAGGA 25

RESULT 7
 ID AA250401 standard; DNA; 24 BP.

XX AA250401;

XX 18-MAY-2000 (first entry)

XX Human angiotensin 5' primer.

XX PCR primer; expression plasmid; tumour activity; cancer;
 XX anti-angiogenic agent; solid tumour; lung metastatic tumour; cytosolic;
 XX gene therapy; ss.

XX Homo sapiens.

XX WO200006759-A2.

XX 10-FEB-2000.

XX 20-JUL-1999; 99WO-US016388.

XX 27-JUL-1998; 98US-0094375P.

XX (VALE-) VALENTIS INC.

XX Min W, Szymanski P, Mehrens D, Ralston R, Sullivan S;

XX WPI; 2000-183133/16.

PT Plasmids comprising tissue specific transcription elements linked to an
 PT anti-angiogenic gene is useful transfection of cells and treatment of,
 PT e.g. cancer.

XX Example 2; Page 62; 103bp; English.

XX The present sequence is human angiotensin 5' PCR primer for amplification
 CC of angiotensin coding sequence from human liver cDNA. The amplified PCR
 CC product was subcloned into an expression plasmid for the treatment of
 CC mammalian diseases, especially cancer. The plasmid can be used for (in
 CC vivo) transfection of a cell in situ in order to modulate tumour
 CC activity. Anti-angiogenic gene inhibits growth of solid tumour and lung
 CC metastatic tumours by intravenous or intramuscular delivery

XX Sequence 24 BP; 8 A; 2 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 7.8;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 46 ATGGAACATAGAAGTGTCTT 69
 |||||
 DB 1 ATGGAACATAGAAGTGTCTT 24

RESULT 8
 ID ADO33415 standard; DNA; 24 BP.
 AC ADO33415;
 XX
 DT 12-AUG-2004 (first entry)
 DE FAM/TAMRA-labeled probe used to analyse human Lp(a) DNA.
 XX
 KW apolipoprotein B; Apob; cardiovascular; antiarteriosclerotic;
 KW antilipemic; antidiabetic; anorectic; cardiast; vasotropic; hypotensive;
 KW anabolic; eating disorder; cytosolic; endocrine; vasotropic;
 KW neuroprotective; noctropic; lipid; cholesterol metabolism;
 KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
 KW Von Gierke's disease; lipodystrophy; Cushing's syndrome;
 KW sexual ateliotic dwarfism; hyperthyroidism; hypertension;
 KW anorexia nervosa; Werner's syndrome; hepatoma; multiple myeloma; uraemia;
 KW impotence; obstructive liver disease; Alzheimer's; dementia; diabetes;
 KW obesity; atherosclerosis; human; ss; probe; apolipoprotein(a); Lp(a).
 OS Homo sapiens.
 XX
 PN WO200404181-A2.
 XX
 PD 27-MAY-2004.
 XX
 PF 13-NOV-2003; 2003WO-US036411.
 XX
 PR 13-NOV-2002; 2002US-0426234P.
 PR 15-MAY-2003; 2003WO-US015493.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Crooke R, Graham M, Lemonidis-Tarpet K, Dobie KW;
 DR WPI; 2004-420321/39.
 PT Antisense oligonucleotide compound that inhibits expression of mRNA
 PT encoding human apolipoprotein B, useful for treating hyperlipidemia,
 PT diabetes, obesity, von Gierke's disease, lipodystrophies, Cushing's
 PT syndrome.
 XX
 PS Example 57; SEQ ID NO 863; 483bp; English.
 XX
 CC The invention relates to a novel antisense compound where the compound
 CC hybridises to and inhibits expression of mRNA encoding human
 CC apolipoprotein B (Apob) after 16-24 hours by at least 30% in 80%
 CC confluent HepG2 cells in culture at a concentration of 150 nM. The
 CC compound of the invention demonstrates cardiovascular,
 CC antidiabetic, antilipemic, antidiabetic, anorectic, cardiast,
 CC vasotropic, hypotensive, anabolic, eating disorder-related, cytostatic,
 CC endocrine, vasotropic, neuroprotective and noctropic activities and may
 CC be useful for inhibiting the expression of apolipoprotein B in cells or
 CC tissues in vivo in order to address a condition associated with abnormal
 CC lipid or cholesterol metabolism. The compound may be useful for
 CC decreasing circulating lipoprotein levels, triglyceride levels,
 CC cholesterol levels, lipid levels, fatty acid levels, acute phase
 CC reactants and chylomicrons and thus may be utilised during treatment of
 CC hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia,
 CC cardiovascular disorders, Von Gierke's disease, lipodystrophy, Cushing's
 CC syndrome, sexual ateliotic dwarfism, hyperthyroidism, hypertension,
 CC anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,
 CC impotence, obstructive liver disease, Alzheimer's disease, dementia,
 CC diabetes, obesity and atherosclerosis. The current sequence is that of
 CC the FAM/TAMRA-labeled probe of the invention which was used to analyse
 CC human apolipoprotein(a) [Lp(a)] DNA.

XX
 SQ Sequence 24 BP; 3 A; 6 C; 10 G; 5 T; 0 U; 0 Other;
 Query Match 0.3%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 7.8;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 322 CCCGTCGTCAGTGGAGTACTGC 345
 |||||
 DB 1 CCCGTCGTCAGTGGAGTACTGC 24

RESULT 9
 ID AAX35370 standard; DNA; 27 BP.
 AC AAX35370;
 XX
 DT 16-JUL-1999 (first entry)
 DE PCR primer used in the construction of multifunctional proteins.
 XX
 KW Angiostatin; endostatin; interferon; thrombospondin;
 KW interferon-inducible protein; platelet factor 4; anti-angiogenic;
 KW anti-tumor; multifunctional protein; angiogenic-mediated disease; cancer;
 KW diabetic retinopathy; macular degeneration; arthritis;
 KW tumor cell production; PCR primer; ss.
 XX
 OS Synthetic.
 XX
 PN WO9916889-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 30-SEP-1998; 98WO-US020464.
 XX
 PR 01-OCT-1997; 97US-0060609P.
 XX
 PA (SEAR) SEARLE & CO G D.
 XX
 PI Bolanowski MA, Caparon MH, Casperson GF, Gregory SA, Klein BK;
 PI McKearn JP;
 DR WPI; 1999-255098/21.
 PT New multifunctional proteins useful for treating angiogenic-mediated
 PT diseases.
 XX
 PS Disclosure; Page 114; 121pp; English.
 XX
 CC The specification describes multifunctional proteins which comprise
 CC combinations of angiotensin, endostatin, interferon, thrombospondin,
 CC interferon-inducible protein and platelet factor 4, and have anti-
 CC angiogenic and/or anti-tumor activity. The multifunctional protein may
 CC exhibit useful properties such as having similar or greater biological
 CC activity when compared to a single factor or by having improved half-life
 CC or decreased adverse side effects, or a combination of these properties.
 CC The proteins can be used for treating an angiogenic-mediated disease,
 CC e.g. cancer, diabetic retinopathy, macular degeneration, or arthritis.
 CC They can also be used for inhibiting the production of tumor cells
 CC (characteristic of lung, breast, ovarian, prostate, pancreatic, gastric,
 CC colon, renal, bladder cancers; melanoma, hepatoma, sarcoma and lymphoma)
 CC in a patient and for inhibiting tumor growth. The present PCR primer was
 CC used to make multifunctional proteins, in the course of the invention
 CC

QY 120 CCAAGATTGCTACATGATGATGACCA 146
 |||||

Query Match 0.3%; Score 23.8; DB 1; Length 27;
 Best Local Similarity 92.6%; Pred. No. 12;
 Matches 25; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

DB 27 CCAGAGCTGCTACACCGTGTATGACA 1

RESULT 10
AAQ70748/c
ID AAQ70748 standard; DNA, 23 BP.
XX
XX
AC AAQ70748;
XX
XX
DT 25-MAR-2003 (revised)
DT 03-MAR-1995 (first entry)
XX
XX
DE Primer for producing probe derived from Apo(a) kringle IV domain.
XX
XX
KM Primer; detection; screening; apolipoprotein; myocardial infarction;
KM low density lipoprotein; restriction fragment length polymorphism; RFLP;
KM ss.
XX
XX
OS Synthetic.
XX
PN EP609059-A2.
XX
PD 03-AUG-1994.
XX
PF 26-JAN-1994; 94EP-00300561.
XX
PR 26-JAN-1993; 93GB-00001453.
XX
PA (CLON-) CLONIT SPA.
PI Colucci G, Taramelli R;
XX
XX WPI; 1994-242397/30.
DR
XX
XX Polynucleotide probes for apolipoprotein (a) gene polymorphisms - used
PT for determining the parental origin of Apo (a) genes and assessing risk
PT of heart disease.
XX
XX
PS Example 1; Page 6; 13pp; English.
XX
XX Two primers (AAQ70748, AAQ70749) were used to amplify the sequence
CC encoding the Apo(a) Kringle IV domain which was later used as a probe to
CC screen a human cosmid library made with the vector pWE15. A restriction
CC fragment length polymorphism (RFLP) in the Apo(a) gene has been
CC associated with myocardial infarction in hypercholesterolemic patients.
CC Detection of such RFLP's can be used to identify individuals which may be
CC predisposed to developing heart disease. See also AAQ70744-47. (Updated
CC on 25-MAR-2003 to correct PN field.)
CC
XX
XX
SQ Sequence 23 BP; 3 A; 3 C; 5 G; 12 T; 0 U; 0 Other;

Query Match 0.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 219 TCAACATTAATGACACACAGAA 241
DB 23 TCAACATTAATGACACACAGAA 1

RESULT 11
AAH79116
ID AAH79116 standard; DNA, 22 BP.
XX
XX
AC AAH79116;
XX
XX
DT 20-NOV-2001 (first entry)
XX
XX
DE Human tumour vascular genesis inhibiting factor related PCR primer 14.
XX
XX Human; endostatin; angiotensin; virus; tumour vascular development;
KM tumour vascular genesis inhibiting factor; PCR primer; ss.
XX

OS Synthetic.
XX
PN CN1298947-A.
XX
XX 13-JUN-2001.
PD
XX
XX 01-DEC-2000; 2000CN-00127680.
XX
XX
PR 01-DEC-2000; 2000CN-00127680.
XX
XX
PA (QIAN/) QIAN Q.
PI
XX
XX Qian Q, Che X, Ceng X;
XX
XX WPI; 2001-503384/56.
DR
XX
XX Virus with specific reproduction in a tumor cell and effective expression
PT of tumor angiogenesis inhibitor and its construction method.
XX
XX
XX Disclosure; Page 20 (Disclosure); 52pp; Chinese.
XX
XX
XX The invention relates to developing a virus with highly-effective
CC expression of tumour vascular genesis inhibiting factor. The virus
CC comprises a nucleotide sequence encoding the vascular genesis inhibiting
CC factor inserted into a non-essential proliferation region of a virus gene
CC group. The virus selectively proliferates in a tumour cell such that
CC along with replication of virus, the nucleotide sequence copy number of
CC the encoded vascular genesis inhibiting factor is increased. The
CC expression of the vascular genesis inhibiting factor inhibits tumour
CC vascular development and inhibits formation, growth and transfer of
CC tumour. The present sequence is that of a PCR primer, useful to the
CC invention.
XX
XX
SQ Sequence 22 BP; 8 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 14;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 46 ATGGAACATTAAGAAAGTGTTC 67
DB 1 ATGGAACATTAAGAAAGTGTTC 22

RESULT 12
AAL44009
ID AAL44009 standard; DNA, 22 BP.
XX
XX
AC AAL44009;
XX
XX
DT 27-SEP-2002 (first entry)
XX
XX
DE Reproductive recombination virus-related oligonucleotide SEQ IN #29.
XX
XX
KM Gene therapy; ss; reproductive recombination virus; tumour cell killing;
KM Epstein-Barr virus; cancer-suppressing gene; vascular inhibition gene;
KM cell factor gene; produg-converting enzyme gene; cell death gene;
KM nasopharyngeal cancer; Hodgkin's lymphoma; gastric cancer; PCR; primer.
XX
XX
XX Unidentified.
OS
XX
XX
XX WO200256917-A1.
PN
XX
XX 25-JUL-2002.
PD
XX
XX 17-JAN-2002; 2002WO-CN000025.
XX
XX
XX 18-JAN-2001; 2001CN-00105247.
PR
XX
XX (VIRG-) VIRGENE BIOTECHNOLOGY LTD.
PA
XX
XX Qian Q, Che X, Sham S, Wu M;
PI

DR WPI; 2002-566772/60.
 XX
 PT Construction of reproductive recombination virus able to specifically
 PT kill Epstein-Barr associated tumor cells, useful in drugs for treating
 PT e.g. nasopharyngeal cancer, Hodgkin's lymphoma and gastric cancer.
 PS Example 5; Page 18; 44pp; Chinese.
 XX
 CC The invention comprises a reproductive recombination virus capable of
 CC killing specifically tumour cells associated with Epstein-Barr (EB)
 CC virus. The virus of the invention comprises an insertion of a target gene
 CC into the non-reproduction-regulating domain in the virus gene group (the
 CC target gene is a cancer-suppressing gene, vascular inhibition gene, cell
 CC factor gene, product-converting enzyme gene or cell death gene). The
 CC reproductive recombination virus of the invention is useful for treating
 CC nasopharyngeal cancer, Hodgkin's lymphoma and gastric cancer. The present
 CC DNA sequence was used in an example of the invention
 CC
 SQ Sequence 22 BP; 8 A; 2 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 0.3%; Score 22; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 14;
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 46 ATGGAACAATAAGAGTGGTTC 67
 Db 1 ATGGAACAATAAGAGTGGTTC 22
 RESULT 13
 AAH79105
 ID AAH79105 standard; DNA; 26 BP.
 XX
 AC AAH79105;
 XX
 DT 20-NOV-2001 (first entry)
 XX
 DE Human angiotensin PCR primer 4.
 XX
 DE Human; endostatin; angiotensin; virus; tumour vascular development;
 KW tumour vascular genesis inhibiting factor; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN CN1298947-A.
 XX
 PD 13-JUN-2001.
 XX
 PF 01-DEC-2000; 2000CN-00127680.
 XX
 PR 01-DEC-2000; 2000CN-00127680.
 XX
 PA (QIAN/) QIAN Q.
 XX
 PI Qian Q, Che X, Ceng X;
 XX
 DR WPI; 2001-503384/56.
 XX
 PT Virus with specific reproduction in a tumor well and effective expression
 PT of tumor angiogenesis inhibitor and its construction method.
 XX
 PS Disclosure; Page 17 (Disclosure); 52pp; Chinese.
 XX
 CC The invention relates to developing a virus with highly-effective
 CC expression of tumour vascular genesis inhibiting factor. The virus
 CC comprises a nucleotide sequence encoding the vascular genesis inhibiting
 CC factor inserted into a non-essential proliferation region of a virus gene
 CC group. The virus selectively proliferates in a tumour cell such that
 CC along with replication of virus, the nucleotide sequence copy number of
 CC the encoded vascular genesis inhibiting factor is increased. The
 CC expression of the vascular genesis inhibiting factor inhibits tumour
 CC vascular development and inhibits formation, growth and transfer of
 CC tumour. The present sequence is that of a PCR primer, useful to the

CC invention
 XX
 SQ Sequence 26 BP; 12 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.3%; Score 20.2; DB 1; Length 26;
 Best Local Similarity 88.0%; Pred. No. 48;
 Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 OY 34 GCCAGTCCCAAAATGGAACATTAAG 58
 Db 2 GCCAGTCCCAAAATGGAACATTAAG 26
 RESULT 14
 ABQ76080
 ID ABQ76080 standard; DNA; 26 BP.
 XX
 AC ABQ76080;
 XX
 DT 30-SEP-2002 (first entry)
 XX
 DE Anticancer gene-associated PCR primer #12.
 XX
 DE Proliferation; anticancer gene; tumour cell; telomerase; promoter;
 KW early virus gene; PCR; primer; ss.
 XX
 OS Unidentified.
 XX
 PN CN1339584-A.
 XX
 PD 13-MAR-2002.
 XX
 PF 12-JUL-2001; 2001CN-00126113.
 XX
 PR 12-JUL-2001; 2001CN-00126113.
 XX
 PA (QIAN/) QIAN Q.
 XX
 PI Qian Q, Wu M, Cen X;
 XX
 DR WPI; 2002-464081/50.
 XX
 PT Telomerase promoter-controlled recombinant viruses proliferating
 PT specifically in tumor cells to highly express antioncogene to kill tumor
 PT cells by synergism, applicable in treating tumor.
 XX
 PS Example 4; Page 14; 25pp; Chinese.
 XX
 CC This invention describes a novel recombinant virus for specific
 CC proliferation and efficient expression of an anticancer gene in tumour
 CC cells. By inserting a telomerase promoter in the upstream area of an
 CC early virus gene, the recombinant virus is made to proliferate
 CC selectively in tumour cells with telomerase activity rather than in
 CC normal cells without telomerase activity. This recombinant virus may be
 CC used to treat several kinds of tumours. This sequence represents a PCR
 CC primer used to illustrate the method described in the disclosure of the
 CC invention
 CC
 SQ Sequence 26 BP; 12 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.3%; Score 20.2; DB 1; Length 26;
 Best Local Similarity 88.0%; Pred. No. 48;
 Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 OY 34 GCCAGTCCCAAAATGGAACATTAAG 58
 Db 2 GCCAGTCCCAAAATGGAACATTAAG 26
 RESULT 15
 AAL44001
 ID AAL44001 standard; DNA; 26 BP.
 XX

```

AC AAL44001;
XX
XX 27-SEP-2002 (first entry)
XX
DE Reproductive recombination virus-related oligonucleotide SEQ IN #21.
XX
XX Gene therapy; ss; reproductive recombination virus; tumour cell killing;
XX Epstein-Barr virus; cancer-suppressing gene; vascular inhibition gene;
XX cell factor gene; produg-converting enzyme gene; cell death gene;
XX nasopharyngeal cancer; Hodgkin's lymphoma; gastric cancer; PCR; primer.
XX
OS Unidentified.
XX
PN WO200256917-A1.
XX
PD 25-JUL-2002.
XX
PF 17-JAN-2002; 2002WO-CN000025.
XX
PR 18-JAN-2001; 2001CN-00105247.
XX
PA (VIRG-) VIRGENE BIOTECHNOLOGY LTD.
XX
PI Qian Q, Che X, Sham S, Wu M;
XX
XX WPI; 2002-566772/60.
XX
DR Construction of reproductive recombination virus able to specifically
XX kill Epstein-Barr associated tumor cells, useful in drugs for treating
XX e.g. nasopharyngeal cancer, Hodgkin's lymphoma and gastric cancer.
XX
PS Example 4; Page 15; 44pp; Chinese.
XX
XX The invention comprises a reproductive recombination virus capable of
XX killing specifically tumour cells associated with Epstein-Barr (EB)
XX virus. The virus of the invention comprises an insertion of a target gene
XX into the non-reproduction-requiring domain in the virus gene group (the
XX target gene is a cancer-suppressing gene, vascular inhibition gene, cell
XX factor gene, produg-converting enzyme gene or cell death gene). The
XX reproductive recombination virus of the invention is useful for treating
XX nasopharyngeal cancer, Hodgkin's lymphoma and gastric cancer. The present
XX DNA sequence was used in an example of the invention
XX
SQ Sequence 26 BP; 12 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.3%; Score 20.2; DB 1; Length 26;
Best Local Similarity 88.0%; Pred. No. 48;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 34 GCCAGTCCCAAAATGCAACATTAAG 58
DB 2 GCGAATTCAAAATGGAACATTAAG 26

```

```

XX
XX 08-JAN-1999; 99WO-US000401.
XX
XX 08-JAN-1998; 98US-0070727P.
XX
XX (RHON ) RHONE-POULENC RORER PHARM INC.
XX
XX Rouy D, Duverger N, Emmanuel F, Denefle P, Houdebine L;
XX Viglietta C, Rubin E, Hughes SD;
XX
XX WPI; 1999-430386/36.
XX
XX A transgenic rabbit that expresses a functional human lipoprotein A.
XX
XX Example 3; Page 46; 73pp; English.
XX
XX The invention provides a transgenic rabbit, which has in its genomic DNA,
XX sequences that encode apolipoprotein (a) and apolipoprotein B
XX polypeptides, which are capable of combining to produce lipoprotein (a).
XX The transgenic rabbit expresses a functional human lipoprotein (a). The
XX rabbit develops human-like atherosclerotic lesions when fed a cholesterol
XX rich diet. The transgenic rabbit is useful as a model for human diseases
XX that are induced and/or exacerbated by lipoprotein (a) expression. The
XX model can be used to identify inhibitors of lipoprotein (a) particle
XX assembly and inhibitors of lipoprotein (a) associated diseases. The
XX rabbit model is advantageous, when compared to the mouse, due partly to
XX its relatively larger size, enabling facile studies of vascular injury
XX and restenosis. In addition, while rabbits are similar to mice in lacking
XX apo(a) and lipoprotein (a), their lipoprotein profile more closely mimics
XX that of humans, with LDL as the predominant plasma lipoprotein. Sequences
XX AAX89305-308 represent primers used in the analysis of transgenic
XX apo(a) and apoB
XX
XX
SQ Sequence 20 BP; 5 A; 9 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 324 CCGTGTACGTGGAGTACT 343
DB 20 CCGTGTACGTGGAGTACT 1

```

```

RESULT 16
AAX89308/C
ID AAX89308 standard; DNA; 20 BP.
XX
XX AAX89308;
XX
XX 21-SEP-1999 (first entry)
XX
XX Primer k1R used in RT-PCR analysis of transgenic apo(a) cDNA.
XX
XX Transgenic rabbit; apolipoprotein (a); apolipoprotein B; lipoprotein;
XX atherosclerotic lesion; cholesterol; vascular injury; restenosis; apoB;
XX PCR primer; ss.
XX
XX Synthetic.
XX
XX WO9935241-A1.
XX
XX 15-JUL-1999.

```

```

RESULT 17
ACC47289/C
ID ACC47289 standard; DNA; 20 BP.
XX
XX ACC47289;
XX
XX 11-AUG-2003 (first entry)
XX
XX Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144372.
XX
XX Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
XX antisense; ss.
XX
XX Synthetic.
XX
XX Homo sapiens.
XX
XX WO2003014307-A2.
XX
XX 20-FEB-2003.
XX
XX 05-AUG-2002; 2002WO-US024920.
XX
XX 07-AUG-2001; 2001US-00923515.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Crooke RM, Graham MJ;
XX
XX WPI; 2003-256565/25.

```

```

XX
PT New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis or
PT cardiovascular disease.
XX
PS Claim 3; Page 87; 120pp; English.
XX
CC The invention relates to a new compound, 8-50 nucleobases in length
CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
CC specifically hybridizes with and inhibits the expression of human
CC apolipoprotein(a). The antisense compounds are useful for preparing a
CC composition for treating abnormal lipid or cholesterol metabolism,
CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
CC represent specific examples of chimeric antisense phosphorothioate
CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
CC apolipoprotein(a) mRNA
XX
SQ Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 516 TGTGACAGAGAACCTGCC 535
DB 20 TGTGACAGAGAACCTGCC 1
XX
RESULT 18
ACC47298/C
ID ACC47298 standard; DNA; 20 BP.
XX
AC ACC47298;
XX
DT 11-AUG-2003 (first entry)
XX
DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144381.
XX
KW Apolipoprotein(a); antiarteriosclerotic; cardiatic; gene therapy; human;
XX antisense; ss.
XX
OS Synthetic.
XX
OS Homo sapiens.
XX
PN WO2003014307-A2.
XX
PD 20-FEB-2003.
XX
PF 05-AUG-2002; 2002WO-US024920.
XX
PR 07-AUG-2001; 2001US-00923515.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ;
XX
PI 2003-256565/25.
XX
DR WPI; 2003-256565/25.
XX
PT New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis or
PT cardiovascular disease.
XX
PS Claim 3; Page 87; 120pp; English.
XX
CC The invention relates to a new compound, 8-50 nucleobases in length
CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
CC specifically hybridizes with and inhibits the expression of human
CC apolipoprotein(a). The antisense compounds are useful for preparing a
CC composition for treating abnormal lipid or cholesterol metabolism,
CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
CC represent specific examples of chimeric antisense phosphorothioate
CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
CC apolipoprotein(a) mRNA
XX

```

```

XX
SQ Sequence 20 BP; 7 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 255 TGGCTTATCATGAACTACT 274
DB 20 TGGCTTATCATGAACTACT 1
XX
RESULT 19
ACC47295/C
ID ACC47295 standard; DNA; 20 BP.
XX
AC ACC47295;
XX
DT 11-AUG-2003 (first entry)
XX
DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144378.
XX
KW Apolipoprotein(a); antiarteriosclerotic; cardiatic; gene therapy; human;
XX antisense; ss.
XX
OS Synthetic.
XX
OS Homo sapiens.
XX
PN WO2003014307-A2.
XX
PD 20-FEB-2003.
XX
PF 05-AUG-2002; 2002WO-US024920.
XX
PR 07-AUG-2001; 2001US-00923515.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ;
XX
PI 2003-256565/25.
XX
DR WPI; 2003-256565/25.
XX
PT New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis or
PT cardiovascular disease.
XX
PS Claim 3; Page 87; 120pp; English.
XX
CC The invention relates to a new compound, 8-50 nucleobases in length
CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
CC specifically hybridizes with and inhibits the expression of human
CC apolipoprotein(a). The antisense compounds are useful for preparing a
CC composition for treating abnormal lipid or cholesterol metabolism,
CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
CC represent specific examples of chimeric antisense phosphorothioate
CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
CC apolipoprotein(a) mRNA
XX
SQ Sequence 20 BP; 9 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 291 TGTGACAGCTCTTATTGTT 310
DB 20 TGTGACAGCTCTTATTGTT 1
XX
RESULT 20
ACC47287/C
ID ACC47287 standard; DNA; 20 BP.
XX

```

AC ACC47287;
XX
DT 11-AUG-2003 (first entry)
XX
DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144370.
XX
KW Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
XX antisense; ss.
OS Synthetic.
XX Homo sapiens.
PN WO2003014307-A2.
XX
PD 20-FEB-2003.
XX
PF 05-AUG-2002; 2002WO-US024920.
XX
PR .07-AUG-2001; 2001US-00923515.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ;
XX
DR WPI; 2003-256565/25.
XX
PT New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis or
PT cardiovascular disease.
PS Claim 3; Page 87; 120pp; English.
XX
CC The invention relates to a new compound, 8-50 nucleobases in length
CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
CC specifically hybridizes with and inhibits the expression of human
CC apolipoprotein(a). The antisense compounds are useful for preparing a
CC composition for treating abnormal lipid or cholesterol metabolism,
CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
CC represent specific examples of chimeric antisense phosphorothioate
CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
CC apolipoprotein(a) mRNA
CC
SQ Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;
XX
XX
Query March 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 375 GACTGCCGTGCGCCTCCGA 394
Db ||||||||||||||||
20 GACTGCCGTGCGCCTCCGA 1
XX
XX
RESULT 21
ACC47299/c
ID ACC47299 standard; DNA; 20 BP.
XX
AC ACC47299;
XX
DT 11-AUG-2003 (first entry)
XX
DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144382.
XX
KW Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
XX antisense; ss.
OS Synthetic.
XX Homo sapiens.
PN WO2003014307-A2.
XX
PD 20-FEB-2003.
XX

PF 05-AUG-2002; 2002WO-US024920.
XX
PR .07-AUG-2001; 2001US-00923515.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ;
XX
DR WPI; 2003-256565/25.
XX
PT New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis or
PT cardiovascular disease.
PS Claim 3; Page 87; 120pp; English.
XX
CC The invention relates to a new compound, 8-50 nucleobases in length
CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
CC specifically hybridizes with and inhibits the expression of human
CC apolipoprotein(a). The antisense compounds are useful for preparing a
CC composition for treating abnormal lipid or cholesterol metabolism,
CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
CC represent specific examples of chimeric antisense phosphorothioate
CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
CC apolipoprotein(a) mRNA
CC
SQ Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX
Query March 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 365 ACGCAGAGGAGCTGCGCTC 384
Db ||||||||||||||||
20 ACGCAGAGGAGCTGCGCTC 1
XX
XX
RESULT 22
ACC47291/c
ID ACC47291 standard; DNA; 20 BP.
XX
AC ACC47291;
XX
DT 11-AUG-2003 (first entry)
XX
DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144374.
XX
KW Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
XX antisense; ss.
OS Synthetic.
XX Homo sapiens.
PN WO2003014307-A2.
XX
PD 20-FEB-2003.
XX
PF 05-AUG-2002; 2002WO-US024920.
XX
PR .07-AUG-2001; 2001US-00923515.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ;
XX
DR WPI; 2003-256565/25.
XX
PT New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis or
PT cardiovascular disease.
PS Claim 3; Page 87; 120pp; English.
XX

CC The invention relates to a new compound, 8-50 nucleobases in length
 CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
 CC specifically hybridizes with and inhibits the expression of human
 CC apolipoprotein(a). The antisense compounds are useful for preparing a
 CC composition for treating abnormal lipid or cholesterol metabolism,
 CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
 CC represent specific examples of chimeric antisense phosphorothioate
 CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
 CC apolipoprotein(a) mRNA
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 526 AGAACCTGCCAAGCTTGTC 545
 DB 20 AGAACCTGCCAAGCTTGTC 1

RESULT 23
 ACC47293/c
 ID ACC47293 standard; DNA; 20 BP.

AC ACC47293;
 XX
 DT 11-AUG-2003 (first entry)

DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144376.
 XX
 KW Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
 XX antisense; ss.

OS Synthetic.
 OS Homo sapiens.

PN WO2003014307-A2.

PD 20-FEB-2003.

PF 05-AUG-2002; 2002WO-US024920.

PR 07-AUG-2001; 2001US-00923515.

PA (ISIS-) ISIS PHARM INC.

PI Crooke RM, Graham MJ;

PI WPI; 2003-256565/25.

PT New antisense compound, useful for preparing a composition for treating
 PT abnormal lipid or cholesterol metabolism, atherosclerosis or
 PT cardiovascular disease.

PS Claim 3; Page 87; 120pp; English.

XX The invention relates to a new compound, 8-50 nucleobases in length
 CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
 CC specifically hybridizes with and inhibits the expression of human
 CC apolipoprotein(a). The antisense compounds are useful for preparing a
 CC composition for treating abnormal lipid or cholesterol metabolism,
 CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
 CC represent specific examples of chimeric antisense phosphorothioate
 CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
 CC apolipoprotein(a) mRNA
 XX

SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 527 GAACCTGCCAAGCTTGTC 546
 DB 20 GAACCTGCCAAGCTTGTC 1

RESULT 24
 ACC47296/c
 ID ACC47296 standard; DNA; 20 BP.

AC ACC47296;

DT 11-AUG-2003 (first entry)

DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144376.

KW Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
 XX antisense; ss.

OS Synthetic.
 OS Homo sapiens.

PN WO2003014307-A2.

PD 20-FEB-2003.

PF 05-AUG-2002; 2002WO-US024920.

PR 07-AUG-2001; 2001US-00923515.

PA (ISIS-) ISIS PHARM INC.

PI Crooke RM, Graham MJ;

PI WPI; 2003-256565/25.

PT New antisense compound, useful for preparing a composition for treating
 PT abnormal lipid or cholesterol metabolism, atherosclerosis or
 PT cardiovascular disease.

PS Claim 3; Page 87; 120pp; English.

XX The invention relates to a new compound, 8-50 nucleobases in length
 CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
 CC specifically hybridizes with and inhibits the expression of human
 CC apolipoprotein(a). The antisense compounds are useful for preparing a
 CC composition for treating abnormal lipid or cholesterol metabolism,
 CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
 CC represent specific examples of chimeric antisense phosphorothioate
 CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
 CC apolipoprotein(a) mRNA
 XX

SQ Sequence 20 BP; 4 A; 9 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 315 GAGGATCCCGATGTCAGT 334
 DB 20 GAGGATCCCGATGTCAGT 1

RESULT 25
 ACC47292/c
 ID ACC47292 standard; DNA; 20 BP.

AC ACC47292;

DT 11-AUG-2003 (first entry)

DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144375.

KW Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;

```

KM antisense; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003014307-A2.
XX
PD 20-FEB-2003.
XX
PF 05-AUG-2002; 2002WO-US024920.
XX
PR 07-AUG-2001; 2001US-00923515.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ;
XX
DR WPI; 2003-256565/25.
XX
PT New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis or
PT cardiovascular disease.
XX
PS Claim 3; Page 87; 120pp; English.
XX
CC The invention relates to a new compound, 8-50 nucleobases in length
CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
CC specifically hybridizes with and inhibits the expression of human
CC apolipoprotein(a). The antisense compounds are useful for preparing a
CC composition for treating abnormal lipid or cholesterol metabolism,
CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
CC represent specific examples of chimeric antisense phosphorothioate
CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
CC apolipoprotein(a) mRNA
XX
SQ Sequence 20 BP; 8 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 292 GTGGCAGCTCTTATTTGTTA 311
Db 20 GTGGCAGCTCTTATTTGTTA 1
XX
RESULT 26
ACC47286/c
ID ACC47286 standard; DNA; 20 BP.
XX
AC ACC47286;
XX
DT 11-AUG-2003 (first entry)
XX
DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144369.
XX
KW Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
KW antisense; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003014307-A2.
XX
PD 20-FEB-2003.
XX
PF 05-AUG-2002; 2002WO-US024920.
XX
PR 07-AUG-2001; 2001US-00923515.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ;
XX

```

```

XX
DR WPI; 2003-256565/25.
XX
PT New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis or
PT cardiovascular disease.
XX
PS Claim 3; Page 87; 120pp; English.
XX
CC The invention relates to a new compound, 8-50 nucleobases in length
CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
CC specifically hybridizes with and inhibits the expression of human
CC apolipoprotein(a). The antisense compounds are useful for preparing a
CC composition for treating abnormal lipid or cholesterol metabolism,
CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
CC represent specific examples of chimeric antisense phosphorothioate
CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
CC apolipoprotein(a) mRNA
XX
SQ Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 522 AGGAGAACTGCCAGCTT 541
Db 20 AGGAGAACTGCCAGCTT 1
XX
RESULT 27
ACC47284/c
ID ACC47284 standard; DNA; 20 BP.
XX
AC ACC47284;
XX
DT 11-AUG-2003 (first entry)
XX
DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144367.
XX
KW Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
KW Apolipoprotein(a); antisense; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003014307-A2.
XX
PD 20-FEB-2003.
XX
PF 05-AUG-2002; 2002WO-US024920.
XX
PR 07-AUG-2001; 2001US-00923515.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ;
XX
DR WPI; 2003-256565/25.
XX
PT New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis or
PT cardiovascular disease.
XX
PS Claim 3; Page 87; 120pp; English.
XX
CC The invention relates to a new compound, 8-50 nucleobases in length
CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
CC specifically hybridizes with and inhibits the expression of human
CC apolipoprotein(a). The antisense compounds are useful for preparing a
CC composition for treating abnormal lipid or cholesterol metabolism,
CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
CC represent specific examples of chimeric antisense phosphorothioate
CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
CC apolipoprotein(a) mRNA
XX

```

CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
 CC apolipoprotein(a) mRNA
 XX
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 174 TGTACAGGAAGACCTGCC 193
 Db 20 TGTACAGGAAGACCTGCC 1

RESULT 28
 ACC47290/c
 ID ACC47290 standard; DNA; 20 BP.
 XX
 XX
 AC ACC47290;

DT 11-AUG-2003 (first entry)

DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144373.

XX Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;

KW antisense; ss.

XX
 OS Synthetic.

OS Homo sapiens.

PN WO2003014307-A2.

PD 20-FEB-2003.

PF 05-AUG-2002; 2002WO-US024920.

PR 07-AUG-2001; 2001US-00923515.

PA (ISIS-) ISIS PHARM INC.

XX Crooke RM, Graham MJ;

XX WPI; 2003-256565/25.

DR New antisense compound, useful for preparing a composition for treating
 XX abnormal lipid or cholesterol metabolism, atherosclerosis or
 PT cardiovascular disease.

XX Claim 3; Page 87; 120pp; English.

CC The invention relates to a new compound, 8-50 nucleobases in length
 CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
 CC specifically hybridizes with and inhibits the expression of human
 CC apolipoprotein(a). The antisense compounds are useful for preparing a
 CC composition for treating abnormal lipid or cholesterol metabolism,
 CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
 CC represent specific examples of chimeric antisense phosphorothioate
 CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
 CC apolipoprotein(a) mRNA

XX Sequence 20 BP; 9 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 293 TGCAGCTCTTATTTAT 312
 Db 20 TGCAGCTCTTATTTAT 1

RESULT 29
 ACC47294/c

ID ACC47294 standard; DNA; 20 BP.

XX
 AC ACC47294;

DT 11-AUG-2003 (first entry)

DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144377.

XX Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;

KW antisense; ss.

XX
 OS Synthetic.

OS Homo sapiens.

PN WO2003014307-A2.

PD 20-FEB-2003.

PF 05-AUG-2002; 2002WO-US024920.

PR 07-AUG-2001; 2001US-00923515.

PA (ISIS-) ISIS PHARM INC.

XX Crooke RM, Graham MJ;

XX WPI; 2003-256565/25.

DR New antisense compound, useful for preparing a composition for treating
 XX abnormal lipid or cholesterol metabolism, atherosclerosis or
 PT cardiovascular disease.

XX Claim 3; Page 87; 120pp; English.

CC The invention relates to a new compound, 8-50 nucleobases in length
 CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
 CC specifically hybridizes with and inhibits the expression of human
 CC apolipoprotein(a). The antisense compounds are useful for preparing a
 CC composition for treating abnormal lipid or cholesterol metabolism,
 CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
 CC represent specific examples of chimeric antisense phosphorothioate
 CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
 CC apolipoprotein(a) mRNA

XX Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 353 CGCATGCTCAGACGAGAA 372
 Db 20 CGCATGCTCAGACGAGAA 1

RESULT 30
 ACC47297/c
 ID ACC47297 standard; DNA; 20 BP.
 XX
 AC ACC47297;

DT 11-AUG-2003 (first entry)

DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144380.

XX Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;

KW antisense; ss.

XX
 OS Synthetic.

OS Homo sapiens.

PN WO2003014307-A2.

PD 20-FEB-2003.
XX
PF 05-AUG-2002; 2002WO-US024920.
XX
PR 07-AUG-2001; 2001US-00923515.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ;
XX WPI; 2003-256565/25.
XX
DR
XX
PT New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis or
PT cardiovascular disease.
PS Claim 3; Page 87; 120pp; English.
XX
XX
CC The invention relates to a new compound, 8-50 nucleobases in length
CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
CC specifically hybridizes with and inhibits the expression of human
CC apolipoprotein(a). The antisense compounds are useful for preparing a
CC composition for treating abnormal lipid or cholesterol metabolism,
CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
CC represent specific examples of chimeric antisense phosphorothioate
CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
CC apolipoprotein(a) mRNA
XX
SQ Sequence 20 BP; 3 A; 4 C; 7 G; 6 T; 0 U; 0 Other;
XX
XX
Query Match 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 345 CAACCTGACGCAATGCTCAG 364
DB 20 CAACCTGACGCAATGCTCAG 1
XX
XX
RESULT 31
ACC47285/c
ID ACC47285 standard; DNA; 20 BP.
XX
XX
AC ACC47285;
XX
XX
DT 11-AUG-2003 (first entry)
XX
XX
DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144368.
XX
XX
KM Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
XX antisense; ss.
XX
XX
OS Synthetic.
OS Homo sapiens.
XX
XX
PN WO2003014307-A2.
XX
XX
PD 20-FEB-2003.
XX
XX
PF 05-AUG-2002; 2002WO-US024920.
XX
XX
PR 07-AUG-2001; 2001US-00923515.
XX
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX
PI Crooke RM, Graham MJ;
XX WPI; 2003-256565/25.
XX
XX
DR
XX
PT New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis or
PT cardiovascular disease.
XX

PS Claim 3; Page 87; 120pp; English.
XX
XX
CC The invention relates to a new compound, 8-50 nucleobases in length
CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
CC specifically hybridizes with and inhibits the expression of human
CC apolipoprotein(a). The antisense compounds are useful for preparing a
CC composition for treating abnormal lipid or cholesterol metabolism,
CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
CC represent specific examples of chimeric antisense phosphorothioate
CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
CC apolipoprotein(a) mRNA
XX
XX
SQ Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;
XX
XX
Query Match 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 352 ACCCAATGCTCAGACGAGA 371
DB 20 ACCCAATGCTCAGACGAGA 1
XX
XX
RESULT 32
ACC47288/c
ID ACC47288 standard; DNA; 20 BP.
XX
XX
AC ACC47288;
XX
XX
DT 11-AUG-2003 (first entry)
XX
XX
DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144371.
XX
XX
KM Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
XX antisense; ss.
XX
XX
OS Synthetic.
OS Homo sapiens.
XX
XX
PN WO2003014307-A2.
XX
XX
PD 20-FEB-2003.
XX
XX
PF 05-AUG-2002; 2002WO-US024920.
XX
XX
PR 07-AUG-2001; 2001US-00923515.
XX
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX
PI Crooke RM, Graham MJ;
XX WPI; 2003-256565/25.
XX
XX
DR
XX
XX
PT New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis or
PT cardiovascular disease.
XX
XX
PS Claim 3; Page 87; 120pp; English.
XX
XX
CC The invention relates to a new compound, 8-50 nucleobases in length
CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
CC specifically hybridizes with and inhibits the expression of human
CC apolipoprotein(a). The antisense compounds are useful for preparing a
CC composition for treating abnormal lipid or cholesterol metabolism,
CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
CC represent specific examples of chimeric antisense phosphorothioate
CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
CC apolipoprotein(a) mRNA
XX
XX
SQ Sequence 20 BP; 3 A; 7 C; 9 G; 1 T; 0 U; 0 Other;
XX
XX
Query Match 0.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 374 GAGTGGCGTGGCGCTCCG 393
    |||||
    20 GGACTGGCGTGGCGCTCCG 1
Db

RESULT 33
AAQ70749 standard; DNA; 19 BP.
XX
AC AAQ70749;
XX
DT 25-MAR-2003 (revised)
DT 03-MAR-1995 (first entry)
DE Primer for producing probe derived from Apo(a) kringle IV domain.
XX
KM Primer; detection; screening; apolipoprotein; myocardial infarction;
KM low density lipoprotein; restriction fragment length polymorphism; RFLP;
KM ss.
XX
OS Synthetic.
XX
PN EPC09059-A2.
XX
PD 03-AUG-1994.
XX
PF 26-JAN-1994; 94EP-00300561.
XX
PR 26-JAN-1993; 93GB-00001453.
XX
PA (CLON-) CLONIT SPA.
XX
PI Colucci G, Taramelli R;
XX
DR WPI; 1994-242397/30.
XX
PT Polynucleotide probes for apolipoprotein (a) gene polymorphisms - used
PT for determining the parental origin of Apo (a) genes and assessing risk
PT of heart disease.
XX
PS Example 1; Page 6; 13pp; English.
XX
CC Two primers (AAQ70748, AAQ70749) were used to amplify the sequence
CC encoding the Apo(a) Kringle IV domain which was later used as a probe to
CC screen a human cosmid library made with the vector pWEIS. A restriction
CC fragment length polymorphism (RFLP) in the Apo(a) gene has been
CC associated with myocardial infarction in hypercholesterolemic patients.
CC Detection of such RFLP's can be used to identify individuals which may be
CC predisposed to developing heart disease. See also AAQ70744-47. (Updated
CC on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 19 BP; 6 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.3%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 98 CACCTGAGCAAGCCATGT 116
    |||||
    1 CACCTGAGCAAGCCATGT 19
Db

RESULT 34
AAK89307 standard; DNA; 19 BP.
XX
AC AAK89307;
XX
DT 21-SEP-1999 (first entry)
XX
XX Primer krlf used in RT-PCR analysis of transgenic apo(a) cDNA.

```

```

XX
KM Transgenic rabbit; apolipoprotein (a); apolipoprotein B; lipoprotein;
KM atherosclerotic lesion; cholesterol; vascular injury; restenosis; apob;
KM PCR primer; ss.
XX
OS Synthetic.
XX
PN WO9935241-A1.
XX
PD 15-JUL-1999.
XX
PF 08-JAN-1999; 99WO-US000401.
XX
PR 08-JAN-1998; 98US-0070727P.
XX
PA (RHON) RHONE-POULENC RORER PHARM INC.
XX
PI Rouy D, Duverger N, Emmanuel F, Denefle P, Houdebine L;
PI Viglietta C, Rubin E, Hughes SD;
XX
DR WPI; 1999-430386/36.
XX
XX A transgenic rabbit that expresses a functional human lipoprotein A.
XX
PS Example 3; Page 46; 73pp; English.
XX
CC The invention provides a transgenic rabbit, which has in its genomic DNA,
CC sequences that encode apolipoprotein (a) and apolipoprotein B
CC polypeptides, which are capable of combining to produce lipoprotein (a).
CC The transgenic rabbit expresses a functional human lipoprotein (a). The
CC rabbit develops human-like atherosclerotic lesions when fed a cholesterol
CC rich diet. The transgenic rabbit is useful as a model for human diseases
CC that are induced and/or exacerbated by lipoprotein (a) expression. The
CC model can be used to identify inhibitors of lipoprotein (a) particle
CC assembly and inhibitors of lipoprotein (a) associated diseases. The
CC rabbit model is advantageous, when compared to the mouse, due partly to
CC its relatively larger size, enabling facile studies of vascular injury
CC and restenosis. In addition, while rabbits are similar to mice in lacking
CC apo(a) and lipoprotein (a), their lipoprotein profile more closely mimics
CC that of humans, with LDL as the predominant plasma lipoprotein. Sequences
CC AAK89305-308 represent primers used in the analysis of transgenic
CC apo(a) and apob
XX
SQ Sequence 19 BP; 6 A; 5 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.3%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 99 ACCTGAGCAAGCCATGTG 117
    |||||
    1 ACCTGAGCAAGCCATGTG 19
Db

RESULT 35
ACC47300/c standard; DNA; 20 BP.
XX
AC ACC47300;
XX
DT 11-AUG-2003 (first entry)
XX
DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144383.
XX
KM Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
KM antisense; ss.
XX
OS Synthetic.
XX
OS Homo sapiens.
XX
PN WO2003014307-A2.
XX
PD 20-FEB-2003.

```

```
XX 05-AUG-2002; 2002WO-US024920.
PF Targeted to a nucleic acid molecule encoding human apolipoprotein(a),
XX specifically hybridizes with and inhibits the expression of human
PR 07-AUG-2001; 2001US-00923515.
XX apolipoprotein(a). The antisense compounds are useful for preparing a
PA (ISIS-) ISIS PHARM INC.
XX composition for treating abnormal lipid or cholesterol metabolism,
PI Crooke RM, Graham MJ;
XX WPI; 2003-256565/25.
DR New antisense compound, useful for preparing a composition for treating
XX abnormal lipid or cholesterol metabolism, atherosclerosis or
PT cardiovascular disease.
PS Claim 3; Page 87; 120pp; English.
XX
CC The invention relates to a new compound, 8-50 nucleobases in length
CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
CC specifically hybridizes with and inhibits the expression of human
CC apolipoprotein(a). The antisense compounds are useful for preparing a
CC composition for treating abnormal lipid or cholesterol metabolism,
CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
CC represent specific examples of chimeric antisense phosphorothioate
CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
CC apolipoprotein(a) mRNA
XX
SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.3%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 48;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 516 TGTCAACGAGAACCTGCC 535
Db 20 TGTCACTGGAGAACCTGCC 1
RESULT 36
ACC47301/C
ID ACC47301 standard; DNA; 20 BP.
XX
AC ACC47301;
XX
DT 11-AUG-2003 (first entry)
DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144384.
XX
KW Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
XX antisense; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003014307-A2.
XX
PD 20-FEB-2003.
XX
PF 05-AUG-2002; 2002WO-US024920.
XX
PR 07-AUG-2001; 2001US-00923515.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ;
XX
DR WPI; 2003-256565/25.
XX
PT New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis or
PT cardiovascular disease.
XX
XX Claim 3; Page 87; 120pp; English.
```

```
XX The invention relates to a new compound, 8-50 nucleobases in length
CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
CC specifically hybridizes with and inhibits the expression of human
CC apolipoprotein(a). The antisense compounds are useful for preparing a
CC composition for treating abnormal lipid or cholesterol metabolism,
CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
CC represent specific examples of chimeric antisense phosphorothioate
CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
CC apolipoprotein(a) mRNA
XX
SQ Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 0.3%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 48;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 527 GAACCTGCCAAGCTTGTC 546
Db 20 GAACCTGCCAAGCTTGTC 1
RESULT 37
ACC47304/C
ID ACC47304 standard; DNA; 20 BP.
XX
AC ACC47304;
XX
DT 11-AUG-2003 (first entry)
DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144387.
XX
KW Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
XX antisense; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003014307-A2.
XX
PD 20-FEB-2003.
XX
PF 05-AUG-2002; 2002WO-US024920.
XX
PR 07-AUG-2001; 2001US-00923515.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ;
XX
DR WPI; 2003-256565/25.
XX
PT New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis or
PT cardiovascular disease.
XX
XX Claim 3; Page 87; 120pp; English.
XX
CC The invention relates to a new compound, 8-50 nucleobases in length
CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
CC specifically hybridizes with and inhibits the expression of human
CC apolipoprotein(a). The antisense compounds are useful for preparing a
CC composition for treating abnormal lipid or cholesterol metabolism,
CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
CC represent specific examples of chimeric antisense phosphorothioate
CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
CC apolipoprotein(a) mRNA
XX
SQ Sequence 20 BP; 5 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.3%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 48;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```



```

XX AA15097;
AC 20-MAY-1998 (first entry)
DT Human apolipoprotein(a) gene PCR primer pcr7.
XX
XX Human apolipoprotein(a) gene 5'-regulatory region; expression;
XX screening; regulation; genetic engineering; gene therapy;
XX atherosclerosis; PCR primer; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX US5721138-A.
XX
XX 24-FEB-1998.
XX
XX 15-MAY-1995; 95US-00441370.
XX
XX 15-DEC-1992; 92US-00991849.
XX
XX (STRD ) UNIV STANFORD.
XX
XX Lawn RM;
XX
XX WPI; 1998-168413/15.
XX
XX Human apolipoprotein (a) gene promoter - useful in genetic engineering
XX and gene therapy and in the treatment of atherosclerosis.
XX
XX Disclosure; Col 8; 16pp; English.
XX
XX The present sequence represents a PCR primer for human apolipoprotein(a).
XX
XX The present invention also describes: (1) a vector containing human
XX apolipoprotein(a) gene 5'-regulatory region DNA; (2) an isolated
XX nucleotide sequence comprising at least 30 consecutive nucleotides of
XX human apolipoprotein(a) gene 5'-regulatory region DNA or its complement;
XX (3) a nucleotide sequence of at least 15 nucleotides capable of forming a
XX DNA triplex with human apolipoprotein(a) gene 5'-regulatory region DNA;
XX and (4) a transfected mammalian cell containing human apolipoprotein(a)
XX gene 5'-regulatory region DNA where the heterologous sequence codes for
XX an enzyme. The new promoter sequence is useful in genetic engineering and
XX gene therapy. The promoter can specifically be used for regulating the
XX expression of apolipoprotein(a), which is useful in the treatment of
XX atherosclerosis
XX
XX Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.28; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 54;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 58 GAAGTGGTCTTCTACT 74
Db 17 GAAGTGGTCTTCTACT 1

```

```

KW epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
KW glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
KW HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NMNT;
KW MADPH quinone oxidoreductase 2; NQO2; sulfoltransferase thermolabile; STM;
KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
KW multidrug resistance associated protein 3; cancer; prostate;
KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
KW altered drug metabolism; cardiovascular function; colorectal tumour;
KW central nervous system; pulmonary; immunological; SNP;
KW single nucleotide polymorphism.
XX
XX Homo sapiens.
XX
XX WO200257410-A2.
XX
XX 25-JUL-2002.
XX
XX 28-NOV-2001; 2001WO-US044838.
XX
XX 28-NOV-2000; 2000US-00724389.
XX
XX (DNAS-) DNA SCI LAB INC.
XX
XX Guide M, Hall J;
XX
XX WPI; 2002-698522/75.
XX
XX Isolated nucleic acid molecules having polymorphisms in known human genes
XX e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
XX for locating, identifying and characterizing the genes responsible for
XX disorder-related traits.
XX
XX Example 22; Page 144; 714pp; English.
XX
XX This invention relates to the sequence of an isolated nucleic acid
XX molecule comprising at least one base variation from that of a known
XX human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),
XX cytochrome P450 02B1 (CYP45002B1), adrenergic receptor beta1 (ADBR1),
XX aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
XX (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
XX inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating
XX protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
XX transferase (HNMT), (kallikrein 2) KLK2, nicotinamide-N-methyl
XX transferase (NMNT), MADPH quinone oxidoreductase 2 (NQO2),
XX sulfoltransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
XX (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
XX transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1
XX (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
XX (MRP3), orphan nuclear receptor (NR112), or acetylcholine muscarinic
XX receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
XX The polymorphisms in the human genes cited in the invention are useful as
XX genetic linkage markers for locating and characterizing the genes that
XX are responsible for specific traits within the genome and eventually
XX identifying the genes responsible for a variety of disorder-related
XX traits as a result of their e.g., overexpression, constitutive
XX expression, mutation or underexpression, which may be used in diagnosing
XX and/or treating the disorder. The nucleic acid molecules comprising the
XX polymorphic sequences contained in CYP4501A1, CYP4501A2, CYP4502B1,
XX ARNT, EPHX2, GST12, NMNT, NQO2, NR112, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
XX MDR1 and/or MDR3 are useful for screening individuals for altered drug
XX metabolism. The polymorphic sequences contained in CYP4501A1, CYP4501A2,
XX AHR, MDR1 and/or MDR3 may also be used to screen individuals for
XX susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
XX used to screen for altered cardiovascular function, in COX2 for altered
XX susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
XX nervous system function, in FLAP and HNMT for altered pulmonary,
XX immunological or haematological function, in KLK2 for altered serine
XX protease activity in the prostate, in CHMR3, CHMR4 or CHMR5 for altered central and
XX peripheral nervous system function. The present sequence represents a
XX polymorphic DNA sequence of the invention

```

```
XX SQ Sequence 21 BP; 7 A; 2 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 475 CATGTAATGACAGAGTTA 494
DB 2 CCTGTAATGACAGAGTTA 21

RESULT 42
AAT93192
ID AAT93192 standard; DNA; 18 BP.
AC AAT93192;
XX
XX 14-MAY-1998 (first entry)
DT
XX Primer for kringle 5 fragment.
XX
XX PCR primer; Kringle 5 peptide; anti-angiogenesis agent; cancer;
XX metastatic solid tumour; carcinoma; sarcoma; lymphoma; haemangioma;
XX psoriasis; arthritis; macular degeneration; diabetic retinopathy;
XX autoimmune disease; ocular disease; capillary proliferation; therapy;
XX kringle 5 receptor; ss.
XX
XX Synthetic.
XX Homo sapiens.
XX
XX WO9741824-A2.
XX
XX 13-NOV-1997.
XX
XX 05-MAY-1997; 97WO-US007700.
XX
XX 03-MAY-1996; 96US-00643219.
XX
XX 03-APR-1997; 97US-00832087.
XX
XX (ABBO ) ABBOTT LAB.
XX
XX Davidson DJ, Wang J, Gubbins EJ;
XX
XX WPI; 1997-558670/51.
XX
XX New kringle 5 peptide(s) and fusion proteins derived from plasminogen -
XX useful as anti-angiogenesis agents for treating cancer, psoriasis,
XX arthritis etc., including gene therapy.
XX
XX Example 20; Page 53; 78pp; English.
XX
XX This sequence is a primer for the coding sequences of the kringle 5 (K5)
XX peptide fragments used in the compounds of the invention. K5 peptide
XX fragments are anti-angiogenesis agents, specifically for treating or
XX preventing cancer, particularly primary or metastatic solid tumours,
XX carcinomas, sarcomas, lymphomas, haemangiomas. They can also be used for
XX treating or preventing psoriasis, arthritis, macular degeneration and
XX diabetic retinopathy. The fragments can also be used to treat autoimmune
XX or ocular diseases, capillary proliferation within atherosclerotic
XX plaque, haemophilic joints, wound granulation, ulcers etc., also as
XX contractile agents that inhibit ovulation and establishment of the placenta.
XX K5 antisera or (ant)agonists can be used similarly, optionally coupled to
XX cytotoxic agents. Antagonists may be used to induce angiogenesis, e.g.
XX for wound healing. The K5 peptides are also used to raise specific
XX antibodies (Ab), for diagnosis and for affinity purification of K5
XX receptors. The K5 receptors may then be expressed in tumour cells to
XX increase their response to the peptides or used for identification of
XX smaller antagonists. The Ab are used to detect/quantify the peptides in
XX biological samples. The K5 peptides (and K5 fusion proteins) selectively
XX inhibit proliferation of endothelial cells with low toxicity against
XX normal cells. Typically they have 800-times greater inhibitory activity
XX against bovine capillary cells in vitro than kringle 1-4 peptides
```

```
XX SQ Sequence 18 BP; 4 A; 6 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 0.2%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 81;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 118 GTCCAGATTGCTACCAT 135
DB 1 GTCCAGACTGCTACCAT 18

RESULT 43
AAA52282
ID AAA52282 standard; DNA; 18 BP.
AC AAA52282;
XX
XX 18-SEP-2000 (first entry)
DT
XX Human plasminogen kringle 5 PCR primer, SEQ ID NO:10.
XX
XX Plasminogen; human; kringle 5 domain; endothelial cell proliferation;
XX angiogenesis; antiproliferative; antiarteriosclerotic; cytostatic;
XX antipsoriatic; antiinflammatory; anticancer; antirheumatic; antiarthritis;
XX antiangiogenic; cancer; tumour; autoimmune disease; Escherichia coli;
XX recombinant expression; PCR primer; ss.
XX
XX Homo sapiens.
XX
XX US6057122-A.
XX
XX 02-MAY-2000.
XX
XX 05-MAY-1997; 97US-00851350.
XX
XX 03-MAY-1996; 96US-00643219.
XX
XX 03-APR-1997; 97US-00832087.
XX
XX (ABBO ) ABBOTT LAB.
XX
XX Davidson DJ;
XX
XX WPI; 2000-349573/30.
XX
XX Preparation of Kringle five peptide fragment for treating various
XX disorders such as angiogenic, ocular, skin diseases and cancer, involves
XX mixing mammalian plasminogen and elastase followed by incubation and
XX isolation.
XX
XX Example 20; Col 45; 48pp; English.
XX
XX The invention relates to a method of preparing plasminogen kringle 5
XX peptide fragments. The method comprises mixing mammalian plasminogen and
XX elastase in the ratio 1:100-1:300, followed by incubating and isolating
XX the fragment. The kringle 5 peptides are inhibitors of angiogenesis and
XX endothelial cell proliferation and migration. The peptides are useful for
XX treating angiogenic diseases, primary and metastatic solid tumours and
XX carcinomas of various organs such as breast, genital tract, endocrine
XX glands, skin, tumours of the brain and eyes and solid tumours arising
XX from haematopoietic malignancies such as leukemias and lymphomas. They
XX are also used for the prophylaxis of various autoimmune diseases (e.g.,
XX rheumatoid arthritis), ocular diseases, skin diseases (e.g., psoriasis),
XX blood vessel diseases (e.g. haemangiomas, Osler-Weber Syndrome),
XX diseases caused by excessive or abnormal stimulation of endothelial cells
XX (e.g., Crohn's disease, atherosclerosis), diseases which have
XX angiogenesis as a pathologic consequence (e.g., cat scratch disease and
XX ulcers). The peptides are also useful as a birth control agent which
XX inhibits ovulation and establishment of the placenta. Sequences AAA52282-
XX A52283 and AAA52285 represent PCR primers used to amplify DNA encoding
XX various human plasminogen kringle 5 fragments for cloning into an
XX Escherichia coli expression vector
```

SQ Sequence 18 BP; 4 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.2%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 81;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 118 GTCCAGATTGCTACCAT 135
 |||||
 Db 1 GTCCAGACTGCTACCAT 18

RESULT 44
 ADK23663
 ID ADK23663 standard; DNA; 18 BP.
 XX
 AC ADK23663;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human plasminogen, PCR primer #5.
 XX
 KM Cytostratic; Antiarthritic; Antidiabetic; Ophthalmological; kringle 5;
 KM anglogenesis; cancer; arthritis; macular degeneration;
 KM diabetic retinopathy; human; plasminogen; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN US6699838-B1.
 XX
 PD 02-MAR-2004.
 XX
 PF 05-SEP-1997; 97US-00924287.
 XX
 PR 03-MAY-1996; 96US-00643219.
 PR 03-APR-1997; 97US-00832087.
 PR 05-MAY-1997; 97US-00851350.
 XX
 PA (ABBO) ABBOTT LAB.
 XX
 PI Davidson DJ;
 XX
 DR WPI; 2004-224006/21.
 XX
 PT Novel compound e.g., kringle 5 fusion protein useful for treating
 PT diseases e.g., cancer, arthritis, macular degeneration and diabetic
 PT retinopathy.
 XX
 PS Example 20; SEQ ID NO 10; 47PD; English.
 XX
 CC The invention relates to a new compound coupled to another protein to
 CC form a conjugate. The compound is a kringle 5 (K5) fusion protein. The
 CC compound is useful for inhibiting angiogenic diseases and for treating
 CC diseases such as cancer, arthritis, macular degeneration and diabetic
 CC retinopathy. The present sequence represents a PCR primer used to clone
 CC the K5 region of human plasminogen.
 XX
 SQ Sequence 18 BP; 4 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.2%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 81;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 118 GTCCAGATTGCTACCAT 135
 |||||
 Db 1 GTCCAGACTGCTACCAT 18

RESULT 45
 AAQ39588/C
 ID AAQ39588 standard; DNA; 19 BP.
 XX
 AC AAQ39588;
 XX

DT 07-OCT-1993 (first entry)
 XX
 DE Mycobacterium gordonae-specific probe #2.
 XX
 KM scotochromogenic bacterium; hybridisation assay; ribosomal RNA; 16S rRNA;
 KM ss.
 XX
 OS Synthetic.
 XX
 PN US5216143-A.
 XX
 PD 01-JUN-1993.
 XX
 PF 28-JUN-1991; 91US-00720585.
 XX
 PR 28-JUN-1991; 91US-00720585.
 XX
 PA (GEP-) GEN-PROBE PROD CO.
 XX
 PI Hogan UJ, Hammond PW;
 XX
 DR WPI; 1993-188590/23.
 XX
 PT Oligonucleotide probes specific for mycobacterium gordonae - used to
 PT distinguish presence of M. gordonae from that of other mycobacteria.
 XX
 PS Claim 2; Col 13; 9pp; English.
 XX
 CC Probe 1 (AAQ39587) is designed based on the wild-type sequence of
 CC M.gordonae 16S rRNA in the region corresponding to nuc.eotides 177-195 of
 CC E.coli 16S rRNA. It is used in a hybridisation assay with Probe 2
 CC (AAQ39588) based on the same region in strains 6.2 and C.V. to ensure
 CC detection of all strains of M.gordonae. Hybridisation was enhanced by the
 CC use of "helper probes" (see AAQ39589-Q39595). All the probes form a
 CC hybridisation complex in 0.1M lithium succinate buffer contg. 10% lithium
 CC lauryl sulphate at 60 deg.C. The novel probes are capable of
 CC distinguishing M.gordonae from closely related Mycobacterium species
 XX

SQ Sequence 19 BP; 1 A; 4 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 0.2%; Score 16.4; DB 1; Length 19;
 Best Local Similarity 94.4%; Pred. No. 94;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 226 AATGACACACAGAAAC 243
 |||||
 Db 18 AATGACACACAGAAAC 1

RESULT 46
 AAQ39594
 ID AAQ39594 standard; RNA; 19 BP.
 XX
 AC AAQ39594;
 XX
 DT 07-OCT-1993 (first entry)
 XX
 DE Mycobacterium gordonae-specific helper probe #8.
 XX
 KM scotochromogenic bacterium; hybridisation assay; ribosomal RNA; 16S rRNA;
 KM ss.
 XX
 OS Synthetic.
 XX
 PN US5216143-A.
 XX
 PD 01-JUN-1993.
 XX
 PF 28-JUN-1991; 91US-00720585.
 XX
 PR 28-JUN-1991; 91US-00720585.
 XX
 PA (GEP-) GEN-PROBE PROD CO.
 XX

```

XX      Hogan JT, Hammond PW;
XX
XX      WPI; 1993-188590/23.
XX
PT      Oligonucleotide probes specific for Mycobacterium gordonae - used to
XX      distinguish presence of M. gordonae from that of other mycobacteria.
XX
PS      Claim 5; Col 13; 9pp; English.
XX
CC      Probe 1 (AAQ39587) is designed based on the wild-type sequence of
CC      M. gordonae 16S rRNA in the region corresponding to nucleotides 177-195 of
CC      E. coli 16S rRNA. It is used in a hybridisation assay with Probe 2
CC      (AAQ39588) based on the same region in strains 6.2 and C.V. to ensure
CC      detection of all strains of M. gordonae. Hybridisation was enhanced by the
CC      use of "helper probes" (see AAQ39589-Q39595). All the probes form a
CC      hybridisation complex in 0.1M lithium succinate buffer contg. 10% lithium
CC      lauryl sulphate at 60 deg.C. The novel probes are capable of
CC      distinguishing M. gordonae from closely related Mycobacterium species
SQ
XX      Sequence 19 BP; 9 A; 5 C; 4 G; 0 T; 1 U; 0 Other;

Query Match      0.2%; Score 16.4; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 94;
Matches 16; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      226 AATAGACACACAGAAAC 243
DB      2 AAUAGACACACAGAAAC 19

RESULT 47
AAQ39595/C
ID      AAQ39595 standard; RNA; 19 BP.
XX
XX      AAQ39595;
XX
DT      07-OCT-1993 (first entry)
XX
DE      Mycobacterium gordonae-specific helper probe #9.
XX
KW      scotochromogenic bacterium; hybridisation assay; ribosomal RNA; 16S rRNA;
XX      ss.
XX
OS      Synthetic.
XX
PN      US5216143-A.
XX
PD      01-JUN-1993.
XX
PF      28-JUN-1991; 91US-00720585.
XX
PR      28-JUN-1991; 91US-00720585.
XX
PA      (GEP- ) GEN-PROBE PROD CO.
XX
PI      Hogan JT, Hammond PW;
XX
DR      WPI; 1993-188590/23.
XX
PT      Oligonucleotide probes specific for Mycobacterium gordonae - used to
XX      distinguish presence of M. gordonae from that of other mycobacteria.
XX
PS      Claim 5; Col 13; 9pp; English.
XX
CC      Probe 1 (AAQ39587) is designed based on the wild-type sequence of
CC      M. gordonae 16S rRNA in the region corresponding to nucleotides 177-195 of
CC      E. coli 16S rRNA. It is used in a hybridisation assay with Probe 2
CC      (AAQ39588) based on the same region in strains 6.2 and C.V. to ensure
CC      detection of all strains of M. gordonae. Hybridisation was enhanced by the
CC      use of "helper probes" (see AAQ39589-Q39595). All the probes form a
CC      hybridisation complex in 0.1M lithium succinate buffer contg. 10% lithium
CC      lauryl sulphate at 60 deg.C. The novel probes are capable of

```

```

CC      distinguishing M. gordonae from closely related Mycobacterium species
XX
XX      Sequence 19 BP; 1 A; 4 C; 5 G; 0 T; 9 U; 0 Other;
SQ
XX
XX      Query Match      0.2%; Score 16.4; DB 1; Length 19;
XX      Best Local Similarity 94.4%; Pred. No. 94;
XX      Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      226 AATAGACACACAGAAAC 243
DB      18 AATAGACACACAGAAAC 1

RESULT 48
AAQ39593
ID      AAQ39593 standard; DNA; 19 BP.
XX
XX      AAQ39593;
XX
AC      07-OCT-1993 (first entry)
XX
DT      07-OCT-1993 (first entry)
XX
DE      Mycobacterium gordonae-specific helper probe #7.
XX
KW      scotochromogenic bacterium; hybridisation assay; ribosomal RNA; 16S rRNA;
XX      ss.
XX
OS      Synthetic.
XX
PN      US5216143-A.
XX
PD      01-JUN-1993.
XX
PF      28-JUN-1991; 91US-00720585.
XX
PR      28-JUN-1991; 91US-00720585.
XX
PA      (GEP- ) GEN-PROBE PROD CO.
XX
PI      Hogan JT, Hammond PW;
XX
DR      WPI; 1993-188590/23.
XX
PT      Oligonucleotide probes specific for Mycobacterium gordonae - used to
XX      distinguish presence of M. gordonae from that of other mycobacteria.
XX
PS      Claim 5; Col 11; 9pp; English.
XX
CC      Probe 1 (AAQ39587) is designed based on the wild-type sequence of
CC      M. gordonae 16S rRNA in the region corresponding to nucleotides 177-195 of
CC      E. coli 16S rRNA. It is used in a hybridisation assay with Probe 2
CC      (AAQ39588) based on the same region in strains 6.2 and C.V. to ensure
CC      detection of all strains of M. gordonae. Hybridisation was enhanced by the
CC      use of "helper probes" (see AAQ39589-Q39595). All the probes form a
CC      hybridisation complex in 0.1M lithium succinate buffer contg. 10% lithium
CC      lauryl sulphate at 60 deg.C. The novel probes are capable of
CC      distinguishing M. gordonae from closely related Mycobacterium species
SQ
XX      Sequence 19 BP; 9 A; 5 C; 4 G; 1 T; 0 U; 0 Other;

Query Match      0.2%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      226 AATAGACACACAGAAAC 243
DB      2 AATAGACACACAGAAAC 19

RESULT 49
ACC80563
ID      ACC80563 standard; DNA; 20 BP.
XX
XX      ACC80563;
AC

```



```

XX 28-AUG-2003 (first entry)
XX
XX Pluripotent stem cell generation method control gene primer albumin #1.
DE
XX Immunosuppressive; ss; primer; pluripotent stem cell; transplantation;
XX major histocompatibility antigen; immune rejection.
XX
XX Homo sapiens.
OS
XX WO2003027278-A1.
XX
XX 03-APR-2003.
XX
XX 20-SEP-2002; 2002WO-JP009732.
XX
XX 21-SEP-2001; 2001JP-00290005.
XX
XX (TRAN-) TRANS-SCI INC.
PA (NAKA/) NAKATSUI N.
PA (TADA/) TADA T.
XX
XX Nakatsuji N, Tada T, Tada M;
PI WPI; 2003-313639/30.
XX
XX Tailor-made pluripotent stem cells for production of donor organs and
PT tissues which do not induce immune rejection when transplanted.
XX
XX Example 2; Page 92; 172pp; Japanese.
XX
XX The invention relates to a method of generating tailor-made pluripotent
CC stem cells having a desired genome, in which the MHC (major
CC histocompatibility) antigens are reduced or absent. This sequence
CC represents a primer used in the method of the invention. The invention
CC also includes methods for the preparation of the pluripotent stem cells,
CC by producing modified stem cells in which the MHC antigens are reduced or
CC absent, then fusing the cells with reprogrammed somatic cells having the
CC desired genome, and removing the genomic material originating from the
CC stem cells. The tailor-made pluripotent stem cells may be used in the
CC production of cells, tissues and organs for transplantation to treat
CC disease conditions in the recipient, without inducing immune rejection
XX
XX Sequence 20 BP; 5 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.2%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 122 AGGATTGCTACCATGCTGA 140
Db 2 AGGAGTGTCTGCATGCTGA 20

```

```

PF 30-NOV-2001; 2001DE-01058680.
XX
XX 30-NOV-2001; 2001DE-01058680.
XX
XX (FIED/) FIEDLER W.
PA (GEHL/) GEHLING U.
PA (HOSS/) HOSSFELD D K.
PA (LOGE/) LOGES S.
XX
XX WPI; 2003-506588/48.
XX
XX In vitro expansion of multipotent stem cells, useful for therapy,
PT diagnosis and tissue engineering, comprises growing them in the presence
PT of fetal liver tyrosine kinase-3 ligand and a growth factor.
XX
XX Example 1; Page 12; 22pp; German.
XX
XX The present invention relates to a method for the in vitro expansion of
CC multipotent stem cells by growing them in the presence of: Flt3 (fetal
CC liver tyrosine kinase-3) ligand (l), and at least one of stem cell factor
CC (SCF), stem cell growth factor (SCGF), vascular endothelial growth factor
CC (VEGF), basic fibroblast growth factor (bFGF), insulin, nerve growth
CC factor (NGF) and transforming growth factor- $\beta$  (TGF $\beta$ ). In addition, the
CC method allows for the differentiation of the cells. Expanded stem cells
CC and/or mature cells differentiated from them, optionally genetically
CC modified, are useful in pharmaceutical compositions, specifically to coat
CC implantable materials (coronary stents or vascular valves) with
CC endothelial cells or to produce artificial tissues and blood vessels, but
CC also for prevention, diagnosis or treatment of human diseases, e.g. as
CC transplants for providing haematopoietic differentiation in vivo (in
CC cancer patients who have received myoblastic therapy), when genetically
CC modified, for treating tumours and leukaemia (e.g. by expressing a
CC protein with angiogenic activity), treatment of inherited blood
CC disorders such as haemophilia and sickle cell anaemia, for diagnosis of
CC metastases and ischaemic lesions (when labeled with 18-fluorine), for
CC inducing formation of new blood vessels, in vivo or in transplant tissue,
CC and for re-endothelialization of blood vessels (treatment of disease or
CC injury in coronary arteries). The present sequence is a PCR primer used
CC in the exemplification of the invention to isolate the human VWF cDNA.
XX
XX Sequence 20 BP; 3 A; 3 C; 7 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.2%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 104 AGCAAGCCATGCTGCTCA 122
Db 19 AGCAAGCCATGCTGCTCA 1

```

```

RESULT 50
ADK65736/c
ID ADK65736 standard; DNA; 20 BP.
XX
XX ADK65736;
XX
XX 06-MAY-2004 (first entry)
DT
XX Human VWF cDNA PCR primer #4.
DE
XX
XX cytoabatic; haematological; antihaemic; cardiant; gene therapy;
KM blood disorder; cancer; ss; primer; PCR; VWF.
XX
XX Homo sapiens.
OS
XX DE10158680-A1.
XX
XX 12-JUN-2003.
XX

```

```

RESULT 51
AD128399/c
ID AD128399 standard; DNA; 20 BP.
XX
XX AD128399;
XX
XX 22-APR-2004 (first entry)
DT
XX Human neuropeptide Y2 receptor antisense oligonucleotide.
DE
XX
XX Human: neuropeptide Y2; antisense; antiangiogenic; ophthalmological;
KM nephrotropic; antipsoriatic; cardiovascular-gen.; cytoabatic; anti-HIV;
XX receptor; ss.
XX
XX Homo sapiens.
OS
XX WO2004002535-A1.
XX
XX 08-JAN-2004.
XX
XX 17-JUN-2003; 2003WO-FI000487.
XX

```

```

PR 27-JUN-2002; 2002US-00180967.
XX
XX (HORM-) HORMOS MEDICAL CORP.
XX
XX Koutu M., Tuohimaa J., Pesonen U., Kallio J., Karvonen M.,
XX WPI; 2004-082891/08.
XX
XX Use of an agent affecting the neuropeptide Y Y2 receptor, i.e. antisense
XX oligonucleotide, for treating or preventing a disease or disorder related
XX to excessive formation of vascular tissue or blood vessels, e.g.
XX retinopathy or cancer.
XX
XX Claim 11; SEQ ID NO 26; 73pp; English.
XX
XX The present sequence is that of an antisense oligonucleotide targeted to
XX human neuropeptide Y2 receptor mRNA AD128374. It is an example of
XX neuropeptide Y2 receptor-targeted antisense oligonucleotides of the
XX invention useful in the treatment or prevention of a disease or disorder
XX related to excessive formation of vascular tissue or blood vessels in a
XX patient. These include neovascular glaucoma, any form of retinopathy, all
XX proliferative retinopathies, including proliferative diabetic
XX retinopathy, retinopathy of prematurity, macular degeneration,
XX maculopathy, micro- or macro-vascular eye complications caused by
XX diabetes, nephropathy, angiodiabetes, psoriasis, iriditis,
XX haemangiomas, angiofibromas, predilection to vision loss and
XX blindness, which are consequences of retinopathy, a metabolic disease, a
XX cardiovascular disease, or a cancerous disease, e.g. tumours and
XX neoplasms, including malignant tumours and neoplasms, blastomas,
XX carcinomas or sarcomas, highly vascular tumours and epidermoid
XX tumours, squamous tumours, head and neck tumours, colorectal tumours,
XX prostate tumours, breast tumours, lung tumours, including small cell and
XX non-small cell lung tumours, pancreatic tumours, thyroid tumours, ovarian
XX cell carcinoma, basal cell carcinoma, and skin cancers that can be
XX treated by suppressing the growth of neovasculation, Kaposi's sarcoma,
XX CNS neoplasms including the growth of neuroblastomas, capillary haemangioblastomas,
XX meningiomas and cerebral metastases, melanoma, gastrointestinal and renal
XX carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, glioblastoma
XX oligonucleotides may have locked nucleic acid and peptide-nucleic acid
XX modifications, or have modified sugar units or internucleotide linkages.
XX They are also useful for investigating the development of a disease or
XX disorder, related to excessive formation of vascular tissue or blood
XX vessels in an experimental animal.
XX
XX Sequence 20 BP; 2 A; 3 C; 5 G; 10 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 1.4e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 239 AAAACTACCCAAATGCTGG 257
XX DB 19 AAAACACACCAAAATGCTGG 1
XX
XX RESULT 52
XX AA276017/c
XX ID AA276017 standard; DNA; 21 BP.
XX
XX AC AA276017;
XX
XX DT 10-SEP-2001 (first entry)
XX
XX DE Human bi-allelic marker downstream amplification primer SEQ ID NO:10373.
XX
XX KM Human genome; bi-allelic marker; high density disequilibrium map;
XX KM genomic map; haplotype; phenotype; polymorphic base; genotyping;
XX KM haplotyping; hybridisation; identification; characterisation;
XX KM amplification; single nucleotide polymorphism; SNP; PCR primer;
XX KM diagnosis; ss.
XX

```

```

OS Homo sapiens.
XX
XX MO9954500-A2.
XX
XX 28-OCT-1999.
XX
XX PD
XX
XX PF 21-APR-1999; 99WO-1B000822.
XX
XX PR 21-APR-1998; 98US-0082614P.
XX PR 23-NOV-1998; 98US-0109732P.
XX
XX PA (GENSET) GENSET.
XX
XX PI Cohen D., Blumenfeld M., Chumakov I.,
XX WPI; 2000-013267/01.
XX
XX DR Novel bi-allelic markers used to construct a high density disequilibrium
XX map of the human genome.
XX
XX PS Claim 9; Page 2442; 2745pp; English.
XX
XX AA265654 to AA269578 represent human bi-allelic markers from the present
XX invention, which contain a polymorphic base at position 24 of their
XX nucleotide sequences. AA269579 to AA277440 represent amplification
XX primers for the bi-allelic markers. The bi-allelic markers of the invention
XX have a variety of uses: they can be used for high density mapping of the
XX human genome, and in complex association studies and haplotyping studies
XX which are useful in determining the genetic basis for disease states.
XX CC Compositions and methods of the invention can also be useful for the
XX identification of the targets for the development of pharmaceutical
XX agents and diagnostic methods, as well as the characterisation of the
XX differential efficacious responses to and side effects from
XX CC pharmaceutical agents acting on a disease as well as other treatment.
XX N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
XX 3367, are not actually given a sequence in the Sequence Listing from the
XX present invention
XX
XX SQ Sequence 21 BP; 2 A; 1 C; 8 G; 10 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 15.8; DB 1; Length 21;
XX Best Local Similarity 89.5%; Pred. No. 1.6e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 233 CCACGAAACTACCCAAA 251
XX DB 21 CCACGAAATATCCACCA 3
XX
XX RESULT 53
XX AAH62205
XX ID AAH62205 standard; DNA; 21 BP.
XX
XX AC AAH62205;
XX
XX DT 09-SEP-2004 (revised)
XX DT 12-SEP-2001 (first entry)
XX
XX DE Fer tyrosine kinase polymorphism containing DNA fragment #106.
XX
XX KM Single nucleotide polymorphism; SNP; human; cancer; inflammation;
XX KM heart disease; paternity testing; forensic science; ds.
XX
XX OS Homo sapiens.
XX OS unidentified.
XX
XX FH Key Location/Qualifiers
XX FT 11 /tag= a
XX FT variation /standard_name= "single nucleotide polymorphism"
XX
XX PN MO200138576-A2.
XX

```

PD 31-MAY-2001.
 XX
 PF 17-NOV-2000; 2000MO-US031639.
 XX
 PR 24-NOV-1999; 99US-0167334P.
 XX
 PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
 XX
 PI Cargill M, Ireland JS, Lander ES;
 XX
 DR WPI; 2001-367705/38.
 XX
 PT New nucleic acid segments of the human genome, particularly from genes
 PT including polymorphic sites, for phenotype correlation, forensics,
 PT paternity testing, medicine and genetic analysis.
 XX
 PS Claim 1; Page 38; 80pp; English.
 XX
 CC DNA sequences AAH62100 - AAH62688 represent segments of human genes which
 CC contain single nucleotide polymorphisms (SNPs). A method is included in
 CC the invention for analysing a nucleic acid sample, which consists of
 CC determining the base occupying any one of the polymorphic sites given in
 CC the SNP containing sequences. The nucleotide sequences can be used in the
 CC diagnosis or monitoring of diseases, such as cancer, inflammation, heart
 CC diseases, diseases of the cardiovascular system, and infection by
 CC microorganisms. The oligonucleotides are also useful in the manufacture
 CC of a medicament for the treatment or prophylaxis of the diseases, and as
 CC a pharmaceutical. SNP containing oligonucleotides are useful in
 CC applications such as phenotype correlation, forensics, paternity testing,
 CC medicine and genetic analysis
 CC
 CC Revised record issued on 09-SEP-2004 : Correction to Feature Table Key
 CC
 XX Sequence 21 BP; 5 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.2%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 1.6e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 121 CAGGATTGCTACCATGGTG 139
 Db 2 CAGGACTGTACCATGGTG 20
 RESULT 54
 ABAK1507
 ID ABAK1507 standard; DNA; 21 BP.
 XX
 AC ABAK1507;
 XX
 DT 21-MAY-2002 (first entry)
 XX
 DE Human CTNNA3 gene splice donor #17.
 XX
 DE Human; alpha-catenin; ds; cytosolic; antiinfectility; CTNNA3;
 KW cadherin-catenin related pathway; heart testis; cancer; gene therapy;
 KW cadherin-catenin related disease; specifically dilated cardiomyopathy;
 KW cardiomyopathy; male infertility; splice donor; splice acceptor;
 KW alpha T-catenin.
 XX
 OS Homo sapiens.
 XX
 PN WO200204636-A1.
 PD 17-JAN-2002.
 XX
 PF 28-JUN-2001; 2001WO-EP007392.
 XX
 PR 12-JUL-2000; 2000EP-00202472.
 PR 14-JUL-2000; 2000US-0218309P.
 XX
 PA (VLA-) VLAAMS INTERUNIVERSITAIR INST BIOTECHNOG.
 XX

PI Van Roy F, Goossens S, Janssens B, Vanpoucke G;
 XX
 DR WPI; 2002-171717/22.
 XX
 PT New alpha catenin polypeptides and polynucleotides encoding them, useful
 PT for predicting, diagnosing or treating cadherin-catenin related diseases,
 PT particularly cardiomyopathies, cancer and male infertility.
 XX
 PS Example; Page 35; 132pp; English.
 XX
 CC The invention relates to human and mouse alpha-catenin polypeptides and
 CC their associated polynucleotides. The polypeptides and related antibodies
 CC are useful for modulating the cadherin-catenin related pathway in
 CC selected organs, such as the heart and testis. The nucleic acids and the
 CC antibodies are useful in the diagnosis and/or prediction of the
 CC likelihood of developing cadherin-catenin related diseases. The nucleic
 CC acids may also be used to predict the likelihood of developing cancer or
 CC in diagnosing cancer, and in gene therapy. The polypeptide, the nucleic
 CC acid or the antibody is useful in manufacturing a medicament for treating
 CC cadherin-catenin related diseases, such as cancer, cardiomyopathy,
 CC specifically dilated cardiomyopathy, and male infertility. Sequences
 CC ABAK1474-ABAK1509 represent splice donors and splice acceptors of the
 CC CTNNA3 gene which encodes human alpha T-catenin
 CC
 XX Sequence 21 BP; 4 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 0.2%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 1.6e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 327 TGTGAGTGGAGTACTGC 345
 Db 2 TGTGAGCTGTGAGTACTGC 20
 RESULT 55
 AAS14648/C
 ID AAS14648 standard; DNA; 19 BP.
 XX
 AC AAS14648;
 XX
 DT 18-DEC-2001 (first entry)
 XX
 DE Human matrix metalloproteinase 3, MMP-3, consensus PCR primer.
 XX
 KW Human; matrix metalloproteinase 3; MMP-3; PCR primer; ss;
 KW chronic inflammatory disease; primary sclerosing cholangitis;
 KW complicating portal hypertension; liver disease; cholestatic disease;
 KW inflammatory bowel disease; ulcerative colitis; thyroiditis;
 KW retro-peritoneal fibrosis; arthritis mediastinal fibrosis; scleroderma;
 KW extra-cellular matrix degradation.
 XX
 OS Homo sapiens.
 XX
 PN WO200171030-A2.
 PD 27-SEP-2001.
 XX
 PF 22-MAR-2001; 2001WO-GB001267.
 XX
 PR 22-MAR-2000; 2000GB-00006960.
 XX
 PA (ISIS-) ISIS INNOVATION LTD.
 PA (OXFO-) OXFORD RADCLIFFE HOSPITAL NHS TRUST.
 XX
 PI Satsangi J, Welsh K, Haider N, Chapman R;
 XX
 DR WPI; 2001-611515/70.
 XX
 PT Determining genotype of the matrix metalloproteinase 3 gene promoter
 PT region, useful to determine susceptibility to chronic inflammatory
 PT disease particularly primary sclerosing cholangitis.
 XX

PS Claim 16; Page 34; 35pp; English.
XX
CC The invention relates to determining the susceptibility of a human to a
CC chronic inflammatory disease, comprising screening the genome for one or
CC more polymorphic variants of the matrix metalloproteinase 3 (MMP-3) gene,
CC e.g., allele 5A or allele 6A. The method is particularly used to determine
CC whether a patient with primary sclerosing cholangitis is likely to
CC develop complicating portal hypertension. The invention is likely to
CC determine susceptibility to chronic inflammatory disease, particularly
CC liver disease, especially cholestatic disease, a fibrosing liver disease
CC or primary sclerosing cholangitis. Other diseases related to primary
CC sclerosing cholangitis include inflammatory bowel disease, ulcerative
CC colitis, thyroiditis, retro-peritoneal fibrosis, arthritis mediastinal
CC fibrosis and scleroderma. MMP-3 regulates extra-cellular matrix
CC degradation, fibrosis and immune activity in the liver and
CC gastrointestinal system. The present sequence is an MMP-3 consensus PCR
CC primer which amplifies a 146bp or 147bp fragment of the MMP-3 gene when
CC used with an allele specific primer (either allele 5A or 6A), identifying
CC the presence of the allele
SQ
Sequence 19 BP; 4 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 0.2%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 285 AGATGCTGTGCGAGCTC 301
DB 17 AGAAGCTGTGCGAGCTC 1
RESULT 56
ABX17704/C
ID ABX17704 standard; DNA, 20 BP.
AC
XX ABX17704;
XX
DT 05-FEB-2003 (first entry)
XX
XX Human urokinase plasminogen activator antisense oligonucleotide #9.
DE Urokinase plasminogen activator; gene therapy; cancer;
XX hyperproliferative disorder; cancer; breast cancer; colon cancer;
XX bone cancer; brain cancer; ovary cancer; cervix cancer;
XX endometrium cancer; stomach cancer; kidney cancer; tumour metastasis;
XX antisense oligonucleotide; ss.
XX
OS Synthetic.
XX
XX WO200279515-A1.
XX
PD 10-OCT-2002.
XX
XX 18-MAR-2002; 2002WO-US008112.
XX
XX 30-MAR-2001; 2001US-00821972.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Baker BF, Freiler SM, Watt AT;
XX WPI; 2003-058441/05.
XX
XX New antisense compound, useful for preparing a composition for treating
XX hyperproliferative disorders, cancer e.g., breast, colon, bone, brain,
XX ovary, cervix, endometrium, stomach or kidney cancer, or tumor
XX metastasis.
XX
XX Example 15; Page 90; 153pp; English.
XX
XX A new compound, which is 8-50 nucleobases in length targeted to a nucleic
XX acid molecule encoding urokinase plasminogen activator, specifically
XX hybridises with and inhibits the expression of urokinase plasminogen

CC activator. The compound is useful for preparing a composition for
CC treating (e.g. by gene therapy) hyperproliferative disorder, cancer e.g.,
CC breast, colon, bone, brain, ovary, cervix, endometrium, stomach or kidney
CC cancer, or tumour metastasis. This sequence represents an antisense
CC oligonucleotide used to modulate expression of urokinase plasminogen
CC activator
XX
SQ Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;
Query Match 0.2%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 271 TACTGACGAGATCCAGA 287
DB 19 TACTGACGAGATCCAGA 3
RESULT 57
ADO22862
ID ADO22862 standard; DNA, 20 BP.
AC
XX ADO22862;
XX
DT 12-AUG-2004 (first entry)
XX
XX Human interleukin 22 receptor DNA target sequence #6.
DE
XX Antisense therapy; human; interleukin 22 receptor; autoimmune disorder;
XX immunosuppressive; ds.
XX
XX Homo sapiens.
XX
XX US2004097447-A1.
XX
PD 20-MAY-2004.
XX
XX 16-NOV-2002; 2002US-00299089.
XX
XX 16-NOV-2002; 2002US-00299089.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Double KW;
XX
XX WPI; 2004-389188/36.
XX
XX New compounds, particularly oligonucleotides targeted to a nucleic acid
XX encoding interleukin 22 receptor, useful for treating diseases associated
XX with interleukin 22 receptor, e.g. autoimmune disorders.
XX
XX Example 15; SEQ ID NO 96; 58pp; English.
XX
XX The present invention relates to antisense compounds targeted to a
XX nucleic acid encoding human interleukin 22 receptor. The antisense
XX compound comprises an antisense oligonucleotide that specifically
XX hybridises with the nucleic acid and inhibits the expression of
XX interleukin 22 receptor. The antisense oligonucleotide is a chimeric
XX oligonucleotide. The antisense oligonucleotide comprises at least one
XX modified internucleoside linkage, preferably a phosphorothioate linkage.
XX It also comprises at least one modified sugar moiety, preferably a 2'-O-
XX methoxyethyl (2'-MOE) sugar moiety. The antisense oligonucleotide further
XX comprises at least one modified nucleobase, preferably a 5-
XX methylcytosine. The antisense oligonucleotides are useful for the
XX treatment of autoimmune disorders. The present sequence represents a
XX human interleukin 22 receptor DNA target sequence for an antisense
XX oligonucleotide.
XX
SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.2%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Seq ID	Seq	Score	DB	Length	Indels	Gaps
338	AGTACTGCACCTGACG	354				
19	AGTCTGCAACTGACG	3				
338	AGTACTGCACCTGACG	354				
19	AGTCTGCAACTGACG	3				

RESULT 59, 17
AAVS1877/C
ID AAVS1877 standard; DNA; 20 BP.
XX
AC AAVS1877;
XX
DT 02-FEB-1999 (first entry)
XX
DE Zea mays genome reverse PCR primer #173.
XX
KM Polymorphic marker; allele-specific probe; amplification; PCR primer;
KW hybridisation; plant; hybrid certification; genetic contribution;
XX progeny; back-cross; hybrid; ancestry; corn; ss.
OS Synthetic.
OS Zea mays.
XX
FN W09824796-A1.
PD 11-JUN-1998.
XX
PF 01-DEC-1997; 97WO-US021782.
XX
PR 02-DEC-1996; 96US-0032069P.
PR 07-MAR-1997; 97US-00813507.
XX
PA (AFFY-) AFFYMETRIX INC.
XX
PI Lemieux B, Landry BS, Sapolsky RJ, Murgineux A;
XX
DR WP1; 1998-333252/29.
XX
PT Brassica species allele-specific oligonucleotide probes and primers -
PT useful for plant breeding.
XX
PS Example 1; Page 53; 65pp; English.
XX
CC AAVS1705-V52008 are reverse PCR primers used to amplify fragments of the
CC Zea mays genome in order to detect polymorphic markers. Such markers can
CC be used in the construction of allele-specific primers and probes for
CC amplification or hybridisation, e.g. to determine common or disparate
CC ancestry between 2 or more plants, to monitor the genetic contribution of
CC an ancestral plant, to trace the progeny of proprietary plants, in
CC certification of a hybrid plant or to identify the progeny of a back-
CC crossed plant with an ancestral plant
XX
SQ Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;

Query March 0.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

376 ACTGCGGTGGCGCTCCGAC 395
|||||
20 ACTGACGTAGCACCCTCCGAC 1

RESULT 60
AAVS8789
ID AAVS8789 standard; DNA; 20 BP.
XX
AC AAVS8789;
XX
DT 16-AUG-1999 (first entry)
XX
DE Primer HuVZAE+2A used in the analysis of human GZA.
XX
KW G protein coupled receptor; GZA; human; cell cycle; leukaemia; lymphoma;
KW therapy; leukemogenesis; tumour suppressor protein; PCR; primer; ss.
OS Synthetic.

```
OS Homo sapiens.
XX
XX WO925830-A1.
XX
XX 27-MAY-1999.
XX
XX 12-NOV-1998; 98WO-US024143.
XX
XX 13-NOV-1997; 97US-0069815.
XX
XX 17-JUL-1998; 98US-00120025.
XX
XX (REGC ) UNIV CALIFORNIA.
XX
XX Weng Z, Witte ON;
XX
XX WPI; 1999-338006/28.
XX
XX A transcriptionally regulated G protein-coupled receptor useful in the
XX inhibition of leukemogenesis.
XX
XX Example 5; Page 16; 62pp; English.
XX
XX Primer HUN2AE+2A was used in the analysis of full-length human G2A cDNA
XX (see AAX58760) isolated from a human spleen cDNA library. G2A is a tumour
XX suppressor gene, which encodes a G protein coupled receptor (see
XX AY06215) that induces cell cycle arrest. The invention provides G2A
XX activators that can be used to arrest the cell cycle in the G2/M
XX transition of cells, especially leukaemia or lymphoma cells. The presence
XX of increased levels of G2A transcript indicates the presence of cancer
XX cells. Expression constructs encoding G2A can be used for inhibition of
XX leukemogenesis, especially by transfecting or infecting bone marrow ex
XX vivo
XX
XX Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 190 TGGCAAGCTTGTCATCTAT 209
Db 1 TGGCACTCTGGGTCTCTAT 20
RESULT 61
AAF73070
ID AAF73070 standard; DNA; 20 BP.
XX
XX AAF73070;
XX
XX 24-APR-2001 (first entry)
XX
XX Human daxx inhibitory antisense phosphorothioate oligonucleotide SEQ:171.
XX
XX Antisense oligonucleotide; daxx; inhibition; phosphorothioate;
XX Fas binding protein; GNP-C binding protein; dap6; BAP; cytosolic;
XX antiinflammatory; death associated protein 6; Ets-1 associated protein;
XX infection; inflammation; tumour formation; ss.
XX
XX Homo sapiens.
XX
XX US6180353-B1.
XX
XX 30-JAN-2001.
XX
XX 24-JAN-2000; 2000US-00490692.
XX
XX 24-JAN-2000; 2000US-00490692.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Dean NM, Cowsett LM;
XX
```

```
DR WPI; 2001-217744/22.
XX
XX Novel antisense compounds capable of modulating expression of daxx useful
XX for diagnosis, prophylaxis and treatment of diseases associated with
XX expression of daxx.
XX
XX Claim 1; Col 49; 59pp; English.
XX
XX The present invention describes an antisense compound (I) up to 30
XX nucleobases in length, where (I) inhibits expression of daxx (also known
XX as Fas binding protein, GNP-C binding protein, dap6 for death associated
XX protein 6 and BAP for Ets-1 associated protein). (I) has cytosolic and
XX antiinflammatory activity, and can be used in antisense therapy and as a
XX modulator of daxx. (I) is useful for inhibiting the expression of daxx in
XX cells or tissues in vitro. (I) can be utilised for diagnosis,
XX therapeutics for the treatment of diseases associated with the expression
XX of daxx, prophylaxis e.g. to prevent or delay infection, inflammation or
XX tumour formation and as research reagent. The present sequence represents
XX an inhibitory human daxx antisense phosphorothioate oligonucleotide which
XX is used in the exemplification of the present invention
XX
XX Sequence 20 BP; 3 A; 7 C; 1 G; 9 T; 0 U; 0 Other;
SQ
Query Match 0.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 73 CTTCTTTTATTTCTGAATC 92
Db 1 CTTCTTTTCTTCGGAATC 20
RESULT 62
AAC67699
ID AAC67699 standard; DNA; 20 BP.
XX
XX AAC67699;
XX
XX 16-FEB-2001 (first entry)
XX
XX Oligonucleotide #10 ISIS #116878.
XX
XX Antiinflammatory; cytosolic; antibacterial; methionine aminopeptidase 2;
XX inhibitor; MetAP2; eukaryotic initiation factor associated protein; p67;
XX eIF-2; protein synthesis; antisense oligonucleotide; infection; human;
XX inflammation; tumour; phosphorothioate; 2-methoxyethyl wing; ss.
XX
XX Homo sapiens.
XX
XX US6136604-A.
XX
XX 24-OCT-2000.
XX
XX 27-OCT-1999; 99US-00428584.
XX
XX 27-OCT-1999; 99US-00428584.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt J;
XX
XX WPI; 2001-030942/04.
XX
XX New antisense compounds which specifically hybridize with and inhibit
XX human methionine aminopeptidase 2 expression, useful for treating
XX methionine aminopeptidase 2 related disorders and preventing inflammation
XX or tumor formation.
XX
XX Example 15; Col 41-42; 39pp; English.
XX
XX Methionine aminopeptidase 2 (also known as MetAP2 and eukaryotic
XX initiation factor [eIF-2] associated protein, p67) is a cellular
XX glycoprotein that promotes protein synthesis in the presence of active
XX
```

CC eIF-2 kinases by protecting the eIF-2 alpha subunit from phosphorylation.
 CC The present invention relates to antisense oligonucleotides (AAC67690-
 CC C67767) which inhibit human methionine aminopeptidase 2 coding sequence
 CC expression (see AAC67683). The present sequence is one such antisense
 CC oligonucleotide. The present sequence may be used for treating a patient
 CC suspected of having or being prone to a disease or condition associated
 CC with expression of MetAP2. In addition, the present sequence can also be
 CC used as research reagents, diagnostics and to distinguish between
 CC functions of various members of a biological pathway. The antisense
 CC oligonucleotide may further be used prophylactically, e.g. to prevent or
 CC delay infection, inflammation or tumour formation. Note: the present
 CC sequence may have a phosphorothioate backbone and 2-methoxyethyl (2'-MOE)
 CC wings
 CC
 XX Sequence 20 BP, 0 A; 6 C; 0 G; 14 T; 0 U; 0 Other;
 SQ
 Query Match 0.2%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.7e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Oy 66 TCTTCTACTTCTTTATTTTC 85
 |||||
 1 TCTTCTCTTCTTTCTTC 20
 Db
 RESULT 63
 AAH80279
 ID AAH80279 standard; cDNA; 20 BP.
 XX
 AC AAH80279;
 XX
 DT 11-SEP-2003 (revised)
 DT 19-SEP-2001 (first entry)
 XX
 DE Oligonucleotide hybridisation potential related cDNA SEQ ID NO: 243.
 XX
 KM Nucleic acid hybridisation; probe; primer; human; rabbit; HIV-1;
 KM disease diagnosis; ss.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN US6251588-B1.
 XX
 PD 26-JUN-2001.
 XX
 PF 10-FEB-1998; 98US-00021701.
 XX
 PR 10-FEB-1998; 98US-00021701.
 XX
 PA (AGIL-) AGILENT TECHNOLOGIES INC.
 XX
 PI Shannon KM, Wolber PK, Delenstarr GC, Webb PG, Kincaid RH;
 DR WPI; 2001-424456/45.
 XX
 PT Predicting the potential of an oligonucleotide to hybridize to a target
 PT nucleotide sequence, useful for evaluating oligonucleotide probe
 PT sequences, by identifying a oligonucleotides based on the evaluation of
 PT parameters.
 XX
 XX Example 2; Col 57; 342pp; English.
 PS
 CC The present invention describes a method for predicting the potential of
 CC an oligonucleotide to hybridise to a (complementary) target nucleotide
 CC sequence, involving identifying a subset of oligonucleotides within the
 CC predetermined number of unique oligonucleotides based on the evaluation
 CC of the parameter. Oligonucleotides in the subset are identified that are
 CC clustered along a region of the nucleotide sequence that is hybridisable
 CC to the target nucleotide sequence. This is useful for evaluating
 CC oligonucleotide probe sequences. The present sequence is an
 CC oligonucleotide described in the exemplification of the invention.
 CC (Updated on 11-SEP-2003 to standardise OS field)
 CC

SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 0.2%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.7e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Oy 284 CAGATGCTGTGACGACTCCT 303
 |||||
 1 CAGATGTTGTCTCAGTCCT 20
 Db
 RESULT 64
 AAH80798
 ID AAH80798 standard; cDNA; 20 BP.
 XX
 AC AAH80798;
 XX
 DT 11-SEP-2003 (revised)
 DT 19-SEP-2001 (first entry)
 XX
 DE Oligonucleotide hybridisation potential related cDNA SEQ ID NO: 762.
 XX
 KM Nucleic acid hybridisation; probe; primer; human; rabbit; HIV-1;
 KM disease diagnosis; ss.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN US6251588-B1.
 XX
 PD 26-JUN-2001.
 XX
 PF 10-FEB-1998; 98US-00021701.
 XX
 PR 10-FEB-1998; 98US-00021701.
 XX
 PA (AGIL-) AGILENT TECHNOLOGIES INC.
 XX
 PI Shannon KM, Wolber PK, Delenstarr GC, Webb PG, Kincaid RH;
 DR WPI; 2001-424456/45.
 XX
 PT Predicting the potential of an oligonucleotide to hybridize to a target
 PT nucleotide sequence, useful for evaluating oligonucleotide probe
 PT sequences, by identifying a oligonucleotides based on the evaluation of
 PT parameters.
 XX
 XX Example 2; Col 71; 342pp; English.
 PS
 CC The present invention describes a method for predicting the potential of
 CC an oligonucleotide to hybridise to a (complementary) target nucleotide
 CC sequence, involving identifying a subset of oligonucleotides within the
 CC predetermined number of unique oligonucleotides based on the evaluation
 CC of the parameter. Oligonucleotides in the subset are identified that are
 CC clustered along a region of the nucleotide sequence that is hybridisable
 CC to the target nucleotide sequence. This is useful for evaluating
 CC oligonucleotide probe sequences. The present sequence is an
 CC oligonucleotide described in the exemplification of the invention.
 CC (Updated on 11-SEP-2003 to standardise OS field)
 CC
 SQ Sequence 20 BP; 4 A; 3 C; 1 G; 12 T; 0 U; 0 Other;
 SQ
 Query Match 0.2%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.7e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Oy 65 TTCTTCTACTTCTTTATTTT 84
 |||||
 1 TTCTACTAATGCTTTTATTT 20
 Db
 RESULT 65
 ABA82239/C
 ID ABA82239 standard; DNA; 20 BP.

```

XX ABA82239;
AC
XX
DT 25-JAN-2002 (first entry)
XX
DE Zmax1 gene region physical map preparation STS marker #198.
XX
KW Human; high bone mass; HBM gene; Zmax1 gene; chromosome 11, 11q13.3;
KW sequence tagged site; STS; osteoporosis; osteoparhic; gene therapy;
KW antisense therapy; vaccine; bone disorder; Paget's disease; adapter;
KW sclerostosis; osteomalacia; fibrous dysplasia; PCR primer; linker; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO20017327-A1.
PN
PD 18-OCT-2001.
XX
PF 21-JUN-2000; 2000WO-US016951.
XX
PR 05-APR-2000; 2000US-00543771.
PR 05-APR-2000; 2000US-00544396.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
PI Carulli JP, Little RD, Recker RR, Johnson ML;
XX
DR WPI; 2001-657171/75.
XX
PT New high bone mass (HBM) and Zmax1 genes and proteins useful for
XX modulating bone mass for the treatment of e.g. osteoporosis.
XX
PS Disclosure; Page 34; 443pp; English.
XX
CC The present invention describes the human Zmax1 gene and the high bone
CC mass (HBM) gene, which are found on chromosome 11q13.3. The Zmax1 and HBM
CC genes have osteopathic activities. The genes can be used in gene therapy,
CC antisense therapy and in the production of vaccines. They can be used in
CC the diagnosis and treatment of bone disorders including osteoporosis,
CC Paget's disease, sclerostosis, osteomalacia and fibrous dysplasia.
CC ABA82038 to ABA82700 and AAG68168 to AAG68193 represent sequences used in
CC the exemplification of the present invention.
XX
SQ Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 324 CGGTGTCAGTGGAGTACT 343
DB 20 CGGTATCAGTGGATTAAT 1

```

```

XX Homo sapiens.
OS
XX
PN WO200181918-A1.
XX
PD 01-NOV-2001.
XX
PF 11-APR-2001; 2001WO-US012005.
XX
PR 20-APR-2000; 2000US-00553875.
XX
PA (RSCC) UNIV CALIFORNIA.
XX
PI Weng Z, Witte ON;
XX
DR WPI; 2002-062048/08.
XX
PT Screening for compound inhibiting T cell hyperproliferation related with
XX e.g. autoimmune disorder, comprises contacting G2A receptor with compound
XX and determining binding between them and whether it activates the
XX receptor.
XX
PS Example 5; Page 26; 104pp; English.
XX
CC The invention relates to identifying a compound which inhibits a T cell
CC hyperproliferation, comprising contacting a G protein-coupled receptor
CC (GPCR) G2A receptor with a test compound determining whether the compound
CC binds to the GPCR G2A and if the compound binds to GPCR G2A, determining
CC whether the compound activates GPCR G2A, where activation of GPCR G2A
CC indicates that the compound is a potential inhibitor of T cell
CC proliferation. Also included are a method for inducing cell cycle arrest
CC in a cell, comprising contacting the cell with a compound which activates
CC GPCR G2A, a method for detecting cancer cells, comprising determining
CC whether the cells express the G2A transcript or G2A protein, where the
CC presence of an increased level of the transcript or the protein compared
CC to a control cell indicates that the cell is a cancer cell, generating a
CC lymphocytes comprising inactivating G2A gene in the mammal and a viable
CC non-human transgenic mammal having an inactivated G2A gene, where the
CC mammal has hyperproliferative T lymphocytes. The methods are useful for
CC identifying a compound which inhibits T cell hyperproliferation which is
CC preferably associated with an autoimmune disorder (e.g. acquired
CC immunodeficiency syndrome, AIDS, severe combined immune deficiency, SCID,
CC DiGeorge syndrome or Bare lymphocyte syndrome), X-linked
CC agammaglobulinemia, inflammatory disorder or malignancy, which include
CC rheumatoid arthritis, psoriasis, inflammatory bowel disease, T cell
CC malignancies and diabetes, are useful for inducing cell cycle arrest in a
CC cell preferably leukaemia or lymphoma cell, and for detecting cancer
CC cells. The present sequence is a primer used to sequence the full-length
CC cDNA encoding Human GPCR G2A
XX
SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 190 TGCCAGCTTGTCATCTAT 209
DB 1 TGCCACTCTGGTCATCTAT 20

```

```

RESULT 66
AA517642
ID AA517642 standard; DNA; 20 BP.
XX
AC AA517642;
XX
DT 26-FEB-2002 (first entry)
XX
DE Human G protein-coupled receptor G2A sequencing primer HUN2AB+2A.
XX
KW Human; G protein-coupled receptor G2A; GPCR; transgenic animal; ss;
KW T cell hyperproliferation; cell cycle arrest; cancer; gene therapy;
KW autoimmune disorder; acquired immunodeficiency syndrome; AIDS;
KW severe combined immune deficiency; SCID; DiGeorge syndrome;
KW Bare lymphocyte syndrome; X-linked agammaglobulinemia; sequencing primer;
KW inflammatory disorder; malignancy; rheumatoid arthritis; psoriasis;
KW inflammatory bowel disease; T cell malignancy; diabetes; leukaemia;
KW lymphoma; HUN2AB+2A.

```

```

RESULT 67
ABK23036/c
ID ABK23036 standard; DNA; 20 BP.
XX
AC ABK23036;
XX
DT 09-APR-2002 (first entry)
XX
DE Human Zmax1 cDNA reverse PCR primer #99.
XX
KW Human; mouse; Zmax1; HBM; high bone mass gene; lipid regulation; stroke;

```


lipid-associated condition; arteriosclerosis; cardiovascular disease; ss;
osteoporosis; atherosclerosis; diabetic atherosclerosis; plaque build-up;
neurovascular condition; wound healing; gene therapy; PCR primer; probe;
bone development disorder; antiarteriosclerotic; cardiovascular;
osteopathic; cerebroprotective.
Homo sapiens.
NM0200192891-A2.
06-DEC-2001.
25-MAY-2001; 2001MO-US016946.
26-MAY-2000; 2000US-00578900.
(GENO-) GENOME THERAPEUTICS CORP.
(UYCR-) UNIV CREIGHTON SCHOOL MEDICINE.
Carulli JP, Little RD, Recker RR, Johnson ML;
WPI; 2002-097784/13.
Identifying molecules involved in lipid regulation, useful for
diagnosing, treating or preventing e.g., arteriosclerosis, comprises
identifying a molecule that binds to high bone mass gene or its
corresponding wild type gene.
Disclosure; Page 39; 409pp; English.
The invention relates to a method for identifying a molecule involved in
lipid regulation comprising identifying a molecule that binds to or
inhibits binding of a molecule to high bone mass (HBM) or its wild type
gene, Zmax1. Compounds identified by the method are useful for treating,
diagnosing, preventing or screening for normal and abnormal lipid-
associated conditions, including arteriosclerosis, cardiovascular
disease, stroke, and osteoporosis. The compounds may also be used in the
treatment or prevention of diabetic atherosclerosis, neurovascular
conditions caused by plaque build-up, poor circulation due to plaque
build-up and associated poor wound healing. The methods may be used in
gene therapy, pharmaceutical development, and diagnostic assays for bone
development disorders. Molecules identified by comparison of Zmax1 and
HBM systems can be used as surrogate markers in pharmaceutical
development, in diagnosis of human or animal bone disease, and in the
treatment of bone diseases. Sequences ABK22776-ABK23411 represent cDNA
molecules encoding human Zmax1 and HBM, and PCR primers, probes, linkers
and adapters of the invention
Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
SO
Query Match 0.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 324 CGGTGTCAGGTCGAGTACT 343
DB 20 CGGTATCAGGTGGATTAAT 1
RESULT 68
ACCA7310/C
ID ACC47310 standard; DNA; 20 BP.
AC ACC47310;
DT 11-AUG-2003 (first entry)
XX
DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144393.
XX
KW Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
KM antisense; ss.
XX
OS Synthetic.

Homo sapiens.
NM02003014307-A2.
20-FEB-2003.
05-AUG-2002; 2002MO-US024920.
07-AUG-2001; 2001US-00923515.
(ISIS-) ISIS PHARM INC.
Crooke RM, Graham MJ;
WPI; 2003-256565/25.
New antisense compound, useful for preparing a composition for treating
abnormal lipid or cholesterol metabolism, atherosclerosis or
cardiovascular disease.
Claim 3; Page 87; 120pp; English.
The invention relates to a new compound, 8-50 nucleobases in length
targeted to a nucleic acid molecule encoding human apolipoprotein(a),
specifically hybridizes with and inhibits the expression of human
apolipoprotein(a). The antisense compounds are useful for preparing a
composition for treating abnormal lipid or cholesterol metabolism,
atherosclerosis or cardiovascular disease. Sequences ACC47284-318
represent specific examples of chimeric antisense phosphorothioate
oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
apolipoprotein(a) mRNA
Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
SO
Query Match 0.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 411 AAGCTTAGAGGCTCTCCG 430
DB 20 AAGCTTAGAGGCTCTCTTG 1
RESULT 69
ACCA5619/C
ID ACC45619 standard; DNA; 20 BP.
AC ACC45619;
DT 02-JUN-2003 (first entry)
XX
DE Human HBM STS marker reverse primer #99.
XX
KW Human; high bone mass; HBM; LRP5; LRP6; transgenic; bone mass modulation;
KM gene therapy; bone density modulation; bone strength; trabecular number;
KW bone size; bone tissue connectivity; bone disease; osteoporosis; PCR;
KM osteomalacia; rickets; Paget's disease; neoplasm of the bone; primer; ss.
XX
OS Homo sapiens.
XX
PN NM0200292764-A2.
XX
PD 21-NOV-2002.
XX
PF 13-MAY-2002; 2002MO-US014876.
XX
PR 11-MAY-2001; 2001US-0290071P.
PR 17-MAY-2001; 2001US-0291311P.
PR 01-FEB-2002; 2002US-0353058P.
PR 04-MAR-2002; 2002US-0361293P.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
(AMHP) WYETH.

SO Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 273 CTGCAGGATCCAGATGCTG 292
DB 20 CTGAAGGATCCAGCTCTG 1

RESULT 72
ADB98317/c
ID ADB98317 standard; DNA; 20 BP.

AC ADB98317;
DT 04-DEC-2003 (first entry)

DE Sequence tagged site #198 used to prepare Zmax1 (LRP5) gene region map.

KM Osteopathic; Gene therapy; High Bone Mass; HBM; LRP5; Zmax1; LRP6;
KW bone mass modulation; osteoporosis; STS; sequence tagged site; ds.

OS Homo sapiens.

PN W0200292000-A2.

XX 21-NOV-2002.

PF 13-MAY-2002; 2002WO-US014877.

XX 11-MAY-2001; 2001US-0290071P.

PR 17-MAY-2001; 2001US-0291311P.

PR 01-FEB-2002; 2002US-0353058P.

PR 04-MAR-2002; 2002US-0361293P.

XX (GENO-) GENOME THERAPEUTICS CORP.

PA (AMHP) WYETH.

XX Allen K, Anisowicz A, Graham JR, Morales A, Yaworsky PJ, Liu W;

DR WPI; 2003-129214/12.

XX New nucleic acid comprising a mutation in LRP5 or LRP6, useful for

PT diagnosing a HBM-like phenotype in a subject and for preparing a

PT composition for modulating bone mass and/or lipid levels in a subject

PT suffering from e.g. osteoporosis.

XX Example 2; Page 62; 629pp; English.

XX The present invention relates to High Bone Mass (HBM), LRP5 (Zmax1) and

CC LRP6 mutants, which results in a HBM-like phenotype when expressed in a

CC cell. The HBM-like phenotype results in bone mass modulation and/or lipid

CC level modulation. The invention is useful for diagnosing a HBM-like

CC phenotype in a subject and for preparing a composition for modulating

CC bone mass and/or lipid levels in a subject suffering from e.g.

CC osteoporosis. The present sequence is a Sequence Tagged Site (STS)

CC marker, which was used to prepare a physical map of the Zmax1 (LRP5) gene

CC region.

SO Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.2%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.7e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 324 CGGTGTCAGTGGGAGTACT 343

DB 20 CGGTATCAGTGGGAGTACT 1

RESULT 73

ADD81170
ID ADD81170 standard; DNA; 20 BP.

AC ADD81170;

DT 29-JAN-2004 (first entry)

DE HIV PRT antisense derived probe #99.

KM ss; oligonucleotide hybridisation potential; efficient hybridisation;

KW large array; minimum oligonucleotide synthesis; probe.

XX Human immunodeficiency virus.

XX US2003054346-A1.

XX 20-MAR-2003.

PF 15-FEB-2001; 2001US-00784674.

XX 10-FEB-1998; 98US-00021701.

PA (SHAN/) SHANNON K W.

PA (WOLB/) WOLBER P K.

PA (DELE/) DELENSTARR G C.

PA (WEBB/) WEBB P G.

PA (KINCAID/) KINCAID R H.

XX Shannon KW, Wolber PK, Delenstarr GC, Webb PG, Kincaid RH;

XX WPI; 2003-743746/70.

XX Predicting potential of oligonucleotides to hybridize to target

PT nucleotide sequence comprises determining and evaluating for each

PT oligonucleotide a parameter predictive of the oligonucleotides ability to

PT hybridize with target.

XX Example 2; SEQ ID NO 243; 423pp; English.

XX The invention relates to a method of predicting the potential of

CC oligonucleotides to hybridize to target nucleotide sequences. The method

CC is useful for predicting the potential of an oligonucleotide to hybridize

CC to a target nucleotide sequence, e.g. RNA or DNA or a sequence that

CC contains chemically modified nucleotides. The method is also useful for

CC predicting the potential of the oligonucleotides to hybridize to a

CC complementary target nucleotide sequence. The method is useful to predict

CC efficient hybridisation oligonucleotides for each of multiple target

CC sequences therefore very large arrays may be constructed and tested with

CC minimum synthesis of oligonucleotides. The present sequence represents a

CC HIV PRT antisense derived probe.

SO Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.2%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.7e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 284 CAGATGCTGTGGCAGCTCT 303

DB 1 CAGATGCTGTCTCAGCTCT 20

RESULT 74

ADD81689

ID ADD81689 standard; DNA; 20 BP.

AC ADD81689;

DT 29-JAN-2004 (first entry)

DE HIV PRT antisense derived probe #618.

KW ss; oligonucleotide hybridisation potential; efficient hybridisation;

KW large array; minimum oligonucleotide synthesis; probe.
 XX
 OS Human immunodeficiency virus.
 XX US2003054346-A1.
 PN 20-MAR-2003.
 PD
 XX 15-FEB-2001; 2001US-00784674.
 PF
 XX 10-FEB-1998; 98US-00021701.
 PR
 XX (SHAN/) SHANNON K W.
 PA (WOLB/) WOLBER P K.
 PA (DELE/) DELENSTARR G C.
 PA (WEBB/) WEBB P G.
 PA (KINCA/) KINCAID R H.
 XX
 PI Shannon KW, Wolber PK, Delenstarr GC, Webb PG, Kincaid RH;
 XX WPI; 2003-743746/70.
 DR
 XX Predicting potential of oligonucleotides to hybridize to target
 PT nucleotide sequence comprising determining and evaluating for each
 PT oligonucleotide a parameter predictive of the oligonucleotides ability to
 PT hybridize with target.
 XX
 PS Example 2; SEQ ID NO 762; 423bp; English.
 XX
 CC The invention relates to a method of predicting the potential of
 CC oligonucleotides to hybridize to target nucleotide sequences. The method
 CC is useful for predicting the potential of an oligonucleotide to hybridize
 CC to a target nucleotide sequence, e.g. RNA or DNA or a sequence that
 CC contains chemically modified nucleotides. The method is also useful for
 CC predicting the potential of the oligonucleotides to hybridize to a
 CC complementary target nucleotide sequence. The method is useful to predict
 CC efficient hybridization oligonucleotides for each of multiple target
 CC sequences therefore very large arrays may be constructed and tested with
 CC minimum synthesis of oligonucleotides. The present sequence represents a
 CC HIV PRT antisense derived probe.
 XX
 SQ Sequence 20 BP; 4 A; 3 C; 1 G; 12 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.7e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 DB 65 TTCTTCTACTCTTTATT 84
 1 TTCTACTAATGCTTTATT 20
 XX
 RESULT 75
 ADJ78427/c
 ID ADJ78427 standard; DNA; 20 BP.
 XX
 AC ADJ78427;
 XX
 DT 06-MAY-2004 (first entry)
 DE
 XX Human perillipin target oligonucleotide SEQ ID NO:135.
 DE
 XX perillipin; perillipin inhibitor; antisense oligonucleotide; antidiabetic;
 KW anorectic; antiarteriosclerotic; cardiatic; metabolic disorder; diabetes;
 KW obesity; atherosclerosis; human; target; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004012745-A1.
 XX
 PD 12-FEB-2004.
 PF 30-JUL-2003; 2003WO-US023760.

XX
 PR 06-AUG-2002; 2002US-00213796.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bhanot S, Freier SM;
 XX
 DR WPI; 2004-157008/15.
 XX
 PT New compounds, particularly antisense oligonucleotides targeted to a
 PT nucleic acids encoding perillipin, useful for treating a metabolic
 PT disorder e.g. obesity, diabetes or atherosclerosis.
 XX
 PS Example 16; SEQ ID NO 135; 167bp; English.
 XX
 CC The present invention describes a compound 8-80 nucleobases in length
 CC targeted to, and which specifically hybridizes with a nucleic acid
 CC molecule encoding perillipin, and inhibits the expression of perillipin.
 CC Also described: (1) a compound 8-80 nucleobases in length that
 CC specifically hybridizes with at least an 8-nucleobase portion of an
 CC active site on a nucleic acid molecule encoding perillipin; (2) a
 CC composition comprising the compound and a carrier or diluent; (3) a
 CC method for inhibiting the expression of perillipin in cells or tissues by
 CC contacting the cells or tissues with the compound so that expression of
 CC perillipin is inhibited; (4) a method of treating an animal having a
 CC disease or condition associated with perillipin by administering to the
 CC animal a therapeutic or prophylactic amount of the compound so that
 CC expression of perillipin is inhibited; and (5) a method for screening an
 CC antisense compound by contacting a preferred target region of a nucleic
 CC acid molecule encoding perillipin with one or more candidate antisense
 CC compounds comprising at least an 8-nucleobase portion that is
 CC complementary to the preferred target region, and selecting for one or
 CC more candidate antisense compounds that inhibit the expression of a
 CC nucleic acid encoding perillipin. The antisense compounds have
 CC antidiabetic, anorectic, antiarteriosclerotic and cardiatic activities,
 CC and can be used in perillipin inhibitors. The compounds, compositions and
 CC methods of the present invention are useful for treating a disease or
 CC condition associated with perillipin, such as a metabolic disorder, e.g.
 CC diabetes, obesity or atherosclerosis. They are also useful in research
 CC and diagnostics for modulating the expression of perillipin. The present
 CC sequence represents a human perillipin target oligonucleotide, which is
 CC used in an example from the present invention.
 XX
 SQ Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.7e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 DB 155 GAGGACGCTACTCCACCACT 174
 20 GCGGACGCTAATGCACCACT 1
 XX
 RESULT 76
 ADJ78345
 ID ADJ78345 standard; DNA; 20 BP.
 XX
 AC ADJ78345;
 XX
 DT 06-MAY-2004 (first entry)
 DE
 XX Human perillipin chimeric phosphorothioate oligonucleotide SEQ ID NO:53.
 DE
 XX perillipin; perillipin inhibitor; antisense oligonucleotide; antidiabetic;
 KW anorectic; antiarteriosclerotic; cardiatic; metabolic disorder; diabetes;
 KW obesity; atherosclerosis; human; phosphorothioate; 2'-O-methoxyethyl; ss.
 XX
 OS Homo sapiens.
 XX
 PN Synthetic.
 XX
 FT Key Location/Qualifiers
 modified_base 1. .20

```
PT FT /*tag= b
PT FT /mod_base= OTHER
PT FT /note= "phosphorothioate linkages"
FT modified_base
FT 1. .5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base
FT 16. .20
FT /*tag= C
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
PN WO2004012745-A1.
XX 12-FEB-2004.
XX 30-JUL-2003; 2003WO-US023760.
XX 06-AUG-2002; 2002US-00213796.
XX (ISIS-) ISIS PHARM INC.
XX Bhanot S, Freiler SM;
XX WPI; 2004-157008/15.
XX
XX PT New compounds, particularly antisense oligonucleotides targeted to a
XX PT nucleic acids encoding perillipin, useful for treating a metabolic
XX PT disorder e.g. obesity, diabetes or atherosclerosis.
XX
XX PS Example 15; SEQ ID NO 53; 167pp; English.
XX
XX CC The present invention describes a compound 8-80 nucleobases in length
XX CC targeted to, and which specifically hybridises with a nucleic acid
XX CC molecule encoding perillipin, and inhibits the expression of perillipin.
XX CC Also described: (1) a compound 8-80 nucleobases in length that
XX CC specifically hybridises with at least an 8-nucleobase portion of an
XX CC active site on a nucleic acid molecule encoding perillipin; (2) a
XX CC composition comprising the compound and a carrier or diluent; (3) a
XX CC method for inhibiting the expression of perillipin in cells or tissues by
XX CC contacting the cells or tissues with the compound so that expression of
XX CC perillipin is inhibited; (4) a method of treating an animal having a
XX CC disease or condition associated with perillipin by administering to the
XX CC animal a therapeutic or prophylactic amount of the compound so that
XX CC expression of perillipin is inhibited; and (5) a method for screening an
XX CC antisense compound by contacting a preferred target region of a nucleic
XX CC acid molecule encoding perillipin with one or more candidate antisense
XX CC compounds comprising at least an 8-nucleobase portion that is
XX CC complementary to the preferred target region, and selecting for one or
XX CC more candidate antisense compounds that inhibit the expression of a
XX CC nucleic acid encoding perillipin. The antisense compounds have
XX CC antidiabetic, anorectic, antiarteriosclerotic and cardiant activities,
XX CC and can be used in perillipin inhibitors. The compounds, compositions and
XX CC methods of the present invention are useful for treating a disease or
XX CC condition associated with perillipin, such as a metabolic disorder, e.g.
XX CC diabetes, obesity or atherosclerosis. They are also useful in research
XX CC and diagnostics for modulating the expression of perillipin. The present
XX CC sequence represents a human perillipin chimeric phosphorothioate antisense
XX CC oligonucleotide, which is used in an example from the present invention.
XX
XX SQ Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 155 GAGGACGTAAGTCTGCACT 174
Db 1 GCGGACGTAATGCACT 20
RESULT 77
ADL17774
```

```
ID ADL17774 standard; DNA; 20 BP.
XX
XX AC ADL17774;
XX
XX DT 06-MAY-2004 (first entry)
XX
XX DE PCR primer used to amplify human MACS2 DNA Segid 11.
XX
XX KW human; PCR; ss; medium chain triglyceride acyl-CoA synthetase; MACS2;
XX KW abnormal lipid metabolism; diabetes; hypertension; obesity;
XX KW cardiac disease; primer.
XX
XX OS Homo sapiens.
XX
XX PN JP2004008030-A.
XX
XX PD 15-JAN-2004.
XX
XX PF 04-JUN-2002; 2002JP-00162967.
XX
XX PR 04-JUN-2002; 2002JP-00162967.
XX
XX PA (KOKU-) KOKURITSU JUNKANKI BYO CENT SOCHO.
XX PA (YAK-) IYAKUHIN FUKUSAYO HIGAI KYUSAI KENKYU SH.
XX
XX DR WPI; 2004-085650/09.
XX
XX XX Novel modified protein having medium chain triglyceride acyl-CoA
XX PT synthetase activity, useful as disease marker for diagnosing disease
XX PT related to abnormal lipid metabolism.
XX
XX PS Example 2; SEQ ID NO 11; 44pp; Japanese.
XX
XX CC This invention relates to a novel isolated nucleic acid molecule encoding
XX CC the medium chain triglyceride acyl-CoA synthetase (MACS2) protein.
XX CC Specifically, it refers to a primer that can be used to amplify MACS2 to
XX CC identify the presence or absence of an L513S variant and hence is useful
XX CC for the diagnosis of an associated lipid-metabolism abnormality. The
XX CC present invention further describes methods to detect diseases related to
XX CC abnormal lipid metabolism including diabetes, hypertension, obesity and
XX CC cardiac disease. Accordingly, the L513S mutation provides a useful
XX CC disease marker for the diagnosis of such diseases. This oligonucleotide
XX CC sequence is a PCR primer used to amplify human MACS2 DNA of the
XX CC invention.
XX
XX SQ Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 285 AGATGCTGTGGCAGCTCCTT 304
Db 1 ACATGCTGTGCGACGCTCCTT 20
RESULT 78
ADK74226
XX ID ADK74226 standard; DNA; 20 BP.
XX
XX AC ADK74226;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #1560.
XX
XX KW Nav1.3; Analgesic; Noctropic; Neuroprotective; post-herpetic neuralgia;
XX KW diabetic neuropathy; arthritic pain; migraine headache;
XX KW infantile epilepsy; ataxia; ss.
XX
XX OS Synthetic.
XX
XX PN WO2004016754-A2.
```

```
XX 26-FEB-2004.
PD
XX 14-AUG-2003; 2003WO-US025465.
PF
XX 14-AUG-2002; 2002US-0403416P.
PR
XX (PHAA ) PHARMACIA CORP.
PA
XX
XX Roberds SL;
PI
XX WPI; 2004-203785/19.
DR
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
XX Claim 4; SEQ ID NO 1560; 417bp; English.
PS
XX
XX The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC headache, seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX
SQ Sequence 20 BP; 6 A; 1 C; 5 G; 8 T; 0 U; 0 Other;
Query Match 0.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 302 CTTATTGTTATACGAGGAT 321
Db 1 CTTATTGATTATAGTAGGAT 20
RESULT 79
ADK75026
ID ADK75026 standard; DNA; 20 BP.
XX
XX ADK75026;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #2360.
DE
XX
XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KM infantile epilepsy; ataxia; ss.
XX
XX Synthetic.
OS
XX
XX WO2004016754-A2.
PN
XX
XX 26-FEB-2004.
PD
XX
XX 14-AUG-2003; 2003WO-US025465.
PF
XX
XX 14-AUG-2002; 2002US-0403416P.
PR
XX (PHAA ) PHARMACIA CORP.
PA
XX
XX Roberds SL;
PI
```

```
XX
XX WPI; 2004-203785/19.
DR
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
XX Claim 4; SEQ ID NO 2360; 417bp; English.
PS
XX
XX The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX
SQ Sequence 20 BP; 6 A; 2 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 0.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 304 TATTGTTATACGAGGATCC 323
Db 1 TATTGATTATAGTAGGATCC 20
RESULT 80
ADK75027
ID ADK75027 standard; DNA; 20 BP.
XX
XX ADK75027;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #2361.
DE
XX
XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KM infantile epilepsy; ataxia; ss.
XX
XX Synthetic.
OS
XX
XX WO2004016754-A2.
PN
XX
XX 26-FEB-2004.
PD
XX
XX 14-AUG-2003; 2003WO-US025465.
PF
XX
XX 14-AUG-2002; 2002US-0403416P.
PR
XX (PHAA ) PHARMACIA CORP.
PA
XX
XX Roberds SL;
PI
XX
XX WPI; 2004-203785/19.
DR
XX
XX New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
XX Claim 4; SEQ ID NO 2361; 417bp; English.
PS
```

CC The present invention relates to an antisense compound targeted to a
 CC nucleic acid molecule encoding Nav1.3, where the antisense compound
 CC specifically hybridizes with and inhibits the expression of Nav1.3. The
 CC compound and composition are useful for treating a disease or condition
 CC associated with Nav1.3, e.g. pain including but not limited to
 CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
 CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
 CC pain from burns, migraine headache, cluster headache, mild-to-moderate
 CC headache; seizure disorder such as childhood seizure disorder, including
 CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
 CC sequence represents a chimeric phosphorothioate oligonucleotide with
 CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
 CC human Nav1.3 expression, the oligonucleotides are designed to target
 CC different regions of the human Nav1.3 RNA.

XX Sequence 20 BP; 6 A; 1 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 0.2%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.7e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

0y 303 TTATTGTTATACGAGGATC 322

Db 1 TTATTGATATAGTAGGATC 20

RESULT 81

AAT37560 AAT37560 standard; mRNA; 15 BP.

XX AAT37560;

XX 11-NOV-1996 (first entry)

XX Apo(a) mRNA (nt. pos. 362) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

KM hammerhead ribozyme; target sequence; diagnosis; treatment;

KM lipoprotein (a); atherosclerosis; myocardial infarction; stroke;

KM reestenosis; heart disease; human; ss.

XX Homo sapiens.

XX MO9609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

XX 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, Mcewiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and

XX treatment of conditions related to lip(a) levels, e.g. atherosclerosis,

XX myocardial infarction, and heart diseases.

XX Claim 2; Page 18; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)

XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms

XX complementary to the present sequence (nucleotide position 362). The

XX ribozyme blocks to some extent apo(a) expression, and can therefore be

XX used to diagnose or treat conditions related to lipoprotein (a) levels,

XX e.g. atherosclerosis, myocardial infarction, stroke, reestenosis and heart

XX disease. PCR was used to generate a substrate for T7 RNA polymerase

XX transcripion from human apo(a) cDNA clones. Labelled transcripts were

XX synthesised in vitro to form 2 templates. The oligonucleotides and

XX labelled transcripts were annealed, RNaseH added and the mixes.

CC incubated. After a designated time the reactions were stopped, and RNA

CC sepd. on sequencing polyacrylamide gels. The percentage of substrate

CC cleaved was determined by autoradiographic quantification, and the most

CC accessible ribozyme target sites chosen

XX Sequence 15 BP; 5 A; 5 C; 3 G; 0 T; 2 U; 0 Other;

0y 355 CAATGCTCAGACGCA 369

Db 1 CAAUGCUCAGACGCA 15

RESULT 82 AAT37568 AAT37568 standard; mRNA; 15 BP.

XX AAT37568;

XX 11-NOV-1996 (first entry)

XX Apo(a) mRNA (nt. pos. 417) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

KM hammerhead ribozyme; target sequence; diagnosis; treatment;

KM lipoprotein (a); atherosclerosis; myocardial infarction; stroke;

KM reestenosis; heart disease; human; ss.

XX Homo sapiens.

XX MO9609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

XX 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, Mcewiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and

XX treatment of conditions related to lip(a) levels, e.g. atherosclerosis,

XX myocardial infarction, and heart diseases.

XX Claim 2; Page 18; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)

XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms

XX complementary to the present sequence (nucleotide position 417). The

XX ribozyme blocks to some extent apo(a) expression, and can therefore be

XX used to diagnose or treat conditions related to lipoprotein (a) levels,

XX e.g. atherosclerosis, myocardial infarction, stroke, reestenosis and heart

XX disease. PCR was used to generate a substrate for T7 RNA polymerase

XX transcribed in vitro to form 2 templates. The oligonucleotides and

XX labelled transcripts were annealed, RNaseH added and the mixes

XX incubated. After a designated time the reactions were stopped, and RNA

XX sepd. on sequencing polyacrylamide gels. The percentage of substrate

XX cleaved was determined by autoradiographic quantification, and the most

XX accessible ribozyme target sites chosen

XX Sequence 15 BP; 4 A; 5 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;

Best Local Similarity 86.7%; Pred. No. 86;

Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 410 CAAGCTAGAGGCTC 424
 |||||:
 DB 1 CAAGCTTAGAGGCTC 15

RESULT 83

AAT37572
 ID AAT37572 standard; mRNA, 15 BP.

AC AAT37572;

DT 11-NOV-1996 (first entry)

DE Apo(a) mRNA (nt. pos. 571) hammerhead ribozyme target sequence.

KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 hammerhead ribozyme; target sequence; diagnosis; treatment;
 lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 restenosis; heart disease; human; ss.

OS Homo sapiens.

PN WO9609392-A1.

PD 28-MAR-1996.

PF 21-SEP-1995; 95WO-US011995.

PR 23-SEP-1994; 94US-00311760.

PT (RIBO-) RIBOZYME PHARM INC.

PS Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;

DR WPI; 1996-188454/19.

PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
 myocardial infarction, and heart diseases.

PS Claim 2; Page 18; 37pp; English.

CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 complementary to the present sequence (nucleotide position 571). The
 ribozyme blocks to some extent apo(a) expression, and can therefore be
 used to diagnose or treat conditions related to lipoprotein (a) levels,
 e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 disease. PCR was used to generate a substrate for T7 RNA polymerase
 transcription from human apo(a) cDNA clones. Labelled transcripts were
 synthesised in vitro to form 2 templates. The oligonucleotides and
 labelled transcripts were annealed, RNaseH added and the mixts.
 incubated. After a designated time the reactions were stopped, and RNA
 sepd. on sequencing polyacrylamide gels. The percentage of substrate
 cleaved was determined by autoradiographic quantification, and the most
 accessible ribozyme target sites chosen

SO Sequence 15 BP; 3 A; 6 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 86;
 Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 564 GCATAGCGGACCCC 578
 |||||:
 DB 1 GCAUAGUGGAGACCC 15

AC AAT37716

DE AAT37716

KT AAT37716 standard; mRNA, 15 BP.

XX

AC AAT37716;
 XX
 DT 13-NOV-1996 (first entry)

DE Apo(a) mRNA (nt. pos. 199) hammerhead ribozyme target sequence.

KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 hammerhead ribozyme; target sequence; diagnosis; treatment;
 lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 restenosis; heart disease; monkey; ss.

OS Cebus apella.

PN WO9609392-A1.

PD 28-MAR-1996.

PF 21-SEP-1995; 95WO-US011995.

PR 23-SEP-1994; 94US-00311760.

PT (RIBO-) RIBOZYME PHARM INC.

PS Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;

DR WPI; 1996-188454/19.

PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
 myocardial infarction, and heart diseases.

PS Claim 3; Page 21; 37pp; English.

CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 complementary to the present sequence (nucleotide position 199). The
 ribozyme blocks to some extent apo(a) expression, and can therefore be
 used to diagnose or treat conditions related to lipoprotein (a) levels,
 e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 disease. PCR was used to generate a substrate for T7 RNA polymerase
 transcription from monkey apo(a) cDNA clones. Labelled transcripts were
 synthesised in vitro to form 2 templates. The oligonucleotides and
 labelled transcripts were annealed, RNaseH added and the mixts.
 incubated. After a designated time the reactions were stopped, and RNA
 sepd. on sequencing polyacrylamide gels. The percentage of substrate
 cleaved was determined by autoradiographic quantification, and the most
 accessible ribozyme target sites chosen

SO Sequence 15 BP; 2 A; 8 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 86;
 Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 401 CCCCGTTCCAGGC 415
 |||||:
 DB 1 CCCCGTCCAGGC 15

AC AAT37728

DE AAT37728

KT AAT37728 standard; mRNA, 15 BP.

XX AAT37728;

DT 13-NOV-1996 (first entry)

DE Apo(a) mRNA (nt. pos. 481) hammerhead ribozyme target sequence.

KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 hammerhead ribozyme; target sequence; diagnosis; treatment;
 lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 restenosis; heart disease; monkey; ss.

OS Cebus apella.

PN WO9609392-A1.

PD 28-MAR-1996.

PF 21-SEP-1995; 95WO-US011995.

PR 23-SEP-1994; 94US-00311760.


```

XX OS Cebus apella.
XX PN W09609392-A1.
XX PD 28-MAR-1996.
XX PF 21-SEP-1995; 95WO-US011995.
XX PR 23-SEP-1994; 94US-00311760.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Stinchcomb DT, Mcwigggen J, Newton RS, Ramharack R;
XX WPI; 1996-188454/19.
XX PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
XX myocardial infarction, and heart diseases.
XX PS Claim 3; Page 21; 37pp; English.
XX CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX complementary to the present sequence (nucleotide position 481). The
XX ribozyme blocks to some extent apo(a) expression, and can therefore be
XX used to diagnose or treat conditions related to lipoprotein (a) levels,
XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX disease. PCR was used to generate a substrate for T7 RNA polymerase
XX transcription from monkey apo(a) cDNA clones. Labelled transcripts were
XX synthesised in vitro to form 2 templates. The oligonucleotides and
XX labelled transcripts were annealed, RNaseH added and the mixts.
XX incubated. After a designated time the reactions were stopped, and RNA
XX sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX cleaved was determined by autoradiographic quantification, and the most
XX accessible ribozyme target sites chosen
XX SQ Sequence 15 BP; 4 A; 6 C; 2 G; 0 T; 3 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 86;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 421 GCTCCTCCGACCA 435
DB 1 GCUCCTUCGACCA 15

RESULT 86
AAT37772
ID AAT37772 standard; mRNA; 15 BP.
XX AAT37772;
XX 18-NOV-1996 (first entry)
XX DE Apo(a) mRNA (nt. pos. 10900) hammerhead ribozyme target sequence.
XX KM Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; monkey; ss.
XX OS Cebus apella.
XX PN W09609392-A1.
XX PD 28-MAR-1996.
XX PF 21-SEP-1995; 95WO-US011995.
XX PR 23-SEP-1994; 94US-00311760.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Stinchcomb DT, Mcwigggen J, Newton RS, Ramharack R;
XX WPI; 1996-188454/19.
XX PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
XX myocardial infarction, and heart diseases.
XX PS Claim 3; Page 21; 37pp; English.
XX CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX complementary to the present sequence (nucleotide position 481). The
XX ribozyme blocks to some extent apo(a) expression, and can therefore be
XX used to diagnose or treat conditions related to lipoprotein (a) levels,
XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX disease. PCR was used to generate a substrate for T7 RNA polymerase
XX transcription from monkey apo(a) cDNA clones. Labelled transcripts were
XX synthesised in vitro to form 2 templates. The oligonucleotides and
XX labelled transcripts were annealed, RNaseH added and the mixts.
XX incubated. After a designated time the reactions were stopped, and RNA
XX sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX cleaved was determined by autoradiographic quantification, and the most
XX accessible ribozyme target sites chosen
XX SQ Sequence 15 BP; 4 A; 6 C; 2 G; 0 T; 3 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 86;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 421 GCTCCTCCGACCA 435
DB 1 GCUCCTUCGACCA 15

```

```

XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Stinchcomb DT, Mcwigggen J, Newton RS, Ramharack R;
XX WPI; 1996-188454/19.
XX PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
XX myocardial infarction, and heart diseases.
XX PS Claim 3; Page 21; 37pp; English.
XX CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX complementary to the present sequence (nucleotide position 10900). The
XX ribozyme blocks to some extent apo(a) expression, and can therefore be
XX used to diagnose or treat conditions related to lipoprotein (a) levels,
XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX disease. PCR was used to generate a substrate for T7 RNA polymerase
XX transcription from monkey apo(a) cDNA clones. Labelled transcripts were
XX synthesised in vitro to form 2 templates. The oligonucleotides and
XX labelled transcripts were annealed, RNaseH added and the mixts.
XX incubated. After a designated time the reactions were stopped, and RNA
XX sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX cleaved was determined by autoradiographic quantification, and the most
XX accessible ribozyme target sites chosen
XX SQ Sequence 15 BP; 3 A; 6 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 86;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 564 GCATAGTCGACCCC 578
DB 1 GCANAGUCGACCCC 15

RESULT 87
AAT37756
ID AAT37756 standard; mRNA; 15 BP.
XX AAT37756;
XX 18-NOV-1996 (first entry)
XX DE Apo(a) mRNA (nt. pos. 10677) hammerhead ribozyme target sequence.
XX KM Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; monkey; ss.
XX OS Cebus apella.
XX PN W09609392-A1.
XX PD 28-MAR-1996.
XX PF 21-SEP-1995; 95WO-US011995.
XX PR 23-SEP-1994; 94US-00311760.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Stinchcomb DT, Mcwigggen J, Newton RS, Ramharack R;
XX WPI; 1996-188454/19.
XX PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
XX myocardial infarction, and heart diseases.
XX PS Claim 3; Page 21; 37pp; English.
XX CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX complementary to the present sequence (nucleotide position 10900). The
XX ribozyme blocks to some extent apo(a) expression, and can therefore be
XX used to diagnose or treat conditions related to lipoprotein (a) levels,
XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX disease. PCR was used to generate a substrate for T7 RNA polymerase
XX transcription from monkey apo(a) cDNA clones. Labelled transcripts were
XX synthesised in vitro to form 2 templates. The oligonucleotides and
XX labelled transcripts were annealed, RNaseH added and the mixts.
XX incubated. After a designated time the reactions were stopped, and RNA
XX sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX cleaved was determined by autoradiographic quantification, and the most
XX accessible ribozyme target sites chosen
XX SQ Sequence 15 BP; 3 A; 6 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 86;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 564 GCATAGTCGACCCC 578
DB 1 GCANAGUCGACCCC 15

```

XX Claim 3; Page 21; 37pp; English.
PS
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 10677). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase
CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed. RNaseH added and the mixts.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen
SQ Sequence 15 BP; 4 A; 7 C; 2 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 86;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 499 GGCACCTACTCCACC 513
|||||:|||||
DB 1 GGCACCAUACCCACC 15

RESULT 88
AAT37564
ID AAT37564 standard; mRNA; 15 BP.
XX
XX AAT37564;
DT 11-NOV-1996 (first entry)
DE Apo(a) mRNA (nt. pos. 408) hammerhead ribozyme target sequence.
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW restenosis; heart disease; human; ss.
XX
XX Homo sapiens.
OS
XX WO9609392-A1.
XX
XX 28-MAR-1996.
PD
XX
XX 21-SEP-1995; 95WO-US011995.
PP
XX 23-SEP-1994; 94US-00311760.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Stinchcomb DT, Mcswigen J, Newton RS, Ramharack R;
PI WPI; 1996-188454/19.
DR
XX
XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to lp(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.
PT
XX
XX Claim 2; Page 18; 37pp; English.
PS
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 408). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase

CC transcription from human apo(a) cDNA clones. Labelled transcripts were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed. RNaseH added and the mixts.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen
SQ Sequence 15 BP; 2 A; 8 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 86;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 401 CCCCGGTTCCAGCC 415
|||||:|||||
DB 1 CCCCGGTTCCAGCC 15

RESULT 89
AAT37726
ID AAT37726 standard; mRNA; 15 BP.
XX
XX AAT37726;
DT 13-NOV-1996 (first entry)
DE Apo(a) mRNA (nt. pos. 417) hammerhead ribozyme target sequence.
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW restenosis; heart disease; monkey; ss.
XX
XX Cebus apella.
OS
XX WO9609392-A1.
XX
XX 28-MAR-1996.
PD
XX
XX 21-SEP-1995; 95WO-US011995.
PP
XX 23-SEP-1994; 94US-00311760.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Stinchcomb DT, Mcswigen J, Newton RS, Ramharack R;
PI WPI; 1996-188454/19.
DR
XX
XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to lp(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.
PT
XX
XX Claim 3; Page 21; 37pp; English.
PS
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 417). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed. RNaseH added and the mixts.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen
SQ Sequence 15 BP; 3 A; 6 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 86;
 Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 420 GGCTCTTCGACCA 434
 |||:|||||
 1 GGCTCTTCGACCA 15

RESULT 90

AAT37753
 ID AAT37753 standard; mRNA; 15 BP.

AC AAT37753;

DT 18-NOV-1996 (first entry)

XX Apo(a) mRNA (nt. pos. 12236) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

KM hammerhead ribozyme; target sequence; diagnosis; treatment;

KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;

XX reestenosis; heart disease; monkey; ss.

XX Cebus apella.

XX WO9609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

XX 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and

PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,

XX myocardial infarction, and heart diseases.

XX Claim 3; Page 21; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)

CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms

CC complementary to the present sequence (nucleotide position 12236). The

CC ribozyme blocks to some extent apo(a) expression, and can therefore be

CC used to diagnose or treat conditions related to lipoprotein (a) levels,

CC e.g. atherosclerosis, myocardial infarction, stroke, reestenosis and heart

CC disease. PCR was used to generate a substrate for T7 RNA polymerase

CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were

CC synthesised in vitro to form 2 templates. The oligonucleotides and

CC labelled transcripts were annealed, RNaseH added and the mixts.

CC incubated. After a designated time the reactions were stopped, and RNA

CC sepd. on sequencing polyacrylamide gels. The percentage of substrate

CC cleaved was determined by autoradiographic quantification, and the most

XX accessible ribozyme target sites chosen

SO Sequence 15 BP; 4 A; 5 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;

Best Local Similarity 80.0%; Pred. No. 86;

Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 120 CCAGATTGCTACCA 134
 |||:|||||

Db 1 CCAGATTGCTACCA 15

RESULT 91

AAT37776
 ID AAT37776 standard; mRNA; 15 BP.

AC AAT37776;

DT 18-NOV-1996 (first entry)

XX Apo(a) mRNA (nt. pos. 10924) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

KM hammerhead ribozyme; target sequence; diagnosis; treatment;

KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;

XX reestenosis; heart disease; monkey; ss.

XX Cebus apella.

XX WO9609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

XX 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and

PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,

XX myocardial infarction, and heart diseases.

XX Claim 3; Page 21; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)

CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms

CC complementary to the present sequence (nucleotide position 10924). The

CC ribozyme blocks to some extent apo(a) expression, and can therefore be

CC used to diagnose or treat conditions related to lipoprotein (a) levels,

CC e.g. atherosclerosis, myocardial infarction, stroke, reestenosis and heart

CC disease. PCR was used to generate a substrate for T7 RNA polymerase

CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were

CC synthesised in vitro to form 2 templates. The oligonucleotides and

CC labelled transcripts were annealed, RNaseH added and the mixts.

CC incubated. After a designated time the reactions were stopped, and RNA

CC sepd. on sequencing polyacrylamide gels. The percentage of substrate

CC cleaved was determined by autoradiographic quantification, and the most

XX accessible ribozyme target sites chosen

SO Sequence 15 BP; 5 A; 4 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;

Best Local Similarity 86.7%; Pred. No. 86;

Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 276 CAGGATCCAGATCC 290
 |||:|||||

Db 1 CAGGATCCAGATCC 15

RESULT 92

AAT37778
 ID AAT37778 standard; mRNA; 15 BP.

AC AAT37778;

DT 18-NOV-1996 (first entry)

XX Apo(a) mRNA (nt. pos. 10976) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

KW hammerhead ribozyme; target sequence; diagnosis; treatment;
 KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 KW restenosis; heart disease; monkey; ss.
 OS
 XX Cebus apella.
 XX
 XX WO9609392-A1.
 XX
 XX PD 28-MAR-1996.
 XX
 XX PF 21-SEP-1995; 95WO-US011995.
 XX
 XX PR 23-SEP-1994; 94US-00311760.
 XX
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX PI Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
 XX WPI; 1996-188454/19.
 XX
 XX PT Enzymatic RNA mol.s. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.
 XX
 XX PS Claim 3; Page 21; 37pp; English.
 XX
 CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 10976). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen
 XX
 SO Sequence 15 BP; 5 A; 4 C; 4 G; 0 T; 2 U; 0 Other;
 Query Match 0.2%; Score 15; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 86;
 Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 276 CAGGAATCCAGATGC 290
 DB 1 CAGGAATCCAGATGC 15
 RESULT 93
 AAT37782
 ID AAT37782 standard; mRNA; 15 BP.
 XX
 XX AC AAT37782;
 XX
 XX DT 18-NOV-1996 (first entry)
 XX
 XX DE Apo(a) mRNA (nt. pos. 10986) hammerhead ribozyme target sequence.
 XX
 KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 KW hammerhead ribozyme; target sequence; diagnosis; treatment;
 KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 KW restenosis; heart disease; monkey; ss.
 OS
 XX Cebus apella.
 XX
 XX WO9609392-A1.
 XX
 XX PD 28-MAR-1996.

PF 21-SEP-1995; 95WO-US011995.
 XX
 XX PR 23-SEP-1994; 94US-00311760.
 XX
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX PI Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
 XX WPI; 1996-188454/19.
 XX
 XX PT Enzymatic RNA mol.s. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.
 XX
 XX PS Claim 3; Page 21; 37pp; English.
 XX
 CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 10986). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen
 XX
 SO Sequence 15 BP; 5 A; 4 C; 4 G; 0 T; 2 U; 0 Other;
 Query Match 0.2%; Score 15; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 86;
 Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 276 CAGGAATCCAGATGC 290
 DB 1 CAGGAATCCAGATGC 15
 RESULT 94
 AAT37784
 ID AAT37784 standard; mRNA; 15 BP.
 XX
 XX AC AAT37784;
 XX
 XX DT 18-NOV-1996 (first entry)
 XX
 XX DE Apo(a) mRNA (nt. pos. 11011) hammerhead ribozyme target sequence.
 XX
 KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 KW hammerhead ribozyme; target sequence; diagnosis; treatment;
 KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 KW restenosis; heart disease; monkey; ss.
 OS
 XX Cebus apella.
 XX
 XX WO9609392-A1.
 XX
 XX PD 28-MAR-1996.
 XX
 XX PF 21-SEP-1995; 95WO-US011995.
 XX
 XX PR 23-SEP-1994; 94US-00311760.
 XX
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX PI Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
 XX WPI; 1996-188454/19.

PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.
 XX
 PS Claim 3; Page 21; 37pp; English.
 CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 11011). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, reestenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen
 CC
 SQ Sequence 15 BP; 5 A; 4 C; 4 G; 0 T; 2 U; 0 Other;
 Query Match 0.2%; Score 15; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 86;
 Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 276 CAGGAATCCAGATGC 290
 1 CAGGAATCCAGATGC 15
 DB
 RESULT 95
 AAT37720
 ID AAT37720 standard; mRNA; 15 BP.
 XX
 AC AAT37720;
 XX
 DT 13-NOV-1996 (first entry)
 XX
 DE Apo(a) mRNA (nt. pos. 400) hammerhead ribozyme target sequence.
 XX
 KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 KW hammerhead ribozyme; target sequence; diagnosis; treatment;
 KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 KW reestenosis; heart disease; monkey; ss.
 XX
 OS Cebus apella.
 XX
 PN WO9609392-A1.
 XX
 PD 28-MAR-1996.
 XX
 PF 21-SEP-1995; 95WO-US011995.
 XX
 PR 23-SEP-1994; 94US-00311760.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Stinchcomb DT, Mcawiggen J, Newton RS, Ramharack R;
 XX
 DR WPI; 1996-188454/19.
 XX
 PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.
 XX
 PS Claim 3; Page 21; 37pp; English.
 CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 400). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be

CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, reestenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen
 CC
 SQ Sequence 15 BP; 3 A; 6 C; 3 G; 0 T; 3 U; 0 Other;
 Query Match 0.2%; Score 15; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 86;
 Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 420 GGCCTCTTCGACACA 434
 1 GGCCTCTTCGACACA 15
 DB
 RESULT 96
 AAT37768
 ID AAT37768 standard; mRNA; 15 BP.
 XX
 AC AAT37768;
 XX
 DT 18-NOV-1996 (first entry)
 XX
 DE Apo(a) mRNA (nt. pos. 10828) hammerhead ribozyme target sequence.
 XX
 KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 KW hammerhead ribozyme; target sequence; diagnosis; treatment;
 KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 KW reestenosis; heart disease; monkey; ss.
 XX
 OS Cebus apella.
 XX
 PN WO9609392-A1.
 XX
 PD 28-MAR-1996.
 XX
 PF 21-SEP-1995; 95WO-US011995.
 XX
 PR 23-SEP-1994; 94US-00311760.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Stinchcomb DT, Mcawiggen J, Newton RS, Ramharack R;
 XX
 DR WPI; 1996-188454/19.
 XX
 PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.
 XX
 PS Claim 3; Page 21; 37pp; English.
 CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 10828). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, reestenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen

XX Sequence 15 BP; 3 A; 6 C; 4 G; 0 T; 2 U; 0 Other;
SQ

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 86;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 564 GCATAGTCGACCCC 578
DB 1 GCAUAGUCGACCCC 15

RESULT 97

ID AAT37558 standard; mRNA; 15 BP.
XX
AC AAT37558;

DT 11-NOV-1996 (first entry)

DE Apo(a) mRNA (nt. pos. 199) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KM lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW restenosis; heart disease; human; ss.

OS Homo sapiens.

XX WO9609392-A1.

PD 28-MAR-1996.

PF 21-SEP-1995; 95WO-US011995.

PR 23-SEP-1994; 94US-00311760.

PA (RIBO-) RIBOZYME PHARM INC.

PI Stinchcomb DT, Mcswigen J, Newton RS, Ramharack R;

DR WPI; 1996-188454/19.

PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.

PS Claim 2; Page 18; 37pp; English.

CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 199). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase
CC transcription from human apo(a) cDNA clones. Labelled transcripts were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed, RNaseH added and the mixts.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen

SQ Sequence 15 BP; 3 A; 5 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;

Best Local Similarity 73.3%; Pred. No. 86;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 192 CCAAGCTTGCTCATC 206

DB 1 CCAAGCTTGCTCATC 15

RESULT 98

ID AAT37718 standard; mRNA; 15 BP.
XX
AC AAT37718;

DT 13-NOV-1996 (first entry)

DE Apo(a) mRNA (nt. pos. 362) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KM lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW restenosis; heart disease; monkey; ss.

OS Cebus apella.

XX WO9609392-A1.

PD 28-MAR-1996.

PF 21-SEP-1995; 95WO-US011995.

PR 23-SEP-1994; 94US-00311760.

PA (RIBO-) RIBOZYME PHARM INC.

PI Stinchcomb DT, Mcswigen J, Newton RS, Ramharack R;

DR WPI; 1996-188454/19.

PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.

PS Claim 3; Page 21; 37pp; English.

CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 362). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase
CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed, RNaseH added and the mixts.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen

SQ Sequence 15 BP; 3 A; 5 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;

Best Local Similarity 80.0%; Pred. No. 86;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 417 AGAGGCTCCTCCGA 431

DB 1 AGAGGCTCCTCCGA 15

RESULT 99

ID AAT37724 standard; mRNA; 15 BP.
XX
AC AAT37724;

DT 13-NOV-1996 (first entry)

```

DE Apo(a) mRNA (nt. pos. 409) hammerhead ribozyme target sequence.
XX
XX Enzymatic RNA molecule; cleavage: apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; monkey; ss.
XX
OS Cebus apella.
XX
XX WO9609392-A1.
XX
XX PD 28-MAR-1996.
XX
XX PF 21-SEP-1995; 95WO-US011995.
XX
XX PR 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Stinchcomb DT, Mcawiggen J, Newton RS, Ramharack R;
XX WPI; 1996-188454/19.
XX
XX DR WPI; 1996-188454/19.
XX
XX PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
XX myocardial infarction, and heart diseases.
XX
XX PS Claim 3; Page 21; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX complementary to the present sequence (nucleotide position 409). The
XX ribozyme blocks to some extent apo(a) expression, and can therefore be
XX used to diagnose or treat conditions related to lipoprotein (a) levels,
XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX disease. PCR was used to generate a substrate for T7 RNA polymerase
XX transcription from monkey apo(a) cDNA clones. Labelled transcripts were
XX synthesised in vitro to form 2 templates. The oligonucleotides and
XX labelled transcripts were annealed, RNaseH added and the mixts.
XX incubated. After a designated time the reactions were stopped, and RNA
XX sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX cleaved was determined by autoradiographic quantification, and the most
XX accessible ribozyme target sites chosen
XX
SQ Sequence 15 BP; 3 A; 6 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 86;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 420 GCGTCCCTTCGACACA 434
DB 1 GGCUCUCCGACACA 15

RESULT 100
AAT37770
ID AAT37770 standard; mRNA; 15 BP.
XX
XX AAT37770;
XX
XX DT 18-NOV-1996 (first entry)
XX
XX DE Apo(a) mRNA (nt. pos. 10899) hammerhead ribozyme target sequence.
XX
XX Enzymatic RNA molecule; cleavage: apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; monkey; ss.
XX
XX OS Cebus apella.
XX
XX OS WO9609392-A1.
XX
XX PN WO9609392-A1.

```

```

XX PD 28-MAR-1996.
XX
XX PF 21-SEP-1995; 95WO-US011995.
XX
XX PR 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Stinchcomb DT, Mcawiggen J, Newton RS, Ramharack R;
XX WPI; 1996-188454/19.
XX
XX DR WPI; 1996-188454/19.
XX
XX PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
XX myocardial infarction, and heart diseases.
XX
XX PS Claim 3; Page 21; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX complementary to the present sequence (nucleotide position 10899). The
XX ribozyme blocks to some extent apo(a) expression, and can therefore be
XX used to diagnose or treat conditions related to lipoprotein (a) levels,
XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX disease. PCR was used to generate a substrate for T7 RNA polymerase
XX transcription from monkey apo(a) cDNA clones. Labelled transcripts were
XX synthesised in vitro to form 2 templates. The oligonucleotides and
XX labelled transcripts were annealed, RNaseH added and the mixts.
XX incubated. After a designated time the reactions were stopped, and RNA
XX sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX cleaved was determined by autoradiographic quantification, and the most
XX accessible ribozyme target sites chosen
XX
SQ Sequence 15 BP; 3 A; 6 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 86;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 564 GCATAGTCGACCC 578
DB 1 GCAUAGUCGACCCC 15

RESULT 101
AAT37554
ID AAT37554 standard; mRNA; 15 BP.
XX
XX AAT37554;
XX
XX DT 11-NOV-1996 (first entry)
XX
XX DE Apo(a) mRNA (nt. pos. 1511) hammerhead ribozyme target sequence.
XX
XX Enzymatic RNA molecule; cleavage: apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; human; ss.
XX
XX OS Homo sapiens.
XX
XX OS WO9609392-A1.
XX
XX PN WO9609392-A1.
XX
XX PD 28-MAR-1996.
XX
XX PF 21-SEP-1995; 95WO-US011995.
XX
XX PR 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Stinchcomb DT, Mcawiggen J, Newton RS, Ramharack R;

```

```
XX DR WPI; 1996-188454/19.
XX
XX Enzymatic RNA mol. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.
XX
XX Claim 2; Page 18; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 151). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase
CC transcribed in vitro to form 2 templates. The oligonucleotides were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed, RNaseH added and the mixts.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen
XX
SQ Sequence 15 BP; 5 A; 2 C; 5 G; 0 T; 3 U; 0 Other;

Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 86;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 144 ACAGAGTTCGAGG 158
Db 1 ACAGAGUUAUCGAGG 15

RESULT 102
AAT37780
ID AAT37780 standard; mRNA; 15 BP.
XX
XX AAT37780;
XX
XX 18-NOV-1996 (first entry)
XX
XX Apo(a) mRNA (nt. pos. 10983) hammerhead ribozyme target sequence.
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; monkey; ss.
XX
XX Cebus apella.
XX
XX OS
XX WO9609392-A1.
XX
XX 28-MAR-1996.
XX
XX 21-SEP-1995; 95MO-US011995.
XX
XX 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
XX WPI; 1996-188454/19.
XX
XX Enzymatic RNA mol. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.
XX
XX Claim 3; Page 21; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
```

```
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 10983). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase
CC transcribed in vitro to form 2 templates. The oligonucleotides were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed, RNaseH added and the mixts.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen
XX
SQ Sequence 15 BP; 5 A; 4 C; 4 G; 0 T; 2 U; 0 Other;

Query Match      0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 86;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 276 CAGGAATCCAGATGC 290
Db 1 CAGGAUCCGAGUCC 15

RESULT 103
AAT37732
ID AAT37732 standard; mRNA; 15 BP.
XX
XX AAT37732;
XX
XX 13-NOV-1996 (first entry)
XX
XX Apo(a) mRNA (nt. pos. 9031) hammerhead ribozyme target sequence.
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; monkey; ss.
XX
XX Cebus apella.
XX
XX OS
XX WO9609392-A1.
XX
XX 28-MAR-1996.
XX
XX 21-SEP-1995; 95MO-US011995.
XX
XX 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
XX WPI; 1996-188454/19.
XX
XX Enzymatic RNA mol. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.
XX
XX Claim 3; Page 21; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 9031). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase
CC transcribed in vitro to form 2 templates. The oligonucleotides were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed, RNaseH added and the mixts.
CC incubated. After a designated time the reactions were stopped, and RNA
```


CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen

SO Sequence 15 BP; 4 A; 3 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;

Best Local Similarity 80.0%; Pred. No. 86;
 Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 147 GAGTATCGAGGCAC 161

Db 1 GAGTATCGAGGCAC 15

RESULT 104
 AAT37552
 ID AAT37552 standard; mRNA; 15 BP.

XX AAT37552;

DT 11-NOV-1996 (first entry)

XX Apo(a) mRNA (nt. pos. 127) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

KM hammerhead ribozyme; target sequence; diagnosis; treatment;

KM lipoprotein (a); atherosclerosis; myocardial infarction; stroke;

KM restenosis; heart disease; human; ss.

XX Homo sapiens.

XX MO9609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

XX 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, Mcawiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and

XX treatment of conditions related to lip(a) levels, e.g. atherosclerosis,

XX myocardial infarction, and heart diseases.

XX Claim 2; Page 18; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)

XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms

XX complementary to the present sequence (nucleotide position 127). The

XX ribozyme blocks to some extent apo(a) expression, and can therefore be

XX used to diagnose or treat conditions related to lipoprotein (a) levels,

XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart

XX disease. PCR was used to generate a substrate for T7 RNA polymerase

XX transcription from human apo(a) cDNA clones. Labelled transcripts were

XX synthesised in vitro to form 2 templates. The oligonucleotides and

XX labelled transcripts were annealed, RNaseH added and the mixts.

XX incubated. After a designated time the reactions were stopped, and RNA

XX sepd. on sequencing polyacrylamide gels. The percentage of substrate

XX cleaved was determined by autoradiographic quantification, and the most

XX accessible ribozyme target sites chosen

XX Sequence 15 BP; 4 A; 5 C; 3 G; 0 T; 3 U; 0 Other;

XX Query Match 0.2%; Score 15; DB 1; Length 15;

XX Best Local Similarity 80.0%; Pred. No. 86;

XX Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 120 CCAGATTGCTACCA 134

Db 1 CCAGATTGCTACCA 15

RESULT 105
 AAT37562
 ID AAT37562 standard; mRNA; 15 BP.

XX AAT37562;

DT 11-NOV-1996 (first entry)

XX Apo(a) mRNA (nt. pos. 400) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

KM hammerhead ribozyme; target sequence; diagnosis; treatment;

KM lipoprotein (a); atherosclerosis; myocardial infarction; stroke;

KM restenosis; heart disease; human; ss.

XX Homo sapiens.

XX MO9609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

XX 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, Mcawiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and

XX treatment of conditions related to lip(a) levels, e.g. atherosclerosis,

XX myocardial infarction, and heart diseases.

XX Claim 2; Page 18; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)

XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms

XX complementary to the present sequence (nucleotide position 400). The

XX ribozyme blocks to some extent apo(a) expression, and can therefore be

XX used to diagnose or treat conditions related to lipoprotein (a) levels,

XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart

XX disease. PCR was used to generate a substrate for T7 RNA polymerase

XX transcription from human apo(a) cDNA clones. Labelled transcripts were

XX synthesised in vitro to form 2 templates. The oligonucleotides and

XX labelled transcripts were annealed, RNaseH added and the mixts.

XX incubated. After a designated time the reactions were stopped, and RNA

XX sepd. on sequencing polyacrylamide gels. The percentage of substrate

XX cleaved was determined by autoradiographic quantification, and the most

XX accessible ribozyme target sites chosen

XX Sequence 15 BP; 2 A; 5 C; 4 G; 0 T; 4 U; 0 Other;

XX Query Match 0.2%; Score 15; DB 1; Length 15;

XX Best Local Similarity 73.3%; Pred. No. 86;

XX Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

XX OY 393 GACTGTTACCCCGCT 407

XX Db 1 GACTGTTACCCCGCT 15

XX RESULT 106

XX AAT37722

XX ID AAT37722 standard; mRNA; 15 BP.

XX AAT37722;

```

XX 13-NOV-1996 (first entry)
XX
XX Apo(a) mRNA (nt. pos. 408) hammerhead ribozyme target sequence.
DE
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; monkey; ss.
XX
OS Cebus apella.
XX
XX MO9609392-A1.
XX
XX 28-MAR-1996.
XX
XX 21-SEP-1995; 95WO-US011995.
XX
XX 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Mcswigen J, Newton RS, Ramharack R;
XX WPI; 1996-188454/19.
XX
XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
XX myocardial infarction, and heart diseases.
XX
XX Claim 3; Page 21; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX (apo(a)) mRNA. Specifically a hammerhead ribozyme, has binding arms
XX complementary to the present sequence (nucleotide position 408). The
XX ribozyme blocks to some extent apo(a) expression, and can therefore be
XX used to diagnose or treat conditions related to lipoprotein (a) levels,
XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX disease. PCR was used to generate a substrate for T7 RNA polymerase
XX transcription from monkey apo(a) cDNA clones. Labelled transcripts were
XX synthesised in vitro to form 2 templates. The oligonucleotides and
XX labelled transcripts were annealed, RNaseH added and the mixts.
XX incubated. After a designated time the reactions were stopped, and RNA
XX sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX cleaved was determined by autoradiographic quantification, and the most
XX accessible ribozyme target sites chosen
XX
XX Sequence 15 BP; 3 A; 6 C; 3 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 0.2%; Score 15; DB 1; Length 15;
XX Best Local Similarity 80.0%; Pred. No. 86;
XX Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 420 GGCCTCTTCGACACA 434
XX |||||:|||||
XX 1 GGCUCUCUCCGACACA 15
XX
XX RESULT 107
XX AAT37730
XX ID AAT37730 standard; mRNA; 15 BP.
XX
XX AC AAT37730;
XX
XX 13-NOV-1996 (first entry)
XX
XX Apo(a) mRNA (nt. pos. 571) hammerhead ribozyme target sequence.
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; monkey; ss.
XX

```

```

OS Cebus apella.
XX
XX MO9609392-A1.
XX
XX 28-MAR-1996.
XX
XX 21-SEP-1995; 95WO-US011995.
XX
XX 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Mcswigen J, Newton RS, Ramharack R;
XX WPI; 1996-188454/19.
XX
XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
XX myocardial infarction, and heart diseases.
XX
XX Claim 3; Page 21; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX (apo(a)) mRNA. Specifically a hammerhead ribozyme, has binding arms
XX complementary to the present sequence (nucleotide position 571). The
XX ribozyme blocks to some extent apo(a) expression, and can therefore be
XX used to diagnose or treat conditions related to lipoprotein (a) levels,
XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX disease. PCR was used to generate a substrate for T7 RNA polymerase
XX transcription from monkey apo(a) cDNA clones. Labelled transcripts were
XX synthesised in vitro to form 2 templates. The oligonucleotides and
XX labelled transcripts were annealed, RNaseH added and the mixts.
XX incubated. After a designated time the reactions were stopped, and RNA
XX sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX cleaved was determined by autoradiographic quantification, and the most
XX accessible ribozyme target sites chosen
XX
XX Sequence 15 BP; 5 A; 2 C; 5 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 0.2%; Score 15; DB 1; Length 15;
XX Best Local Similarity 80.0%; Pred. No. 86;
XX Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 144 ACAGAGTTATCGAGG 158
XX |||||:|||||
XX 1 ACAGAGUUAUCGAGC 15
XX
XX RESULT 108
XX AAT37556
XX ID AAT37556 standard; mRNA; 15 BP.
XX
XX AC AAT37556;
XX
XX 11-NOV-1996 (first entry)
XX
XX Apo(a) mRNA (nt. pos. 154) hammerhead ribozyme target sequence.
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; human; ss.
XX
XX Homo sapiens.
XX
XX MO9609392-A1.
XX
XX 28-MAR-1996.
XX
XX 21-SEP-1995; 95WO-US011995.
XX
XX 23-SEP-1994; 94US-00311760.
XX

```

PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
 XX WPI; 1996-188454/19.
 XX
 PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.
 PS
 PS Claim 2; Page 18; 37pp; English.
 XX
 CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 154). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from human apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen
 CC
 SQ Sequence 15 BP; 4 A; 3 C; 5 G; 0 T; 3 U; 0 Other;
 Query Match 0.2%; Score 15; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 86;
 Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 147 GAGTTATCGAGCCAC 161
 |||::|||
 1 GAGTUAUCGAGGCAC 15
 DB
 RESULT 109
 AAT37566
 ID AAT37566 standard; mRNA; 15 BP.
 XX
 AC AAT37566;
 XX
 DT 11-NOV-1996 (first entry)
 XX
 DE Apo(a) mRNA (nt. pos. 409) hammerhead ribozyme target sequence.
 XX
 KM Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 KM hammerhead ribozyme; target sequence; diagnosis; treatment;
 KM lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 KM restenosis; heart disease; human; ss.
 XX
 OS Homo sapiens.
 OS
 PN W09609392-A1.
 PD 28-MAR-1996.
 XX
 PF 21-SEP-1995; 95WO-US011995.
 XX
 PR 23-SEP-1994; 94US-00311760.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
 XX WPI; 1996-188454/19.
 XX
 PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.
 XX

PS Claim 2; Page 18; 37pp; English.
 XX
 CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 409). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from human apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen
 CC
 SQ Sequence 15 BP; 2 A; 7 C; 3 G; 0 T; 3 U; 0 Other;
 Query Match 0.2%; Score 15; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 86;
 Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 402 CCCGATTCCAGCCT 416
 |||::|||
 1 CCCGATCCAGGCCU 15
 DB
 RESULT 110
 AAT37751
 ID AAT37751 standard; mRNA; 15 BP.
 XX
 AC AAT37751;
 XX
 DT 18-NOV-1996 (first entry)
 XX
 DE Apo(a) mRNA (nt. pos. 12235) hammerhead ribozyme target sequence.
 XX
 KM Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 KM hammerhead ribozyme; target sequence; diagnosis; treatment;
 KM lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 KM restenosis; heart disease; monkey; ss.
 XX
 OS Cebus apella.
 OS
 PN W09609392-A1.
 PD 28-MAR-1996.
 XX
 PF 21-SEP-1995; 95WO-US011995.
 XX
 PR 23-SEP-1994; 94US-00311760.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
 XX WPI; 1996-188454/19.
 XX
 PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.
 PS
 PS Claim 3; Page 21; 37pp; English.
 XX
 CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 12235). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were

CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed. RNaseH added and the mixes.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen
XX

SQ Sequence 15 BP; 4 A; 5 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 86;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 120 CCAGGATTGCTACCA 134
|||:|:|:|:|:|
DB 1 CCAGGATUGCUACCA 15

RESULT 111

AAAT37570
ID AAAT37570 standard; mRNA; 15 BP.

AC AAAT37570;

DT 11-NOV-1996 (first entry)

XX Apo(a) mRNA (nt. pos. 481) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

XX hammerhead ribozyme; target sequence; diagnosis; treatment;

XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;

XX restenosis; heart disease; human; ss.

OS Homo sapiens.

XX WO9609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

XX 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

XX StIncomb DT, Mcswiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and

XX treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,

XX myocardial infarction, and heart diseases.

XX Claim 2; Page 18; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)

XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms

XX complementary to the present sequence (nucleotide position 481). The

XX ribozyme blocks to some extent apo(a) expression, and can therefore be

XX used to diagnose or treat conditions related to lipoprotein (a) levels,

XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart

XX disease. PCR was used to generate a substrate for T7 RNA polymerase

XX transcribed in vitro to form 2 templates. The oligonucleotides and

XX labelled transcripts were annealed, RNaseH added and the mixes.

XX incubated. After a designated time the reactions were stopped, and RNA

XX sepd. on sequencing polyacrylamide gels. The percentage of substrate

XX cleaved was determined by autoradiographic quantification, and the most

XX accessible ribozyme target sites chosen

Best Local Similarity 80.0%; Pred. No. 86;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 474 CCATGTAATGACA 488
|||:|:|:|:|:|
DB 1 CCAUGGUAUGACCA 15

RESULT 112

AAV15098/c
ID AAV15098 standard; DNA; 15 BP.

AC AAV15098;

DT 20-MAY-1998 (first entry)

XX Human apolipoprotein(a) gene probe.

XX Human; apolipoprotein(a) gene 5'-regulatory region; expression;

XX screening; regulation; genetic engineering; gene therapy;

XX atherosclerosis; probe; ss.

XX Synthetic.

XX Homo sapiens.

XX US5721138-A.

XX 24-FEB-1998.

XX 15-MAY-1995; 95US-00441370.

XX 15-DEC-1992; 92US-00991849.

XX (STRD) UNIV STANFORD.

XX Lawn RM;

XX WPI; 1998-168413/15.

XX Human apolipoprotein (a) gene promoter - useful in genetic engineering

XX and gene therapy and in the treatment of atherosclerosis.

XX Disclosure; Col 8; 16pp; English.

XX The present sequence represents a probe for human apolipoprotein (a). The

XX present invention also describes: (1) a vector containing human

XX apolipoprotein(a) gene 5'-regulatory region DNA; (2) an isolated

XX nucleotide sequence comprising at least 30 consecutive nucleotides of

XX human apolipoprotein(a) gene 5'-regulatory region DNA or its complement;

XX (3) a nucleotide sequence of at least 15 nucleotides capable of forming a

XX DNA triplex with human apolipoprotein(a) gene 5'-regulatory region DNA;

XX and (4) a transfected mammalian cell containing human apolipoprotein(a)

XX gene 5'-regulatory region DNA where the heterologous sequence codes for

XX an enzyme. The new promoter sequence is useful in genetic engineering and

XX gene therapy. The promoter can specifically be used for regulating the

XX expression of apolipoprotein(a), which is useful in the treatment of

XX atherosclerosis

SQ Sequence 15 BP; 3 A; 5 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 86;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 105 GCAAGCCATGTGGT 119
|||:|:|:|:|:|
DB 15 GCAAGCCATGTGGT 1

RESULT 113

ABT40093
ID ABT40093 standard; DNA; 17 BP.

XX

AC ABT40093;
 XX
 DT 13-JUN-2003 (first entry)
 DE Tumour suppression related human fukutin oligo SEQ ID No 5730.
 XX
 KW Cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
 XX antiense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 XX human fukutin; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO2003025175-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004208.
 XX
 PR 17-SEP-2001; 2001FR-00011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313353/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 703; 720pp; French.
 XX
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 4 A; 2 C; 2 G; 9 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 15; DB 1; Length 17;
 XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 DB Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX 75 TCTTTTATTTCTGAA 89
 XX |||||
 DB 3 TCTTTTATTTCTGAA 17
 XX
 RESULT 114
 ADB45751
 ID ADB45751 standard; DNA; 17 BP.
 XX
 AC ADB45751;
 XX

DT 18-DEC-2003 (first entry)
 XX
 DE Tumour suppression/reversion associated nucleotide #6074.
 XX
 KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
 XX primer; probe; tumour suppression; tumour reversion; apoptosis;
 KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
 XX diagnosis.
 XX
 OS Homo sapiens.
 XX
 PN WO2003040369-A2.
 XX
 PD 15-MAY-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004219.
 XX
 PR 17-SEP-2001; 2001FR-00011981.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-441574/41.
 XX
 PT New nucleic acid encoding human prostate membrane-specific antigen,
 PT useful e.g. for treatment of tumors and viral infection, also related
 PT polypeptide and antibodies.
 XX
 PS Disclosure; Page 742; 771pp; French.
 XX
 CC The invention relates to the isolation of 6327 nucleotide sequences,
 CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
 CC sequence having at least 80% identity, after optimal alignment, with the
 CC nucleotides, a sequence that hybridizes under stringent conditions with
 CC the nucleotides, or the complement, or corresponding RNA, of the
 CC nucleotides. The nucleotides are used as probes or primers for detecting,
 CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
 CC sense and antisense sequences, of nucleotides involved in tumour
 CC suppression or reversion, apoptosis and or viral resistance, to produce
 CC recombinant polypeptides, and to prepare transgenic animals, as
 CC experimental models. The nucleotides (also vectors containing them and
 CC cells containing the vectors), the encoded polypeptides and antibodies
 CC (ab) against the polypeptides are useful for prevention and/or treatment
 CC of viral infections or diseases characterized by development of tumours
 CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
 CC Analysis of the expression of the nucleotides can be used for diagnosis
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can
 CC also be used to screen for their specific interactive molecules,
 CC potentially useful for treating diseases associated with abnormal
 CC expression of the nucleotides.
 XX
 SQ Sequence 17 BP; 4 A; 2 C; 2 G; 9 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 15; DB 1; Length 17;
 XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 DB Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX 75 TCTTTTATTTCTGAA 89
 XX |||||
 DB 3 TCTTTTATTTCTGAA 17
 XX
 RESULT 115
 ADI50461
 ID ADI50461 standard; DNA; 17 BP.
 XX
 AC ADI50461;
 XX
 DT 15-APR-2004 (first entry)
 XX
 DE Human tumour suppression/reversion-related DNA sequence SegID2964.
 XX

KM tumour suppression; tumour reversion; apoptosis; virus resistance;
 KM cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
 KM primer; PCR; gene chip; antisense; viral disease; tumour;
 KM cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
 OS Homo sapiens.
 PN WO2003025177-A2.
 PD 27-MAR-2003.
 PF 17-SEP-2002; 2002WO-IE004523.
 PR 17-SEP-2001; 2001FR-00011980.
 PA (MOLE-) MOLECULAR ENGINES LAB.
 PI Telerman A, Amson R, Thijnder M;
 DR WPI; 2003-313354/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 XX and transfected cells.
 PS Disclosure; SEQ ID NO 2364; 30pp; French.
 CC This invention relates to novel isolated nucleic acid sequences involved
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis
 CC and/or resistance to viruses. The invention may be useful for the
 CC development of compounds with a cytostatic, virucide, neuroprotective,
 CC nootropic or neuroleptic activity. The DNA sequences may be useful as
 CC probes and primers for detecting, identifying, quantifying and/or
 CC amplifying nucleic acid, for example as one component of a gene chip, in
 CC vitro as antisense reagents and for production of recombinant
 CC polypeptides. The invention may therefore be useful for preparation of
 CC pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumors or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The
 CC present sequence is that of a nucleic acid sequence of the invention.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/publishedpct_sequences
 XX
 SQ Sequence 17 BP; 4 A; 2 C; 2 G; 9 T; 0 U; 0 Other;
 Query Match 0.2%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 75 TCTTTTATTTCTGAA 89
 Db 3 TCTTTTATTTCTGAA 17
 RESULT 116
 AAQ39591
 ID AAQ39591 standard; RNA; 19 BP.
 XX
 AC AAQ39591;
 XX
 DT 07-OCT-1993 (first entry)
 XX
 DE Mycobacterium gordonae-specific helper probe #5.
 XX
 KM scotochromogenic bacterium; hybridisation assay; ribosomal RNA; 16S rRNA;
 KM ss.
 XX
 OS Synthetic.
 XX
 PN US5216143-A.
 XX
 PD 01-JUN-1993.

XX
 PF 28-JUN-1991; 91US-00720585.
 XX
 PR 28-JUN-1991; 91US-00720585.
 XX
 PA (GEP-) GEN-PROBE PROD CO.
 XX
 PI Hogan JJ, Hammond PW;
 DR WPI; 1993-188590/23.
 XX
 PF Oligonucleotide probes specific for mycobacterium gordonae - used to
 PT distinguish presence of M. gordonae from that of other mycobacteria.
 XX
 PS Claim 5; Col 11; 9pp; English.
 CC Probe 1 (AAQ39587) is designed based on the wild-type sequence of
 CC M. gordonae 16S rRNA in the region corresponding to nucleotides 177-195 of
 CC E. coli 16S rRNA. It is used in a hybridisation assay with Probe 2
 CC (AAQ39588) based on the same region in strains 6.2 and C.V. to ensure
 CC detection of all strains of M. gordonae. Hybridisation was enhanced by the
 CC use of "helper probes" (see AAQ39589-039595). All the probes form a
 CC hybridisation complex in 0.1M lithium succinate buffer contg. 10% lithium
 CC lauryl sulphate at 60 deg.C. The novel probes are capable of
 CC distinguishing M. gordonae from closely related Mycobacterium species
 XX
 SQ Sequence 19 BP; 8 A; 5 C; 5 G; 0 T; 1 U; 0 Other;
 Query Match 0.2%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 83.3%; Pred. No. 1.8e+02;
 Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 226 AATAGACACGACGAAAC 243
 Db 2 AATAGACACGACGACAC 19
 RESULT 117
 AAQ39592/c
 ID AAQ39592 standard; RNA; 19 BP.
 XX
 AC AAQ39592;
 XX
 DT 07-OCT-1993 (first entry)
 XX
 DE Mycobacterium gordonae-specific helper probe #6.
 XX
 KM scotochromogenic bacterium; hybridisation assay; ribosomal RNA; 16S rRNA;
 KM ss.
 XX
 OS Synthetic.
 XX
 PN US5216143-A.
 XX
 PD 01-JUN-1993.
 XX
 PF 28-JUN-1991; 91US-00720585.
 XX
 PR 28-JUN-1991; 91US-00720585.
 XX
 PA (GEP-) GEN-PROBE PROD CO.
 XX
 PI Hogan JJ, Hammond PW;
 DR WPI; 1993-188590/23.
 XX
 PF Oligonucleotide probes specific for mycobacterium gordonae - used to
 PT distinguish presence of M. gordonae from that of other mycobacteria.
 XX
 PS Claim 5; Col 11; 9pp; English.
 CC Probe 1 (AAQ39587) is designed based on the wild-type sequence of
 CC M. gordonae 16S rRNA in the region corresponding to nucleotides 177-195 of

```

CC E.coli 16S rRNA. It is used in a hybridisation assay with Probe 2
CC (AAQ39588) based on the same region in strains 6.2 and C.V. to ensure
CC detection of all strains of M.gordonae. Hybridisation was enhanced by the
CC use of "helper probes" (see AAQ39589-Q39595). All the probes form a
CC hybridisation complex in 0.1M lithium succinate buffer contg. 10% lithium
CC lauryl sulphate at 60 deg.C. The novel probes are capable of
CC distinguishing M.gordonae from closely related Mycobacterium species
XX
SQ Sequence 19 BP; 1 A; 5 C; 5 G; 0 T; 8 U; 0 Other;
Query Match 0.2%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 226 AATGACACACAGAAAC 243
DB 18 AATGACACACAGAGACAC 1
RESULT 118
AAQ39590
ID AAQ39590 standard; DNA; 19 BP.
XX
AC AAQ39590;
XX
DT 07-OCT-1993 (first entry)
XX
DE Mycobacterium gordonae-specific helper probe #4.
XX
KM scotochromogenic bacterium; hybridisation assay; ribosomal RNA; 16S rRNA;
XX ss.
XX
OS Synthetic.
XX
PN US5216143-A.
XX
PD 01-JUN-1993.
XX
PF 28-JUN-1991; 91US-00720585.
XX
PR 28-JUN-1991; 91US-00720585.
XX
PA (GEP- ) GEN-PROBE PROD CO.
XX
PI Hogan JJ, Hammond PW;
XX
DR WPI; 1993-188590/23.
XX
PT Oligonucleotide probes specific for mycobacterium gordonae - used to
PT distinguish presence of M. gordonae from that of other mycobacteria.
XX
PS Claim 5; Col 11; 9pp; English.
XX
CC Probe 1 (AAQ39587) is designed based on the wild-type sequence of
CC M.gordonae 16S rRNA in the region corresponding to nucleotides 177-195 of
CC E.coli 16S rRNA. It is used in a hybridisation assay with Probe 2
CC (AAQ39588) based on the same region in strains 6.2 and C.V. to ensure
CC detection of all strains of M.gordonae. Hybridisation was enhanced by the
CC use of "helper probes" (see AAQ39589-Q39595). All the probes form a
CC hybridisation complex in 0.1M lithium succinate buffer contg. 10% lithium
CC lauryl sulphate at 60 deg.C. The novel probes are capable of
CC distinguishing M.gordonae from closely related Mycobacterium species
XX
SQ Sequence 19 BP; 8 A; 5 C; 5 G; 1 T; 0 U; 0 Other;
Query Match 0.2%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 226 AATGACACACAGAAAC 243
DB 2 AATGACACACAGAGACAC 19

```

```

RESULT 119
AAQ39587/C
ID AAQ39587 standard; DNA; 19 BP.
XX
AC AAQ39587;
XX
DT 07-OCT-1993 (first entry)
XX
DE Mycobacterium gordonae-specific probe #1.
XX
KM scotochromogenic bacterium; hybridisation assay; ribosomal RNA; 16S rRNA;
XX ss.
XX
OS Synthetic.
XX
PN US5216143-A.
XX
PD 01-JUN-1993.
XX
PF 28-JUN-1991; 91US-00720585.
XX
PR 28-JUN-1991; 91US-00720585.
XX
PA (GEP- ) GEN-PROBE PROD CO.
XX
PI Hogan JJ, Hammond PW;
XX
DR WPI; 1993-188590/23.
XX
PT Oligonucleotide probes specific for mycobacterium gordonae - used to
PT distinguish presence of M. gordonae from that of other mycobacteria.
XX
PS Claim 1; Col 13; 9pp; English.
XX
CC Probe 1 (AAQ39587) is designed based on the wild-type sequence of
CC M.gordonae 16S rRNA in the region corresponding to nucleotides 177-195 of
CC E.coli 16S rRNA. It is used in a hybridisation assay with Probe 2
CC (AAQ39588) based on the same region in strains 6.2 and C.V. to ensure
CC detection of all strains of M.gordonae. Hybridisation was enhanced by the
CC use of "helper probes" (see AAQ39589-Q39595). All the probes form a
CC hybridisation complex in 0.1M lithium succinate buffer contg. 10% lithium
CC lauryl sulphate at 60 deg.C. The novel probes are capable of
CC distinguishing M.gordonae from closely related Mycobacterium species
XX
SQ Sequence 19 BP; 1 A; 5 C; 5 G; 8 T; 0 U; 0 Other;
Query Match 0.2%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 226 AATGACACACAGAAAC 243
DB 18 AATGACACACAGAGACAC 1
RESULT 120
ABL53411/C
ID ABL53411 standard; DNA; 19 BP.
XX
AC ABL53411;
XX
DT 31-MAY-2002 (first entry)
XX
DE Haemagglutination or haemadsorption related DNA T7-5.
XX
KM Haemagglutination; haemadsorption; fungal infection; phenoloxidase; ds.
XX
OS Unidentified.
XX
PN KR2001005404-A.
XX
PD 15-JAN-2001.

```

```

XX 28-JUN-1999; 99KR-00026408.
XX
XX 28-JUN-1999; 99KR-00026408.
XX
XX (SAMY-) SAMYANG GENEX CORP.
XX
XX Hong SS, Lee BR, Lee HS, Park JT;
XX WPI, 2001-472806/51.
XX
XX Protein related to hemagglutination or hemadsorption reaction and gene
XX thereof.
XX
XX Disclosure; Page 7; 9pp; Korean.
XX
XX The invention relates to a protein related to the hemagglutination or
XX hemadsorption reaction and the gene thereof are provided to screen
XX effective candidates in the diagnosis of fungal infection. The protein of
XX the invention performs coagulation of foreign material. A phenoloxidase
XX distinguishes and recognises self and non-self selectively. The
XX phenoloxidase and the gene thereof induce coagulation and adsorption of a
XX foreign material by using blood cell so as to block diffusion. The
XX protein selectively removes fungi and bacteria invading a body, and is
XX used in the diagnosis of pathogenic foreign material. A pro-phenoloxidase
XX is used in detection of melanin forming repressor. The current sequence
XX represents haemagglutination or haemadsorption related DNA referred to as
XX
XX
XX Sequence 19 BP; 3 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 14.8; DB 1; Length 19;
XX Best Local Similarity 88.9%; Pred. No. 1.8e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 165 CTCGACCACTGTCACAGG 182
XX 18 CTCGACCACTGTCACACTGG 1
XX
XX RESULT 121
XX ADN34436
XX ID ADN34436 standard; RNA; 19 BP.
XX
XX AC ADN34436;
XX
XX 01-JUL-2004 (first entry)
XX
XX Lower strand of cyclin D1 targeted double stranded siNA #217.
XX
XX short interfering nucleic acid; siNA; cyclin; Cytostatic; Vasotropic;
XX cancer; cell-proliferation disorder; restenosis; drug screening;
XX genetic engineering; pharmacogenomics; gene mapping;
XX single nucleotide polymorphisms; ss.
XX
XX Homo sapiens.
XX
XX WO2003072705-A2.
XX
XX 04-SEP-2003.
XX
XX 06-FEB-2003; 2003WO-US003662.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 17-SEP-2002; 2002US-0411275P.
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.

```

```

XX Thompson J, Mcswiggen J, Beigelman L;
XX WPI, 2003-689983/65.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
XX diagnosis of cancer and restenosis, down regulates expression of at least
XX one cyclin gene.
XX
XX Example 3; SEQ ID NO 456; 144pp; English.
XX
XX The present invention relates to a short interfering nucleic acid (siNA)
XX that down regulates expression of at least one cyclin gene by RNA
XX interference. siNA are used to modulate expression of cyclin genes, in
XX cells, tissue explants or organisms, e.g. for treating a wide range of
XX cancers and other cell-proliferation disorders such as restenosis, but
XX also for drug screening, diagnosis, target identification and validation;
XX genetic engineering, pharmacogenomics, studying gene function and gene
XX mapping (e.g. of single-nucleotide polymorphisms). The present sequence
XX represents the lower strand of cyclin D1 targeted double stranded siNA.
XX
XX
XX Sequence 19 BP; 5 A; 7 C; 5 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 0.2%; Score 14.8; DB 1; Length 19;
XX Best Local Similarity 83.3%; Pred. No. 1.8e+02;
XX Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 519 CACGAGAGAACCTGCCA 536
XX 1 CACGAGAGUAGCCUGCCA 18
XX
XX RESULT 122
XX ADN34197/C
XX ID ADN34197 standard; RNA; 19 BP.
XX
XX AC ADN34197;
XX
XX 01-JUL-2004 (first entry)
XX
XX Upper strand of cyclin D1 targeted double stranded siNA #217.
XX
XX short interfering nucleic acid; siNA; cyclin; Cytostatic; Vasotropic;
XX cancer; cell-proliferation disorder; restenosis; drug screening;
XX genetic engineering; pharmacogenomics; gene mapping;
XX single nucleotide polymorphisms; ss.
XX
XX Homo sapiens.
XX
XX WO2003072705-A2.
XX
XX 04-SEP-2003.
XX
XX 06-FEB-2003; 2003WO-US003662.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 17-SEP-2002; 2002US-0411275P.
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Thompson J, Mcswiggen J, Beigelman L;
XX WPI, 2003-689983/65.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
XX diagnosis of cancer and restenosis, down regulates expression of at least
XX one cyclin gene.

```


XX Example 3; SEQ ID NO 217; 14bp; English.

XX The present invention relates to a short interfering nucleic acid (siNA) that down regulates expression of at least one cyclin gene by RNA interference. siNA are used to modulate expression of cyclin genes, in cells, tissue explants or organisms, e.g. for treating a wide range of cancers and other cell-proliferation disorders such as metastasis, but also for drug screening, diagnosis, target identification and validation; genetic engineering, pharmacogenomics, studying gene function and gene mapping (e.g. of single-nucleotide polymorphisms). The present sequence represents the upper strand of cyclin D1 targeted double stranded siNA which is identical to the cyclin D1 transcript target sequence.

XX Sequence 19 BP; 2 A; 5 C; 7 G; 0 T; 5 U; 0 Other;

QY Query Match 0.2%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

DB 519 CACAGGAAGACCTGCCA 536
19 CACAGGATGACCTGCCA 2

RESULT 123
ID AAA25065 standard; DNA; 17 BP.

XX AAA25065;

XX 19-JUL-2000 (first entry)

DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1563.

XX Oestrogen receptor; c-rafi; k-ras; bcl-2; ribozyme; cleavage;
KM hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW gene expression modification; cancer; phosphorothioate; endonuclease;
KM anticancer; breast cancer; endometrium cancer; ss.

XX Homo sapiens.

XX MO9954459-A2.

XX 28-OCT-1999.

XX 19-APR-1999; 99WO-US008547.

XX 20-APR-1998; 98US-0082404P.

XX 23-JUN-1998; 98US-00103636.

PA (RIBO-) RIBOZYME PHARM INC.

PI Thompson JD, Beigelman L, Mcswiggen JA, Karpelesky A, Bellon L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerl P;
PI Matulic-Adamic J;

XX WPI; 2000-013248/01.

XX New nucleic acids that interact, and optionally cleave, target sequences, used to treat cancer.

XX Claim 77; Page 67; 148pp; English.

XX The present invention describes nucleic acids (A) that interact stably with a target sequence and contain at least one phosphoro(di)thioate link, having endonuclease activity. (A), and more generally any catalytic nucleic acid (A') that modulates expression of the oestrogen receptor gene, are used to treat cancer (particularly of breast or endometrium), in vivo or by transforming cells ex vivo and implanting treated cells, or for other conditions associated with levels of oestrogen receptor. Because of the high selectivity for targeted RNA, (A) can also be used to correlate inhibition of gene expression with alterations in phenotype,

CC particularly for identification of therapeutic targets, and as research CC reagents (for RNA, in the same way that restriction endonucleases are CC used with DNA). The combination of modifications in (A) improves CC resistance to nucleases, binding affinity and/or activity. AAA23503 to CC AA24747 represent oestrogen receptor hammerhead ribozyme sequences, and CC AA24748 to AAA25992 represent their corresponding target sequences. CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme CC sequences, and AAA26107 to AAA26218 represent their corresponding target CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and CC antisense oligonucleotides used in the exemplification of the present CC invention

XX Sequence 17 BP; 5 A; 3 C; 3 G; 6 T; 0 U; 0 Other;

QY Query Match 0.2%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

DB 481 AATGACAGAGTTATC 496
17 AATGACAGAGTTATC 2

RESULT 124
ID ACA99849 standard; DNA; 17 BP.

XX ACA99849;

XX 28-JUL-2003 (first entry)

DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #342.

XX Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KM G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.

XX Homo sapiens.

XX WO2003031621-A2.

XX 17-APR-2003.

XX 11-OCT-2002; 2002WO-US032599.

XX 12-OCT-2001; 2001US-0329000P.

PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.

PI Zhang J;

XX WPI; 2003-381720/36.

XX New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing, PT investigating and/or treating disorders associated with aberrant PT expression or activity of GPCR-A-1, such as tumors and cancers.

XX Example 2; SEQ ID NO 366; 156pp; English.

XX The invention describes an isolated nucleic acid encoding a G protein CC coupled receptor (GPCR), mutations of which cause cancer, comprising a CC 225 or 1921 base pair sequence, or their degenerate variants, encoding a CC 409 residue amino acid sequence, all given in the specification, with or CC without conservative amino acid substitutions, or complements of the CC sequence of them. The encoding nucleic acid is not more than 100 kbase in CC length. The methods and compositions of the present invention are useful CC for diagnosing, investigating and/or treating disorders associated with CC aberrant expression or activity of GPCR-A-1, such as tumours and cancers. CC This sequence represents an oligonucleotide used to analyse the gene CC encoding human G-protein coupled receptor GPCR-A-1

XX Sequence 17 BP; 8 A; 2 C; 5 G; 2 T; 0 U; 0 Other;

QY Query Match 0.2%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 45 AATGGAACATTAAGAA 60
|||||
Db 1 AATGAGCATTAAGAA 16

RESULT 125

ACA99848
ID ACA99848 standard; DNA; 17 BP.

XX
AC ACA99848;

XX
DT 28-JUL-2003 (first entry)

XX G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #341.

DE Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;

KW G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.

XX Homo sapiens.

OS WO2003031621-A2.

XX
PN 17-APR-2003.

XX
PF 11-OCT-2002; 2002WO-US032599.

XX
PR 12-OCT-2001; 2001US-0329000P.

XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.

XX
PI Zhang J;

XX
DR WPI; 2003-381720/36.

XX
PT New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
investigating and/or treating disorders associated with aberrant
expression or activity of GPCR-A-1, such as tumors and cancers.

XX
PS Example 2; SEQ ID NO 365; 156bp; English.

XX
CC The invention describes an isolated nucleic acid encoding a G protein
coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC 409 residue amino acid sequence, all given in the specification, with or
CC without conservative amino acid substitutions, or complements of the
CC sequence of them. The encoding nucleic acid is not more than 100 kbases in
CC length. The methods and compositions of the present invention are useful
CC for diagnosing, investigating and/or treating disorders associated with
CC aberrant expression or activity of GPCR-A-1, such as tumours and cancers.
CC This sequence represents an oligonucleotide used to analyse the gene
CC encoding human G-protein coupled receptor GPCR-A-1.

XX
SQ Sequence 17 BP; 8 A; 1 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 45 AATGGAACATTAAGAA 60
|||||
Db 2 AATGAGCATTAAGAA 17

RESULT 126

AB264673
ID AB264673 standard; RNA; 17 BP.

XX
AC AB264673;

XX
DT 21-MAR-2003 (first entry)

XX
DE Human HER2 DNAzyme substrate #130.

XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.

OS Homo sapiens.

XX
PN WO200297114-A2.

XX
PD 05-DEC-2002.

XX
PE 29-MAY-2002; 2002WO-US016840.

XX
PR 29-MAY-2001; 2001US-0294140P.

XX
PR 06-JUN-2001; 2001US-0296249P.

XX
PR 10-SEP-2001; 2001US-0318471P.

XX
PA (RIBO-) RIBOZYME PHARM INC.

XX
PI Meswigen J;

XX
DR WPI; 2003-140484/13.

XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.

XX
PS Claim 4; Page 135; 185bp; English.

XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, AIDS. The sequences
CC shown in AB259889 - AB262216, AB264544 - AB265531, AB265520 - AB265524,
CC AB265530 - AB265585 represent substrate/target sequences for the human
CC ribozymes of the invention

XX
SQ Sequence 17 BP; 3 A; 8 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.6e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 167 CCACCCTGTCAAGG 182
|||||
Db 1 CCACCCUGUCACAGG 16

RESULT 127

ADB39822
ID ADB39822 standard; DNA; 17 BP.

XX
AC ADB39822;

XX
DT 18-DEC-2003 (revised)

XX
DT 04-DEC-2003 (first entry)

XX
DE Tumour suppression/reversion associated nucleotide #145.

XX
KW cyostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
diagnosis.

XX
OS Homo sapiens.

PR 26-SEP-2000; 2000US-0235640P.
 XX
 PA (XENO-) XENON GENETICS INC.
 XX
 PI Brownlie A;
 XX
 DR WPI; 2002-372121/40.
 XX
 PT Isolated polynucleotides encoding human stearyl-coA desaturase with
 PT delta-9 desaturase activity, useful for preventing diagnosing and
 PT treating e.g. cardiovascular disease, baldness and skin diseases.
 XX
 PS Example 2; Page 32; 53pp; English.
 XX
 CC The invention relates to isolated polynucleotides encoding human stearyl
 CC -CoA desaturase (hSCDS) with Delta-9 desaturase activity. hSCDS may be
 CC used in the prevention, diagnosis and treatment of diseases associated
 CC with inappropriate hSCDS expression and used to treat disorders
 CC associated with decreased expression by rectifying mutations or deletions
 CC in a patient's genome that affect the activity of hSCDS by expressing
 CC inactive proteins or to supplement the patient's own production of hSCDS.
 CC Disorders that may be prevented and/or treated using the modulators
 CC including, for example cholesterol disorders, lipidemias, cardiovascular
 CC disease, diabetes, obesity, baldness, skin diseases, cancer and multiple
 CC sclerosis. Human SCDS is used in gene therapy and protein therapy and
 CC also used as vaccine. The present sequence is human SCDS cDNA amplifying
 CC PCR primer
 XX
 SQ Sequence 18 BP; 3 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 14.4; DB 1; Length 18;
 Db Best Local Similarity 93.8%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 26 CACTGCTGGCCAGTCC 41
 Db 3 CACTGCTGTCACAGTCC 18
 XX
 RESULT 132
 ABT06163/c
 ID ABT06163 standard; DNA; 18 BP.
 XX
 AC ABT06163;
 XX
 DT 28-OCT-2002 (first entry)
 XX
 DE Human light chain lambda gene related PCR primer SEQ ID No 177.
 XX
 KW Single Primer Amplification; nested oligonucleotide extension reaction;
 KW hairpin; SPA; library; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200248401-A2.
 PD 20-JUN-2002.
 XX
 PF 10-DEC-2001; 2001WO-US047727.
 XX
 PR 11-DEC-2000; 2000US-0254669P.
 PR 19-SEP-2001; 2001US-0323400P.
 XX
 PA (ALEX-) ALEXION PHARM INC.
 XX
 PI Bowdish KS, Barbas-Frederickson S, Lin Y, McWhirter J, Maryama T;
 XX
 DR WPI; 2002-500537/53.
 XX
 PT Amplifying nucleic acid by synthesizing template nucleic acid containing
 PT a predetermined sequence and hairpin structure and using the template for
 PT target amplification by Single Primer Amplification.

PS Example 6; Page 36; 54pp; English.
 XX
 CC The invention relates to a method for amplifying a nucleic acid using a
 CC Single Primer Amplification (SPA). The method comprises synthesizing a
 CC template nucleic acid containing a predetermined sequence and hairpin
 CC structure with the nested oligonucleotide extension reaction. The method
 CC is useful for amplifying a nucleic acid, preferably for amplifying a
 CC family of related nucleic acid sequences to build a complex library of
 CC polypeptides encoded by the sequences. The engineered nucleic acid strand
 CC is useful for amplifying a nucleic acid strand by providing a nucleic
 CC acid with a predetermined sequence engineered onto its 3' end, a
 CC sequence complementary to the predetermined sequence and a hairpin
 CC structure between them and contacting the engineered nucleic acid strand
 CC with a primer containing at least a portion of the predetermined
 CC sequence. This process is done in the presence of a polymerase and
 CC nucleotides under conditions suitable for polymerisation to produce a
 CC complementary nucleic acid strand. The method of the invention is useful
 CC for producing large amounts of a target nucleic acid sequence and for
 CC amplifying simultaneously more than one different target nucleic acid
 CC sequence located on the same or different nucleic acid molecules. This
 CC polynucleotide sequence represents a PCR primer of the invention
 XX
 SQ Sequence 18 BP; 1 A; 4 C; 5 G; 8 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 14.4; DB 1; Length 18;
 Db Best Local Similarity 93.8%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 95 CAGCACTGAGCAAG 110
 Db 16 CAGAACTGAGCAAG 1
 XX
 RESULT 133
 ACD05030/c
 ID ACD05030 standard; DNA; 18 BP.
 XX
 AC ACD05030;
 XX
 DT 05-AUG-2003 (first entry)
 XX
 DE Tumour necrosis factor alpha associated primer #1.
 XX
 KW Tumour necrosis factor alpha; TNF-alpha; antiinflammatory; antiinflammatory;
 KW antiarthritic; antidiabetic; dermatological; hepatotropic; antiaslomatic;
 KW inflammatory disorder; inflammatory bowel disease; Crohn's disease;
 KW colitis; Rheumatoid arthritis; diabetes; pancreatitis;
 KW multiple sclerosis; atopic dermatitis; asthma; hepatitis; primer; ss.
 XX
 OS Synthetic.
 XX
 PN US2003022848-A1.
 PD 30-JAN-2003.
 XX
 PF 02-APR-2001; 2001US-00824322.
 XX
 PR 05-OCT-1998; 98US-00166186.
 PR 18-MAY-1999; 99US-00313932.
 XX
 PA (BAKE/) BAKER B F.
 PA (BENNY/) BENNETT C F.
 PA (BUTL/) BUTLER M M.
 PA (SHAN/) SHANAHAN W R.
 XX
 PI Baker BF, Bennett CF, Butler MM, Shanahan WR;
 XX
 DR WPI; 2003-447433/42.
 XX
 PT Treating inflammatory disorders such as inflammatory bowel disease,
 PT Crohn's disease or Rheumatoid arthritis, in a subject, by administering
 PT oligonucleotide which inhibits expression of human tumor necrosis factor
 PT alpha.

```
XX Example 5; Page 16; 142pp; English.
PS
CC The invention describes a method of treating an inflammatory disorder in
CC an individual, comprising administering to the individual an
CC oligonucleotide upto 30 nucleotides in length complementary to a nucleic
CC acid molecule encoding human tumor necrosis factor (TNF)-alpha. The
CC method is useful for treating an inflammatory disorder such as
CC inflammatory bowel disease, Crohn's disease, colitis or rheumatoid
CC arthritis, in an individual. The method is also useful for treating
CC diabetes, pancreatitis, multiple sclerosis, atopic dermatitis, asthma,
CC and hepatitis in an individual. This sequence represents a reverse
CC transcriptase primer used to isolate DNA encoding tumour necrosis factor
CC alpha (TNF-alpha) to test the function of antisense oligonucleotides for
CC modulating gene expression
XX
SQ Sequence 18 BP; 1 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
Query Match
Best Local Similarity 0.2%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 430 GAACAAGCACCAGCTG 445
Db 16 GAACAAGCACCAGCTG 1
RESULT 134
ADF71306
ID ADF71306 standard; RNA; 19 BP.
AC ADF71306;
XX 12-FEB-2004 (first entry)
DT
XX Protein tyrosine phosphatase type IV (PRL3) gene siNA, SEQ ID NO 91.
DE
XX short interfering nucleic acid; siNA;
KM protein tyrosine phosphatase type IV; PRL3; RNA interference; cytostatic;
KW cancer; ss.
XX Homo sapiens.
OS
XX WO2003070886-A2.
PN
XX 28-AUG-2003.
PD
XX 11-FEB-2003; 2003WO-US004347.
PF
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Mcswiggen J, Beigelman L, Usman N;
PI WPI; 2003-697606/66.
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of a protein tyrosine
PT phosphatase type IVA gene.
XX
XX Example 3; SEQ ID NO 91; 131pp; English.
PS
CC The invention relates to a novel short interfering nucleic acid (siNA)
CC that downregulates expression of a protein tyrosine phosphatase type IV
CC (PRL3) gene by RNA interference. The invention further relates to
CC modulating the expression of PRL3 genes in cells, tissue explants or
```

```
CC organisms by the introduction of an siNA; kits for in vitro or in vivo
CC delivery of an siNA, conjugates and/or complexes of siNA; and vectors
CC that express siNA. The novel siNA's of the invention have cytostatic
CC activity. siNA's are used to modulate expression of PRL3 genes, in cells,
CC tissue explants or organisms, e.g. for treating cancer but also for drug
CC screening; diagnosis; target identification and validation; genetic
CC engineering; pharmacogenomics; studying gene function and gene mapping
CC (e.g. of single-nucleotide polymorphisms). This polynucleotide sequence
CC represents a short interfering nucleic acid for downregulating the
CC expression of a protein tyrosine phosphatase type IV (PRL3) gene of the
CC invention.
XX
SQ Sequence 19 BP; 7 A; 3 C; 8 G; 0 T; 1 U; 0 Other;
Query Match
Best Local Similarity 0.2%; Score 14.4; DB 1; Length 19;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 367 GCAGAGGAGCTGCGC 382
Db 1 GCAGAGGAGCTGCGCAG 16
RESULT 135
ADF71237/C
ID ADF71232 standard; RNA; 19 BP.
AC ADF71232;
XX 12-FEB-2004 (first entry)
DT
XX Protein tyrosine phosphatase type IV (PRL3) gene siNA, SEQ ID NO 17.
DE
XX short interfering nucleic acid; siNA;
KM protein tyrosine phosphatase type IV; PRL3; RNA interference; cytostatic;
KW cancer; ss.
XX Homo sapiens.
OS
XX WO2003070886-A2.
PN
XX 28-AUG-2003.
PD
XX 11-FEB-2003; 2003WO-US004347.
PF
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Mcswiggen J, Beigelman L, Usman N;
PI WPI; 2003-697606/66.
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of a protein tyrosine
PT phosphatase type IVA gene.
XX
XX Example 3; SEQ ID NO 17; 131pp; English.
PS
CC The invention relates to a novel short interfering nucleic acid (siNA)
CC that downregulates expression of a protein tyrosine phosphatase type IV
CC (PRL3) gene by RNA interference. The invention further relates to
CC modulating the expression of PRL3 genes in cells, tissue explants or
CC organisms by the introduction of an siNA; kits for in vitro or in vivo
CC delivery of an siNA, conjugates and/or complexes of siNA; and vectors
CC that express siNA. The novel siNA's of the invention have cytostatic
CC activity. siNA's are used to modulate expression of PRL3 genes, in cells,
```

CC tissue explants or organisms, e.g. for treating cancer but also for drug
CC screening; diagnosis; target identification and validation; genetic
CC engineering; pharmacogenomics; studying gene function and gene mapping
CC (e.g. of single-nucleotide polymorphisms). This polynucleotide sequence
CC represents a short interfering nucleic acid for downregulating the
CC expression of a protein tyrosine phosphatase type IV (PTN3) gene of the
CC invention.
XX
SQ Sequence 19 BP; 1 A; 8 C; 3 G; 0 T; 7 U; 0 Other;
Query Match 0.2%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 367 GCAGAGGAGCTGCCG 382
DB 19 GCAGAGGAGCTGCAG 4
RESULT 136
ADG34746
ID ADG34746 standard; RNA, 19 BP.
XX
AC ADG34746;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human TNF siNA oligonucleotide SEQ ID NO:98.
XX
XX RNA interference; short interfering nucleic acid; siNA;
KM short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KM short hairpin RNA; shRNA; expression modulation; gene therapy;
KM drug screening; diagnosis; therapeutic target identification;
KM pharmacogenomics; gene function analysis; gene mapping;
KM tumour necrosis factor; TNF; human; DNA-RNA hybrid; ss; antibacterial;
KM immunosuppressive; antirheumatic; antiarthritic; anti-HIV; antiporiatic;
KM antiinflammatory; septic shock; rheumatoid arthritis; HIV/AIDS;
KM psoriasis; inflammation; autoimmune disease.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070897-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US004741.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-036782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 28-NOV-2002; 2002US-0429359P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswigen J, Beigelman L;
XX
DR WPI; 2003-697609/66.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of septic shock or rheumatoid arthritis, downregulates
PT expression of the tumor necrosis factor gene.
XX
PS Example 3; SEQ ID NO 98; 141bp; English.
XX
XX The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human tumour necrosis factor (TNF) gene by
CC RNA interference. The siNA may or may not comprise ribonucleotides and
CC may be double or single stranded. They further comprise sense and

CC antisense regions, or alternatively are assembled from a sense
CC oligonucleotide and an antisense oligonucleotide. Specifically, the siNA
CC include short interfering RNA (siRNA), double-stranded RNA, micro-RNA
CC (miRNA) and short hairpin RNA (shRNA). The siNA can be unmodified or
CC chemically modified, can contain deoxyribonucleotides, and can be
CC chemically synthesised, expressed from a vector or enzymatically
CC synthesised. The invention also relates to kits for the in vitro or in
CC vivo delivery of siNA; conjugates and/or complexes of siNA; and vectors
CC that express siNA. The siNA are used to modulate expression of the TNF
CC gene in cells, tissue explants or organisms (e.g., by ex vivo gene
CC therapy), or in grafts and transplants for the treatment of a variety of
CC conditions. The TNF siNA have antibacterial, immunosuppressive,
CC antirheumatic, antiarthritic, anti-HIV, antiporiatic and
CC antiinflammatory activities. They may be used for treating septic shock,
CC rheumatoid arthritis, HIV/AIDS, psoriasis, inflammation and autoimmune
CC diseases. The siNA are also useful for drug screening, diagnosis,
CC therapeutic target identification and validation, genetic engineering,
CC pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC single nucleotide polymorphisms). The present sequence represents the
CC lower strand of a human TNF-targeted double-stranded siNA.
XX
SQ Sequence 19 BP; 6 A; 6 C; 6 G; 0 T; 1 U; 0 Other;
Query Match 0.2%; Score 14.4; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
OY 430 GAACAGCACCAGCTG 445
DB 3 GAACAGCACCAGCTCG 18
RESULT 137
ADG34658/c
ID ADG34658 standard; RNA, 19 BP.
XX
AC ADG34658;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human TNF siNA oligonucleotide SEQ ID NO:10.
XX
XX RNA interference; short interfering nucleic acid; siNA;
KM short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KM short hairpin RNA; shRNA; expression modulation; gene therapy;
KM drug screening; diagnosis; therapeutic target identification;
KM pharmacogenomics; gene function analysis; gene mapping;
KM tumour necrosis factor; TNF; human; DNA-RNA hybrid; ss; antibacterial;
KM immunosuppressive; antirheumatic; antiarthritic; anti-HIV; antiporiatic;
KM antiinflammatory; septic shock; rheumatoid arthritis; HIV/AIDS;
KM psoriasis; inflammation; autoimmune disease; target sequence.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070897-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US004741.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-036782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 28-NOV-2002; 2002US-0429359P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswigen J, Beigelman L;

```

XX WPI; 2003-697609/66.
XX
XX
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
XX diagnosis of septic shock or rheumatoid arthritis, downregulates
XX expression of the tumor necrosis factor gene.
XX
XX Example 3; SEQ ID NO 10; 141bp; English.
XX
XX The invention relates to short interfering nucleic acids (siNA) which
XX downregulate expression of the human tumour necrosis factor (TNF) gene by
XX RNA interference. The siNAs may or may not comprise ribonucleotides and
XX may be double or single stranded. They further comprise sense and
XX antisense regions, or alternatively, are assembled from a sense
XX oligonucleotide and an antisense oligonucleotide. Specifically, the siNAs
XX include short interfering RNA (siRNA), double-stranded RNA, micro-RNA
XX (miRNA), and short hairpin RNA (shRNA). The siNAs can be unmodified or
XX chemically modified, can contain deoxyribonucleotides, and can be
XX synthesized. The invention also relates to kits for the in vitro or in
XX vivo delivery of siNA; conjugates and/or complexes of siNA; and vectors
XX that express siNA. The siNAs are used to modulate expression of the TNF
XX gene in cells, tissue explants or organisms (e.g., by ex vivo gene
XX therapy, or in grafts and transplants for the treatment of a variety of
XX conditions. The TNF siNAs have antibacterial, immunosuppressive,
XX anti-inflammatory, antiarthritic, anti-HIV, antiproliferative and
XX antineoplastic activities. They may be used for treating septic shock,
XX rheumatoid arthritis, HIV/AIDS, psoriasis, inflammation and autoimmune
XX diseases. The siNAs are also useful for drug screening, diagnosis,
XX therapeutic target identification and validation, genetic engineering,
XX pharmacogenomics, studying gene function, and gene mapping (e.g., of
XX single nucleotide polymorphisms). The present sequence represents the
XX upper strand of a human TNF-targeted double-stranded siNA, which is
XX identical to the TNF transcript target sequence.
XX
XX Sequence 19 BP; 1 A; 6 C; 6 G; 0 T; 6 U; 0 Other;
XX
XX Query Match 0.2%; Score 14.4; DB 1; Length 19;
XX Best Local Similarity 93.8%; Pred. No. 2.1e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 430 GAACAAGCAGCCACTG 445
XX |||||
XX 17 GAACAAGCAGCCCTG 2
XX
XX RESULT 138
XX ADG09449/C
XX ID ADG09449 standard; DNA; 19 BP.
XX AC
XX ADG09449;
XX
XX 26-FEB-2004 (first entry)
XX
XX TNF-alpha-related gene PAN PCR primer SEQ ID NO:17.
XX
XX DE
XX TNF-alpha-related gene PAN PCR primer SEQ ID NO:17.
XX
XX KW tumour necrosis factor; TNF; tumour necrosis factor alpha; TNF-alpha;
XX TNF-related gene; TNF-alpha-related gene; cancer; human; PCR primer; ss.
XX
XX OS Synthetic.
XX
XX Homo sapiens.
XX
XX EP1361433-A2.
XX
XX 12-NOV-2003.
XX
XX PD
XX 08-APR-2003; 2003EP-00252225.
XX
XX PR 09-APR-2002; 2002JP-00107126.
XX
XX (HAYB ) HAYASHIBARA SEIBUTSU KAGAKU.
XX
XX Yanai Y, Yamamoto S, Yamamoto K, Ikegami H,

```

XX	WP1; 2004-055141/06.
XX	
DR	Estimating therapeutic efficacy of tumor necrosis factor involves
PT	evaluating expression level of tumor necrosis factor-related gene in
PT	cancer cell.
XX	
PS	Example 2; SEQ ID NO 17; 56pp; English.
CC	
CC	The present invention describes a method (M1) for estimating therapeutic
CC	efficacy of tumour necrosis factor (TNF). M1 involves evaluating the
CC	expression level of a TNF-related gene in a cancer cell. Also described
CC	is a kit for estimating the therapeutic efficacy of TNF, which is used in
CC	the treatment of cancers. The kit comprises a thermostable DNA polymerase
CC	and an oligonucleotide primer comprising a DNA sequence encoding a gene
CC	chosen from a protein kinase B (Akt-1) gene, death receptor (DR3) gene,
CC	multidrug resistance-associated protein (MRP5) gene, and multidrug
CC	resistance-associated protein (MRP6) gene. The present sequence
CC	represents a PCR primer which is used in an example from the present
CC	invention.
SQ	
SQ	Sequence 19 BP; 2 A; 4 C; 7 G; 6 T; 0 U; 0 Other;
Query Match	0.2%; Score 14.4; DB 1; Length 19;
Best Local Similarity	93.8%; Pred. No. 2.1e+02;
Matches 15; Conservative	0; Mismatches 1; Indels 0; Gaps 0
Oy	407 TTCCAAGCCTGAGGC 422
Db	17 TTCCAAGCCCGAGGC 2
RESULT 139	
ADQ27987/C	
ID ADQ27987 standard; DNA; 19 BP.	
XX AC	
AC ADQ27987;	
XX 09-SEP-2004 (first entry)	
DE siPAK1-0 targeted to the PAK1 gene as apoptosis inducer.	
XX ss: cytosaratic; Apoptosis inducer; proteasome inhibitor;	
KW short interfering RNA; siRNA; RNA interference; gene silencing.	
XX Synthetic.	
OS WO2004050895-A2.	
PV PD	
PD 17-JUN-2004.	
XX 25-NOV-2003; 2003WO-US037940.	
PE 27-NOV-2002; 2002US-0429842P.	
PR 21-FEB-2003; 2003US-0448960P.	
PR 12-AUG-2003; 2003US-0494714P.	
PR 22-SEP-2003; 2003US-0504901P.	
XX (IRM1-) IRM LLC.	
PA Nasoff M, Deveraux QJ, Knee DA, Aza-Blanc P, Hampton GM;	
PI Wagner K;	
PI WPL; 2004-450739/42.	
XX WPL; 2004-450739/42.	
PT Inducing apoptosis in cancer cell, involves contacting cell with anti-DR4	
PT or anti-DR5 affinity agent agonist and apoptosis-inducing agent.	
XX Example 57; Page 87; 134pp; English.	
XX The invention relates to a method of inducing apoptosis in a cancer cell,	
CC by contacting cells with an anti-DR4/anti-DR5 affinity agent agonist and	
CC apoptosis-inducing agent, or with an affinity agent with binding	

CC specificity of an antibody comprising heavy chain variable region and
CC light chain variable region. The method is useful for inducing apoptosis
CC in a cancer cell such as colon cancer cell or pancreatic cancer cell.
CC This sequence represents an siRNA designated siPAK1-0 targeted to the PAK
CC gene and used in the method of the invention.

XX Sequence 19 BP; 7 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 14.4; DB 1; Length 19;

Best Local Similarity 93.8%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 286 GATGCTGTGCAGCTC 301

Db 17 GATGCTGTGCAGCTC 2

RESULT 140

AAT37582

ID AAT37582 standard; mRNA; 15 BP.

AC AAT37582;

DT 11-NOV-1996 (first entry)

XX Apo(a) mRNA (int. pos. 10225) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

XX hammerhead ribozyme; target sequence; diagnosis; treatment;

XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;

XX restenosis; heart disease; human; ss.

XX Homo sapiens.

XX WO9609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

XX 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, Mcawiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

XX Claim 2; Page 18; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a).

XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms

XX complementary to the present sequence (nucleotide position 10225). The

XX ribozyme blocks to some extent apo(a) expression, and can therefore be

XX used to diagnose or treat conditions related to lipoprotein (a) levels,

XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart

XX disease. PCR was used to generate a substrate for T7 RNA polymerase

XX transcription from human apo(a) cDNA clones. Labelled transcripts were

XX synthesised in vitro to form 2 templates. The oligonucleotides and

XX labelled transcripts were annealed, RNaseH added and the mixts.

XX incubated. After a designated time the reactions were stopped, and RNA

XX sepd. on sequencing polyacrylamide gels. The percentage of substrate

XX cleaved was determined by autoradiographic quantification, and the most

XX accessible ribozyme target sites chosen

XX Sequence 15 BP; 3 A; 4 C; 1 G; 0 T; 7 U; 0 Other;

XX Query Match 0.2%; Score 14; DB 1; Length 15;

XX Best Local Similarity 50.0%; Pred. No. 1.3e+02;

Matches 7; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

OY 301 CCTATTGTTATAC 314

Db 2 CCUUAUGUUAUAC 15

Query Match 0.2%; Score 14; DB 1; Length 15;

Best Local Similarity 57.1%; Pred. No. 1.3e+02;

Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

OY 197 CTTGTCATCATG 210

Db 2 CUUGUCUACUUG 15

RESULT 141

AAT37757

ID AAT37757 standard; mRNA; 15 BP.

AC AAT37757;

DT 18-NOV-1996 (first entry)

XX Apo(a) mRNA (int. pos. 12327) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

XX hammerhead ribozyme; target sequence; diagnosis; treatment;

XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;

XX restenosis; heart disease; monkey; ss.

XX Cebus apella.

XX WO9609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

XX 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, Mcawiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

XX Claim 3; Page 21; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)

XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms

XX complementary to the present sequence (nucleotide position 12327). The

XX ribozyme blocks to some extent apo(a) expression, and can therefore be

XX used to diagnose or treat conditions related to lipoprotein (a) levels,

XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart

XX disease. PCR was used to generate a substrate for T7 RNA polymerase

XX transcription from monkey apo(a) cDNA clones. Labelled transcripts were

XX synthesised in vitro to form 2 templates. The oligonucleotides and

XX labelled transcripts were annealed, RNaseH added and the mixts.

XX incubated. After a designated time the reactions were stopped, and RNA

XX sepd. on sequencing polyacrylamide gels. The percentage of substrate

XX cleaved was determined by autoradiographic quantification, and the most

XX accessible ribozyme target sites chosen

XX Sequence 15 BP; 2 A; 3 C; 3 G; 0 T; 7 U; 0 Other;

XX Query Match 0.2%; Score 14; DB 1; Length 15;

XX Best Local Similarity 57.1%; Pred. No. 1.3e+02;

XX Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

XX OY 197 CTTGTCATCATG 210

XX Db 2 CUUGUCUACUUG 15

XX RESULT 142

XX AAT37598

XX ID AAT37598 standard; mRNA; 15 BP.

```

XX AC AAT37598;
XX XX
XX 11-NOV-1996 (first entry)
XX DE
XX Apo(a) mRNA (nt. pos. 10677) hammerhead ribozyme target sequence.
XX KM Enzymatic RNA molecule; cleavage: apolipoprotein (a); apo(a);
XX KM hammerhead ribozyme; target sequence; diagnosis; treatment;
XX KM lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX KM restenosis; heart disease; human; ss.
XX OS Homo sapiens.
XX PN WO9609392-A1.
XX PD 28-MAR-1996.
XX PF 21-SEP-1995; 95WO-US011995.
XX PR 23-SEP-1994; 94US-00311760.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Stinchcomb DT, McSwiggen J, Newton RS, Ramnarack R;
XX DR WPI; 1996-188454/19.
XX PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
XX PT myocardial infarction, and heart diseases.
XX PS
XX PS Claim 2; Page 18; 37pp; English.
XX CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX CC complementary to the present sequence (nucleotide position 10677). The
XX CC ribozyme blocks to some extent apo(a) expression, and can therefore be
XX CC used to diagnose or treat conditions related to lipoprotein (a) levels,
XX CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX CC disease. PCR was used to generate a substrate for T7 RNA polymerase.
XX CC transcribed in vitro to form 2 templates. The oligonucleotides and
XX CC labelled transcripts were annealed, RNaseH added and the mixts.
XX CC incubated. After a designated time the reactions were stopped, and RNA
XX CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX CC cleaved was determined by autoradiographic quantification, and the most
XX CC accessible ribozyme target sites chosen
XX SO
XX Sequence 15 BP; 4 A; 4 C; 4 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 0.2%; Score 14; DB 1; Length 15;
XX Best Local Similarity 85.7%; Pred. No. 1.3e+02;
XX Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 410 CAAGCCTAGAGGCT 423
XX |||||:|||||:
XX 1 CAAGCCUAGAGGCTU 14
XX DB
XX
XX RESULT 143
XX AAA60130
XX ID AAA60130 standard; DNA; 15 BP.
XX AC AAA60130;
XX XX
XX DT 17-OCT-2000 (first entry)
XX DE Human APC gene variant I130K scanning oligonucleotide # 4.
XX KM Human, adenomatous polyposis carcinoma; APC; scanning oligonucleotide;
XX KM colorectal cancer; genotype analysis;
XX KM short oligonucleotide mass analysis; SOMA. ss.

```

```

XX OS Homo sapiens.
XX XX
XX Key Location/Qualifiers
XX FT mic_difference 1
XX FT /tag= a
XX FT /note= "5' pA"
XX PN WO200011300-A2.
XX PD 02-JUN-2000.
XX PF 22-NOV-1999; 99WO-US027523.
XX PR 24-NOV-1998; 98US-00198340.
XX PA (UYUO ) UNIV JOHNS HOPKINS.
XX PI Laken SJ, Vogelstein B, Kinzler KW, Groopman JD, Jackson PE,
XX PI Friesen MD;
XX DR WPI; 2000-422808/36.
XX PT Genotype analysis method, defined as SOMA (short oligonucleotide mass
XX PT analysis), of short, defined amplification products using electro-spray
XX PT ionization mass spectrometry, useful for analyzing the genotype of living
XX PT organisms.
XX PS
XX PS Example 2; Page 14; 40pp; English.
XX CC The present invention relates to a method of genotype analysis in which
XX CC short PCR products are analysed by electro-spray ionization mass
XX CC spectrometry (ESI-MS). This method has been named Short Oligonucleotide
XX CC Mass Analysis (SOMA). Short oligonucleotides of the human adenomatous
XX CC polyposis carcinoma (APC) gene variant I1307K, were produced by PCR. The
XX CC I130K APC gene variant is associated with an approximate 2-fold increase
XX CC in colorectal cancer risk. The present sequence is a scanning
XX CC oligonucleotide used to detect the I1307K variants oligonucleotides
XX CC produced in the present invention
XX SO
XX Sequence 15 BP; 1 A; 3 C; 1 G; 10 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 14; DB 1; Length 15;
XX Best Local Similarity 100.0%; Pred. No. 1.3e+02;
XX Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 74 TTCCTTTATTCTG 87
XX |||||:|||||:
XX 1 TTCCTTTATTCTG 14
XX DB
XX
XX RESULT 144
XX ABA78841/C
XX ID ABA78841 standard; DNA; 17 BP.
XX AC ABA78841;
XX XX
XX DT 24-JAN-2002 (first entry)
XX DE APC mutation correcting oligonucleotide SEQ ID NO: 1687.
XX KM Human, gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX KM retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX KM cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX KM adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX KM haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MTH1; APOE;
XX KM mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein B; LDLR;
XX KM familial hypercholesterolemia; UGT1; syndrome; APP; PSBN1; antisense;
XX KM UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX KM Alzheimer's disease; cytostatic; antiskilling; antihaemic; haemostatic;
XX KM antileptic; ss.
XX OS Homo sapiens.

```

```

XX XX WO200173002-A2.
XX PN
XX XX
XX PD 04-OCT-2001.
XX PF 27-MAR-2001; 2001WO-US009761.
XX PR 27-MAR-2000; 2000US-0192176P.
XX PR 27-MAR-2000; 2000US-0192179P.
XX PR 01-JUN-2000; 2000US-0208538P.
XX PR 30-OCT-2000; 2000US-0244989P.
XX XX
XX PA (UYDE ) UNIV DELAWARE.
XX PI Kmiec EB, Gamper HB, Rice MC;
XX PI WPI; 2001-639230/73.
XX DR
XX XX
XX PT Oligonucleotide for targeted alterations of genetic sequences and for
XX PT treating cystic fibrosis, comprises at least one mismatch and chemical
XX PT modification.
XX PS
XX PS Claim 7; Page 144; 294pp; English.
XX CC The present invention provides single-stranded oligonucleotides which can
XX CC be used for the targeted alteration of genomic sequences, where the
XX CC oligonucleotide has at least one mismatch compared with the genomic
XX CC sequence to be altered. In particular, these sequences are directed at
XX CC the following genes: adenosine deaminase, p53, beta-globin,
XX CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
XX CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX CC apolipoprotein B (APOB), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX CC haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
XX CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX CC various syndromes. The present sequence is one of the gene correcting
XX CC oligonucleotides of the invention
XX SQ
XX
XX Query Match 0.2%; Score 14; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 1.8e+02;
XX Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 74 TTCTTTATTTCTG 87
Db 16 TTCTTTATTTCTG 3

RESULT 145
ABA78842
ID ABA78842 standard; DNA; 17 BP.
XX
XX ABA78842;
XX
XX 24-JAN-2002 (first entry)
XX
XX APC mutation correcting oligonucleotide SEQ ID NO: 1688.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOB;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytoskeletal; antisticking; antianaemic; haemostatic;
XX antilipemic; ss.

```

```

OS Homo sapiens.
XX
XX PN WO200173002-A2.
XX XX
XX PD 04-OCT-2001.
XX PF 27-MAR-2001; 2001WO-US009761.
XX PR 27-MAR-2000; 2000US-0192176P.
XX PR 27-MAR-2000; 2000US-0192179P.
XX PR 01-JUN-2000; 2000US-0208538P.
XX PR 30-OCT-2000; 2000US-0244989P.
XX XX
XX PA (UYDE ) UNIV DELAWARE.
XX PI Kmiec EB, Gamper HB, Rice MC;
XX PI WPI; 2001-639230/73.
XX DR
XX XX
XX PT Oligonucleotide for targeted alterations of genetic sequences and for
XX PT treating cystic fibrosis, comprises at least one mismatch and chemical
XX PT modification.
XX PS
XX PS Claim 7; Page 144; 294pp; English.
XX CC The present invention provides single-stranded oligonucleotides which can
XX CC be used for the targeted alteration of genomic sequences, where the
XX CC oligonucleotide has at least one mismatch compared with the genomic
XX CC sequence to be altered. In particular, these sequences are directed at
XX CC the following genes: adenosine deaminase, p53, beta-globin,
XX CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
XX CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX CC apolipoprotein B (APOB), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX CC haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
XX CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX CC various syndromes. The present sequence is one of the gene correcting
XX CC oligonucleotides of the invention
XX SQ
XX
XX Query Match 0.2%; Score 14; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 1.8e+02;
XX Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 74 TTCTTTATTTCTG 87
Db 2 TTCTTTATTTCTG 15

RESULT 146
ADK71405/c
ID ADK71405 standard; DNA; 18 BP.
XX
XX ADK71405;
XX
XX 06-MAY-2004 (first entry)
XX
XX Drug-tolerant gene related PCR primer.
XX
XX detection; drug-tolerant gene; gene chip; probe; PCR; amplification;
XX hybridisation; primer; ss.
XX
XX Synthetic.
XX OS
XX CN1396271-A.
XX PN
XX 12-FEB-2003.
XX PD
XX 13-JUL-2001; 2001CN-00120441.

```

XX 13-JUL-2001; 2001CN-00120441.
XX
XX (SANX-) SANXIONG HI TECH DEV CO LTD BEIJING.
XX
XX Liu Y, Wang H, Li L,
XX WPI; 2003-442250/42.
XX
XX Detection to drug tolerant gene by gene chip technique.
XX
XX
XX Claim 4; Page 21; 32pp; Chinese.
XX
XX The present invention describes a process for detecting a drug-tolerant
XX gene with a gene chip technique. The method comprises fixing the DNA
XX sequence of an oligonucleotide probe to a carrier of a gene chip, the DNA
XX target drug-tolerant gene, PCR amplification, and hybridization of a
XX PCR resultant with a probe on the chip. The present sequence represents a
XX PCR primer which is used in the exemplification of the present invention.
XX
SQ Sequence 18 BP; 1 A; 4 C; 7 G; 6 T; 0 U; 0 Other;
Query Match 0.2%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 210 GACGACGACATCAAC 223
Db 17 GACGACGACATCAAC 4
RESULT 147
AAV97376
ID AAV97376 standard; RNA; 17 BP.
AC AAV97376;
XX
XX 17-MAR-1999 (first entry)
XX
XX Human EGF-R target sequence nucleotide position 1339.
XX
XX Human; epidermal growth factor receptor; EGF-R; target sequence:
XX hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
XX cancer; genetic drift; detection; mutation; ss.
XX
XX Homo sapiens.
XX
XX WO9833893-A2.
XX
XX 06-AUG-1998.
XX
XX 14-JAN-1998; 98WO-US000730.
XX
XX 31-JAN-1997; 97US-0036476P.
XX 04-DEC-1997; 97US-00585162.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (UYAS-) UNITV ASTON.
XX
XX Akhtar S, Fell P, Mcswiggen JA;
XX WPI; 1998-437449/37.
XX
XX Enzymatic nucleic acids - which cleave RNA derived from an epidermal
XX growth factor receptor, useful for inhibiting cell proliferation and for
XX treating cancers.
XX
XX Claim 5; Page 71; 109pp; English.
XX
XX The present invention describes enzymatic nucleic acid molecules (NAmes)
XX which specifically cleave RNA derived from an epidermal growth factor
XX receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090

CC represent specifically claimed target sequence from human EGF-R. AAV98044
CC to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
CC hairpin ribozymes respectively for human EGF-R. The NAmes are useful for
CC cleaving EGF-R RNA in the treatment of a condition associated with EGFR
CC expression levels e.g. to inhibit cell proliferation in the prevention or
CC treatment of cancers. The NAmes can also be used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of EGF-R RNA in a cell
XX
SQ Sequence 17 BP; 3 A; 8 C; 1 G; 0 T; 5 U; 0 Other;
Query Match 0.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
Qy 501 CACATACCCACCACTG 517
Db 1 CACATACCCACCACTG 17
RESULT 148
ABN02462
ID ABN02462 standard; DNA; 17 BP.
XX
XX ABN02462;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2454.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016991.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0268660P.
XX
XX (ABOM-) ABOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 2454; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1

PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-026860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPL-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPL-1.
XX
XX Disclosure; SEQ ID NO 2453; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPL-1). The protein and polynucleotide sequences of hGDMPL-
XX 1 can be used in gene therapy and vaccine production. The hGDMPL-1
XX nucleic acids can be used as probes to detect, characterize and quantify
XX hGDMPL-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPL-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPL-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPL
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPL proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionization, as
XX therapeutic supplement in patients having specific deficiency in hGDMPL-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPL-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPL-1, in particular heart
XX and skeletal muscle disorders. hGDMPL-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPL-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
SQ Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 246 CCCAAATCTGGCTTGA 262
Db 1 CCCAGATGCTGGCTGGA 17
RESULT 151
AAL48306
ID AAL48306 standard; DNA; 17 BP.
XX
XX AAL48306;
XX
XX 03-OCT-2002 (first entry)
XX
XX Human ribozyme cleavage site #2.
XX
XX Ribozyme; catalytic nucleic acid; infection; PCR; target site; ss.
XX
XX Homo sapiens.
XX
XX WO200246449-A2.
XX
XX 13-JUN-2002.
XX
XX 07-DEC-2001; 2001WO-US046178.
XX

PR 07-DEC-2000; 2000US-0251810P.
XX
XX (UYPE-) UNIV PENNSYLVANIA STATE.
XX
XX PA
XX
XX Clawson G, Pan W;
XX
XX WPI; 2002-519672/55.
XX
XX
XX Identifying cleavage sites of a target RNA, by adding target RNA to
XX library of nucleic acids e.g. ribozyme, which comprise catalytic core
XX flanked by random nucleotides and isolating nucleic acid that cleave
XX target RNA.
XX
XX Example 5; Page 52; 79pp; English.
XX
XX The present invention relates to a method of identifying cleavage sites
XX in a target RNA which are accessible to a ribozyme comprising a catalytic
XX core flanked by random nucleotides. A target RNA is added to the library
XX of nucleic acids and nucleic acids that bind to and/or cleave the target
XX RNA are isolated. The method is useful for identifying ribozyme cleavage
XX sites in sequences and in real time PCR assays. The present sequence is a
XX ribozyme target site described in the exemplification of the invention
XX
SQ Sequence 17 BP; 1 A; 4 C; 3 G; 0 T; 9 U; 0 Other;
Query Match 0.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 41.2%; Pred. No. 2e+02;
Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;
QY 60 AGTGTCTTCTACTTC 76
Db 1 AGTGUUUCUUCGCTUC 17
RESULT 152
ACN10466/c
ID ACN10466 standard; RNA; 17 BP.
XX
XX ACN10466;
XX
XX 22-APR-2004 (first entry)
XX
XX MNV minus strand Inozyme substrate SEQ ID NO 10469.
XX
XX MNV; West Nile Virus; antiinflammatory; cytosolic; hepatotropic;
XX WNV; West Nile Virus; antiinflammatory; cytosolic; hepatotropic;
XX virocid; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Amberzyme; Zinzyne; ss.
XX
XX West Nile Virus.
XX
XX
XX WO200268637-A2.
XX
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX (BLAT/) BLATT L.
XX
XX (MCSW/) MCSWIGSEN J A.
XX
XX Blatt L, Mcswigen JA;
XX
XX WPI; 2002-706994/76.
XX
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 10469; 495pp; English.
PS

```
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inosyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 6 C; 4 G; 0 T; 5 U; 0 Other;
XX
Query Match 0.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2;

QY 344 GCAACCTGACGCATGC 360
    |||||
    17 GCAAGCTGAGGCATGC 1

RESULT 153
ACA99847
ID ACA99847 standard; DNA; 17 BP.
XX
AC ACA99847;
XX
DT 28-JUL-2003 (first entry)
XX
DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #340.
XX
KW Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KM G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS Homo sapiens.
XX
PN WO2003031621-A2.
XX
PD 17-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032599.
XX
PR 12-OCT-2001; 2001US-0329000P.
XX
PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Zhang J;
XX
PI Zhang J;
XX
DR WPI; 2003-381720/36.
XX
PT New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT investigating and/or treating disorders associated with aberrant
PT expression or activity of GPCR-A-1, such as tumors and cancers.
XX
PS Example 2; SEQ ID NO 364; 156bp; English.
XX
CC The invention describes an isolated nucleic acid encoding a G protein
CC coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC 409 residue amino acid sequence, all given in the specification, with or
CC without conservative amino acid substitutions, or complements of the
CC sequence of them. The encoding nucleic acid is not more than 100 kbase in
CC length. The methods and compositions of the present invention are useful
CC for diagnosing, investigating and/or treating disorders associated with
CC aberrant expression or activity of GPCR-A-1, such as tumours and cancers.
CC This sequence represents an oligonucleotide used to analyse the gene
CC encoding human G-protein coupled receptor GPCR-A-1
```

```
XX
SQ Sequence 17 BP; 8 A; 1 C; 5 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2;

QY 43 AAATGGACATTAAGGA 59
    |||||
    1 ATTAATGGACATTAAGGA 17

Db 1 ATTAATGGACATTAAGGA 17

RESULT 154
ACA99851
ID ACA99851 standard; DNA; 17 BP.
XX
AC ACA99851;
XX
DT 28-JUL-2003 (first entry)
XX
DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #344.
XX
KW Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KM G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS Homo sapiens.
XX
PN WO2003031621-A2.
XX
PD 17-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032599.
XX
PR 12-OCT-2001; 2001US-0329000P.
XX
PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Zhang J;
XX
PI Zhang J;
XX
DR WPI; 2003-381720/36.
XX
PT New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT investigating and/or treating disorders associated with aberrant
PT expression or activity of GPCR-A-1, such as tumors and cancers.
XX
PS Example 2; SEQ ID NO 368; 156bp; English.
XX
CC The invention describes an isolated nucleic acid encoding a G protein
CC coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC 409 residue amino acid sequence, all given in the specification, with or
CC without conservative amino acid substitutions, or complements of the
CC sequence of them. The encoding nucleic acid is not more than 100 kbase in
CC length. The methods and compositions of the present invention are useful
CC for diagnosing, investigating and/or treating disorders associated with
CC aberrant expression or activity of GPCR-A-1, such as tumours and cancers.
CC This sequence represents an oligonucleotide used to analyse the gene
CC encoding human G-protein coupled receptor GPCR-A-1
XX
SQ Sequence 17 BP; 6 A; 2 C; 6 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2;

QY 47 TGGAACTAATGAAGTG 63
    |||||
    1 TGGAGCATTAAGGAAGTG 17

Db 1 TGGAGCATTAAGGAAGTG 17

RESULT 155
ACA99850
ID ACA99850 standard; DNA; 17 BP.
```

```

XX AC ACA99850;
XX
XX DT 28-JUL-2003 (first entry)
XX
XX DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #343.
XX
XX KM Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
XX KM G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytosolic; ss.
XX OS Homo sapiens.
XX
XX PN MO2003031621-A2.
XX
XX PD 17-APR-2003.
XX
XX PF 11-OCT-2002; 2002WO-US032599.
XX
XX PR 12-OCT-2001; 2001US-0329000P.
XX
XX PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
XX PI Zhang J;
XX
XX DR WPI; 2003-381720/36.
XX
XX PT New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
XX PT investigating and/or treating disorders associated with aberrant
XX PT expression or activity of GPCR-A-1, such as tumors and cancers.
XX
XX PS Example 2; SEQ ID NO 367; 156bp; English.
XX
XX CC The invention describes an isolated nucleic acid encoding a G protein
XX CC coupled receptor (GPCR), mutations of which cause cancer, comprising a
XX CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
XX CC 409 residue amino acid sequence, or their degenerate variants, encoding a
XX CC without conservative amino acid substitutions, or complements of the
XX CC sequence of them. The encoding nucleic acid is not more than 100 kbase in
XX CC length. The methods and compositions of the present invention are useful
XX CC for diagnosing, investigating and/or treating disorders associated with
XX CC aberrant expression or activity of GPCR-A-1, such as tumours and cancers.
XX CC This sequence represents an oligonucleotide used to analyse the gene
XX CC encoding human G-protein coupled receptor GPCR-A-1
XX
XX SQ Sequence 17 BP; 7 A; 2 C; 5 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
XX Matches 15; Conservative 0; Mismatches 2;
XX
XX QY 46 ATGGAACATTAAGAAGT 62
XX ||||| ||||| |||||
XX Db 1 ATGAGCATTAAGAAGT 17
XX
XX RESULT 156
XX ADB42737/c
XX ID ADB42737 standard; DNA, 17 BP.
XX
XX AC ADB42737;
XX
XX DT 18-DEC-2003 (revised)
XX DT 04-DEC-2003 (first entry)
XX
XX DE Tumour suppression/reversion associated nucleotide #3060.
XX
XX KM cytosolic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
XX KM primer; probe; tumour suppression; tumour reversion; apoptosis;
XX KM virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
XX diagnosis.
XX
XX OS Homo sapiens.
XX

```

```

XX PN MO2003040369-A2.
XX
XX PD 15-MAY-2003.
XX
XX PF 17-SEP-2002; 2002WO-IB004219.
XX
XX PR 17-SEP-2001; 2001FR-00011981.
XX
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX
XX PI Telerman A, Amson R, Tuijinder M;
XX
XX DR WPI; 2003-441574/41.
XX
XX PT New nucleic acid encoding human prostate membrane-specific antigen,
XX PT useful e.g. for treatment of tumors and viral infection, also related
XX PT polypeptide and antibodies.
XX
XX PS Disclosure; Page 389; 771pp; French.
XX
XX CC The invention relates to the isolation of 6327 nucleotide sequences,
XX CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
XX CC sequence having at least 80% identity after optimal alignment, with the
XX CC nucleotides, a sequence that hybridizes under stringent conditions with
XX CC the nucleotides, or the complement, or corresponding RNA, of the
XX CC nucleotides. The nucleotides are used as probes or primers for detecting,
XX CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
XX CC sense and antisense sequences, of nucleotides involved in tumour
XX CC suppression or reversion, apoptosis and or viral resistance, to produce
XX CC recombinant polypeptides, and to prepare transgenic animals, as
XX CC experimental models. The nucleotides (also vectors containing them and
XX CC (ab) against the polypeptide are useful for prevention and/or treatment
XX CC of viral infections or diseases characterized by development of tumours
XX CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
XX CC Analysis of the expression of the nucleotides can be used for diagnosis
XX CC and/or prognosis of these diseases. The nucleotides and polypeptides can
XX CC also be used to screen for their specific interactive molecules,
XX CC potentially useful for treating diseases associated with abnormal
XX CC expression of the nucleotides.
XX
XX SQ Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
XX Matches 15; Conservative 0; Mismatches 2;
XX
XX QY 248 CAAATGCTGCTTGATC 264
XX ||||| ||||| |||||
XX Db 17 CAAAGCTGCTTGATC 1
XX
XX RESULT 157
XX ADC04247/c
XX ID ADC04247 standard; DNA, 17 BP.
XX
XX AC ADC04247;
XX
XX DT 18-DEC-2003 (first entry)
XX DT
XX DE Human Na/H exchanger-like protein 1 gene oligonucleotide #694.
XX
XX KM ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
XX KM NH2LFL; passive replacement therapy; vaccine; diagnosis.
XX
XX OS Homo sapiens.
XX
XX PN EP1273660-A2.
XX
XX PD 08-JAN-2003.
XX
XX PF 25-JAN-2002; 2002BP-00001160.
XX

```


PR 30-JAN-2001; 2001WO-US000666.
 PR 23-MAY-2001; 2001US-00864761.
 PR 21-DEC-2001; 2001US-0343331P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y;
 XX
 DR WPI; 2003-302724/30.
 XX
 PT New human sodium-hydrogen exchanger like protein 1 (NHEPL1), useful as a
 PT passive replacement therapy or as a vaccine for treating or preventing
 PT disorders associated with aberrant expression or activity of human
 PT NHEPL1.
 XX
 PS Example 2; SEQ ID NO 734; 468bp; English.
 XX
 CC The invention relates to a nucleic acid molecule which encodes a Na⁺/H⁺
 CC exchanger like protein (NHEPL1). The NHEPL1 nucleic acid molecule, NHEPL1
 CC polypeptide, an antibody against the protein or its antigen-binding
 CC fragment is useful in therapy. The NHEPL1 nucleic acid molecule, NHEPL1
 CC polypeptide and an agonist are particularly useful for manufacturing a
 CC medicament for treating or preventing a disorder associated with
 CC decreased expression or activity of human NHEPL1. The antibody or its
 CC antigen-binding fragment, and an antagonist, are useful for manufacturing
 CC a medicament for treating or preventing a disorder associated with
 CC increased expression or activity of human NHEPL1. The NHEPL1 nucleic acid
 CC or protein is useful as passive replacement therapy, as a vaccine, or in
 CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
 CC spanning the sequence of the human NHEPL1 gene (ADC03514).
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 167 CCACCACTGTCACGGA 183
 17 CCACCACTGTCACGGA 1
 Db
 RESULT 158
 ADD69470/c
 ID ADD69470 standard; DNA; 17 BP.
 XX
 AC ADD69470;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE 3' anchored (ISSR)-PCR primer - SEQ ID 28.
 XX
 KM inter-simple sequence repeat; ISSR; SSR; PCR; primer; genotyping; plant;
 KM animal; Basmati rice; ss.
 XX
 OS Synthetic.
 XX
 PN WO2003085133-A2.
 PN
 PD 16-OCT-2003.
 PD
 PF 09-JAN-2003; 2003WO-IB000041.
 PF
 PR 08-APR-2002; 2002IN-CH000260.
 PR
 PA (DNAF-) CENT DNA FINGERPRINTING & DIAGNOSTICS.
 XX
 PI Nagaraaju JG;
 PI
 DR WPI; 2003-804317/75.
 DR
 XX New set of inter-simple sequence repeats (ISSR)-PCR primers for
 PT genotyping eukaryotes, useful for genotyping diverse genomes of plant and

PT animal systems.
 XX
 PS Claim 1; SEQ ID NO 28; 60pp; English.
 XX
 CC The invention relates to a novel set of inter-simple sequence repeats
 CC (ISSR)-PCR primers for genotyping eukaryotes. The primers of the
 CC invention may be useful for genotyping diverse genomes of plant and
 CC animal systems, in particular for distinguishing Basmati rice varieties
 CC from non-Basmati rice varieties and traditional Basmati rice varieties
 CC from evolved Basmati rice varieties. The current sequence is that of the
 CC 3' anchored (ISSR)-PCR primer of the invention.
 XX
 SQ Sequence 17 BP; 11 A; 1 C; 4 G; 1 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 62 TGGTCTTCTTCTTCTT 78
 17 TAGTCTTCTTCTTCTT 1
 Db
 RESULT 159
 ADL47944
 ID ADL47944 standard; RNA; 17 BP.
 XX
 AC ADL47944;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human IKK-gamma substrate sequence #454.
 XX
 KM antisense oligonucleotide; neurite growth inhibitor; NCGO;
 KM prostaglandin D2 receptor; PTGDR; Ikappab kinase; IKK;
 KM protein kinase PKR; cerebrovascular accident;
 KM central nervous system injury; CNS injury; spinal cord injury; cancer;
 KM melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KM metastasis; asthma; Crohn's disease; diabetes; obesity;
 KM autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KM graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KM allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KM substrate; ds.
 XX
 OS Unidentified.
 XX
 FN WO200281628-A2.
 FN
 PD 17-OCT-2002.
 PD
 PF 03-APR-2002; 2002WO-US010512.
 PF
 PR 05-APR-2001; 2001US-00827395.
 PR
 PR 29-MAY-2001; 2001US-0284412P.
 PR
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA
 PI Blatt L, Chowrira B, Haeblerl P, Mcswiggen J, Fossnaugh K;
 PI
 DR WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor; prostaglandin D2 receptor; Ikappab kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 PS Claim 59; SEQ ID NO 1477; 317bp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2e+02; 2; Mismatches 0; Gaps 0;
Matches 13; Conservative 2; Indels 0; Gaps 0;

OY 335 GGAGTACTGCAACTG 351
Db 1 GGAGTACGCAACTCG 17

RESULT 160

ADL48360
ID ADL48360 standard; RNA; 17 BP.

XX ADL48360;

XX 20-MAY-2004 (first entry)

XX Human IKK-gamma substrate sequence #870.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX proteoglycan D2 receptor; PTGDR; Ikappab kinase; IKK;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
XX Unidentified.

XX WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowira B, Haeblerl P, Meswigen J, Fossnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

XX growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or

XX protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1893; 317bp; English.

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 7 A; 3 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2e+02; 2; Mismatches 0; Gaps 0;
Matches 13; Conservative 2; Indels 0; Gaps 0;

OY 336 GGAGTACTGCAACTGA 352
Db 1 GGAGTACGCAACTGA 17

RESULT 161

AAZ56074/C
ID AAZ56074 standard; DNA; 18 BP.

XX AAZ56074;

XX 23-MAR-2000 (first entry)

XX Phospholipase A2 group IV antisense molecule #43.

XX Phospholipase A2 group IV; PLA2; antisense compound; inhibic; tumour;
XX infection; inflammation; phosphorothioate; ss.
XX Homo sapiens.

XX Key

XX Location/Qualifiers

XX misc_feature 1..18

XX /tag= a

XX /note= "Phosphorothioate internucleoside linkage"

XX modified_base 1..4

XX /tag= b

XX /note= "Optionally 2'-methoxyethyl (2'-MOE) nucleotides.

XX Cytidine residues in the 2'-MOE wing are 5-

XX methylcytidine"

XX modified_base 15..18

XX /tag= c

XX /note= "Optionally 2'-methoxyethyl (2'-MOE) nucleotides.

XX Cytidine residues in the 2'-MOE wing are 5-

XX methylcytidine"

XX US6008344-A.

XX 28-DEC-1999.

XX 23-FEB-1999; 99US-00255893.

XX 23-FEB-1999; 99US-00255893.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Cowsett LM;

XX WPI; 2000-086226/07.

XX Antisense oligonucleotides inhibit expression of human phospholipase A2

XX Group IV, useful for diagnosis, treatment and prevention of tumors,

XX infection and inflammation.

XX Claim 11; Col 39; 32pp; English.

CC		assays; oligo- or poly-nucleotides that modulate expression of a target
CC		sequence, particularly antisense sequences and ribozymes, potentially
CC		useful as pharmaceuticals. RC provide (a) effective analysis of
CC		biological activity of many test sequences against specific targets;
CC		(b)
CC		monitoring of mRNA levels without the cost and extensive pipetting
CC		required in reverse transcription PCR; and (c) use of high-throughput,
CC		microtitre well formats for screening, with the reaction (light emission)
CC		read directly from the wells, with exactly the same conditions for each
CC		well (no need for a set of probes as in e.g. the Tagman assay). The
CC		method is especially useful for screening primary cells (or other cells
CC		that are difficult to obtain) or where target mRNA is expressed at very
CC		low levels. The present sequence is used in the exemplification of the
CC		present invention.
SQ		
SX	Sequence 18 BP; 4 A; 9 C; 2 G; 3 T; 0 U; 0 Other;	
Dq	Query Match 0.2%; Score 13.6; DB 1; Length 18; Best Local Similarity 88.2%; Pred. No. 2.3e+02; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Gy	324 CGGTGTCAGTGGAGT 340 Db 18 CAGTGCGCAGTGGAGT 2	
RESULT 163		
ID	ADO33415/c	
XX	ADO33415 standard; DNA; 24 BP.	
AC	ADO33415;	
DT		
DE	12-AUG-2004 (first entry)	
xx	FAM/TAMRA-labelled probe used to analyse human Lp(a) DNA.	
KM	apolipoprotein B; ApOB; cardiovascular; arteriosclerotic;	
KW	antilipemic; antidiabetic; anorectic; cardiac; vasotropic; hypotenative;	
KV	anabolic; eating disorder; cytostatic; endocrine; vasotropic;	
KW	neuroprotective; noctropic; lipid; cholesterol metabolism;	
KW	hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;	
KW	Von Gierke's disease; lipodystrophy; Cushing's syndrome;	
KW	sexual ateleiotic dwarfism; hyperthyroidism; hypertension;	
KW	anorexia nervosa; Werner's syndrome; hepatoma; multiple myeloma; uraemia;	
KW	impotence; obstructive liver disease; Alzheimer's; dementia; diabetes;	
OS	obesity; atherosclerosis; human; ss; probe; apolipoprotein(a); Lp(a).	
XX	Homo sapiens.	
PN	WO2004044181-A2.	
PD	27-MAY-2004.	
PE	13-NOV-2003; 2003WO-USO36411.	
PR	13-NOV-2002; 2002US-0426234P.	
PR	15-MAY-2003; 2003WO-USO15493.	
PA	(ISIS-) ISIS PHARM INC.	
FI	Crooke R, Graham M, Lemonidis-Tardet K, Dobie KW;	
DR	WI; 2004-420321/39.	
PT	Antisense oligonucleotide compound that inhibits expression of mRNA	
PT	encoding human apolipoprotein B, useful for treating hyperlipidemia,	
PT	diabetes, obesity, von Gierke's disease, lipodystrophies, Cushing's	
PT	syndrome.	
PS	Example 57; SEQ ID NO 863; 483bp; English.	
CC	The invention relates to a novel antisense compound where the compound	
CC	hybridises to and inhibits expression of mRNA encoding human	
CC	apolipoprotein B (ApOB) after 16-24 hours by at least 30% in 80%	

CC confluent HepG2 cells in culture at a concentration of 150 nM. The
 CC compound of the invention demonstrates cardiovascular, CC
 CC antiarteriosclerotic, antilipemic, antidiabetic, anorectic, cardiant,
 CC vasotrophic, hypotensive, anabolic, eating disorder-related, cytostatic,
 CC endocrine, vasotropic, neuroprotective and nootropic activities and may
 CC be useful for inhibiting the expression of apolipoprotein B in cells or
 CC tissues in vivo in order to address a condition associated with abnormal
 CC lipid or cholesterol metabolism. The compound may be useful for
 CC decreasing circulating lipoprotein levels, triglyceride levels,
 CC cholesterol levels, lipid levels, fatty acid levels, acute phase
 CC reactants and chylomicrons and thus may be utilized during treatment of
 CC hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia,
 CC cardiovascular disorders, Von Gierke's disease, lipodystrophy, Cushing's
 CC syndrome, sexual ateliotic dwarfism, hyperthyroidism, hypertension,
 CC anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,
 CC lipodystrophy, obstructive liver disease, Alzheimer's disease, dementia,
 CC diabetes, obesity and arteriosclerosis. The current sequence is that of
 CC the FAM/7MMPA-labelled probe of the invention which was used to analyse
 CC human apolipoprotein(a) [Lp(a)] DNA.

SO Sequence 24 BP; 3 A; 6 C; 10 G; 5 T; 0 U; 0 Other;

Query Match 0.2%; Score 13.6; DB 1; Length 24;

Best Local Similarity 80.0%; Pred. No. 4.7e+02;

Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

336 GCAGTCTCGACCTGACGC 355

24 GCAGTCTCTCCACCTGACAC 5

RESULT 164

AAT37574

ID AAT37574 standard; mRNA; 15 BP.

XX AAT37574;

11-NOV-1996 (first entry)

Apo(a) mRNA (nt. pos. 9031) hammerhead ribozyme target sequence.

Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

hammerhead ribozyme; target sequence; diagnosis; treatment;

lipoprotein (a); arteriosclerosis; myocardial infarction; stroke;

restenosis; heart disease; human; ss.

Homo sapiens.

WO9609392-A1.

28-MAR-1996.

21-SEP-1995; 95WO-US011995.

23-SEP-1994; 94US-00311760.

(RIBO-) RIBOZYME PHARM INC.

Stinchcomb DT, Mcswigen J, Newton RS, Ramharack R;

WPI; 1996-188454/19.

Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 treatment of conditions related to Lp(a) levels, e.g. arteriosclerosis,
 myocardial infarction, and heart diseases.

Claim 2; Page 18; 37pp; English.

A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 complementary to the present sequence (nucleotide position 9031). The
 ribozyme blocks to some extent apo(a) expression, and can therefore be
 used to diagnose or treat conditions related to lipoprotein (a) levels.

CC e.g. arteriosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from human apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sep'd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen

SO Sequence 15 BP; 5 A; 4 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 13.4; DB 1; Length 15;

Best Local Similarity 80.0%; Pred. No. 1.7e+02;

Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

474 CCATGCTAATGACCA 488

1 CCACGGTAUGGACA 15

RESULT 165

AAT37749

ID AAT37749 standard; mRNA; 15 BP.

XX AAT37749;

18-NOV-1996 (first entry)

Apo(a) mRNA (nt. pos. 12159) hammerhead ribozyme target sequence.

Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

hammerhead ribozyme; target sequence; diagnosis; treatment;

lipoprotein (a); arteriosclerosis; myocardial infarction; stroke;

restenosis; heart disease; monkey; ss.

Cebus apella.

WO9609392-A1.

28-MAR-1996.

21-SEP-1995; 95WO-US011995.

23-SEP-1994; 94US-00311760.

(RIBO-) RIBOZYME PHARM INC.

Stinchcomb DT, Mcswigen J, Newton RS, Ramharack R;

WPI; 1996-188454/19.

Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 treatment of conditions related to Lp(a) levels, e.g. arteriosclerosis,
 myocardial infarction, and heart diseases.

Claim 3; Page 21; 37pp; English.

A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 complementary to the present sequence (nucleotide position 12159). The
 ribozyme blocks to some extent apo(a) expression, and can therefore be
 used to diagnose or treat conditions related to lipoprotein (a) levels,
 e.g. arteriosclerosis, myocardial infarction, stroke, restenosis and heart
 disease. PCR was used to generate a substrate for T7 RNA polymerase
 transcription from monkey apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sep'd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen

SO Sequence 15 BP; 4 A; 5 C; 2 G; 0 T; 4 U; 0 Other;

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.7e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY 421 GCTCCTTCGACAA 435
|||:|||||
DB 1 GCUCUCUCGACAA 15

RESULT 166
AAT37710
ID AAT37710 standard; mRNA; 15 BP.

AC AAT37710;
DT 13-NOV-1996 (first entry)

DE Apo(a) mRNA (nt. pos. 127) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW restenosis; heart disease; monkey; ss.

XX Cebus apella.

XX W09609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

XX 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
myocardial infarction, and heart diseases.

XX Claim 3; Page 21; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
(apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
complementary to the present sequence (nucleotide position 127). The
ribozyme blocks to some extent apo(a) expression, and can therefore be
used to diagnose or treat conditions related to lipoprotein (a) levels,
e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
disease. PCR was used to generate a substrate for T7 RNA polymerase
transcription from monkey apo(a) cDNA clones. Labelled transcripts were
synthesised in vitro to form 2 templates. The oligonucleotides and
labelled transcripts were annealed, RNaseH added and the mixts.
incubated. After a designated time the reactions were stopped, and RNA
sepd. on sequencing polyacrylamide gels. The percentage of substrate
cleaved was determined by autoradiographic quantification, and the most
accessible ribozyme target sites chosen

XX Sequence 15 BP; 1 A; 8 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.7e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY 377 CTGCGGTGCGCCTC 391
|||:|||||
DB 1 CUGCGUCGACACUC 15

RESULT 167
AAT37584
ID AAT37584 standard; mRNA; 15 BP.

XX AAT37584;

DT 11-NOV-1996 (first entry)

DE Apo(a) mRNA (nt. pos. 10345) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW restenosis; heart disease; human; ss.

XX Homo sapiens.

XX W09609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

XX 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
myocardial infarction, and heart diseases.

XX Claim 2; Page 18; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
(apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
complementary to the present sequence (nucleotide position 10345). The
ribozyme blocks to some extent apo(a) expression, and can therefore be
used to diagnose or treat conditions related to lipoprotein (a) levels,
e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
disease. PCR was used to generate a substrate for T7 RNA polymerase
transcription from human apo(a) cDNA clones. Labelled transcripts were
synthesised in vitro to form 2 templates. The oligonucleotides and
labelled transcripts were annealed, RNaseH added and the mixts.
incubated. After a designated time the reactions were stopped, and RNA
sepd. on sequencing polyacrylamide gels. The percentage of substrate
cleaved was determined by autoradiographic quantification, and the most
accessible ribozyme target sites chosen

XX Sequence 15 BP; 3 A; 5 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.7e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY 420 GGCTCCTTCGACAA 434
|||:|||||
DB 1 GCUCUCUCGACAA 15

RESULT 168

AAT37628
ID AAT37628 standard; mRNA; 15 BP.

XX AAT37628;

DT 11-NOV-1996 (first entry)

DE Apo(a) mRNA (nt. pos. 11098) hammerhead ribozyme target sequence.

```

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW restenosis; heart disease; human; ss.
XX
OS Homo sapiens.
XX
XX MO9609392-A1.
XX
XX 28-MAR-1996.
XX
XX 21-SEP-1995; 95WO-US011995.
XX
XX 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
XX WPI; 1996-188454/19.
XX
XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
XX myocardial infarction, and heart diseases.
XX
XX Claim 2; Page 18; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX complementary to the present sequence (nucleotide position 11098). The
XX ribozyme blocks to some extent apo(a) expression, and can therefore be
XX used to diagnose or treat conditions related to lipoprotein (a) levels,
XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX disease. PCR was used to generate a substrate for T7 RNA polymerase
XX transcribed from human apo(a) cDNA clones. Labelled transcripts were
XX synthesised in vitro to form 2 templates. The oligonucleotides and
XX labelled transcripts were annealed, RNaseH added and the mixts.
XX incubated. After a designated time the reactions were stopped, and RNA
XX sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX cleaved was determined by autoradiographic quantification, and the most
XX accessible ribozyme target sites chosen
XX
SQ Sequence 15 BP; 3 A; 3 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.7e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 147 GAGTTATCGAGGCAC 161
DB 1 GAGTUAUCGAGGCUC 15

RESULT 169
AAT37762
ID AAT37762 standard; mRNA; 15 BP.
XX
XX AAT37762;
XX
XX 18-NOV-1996 (first entry)
XX
XX Apo(a) mRNA (nt. pos. 10741) hammerhead ribozyme target sequence.
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW restenosis; heart disease; monkey; ss.
XX
XX Cebus apella.
XX
XX MO9609392-A1.
XX
XX
XX

```

```

PD 28-MAR-1996.
XX
XX 21-SEP-1995; 95WO-US011995.
XX
XX 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
XX WPI; 1996-188454/19.
XX
XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
XX myocardial infarction, and heart diseases.
XX
XX Claim 3; Page 21; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX complementary to the present sequence (nucleotide position 10741). The
XX ribozyme blocks to some extent apo(a) expression, and can therefore be
XX used to diagnose or treat conditions related to lipoprotein (a) levels,
XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX disease. PCR was used to generate a substrate for T7 RNA polymerase
XX transcribed from monkey apo(a) cDNA clones. Labelled transcripts were
XX synthesised in vitro to form 2 templates. The oligonucleotides and
XX labelled transcripts were annealed, RNaseH added and the mixts.
XX incubated. After a designated time the reactions were stopped, and RNA
XX sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX cleaved was determined by autoradiographic quantification, and the most
XX accessible ribozyme target sites chosen
XX
SQ Sequence 15 BP; 5 A; 4 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.7e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 170 CCACGTCTCACAGAA 184
DB 1 CCACUGUACACAGAA 15

RESULT 170
AAT37579
ID AAT37579 standard; mRNA; 15 BP.
XX
XX AAT37579;
XX
XX 11-NOV-1996 (first entry)
XX
XX Apo(a) mRNA (nt. pos. 11779) hammerhead ribozyme target sequence.
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW restenosis; heart disease; human; ss.
XX
XX Homo sapiens.
XX
XX MO9609392-A1.
XX
XX 28-MAR-1996.
XX
XX 21-SEP-1995; 95WO-US011995.
XX
XX 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
XX
XX
XX

```

DR WPI; 1996-188454/19.

XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and

PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,

PT myocardial infarction, and heart diseases.

XX

PS Claim 2; Page 18; 37pp; English.

XX

CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)

CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms

CC complementary to the present sequence (nucleotide position 11779). The

CC ribozyme blocks to some extent apo(a) expression, and can therefore be

CC used to diagnose or treat conditions related to lipoprotein (a) levels,

CC e.g. atherosclerosis, myocardial infarction, stroke, reestenosis and heart

CC disease. PCR was used to generate a substrate for T7 RNA polymerase

CC transcription from human apo(a) cDNA clones. Labelled transcripts were

CC synthesised in vitro to form 2 templates. The oligonucleotides and

CC labelled transcripts were annealed, RNaseH added and the mixts.

CC incubated. After a designated time the reactions were stopped, and RNA

CC sepd. on sequencing polyacrylamide gels. The percentage of substrate

CC cleaved was determined by autoradiographic quantification, and the most

CC accessible ribozyme target sites chosen

CC

SQ Sequence 15 BP; 5 A; 6 C; 2 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 13.4; DB 1; Length 15;

Best Local Similarity 80.0%; Pred. No. 1.7e+02;

Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 168 CACCACCTGTACAGG 182

Db 1 CACCACUACACAGG 15

|||||:|||||

RESULT 171

AAT37578

ID AAT37578 standard; mRNA; 15 BP.

XX

AC AAT37578;

XX

DT 11-NOV-1996 (first entry)

XX

DE Apo(a) mRNA (nt. pos. 10222) hammerhead ribozyme target sequence.

XX

KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

KW hammerhead ribozyme; target sequence; diagnosis; treatment;

KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;

KW reestenosis; heart disease; human; ss.

XX

OS Homo sapiens.

XX

PN WO9609392-A1.

XX

PD 28-MAR-1996.

XX

PF 21-SEP-1995; 95WO-US011995.

XX

PR 23-SEP-1994; 94US-00311760.

XX

PA (RIBO-) RIBOZYME PHARM INC.

XX

PI Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;

XX

DR WPI; 1996-188454/19.

XX

XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and

PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,

PT myocardial infarction, and heart diseases.

XX

PS Claim 2; Page 18; 37pp; English.

XX

CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)

CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms

CC complementary to the present sequence (nucleotide position 11779). The

CC ribozyme blocks to some extent apo(a) expression, and can therefore be

CC used to diagnose or treat conditions related to lipoprotein (a) levels,

CC e.g. atherosclerosis, myocardial infarction, stroke, reestenosis and heart

CC disease. PCR was used to generate a substrate for T7 RNA polymerase

CC transcription from human apo(a) cDNA clones. Labelled transcripts were

CC synthesised in vitro to form 2 templates. The oligonucleotides and

CC labelled transcripts were annealed, RNaseH added and the mixts.

CC incubated. After a designated time the reactions were stopped, and RNA

CC sepd. on sequencing polyacrylamide gels. The percentage of substrate

CC cleaved was determined by autoradiographic quantification, and the most

CC accessible ribozyme target sites chosen

CC

SQ Sequence 15 BP; 5 A; 6 C; 2 G; 0 T; 2 U; 0 Other;

CC complementary to the present sequence (nucleotide position 10222). The

CC ribozyme blocks to some extent apo(a) expression, and can therefore be

CC used to diagnose or treat conditions related to lipoprotein (a) levels,

CC e.g. atherosclerosis, myocardial infarction, stroke, reestenosis and heart

CC disease. PCR was used to generate a substrate for T7 RNA polymerase

CC transcription from human apo(a) cDNA clones. Labelled transcripts were

CC synthesised in vitro to form 2 templates. The oligonucleotides and

CC labelled transcripts were annealed, RNaseH added and the mixts.

CC incubated. After a designated time the reactions were stopped, and RNA

CC sepd. on sequencing polyacrylamide gels. The percentage of substrate

CC cleaved was determined by autoradiographic quantification, and the most

CC accessible ribozyme target sites chosen

CC

SQ Sequence 15 BP; 3 A; 4 C; 2 G; 0 T; 6 U; 0 Other;

Query Match 0.2%; Score 13.4; DB 1; Length 15;

Best Local Similarity 53.3%; Pred. No. 1.7e+02;

Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGCTCCTATGTGA 311

Db 1 AGCCCCUAGUGUUA 15

|||||:|||||

RESULT 172

AAT37580

ID AAT37580 standard; mRNA; 15 BP.

XX

AC AAT37580;

XX

DT 11-NOV-1996 (first entry)

XX

DE Apo(a) mRNA (nt. pos. 10223) hammerhead ribozyme target sequence.

XX

KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

KW hammerhead ribozyme; target sequence; diagnosis; treatment;

KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;

KW reestenosis; heart disease; human; ss.

XX

OS Homo sapiens.

XX

PN WO9609392-A1.

XX

PD 28-MAR-1996.

XX

PF 21-SEP-1995; 95WO-US011995.

XX

PR 23-SEP-1994; 94US-00311760.

XX

PA (RIBO-) RIBOZYME PHARM INC.

XX

PI Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;

XX

DR WPI; 1996-188454/19.

XX

XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and

PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,

PT myocardial infarction, and heart diseases.

XX

PS Claim 2; Page 18; 37pp; English.

XX

CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)

CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms

CC complementary to the present sequence (nucleotide position 10223). The

CC ribozyme blocks to some extent apo(a) expression, and can therefore be

CC used to diagnose or treat conditions related to lipoprotein (a) levels,

CC e.g. atherosclerosis, myocardial infarction, stroke, reestenosis and heart

CC disease. PCR was used to generate a substrate for T7 RNA polymerase

CC transcription from human apo(a) cDNA clones. Labelled transcripts were

CC synthesised in vitro to form 2 templates. The oligonucleotides and

CC labelled transcripts were annealed, RNaseH added and the mixts.

CC incubated. After a designated time the reactions were stopped, and RNA

CC sepd. on sequencing polyacrylamide gels. The percentage of substrate

Query Match	0.2%	Score 13.4	D8 1	Length 15
Best local Similarity	66.7%	Pred. No. 1.7e+02		
Matches	10	Conservative	4	Mismatches 1
				Indels 0
				Gaps 0
QY	201	GTGCATCTATGACACC	215	

RESULT 175
AA137760
ID AA137760 standard; mRNA; 15 BP
XX
AC AA137760;
XX


```

DT 18-NOV-1996 (first entry)
XX
XX Apo(a) mRNA (nt. pos. 10736) hammerhead ribozyme target sequence.
DE
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; monkey; ss.
XX
XX Cebus apella.
OS
XX
XX WO9609392-A1.
XX
XX
XX 28-MAR-1996.
XX
XX
XX 21-SEP-1995; 95WO-US011995.
XX
XX 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Mcswigen J, Newton RS, Ramharack R;
XX WPI; 1996-188454/19.
XX
XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.
XX
XX Claim 3; Page 21; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX complementary to the present sequence (nucleotide position 10736). The
XX ribozyme blocks to some extent apo(a) expression, and can therefore be
XX used to diagnose or treat conditions related to lipoprotein (a) levels,
XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX disease. PCR was used to generate a substrate for T7 RNA polymerase
XX transcribed from monkey apo(a) cDNA clones. Labelled transcripts were
XX synthesised in vitro to form 2 templates. The oligonucleotides and
XX labelled transcripts were annealed, RNaseH added and the mixts.
XX incubated. After a designated time the reactions were stopped, and RNA
XX sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX cleaved was determined by autoradiographic quantification, and the most
XX accessible ribozyme target sites chosen
XX
XX Sequence 15 BP; 5 A; 4 C; 3 G; 0 T; 3 U; 0 Other;
SQ
Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.7e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 170 CCACTGTCACAGAA 184
DB 1 CCACUGUUAACAGAA 15
RESULT 176
AAT37573
ID AAT37573 standard; mRNA; 15 BP.
XX
XX AAT37573;
AC
XX 11-NOV-1996 (first entry)
XX
XX Apo(a) mRNA (nt. pos. 11440) hammerhead ribozyme target sequence.
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; human; ss.
XX
XX Homo sapiens.
OS

```

```

XX
XX WO9609392-A1.
XX
XX 28-MAR-1996.
XX
XX
XX 21-SEP-1995; 95WO-US011995.
XX
XX 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Mcswigen J, Newton RS, Ramharack R;
XX WPI; 1996-188454/19.
XX
XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.
XX
XX Claim 2; Page 18; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX complementary to the present sequence (nucleotide position 11440). The
XX ribozyme blocks to some extent apo(a) expression, and can therefore be
XX used to diagnose or treat conditions related to lipoprotein (a) levels,
XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX disease. PCR was used to generate a substrate for T7 RNA polymerase
XX transcribed from human apo(a) cDNA clones. Labelled transcripts were
XX synthesised in vitro to form 2 templates. The oligonucleotides and
XX labelled transcripts were annealed, RNaseH added and the mixts.
XX incubated. After a designated time the reactions were stopped, and RNA
XX sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX cleaved was determined by autoradiographic quantification, and the most
XX accessible ribozyme target sites chosen
XX
XX Sequence 15 BP; 5 A; 3 C; 4 G; 0 T; 3 U; 0 Other;
SQ
Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.7e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 171 CACTGTCACAGAA 185
DB 1 CACUGUUAACAGAG 15
RESULT 177
AAT37605
ID AAT37605 standard; mRNA; 15 BP.
XX
XX AAT37605;
AC
XX 11-NOV-1996 (first entry)
XX
XX Apo(a) mRNA (nt. pos. 12453) hammerhead ribozyme target sequence.
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; human; ss.
XX
XX Homo sapiens.
OS
XX
XX WO9609392-A1.
XX
XX 28-MAR-1996.
XX
XX 21-SEP-1995; 95WO-US011995.
XX
XX 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX

```

XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
 XX WPI; 1996-188454/19.
 DR
 XX
 PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.
 XX
 PS Claim 2; Page 18; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 12453). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from human apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen

SQ Sequence 15 BP; 4 A; 7 C; 1 G; 0 T; 3 U; 0 Other;

Query Match 0.2%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 1.7e+02;
 Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 500 GCACATCTCCACCA 514
 Db 1 GCACATCTCCACCA 15

RESULT 178

AA137740
 ID AA137740 standard; mRNA; 15 BP.

XX
 AC AA137740;

XX
 DT 13-NOV-1996 (first entry)

XX Apo(a) mRNA (nt. pos. 10225) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 KW hammerhead ribozyme; target sequence; diagnosis; treatment;
 KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 KW restenosis; heart disease; monkey; ss.

XX Cebus apella.

XX WO9609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

XX 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.

XX Claim 3; Page 21; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 10225). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen

SQ Sequence 15 BP; 3 A; 4 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 0.2%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 73.3%; Pred. No. 1.7e+02;
 Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 417 AGAGGCTCTTCGA 431
 Db 1 AGAGGCTCTTCGA 15

RESULT 179
 AA137764
 ID AA137764 standard; mRNA; 15 BP.

XX
 AC AA137764;

XX 18-NOV-1996 (first entry)

XX Apo(a) mRNA (nt. pos. 10742) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 KW hammerhead ribozyme; target sequence; diagnosis; treatment;
 KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 KW restenosis; heart disease; monkey; ss.

XX Cebus apella.

XX WO9609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

XX 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.

XX Claim 3; Page 21; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 10742). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and

CC labelled transcripts were annealed, RNaseH added and the mixes.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen

XX Sequence 15 BP; 5 A; 4 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 0.2%; Score 13.4; DB 1; Length 15;

Best Local Similarity 80.0%; Pred. No. 1.7e+02;

Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Oy 170 CCACTGTCACAGAA 184

Db 1 CCACUCUUCACAGAA 15

RESULT 180

AAT37714

ID AAT37714 standard; mRNA; 15 BP.

XX AAT37714;

DT 13-NOV-1996 (first entry)

DE Apo(a) mRNA (nt. pos. 154) hammerhead ribozyme target sequence.

KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

KW hammerhead ribozyme; target sequence; diagnosis; treatment;

KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;

KW restenosis; heart disease; monkey; ss.

XX Cebus apella.

XX WO9609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

XX 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and

PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,

PT myocardial infarction, and heart diseases.

XX Claim 3; Page 21; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)

XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms

XX complementary to the present sequence (nucleotide position 154). The

XX ribozyme blocks to some extent apo(a) expression, and can therefore be

XX used to diagnose or treat conditions related to lipoprotein (a) levels,

XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart

XX disease. PCR was used to generate a substrate for T7 RNA polymerase

XX transcription from monkey apo(a) cDNA clones. Labelled transcripts were

XX synthesised in vitro to form 2 templates. The oligonucleotides and

XX labelled transcripts were annealed, RNaseH added and the mixes.

XX incubated. After a designated time the reactions were stopped, and RNA

XX sepd. on sequencing polyacrylamide gels. The percentage of substrate

XX cleaved was determined by autoradiographic quantification, and the most

XX accessible ribozyme target sites chosen

XX Sequence 15 BP; 1 A; 8 C; 3 G; 0 T; 3 U; 0 Other;

XX Query Match 0.2%; Score 13.4; DB 1; Length 15;

XX Best Local Similarity 73.3%; Pred. No. 1.7e+02;

Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

RESULT 181

AAT37736

ID AAT37736 standard; mRNA; 15 BP.

XX AAT37736;

DT 13-NOV-1996 (first entry)

DE Apo(a) mRNA (nt. pos. 10222) hammerhead ribozyme target sequence.

KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

KW hammerhead ribozyme; target sequence; diagnosis; treatment;

KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;

KW restenosis; heart disease; monkey; ss.

XX Cebus apella.

XX WO9609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

XX 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and

PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,

PT myocardial infarction, and heart diseases.

XX Claim 3; Page 21; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)

XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms

XX complementary to the present sequence (nucleotide position 10222). The

XX ribozyme blocks to some extent apo(a) expression, and can therefore be

XX used to diagnose or treat conditions related to lipoprotein (a) levels,

XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart

XX disease. PCR was used to generate a substrate for T7 RNA polymerase

XX transcription from monkey apo(a) cDNA clones. Labelled transcripts were

XX synthesised in vitro to form 2 templates. The oligonucleotides and

XX labelled transcripts were annealed, RNaseH added and the mixes.

XX incubated. After a designated time the reactions were stopped, and RNA

XX sepd. on sequencing polyacrylamide gels. The percentage of substrate

XX cleaved was determined by autoradiographic quantification, and the most

XX accessible ribozyme target sites chosen

XX Sequence 15 BP; 4 A; 6 C; 1 G; 0 T; 4 U; 0 Other;

XX Query Match 0.2%; Score 13.4; DB 1; Length 15;

XX Best Local Similarity 73.3%; Pred. No. 1.7e+02;

XX Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

XX Oy 556 CCACTGTCGATAGT 570

XX Db 1 CCACACUCUUCACAGU 15

XX RESULT 182

XX AAT37608

XX ID AAT37608 standard; mRNA; 15 BP.

```

XX AC AAT37608;
XX XX
XX DT 11-NOV-1996 (first entry)
XX XX
XX DE Apo(a) mRNA (nt. pos. 10792) hammerhead ribozyme target sequence.
XX XX
XX KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX KW hammerhead ribozyme; target sequence; diagnosis; treatment;
XX KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX KW restenosis; heart disease; human; ss.
XX OS
XX XX Homo sapiens.
XX EN WO9609392-A1.
XX PD
XX XX 28-MAR-1996.
XX PF
XX XX 21-SEP-1995; 95WO-US011995.
XX PR 23-SEP-1994; 94US-00311760.
XX XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI
XX PI Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
XX DR WPI; 1996-186454/19.
XX PT
XX PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
XX PT myocardial infarction, and heart diseases.
XX PS
XX PS Claim 2; Page 18; 37pp; English.
XX XX
XX CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX CC complementary to the present sequence (nucleotide position 10792). The
XX CC ribozyme blocks to some extent apo(a) expression, and can therefore be
XX CC used to diagnose or treat conditions related to lipoprotein (a) levels,
XX CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX CC disease. PCR was used to generate a substrate for T7 RNA polymerase
XX CC transcription from human apo(a) cDNA clones. Labelled transcripts were
XX CC synthesised in vitro to form 2 templates. The oligonucleotides and
XX CC labelled transcripts were annealed, RNaseH added and the mixes
XX CC incubated. After a designated time the reactions were stopped, and RNA
XX CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX CC cleaved was determined by autoradiographic quantification, and the most
XX CC accessible ribozyme target sites chosen
XX CC
XX SQ Sequence 15 BP; 6 A; 4 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.7e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 525 AAGAACCTGCCAACC 539
DB 1 AAGAACUUGCCACAC 15

RESULT 183
AAT37589
ID AAT37589 standard; mRNA; 15 BP.
XX AC AAT37589;
XX XX
XX DT 11-NOV-1996 (first entry)
XX XX
XX XX Apo(a) mRNA (nt. pos. 12159) hammerhead ribozyme target sequence.
XX XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX KW hammerhead ribozyme; target sequence; diagnosis; treatment;
XX KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;

```

```

KW KW restenosis; heart disease; human; ss.
XX OS
XX OS Homo sapiens.
XX PN WO9609392-A1.
XX PD
XX XX 28-MAR-1996.
XX PF
XX XX 21-SEP-1995; 95WO-US011995.
XX PR 23-SEP-1994; 94US-00311760.
XX XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI
XX PI Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
XX DR WPI; 1996-186454/19.
XX PT
XX PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
XX PT myocardial infarction, and heart diseases.
XX PS
XX PS Claim 2; Page 18; 37pp; English.
XX XX
XX CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX CC complementary to the present sequence (nucleotide position 12159). The
XX CC ribozyme blocks to some extent apo(a) expression, and can therefore be
XX CC used to diagnose or treat conditions related to lipoprotein (a) levels,
XX CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX CC disease. PCR was used to generate a substrate for T7 RNA polymerase
XX CC transcription from human apo(a) cDNA clones. Labelled transcripts were
XX CC synthesised in vitro to form 2 templates. The oligonucleotides and
XX CC labelled transcripts were annealed, RNaseH added and the mixes
XX CC incubated. After a designated time the reactions were stopped, and RNA
XX CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX CC cleaved was determined by autoradiographic quantification, and the most
XX CC accessible ribozyme target sites chosen
XX CC
XX SQ Sequence 15 BP; 5 A; 5 C; 1 G; 0 T; 4 U; 0 Other;

Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.7e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY 548 CTATGACACCACT 562
DB 1 CUAUGAUCACACACU 15

RESULT 184
AAT37738
ID AAT37738 standard; mRNA; 15 BP.
XX AC AAT37738;
XX XX
XX DT 13-NOV-1996 (first entry)
XX XX
XX XX Apo(a) mRNA (nt. pos. 10223) hammerhead ribozyme target sequence.
XX XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX KW hammerhead ribozyme; target sequence; diagnosis; treatment;
XX KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX KW restenosis; heart disease; monkey; ss.
XX XX
XX OS Cebus apella.
XX XX
XX PN WO9609392-A1.
XX PD
XX XX 28-MAR-1996.
XX PF
XX XX 21-SEP-1995; 95WO-US011995.
XX XX

```

```

XX 23-SEP-1994;      94US-00311760.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Stinchcomb DT, Mcswigen J, Newton RS, Ramharack R;
DR WPI, 1996-188454/19.
XX
XX XX Enzymatic RNA moles, which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.
PS Claim 3; Page 21; 37pp; English.
XX
CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 10223). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase
CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed, RNaseH added and the mixts.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen
XX
SQ Sequence 15 BP; 3 A; 4 C; 4 G; 0 T; 4 U; 0 Other;
Query Match          0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. NO. 1.7e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 417 AGAGGCTCCTCCGA 431
Db 1 AGAGGCUCUUCUGA 15
RESULT 185
AA137759
ID AA137759 standard; mRNA, 15 BP.
XX
XX AC AA137759;
XX
XX DT 18-NOV-1996 (first entry)
XX
XX DE Apo(a) mRNA (nt. pos. 12330) hammerhead ribozyme target sequence.
XX
XX KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW restenosis; heart disease; monkey; ss.
XX
XX OS Cebus apella.
XX
XX PN WO9609392-A1.
XX
XX PD 28-MAR-1996.
XX
XX PF 21-SEP-1995; 95WO-US011995.
XX
XX PR 23-SEP-1994; 94US-00311760.
XX
XX RA (RIBO-) RIBOZYME PHARM INC.
XX
XX ST Stinchcomb DT, Mcswigen J, Newton RS, Ramharack R;
XX WPI, 1996-188454/19.
XX
XX Enzymatic RNA moles, which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,

```

myocardial infarction, and heart diseases.

Claim 3: Page 21; 37pp; English.

A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a) (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms complementary to the present sequence (nucleotide position 12330). The ribozyme blocks to some extent apo(a) expression, and can therefore be used to diagnose or treat conditions related to lipoprotein (a) levels, e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart disease. PCR was used to generate a substrate for T7 RNA polymerase transcription from monkey apo(a) cDNA clones. Labelled transcripts were synthesised in vitro to form 2 templates. The oligonucleotides and labelled transcripts were annealed, RNaseH added and the mixts. incubated. After a designated time the reactions were stopped, and RNA sepd. on sequencing polyacrylamide gels. The percentage of substrate cleaved was determined by autoradiographic quantification, and the most accessible ribozyme target sites chosen

Sequence 15 BP; 4 A; 2 C; 3 G; 0 T; 6 U; 0 Other;

Query Match	0.2%	Score 13.4	DB 1	Length 15;
Best Local Similarity	60.0%	Pred. No. 1.7e+02;		
Matches	9;	Conservative 5;	Mismatches 1;	Indels 0; Gaps 0;

199 TGGTCATCTATGACA 213
:|:|:|:|:|:|:|:|
Db 1 UGGUCACUUNAGAVA 15

RESULT 186
AAT37586
AAT37586 standard; mRNA; 15 BP.
AC AAT37586;
XX
DT 11-NOV-1996 (first entry)
XX
DE Apo(a) mRNA (nt. pos. 10346) hammerhead ribozyme target sequence.
XX
KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
KM lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; human; ss.
XX
OS Homo sapiens.
XX
PN WO960392-A1.
XX
PD 28-MAR-1996.
XX
PF 21-SEP-1995; 95WO-US011995.
XX
PR 23-SEP-1994; 94US-00311760.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Mcawiggen J, Newton RS, Ramharack R;
XX WPI; 1996-188454/19.
XX
PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to lp(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.
XX
PS Claim 2; Page 18; 37pp; English.

A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a) (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms complementary to the present sequence (nucleotide position 10346). The ribozyme blocks to some extent apo(a) expression, and can therefore be used to diagnose or treat conditions related to lipoprotein (a) levels, e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart

CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from human apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen
 XX
 XX Sequence 15 BP; 4 A; 5 C; 2 G; 0 T; 4 U; 0 Other;
 SQ
 Query Match 0.2%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 73.3%; Pred. No. 1.7e+02;
 Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
 QY 421 GCTCTCTCCGACAA 435
 1 GCCTCCUCCGACAA 15
 Db
 RESULT 187
 AAT37717
 ID AAT37717 standard; mRNA; 15 BP.
 AC AAT37717;
 XX
 XX 13-NOV-1996 (first entry)
 DT
 XX Apo(a) mRNA (nt. pos. 11257) hammerhead ribozyme target sequence.
 DE
 XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 KW hammerhead ribozyme; target sequence; diagnosis; treatment;
 KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 KM restenosis; heart disease; monkey; ss.
 XX Cebus apella.
 OS
 XX WO9609392-A1.
 PN
 XX 28-MAR-1996.
 PD
 XX 21-SEP-1995; 95WO-US011995.
 PF
 XX 23-SEP-1994; 94US-00311760.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
 PI WPI; 1996-188454/19.
 DR
 XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.
 PT
 XX Claim 3; Page 21; 37pp; English.
 PS
 XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 11257). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen
 XX
 XX Sequence 15 BP; 3 A; 4 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 0.2%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 66.7%; Pred. No. 1.7e+02;
 Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
 QY 124 GATGTCATCCATGGT 138
 1 GACUCGACCAUGGU 15
 Db
 RESULT 188
 AAT37729
 ID AAT37729 standard; mRNA; 15 BP.
 AC AAT37729;
 XX
 XX 13-NOV-1996 (first entry)
 DT
 XX Apo(a) mRNA (nt. pos. 11427) hammerhead ribozyme target sequence.
 DE
 XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 KW hammerhead ribozyme; target sequence; diagnosis; treatment;
 KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 KM restenosis; heart disease; monkey; ss.
 XX Cebus apella.
 OS
 XX WO9609392-A1.
 PN
 XX 28-MAR-1996.
 PD
 XX 21-SEP-1995; 95WO-US011995.
 PF
 XX 23-SEP-1994; 94US-00311760.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
 PI WPI; 1996-188454/19.
 DR
 XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.
 PT
 XX Claim 3; Page 21; 37pp; English.
 PS
 XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 11427). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen
 XX
 XX Sequence 15 BP; 3 A; 4 C; 3 G; 0 T; 5 U; 0 Other;
 SQ
 Query Match 0.2%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 60.0%; Pred. No. 1.7e+02;
 Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
 QY 199 TGGTCATCTATGACA 213
 1 UGGUCUCUUAUGACA 15
 Db

```

RESULT 189
AAT37734
ID AAT37734 standard; mRNA; 15 BP.
XX
AC AAT37734;
XX
DT 13-NOV-1996 (first entry)
XX
DE Apo(a) mRNA (nt. pos. 10207) hammerhead ribozyme target sequence.
XX
KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW restenosis; heart disease; monkey; ss.
XX
OS Cebus apella.
XX
PN MO9609392-A1.
XX
PD 28-MAR-1996.
XX
PF 21-SEP-1995; 95WO-US011995.
XX
PR 23-SEP-1994; 94US-00311760.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
XX
DR WPI; 1996-188454/19.
XX
PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.
XX
PS Claim 3; Page 21; 37pp; English.
XX
CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 10207). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase
CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed, RNaseH added and the mixts.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen
XX
SQ Sequence 15 BP; 4 A; 6 C; 1 G; 0 T; 4 U; 0 Other;
XX
Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.7e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
OY 556 CCACACTCGCATAGT 570
DB 1 CCACACUCUCAUADU 15
XX
RESULT 190
AAT37758
ID AAT37758 standard; mRNA; 15 BP.
XX
AC AAT37758;
XX
DT 18-NOV-1996 (first entry)
XX
DE Apo(a) mRNA (nt. pos. 10687) hammerhead ribozyme target sequence.
XX

```

```

KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW restenosis; heart disease; monkey; ss.
XX
OS Cebus apella.
XX
PN MO9609392-A1.
XX
PD 28-MAR-1996.
XX
PF 21-SEP-1995; 95WO-US011995.
XX
PR 23-SEP-1994; 94US-00311760.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
XX
DR WPI; 1996-188454/19.
XX
PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.
XX
PS Claim 3; Page 21; 37pp; English.
XX
CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 10687). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase
CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed, RNaseH added and the mixts.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen
XX
SQ Sequence 15 BP; 5 A; 4 C; 3 G; 0 T; 3 U; 0 Other;
XX
Query Match 0.2%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.7e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
OY 170 CCACGTGACAGGA 184
DB 1 CCACUCUUAACAGGA 15
XX
RESULT 191
AAT37719
ID AAT37719 standard; mRNA; 15 BP.
XX
AC AAT37719;
XX
DT 13-NOV-1996 (first entry)
XX
DE Apo(a) mRNA (nt. pos. 11266) hammerhead ribozyme target sequence.
XX
KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW restenosis; heart disease; monkey; ss.
XX
OS Cebus apella.
XX
PN MO9609392-A1.
XX
PD 28-MAR-1996.
XX

```

```

XX 21-SEP-1995; 95WO-US011995.
XX 23-SEP-1994; 94US-00311760.
XX (RIBO-) RIBOZYME PHARM INC.
XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
XX WPI, 1996-188454/19.
XX
XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
XX myocardial infarction, and heart diseases.
XX
XX Claim 3; Page 21; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX complementary to the present sequence (nucleotide position 11266). The
XX ribozyme blocks to some extent apo(a) expression, and can therefore be
XX used to diagnose or treat conditions related to lipoprotein (a) levels,
XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX disease. PCR was used to generate a substrate for T7 RNA polymerase
XX transcribed in vitro to form 2 templates. The oligonucleotides were
XX labelled transcripts were annealed, RNaseH added and the mixts.
XX incubated. After a designated time the reactions were stopped, and RNA
XX sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX cleaved was determined by autoradiographic quantification, and the most
XX accessible ribozyme target sites chosen
XX
SQ Sequence 15 BP; 3 A; 3 C; 5 G; 0 T; 4 U; 0 Other;
XX
XX Query Match 0.2%; Score 13.4; DB 1; Length 15;
XX Best Local Similarity 73.3%; Pred. No. 1.7e+02;
XX Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
XX
QY 147 GAGTTATGAGGCAC 161
XX |||:::|||
DB 1 GAGUUNUCCAGGCUC 15
XX
RESULT 192
AAT37731
XX AAT37731 standard; mRNA; 15 BP.
XX
AC AAT37731;
XX
DT 13-NOV-1996 (first entry)
XX
DE Apo(a) mRNA (nt. pos. 11429) hammerhead ribozyme target sequence.
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; monkey; ss.
XX
XX Cebus apella.
XX
XX WO9609392-A1.
XX
XX 28-MAR-1996.
XX
XX 21-SEP-1995; 95WO-US011995.
XX
XX 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
XX WPI, 1996-188454/19.
XX
DR

```

```

XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
XX myocardial infarction, and heart diseases.
XX
XX Claim 3; Page 21; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX complementary to the present sequence (nucleotide position 11429). The
XX ribozyme blocks to some extent apo(a) expression, and can therefore be
XX used to diagnose or treat conditions related to lipoprotein (a) levels,
XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX disease. PCR was used to generate a substrate for T7 RNA polymerase
XX transcribed in vitro to form 2 templates. The oligonucleotides were
XX labelled transcripts were annealed, RNaseH added and the mixts.
XX incubated. After a designated time the reactions were stopped, and RNA
XX sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX cleaved was determined by autoradiographic quantification, and the most
XX accessible ribozyme target sites chosen
XX
SQ Sequence 15 BP; 3 A; 4 C; 3 G; 0 T; 5 U; 0 Other;
XX
XX Query Match 0.2%; Score 13.4; DB 1; Length 15;
XX Best Local Similarity 60.0%; Pred. No. 1.7e+02;
XX Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
XX
QY 199 TGGTCACTATGACA 213
XX |||:::|||
DB 1 UGUCUCCUUAUGACA 15
XX
RESULT 193
AAT37761
XX AAT37761 standard; mRNA; 15 BP.
XX
AC AAT37761;
XX
DT 18-NOV-1996 (first entry)
XX
DE Apo(a) mRNA (nt. pos. 12337) hammerhead ribozyme target sequence.
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; monkey; ss.
XX
XX Cebus apella.
XX
XX WO9609392-A1.
XX
XX 28-MAR-1996.
XX
XX 21-SEP-1995; 95WO-US011995.
XX
XX 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
XX WPI, 1996-188454/19.
XX
XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
XX myocardial infarction, and heart diseases.
XX
XX Claim 3; Page 21; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX complementary to the present sequence (nucleotide position 12337). The
XX

```


CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen

XX
 SQ Sequence 15 BP; 4 A; 4 C; 2 G; 0 T; 5 U; 0 Other;

Qy Query Match 0.2%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 66.7%; Pred. No. 1.7e+02;
 Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Db 201 GTCATCTATGACACC 215
 1 GUCATCAGAGAAC 15

RESULT 194
 AAT37766
 ID AAT37766 standard; mRNA; 15 BP.
 AC AAT37766;
 XX
 DT 18-NOV-1996 (first entry)
 XX
 DE Apo(a) mRNA (nt. pos. 10792) hammerhead ribozyme target sequence.
 XX
 KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 KW hammerhead ribozyme; target sequence; diagnosis; treatment;
 KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 KW restenosis; heart disease; monkey; ss.
 XX
 OS Cebus apella.
 XX
 PN MO9609392-A1.
 XX
 PD 28-MAR-1996.
 XX
 PF 21-SEP-1995; 95WO-US011995.
 XX
 PR 23-SEP-1994; 94US-00311760.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Stinchcomb DT, McSwiggen J, Newton RS, Ramharack R;
 XX
 DR WPI; 1996-188454/19.
 XX
 PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to lp(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.
 PT
 XX
 PS Claim 3; Page 21; 37pp; English.
 XX
 XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 10792). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC cleaved was determined by autoradiographic quantification, and the most

CC accessible ribozyme target sites chosen

XX
 SQ Sequence 15 BP; 5 A; 3 C; 4 G; 0 T; 3 U; 0 Other;

Qy Query Match 0.2%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 1.7e+02;
 Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Db 171 CACTGTCAACGAGAG 185
 1 CACUGUACAGAGAG 15

RESULT 195
 AAT37576
 ID AAT37576 standard; mRNA; 15 BP.
 AC AAT37576;
 XX
 DT 11-NOV-1996 (first entry)
 XX
 DE Apo(a) mRNA (nt. pos. 10207) hammerhead ribozyme target sequence.
 XX
 KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 KW hammerhead ribozyme; target sequence; diagnosis; treatment;
 KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 KW restenosis; heart disease; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN MO9609392-A1.
 XX
 PD 28-MAR-1996.
 XX
 PF 21-SEP-1995; 95WO-US011995.
 XX
 PR 23-SEP-1994; 94US-00311760.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Stinchcomb DT, McSwiggen J, Newton RS, Ramharack R;
 XX
 DR WPI; 1996-188454/19.
 XX
 PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to lp(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.
 PT
 XX
 PS Claim 2; Page 18; 37pp; English.
 XX
 XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 10207). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from human apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC cleaved was determined by autoradiographic quantification, and the most

Qy 282 TCCAGATGCTGTGAC 296
 :|||||:|:|:|

Db 1 UCCAGAUCCUGGC 15

RESULT 196
AAA60234/c
ID AAA60234 standard; DNA, 17 BP.
XX
AC AAA60234;
XX
DT 07-DEC-2000 (first entry)
XX
DE Human HPC2 CDNA sequencing primer SEQ ID NO: 55.
XX
KW Human; mouse; prostate cancer predisposing gene; HPC2;
KW human chromosome 17p; gene therapy; peptide therapy; drug design;
KW PCR primer; sequencing primer; ss.
XX
OS Homo sapiens.
XX
PN MO200027864-A1.
XX
PD 18-MAY-2000.
XX
PF 05-NOV-1999; 99WO-US026055.
XX
PR 06-NOV-1998; 98US-0107468P.
XX
PA (MYRI-) MYRIAD GENETICS INC.
XX
PI Tavtigian SV, Teng DHF, Sward J, Rommens JM,
XX WPI; 2000-376481/32.
XX
PT Human prostate cancer (HPC)2 nucleic acids, polypeptides, and antibodies,
PT useful for treatment and diagnosis of prostate cancer.
XX
PS Example 3; Page 56; 157pp; English.
XX
CC The present sequence is a primer used in the isolation of the human and
CC murine prostate cancer predisposing genes HPC2 and Mm.HPC2. The human
CC version of the gene is found on chromosome 17p. Some alleles cause a
CC predisposition to cancer, particularly prostate cancer. This gene and its
CC protein can be used in peptide and gene therapy for cancer patients, as
CC well as being useful as diagnostic tools (both for cancer sufferers and
CC those with a predisposition to the disease) and in the production of
CC cancer drugs
XX
SQ Sequence 17 BP; 6 A; 4 C; 6 G; 1 T; 0 U; 0 Other;
0.2%; Score 13.4; DB 1; Length 17;
Query Match 93.3%; Pred. No. 2.3e+02;
Best Local Similarity 0; Mismatches 1; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 17 CTTTCGACACCTGC 31
Db 15 CTTTCGACCTGC 1

RESULT 197
ABK03734/c
ID ABK03734 standard; RNA, 17 BP.
XX
AC ABK03734;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human CD20 Amberzyme #83.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotrophic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;

KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
XX
OS Synthetic.
XX
PN MO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM,
XX WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 30; Page 168; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a
CC DNAzyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
CC an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA
CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targeting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO expression of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is an amberzyme molecule of the invention
XX
SQ Sequence 17 BP; 11 A; 0 C; 4 G; 0 T; 2 U; 0 Other;
0.2%; Score 13.4; DB 1; Length 17;
Query Match 93.3%; Pred. No. 2.3e+02;
Best Local Similarity

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 70 CTACTCTTTATTT 84
 |||||
 DB 15 CTCTCTTTATTT 1

RESULT 198
 AAS98969/C
 ID AAS98969 standard; DNA, 17 BP.
 XX
 AC AAS98969;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human prostate cancer predisposing gene (HPC2) sequencing primer #20.
 XX
 KM Human; mouse; HPC2; prostate cancer; neoplastic growth; cytosolic; ss;
 KM gene therapy; prostate cancer predisposing gene; chimpanzee; gorilla;
 KM sequencing primer; PCR primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200185911-A2.
 XX
 PD 15-NOV-2001.
 XX
 PF 07-MAY-2001; 2001WO-US014602.
 XX
 PR 05-MAY-2000; 2000US-00564805.
 XX
 PA (MYRI-) MYRIAD GENETICS INC.
 PA (HOSP-) HOSPITAL FOR SICK CHILDREN.
 XX
 PI Tavitjian SV, Teng DHF, Simard J, Rommens JM;
 XX
 DR WPI; 2002-066599/09.
 XX
 PT Novel nucleic acid sequence encoding HPC2 polypeptide, which is marker
 PT for prostate cancer; is useful in gene therapy techniques to restore HPC2
 PT normal levels by which neoplastic growth is suppressed in recipient cell.
 XX
 PS Example 5; Page 68; 239pp; English.

CC The invention relates to a human prostate cancer predisposing gene coding
 CC for an HPC2 polypeptide. The DNA and protein sequences are useful as
 CC diagnostic reagents for identifying a mutant HPC2 nucleotide sequence in
 CC a suspected mutant HPC2 allele by comparing the sequence of the suspected
 CC mutant HPC2 allele with a wild-type HPC2 sequence. The sequences are also
 CC useful for detecting an alteration in HPC2, where the alteration is
 CC associated with cancer in a human. The method involves analysing an HPC2
 CC gene or an HPC2 gene expression product from a tissue of the human. The
 CC HPC2 gene is useful as a marker for prostate cancer and can be used in
 CC gene therapy techniques to suppress neoplastic growth of recipient cells
 CC which carry the mutant HPC2 allele. The sequences represent primers used
 CC in the methods of the invention, cDNA encoding human and mouse HPC2 and
 CC cDNA encoding HPC2 paralogues and orthologues
 XX

SO Sequence 17 BP; 6 A; 4 C; 6 G; 1 T; 0 U; 0 Other;
 Query Match 0.2%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 17 CTTTCTGGACACTGC 31
 |||||
 DB 15 CTTTCTGGACTCTGC 1

RESULT 199
 ABR35963
 ID ABR35963 standard; DNA, 17 BP.
 XX

AC ABR35963;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID No 1600.
 XX
 KM Cytosolic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KM antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KM schizophrenia; protein chip; gene therapy; tumour suppression;
 KM human fukutin; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO2003025175-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004208.
 XX
 PR 17-SEP-2001; 2001FR-00011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Teierman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313353/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 220; 720pp; French.

CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, ce, is containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX

SO Sequence 17 BP; 7 A; 3 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 0.2%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 218 ATCAACTAATAGCA 232
 |||||
 DB 2 ATCAACATCATAGCA 16

RESULT 200
 ABR37510
 ID ABR37510 standard; DNA, 17 BP.
 XX
 AC ABR37510;
 XX

DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 3147.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001PR-00011978.
XX
PA (MOLR-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumours and cell degeneration, also related polypeptides, antibodies
XX and transfect cells.
XX
PS Disclosure; Page 401; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 4 A; 3 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 0.2%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 75 TCTTTATTTCTGAA 89
DB 3 TCCTTATTTCTGAA 17

RESULT 201
AB265103/c
ID AB265103 standard; RNA; 17 BP.
XX
AC AB265103;
XX
XX 21-MAR-2003 (first entry)
XX

DE Human HER2 DNzyme substrate #560.
XX
XX
KW Human; ribozyme; short interfering RNA; siRNA, HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcwiggan J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
XX HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 4; Page 143; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosstatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in AB259889 - AB262246, AB264544 - AB265331, AB266520 - AB266524,
CC AB266530 - AB266585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
Query Match 0.2%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 276 CAGGATCCAGATGC 290
DB 15 CAGGATCCAGATGC 1

RESULT 202
ACC67694/c
ID ACC67694 standard; DNA; 17 BP.
XX
AC ACC67694;
XX
DT 01-JUN-2003 (first entry)
XX
XX
DE Murine oligonucleotide associated with tumour suppression, SEQ ID 4941.
XX

Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX
OS Mus musculus.
XX
XX
PN WO2003025176-A2.
XX

```

PD 27-MAR-2003.
XX
XX 17-SEP-2002; 2002MO-IB004210.
XX
XX 17-SEP-2001; 2001FR-00011979.
XX
XX (MOLR-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M,
XX WPI; 2003-333167/31.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX Disclosure; Page 608; 738pp; French.
XX
XX The present invention relates to murine oligonucleotides (ACC62754-
XX ACC68806), which are associated with tumour suppression, tumour
XX reversion, apoptosis and virus resistance. The oligonucleotides are
XX useful as (1) as probes and primers for detecting, identifying,
XX quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX gene chip; in vitro as (anti)sense reagents; and (2) for production of
XX recombinant polypeptides. The oligonucleotides are useful for preparation
XX of pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia
XX
XX Sequence 17 BP; 4 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 13.4; DB 1; Length 17;
XX Best Local Similarity 93.3%; Pred. No. 2.3e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 351 GACGCAATGCTCAGA 365
XX |||||
XX 17 GACGCTATGCTCAGA 3
XX
XX RESULT 203
XX ADB39010
XX ID ADB39010 standard; DNA; 17 BP.
XX
XX ADB39010;
XX
XX 04-DEC-2003 (first entry)
XX
XX PCR primer MSIR related to Manduca sexta (tobacco hornworm) APN1a gene.
XX
XX pesticide agent; aminopeptidase N; APN; insect cell; APN inhibitor;
XX exopeptidase; ingested protein; toxin interaction; APN1a;
XX tobacco hornworm; ss; primer; MSIR.
XX
XX Manduca sexta.
XX
XX US6586197-B1.
XX
XX 01-JUL-2003.
XX
XX 07-SEP-2000; 2000US-00657931.
XX
XX 07-SEP-1999; 99US-0153116P.
XX
XX (UYGE-) UNIV GEORGIA RES FOUND INC.
XX
XX Adang MJ, Luo K;
XX
XX WPI; 2003-615532/58.
XX
XX Isolated polynucleotide encoding aminopeptidase N, useful for identifying
XX and screening novel pesticide agents and in facilitating study of
XX aminopeptidase N-toxin interactions.

```

```

XX
XX Example 1; Col 10; 77pp; English.
XX
XX This invention relates to a materials and methods for the identification
XX of novel pesticide agents. Specifically, the invention relates to a novel
XX aminopeptidase N (APN) isolated from Manduca sexta, insect cells
XX expressing APN and methods of screening pesticide agents and APN
XX inhibitors. APN is an exopeptidase that hydrolyses neutral amino acids
XX from the amino (N-) terminal of different proteins. APN has an important
XX role for the final hydrolysis step of ingested proteins and has important
XX pathological roles in other tissues. The methods and compositions of the
XX present invention are useful for identifying and screening novel
XX pesticide agents and in facilitating study of APN-toxin interactions. The
XX present sequence is that of a PCR primer used to amplify the gene
XX encoding the APN1a protein of the invention from Manduca sexta (tobacco
XX hornworm).
XX
XX Sequence 17 BP; 5 A; 4 C; 3 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 13.4; DB 1; Length 17;
XX Best Local Similarity 93.3%; Pred. No. 2.3e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 470 GCTACCATGCTAATG 484
XX |||||
XX 3 GCTACCATGCTAATG 17
XX
XX RESULT 204
XX ADL4870/c
XX ID ADL4870 standard; RNA; 17 BP.
XX
XX ADL4870;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human IKK-gamma substrate sequence #1380.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NNGO;
XX prostaglandin D2 receptor; PRGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeblerl P, Mcawiggen J, Fossnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2403; 317pp; English.

```

CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.

CC SQ Sequence 17 BP; 4 A; 9 C; 3 G; 0 T; 1 U; 0 Other;

Query Match 0.2%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 324 CCGGTCCAGGTGGA 338
DB 15 CCGGTCCAGGTGGA 1

RESULT 205
AAH89308

ID AAH89308 standard; DNA; 20 BP.

XX AAX89308;

DT 21-SEP-1999 (first entry)

DE Primer k1r1 used in RT-PCR analysis of transgenic apo(a) cDNA.

KM Transgenic rabbit; apolipoprotein (a); apolipoprotein B; lipoprotein;
KM atherosclerotic lesion; cholesterol; vascular injury; restenosis; apoB;
KM PCR primer; ss.

OS Synthetic.

PN WO935241-A1.

PD 15-JUL-1999.

PF 08-JAN-1999; 99WO-US000401.

PR 08-JAN-1998; 98US-0070727P.

PA (RHON) RHONE-POULENC ROBER PHARM INC.

PI Rouy D, Duverger N, Emmanuel F, Deneffe P, Houdebine L;
PI Vglitelta C, Rubin E, Hughes SD;

DR WPI; 1999-430386/36.

A transgenic rabbit that expresses a functional human lipoprotein A.

PS Example 3; Page 46; 73pp; English.

XX The invention provides a transgenic rabbit, which has in its genomic DNA,
CC sequences that encode apolipoprotein (a) and apolipoprotein B
CC polypeptides, which are capable of combining to produce lipoprotein (a).
CC The transgenic rabbit expresses a functional human lipoprotein (a). The
CC rabbit develops human-like atherosclerotic lesions when fed a cholesterol
CC rich diet. The transgenic rabbit is useful as a model for human diseases
CC that are induced and/or exacerbated by lipoprotein (a) expression. The
CC model can be used to identify inhibitors of lipoprotein (a) particle
CC assembly and inhibitors of lipoprotein (a) associated diseases. The
CC rabbit model is advantageous, when compared to the mouse, due partly to

CC its relatively larger size, enabling facile studies of vascular injury,
CC and restenosis. In addition, while rabbits are similar to mice in lacking
CC apo(a) and lipoprotein (a), their lipoprotein profile more closely mimics
CC that of humans, with LDL as the predominant plasma lipoprotein. Sequences
CC AAH89305-308 represent primers used in the analysis of transgenic
CC apo(a) and apoB

CC SQ Sequence 20 BP; 5 A; 9 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 3.7e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 338 AGTACTGCAACCTGACGC 355
DB 1 AGTACTGCAACCTGACGC 18

RESULT 206
ABH38632/C

ID ABH38632 standard; DNA; 13 BP.

XX ABH38632;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 238609 for detecting SNP TSC0009812.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 238609; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABJ00010-ABJ2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp://wipo.int/pub/published_pct_sequences

CC SQ Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 0.2%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 239 AAACTACCCAAA 251
XX |||||
DB 13 AAAACTACCCAAA 1

RESULT 207
ABF92992/c
XX ID ABF92992 standard; DNA; 13 BP.
XX ABF92992;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 192989 for detecting SNP TSC0047477.
XX
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 192989; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 0 C; 6 G; 6 T; 0 U; 0 Other;

QY 212 CACCACATCAACA 224
XX |||||
DB 13 CACCACATCAACA 1

RESULT 208
ABF92993
XX ID ABF92993 standard; DNA; 13 BP.
XX ABF92993;
XX
XX 22-FEB-2002 (first entry)
XX

DE Oligonucleotide SEQ ID NO 192990 for detecting SNP TSC0047477.
XX
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 192990; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 6 C; 0 G; 1 T; 0 U; 0 Other;

QY 212 CACCACATCAACA 224
XX |||||
DB 1 CACCACATCAACA 13

RESULT 209
ABH38633
XX ID ABH38633 standard; DNA; 13 BP.
XX AHB38633;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 238610 for detecting SNP TSC0009812.
XX
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX

```
XX 07-APR-2000; 2000DE-01019173.
PR (EPIC-) EPIGENOMICS AG.
PA
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 238610; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. AAC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 8 A; 4 C; 0 G; 1 T; 0 U; 0 Other;

Query Match      0.2%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      239 AAAACTACCCCAA 251
      |||||
      1 AAAACTACCCCAA 13

RESULT 210
AAT37737
ID AAT37737 standard; mRNA; 15 BP.
XX
XX AAT37737;
XX
XX 13-NOV-1996 (first entry)
XX
XX Apo(a) mRNA (nt. pos. 11670) hammerhead ribozyme target sequence.
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; monkey; ss.
XX
XX Cebus apella.
XX
XX WO9609392-A1.
XX
XX 28-MAR-1996.
XX
XX 21-SEP-1995; 95WO-US011995.
XX
XX 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, McSwiggen J, Newton RS, Ramharack R;
XX WPI; 1996-188454/19.
XX
XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
XX myocardial infarction, and heart diseases.
PT
```

```
XX
XX Claim 3; Page 21; 37pp; English.
PS
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX complementary to the present sequence (nucleotide position 11670). The
XX ribozyme blocks to some extent apo(a) expression, and can therefore be
XX used to diagnose or treat conditions related to lipoprotein (a) levels,
XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX disease. PCR was used to generate a substrate for T7 RNA polymerase
XX transcription from monkey apo(a) cDNA clones. Labelled transcripts were
XX synthesised in vitro to form 2 templates. The oligonucleotides and
XX labelled transcripts were annealed, RNaseH added and the mixes
XX incubated. After a designated time the reactions were stopped, and RNA
XX sepd. on sequencing polyacrylamide gels. The percentage of substrate
XX cleaved was determined by autoradiographic quantification, and the most
XX accessible ribozyme target sites chosen
SQ Sequence 15 BP; 7 A; 4 C; 1 G; 0 T; 3 U; 0 Other;

Query Match      0.2%; Score 13; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      579 AGAATCTACCCA 591
      |||||
      3 AGAATCTACCCA 15

RESULT 211
AAT37587
ID AAT37587 standard; mRNA; 15 BP.
XX
XX AAT37587;
XX
XX 11-NOV-1996 (first entry)
XX
XX
XX Apo(a) mRNA (nt. pos. 12013) hammerhead ribozyme target sequence.
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; human; ss.
XX
XX Homo sapiens.
XX
XX WO9609392-A1.
XX
XX 28-MAR-1996.
XX
XX 21-SEP-1995; 95WO-US011995.
XX
XX 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, McSwiggen J, Newton RS, Ramharack R;
XX WPI; 1996-188454/19.
XX
XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
XX treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
XX myocardial infarction, and heart diseases.
PT
XX
XX Claim 2; Page 18; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
XX (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
XX complementary to the present sequence (nucleotide position 12013). The
XX ribozyme blocks to some extent apo(a) expression, and can therefore be
XX used to diagnose or treat conditions related to lipoprotein (a) levels,
XX e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
XX disease. PCR was used to generate a substrate for T7 RNA polymerase
XX
```


CC transcription from human apo(a) cDNA clones. Labelled transcripts were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed, RNaseH added and the mixts.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen

XX
SQ Sequence 15 BP; 3 A; 7 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 13; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 402 CCCGTTCCAGC 414
|||:|:|:|:|:|:|
Db 1 CCCGGUCCAGC 13

RESULT 212

AAT37735
ID AAT37735 standard; mRNA; 15 BP.

XX AAT37735;

DT 13-NOV-1996 (first entry)

DE Apo(a) mRNA (nt. pos. 11653) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

KM hammerhead ribozyme; target sequence; diagnosis; treatment;

KM lipoprotein (a); atherosclerosis; myocardial infarction; stroke;

XX reestenosis; heart disease; monkey; ss.

OS Cebus apella.

PN MO9609392-A1.

XX 28-MAR-1996.

PF 21-SEP-1995; 95WO-US011995.

PR 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

PI Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

DR Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and

XX treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,

PT myocardial infarction, and heart diseases.

XX Claim 3; Page 21; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)

CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms

CC complementary to the present sequence (nucleotide position 11653). The

CC ribozyme blocks to some extent apo(a) expression, and can therefore be

CC used to diagnose or treat conditions related to lipoprotein (a) levels,

CC e.g. atherosclerosis, myocardial infarction, stroke, reestenosis and heart

CC disease. PCR was used to generate a substrate for T7 RNA polymerase

CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were

CC synthesised in vitro to form 2 templates. The oligonucleotides and

CC labelled transcripts were annealed, RNaseH added and the mixts.

CC incubated. After a designated time the reactions were stopped, and RNA

CC sepd. on sequencing polyacrylamide gels. The percentage of substrate

CC cleaved was determined by autoradiographic quantification, and the most

CC accessible ribozyme target sites chosen

XX Sequence 15 BP; 7 A; 4 C; 1 G; 0 T; 3 U; 0 Other;

Query Match 0.2%; Score 13; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 579 AGAATCTACCCA 591
|||:|:|:|:|:|:|
Db 3 AGAATCTACCCA 15

RESULT 213

AA264031
ID AA264031 standard; RNA; 15 BP.

XX AA264031;

DT 28-MAR-2000 (first entry)

DE Substrate for hammerhead ribozyme which cleaves HCV RNA at nt. 4219.

XX Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;

KM cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;

XX autoimmune disease; ss.

OS Hepatitis C virus.

PN MO9955847-A2.

XX 04-NOV-1999.

PF 26-APR-1999; 99WO-US009027.

PR 27-APR-1998; 98US-0083217P.

XX 18-SEP-1998; 98US-0100842P.

PR 25-FEB-1999; 99US-00257608.

XX 23-MAR-1999; 99US-00274553.

XX (RIBO-) RIBOZYME PHARM INC.

PI Blatt L, Mcswiggen JA, Roberts E, Pavco PA, Macejak D;

XX WPI; 2000-062023/05.

DR Novel ribozymes for the treatment of diseases and conditions related to

XX hepatitis C infection.

PT Claim 1; Page 78; 123pp; English.

XX The present sequence represents the preferred target sequence of an

CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves

CC the Hepatitis C virus (HCV) RNA sequence at the base position given in

CC the descriptor line. The HCV sequence was screened for optimal ribozyme

CC target sites using a computer folding algorithm and regions of the mRNA

CC which did not form secondary folding structures and contained potential

CC ribozyme cleavage sites were identified. Ribozymes were synthesised to

CC target these sites and their activities optimised by either varying the

CC length of the binding arms or by modification to prevent degradation by

CC nucleases. The ribozymes of the invention inhibit gene expression and/or

CC viral replication, and are used to treat diseases associated with

CC Hepatitis C virus (HCV) infection, e.g. cirrhosis, liver failure and

CC hepatocellular carcinoma. The ribozymes may be used in combination with

CC interferon to treat HCV infection, other infectious diseases, autoimmune

CC diseases, and cancer

XX Sequence 15 BP; 4 A; 7 C; 1 G; 0 T; 3 U; 0 Other;

Query Match 0.2%; Score 13; DB 1; Length 15;

Best Local Similarity 84.6%; Pred. No. 1.9e+02;

Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 159 CACGTAATCCACC 171
|||:|:|:|:|:|:|
Db 3 CACGTAATCCACC 15

```
RESULT 214
AAA60129/c
ID AAA60129 standard; DNA; 15 BP.
XX
AC AAA60129;
XX
DT 17-OCT-2000 (first entry)
XX
DE Human APC gene variant 1130K scanning oligonucleotide # 3.
XX
KW Human; adenomatous polyposis carcinoma; APC; scanning oligonucleotide;
KW colorectal cancer; genotype analysis;
KW short oligonucleotide mass analysis; SOMA; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT misc_difference 1
FT /*tag= a
FT /note= "5' PA"
XX
PN WO200031300-A2.
XX
PD 02-JUN-2000.
XX
PF 22-NOV-1999; 99WO-US027523.
XX
PR 24-NOV-1998; 98US-00198340.
XX
PA (UYJO ) UNITV JOHNS HOPKINS.
XX
PI Laken SJ, Vogelstein B, Kinzler KW, Groopman JD, Jackson PE,
PI Friesen MD;
XX
DR WPI; 2000-422808/36.
XX
PT Genotype analysis method, defined as SOMA (short oligonucleotide mass
PT analysis), of short, defined amplification products using electro-spray
PT ionization mass spectrometry, useful for analyzing the genotype of living
PT organisms.
XX
PS Example 2; Page 14; 40pp; English.
XX
CC The present invention relates to a method of genotype analysis in which
CC short PCR products are analysed by electro-spray ionisation mass
CC spectrometry (ESI-MS). This method has been named Short Oligonucleotide
CC Mass Analysis (SOMA). Short oligonucleotides of the human adenomatous
CC polyposis carcinoma (APC) gene variant 11307K, were produced by PCR. The
CC 1130K APC gene variant is associated with an approximate 2-fold increase
CC in colorectal cancer risk. The present sequence is a scanning
CC oligonucleotide used to detect the 11307K variants oligonucleotides
CC produced in the present invention
XX
SQ Sequence 15 BP; 12 A; 0 C; 2 G; 1 T; 0 U; 0 Other;
Query Match 0.2%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 74 TTCTTTATTTCT 86
DB 13 TTCTTTATTTCT 1
RESULT 215
ABX01084
ID ABX01084 standard; RNA; 15 BP.
XX
AC ABX01084;
XX
DT 23-DEC-2002 (first entry)
XX
```

```
DE Hepatitis C virus substrate #866 for HCV hammerhead ribozyme #866.
XX
KW Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
KW HCV ribozyme; HCV expression; HCV replication; cirrhosis; virocid;
KW liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
KW type I interferon; interferon alpha; interferon beta; cytostatic;
KW interferon gamma; consensus interferon; hepatotropic; antiinflammatory;
KW substrate; hammerhead ribozyme; HH ribozyme; ss.
XX
OS Hepatitis C virus.
XX
PN US2002082225-A1.
XX
PD 27-JUN-2002.
XX
PF 23-MAR-1999; 99US-00274553.
XX
PR 23-MAR-1999; 99US-00274553.
XX
PA (BLATT/) BLATT L.
PA (MCSW/) MCSWIGEN J A.
PA (ROBE/) ROBERTS B.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
PI Blatt L, Meswigen JA, Roberts B, Pavco PA, Macejack D;
XX
DR WPI; 2002-617759/66.
XX
PT New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
PT replication and are useful to treat hepatitis C virus infections and
PT cirrhosis, liver failure or hepatocellular carcinoma.
XX
PS Claim 1; Page 46; 80pp; English.
XX
CC The present invention relates to enzymatic nucleic acids which
CC specifically cleave RNA derived from Hepatitis C virus (HCV). The
CC enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin
CC (HP) motif where the binding arms comprise sequences complementary to one
CC of the substrate sequences defined in the specification. The HCV
CC ribozymes are useful for modulating the expression and/or replication of
CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating
CC a condition associated with HCV infection in conjunction with one or more
CC other drug therapies, particularly type I interferon, especially
CC sequence represents a substrate for a HCV hammerhead (HH) ribozyme. Note:
CC Some of the sequence data for this patent did not form part of the
CC printed specification. The complete sequence data for this patent was
CC obtained in electronic format directly from the USPTO web site at
CC seqdata.uspto.gov/patseq/patseq.html
XX
SQ Sequence 15 BP; 4 A; 7 C; 1 G; 0 T; 3 U; 0 Other;
Query Match 0.2%; Score 13; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 159 CACGTACTCCACC 171
DB 3 CACGACUCCACC 15
RESULT 216
ABK02857/c
ID ABK02857 standard; RNA; 17 BP.
XX
AC ABK02857;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human CD20 Hammerhead ribozyme #156.
XX
```

KM Human; ss; antisense therapy; cytosolic; antiinflammatory; haemostatic;
 KM cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KM muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KM DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukemia;
 KM B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukemia;
 KM human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KM MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
 KM inflammatory arthropathy; central nervous system injury;
 KM cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KM chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KM Parkinson's disease; ataxia; Huntington's disease;
 KM Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 PN WO200159103-A2.
 XX
 PD 16-AUG-2001.
 XX
 PF 09-FEB-2001; 2001WO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, Mcswiggen J, Chowrira BM;
 XX
 DR WPI; 2001-607195/69.
 XX
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 PS Claim 30; Page 142; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNazyme) an inozyme (an endolytic nucleic acid cleaving an NGN motif) or
 CC possessing an NGN motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapeutics. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukemia (MCL), human immunodeficiency virus associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapeutics. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a hammerhead ribozyme of the invention

XX
 SO Sequence 17 BP; 11 A; 0 C; 3 G; 0 T; 3 U; 0 Other;
 Query Match 0.2%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.7e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 73 CTTCTTTATTTC 85
 Db 16 CTTCTTTATTTC 4
 RESULT 217
 ABZ62017
 ID ABZ62017 standard; RNA; 17 BP.
 XX
 AC ABZ62017;
 XX
 DT 21-MAR-2003 (first entry)
 XX
 DE Human H-Ras DNazyme target #808.
 XX
 KW Human; ribozyme; short interfering RNA; siRNA; HRR2; K-Ras;
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
 KW anti-rheumatic; cancer; AIDS; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200297114-A2.
 XX
 PD 05-DEC-2002.
 XX
 PF 29-MAY-2002; 2002WO-US016840.
 XX
 PR 29-MAY-2001; 2001US-0294140P.
 PR 06-JUN-2001; 2001US-0296249P.
 PR 10-SEP-2001; 2001US-0318471P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Mcswiggen J;
 XX
 DR WPI; 2003-140484/13.
 XX
 PT Novel short interfering RNA and enzymatic nucleic acid useful for
 PT treating cancer, modulates the expression of a nucleic acid encoding
 PT HRR2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
 XX
 PS Claim 58; Page 126; 185pp; English.
 XX
 CC The invention relates to a novel short interfering RNA (siRNA) nucleic
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates
 CC expression of a nucleic acid molecule encoding HRR2, K-Ras, H-Ras, N-Ras,
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
 CC acid molecule of the invention has cytosolic, anti-HIV, and anti-
 CC rheumatic activity. The nucleic acid molecules are useful for reducing
 CC HRR2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
 CC also useful for treating breast, ovarian, colorectal, lung, prostate,
 CC bladder, or pancreatic cancer, and HIV infection, AIDS. The sequences
 CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ65520 - ABZ65524,
 CC ABZ65530 - ABZ65585 represent substrate/target sequences for the human
 CC ribozymes of the invention
 XX
 SQ Sequence 17 BP; 5 A; 9 C; 1 G; 0 T; 2 U; 0 Other;
 Query Match 0.2%; Score 13; DB 1; Length 17;
 Best Local Similarity 92.3%; Pred. No. 2.7e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 Oy 553 ACACCACTCGGC 565
 Db 2 ACACCACTCGGC 14

```

RESULT 218
ABZ62016
ID ABZ62016 standard; RNA; 17 BP.
XX
AC ABZ62016;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human H-Ras DNAzyme target #807.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
KW anti-thematic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
MO MO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318472P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PI Mcswiggen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
XX HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
PS Claim 58; Page 126; 185pp; English.
XX
SQ The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosatic, anti-HIV, and anti-
CC rhematic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ6524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SO Sequence 17 BP; 5 A; 9 C; 2 G; 0 T; 1 U; 0 Other;
Query Match 0.2%; Score 13; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0
QY 553 ACACCAACATCTGCC 565
DB |||||:||||
4 ACACCAACATCTGCC 16
RESULT 219
ACD63821/c
ID ACD63821 standard; RNA; 17 BP.
XX
AC ACD63821;
XX
DT 30-SEP-2003 (first entry)
XX
DE HCV minus strand DNAzyme substrate sequence #123c.
XX

```

KM	Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW	RNA stability; RNA expression; RNA synthesis; antisense;
KW	enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KM	amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW	HBV reverse transcriptase; Enhancer I region; viral replication;
KW	degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW	liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KM	viricide; antiinflammatory; substrate; ss.
XX	Hepatitis C virus.
OS	
XX	WO200281494-A1.
XX	
XX	17-OCT-2002.
PD	
XX	
PF	26-MAR-2002; 2002WO-US009187.
PR	
PR	26-MAR-2001; 2001US-00817879.
PR	08-JUN-2001; 2001US-00877478.
PR	08-JUN-2001; 2001US-02968748.
PR	24-OCT-2001; 2001US-0335055P.
PR	05-DEC-2001; 2001US-0337055P.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
PA	(BLAT/) BLATT L.
PA	(MACE/) MACEJAK D.
PA	(MCSW/) MORSWIGEN J.
PA	(MORS/) MORRISSEY D.
PA	(PAVC/) PAVCO P.
PA	(LEEP/) LEE P.
PA	(DRAE/) DRAPER K.
PA	(ROBE/) ROBERTS E.
XX	
PI	Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P,
PI	Draper K, Roberts E,
XX	
DR	WPI; 2003-229207/22.
XX	
PT	Novel compound useful for treating cirrhosis, liver failure,
PT	hepatocellular carcinoma, or condition associated with hepatitis C virus
XX	infection.
XX	
PS	Claim 1; Page 297; 387pp; English.
XX	
CC	The present invention relates to nucleic acid molecules which modulate
CC	the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC	Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC	and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC	inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC	are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC	transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC	as oligonucleotides that specifically bind the Enhancer I region of HBV
CC	DNA. The nucleic acids may be used to modulate the expression of HBV
CC	genes and HBV viral replication. Also disclosed is a method for screening
CC	compounds and/or potential therapies directed against HBV, and compounds
CC	that modulate the expression and/or replication of HCV. The compounds and
CC	methods of the invention are useful for the treatment of degenerative and
CC	disease states related to HBV and HCV infection, replication and gene
CC	expression such as cirrhosis, liver failure, and hepatocellular
CC	carcinoma. The present sequence represents a substrate for one of the HCV
CC	DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC	invention
SQ	
Sequence	17 BP; 4 A; 1 C; 7 G; 0 T; 5 U; 0 Other;
Query Match	0.2%; Score 13; DB 1; Length 17;
Best Local Similarity	100.0%; Pred. No. 2,7e+02;
Matches	13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	159 CACGACTCTCACC 171
DB	15 CACGACTCTCACC 3

RESULT 220
ACD58848
ID ACD58848 standard; RNA, 17 BP.
XX
AC ACD58848;
XX
24-SEP-2003 (first entry)
XX
XX
HCV DNAzyme substrate sequence #1042.
XX
XX
Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KM RNA stability; RNA expression; RNA synthesis; antisense;
KM enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KM amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
KM HBV reverse transcriptase; Enhancer I region; viral replication;
KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KM virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis C virus.
XX
PN WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002MO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
DR WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Claim 1; Page 252; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC invention

XX
SQ Sequence 17 BP; 4 A; 8 C; 1 G; 0 T; 4 U; 0 Other;
XX
Query Match 0.2%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 2.7e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY 159 CACGACTCCACC 171
||||:|||||
Db 4 CACGACUCCACC 16
XX
RESULT 221
ACD63822/c
ID ACD63822 standard; RNA, 17 BP.
XX
AC ACD63822;
XX
30-SEP-2003 (first entry)
XX
XX
HCV minus strand DNAzyme substrate sequence #1237.
XX
XX
Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KM RNA stability; RNA expression; RNA synthesis; antisense;
KM enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KM amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
KM HBV reverse transcriptase; Enhancer I region; viral replication;
KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KM virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis C virus.
XX
PN WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002MO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
DR WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Claim 1; Page 297; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC invention

CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HIV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC invention

XX
SQ Sequence 17 BP; 3 A; 1 C; 9 G; 0 T; 4 U; 0 Other;

Query Match 0.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 159 CACGTACTCCACC 171
DB 13 CACGTACTCCACC 1

RESULT 222

ID AD183796 standard; RNA; 17 BP.
XX
AC AD183796;

DT 03-JUN-2004 (first entry)
XX

DE HCV DNAzyme substrate sequence #1042.
XX

KM ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNAzyme.

OS Hepatitis C virus.
XX

PN US2003125270-A1.
XX

PD 03-JUL-2003.
XX

PF 18-DEC-2000; 2000US-00740332.
XX

PR 18-DEC-2000; 2000US-00740332.
XX

PA (BLAT/) BLATT L.
XX

PA (MCSW/) MCSWIGEN J.
XX

PA (ROBE/) ROBERTS E.
XX

PA (PAVC/) PAVCO P A.
XX

PA (MACE/) MACEJACK D.
XX

PI Blatt L, Mcswigen J, Roberts E, Pavco PA, Macejack D;
XX

DR WPI; 2004-031273/03.
XX

PT Enzymatic nucleic acid molecules which specifically cleave RNA derived
XX from hepatitis C virus (HCV), useful for the treatment of HCV infections,
XX especially in combination with type I interferon therapy.

PS Claim 1; SEQ ID NO 1042; 198pp; English.
XX

CC The invention relates to an enzymatic nucleic acid molecule which
XX specifically cleaves RNA derived from hepatitis C virus (HCV), in which
XX the binding arms of the enzymatic nucleic acid molecule comprises
XX sequences complementary to any of the defined substrate sequences given
XX in the specification. The nucleic acid molecule may be administered for
XX the treatment of HCV infections, especially in combination with type I
XX interferons. The present sequence represents a HCV DNAzyme substrate
XX sequence.

SQ Sequence 17 BP; 4 A; 8 C; 1 G; 0 T; 4 U; 0 Other;

Query Match 0.2%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 2.7e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 159 CACGTACTCCACC 171
DB 4 CACGTACTCCACC 16

RESULT 223

ID AD186267/c
XX
AC AD186267;

DT 03-JUN-2004 (first entry)
XX

DE HCV DNAzyme substrate sequence #3513.
XX

KM ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNAzyme.

OS Hepatitis C virus.
XX

PN US2003125270-A1.
XX

PD 03-JUL-2003.
XX

PF 18-DEC-2000; 2000US-00740332.
XX

PR 18-DEC-2000; 2000US-00740332.
XX

PA (BLAT/) BLATT L.
XX

PA (MCSW/) MCSWIGEN J.
XX

PA (ROBE/) ROBERTS E.
XX

PA (PAVC/) PAVCO P A.
XX

PA (MACE/) MACEJACK D.
XX

PI Blatt L, Mcswigen J, Roberts E, Pavco PA, Macejack D;
XX

DR WPI; 2004-031273/03.
XX

PT Enzymatic nucleic acid molecules which specifically cleave RNA derived
XX from hepatitis C virus (HCV), useful for the treatment of HCV infections,
XX especially in combination with type I interferon therapy.

PS Claim 1; SEQ ID NO 3513; 198pp; English.
XX

CC The invention relates to an enzymatic nucleic acid molecule which
XX specifically cleaves RNA derived from hepatitis C virus (HCV), in which
XX the binding arms of the enzymatic nucleic acid molecule comprises
XX sequences complementary to any of the defined substrate sequences given
XX in the specification. The nucleic acid molecule may be administered for
XX the treatment of HCV infections, especially in combination with type I
XX interferons. The present sequence represents a HCV DNAzyme substrate
XX sequence.

SQ Sequence 17 BP; 4 A; 1 C; 7 G; 0 T; 5 U; 0 Other;

Query Match 0.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 159 CACGTACTCCACC 171
DB 15 CACGTACTCCACC 3

RESULT 224

ID AD186268/c
XX
AC AD186268;

AD186268;

```

XX 03-JUN-2004 (first entry)
DE HCV DNAzyme substrate sequence #3514.
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KM HCV infection; type I interferon; DNAzyme.
XX Hepatitis C virus.
OS US2003125270-A1.
XX 03-JUL-2003.
XX 18-DEC-2000; 2000US-00740332.
XX 18-DEC-2000; 2000US-00740332.
XX 18-DEC-2000; 2000US-00740332.
XX (BLAT/) BLATT L.
PA (MCSW/) MCSWIGSEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX Blatts L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
XX WPI; 2004-031273/03.
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX Claim 1; SEQ ID NO 3514; 198bp; English.
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNAzyme substrate
CC sequence.
XX Sequence 17 BP; 3 A; 1 C; 9 G; 0 T; 4 U; 0 Other;
SQ
Query Match 0.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 159 CACGTACTCCACC 171
DB 13 CACGTACTCCACC 1

```

RESULT 225
ADE14089/C
ID ADE14089 standard; DNA, 16 BP.
XX ADE14089;
XX 29-JAN-2004 (first entry)
XX Optineurin promoter motif, repeat element or regulatory region #198.
XX Human; optineurin; ds; ophthalmological; single nucleotide polymorphism;
KM SNP; glaucoma; progressive ocular hypertensive disorder;
KM glaucoma related disorder; motif; repeat element; regulatory region.
XX Homo sapiens.
XX US2003190617-A1.
XX 09-OCT-2003.
XX

```

XX 06-MAR-2002; 2002US-00091281.
XX 06-MAR-2002; 2002US-00091281.
XX (SIEE/) SI E.
PA (RAYM/) RAYMOND V.
PA (MORI/) MORISSETTE J.
XX Raymond V, Morissette J, Si E;
XX WPI; 2003-864168/80.
XX New nucleic acid sequences of the optineurin gene are useful to detect
PT polymorphisms particularly single nucleotide polymorphisms in the
PT optineurin promoter to diagnose, prognosis and treat glaucoma and related
PT disorders.
XX Claim 11; SEQ ID NO 200; 159bp; English.
XX The invention relates to an isolated nucleic acid (NI) comprising at
CC least 20 but not more than 1500 consecutive nucleotides of the optineurin
CC promoter appearing as ADE13890. Also included are the optineurin promoter
CC operably linked to a heterologous nucleic acid, a nucleic acid capable of
CC detecting a single nucleotide polymorphism (SNP) in the optineurin
CC promoter, a host cell comprising the promoter operably linked to a
CC heterologous sequence, diagnosing or prognosing glaucoma in a sample
CC obtained from a cell or bodily fluid (comprising detecting a polymorphism
CC in a promoter region of the optineurin gene, associated with a glaucoma
CC phenotype), detecting a SNP sequence variation in a sample containing
CC DNA, detecting the presence of an optineurin promoter sequence variation
CC in a sample containing DNA, determining the presence or increased
CC susceptibility to glaucoma or to a progressive ocular hypertensive
CC disorder resulting in loss of visual field in a patient (or the severity
CC or progression of glaucoma in a patient, comprising providing
CC amplification reaction primers that direct amplification of a selected
CC nucleic acid region containing the variation within the optineurin
CC promoter and amplifying the DNA) and detecting a polymorphism (comprising
CC obtaining a sample containing human genomic DNA, providing a nucleic acid
CC capable of detecting a SNP located within an optineurin promoter, and
CC detecting the polymorphism). The invention is used to diagnose and
CC prognose glaucoma and also to treat glaucoma related disorders. The
CC present sequence is an optineurin promoter motif, repeat element or
CC putative regulatory region.
XX Sequence 16 BP; 0 A; 5 C; 2 G; 9 T; 0 U; 0 Other;
SQ
Query Match 0.2%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 44 AAATGGAACATTAAGA 59
DB 16 AAAGGGAACACAAAGA 1

```

RESULT 226
AAK64002
ID AAK64002 standard; RNA, 17 BP.
XX AAK64002;
XX 20-JUL-1999 (first entry)
XX Rabbit stromelysin hammerhead target SEQ ID NO:634.
XX Arthritic condition; graft tolerance; immune response; target; cleavage;
KM hammerhead ribozyme; human; rabbit; mouse; collagenase;
KM stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KM rheumatoid arthritis; autoimmune disease; allergy; inflammation;
XX diagnosis; ss.
XX Oryctolagus cuniculus.
XX

XX 27-MAR-1998; 98US-0079678P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswigen JA;
 XX WPI; 1999-591315/50.
 DR
 XX Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.
 XX
 XX Claim 56; Page 110; 305pp; English.
 PS
 CC The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC for integrin subunit beta 3, and AAA22476 to AAA23342 represent ribozyme sequence
 CC AAA2422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (AMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 CC
 SQ Sequence 17 BP; 4 A; 0 C; 5 G; 0 T; 8 U; 0 Other;
 Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 214 CCACATCAACATATA 229
 DB 16 CCACTTCACATATA 1
 RESULT 231
 AAA17246/C
 ID AAA17246 standard; RNA; 17 BP.
 XX
 AC AAA17246;
 XX
 DT 19-JUN-2000 (first entry)
 DE Aryl hydrocarbon nuclear transport substrate sequence SEQ ID NO:472.
 XX
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW Kippel-Trenunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX
 OS Homo sapiens.
 XX

PN W09950403-A2.
 XX
 XX 07-OCT-1999.
 PD
 XX 24-MAR-1999; 99WO-US006507.
 PF
 XX 27-MAR-1998; 98US-0079678P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswigen JA;
 XX WPI; 1999-591315/50.
 DR
 XX Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.
 XX
 XX Claim 53; Page 67; 305pp; English.
 PS
 CC The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC for integrin subunit beta 3, and AAA22476 to AAA23342 represent ribozyme sequence
 CC AAA2422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (AMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 CC
 SQ Sequence 17 BP; 1 A; 1 C; 8 G; 0 T; 7 U; 0 Other;
 Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 498 AGGCACATCACTCCACC 513
 DB 16 AGACACATCACTCCACC 1
 RESULT 232
 AAA18736
 ID AAA18736 standard; RNA; 17 BP.
 XX
 AC AAA18736;
 XX
 DT 19-JUN-2000 (first entry)
 DE Human TIE-2 substrate sequence SEQ ID NO:1962.
 XX
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW

KW tubercous sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX Homo sapiens.
 PN MO9950403-A2.
 XX
 PD 07-OCT-1999.
 XX
 PF 24-MAR-1999; 99WO-US006507.
 XX
 PR 27-MAR-1998; 98US-0079678P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
 XX WPI; 1999-591315/50.
 XX
 PT Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.
 PS
 PS Claim 56; Page 113; 305pp; English.
 XX
 CC The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC AAA17168 and AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiodiroma of tubercous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenauay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 0 G; 0 T; 11 U; 0 Other;
 Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 25.0%; Pred. No. 2.9e+02;
 Matches 4; Conservative 10; Mismatches 2; Indels 0; Gaps 0;
 Oy 68 TTCTACTCTTTATT 83
 Db 2 UUCUAAUUCUUCUAAU 17
 RESULT 233
 AAA18737 standard; RNA; 17 BP.
 XX
 AC AAA18737;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE Human TIE-2 substrate sequence SEQ ID NO:1963.
 XX
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;

KW hammerhead ribozyme; angiogenic factor; cytosstatic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiodiroma;
 KW tubercous sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX
 XX Homo sapiens.
 OS
 PN MO9950403-A2.
 XX
 PD 07-OCT-1999.
 XX
 PF 24-MAR-1999; 99WO-US006507.
 XX
 PR 27-MAR-1998; 98US-0079678P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
 XX WPI; 1999-591315/50.
 XX
 PT Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.
 PS
 PS Claim 56; Page 114; 305pp; English.
 XX
 CC The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC AAA17168 and AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiodiroma of tubercous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenauay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 0 G; 0 T; 11 U; 0 Other;
 Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 25.0%; Pred. No. 2.9e+02;
 Matches 4; Conservative 10; Mismatches 2; Indels 0; Gaps 0;
 Oy 68 TTCTACTCTTTATT 83
 Db 1 UUCUAAUUCUUCUAAU 16
 RESULT 234
 AA231710/C
 ID AA231710 standard; DNA; 17 BP.
 XX
 AC AA231710;
 XX
 DT 19-JAN-2000 (first entry)

XX DE PCR primer 127 for CMVp-pres2 junction.
XX
KW PCR primer; pres2 antigen; protein expression; selectable marker gene;
KW internal ribosome entry site; IRES; vaccine; therapy; diagnosis; antigen;
XX immune response; HBV; ss.
OS Synthetic.
XX
PN WO953046-A2.
XX
PD 21-OCT-1999.
XX
PF 13-APR-1999; 99WO-US008069.
XX
PR 14-APR-1998; 98US-0081777P.
XX
PA (CHIR) CHIRON CORP.
XX
PI Selby M, Thudium K, Dina D;
XX
DR WPI; 1999-620421/53.
XX
PT Expressing recombinant polypeptide in mammalian cells, particularly for
XX producing hepatitis B antigen for vaccination.
XX
PS Example 1; Page 33; 51pp; English.
XX
CC This sequence represents a PCR primer for the CMVp-pres2 junction
CC sequence. The invention relates to a method for expressing recombinant
CC polypeptide (I) in mammalian cells without subcloning the coding
CC sequence. The method comprises co-transfecting mammalian cells with three
CC nucleic acid elements: (1) containing a promoter; (2) containing a
CC selectable marker gene (SMG), internal ribosome entry site (IRES) and
CC transcription terminator (TT); and (3) containing a gene encoding (I).
CC The cells are cultured so that (1) and SMG are expressed, those
CC expressing SMG are selected, and selected cells that also express (I) are
CC identified. In (2), IRES is upstream of SMG and TT is downstream of SMG.
CC The method is used to produce (I) that are useful in vaccines, therapy
CC and diagnosis, e.g. antigens (from a wide variety of viruses, bacteria,
CC parasites, fungi or tumors, for generating an immune response),
CC hormones, mediators of transcription or translation, enzymes, metabolic
CC intermediates, immunomodulators etc. Specifically it is used to produce
CC the pres2 antigen of hepatitis B virus. When the 3 elements are co-
CC transfected, they become linked together such that expressions are co-
CC requires co-expression of (I), eliminating the need for subcloning of (I)
CC into an expression cassette. The method allows direct use of polymerase
CC chain reaction products and synthetic or natural DNA, for rapid
CC expression of one or more genes (e.g. from a cDNA library) in mammalian
CC cells. Expressing SMG and (I) from a single promoter reduces the problem
CC of false positives and, putting (I) upstream of IRES means that it is
CC expressed at higher level than SMG, i.e. selected cells will be high-
CC level expressors of (I)
XX
SQ Sequence 17 BP; 2 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 318 GGATCCCGGTGTCAGG 333
Db 17 GGATCCCGAGTCTCAGG 2
XX
RESULT 235
ID AAV55682
XX AAV55682 standard; DNA; 17 BP.
AC AAV55682;
XX
DT 18-MAR-1999 (first entry)
XX

DE PCR primer for Human tissue kallikrein gene promoter allele.
XX
KW Tissue kallikrein gene promoter; human; allele; polymorphic region;
KW essential hypertension; detection; PCR primer; ss.
XX
OS Synthetic.
XX Homo sapiens.
XX
PN WO951822-A1.
XX
PD 19-NOV-1998.
XX
PF 14-MAY-1998; 98WO-US009831.
XX
PR 14-MAY-1997; 97US-00856141.
XX
PA (UYSC-) UNIV SOUTH CAROLINA MEDICAL RES FOUND.
XX
PI Chao L, Chao J;
XX
DR WPI; 1999-045235/04.
XX
PT New tissue kallikrein gene promoter alleles - used to detect hypertension
XX risk alleles are in the promoter region and correlate with an increased
XX risk of developing essential hypertension.
XX
PS Example; Page 22; 55pp; English.
XX
CC This sequence is a primer for an allele of the polymorphic region of the
CC human tissue kallikrein gene (TKG) promoter. The allele is detected in
CC the method of the invention, for identifying a person as having an
CC increased risk of developing essential hypertension (EH), which comprises
CC detecting an allele in the promoter region of the person's TKG which is
CC correlated with an increased EH risk. The method determines whether a
XX person has an increased or decreased risk of developing EH
XX
SQ Sequence 17 BP; 4 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 273 CTGCAGGAATTCAGAT 288
Db 1 CTGCAGGAATCTAGTT 16
XX
RESULT 236
ID AAC62123/C
XX AAC62123 standard; DNA; 17 BP.
AC AAC62123;
XX
DT 06-MAR-2001 (first entry)
XX
DE PCR primer Rdb6.3 for calcium-dependent serine-protease cDNA fragment.
XX
KW Calcium-dependent serine-protease; Pf-SUB2; merocaine differentiation;
KW major surface protein 1; MSP1-42; erythrocyte entry; malaria; PCR primer;
XX ss.
OS Plasmidium falciparum.
XX
PN FR2791685-A1.
XX
PD 06-OCT-2000.
XX
PF 31-MAR-1999; 99FR-00004039.
XX
PR 31-MAR-1999; 99FR-00004039.
XX
PA (INSP) INST PASTEUR.
XX (CNRS) CNRS CENT NAT RECH SCI.

XX Barale JC, Langsley G, Braun BC, Pereira Da Silva L, Blisnick T;
XX WPI; 2000-658021/64.
XX Polypeptide with calcium-dependent serine-protease activity, for the
PT prevention, treatment, and detection of malarial infections due to
XX Plasmodium falciparum.
XX Disclosure; Page 20, 47pp; French.
XX PCR primers AAC62122-23 were used to amplify a fragment of the cDNA
CC encoding a polypeptide (PF-SUB2) which has a calcium-dependent serine-
CC protease activity. The PF-SUB2 gene is expressed during the
CC differentiation phase of merozoites. The protein is implicated in
CC maturation of the major surface protein 1 of merozoites (MSPI-42). The
CC enzyme is also crucial for entry of the parasite into erythrocytes. The
CC polypeptides and polynucleotides are used to identify inhibitors of PF-
CC SUB2. These inhibitors e.g. antibodies, are used for the detection,
CC prevention, and treatment of malaria due to Plasmodium falciparum
CC infection
XX
SQ Sequence 17 BP, 2 A, 7 C, 4 G, 4 T, 0 U, 0 Other;
XX
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 23 GGACACTGCTGGCCAG 38
Db 17 GGACACTGTCAGGTCAAG 2
XX
RESULT 237
AAA56170
ID AAA56170 standard; DNA; 17 BP.
XX
XX AAA56170;
AC
XX
DT 26-JUL-2000 (first entry)
XX
DE Human genomic SNP allele specific oligonucleotide SEQ ID NO:227.
XX
XX Human: single nucleotide polymorphism; SNP; genotyping; DNA analysis;
KM allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
KM genomic classification; identification; DNA fingerprinting;
KM tumour characterisation; hybridisation; ss.
XX
OS Homo sapiens.
XX
PN WO200018960-A2.
XX
XX 06-APR-2000.
PD
XX
PF 24-SEP-1999; 99WO-US022283.
XX
PR 25-SEP-1998; 98US-0101757P.
XX
PA (MASI) MASSACHUSETTS INST TECHNOLOGY.
XX
PI Landers JE, Jordan B, Housman DE, Charest A;
XX WPI; 2000-293181/25.
DR
XX
XX Detection of single nucleotide polymorphisms in genomes by preparation
PT and analysis of reduced complexity genomes, useful for genotyping,
XX fingerprinting and determining allele frequency of SNPs.
XX
PS Disclosure; Page 60, 11pp; English.
XX
XX A method has been developed for detecting the presence or absence of a
CC single nucleotide polymorphism (SNP) allele in a genomic sample. The
CC method comprises preparing a reduced complexity genome (RCG) from the

CC genomic sample and analysing the RCG for the presence or absence of a SNP
CC allele. The method can be used to characterise a tumour, to generate a
CC genomic pattern for an individual genome or to generate a genomic
CC classification code for a genome. The method can be used to assess
CC whether a subject is at risk for developing a disease or to identify a
CC set of SNP alleles associated with a disease. The method can also be used
CC to perform linkage analysis. AAA5944 to AAA5947 represent sequences
CC used in the exemplification of the present invention. AAA5948 to
CC AAA5632 represent nucleotide sequences containing SNPs
XX
SQ Sequence 17 BP, 7 A, 8 C, 1 G, 1 T, 0 U, 0 Other;
XX
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 208 ATGACACCATCATCAG 223
Db 1 ATGACACCATCATCAG 16
XX
RESULT 238
AAA5496
ID AAA5496 standard; DNA; 17 BP.
XX
XX AAA5496;
AC
XX
DT 19-JUL-2000 (first entry)
XX
DE Oestrogen receptor hamsterhead ribozyme target sequence SEQ ID NO:194.
XX
XX Oestrogen receptor; c-rafi; k-rafi; bcl-2; ribozyme; cleavage;
KM hamsterhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KM gene expression modification; cancer; phosphotriester; endonuclease;
KM anticancer; breast cancer; endometrium cancer; ss.
XX
OS Homo sapiens.
XX
PN WO954459-A2.
XX
XX 28-OCT-1999.
PD
XX
PF 19-APR-1999; 99WO-US008547.
XX
PR 20-APR-1998; 98US-0082404P.
PR 23-JUN-1998; 98US-00103636.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
PI Thompson JD, Beigelman L, McSwigen JA, Karpetsky A, Bellon L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haberli P;
PI Maculic-Adamic J;
XX
XX WPI; 2000-013248/01.
DR
XX
XX New nucleic acids that interact, and optionally cleave, target sequences,
PT used to treat cancer.
XX
PS Claim 77; Page 81, 148pp; English.
XX
XX The present invention describes nucleic acids (A) that interact stably
CC with a target sequence and contain at least one phosphorodithioate
CC link, having endonuclease activity. (A), and more generally any catalytic
CC nucleic acid (A') that modulates expression of the oestrogen receptor
CC gene, are used to treat cancer (particularly of breast or endometrium),
CC in vivo or by transforming cells ex vivo and implanting treated cells, or
CC for other conditions associated with levels of oestrogen receptor.
CC Because of the high selectivity for targeted RNA, (A) can also be used to
CC correlate inhibition of gene expression with alterations in phenotype,
CC particularly for identification of therapeutic targets, and as research
CC reagents (for RNA, in the same way that restriction endonucleases are
CC used with DNA). The combination of modifications in (A) improves
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to

```
CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
CC AAA24748 to AAA25992 represent their corresponding target sequences.
CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
CC sequences, and AAA26107 to AAA26218 represent their corresponding target
CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
CC antisense oligonucleotides used in the exemplification of the present
CC invention
XX
SQ Sequence 17 BP; 5 A; 6 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 275 GCAGGAATCCAGATGC 290
Db 1 GCACTATCCAGATGC 16
RESULT 239
AAC70658/c
ID AAC70658 standard; DNA; 17 BP.
XX
AC AAC70658;
XX
DT 09-FEB-2001 (first entry)
XX
DE Single nucleotide polymorphism PCR primer #326.
XX
KW Single nucleotide polymorphism; SNP; human; genetic disease;
KW disease susceptibility; cardiovascular system; endocrine system;
KW neurological system; forensic testing; paternity testing; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200058519-A2.
PD 05-OCT-2000.
XX
PF 30-MAR-2000; 2000WO-US008440.
XX
PR 31-MAR-1999; 99US-0127248P.
XX
PA (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
PA (AFPY-) AFFYMETRIX INC.
XX
PI Altschuler D, Cargill M, Daley GO, Ireland JS, Lander ES;
PI Lipshutz RJ, Patil N, Sklar P;
XX
DR WPI; 2000-611722/58.
XX
PT Nucleic acid selected from one of 106 genes comprising single nucleotide
PT polymorphisms, allele-specific oligonucleotides to the genes are useful
PT for phenotypic correlations, forensics, paternity testing, medicine and
XX genetic analysis.
XX
PS Claim 8; Fig 5; 214pp; English.
XX
CC The present invention is concerned with a number of human single
CC nucleotide polymorphisms (SNPs) which the inventors identified in human
CC genes. These SNPs can be used in disease diagnosis and prediction of an
CC individual's susceptibility to disease, in forensic and paternity testing
CC and in genetic mapping. In particular, the SNPs of the invention can be
CC used to diagnose susceptibility to diseases of the cardiovascular,
CC endocrine and neurological systems, such as coronary artery disease,
CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
CC diseases
XX
SQ Sequence 17 BP; 3 A; 3 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 420 GGCTCCTTCGACGAA 435
Db 17 GGCTCCTTCGACGAA 2
RESULT 240
AAC70652/c
ID AAC70652 standard; DNA; 17 BP.
XX
AC AAC70652;
XX
DT 09-FEB-2001 (first entry)
XX
DE Single nucleotide polymorphism PCR primer #322.
XX
KW Single nucleotide polymorphism; SNP; human; genetic disease;
KW disease susceptibility; cardiovascular system; endocrine system;
KW neurological system; forensic testing; paternity testing; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200058519-A2.
PD 05-OCT-2000.
XX
PF 30-MAR-2000; 2000WO-US008440.
XX
PR 31-MAR-1999; 99US-0127248P.
XX
PA (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
PA (AFPY-) AFFYMETRIX INC.
XX
PI Altschuler D, Cargill M, Daley GO, Ireland JS, Lander ES;
PI Lipshutz RJ, Patil N, Sklar P;
XX
DR WPI; 2000-611722/58.
XX
PT Nucleic acid selected from one of 106 genes comprising single nucleotide
PT polymorphisms, allele-specific oligonucleotides to the genes are useful
PT for phenotypic correlations, forensics, paternity testing, medicine and
XX genetic analysis.
XX
PS Claim 8; Fig 5; 214pp; English.
XX
CC The present invention is concerned with a number of human single
CC nucleotide polymorphisms (SNPs) which the inventors identified in human
CC genes. These SNPs can be used in disease diagnosis and prediction of an
CC individual's susceptibility to disease, in forensic and paternity testing
CC and in genetic mapping. In particular, the SNPs of the invention can be
CC used to diagnose susceptibility to diseases of the cardiovascular,
CC endocrine and neurological systems, such as coronary artery disease,
CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
CC diseases
XX
SQ Sequence 17 BP; 3 A; 3 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 420 GGCTCCTTCGACGAA 435
Db 17 GGCTCCTTCGACGAA 2
RESULT 241
AAC70691/c
ID AAC70691 standard; DNA; 17 BP.
XX
AC AAC70691;
XX
DT 09-FEB-2001 (first entry)
```

```

XX Single nucleotide polymorphism PCR primer #348.
DE
XX
XX Single nucleotide polymorphism; SNP; human; genetic disease;
KM disease susceptibility; cardiovascular system; endocrine system;
KM neurological system; forensic testing; paternity testing; PCR primer; ss.
XX
XX Homo sapiens.
XX
XX W0200058519-A2.
XX
XX
XX 05-OCT-2000.
XX
XX
XX 30-MAR-2000; 2000WO-US008440.
XX
XX
XX 31-MAR-1999; 99US-0127248P.
XX
XX (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
XX (AFHY-) AFFYMETRIX INC.
XX
XX Altschuler D, Cargill M, Daley GO, Ireland JS, Lander ES;
XX Lipshutz RJ, Patil N, Sklar P;
XX WPI; 2000-611722/58.
XX
XX Nucleic acid selected from one of 106 genes comprising single nucleotide
XX polymorphisms, allele-specific oligonucleotides to the genes are useful
XX for phenotypic correlations, forensics, paternity testing, medicine and
XX genetic analysis.
XX
XX Claim 8; Fig 5; 214pp; English.
XX
XX The present invention is concerned with a number of human single
XX nucleotide polymorphisms (SNPs) which the inventors identified in human
XX genes. These SNPs can be used in disease diagnosis and prediction of an
XX individual's susceptibility to disease, in forensic and paternity testing
XX and in genetic mapping. In particular, the SNPs of the invention can be
XX used to diagnose susceptibility to diseases of the cardiovascular,
XX endocrine and neurological systems, such as coronary artery disease,
XX schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
XX diseases
XX
XX Sequence 17 BP; 3 A; 3 C; 8 G; 3 T; 0 U; 0 Other;
XX
XX
XX Query Match 0.2%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.9e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 420 GGCTCCTTCGACAA 435
XX
XX 17 GGCTCCTTCGACAA 2
XX
XX
XX RESULT 242
XX AAC70709/c
XX ID AAC70709 standard; DNA; 17 BP.
XX
XX AAC70709,
XX
XX 09-FEB-2001 (first entry)
XX
XX Single nucleotide polymorphism PCR primer #360.
XX
XX Single nucleotide polymorphism; SNP; human; genetic disease;
XX disease susceptibility; cardiovascular system; endocrine system;
XX neurological system; forensic testing; paternity testing; PCR primer; ss.
XX
XX Homo sapiens.
XX
XX W0200058519-A2.
XX
XX
XX 05-OCT-2000.
XX
XX

```

```

PF 30-MAR-2000; 2000WO-US008440.
XX
XX 31-MAR-1999; 99US-0127248P.
XX
XX (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
XX (AFHY-) AFFYMETRIX INC.
XX
XX Altschuler D, Cargill M, Daley GO, Ireland JS, Lander ES;
XX Lipshutz RJ, Patil N, Sklar P;
XX WPI; 2000-611722/58.
XX
XX Nucleic acid selected from one of 106 genes comprising single nucleotide
XX polymorphisms, allele-specific oligonucleotides to the genes are useful
XX for phenotypic correlations, forensics, paternity testing, medicine and
XX genetic analysis.
XX
XX Claim 8; Fig 5; 214pp; English.
XX
XX The present invention is concerned with a number of human single
XX nucleotide polymorphisms (SNPs) which the inventors identified in human
XX genes. These SNPs can be used in disease diagnosis and prediction of an
XX individual's susceptibility to disease, in forensic and paternity testing
XX and in genetic mapping. In particular, the SNPs of the invention can be
XX used to diagnose susceptibility to diseases of the cardiovascular,
XX endocrine and neurological systems, such as coronary artery disease,
XX schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
XX diseases
XX
XX Sequence 17 BP; 3 A; 3 C; 8 G; 3 T; 0 U; 0 Other;
XX
XX
XX Query Match 0.2%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.9e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 420 GGCTCCTTCGACAA 435
XX
XX 17 GGCTCCTTCGACAA 2
XX
XX
XX RESULT 243
XX AAC70673/c
XX ID AAC70673 standard; DNA; 17 BP.
XX
XX AAC70673;
XX
XX 09-FEB-2001 (first entry)
XX
XX Single nucleotide polymorphism PCR primer #336.
XX
XX Single nucleotide polymorphism; SNP; human; genetic disease;
XX disease susceptibility; cardiovascular system; endocrine system;
XX neurological system; forensic testing; paternity testing; PCR primer; ss.
XX
XX Homo sapiens.
XX
XX W0200058519-A2.
XX
XX
XX 05-OCT-2000.
XX
XX
XX 30-MAR-2000; 2000WO-US008440.
XX
XX
XX 31-MAR-1999; 99US-0127248P.
XX
XX (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
XX (AFHY-) AFFYMETRIX INC.
XX
XX Altschuler D, Cargill M, Daley GO, Ireland JS, Lander ES;
XX Lipshutz RJ, Patil N, Sklar P;
XX WPI; 2000-611722/58.
XX
XX Nucleic acid selected from one of 106 genes comprising single nucleotide

```

PT polymorphisms, allele-specific oligonucleotides to the genes are useful
 PT for phenotypic correlations, forensics, paternity testing, medicine and
 XX genetic analysis.

PS Claim 8; Fig 5; 214pp; English.

CC The present invention is concerned with a number of human single
 CC nucleotide polymorphisms (SNPs) which the inventors identified in human
 CC genes. These SNPs can be used in disease diagnosis and prediction of an
 CC individual's susceptibility to disease, in forensic and paternity testing
 CC and in genetic mapping. In particular, the SNPs of the invention can be
 CC used to diagnose susceptibility to diseases of the cardiovascular,
 CC endocrine and neurological systems, such as coronary artery disease,
 CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
 CC diseases

SQ Sequence 17 BP; 3 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 420 GGCTCCTTCGACAA 435
 |||||
 17 GGCTCCTTCACGCA 2

Db

RESULT 244
 AAC70685/c
 ID AAC70685 standard; DNA; 17 BP.

AC AAC70685;
 XX
 DT 09-FEB-2001 (first entry)
 XX

DE Single nucleotide polymorphism PCR primer #344.

XX Single nucleotide polymorphism; SNP; human; genetic disease;
 KW disease susceptibility; cardiovascular system; endocrine system;
 KW neurological system; forensic testing; paternity testing; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200058519-A2.
 XX
 PD 05-OCT-2000.
 XX
 PF 30-MAR-2000; 2000WO-US008440.
 XX
 PR 31-MAR-1999; 99US-0127248P.
 XX

PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
 PA (AFY-) AFFYMETRIX INC.

PI Alshuler D, Cargill M, Daley GQ, Ireland JS, Lander ES;
 PI Lipshutz RJ, Patil N, Sklar P;
 PI
 XX
 DR WPI; 2000-611722/58.

XX Nucleic acid selected from one of 106 genes comprising single nucleotide
 PT polymorphisms, allele-specific oligonucleotides to the genes are useful
 PT for phenotypic correlations, forensics, paternity testing, medicine and
 PT genetic analysis.

PS Claim 8; Fig 5; 214pp; English.

XX The present invention is concerned with a number of human single
 CC nucleotide polymorphisms (SNPs) which the inventors identified in human
 CC genes. These SNPs can be used in disease diagnosis and prediction of an
 CC individual's susceptibility to disease, in forensic and paternity testing
 CC and in genetic mapping. In particular, the SNPs of the invention can be
 CC used to diagnose susceptibility to diseases of the cardiovascular,
 CC endocrine and neurological systems, such as coronary artery disease,
 CC

CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
 CC diseases

SQ Sequence 17 BP; 3 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 420 GGCTCCTTCGACAA 435
 |||||
 17 GGCTCCTTCACGCA 2

Db

RESULT 245
 AAC70688/c
 ID AAC70688 standard; DNA; 17 BP.

AC AAC70688;
 XX
 DT 09-FEB-2001 (first entry)
 XX

DE Single nucleotide polymorphism PCR primer #346.

XX Single nucleotide polymorphism; SNP; human; genetic disease;
 KW disease susceptibility; cardiovascular system; endocrine system;
 KW neurological system; forensic testing; paternity testing; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200058519-A2.
 XX
 PD 05-OCT-2000.
 XX
 PF 30-MAR-2000; 2000WO-US008440.
 XX
 PR 31-MAR-1999; 99US-0127248P.
 XX

PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
 PA (AFY-) AFFYMETRIX INC.

PI Alshuler D, Cargill M, Daley GQ, Ireland JS, Lander ES;
 PI Lipshutz RJ, Patil N, Sklar P;
 PI
 XX
 DR WPI; 2000-611722/58.

XX Nucleic acid selected from one of 106 genes comprising single nucleotide
 PT polymorphisms, allele-specific oligonucleotides to the genes are useful
 PT for phenotypic correlations, forensics, paternity testing, medicine and
 PT genetic analysis.

PS Claim 8; Fig 5; 214pp; English.

XX The present invention is concerned with a number of human single
 CC nucleotide polymorphisms (SNPs) which the inventors identified in human
 CC genes. These SNPs can be used in disease diagnosis and prediction of an
 CC individual's susceptibility to disease, in forensic and paternity testing
 CC and in genetic mapping. In particular, the SNPs of the invention can be
 CC used to diagnose susceptibility to diseases of the cardiovascular,
 CC endocrine and neurological systems, such as coronary artery disease,
 CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
 CC diseases

SQ Sequence 17 BP; 3 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 420 GGCTCCTTCGACAA 435
 |||||
 17 GGCTCCTTCACGCA 2

Db

QY 359 GCTCAGACGAGAGG 374
 ID ABRK02172/c
 ID ABRK02172 standard; RNA; 17 BP.
 XX
 AC ABRK02172;
 DT 12-MAR-2002 (first entry)
 DE Human NCOG DNazyme #84.
 XX
 KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NCOG; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200159103-A2.
 XX
 PD 16-AUG-2001.
 XX
 PF 09-FEB-2001; 2001WO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLATT) BLATT L.
 PA (MCSW/) MCSWIGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, Mcswigen J, Chowrira BM;
 XX
 DR WPI; 2001-607195/69.
 XX
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 PS Claim 88; Page 114; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NCOG). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell

CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NCOG-
 CC targeting nucleic acid is used to cleave RNA of the NCOG gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NCOG activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NCOG. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NCOG-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NCOG expression. The present
 CC sequence is a DNazyme molecule of the invention
 XX
 SQ Sequence 17 BP; 14 A; 0 C; 2 G; 0 T; 1 U; 0 Other;
 XX
 QY 65 TTCTTCTACTTCTTT 80
 Db 17 TTCTTCTATTTT 2
 XX
 RESULT 249
 ABRK0325/c
 ID ABRK0325 standard; RNA; 17 BP.
 XX
 AC ABRK0325;
 XX
 DT 12-MAR-2002 (first entry)
 DE Human NCOG Hammerhead Ribozyme #325.
 XX
 KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NCOG; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200159103-A2.
 XX
 PD 16-AUG-2001.
 XX
 PF 09-FEB-2001; 2001WO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLATT) BLATT L.
 PA (MCSW/) MCSWIGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, Mcswigen J, Chowrira BM;
 XX
 DR WPI; 2001-607195/69.
 XX
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense

PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 XX
 PS Claim 88; Page 71; 200pp; English.
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOCO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an amberyzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg^{2+} .
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a hammerhead ribozyme of the invention
 XX
 SQ Sequence 17 BP; 9 A; 1 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 1; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 73 CTTCTTTTATTCGGA 88
 Db 16 CTTCTTTTATTCGGA 1
 RESULT 250
 ABR02475
 ID ABR02475 standard; RNA; 17 BP.
 XX
 AC ABR02475;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human NOGO Amberzyme #147.
 XX
 KM Human; ss; antisense therapy; cyostatic; antiinflammatory; haemostatic;
 KM cerebroprotective; neuroprotective; antiparkinsonian;
 KM muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KM DNzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukemia;
 KM B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukemia;
 KM human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KM MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KM inflammatory arthropathy; central nervous system injury;
 KM cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KM chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KM Parkinson's disease; ataxia; Huntington's disease;
 KM Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.

OS Synthetic.
 XX
 PN WO200159103-A2.
 XX
 PD 16-AUG-2001.
 XX
 PP 09-FEB-2001; 2001WO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSN/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 PI Blatt L, Mcswiggen J, Chowrira BM;
 DR WPI; 2001-607195/69.
 XX
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 XX
 PS Claim 88; Page 133; 200pp; English.
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOCO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an amberyzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg^{2+} .
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg^{2+} . Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is an amberyzyme molecule of the invention
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
 Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 62.5%; Pred. No. 2.9e+02;
 Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 288 TGCTGTGAGAGCTCT 303
 Db 2 UGCAGUGAAGGCTCT 17
 RESULT 251
 ABR08432

ID AEN08432 standard; DNA; 17 BP.
AC AEN08432;
XX
DT 29-MAY-2002 (first entry)
XX
DB Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8424.
XX
KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AECOM-) AECOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR MPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 8424; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at [ftp.wipo.int/pub/published_pct_sequence](http://wipo.int/pub/published_pct_sequence)
XX
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 363 AGACGACAGAGGACT 378
DB 1 AGACGACAGAGGACT 16
RESULT 252
AEN08701
ID AEN08701 standard; DNA; 17 BP.
AC AEN08701;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8693.
XX
KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AECOM-) AECOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR MPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 8693; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The

CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 7 A; 4 C; 2 T; 0 U; 0 Other;
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 264 CATGACTCTCTGCAGC 279
Db 1 CAAGAACCACTGCAGC 16
RESULT 253
ABN07685/C
ID ABN07685 standard; DNA; 17 BP.
XX
AC ABN07685;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7677.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
XX Disclosure; SEQ ID NO 7677; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1

CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements. and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 10 A; 1 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 65 TTCTTCTACTCTCTTT 80
Db 16 TTCTTCTGCTCTTCT 1
RESULT 254
ABN08431
ID ABN08431 standard; DNA; 17 BP.
XX
AC ABN08431;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8423.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX

30-JAN-2001; 2001WO-US000665.

06-DEC-2001.

PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-026860P.
 PA (AEOM-) AEOMICA INC.
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 DR
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
 PS Disclosure; SEQ ID NO 7529; 214pp; English.
 XX
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP-
 CC 1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 445 GAGCAAGCGCTGGG 460
 |||||
 Db 1 GAGCAAGCGCTGGG 16
 RESULT 257
 ABN07684/c
 ID ABN07684 standard; DNA; 17 BP.
 XX
 AC ABN07684;
 XX 29-MAY-2002 (first entry)
 DT
 XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7676.

XX
 KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KM skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-026860P.
 PA (AEOM-) AEOMICA INC.
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 DR
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
 PS Disclosure; SEQ ID NO 7676; 214pp; English.
 XX
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP-
 CC 1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 10 A; 1 C; 6 G; 0 T; 0 U; 0 Other;
 Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 65 TTCTTACTTCTTT 80
 |||||
 Db 17 TTCTTCTGCTTCTTCT 2

RESULT 258
ABN01166
ID ABN01166 standard; DNA, 17 BP.
XX
AC ABN01166;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1158.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOmica INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 1158; 214pp; English.
XX
XX
The present invention describes a human genome-derived myosin-like
protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
1 can be used in gene therapy and vaccine production. The hGDMLP-1
nucleic acids can be used as probes to detect, characterise and quantify
hGDMLP-1 nucleic acids in samples, as amplification substrates, to
provide initial substrates for the recombinant engineering of hGDMLP-1
protein variants having desired phenotypic improvements, and for
expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
used as immunogens to raise antibodies that specifically recognise hGDMLP
-1 proteins, as standards in assays used to determine the concentration
and/or amount specifically of hGDMLP proteins, as specific biomolecule
capture probes for surface-enhanced laser desorption/ionization, as
therapeutic supplement in patients having specific deficiency in hGDMLP-1
production, and in vaccines or for replacement therapy. The
polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
disease associated with the expression of hGDMLP-1, in particular heart
and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
The present sequence represents an oligomer used in the screening of the
hGDMLP-1 sequence in the exemplification of the present invention. N.B.
The sequence data for this patent did not form part of the printed
specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 5 A; 5 C; 5 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 569 GTCCGACCCCGAATTA 584
DB 2 GACGTCGCCGAGATTA 17
XX
RESULT 259
ABN02460
ID ABN02460 standard; DNA, 17 BP.
XX
AC ABN02460;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2452.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOmica INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 2452; 214pp; English.
XX
XX
The present invention describes a human genome-derived myosin-like
protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
1 can be used in gene therapy and vaccine production. The hGDMLP-1
nucleic acids can be used as probes to detect, characterise and quantify
hGDMLP-1 nucleic acids in samples, as amplification substrates, to
provide initial substrates for the recombinant engineering of hGDMLP-1
protein variants having desired phenotypic improvements, and for
expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
used as immunogens to raise antibodies that specifically recognise hGDMLP
-1 proteins, as standards in assays used to determine the concentration

CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The hGDMLP-1
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
CC
SQ Sequence 17 BP; 2 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 246 CCGAATGCTGGCTTG 261
Db 2 CCGAGATCTGCTGG 17

RESULT 260
ABN07780
ID ABN07780 standard; DNA; 17 BP.
AC ABN07780;
XX
XX 29-MAY-2002 (first entry)
DT
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7772.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
PD
XX
XX 25-MAY-2001; 2001WO-US016981.
PF
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX 30-JAN-2001; 2001WO-US000661.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 30-JAN-2001; 2001WO-US000670.
XX
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME,
XX
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX description ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 7772; 214pp; English.

XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
CC
SQ Sequence 17 BP; 3 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 323 CCGGTGCTGCTGGCA 338
Db 2 CCGATGCTCGGTGGCA 17

RESULT 261
ABN08700
ID ABN08700 standard; DNA; 17 BP.
AC ABN08700;
XX
XX 29-MAY-2002 (first entry)
DT
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8692.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
PD
XX
XX 25-MAY-2001; 2001WO-US016981.
PF
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX 30-JAN-2001; 2001WO-US000661.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 30-JAN-2001; 2001WO-US000670.
XX
XX 05-FEB-2001; 2001US-0266860P.
XX

PA (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI WPI; 2002-179446/23.
 DR
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.
 XX
 PS Disclosure; SEQ ID NO 8692; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 8 A; 4 C; 4 G; 1 T; 0 U; 0 Other;
 XX
 Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 264 CATGAACACTGTCAGG 279
 |||||
 2 CAGAGACAACTGTCAGG 17
 Db
 RESULT 262
 ABN07782
 ID ABN07782 standard; DNA; 17 BP.
 XX
 AC ABN07782;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7774.
 XX
 KM Human, genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 XX skeletal muscle disorder; amplicon; screening; ss.
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 PD
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 XX

PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI WPI; 2002-179446/23.
 DR
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.
 XX
 PS Disclosure; SEQ ID NO 7774; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 2 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 324 CGGTGCGGTGGGAG 339
 |||||
 1 CAGTGTCCGTTGGGAG 16
 Db
 RESULT 263
 ABN10122/c
 ID ABN10122 standard; DNA; 17 BP.
 XX
 AC ABN10122;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10114.
 XX
 KM Human, genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 XX skeletal muscle disorder; amplicon; screening; ss.
 OS Homo sapiens.
 XX

FN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (ABOM-) ABOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMRP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMRP-1.
XX
PS Disclosure; SEQ ID NO 10114; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMRP-1). The protein and polynucleotide sequences of hGDMRP-
CC 1 can be used in gene therapy and vaccine production. The hGDMRP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMRP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMRP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMRP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMRP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMRP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMRP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMRP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMRP-1, in particular heart
CC and skeletal muscle disorders. hGDMRP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMRP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX
DT 29-MAY-2002 (first entry)
XX
XX Human GDMRP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1159.
DE Human GDMRP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1159.
XX
XX Human; genome-derived myosin-like protein 1; hGDMRP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
OS Homo sapiens.
XX
XX WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (ABOM-) ABOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMRP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMRP-1.
XX
PS Disclosure; SEQ ID NO 1159; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMRP-1). The protein and polynucleotide sequences of hGDMRP-
CC 1 can be used in gene therapy and vaccine production. The hGDMRP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMRP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMRP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMRP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMRP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMRP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMRP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMRP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMRP-1, in particular heart
CC and skeletal muscle disorders. hGDMRP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMRP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 6 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 569 GTCCGAGCCCGAGATA 584
| | | | | | | | | |
Db 1 GAGCGTCCCGAGATA 16

RESULT 265
ABN02463
ID ABN02463 standard; DNA, 17 BP.
XX
AC ABN02463;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2455.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.

OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (ABOM-) ABOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
DR

PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT description ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 2455; 214pp; English.
XX
XX

CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser description ionization, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.

CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
XX

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX

QY 248 CAATGCTGCGCTGAT 263
| | | | | | | | | |
Db 1 CAGATGCTGCGCTGAT 16

RESULT 266
ABN07536
ID ABN07536 standard; DNA, 17 BP.
XX
AC ABN07536;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7528.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.

OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (ABOM-) ABOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
DR

PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT description ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 7528; 214pp; English.
XX
XX

CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1

CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
CC
SQ Sequence 17 BP; 5 A; 2 C; 8 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 2;
Oy 445 GAGCAAGGCTGGG 460
Db 2 GAGCAAGGCTGGG 17
|||||
RESULT 267
ABO63767/c
ID ABO63767 standard; DNA; 17 BP.
XX
AC ABO63767;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (ABO63232) probe # 480.
XX
XX Human, KTOM1a; kidney tumour overexpressed membrane; cytosolic;
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KM kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
XX
XX 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Zhang J;
XX
XX WPI; 2002-479509/51.
XX
XX New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT

PT acids encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
XX Example 2; Page 220; 418bp; English.
XX
XX The invention relates to a novel isolated nucleic acid encoding human
XX KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
XX invention has cytosolic activity. The nucleotide may have a use in gene
XX therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
XX monitor a disease caused by altered expression of human KTOM1.
XX Compositions comprising the nucleic acids, proteins or antibodies may be
XX used to treat subjects having defects in KTOM1 which can manifest as
XX cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
XX heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
XX function. The sequence represents a probe used in the invention to scan
XX the nt 1-1001 portion of human KTOM1a (ABO63232)
XX
SQ Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 2;
Oy 411 AAGCTAGAGGCTCCT 426
Db 16 ATGCTGAGGCTCCT 1
|||||
RESULT 268
ABO63764/c
ID ABO63764 standard; DNA; 17 BP.
XX
AC ABO63764;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (ABO63232) probe # 477.
XX
XX Human, KTOM1a; kidney tumour overexpressed membrane; cytosolic;
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KM kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
XX
XX 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Zhang J;
XX
XX WPI; 2002-479509/51.
XX
XX

PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
 PT acids encoding the protein, useful for treating subjects having defects
 PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
 PT e.g., liver or bone.
 XX
 PS Example 2; Page 220; 418pp; English.
 XX
 CC The invention relates to a novel isolated nucleic acid encoding human
 CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
 CC invention has cytoskeletal activity. The nucleotide may have a use in gene
 CC therapy. The KTOM1 nucleic acid may be used to diagnose, treat or
 CC monitor a disease caused by altered expression of human KTOM1.
 CC Compositions comprising the nucleic acids, proteins or antibodies may be
 CC used to treat subjects having defects in KTOM1 which can manifest as
 CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
 CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
 CC function. The sequence represents a probe used in the invention to scan
 CC the nt 1-1001 portion of human KTOM1a (AB063232)
 CC
 SQ Sequence 17 BP; 4 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
 Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 413 GCCTGAGGCTCTCTC 428
 DB 17 GCCTGAGGCTCTCTGC 2
 RESULT 269
 AB063766/C
 ID AB063766 standard; DNA; 17 BP.
 AC AB063766;
 XX
 DT 20-AUG-2002 (first entry)
 XX
 DE Human KTOM1a portion (AB063232) probe # 479.
 XX
 KM Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytoskeletal;
 KM gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
 KM kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
 OS Homo sapiens.
 XX
 PN WO200224750-A2.
 XX
 PD 28-MAR-2002.
 XX
 PF 21-SEP-2001; 2001WO-US029656.
 XX
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001US-0000670.
 PR 23-MAY-2001; 2001US-00864761.
 PR 28-AUG-2001; 2001US-0315676P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Zhang J;
 XX
 DR WPI; 2002-479509/51.

XX
 PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
 PT acids encoding the protein, useful for treating subjects having defects
 PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
 PT e.g., liver or bone.
 XX
 PS Example 2; Page 220; 418pp; English.
 XX
 CC The invention relates to a novel isolated nucleic acid encoding human
 CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
 CC invention has cytoskeletal activity. The nucleotide may have a use in gene
 CC therapy. The KTOM1 nucleic acid may be used to diagnose, treat or
 CC monitor a disease caused by altered expression of human KTOM1.
 CC Compositions comprising the nucleic acids, proteins or antibodies may be
 CC used to treat subjects having defects in KTOM1 which can manifest as
 CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
 CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
 CC function. The sequence represents a probe used in the invention to scan
 CC the nt 1-1001 portion of human KTOM1a (AB063232)
 CC
 SQ Sequence 17 BP; 4 A; 6 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 411 AAGCTGAGGCTCTCT 426
 DB 17 ATGCTGAGGCTCTCT 2
 RESULT 270
 AB063765/C
 ID AB063765 standard; DNA; 17 BP.
 AC AB063765;
 XX
 DT 20-AUG-2002 (first entry)
 XX
 DE Human KTOM1a portion (AB063232) probe # 478.
 XX
 KM Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytoskeletal;
 KM gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
 KM kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
 OS Homo sapiens.
 XX
 PN WO200224750-A2.
 XX
 PD 28-MAR-2002.
 XX
 PF 21-SEP-2001; 2001WO-US029656.
 XX
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001US-0000670.
 PR 23-MAY-2001; 2001US-00864761.
 PR 28-AUG-2001; 2001US-0315676P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Zhang J;
 XX

DR WPI; 2002-479509/51.
XX
PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acids encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
PS Example 2; Page 220; 418bp; English.
XX
CC The invention relates to a novel isolated nucleic acid encoding human
CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC invention has cytosolic activity. The nucleotide may have a use in gene
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTOM1a (AB063232)
XX
SQ Sequence 17 BP; 4 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 413 CCTAGAGGCTCTTC 428
DB 16 GCCTGAGGCTCTTCG 1
RESULT 271
AAL43459
ID AAL43459 standard; DNA; 17 BP.
AC AAL43459;
XX
XX 02-SEP-2002 (first entry)
XX
XX Human tissue kallikrein gene 5' region PCR primer hKPM1.
XX
XX Human; PCR; primer; ss; blood pressure regulation; hKPM1;
XX restricted sodium intake; angiotensin-converting enzyme inhibitor;
XX tissue kallikrein gene promoter; chromosome 19q13.3-13.4;
XX essential hypertension.
XX
XX Homo sapiens.
XX
XX US6376182-B1.
XX
XX 23-APR-2002.
XX
XX 31-JAN-2000; 2000US-00495140.
XX
XX 14-MAY-1997; 97US-00856141.
XX 03-SEP-1999; 99US-00389566.
XX
XX (UYSC-) UNIV SOUTH CAROLINA MEDICAL.
XX
XX Chao L, Chao J, Song Q;
XX
XX WPI; 2002-478280/51.
XX
XX Detection of allelic variation in promoter region of human tissue
XX kallikrein gene identifies subject's ability to regulate blood pressure
XX via dietary sodium intake and likelihood of developing essential
XX hypertension.
XX
XX Example; Col 25; 36pp; English.
XX
XX The invention comprises a method for identifying a human subject with an
XX increased/decreased likelihood of regulating blood pressure with either a

CC restricted sodium intake or an angiotensin-converting enzyme inhibitor.
CC The method involves detecting an allele in the human tissue kallikrein
CC gene/promoter region (located on chromosome 19q13.3-13.4) correlated to
CC increased/decreased likelihood. The method of the invention is useful for
CC identifying humans with an increased risk of having essential
CC hypertension. The present DNA sequence represents a PCR primer that was
CC used to amplify the 5' region of the human tissue kallikrein gene
XX
SQ Sequence 17 BP; 4 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 273 CTGAGGATTCAGAT 288
DB 1 CTGAGGATTCAGAT 16
RESULT 272
ABK19430/C
ID ABK19430 standard; RNA; 17 BP.
AC ABK19430;
XX
XX 09-APR-2002 (first entry)
XX
XX Human ERG Amberzyme target sequence Seq ID No 2077.
XX
XX
XX Human; hammerhead ribozyme; cytosolic; antitumor; antidiabetic;
XX ophthalmological; antiarthritic; antipneumatic; virucide; osteopathic;
XX vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
XX tumour angiogenesis; diabetic retinopathy; macular degeneration;
XX neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
XX angioidioma of tuberous sclerosis; port-wine stain; wound healing;
XX Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
XX Osler-Weber-rendu syndrome; leukaemia; osteoporosis; DNAzyme; inozyme;
XX amberzyme.
XX
XX Homo sapiens.
XX
XX WO200188124-A2.
XX
XX 22-NOV-2001.
XX
XX 16-MAY-2001; 2001WO-US015866.
XX
XX 16-MAY-2000; 2000US-00572021.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (GLAX) GLAXO GROUP LTD.
XX
XX Jarvis T, Von Carlwiltz I, Mcswigen JA, McLaughlin F, Randi AM,
XX WPI; 2002-082995/11.
XX
XX Novel polynucleotide which down regulates expression of Ets-related gene,
XX useful for treating cancer, diabetic retinopathy, macular degeneration,
XX arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX
XX Claim 4; Page 128; 149pp; English.
XX
XX The invention relates to a nucleic acid molecule (I) which down regulates
XX expression of an Ets-related gene (ERG). (I) is useful for treating
XX conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
XX tumour angiogenesis, diabetic retinopathy, macular degeneration,
XX neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
XX vulgaris, angioidioma of tuberous sclerosis, port-wine stains, Sturge
XX Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
XX syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
XX treating a patient having a condition associated with the level of ERG,
XX by contacting cells of the patient with (I) under conditions suitable for
XX the treatment. The method comprises the use of one or more therapies

CC under conditions suitable for the treatment. Leukaemia or tumour
CC angiogenesis is treated by administering (I) to the patient in
CC conjunction with one or more of other therapies such as radiation or
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC cation such as Mg²⁺. (I) is useful for diagnosis of conditions and
CC diseases related to the expression of ERG, and as diagnostic tool to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ERG RNA in a cell. (I) is useful for specifically
CC targeting genes that share homology with ERG gene or ERG fusion genes.
CC ABK17354-ABK22719 represent nucleic acids, including antisense and
CC enzymatic nucleic acid molecules which regulate expression of ERG, and
CC related PCR primers of the invention
XX
SQ Sequence 17 BP; 11 A; 2 C; 2 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 77 TTTTATTCGAATC 92
17 TTTGTTCTGAATC 2

Db

RESULT 273
ABK17417
ID ABK17417 standard; RNA; 17 BP.
XX
XX ABK17417;
XX
DT 09-APR-2002 (first entry)
XX
XX
DE Human ERG hammerhead ribozyme target sequence, Seq ID No 64.
XX
XX Human; hammerhead ribozyme; cytosstatic; antitumour; anti-diabetic;
XX ophthalmological; anti-arthritic; antipsoriatic; virucide; osteopathic;
XX vulnerability; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
XX tumour angiogenesis; diabetic retinopathy; macular degeneration;
XX neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
XX angiofibroma of tuberosus sclerosus; port-wine stain; wound healing;
XX Sturge Weber syndrome; Kippel-Trennau-Weber syndrome; leukaemia; ss;
XX Osler-Weber-rendu syndrome; leukaemia; osteoporosis; DNAzyme; Inozyme;
XX
XX
OS Homo sapiens.
XX
XX WO200188124-A2.
XX
XX 22-NOV-2001.
XX
XX 16-MAY-2001; 2001WO-US015866.
XX
XX 16-MAY-2000; 2000US-00572021.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (GLAX) GLAXO GROUP LTD.
XX
XX Jarvis T, Von Carlowitz I, Mcswigen JA, McLaughlin F, Randi AM;
XX WPI; 2002-082995/11.
XX
XX Novel polynucleotide which down regulates expression of Ets-related gene,
XX useful for treating cancer, diabetic retinopathy, macular degeneration,
XX arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX
XX Claim 4; Page 60; 149pp; English.
XX
XX The invention relates to a nucleic acid molecule (I) which down regulates
XX expression of an Ets-related gene (ERG). (I) is useful for treating
XX conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
XX tumour angiogenesis, diabetic retinopathy, macular degeneration,
XX

CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC vulgaris, angiofibroma of tuberosus sclerosus, port-wine stains, Sturge
CC Weber syndrome, Kippel-Trennau-Weber syndrome, Osler-Weber-rendu
CC syndrome, leukaemia, osteoporosis and wound healing" (I) is useful for
CC treating a patient having a condition associated with the level of ERG,
CC by contacting cells of the patient with (I) under conditions suitable for
CC the treatment. The method comprises the use of one or more therapies
CC under conditions suitable for the treatment. Leukaemia or tumour
CC angiogenesis is treated by administering (I) to the patient in
CC conjunction with one or more of other therapies such as radiation or
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC cation such as Mg²⁺. (I) is useful for diagnosis of conditions and
CC diseases related to the expression of ERG, and as diagnostic tool to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ERG RNA in a cell. (I) is useful for specifically
CC targeting genes that share homology with ERG gene or ERG fusion genes.
CC ABK17354-ABK22719 represent nucleic acids, including antisense and
CC enzymatic nucleic acid molecules which regulate expression of ERG, and
CC related PCR primers of the invention
XX
SQ Sequence 17 BP; 4 A; 4 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.9e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 145 CAGAGTTATCGAGCA 160
2 CAGAGUUAUCGUGCA 17

Db

RESULT 274
ABV90092/c
ID ABV90092 standard; DNA; 17 BP.
XX
XX ABV90092;
XX
DT 23-DEC-2002 (first entry)
XX
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 805.
XX
XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
XX Rho GTPase; signal transduction; gene expression; cancer; vaccine;
XX gene therapy; transgenic; ss.
XX
XX
OS Homo sapiens.
XX
XX EP1239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-00001165.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 23-MAY-2001; 2001US-00864761.
XX 10-OCT-2001; 2001US-0328205P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Shannon M;
XX
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
XX
XX

PT -1, useful for treating disorders associated with decreased expression or
 PT activity of human POSHL1.
 XX
 PS Example 2; SEQ ID NO 805; 60pp + Sequence Listing; English.
 XX
 CC The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
 CC (S1) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention. Note: The present sequence did not form part of the
 CC printed specification, but is based on sequence information supplied to
 CC Derwent by the European Patent Office
 XX
 SQ Sequence 17 BP; 4 A; 8 C; 4 G; 1 T; 0 U; 0 Other;
 XX
 Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 269 GCTGTGCAGCTCCTT 304
 Db 17 GCTGGGCGAGCTGCTT 2
 XX
 RESULT 275
 ABV90093/c
 ID ABV90093 standard; DNA; 17 BP.
 XX
 AC ABV90093;
 XX
 XX 23-DEC-2002 (first entry)
 XX
 DE Human POSHL1 scanning oligonucleotide SEQ ID NO 806.
 XX
 XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KM Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KM gene therapy; transgenic; ss.
 XX
 OS Homo sapiens.
 XX
 PN EPI239051-A2.
 XX
 PD 11-SEP-2002.
 XX
 PF 28-JAN-2002; 2002EP-00001165.
 XX
 XX 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 23-MAY-2001; 2001US-00864761.
 PR 10-OCT-2001; 2001US-0328205P.
 XX
 XX (AEOM-) AEOMICA INC.
 PA Shannon M;
 XX
 PI
 XX

DR WPI; 2002-684061/74.
 XX
 XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
 PT -1, useful for treating disorders associated with decreased expression or
 PT activity of human POSHL1.
 XX
 PS Example 2; SEQ ID NO 806; 60pp + Sequence Listing; English.
 XX
 CC The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
 CC (S1) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention. Note: The present sequence did not form part of the
 CC printed specification, but is based on sequence information supplied to
 CC Derwent by the European Patent Office
 XX
 SQ Sequence 17 BP; 4 A; 8 C; 4 G; 1 T; 0 U; 0 Other;
 XX
 Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 289 GCTGTGCAGCTCCTT 304
 Db 16 GCTGGGCGAGCTGCTT 1
 XX
 RESULT 276
 AAS19261
 ID AAS19261 standard; DNA; 17 BP.
 XX
 AC AAS19261;
 XX
 XX 29-AUG-2003 (revised)
 DT 26-MAR-2002 (first entry)
 XX
 DE HIV env PCR primer #1.
 XX
 XX T0 terminator; PGA; DNA vaccine; anti-HIV; virucide; ss;
 KM Human Immunodeficiency Virus; HIV; Gag; HIV gp120; HIV Pol; HIV Env;
 KM HIV VLP; measles fusion protein; measles haemagglutinin; PCR primer;
 KM measles nucleoprotein; influenza haemagglutinin; C3d gene;
 XX cell-mediated immune response; humoral immune response; infection.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN WO200192470-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 02-MAR-2001; 2001WO-US006795.
 PR 02-MAR-2000; 2000US-0186364P.
 PR 01-DEC-2000; 2000US-0251083P.
 PA (UYEM-) UNIV EMORY.
 XX
 XX Robinson HL, Smith JM, Rose TM, Bright RA, Hua J, Ellenberger D;
 PI WPI; 2002-075465/10.
 XX
 DR

PT Novel pGA vector useful for immunizing patient against measles, influenza
PT has termination sequence encoding lambda TO terminator and a eukaryotic
PT transcription cassette with vaccine insert encoding immunogens of
PT pathogens.

PS Example 5; Page 48; 174pp; English.

XX
CC The invention relates to a vector (a pGA construct) comprising a
CC termination sequence coding for the lambda TO terminator, a prokaryotic
CC origin of replication, a selectable marker gene and a eukaryotic
CC transcription cassette comprising a vaccine insert encoding one or more
CC immunogens derived from a pathogen e.g. Human Immunodeficiency Virus
CC (HIV) Gag, HIV gp120, HIV Pol, HIV Env, HIV VLP, or its mutants, measles
CC haemagglutinin, or its mutants, or subsequences, and optionally at least
CC one C3d gene, is useful for immunising or treating a patient, when
CC administered by an intramuscular or intradermal route. The immunisation
CC methods using pGA elicit both cell-mediated and humoral immune responses
CC that may limit the infection, spread or growth of the pathogen and result
CC in protection against subsequent challenge against the pathogen. The
CC terminator sequence prevents read-through from the kanamycin
CC cassette into vaccine sequences while the plasmid is being produced in
CC bacteria. Prevention of transcriptional read-through stabilises vaccine
CC insert sequences by limiting the exposure of secondary structures that
CC can be recognised by bacterial endonucleases. The present sequence is a
CC PCR primer used to amplify the HIV env gene for cloning into the pGA
CC vectors. (Updated on 29-AUG-2003 to standardise OS field)

XX Sequence 17 BP; 3 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

QY Query Match

Best Local Similarity 0.2%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 460 GTGACGAGTGTCTACC 475
1 GGGCAGAGAGTCTTACC 16

RESULT 277

ACN10465/C
ID ACN10465 standard; RNA; 17 BP.

XX ACN10465;

XX 22-APR-2004 (first entry)

DE MNV minus strand Inozyme substrate SEQ ID NO 10468.

XX MNV; West Nile Virus; antiinflammatory; cytosstatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.

XX West Nile Virus.

XX WO200268637-A2.

XX 06-SEP-2002.

XX 19-OCT-2001; 2001WO-US048350.

XX 20-OCT-2000; 2000US-024241P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (MNV), useful for treating a condition related to MNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

PS Claim 23; SEQ ID NO 10468; 495pp; English.

XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC treating a condition related to MNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3',3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

XX Sequence 17 BP; 2 A; 6 C; 4 G; 0 T; 5 U; 0 Other;

QY Query Match

Best Local Similarity 0.2%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 345 CAACTGACGCAATGC 360
17 CAAGCTGAGCAATGC 2

RESULT 278

ACN10807
ID ACN10807 standard; RNA; 17 BP.

XX ACN10807;

XX 22-APR-2004 (first entry)

DE MNV minus strand Inozyme substrate SEQ ID NO 10810.

XX MNV; West Nile Virus; antiinflammatory; cytosstatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.

XX West Nile Virus.

XX WO200268637-A2.

XX 06-SEP-2002.

XX 19-OCT-2001; 2001WO-US048350.

XX 20-OCT-2000; 2000US-024241P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (MNV), useful for treating a condition related to MNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

PS Claim 23; SEQ ID NO 10810; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication

CC molecule of the invention
XY

XX

SO Sequence 17 BP; 5 A; 5 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 104 AGCAAGCCATGTGGT 119
DB 17 AGCAGAGCCATTTGGT 2

RESULT 281

ACN07170
ID ACN07170 standard; RNA; 17 BP.

AC ACN07170;

DT 22-APR-2004 (first entry)

DE MNV Amberzyme substrate SEQ ID NO 7173.

XX MNV; West Nile Virus; antiinflammatory; cytototoxic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KM encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KM Amberzyme; Zinzyme; ss.

OS West Nile Virus.

XX WO200268637-A2.

PN 06-SEP-2002.

PD 19-OCT-2001; 2001WO-US048350.

PR 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

DR WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus

PT (MNV), useful for treating a condition related to MNV infection e.g.

PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 7173; 495bp; English.

CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC treating a condition related to MNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2',-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3',-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

XX Sequence 17 BP; 7 A; 2 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;

Best Local Similarity 56.2%; Pred. No. 2.9e+02;

QY Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

DB 2 CUGAUGAUCGUGAA 17

RESULT 282

ACN07622/C
ID ACN07622 standard; RNA; 17 BP.

AC ACN07622;

DT 22-APR-2004 (first entry)

DE MNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 7625.

XX MNV; West Nile Virus; antiinflammatory; cytototoxic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KM encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KM Amberzyme; Zinzyme; ss.

OS West Nile Virus.

XX WO200268637-A2.

PN 06-SEP-2002.

PD 19-OCT-2001; 2001WO-US048350.

PR 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

DR WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus

PT (MNV), useful for treating a condition related to MNV infection e.g.

PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 7625; 495bp; English.

CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC treating a condition related to MNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2',-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3',-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

XX Sequence 17 BP; 5 A; 3 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.9e+02;

QY Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

DB 254 CTGCGTTGATCATGAA 269

16 CTGAATTCATCATGAA 1

RESULT 283
ACN06696
ID ACN06696 standard; RNA; 17 BP.

```

XX ACN06696;
XX 22-APR-2004 (first entry)
XX
XX MNV Amberzyme substrate SEQ ID NO 6699.
XX
XX MNV; West Nile Virus; antiinflammatory; cyostatic; hepatotropic;
XX viruslike; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Amberzyme; Zinzyne; ss.
XX
XX West Nile Virus.
XX
XX MO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (MNV), useful for treating a condition related to MNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 6699; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (MNV). The nucleic acid molecules are useful for
XX treating a condition related to MNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyne. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
XX Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 0.2%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 75.0%; Pred. No. 2.9e+02;
XX Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
XX
XX 345 CAACCTGACGCATGTC 360
XX |||||:|||||
XX 1 CAAGCUGAGGCAUCC 16
XX
XX RESULT 284
XX ACN08143/c
XX ID ACN08143 standard; RNA; 17 BP.
XX
XX ACN08143;
XX
XX 22-APR-2004 (first entry)
XX
XX MNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8146.
XX

```

```

XX MNV; West Nile Virus; antiinflammatory; cyostatic; hepatotropic;
XX viruslike; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Amberzyme; Zinzyne; ss.
XX
XX West Nile Virus.
XX
XX MO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (MNV), useful for treating a condition related to MNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 8146; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (MNV). The nucleic acid molecules are useful for
XX treating a condition related to MNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyne. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
XX Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
XX
XX Query Match 0.2%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.9e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 344 GCAACCTGACGCATG 359
XX |||||:|||||
XX 16 GCAAGCTGAGGCAATG 1
XX
XX RESULT 285
XX ACN03095
XX ID ACN03095 standard; RNA; 17 BP.
XX
XX ACN03095;
XX
XX 22-APR-2004 (first entry)
XX
XX MNV Inozyme substrate SEQ ID NO 3098.
XX
XX MNV; West Nile Virus; antiinflammatory; cyostatic; hepatotropic;
XX viruslike; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Amberzyme; Zinzyne; ss.
XX
XX West Nile Virus.
XX

```

```

XX PN WO200268637-A2.
XX
XX PD 06-SEP-2002.
XX
XX PF 19-OCT-2001; 2001WO-US048350.
XX
XX PR 20-OCT-2000; 2000US-0242411P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J A.
XX PI Blatt L, Mcswigen JA;
XX
XX DR WPI; 2002-706994/76.
XX
XX PT New nucleic acid molecule that modulates replication of West Nile Virus
XX PT (WNV), useful for treating a condition related to WNV infection e.g.
XX PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX PS Claim 23; SEQ ID NO 3098; 495bp; English.
XX
XX CC The invention relates to nucleic acid molecules that modulate replication
XX CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX CC treating a condition related to WNV infection e.g. pancreatitis,
XX CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX CC molecule is selected from the group of ribozymes consisting of
XX CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
XX CC nucleic acid molecules further comprise at least five ribose residues, at
XX CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX CC least three of the 5' terminal nucleotides and a 3' end modification of a
XX CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX CC in the specification. The present sequence is that of a nucleic acid
XX CC molecule of the invention
XX
XX SQ Sequence 17 BP; 4 A; 3 C; 5 G; 0 T; 5 U; 0 Other;

Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.9e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      104 AGCAAGCCATGTGCT 119
      |||||:||||:
Db      1 AGCAGAGCCAUUGGU 16

RESULT 286
ACN05378
ID ACN05378 standard; RNA; 17 BP.
XX
XX AC ACN05378;
XX
XX DT 22-APR-2004 (first entry)
XX
XX DE WNV DNAzyme substrate SEQ ID NO 5381.
XX
XX KW WNV; West Nile Virus; antiinflammatory; cytosstatic; hepatotropic;
XX KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX KW encephalitis; myocarditis; meningitis; infection; hepatitis;
XX KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX KW Amberzyme; Zinzyme; ss.
XX
XX OS West Nile Virus.
XX
XX PN WO200268637-A2.
XX
XX PD 06-SEP-2002.
XX
XX PF 19-OCT-2001; 2001WO-US048350.
XX
XX PI Blatt L, Mcswigen JA;

```

```

PR 20-OCT-2000; 2000US-0242411P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J A.
XX
XX PI Blatt L, Mcswigen JA;
XX
XX DR WPI; 2002-706994/76.
XX
XX PT New nucleic acid molecule that modulates replication of West Nile Virus
XX PT (WNV), useful for treating a condition related to WNV infection e.g.
XX PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX PS Claim 23; SEQ ID NO 5381; 495bp; English.
XX
XX CC The invention relates to nucleic acid molecules that modulate replication
XX CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX CC treating a condition related to WNV infection e.g. pancreatitis,
XX CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX CC molecule is selected from the group of ribozymes consisting of
XX CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
XX CC nucleic acid molecules further comprise at least five ribose residues, at
XX CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX CC least three of the 5' terminal nucleotides and a 3' end modification of a
XX CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX CC in the specification. The present sequence is that of a nucleic acid
XX CC molecule of the invention
XX
XX SQ Sequence 17 BP; 7 A; 2 C; 3 G; 0 T; 5 U; 0 Other;

Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 2.9e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY      254 CTGCTTGATCATGAA 269
      ||:||||:|||||
Db      1 CUGAUGAUGAUGAA 16

RESULT 287
ACN06695
ID ACN06695 standard; RNA; 17 BP.
XX
XX AC ACN06695;
XX
XX DT 22-APR-2004 (first entry)
XX
XX DE WNV Amberzyme substrate SEQ ID NO 6698.
XX
XX KW WNV; West Nile Virus; antiinflammatory; cytosstatic; hepatotropic;
XX KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX KW encephalitis; myocarditis; meningitis; infection; hepatitis;
XX KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX KW Amberzyme; Zinzyme; ss.
XX
XX OS West Nile Virus.
XX
XX PN WO200268637-A2.
XX
XX PD 06-SEP-2002.
XX
XX PF 19-OCT-2001; 2001WO-US048350.
XX
XX PR 20-OCT-2000; 2000US-0242411P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J A.
XX
XX PI Blatt L, Mcswigen JA;

```

```

XX DR WPI; 2002-706994/76.
XX
XX PT New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX PS Claim 23; SEQ ID NO 6698; 495pp; English.
XX
XX CC The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Ambenzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention.
XX
XX SQ Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 0.2%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 75.0%; Pred. No. 2.9e+02;
XX Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 344 GCACCTGACGCAATG 359
XX 2 GCACGCGAGGCAAG 17
XX
XX RESULT 288
XX ACN08394
XX ID ACN08394 standard; RNA; 17 BP.
XX
XX AC ACN08394;
XX
XX DT 22-APR-2004 (first entry)
XX
XX DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8397.
XX
XX KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Ambenzyme; Zinzyme; ss.
XX
XX OS West Nile Virus.
XX
XX PN WO200268637-A2.
XX
XX PD 06-SEP-2002.
XX
XX PF 19-OCT-2001; 2001WO-US048350.
XX
XX PR 20-OCT-2000; 2000US-024241P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLATT) BLATT L.
XX PA (MCSW/) MCSWIGGEN J A.
XX
XX PI Blatt L, Mcswiggen JA;
XX
XX DR WPI; 2002-706994/76.
XX
XX PT New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX

```

```

XX PS Claim 23; SEQ ID NO 8397; 495pp; English.
XX
XX CC The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Ambenzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention.
XX
XX SQ Sequence 17 BP; 1 A; 5 C; 2 G; 0 T; 9 U; 0 Other;
XX
XX Query Match 0.2%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 31.2%; Pred. No. 2.9e+02;
XX Matches 5; Conservative 9; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 67 CTTCTACTTCTTTAT 82
XX 1 CUCUCUCUCUCUUAU 16
XX
XX DB
XX
XX RESULT 289
XX ACA99846
XX ID ACA99846 standard; DNA; 17 BP.
XX
XX AC ACA99846;
XX
XX DT 28-JUN-2003 (first entry)
XX
XX DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #339.
XX
XX KW Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
XX G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO2003031621-A2.
XX
XX PD 17-APR-2003.
XX
XX PF 11-OCT-2002; 2002WO-US032599.
XX
XX PR 12-OCT-2001; 2001US-0329000P.
XX
XX PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
XX PI Zhang J;
XX
XX DR WPI; 2003-381720/36.
XX
XX PT New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
XX investigating and/or treating disorders associated with aberrant
XX expression or activity of GPCR-A-1, such as tumors and cancers.
XX
XX PS Example 2; SEQ ID NO 363; 156pp; English.
XX
XX CC The invention describes an isolated nucleic acid encoding a G protein
XX coupled receptor (GPCR), mutations of which cause cancer, comprising a
XX 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
XX 409 residue amino acid sequence, all given in the specification, with or
XX without conservative amino acid substitutions, or complements of the
XX sequence of them. The encoding nucleic acid is not more than 100 kbase in
XX length. The methods and compositions of the present invention are useful
XX for diagnosing, investigating and/or treating disorders associated with
XX aberrant expression or activity of GPCR-A-1, such as tumours and cancers.
XX This sequence represents an oligonucleotide used to analyse the gene
XX

```

CC encoding human G-protein coupled receptor GPCR-A-1
XX
SQ Sequence 17 BP; 7 A; 1 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 AAAATGGAACATTAAG 58
DB 2 ATATGAGAGCATTAAG 17

RESULT 290

ACA99852
ID ACA99852 standard; DNA; 17 BP.

AC ACA99852;

XX 28-JUL-2003 (first entry)

DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #345.

XX Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;

KW G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytosolic; ss.

XX Homo sapiens.

OS WO2003031621-A2.

PN 17-APR-2003.

PF 11-OCT-2002; 2002WO-US032599.

PR 12-OCT-2001; 2001US-032900P.

XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.

PI Zhang Y;

DR WPI; 2003-381720/36.

PT New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT investigating and/or treating disorders associated with aberrant
XX expression or activity of GPCR-A-1, such as tumors and cancers.

PS Example 2; SEQ ID NO 369; 156bp; English.

XX The invention describes an isolated nucleic acid encoding a G protein
CC coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC 409 residue amino acid sequence, all given in the specification, with or
CC without conservative amino acid substitutions, or complements of the
CC sequence of them. The encoding nucleic acid is not more than 100 kbase in
CC length. The methods and compositions of the present invention are useful
CC for diagnosing, investigating and/or treating disorders associated with
CC aberrant expression or activity of GPCR-A-1, such as tumours and cancers.
CC This sequence represents an oligonucleotide used to analyse the gene
XX encoding human G-protein coupled receptor GPCR-A-1

SQ Sequence 17 BP; 6 A; 2 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 48 GGAACATTAAGAGTG 63
DB 1 GGAGCATTAAGAACTG 16

RESULT 291
ABT36565/c

ID ABT36565 standard; DNA; 17 BP.

XX ABT36565;

AC 12-JUN-2003 (first entry)

DT Tumour suppression related human fukutin oligo SEQ ID No 2202.

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;

KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;

KW schizophrenia; protein chip; gene therapy; tumour suppression;

XX human fukutin; ds.

OS Homo sapiens.

PN WO2003025175-A2.

PD 27-MAR-2003.

PF 17-SEP-2002; 2002WO-IB004208.

PR 17-SEP-2001; 2001FR-00011978.

PA (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Amson R, Tuijinder M;

XX WPI; 2003-313353/30.

DR New isolated nucleic acid, useful for treating viral diseases associated

PT with tumors and cell degeneration, also related polypeptides, antibodies

PT and transfected cells.

XX Disclosure, Page 290; 720bp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
XX related human fukutin oligonucleotide of the invention

SQ Sequence 17 BP; 6 A; 4 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 307 TGTATATGAGGAGTC 322
DB 16 TGTATATGAGATC 1

RESULT 292
ABT35136/c
ID ABT35136 standard; DNA; 17 BP.

AC ABT35136;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID No 773.
 XX
 DE Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KM antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KM schizophrania; protein chip; gene therapy; tumour suppression;
 KM human fukutin; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO2003025175-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004208.
 XX
 PR 17-SEP-2001; 2001FR-00011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313353/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 123; 720pp; French.
 XX
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrania. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 3 A; 2 C; 4 G; 8 T; 0 U; 0 Other;
 OY Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Db 579 AGAATCTACCCAAAT 594
 17 AGAATCTACCCAGAT 2
 RESULT 293
 ABT35773/C
 ID ABT35773 standard; DNA; 17 BP.
 XX ABT35773;
 AC
 XX
 XX

DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID No 1410.
 XX
 DE Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KM antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KM schizophrania; protein chip; gene therapy; tumour suppression;
 KM human fukutin; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO2003025175-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004208.
 XX
 PR 17-SEP-2001; 2001FR-00011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313353/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 197; 720pp; French.
 XX
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrania. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 9 A; 2 C; 3 G; 3 T; 0 U; 0 Other;
 OY Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Db 77 TTTTATTTCTGAATC 92
 16 TTTTATTTCTGATC 1
 RESULT 294
 ABT39537/C
 ID ABT39537 standard; DNA; 17 BP.
 XX ABT39537;
 AC
 XX
 XX
 DT 12-JUN-2003 (first entry)
 XX

Tumour suppression related human leukocyte antigen

Enzymatic nucleic acid: nuclear factor kappa B, NFkB, transcription factor

KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edutrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; BS.
 XX
 OS Homo sapiens.
 XX
 XX US2002177568-A1.
 XX
 XX 28-NOV-2002.
 PD
 PD 23-MAY-2001; 2001US-00864785.
 PF
 XX 07-DEC-1992; 92US-00967132.
 PR 18-MAY-1994; 94US-00245466.
 PR 15-AUG-1994; 94US-00291932.
 PR 23-DEC-1996; 96US-00777916.
 XX
 PA (STTN/) STINCHOMB D T.
 PA (MCSW/) MCSWIGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 PI Stinchcomb DT, Mcswiggen J, Draper KG;
 XX
 DR WPI; 2003-340953/32.
 XX
 XX
 PT Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.
 XX
 XX
 PS Claim 3; Page 31; 72pp; English.
 XX
 XX The invention describes an enzymatic nucleic acid molecule (1) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFkB), where (1) is an inozyme, zinczyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (1) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edutrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule
 XX
 SO Sequence 17 BP; 3 A; 10 C; 3 G; 0 T; 1 U; 0 Other;
 Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e-02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0.
 451 AGGCTGGGGGTCACAG 466
 |||
 17 AGGGCTGGGGGTCG 2

44
 RESULT 297
 ACAA06466/c
 ID ACAA06466 standard; RNA; 17 BP.
 XX
 XX ACAA06466;
 AC
 XX 03-JUN-2003 (first entry)
 XX
 XX
 DE NFKB sub-unit modulating inozyme substrate #285.
 XX
 XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edetrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
 KW
 OS
 OS Homo sapiens.
 XX
 XX US2002177568-A1.
 PN
 XX 28-NOV-2002.
 PD
 PF 23-MAY-2001; 2001US-00864785.
 XX
 PR 07-DEC-1992; 92US-00987132.
 PR 18-MAY-1994; 94US-00245466.
 PR 15-AUG-1994; 94US-00221932.
 PR 23-DEC-1996; 96US-00777916.
 XX
 PA (STIN/) STINCHCOMB D T.
 PA (MCSW/) MCSWIGEN J.
 PA (DRAP/) DRAPER K G.
 PI Stinchcomb DT, Mcswigen J, Draper KG;
 DR WPI; 2003-340953/32.
 XX
 PT Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.
 PT
 PS
 XX
 XX
 XX Claim 3; Page 31; 72pp; English.
 CC The invention describes an enzymatic nucleic acid molecule (1) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFKB), where (1) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (1) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edetrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury

CC (central nervous system (CNS) and myocardial), glomerulonephritis,
CC sepsis, allergic airway inflammation, inflammatory bowel disease or
CC infection. This sequence represents the substrate of a novel enzymatic
CC nucleic acid molecule
XX
SQ Sequence 17 BP; 4 A; 10 C; 2 G; 0 T; 1 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. NO. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 451 AGGCGTGGGGTGCAGG 466
DB 16 AGGCGTGGGGTGCAGG 1

RESULT 298
AB260124
ID AB260124 standard, RNA; 17 BP.

AC AB260124;

DT 21-MAR-2003 (first entry)

DE Human K-Ras DNAzyme substrate #236.

KM Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
KM anti-rheumatic; cancer; AIDS; ss.

OS Homo sapiens.

PN WO200297114-A2.

PD 05-DEC-2002.

PF 29-MAY-2002; 2002WO-US016840.

PR 29-MAY-2001; 2001US-0294140P.

PR 06-JUN-2001; 2001US-0296249P.

PR 10-SEP-2001; 2001US-0318471P.

XX (RIBO-) RIBOZYME PHARM INC.

PI Mcswigen J;

DR WPI; 2003-140484/13.

PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.

PS Claim 58; Page 89; 185pp; English.

CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosolic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in AB259889 - AB262216, AB264544 - AB265531, AB266520 - AB266524,
CC AB266530 - AB266585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX

SQ Sequence 17 BP; 2 A; 3 C; 0 G; 0 T; 12 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 25.0%; Pred. NO. 2.9e+02;
Matches 4; Conservative 10; Mismatches 2; Indels 0; Gaps 0;

QY 71 TACTTCTTTATTCT 86
DB 1 UACUCUUAUUUUUCU 16

RESULT 299
ADB40647/C
ID ADB40647 standard, DNA; 17 BP.

AC ADB40647;

DT 18-DEC-2003 (revised)

DT 04-DEC-2003 (first entry)

DE Tumour suppression/reversion associated nucleotide #970.

KM cytosolic; antiviral; neuroprotective; neurotropic; neuroleptic; ss;
KM primer; probe; tumour suppression; tumour reversion; apoptosis;
KM virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KM diagnosis.

OS Homo sapiens.

PN WO2003040369-A2.

PD 15-MAY-2003.

PF 17-SEP-2002; 2002WO-IB004219.

PR 17-SEP-2001; 2001FR-00011981.

XX (MOLE-) MOLECULAR ENGINES LAB.

PA Telerman A, Amson R, Tuijinder M;

PI WPI; 2003-441574/41.

PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.

PS Disclosure; Page 145; 771pp; French.

CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX

SQ Sequence 17 BP; 6 A; 3 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. NO. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 17 CTTTCTGACACTGCT 32
DB 17 CTTTCTGAAACTGAT 2

```

RESULT 300
ADCC04246/c
ID   ADC04246 standard; DNA, 17 BP.
XX
XX
AC   ADC04246;
XX
XX   18-DEC-2003 (first entry)
DT
XX
DE   Human Na/H exchanger-like protein 1 gene oligonucleotide #693.
XX
XX   ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KM   NHEPL1; passive replacement therapy; vaccine; diagnosis.
XX
XX   Homo sapiens.
OS
XX   EP1273660-A2.
PN
XX   08-JAN-2003.
PD
XX   25-JAN-2002; 2002EP-00001160.
PF
XX
XX   30-JAN-2001; 2001WO-US000666.
PR   23-MAY-2001; 2001US-00864761.
PR   21-DEC-2001; 2001US-0343331P.
XX
XX   (AEOM-) AEOMICA INC.
PA
XX
XX   Gu Y;
PI
XX
XX   WPI; 2003-302724/30.
DR
XX
XX   New human sodium-hydrogen exchanger like protein 1 (NHEPL1), useful as a
PT   passive replacement therapy or as a vaccine for treating or preventing
PT   disorders associated with aberrant expression or activity of human
PT   NHEPL1.
XX
XX   Example 2; SEQ ID NO 733; 468bp; English.
PS
XX
XX   The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC   exchanger like protein (NHEPL1). The NHEPL1 nucleic acid molecule, NHEPL1
CC   polypeptide, an antibody against the protein or its antigen-binding
CC   fragment is useful in therapy. The NHEPL1 nucleic acid molecule, NHEPL1
CC   polypeptide and an agonist are particularly useful for manufacturing a
CC   medicament for treating or preventing a disorder associated with
CC   decreased expression or activity of human NHEPL1. The antibody or its
CC   antigen-binding fragment, and an antagonist, are useful for manufacturing
CC   a medicament for treating or preventing a disorder associated with
CC   increased expression or activity of human NHEPL1. The NHEPL1 nucleic acid
CC   or protein is useful as passive replacement therapy, as a vaccine, or in
CC   diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC   spanning the sequence of the human NHEPL1 gene (ADC03514).
XX
XX   Sequence 17 BP; 4 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY      168 CACCACCTGTACAGGA 183
DB      17 CAGCACTGTCTACTGCA 2

```

```

DE   Human Na/H exchanger-like protein 1 gene oligonucleotide #699.
XX
XX   ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KM   NHEPL1; passive replacement therapy; vaccine; diagnosis.
XX
XX   Homo sapiens.
OS
XX   EP1273660-A2.
PN
XX   08-JAN-2003.
PD
XX   25-JAN-2002; 2002EP-00001160.
PF
XX
XX   30-JAN-2001; 2001WO-US000666.
PR   23-MAY-2001; 2001US-00864761.
PR   21-DEC-2001; 2001US-0343331P.
XX
XX   (AEOM-) AEOMICA INC.
PA
XX
XX   Gu Y;
PI
XX
XX   WPI; 2003-302724/30.
DR
XX
XX   New human sodium-hydrogen exchanger like protein 1 (NHEPL1), useful as a
PT   passive replacement therapy or as a vaccine for treating or preventing
PT   disorders associated with aberrant expression or activity of human
PT   NHEPL1.
XX
XX   Example 2; SEQ ID NO 739; 468bp; English.
PS
XX
XX   The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC   exchanger like protein (NHEPL1). The NHEPL1 nucleic acid molecule, NHEPL1
CC   polypeptide, an antibody against the protein or its antigen-binding
CC   fragment is useful in therapy. The NHEPL1 nucleic acid molecule, NHEPL1
CC   polypeptide and an agonist are particularly useful for manufacturing a
CC   medicament for treating or preventing a disorder associated with
CC   decreased expression or activity of human NHEPL1. The antibody or its
CC   antigen-binding fragment, and an antagonist, are useful for manufacturing
CC   a medicament for treating or preventing a disorder associated with
CC   increased expression or activity of human NHEPL1. The NHEPL1 nucleic acid
CC   or protein is useful as passive replacement therapy, as a vaccine, or in
CC   diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC   spanning the sequence of the human NHEPL1 gene (ADC03514).
XX
XX   Sequence 17 BP; 3 A; 4 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match      0.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY      24 GACACTGTGCGCAGT 39
DB      2 GACAGTGTGCGCACT 17

```

```

RESULT 301
ADCC04252
ID   ADC04252 standard; DNA, 17 BP.
XX
XX   ADC04252;
AC
XX
XX   18-DEC-2003 (first entry)
DT
XX

```

```

RESULT 302
ADCC04253
ID   ADC04253 standard; DNA, 17 BP.
XX
XX   ADC04253;
AC
XX
XX   18-DEC-2003 (first entry)
DT
XX
XX   Human Na/H exchanger-like protein 1 gene oligonucleotide #700.
DE
XX
XX   ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KM   NHEPL1; passive replacement therapy; vaccine; diagnosis.
XX
XX   Homo sapiens.
OS
XX   EP1273660-A2.
PN
XX
XX   08-JAN-2003.
PD

```


CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and/or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.

SO Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 261 GATCATGACTACTGTC 276

Db 1 GATCAGAGCCTACTGTC 16

RESULT 305

ADE06477 standard; DNA; 17 BP.

AC ADE06477;

DT 29-JAN-2004 (first entry)

DE HIV-1 ENV PCR primer #1.

XX HIV infection; Anti-HIV; vaccine; PCR; primer; ss.

OS Human immunodeficiency virus 1.

PN WO2003076591-A2.

PD 18-SEP-2003.

PF 10-MAR-2003; 2003MO-US007177.

PR 08-MAR-2002; 2002US-00093953.

PR 03-JAN-2003; 2003US-00336566.

PA (UYEM-) UNIV EMORY.

XX (USSH) US DEPT HEALTH & HUMAN SERVICES.

PI Robinson HL, Smith J, Hua J, Moss B;

DR WPI; 2003-731822/69.

PT A composition for generating an immune response against HIV comprises a
PT vector comprising a vaccine insert encoding one or more antigens that
PT elicit an immune response against HIV.

PS Example 8; Page 42; 133p; English.

CC The present invention relates to a composition comprising a first vector
CC with a vaccine insert encoding one or more antigens that elicit an immune
CC response against HIV or a first subtype or recombinant form; and a second
CC vector comprising a vaccine insert encoding one or more antigens that
CC elicit an immune response against an HIV of a second subtype or
CC recombinant form. The composition is useful in generating an immune

CC response against HIV. The insert of the first vector or the insert of the
CC second vector comprises the sequences of two or more of: a gag, pol, env,
CC tat, rev, nef, vif, vpr or vpu gene; or their mutants, and optionally;
CC non-coding regulatory sequences of the HIV genome. At least one of the
CC two or more sequences comprises mutations that limit the encapsidation of
CC viral RNA, or a gag sequence having a mutation in one or more of the
CC sequences encoding a zinc finger. All or part of cis-acting RNA
CC encapsidation sequences have been deleted from the non-coding regulatory
CC sequences of HIV-1. The two or more sequences comprise a pol sequence
CC having a mutation that inhibits one or more of the enzymatic activities
CC of pol. The enzymatic activity is integrase activity, reverse
CC transcriptase activity or protease activity. The enzymatic activity is
CC inhibited by deleting a portion of the pol sequence or introducing one or
CC more point mutations into the pol sequence. The present sequence was used
CC in an example from the invention.

SO Sequence 17 BP; 3 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.2%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 460 GTGCAGAGTGCTACC 475

Db 1 GGCAGAGAGTGCTAGC 16

RESULT 306

ADF55656 standard; DNA; 17 BP.

AC ADF55656;

DT 12-FEB-2004 (first entry)

DE Human kallikrein primer #1.

XX human; kallikrein; primer; ss; essential hypertension;

XX dietary sodium intake; angiotensin-converting enzyme.

OS Homo sapiens.

PN US2003157490-A1.

PD 21-AUG-2003.

PF 29-JAN-2002; 2002US-00059877.

PR 29-JAN-2002; 2002US-00059877.

PA (UYSC-) UNIV SOUTH CAROLINA MEDICAL.

PI Chao L, Chao J, Song Q;

DR WPI; 2003-766149/72.

PT New nucleic acids comprising alleles of the human tissue kallikrein gene
PT useful for identifying subjects with increased risk of developing
PT essential hypertension, and for predicting the responsiveness of
PT hypertension patients to therapy.

PS Example; SEQ ID NO 1; 37p; English.

CC The invention relates to an isolated nucleic acid consisting of the
CC nucleotide sequence of any of four fully defined polynucleotide sequences
CC (alleles G, J, M or R, respectively). The nucleic acids are useful in
CC methods to identify a human subject with an increased (or reduced) risk
CC of having essential hypertension, particularly subjects with
CC polymorphisms in the human tissue kallikrein gene promoter associated
CC with the condition. Detection of particular polymorphisms can also be
CC used to assess the likely responsiveness of a hypertension patient to
CC particular treatments such as dietary sodium intake, or treatment with
CC angiotensin-converting enzyme. The present sequence represents a human

RESULT 309
AD151393
AD151393 standard; DNA; 17 BP

DR WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1994; 317pp; English.
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC osteoarthritis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 CC
 SQ Sequence 17 BP; 2 A; 3 C; 4 G; 0 T; 8 U; 0 Other;
 Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 238 GAAACTACCCCAATG 253
 Db 17 GGAACACACCCCAATG 2
 RESULT 314
 AD185077
 ID AD185077 standard; RNA; 17 BP.
 XX
 AC AD185077;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 DE HCV DNazyme substrate sequence #2323.
 XX
 KM ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
 KM HCV infection; type I interferon; DNazyme.
 XX
 OS Hepatitis C virus.
 XX
 PN US2003125270-A1.
 XX
 PD 03-JUL-2003.
 XX
 PF 18-DEC-2000; 2000US-00740332.
 XX
 PR 18-DEC-2000; 2000US-00740332.
 XX
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGEN J.
 PA (ROBE/) ROBERTS E.
 PA (PAVC/) PAVCO P A.
 PA (MACE/) MACEJACK D.
 PI Blatt L, Mcswigen J, Roberts E, Pavco PA, Macejack D;
 XX WPI; 2004-031273/03.
 DR Enzymatic nucleic acid molecules which specifically cleave RNA derived
 XX from hepatitis C virus (HCV), useful for the treatment of HCV infections,
 PT especially in combination with type I interferon therapy.
 XX

PS Claim 1; SEQ ID NO 2323; 198pp; English.
 CC The invention relates to an enzymatic nucleic acid molecule which
 CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
 CC the binding arms of the enzymatic nucleic acid molecule comprises
 CC sequences complementary to any of the defined substrate sequences given
 CC in the specification. The nucleic acid molecule may be administered for
 CC the treatment of HCV infections, especially in combination with type I
 CC interferons. The present sequence represents a HCV DNazyme substrate
 CC sequence.
 CC
 SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 0.2%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 2.9e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 360 CTCAGACGCGAAGG 375
 Db 2 CTCAGACGCGAGCUGG 17
 RESULT 315
 ABC90246/C
 ID ABC90246 standard; DNA; 13 BP.
 XX
 AC ABC90246;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 90263 for detecting SNP TSC0022617.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-1B000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 90263; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AEI00010-AEI82073
 CC represent the oligomers described in the invention. NCMS: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 1 Other;

Query Match 0.2% Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.5e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 580 GAATGCTACCCAA 592
 :|||||
 Db 13 RAATGCTACCCAA 1

RESULT 316
 ABC90247
 ID ABC90247 standard; DNA; 13 BP.
 XX
 AC ABC90247;
 XX
 DT 21-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 90264 for detecting SNP TSC0022617.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX

XX WO200177384-A2.
 XX

PD 18-OCT-2001.
 XX

PF 06-APR-2001; 2001WO-IB000713.
 XX

PR 07-APR-2000; 2000DE-01019173.
 XX

PA (EPIC-) EPIGENOMICS AG.
 XX

PI Olek A, Piepenbrock C, Berlin K;
 XX

DR WPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

PS Claim 1; SEQ ID NO 90264; 29pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer. The
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB102073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SO Sequence 13 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 1 Other;

Query Match 0.2% Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.5e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 580 GAATGCTACCCAA 592
 :|||||
 Db 1 RAATGCTACCCAA 13

RESULT 317
 AA167426/C
 ID AA167426 standard; DNA; 15 BP.
 XX

AC AA167426;
 XX

DT 11-FEB-2002 (first entry)
 XX

DE Human FKBP8 allele-specific oligonucleotide (ASO) primer.
 XX

KW FK506-binding protein 8; FKBP8; haplotyping; polymorphism; cancer; ss;
 KW immunosuppression; human; allele-specific oligonucleotide; ASO; primer.
 XX
 OS Homo sapiens.
 XX

FN WO200172965-A2.
 XX

PD 04-OCT-2001.
 XX

PF 26-MAR-2001; 2001WO-US009718.
 XX

PR 24-MAR-2000; 2000US-0192125P.
 XX

PA (GENA-) GENAISANCE PHARM INC.
 XX

PI Anastasio AE, Bentivegna SC, Choi YJ, Klem SE, Koshy B,
 PI Stephens JC;
 XX

DR WPI; 2001-626261/72.
 XX

PT New haplotypes of the FK506-binding protein 8 gene, useful for genotyping
 PT that gene in individual and to design new therapy for associated disease
 PT such as immunosuppression and cancer.
 XX

PS Claim 15; Page 14; 98pp; English.
 XX

CC The invention relates to haplotyping the FK506-binding protein 8 (38KD)
 CC (FKBP8) gene in an individual. The method involves determining the
 CC identity of the nucleotide pair at one or more polymorphic sites selected
 CC from P1 to P26 (described in the specification). The invention is useful
 CC to improve the efficiency and reliability of several steps in the
 CC discovery and development of drugs for treating diseases associated with
 CC FKBP8 activity, for example immunosuppression and cancer. Sequences
 CC AA167406-431 represent allele-specific oligonucleotide (ASO) primers for
 CC detecting FKBP8 gene polymorphisms. Note: these sequences appear in the
 CC disclosure (sequence id numbering from 31, 33, 35, 81). These sequences
 CC differ from those with the same seq id No.s indicated under the sequence
 CC listing
 XX

SO Sequence 15 BP; 3 A; 7 C; 2 G; 2 T; 0 U; 1 Other;

Query Match 0.2% Score 12.6; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 2.3e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 458 GGGTGCAGGAGTG 470
 :|||||
 Db 14 RGGTGCAGGAGTG 2

RESULT 318

ACC47292
 ID ACC47292 standard; DNA; 20 BP.
 XX

AC ACC47292;
 XX

DT 11-AUG-2003 (first entry)
 XX

DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144375.
 XX

KW Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
 KW antisense; ss.
 XX

OS Synthetic.
 OS Homo sapiens.
 XX

FN WO2003014307-A2.

XX 20-FEB-2003.
XX
XX
XX 05-AUG-2002; 2002MO-US024920.
XX
XX 07-AUG-2001; 2001US-00923515.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Crooke RM, Graham MJ;
XX
XX WPI; 2003-256565/25.
XX
XX New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis or
PT cardiovascular disease.
XX
XX Claim 3; Page 87; 120pp; English.
XX
XX The invention relates to a new compound, 8-50 nucleobases in length
CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
CC specifically hybridizes with and inhibits the expression of human
CC apolipoprotein(a). The antisense compounds are useful for preparing a
CC composition for treating abnormal lipid or cholesterol metabolism,
CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
CC represent specific examples of chimeric antisense phosphorothioate
CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
CC apolipoprotein(a) mRNA
XX
XX Sequence 20 BP; 8 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 12.6; DB 1; Length 20;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 176 TCACAGGAGGAGCTGCCA 194
Db 1 TAACATATAGGAGCTGCCA 19
RESULT 319
ACCA7290
ID ACC47290 standard; DNA; 20 BP.
XX
XX ACC47290;
XX
XX 11-AUG-2003 (first entry)
XX
XX Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144373.
XX
XX Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
KW antisense; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX W02003014307-A2.
XX
XX 20-FEB-2003.
XX
XX 05-AUG-2002; 2002WO-US024920.
XX
XX 07-AUG-2001; 2001US-00923515.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Crooke RM, Graham MJ;
XX
XX WPI; 2003-256565/25.
XX
XX New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis or
PT cardiovascular disease.

XX Claim 3; Page 87; 120pp; English.
XX
XX
XX The invention relates to a new compound, 8-50 nucleobases in length
CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
CC specifically hybridizes with and inhibits the expression of human
CC apolipoprotein(a). The antisense compounds are useful for preparing a
CC composition for treating abnormal lipid or cholesterol metabolism,
CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
CC represent specific examples of chimeric antisense phosphorothioate
CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
CC apolipoprotein(a) mRNA
XX
XX Sequence 20 BP; 9 A; 4 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 12.6; DB 1; Length 20;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 176 TCACAGGAGGAGCTGCCA 194
Db 2 TAACATATAGGAGCTGCCA 20
RESULT 320
AAQ36858/C
ID AAQ36858 standard; DNA; 15 BP.
XX
XX AAQ36858;
XX
XX 25-MAR-2003 (revised)
DT 22-JUN-1993 (first entry)
XX
XX PCR primer for 5' fixed sequence contg. T7 promoter and RBS.
XX
XX Systematic peptide evolution by reverse translation; SPERT; ligand;
KW specific; inhibitors; probes; assay; cell sorting; ss.
XX
XX Synthetic.
XX
XX W09303172-A1.
XX
XX 18-FEB-1993.
XX
XX 31-JAN-1992; 92MO-US000801.
XX
XX 01-AUG-1991; 91US-00739055.
XX
XX (UTRE-) UNIV RES CORP.
XX
XX Gold L, Tuerk C, Pribnow D, Smith JD;
XX
XX WPI; 1993-076529/09.
XX
XX Systematic polypeptide evolution by reverse translation - used for prodn.
PT of polypeptide ligand specific for desired target molecule.
XX
XX Example 1; Page 84; 98pp; English.
XX
XX SPERT is used to select novel polypeptides that bind the antibody of the
CC epitope commonly recognised by the antisera from autoimmune mice which
CC are the fl progeny of a cross of NZB and NZM parents (Portanova et al.,
CC J. Immunol. 144, 4633, 1990). The known epitope consists of ca. 10 amino
CC acids at the N-terminus of the histone H2B protein. To make mRNA encoding
CC candidate polypeptides a 5' fixed sequence composed of a T7 promoter
CC sequence and a ribosome binding site which is recognised by both
CC prokaryotic and eukaryotic ribosomes, terminating in a restriction
CC endonuclease site is synthesised and cloned using a number of
CC oligonucleotides (example shown). A 3' fixed sequence is placed into a
CC restriction site to provide an mRNA encoding the C-terminal trailer
CC sequence of ca. 100 nucleotides lacking stop codons. In addition, a 3'
CC primer annealing site is provided so that cDNA synthesis can be
CC accomplished on the mRNA recovered from partitioned ribosome complexes.

CC See also AA036845-63. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 15 BP; 4 A; 5 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.2%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 2.5e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 467 AGTGTACCATGCT 480
 |||||
 DB 14 AGTGTCCATGCT 1

RESULT 321

AAAT37571
 ID AAAT37571 standard; mRNA; 15 BP.

XX
 AC AAAT37571;

XX
 DT 11-NOV-1996 (first entry)

DE Apo(a) mRNA (nt. pos. 11429) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 KW hammerhead ribozyme; target sequence; diagnosis; treatment;
 KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 KW restenosis; heart disease; human; ss.

XX Homo sapiens.

XX WO9609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

XX 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, McSwiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.

XX Claim 2; Page 18; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 11429). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from human apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen

XX Sequence 15 BP; 3 A; 7 C; 0 G; 0 T; 5 U; 0 Other;

Query Match 0.2%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 71.4%; Pred. No. 2.5e+02;
 Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 503 CATACCTCCACCACT 516
 ||:|||||||

DB 2 CAUUCUCCACCACT 15

RESULT 322

AAAT37771

ID AAAT37771 standard; mRNA; 15 BP.

XX
 AC AAAT37771;

XX 18-NOV-1996 (first entry)

DE Apo(a) mRNA (nt. pos. 12650) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 KW hammerhead ribozyme; target sequence; diagnosis; treatment;
 KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 KW restenosis; heart disease; monkey; ss.

XX Cebus apella.

XX WO9609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

XX 23-SEP-1994; 94US-00311760.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, McSwiggen J, Newton RS, Ramharack R;

XX WPI; 1996-188454/19.

PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.

XX Claim 3; Page 21; 37pp; English.

XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 12650). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen

XX Sequence 15 BP; 3 A; 4 C; 2 G; 0 T; 6 U; 0 Other;

Query Match 0.2%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 64.3%; Pred. No. 2.5e+02;
 Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 193 CAGCTTGCTATC 206
 |||::|||::|||

DB 2 CAUUCUCCACCACT 15

RESULT 323

AAAT37723

ID AAAT37723 standard; mRNA; 15 BP.

XX
 AC AAAT37723;

XX 13-NOV-1996 (first entry)

```

XX Apo(a) mRNA (nt. pos. 11347) hammerhead ribozyme target sequence.
DE
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; monkey; ss.
XX
XX Cebus apella.
OS
XX
XX MO9609392-A1.
PN
XX
XX 28-MAR-1996.
PD
XX
XX 21-SEP-1995; 95WO-US011995.
PF
XX
XX 23-SEP-1994; 94US-00311760.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Stinchcomb DT, Mcawiggen J, Newton RS, Ramharack R;
PI
XX WPI; 1996-188454/19.
DR
XX
XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.
PT
XX
XX Claim 3; Page 21; 37pp; English.
PS
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 11347). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase
CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed, RNaseH added and the mixts.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen
CC
XX
XX Sequence 15 BP; 3 A; 7 C; 0 G; 0 T; 5 U; 0 Other;
SQ
XX
XX
XX Query Match 0.2%; Score 12.4; DB 1; Length 15;
XX Best Local Similarity 71.4%; Pred. No. 2.5e+02;
XX Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
XX
XX 503 CATACTCCACCACCT 516
OY ||:|||||:
DB 2 CAUUCUCCACCACU 15
XX
XX
XX RESULT 324
XX AAT37774
XX ID AAT37774 standard; mRNA; 15 BP.
XX
XX
XX AAT37774;
AC
XX
XX 18-NOV-1996 (first entry)
DT
XX
XX Apo(a) mRNA (nt. pos. 10906) hammerhead ribozyme target sequence.
DE
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; monkey; ss.
XX
XX Cebus apella.
OS
XX
XX

```

```

PN MO9609392-A1.
XX
XX 28-MAR-1996.
PD
XX
XX 21-SEP-1995; 95WO-US011995.
PF
XX
XX 23-SEP-1994; 94US-00311760.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Stinchcomb DT, Mcawiggen J, Newton RS, Ramharack R;
PI
XX WPI; 1996-188454/19.
DR
XX
XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.
PT
XX
XX Claim 3; Page 21; 37pp; English.
PS
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 10906). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase
CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed, RNaseH added and the mixts.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen
CC
XX
XX Sequence 15 BP; 9 A; 3 C; 0 G; 0 T; 3 U; 0 Other;
SQ
XX
XX
XX Query Match 0.2%; Score 12.4; DB 1; Length 15;
XX Best Local Similarity 78.6%; Pred. No. 2.5e+02;
XX Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
XX
XX 239 AAAACTACCCCAAT 252
OY |||||:|||||:
DB 2 AAAACUACCAAU 15
XX
XX
XX RESULT 325
XX AAT37727
XX ID AAT37727 standard; mRNA; 15 BP.
XX
XX
XX AAT37727;
AC
XX
XX 13-NOV-1996 (first entry)
DT
XX
XX Apo(a) mRNA (nt. pos. 11423) hammerhead ribozyme target sequence.
DE
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
XX hammerhead ribozyme; target sequence; diagnosis; treatment;
XX lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
XX restenosis; heart disease; monkey; ss.
XX
XX Cebus apella.
OS
XX
XX
XX MO9609392-A1.
PN
XX
XX 28-MAR-1996.
PD
XX
XX 21-SEP-1995; 95WO-US011995.
PF
XX
XX 23-SEP-1994; 94US-00311760.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX

```

PI Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
XX
XX
DR WPI; 1996-188454/19.
XX
XX
PT Enzymatic RNA mol. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.
XS
XS Claim 3; Page 21; 37pp; English.
XX

A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a) (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms complementary to the present sequence (nucleotide position 11423). The ribozyme blocks to some extent apo(a) expression, and can therefore be used to diagnose or treat conditions related to lipoprotein (a) levels e.g. atherosclerosis, myocardial infarction, stroke, reestenosis and heart disease. PCR was used to generate a substrate for T7 RNA polymerase transcribed from monkey apo(a) cDNA clones. Labelled transcripts were synthesised in vitro to form 2 templates. The oligonucleotides and labelled transcripts were annealed, RNaseH added and the mixts. incubated. After a designated time the reactions were stopped, and RNA sepd. on sequencing polyacrylamide gels. The percentage of substrate cleaved was determined by autoradiographic quantification, and the most accessible ribozyme target sites chosen.

Sequence 15 BP; 1 A; 4 C; 3 G; 0 T; 7 U; 0 Other;

Query Match	0.28	Score 12.4	DB 1	Length 15
Best Local Similarity	50.0%	Pred. No. 2.5e+02		
Matches	7	Conservative	6	Mismatches 1
				Indels 0
				Gaps 0

QY 197 CTGTGTCATCTATG 210
|::||:|:|:|:
Db 2 CUGGUCCTCTAUG 15

RESULT 326

AAX31192 standard; DNA; 15 BP.

AC AAX31192;

DT 21-MAY-1999 (first entry)

Tag sequence of a transcript increased in colorectal cancer.

tag sequence; colorectal cancer; pancreatic cancer; colon cancer; diagnosis; prognosis; treatment

diagnosis; prognosis; treatment; ss.

OS Homo sapiens.

WO9853319-A2.

PD 26-NOV-1998.

20-MAY-1998; 98WO-US010277.

21-MAY-1997; 97US-0047352P.

(UYJO) UNIV JOHNS HOPKINS.

PI Vogelstein B, Kinzler KW;

WPI; 1999-070161/06

Use of isolated gene transcripts - useful for developing products for the diagnosis, prognosis and treatment of cancers, particularly colon and pancreatic cancer.

Claim 2; Page 35; 120pp; English.

AXX30947-31815 represent tag sequences of transcripts that are differentially expressed in colorectal cancer, in pancreatic cancer

in both. The tag sequences can be used to identify genes by matching the tag to a gen data base member, or by using the tag sequences as probes to isolate unidentified genes from cDNA libraries. The tag sequences can also be used in a method for diagnosing colon or pancreatic cancer in a sample suspected of being neoplastic. The method comprises comparing the level of at least one transcript in a first sample of a tissue to a second sample, where the first sample is a colonic tissue suspected of being neoplastic and the second sample is a normal human colonic tissue. The transcript is identified by a tag selected from AAX0947-11815. The methods of the invention can be used in the diagnosis, prognosis and treatment of cancer.

Sequence 15 BP; 3 A; 3 C; 6 G; 3 T; 0 U; 0 Other;

Query Match	0.2%;	Score 12.4;	DB 1;	Length 15;
Best Local Similarity	92.9%;	Pred. No. 2.5e+02;		
Matches 13;	Conservative 0;	Mismatches 11;	Indels 0;	Gaps 0

Qy	133	CATGCTGATGGACA	146
Db	1	CATGCTGCTGGACA	14

RESULT 327

ID AAX31710 standard; DNA; 15 BP

AC AAX31710;

DT 21-MAY-1999 (first entry)

DE Transcript tag sequence increased in pancreatic and colorectal cancer.

diagnosis; prognosis; treatment; ss.
KW diagnosis; prognosis; treatment; ss.

diagnosis; prognosis; treatment; ss.

OS Homo sapiens.

PN W09853319-A2.

PD 26-NOV-1998.

PF 20-MAY-1998; 98WO-US010277.

PR 21-MAY-1997; 97US-0047352P.

PA (UYJO) UNIV JOHNS HOPKINS

PI Vogelstein B, Kinzler KW

WPI; 1999-070161/06.

PT Use of isolated gene transcripts - useful for developing products for the
PT diagnosis, prognosis and treatment of cancers, particularly colon and
PT pancreatic cancer.

PS Disclosure; Page 71; 120pp; English.

AAK30947-11815 represent tag sequences of transcripts that are differentially expressed in colorectal cancer, in pancreatic cancer, or in both. The tag sequences can be used to identify genes by matching the tag to a gen data base member, or by using the tag sequences as probes to isolate unidentified genes from cDNA libraries. The tag sequences can also be used in a method for diagnosing colon or pancreatic cancer in a sample suspected of being neoplastic. The method comprises comparing the level of at least one transcript in a first sample of a tissue to a second sample, where the first sample is a colonic tissue suspected of being neoplastic and the second sample is a normal human colonic tissue. The transcript is identified by a tag selected from AAK30947-31815. The methods of the invention can be used in the diagnosis, prognosis and treatment of cancer.

Sequence 15 BP; 3 A; 3 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 2.5e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 133 CATGCTGATGACA 146
 |||||
 1 CATGCTGATGACA 14

RESULT 328
 AAX25553

ID AAX25553 standard; DNA; 15 BP.

XX AAX25553;

DT 02-AUG-1999 (first entry)

DE Arabidopsis seed-specific gene AtCS3 gene primer 8g.3p.

XX AtCS3; seed-specific gene; promoter; transgenic plant; fatty acid; lipid;
 KM oilseed; PCR; primer; ss.

XX Synthetic.

OS Arabidopsis thaliana.

PN WO9920775-A1.

XX 29-APR-1999.

PF 20-OCT-1998; 98WO-EP006978.

XX 22-OCT-1997; 97US-00956182.

PA (RHON) RHONE-POULENC AGROCHIMIE.

PI Nuccio M, Thomas T;

XX WPI; 1999-302745/25.

PT Arabidopsis thaliana regulatory regions useful for heterologous gene
 expression in plants.

PS Example 5; Page 104; 116pp; English.

XX This primer, termed 8g.3p, was used with primer 8g.5p (see AAX25553) in
 CC the Pfu polymerase amplification of Arabidopsis thaliana var. Landsberg
 CC erecta cDNA in order to generate a 166 bp fragment of the seed-specific
 CC AtCS3 gene (see also AAX25547). This fragment was used to construct a
 CC riboprobe that was utilized in mapping the transcription start site for
 CC AtCS3. The invention provides Arabidopsis seed-specific AtCS3 and AtS1
 CC genes (see also AAX25546) and their 5' regulatory regions (see AAX25560-
 CC 63). These regulatory regions are useful in expression cassettes and
 CC vectors for the transformation of plants such as sunflower, soybean,
 CC maize, cotton, tobacco, peanut, oilseed rape and Arabidopsis, providing
 CC seed-specific expression of heterologous or native genes. Also provided
 CC are methods of modulating the levels of a heterologous gene, especially a
 CC fatty acid synthase or lipid metabolism gene, by transforming a plant
 CC with these expression cassettes and expression vectors

XX Sequence 15 BP; 7 A; 3 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 0.2%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 2.5e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 520 ACAGGAAGACCTG 533
 |||||
 1 ACAGGAAGACCTG 14

RESULT 329
 AAV64955/c

ID AAV64955 standard; DNA; 15 BP.

XX AAV64955;

DT 05-FEB-1999 (first entry)

DE Mouse histone H2B protein epitope oligonucleotide fragment #6.

XX Ligand; assay; diagnostic; inhibitor; probe; cell sorting; catalysis;
 KM sequestering agent; epitope; ss.

XX Synthetic.

OS Mus sp.

PN US5843701-A.

XX 01-DEC-1998.

PF 31-JAN-1992; 92US-00829461.

XX 02-AUG-1990; 90US-00561968.

PR 01-AUG-1991; 91US-00739055.

PA (NEXS-) NEXSTAR PHARM INC.

PI Smith JD, Prihnow D, Tuerk C, Gold L;

XX WPI; 1999-044575/04.

PT Production of polypeptide ligands using mRNA-polypeptide conjugates - by
 XX affinity selection, RNA amplification and polypeptide synthesis.

PS Example 10; Col 43-44; 35pp; English.

XX AAV64950-V64972 are sequences used in a method for the production of a
 CC polypeptide ligand of a target molecule. The polypeptide products can be
 CC used in assays, in diagnostic procedures, in cell sorting, as inhibitors
 CC of target molecule function, as probes, as sequestering agents, or may
 CC have catalytic activity

XX Sequence 15 BP; 4 A; 5 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.2%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 2.5e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 467 AGTCTACCATGGT 480
 |||||
 14 AGTCTGCTCATGGT 1

RESULT 330

ID AAV60128 standard; DNA; 15 BP.

XX AAV60128;

DT 17-OCT-2000 (first entry)

DE Human APC gene variant 1130K scanning oligonucleotide # 2.

XX Human; adenomatous polyposis carcinoma; APC; scanning oligonucleotide;
 KM colorectal cancer; genotype analysis;
 XX short oligonucleotide mass analysis; SOMA; ss.

OS Homo sapiens.

XX Key Location/Qualifiers

FT misc_difference 1/*tag= a
 FT /note= "5' pA"

PN WO200031300-A2.

XX 02-JUN-2000.
 PD Best Local Similarity 0.2%; Score 12.4; DB 1; Length 15;
 XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 PF 22-NOV-1999; 99WO-US027523.
 XX 24-NOV-1998; 98US-00198340.
 XX (UYJO) UNITV JOHNS HOPKINS.
 PA Laken SJ, Vogelstein B, Kinzler KW, Groopman JD, Jackson PE,
 PI Friesen MD;
 XX WPI; 2000-422808/36.
 DR
 XX
 PT Genotype analysis method, defined as SOMA (short oligonucleotide mass
 PT analysis), of short, defined amplification products using electro-spray
 PT ionization mass spectrometry, useful for analyzing the genotype of living
 PT organisms.
 XX
 PS Example 2; Page 14; 40pp; English.
 CC The present invention relates to a method of genotype analysis in which
 CC short PCR products are analysed by electro-spray ionisation mass
 CC spectrometry (ESI-MS). This method has been named Short Oligonucleotide
 CC Mass Analysis (SOMA). Short oligonucleotides of the human adenomatous
 CC polyposis carcinoma (APC) gene variant 11307K, were produced by PCR. The
 CC 1130K APC gene variant is associated with an approximate 2-fold increase
 CC in colorectal cancer risk. The present sequence is a scanning
 CC oligonucleotide used to detect the 11307K variants oligonucleotides
 CC produced in the present invention
 XX
 SQ Sequence 15 BP; 0 A; 3 C; 1 G; 11 T; 0 U; 0 Other;
 Query Match
 Best Local Similarity 92.9%; Pred. No. 2.5e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 74 TTCTTTTATTTCTG 87
 Db 1 TTCTTTTATTTCTG 14
 RESULT 331
 AAF53634/C
 ID AAF53634 standard; DNA; 15 BP.
 AC AAF53634;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGF-I oligonucleotide #4594.
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 DR WPI; 2001-041421/05.

PI Wraight CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 DR
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 8; Page 90; 201pp; English.
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or [IGFBP3], which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC P45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 2 A; 8 C; 3 G; 2 T; 0 U; 0 Other;
 Query Match
 Best Local Similarity 92.9%; Pred. No. 2.5e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 324 CGGTGTCAAGTGGG 337
 Db 14 CGGTGTCAAGTGGG 1
 RESULT 332
 AAF53633/C
 ID AAF53633 standard; DNA; 15 BP.
 AC AAF53633;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGF-I oligonucleotide #4593.
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wraight CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 DR

PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisenesc nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 8; Page 90; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisenesc oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisenesc
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC P4161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, rubea, pilaris, seborrhea, keloids, keratosis,
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
CC
XX
SQ Sequence 15 BP; 3 A; 8 C; 3 G; 1 T; 0 U; 0 Other;
Query Match 0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 324 CGGTGTCAGTGGC 337
DB 15 CGGTGTCAGCGCG 2
RESULT 333
AAF76909/C
ID AAF76909 standard; DNA; 15 BP.
XX
AC AAF76909;
XX
XX 29-MAY-2001 (first entry)
XX
DE DNA fragment.
XX
XX Liganid isolation; systemic polypeptide evolution by reverse translation;
KM SEPT; ss.
XX
XX Synthetic.
OS
XX
PN US6194550-B1.
XX
PD 27-FEB-2001.
XX
PF 23-NOV-1998; 98US-00197649.
XX
PR 02-AUG-1990; 90US-00561968.
PR 01-AUG-1991; 91US-00739055.
PR 31-JAN-1992; 92US-00829461.
XX
XX (GOLD/) GOLD L.
PA (TUER/) TUERK C.
PA (PRIB/) PRIENOW D.
PA (SMIT/) SMITH J D.
XX
PI Gold L, Tuerk C, Prienow D, Smith JD;
XX
XX WPI; 2001-243412/25.
XX
XX Isolating a polypeptide ligand to a target molecule, useful for
PT ribosome assays, comprising partitioning candidate mixtures comprised of
PT ribosome complexes or mRNA-polypeptide copolymers relative to their
PT affinity to the target molecule.
XX

PS Example; Col 37-38; 35pp; English.
XX
XX The present sequence was used in an example illustrating an invention
CC relating to a method for isolating a polypeptide ligand for a desired
CC target molecule. The method involves synthesizing a nucleic acid mixture
CC comprising mRNA having translatable and non-translatable regions and a
CC mixture of nucleic acid-polypeptide copolymers, each comprising the mRNA
CC and a polypeptide encoded by its associated mRNA. The copolymers are
CC partitioned relative to their affinity to the target. The method is
CC termed systemic polypeptide evolution by reverse translation (SEPT). The
CC polypeptides ligands of small molecule targets are useful in assay
CC methods, diagnostic procedures, cell sorting, as inhibitors of target
CC molecule function, as probes, as drug delivery vehicles and modifiers of
CC hormone action and have therapeutic uses as sequestering agents. The
CC target molecules include natural and synthetic polymers, including
CC proteins, hormones, receptors and cell surfaces, nucleic acids and small
CC molecules such as drugs, metabolites, cofactors and toxins. Polypeptide
CC ligands are isolated and rapidly identified by this method
XX
SQ Sequence 15 BP; 4 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 467 AGTGCTACATGCT 480
DB 14 AGTGCTCATGTGT 1
RESULT 334
ABK97511
ID ABK97511 standard; DNA; 15 BP.
XX
AC ABK97511;
XX
XX 07-OCT-2002 (first entry)
XX
XX Human LCAT gene polymorphism detection ASO primer #20.
DE
XX
XX Lecithin-cholesterol acyltransferase; LCAT; Norum disease; gene therapy;
KM fish-eye disease; atherosclerotic cardiovascular disease; forensic;
KM population diversity; anthropological lineage; paternity testing; human;
KM polymorphism; allele-specific oligonucleotide; ASO; PCR; primer; ss.
XX
XX Homo sapiens.
OS
XX
XX MO200253575-A1.
XX
XX 11-JUL-2002.
XX
XX 03-JAN-2001; 2001WO-US000092.
XX
XX 03-JAN-2001; 2001WO-US000092.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Chew A, Denton RR, Nandabalan K, Stephens JC;
XX
XX WPI; 2002-557737/59.
XX
XX Novel isolated polymorphic variant polymorphonucleotide of lecithin-cholesterol
PT acyltransferase gene, useful for studying expression and biological
PT function of the gene, and for therapeutic, diagnostic or forensic
PT purposes.
XX
XX
XX Claim 16; Page 17; 72pp; English.
XX
XX The present invention relates to a new polymorphonucleotide comprising a
CC nucleotide sequence which is a polymorphic variant of a reference
CC sequence for lecithin-cholesterol acyltransferase (LCAT). The invention
CC is useful for identifying an association between a trait (preferably a
CC clinical response to drug targeting LCAT) and at least one genotype or

CC haplotype of LCAT gene. The method of the invention has applicability in
 CC developing diagnostic tests and therapeutic treatments for Norum disease,
 CC fish-eye disease and atherosclerotic cardiovascular disease. The
 CC haplotyping and genotyping methods are useful for studying population
 CC diversity, anthropological lineage, the significance of diversity and
 CC lineage at the phenotypic level, paternity testing, forensic applications
 CC and for identifying association between the LCAT genetic variation and a
 CC trait such as level of drug response or susceptibility to disease. In
 CC addition, the methods for identifying the LCAT haplotypes present in
 CC individuals are useful in the development of drugs targeting LCAT. For
 CC example, determining the frequency of individual LCAT haplotypes in a
 CC population with a specific disease, e.g. Norum disease, will facilitate
 CC the development of drugs targeting the LCAT isoform(s) that are most
 CC frequent in that disease population. The present nucleic acid sequence
 CC represents one of a collection (ABK97492-ABK97519) of allele-specific
 CC oligonucleotide (ASO) primers that were used in the invention to detect
 CC polymorphisms in the human LCAT gene

SO Sequence 15 BP; 4 A; 6 C; 4 G; 1 T; 0 U; 0 Other;

Query Match Best Local Similarity 92.2%; Score 12.4; DB 1; Length 15;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 90 ATCAGCAGCAGCCTG 103
 Db 2 ACCAGCAGCAGCCTG 15

RESULT 335

AA172774/c
 ID AA172774 standard; DNA; 15 BP.

XX AA172774;

DT 22-JUL-2002 (first entry)

DE Oligo #6 for cloning T7 promoter and RBS containing mRNA.

XX T7 promoter; ribosome binding site; RBS; prokaryotic; eukaryotic;
 KW ribosome; mRNA; circle-solid; polypeptide copolymer; mcs; PC; SPERT;
 KW Systematic Polypeptide Evolution by Reverse Translation; assay;
 KW diagnosis; cell sorting; inhibitor; probe; sequestering agent;
 KW ribosome complex; ss.

XX Synthetic.

XX US2002038000-A1.

XX 28-MAR-2002.

XX 22-FEB-2001; 2001US-00790399.

XX 02-AUG-1990; 90US-00561968.

XX 01-AUG-1991; 91US-00739055.

XX 23-NOV-1998; 98US-00197649.

XX (GOLD/) GOLD L.

XX (TUERK/) TUERK C.

XX (PRIIB/) PRIIBOW D.

XX (SMIT/) SMITH J D.

XX Gold L, Tuerk C, Priibow D, Smith JD,

XX WPI; 2002-329128/36.

XX New methods (termed SPERT (Systematic Polypeptide Evolution by Reverse

XX Translation)) for selecting high-affinity polypeptide ligands that

XX specifically bind target molecules, e.g. proteins, carbohydrates, toxins,

XX drugs and receptors.

XX Example 1; Page 21; 38pp; English.

CC The sequences given in AA172769-81 are oligonucleotides which were used
 CC to make mRNA encoding a candidate polypeptide, a 5' fixed sequence
 CC composed of a T7 promoter sequence and a ribosome binding site which is
 CC recognised by both prokaryotic and eukaryotic ribosomes, terminating in a
 CC restriction endonuclease site. The resulting nucleic acid was used in the
 CC method of the invention for preparing ligands of target molecules in
 CC which mixtures of ribosome complexes or mRNA-circle-solid polypeptide
 CC copolymers (mcs; pcs) are partitioned by affinity to the target and
 CC amplified to create candidate mixtures enriched in ribosome complexes or
 CC mcs; pcs with an affinity to the target, are new. The methods are termed
 CC SPERT (Systematic Polypeptide Evolution by Reverse Translation). The
 CC SPERT methods are useful for isolating polypeptide ligands for desired
 CC target molecules. The polypeptide products are useful for any purpose to
 CC which a binding reaction may be put, for example in assay methods,
 CC diagnostic procedures, cell sorting, as inhibitors in assay methods,
 CC function, as probes, as sequestering agents and the like. In addition,
 CC polypeptide products of the invention can have catalytic activity. Target
 CC molecules include natural and synthetic polymers, including proteins,
 CC polysaccharides, glycoproteins, hormones, receptors and cell surfaces,
 CC nucleic acids, and small molecules such as drugs, metabolites, cofactors,
 CC transition state analogues and toxins. The novel SPERT method involves
 CC utilizing a candidate mixture of polypeptides having a randomized amino
 CC acid sequence. Each member of the mixture is linked to an individualized
 CC mRNA, which encodes the amino acid sequence of that polypeptide. The
 CC candidate polypeptides are partitioned according to their property of
 CC binding to a given desired target molecule. The partitioning is carried
 CC out in such a way that each mRNA encoding a polypeptide is partitioned
 CC exactly together with that polypeptide. In this way each polypeptide is
 CC partitioned together with that polypeptide. In this way each polypeptide is
 CC vitro process. Ultimately, both the means for further amplifying it by an in
 CC the desired target and the mRNA encoding the polypeptide ligand of
 CC simultaneously selected, allowing further synthesis of the selected
 CC polypeptide as desired, and further amplification of the coding sequence.
 CC It is therefore not necessary to analyse the amino acid sequence of the
 CC selected polypeptide (using protein chemistry) in order to produce it in
 CC desired quantities

SO Sequence 15 BP; 4 A; 5 C; 4 G; 2 T; 0 U; 0 Other;

Query Match Best Local Similarity 92.2%; Score 12.4; DB 1; Length 15;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 467 AGTGCTACCATGAT 480
 Db 14 AGTGCTGCCATGAT 1

RESULT 336

ABK32146
 ID ABK32146 standard; DNA; 15 BP.

XX ABK32146;

DT 23-APR-2002 (first entry)

DE Human colon cancer SAGE tag #247.

XX Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;

XX serial analysis of gene expression; diagnostic; prognostic; probe;

XX cancer marker; ss.

XX Homo sapiens.

XX US6333152-B1.

XX 25-DEC-2001.

XX 20-MAY-1998; 98US-00081646.

XX 20-MAY-1998; 98US-00081646.

XX (UYJO) UNIV JOHNS HOPKINS.

XX
PI Vogelstein B, Kinzler KM, Zhang L, Zhou W;
XX WPI: 2002-153821/20.
DR
XX New human nucleic acid containing specific SAGE tags, useful as
PT diagnostic markers for cancer, also derived probes.
XX
PS Disclosure: Col 31; 161bp; English.
XX
CC The invention relates to an isolated, purified human nucleic acid (I)
CC that has the same sequence as a mRNA found in humans and is a SAGE
CC (serial analysis of gene expression) tag comprising a single stranded
CC probe containing at least 10 consecutive nucleotides. SAGE tags, are
CC diagnostic and prognostic markers of cancer, especially of the colon and
CC pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer
CC SAGE tags of the invention
XX
SQ Sequence 15 BP; 3 A; 3 C; 6 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 133 CATGCTGATGACCA 146
Db 1 CATGCTGATGACCA 14
XX
RESULT 337
ABK32664
ID ABK32664 standard; DNA; 15 BP.
XX
AC ABK32664;
XX
DT 23-APR-2002 (first entry)
XX
DE Human colorectal and pancreatic cancer SAGE tag #31.
XX
KW Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;
KW Serial analysis of gene expression; diagnostic; prognostic; probe;
KW cancer marker; ss.
XX
OS Homo sapiens.
XX
XX US6333152-B1.
PN 25-DEC-2001.
PD
XX
PF 20-MAY-1998; 98US-00081646.
XX
PR 20-MAY-1998; 98US-00081646.
XX
XX (UYJO) UNIV JOHNS HOPKINS.
PA
PI Vogelstein B, Kinzler KM, Zhang L, Zhou W;
XX
XX WPI: 2002-153821/20.
DR
XX New human nucleic acid containing specific SAGE tags, useful as
PT diagnostic markers for cancer, also derived probes.
XX
PS Disclosure: Col 85; 161bp; English.
XX
CC The invention relates to an isolated, purified human nucleic acid (I)
CC that has the same sequence as a mRNA found in humans and is a SAGE
CC (serial analysis of gene expression) tag comprising a single stranded
CC probe containing at least 10 consecutive nucleotides. SAGE tags, are
CC diagnostic and prognostic markers of cancer, especially of the colon and
CC pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer
CC SAGE tags of the invention
XX
SQ Sequence 15 BP; 3 A; 3 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 133 CATGCTGATGACCA 146
Db 1 CATGCTGATGACCA 14
XX
RESULT 338
ABX76573/c
ID ABX76573 standard; DNA; 15 BP.
XX
XX ABX76573;
AC
XX 01-APR-2003 (first entry)
DT
XX
DE M. avium 16S rRNA mutated probe #3.
XX
XX Probe: 23S rRNA; 16S rRNA; tuberculosis; MTC; MOTT; peptide nucleic acid;
KW mycobacterium tuberculosis complex; precursor rRNA; rDNA; 5S rRNA; ss;
KW mycobacterium other than tuberculosis; mutant;
KW 16S-mediated streptomycin resistance.
XX
OS Mycobacterium tuberculosis.
OS Synthetic.
XX
XX US2002137035-A1.
PN 26-SEP-2002.
PD
XX 07-APR-2000; 2000US-00544934.
PF
XX 07-APR-2000; 2000US-00544934.
PR
XX 07-APR-2000; 2000US-00544934.
PR
XX (STEN/) STENDER H.
PA (LUND/) LUND K.
PA (MOLL/) MOLLERUP T A.
XX
XX Stender H, Lund K, Mollerup TA;
XX WPI: 2003-174116/17.
DR
XX Peptide nucleic acid probes for detecting target sequences of
PT Mycobacteria in samples, e.g., sputum, which are capable of hybridizing
PT to a target sequence of mycobacterial rDNA, precursor rRNA or rRNA
PT forming detectable hybrids.
XX
PS Claim 22; Page 40; 74pp; English.
XX
XX The invention relates to a peptide nucleic acid capable of hybridizing to
CC a target sequence of Mycobacterial rDNA, precursor rRNA or rRNA (5S, 16S
CC or 23S) forming detectable hybrids. Also included are detecting a target
CC sequence of mycobacteria in a sample comprising contacting rRNA or rDNA
CC in the sample with peptide nucleic acid probes (hybridisation takes place
CC between the probe and the rRNA or rDNA), observing or measuring any
CC formed detectable hybrids and relating the observation or measurement to
CC the presence of a target sequence of mycobacteria in the sample, and a
CC kit for detecting a target sequence of mycobacteria in particular a
CC target sequence of mycobacteria of M. tuberculosis complex (MTC). The
CC probes are used for detecting a target sequence of MTC (and
CC distinguishing them from mycobacterium other than tuberculosis, MOTT)
CC present in a sample, e.g. sputum, laryngeal swabs, gastric lavage,
CC bronchial washings, biopsies, aspirates, expectorates, body fluids,
CC urine, tissue sections as well as food samples, soil, air and water
CC samples and their cultures. The probe is able to penetrate the cell wall
CC of the mycobacteria. It is able to hybridise to Mycobacterial precursor
CC rRNA and rRNA without harsh treatment of the mycobacterial cells,
CC therefore avoiding a risk of interfering with the morphology of the
CC cells. The present sequence is a mutant M. tuberculosis probe for 16S
CC rRNA around position 452, associated with 16S-mediated streptomycin
CC resistance

XX Sequence 15 BP; 0 A; 4 C; 4 G; 7 T; 0 U; 0 Other;
 SQ Query Match 0.2%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 2.5e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 524 GAAGAACCTGCCAA 537
 |||||
 14 GAAGAACCGGCCAA 1

Db 14 GAAGAACCGGCCAA 1

RESULT 339
 ABX76572/C
 ID ABX76572 standard; DNA; 15 BP.
 XX
 AC ABX76572;
 XX
 DT 01-APR-2003 (first entry)
 XX
 DE M. avium 16S rRNA mutated probe #2.
 XX
 KW Probe; 23S rRNA; 16S rRNA; tuberculosis; MTC; MOT; peptide nucleic acid;
 KW mycobacterium tuberculosis complex; precursor rRNA; rDNA; 5S rRNA; ss;
 KW mycobacterium other than tuberculosis; mutant;
 KW 16S-mediated streptomycin resistance.
 XX
 OS Mycobacterium tuberculosis.
 OS Synthetic.
 XX
 PN US200237035-A1.
 XX
 PD 26-SEP-2002.
 XX
 PF 07-APR-2000; 2000US-00544934.
 XX
 PR 07-APR-2000; 2000US-00544934.
 XX
 PA (STEN/) STENDER H.
 PA (LUND/) LUND K.
 PA (MOLL/) MOLLERUP T A.
 XX
 PI Stender H, Lund K, Mollerup TA;
 XX
 DR WPI; 2003-174116/17.
 XX
 PT Peptide nucleic acid probes for detecting target sequences of
 PT Mycobacteria in samples, e.g., sputum, which are capable of hybridizing
 PT to a target sequence of mycobacterial rDNA, precursor rRNA or rRNA
 PT forming detectable hybrids.
 XX
 PS Claim 22; Page 40; 74pp; English.
 XX
 CC The invention relates to a peptide nucleic acid capable of hybridizing to
 CC a target sequence of Mycobacterial rDNA, precursor rRNA or rRNA (5S, 16S
 CC or 23S) forming detectable hybrids. Also included are detecting a target
 CC sequence of mycobacteria in a sample comprising contacting rRNA or rDNA
 CC in the sample with peptide nucleic acid probes (hybridisation takes place
 CC between the probe and the rRNA or rDNA), observing or measuring any
 CC formed detectable hybrids and relating the observation or measurement to
 CC the presence of a target sequence of mycobacteria in the sample, and a
 CC kit for detecting a target sequence of mycobacteria in particular a
 CC target sequence of mycobacteria of M. tuberculosis complex (MTC). The
 CC probes are used for detecting a target sequence of MTC (and
 CC distinguishing them from mycobacterium other than tuberculosis, MOT)
 CC present in a sample, e.g. sputum, laryngeal swabs, gastric lavage,
 CC bronchial washings, biopsies, aspirates, expectorates, body fluids,
 CC urine, tissue sections as well as food samples, soil, air and water
 CC samples and their cultures. The probe is able to penetrate the cell wall
 CC of the mycobacteria. It is able to hybridise to Mycobacterial precursor
 CC rRNA and rRNA without harsh treatment of the mycobacterial cells,
 CC therefore avoiding a risk of interfering with the morphology of the
 CC cells. The present sequence is a mutant M. tuberculosis probe for 16S

CC rRNA around position 452, associated with 16S-mediated streptomycin
 CC resistance
 CC
 XX Sequence 15 BP; 0 A; 5 C; 4 G; 6 T; 0 U; 0 Other;
 SQ Query Match 0.2%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 2.5e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 182 GAAGAACCTGCCAA 195
 |||||
 14 GAAGAACCGGCCAA 1

Db 14 GAAGAACCGGCCAA 1

RESULT 340
 ADC84107
 ID ADC84107 standard; DNA; 15 BP.
 XX
 AC ADC84107;
 XX
 DT 01-JAN-2004 (first entry)
 XX
 DE Human papillomavirus type 59 (HPV 59) detection oligonucleotide #1.
 XX
 KW probe; human papilloma virus; HPV; detection; identification; ss.
 XX
 OS Human papillomavirus type 59.
 XX
 PN EPI302550-A1.
 XX
 PD 16-APR-2003.
 XX
 PF 10-OCT-2001; 2001EP-00123379.
 XX
 PR 10-OCT-2001; 2001EP-00123379.
 XX
 PA (KING-) KING CAR FOOD IND CO LTD.
 XX
 PI Lin C, Lin R, You C, Huang H, Lee B, Lee H, Lin Y, Fan C;
 PI Heu H, Shih C, Yeh C, Kao Y, Pan C, Chan P;
 XX
 DR WPI; 2003-432398/41.
 XX
 PT Detector for identifying human papilloma virus subtypes, comprises
 PT carrier having two parts carrying first and second oligonucleotides that
 PT respectively hybridize with DNA contained in first and second subtypes of
 PT the virus.
 XX
 PS Claim 4; SEQ ID NO 337; 221pp; English.
 XX
 CC The invention comprises oligonucleotides for detecting and identifying
 CC subtypes of human papilloma virus (HPV) contained in a sample. The
 CC oligonucleotides of the invention are useful for simultaneously detecting
 CC and identifying subtypes of HPVs. The present DNA sequence represents an
 CC HPV detection oligonucleotide of the invention.
 XX
 SQ Sequence 15 BP; 2 A; 5 C; 0 G; 8 T; 0 U; 0 Other;
 XX

QY 65 TTCTTACTTCTT 78
 |||||
 1 TTCTTACTTCTT 14

Db 1 TTCTTACTTCTT 14

RESULT 341
 ADF44009
 ID ADF44009 standard; DNA; 15 BP.
 XX
 AC ADF44009;
 XX

```
DT 12-FEB-2004 (first entry)
XX
XX HPV 59 detecting probe M5901.
DE
XX detection; human papillomavirus; HPV subtype; probe; ss.
XX
XX Human papillomavirus type 59.
OS
XX JP2002360271-A.
PN
XX
XX 17-DEC-2002.
PD
XX
XX 28-NOV-2001; 2001JP-00362595.
PF
XX
XX 04-MAY-2001; 2001TW-00110785.
PR
XX
XX (KING-) KING CAR FOOD IND CO LTD.
PA
XX WPI; 2003-600935/57.
DR
XX
XX A detecting apparatus and a detecting method for identifying the subtypes
PT of many species of human papilloma viruses at the same time and a
PT composition for the detection.
PS
XX Claim 1; SEQ ID NO 366; 166pp; Japanese.
CC
XX This invention describes a novel detecting apparatus for identifying the
CC subtypes of human papillomaviruses (HPV) contained in a sample which
CC comprises a carrier which can load sample, a first oligonucleotide loaded
CC on first part of the carrier and a second oligonucleotide loaded on
CC second part of carrier, in which first and second oligonucleotides
CC hybridise with the DNA of the first and the second HPV subtype and can
CC identify HPV subtype contained in sample at the same time. ADF43644-
CC ADF44489 represent oligonucleotide probes used in the method of the
CC invention.
CC
XX Sequence 15 BP; 2 A; 5 C; 0 G; 8 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.2%; Score 12.4; DB 1; Length 15;
XX Best Local Similarity 92.9%; Pred. No. 2.5e+02;
XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 65 TTCTTACTTCTT 78
Db 1 TTCTTACTTCTT 14

RESULT 342
AA297835
ID AA297835 standard; DNA; 16 BP.
XX
XX AA297835;
AC
XX
XX 15-SEP-2003 (revised)
DT
XX 26-APR-2000 (first entry)
DT
XX
XX HIV-1 protease gene probe SEQ ID NO:325.
DE
XX
XX Human immunodeficiency virus; HIV; protease; probe; detection;
XX drug selected mutation; hybridisation; genotyping; infection;
XX drug resistance; ss.
XX
XX Human immunodeficiency virus 1.
OS
XX
XX WO9967428-A2.
PN
XX
XX 29-DEC-1999.
PD
XX
XX 22-JUN-1999; 99WO-EP004317.
PF
XX
XX 24-JUN-1998; 98EP-00870143.
PR
XX
XX (INNO-) INNOGENETICS NV.
PA
```

```
XX
XX Stuyver L;
PI
XX WPI; 2000-147219/13.
DR
XX
XX Detection of drug-selected mutations in the HIV protease gene used to
XX treat HIV infections.
PT
XX
XX Claim 3; Page 40; 76pp; English.
PS
XX
XX The present invention describes the detection of drug-selected mutations
CC in the HIV protease gene. The method of detection allows the simultaneous
CC characterisation of a range of codons involved in drug resistance using
CC sets of probes optimised to function together in a reverse-hybridisation
CC assay. AA297517 to AA297997 represent specifically claimed probes for use
CC in the assay, and AA297479 to AA297501 represent specifically claimed HIV
CC protease gene polymorphic nucleotide sequences. AA297502 to AA297515, and
CC AA298004 to AA298007, represent PCR primers for the HIV protease gene,
CC and AA297516 represents an HIV protease probe used in an example from the
CC present invention. The method, probes and primers can be used for the
CC detection of drug-selected mutations in the HIV protease gene. The method
CC allows the simultaneous characterisation of a range of codons involved in
CC drug resistance. The method may also be used for HIV protease genotyping
CC assays. The probes are able to discriminate between wild type and mutated
CC protease sequences. The method allows rapid and reliable detection of
CC drug-selected mutation in HIV. (Updated on 15-SEP-2003 to standardise OS
CC field)
CC
XX Sequence 16 BP; 6 A; 2 C; 3 G; 5 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.2%; Score 12.4; DB 1; Length 16;
XX Best Local Similarity 92.9%; Pred. No. 2.9e+02;
XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 219 TCACATATATGGA 232
Db 3 TCACATATATGGA 16

RESULT 343
ABL31194/c
ID ABL31194 standard; DNA; 16 BP.
XX
XX ABL31194;
AC
XX
XX 21-MAR-2002 (first entry)
DT
XX
XX Human HLA genotyping oligonucleotide SEQ ID NO 683.
DE
XX
XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
XX immunogenetic; transplantation; genetic disease; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200192572-A1.
FN
XX
XX 06-DEC-2001.
PD
XX
XX 01-JUN-2001; 2001WO-JP004662.
PF
XX
XX 01-JUN-2000; 2000JP-00164798.
PR
XX
XX (NISN ) NISSHINEO IND. INC.
PA (SYST-) SYSTEM RES INC.
XX
XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX WPI; 2002-122074/16.
DR
XX
XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of
XX individuals e.g. by determining immunogenetic differences when
XX transplanting between them.
XX
```

PS Claim 10; Page 222; 345pp; Japanese.
XX
CC The invention relates to a typing kit for judging human leukocyte antigen
CC (HLA) genotype of a sample by hybridizing a substrate on which 10-24 base
CC oligonucleotides (AB120512-AB131809) originating in the sequences of
CC genes e.g. belonging to HLA class I antigens on human genome and
CC containing gene polymorphisms as alloantigens have been immobilised as
CC primers for amplification of cleaved nucleic acids relating to gene
CC polymorphisms. The method is useful for judging HLA genotypes of
CC individuals by determining immunogenetic differences before transplanting
CC between them, providing genetic information to decide compatibility of
CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
CC diagnosis of genetic diseases and identifying individuals
SQ Sequence 16 BP; 3 A; 3 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 0.2%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 158 GCACGACCTCCACC 171
Db 14 GCACTACTCTCC 1
RESULT 344
ADB99302/C
ID ADB99302 standard; DNA; 16 BP.
XX
AC ADB99302;
XX
DT 04-DEC-2003 (first entry)
XX
DE PCR primer Seq ID3 related to human GPR72 protein.
XX
KW seven transmembrane G protein coupled receptor; GPR72;
KW signal transduction pathway; G-protein; G-protein coupled receptor; GPCR;
KW hormone receptor; neurotransmitter receptor; growth factor receptor;
KW vasotrophic; antidiagonal; antidiarrhythmic; hypotensive; thrombolytic;
KW antiarteriosclerotic; antiparkinsonian; nootropic; neuroprotective;
KW cerebroprotective; neuroleptic; tranquilizer; analgesic;
KW antiinflammatory; nephrotoxic; uteronic; antiaesthetic; gene therapy;
KW anaemia; thalassaemia; leukaemia; idiopathic thrombocytopenic purpura;
KW giant platelet disease; heart failure; myocardial infarction; ischaemia;
KW angina; arrhythmia; hypertension; thrombosis; atherosclerosis;
KW Parkinson's disease; dementia; multiple sclerosis; stroke; Alzheimer's
KW Alzheimer's disease; Pick's disease; schizophrenia with dementia;
KW Korsakoff's psychosis; attention deficit hyperactivity disorder; pain;
KW lupus nephritis; benign prostatic hyperplasia; urinary incontinence;
KW erectile dysfunction; pelvic pain; chronic; acute renal failure; human;
KW ss; primer; PCR.
XX
OS Homo sapiens.
XX
PN WO2003065044-A2.
XX
PD 07-AUG-2003.
XX
PF 02-JAN-2003; 2003WO-EP000476.
XX
PR 01-FEB-2002; 2002EP-00001941.
XX
PA (FARB) BAYER AG.
XX
PI Golz S, Brueggemeier U, Geerts A;
XX WPI; 2003-663500/62.
XX
PT Screening therapeutic agents for treating e.g. ischemia, stroke, pain or
PT Alzheimer's disease in a mammal, by determining the binding to a test
PT compound, or activity in the presence of a test compound, of a GPR72 G

PT protein coupled receptor.
XX
PS Example 2; Fig 3; 117pp; English.
XX
CC This invention relates to a novel method of screening for therapeutic
CC agents useful for treating mammals for diseases associated with a seven
CC transmembrane G protein coupled receptor (designated GPR72). Many
CC medically significant biological processes are mediated by signal
CC transduction pathways that involve G-proteins. The family of G-protein
CC coupled receptors (GPCRs) includes receptors for hormones,
CC neurotransmitters, growth factors and viruses. Compounds which modulate
CC the activity of the GPCR of the invention, GPR72, may have antianaemic,
CC cyostatic, haemostatic, cardiant, vasotrophic, antidiagonal,
CC antiarrhythmic, hypotensive, cardiatic, vasotrophic, antidiagonal,
CC antiparkinsonian, nootropic, neuroprotective, cerebroprotective,
CC neuroleptic, tranquilizer, analgesic, antiinflammatory, nephrotoxic,
CC uteronic or antiaesthetic activities. The DNA or amino acid sequences of
CC GPR72 may also be useful for gene therapy. The regulator of GPR72 may be
CC useful for preparing a pharmaceutical composition for treating many
CC diseases, or for regulating GPR72 activity in a mammal having any of
CC these diseases. In particular, these diseases include anaemia,
CC thalassaemia, leukaemia, idiopathic thrombocytopenic purpura, giant
CC platelet disease, heart failure, myocardial infarction, ischaemia,
CC angina, arrhythmia, hypertension, thrombosis, atherosclerosis,
CC Parkinson's disease, dementia, multiple sclerosis, stroke, Alzheimer's
CC disease, Pick's disease, schizophrenia with dementia, Korsakoff's
CC psychosis, attention deficit hyperactivity disorders, pain, lupus
CC nephritis, benign prostatic hyperplasia, urinary incontinence, erectile
CC dysfunction, pelvic pain, chronic or acute renal failure. The mammal may
CC be a dog, cat, cow, horse, rabbit, monkey or human. The present sequence
CC is that of a PCR primer which was used for the amplification of the gene
CC encoding the human GPR72 receptor against which the therapeutic agents of
CC the invention are targeted.
SQ Sequence 16 BP; 3 A; 4 C; 8 G; 1 T; 0 U; 0 Other;
Query Match 0.2%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 379 GCCGTGCGCCTCC 392
Db 15 GCCGTAGCGCCTCC 2
RESULT 345
ACC47295
ID ACC47295 standard; DNA; 20 BP.
XX
AC ACC47295;
XX
DT 11-AUG-2003 (first entry)
XX
DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144378.
XX
KW Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
KW antisense; ss.
XX
OS Synthetic.
XX
PN WO2003014307-A2.
XX
PD 20-FEB-2003.
XX
PF 05-AUG-2002; 2002WO-US024920.
XX
PR 07-AUG-2001; 2001US-00923515.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ;

DR WPI; 2003-256565/25.
XX New antitense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis or
XX cardiovascular disease.
PS Claim 3; Page 87; 120pp; English.
XX
CC The invention relates to a new compound, 8-50 nucleobases in length
CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
CC specifically hybridizes with and inhibits the expression of human
CC apolipoprotein(a). The antitense compounds are useful for preparing a
CC composition for treating abnormal lipid or cholesterol metabolism,
CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
CC represent specific examples of chimeric antisense phosphorocholate
CC oligonucleotides having 2'-MOB wings and a deoxy gap targeting human
CC apolipoprotein(a) mRNA
XX
SQ Sequence 20 BP; 9 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 0.2%; Score 12.2; DB 1; Length 20;
Best Local Similarity 82.4%; Pred. No. 5.2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 178 ACAGAGACGACCTGCCA 194
DB 2 ACATTAAGAGCTGCCA 18
|||||
|||||
RESULT 346
ABI34086/c
ID ABI34086 standard; DNA; 12 BP.
XX
AC ABI34086;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 334059 for detecting SNP TSC0037920.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 334059; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.2%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 501 CACACTCTCCAC 512
DB 12 CACACTCTCCAC 1
|||||
|||||
RESULT 347
ABH80898
ID ABH80898 standard; DNA; 12 BP.
XX
AC ABH80898;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 280891 for detecting SNP TSC0009221.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 280891; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AEI00010-AEI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 0.2%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 240 AACCTACCCAA 251
|||||
|||||

Db 1 AACTACCCAA 12

RESULT 348
AB148149/c
ID AB148149 standard; DNA; 12 BP.
XX
AC AB148149;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 348122 for detecting SNP TSC0045457.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 348122; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABP00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 1 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 0.2%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 64 GTTCTTACTT 75
DB 12 GTTCTTACTT 1

RESULT 349
ABH80536
ID ABH80536 standard; DNA; 12 BP.
XX
AC ABH80536;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 280529 for detecting SNP TSC0008729.
XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 280529; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABP00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 0.2%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 239 AACTACCCAA 250
DB 1 AACTACCCAA 12

RESULT 350
AB162899
ID AB162899 standard; DNA; 12 BP.
XX
AC AB162899;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 362872 for detecting SNP TSC0053503.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 362872; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 3 C; 0 G; 8 T; 0 U; 0 Other;
Query Match 0.2%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 68 TTCTACTTCTTT 79
Db 1 TTCTACTTCTTT 12
RESULT 351
ABC78851
ID ABC78851 standard; DNA; 13 BP.
XX ABC78851;
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 78868 for detecting SNP TSC0020075.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIC-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 78868; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 0.2%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 240 AAATACCCAAA 251
Db 1 AAATACCCAAA 12
RESULT 352
ABH23673
ID ABH23673 standard; DNA; 13 BP.
XX ABH23673;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 223650 for detecting SNP TSC0054443.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIC-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 223650; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 1 A; 5 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 0.2%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 65 TTCTTCTACTTC 76
|||
1 TTCTTCTACTTC 12

RESULT 353

ABC49265
ID ABC49265 standard; DNA; 13 BP.

AC ABC49265;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 49282 for detecting SNP TSC0013960.

KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.

PS Claim 1; SEQ ID NO 49282; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 581 AATACTACCCAA 592
|||||
2 AATCTACCCAA 13

RESULT 354
ABF56286

ID ABF56286 standard; DNA; 13 BP.

AC ABF56286;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 156283 for detecting SNP TSC0039423.

KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.

PS Claim 1; SEQ ID NO 156283; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 5 A; 1 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 309 TTATACGAGGA 320
|||||
2 TTATACGAGGA 13

RESULT 355

ABC52287
ID ABC52287 standard; DNA; 13 BP.

AC ABC52287;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 52304 for detecting SNP TSC0014513.

KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.

```

XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 52304; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 12; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2e+02;
XX Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 218 ATCAACATATA 229
Db 2 ATCAACATATA 13

```

```

DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 223649; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 0 C; 5 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 12; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2e+02;
XX Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 65 TTCTTCACTTC 76
Db 13 TTCTTCACTTC 2

```

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 0.2%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 218 ATCAACATATA 229
DB 12 ATCAACATATA 1
RESULT 358
ID ABC50727 standard; DNA; 13 BP.
AC ABC50727;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 50744 for detecting SNP TSC0014227.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-1B000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 50744; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 0.2%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 218 ATCAACATATA 229
DB 2 ATCAACATATA 13
RESULT 359
ID ABC49264/C
AC ABC49264 standard; DNA; 13 BP.
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 49281 for detecting SNP TSC0013960.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-1B000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 49281; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.2%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 581 AATACTACCCCA 592
DB 12 AATACTACCCCA 1
RESULT 360
ID ABC50726/C
AC ABC50726 standard; DNA; 13 BP.
XX
DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 50743 for detecting SNP TSC0014227.
 DE
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIC-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 CC
 PS Claim 1; SEQ ID NO 50743; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 CC Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 0.2%; Score 12; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2e+02; Mismatches 0; Gaps 0;
 Matches 12; Conservative 0; Indels 0;
 OY 218 ATCAACATAATA 229
 DB 12 ATCAACATAATA 1
 RESULT 361
 ABC78850/c
 ID ABC78850 standard; DNA; 13 BP.
 XX
 XX ABC78850;
 AC
 XX 21-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide SEQ ID NO 78867 for detecting SNP TSC0020075.
 DE
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX

PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIC-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 CC
 PS Claim 1; SEQ ID NO 78867; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 CC Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 0.2%; Score 12; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2e+02; Mismatches 0; Gaps 0;
 Matches 12; Conservative 0; Indels 0;
 OY 240 AAACACCCAAA 251
 DB 13 AAACACCCAAA 2
 RESULT 362
 ABF56287/c
 ID ABF56287 standard; DNA; 13 BP.
 XX
 XX ABF56287;
 AC
 XX 21-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide SEQ ID NO 156284 for detecting SNP TSC0039423.
 DE
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIC-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 CC
 PS

XX Claim 1; SEQ ID NO 156284; 29pp + Sequence Listing; German.

PS This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 3 A; 4 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 0.2%; Score 12; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2e+02;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 309 TTATACGACGCA 320

Db 12 TTATACGACGCA 1

RESULT 363

AAT55651/C

ID AAT55651 standard; RNA; 15 BP.

AC AAT55651;

AT 25-MAR-2003 (revised)

DT 21-MAR-1997 (first entry)

DE Human TNF-alpha hammerhead ribozyme target sequence (nt position 177).

XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;

KW gene expression; downregulation; interleukin-5; IL-5; TCM-1;

KW intercellular adhesion molecule; rel A; tumour necrosis factor;

KW translocation; chronic myelogenous leukaemia; CML; cancer;

KW Philadelphia chromosome; inflammation; autoimmune disease;

KW atherosclerosis; myocardial infarction; stroke; restenosis;

KW transplant rejection; rheumatoid arthritis; psoriasis;

KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;

KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;

ss.

KW Homo sapiens.

OS Homo sapiens.

XX W09523225-A2.

XX 31-AUG-1995.

PD 23-FEB-1995; 95WO-IB000156.

XX 23-FEB-1994; 94US-00201109.

PR 29-MAR-1994; 94US-00218934.

PR 04-APR-1994; 94US-00222795.

PR 07-APR-1994; 94US-00222483.

PR 15-APR-1994; 94US-00227958.

PR 18-MAY-1994; 94US-00228041.

PR 06-JUL-1994; 94US-00245736.

PR 15-AUG-1994; 94US-00291932.

PR 16-AUG-1994; 94US-00291433.

PR 17-AUG-1994; 94US-00293620.

PR 19-AUG-1994; 94US-00293520.

PR 02-SEP-1994; 94US-00300000.

PR 08-SEP-1994; 94US-00303039.

PR 23-SEP-1994; 94US-00311486.

PR 23-SEP-1994; 94US-00311749.

PR 28-SEP-1994; 94US-00314397.

PR 03-OCT-1994; 94US-00316771.

PR 07-OCT-1994; 94US-00319492.

PR 11-OCT-1994; 94US-00321993.

PR 04-NOV-1994; 94US-00334847.

PR 10-NOV-1994; 94US-00337608.

PR 28-NOV-1994; 94US-00345516.

PR 16-DEC-1994; 94US-00357577.

PR 23-DEC-1994; 94US-00363233.

PR 30-JAN-1995; 95US-00380734.

XX (RIBO-) RIBOZYME PHARM INC.

XX Strincomb DT, Chowitra B, Dizenzo A, Draper KG, Dudycz LM;

PI Grimm S, Karpetsky A, Kisich K, Matulic-Adamic J, Mewissen JA;

PI Modak A, Pavco P, Belgelman U, Sullivan SM, Sweedler D, Thompson JD;

PI Tracz D, Ueman N, Wincott FE, Woolf T;

XX WPI; 1995-351090/45.

XX Ribozymes having modified bases and methods for producing them - for use

PT in inhibiting disease related genes.

PS Claim 2; Page 241; 407pp; English.

XX The present sequence represents a preferred target sequence for an

CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves TNF-alpha mRNA at

CC the nucleotide base position indicated in the DE line. Regions of the

CC mRNA that do not form secondary folding structures and contain

CC potential hammerhead and hairpin ribozyme cleavage sites were identified

CC by computer analysis. Ribozymes directed against these mRNA sequences

CC were designed and synthesised with modifications that improve their

CC nuclease resistance. The ribozymes are designed to cleave the target

CC sequences and thereby inhibit TNF-alpha expression, making them

CC potentially useful for treating rheumatoid arthritis, septic shock and

CC other inflammatory disorders including psoriasis, as well as for

CC treatment of AIDS. (Updated on 25-MAR-2003 to correct PI field.)

XX SQ Sequence 15 BP; 0 A; 5 C; 4 G; 0 T; 6 U; 0 Other;

Query Match 0.2%; Score 12; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 2.9e+02;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 430 GAACAAGCACCG 441

Db 12 GAACAAGCACCG 1

RESULT 364

AAT37610

ID AAT37610 standard; mRNA; 15 BP.

AC AAT37610;

AT 11-NOV-1996 (first entry)

DE Apo(a) mRNA (nt. pos. 10828) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);

KW hammerhead ribozyme; target sequence; diagnosis; treatment;

KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;

KW restenosis; heart disease; human; ss.

XX Homo sapiens.

OS Homo sapiens.

XX W09609392-A1.

XX 28-MAR-1996.

XX 21-SEP-1995; 95WO-US011995.

PR 23-SEP-1994; 94US-00311760.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
 PI WPI; 1996-188454/19.
 XX
 DR Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.
 PS Claim 2; Page 18; 37pp; English.
 XX
 CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 10828). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcribed from human apo(a) cDNA clones. Labeled transcripts were
 CC synthesized in vitro to form 2 templates. The oligonucleotides and
 CC labeled transcripts were annealed, RNaseH added and the mixts.
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen
 CC
 SQ Sequence 15 BP; 4 A; 5 C; 4 G; 0 T; 2 U; 0 Other;
 Query Match 0.2%; Score 12; DB 1; Length 15;
 Best Local Similarity 83.3%; Pred. No. 2.9e+02;
 Matches 10; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 OY 564 GCATAGTCGAC 575
 |||:|||||
 4 GCAUAGUCGAC 15
 DB
 RESULT 365
 AAX31474/C
 ID AAX31474 standard; DNA; 15 BP.
 XX
 AC AAX31474;
 XX
 DT 21-MAY-1999 (first entry)
 XX
 DE Tag sequence of a transcript decreased in colorectal cancer.
 XX
 KW Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
 KM diagnosis; prognosis; treatment; ss.
 XX
 OS Homo sapiens.
 OS
 PN WO9853319-A2.
 XX
 PD 26-NOV-1998.
 XX
 PF 20-MAY-1998; 98WO-US010277.
 XX
 PR 21-MAY-1997; 97US-0047352P.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Vogelstein B, Kinzler KW;
 XX
 DR WPI; 1999-070161/06.
 XX
 PT Use of isolated gene transcripts - useful for developing products for the
 PT diagnosis, prognosis and treatment of cancers, particularly colon and
 PT pancreatic cancer.
 XX

PS Claim 1; Page 52; 120pp; English.
 XX
 CC AAX30947-31815 represent tag sequences of transcripts that are
 CC differentially expressed in colorectal cancer, in pancreatic cancer, or
 CC in both. The tag sequences can be used to identify genes by matching the
 CC tag to a gen data base member, or by using the tag sequences as probes to
 CC isolate unidentified genes from cDNA libraries. The tag sequences can
 CC also be used in a method for diagnosing colon or pancreatic cancer in a
 CC sample suspected of being neoplastic. The method comprises comparing the
 CC level of at least one transcript in a first sample of a tissue to a
 CC second sample, where the first sample is a colonic tissue suspected of
 CC being neoplastic and the second sample is a normal human colonic tissue.
 CC The transcript is identified by a tag selected from AAX30947-31815. The
 CC methods of the invention can be used in the diagnosis, prognosis and
 CC treatment of cancer
 CC
 SQ Sequence 15 BP; 1 A; 3 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 0.2%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 104 AGCAAGCCATG 115
 |||||
 12 AGCAAGCCATG 1
 DB
 RESULT 366
 AA264032
 ID AA264032 standard; RNA; 15 BP.
 XX
 AC AA264032;
 XX
 DT 28-MAR-2000 (first entry)
 XX
 DE Substrate for hammerhead ribozyme which cleaves HCV RNA at nt. 4222.
 XX
 KW Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;
 KM cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;
 KM autoimmune disease; ss.
 XX
 OS Hepatitis C virus.
 OS
 PN WO9955847-A2.
 XX
 PD 04-NOV-1999.
 XX
 PF 26-APR-1999; 99WO-US009027.
 XX
 PR 27-APR-1998; 98US-0083217P.
 PR 18-SEP-1998; 98US-0100642P.
 PR 25-FEB-1999; 99US-00257608.
 PR 23-MAR-1999; 99US-00274553.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Mcswiggen JA, Roberts E, Pavco PA, Macejak D;
 XX
 DR WPI; 2000-062023/05.
 XX
 PT Novel ribozymes for the treatment of diseases and conditions related to
 PT hepatitis C infection.
 XX
 PS Claim 1; Page 78; 123pp; English.
 XX
 CC The present sequence represents the preferred target sequence of an
 CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
 CC the Hepatitis C virus (HCV) RNA sequence at the base position given in
 CC the descriptor line. The HCV sequence was screened for optimal ribozyme
 CC target sites using a computer folding algorithm and regions of the mRNA
 CC which did not form secondary folding structures and contained potential
 CC ribozyme cleavage sites were identified. Ribozymes were synthesized to
 CC target these sites and their activities optimised by either varying the

CC length of the binding arms or by modification to prevent degradation by nucleases. The ribozymes of the invention inhibit gene expression and/or viral replication, and are used to treat diseases associated with Hepatitis C virus (HCV) infection, e.g. cirrhosis, liver failure and hepatocellular carcinoma. The ribozymes may be used in combination with interferon to treat HCV infection, other infectious diseases, autoimmune diseases, and cancer

XX
SQ Sequence 15 BP; 4 A; 6 C; 1 G; 0 T; 4 U; 0 Other;

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 83.3%; Pred. No. 2.9e+02;
Matches 10; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 160 AGCTACTCCACC 171
DB 1 ACGUACUCCACC 12

RESULT 367
AA169910
ID AA169910 standard; DNA; 15 BP.

AC AA169910;
XX
DT 11-SEP-2003 (revised)
DT 06-AUG-2003 (revised)
DT 14-DEC-2001 (first entry)
XX
DE Probe #2.
XX
XX Probe; detection; ss.
XX
XX Enterobacteria phage M13.
OS
XX JP2001245699-A.
XX
XX 11-SEP-2001.
XX
XX 30-OCT-1991; 2001JP-00026141.
XX
XX 30-OCT-1991; 2000JP-00135040.
XX
XX (HITA) HITACHI LTD.
XX
XX WPI; 2001-610082/70.
XX
XX Method for detection of nucleic acids, comprises formation of a polynucleotide hybrid.
PT
XX Example 1; Page 8; 9pp; Japanese.
XX
XX The present invention relates to a method for detecting nucleic acids. The method involves using probes to hybridise target molecules. The method allows correct and simple detection of target nucleic acid both in solid and liquid phases. The present sequence is a probe which was used in an example from the present invention. (Updated on 06-AUG-2003 to correct OS field.) (Updated on 11-SEP-2003 to standardise OS field)
XX
SQ Sequence 15 BP; 3 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 190 TGCCAAGCTTGG 201
DB 3 TGCCAAGCTTGG 14

RESULT 368
AA167325/c
ID AA167325 standard; DNA; 15 BP.

XX
AC AA167325;
XX
DT 11-FEB-2002 (first entry)
XX
XX Human FKBP8 allele-specific oligonucleotide (ASO) primer.
XX
XX FK506-binding protein 8; FKBP8; haplotyping; polymorphism; cancer; ss; immunosuppression; human; allele-specific oligonucleotide; ASO; primer.
XX
XX Homo sapiens.
XX
XX WO200172965-A2.
XX
XX 04-OCT-2001.
XX
XX 26-MAR-2001; 2001WO-US009718.
XX
XX 24-MAR-2000; 2000US-0192125P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Anastasio AE, Bentivegna SC, Choi YJ, Kilem SE, Koshy B;
XX Stephens JC;
XX
XX WPI; 2001-626261/72.
XX
XX
XX New haplotypes of the FK506-binding protein 8 gene, useful for genotyping that gene in individual and to design new therapy for associated disease such as immunosuppression and cancer.
XX
XX Claim 15; Page 74; 98pp; English.
XX
XX The invention relates to haplotyping the FK506-binding protein 8 (38kd) (FKBP8) gene in an individual. The method involves determining the identity of the nucleotide pair at one or more polymorphic sites selected from PI to P26 (described in the specification). The invention is useful to improve the efficiency and reliability of several steps in the discovery and development of drugs for treating diseases associated with FKBP8 activity, for example immunosuppression and cancer. Sequences CC AA167300-351 represent allele-specific oligonucleotide (ASO) primers for detecting FKBP8 gene polymorphisms. Note: some of these sequences (alternate sequence Id numbering- 31, 33, 35, .81) differ from those with CC the same seq Id No.s indicated in the disclosure
XX
SQ Sequence 15 BP; 2 A; 9 C; 2 G; 1 T; 0 U; 1 Other;

Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.9e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 449 AAAGCCTGGGGTG 462
DB 14 AAGGCCCTGGGGTG 1

RESULT 369
AA167341
ID AA167341 standard; DNA; 15 BP.

AC AA167341;
XX
DT 11-FEB-2002 (first entry)
XX
XX Human FKBP8 allele-specific oligonucleotide (ASO) primer.
XX
XX FK506-binding protein 8; FKBP8; haplotyping; polymorphism; cancer; ss; immunosuppression; human; allele-specific oligonucleotide; ASO; primer.
XX
XX Homo sapiens.
XX
XX WO200172965-A2.
XX
XX

PD 04-OCT-2001.
 XX
 PF 26-MAR-2001; 2001WO-US009718.
 XX
 PR 24-MAR-2000; 2000US-0192125P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Anastasio AE, Bentivegna SC, Choi JY, Kliehm SE, Koshy B;
 PI Stephens JC;
 XX WPI; 2001-626261/72.
 DR
 XX
 PT New haplotypes of the FK506-binding protein 8 gene, useful for genotyping
 PT that gene in individual and to design new therapy for associated disease
 PT such as immunosuppression and cancer.
 PT
 XX
 PS Claim 15; Page 77; 98pp; English.
 XX
 CC The invention relates to haplotyping the FK506-binding protein 8 (38kD)
 CC (FKBP8) gene in an individual. The method involves determining the
 CC identity of the nucleotide pair at one or more polymorphic sites selected
 CC from PI to P26 (described in the specification). The invention is useful
 CC to improve the efficiency and reliability of several steps in the
 CC discovery and development of drugs for treating diseases associated with
 CC FKBP8 activity, for example immunosuppression and cancer. Sequences
 CC AA167300-351 represent allele-specific oligonucleotide (ASO) primers for
 CC detecting FKBP8 gene polymorphisms. Note: some of these sequences
 CC (alternate sequence id numbering - 31, 33, 35, .81) differ from those with
 CC the same seq id No.s indicated in the disclosure
 CC
 XX
 SQ Sequence 15 BP; 2 A; 2 C; 7 G; 3 T; 0 U; 1 Other;
 XX
 Query Match 0.2%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 459 GGTGACGAGTGTG 470
 Db 1 GGTGACGAGTGTG 12
 XX
 RESULT 370
 AA167418
 ID AA167418 standard; DNA; 15 BP.
 XX
 AC AA167418;
 XX
 DT 11-FEB-2002 (first entry)
 XX
 DE Human FKBP8 allele-specific oligonucleotide (ASO) primer.
 XX
 KW FK506-binding protein 8; FKBP8; haplotyping; polymorphism; cancer; ss;
 KM immunosuppression; human; allele-specific oligonucleotide; ASO; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200172965-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 26-MAR-2001; 2001WO-US009718.
 XX
 PR 24-MAR-2000; 2000US-0192125P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Anastasio AE, Bentivegna SC, Choi JY, Kliehm SE, Koshy B;
 PI Stephens JC;
 XX WPI; 2001-626261/72.
 DR
 XX
 PT New haplotypes of the FK506-binding protein 8 gene, useful for genotyping

PT that gene in individual and to design new therapy for associated disease
 PT such as immunosuppression and cancer.
 PT
 XX
 PS Claim 15; Page 14; 98pp; English.
 XX
 CC The invention relates to haplotyping the FK506-binding protein 8 (38kD)
 CC (FKBP8) gene in an individual. The method involves determining the
 CC identity of the nucleotide pair at one or more polymorphic sites selected
 CC from PI to P26 (described in the specification). The invention is useful
 CC to improve the efficiency and reliability of several steps in the
 CC discovery and development of drugs for treating diseases associated with
 CC FKBP8 activity, for example immunosuppression and cancer. Sequences
 CC AA167406-431 represent allele-specific oligonucleotide (ASO) primers for
 CC detecting FKBP8 gene polymorphisms. Note: these sequences appear in the
 CC disclosure (sequence id numbering from 31, 33, 35, .81). These sequences
 CC differ from those with the same seq id No.s indicated under the sequence
 CC listing
 CC
 XX
 SQ Sequence 15 BP; 1 A; 2 C; 9 G; 2 T; 0 U; 1 Other;
 XX
 Query Match 0.2%; Score 12; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred. No. 2.9e+02;
 Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 Oy 450 AAGGCTGTGGGTGC 463
 Db 1 AAGGCTGTGGGTGT 14
 XX
 RESULT 371
 AA169904
 ID AA169904 standard; DNA; 15 BP.
 XX
 AC AA169904;
 XX
 DT 11-SEP-2003 (revised)
 DT 06-AUG-2003 (revised)
 DT 14-DEC-2001 (first entry)
 XX
 DE Probe #2.
 XX
 KW Probe; detection; ss.
 KM Enterobacteria phage M13.
 OS JP2001245683-A.
 PN 11-SEP-2001.
 PD 30-OCT-1991; 2001JP-00026140.
 PF 30-OCT-1991; 2000JP-00135040.
 PR 30-OCT-1991; 2000JP-00135040.
 XX
 PA (HITA) HITACHI LTD.
 XX
 DR WPI; 2001-610078/70.
 XX
 PT Probe for detection of nucleic acid comprises a donor and a receptor
 PT separated with 10 or more bases in a single stranded polynucleotide.
 XX
 PS Example 1; Page 8; 9pp; Japanese.
 XX
 CC The present sequence is a probe which has a donor and a receptor
 CC separated with 10 or more bases in a single stranded polynucleotide. The
 CC probe can be used for detection of a target nucleic acid both in solid
 CC and liquid phases. (Updated on 06-AUG-2003 to correct OS field.) (Updated
 CC on 11-SEP-2003 to standardise OS field)
 CC
 XX
 SQ Sequence 15 BP; 3 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.2%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 190 TGCCAGCTGG 201
 |||||
 DB 3 TGCCAGCTGG 14

RESULT 372

AAf77683
 ID AAF77683 standard; DNA; 15 BP.

AAf77683;

DT 29-MAY-2001 (first entry)

DE Nucleic acid detection probe related sequence SEQ ID NO: 2.

KW Nucleic acid detection; probe; energy donor; energy receptor; ds.

XX Unidentified.

PN JP2000342286-A.

PD 12-DEC-2000.

PF 30-OCT-1991; 2000JP-00135040.

PR 30-OCT-1991; 91JP-00285221.

PA (HITA) HITACHI LTD.

DR WPI; 2001-260291/27.

PT A probe used for the detection of nucleic acid, comprises a single-

PT stranded polynucleotide having a base sequence of an intermediate portion

XX constituted by at least 10 bases.

XX Disclosure; Page 8; 9pp; Japanese.

CC The present invention provides a probe which can be used for the

CC detection of nucleic acid and is constituted by a single-stranded

CC polynucleotide having a base sequence of an intermediate portion

CC constituted by at least 10 bases. It can be used in the detection of

XX nucleic acids

XX Sequence 15 BP; 3 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.2%; Score 12; DB 1; Length 15;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 190 TGCCAGCTGG 201

DB 3 TGCCAGCTGG 14

RESULT 373

AAf69556/c
 ID AAF69556 standard; DNA; 15 BP.

AAf69556;

DT 18-APR-2001 (first entry)

DE Human IL4Ra1pha gene probe #196.

KW Polymorphism; human; interleukin 4 receptor-alpha; IL4R-alpha;

XX allergic disease; probe; ss.

OS Homo sapiens.

PN WO200104270-A1.

PD 18-JAN-2001.

XX 13-JUL-2000; 2000WO-US019094.
 PF 13-JUL-1999; 99US-0143435P.

XX (GENA-) GENAISSANCE PHARM INC.

PI Chew A, Denton RR, Duda A, Nandabalan K, Stephens JC;

PI Windemuth AK;

DR WPI; 2001-103078/11.

PT New isolated polynucleotide useful for the identification of therapeutics

PT in allergic diseases is new.

PS Claim 15; Page 45; 188pp; English.

CC The present invention relates to polymorphisms of the human interleukin 4

CC receptor-alpha gene (IL4R-alpha; see AAF57718 for the reference

CC sequence). Polynucleotides comprising polymorphic gene variants are

CC useful for therapeutic purposes. For example, where a patient may benefit

CC from expression of a particular IL4Ra1pha protein isoform, an expression

CC vector encoding the isoform may be administered to the patient. It may

CC be desirable to decrease or block expression of a particular IL4Ra1pha

CC organ, tissue or cell population with an expression vector that expresses

CC high levels of untranslatable mRNA for the isogene. Specific therapeutics

CC identified by these methods may be useful for allergic diseases. The

CC present sequence is a probe for human IL4R-alpha

XX

XX Sequence 15 BP; 2 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

XX Query Match

Best Local Similarity 0.2%; Score 12; DB 1; Length 15;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 354 GCATGCTCAGA 365

DB 12 GCATGCTCAGA 1

AAf69554/c

AAf69554; standard; DNA; 15 BP.

DT 18-APR-2001 (first entry)

DE Human IL4Ra1pha gene probe #194.

KW Polymorphism; human; interleukin 4 receptor-alpha; IL4R-alpha;

XX allergic disease; probe; ss.

OS Homo sapiens.

PN WO200104270-A1.

PD 18-JAN-2001.

DT 13-JUL-2000; 2000WO-US019094.

PR 13-JUL-1999; 99US-0143435P.

PA (GENA-) GENAISSANCE PHARM INC.

PI Chew A, Denton RR, Duda A, Nandabalan K, Stephens JC;

PI Windemuth AK;

DR WPI; 2001-103078/11.

PT New isolated polynucleotide useful for the identification of therapeutics

PT in allergic diseases is new.

```

XX Claim 15; Page 45; 188pp; English.
PS
XX The present invention relates to polymorphisms of the human interleukin 4
CC receptor-alpha gene (IL4R-alpha; see AAF57718 for the reference
CC sequence). Polynucleotides comprising polymorphic gene variants are
CC useful for therapeutic purposes. For example, where a patient may benefit
CC from expression of a particular IL4Ralpha protein isoform, an expression
CC vector encoding the isoform may be administered to the patient. It may
CC be desirable to decrease or block expression of a particular IL4Ralpha
CC isoform, which may be done by turning off by transforming a targeted
CC organ, tissue or cell population with an expression vector that expresses
CC high levels of untranslatable mRNA for the isoform. Specific therapeutics
CC identified by these methods may be useful for allergic diseases. The
CC present sequence is a probe for human IL4R-alpha
XX
SQ Sequence 15 BP; 3 A; 4 C; 4 G; 4 T; 0 U; 0 Other;

Query Match          0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      354 GCAATGCTCAGA 365
      |||||
      12 GCAATGCTCAGA 1

Db
RESULT 375
ABI98938/c
ID ABI98938 standard; DNA; 15 BP.
XX
AC ABI98938;
XX
DT 18-FEB-2002 (first entry)
XX
DE Oligonucleotide CP13.
XX
DE Oligonucleotide CP13.
XX
KM Virucide; vaccine; virus; virulence; canine distemper virus; CDV;
XX measles; dog; ds.
XX
OS Synthetic.
XX
PN US6309647-B1.
XX
PD 30-OCT-2001.
XX
PF 15-JUL-1999; 99US-00354138.
XX
PR 15-JUL-1999; 99US-00354138.
XX
PA (AVERT ) AVENTIS PASTEUR.
XX
PI Paolletti E, Tartaglia J, Taylor J, Gettig R;
XX WPI; 2002-040232/05.
XX
DR Novel virus, useful for inducing immune response in dog against CDV,
XX comprising the modified recombinant virus having attenuated virulence
XX comprising exogenous DNA sequences encoding antigens of canine distemper
XX virus (CDV) or measles virus.
XX
PS Example 20; Col 64; 147pp; English.
XX
XX The present invention relates to modified recombinant viruses, comprising
XX inactivated virus-encoded genetic functions so that the viruses have
XX attenuated virulence, yet retained efficiency. The viruses can contain
XX DNA encoding a canine distemper virus (CDV) antigen or measles M or N
XX antigen. The recombinant viruses are useful for inducing an antigenic or
XX immunological response in a dog or other carnivore against CDV. The
XX present sequence was used in an example from the present invention
XX
SQ Sequence 15 BP; 2 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

```

```

Query Match          0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      314 CGACGGATCCCG 325
      |||||
      12 CGACGGATCCCG 1

Db
RESULT 376
ABL01163
ID ABL01163 standard; DNA; 15 BP.
XX
AC ABL01163;
XX
DT 12-MAR-2002 (first entry)
XX
XX Human AKR1B1 gene polymorphism detection ASO primer SEQ ID NO:60.
XX
XX Human; aldo-keto reductase family 1 member B1; aldose reductase; as;
XX AKR1B1; chromosome 7q35; detection; polymorphism; ASO; probe; primer;
XX allele-specific oligonucleotide; antidiabetic; gene therapy; diabetes.
XX
XX Homo sapiens.
XX
XX MO200179223-A2.
XX
XX 25-OCT-2001.
XX
XX 12-APR-2001; 2001WO-US011944.
XX
XX 12-APR-2000; 2000US-0196315P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Choi JY, Nandabalan K, Rounds E, Sanchis A;
XX WPI; 2002-075056/10.
XX
XX Novel polymorphic variants of aldo-keto reductase family 1, member b1
XX gene useful in studying expression and function of the protein, useful
XX for screening drugs to treat diseases e.g. diabetes.
XX
XX Claim 16; Page 14; 103pp; English.
XX
XX The present invention describes an isolated polynucleotide (I) comprising
XX a sequence which is a polymorphic variant (PV) of a reference sequence
XX for aldo-keto reductase family 1, member B1 (AKR1B1) gene or its
XX fragment, having the 2214 base pair sequence given in ABL01105. AKR1B1
XX has antidiabetic activity and can be used in gene therapy. AKR1B1 can be
XX used in the treatment of diabetes. The human AKR1B1 gene is located on
XX chromosome 7q35. ABL01107 to ABL01129 represent allele-specific
XX oligonucleotide (ASO) probes used in the detection of polymorphisms in
XX the human AKR1B1 gene; ABL01130 to ABL01175 represent ASO primers used in
XX the detection of polymorphisms in the human AKR1B1 gene; and ABL01176 to
XX ABL01221 represent preferred primers used in the detection of
XX polymorphisms in the human AKR1B1 gene
XX
SQ Sequence 15 BP; 5 A; 5 C; 2 G; 2 T; 0 U; 1 Other;

Query Match          0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.9e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      91 TCAGCAGCAGCTGA 104
      |||||
      2 TCAGCAGCAGCTGA 15

Db
RESULT 377
ABL57605
ID ABL57605 standard; DNA; 15 BP.
XX

```

```

AC ABL57605;
XX
DT 08-OCT-2002 (first entry)
XX
DE Human SCYA24 ASO probe #5.
XX
KM SCYA24; human; small inducible cytokine; isogene; antiasthmatic; asthma;
KW gene therapy; respiratory inflammatory disease; polymorphism; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200220851-A1.
XX
PD 14-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US028328.
XX
PR 08-SEP-2000; 2000US-0231129P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Anaestasio AE, Han J, Kazemi A;
XX
DR MPI; 2002-351785/38.
XX
PS Claim 16; Page 14; 98pp; English.
XX
CC The invention relates to a novel isolated polynucleotide comprising a
CC small inducible cytokine subfamily A (cys-cys), member 24 (SCYA24)
CC isogene. The polypeptide of the invention has antiasthmatic activity. The
CC polynucleotide may have a use in gene therapy. The polynucleotide and
CC polypeptide are useful in the development of drugs for treating
CC diseases associated with SCYA24 activity, e.g. respiratory inflammatory
CC diseases such as asthma. Allele-specific oligonucleotide (ASO) probes
CC used for detecting polymorphisms in the SCYA24 gene are represented in
CC ABL57601-ABL57615
XX
SQ Sequence 15 BP; 1 A; 4 C; 4 G; 5 T; 0 U; 1 Other;
XX
Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.9e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 58 GAAGTGGTTCTTCT 71
DB 1 GACGTGGYTCTTCT 14

```

RESULT 378
AB97008/c
ID AB97008 standard; DNA; 15 BP.
XX
AC AB97008;
XX
DT 18-JUN-2002 (first entry)
XX
DE ZFP36 allele-specific probe for detecting polymorphisms SEQ ID 9.
XX
KM Polymorphic variant; ZFP36; immunosuppressive; antiarthritic;
KW antiarthritic; drug screening; isogene; haplotype pair;
KM autoimmune disease; rheumatoid arthritis; haplotyping; genotyping;
KW allele specific oligonucleotide; ASO; single nucleotide polymorphism;
KM SNP; zinc finger protein; mouse zfp-36; ss; gene therapy; transgenic;
XX
OS Homo sapiens.
XX
PN WO200179226-A2.
XX

```

PD 25-OCT-2001.
XX
XX 13-APR-2001; 2001WO-US012254.
XX
PR 13-APR-2000; 2000US-0196602P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Choi JY, Klem SE, Koshy B, Parks KE;
XX
DR MPI; 2002-075059/10.
XX
XX
PT Novel polymorphic variants of zinc finger protein homologous to zfp-36 in
PT mouse gene, useful in studying expression and function of the protein,
PT useful for screening drugs to treat diseases e.g. rheumatoid arthritis.
XX
PS Claim 16; Page 13; 60pp; English.
XX
CC The present sequence is that of an oligonucleotide used for assaying a
CC polymorphism in the zinc finger protein homologous to zfp-36 in mouse
CC (ZFP36) gene of the invention. The specification describes a newly
CC isolated polynucleotide comprising a sequence which is a polymorphic
CC variant (PV) of a reference sequence for the ZFP36 gene (see AB97001) or
CC its fragment and its encoded protein. The ZFP36 polynucleotides and
CC polypeptides have antiarthritic, immunosuppressive and antiarthritic
CC activities. The ZFP36 polypeptide is useful for screening drugs targeting
CC the ZFP36 polypeptide. ZFP36 isogenes or haplotype pairs are useful for
CC improving the efficiency and reliability of the discovery and development
CC of drugs for treating diseases associated with ZFP36 activity, e.g.,
CC autoimmune diseases such as rheumatoid arthritis. Haplotyping the ZFP36
CC gene in an individual gives useful information for validating ZFP36 as a
CC candidate target for treating a specific condition predicted to be
CC associated with ZFP36 activity. Genotyping the ZFP36 gene of an
CC individual can give information used for developing diagnostic tests and
CC therapeutic treatments. The isolated polynucleotide is useful in studying
CC the expression and function of ZFP36 and in drug screening. Antibodies
CC specific for the ZFP36 protein are useful in many diagnostic and
CC prognostic formats and therapeutic methods. A recombinant non-human
CC organism transformed with the ZFP36 gene is useful in studying expression
CC of the ZFP36 isogenes in vivo, for in vivo drug screening and testing.
CC Allele-specific oligonucleotides (ASO) are useful as probes and primers
CC and for assaying a polymorphism in the target region
XX
SQ Sequence 15 BP; 0 A; 7 C; 4 G; 3 T; 0 U; 1 Other;
XX
Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.9e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 181 GGAGGACCTGCCA 194
DB 14 GGAGGRCGCCCA 1

```

RESULT 379
AAL42374
ID AAL42374 standard; DNA; 15 BP.
XX
AC AAL42374;
XX
DT 28-JUN-2002 (first entry)
XX
DE Human G protein gamma 7 allele specific oligonucleotide primer 1.
XX
KM Human; ss; guanine nucleotide binding protein gamma 7; G protein; GNG7;
KW novel polymorphic site; drug screening; gene therapy;
KM GNG7-related disease; pancreatic cancer; GNG7 haplotyping;
KW GNG7 genotyping; allele specific oligonucleotide; primer.
XX
OS Homo sapiens.
XX
PN WO200218647-A1.
XX

```

PD 07-MAR-2002.
XX
XX 23-AUG-2001; 2001WO-US026279.
XX
XX 25-AUG-2000; 2000US-0228234P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Finkel K, Kiem SE, Koshy B;
XX
XX WPI; 2002-315548/35.
XX
XX Novel genetic variants of guanine nucleotide binding protein, gamma 7
XX gene useful in studying expression and function of the protein, and for
XX screening drugs to treat diseases e.g. pancreatic cancer.
XX
XX Claim 16; Page 12; 62pp; English.
XX
XX The invention comprises the nucleotide and amino acid sequences of the
XX human guanine nucleotide binding protein (G protein) gamma 7 (GNG7). The
XX invention specifically relates to the discovery of three novel
XX polymorphic sites in the GNG7 gene. The GNG7 nucleotide and protein
XX sequences are useful for screening for drugs which target GNG7 and may be
XX used to treat (gene therapy) GNG7-related diseases (e.g. pancreatic
XX cancer). The GNG7 nucleotide sequence can be used for haplotyping GNG7,
XX genotyping GNG7 and predicting the haplotype pair for GNG7 in an
XX individual. The present DNA sequence represents a human GNG7 allele
XX specific oligonucleotide primer
XX
XX Sequence 15 BP; 3 A; 4 C; 5 G; 2 T; 0 U; 1 Other;
XX
XX Query Match 0.2%; Score 12; DB 1; Length 15;
XX Best Local Similarity 85.7%; Pred. No. 2.9e+02;
XX Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
XX 444 TGAGCAAGGCGCTG 457
XX |||||:|||||
XX 2 TGAGCCAAAGGCGCKG 15
XX
XX RESULT 380
XX AAD45863/c
XX ID AAD45863 standard; DNA; 15 BP.
XX
XX AAD45863;
XX
XX 27-DEC-2002 (first entry)
XX
XX Human TNF alpha gene polymorphism detecting ASO probe #4.
XX
XX Human; tumour necrosis factor; TNF alpha; cancer; inflammatory disorder;
XX diabetes; gene therapy; cytosolic; allele specific oligonucleotide; ASO;
XX probe; ss.
XX
XX Homo sapiens.
XX
XX W0200260918-A2.
XX
XX 08-AUG-2002.
XX
XX 03-DEC-2001; 2001WO-US046947.
XX
XX 01-DEC-2000; 2000US-0250918P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Bentivegna SC, Denton RR, Nandabalan K, Saueker EA;
XX
XX WPI; 2002-698545/75.
XX
XX New genetic variants comprising human Tumour Necrosis Factor alpha (TNF)
XX isogene, useful for studying the expression and function of TNF and in
XX screening for drugs to treat cancer, diabetes or inflammatory disorders.

```

```

XX
XX Claim 15; Page 13; 66pp; English.
XX
XX The present invention relates to novel genetic variants of human tumour
XX necrosis factor (TNF) alpha genes. The polymorphic variants are useful in
XX studying the expression and function of TNF, in expressing TNF protein
XX for use in screening for candidate drugs to treat diseases related to TNF
XX activity. The pharmaceutical compositions comprising TNF polynucleotide,
XX an antisense oligonucleotide directed against one of the novel TNF
XX isogenes, a polynucleotide encoding the antisense oligonucleotide or
XX another compound that inhibits expression of the TNF isogene are useful
XX for treating disorders affected by expression or function of the TNF
XX isogene e.g. cancer, diabetes or inflammatory disorders. Sequences of the
XX invention are also used in gene therapy. The present DNA sequence is an
XX allele specific oligonucleotide (ASO) probe used to detect human TNF
XX alpha gene polymorphisms
XX
XX Sequence 15 BP; 1 A; 4 C; 5 G; 4 T; 0 U; 1 Other;
XX
XX Query Match 0.2%; Score 12; DB 1; Length 15;
XX Best Local Similarity 85.7%; Pred. No. 2.9e+02;
XX Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
XX 432 ACAAGCACCGACTG 445
XX |||||:|||||
XX 15 ACAAGCAMCGCCTG 2
XX
XX RESULT 381
XX ABK63975
XX ID ABK63975 standard; DNA; 15 BP.
XX
XX ABK63975;
XX
XX 18-JUN-2002 (first entry)
XX
XX Human BF gene allele-specific oligonucleotide probe #10.
XX
XX Human; B-factor; properdin; BF; probe; ss; gene therapy; drug screening;
XX antidiabetic; dermatological; diabetes; immunosuppressive;
XX antiinflammatory; systemic lupus erythematosus.
XX
XX Homo sapiens.
XX
XX W0200218414-A2.
XX
XX 07-MAR-2002.
XX
XX 29-AUG-2001; 2001WO-US027098.
XX
XX 29-AUG-2000; 2000US-0228940P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Anastasio AE, Finkel K, Kazemi A, Koshy B;
XX
XX WPI; 2002-304244/34.
XX
XX New genetic variants having polymorphisms in the B-Factor, Properdin (BF)
XX gene, useful for studying the function of BF, and for treating disorders
XX affected by expression or function of the BF isogene.
XX
XX Claim 17; Page 15; 151pp; English.
XX
XX The invention relates to single nucleotide polymorphisms in the gene
XX encoding the human B-factor properdin protein (BF). A method for
XX haplotyping the BF gene in an individual comprises identifying the
XX nucleotide at one or more polymorphic sites and determining whether one
XX of the copies of the gene is defined by one of the BF haplotypes given in
XX the specification or whether both copies are defined by a haplotype pair.
XX This method is useful in genotyping, whereby all possible haplotype pairs
XX can be assigned to specific genotypes. An association between a trait and
XX a haplotype or haplotype pair of the BF gene can be identified by

```

CC comparing the frequency of the haplotype or haplotype pair in a
CC population exhibiting the trait with the frequency of the haplotype or
CC haplotype pair in a reference population, where a higher haplotype
CC frequency in the trait population indicates the trait is associated with
CC the haplotype or haplotype pair. BF and its corresponding DNA are used
CC for studying the expression and function of BF, for use in screening for
CC candidate drugs to treat diseases related to BF activity, such as
CC diabetes and systemic lupus erythematosus. Sequences ABK63966-ABK63993
CC represent allele-specific oligonucleotide probes used to detect human BP
CC gene polymorphisms
XX
SQ Sequence 15 BP; 4 A; 5 C; 2 G; 3 T; 0 U; 1 Other;
Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.9e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Qy 202 TCATCTATGACACC 215
Db 1 TCATGTATGACACC 14
RESULT 382
ABK32428/c
ID ABK32428 standard; DNA; 15 BP.
XX
AC ABK32428;
XX
DT 23-APR-2002 (first entry)
XX
DE Human colon cancer SAGE tag #529.
XX
KW Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;
KW serial analysis of gene expression; diagnostic; prognostic; probe;
KW cancer marker; ss.
XX
OS Homo sapiens.
XX
PN US633352-B1.
XX
PD 25-DEC-2001.
XX
PF 20-MAY-1998; 98US-00081646.
XX
PR 20-MAY-1998; 98US-00081646.
XX
PA (UYJO) UNIV JOHNS HOPKINS.
XX
PI Vogelstein B, Kinzler KW, Zhang L, Zhou W;
XX
DR WPI; 2002-153821/20.
XX
PT New human nucleic acid containing specific SAGE tags, useful as
PT diagnostic markers for cancer, also derived probes.
XX
PS Disclosure; Col 57; 161pp; English.
XX
CC The invention relates to an isolated, purified human nucleic acid (1)
CC that has the same sequence as a RNA found in humans and is a SAGE
CC (serial analysis of gene expression) tag comprising a single stranded
CC probe containing at least 10 consecutive nucleotides. SAGE tags, are
CC diagnostic and prognostic markers of cancer, especially of the colon and
CC pancreas. ABK3300-ABK32770 represent human colon and pancreatic cancer
CC SAGE tags of the invention
XX
SQ Sequence 15 BP; 1 A; 3 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 104 AGCAAGCCATG 115
Db 1 AGCAAGCCATG 115

Db 12 AGCAAGCCATG 1
RESULT 383
ABX01085
ID ABX01085 standard; RNA; 15 BP.
XX
AC ABX01085;
XX
DT 23-DEC-2002 (first entry)
XX
DE Hepatitis C virus substrate #867 for HCV hammerhead ribozyme #867.
XX
KW Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
KW HCV ribozyme; HCV expression; HCV replication; cirrhosis; vinnicide;
KW liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
KW type I interferon; interferon alpha; interferon beta; cytosstatic;
KW interferon gamma; consensus interferon; hepatotropic; antiinflammatory;
KW substrate; hammerhead ribozyme; HH ribozyme; ss.
XX
OS Hepatitis C virus.
XX
PN US2002082225-A1.
XX
PD 27-JUN-2002.
XX
PF 23-MAR-1999; 99US-00274553.
XX
PR 23-MAR-1999; 99US-00274553.
XX
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
PA (ROBE/) ROBERTS B.
PA (PAVO/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
PI Blatt L, Mcswigen JA, Roberts B, Pavco PA, Macejack D;
XX
DR WPI; 2002-617759/66.
XX
PT New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
PT replication and are useful to treat hepatitis C virus infections and
PT cirrhosis, liver failure or hepatocellular carcinoma.
XX
PS Claim 1; Page 46; 80pp; English.
XX
CC The present invention relates to enzymatic nucleic acids which
CC specifically cleave RNA derived from Hepatitis C virus (HCV). The
CC enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin
CC (HP) motif where the binding arms comprise sequences complementary to one
CC of the substrate sequences defined in the specification. The HCV
CC ribozymes are useful for modulating the expression and/or replication of
CC HCV. They can be used to treat cirrhosis, liver failure and/or
CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating
CC a condition associated with HCV infection in conjunction with one or more
CC other drug therapies, particularly type I interferon, especially
CC interferon alpha, beta or gamma or consensus interferon. The present
CC sequence represents a substrate for a HCV hammerhead (HH) ribozyme. Note:
CC Some of the sequence data for this patent did not form part of the
CC printed specification. The complete sequence data for this patent was
CC obtained in electronic format directly from the USPTO web site at
CC seqdata.uspto.gov/patidentrty.html
XX
SQ Sequence 15 BP; 4 A; 6 C; 1 G; 0 T; 4 U; 0 Other;
Query Match 0.2%; Score 12; DB 1; Length 15;
Best Local Similarity 83.3%; Pred. No. 2.9e+02;
Matches 10; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 160 ACCTACTCCACC 171
Db 1 ACCTACTCCACC 171

RESULT 384
 ID ABX10152 standard; cDNA; 15 BP.
 XX
 AC ABX10152;
 XX
 DT 27-JAN-2003 (first entry)
 XX
 DE Human TIGR/Myocilin variant cDNA deletion 5' flank #14.
 XX
 XX Human; ss; TIGR; MYOC; Myocilin; Glaucoma; blindness;
 KM trabecular meshwork inducible glucocorticoid responsive protein;
 KM retinal degenerative disease; RRD; retinitis pigmentosa;
 KM macular degeneration; Usher syndrome; cardiovascular disease;
 KM congenital heart disease; myocardial ischemia; stroke;
 KM acute endocarditis; hypertensive heart disease; arrhythmia;
 KM arteriosclerotic heart disease.
 XX
 XX Homo sapiens.
 OS
 XX
 XX W0200282969-A2.
 XX
 PD 24-OCT-2002.
 XX
 PF 11-DEC-2001; 2001WO-US048622.
 XX
 PR 05-APR-2001; 2001US-0281442P.
 PR 23-JUL-2001; 2001US-0306889P.
 XX
 PA (KONG/) KONG T H.
 XX
 PI Kong TH;
 XX
 DR WPI; 2003-058597/05.
 XX
 PT Determining the presence or the risk of having glaucoma, retinal
 PT degenerative or cardiovascular diseases in a subject, comprises
 PT generating transcriptional or translational profiles based on myocilin
 PT nucleic acids and proteins.
 XX
 XX
 XX Disclosure; Fig 4c; 55pp; English.
 XX
 CC The invention relates to determining whether a subject has or is at risk
 CC of developing glaucoma, retinal degenerative disease, or a cardiovascular
 CC disease, comprising generating a transcriptional or translational profile
 CC (i.e. 'fingerprint') in the subject or in a sample obtained from the
 CC subject, based on the expression of the different myocilin (MYOC, also
 CC known as trabecular meshwork inducible glucocorticoid responsive protein,
 CC TIGR) mRNA species or polypeptide forms, where a difference in the
 CC profile relative to that in a normal subject indicates that the subject
 CC has or is at risk of developing the above-mentioned diseases. Also
 CC included are: (1) a method for establishing MYOC genetic population
 CC profile in a population of individuals having glaucoma, retinal
 CC degenerative disease, or a cardiovascular disease; (2) a method for
 CC pharmacogenetically selecting a therapy to administer to an individual
 CC having glaucoma, retinal degenerative disease, or a cardiovascular
 CC disease, comprising determining MYOC genetic profile of an individual and
 CC comparing the individual's MYOC genetic profile to MYOC genetic
 CC population profile, to select a therapy for administration to the
 CC individual; and a kit for determining whether a subject has or is likely
 CC to develop glaucoma, retinal degenerative disease, or a cardiovascular
 CC disease, comprising a probe or primer which hybridises to the MYOC
 CC nucleic acid, or an antibody or peptide probe capable of specifically
 CC binding to the novel MYOC polypeptide(s), and instructions for use. The
 CC method is useful for the prognosis and/or diagnosis of glaucoma, retinal
 CC degenerative diseases (RDD) or cardiovascular diseases (e.g. blindness,
 CC retinitis pigmentosa, macular degeneration, Usher syndrome, congenital
 CC heart disease, myocardial ischemia, stroke, acute endocarditis,
 CC hypertensive heart disease, arrhythmia and arteriosclerotic heart
 CC disease), and in screening assays for the identification of therapeutics
 CC and the evaluation of their effectiveness for treating the above-
 CC mentioned diseases in a subject. The present sequence represents the 5'

CC Flanking sequence surrounding the deletion present in a MYOC cDNA variant
 XX
 XX Sequence 15 BP; 2 A; 5 C; 5 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.2%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 32 TGGCCAGTCCCA 43
 DB 4 TGGCCAGTCCCA 15
 XX
 RESULT 385
 ID ADM66138 standard; DNA; 15 BP.
 XX
 AC ADM66138;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 DE Canaripox virus C3 open reading frame deletion construct; oligo. CP13.
 XX
 XX Canaripox virus; ss; NYVAC; TROVAC; ALVAC; rabies glycoprotein G; rabies;
 KM vaccine.
 KM
 XX Synthetic.
 OS
 XX US2003082204-A1.
 XX
 PN 01-MAY-2003.
 PD
 XX
 PF 13-SEP-2001; 2001US-00951061.
 XX
 PR 20-NOV-1990; 90US-00621614.
 PR 07-MAR-1991; 91US-00666056.
 PR 11-JUN-1991; 91US-00713967.
 PR 22-OCT-1991; 91US-00776867.
 PR 06-MAR-1992; 92US-00847951.
 PR 31-AUG-1992; 92US-00938283.
 PR 08-JUN-1993; 93US-00073962.
 PR 12-AUG-1993; 93US-00105483.
 PR 06-APR-1994; 94US-00224657.
 PR 15-JUL-1999; 99US-00354138.
 XX
 XX (AVET) AVENTIS PASTEUR.
 PA
 PA Paolletti E, Tartaglia J, Taylor J, Gettig R;
 PI
 DR WPI; 2003-567445/53.
 XX
 PT New recombinant viruses comprising exogenous DNA encoding rabies
 PT glycoprotein G useful for eliciting protective immunity against rabies
 PT virus in a carnivore.
 XX
 XX Example 20; SEQ ID NO 104; 93pp; English.
 XX
 CC The invention relates to recombinant vaccinia and canaripox viruses
 CC comprising exogenous DNA encoding rabies glycoprotein G in a nonessential
 CC region of the virus genome. Also included are a recombinant vaccinia virus
 CC (comprising exogenous DNA encoding rabies glycoprotein G in a
 CC nonessential region of the virus genome, where at least one open reading
 CC frame (ORF) selected from J2, B13, +B14R, A26L, 156R, CTL-R1L, and 14L is
 CC deleted from the virus), a recombinant canaripox virus (produced by
 CC attenuation through multiple serial passages on chick embryo fibroblasts,
 CC subjecting a master seed from to successive plaque purifications under
 CC agar and amplifying a plaque clone through multiple additional passages,
 CC where the virus contains exogenous DNA encoding rabies glycoprotein G in
 CC a nonessential region of the virus genome), inducing an antigenic or
 CC immunological response in a carnivore against rabies virus (by
 CC administering to the dog, cat or other carnivore a composition comprising
 CC the virus above in a mixture with a carrier), expressing a gene product
 CC in a cell cultured in vitro by introducing into the cell a virus of the

CC invention. One or more (optionally all) ORFs selected from a thymidine
 CC kinase gene, a haemorrhagic region, an A type inclusion body, a
 CC haemagglutinin gene, a host range region, and a ribonucleotide reductase
 CC large subunit gene, may also be deleted. The attenuated Vaccinia virus is
 CC termed a NYAVAC virus. The attenuated canarypox virus is termed ALVAC
 CC TROVAC. The recombinant viruses are useful as vaccines for protecting a
 CC dog, cat or other carnivore against rabies. The modified recombinant
 CC viruses are effective as vaccines and are safer than some other
 CC recombinant viruses due to the deletion of genes affecting virulence that
 CC are not essential for virus growth in tissue culture. The present
 CC sequence is an oligonucleotide or primer used in the construction of the
 CC attenuated canarypox viruses of the invention.

SQ Sequence 15 BP; 2 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.2%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 314 CGAGGAGTCCCG 325
 Db 12 CGAGGAGTCCCG 1

RESULT 386

ID AAF95086 standard; DNA; 16 BP.
 AC AAF95086;

DT 23-MAY-2001 (first entry)
 XX

DE Wild-type capture oligonucleotide #13.
 XX

KM Tubercle bacillus; drug sensitivity; drug resistance; rifampicin;
 KM streptomycin; kanamycin; isoniazid; ethambutol; rpoB gene; rrs gene;
 KM rpsL gene; inhA gene; katG gene; embB gene; probe; PCR primer; ss.
 XX

OS Mycobacterium tuberculosis.
 XX

PN EP1076099-A2.
 XX

PD 14-FEB-2001.
 XX

PF 02-AUG-2000; 2000EP-00306563.
 XX

PR 03-AUG-1999; 99JP-00220357.
 XX

PA (NISN) NISSHINO IND INC.
 PA (SYST-) SYSTEM RES INC.
 XX

P1 Suzuki Y, Nishida M, Takenishi S;
 XX

WPI; 2001-24696/26.
 DR

PT New oligonucleotides, nucleic acid probes and primers are useful for
 PT differentiating drug-resistance and determining infection with tubercle
 PT bacilli.
 XX

PS Claim 21; Page 40; 114pp; English.
 XX

CC The present invention relates to oligonucleotides based on nucleotide
 CC sequences obtained from both wild-type tubercle bacilli (MTB) that are
 CC susceptible to a drug and mutant-type tubercle bacilli (MTB) that are
 CC resistant to a drug. The drugs used in the present invention are
 CC rifampicin (RFP), streptomycin (SM), kanamycin (KM), isoniazid (INH) and
 CC ethambutol (EB). The rpoB gene is responsible for resistance to RFP; the
 CC rrs gene is responsible for resistance to SM and KM; the rpsL gene is
 CC responsible for resistance to INH; the katG gene is responsible for
 CC resistance to INH; the inhA gene is responsible for resistance to INH;
 CC and the embB gene is responsible for resistance to EB. The present
 CC invention also relates to nucleic acid probes having part of a nucleotide

CC sequence of tubercle bacilli (TB) responsible for drug resistance and
 CC primers used to generate the probes. The present sequence is an
 CC oligonucleotide of the present invention. The oligonucleotides of the
 CC present invention can be used to enable the differentiation of drug
 CC resistance and the determination of infection with tubercle bacilli
 CC simultaneously
 XX

SQ Sequence 16 BP; 3 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 12; DB 1; Length 16;
 Best Local Similarity 100.0%; Pred. No. 3.4e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 182 GAAGACCTGCC 193
 Db 4 GAAGACCTGCC 15

RESULT 387

ID ACC47284 standard; DNA; 20 BP.
 AC ACC47284;

DT 11-AUG-2003 (first entry)
 XX

DE Human apolipoprotein(a) mRNA inhibiting antisense oligo ISIS 144367.
 XX

KM Apolipoprotein(a); antiarteriosclerotic; cardiant; gene therapy; human;
 KM antisense; ss.
 XX

OS Synthetic.
 OS Homo sapiens.
 XX

PN M02003014307-A2.
 XX

PD 20-FEB-2003.
 XX

PF 05-AUG-2002; 2002MO-US024920.
 XX

PR 07-AUG-2001; 2001US-00923515.
 XX

PA (ISIS-) ISIS PHARM INC.
 XX

PI Crooke RM, Graham MJ;
 XX

DR WPI; 2003-256565/25.
 XX

PT New antisense compound, useful for preparing a composition for treating
 PT abnormal lipid or cholesterol metabolism, atherosclerosis or
 PT cardiovascular disease.
 XX

PS Claim 3; Page 87; 120pp; English.
 XX

CC The invention relates to a new compound, 8-50 nucleobases in length
 CC targeted to a nucleic acid molecule encoding human apolipoprotein(a),
 CC specifically hybridizes with and inhibits the expression of human
 CC apolipoprotein(a). The antisense compounds are useful for preparing a
 CC composition for treating abnormal lipid or cholesterol metabolism,
 CC atherosclerosis or cardiovascular disease. Sequences ACC47284-318
 CC represent specific examples of chimeric antisense phosphorothioate
 CC oligonucleotides having 2'-MOE wings and a deoxy gap targeting human
 CC apolipoprotein(a) mRNA
 XX

SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.2%; Score 12; DB 1; Length 20;
 Best Local Similarity 75.0%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 294 GGAGCTCTTATGTTAA 313
 Db 1 GGAGCTCTTATGTTAA 20

RESULT 388
 AAT55730/C
 ID AAT55730 standard; RNA; 15 BP.
 XX
 AC AAT55730;
 XX
 DT 25-MAR-2003 (revised)
 DT 25-MAR-1997 (first entry)
 XX
 DE Human TNF-alpha hammerhead ribozyme target sequence (nt position 1091).
 XX
 KM Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
 KM gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
 KM intercellular adhesion molecule; rel A; tumour necrosis factor;
 KM TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
 KM translocation; chronic myelogenous leukaemia; CML; cancer;
 KM Philadelphia chromosome; inflammation; autoimmune disease;
 KM atherosclerosis; myocardial infarction; stroke; restenosis;
 KM transplant rejection; rheumatoid arthritis; psoriasis;
 KM myocardial ischaemia; Kawasaki disease; septic shock; HIV;
 KM human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
 ss.
 XX Homo sapiens.
 OS
 XX
 PN W09523225-A2.
 XX
 PD 31-AUG-1995.
 XX
 PF 23-FEB-1995; 95WO-IB000156.
 XX
 PR 23-FEB-1994; 94US-00201109.
 PR 29-MAR-1994; 94US-00218934.
 PR 04-APR-1994; 94US-00222795.
 PR 07-APR-1994; 94US-00224483.
 PR 15-APR-1994; 94US-00227958.
 PR 15-APR-1994; 94US-00228041.
 PR 18-MAY-1994; 94US-00245736.
 PR 06-JUL-1994; 94US-00291280.
 PR 15-AUG-1994; 94US-00291932.
 PR 16-AUG-1994; 94US-00291433.
 PR 17-AUG-1994; 94US-00292620.
 PR 19-AUG-1994; 94US-00293520.
 PR 02-SEP-1994; 94US-00300000.
 PR 08-SEP-1994; 94US-00303039.
 PR 23-SEP-1994; 94US-00311486.
 PR 23-SEP-1994; 94US-00311749.
 PR 28-SEP-1994; 94US-00314397.
 PR 03-OCT-1994; 94US-00316771.
 PR 07-OCT-1994; 94US-00319492.
 PR 11-OCT-1994; 94US-00321993.
 PR 04-NOV-1994; 94US-00334847.
 PR 10-NOV-1994; 94US-00337608.
 PR 28-NOV-1994; 94US-00345516.
 PR 16-DEC-1994; 94US-00357577.
 PR 23-DEC-1994; 94US-00363233.
 PR 30-JAN-1995; 95US-00380734.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LM,
 PI Grimm S, Kapelsky A, Kisich K, Natulic-Adamic J, McSwiggen JA,
 PI Modak A, Pavco P, Bejlegman L, Sullivan SM, Sweedler D, Thompson JD,
 PI Tracz D, Usman N, Wincott FE, Woolf T;
 XX
 XX WPI; 1995-351090/45.
 XX
 XX Ribozymes having modified bases and methods for producing them - for use
 PT in inhibiting disease related genes.
 XX
 PS Claim 2; Page 242; 407pp; English.

XX
 CC The present sequence represents a preferred target sequence for an
 CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves TNF-alpha mRNA at
 CC the nucleotide base position indicated in the DE line. Regions of the
 CC mRNA that do not form secondary folding structures and that contain
 CC potential hammerhead and hairpin ribozyme cleavage sites were identified
 CC by computer analysis. Ribozymes directed against these mRNA sequences
 CC were designed and synthesised with modifications that improve their
 CC nuclease resistance. The ribozymes are designed to cleave the target
 CC sequences and thereby inhibit TNF-alpha expression, making them
 CC potentially useful for treating rheumatoid arthritis, septic shock and
 CC other inflammatory disorders including psoriasis, as well as for
 CC treatment of AIDS. (Updated on 25-MAR-2003 to correct PI field.)
 XX
 SQ Sequence 15 BP; 1 A; 3 C; 5 G; 0 T; 6 U; 0 Other;
 Query Match 0.2%; Score 11.6; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 3.1e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Oy 31 CTGGCCAGTCCCA 45
 Db 15 CTGGCCAGACCA 1
 RESULT 389
 AAT37611
 ID AAT37611 standard; mRNA; 15 BP.
 XX
 AC AAT37611;
 XX
 DT 11-NOV-1996 (first entry)
 XX
 DE Apo(a) mRNA (nt. pos. 12650) hammerhead ribozyme target sequence.
 XX
 KM Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 KM hammerhead ribozyme; target sequence; diagnosis; treatment;
 KM lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 KM restenosis; heart disease; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN W09609392-A1.
 XX
 PD 28-MAR-1996.
 XX
 PF 21-SEP-1995; 95WO-US011995.
 XX
 PR 23-SEP-1994; 94US-00311760.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Stinchcomb DT, McSwiggen J, Newton RS, Ramharack R;
 XX
 XX WPI; 1996-188454/19.
 XX
 XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.
 XX
 PS Claim 2; Page 18; 37pp; English.

A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a) (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms complementary to the present sequence (nucleotide position 12650). The ribozyme blocks to some extent apo(a) expression, and can therefore be used to diagnose or treat conditions related to lipoprotein (a) levels, e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart disease. PCR was used to generate a substrate for T7 RNA polymerase transcription from human apo(a) cDNA clones. Labelled transcripts were synthesised in vitro to form 2 templates. The oligonucleotides and labelled transcripts were annealed, RNaseH added and the mixts. incubated. After a designated time the reactions were stopped, and RNA

CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen
XX
SQ Sequence 15 BP; 5 A; 5 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 3.1e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 355 CAAATGCTCAGACCA 369
Db 1 CGAUGCUCAGACCA 15

RESULT 390

AAT37569
ID AAT37569 standard; mRNA; 15 BP.

AC AAT37569;

DT 11-NOV-1996 (first entry)

XX Apo(a) mRNA (nt. pos. 11427) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW restenosis; heart disease; human; ss.

OS Homo sapiens.

XX W09609392-A1.

PD 28-MAR-1996.

PF 21-SEP-1995; 95WO-US011995.

PR 23-SEP-1994; 94US-00311760.

PA (RIBO-) RIBOZYME PHARM INC.

PI Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;

DR WPI; 1996-188454/19.

PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to lp(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.

PS Claim 2; Page 18; 37pp; English.

CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 11427). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase
CC transcripction from human apo(a) cDNA clones. Labelled transcripts were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed, RNaseH added and the mixts.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen

XX SQ Sequence 15 BP; 3 A; 7 C; 1 G; 0 T; 4 U; 0 Other;

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 3.1e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 500 CGAATCTACTCCACCA 514
Db 1 GCUCAUUUCACCA 15

RESULT 391

AAT37721
ID AAT37721 standard; mRNA; 15 BP.

AC AAT37721;

DT 13-NOV-1996 (first entry)

XX Apo(a) mRNA (nt. pos. 11305) hammerhead ribozyme target sequence.

XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW restenosis; heart disease; monkey; ss.

OS Cebus apella.

XX W09609392-A1.

PD 28-MAR-1996.

PF 21-SEP-1995; 95WO-US011995.

PR 23-SEP-1994; 94US-00311760.

PA (RIBO-) RIBOZYME PHARM INC.

PI Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;

DR WPI; 1996-188454/19.

PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to lp(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.

PS Claim 3; Page 21; 37pp; English.

CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 11305). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase
CC transcripction from monkey apo(a) cDNA clones. Labelled transcripts were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed, RNaseH added and the mixts.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen

XX SQ Sequence 15 BP; 2 A; 6 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 3.1e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 496 CGAGGCACATCTCC 510
Db 1 CGAGGCUCAUUUC 15

RESULT 392

AAT37596
ID AAT37596 standard; mRNA; 15 BP.

AC AAT37596;

[illegible]

OS	Synthetic.
XX	2-7+3T _A
PN	WO9620166-A2.
XX	
PD	14-MAY-1998.
XX	
Pf	06-NOV-1997; 97WO-USO20444.
XX	
PR	06-NOV-1996; 96US-.007444A81.
PR	06-NOV-1996; 96US-.007445S80.
PR	06-NOV-1996; 96US-.007460J36.
PR	06-NOV-1996; 96US-.007460S55.
PR	23-JAN-1997; 97US-.007869E88.
PR	23-JAN-1997; 97US-.007869E39.
PR	19-SEP-1997; 97US-.009333782.
PR	08-OCT-1997; 97US-.00947801.
XX	
PA	(SEQU-) SEQUENOM INC.
PI	Koester H, Tang K, Fu D, Sigert CW, Little DP, Higgins GS;
PI	Braun A, Damhoffler-Demar B, Jurinke C, Van Den Boom D, Xiang G;
PI	Lough DM;
DR	WPI, 1998-286975/25.
XX	
PT	Sequencing nucleic acid by mass spectrometric analysis - for detecting
PT	nucleic acids, telomerase activity, oncogene mutations, or cancer-
PT	specific sequences, for diagnosis of disease.
PS	Disclosure, Page 322; 478pp; English.
XX	
CC	A process has been developed for determining the sequence of a target
CC	nucleic acid. The process comprises: (I) generating at least two
CC	fragments (F) from the target nucleic acid; and (II) analysing F by mass
CC	spectrometry (MS). The sequences in AAU939483 to AAU93592 are specifically
CC	claimed primers for use in the mass spectrometric analysis of the above
CC	process. The process is used to detect genetic diseases (e.g.
CC	haemophilia, thalassemia, Duchenne muscular dystrophy, Alzheimer's
CC	disease, cystic fibrosis and many others) or chromosomal abnormalities
CC	(or predisposition); infections and cancers; also for establishing
CC	identity and heredity. Particular applications are diagnosis of
CC	neuroblastoma, detecting telomerase, determining family relationships and
CC	HLA compatibility, and in genetic fingerprinting. Compared with known
CC	methods using MS, this process requires fewer specific reagents and is
CC	better suited to automation. Extended primers are shorter; primer
CC	annealing is more efficient and the process allows detection of many
CC	sequences simultaneously. The present sequence represent an
CC	oligonucleotide from the present invention, which is not actually
CC	specified within the specification, only within the sequence listing
CC	
SO	Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;
QY	
Query Match	0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity	86.7%; Pred. No.3.le+02;
Matches 13; Conservative	0; Mismatches 2; Indels 0; Gaps 0;
Db	321 TCCCAGTCACGATG 335 15 TTCACGACTCAGTG 1
RESULT 394	
AAU93847.C	
ID	AAU93847 standard; RNA; 15 BP.
XX	
AC	AAU93847;
XX	
DT	18-FEB-1999 (first entry)
XX	
DS	Target sequence with sequence homology to c-rafa and A-rafa position 2400.
XX	
KW	Human; c-rafa; A-rafa; hammerhead ribozyme; hairpin ribozyme; target; substrate; catalyst; modulation; expression; raf gene; delivery;

screening; identification; synthesis; deprotection; purification; cancer; inflammation; psoriasis; non-hepatic ascites; infection; genetic drift; resection; rheumatoid arthritis; ss.

OS Homo sapiens.

XX WO9850530-A2.

XX

XX 12-NOV-1998.

XX

XX 05-MAY-1998; 98WO-US009249.

XX

XX 09-MAY-1997; 97US-0046059P.

XX 09-JUN-1997; 97US-0049002P.

XX 03-JUL-1997; 97US-0051718P.

XX 22-AUG-1997; 97US-0056808P.

XX 02-OCT-1997; 97US-0061321P.

XX 02-OCT-1997; 97US-0061324P.

XX 05-NOV-1997; 97US-0064866P.

XX 19-DEC-1997; 97US-0068212P.

XX

XX (RIBO-) RIBOZYME PHARM INC.

XX

XX Jarvis T, Marulic-Adamic J, Reynolds M, Kisich K, Bellon L,

XX Parry T, Belgeiman L, Mcswigen JA, Karpelisky A, Burgin A;

XX Thompson J, Workman CT, Beaudry A, Sweedler D;

XX WPI; 1999-009494/01.

XX

XX Identifying new catalytic nucleic acid that modulates selected processes

XX - especially ribozymes that cleave Raf RNA for treating cancer,

XX resection, and also new ribozymes and modified nucleoside triphosphates

XX used as antiviral agents and synchons.

XX

XX Claim 180; Page 176; 259pp; English.

XX

XX A method has been developed for the identification of a nucleic acid

XX capable of modulating a process in a biological system. The method

XX comprises: (a) introducing into the system a random library of nucleic

XX acid catalysts (NAC) having a substrate binding domain (SBD), comprising

XX a random sequence, and a catalytic domain (CD); and (b) identifying NAC

XX in systems where modulation has occurred and/or determining the sequence

XX of at least part of the SBDs in such systems. Nucleic acid molecules with

XX endonuclease activity and catalytic activity, from the present invention,

XX are used to modulate gene expression in plant and mammalian cells and to

XX cleave target nucleic acid, particularly for treating systemic diseases

XX caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic

XX ascites and infection. They may also be used to detect genetic drift and

XX mutations in diseased cells and to determine c-raf RNA. Specifically NACs

XX with RNA-cleaving activity that modulate expression of the Raf gene, are

XX used to treat cancer, resection, psoriasis or rheumatoid arthritis, or

XX generally any condition associated with the level of c-raf. Introduction

XX of sugar/phosphate modifications increases stability against nuclease and

XX activity. AAV90922 to AAV93877 represent NACs that can be used in the

XX method, specifically for modulating the expression of a Raf gene

XX

XX Sequence 15 BP; 0 A; 4 C; 3 G; 0 T; 8 U; 0 Other;

XX

XX Query Match 0.2%; Score 11.8; DB 1; Length 15;

XX Best Local Similarity 86.7%; Pred. No. 3.1e+02;

XX Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX

XX 363 AGACGCGAAGGAGC 377

XX |||||

XX 15 AGACACAAAAGGAGC 1

XX

XX RESULT 395

XX AAZ07074/c

XX ID AAZ07074 standard; DNA; 15 BP.

XX

XX AC AAZ07074;

XX

DT 07-OCT-1999 (first entry)

XX

XX Peptide nucleic acid oligomer #4.

XX

XX Peptide nucleic acid; PNA; polymer; solubility; modulation; synthesis;

XX purification; analysis; ss.

XX

XX Synthetic.

XX

XX Key Location/Qualifiers

XX modified_base 1

XX /*tag= a

XX /note= "a is modified to Flu-Ob-a where Flu is 5-(6)-

XX carboxyfluorescein, O is 8-amino-3,6-dioxoacetic acid

XX and E is an uncharged ether modifying moiety"

XX modified_base 15

XX /*tag= b

XX /note= "a is modified to a-E-NH2, which is an amidated

XX uncharged ether modifying moiety"

XX

XX WO9937670-A1.

XX

XX 29-JUL-1999.

XX

XX 19-JAN-1999; 99WO-US001024.

XX

XX 27-JAN-1998; 98US-0072772P.

XX 04-JAN-1999; 99US-00225048.

XX

XX (BOST-) BOSTON PROBES INC.

XX

XX G1dea BD, Coull JM;

XX WPI; 1999-479032/40.

XX

XX Branched compositions for improving the solubility of synthetic polymers

XX or minimizing or eliminating polymer self-aggregation, particularly in

XX peptide nucleic acids.

XX

XX Example 12; Page 40; 81pp; English.

XX

XX The present invention describes a branched composition (I) which is

XX useful for improving the solubility of synthetic polymers (II) or aids in

XX minimizing or eliminating self-aggregation of (II), where (II) is a

XX nucleic acid (or analogue), peptide, peptide nucleic acid (PNA), or a

XX polyamide, chimera or a linked polymer. Modification of (II) by (I) can

XX facilitate synthesis, purification and analysis of many insoluble

XX polymers, and particularly purine-rich PNA polymers labeled with

XX hydrophobic labels. The products can be used in research, diagnostic and

XX therapeutic applications. The present sequence represents a PNA used in

XX the exemplification of the present invention

XX

XX Sequence 15 BP; 10 A; 0 C; 5 G; 0 T; 0 U; 0 Other;

XX

XX Query Match 0.2%; Score 11.8; DB 1; Length 15;

XX Best Local Similarity 86.7%; Pred. No. 3.1e+02;

XX Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX

XX 66 TCTTCACTCTTTT 80

XX |||||

XX 15 TCTTCTTCTTCTT 1

XX

XX RESULT 396

XX AAF49718/c

XX ID AAF49718 standard; DNA; 15 BP.

XX

XX AC AAF49718;

XX

XX 30-MAR-2001 (first entry)

XX

XX DE IGF-I oligonucleotide #678.

XX

KM Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KM cytoskeletal; dermatological; cardiant; virucide; ophthalmological; keloid;
 KM skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KM growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KM hyperneovascular condition; hyperplasia; kidney disease;
 KM neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN W0200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURDOCH CHILDRENS RES INST.
 XX
 PI Wright CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 8; Page 65; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 CC
 XX
 SO Sequence 15 BP; 5 A; 5 C; 3 G; 2 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 3.1e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 DB 10 GGACACACTTCTCG 24
 15 GGACACACTTCTCG 1
 XX
 RESULT 397
 AAF51714/C
 ID AAF51714 standard; DNA; 15 BP.
 XX
 AC AAF51714;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGF-I oligonucleotide #2674.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytoskeletal; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW hyperneovascular condition; hyperplasia; kidney disease;

KM growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KM hyperneovascular condition; hyperplasia; kidney disease;
 KM neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN W0200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURDOCH CHILDRENS RES INST.
 XX
 PI Wright CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 8; Page 78; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 CC
 XX
 SO Sequence 15 BP; 3 A; 3 C; 5 G; 4 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 3.1e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 DB 10 GGACACACTTCTCG 24
 15 GGACACACTTCTCG 1
 XX
 RESULT 398
 AAF53074
 ID AAF53074 standard; DNA; 15 BP.
 XX
 AC AAF53074;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGF-I oligonucleotide #4034.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytoskeletal; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

```

OS XX Homo sapiens.
XX XX
XX XX WO200078341-A1.
XX XX
XX XX 28-DEC-2000.
XX XX
XX XX 21-JUN-2000; 2000WO-AU000693.
XX XX
XX XX 21-JUN-1999; 99US-0140345P.
XX XX
XX XX (MURDOCH CHILDRENS RES INST.
XX XX
XX XX Wright CJ, Werther GA, Edmondson SR;
XX XX WPI; 2001-041421/05.
XX XX
XX XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX XX inhibits or reduces growth factor mediated cell proliferation and/or
XX XX inflammation.
XX XX
XX XX Example 8; Page 87; 201pp; English.
XX XX
XX XX The present invention relates to a method for ameliorating the effects of
XX XX skin disorders. The method comprises contacting the skin with an
XX XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX XX inhibiting or reducing growth factor mediated cell proliferation,
XX XX inflammation and/or other disorders. The present sequence is an
XX XX oligonucleotide which can be used to design the antisense
XX XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX XX ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
XX XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX XX hyperneovascular condition such as a neovascular condition of the retina,
XX XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX XX disease, kidney disease, hyperproliferation of the inside of blood
XX XX vessels or any other hyperplasia
XX XX
XX XX Sequence 15 BP; 0 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
XX XX
XX XX Query Match 0.2%; Score 11.8; DB 1; Length 15;
XX XX Best Local Similarity 86.7%; Pred. No. 3.1e+02;
XX XX Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX XX
XX XX 452 GGGCTGGGGTGGAG 466
XX XX 1 GGGCTGGGGTGGAG 15
XX XX
XX XX RESULT 399
XX XX AAF53632/C
XX XX ID AAF53632 standard; DNA; 15 BP.
XX XX
XX XX AAF53632;
XX XX
XX XX 30-MAR-2001 (first entry)
XX XX
XX XX IGF-1 oligonucleotide #4592.
XX XX
XX XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX XX cytostatic; dermatological; cardiant; vincide; ophthalmological; keloid;
XX XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX XX growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
XX XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX XX hyperneovascular condition of the retina; ss.
XX XX
XX XX Homo sapiens.
XX XX
XX XX WO200078341-A1.

```

```

XX XX
XX XX 28-DEC-2000.
XX XX
XX XX 21-JUN-2000; 2000WO-AU000693.
XX XX
XX XX 21-JUN-1999; 99US-0140345P.
XX XX
XX XX (MURDOCH CHILDRENS RES INST.
XX XX
XX XX Wright CJ, Werther GA, Edmondson SR;
XX XX WPI; 2001-041421/05.
XX XX
XX XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX XX inhibits or reduces growth factor mediated cell proliferation and/or
XX XX inflammation.
XX XX
XX XX Example 8; Page 90; 201pp; English.
XX XX
XX XX The present invention relates to a method for ameliorating the effects of
XX XX skin disorders. The method comprises contacting the skin with an
XX XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX XX inhibiting or reducing growth factor mediated cell proliferation,
XX XX inflammation and/or other disorders. The present sequence is an
XX XX oligonucleotide which can be used to design the antisense
XX XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX XX ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
XX XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX XX hyperneovascular condition such as a neovascular condition of the retina,
XX XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX XX disease, kidney disease, hyperproliferation of the inside of blood
XX XX vessels or any other hyperplasia
XX XX
XX XX Sequence 15 BP; 3 A; 9 C; 2 G; 1 T; 0 U; 0 Other;
XX XX
XX XX Query Match 0.2%; Score 11.8; DB 1; Length 15;
XX XX Best Local Similarity 86.7%; Pred. No. 3.1e+02;
XX XX Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX XX
XX XX 325 GGTGTCAAGTGGAG 339
XX XX 15 GGTGTCAAGCGGGTG 1
XX XX
XX XX RESULT 400
XX XX AAF46987/C
XX XX ID AAF46987 standard; DNA; 15 BP.
XX XX
XX XX AAF46987;
XX XX
XX XX 30-MAR-2001 (first entry)
XX XX
XX XX IGFBP3 oligonucleotide #407.
XX XX
XX XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX XX cytostatic; dermatological; cardiant; vincide; ophthalmological; keloid;
XX XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX XX growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
XX XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX XX hyperneovascular condition of the retina; ss.
XX XX
XX XX Homo sapiens.
XX XX
XX XX WO200078341-A1.
XX XX
XX XX 28-DEC-2000.
XX XX
XX XX 21-JUN-2000; 2000WO-AU000693.

```



```

XX PR 21-JUN-1999; 99US-0140345P.
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX PA Wright CJ, Werther GA, Edmondson SR;
XX PI WPI; 2001-041421/05.
XX DR
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX PS Example 7; Page 46; 201pp; English.
XX CC The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisense
XX CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX CC F45161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX SO Sequence 15 BP; 2 A; 5 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 377 CTGCGCTGCGGCTTC 391
Db 15 CAGCGGTGCGGCTTC 1

RESULT 401
AAF52290/C
ID AAF52290 standard; DNA; 15 BP.
XX AC AAF52290;
XX DT 30-MAR-2001 (first entry)
XX DE IGF-I oligonucleotide #3250.
XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX KW cytosaratic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX KW growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
XX KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX KW hyperneovascular condition; hyperplasia; kidney disease;
XX KW neovascular condition of the retina; ss.
XX OS Homo sapiens.
XX PN WO200078341-A1.
XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000WO-AU000693.
XX PR 21-JUN-1999; 99US-0140345P.
XX PA (MURD-) MURDOCH CHILDRENS RES INST.

```

```

XX PI Wright CJ, Werther GA, Edmondson SR;
XX DR WPI; 2001-041421/05.
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX PS Example 8; Page 82; 201pp; English.
XX CC The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisense
XX CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX CC F45161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX SO Sequence 15 BP; 3 A; 5 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CTGGGATTGGGACAC 15
Db 15 CTGGCCTTGGGACAC 1

RESULT 402
AAF50542/C
ID AAF50542 standard; DNA; 15 BP.
XX AC AAF50542;
XX DT 30-MAR-2001 (first entry)
XX DE IGF-I oligonucleotide #1502.
XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX KW cytosaratic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX KW growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
XX KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX KW hyperneovascular condition; hyperplasia; kidney disease;
XX KW neovascular condition of the retina; ss.
XX OS Homo sapiens.
XX PN WO200078341-A1.
XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000WO-AU000693.
XX PR 21-JUN-1999; 99US-0140345P.
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX PI Wright CJ, Werther GA, Edmondson SR;
XX DR WPI; 2001-041421/05.

```

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.

PS Example 8; Page 70; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor (IGF)-1
CC receptor, IGF binding protein (IGFBP)-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF4511 and AAF4513-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia

XX Sequence 15 BP; 3 A; 4 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.8; DB 1; Length 15;

Best Local Similarity 86.7%; Pred. No. 3.1e+02;

Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 171 CACTGTACAGGAG 185

Db 15 CACTTTCACAGAGG 1

RESULT 403

AAF50839/C

ID AAF50839 standard; DNA; 15 BP.

AC AAF50839;

DT 30-MAR-2001 (first entry)

XX IGF-I oligonucleotide #1799.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytoskeletal; dermatological; cardiac; vitreous; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.

XX Homo sapiens.

OS WO200078341-A1.

XX 28-DEC-2000.

PD 21-JUN-2000; 2000WO-AU000693.

PF 21-JUN-1999; 99US-0140345P.

PR (MURD-) MURDOCH CHILDRENS RES INST.

XX Wraight CJ, Werther GA, Edmondson SR;

PI WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering

PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that

PT inhibits or reduces growth factor mediated cell proliferation and/or

PT Inflammation.

XX Example 8; Page 72; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor (IGF)-1
CC receptor, IGF binding protein (IGFBP)-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF4511 and AAF4513-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia

XX Sequence 15 BP; 2 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.8; DB 1; Length 15;

Best Local Similarity 86.7%; Pred. No. 3.1e+02;

Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 129 CTACATGGTGATGG 143

Db 15 CCACCATGGTGAGGG 1

RESULT 404

AAF50836/C

ID AAF50836 standard; DNA; 15 BP.

AC AAF50836;

DT 30-MAR-2001 (first entry)

XX IGF-I oligonucleotide #1796.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytoskeletal; dermatological; cardiac; vitreous; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.

XX Homo sapiens.

OS WO200078341-A1.

XX 28-DEC-2000.

PD 21-JUN-2000; 2000WO-AU000693.

PF 21-JUN-1999; 99US-0140345P.

PR (MURD-) MURDOCH CHILDRENS RES INST.

XX Wraight CJ, Werther GA, Edmondson SR;

PI WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering

PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that

PT inhibits or reduces growth factor mediated cell proliferation and/or

PT inflammation.

XX Example 8; Page 72; 201pp; English.

CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrheoa, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia

XX Sequence 15 BP; 0 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 3.1e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 289 GCTGTGGCAGCTCTCT 303
 Db 1 GCTGTGGGAGCTCTCT 15

RESULT 407

AAF52128
 ID AAF52128 standard; DNA; 15 BP.

AC AAF52128;

DT 30-MAR-2001 (first entry)

DE IGF-1 oligonucleotide #3088.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cyostatic; dermatological; cardiant; vitruclide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrheoa; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

XX Homo sapiens.

XX MO200078341-A1.

XX 28-DEC-2000.

XX 21-JUN-2000; 2000MO-AU000693.

XX 21-JUN-1999; 99US-0140345P.

XX (MURD-) MURDOCH CHILDRENS RES INST.

XX Wright CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.

XX Example 8; Page 81; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense

CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrheoa, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,

CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia

XX Sequence 15 BP; 5 A; 2 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 3.1e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 182 GAAGACCTGGCAG 196
 Db 1 GAAGAGTTGCCAG 15

RESULT 408

AAF47405
 ID AAF47405 standard; DNA; 15 BP.

XX AAF47405;

DT 30-MAR-2001 (first entry)

DE IGFBP3 oligonucleotide #825.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cyostatic; dermatological; cardiant; vitruclide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrheoa; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

XX Homo sapiens.

XX MO200078341-A1.

XX 28-DEC-2000.

XX 21-JUN-2000; 2000MO-AU000693.

XX 21-JUN-1999; 99US-0140345P.

XX (MURD-) MURDOCH CHILDRENS RES INST.

XX Wright CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.

XX Example 7; Page 49; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense

CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrheoa, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia

Sequence 15 BP; 6 A; 2 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 172 ACTGTCACAGGAGG 186
DB 1 ACTGTGACAGAGG 15

RESULT 409
AAFS0837/c
ID AAF50837 standard; DNA; 15 BP.
AC AAF50837;
XX 30-MAR-2001 (first entry)
DT IGF-I oligonucleotide #1797.
DE
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX Homo sapiens.
OS
XX MO200078341-A1.
PN
XX 28-DEC-2000.
PD
XX 21-JUN-2000; 2000WO-AU00693.
PF
XX 21-JUN-1999; 99US-0140345P.
PR
XX (MURDOCH CHILDRENS RES INST.
PA
XX (MURDOCH CHILDRENS RES INST.
PI Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
DR
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 8; Page 72; 201pp; English.
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotide of the present invention (see AAF45151 and AAF45153-
XX P45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia

Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.1e+02;

Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 131 ACCATGCGATGAGC 145
DB 15 ACCATGCGATGAGGTC 1

RESULT 410
AAFS3635/c
ID AAF53635 standard; DNA; 15 BP.
AC AAF53635;
XX 30-MAR-2001 (first entry)
DT IGF-I oligonucleotide #4595.
DE
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX Homo sapiens.
OS
XX MO200078341-A1.
PN
XX 28-DEC-2000.
PD
XX 21-JUN-2000; 2000WO-AU00693.
PF
XX 21-JUN-1999; 99US-0140345P.
PR
XX (MURDOCH CHILDRENS RES INST.
PA
XX (MURDOCH CHILDRENS RES INST.
PI Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
DR
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 8; Page 90; 201pp; English.
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotide of the present invention (see AAF45151 and AAF45153-
XX P45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia

Sequence 15 BP; 2 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 15 CACGGTGCAGCCG 1

RESULT 411
AAF69969
ID AAF69969 standard; DNA; 15 BP.
XX
XX AAF69969;
XX
XX 18-APR-2001 (first entry)
XX
XX Human TNFRSF1B gene ASO probe, SEQ ID NO: 25.
DE
XX
XX Human; TNFRSF1B; osteoclastogenesis inhibitory factor;
KW single nucleotide polymorphism; SNP; osteoclast recruitment;
KW osteoclast function; osteoporosis; metastatic bone disease;
KW Paget's disease; rheumatoid arthritis; periodontal bone disease; ASO;
KW allele-specific oligonucleotide; probe; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200104137-A1.
PN
XX 18-JAN-2001.
PD
XX
XX 10-JUL-2000; 2000WO-US018803.
PF
XX
XX 09-JUL-1999; 99US-0143020P.
PR
XX
XX (GENA-) GENA155ANCE PHARM INC.
PA
XX
XX Chew A, Denton RR, Duda A, Nandabalan K, Stephens JC;
PI WPI; 2001-147175/15.
XX
XX Human Osteoclastogenesis Inhibitory Factor nucleotides, comprising single
PT nucleotide polymorphisms, useful for studying e.g. osteoporosis, Paget's
PT disease and rheumatoid arthritis.
XX
XX
XX Claim 15; Page 21; 114pp; English.
PS
XX
XX The present sequence is a probe used to detect polymorphisms in the human
CC osteoclastogenesis inhibitory factor (TNFRSF1B). Polynucleotides
CC comprising one or more of twenty four novel single nucleotide
CC polymorphisms in the TNFRSF1B gene have been identified. TNFRSF1B
CC regulate osteoclast recruitment and function. An understanding of
CC variations in the gene should thus be useful in developing new therapies
CC for metabolic disorders caused by abnormal osteoclast recruitment and
CC function such as osteoporosis, metastatic bone disease, Paget's disease,
CC rheumatoid arthritis and periodontal bone disease
XX
XX Sequence 15 BP; 8 A; 2 C; 2 G; 3 T; 0 U; 0 Other;
SQ

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 221 AACATATAGACCA 235
Db 1 AACATATAGTACCA 15

RESULT 412
ABX03881
ID ABX03881 standard; DNA; 15 BP.
XX
XX ABX03881;
XX
XX 09-JAN-2003 (first entry)
DT
XX
XX F. nucleatum 16S rRNA fragment.
DE
XX
XX Detection; probe; diagnosis; oral disease; periodontitis; caries; therapy;
KW

KW polymorphism; virulence factor; antibiotic resistance gene; prognosis;
KW oral infection; detection; pathogen; coronary heart disease;
XX diabetic symptom; ss.
XX
XX Fusobacterium nucleatum.
XX
XX DE20110013-U1.
XX
XX 18-OCT-2001.
XX
XX 13-MAR-2001; 2001DE-02010013.
PF
XX
XX 13-MAR-2001; 2001DE-01012348.
PR
XX 13-MAR-2001; 2001DE-02010013.
XX
XX (ROET/) ROETGER A.
PA
XX
XX WPI; 2001-657777/76.
DR
XX
XX Oligonucleotide array, useful for diagnosing oral diseases, particularly
PT periodontitis, carries human or microbial reference sequences.
PT
XX
XX Claim 8; Page 16; 58pp; German.
PS
XX
XX This invention describes a novel nucleotide carrier with probes used for
CC diagnosis of oral diseases, particularly periodontitis, but also carries
CC especially to identify genetic predisposition (as indicated by
CC polymorphisms) to disease and to identify causative microorganisms or
CC their associated virulence factors and antibiotic resistance genes, e.g.
CC for selection of therapy and for prognosis. They are also useful for
CC research into oral infections. The carriers allow simultaneous detection
CC of both host and pathogen parameters, providing quickly and simply an
CC individual's periodontitis profile, including detection of pathogens that
CC are associated with increased risk of coronary heart diseases and/or
CC aggravation of diabetic symptoms, and of opportunistic pathogens.
CC ABX03870-ABX04044 represent DNA fragments used to illustrate the method
CC of the invention
XX
XX Sequence 15 BP; 4 A; 3 C; 6 G; 2 T; 0 U; 0 Other;
SQ

Query Match 0.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 105 GCAAGCCATGCT 119
Db 1 GCAAGCCGTAGCT 15

RESULT 413
AAF73827
ID AAF73827 standard; DNA; 15 BP.
XX
XX AAF73827;
XX
XX 30-APR-2001 (first entry)
DT
XX
XX Human SLC6A4 allele-specific oligonucleotide probe #9.
DE
XX
XX Solute carrier family 6 neurotransmitter transporter, section 4, SLC6A4,
KW genotyping; allele specific oligonucleotide; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200109161-A1.
PN
XX
XX 08-FEB-2001.
PD
XX
XX 31-JUL-2000; 2000WO-US020638.
PF
XX
XX 29-JUL-1999; 99US-0146290P.
PR
XX
XX (GENA-) GENA155ANCE PHARM INC.
PA

XX Denton RR, Duda A, Nandabalan K, Sanchis A, Stephens JC;
 XX WPI; 2001-123317/13.
 XX
 PT New isolated polynucleotide comprising a polymorphic variant for the
 PT solute carrier family 6 neurotransmitter transporter, serotonin member 4
 PT gene for identifying drugs for treating disorders related to expression
 PT of the protein.
 XX
 PS Claim 12; Page 19; 152pp; English.
 XX
 CC The present invention relates to a polymorphic variant of a reference
 CC sequence for the solute carrier family 6 neurotransmitter transporter,
 CC serotonin member 4 (SLC6A4) gene or a fragment of it or a sequence
 CC complementary to the first sequence. The invention is used in producing a
 CC recombinant organism that can be used to express SLC6A4 for protein
 CC structure analysis and binding studies. A composition comprising a
 CC genotyping oligonucleotide is used to detect a polymorphism in the SLC6A4
 CC gene.
 XX
 SQ Sequence 15 BP; 4 A; 5 C; 5 G; 1 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 3.1e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Oy 359 GCTCAGACGCCAGAG 373
 Db 1 GCTCAGACGCCAGAG 15
 RESULT 414
 ABK12188/C
 ID ABK12188 standard; DNA; 15 BP.
 XX
 AC ABK12188;
 XX
 DT 18-JUN-2002 (first entry)
 XX
 DE Human Tachykinin Receptor 1 allele specific oligonucleotide primer #9.
 XX
 KW Human; ss; primer; TACR1; Tachykinin receptor 1; chromosome 2; PCR; SNP;
 KW single nucleotide polymorphism; gene therapy; haplotype; genotype; pain;
 KW depression; vomiting; acute inflammatory diarrhoea; ASO;
 KW opiate addiction; drug screening; allele specific oligonucleotide.
 XX
 OS Homo sapiens.
 XX
 PN WO200216399-A2.
 XX
 PD 28-FEB-2002.
 XX
 PF 27-AUG-2001; 2001WO-US026663.
 XX
 PR 25-AUG-2000; 2000US-0227815P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Anastasio AE, Kazemi A;
 XX
 DR WPI; 2002-280907/32.
 XX
 PT Novel isolated polynucleotide which is a polymorphic variant of
 PT tachykinin receptor 1 (TACR1) gene useful for expressing TACR1 protein
 PT isoform used in screening drug candidates to treat pain, depression,
 PT vomiting.
 XX
 PS Claim 17; Page 14; 89pp; English.
 XX
 CC The invention relates to an isolated polynucleotide sequence which
 CC comprises a tachykinin receptor 1 (TACR1) isogene (SG) that is any one of
 CC 16 SG as given in specification, where each SG comprises specific regions

CC of the TACR1 genomic DNA appearing as ABK12169, and is defined by
 CC polymorphisms at positions (p) 3164, 3319, 3906, 4339, 4444, 92915,
 CC 94601, 94821, 94892, 94960. Also included are fragments of the TACR1
 CC isogenes and TACR1 CDNA, a transgenic non-human animal transformed with
 CC the TACR1 isogene or coding region, haplotyping (or genotyping) the TACR1
 CC of an individual by determining either the haplotype of one or both
 CC copies of the TACR1 gene, predicting the haplotype pair for the TACR1
 CC gene of an individual, identifying an association between a trait and a
 CC haplotype pair, an isolated oligonucleotide for detecting the
 CC polymorphisms, a computer system for storing and analysing polymorphism
 CC data and a genome anchoring system for TACR1 gene. The TACR1 isogene is useful
 CC for studying expression and function of TACR1 and expressing TACR1
 CC protein for use in screening for candidate drugs to treat diseases
 CC related to TACR1 activity. The polymorphism and haplotype data is useful
 CC for validating whether TACR1 is a suitable target for drugs to treat
 CC pain, depression, vomiting, acute inflammatory diarrhoea and opiate
 CC addiction, screening for such drugs and reducing bias in clinical trials
 CC of such drugs. The genotyping method is useful for determining whether an
 CC individual has one of the haplotype pairs. The haplotyping method is
 CC useful for improving efficiency and outcome of several steps in discovery
 CC and development of drugs for treating the diseases. The haplotyping
 CC method is also useful for validating TACR1 as a candidate target for
 CC treating a specific condition or disease predicted to be associated with
 CC TACR1 activity. The method is also useful for screening compounds to
 CC treat a specific condition or disease predicted to be associated with
 CC TACR1 activity. The methods are useful for identifying an association
 CC between susceptibility to a disease, staging of a disease, or response to
 CC a drug. The gene for TACR1 is located on human chromosome 2. The present
 CC sequence is an allele specific oligonucleotide (ASO) PCR primer used to
 CC detect polymorphisms in the TACR1 gene
 XX
 SQ Sequence 15 BP; 5 A; 3 C; 4 G; 2 T; 0 U; 1 Other;
 Query Match 0.2%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 3.1e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Oy 197 CTTGTCATCTATGA 211
 Db 15 CRTGTCCTCTATCA 1
 RESULT 415
 ABV72564/C
 ID ABV72564 standard; DNA; 15 BP.
 XX
 AC ABV72564;
 XX
 DT 12-FEB-2003 (first entry)
 XX
 DE Consensus sequence of methanol regulated promoters of yeast.
 XX
 KW Yeast; alcohol oxidase 1; AOX1; AOX2; promoter; formaldehyde; methanol;
 KW protein production; peroxisome biogenesis; ss.
 XX
 OS Synthetic.
 XX
 PN WO200281650-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 05-APR-2002; 2002WO-US012851.
 XX
 PR 05-APR-2001; 2001US-0281861P.
 XX
 PA (UYNE-) UNIV NEBRASKA.
 XX
 PI Inan M, Meagher MM, Benson AK;
 XX
 DR WPI; 2003-058528/05.
 XX
 PT Novel alcohol oxidase 1 regulatory nucleotide sequences useful for
 PT enhancing expression of genes of interest in a variety of host cells,

PT especially yeast cells.
 XX
 PS Disclosure; Fig 6; 66pp; English.
 CC The present sequence represents a consensus sequence of methanol
 CC regulated promoters of methylotrophic yeast. The specification describes
 CC 5' regulatory sequences within the alcohol oxidase I (AOX1) promoter
 CC region. AOX1 catalyses the oxidation of methanol to formaldehyde. The
 CC AOX1 promoter is an inducible promoter, primarily induced by methanol and
 CC starvation, and repressed in response to glucose and ethanol. The AOX1 5'
 CC regulatory sequences can be used to produce expression cassettes and
 CC vectors, which are useful for protein production. The regulatory
 CC sequences are useful to increase expression of genes of interest in a
 CC variety of host cells, in a research setting to further characterize
 CC promoter function and to study peroxisome biogenesis. They are also
 CC useful as probes
 XX
 SQ Sequence 15 BP; 4 A; 1 C; 7 G; 3 T; 0 U; 0 Other;
 QY Query Match 0.2%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 3.1e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Db 549 TATGACACCACTC 563
 15 TTTGACCCACACTC 1
 RESULT 416
 ADO81041/c
 ID ADO81041 standard; DNA; 15 BP.
 AC ADO81041;
 XX
 XX 29-UTU-2004 (first entry)
 DT
 XX
 DE Cow prion protein microsatellite locus primer #53.
 XX
 XX gene typing; polymorphic microsatellite loci; PMU;
 KM disease predisposition; microsatellite marker; prion disease;
 KM cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
 KM milk protein; hormone; transcription factor; PT7-blue-vector; cow;
 KM microsatellite; PCR; primer; ss.
 XX
 OS Bos taurus.
 XX
 XX DE10236711-A1.
 PN
 XX
 XX 26-FEB-2004.
 PD
 XX
 XX 09-AUG-2002; 2002DE-01036711.
 PF
 XX
 XX 09-AUG-2002; 2002DE-01036711.
 PR
 XX
 XX (UYHO-) UNIV HOHENHEIM.
 PA
 XX
 PI Geldermann H, Preuss S, Han Y;
 XX
 XX WPI; 2004-215730/21.
 DR
 XX
 PT Typing genes that contain polymorphic microsatellite loci, useful for
 PT identifying predisposition to disease, by amplification and determining
 PT length of amplicons.
 XX
 XX Example 3; Page 27; 64pp; German.
 XX
 CC The invention describes a method of typing (M1) a gene (I) that has one
 CC or more polymorphic microsatellite loci (PML). The method comprises: PCR
 CC amplification of at least one DNA region of (I) that includes PML, using
 CC as template a DNA sample containing at least one segment of (I); and
 CC determining the length of the resulting amplicon(s). Also described are:
 CC a method of determining (M2) microsatellite markers (MM) for
 CC predisposition to a disease, associated with a gene that includes one or

CC more PMU; and prediagnosis (M3) of diseases associated with gene that
 CC include PMU. The method is used to identify microsatellite markers, in a
 CC disease-related gene, that are associated with a predisposition to
 CC diseases and for prediagnosis of such diseases, especially prion diseases
 CC but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
 CC metabolic diseases; also to type genes that encode milk proteins,
 CC hormones or transcription factors. The method is simpler, quicker and
 CC particularly less expensive than known methods based on sequencing. This
 CC sequence represents a primer used to genotype a region of the cow prion
 CC protein (PrP) comprising a polymorphic microsatellite locus.
 XX
 SQ Sequence 15 BP; 5 A; 6 C; 4 G; 0 T; 0 U; 0 Other;
 QY Query Match 0.2%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 3.1e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Db 289 GCTGTGGAGCTCTCT 303
 15 GCTGTGGAGCTCTCTCT 1
 RESULT 417
 ID ABR33431/c
 ID ABR33431 standard; DNA; 13 BP.
 AC ABR33431;
 XX
 XX 21-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 133428 for detecting SNP TSC0033280.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-1B000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX
 XX WPI; 2001-657177/75.
 DR
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX
 XX Claim 1; SEQ ID NO 133428; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989, and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/publicated_pct_sequences
 XX
 SQ Sequence 13 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 1 Other;


```

Query Match          0.2%; Score 11.6; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2.3e+02;
Matches 11; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      303 TTATGTTATAC 314
      12 TTATGTTATAY 1

RESULT 418
ABH24411
ID      ABH24411 standard; DNA; 13 BP.
XX
AC      ABH24411;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 224388 for detecting SNP TSC0054677.
XX
KM      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPIC-) EPICENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 224388; 29bp + Sequence Listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 2 A; 3 C; 0 G; 7 T; 0 U; 1 Other;
XX
Query Match          0.2%; Score 11.6; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2.3e+02;
Matches 11; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      64 GTTCTTCTACTT 75
      1 RTTCTTCTACTT 12

RESULT 419
ABH24410/C
ID      ABH24410 standard; DNA; 13 BP.
XX

```

```

AC      ABH24410;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 224387 for detecting SNP TSC0054677.
XX
KM      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPIC-) EPICENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 224387; 29bp + Sequence Listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 7 A; 0 C; 3 G; 2 T; 0 U; 1 Other;
XX
Query Match          0.2%; Score 11.6; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2.3e+02;
Matches 11; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      64 GTTCTTCTACTT 75
      13 RTTCTTCTACTT 2

RESULT 420
ABF33430
ID      ABF33430 standard; DNA; 13 BP.
XX
AC      ABF33430;
XX
DT      21-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 133427 for detecting SNP TSC0033280.
XX
KM      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX

```

```

XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001MO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPiG-) EPiGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 133427; 29bp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP0010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 1 Other;
XX
Query Match 0.2%; Score 11.6; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2.3e+02;
Matches 11; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 303 TTATGTTATAC 314
Db 2 TTATGTTATAT 13
XX
RESULT 421
AAV11097/C
ID AAV11097 standard; RNA; 13 BP.
XX
AC AAV11097;
XX
DT 25-MAR-2003 (revised)
DT 14-JUL-1998 (first entry)
XX
DE Human ribozyme target sequence from HLA-DRB 10DRB #2.
XX
KW Ribozyme; target; human lymphocyte antigen; HLA-DRB; MHC allele;
KW major histocompatibility complex; cleavage; suppression; transplant;
KW incompatibility; autoimmune disease; juvenile diabetes;
KW rheumatoid arthritis; ss.
XX
OS Homo sapiens.
XX
PN MO9704087-A1.
XX
PD 06-FEB-1997.
XX
PF 18-JUL-1996; 96MO-EP003173.
XX
PR 18-JUL-1995; 95EP-00111256.
XX
PA (KRUPP) KRUPP G.
PA (MARG) MARGET M.
PA (WEST) WESTPHAL E.
PA (MUEL) MUELLER-RUCHHOLTZ W.

```

```

XX PI Krupp G, Marget M, Westphal E, Mueller-Ruchholtz W;
XX DR WPI; 1997-132628/12.
XX
XX Ribozyme that cleaves specific MHC allele(s) - used to inhibit graft
PT versus host reactions, to overcome blood incompatibility and to treat
PT auto-immune disease.
XX
XX Claim 5; Fig 1; 76pp; German.
XX
CC AAV10915-V11123 are target sequences for a novel ribozyme which cleaves
CC specific alleles from the major histocompatibility complex (MHC). This
CC ribozyme contains a catalytic region and a hybridisation region which is
CC complementary to all mRNA transcribed from vertebrate genes of a specific
CC family of closely related MHC alleles or to mRNA from a single MHC
CC allele, and is able to cleave such mRNA. The mRNA has a target region
CC which in case is essentially conserved in all genes of the family but
CC differs from genes of all other MHC alleles to such a degree that no
CC cleavage of mRNA transcribed from these other alleles occurs. This allows
CC the selective reduction or inhibition of expression of all genes of a
CC family or of a single gene. This ribozyme can be used for permanent or
CC transient suppression of expression of MHC alleles, in vivo or in vitro.
CC Specific applications are to prevent guest vs. host or host vs. guest
CC reactions, to prevent blood incompatibilities (partic. of the ABO, rheus
CC and Kell systems) and to treat autoimmune diseases such as juvenile
CC diabetes and rheumatoid arthritis. The use of this ribozyme avoids the
CC need for immunosuppressants in transplant patients. It provides very
CC specific reduction of particular HLA molecules that cause incompatibility
CC between donor and recipient. (Updated on 25-MAR-2003 to correct PA
CC field.) (Updated on 25-MAR-2003 to correct PI field.)
XX
SQ Sequence 13 BP; 3 A; 2 C; 6 G; 0 T; 2 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 158 GCACGACTCCAC 170
Db 13 GCACGACTCTC 1
XX
RESULT 422
AAC85841/C
ID AAC85841 standard; DNA; 13 BP.
XX
AC AAC85841;
XX
DT 06-AUG-2001 (first entry)
DT
XX
DE Consensus translational initiator sequence #2.
XX
KW Consensus translational initiator sequence; CITS; fungus; hormone;
KW receptor; antibody; reporter; enzyme; amylase; aminopeptidase;
KW carboxypeptidase; catalase; cellulase; chitinase; cutinase;
KW cyclooxygenase; glycosyltransferase; deoxyribonuclease; esterase;
KW alpha-galactosidase; beta-galactosidase; glucanase; alpha-glucosidase;
KW beta-glucosidase; invertase; laccase; lipase; mannosidase; mutanase;
KW oxidase; pectinolytic enzyme; peroxidase; phytase; polyphenoloxidase;
KW proteolytic enzyme; ribonuclease; transglutaminase; xylanase; ss.
XX
OS Synthetic.
XX
PN MO200140489-A1.
XX
PD 07-JUN-2001.
XX
PF 20-NOV-2000; 2000MO-US031910.
XX
PR 30-NOV-1999; 99US-00451503.
XX
PA (NOVO) NOVO NORDISK BIOTECH INC.

```

XX Yaver DS, Bellini DA;
 XX WPI; 2001-374845/39.
 XX Producing polypeptides such as hormones, enzymes, antibodies, by
 PT culturing fungal cells comprising consensus translational initiator
 PT sequences operably linked to nucleic acid sequences encoding the
 PT polypeptides.
 XX Claim 2; Page 56; 67pp; English.
 XX The sequences given in AAC59840-43 represent consensus translational
 CC initiator sequences (CITS's) which were used in the method of the
 CC invention. The method allows for producing a polypeptide, by cultivating
 CC a fungal host cell containing a nucleic acid (SI) encoding the poly-
 CC peptide operably linked to another nucleic acid containing a CITS foreign
 CC to SI. The 3' end of the CITS is immediately upstream of the initiator
 CC codon of SI. The polypeptide is then isolated from the cultivation
 CC medium. The method is useful for producing a polypeptide, preferably a
 CC hormone or its variant, receptor, antibody, or fragments of these, a
 CC reporter or an enzyme, including aminopeptidase, amylase, carboxylase,
 CC carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin,
 CC glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase,
 CC beta-galactosidase, glucosylase, alpha-glucosidase, beta-glucosidase,
 CC invertase, lactase, lipase, mannosidase, mutanase, oxidase, pectinolytic
 CC enzyme, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme,
 CC ribonuclease, transglutaminase or xylanase. The fungal host cell produces
 CC 400% more polypeptide relative to a fungal cell containing a non-CITS
 CC operably linked to the polypeptide encoding sequence
 XX
 SQ Sequence 13 BP; 2 A; 5 C; 2 G; 4 T; 0 U; 0 Other;
 QY Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Db 133 CATGTCATGAC 145
 13 CATGTCATGAC 1
 RESULT 423
 ABC22089/c
 ID ABC22089 standard; DNA; 13 BP.
 XX ABC22089;
 AC
 XX 20-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 22106 for detecting SNP TSC0004395.
 XX
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 22106; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 3 C; 1 G; 3 T; 0 U; 0 Other;
 QY Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Db 305 ATTGTATACGAC 317
 13 ATTGTATACGAC 1
 RESULT 424
 ABC09203
 ID ABC09203 standard; DNA; 13 BP.
 XX ABC09203;
 AC
 XX 20-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 9194 for detecting SNP TSC0002444.
 XX
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 9194; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 5 A; 2 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 80 TATTCGAAATC 92
 Db 1 TATTCGAAATC 13

RESULT 425
 ABC84204/c
 ID ABC84204 standard; DNA; 13 BP.
 XX
 AC ABC84204;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 84221 for detecting SNP TSC0021175.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 84221; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 215 CACATCAACATTA 227
 |||||

Db 13 CACATCAACATTA 1

RESULT 426
 ABC78998/c
 ID ABC78998 standard; DNA; 13 BP.
 XX
 AC ABC78998;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 79015 for detecting SNP TSC0020111.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 79015; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 215 CACATCAACATTA 227
 Db 13 CACATCAACAAA 1

RESULT 427
 ABC09202/c
 ID ABC09202 standard; DNA; 13 BP.
 XX
 AC ABC09202;

DT 20-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 9193 for detecting SNP TSC0002444.

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 9193; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 2 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 80 TATTTCGAATC 92
XX
DB 13 TATTCTAAATC 1
XX
RESULT 428
ABF63776/c
ID ABF63776 standard; DNA; 13 BP.
XX
AC ABF63776;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 163773 for detecting SNP TSC0041144.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX

XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 163773; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 240 AAATACCAAT 252
XX
DB 13 AAATACCAAT 1
XX
RESULT 429
ABH62772
ID ABH62772 standard; DNA; 13 BP.
XX
AC ABH62772;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 262749 for detecting SNP TSC0063739.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 262749; 29pp + Sequence Listing; German.
XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABP00010-ABP9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 303 TTATTGTTATACG 315
Db 1 TTATTGTTATACG 13

RESULT 430

ABC92901
ID ABC92901 standard; DNA; 13 BP.

XX ABC92901;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 92918 for detecting SNP TSC0023234.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 92918; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABP00010-ABP9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 212 CACCACATCAACA 224
Db 1 CACCACATCAACA 13

RESULT 431

ABC20648/C
ID ABC20648 standard; DNA; 13 BP.

XX ABC20648;

DT 20-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 20665 for detecting SNP TSC0004205.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 20665; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABP00010-ABP9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 164 ACTCCACCACTCT 176
Db 13 ACTCCACCACTAT 1

RESULT 432

ABC75630

```

ID ABC75630 standard; DNA; 13 BP.
XX
XX ABC75630;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 75647 for detecting SNP TSC0019390.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 75647; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 1 C; 2 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY 79 TTATTCGAAAT 91
XX ||||| |||||
Db 1 TTATTCGAAAT 13
XX
RESULT 433
ABC75631/c
ID ABC75631 standard; DNA; 13 BP.
XX
XX ABC75631;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 75648 for detecting SNP TSC0019390.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX

```

```

XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 75648; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 2 C; 1 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY 79 TTATTCGAAAT 91
XX ||||| |||||
Db 13 TTATTCGAAAT 1
XX
RESULT 434
ABC84205
ID ABC84205 standard; DNA; 13 BP.
XX
XX ABC84205;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 84222 for detecting SNP TSC0021175.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX

```

DR WPI: 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 XX Claim 1; SEQ ID NO 84222; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 215 CACATCAACATA 227
 DB 1 CACATCAACATA 13
 RESULT 435
 ID ABF31796/c
 AC ABF31796; DNA; 13 BP.
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 131793 for detecting SNP TSC0032899.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI: 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 131793; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 9 A; 0 C; 2 G; 2 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 74 TTCTTTATTTCCT 86
 DB 13 TTCTTTATTTCCT 1
 RESULT 436
 ID ABF39371
 AC ABF39371; DNA; 13 BP.
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 139368 for detecting SNP TSC0034894.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI: 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 139368; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 233 CCACAGAAACTA 245
 Db 1 CCACAGAAACTA 13

RESULT 437
 ABF99419
 ID ABF99419 standard; DNA; 13 BP.
 AC ABE99419;
 DT 22-FEB-2002 (first entry)

Oligonucleotide SEQ ID NO 199416 for detecting SNP TSC0049067.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIC-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 CC
 PS Claim 1; SEQ ID NO 199416; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 2 A; 4 C; 0 G; 7 T; 0 U; 0 Other;
 SQ

Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 67 CTCTACTTCTTT 79
 Db 1 CTCTACTTCTAT 13

RESULT 438
 ABH40717
 ID ABH40717 standard; DNA; 13 BP.
 AC ABH40717;
 XX
 XX 22-FEB-2002 (first entry)
 DT

XX Oligonucleotide SEQ ID NO 240694 for detecting SNP TSC000262.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIC-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 CC
 PS Claim 1; SEQ ID NO 240694; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 8 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
 SQ

Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 237 AGAAACTACCA 249
 Db 1 AAAAACTACCA 13

RESULT 439
 ABC22088
 ID ABC22088 standard; DNA; 13 BP.
 AC ABC22088;
 DT 20-FEB-2002 (first entry)

Oligonucleotide SEQ ID NO 22105 for detecting SNP TSC0004395.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 PD
 XX

PF 06-APR-2001; 2001WO-IB000713.
XX
PS 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 22105; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 1 C; 3 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 305 ATTGTTATACGAG 317
Db 1 ATTGTTATACGAG 13
XX
RESULT 440
ABC06060/C
ID ABC06060 standard; DNA; 13 BP.
XX
AC ABC06060;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 6051 for detecting SNP TSC0001919.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX
PS Claim 1; SEQ ID NO 6051; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 0 C; 3 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 67 CTCTACTTCTTT 79
Db 13 CTCTACTTCTTT 1
XX
RESULT 441
ABC55652/C
ID ABC55652 standard; DNA; 13 BP.
XX
AC ABC55652;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 55669 for detecting SNP TSC0015178.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 55669; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;

Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

217 CATCACTAATA 229

13 CATCACTAATA 1

RESULT 442

ABP92995

ID ABP92995 standard; DNA; 13 BP.

AC ABP92995;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 192992 for detecting SNP TSC0047477.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

PS Claim 1; SEQ ID NO 192992; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

RESULT 443
ABH21122 standard; DNA; 13 BP.

XX ABH21122;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 221099 for detecting SNP TSC0053804.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

PS Claim 1; SEQ ID NO 221099; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;

Best Local Similarity 92.3%; Pred. No. 2.5e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

217 AATATCTACCCAA 593
13 AATATCTACCCAA 1

RESULT 444

ABP47023/C

ID ABP47023 standard; DNA; 13 BP.

AC ABP47023;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 147020 for detecting SNP TSC0037101.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPig-) EPiGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 147020; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 4 C; 0 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 50 AACATAGGAAGT 62
DB 13 AAGATAAGGAAGT 1
XX
RESULT 445
ID ABH64141 standard; DNA; 13 BP.
XX
AC ABH64141;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 264118 for detecting SNP TSC0000657.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPig-) EPiGENOMICS AG.

XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 264118; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 2 C; 0 G; 9 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 43 AAAATGGAATA 55
DB 13 AAAATGGAATA 1
XX
RESULT 446
ID ABH65196 standard; DNA; 13 BP.
XX
AC ABH65196;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 265173 for detecting SNP TSC0001077.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPig-) EPiGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 265173; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABCG9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
QY Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
Db 78 TTTATTTCTGAAA 90
1 TTTATTTGTGAAA 13
XX
RESULT 447
ABCG5068/c
ID ABCG5068 standard; DNA; 13 BP.
XX
AC ABCG5068;
XX
XX 20-FEB-2002 (first entry)
XX
DT
XX
DE Oligonucleotide SEQ ID NO 35085 for detecting SNP TSC0011139.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX (EPIC-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 35085; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABCG9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
XX

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 502 ACATCTCCACCA 514
13 ACACACTCCACCA 1
XX
Db 13 ACACACTCCACCA 1
XX
RESULT 448
ABH01372/c
ID ABH01372 standard; DNA; 13 BP.
XX
AC ABH01372;
XX
XX 22-FEB-2002 (first entry)
XX
DT
XX
DE Oligonucleotide SEQ ID NO 201349 for detecting SNP TSC0049529.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX (EPIC-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 201349; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABCG9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 9 A; 0 C; 1 G; 3 T; 0 U; 0 Other;
XX
QY Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
Db 71 TACTTCTTTATT 83
13 TACTTATTATT 1
XX
RESULT 449
ABF76677
ID ABF76677 standard; DNA; 13 BP.
XX

AC ABF76677;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 176674 for detecting SNP TSC0043845.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
XX Claim 1; SEQ ID NO 176674; 29pp + Sequence Listing; German.
XX
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 581 AATACTACCCAAA 593
DB 1 AATACTACTTAAA 13
XX
XX
XX RESULT 450
XX ABF52447
XX ID ABF52447 standard; DNA; 13 BP.
XX AC ABF52447;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 152444 for detecting SNP TSC0038526.
XX
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX

XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
XX Claim 1; SEQ ID NO 152444; 29pp + Sequence Listing; German.
XX
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 1 A; 5 C; 0 G; 7 T; 0 U; 0 Other;
XX
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 66 TCTTCTACTTCT 78
DB 1 TCTTCTACTTCT 13
XX
XX
XX RESULT 451
XX ABH29162/C
XX ID ABH29162 standard; DNA; 13 BP.
XX AC ABH29162;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 229139 for detecting SNP TSC0055903.
XX
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIC-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 229139; 29pp + Sequence Listing; German.

XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989, and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX

XX Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;

XX

XX Query Match 0.2%; Score 11.4; DB 1; Length 13;

XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;

XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0

Oy 504 ATACTCCACCACT 516
| | | | | | | | | | | | | | | | | | | | | |
Db 13 AAAGTCACCACT 1

RESULT 452

ABC20649

ID ABC20649 standard; DNA; 13 BP.

XX

AC ABC20649;

XX

XX 20-FEB-2002 (first entry)

XX

XX Oligonucleotide SEQ ID NO 20666 for detecting SNP TSC0004205.

XX

XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

XX Homo sapiens.

XX

OS WO200177384-A2.

PN 18-OCT-2001.

XX

PD 06-APR-2001; 2001WO-IB000713.

XX

PF 07-APR-2000; 2000DE-01019173.

XX

PR (EPIG-) EPIGENOMICS AG.

PA

XX Olek A, Piepenbrock C, Berlin K;

XX

PI WPI; 2001-657177/75.

XX

XX

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX

XX Claim 1; SEQ ID NO 20666; 29pp + Sequence Listing; German.

XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989, and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX

XX Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;

XX

XX Query Match 0.2%; Score 11.4; DB 1; Length 13;

XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;

XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0

Oy 504 ATACTCCACCACT 516
| | | | | | | | | | | | | | | | | | | | | |
Db 13 AAAGTCACCACT 1

RESULT 452

ABC20649

ID ABC20649 standard; DNA; 13 BP.

XX

AC ABC20649;

XX

XX 20-FEB-2002 (first entry)

XX

XX Oligonucleotide SEQ ID NO 20666 for detecting SNP TSC0004205.

XX

XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

XX Homo sapiens.

XX

OS WO200177384-A2.

PN 18-OCT-2001.

XX

PD 06-APR-2001; 2001WO-IB000713.

XX

PF 07-APR-2000; 2000DE-01019173.

XX

PR (EPIG-) EPIGENOMICS AG.

PA

XX Olek A, Piepenbrock C, Berlin K;

XX

PI WPI; 2001-657177/75.

XX

XX

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX

XX Claim 1; SEQ ID NO 20666; 29pp + Sequence Listing; German.

XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989, and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX

XX Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;

XX

XX Query Match 0.2%; Score 11.4; DB 1; Length 13;

XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;

XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0

Oy 504 ATACTCCACCACT 516
| | | | | | | | | | | | | | | | | | | | | |
Db 13 AAAGTCACCACT 1

RESULT 452

ABC20649

ID ABC20649 standard; DNA; 13 BP.

XX

AC ABC20649;

XX

XX 20-FEB-2002 (first entry)

XX

XX Oligonucleotide SEQ ID NO 20666 for detecting SNP TSC0004205.

XX

XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

XX Homo sapiens.

XX

OS WO200177384-A2.

PN 18-OCT-2001.

XX

PD 06-APR-2001; 2001WO-IB000713.

XX

PF 07-APR-2000; 2000DE-01019173.

XX

PR (EPIG-) EPIGENOMICS AG.

PA

XX Olek A, Piepenbrock C, Berlin K;

XX

PI WPI; 2001-657177/75.

XX

XX

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX

XX Claim 1; SEQ ID NO 20666; 29pp + Sequence Listing; German.

XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989, and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX

XX Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;

XX

XX Query Match 0.2%; Score 11.4; DB 1; Length 13;

XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;

XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0

Oy 504 ATACTCCACCACT 516
| | | | | | | | | | | | | | | | | | | | | |
Db 13 AAAGTCACCACT 1

RESULT 452

ABC20649

ID ABC20649 standard; DNA; 13 BP.

XX

AC ABC20649;

XX

XX 20-FEB-2002 (first entry)

XX

XX Oligonucleotide SEQ ID NO 20666 for detecting SNP TSC0004205.

XX

XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

XX Homo sapiens.

XX

OS WO200177384-A2.

PN 18-OCT-2001.

XX

PD 06-APR-2001; 2001WO-IB000713.

XX

PF 07-APR-2000; 2000DE-01019173.

XX

PR (EPIG-) EPIGENOMICS AG.

PA

XX Olek A, Piepenbrock C, Berlin K;

XX

PI WPI; 2001-657177/75.

XX

XX

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX

XX Claim 1; SEQ ID NO 20666; 29pp + Sequence Listing; German.

XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989, and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX

XX Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;

XX

XX Query Match 0.2%; Score 11.4; DB 1; Length 13;

CC	-ABC99989; ABR00010-ABR99989; ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp://wipo.int/pub/published_pct_sequences
SQ	Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
Query Match	0.2%; Score 11.4; DB 1; Length 13; Best Local Similarity 92.3%; Pred.No. 2.5e+02;
Matches 12;	Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY	164 ACTGCACCACTGT 176 1 ACTCCACCACCTAT 13
Db	
RESULT 453	
ABP44475	
ID	ABF44475 standard; DNA; 13 BP.
XX AC	
XX ABF44475;	
XX DT	21-FEB-2002 (first entry)
DE	Oligonucleotide SEQ ID NO 144472 for detecting SNP TSC0036322.
DX	
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer; SB; central nervous system; gastrointestinal; respiratory; immune; metabolic. OS Homo sapiens.
XX	
PX WO200177384-A2.	
PN	
PD	18-OCT-2001.
PF	06-APR-2001; 2001WO-IB000713.
PR	07-APR-2000; 2000DE-01019173.
XX PA	(EPIG-) EPIDENOMICS AG.
PI Olek A. Piepenbrock C. Berlin K;	
DR WPI; 2001-657177/75.	
PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.	
PS Claim 1; SEQ ID NO 144472; 29pp + Sequence Listing; German.	
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989; ABR00010-ABR99989; ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp://wipo.int/pub/published_pct_sequences	
SQ	Sequence 13 BP; 3 A; 2 C; 0 G; 8 T; 0 U; 0 Other;
Query Match	0.2%; Score 11.4; DB 1; Length 13; Best Local Similarity 92.3%; Pred.No. 2.5e+02;
Matches 12;	Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY	302 CTATTGTTATAC 314

```

Db      1 CTTATTTTATTAC 13
||||| |||||
ABH21123
ID   ABH21123 standard; DNA; 13 BP.
XX
AC   ABH21123;
XX
DT   22-FEB-2002 (first entry)
DE
Oligonucleotide SEQ ID NO 221100 for detecting SNP TSC0053804.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX   central nervous system; gastrointestinal; respiratory; immune; metabolic
OS   Homo sapiens.
XX
PN   WO200177384-A2.
PD   18-OCT-2001.
PF   06-APR-2001; 2001WO-IB000713.
PR   07-APR-2000; 2000DE-01019173.
PA   (EPIG-) EPIGENOMICS AG.
PI   Olek A, Piepenbrock C, Berlin K;
DR   WPI, 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
PS   Claim 1; SEQ ID NO 221100; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC000010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI982073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
SQ
Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
Query Match          0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY    581 AATACTACCCAAA 593
      ||||| |||||
DB    1 AATACTACCCAAA 13
RESULT 455
ABP47022 ID ABR47022 standard; DNA; 13 BP.
XX
AC   ABR47022;
XX
DT   21-FEB-2002 (first entry)
DE
Oligonucleotide SEQ ID NO 147019 for detecting SNP TSC0037101.

```

XX	CNS;
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic
XX	
OS	Homo sapiens.
XX	
PN	WO200177384-A2.
XX	
PD	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIC-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
XX	
DR	WPI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
PS	Claim 1; SEQ ID NO 147019; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABC99989, ABR00010-ABR99989, ABH0010-ABH99989 and ABI0010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the invention. NOTE: The sequence
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
CC	
SEQ	Sequence 13 BP; 7 A; 0 C; 4 G; 2 T; 0 U; 0 Other;
Query Match	0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity	92.3%; Pred.No. 2.5e+02;
Matches 12; Conservative	0; Mismatches 1; Indels 0; Gaps 0;
OY	50 AACATAAGAGACT 62
DB	1 AAGATTAAGAGACT 13
RESULT 456	
ABH24304/c	
ABH24304 standard; DNA; 13 BP.	
XX	
AC	ABH24304;
XX	
DT	22-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 224281 for detecting SNP TSC0054648.
XX	
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
PN	WO200177384-A2.
XX	
PD	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	

PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 224281; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY 235 ACAGAAACTACC 247
Db 13 ACACAAACTACC 1
XX
RESULT 457
ABF52446/C
ID ABF52446 standard; DNA; 13 BP.
XX
XX ABF52446;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 152443 for detecting SNP TSC0038526.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 152443; 29pp + Sequence Listing; German.

XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 0 C; 5 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY 66 TCCTCTCTCTCT 78
Db 13 TCCTCTCTCTCT 1
XX
RESULT 458
ABH40716/C
ID ABH40716 standard; DNA; 13 BP.
XX
XX ABH40716;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 240693 for detecting SNP TSC0000262.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 240693; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX

```
XX SQ Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 237 AGAAACTACCCA 249
13 AAAAACTACCCA 1
Db
RESULT 459
ABH58627
ID ABH58627 standard; DNA; 13 BP.
XX AC ABH58627;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 258604 for detecting SNP TSC0062877.
XX SNF: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX OS
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 258604; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 6 A; 7 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 212 CACCACATCACA 224
1 CACCACACACACA 13
Db
RESULT 460
```

```
ABH64140
ID ABH64140 standard; DNA; 13 BP.
XX AC ABH64140;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 264117 for detecting SNP TSC0000657.
XX SNF: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX OS
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 264117; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 9 A; 0 C; 2 G; 2 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 43' AAAATGGAACATA 55
1 AAAATGGAATA 13
Db
RESULT 461
ABC50178/C
ID ABC50178 standard; DNA; 13 BP.
XX AC ABC50178;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 50195 for detecting SNP TSC0014122.
XX SNF: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
```

```

OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 50195; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 1 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 423 TCCTTCGACAA 435
XX |||||
XX 13 TCCTTCGAAAAA 1
XX
XX RESULT 462
XX ABC75583
XX ID ABC75583 standard; DNA; 13 BP.
XX
XX ABC75583;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 75600 for detecting SNP TSC0019382.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; 89;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX
XX

```

```

XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 75600; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 236 CAGAAAACCTACC 248
XX |||||
XX 1 CAAAAAACTACCC 13
XX
XX RESULT 463
XX ABF08148
XX ID ABF08148 standard; DNA; 13 BP.
XX
XX ABF08148;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 108145 for detecting SNP TSC0027083.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; 89;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 108145; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX

```

```
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 0 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 478 GGTATGACAGAGA 490
DB 1 GGTATGATGATGA 13
RESULT 464
ABF08149/c
ID ABF08149 standard; DNA; 13 BP.
XX
AC ABF08149;
XX
DT 21-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 108146 for detecting SNP TSC0027083.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PP 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WP1; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 108146; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 5 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
```

```
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 478 GGTATGACAGAGA 490
DB 13 GGTATGATGATGA 1
RESULT 465
ABC37566
ID ABC37566 standard; DNA; 13 BP.
XX
AC ABC37566;
XX
DT 20-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 37583 for detecting SNP TSC0011697.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PP 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WP1; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 37583; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 9 G; 2 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 456 TGGCGTCGAGAG 468
DB 1 TGGCGTCGAGAG 13
RESULT 466
ABF22616/c
ID ABF22616 standard; DNA; 13 BP.
XX
AC ABF22616;
XX
```

DT 21-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 122613 for detecting SNP TSC0030639.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 122613; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 8 A; 0 C; 2 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 71 TACTCTTTTATT 83
 Db 13 TACTCTTTTATT 1
 RESULT 467
 ABF22617
 ID ABF22617 standard; DNA; 13 BP.
 XX
 XX ABF22617;
 XX
 XX 21-FEB-2002 (first entry)
 XX
 XX Oligonucleotide SEQ ID NO 122614 for detecting SNP TSC0030639.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX

XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 122614; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 3 A; 2 C; 0 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 71 TACTCTTTTATT 83
 Db 1 TACTCTTTTATT 13
 RESULT 468
 ABF92997
 ID ABF92997 standard; DNA; 13 BP.
 XX
 XX ABF92997;
 XX
 XX 22-FEB-2002 (first entry)
 XX
 XX Oligonucleotide SEQ ID NO 122994 for detecting SNP TSC0047477.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.
 XX
 PS Claim 1, SEQ ID NO 192994; 29pp + Sequence Listing; German.
 CC
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 5 A; 6 C; 1 G; 1 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 212 CACCACTCAACA 224
 DB 1 CACCACTCAACA 13
 RESULT 469
 ABH24305
 ID ABH24305 standard; DNA; 13 BP.
 AC ABH24305;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 224282 for detecting SNP TSC0054648.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 EN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 224282; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 235 ACAGAAACTACC 247
 DB 1 ACAGAAACTACC 13
 RESULT 470
 ABH34644/c
 ID ABH34644 standard; DNA; 13 BP.
 AC ABH34644;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 234621 for detecting SNP TSC0057256.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 EN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 234621; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 9 A; 0 C; 2 G; 2 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 69 TCTACTTCTTTTA 81
 DB 13 TCTACTTCTTTTA 1

```
RESULT 471
ABC75582/c
ID ABC75582 standard; DNA; 13 BP.
XX
XX ABC75582;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 75599 for detecting SNP TSC0019382.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 75599; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 236 CAGAAACTACCC 248
XX |||||||
XX 13 CAAAAAATCAACC 1
XX
XX RESULT 472
ABC55354/c
ID ABC55354 standard; DNA; 13 BP.
XX
XX ABC55354;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 55371 for detecting SNP TSC0015123.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
```

```
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 55371; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 550 ATGACACCACT 562
XX |||||||
XX 13 ATCACACCACT 1
XX
XX RESULT 473
ABC06061
ID ABC06061 standard; DNA; 13 BP.
XX
XX ABC06061;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 6052 for detecting SNP TSC001919.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
```

PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 6052; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 3 C; 0 G; 9 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY 67 CTTCTACTTCTTT 79
DB 1 CTTTACTTCTTT 13
XX
RESULT 474
ABF12440/C
ID ABF12440 standard; DNA; 13 BP.
XX
AC ABF12440;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 112437 for detecting SNP TSC0028115.
XX
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 112437; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 0 C; 3 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY 66 TCTTCTACTTCTT 78
DB 13 TCTTCTACTTCTT 1
XX
RESULT 475
ABF63777
ID ABF63777 standard; DNA; 13 BP.
XX
AC ABF63777;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 163774 for detecting SNP TSC0041144.
XX
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 163774; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 240 AAATACCCCAAT 252
 |||||
 1 AAATTACCCCAAT 13

RESULT 476
 ABH43729
 ID ABH43729 standard; DNA; 13 BP.
 XX
 AC ABH43729;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 243706 for detecting SNP TSC0059455.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 243706; 29bp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 501 CACATACCCACC 513
 |||||
 1 CACATACCTACC 13

RESULT 477
 ABF00547
 ID ABF00547 standard; DNA; 13 BP.

XX
 AC ABF00547;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 100544 for detecting SNP TSC0025013.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 100544; 29bp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 2 C; 0 G; 8 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 71 TACTCTTTTATT 83
 |||||
 1 TACTCTTATATT 13

RESULT 478
 ABC55653
 ID ABC55653 standard; DNA; 13 BP.
 XX
 AC ABC55653;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 55670 for detecting SNP TSC0015178.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX

PN WO200177384-A2.
XX
PT 18-OCT-2001.
PD
XX
PF 06-APR-2001; 2001WO-IB000713.
PR
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 55670; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 217 CATCAACTAATA 229
DB 1 CATCAACTACTA 13
RESULT 479
ABC33821
ID ABC33821 standard; DNA; 13 BP.
XX
AC ABC33821;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 33838 for detecting SNP TSC0010834.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.

XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 33838; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 582 ATACTCCCAAT 594
DB 1 ATACTCCCAAT 13
RESULT 480
ABF4472/C
ID ABF4472 standard; DNA; 13 BP.
XX
AC ABF4472;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 144469 for detecting SNP TSC0036322.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 144469; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 7 A; 0 C; 2 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 302 CTTATGTTATAC 314
 Db 13 CTTATGTTATAC 1
 RESULT 481
 ABF44473
 ID ABF44473 standard; DNA; 13 BP.
 XX
 AC ABF44473;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 144470 for detecting SNP TSC0036322.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 144470; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 4 A; 2 C; 0 G; 7 T; 0 U; 0 Other;
 XX
 Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 302 CTTATGTTATAC 314
 Db 13 CTTATGTTATAC 13
 RESULT 482
 ABH01373
 ID ABH01373 standard; DNA; 13 BP.
 XX
 AC ABH01373;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 201350 for detecting SNP TSC049529.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 201350; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 3 A; 1 C; 0 G; 9 T; 0 U; 0 Other;
 XX
 Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 71 TACTTCTTTATT 83
 Db 1 TACTTATTTATT 13
 RESULT 483
 ABH38635
 ID ABH38635 standard; DNA; 13 BP.
 XX
 AC ABH38635;
 XX
 DT 22-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 238612 for detecting SNP TSC0009812.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 238612; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 239 AAAACTACCCCAA 251
Db 1 AAAACTCCCCCAA 13
XX
XX
XX RESULT 484
ABF65743
XX ID ABF65743 standard; DNA; 13 BP.
XX
XX ABF65743;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 165740 for detecting SNP TSC0041570.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX

XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 165740; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 581 AATATACCCCAA 593
Db 1 AATATACCCCAA 13
XX
XX
XX RESULT 485
ABC20929
XX ID ABC20929 standard; DNA; 13 BP.
XX
XX ABC20929;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 20946 for detecting SNP TSC004248.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX

PS Claim 1; SEQ ID NO 20946; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 4 A; 1 C; 0 G; 8 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 77 TTTATTTCGAA 89
 |||||
 1 TTTATTTCGAA 13

Db 1 TTTATTTCGAA 13

RESULT 486
 ABC47607 standard; DNA; 13 BP.
 AC ABC47607;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 47624 for detecting SNP TSC0013654.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
 PT
 XX
 PS Claim 1; SEQ ID NO 47624; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SO Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 215 CACATCAACATTA 227
 |||||
 1 CACATCAACATTA 13

Db 1 CACATCAACATTA 13

RESULT 487
 ABF00460/C
 ID ABF00460 standard; DNA; 13 BP.
 AC ABF00460;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 100457 for detecting SNP TSC0025001.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
 PT
 XX
 PS Claim 1; SEQ ID NO 100457; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 239 AAAACTACCCAAA 251
 |||||
 13 AAAATTACCCAAA 1

Db 13 AAAATTACCCAAA 1

```
RESULT 488
ABF12441
ID ABF12441 standard; DNA; 13 BP.
XX
AC ABF12441;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 112438 for detecting SNP TSC0028115.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 112438; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 3 C; 0 G; 9 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY 66 TCTTCTACTTCTT 78
1 TCTTCTACTTTT 13
XX
Db 1 TCTTCTACTTTT 13
XX
RESULT 489
ABC37567/c
ID ABC37567 standard; DNA; 13 BP.
XX
AC ABC37567;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 37584 for detecting SNP TSC0011697.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
```

```
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 37584; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 9 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY 456 TGGCGTGACGAG 468
13 TGGCGTGACGAG 1
XX
Db 13 TGGCGTGACGAG 1
XX
RESULT 490
ABF93321
ID ABF93321 standard; DNA; 13 BP.
XX
AC ABF93321;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 193318 for detecting SNP TSC0047561.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
```

PI	Olek A, Piepenbrock C, Berlin K;
DR	WPI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
XX	methylation status.
XX	
PS	Claim 1; SEQ ID NO 193318; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
SQ	Sequence 13 BP; 5 A; 4 C; 4 T; 0 U; 0 Other;
	Query Match 0.2%; Score 11.4; DB 1; Length 13;
	Best Local Similarity 92.3%; Pred. No. 2.5e+02;
	Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0
OY	582 ATACTACCCCAAT 594
Db	1 ATACTACCCCAAT 13
RESULT 491	
ABF99418/C	
ID	ABF99418 standard; DNA; 13 BP.
XX	
AC	ABF99418;
XX	
DT	22-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 199415 for detecting SNP TSC0049067.
XX	
SNP;	single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
WO	200177384-A2.
XX	
PD	18-OCT-2001.
XX	
XX	
XX	06-APR-2001; 2001WO-IB000713.
XX	
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIC-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
XX	
DR	WPI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
XX	methylation status.
XX	
PS	Claim 1; SEQ ID NO 199415; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The

CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABG9989, ABH00010-ABF9989, ABH00010-ABH9989 and AB100010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
SQ	Sequence 13 BP; 7 A; 0 C; 4 G; 2 T; 0 U; 0 Other;
Query Match	0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity	92.3%; Pred.No.2.5e+02;
Matches 12; Conservative	0; Mismatches 1; Indels 0; Gaps 0
Oy	67 CTCTACTTCTTT 79 13 CTTCATTCTAT 1
Db	13 CTTCATTCTAT 1
RESULT 492	
ABH34645	ID ABH34645 standard; DNA; 13 BP.
AC	ABH34645;
XX	22-FEB-2002 (first entry)
DT	
XX	
DE	Oligonucleotide SEQ ID NO 234622 for detecting SNP TSC057256.
XX	
KM	SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
FN	WO200177384-A2.
PD	18-OCT-2001.
PF	06-APR-2001; 2001WO-IB000713.
PR	07-APR-2000; 2000DE-01019173.
PA	(EPIG-) EPIGENOMICS AG.
PI	Olek A, Piepenbrock C, Berlin K;
PT	WPI; 2001-657177/75.
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
PS	Claim 1; SEQ ID NO 234622; 29pp + Sequence Listing; German.
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABC9989, ABH00010-ABF9989, ABH00010-ABH9989 and AB100010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
SQ	Sequence 13 BP; 2 A; 2 C; 0 G; 9 T; 0 U; 0 Other;
Query Match	0.2%; Score 11.4; DB 1; Length 13;

Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 69 TCTACTTCTTTA 81
DB 1 TCTATTCTTTA 13

RESULT 493
ABH58626/c
ID ABH58626 standard; DNA; 13 BP.
AC ABH58626;
XX
XX
XX 22-FEB-2002 (first entry)
XX
XX
XX Oligonucleotide SEQ ID NO 258603 for detecting SNP TSC0062877.
DE
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX
XX Claim 1; SEQ ID NO 258603; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at [ftp.wipo.int/pub/publ/published_pct_sequences](http://wipo.int/pub/publ/published_pct_sequences)

Sequence 13 BP; 0 A; 0 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 212 CACCACATCAACA 224
DB 13 CACCACATCAACA 1

RESULT 494
ABC45745
ID ABC45745 standard; DNA; 13 BP.
XX
XX ABC45745;

XX
DT 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 45762 for detecting SNP TSC0013302.
DE
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX
XX Claim 1; SEQ ID NO 45762; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at [ftp.wipo.int/pub/publ/published_pct_sequences](http://wipo.int/pub/publ/published_pct_sequences)

Sequence 13 BP; 1 A; 1 C; 0 G; 11 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 74 TTCTTTTATTCT 86
DB 1 TTCTTTTATTCT 13

RESULT 495
ABC20928/c
ID ABC20928 standard; DNA; 13 BP.
XX
XX ABC20928;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 20945 for detecting SNP TSC0004248.
DE
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX


```

PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPiGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 20945; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 0 C; 1 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY 77 TTTATTTCCTGAA 89
Db 13 TTTATTTCCTAAA 1

```

RESULT 496
ABC77744/C
ID ABC77744 standard; DNA; 13 BP.
XX
AC ABC77744;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 77761 for detecting SNP TSC0019798.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPiGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is

```

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 77761; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY 237 AGAAGACTACCCA 249
Db 13 ACAAGACTACCCA 1

```

RESULT 497
ABF92994/C
ID ABF92994 standard; DNA; 13 BP.
XX
AC ABF92994;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 192991 for detecting SNP TSC0047477.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPiGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 192991; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 1 A; 1 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 212 CACCATCATCAACA 224
DB 13 CACCATCATCGACA 1

RESULT 498

ABH29163
ID ABH29163 standard; DNA; 13 BP.

AC ABH29163;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 229140 for detecting SNP TSC0055903.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PS Claim 1; SEQ ID NO 229140; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 504 ATACTCCACCACT 516
I | | | | | | | | | |

DB 1 AAATCCACCACT 13

RESULT 499

ABH08913
ID ABH08913 standard; DNA; 13 BP.

AC ABH08913;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 208890 for detecting SNP TSC0051007.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PS Claim 1; SEQ ID NO 208890; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 5 A; 3 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 81 ATTTCGAAATCA 93
DB 1 ATTTCGAAATCA 13

RESULT 500

ABH38634/C
ID ABH38634 standard; DNA; 13 BP.

AC ABH38634;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 238611 for detecting SNP TSC0009812.

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 238611; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 239 AAAACTACCCAAA 251
Db 13 AAAACTCCCCAAA 1
RESULT 501
ABC47606/C
ID ABC47606 standard; DNA; 13 BP.
XX
XX ABC47606;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 47623 for detecting SNP TSC0013654.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX

XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 47623; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 215 CACATCAACATTA 227
Db 13 CACATCAACATTA 1
RESULT 502
ABF00461
ID ABF00461 standard; DNA; 13 BP.
XX
XX ABF00461;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 100458 for detecting SNP TSC0025001.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 100458; 29pp + Sequence Listing; German.
XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

QY Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Db 239 AAAACTACCCAAA 251
1 AAAATTACCCAAA 13

RESULT 503
ABF00546/C
ID ABF00546 standard; DNA; 13 BP.
XX ABF00546;
XX

XX 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 100543 for detecting SNP TSC0025013.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K,

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 100543; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 8 A; 0 C; 2 G; 3 T; 0 U; 0 Other;

QY Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Db 71 TACTTCTTTTATT 83
13 TACTTCTTATAT 1

RESULT 504
ABC33820/C
ID ABC33820 standard; DNA; 13 BP.
XX ABC33820;
XX

XX 20-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 33837 for detecting SNP TSC0010834.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 33837; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;

QY Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Db 582 ATACTACCCAAT 594
13 ATACTTCCCAAT 1

RESULT 505
ABF31797

```

ID  ABR31797 standard; DNA; 13 BP.
XX
AC  ABR31797;
XX
DT  21-FEB-2002 (first entry)
XX
DE  Oligonucleotide SEQ ID NO 131794 for detecting SNP TSC0032899.
XX
KM  SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
PF  06-APR-2001; 2001WO-IB000713.
XX
PR  07-APR-2000; 2000DE-01019173.
XX
PA  (EPIC-) EPIGENOMICS AG.
XX
PI  Olek A, Piepenbrock C, Berlin K;
XX
DR  WPI; 2001-657177/75.
XX
PT  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
PS  Claim 1; SEQ ID NO 131794; 29pp + Sequence Listing; German.
XX
CC  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 13 BP; 2 A; 2 C; 0 G; 9 T; 0 U; 0 Other;
XX
Query Match          0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY  74 TTTCTTTATTTCT 86
    |||||
    TTTCTTTATTTCT 13
XX
Db  1 TTTCTTTATTTCT 13
XX
RESULT 506
ABF4474/C
ID  ABF4474 standard; DNA; 13 BP.
XX
AC  ABF4474;
XX
DT  21-FEB-2002 (first entry)
XX
DE  Oligonucleotide SEQ ID NO 144471 for detecting SNP TSC0036322.
XX
KM  SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.

```

```

XX
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
PD  06-APR-2001; 2001WO-IB000713.
XX
PF  07-APR-2000; 2000DE-01019173.
XX
PR  (EPIC-) EPIGENOMICS AG.
XX
PI  Olek A, Piepenbrock C, Berlin K;
XX
DR  WPI; 2001-657177/75.
XX
PT  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
PS  Claim 1; SEQ ID NO 144471; 29pp + Sequence Listing; German.
XX
CC  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 13 BP; 8 A; 0 C; 2 G; 3 T; 0 U; 0 Other;
XX
Query Match          0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY  302 CTTATTTGTTATAC 314
    |||||
    CTTATTTTATATAC 1
XX
Db  13 CTTATTTTATATAC 1
XX
RESULT 507
ABH14748/C
ID  ABH14748 standard; DNA; 13 BP.
XX
AC  ABH14748;
XX
DT  22-FEB-2002 (first entry)
XX
DE  Oligonucleotide SEQ ID NO 214725 for detecting SNP TSC0052253.
XX
KM  SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
PF  06-APR-2001; 2001WO-IB000713.
XX
PR  07-APR-2000; 2000DE-01019173.
XX
PA  (EPIC-) EPIGENOMICS AG.
XX
PI  Olek A, Piepenbrock C, Berlin K;
XX

```

CC central nervous system, cardiovascular and metabolic disorders. The
CC -ABG9989, ABP00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match Best Local Similarity 0.2%; Score 11.4; DB 1; Length 13;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0

OY 581 AATACTACCCCAA 593
|||||
DB 13 AATAATACCANA 1

RESULT 509
ABH43728/C ID ABH43728 standard; DNA; 13 BP.
XX
XX AC ABH43728;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 243705 for detecting SNP TSC0059455.

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.
Homo sapiens.
WO200177384-A2.
18-OCT-2001.
06-APR-2001; 2001WO-IB000713.
07-APR-2000; 2000DE-01019173.
(EPIG-) EPIGENOMICS AG.
Olek A, Piepenbrock C, Berlin K;
WPI; 2001-657177/75.

Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.

Claim 1; SEQ ID NO 243705; 29bp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligomers are also used for detecting cell type differentiation. ABC00010
-ABC9989, ABP00010-ABP9989, ABH00010-ABH9989 and ABI00010-ABI2073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;

Query Match Best Local Similarity 0.2%; Score 11.4; DB 1; Length 13;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0

OY 501 CACACTACTCCACC 513
DB 13 CACACTACTCTACC 1
RESULT 510
ABH62773/c
ID ABH62773 standard; DNA; 13 BP.
AC ABH62773;
DT 22-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 262750 for detecting SNP TSC0063739.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 262750; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 303 TTATTGTTATACG 315
DB 13 TTATTGTTATATG 1
RESULT 511
ABC50179
ID ABC50179 standard; DNA; 13 BP.
AC ABC50179;
XX
XX 21-FEB-2002 (first entry)
DT

XX Oligonucleotide SEQ ID NO 50196 for detecting SNP TSC0014122.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 50196; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 4 C; 1 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 423 TCCTTCCGACAA 435
DB 1 TCCTTCCGAAAA 13
RESULT 512
ABH14749
ID ABH14749 standard; DNA; 13 BP.
AC ABH14749;
XX
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide SEQ ID NO 214726 for detecting SNP TSC0052253.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX

PF 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 214726; 29bp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY 503 CATTCTCCACAC 515
XX
XX 1 CATTACACACAC 13
XX
XX
XX RESULT 513
XX ABC45744/C
XX ID ABC45744 standard; DNA, 13 BP.
XX
XX AC ABC45744;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 45761 for detecting SNP TSC0013302.
XX
XX DE SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX PN 18-OCT-2001.
XX
XX PD 06-APR-2001; 2001WO-IB000713.
XX
XX PF 07-APR-2000; 2000DE-01019173.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIC-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX
XX Claim 1; SEQ ID NO 45761; 29bp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 11 A; 0 C; 1 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY 74 TTCTTTATTTCT 86
XX
XX 13 TTCTTTATTTT 1
XX
XX
XX RESULT 514
XX ABC35069
XX ID ABC35069 standard; DNA, 13 BP.
XX
XX AC ABC35069;
XX
XX 20-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 35086 for detecting SNP TSC0011139.
XX
XX KM SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX PN 18-OCT-2001.
XX
XX PD 06-APR-2001; 2001WO-IB000713.
XX
XX PF 07-APR-2000; 2000DE-01019173.
XX
XX PR (EPIC-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 35086; 29bp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 502 ACATCTCCACCA 514
DB 1 ACACACTCCACCA 13
RESULT 515
ABF9370/C
XX ID ABF9370 standard; DNA, 13 BP.
XX AC ABF9370;
XX DT 21-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 139367 for detecting SNP TSC0034894.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX MO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 139367; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 233 CCACAGAAACTA 245
DB 13 CCACAGAAACTA 1

RESULT 516
ABF6676/C
XX ID ABF6676 standard; DNA, 13 BP.
XX AC ABF6676;
XX DT 22-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 176673 for detecting SNP TSC0043845.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX MO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 176673; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 581 AATCTACCCAAA 593
DB 13 AATCTACCTAAA 1
RESULT 517
ABH65197/C
XX ID ABH65197 standard; DNA, 13 BP.
XX AC ABH65197;
XX DT 22-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 265174 for detecting SNP TSC0001077.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

```
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 265174; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX Oy 78 TTTATTTCTGAAA 90
XX 13 TTTATTTCTGAAA 1
XX
XX RESULT 518
XX ABC77745
XX ID ABC77745 standard; DNA; 13 BP.
XX
XX ABC77745;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 77762 for detecting SNP TSC0019798.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
```

```
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 77762; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX Oy 237 AGAAACTACCCA 249
XX 1 ACAAACTACCCA 13
XX
XX RESULT 519
XX ABC55355
XX ID ABC55355 standard; DNA; 13 BP.
XX
XX ABC55355;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 55372 for detecting SNP TSC0015123.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 55372; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
```

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
 QY Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Db 550 ATGACACCACT 562
 1 ATGACACCACT 13
 RESULT 520
 ABF92996/c
 ID ABF92996 standard; DNA; 13 BP.
 XX
 AC ABF92996;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 192993 for detecting SNP TSC0047477.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 192993; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 1 A; 1 C; 6 G; 5 T; 0 U; 0 Other;
 XX

Query Match 0.2%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 212 CACCACATCAACA 224
 Db 13 CACCACGTCAACA 1
 RESULT 521
 ABH08912/c
 ID ABH08912 standard; DNA; 13 BP.
 XX
 AC ABH08912;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 208889 for detecting SNP TSC0051007.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 208889; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 1 C; 3 G; 5 T; 0 U; 0 Other;
 XX
 QY 81 ATTTCTGAATCA 93
 Db 13 ATTTCCGAATCA 1
 RESULT 522
 ABC92900/c
 ID ABC92900 standard; DNA; 13 BP.
 XX

```

AC ABC92900;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 92917 for detecting SNP TSC0023234.
XX
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 92917; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
Oy 212 CACCATCACA 224
XX |||||
XX 13 CACCATCACA 1
XX
RESULT 523
ABC78999
ID ABC78999 standard; DNA, 13 BP.
XX
XX ABC78999;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 79016 for detecting SNP TSC0020111.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX

```

```

XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 79016; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 2.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
Oy 215 CACATCACA 227
XX |||||
XX 1 CACATCACA 13
XX
RESULT 524
ABF93320/c
ID ABF93320 standard; DNA, 13 BP.
XX
XX ABF93320;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 193317 for detecting SNP TSC0047561.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX

```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 19317, 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 582 ATACTACCAAT 594
DB 13 ATACTACCAAT 1

RESULT 525
AB146224
ID AB146224 standard; DNA; 13 BP.
XX
AC AB146224;
XX
DT 26-APR-2002 (first entry)
XX
XX HIV-1 INVADER assay oligonucleotide SEQ ID NO:191.
DE
XX Nucleic acid accessible hybridisation site; detection; hybridisation;
XX characterisation; identification; nucleic acid structure; diagnosis;
XX PCR primer; probe; ss.
XX
XX Human immunodeficiency virus 1.
OS Synthetic.
XX
XX WO200198537-A2.
XX
XX 27-DEC-2001.
PD
XX 15-JUN-2001; 2001WO-US019401.
PF
XX 17-JUN-2000; 2000US-0212308P.
PR
XX 15-JUN-2001; 2001US-00212308.
XX
XX (THIR-) THIRD WAVE TECHNOLOGIES INC.
PA
XX Lyamichev V, Allawi H, Dong F, Neri BP, Veneri IT;
XX WPI; 2002-049698/06.
DR
XX WPI; 2002-049698/06.
XX
XX Identifying oligonucleotides hybridizing to nucleic acids containing
PT secondary structure, useful in clinical diagnosis, comprises identifying
PT primers that interact with the target to form an extension product under
PT amplification conditions.
XX
XX Claim 48; Fig 59; 409pp; English.
XX
XX The present invention describes a method for identifying oligonucleotides
CC with desired hybridisation properties to nucleic acid targets containing
CC secondary structure. The method comprises amplifying a target nucleic
CC acid having at least one accessible and one inaccessible site. Primers

CC that form an extension product are identified as the oligonucleotides
CC which can interact with the folded target nucleic acid. Oligonucleotides
CC from the present invention can be used in novel detection methods for
CC clinical diagnostic purposes, including the detection and identification
CC of pathogenic organisms (e.g. HIV). The method allows the ability to
CC rapidly analyse nucleic acid structures. AB146034 to AB146367 represent
CC sequences used in the exemplification of the present invention
XX
SQ Sequence 13 BP; 1 A; 8 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 380 CCGTCGCGCCTCC 392
DB 1 CCGTCGCGCCTCC 13

RESULT 526
AAD59502/c
ID AAD59502 standard; DNA; 13 BP.
XX
AC AAD59502;
XX
DT 18-DEC-2003 (first entry)
XX
XX Aspergillus oryzae consensus translational initiator oligonucleotide #2.
DE
XX Translational initiator; polypeptide production; ss.
XX
XX Aspergillus oryzae.
XX
XX US6461837-B1.
XX
XX 08-OCT-2002.
PD
XX 20-NOV-2000; 2000US-00717847.
PF
XX 30-NOV-1999; 99US-00451503.
PR
XX (NOVO) NOVOSYMES BIOTECH INC.
PA
XX Yaver DS, Bellini DA;
XX WPI; 2003-110237/10.
DR
XX Producing polypeptide, by cultivating fungal cell with gene encoding the
PT polypeptide operably linked to a sequence comprising consensus
PT translational initiator sequence foreign to the gene and isolating
PT polypeptide.
XX
XX Claim 20; Col 27; 34pp; English.
XX
XX The invention relates to methods for producing polypeptide which involves
CC cultivating fungal cell with gene encoding the polypeptide operably
CC linked to a sequence comprising consensus translational initiator
CC sequence foreign to the gene and isolating polypeptide. The invention is
CC useful for production of a polypeptide, such as hormone or hormone
CC variant, enzyme, receptor or its portion and antibody or its portion. The
CC present sequence is Aspergillus oryzae consensus translational initiator
CC oligonucleotide. This sequence is used to illustrate the method of the
CC invention. Note: This sequence SEQ ID NO:2 is stated to be similar to the
CC sequence shown in column 3. However this sequence contains additional
CC bases at the 3' end
XX
SQ Sequence 13 BP; 2 A; 5 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 133 CATGCTGATGAC 145

```

Db      13 CATGCTGAAGAC 1
|||||
RESULT 527
ABT17625
ID      ABT17625 standard; DNA; 13 BP.
XX
XX      ABT17625;
XX
XX      10-APR-2003 (first entry)
XX
DE      Invader detection assay related synthetic target SEQ ID No 125.
XX
XX      Pooled sample; INVADER detection assay; allele frequency; polymorphism;
XX      rare mutation; blood; plasma donation; pathogenic contamination; ds.
XX
XX      Unidentified.
XX
XX      WO200290572-A2.
XX
XX      14-NOV-2002.
XX
XX      09-MAY-2002; 2002WO-US014765.
XX
XX      09-MAY-2001; 2001US-0289766P.
XX      02-OCT-2001; 2001US-0326549P.
XX      09-MAY-2002; 2002US-00326549.
XX
XX      (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX
XX      Fors L, Neri BP, Brow MAD, De Arruda Indig M, Roeven R;
XX
XX      WPI; 2003-12055/11.
XX
XX      Use of an INVADER detection assay for testing nucleic acids in pooled
XX      samples without prior amplification, e.g. for detecting rare mutations,
XX      or testing large numbers of blood or plasma donations to eliminate
XX      contaminated units.
XX
XX      Disclosure; Fig 11; 77pp; English.
XX
XX      The invention relates to a novel method for performing nucleic acid
XX      testing on a pooled sample, comprising employing an INVADER detection
XX      assay. The method is useful for detecting target nucleic acid sequences
XX      in pooled samples without prior amplification of the target. The method
XX      is particularly useful for detecting an allele frequency of a
XX      polymorphism, detecting a rare mutation, or testing large numbers of
XX      blood or plasma donations to eliminate units having pathogenic (e.g.
XX      viral) contamination. This polynucleotide sequence represents a synthetic
XX      target used in the INVADER detection method of the invention
XX
XX      Sequence 13 BP; 1 A; 8 C; 2 G; 2 T; 0 U; 0 Other;
SQ
Query Match      0.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      380 CCGTCGCGCCGCC 392
      |||||
      1 CCGTCGCGCCCTCC 13
DB
RESULT 528
AAQ78416/c
ID      AAQ78416 standard; DNA; 14 BP.
XX
XX      AAQ78416;
XX
XX      25-MAR-2003 (revised)
XX      27-JUN-1995 (first entry)
XX
XX      TGF-beta gene phosphorothioate antisense oligonucleotide.
DE

```

```

XX      Transforming growth factor beta; TGF-beta; antisense; treatment; tumour;
XX      angiogenesis; breast tumour; neurofibroma; glioma; glioblastoma;
XX      carcinogenesis; carcinoma; oesophagus; oesophageal; gastric; gut;
XX      immunosuppression; oligonucleotide; ss.
XX
XX      Synthetic.
XX
XX      WO9425588-A2.
XX
XX      10-NOV-1994.
XX
XX      29-APR-1994; 94WO-EP001362.
XX
XX      30-APR-1993; 93EP-00107089.
XX      13-MAY-1993; 93EP-00107849.
XX
XX      (BIOG-) BIOGNOSTIK GFS BIOMOLEKULARE DIAGNOSTIK.
XX
XX      Schlingensiepen G, Brysch W, Schlingensiepen K, Schlingensiepen R;
XX      Bogdahn U;
XX
XX      WPI; 1994-358266/44.
XX
XX      New transforming growth factor beta antisense oligo:nucleotide(s) - for
XX      treating immunosuppression, tumours, etc.
XX
XX      Claim 6; Page 42; 74pp; English.
XX
XX      The antisense oligonucleotides are useful in the treatment of tumours in
XX      CC which expression of TGF-beta is of relevance for pathogenicity and/or
XX      CC inhibition of pathological angiogenesis. They are used especially for the
XX      CC treatment of the immunosuppressive effect of TGF-beta, augmentation of
XX      CC the proliferation of cytotoxic lymphocytes, treatment of endogenous
XX      CC hyperexpression of TGF-beta, treatment of breast tumours, neurofibromas
XX      CC and malignant gliomas, including glioblastomas, treatment and prophylaxis
XX      CC of skin carcinogenesis, and treatment of oesophageal and gastric
XX      CC carcinomas. See AAQ78352-Q78488. The sequences given in GENESQ files
XX      CC AAQ78352-Q78407 and AAQ78488 are antisense oligodeoxynucleotides of TGF-
XX      CC beta 1. The sequences given in GENESQ files AAQ78408-78487 are antisense
XX      CC oligodeoxynucleotides of TGF-beta 2 in the form of phosphorothioate
XX      CC analogues. (Updated on 25-MAR-2003 to correct PN field.)
XX
XX      Sequence 14 BP; 2 A; 2 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match      0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      575 CCCGAGAACTACTA 587
      |||||
      14 CCCGAGAACTACTA 2
DB
RESULT 529
AAV11052/c
ID      AAV11052 standard; RNA; 14 BP.
XX
XX      AAV11052;
XX
XX      25-MAR-2003 (revised)
XX      14-JUL-1998 (first entry)
XX
XX      Human ribozyme target sequence from HLA-DQB 05DQB #1.
XX
XX      Ribozyme; target; human lymphocyte antigen; HLA-DQB; MHC allele;
XX      KW major histocompatibility complex; cleavage; suppression; transplant;
XX      KW incompatibility; autoimmune disease; juvenile diabetes;
XX      XX rheumatoid arthritis; ss.
XX
XX      Homo sapiens.
XX
XX      W09704087-A1.
PN

```

```

XX 06-FEB-1997.
PD 18-JUL-1996; 96WO-EP003173.
XX 18-JUL-1996; 96WO-EP003173.
XX 18-JUL-1995; 95BP-00111256.
XX (KRUPP/) KRUPP G.
PA (MARG/) MARGRET M.
PA (WEST/) WESTPHAL E.
PA (MOEL/) MUELLER-RUCHHOLTZ W.
PI Krupp G, Margret M, Westphal E, Mueller-Ruchholtz W;
XX WPI; 1997-132628/12.
XX Ribozyne that cleaves specific MHC allele(s) - used to inhibit graft
PT versus host reactions, to overcome blood incompatibility and to treat
PT auto-immune disease.
XX Claim 5; Fig 1; 76pp; German.
XX AAV10915-V11123 are target sequences for a novel ribozyme which cleaves
CC specific alleles from the major histocompatibility complex (MHC). This
CC ribozyme contains a catalytic region and a hybridisation region which is
CC complementary to all mRNA transcribed from vertebrate genes of a specific
CC family of closely related MHC alleles or to mRNA from a single MHC
CC allele, and is able to cleave such mRNA. The mRNA has a target region
CC which in case is essentially conserved in all genes of the family but
CC differs from genes of all other MHC alleles to such a degree that no
CC cleavage of mRNA transcribed from these other alleles occurs. This allows
CC the selective reduction or inhibition of expression of all genes of a
CC family or of a single gene. This ribozyme can be used for permanent or
CC transient suppression of expression of MHC alleles, in vivo or in vitro.
CC Specific applications are to prevent guest vs. host or host vs. guest
CC reactions, to prevent blood incompatibilities (partic. of the ABO, rhesus
CC and kell systems) and to treat autoimmune diseases such as juvenile
CC diabetes and rheumatoid arthritis. The use of this ribozyme avoids the
CC need for immunosuppressants in transplant patients. It provides very
CC specific reduction of particular HLA molecules that cause incompatibility
CC between donor and recipient. (Updated on 25-MAR-2003 to correct PA
CC field.) (Updated on 25-MAR-2003 to correct PI field.)
XX Sequence 14 BP; 3 A; 2 C; 7 G; 0 T; 2 U; 0 Other;
SQ
Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 158 GCAGCTACTCCAC 170
DB 13 GCAGCTACTCCTC 1

```

```

PF 05-JUL-1996; 96JP-00195419.
XX 03-OCT-1995; 95JP-00279752.
XX (TOAG ) TOA GOSEI CHEM IND LTD.
XX WPI; 1997-375653/35.
XX Method for preparing an anti-sense nucleic acid - useful for preventing
PT expression of a target gene.
XX Example; Page 18; 25pp; Japanese.
XX The present sequence is an oligonucleotide antisense to human vascular
CC endothelial growth factor (hVEGF) cDNA. It was prepared by hybridising
CC several random nucleotide sequences to DNA or RNA encoding a target
CC protein, i.e. hVEGF cDNA, to obtain hybridising antisense
CC oligonucleotides, which preferably prevent the expression of the target
CC protein, and optionally lysing the hybridisation site with a nucleic acid
CC degrading substance
XX Sequence 14 BP; 2 A; 6 C; 5 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 382 GTCGCGCCTCCGA 394
DB 13 GTCGCGCCTCCGA 1

```

```

RESULT 531
AAV48616/c
ID AAV48616 standard; DNA; 14 BP.
XX AAT79148;
AC AAT79148;
XX 08-OCT-1997 (first entry)
DT Human VEGF cDNA antisense oligonucleotide A083N.
XX Human, vascular endothelial growth factor; VEGF; antisense; preparation;
KM oligonucleotide; ss.
XX Synthetic.
OS JF09154579-A.
XX 17-JUN-1997.

```

```

RESULT 531
AAV48616/c
ID AAV48616 standard; DNA; 14 BP.
XX AAV48616;
AC AAV48616;
XX 15-OCT-1998 (first entry)
DT Junb gene antisense oligonucleotide Junb-N-2.
XX Junb; Junb; antisense oligonucleotide; modulate; gene expression; ss.
XX Synthetic.
OS Homo sapiens.
XX EP856579-A1.
XX 05-AUG-1998.
XX 31-JAN-1997; 97BP-00101531.
XX 31-JAN-1997; 97BP-00101531.
XX (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX Schlingensiepen K, Brysch W;
XX WPI; 1998-400910/35.
XX Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT consecutive guanosine or inosine - and have specific ratio of residues
PT able to form two or three hydrogen bonds, have greater activity and
PT reduced toxicity, used therapeutically or to modulate growth of cells in
XX culture.
XX Example 3; Fig 5b; 286pp; English.
XX AAV48564-708 represent antisense oligonucleotides directed against the
CC Junb and Junb genes. Of these, only oligonucleotides AAV48565-614
CC resulted in effective downregulation of negative growth control by Junb
CC or Junb, while AAV48615-708 had little effect. The oligonucleotides

```

CC exemplify the invention. The specification describes oligonucleotides
 CC that contain 8-30 nucleotides, which contain at most 8 nucleotides that
 CC can each form three hydrogen bonds to cytosine, do not contain four
 CC consecutive nucleotides able to form three H-bonds each to four
 CC consecutive cytosines, do not contain two sequences of three consecutive
 CC nucleotides each able to form three H-bonds to three consecutive
 CC cytosines, and the ratio between residues able to form two H-bonds each
 CC (2R) or three such bonds (3R) is given by $2R/3R = 0.33-0.72$. The
 CC oligonucleotides are used to modulate expression of genes, particularly
 CC the genes for p53, ErbB-2, JunB, JunD, TGF-beta 1 or Delta 2 to control
 CC proliferation of primary cell cultures (e.g. bone marrow stem, liver or
 CC kidney cells), osteoclasts, osteoblasts and/or keratinocytes). The
 CC oligonucleotides can also be used to analyse function of proteins (by
 CC altering their expression or activity) and therapeutically, e.g. in cases
 CC of cancer or (targeting TGF) for stimulating the immune system

SO Sequence 14 BP; 2 A; 2 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 14;
 Best Local Similarity 92.3%; Pred. No. 3e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 41 CCAAAATGGACA 53
 Db 13 CTAATAATGGACA 1

RESULT 532
 AAV57062/C
 ID AAV57062 standard; DNA; 14 BP.

AC AAV57062;
 DT 25-MAR-2003 (revised)
 DT 21-DEC-1998 (first entry)

XX Human Notch3 gene exon 31/inton 31 boundary sequence.

XX Human; Notch3; transmembrane receptor; lateral inhibition; regulation;
 KW developmental cascade; neurogenic gene; mutant; neurological disorder;
 KW cerebral autosomal dominant arteriopathy; subcortical infarct; CADASIL;
 KW leukoencephalopathy; therapy; intron; exon; ss.

OS Homo sapiens.

XX Key Location/Qualifiers
 FH 1. .6
 PT exon /*tag= a

PT /number= 31
 PT 7. .14
 PT /*tag= b
 PT /number= 31

XX PR2751986-A1.

XX 06-FEB-1998.

XX 16-APR-1997; 97FR-00004680.

XX 01-AUG-1996; 96FR-00009733.

XX (INRM) INSERM INST NAT SANTE & RECH MEDICALE.

XX Tournier LE, Jouteil A, Bousser MG, Bach JF;

XX WPI; 1998-133138/13.

XX Human Notch3 nucleic acids - and methods for identifying pre-disposition
 PT to cerebral autosomal dominant arteriopathy with sub-cortical infarcts
 PT and leukoencephalopathy.

XX Example 3; Page 22; 45p; French.

CC This sequence represents the boundary between exon 31 and intron 31 of
 CC the human Notch3 gene. Notch3 is a transmembrane receptor protein
 CC involved in lateral inhibition and regulating developmental cascades of
 CC neurogenic genes. Mutated Notch3 proteins are thought to be involved in
 CC neurological disorders, especially of the cerebral autosomal dominant
 CC arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
 CC type. Blocking expression of a mutated Notch3 gene or by substitution
 CC therapy with non-mutated Notch3 gene or protein can be used to treat
 CC CADASIL or related disorders. (Updated on 25-MAR-2003 to correct PI
 CC field.)

SO Sequence 14 BP; 2 A; 1 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 14;
 Best Local Similarity 92.3%; Pred. No. 3e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 528 AACCTGCCAGCT 540
 Db 13 AACCTACCAAGCT 1

RESULT 533
 AAZ59021/C
 ID AAZ59021 standard; DNA; 14 BP.

AC AAZ59021;

DT 11-APR-2000 (first entry)

XX Triple helix forming target sequence from ori-gamma plasmids.

XX Antitumour; antiviral; antimicrobial; transfer vector; targeting system;
 KW triplex; triple helix; antisense; ribozyme; gene therapy; blood factor;
 KW hormone; tumour suppressor; antigenic peptide; vaccine; immunotherapy;
 KW cancer; PCR; ori; origin of replication; ss.

OS Unidentified.

XX W09949067-A1.

XX 30-SEP-1999.

XX 19-MAR-1999; 99WC-FR000643.

XX 24-MAR-1998; 98FR-00003573.

XX 18-MAY-1998; 98US-0085848P.

XX (RHON) RHONE-POULENC RORER SA.

XX Giolina C, Scherman D, Wils P;

XX WPI; 1999-572204/48.

XX New nucleic acid transfer vector comprising double-stranded DNA linked to
 PT oligonucleotide, used for gene therapy.
 PS Claim 13; Page 40; 72pp; French.

XX The invention relates to a method of delivering a therapeutic double
 CC stranded DNA to a target cell or tissue by administering the DNA in a
 CC transfer vector. The vector comprises the double-stranded DNA molecule
 CC and at least one oligonucleotide that is linked to a targeting system and
 CC can form a triplex with a specific sequence within target cell or tissue.
 CC This sequence represents an example of a target sequence able to form a
 CC triple helix with the oligonucleotides. The sequence is found in the
 CC gamma origin of replication of plasmids such as pCOR. The vector is used
 CC to deliver therapeutic DNA (including antisense sequences or ribozymes)
 CC for gene therapy, e.g. sequences that encode enzymes, blood factors,
 CC hormones, tumour suppressors, also antigenic peptides for use as vaccines
 CC or immunotherapeutic agents for control of microbial or viral infections,
 CC or cancer

SQ Sequence 14 BP; 12 A; 0 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 14;
 Best Local Similarity 92.3%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 74 TTCTTTATTTCT 86
 |||||
 14 TTCTTTATTTCT 2

Db

RESULT 534
 AA264788/c
 ID AA264788 standard; RNA; 14 BP.
 AC AA264788;
 XX 28-MAR-2000 (first entry)
 XX
 DE Substrate for hairpin ribozyme which cleaves HCV at nt. 4441.
 XX
 KM Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;
 KM cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;
 KM autoimmune disease; ss.
 XX
 XX Hepatitis C virus.
 XX
 PN W09955847-A2.
 PD 04-NOV-1999.
 XX
 PF 26-APR-1999; 99WO-US009027.
 XX
 PR 27-APR-1998; 98US-0083217P.
 PR 18-SEP-1998; 98US-0100842P.
 PR 25-FEB-1999; 99US-00257608.
 PR 23-MAR-1999; 99US-00274553.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, McSwiggen JA, Roberts E, Pavco PA, Macejak D;
 DR WPI; 2000-062023/05.
 XX
 PT Novel ribozymes for the treatment of diseases and conditions related to
 PT hepatitis C infection.
 XX
 XX Claim 2; Page 97; 123pp; English.
 XX
 CC The present sequence represents the preferred target sequence of an
 CC enzymatic nucleic acid, especially a hairpin ribozyme, which cleaves the
 CC Hepatitis C virus (HCV) RNA sequence at the base position given in the
 CC descriptor line. The HCV sequence was screened for optimal ribozyme
 CC target sites using a computer folding algorithm and regions of the mRNA
 CC which did not form secondary folding structures and contained potential
 CC ribozyme cleavage sites were identified. Ribozymes were synthesised to
 CC target these sites and their activities optimised by either varying the
 CC length of the binding arms or by modification to prevent degradation by
 CC nucleases. The ribozymes of the invention inhibit gene expression and/or
 CC viral replication, and are used to treat diseases associated with
 CC Hepatitis C virus (HCV) infection, e.g. cirrhosis, liver failure and
 CC hepatocellular carcinoma. The ribozymes may be used in combination with
 CC interferon to treat HCV infection, other infectious diseases, autoimmune
 CC diseases, and cancer
 XX
 SQ Sequence 14 BP; 3 A; 6 C; 2 G; 0 T; 3 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 14;
 Best Local Similarity 92.3%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 137 GTGATGCACAGAG 149
 |||||

Db 14 GTGTTGACAGAG 2

RESULT 535
 AA26129
 ID AA26129 standard; DNA; 14 BP.
 AC AA26129;
 XX
 XX 19-JUL-2000 (first entry)
 XX
 DE Oestrogen receptor hairpin ribozyme target sequence SEQ ID NO:2627.
 XX
 KM Oestrogen receptor; c-ras; bcl-2; ribozyme; cleavage;
 KM hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
 KM gene expression modification; cancer; phosphothioate; endonuclease;
 KM anticancer; breast cancer; endometrium cancer; ss.
 XX
 XX Homo sapiens.
 XX
 PN W09954459-A2.
 PD 28-OCT-1999.
 XX
 PF 19-APR-1999; 99WO-US008547.
 XX
 PR 20-APR-1998; 98US-0082404P.
 PR 23-JUN-1998; 98US-00103636.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Thompson JD, Beigelman L, McSwiggen JA, Karpelsky A, Bellon L;
 PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haberli P;
 PI Maculic-Adamic J;
 DR WPI; 2000-013248/01.
 XX
 XX New nucleic acids that interact, and optionally cleave, target sequences,
 PT used to treat cancer.
 XX
 XX Claim 79; Page 99; 148pp; English.
 XX
 CC The present invention describes nucleic acids (A) that interact stably
 CC with a target sequence and contain at least one phosphoro(di)thioate
 CC link, having endonuclease activity. (A), and more generally any catalytic
 CC nucleic acid (A') that modulates expression of the oestrogen receptor
 CC gene, are used to treat cancer (particularly of breast or endometrium),
 CC in vivo or by transforming cells ex vivo and implanting treated cells, or
 CC for other conditions associated with levels of oestrogen receptor.
 CC Because of the high selectivity for targeted RNA, (A) can also be used to
 CC correlate inhibition of gene expression with alterations in phenotype,
 CC particularly for identification of therapeutic targets, and as research
 CC reagents (for RNA, in the same way that restriction endonucleases are
 CC used with DNA). The combination of modifications in (A) improves
 CC resistance to nucleases, binding affinity and/or activity. AA23503 to
 CC AA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
 CC AA24748 to AA25992 represent their corresponding target sequences.
 CC AA25993 to AA26105 represent oestrogen receptor hairpin ribozyme
 CC sequences, and AA26107 to AA26218 represent their corresponding target
 CC sequences. AA26219 to AA26271 represent other ribozyme sequences and
 CC antisense oligonucleotides used in the exemplification of the present
 CC invention
 XX
 SQ Sequence 14 BP; 2 A; 4 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 14;
 Best Local Similarity 92.3%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 448 CAAAGCCTGCGG 460
 |||||
 1 CAAAGCCTGCGG 13

```

RESULT 536
AAS21101/C
ID AAS21101 standard; DNA; 14 BP.
XX
AC AAS21101;
XX
DT 20-MAR-2002 (first entry)
XX
DE Oligonucleotide corresponding to pXJ3296 DNA sequence.
XX
KM ss; DNA purification; triple helix; plasmid purification;
KM double purification.
XX
OS Synthetic.
XX
PN WO200192511-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US017122.
XX
PR 26-MAY-2000; 2000US-00580923.
XX
PA (AVERT ) AVENTIS PHARMA SA.
XX
PI Crouzet J, Scherman D, Wils P, Blanche F, Cameron B;
XX WPI; 2002-097772/13.
XX
PT Purifying double-stranded (ds) DNA from a solution containing dsDNA and
PT other components, comprises passing the solution through a support
PT comprising a covalently coupled oligonucleotide able to form a triple
XX helix with the dsDNA.
XX
PS Claim 2; Page 23; 40pp; English.
XX
CC This invention comprises a method of purifying double-stranded DNA from a
CC solution containing the double-stranded DNA mixed with other components,
CC comprising passing the solution through a support comprising a covalently
CC coupled oligonucleotide capable of forming a triple helix with the double
CC double-stranded DNA by hybridisation with a specific sequence present in the
CC DNA contained in a solution and mixed with other components. The new
CC method is a simple, rapid and effective method for DNA purification, and
CC makes it possible to obtain especially high purities with high yields.
CC The method enables DNA to be purified from complex mixtures comprising
CC other nucleic acids, proteins, endotoxins, nucleases and the like. The
CC supports may be readily recycled, and the DNAs obtained display improved
CC properties to pharmaceutical safety. Further, the method entails only one
CC step contrary to prior art. The present sequence represents an
CC oligonucleotide corresponding to a sequence contained within plasmid
CC pXJ3296, that is capable of forming a triple helix for use in the DNA
CC double purification method of the invention
XX
SQ Sequence 14 BP; 12 A; 0 C; 2 G; 0 T; 0 U; 0 Other;
XX
Query Match
Best Local Similarity 0.2%; Score 11.4; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 74 TTCTTTATTTCT 86
DB 14 TTCTTTTTTCT 2

```

```

XX
DE Oligonucleotide used to prepare a DNA triplex affinity gel.
XX
KM ss; DNA purification; triple helix; plasmid purification;
XX homopyrimidine oligonucleotide.
XX
OS Synthetic.
XX
PN WO200192511-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US017122.
XX
PR 26-MAY-2000; 2000US-00580923.
XX
PA (AVERT ) AVENTIS PHARMA SA.
XX
PI Crouzet J, Scherman D, Wils P, Blanche F, Cameron B;
XX WPI; 2002-097772/13.
XX
PT Purifying double-stranded (ds) DNA from a solution containing dsDNA and
PT other components, comprises passing the solution through a support
PT comprising a covalently coupled oligonucleotide able to form a triple
XX helix with the dsDNA.
XX
PS Claim 1; Page 23; 40pp; English.
XX
CC This invention comprises a method of purifying double-stranded DNA from a
CC solution containing the double-stranded DNA mixed with other components,
CC comprising passing the solution through a support comprising a covalently
CC coupled oligonucleotide capable of forming a triple helix with the double
CC double-stranded DNA by hybridisation with a specific sequence present in the
CC DNA contained in a solution and mixed with other components. The new
CC method is a simple, rapid and effective method for DNA purification, and
CC makes it possible to obtain especially high purities with high yields.
CC The method enables DNA to be purified from complex mixtures comprising
CC other nucleic acids, proteins, endotoxins, nucleases and the like. The
CC supports may be readily recycled, and the DNAs obtained display improved
CC properties to pharmaceutical safety. Further, the method entails only one
CC step contrary to prior art. The present sequence represents a homopurine
CC oligonucleotide used to purify the PCOR plasmid using an oligonucleotide
CC gamma) of the plasmid
XX
SQ Sequence 14 BP; 0 A; 2 C; 0 G; 12 T; 0 U; 0 Other;
XX
Query Match
Best Local Similarity 0.2%; Score 11.4; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 74 TTCTTTATTTCT 86
DB 1 TTCTTTTCT 13

```

RESULT 538
ABX01625/C
ID ABX01625 standard; RNA; 14 BP.
XX
AC ABX01625;
XX
DT 23-DEC-2002 (first entry)
XX
DE Hepatitis C virus substrate #110 for HCV hairpin ribozyme #110.
XX
KM Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
KM HCV ribozyme; HCV expression; HCV replication; cirrhosis; virulence;
KM liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
KM type I interferon; interferon alpha; interferon beta; cytostatic;
KM interferon gamma; consensus interferon; hepatotropic; anti-inflammatory;

KM substrate; hairpin ribozyme; HP ribozyme; ss.
 XX Hepatitis C virus.
 OS US2002082225-A1.
 PN 27-JUN-2002.
 PD 23-MAR-1999; 99US-00274553.
 XX 23-MAR-1999; 99US-00274553.
 PR 23-MAR-1999; 99US-00274553.
 XX (BLAT/) BLATT L.
 PA (MCSM/) MCSWIGEN J A.
 PA (ROBE/) ROBERTS B.
 PA (PAVC/) PAVCO P A.
 PA (MACE/) MACEJACK D.
 PI Blatt L, Mcswigen JA, Roberts B, Pavco PA, Macejack D;
 PI WPI; 2002-617759/66.
 DR WPI; 2002-617759/66.
 XX New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
 PT replication and are useful to treat hepatitis C virus infections and
 PT cirrhosis, liver failure or hepatocellular carcinoma.
 XX Claim 2; Page 61; 80pp; English.
 PS The present invention relates to enzymatic nucleic acids which
 CC specifically cleave RNA derived from Hepatitis C virus (HCV). The
 CC enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin
 CC (HP) motif where the binding arms comprise sequences complementary to one
 CC of the substrate sequences defined in the specification. The HCV
 CC ribozymes are useful for modulating the expression and/or replication of
 CC HCV. They can be used to treat cirrhosis, liver failure and/or
 CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating
 CC a condition associated with HCV infection in conjunction with one or more
 CC other drug therapies, particularly type I interferon, especially
 CC interferon alpha, beta or gamma or consensus interferon. The present
 CC sequence represents a substrate for a HCV hairpin (HP) ribozyme. Note:
 CC Some of the sequence data for this patent did not form part of the
 CC printed specification. The complete sequence data for this patent was
 CC obtained in electronic format directly from the USPTO web site at
 CC seqdata.uspto.gov/patidentry.html
 CC Sequence 14 BP; 3 A; 6 C; 2 G; 0 T; 3 U; 0 Other;
 SQ Query Match 0.2%; Score 11.4; DB 1; Length 14;
 Best Local Similarity 92.3%; Pred. No. 3e+02; Mismatches 1; Indels 0; Gaps 0;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 137 GTGATGACAGAG 149
 Db 14 GTGTTGACAGAG 2
 RESULT 539
 ADE64664
 ID ADE64664 standard; DNA; 14 BP.
 AC ADE64664;
 XX 29-JAN-2004 (first entry)
 DT 29-JAN-2004 (first entry)
 XX yak milk protein gene related oligo, 454-467.
 DE yak milk; alpha-lactalbumin; beta-lactoglobulin; alpha SI-casein;
 KM alpha S2-casein; beta-casein; kappa-casein; lactoferritin; ss.
 XX Bos grunniens.
 OS CN1357627-A.
 PN CN1357627-A.
 XX

PD 10-JUL-2002.
 XX 08-DEC-2000; 2000CN-00134189.
 PF 08-DEC-2000; 2000CN-00134189.
 XX 08-DEC-2000; 2000CN-00134189.
 PR 08-DEC-2000; 2000CN-00134189.
 XX (LINN/) LI N.
 PA Li N, Fan B, Wu C;
 PI WPI; 2002-741796/81.
 DR WPI; 2002-741796/81.
 XX Seven kinds of yak milk protein gene sequence.
 PT Disclosure; Page 8 (disclosure); 41pp; Chinese.
 PS The present invention discloses seven kinds of full length and partial
 CC sequences of a yak milk protein gene. They include alpha-lactalbumin
 CC gene full length sequence, alpha-lactalbumin gene 5' lateral wing
 CC sequence, beta-lactoglobulin gene 5' lateral wing and 3' terminal
 CC sequence, alpha SI-casein gene 5' lateral wing and 3' terminal sequence,
 CC alpha S2-casein gene 5' lateral wing sequence, beta-casein gene 5' lateral wing
 CC and 3' terminal sequence, and lactoferritin gene 5' lateral wing
 CC sequence. This polynucleotide sequence represents an oligo relating to
 CC the yak milk protein genes of the invention.
 XX Sequence 14 BP; 1 A; 3 C; 1 G; 9 T; 0 U; 0 Other;
 SQ Query Match 0.2%; Score 11.4; DB 1; Length 14;
 Best Local Similarity 92.3%; Pred. No. 3e+02; Mismatches 1; Indels 0; Gaps 0;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 72 ACTTCTTTTATT 84
 Db 2 ACTTCTTTTATT 14
 RESULT 540
 AAL51214
 ID AAL51214 standard; DNA; 14 BP.
 AC AAL51214;
 XX 27-OCT-2003 (revised)
 DT 27-OCT-2003 (revised)
 DT 28-MAR-2003 (first entry)
 XX Adenovirus cap protein recognition sequence - SEQ ID No 30.
 DE DART; gene therapy; ds; dynamic action reference tool; viral infection;
 KM recognition sequence motif; disease-associated molecule detection;
 KM inflammatory disorder; cardiovascular disease; cancer; genetic disorder;
 KM autoimmune disease; Alzheimer's disease; Huntington's disease;
 KM autoimmune disorder; rheumatoid arthritis; hyperimmune disorder; allergy.
 XX unidentified adenovirus.
 OS WO200279393-A2.
 PN WO200279393-A2.
 PD 10-OCT-2002.
 PD 02-APR-2002; 2002WO-US010566.
 PF 02-APR-2002; 2002WO-US010566.
 XX 02-APR-2001; 2001US-0281133P.
 PR 03-APR-2001; 2001US-0281342P.
 XX (UNIW) UNIV WASHINGTON.
 PA Roberts RL, De Figueiredo P;
 PI WPI; 2003-129080/12.
 DR WPI; 2003-129080/12.
 XX Novel dynamic action reference tool (DART) comprising a molecular shaft
 PT

PT covalently linked to a linkage polypeptide covalently linked to a
PT molecular point, useful for isolating and analyzing nucleic acids,
XX polypeptides.

PS Disclosure; Page 49; 205pp; English.

CC The invention comprises dynamic action reference tools (DARTs). The DARTs
CC of the invention contain a molecular shaft covalently linked to a linkage
CC polypeptide, which is covalently linked to a molecular point. The DARTs
CC of the invention are useful for joining first and second nucleic acids,
CC where the second nucleic acid comprises a recognition sequence motif. The
CC DARTs of the invention are also useful for reducing the expression of a
CC target nucleic acid in a cell, and detecting a disease-associated
CC molecule in a biological sample. The DARTs of the invention may be used
CC in the treatment of: viral infections; inflammatory disorders; autoimmune diseases;
CC cardiovascular disease; cancers; genetic disorders; autoimmune diseases;
CC Alzheimer's disease; Huntington's disease; autoimmune disorders (e.g.
CC rheumatoid arthritis); and hyperimmune disorders (e.g. allergy). The
CC present DNA sequence was used in the invention. (Updated on 27-OCT-2003
CC to standardise OS field)

SQ Sequence 14 BP; 6 A; 3 C; 0 G; 5 T; 0 U; 0 Other;

Query Match

Best Local Similarity 92.3%; Score 11.4; DB 1; Length 14;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 217 CATCAACATATATA 229

Db 1 CATCAACATATATA 13

RESULT 541

ADN41976

ID ADN41976 standard; DNA; 14 BP.

AC ADN41976;

DT 15-JUL-2004 (first entry)

DE Nucleotide sequence which forms a stable triple helix structure.

KW replication initiation protein; origin of replication; p1r gene;
KW p1 protein; vaccine; gene therapy; genetic disease; dystrophy;
KW cystic fibrosis; neurodegenerative disease; Alzheimer's disease;
KW Parkinson's disease; ALS; cancer; coagulation disorder;
KW dyslipoproteinaemia; viral infection; hepatitis; AIDS; plasmid R6K; ss.

OS Escherichia coli.

PN WO2004033664-A2.

PD 22-APR-2004.

PF 14-OCT-2003; 2003WO-US032512.

PR 11-OCT-2002; 2002US-00268948.

PA (GENC-) GENCELL SA.

PA (AVET) AVENTIS PHARM INC.

PI Soubrier F;

DR WPI; 2004-340923/31.

XX New prokaryotic recombinant host cell comprising a heterologous
PT therapeutic gene and a conditional origin of replication, useful in
PT vaccination and in treating or preventing genetic diseases,
PT neurodegenerative diseases or cancers.

PS Disclosure; Page 10; 121pp; English.

CC The specification describes a prokaryotic recombinant host cell,

CC comprising a heterologous replication initiation protein that activates a
CC conditional origin of replication or a heterologous p1r gene encoding a
CC p1 protein and an extrachromosomal DNA molecule comprising a heterologous
CC therapeutic gene and a conditional origin of replication whose
CC functionality in the prokaryotic recombinant host cell requires a
CC replication initiating protein or p1 protein which is foreign to the host
CC cell. The prokaryotic recombinant host cells of the invention are useful
CC in vaccination, in gene therapy and in producing recombinant proteins.
CC The DNA molecules and compositions are useful in treating or preventing
CC pathologies including genetic diseases (dystrophy or cystic fibrosis),
CC neurodegenerative diseases (Alzheimer's disease, Parkinson's disease or
CC ALS), cancer, pathologies associated with coagulation disorders or with
CC dyslipoproteinaemia, pathologies associated with viral infections
CC (hepatitis or AIDS) or in agronomic and veterinary fields. The present
CC sequence is able to form a stable triple helix structure with ADN41975
CC which is a homopurine sequence contained in the gamma origin of
CC replication of PCOR. The present sequence may be incorporated into DNA
CC molecules of the invention.

SQ Sequence 14 BP; 0 A; 2 C; 0 G; 12 T; 0 U; 0 Other;

Query Match

Best Local Similarity 92.3%; Score 11.4; DB 1; Length 14;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 74 TTCTTTTATTTCCT 86

Db 1 TTCTTTTATTTCCT 13

RESULT 542

ADN41978

ID ADN41978 standard; DNA; 14 BP.

AC ADN41978;

DT 15-JUL-2004 (first entry)

DE Sequence targeting DNA in origins of replication of ColE1 or PCOR.

KW replication initiation protein; origin of replication; p1r gene;
KW p1 protein; vaccine; gene therapy; genetic disease; dystrophy;
KW cystic fibrosis; neurodegenerative disease; Alzheimer's disease;
KW Parkinson's disease; ALS; cancer; coagulation disorder;
KW dyslipoproteinaemia; viral infection; hepatitis; AIDS; plasmid R6K; ss.

OS Escherichia coli.

PN WO2004033664-A2.

PD 22-APR-2004.

PF 14-OCT-2003; 2003WO-US032512.

PR 11-OCT-2002; 2002US-00268948.

PA (GENC-) GENCELL SA.

PA (AVET) AVENTIS PHARM INC.

PI Soubrier F;

DR WPI; 2004-340923/31.

XX New prokaryotic recombinant host cell comprising a heterologous
PT therapeutic gene and a conditional origin of replication, useful in
PT vaccination and in treating or preventing genetic diseases,
PT neurodegenerative diseases or cancers.

PS Disclosure; Page 10; 121pp; English.

CC The specification describes a prokaryotic recombinant host cell,
CC comprising a heterologous replication initiation protein that activates a
CC conditional origin of replication or a heterologous p1r gene encoding a

CC pi protein and an extrachromosomal DNA molecule comprising a heterologous
CC therapeutic gene and a conditional origin of replication whose
CC functionality in the prokaryotic recombinant host cell requires a
CC replication initiating protein or pi protein which is foreign to the host
CC cell. The prokaryotic recombinant host cells of the invention are useful
CC in vaccination, in gene therapy and in producing recombinant proteins.
CC The DNA molecules and compositions are useful in treating or preventing
CC pathologies including genetic diseases (dystrophy or cystic fibrosis),
CC neurodegenerative diseases (Alzheimer's disease, Parkinson's disease or
CC ALS), cancers, pathologies associated with coagulation disorders or with
CC dyslipoproteinaemias, pathologies associated with viral infections
CC (hepatitis or AIDS) or in agronomic and veterinary fields. ADN41977-
CC ADN41978 target DNA sequences located in the origin of replication of
CC either ColEI or pCOR. The present sequence may be incorporated into DNA
CC molecules of the invention.

XX SQ Sequence 14 BP; 0 A; 2 C; 0 G; 12 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 74 TTCTTTATTCT 86
|||||
1 TTCTTTATTCT 13

Db

RESULT 543
ADN41975/c
ID ADN41975 standard; DNA; 14 BP.

XX AC ADN41975;
XX DT 15-JUL-2004 (first entry)
XX DE 12-mer homopurine sequence which forms a stable triple helix structure.

XX KW replication initiation protein; origin of replication; piR gene;
XX KM pi protein; vaccine; gene therapy; genetic diseases; dystrophy;
XX KM cystic fibrosis; neurodegenerative disease; Alzheimer's disease;
XX KM Parkinson's disease; ALS; cancer; coagulation disorder;
XX KM dyslipoproteinaemia; viral infection; hepatitis; AIDS; plasmid R6K; ss.
XX OS Escherichia coli.

XX PN WO2004033664-A2.
XX PD 22-APR-2004.
XX PF 14-OCT-2003; 2003WO-US032512.
XX PR 11-OCT-2002; 2002US-00268948.
XX PA (GENC-) GENCELL SA.
XX PA (AVET) AVENTIS PHARM INC.
XX PI Soubrier F;
XX DR WPI; 2004-340923/31.
XX PT New prokaryotic recombinant host cell comprising a heterologous
XX PT therapeutic gene and a conditional origin of replication, useful in
XX PT vaccination and in treating or preventing genetic diseases,
XX PT neurodegenerative diseases or cancers.
XX PS Disclosure; Page 10; 121pp; English.

XX CC The specification describes a prokaryotic recombinant host cell,
XX CC comprising a heterologous replication initiation protein that activates a
XX CC conditional origin of replication or a heterologous piR gene encoding a
XX CC pi protein and an extrachromosomal DNA molecule comprising a heterologous
XX CC therapeutic gene and a conditional origin of replication whose
XX CC functionality in the prokaryotic recombinant host cell requires a

CC replication initiating protein or pi protein which is foreign to the host
CC cell. The prokaryotic recombinant host cells of the invention are useful
CC in vaccination, in gene therapy and in producing recombinant proteins.
CC The DNA molecules and compositions are useful in treating or preventing
CC pathologies including genetic diseases (dystrophy or cystic fibrosis),
CC neurodegenerative diseases (Alzheimer's disease, Parkinson's disease or
CC ALS), cancers, pathologies associated with coagulation disorders or with
CC dyslipoproteinaemias, pathologies associated with viral infections
CC (hepatitis or AIDS) or in agronomic and veterinary fields. The present
CC sequence represents a homopurine sequence (contained in the gamma origin
CC of replication of pCOR), which is able to form a stable triple helix
CC structure with ADN41976. The present sequence may be incorporated into
CC DNA molecules of the invention.

XX SQ Sequence 14 BP; 12 A; 0 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 74 TTCTTTATTCT 86
|||||
14 TTCTTTATTCT 2

Db

RESULT 544
AAQ22407/c
ID AAQ22407 standard; DNA; 15 BP.

XX AC AAQ22407;
XX DT 09-JAN-2003 (revised)
XX DT 24-JUL-1992 (first entry)
XX DE Antisense sequence of nuclease resistant oligonucleotide for modulating
XX DE the activity of a selected sequence of RNA or DNA.

XX KW Antisense oligonucleotide; therapeutic; diagnostic; antisense binding;
XX KM ss.
XX OS Synthetic.
XX PN WO9203568-A.
XX PD 05-MAR-1992.
XX PF 12-AUG-1991; 91WO-US005720.
XX PR 13-AUG-1990; 90US-00566977.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Cook PD, Kawasaki AM;
XX DR WPI; 1992-096911/12.
XX PT Nuclease resistant 2'-deoxy-furansyl modified oligo-nucleotide(s) - are
XX PT specifically hybridised with DNA and RNA sequences to modulate gene
XX PT expression, for treating e.g. HIV, herpes and papillomavirus.
XX PS Example; Table 1, Page 56; 73pp; English.

XX CC The oligonucleotides of the invention have a sequence specifically
XX CC hybridisable with the selected sequence; and at least one modified 2' -
XX CC deoxyfuranosyl moiety. They are useful (as antisense oligonucleotides) as
XX CC therapeutics, diagnostics and research reagents. The selected sequence of
XX CC RNA or DNA may comprise a portion of the genome of HIV, herpes virus, or
XX CC papilloma virus, for use in treatment and diagnosis. (Updated on 09-JAN-
XX CC 2003 to add missing OS field.)

XX SQ Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 560 ACTCGCATGTCG 572
Db 13 ACTTGCAATGTCG 1

RESULT 545
AAQ22408/c
ID AAQ22408 standard; RNA; 15 BP.

AC AAQ22408;
XX
DT 09-JAN-2003 (revised)
DT 24-JUN-1992 (first entry)

DE Antisense sequence of nuclease resistant oligonucleotide for modulating
XX the activity of a selected sequence of RNA or DNA.

KW Antisense oligonucleotide; therapeutic; diagnostic; antisense binding;
XX ss.

OS Synthetic.
XX

PN WO9203568-A.
XX

PD 05-MAR-1992.
XX

PF 12-AUG-1991; 91WO-US005720.
XX

PR 13-AUG-1990; 90US-00566977.
XX

PA (ISIS-) ISIS PHARM INC.
XX

PI Cook PD, Kawasaki AM;
XX

DR WPI; 1992-096911/12.
XX

PT Nuclease resistant 2'-deoxy-furanosyl modified oligo-nucleotide(s) - are
XX specifically hybridised with DNA and RNA sequences to modulate gene
XX expression, for treating e.g. HIV, herpes and papillomavirus.
XX

PS Example; Table 1, Page 56; 73pp; English.
XX

CC The oligonucleotides of the invention have a sequence specifically
XX hybridisable with the selected sequence; and at least one modified 2' -
XX deoxyfuranosyl moiety. They are useful (as antisense oligonucleotides) as
XX therapeutics, diagnostics and research reagents. The selected sequence of
XX RNA or DNA may comprise a portion of the genome of HIV, herpes virus, or
XX papilloma virus, for use in treatment and diagnosis. (Updated on 09-JAN-
XX 2003 to add missing OS field.)

SO Sequence 15 BP; 5 A; 4 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 560 ACTCGCATGTCG 572
Db 13 ACTTGCAATGTCG 1

RESULT 546
AAQ20399/c
ID AAQ20399 standard; DNA; 15 BP.

AC AAQ20399;
XX

DT 10-APR-1992 (first entry)
XX

DE Capture probe #1 for detecting HPV-6 E7 gene DNA.

XX
KM Detection probe; sandwich hybridisation assay; human papilloma virus; ss.
XX
OS Synthetic.
XX

PN WO9119812-A.
XX

PD 26-DEC-1991.
XX

PF 11-JUN-1990; 90FR-00007249.
XX

PR 11-JUN-1990; 90FR-00007249.
XX

PA (INMR) BIO MERIEUX.
XX

PI Cros P, Allibert P, Mallet F, Mabilat C, Mandrand B,
XX

DR WPI, 1992-024428/03.
XX

PT Sandwich hybridisation of single strand nucleic acid - using short
XX immobilised capture probe and detection probe with non-radioactive label,
XX for diagnosing e.g. human papilloma virus or HIV.
XX

PS Claim 27; Page 37; 51pp; French.
XX

CC Target DNA corresponding to the E7 gene of HPV-6 is detected using one or
XX both of the capture probes AAQ20399 and AAQ20400 fixed passively to a
XX solid hydrophobic support together with one or both of detection probe(s)
XX CC AAQ20401 and AAQ20402 labelled with a non-radioactive marker. The capture
XX and detection probes are able to hybridise to non-overlapping segments
XX of the target sequence. See AAQ20389-Q20420 and AAQ20630-Q20663

SO Sequence 15 BP; 7 A; 3 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 18 TTTCTGCACACTG 30
Db 13 TTTCTGTACACTG 1

RESULT 547
AAQ1490/c
ID AAQ1490 standard; DNA; 15 BP.

AC AAQ1490;
XX

DT 25-MAR-2003 (revised)
XX

DT 24-AUG-1993 (first entry)
XX

DE Target region for 5-lipoxygenase.
XX

KW Chiral oligonucleotide; antisense therapy; sugar linkage; Rp; Sp; ss.
XX

OS Synthetic.
XX

PN WO9308296-A1.
XX

PD 29-APR-1993.
XX

PF 14-OCT-1992; 92WO-US008797.
XX

PR 15-OCT-1991; 91US-00777670.
XX

PR 16-OCT-1991; 91US-00777007.
XX

PA (ISIS-) ISIS PHARM INC.
XX

PI HoKe GD, Cook PD;
XX

DR WPI; 1993-152487/18.
XX

PT	Synthesis of new oligo:nucleotide(s) with chiral inter-sugar links - by
PT	nucleophilic substitution or polymerase catalysed primer extension,
PT	useful in anti-sense therapy for controlling protein expression.
XX	
PS	Disclosure; Page 93; 114pp; English.
XX	
CC	The invention describes oligonucleotides with chiral inter-sugar links
CC	(Sp or Rp). Various therapeutic areas can be targeted with these
CC	antisense oligomers to inhibit RNA translation in vivo. For example, the
CC	sequence shown is a target region of 5-lipoxygenase. An antisense
CC	oligomer to this target sequence may be used to diagnose and treat
CC	diseases caused by 5-lipoxygenase. See also AAQ41482-91. (Updated on 25-
CC	MAR-2003 to correct PN field.)
XX	
SQ	Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
XX	
Query Match	0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity	92.3%; Pred. No. 3 6e+02;
Matches 12; Conservative	0; Mismatches 1; Indels 0; Gaps 0
QY	560 ACTCGCATAGTCG 572
Db	13 ACTTCGATAGTCG 1
RESULT 548	
AAQ85837/C	
ID	AAQ85837 standard; DNA; 15 BP.
XX	
AC	AAQ85837;
XX	
DT	25-MAR-2003 (revised)
DT	09-NOV-1995 (first entry)
XX	
DE	2'-O-alkylamino-containing DNA oligomer #2.
XX	
KW	Alkylamino group; ribofuranosyl sugar; antisense therapy; virus; HIV;
KW	herpes; papilloma; antiviral; ss.
XX	
OS	Synthetic.
XX	
PN	WO9506659-A1.
PD	09-MAR-1995.
XX	
PF	02-SEP-1994; 94WO-US010131.
XX	
PR	03-SEP-1993; 93US-00117363.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	
PI	Cook PD, Manoharan M, Guinosso CJ;
NR	WPI; 1995-115397/15.
XX	
PT	New amine-derivatised nucleoside(s) and oligo:nucleoside(s) - useful as
PT	diagnostics, therapeutics and research reagents, partic. in anti-sense
PT	therapy.
XX	
PS	Example 130; Page 94; 117pp; English.
XX	
CC	Oligonucleotides AAQ85836-9 are target oligonucleotides generated to
CC	contain one or more modified deoxyadenosine nucleotides containing either
CC	2'-O-propyl-, -aminopropyl, butyl, pentyl, aminopentyl or butyl-imidazole
CC	linker groups. The modified oligomer are used in assays to measure the
CC	heteroduplex stability of the oligomer with its target sequence. The
CC	modified oligomer is an example of a compound (see AAQ85799-085839 for
CC	other examples) e.g. a nucleoside or oligonucleoside, which contains a
CC	ribofuranosyl sugar portion and a base portion, such that at least one of
CC	the nucleoside contains at a 2'-O-, 3'-O- or 5'-O-position, a
CC	substitution (see AAQ85799 for details of the substitutions). The
CC	compounds are useful in diagnostics, therapeutics and as research
CC	reagents particularly in antisense therapy for killing cells and viruses

CC		such as HIV, herpes or papilloma viruses.. (Updated on 25-MAR-2003 to correct PN field.)
XX		
SQ	Sequence	15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
OY		Query Match 0.2%; Score 11.4; DB 1; Length 15; Best Local Similarity 92.3%; Pred. No. 3.6e+02; Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0
DB	560 ACTCGCATAGTCG 572 13 ACTTGCATAGTCG 1	
RESULT 549		
AAT01730/C		
ID	AAT01730 standard; DNA; 15 BP.	
XX		
AC	AAT01730;	
DT	17-DEC-1995 (first entry)	
XX		
DE	Peptide nucleic acid targeting HPV genome.	
XX		
KM	peptide nucleic acid; PNA; cytomagalovirus; CMV; papillomavirus;	
KW	antiviral; diagnostic; ss.	
XX		
OS	Synthetic.	
XX		
FH	Key	Location/Qualifiers
FT	misc_feature	1..15
FT	/*tag= a	/note= "at least one (and preferably all) of the backbone
FT		nucleotides are composed of amide units, so that the
FT		oligomer consists of the nucleobases attached covalently
FT		to a polyamide backbone"
FN		
PN	WO9504748-A1.	
PD	16-FEB-1995.	
XX		
PF	09-AUG-1994; 94MO-US009039.	
PR	09-AUG-1993; 93US-00104438.	
PA	(ISIS-) ISIS PHARM INC.	
PI	Anderson KP, Crooke ST, Mirabelli CK, Ecker DJ, Cowsett LM;	
XX		
DR	WPI; 1995-090841/12.	
PT	New peptide nucleic acid oligomers hybridizable to cytomegalovirus or	
PRT	papilloma.virus - are stable anti:sense molecules with high affinity for	
XX	single stranded DNA, used for treating infections.	
PS	Claim 10; Page 52; 65pp; English.	
XX		
XX	New oligomers are claimed which (A) have at least one peptide nucleic	
CC	acid (PNA) subunit and (B) have a sequence hybridizable to AUG region, 5'	
CC	untranslated region, intron/exon (I/E) junction or coding sequence of	
CC	cytomegalovirus gene selected from DNA polymerase, IE.. and IZ, or	
CC	hybridizable to the E, B2, E4, E5, E6, E7, L1 or L2 reading frames of a	
CC	papillomavirus. The PNAs can be used to target RNA and single stranded	
CC	DNA (ssDNA) to produce antisense-type gene regulation moieties. Hence	
CC	they may be used therapeutically for modulating cytomegalovirus and	
CC	papillomavirus processes and also as diagnostics (e.g., as probes for	
CC	specific mRNAs). PNA oligomers have high affinity for complementary	
CC	single stranded DNA. They are also able to form triple helices in which a	
CC	first PNA strand binds with RNA or ssDNA and a second PNA strand binds	
CC	with the resulting double helix or with the first PNA strand. The PNAs	
CC	possess no significant charge and are water soluble, which facilitates	
CC	cellular uptake. Further, since they contain amides of non-biological	
CC	amino acids, they are biostable and resistant to enzymatic degradation by	

CC proteases. The present sequence targets a portion of the papillomavirus
 CC genome
 XX
 SO Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 560 ACTGCATAGTCG 572
 Db 13 ACTGCATAGTCG 1
 RESULT 550
 AAT52494
 AAT52494 standard; RNA; 15 BP.
 AC AAT52494;
 XX
 DT 25-MAR-2003 (revised)
 DT 10-APR-1997 (first entry)
 DE Mouse ICAM hammerhead ribozyme target sequence (nt. position 2837).
 XX
 KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
 KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
 KW intercellular adhesion molecule; rel A; tumour necrosis factor;
 KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
 KW Philadelphia chromosome; inflammatory leukemias; CML; cancer;
 KW Philadelphia chromosome; inflammatory leukemias; CML; cancer;
 KW athroscleorosis; myocardial infarction; stroke; restenosis;
 KW transplant rejection; rheumatoid arthritis; psoriasis;
 KW myocardiial ischaemia; Kawasaki disease; septic shock; HIV;
 KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
 KW ss.
 OS Mus musculus.
 XX
 XX W09523225-A2.
 XX
 PD 31-AUG-1995.
 XX
 PF 23-FEB-1995; 95WO-IB000156.
 XX
 PR 23-FEB-1994; 94US-00201109.
 PR 29-MAR-1994; 94US-00218934.
 PR 04-APR-1994; 94US-00222795.
 PR 07-APR-1994; 94US-00224483.
 PR 15-APR-1994; 94US-00227958.
 PR 15-APR-1994; 94US-00228041.
 PR 18-MAY-1994; 94US-00245736.
 PR 06-JUL-1994; 94US-00271280.
 PR 15-AUG-1994; 94US-00291932.
 PR 16-AUG-1994; 94US-00291933.
 PR 17-AUG-1994; 94US-00291933.
 PR 19-AUG-1994; 94US-00292620.
 PR 02-SEP-1994; 94US-00300000.
 PR 08-SEP-1994; 94US-00303039.
 PR 23-SEP-1994; 94US-00311486.
 PR 23-SEP-1994; 94US-00311749.
 PR 28-SEP-1994; 94US-00314397.
 PR 03-OCT-1994; 94US-00316771.
 PR 07-OCT-1994; 94US-00319492.
 PR 11-OCT-1994; 94US-00321993.
 PR 04-NOV-1994; 94US-00334847.
 PR 10-NOV-1994; 94US-00337608.
 PR 28-NOV-1994; 94US-00345516.
 PR 16-DEC-1994; 94US-00357577.
 PR 23-DEC-1994; 94US-00363233.
 PR 30-JAN-1995; 94US-00380734.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.

XX
 PI Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LM;
 PI Grimm S, Karpelesky A, Kisich K, Matulic-Adamic J, Mewissen JA;
 PI Modak M, Pavco P, Belgelman L, Sullivan SM, Sweedler D, Thompson JD;
 PI Tracz D, Usman N, Wincott FE, Wolf T;
 XX WPI; 1995-351090/45.
 DR
 XX
 PT Ribozymes having modified bases and methods for producing them - for use
 PT in inhibiting disease related genes.
 XX
 PS Claim 2; Page 180; 407pp; English.
 XX
 CC The present sequence represents a preferred target sequence for an
 CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
 CC nucleotide base position indicated in the DE line. Regions of the mRNA
 CC that do not form secondary folding structures and that contain potential
 CC hammerhead and hairpin ribozyme cleavage sites were identified by
 CC computer analysis. Ribozymes directed against these mRNA sequences were
 CC designed and synthesised with modifications that improve their nuclease
 CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
 CC inhibit ICAM-1 expression, making them useful for reducing transplant
 CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
 CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
 CC correct PI field.)
 CC
 SO Sequence 15 BP; 2 A; 2 C; 5 G; 0 T; 6 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 46.2%; Pred. No. 3.6e+02;
 Matches 6; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
 QY 59 AAGTGTTCTTCT 71
 Db 1 AAGUGGUCUCUCU 13
 RESULT 551
 AAT52447
 AAT52447 standard; RNA; 15 BP.
 ID
 XX AAT52447;
 AC
 XX
 DT 25-MAR-2003 (revised)
 DT 09-APR-1997 (first entry)
 DE Mouse ICAM hammerhead ribozyme target sequence (nt. position 2376).
 XX
 KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
 KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
 KW intercellular adhesion molecule; rel A; tumour necrosis factor;
 KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
 KW Philadelphia chromosome; inflammatory leukemias; CML; cancer;
 KW Philadelphia chromosome; inflammatory leukemias; CML; cancer;
 KW athroscleorosis; myocardial infarction; stroke; restenosis;
 KW transplant rejection; rheumatoid arthritis; psoriasis;
 KW myocardiial ischaemia; Kawasaki disease; septic shock; HIV;
 KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
 KW ss.
 OS Mus musculus.
 XX
 XX W09523225-A2.
 XX
 PD 31-AUG-1995.
 XX
 PF 23-FEB-1995; 95WO-IB000156.
 XX
 PR 23-FEB-1994; 94US-00201109.
 PR 29-MAR-1994; 94US-00218934.
 PR 04-APR-1994; 94US-00222795.
 PR 07-APR-1994; 94US-00224483.
 PR 15-APR-1994; 94US-00227958.

PR 15-APR-1994; 94US-00228041.
 PR 18-MAY-1994; 94US-00245736.
 PR 06-JUL-1994; 94US-00271280.
 PR 15-AUG-1994; 94US-00291932.
 PR 16-AUG-1994; 94US-00291433.
 PR 17-AUG-1994; 94US-00292620.
 PR 19-AUG-1994; 94US-00293520.
 PR 02-SEP-1994; 94US-00300000.
 PR 08-SEP-1994; 94US-00303039.
 PR 23-SEP-1994; 94US-00311486.
 PR 23-SEP-1994; 94US-00311749.
 PR 28-SEP-1994; 94US-00314397.
 PR 03-OCT-1994; 94US-00316771.
 PR 07-OCT-1994; 94US-00319492.
 PR 11-OCT-1994; 94US-00321993.
 PR 04-NOV-1994; 94US-00334847.
 PR 10-NOV-1994; 94US-00337608.
 PR 28-NOV-1994; 94US-00345516.
 PR 16-DEC-1994; 94US-00357577.
 PR 23-DEC-1994; 94US-00363233.
 PR 30-JAN-1995; 95US-00380734.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Stinchcomb DT, Chowrira B, DiRenzo A, Draper KG, Dudyycz LM;
 PI Grimm S, Karpelisky A, Kisch K, Matulic-Adamic J, McSwiggen JA;
 PI Motak A, Pavco P, Belgiehan L, Sullivan SM, Svedler D, Thompson JD;
 PI Tracz D, Ueman N, Wincott FB, Woolf T;
 XX WPI; 1995-351090/45.
 XX
 PT Ribozymes having modified bases and methods for producing them - for use
 PT in inhibiting disease related genes.
 XX
 PS Claim 2; Page 179; 407pp; English.
 XX
 CC The present sequence represents a preferred target sequence for an
 CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICM-1 mRNA at the
 CC nucleotide base position indicated in the DE line. Regions of the mRNA
 CC that do not form secondary folding structures and that contain potential
 CC hammerhead and hairpin ribozyme cleavage sites were identified by
 CC computer analysis. Ribozymes directed against these mRNA sequences were
 CC designed and synthesized with modifications that improve their nuclease
 CC resistance. The ribozymes cleave the ICM-1 target sequences and thereby
 CC inhibit ICM-1 expression, making them useful for reducing transplant
 CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
 CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
 CC correct PI field.)
 CC
 SQ Sequence 15 BP; 2 A; 2 C; 5 G; 0 T; 6 U; 0 Other;
 QY Query Match 0.2%; Score 11.4; DB 1; Length 15;
 DB Best Local Similarity 46.2%; Pred. No. 3.6e+02;
 Matches 6; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
 QY 59 AAGTGGTCTTCT 71
 DB 1 AGGCGGUCUUCU 13
 XX
 RESULT 552
 AAT37743
 ID AAT37743 standard; mRNA; 15 BP.
 XX
 AC AAT37743;
 XX
 DT 13-NOV-1996 (first entry)
 XX
 DB Apo(a) mRNA (nt. pos. 11824) hammerhead ribozyme target sequence.
 XX
 KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 KW hammerhead ribozyme; target sequence; diagnosis; treatment;
 KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;

KW restenosis; heart disease; monkey; ss.
 XX
 XX Cebus, apella.
 OS
 XX W09609392-A1.
 PN
 XX 28-MAR-1996.
 PD
 XX 21-SEP-1995; 95WO-US011995.
 XX
 PR 23-SEP-1994; 94US-00311760.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Stinchcomb DT, McSwiggen J, Newton RS, Ramnarack R;
 XX WPI; 1996-188454/19.
 XX
 DR
 XX
 PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
 PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
 PT myocardial infarction, and heart diseases.
 XX
 PS Claim 3; Page 21; 37pp; English.
 XX
 CC A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
 CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
 CC complementary to the present sequence (nucleotide position 11824). The
 CC ribozyme blocks to some extent apo(a) expression, and can therefore be
 CC used to diagnose or treat conditions related to lipoprotein (a) levels,
 CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
 CC disease. PCR was used to generate a substrate for T7 RNA polymerase
 CC transcription from monkey apo(a) cDNA clones. Labelled transcripts were
 CC synthesised in vitro to form 2 templates. The oligonucleotides and
 CC labelled transcripts were annealed, RNases added and the mixts
 CC incubated. After a designated time the reactions were stopped, and RNA
 CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
 CC cleaved was determined by autoradiographic quantification, and the most
 CC accessible ribozyme target sites chosen
 CC
 SQ Sequence 15 BP; 4 A; 6 C; 2 G; 0 T; 3 U; 0 Other;
 QY Query Match 0.2%; Score 11.4; DB 1; Length 15;
 DB Best Local Similarity 76.9%; Pred. No. 3.6e+02;
 Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 402 CCCGTTCCAAAC 414
 DB 2 CCCAGUUCCAAGC 14
 XX
 RESULT 553
 AAT37577
 ID AAT37577 standard; mRNA; 15 BP.
 XX
 AC AAT37577;
 XX
 DT 11-NOV-1996 (first entry)
 XX
 DB Apo(a) mRNA (nt. pos. 11670) hammerhead ribozyme target sequence.
 XX
 KW Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
 KW hammerhead ribozyme; target sequence; diagnosis; treatment;
 KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
 KW restenosis; heart disease; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN W09609392-A1.
 XX
 DB 28-MAR-1996.
 PD
 XX 21-SEP-1995; 95WO-US011995.
 XX
 PF

```

PR 23-SEP-1994; 94US-00311760.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Mcswigen J, Newton RS, Ramharack R;
XX
XX WPI; 1996-188454/19.
XX
PT Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.
XX
PS Claim 2, Page 18; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 11670). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase
CC transcribed from human apo(a) cDNA clones. Labelled transcripts were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed, RNaseH added and the mixts.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen
XX
SQ Sequence 15 BP; 4 A; 6 C; 2 G; 0 T; 3 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 76.9%; Pred. No. 3.6e+02;
Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 402 CCCGTTCCAGC 414
DB 2 CCCAGUCCAGC 14
XX
RESULT 554
AAT8763
ID AAT8763 standard; DNA; 15 BP.
XX
XX AAT8763;
XX
AC AAT8763;
XX
DT 25-MAR-2003 (revised)
DT 21-JUL-1997 (first entry)
XX
DE CD16 type I and II 5' primer, CD16p1.
XX
XX Human; CD16-II; autoimmune disease; inflammation; RT-PCR;
XX polymerase chain reaction; lung; Fc-gamma receptor III; ss.
XX
OS Synthetic.
XX
XX W09634953-A2.
XX
XX 07-NOV-1996.
XX
XX 03-MAY-1996; 96MO-IB000590.
XX
XX 03-MAY-1995; 95US-00433123.
XX
XX (ISTF) ARS APPLIED RES SYST HOLDING NV.
XX
XX Lwo S;
XX
XX WPI; 1996-506158/50.
XX
XX Isolated human CD16-II variant - useful to develop prods. for diagnosis
XX and treatment of autoimmune diseases and inflammatory illnesses.
XX

```

```

PS Example; Page 7; 38pp; English.
XX
XX The sequences given in AAT8761-63 are primers which were used to amplify
CC CD16 type I and type II isoforms. RNA derived from human lung tissue was
CC used as a template for first strand cDNA synthesis. These reactions lead
CC to the isolation and identification of naturally occurring CD16-II
CC variants. CD16-II variants can be used for the treatment and diagnosis of
CC autoimmune diseases, and inflammatory illnesses. (Updated on 25-MAR-2003
CC to correct PA field.)
XX
SQ Sequence 15 BP; 2 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 291 TGTGCGAGCTGCT 303
DB 2 TGTGCGAGCTGCT 14
XX
RESULT 555
AAX66181/c
ID AAX66181 standard; RNA; 15 BP.
XX
XX AAX66181;
XX
AC AAX66181;
XX
DT 20-JUL-1999 (first entry)
XX
XX Mouse B7-2 hammerhead ribozyme target SEQ ID NO:2813.
XX
XX Arthritic condition; graft tolerance; immune response; target; cleavage;
XX hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
XX streptolysin; synovial membrane; joint; arthritis; osteoarthritis;
XX rheumatoid arthritis; autoimmune disease; allergy; inflammation;
XX diagnosis; ss.
XX
XX Mus sp.
XX
XX W09618736-A2.
XX
XX 20-JUN-1996.
XX
XX 22-NOV-1995; 95WO-US015516.
XX
XX 13-DEC-1994; 94US-00354920.
XX 23-DEC-1994; 94US-00363253.
XX 23-DEC-1994; 94US-00363254.
XX 17-FEB-1995; 95US-00390850.
XX 20-APR-1995; 95US-00426124.
XX 02-MAY-1995; 95US-00432874.
XX 04-MAY-1995; 95US-00434509.
XX 07-JUL-1995; 95US-0000954P.
XX 07-JUL-1995; 95US-0000974P.
XX 07-AUG-1995; 95US-00512861.
XX 05-OCT-1995; 95US-00541365.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
XX Mcswigen J, Gustofson J, Usman N, Wincoff F, Matulic-Adamic J;
XX Karpelisky A, Thompson JD, Modak A, Burgin A;
XX
XX WPI; 1996-300653/30.
XX
XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
XX the treatment of arthritis, induction of graft tolerance or treatment of
XX auto-immune diseases.
XX
XX Claim 10; Page 16; 307pp; English.
XX
XX The present invention describes a novel enzymatic nucleic acid (ENA)
XX having a hammerhead motif (HM) comprising: (1) at least 5 ribose residues
XX

```

CC ; (iii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis.
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention

SQ Sequence 15 BP; 2 A; 1 C; 5 G; 0 T; 7 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 577 CCAGAACTACTACC 589
 ||| |||||
 14 CCAAAATCTACC 2

RESULT 556
 AAX66151/c
 ID AAX66151 standard; RNA; 15 BP.

XX
 AC AAX66151;
 XX
 DT 20-JUN-1999 (first entry)
 XX
 DE Mouse B7-2 hammerhead ribozyme target SEQ ID NO:2783.
 XX
 KW Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.
 XX
 OS Mus sp.
 XX
 PN WO9618736-A2.
 XX
 PD 20-JUN-1996.
 XX
 PF 22-NOV-1995; 95WO-US015516.
 XX
 PR 13-DEC-1994; 94US-00354920.
 PR 23-DEC-1994; 94US-00363253.
 PR 23-DEC-1994; 94US-00363254.
 PR 17-FEB-1995; 95US-00390850.
 PR 20-APR-1995; 95US-00426124.
 PR 02-MAY-1995; 95US-00432874.
 PR 04-MAY-1995; 95US-00434509.
 PR 07-JUL-1995; 95US-0000951P.
 PR 07-JUL-1995; 95US-0000974P.
 PR 07-AUG-1995; 95US-00512861.
 PR 05-OCT-1995; 95US-00541365.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
 PI Mcawiggen J, Gustofson J, Usman N, Wincoff F, Matulic-Adamic J;
 PI Karpelesky A, Thompson JD, Modak A, Burgin A;
 XX
 DR WPI; 1996-300653/30.
 XX
 PT Enzymatic nucleic acid molecules having a hammer-head motif - used for

PT the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.

XX
 PR Claim 10; Page 196; 307pp; English.

XX
 CC The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention

SQ Sequence 15 BP; 3 A; 3 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 84 TCTGAATCAGCA 96
 ||||| |||||
 13 TCTGATCAGCA 1

Db 13 TCTGATCAGCA 1

RESULT 557
 AAX66617/c
 ID AAX66617 standard; RNA; 15 BP.

XX
 AC AAX66617;
 XX
 DT 20-JUN-1999 (first entry)
 XX
 DE Human CD40 hammerhead ribozyme target SEQ ID NO:3249.
 XX
 KW Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9618736-A2.
 XX
 PD 20-JUN-1996.
 XX
 PF 22-NOV-1995; 95WO-US015516.
 XX
 PR 13-DEC-1994; 94US-00354920.
 PR 23-DEC-1994; 94US-00363253.
 PR 23-DEC-1994; 94US-00363254.
 PR 17-FEB-1995; 95US-00390850.
 PR 20-APR-1995; 95US-00426124.
 PR 02-MAY-1995; 95US-00432874.
 PR 04-MAY-1995; 95US-00434509.
 PR 07-JUL-1995; 95US-0000951P.
 PR 07-JUL-1995; 95US-0000974P.
 PR 07-AUG-1995; 95US-00512861.
 PR 05-OCT-1995; 95US-00541365.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
 PI Mcawiggen J, Gustofson J, Usman N, Wincoff F, Matulic-Adamic J;
 PI Karpelesky A, Thompson JD, Modak A, Burgin A;
 XX
 DR WPI; 1996-300653/30.
 XX
 PT Enzymatic nucleic acid molecules having a hammer-head motif - used for

PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P,
 PI Mswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J,
 PI Karpelesky A, Thompson JD, Modak A, Burgin A;
 DR WPI; 1996-300653/30.

XX
 XX
 PT Enzymatic nucleic acid molecules having a hammer-head motif - used for
 PT the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.

XX
 XX
 PS Claim 10; Page 204; 307pp; English.

CC The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention

XX
 SQ Sequence 15 BP; 1 A; 2 C; 5 G; 0 T; 7 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 231 GACCAAGAAAC 243
 DB 15 GACCAAGAAAC 3

RESULT 558
 AAX6153/C
 ID AAX6153 standard; RNA; 15 BP.

XX
 AC AAX6153;
 XX
 DT 20-JUL-1999 (first entry)

DE Mouse B7-2 hammerhead ribozyme target SEQ ID NO:2785.

XX
 KW Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.

XX
 OS Mus sp.
 XX
 PN WO9618736-A2.

XX
 PD 20-JUN-1996.

XX
 PF 22-NOV-1995; 95WO-US015516.

XX
 PR 13-DEC-1994; 94US-00354920.

XX
 PR 23-DEC-1994; 94US-00363253.

XX
 PR 17-FEB-1995; 94US-00363254.

XX
 PR 20-APR-1995; 95US-00426124.

XX
 PR 02-MAY-1995; 95US-00432874.

XX
 PR 04-MAY-1995; 95US-00434509.

PR 07-JUL-1995; 95US-0000951P.
 PR 07-JUL-1995; 95US-0000974P.
 PR 07-AUG-1995; 95US-00512861.
 PR 05-OCT-1995; 95US-00541365.

XX
 XX
 PA (RIBO-) RIBOZYME PHARM INC.

XX
 PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P,
 PI Mswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J,
 PI Karpelesky A, Thompson JD, Modak A, Burgin A;
 DR WPI; 1996-300653/30.

XX
 XX
 PT Enzymatic nucleic acid molecules having a hammer-head motif - used for
 PT the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.

XX
 XX
 PS Claim 10; Page 196; 307pp; English.

CC The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention

XX
 SQ Sequence 15 BP; 3 A; 3 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 84 TCTGAATCAGCA 96
 DB 13 TCTGAATCAGCA 1

RESULT 559
 AAX6182/C
 ID AAX6182 standard; RNA; 15 BP.

XX
 AC AAX6182;
 XX
 DT 20-JUL-1999 (first entry)

DE Mouse B7-2 hammerhead ribozyme target SEQ ID NO:2814.

XX
 KW Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.

XX
 OS Mus sp.
 XX
 PN WO9618736-A2.

XX
 PD 20-JUN-1996.

XX
 PF 22-NOV-1995; 95WO-US015516.

PR 13-DEC-1994; 94US-00354920.
 PR 23-DEC-1994; 94US-00363253.
 PR 23-DEC-1994; 94US-00363254.
 PR 17-FEB-1995; 95US-00390850.
 PR 20-APR-1995; 95US-00426124.
 PR 02-MAY-1995; 95US-00432874.
 PR 04-MAY-1995; 95US-00434509.
 PR 07-JUL-1995; 95US-0000951P.
 PR 07-JUL-1995; 95US-0000974P.
 PR 07-AUG-1995; 95US-00512861.
 PR 05-OCT-1995; 95US-00541365.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Payco P;
 PI Mcswigen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
 PI Karpelsky A, Thompson JD, Modak A, Burgin A;
 XX
 DR WPI; 1996-300653/30.
 XX
 PT Enzymatic nucleic acid molecules having a hammer-head motif - used for
 PT the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.
 PS
 PI
 XX
 PS
 PS
 PS
 XX
 CC The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis.
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention
 CC
 XX
 SQ Sequence 15 BP; 2 A; 1 C; 5 G; 0 T; 7 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 577 CCAGATCTACTACC 589
 Db 14 CCAAAATACTACC 2
 XX
 RESULT 560
 AAX6152/c
 ID AAX6152 standard; RNA; 15 BP.
 XX
 AC AAX6152;
 XX
 XX 20-JUL-1999 (first entry)
 XX
 DE Mouse B7-2 hammerhead ribozyme target SEQ ID NO:2784.
 XX
 KW Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.
 XX
 OS Mus sp.

XX
 PN MO9618736-A2.
 XX 20-JUN-1996.
 PD
 XX
 PF 22-NOV-1995; 95WO-US015516.
 XX
 PR 13-DEC-1994; 94US-00354920.
 PR 23-DEC-1994; 94US-00363253.
 PR 23-DEC-1994; 94US-00363254.
 PR 17-FEB-1995; 95US-00390850.
 PR 20-APR-1995; 95US-00426124.
 PR 02-MAY-1995; 95US-00432874.
 PR 04-MAY-1995; 95US-00434509.
 PR 07-JUL-1995; 95US-0000951P.
 PR 07-JUL-1995; 95US-0000974P.
 PR 07-AUG-1995; 95US-00512861.
 PR 05-OCT-1995; 95US-00541365.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Payco P;
 PI Mcswigen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
 PI Karpelsky A, Thompson JD, Modak A, Burgin A;
 XX
 DR WPI; 1996-300653/30.
 XX
 PT Enzymatic nucleic acid molecules having a hammer-head motif - used for
 PT the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.
 PS
 PI
 XX
 PS
 PS
 PS
 XX
 CC The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis.
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention
 CC
 XX
 SQ Sequence 15 BP; 3 A; 3 C; 4 G; 0 T; 5 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 84 TCTGAATCAGCA 96
 Db 13 TCTGAGATCAGCA 1
 XX
 RESULT 561
 AAX6154/c
 ID AAX6154 standard; RNA; 15 BP.
 XX
 AC AAX6154;
 XX
 XX 20-JUL-1999 (first entry)
 XX
 DE Mouse B7-2 hammerhead ribozyme target SEQ ID NO:2786.
 XX

KW Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW streptolysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.
 XX
 OS Mus sp.
 PN WO9618736-A2.
 XX
 PD 20-JUN-1996.
 XX
 PF 22-NOV-1995; 95WO-US015516.
 XX
 PR 13-DEC-1994; 94US-00354920.
 PR 23-DEC-1994; 94US-00363253.
 PR 23-DEC-1994; 94US-00363254.
 PR 17-FEB-1995; 95US-00390850.
 PR 20-APR-1995; 95US-00426124.
 PR 02-MAY-1995; 95US-00432874.
 PR 04-MAY-1995; 95US-00434509.
 PR 07-JUL-1995; 95US-0000951P.
 PR 07-JUL-1995; 95US-0000974P.
 PR 07-AUG-1995; 95US-00512861.
 PR 05-OCT-1995; 95US-00541365.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Payco P,
 PI Mcswigen J, Gustofson J, Usman N, Minocit F, Maculic-Adamic J,
 PI Karpelesky A, Thompson JD, Nodak A, Burgin A;
 XX
 DR WPI; 1996-300653/30.
 XX
 PT Enzymatic nucleic acid molecules having a hammer-head motif - used for
 PT the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.
 XX
 PS Claim 10; Page 196; 307Pp; English.
 XX
 CC The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and streptolysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC streptolysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention
 CC
 SQ Sequence 15 BP; 3 A; 3 C; 4 G; 0 T; 5 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 11.4; DB 1; Length 15;
 DB Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 84 TCTGAATCAGCA 96
 |||||
 DB 13 TCTGAGATCAGCA 1
 |||||
 RESULT 562
 AAT33482/c
 ID AAT33482 standard; DNA; 15 BP.

XX
 AC AAT33482;
 XX
 DT 18-FEB-1997 (first entry)
 XX
 DE Oligomeric compound with 2'-O-substituted pyrimidine nucleoside.
 XX
 KW Oligomer; pyrimidine; inhibition; gene expression; gene therapy;
 KW research; diagnostic reagent; diagnosis; protein kinase C; PKC; ss.
 XX
 OS Synthetic.
 XX
 PN WO9627606-A1.
 XX
 PD 12-SEP-1996.
 XX
 PF 06-MAR-1996; 96WO-US003174.
 XX
 PR 06-MAR-1995; 95US-00398901.
 PR 07-JUN-1995; 95US-00475467.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Cook PD, Sanghvi YS, Sprankle KG, Ross BS, Griffey RH;
 PI Springer RH;
 XX
 DR WPI; 1996-425375/42.
 XX
 PT New 2'-O-substituted pyrimidine monomeric nucleoside sub-unit(s) - used
 PT for the prep. of oligomeric cpds. which can be used for gene therapy or
 PT as research or diagnostic reagents.
 XX
 PS Procedure 2; Page 65; 97Pp; English.
 XX
 CC Oligomeric compounds containing 2'-O-substituted pyrimidine nucleoside
 CC subunits can be used for inhibiting specific gene expression in gene
 CC therapy and as research and diagnostic reagents. The oligomeric compounds
 CC exhibit high binding affinity to nucleic acids and high nuclease
 CC resistance. This sequence is a deoxyphosphodiester 15 mer
 CC oligoribonucleotide which was used in hybridisation stability studies.
 CC Modifications to the sequence included 2'-O-methyl, 2'-O-propyl, 2'-O-
 CC pentyl substitutions on the sugar molecule as well as having a
 CC phosphorothioate backbone. The melting temperatures for each of these
 CC modified oligoribonucleotides was 45.1, 62.8, 58.5 and 45.9 degrees
 CC Celsius respectively
 CC
 SQ Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 11.4; DB 1; Length 15;
 DB Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 560 ACTGCATAGTCG 572
 |||||
 DB 13 ACTGCATAGTCG 1
 |||||
 RESULT 563
 AAT49219/c
 ID AAT49219 standard; DNA; 15 BP.
 XX
 AC AAT49219;
 XX
 DT 02-JUL-2002 (revised)
 DT 03-SEP-1997 (first entry)
 XX
 DE Specific phosphorothioate.
 XX
 KW phosphorothioate; therapeutic; RNase H activity; ras; antisense;
 KW inhibit translation; treating; hepatitis; inflammatory disease;
 KW intercellular cell adhesion factor; ICAM-1; cytomegalovirus retinitis;
 KW cancer; protein kinase C alpha; C-ras; Ha-ras; Ki-ras; AIDS; chiral;
 KW thermodynamic stability; hepatitis C virus; ss.

```
XX OS Synthetic.
XX PN W09639154-A1.
XX PD 12-DEC-1996.
XX PE 05-JUN-1996; 96WO-US008757.
XX PR 06-JUN-1995; 95US-00466692.
XX PR 06-JUN-1995; 95US-00467597.
XX PR 06-JUN-1995; 95US-00468447.
XX PR 06-JUN-1995; 95US-00468569.
XX PR 06-JUN-1995; 95US-00469851.
XX PR 06-JUN-1995; 95US-00470129.
XX PR 06-JUN-1995; 95US-00471966.
XX PR 06-JUN-1995; 95US-00471967.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Cook PD, Hoke G;
XX WPI; 1997-042838/04.
XX PT Sequence-specific oligo:nucleotide(s) useful in anti-sense therapy -
PT contain phosphorothioate linkages of high chiral purity, also used to
PT induce RNase H activity.
XX PS Example 3; Page 26; 49pp; English.
XX CC Claimed phosphorothioate oligonucleotides (AAT42904-14) are useful
XX CC therapeutically, e.g. by eliciting RNase H activity ras antisense
XX CC molecules to inhibit translation. Uses of the oligos include treating
XX CC hepatitis, inflammatory diseases mediated by intercellular cell adhesion
XX CC factor ICM-1 and cytomegalovirus reinitis, as well as treatment of
XX CC cancers mediated by protein kinase C alpha, c-rai kinase, Ha-ras or Ki-
XX CC ras and treating AIDS. The sequence-specific phosphorothioate
XX CC oligonucleotides have substantially chiral pure intersugar linkages
XX CC which increase the thermodynamic stability of heteroduplexes with target
XX CC RNA and DNA. The present sequence is used as a specific phosphorothioate
XX CC having pure Rp intersugar linkages. (Updated on 02-JUL-2002 to add
XX CC missing PA field.)
XX SQ Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1
RESULT 564
AAT51082/C
ID AAT51082 standard; DNA; 15 BP.
XX AC AAT51082;
XX DT 25-MAR-2003 (revised)
XX DT 13-MAR-1997 (first entry)
XX DE Phosphorothioate oligonucleotide of the invention.
XX RNA transcription inhibitor; hepatitis C virus; HCV; inflammation; AIDS;
XX phosphorothioate oligonucleotide; primer; nuclease; RNaseH; therapy;
XX thermodynamic stability; cytomegalovirus infection; cancer; ss.
XX OS Synthetic.
XX US5576302-A.
XX PN
XX FT
```

```
PD 19-NOV-1996.
XX PE 06-JUN-1995; 95US-00468447.
XX PR 15-OCT-1991; 91US-00777670.
XX PR 16-OCT-1991; 91US-00777007.
XX PR 05-MAY-1993; 93US-00058023.
XX PR 29-AUG-1994; 94US-00297703.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Cook PD, Hoke G;
XX WPI; 1997-011289/01.
XX PT New oligo:nucleotide(s) for inhibiting transcription of hepatitis C virus
XX PT RNA - contain diastereomerically pure phosphorothioate links for
XX PT formation of more stable complexes with target nucleic acid.
XX PS Example 3; Col 15; 18pp; English.
XX CC This sequence represents a phosphorothioate oligonucleotide of the
XX CC invention (see AAT51082). This oligonucleotide was synthesized using
XX CC phosphorothioate substituted dNTP's, the template sequence represented by
XX CC AAT51080, and the primer represented by AAT51081. 75-100 % of the
XX CC nucleotides in the oligonucleotides of the invention are preferably
XX CC joined by either Sp or Rp phosphorothioate 3' to 5' links. To create the
XX CC sequences, 2'-deoxyribonucleoside-5'-O-(1-thiophosphates) (dNTPalphas) is
XX CC prepared as a racemic mixture, and the pure Sp and Rp diastereomers are
XX CC isolated (such as by reverse-phase HPLC on ODS Hypersil). The chiral
XX CC products are then used to make these sequences enzymatically in the
XX CC presence of a template, primer, and nuclease. Alternatively these
XX CC sequences can be chemically synthesized. Oligonucleotides with chirally
XX CC pure intersugar links form heteroduplexes with target RNA or DNA of
XX CC greater thermodynamic stability (compared with racemic mixtures), and
XX CC elicit RNaseH activity. Chirally pure oligonucleotides also have a better
XX CC resistance to nuclease digestion. As these sequences inhibit HCV RNA
XX CC transcription, they can be used as therapeutic, diagnostic, and research
XX CC agents. More generally, chirally pure phosphorothioate oligonucleotides
XX CC can be used as therapeutic agents in the same way as racemic (or non-
XX CC sulphur substituted) compounds, such as to treat AIDS, inflammation,
XX CC cytomegalovirus infection, and various cancers. (Updated on 25-MAR-2003
XX CC to correct PF field.)
XX SQ Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1
RESULT 565
AAV53024/C
ID AAV53024 standard; DNA; 15 BP.
XX AC AAV53024;
XX DT 11-JAN-1999 (first entry)
XX DE Cytochrome c oxidase COX 2 gene base 7650 common probe.
XX COX 2 gene; cytochrome c oxidase; Alzheimer's disease; diagnosis;
XX mitochondrial DNA; probe; oligonucleotide ligation assay; ds.
XX OS Synthetic.
XX OS Homo sapiens.
XX Key Location/Qualifiers
XX FT misc_feature 1
```

```

FT      /*tag= a
FT      /note= "5' phosphorylation"
FT      misc_feature
FT      15
FT      /tag= b
FT      /note= "3' FAM fluorescein derivative"
PN      WO9808335-A1.
XX
XX      03-SEP-1998.
XX
XX      27-FEB-1998; 98WO-US003429.
XX
XX      28-FEB-1997; 97US-00810599.
XX
XX      (MITO-) MITOKOR.
XX
XX      Parker WD, Herrnstadt C, Ghosh S, Fahy ED,
XX      WPI; 1998-481216/41.
XX
XX      Detecting the presence or risk of Alzheimer's disease - by detecting
XX      mutations in the sequence of a mitochondrial cytochrome C oxidase gene in
XX      mitochondrial nucleic acid.
XX
XX      Claim 27; Page 28; 125pp; English.
XX
XX      Wild-type (see AAV53022), mutant (see AAV53023) and common (see AAV53024)
XX      probes were used to detect an Alzheimer's disease (AD)-associated
XX      mutation at base 7650 of the human mitochondrial cytochrome c oxidase
XX      subunit II COX 2 gene (see AAV53012). This missense mutation results in a
XX      Thr to Ile amino acid substitution in the encoded protein.
XX      Oligonucleotide ligation assay is performed using template DNA that spans
XX      the nucleotide 7650 site and which was generated from subject
XX      mitochondrial DNA by PCR (see AAV53035-36). The invention relates to
XX      methods of detecting mutations in mitochondrial COX genes that segregate
XX      with AD, and methods for determining the amount of heteroplasmy of
XX      mitochondrial nucleic acid. The invention provides methods for detecting
XX      such mutations, as a diagnostic of AD, either before or after the onset
XX      of clinical symptoms
XX
XX      Sequence 15 BP; 3 A; 5 C; 2 G; 5 T; 0 U; 0 Other;
XX
Query Match      0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      257 GCTTGATCATGAA 269
Db      15 GCGTGATCATGAA 3

RESULT 566
AAV48790/C
ID      AAV48790 standard; DNA, 15 BP.
XX
XX      AAV48790;
XX
XX      15-OCT-1998 (first entry)
XX
XX      ErbB-2 gene antisense oligonucleotide ErbB-2-82.
XX
XX      ErbB-2; antisense oligonucleotide; modulate; gene expression; ss.
XX
XX      Synthetic.
XX      OS      Homo sapiens.
XX
XX      EP856579-A1.
XX
XX      05-AUG-1998.
XX
XX      31-JAN-1997; 97EP-00101531.
XX
XX      31-JAN-1997; 97EP-00101531.
XX
XX      31-JAN-1997; 97EP-00101531.
XX

```

```

XX      (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
XX      Schlingensiepen K, Brysch W;
XX      WPI; 1998-400910/35.
XX
XX      Preparation of antisense oligo:nucleotide(s) which lack long runs of
XX      consecutive guanosine or inosine - and have specific ratio of residues
XX      able to form two or three hydrogen bonds, have greater activity and
XX      reduced toxicity, used therapeutically or to modulate growth of cells in
XX      culture.
XX
XX      Claim 10; Fig 6b; 286pp; English.
XX
XX      AAV48709-886 represent antisense oligonucleotides directed against the
XX      ErbB-2 gene. Of these, only oligonucleotides AAV48709-91 resulted in
XX      significant reduction in ErbB-2 protein expression, while
XX      oligonucleotides AAV48792-886 had little effect. The oligonucleotides
XX      exemplify the invention. The specification describes oligonucleotides
XX      that contain 8-30 nucleotides, which contain at most 8 nucleotides that
XX      can each form three hydrogen bonds to cytosine; do not contain four
XX      consecutive nucleotides able to form three H-bonds each to four
XX      consecutive cytosines; do not contain two sequences of three consecutive
XX      nucleotides each able to form three H-bonds to three consecutive
XX      cytosines, and the ratio between residues able to form two H-bonds each
XX      (2R) or three such bonds (3R) is given by 2R/3R = 0.33-0.72. The
XX      oligonucleotides are used to modulate expression of genes, particularly
XX      the genes for p53, Erb-2, JunB, JunD, TGF-beta 1 or beta 2 to control
XX      proliferation of primary cell cultures (e.g. bone marrow stem, liver or
XX      kidney cells, osteoclasts, osteoblasts and/or keratinocytes). The
XX      oligonucleotides can also be used to analyse function of proteins (by
XX      altering their expression or activity) and therapeutically, e.g. in cases
XX      of cancer or (targeting TGF) for stimulating the immune system
XX
XX      Sequence 15 BP; 2 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
XX
Query Match      0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      527 GAACCTGCCAAGC 539
Db      14 GAACCTGCCATGC 2

RESULT 567
AAV19664/C
ID      AAV19664 standard; DNA, 15 BP.
XX
XX      AAV19664;
XX
XX      25-MAR-2003 (revised)
XX      DT      12-JUN-1998 (first entry)
XX
XX      Human bcl-2 antisense oligonucleotide 10.
XX
XX      Antisense oligonucleotide; bcl-2 gene; lymphoma; leukaemia; human;
XX      cancer; ss.
XX
XX      Synthetic.
XX      OS      Homo sapiens.
XX
XX      US5734033-A.
XX
XX      31-MAR-1998.
XX
XX      24-MAR-1994; 94US-00217082.
XX
XX      22-DEC-1988; 88US-00288692.
XX      21-FEB-1992; 92US-00840716.
XX
XX      (UYPE-) UNIV PENNSYLVANIA.
XX

```


XX	Read J,
PI	WPI; 1998-229881/20.
XX	Anti-sense oligo:nucleotide(s) complementary to BCL-2 mRNA - useful for
DR	treating cancers, e.g. lymphoma(s) and some leukaemia(s).
XX	Claim 6; Col 14; 21pp; English.
PS	This antiense oligonucleotide is complementary to the translation
CC	initiation site of the human bcl-2 mRNA. The Bcl-2 antisense
CC	oligonucleotides are phosphorothioate derivatives and can straddle
CC	strategic sites such as the translation initiation site, donor and
CC	acceptor splicing sites, or sites for transportation or degradation.
CC	Blocking translation at such strategic sites prevents the formation of a
CC	functional bcl-2 gene product. These oligonucleotides may be used for
CC	treating cancers associated with high levels of bcl-2 gene expression,
CC	especially lymphomas and some leukaemias. (updated on 25-MAR-2003 to
CC	correct PF field.)
SQ	Sequence 15 BP; 1 A; 5 C; 9 G; 0 T; 0 U; 0 Other;
QY	Query Match 0.2%; Score 11.4; DB 1; Length 15; Best Local Similarity 92.3%; Pred No. 3.6e+02; Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0.
DB	377 CTGCGGTGGCGC 389 13 CGCGGTGGCGC 1
RESULT 568	
AAAX15078/C	
ID	AAAX15078 standard; DNA; 15 BP.
AC	AAAX15078;
XX	
XX	20-MAR-2003 (revised)
DT	16-APR-1999 (first entry)
XX	
DE	Nuclease resistant oligonucleotide.
XX	
KM	Nuclease resistant; ribofuranosyl moiety; 2'-aminoalkoxy; tumour;
KW	2'-imidazolylalkoxy; modulation; activity; AIDS; atherosclerosis; ss.
XX	
OS	Synthetic.
XX	
FH	Key Location/Qualifiers
FT	modified_base 1..15
FT	/tag= a
FT	/note= "2'-deoxy-2'-fluoro moieties attached to: (i)
FT	adenosine bases; (ii) adenosine and thymidine bases;
FT	(iii) adenosine, thymidine and cytidine bases; or (iv)
FT	adenosine, thymidine, cytidine and guanosine bases"
XX	
PV	US5872232-A.
PN	
PD	16-FEB-1999.
XX	
PF	06-JUN-1995; 95US-00471973.
XX	
PR	11-JAN-1990; 90US-00463358.
PR	13-AUG-1990; 90US-00566977.
PR	12-AUG-1991; 91WO-US005720.
PR	05-MAR-1992; 92US-00835932.
PR	01-JUL-1992; 92US-00854634.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	
PI	Cook PD, Kawasaki AM;
XX	
DR	WPI; 1999-166721/14.

XX	New 2'-O-modified oligo-nucleotide(s) - comprising nucleotide(s)
PT	comprising a 2'-aminoalkoxy or 2'-imidazolylalkoxy substituent, used for
PT	hybridisation to RNA or DNA.
XX	
PS	Example 13; Col 35; 48pp; English.
XX	
CC	The present oligonucleotide exemplifies the oligonucleotides of the
CC	invention. Oligonucleotides of the invention are nuclease resistant, and
CC	comprise covalently-bound nucleosides that individually include a ribose
CC	or deoxyribose sugar portion and base portion where the nucleosides are
CC	joined together by internucleoside linkages such that the base portion of
CC	the nucleosides form a mixed base sequence that is complementary to a RNA
CC	base sequence or to a DNA base sequence. At least one of the nucleosides
CC	has a modified riboturanosyl moiety bearing a 2'-aminoalkoxy or 2'-
CC	imidazolylalkoxy substituent. The nuclease resistant compounds can be
CC	used for modulating the activity of DNA or RNA. They can be used for
CC	treating organisms having a disease characterised by the undesired
CC	production of a protein. Diverse organisms such as bacteria, yeast,
CC	protozoa, algae, plant and higher animal forms including warm-blooded
CC	animals can be treated in this manner. The compounds can be used for
CC	treating e.g. AIDS, atherosclerosis or tumours. They can also be used in
CC	diagnostic methods for detecting the presence or absence of abnormal RNA
CC	molecules, or abnormal or inappropriate expression of normal RNA
CC	molecules in organisms or cells. (Updated on 20-MAR-2003 to correct PR
CC	field.)
XX	
SQ	Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
	Query Match 0.2%; Score 11.4; DB 1; Length 15;
	Best Local Similarity 92.3%; Pred. No. 3.6e+02;
	Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0.
OY	560 ACTGCATAGTCG 572
	13 ACTTGCAATGTCG 1
DB	
RESULT 569	
AAK15081/C	
ID	AAK15081 standard; RNA; 15 BP.
AC	
XX	AAK15081:
XX	
DT	20-MAR-2003 (revised)
DT	16-APR-1999 (first entry)
XX	
DE	Nuclease resistant oligonucleotide.
XX	
XX	Nuclease resistant; ribofuranosyl moiety; 2'-aminoalkoxy; tumour;
KW	2'-imidazolylalkoxy; modulation; activity; AIDS; atherosclerosis; ss.
XX	
OS	Synthetic.
XX	
FH	Key
FT	modified_base
FT	1 Location/Qualifiers
FT	/*tag= a
FT	/note= "2'-deoxy-2'-methylthio substituent attached"
FT	4
FT	/*tag= b
FT	/note= "2'-deoxy-2'-methylthio substituent attached"
FT	5
FT	/*tag= C
FT	/note= "2'-deoxy-2'-methylthio substituent attached"
FT	7
FT	/*tag= d
FT	/note= "2'-deoxy-2'-methylthio substituent attached"
FT	9
FT	/*tag= e
FT	/note= "2'-deoxy-2'-methylthio substituent attached"
FT	13
FT	/*tag= e
FT	/note= "2'-deoxy-2'-methylthio substituent attached"
FT	

```
XX US5872232-A.
PN
XX
XX 16-FEB-1999.
PD
XX
XX 06-JUN-1995; 95US-00471973.
PF
XX
PR 11-JAN-1990; 90US-00463358.
PR 13-AUG-1990; 90US-00566977.
PR 12-AUG-1991; 91WO-US005720.
PR 05-MAR-1992; 92US-00835932.
PR 01-JUL-1992; 92US-00854634.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cook PD, Kawasaki AM;
PI
XX
XX WPI; 1999-166721/14.
DR
XX
XX New 2'-O-modified oligo-nucleotide(s) - comprising nucleotide(s)
PT comprising a 2'-aminoalkoxy or 2'-imidazolylalkoxy substituent, used for
PT hybridisation to RNA or DNA.
XX
XX Example 13; Col 35; 48pp; English.
XX
XX The present oligonucleotide exemplifies the oligonucleotides of the
CC invention. Oligonucleotides of the invention are nuclease resistant, and
CC comprise covalently-bound nucleosides that individually include a ribose
CC or deoxyribose sugar portion and base portion where the nucleosides are
CC joined together by internucleoside linkages such that the base portion of
CC the nucleosides form a mixed base sequence that is complementary to a RNA
CC base sequence or to a DNA base sequence. At least one of the nucleosides
CC has a modified ribofuranosyl moiety bearing a 2'-aminoalkoxy or 2'-
CC imidazolylalkoxy substituent. The nuclease resistant compounds can be
CC used for modulating the activity of DNA or RNA. They can be used for
CC treating organisms having a disease characterised by the undesired
CC production of a protein. Diverse organisms such as bacteria, yeast,
CC protozoa, algae, plant and higher animal forms including warm-blooded
CC animals can be treated in this manner. The compounds can be used for
CC treating e.g. AIDS, atherosclerosis or tumours. They can also be used in
CC diagnostic methods for detecting the presence or absence of abnormal RNA
CC molecules, or abnormal or inappropriate expression of normal RNA
CC molecules in organisms or cells. (Updated on 20-MAR-2003 to correct PR
CC field.)
XX
XX Sequence 15 BP; 5 A; 4 C; 3 G; 0 T; 3 U; 0 Other;
SQ
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1
RESULT 570
AAV73854/c
ID AAV73854 standard; DNA; 15 BP.
XX
XX AAV73854;
AC
XX
XX 17-OCT-2003 (revised)
DT 25-FEB-1999 (first entry)
XX
XX 5'-lipoxigenase DNA target region for antisense inhibition.
DE
XX Antisense; inhibition; chiral phosphate linkage; reporter gene; drug;
KM RNase H activity; nuclease resistance; hybridisation; diagnostic;
KM cellular absorption; transport; enzymatic interaction; ss.
XX
XX unidentified.
XX
```

```
PN US5852188-A.
XX
XX 22-DEC-1998.
PD
XX
XX 19-APR-1996; 96US-00635009.
PF
XX
PR 11-JAN-1990; 90US-00463358.
PR 13-AUG-1990; 90US-00566977.
PR 11-JAN-1991; 91WO-US000243.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cook PD;
PI
XX
XX WPI; 1999-080505/07.
DR
XX
XX New oligo-nucleotide(s) for e.g. testing anti-sense activity - comprise
PT non-naturally occurring nucleoside unit and chiral phosphate linkages.
PT
XX
XX Disclosure; Col 12; 18pp; English.
XX
XX This sequence is used as a target sequence for a novel method to test for
CC antisense activity using an oligonucleotide comprising nucleoside units
CC linked via phosphate linkages in which at least one of the nucleoside
CC units is a non-naturally occurring nucleoside unit and at least two of
CC the nucleoside units are linked via chiral phosphate linkages. The
CC oligonucleotides can be used to test for antisense activity using
CC reporter genes in assays and to test antisense activity against selected
CC cellular target mRNA's in cultured cells. Some of the oligonucleotides
CC are useful for to elicit RNase H activity as a termination event or to
CC increase nuclease resistance. The oligonucleotides are expected to
CC exhibit one or more properties such as hybridisation with target RNA's
CC and DNA's, cellular absorption, transport, or to improve enzymatic
CC interaction without diminishing existing properties giving improved,
CC drug, diagnostics and research agents. (Updated on 17-OCT-2003 to
CC standardise OS field)
XX
XX Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1
RESULT 571
AAV73854/c
ID AAV73854 standard; DNA; 15 BP.
XX
XX AAV73854;
AC
XX
XX 20-APR-1999 (first entry)
DT
XX
XX 2'-modified oligonucleotide.
DE
XX
XX Nuclease resistant; modified; deoxyfuranosyl moiety; therapy; infection;
KM AIDS; atherosclerosis; tumour; ss.
XX
XX Synthetic.
OS
XX
XX US5859221-A.
PN
XX
XX 12-JAN-1999.
PD
XX
XX 06-JUN-1995; 95US-00468037.
PF
XX
PR 11-JAN-1990; 90US-00463358.
PR 13-AUG-1990; 90US-00566977.
PR 12-AUG-1991; 91WO-US005720.
PR 05-MAR-1992; 92US-00835932.
XX
```

```

PR 01-JUL-1992; 92US-00854634.
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX Cook PD, Kawasaki AM;
XX
XX WPI; 1999-120005/10.
XX
XX Nuclease resistant oligonucleotide analogues - having nucleosides
PT including modified deoxyfuranosyl moiety bearing 2'-substituent to
PT increase binding affinity.
XX
XX Example 13; Col 35; 49pp; English.
XX
XX The invention relates to a nuclease resistant compound that hybridises
CC with RNA or DNA. The compound comprises covalently-bound nucleosides that
CC individually include a ribose or deoxyribose sugar portion and a base
CC portion, where the nucleosides are joined together by internucleoside
CC linkages such that the base portion of the nucleosides form a mixed base
CC sequence that is complementary to a RNA base sequence or to a DNA base
CC sequence; and where at least 1 of the nucleosides includes a modified
CC deoxyfuranosyl moiety bearing a 2'-substituent selected from cyano,
CC fluoromethyl, thioalkoxy, alkylsulphonyl, alkylsulphonyl, allyloxy and
CC alkenoxy groups. The nuclease resistant oligonucleotides (ONs) can bind
CC to and modulate the activity of DNA or RNA and can be used for treating
CC organisms having a disease characterised by the undesired production of a
CC protein. They can be used in therapeutic or prophylactic treatment in
CC organisms such as bacteria, yeast, protozoa, algae, plant and higher
CC animal forms including warm-blooded animals. The ONs can also be used for
CC treating infections, AIDS, atherosclerosis or tumours. The products can
CC be used for detection and diagnosis. The ONs provide enhanced binding to
CC targets. Increased binding of 2'-sugar modified sequence-specific ONs
CC provides superior potency and specificity compared to phosphorus-modified
CC ONs. The present sequence represents a 2'-modified oligonucleotide
XX
XX Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

```

```

PR 11-JAN-1990; 90US-00463358.
PR 13-AUG-1990; 90US-00566977.
PR 12-AUG-1991; 91WO-US0005720.
PR 05-MAR-1992; 92US-00835932.
PR 01-JUL-1992; 92US-00854634.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cook PD, Kawasaki AM;
XX
XX WPI; 1999-120005/10.
XX
XX Nuclease resistant oligonucleotide analogues - having nucleosides
PT including modified deoxyfuranosyl moiety bearing 2'-substituent to
PT increase binding affinity.
XX
XX Example 13; Col 35; 49pp; English.
XX
XX The invention relates to a nuclease resistant compound that hybridises
CC with RNA or DNA. The compound comprises covalently-bound nucleosides that
CC individually include a ribose or deoxyribose sugar portion and a base
CC portion, where the nucleosides are joined together by internucleoside
CC linkages such that the base portion of the nucleosides form a mixed base
CC sequence that is complementary to a RNA base sequence or to a DNA base
CC sequence; and where at least 1 of the nucleosides includes a modified
CC deoxyfuranosyl moiety bearing a 2'-substituent selected from cyano,
CC fluoromethyl, thioalkoxy, alkylsulphonyl, alkylsulphonyl, allyloxy and
CC alkenoxy groups. The nuclease resistant oligonucleotides (ONs) can bind
CC to and modulate the activity of DNA or RNA and can be used for treating
CC organisms having a disease characterised by the undesired production of a
CC protein. They can be used in therapeutic or prophylactic treatment in
CC organisms such as bacteria, yeast, protozoa, algae, plant and higher
CC animal forms including warm-blooded animals. The ONs can also be used for
CC treating infections, AIDS, atherosclerosis or tumours. The products can
CC be used for detection and diagnosis. The ONs provide enhanced binding to
CC targets. Increased binding of 2'-sugar modified sequence-specific ONs
CC provides superior potency and specificity compared to phosphorus-modified
CC ONs. The present sequence represents a modified oligonucleotide
XX
XX Sequence 15 BP; 5 A; 4 C; 3 G; 0 T; 3 U; 0 Other;
SQ
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

```

PR 27-APR-1998; 98US-0083217P.
PR 18-SEP-1998; 98US-0100842P.
PR 25-FEB-1999; 99US-00257608.
PR 23-MAR-1999; 99US-00274553.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PI Blatt L, Mewswigen JA, Roberts E, Pavco PA, Macejak D;
DR WPI; 2000-062023/05.
XX
XX Novel ribozymes for the treatment of diseases and conditions related to
PT hepatitis C infection.
XX
PS Claim 1; Page 58; 123pp; English.
XX
XX The present sequence represents the preferred target sequence of an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the Hepatitis C virus (HCV) RNA sequence at the base position given in
CC the descriptor line. The HCV sequence was screened for optimal ribozyme
CC target sites using a computer folding algorithm and regions of the mRNA
CC which did not form secondary folding structures and contained potential
CC ribozyme cleavage sites were identified. Ribozymes were synthesised to
CC target these sites and their activities optimised by either varying the
CC length of the binding arms or by modification to prevent degradation by
CC nucleases. The ribozymes of the invention inhibit gene expression and/or
CC viral replication, and are used to treat diseases associated with
CC Hepatitis C virus (HCV) infection, e.g. cirrhosis, liver failure and
CC hepatocellular carcinoma. The ribozymes may be used in combination with
CC interferon to treat HCV infection, other infectious diseases, autoimmune
CC diseases, and cancer
XX
SQ Sequence 15 BP; 3 A; 6 C; 2 G; 0 T; 4 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 137 GTGATGCACACAG 149
Db 14 GTGTTGCACACAG 2
XX
RESULT 574
AAZ62577/c
ID AAZ62577 standard; RNA; 15 BP.
XX
AC AAZ62577;
XX
DT 28-MAR-2000 (first entry)
XX
DE Substrate for HH ribozyme HCV-3334 which cleaves HCV RNA at nt. 3334.
XX
XX Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;
KM cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;
KW autoimmune disease; ss.
XX
OS Hepatitis C virus.
XX
PN WO9955847-A2.
XX
PD 04-NOV-1999.
XX
PF 26-APR-1999; 99WO-US009027.
XX
XX 27-APR-1998; 98US-0083217P.
PR 18-SEP-1998; 98US-0100842P.
PR 25-FEB-1999; 99US-00257608.
PR 23-MAR-1999; 99US-00274553.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PI Blatt L, Mewswigen JA, Roberts E, Pavco PA, Macejak D;

XX
DR WPI; 2000-062023/05.
XX
XX Novel ribozymes for the treatment of diseases and conditions related to
PT hepatitis C infection.
XX
PS Claim 1; Page 56; 123pp; English.
XX
XX The present sequence represents the preferred target sequence of an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the Hepatitis C virus (HCV) RNA sequence at the base position given in
CC the descriptor line. The HCV sequence was screened for optimal ribozyme
CC target sites using a computer folding algorithm and regions of the mRNA
CC which did not form secondary folding structures and contained potential
CC ribozyme cleavage sites were identified. Ribozymes were synthesised to
CC target these sites and their activities optimised by either varying the
CC length of the binding arms or by modification to prevent degradation by
CC nucleases. The ribozymes of the invention inhibit gene expression and/or
CC viral replication, and are used to treat diseases associated with
CC Hepatitis C virus (HCV) infection, e.g. cirrhosis, liver failure and
CC hepatocellular carcinoma. The ribozymes may be used in combination with
CC interferon to treat HCV infection, other infectious diseases, autoimmune
CC diseases, and cancer
XX
SQ Sequence 15 BP; 3 A; 3 C; 4 G; 0 T; 5 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 36 CAGTCCCAAAATG 48
Db 15 CAGTCCCAAGATG 3
XX
RESULT 575
AAZ97834
ID AAZ97834 standard; DNA; 15 BP.
XX
AC AAZ97834;
XX
DT 15-SEP-2003 (revised)
DT 26-APR-2000 (first entry)
XX
DE HIV-1 protease gene probe SEQ ID NO:324.
XX
XX Human immunodeficiency virus; HIV; protease; probe; detection;
KM drug selected mutation; hybridisation; genotyping; infection;
KW drug resistance; ss.
XX
OS Human immunodeficiency virus 1.
XX
PN WO9967428-A2.
XX
PD 29-DEC-1999.
XX
PF 22-JUN-1999; 99WO-EP004317.
XX
PR 24-JUN-1998; 98EP-00870143.
XX
PA (INNO-) INNOGENETICS NV.
XX
PI Stuyver L,
XX
DR WPI; 2000-147219/13.
XX
XX Detection of drug-selected mutations in the HIV protease gene used to
PT treat HIV infections.
XX
PS Claim 3; Page 40; 76pp; English.
XX
XX The present invention describes the detection of drug-selected mutations
CC in the HIV protease gene. The method of detection allows the simultaneous

CC characterisation of a range of codons involved in drug resistance using
 CC sets of probes optimised to function together in a reverse-hybridisation
 CC assay. AA297517 to AA297997 represent specifically claimed probes for use
 CC in the assay, and AA297479 to AA297501 represent specifically claimed HIV
 CC protease gene polymorphic nucleotide sequences. AA297502 to AA297515, and
 CC AA298004 to AA298007, represent PCR primers for the HIV protease gene,
 CC and AA297516 represents an HIV protease probe used in an example from the
 CC present invention. The method, probes and primers can be used for the
 CC detection of drug-selected mutations in the HIV protease gene. The method
 CC allows the simultaneous characterisation of a range of codons involved in
 CC drug resistance. The method may also be used for HIV protease genotyping
 CC assays. The probes are able to discriminate between wild type and mutated
 CC protease sequences. The method allows rapid and reliable detection of
 CC drug-selected mutation in HIV. (Updated on 15-SEP-2003 to standardise OS
 CC field)

XX Sequence 15 BP; 5 A; 2 C; 3 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 219 TCACATATATAGG 231
 |||||
 Db 3 TCAACATATATTGG 15

RESULT 576
 AA240170
 ID AA240170 standard; DNA; 15 BP.
 XX
 AC AA240170;
 XX
 DT 18-FEB-2000 (first entry)
 XX
 XX PCR primer for human semaphorin, DCSema, coding sequence.
 DE
 XX
 KM Semaphorin; DCSema; human; inflammatory disease; VESPR; interleukin-12;
 KM IL-12; immune response; aggressive micrometastasing tumour; therapy;
 KM immune suppression; autoimmune disorder; semaphorin receptor;
 KM immune regulation; viral infection; PCR primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO995676-A2.
 XX
 PD 18-NOV-1999.
 XX
 PF 05-MAY-1999; 99WO-US009831.
 XX
 PR 14-MAY-1998; 98US-0085497P.
 XX
 PA (IMMV) IMMUNEX CORP.
 XX
 PI Spriggs MK;
 XX
 DR WPI; 2000-053100/04.
 XX
 PT Novel neurologic regulator polypeptide for treating inflammatory
 PT diseases, autoimmune disorders, etc.,.
 XX
 XX Example 2; Page 21; 41pp; English.
 PS
 XX This sequence represents a PCR primer for DNA encoding the human
 CC semaphorin protein, designated DCSema, of the invention. DCSema is used
 CC for treating inflammatory diseases. DCSema ligands bind with VESPR to
 CC enhance or promote interleukin-12 (IL-12) production which induces an
 CC immune response against aggressive micrometastasing tumours. They are
 CC associated with immune suppression of mature dendritic cells and
 CC therefore can be used for treating autoimmune disorders. They can be
 CC employed to measure biological activity of any semaphorin receptor in
 CC terms of its binding affinity for semaphorin ligand and also for

CC detecting semaphorin receptor by in vitro assays. DCSema polypeptides are
 CC used as reagents in quality assurance studies (to monitor shelf life and
 CC stability of semaphorin receptor under different conditions). They are
 CC also used as a research tool for studying the role of this ligand and its
 CC receptor in immune regulation and are also used as carriers for
 CC delivering diagnostic or therapeutic agents to cells expressing
 CC semaphorin receptor. They are shown to play a role as immune regulators
 CC in viral infection

XX Sequence 15 BP; 2 A; 6 C; 0 G; 7 T; 0 U; 0 Other;
 SQ

Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 66 TCTTCTACTTCTT 78
 |||||
 Db 1 TCTACTACTTCTT 13

RESULT 577
 AA248137/C
 ID AA248137 standard; DNA; 15 BP.
 XX
 AC AA248137;
 XX
 DT 14-MAR-2000 (first entry)
 XX
 XX Polyrribonucleotide solid phase synthesis oligonucleotide SEQ ID NO:21.
 DE
 XX
 KM Polyrribonucleotide solid phase synthesis; diagnosis; hybridisation;
 KM protein production modulation; 2'-deoxyfuranosyl moiety; anti-HIV;
 KM antiarteriosclerotic; nuclease resistant; atherosclerosis; AIDS;
 KM abnormal cell proliferation; tumour formation; ss.
 XX
 OS Synthetic.
 OS US6005087-A.
 XX
 PD 21-DEC-1999.
 XX
 PF 05-MAR-1998; 98US-00035357.
 XX
 PR 11-JAN-1990; 90US-00463358.
 PR 13-AUG-1990; 90US-00566977.
 PR 12-AUG-1991; 91WO-US005720.
 PR 05-MAR-1992; 92US-00835932.
 PR 01-JUL-1992; 92US-00854634.
 PR 06-JUN-1995; 95US-00468037.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Kawasaki AM, Cook PD;
 XX
 DR WPI; 2000-072074/06.
 XX
 PT Nuclease resistant oligonucleotides useful as research agents, diagnostic
 PT agents, and in the treatment of atherosclerosis and AIDS.
 XX
 XX Example 13; Col 35; 49pp; English.
 PS
 XX The present invention describes nuclease resistant oligonucleotides (1)
 CC comprising 2'-fluoro modified ribofuranosyl nucleotides. (1) comprise
 CC covalently bound nucleotides, where the nucleotides are joined together
 CC by: (a) internucleotide linkages such that the base portion of the
 CC nucleotides forms a mixed base sequence; and (b) at least one of the
 CC nucleotides includes a modified ribofuranosyl group bearing a 2'-fluoro
 CC substituent; provided that at least two of the nucleotides are 2'-fluoro
 CC modified ribofuranosyl nucleotides when the internucleotide linkages are
 CC phosphodiester nucleotides. (1) bind to their target mRNA and inhibit its
 CC expression. (1) are resistant to nuclease degradation and hybridise with
 CC appropriate strength and fidelity to its target RNA/DNA. (1) are also
 CC useful as research agents, diagnostic agents and as oligonucleotide

therapeutics. (I) may be used to treat atherosclerosis following angioplasty to prevent reocclusion of the treated arteries. (I) may also be used in conjunction with AZT to treat AIDS patients. (I) have been used to modulate the expression of Raf gene, a cellular gene whose activation form has been implicated in abnormal cell proliferation and tumour formation. (I) are also used to modulate the expression of protein kinase C. (I) exhibit hybridisation properties of higher quality than phosphorous modified oligonucleotide duplexes containing methyolphosphonates, phosphoramidates and phosphate triesters. The present sequence represent an oligonucleotide used in the exemplification of the present invention

Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTCGCATAGTCG 572
DB 13 ACTTCATAGTCG 1

RESULT 578

AAZ48140/C
ID AAZ48140 standard; RNA; 15 BP.

AAZ48140;

14-MAR-2000 (first entry)

Oligonucleotide SEQ ID NO:24.

Polyribonucleotide solid phase synthesis; diagnosis; hybridisation; protein production modulation; 2'-deoxyfuranosyl moiety; anti-HIV; antiaertherosclerotic; nuclease resistant; atherosclerosis; AIDS; abnormal cell proliferation; tumour formation; ss.

Synthetic.

US6005087-A.

21-DEC-1999.

05-MAR-1998; 98US-00035357.

11-JAN-1990; 90US-00463358.

13-AUG-1990; 90US-00566977.

12-AUG-1991; 91WO-US005720.

05-MAR-1992; 92US-00835932.

01-JUL-1992; 92US-00854634.

06-JUN-1995; 95US-00468037.

(ISIS-) ISIS PHARM INC.

Kawasaki AM, Cook PD;

WPI; 2000-072074/06.

Nuclease resistant oligonucleotides useful as research agents, diagnostic agents, and in the treatment of atherosclerosis and AIDS.

Example 13; Col 36; 49pp; English.

The present invention describes nuclease resistant oligonucleotides (I) comprising 2'-fluoro modified ribofuranosyl nucleotides. (I) comprise covalently bound nucleotides, where the nucleotides are joined together by: (a) internucleotide linkages such that the base portion of the nucleotides forms a mixed base sequence; and (b) at least one of the nucleotides includes a modified ribofuranosyl group bearing a 2'-fluoro substituent; provided that at least two of the nucleotides are 2'-fluoro modified ribofuranosyl nucleotides when the internucleotide linkages are phosphodiester nucleotides. (I) bind to their target mRNA and inhibit its

expression. (I) are resistant to nuclease degradation and hybridise with appropriate strength and fidelity to its target RNA/DNA. (I) are also useful as research agents, diagnostic agents and as oligonucleotide therapeutics. (I) may be used to treat atherosclerosis following angioplasty to prevent reocclusion of the treated arteries. (I) may also be used in conjunction with AZT to treat AIDS patients. (I) have been used to modulate the expression of Raf gene, a cellular gene whose activation form has been implicated in abnormal cell proliferation and tumour formation. (I) are also used to modulate the expression of protein kinase C. (I) exhibit hybridisation properties of higher quality than phosphorous modified oligonucleotide duplexes containing methyolphosphonates, phosphoramidates and phosphate triesters. The present sequence represent an oligonucleotide used in the exemplification of the present invention

Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTCGCATAGTCG 572
DB 13 ACTTCATAGTCG 1

RESULT 579

AAA60127/C
ID AAA60127 standard; DNA; 15 BP.

AAA60127;

17-OCT-2000 (first entry)

Human APC gene variant 1130K scanning oligonucleotide # 1.

Human; adenomatous polyposis carcinoma; APC; scanning oligonucleotide; colorectal cancer; genotype analysis;

short oligonucleotide mass analysis; SOMA; ss.

Homo sapiens.

Key Location/Qualifiers

FT misc_difference 1 /*tag= a

FT /*tag= "5" PA"

PN MO200031300-A2.

02-JUN-2000.

22-NOV-1999; 99WO-US027523.

24-NOV-1998; 98US-00198340.

(UYGO) UNITV JOHNS HOPKINS.

Laken SJ, Vogelstein B, Kinzler KW, Groopman JD, Jackson PE;

Friesen MD;

WPI; 2000-422808/36.

Genotype analysis method, defined as SOMA (short oligonucleotide mass analysis), of short, defined amplification products using electro-spray ionization mass spectrometry, useful for analyzing the genotype of living organisms.

Example 2; Page 14; 40pp; English.

The present invention relates to a method of genotype analysis in which short PCR products are analysed by electro-spray ionisation mass spectrometry (ESI-MS). This method has been named Short Oligonucleotide Mass Analysis (SOMA). Short oligonucleotides of the human adenomatous

CC polyposis carcinoma (APC) gene variant I1307K, were produced by PCR. The
 CC I130K APC gene variant is associated with an approximate 2-fold increase
 CC in colorectal cancer risk. The present sequence is a scanning
 CC oligonucleotide used to detect the I1307K variants oligonucleotides
 CC produced in the present invention

XX Sequence 15 BP; 13 A; 0 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 3.6e+02; Mismatches 1; Indels 0; Gaps 0;

74 TTTCTTTATTTCT 86
 |||||
 13 TTTCTTTTTTCT 1

RESULT 580

AAA63373

ID AAA63373 standard; DNA; 15 BP.

AC AAA63373;

DT 06-MAR-2001 (first entry)

DE C-1027 gene cluster forward PCR primer for ORF 3.

KW Eneidiyne C-1027 biosynthesis gene cluster; apoprotein; chromophore;

KM PCR primer; ss.

XX Streptomyces globisporus.

XX W0200040596-A1.

XX 13-JUL-2000.

PF 06-JAN-2000; 2000WO-US000446.

XX 06-JAN-1999; 99US-0115434P.

PR 05-JAN-2000; 2000US-00477962.

PA (REGC) UNIV CALIFORNIA.

XX Shen B, Liu W, Christenson SD, Standage S;

DR WPI; 2000-465947/40.

PT Isolated nucleic acid comprising a nucleic acid encoding any of C-1027
 PT open reading frames (ORFs) -7 to 42, excluding ORF 9 (caga), useful for
 PT the production of enediyne C-1027 antitumor antibiotics.

PS Disclosure; Page 16; 160pp; English.

XX The present invention is concerned with the elucidation of the gene
 CC cluster from Streptomyces globisporus which regulates enediyne C-1027
 CC synthesis. Eneidiyne C-1027 is an antibiotic, consisting of an apoprotein
 CC and a non-peptidic chromophore, which causes damage to DNA. The primers
 CC AAA63373-A63451 were used to isolate the open reading frames which
 CC comprise the gene cluster. The sequences within the gene cluster can be
 CC used to produce the protein and to identify antagonists, both of which
 CC can be used in the treatment of cancer

XX Sequence 15 BP; 4 A; 2 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 3.6e+02; Mismatches 1; Indels 0; Gaps 0;

336 GGAGTACTGCAC 348
 |||||
 3 GGAGTACTGCAC 15

RESULT 581

AAK9574/C

ID AAK9574 standard; DNA; 15 BP.

AC AAK9574;

DT 06-AUG-2002 (first entry)

DE DNA tagging related KMCHO sense oligonucleotide sequence.

KW Molecular tagging; microorganism; DNA tagging; KMCHO; de.

XX Unidentified.

XX KR9074315-A.

PD 05-OCT-1999.

PF 10-MAR-1998; 98KR-00007815.

XX 10-MAR-1998; 98KR-00007815.

PA (KOOC-) KOREA OCEAN RES & DEV INST.

PI Cho GW, Shin JH, Suh YW, Hong GH;

DR WPI; 2000-584935/55.

PT Method for molecular tagging to microorganism using DNA base sequence.

PS Disclosure; Page 3; 4pp; Korean.

CC The invention relates to a method for the molecular tagging of
 CC microorganisms using DNA base sequences. This polynucleotide sequence
 CC represents an oligonucleotide relating to the DNA tagging sequences of
 CC the invention

XX Sequence 15 BP; 5 A; 2 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 3.6e+02; Mismatches 1; Indels 0; Gaps 0;

207 TATGACACCAT 219
 |||||
 13 TATGACACCAT 1

RESULT 582

AAF92147/C

ID AAF92147 standard; DNA; 15 BP.

AC AAF92147;

DT 15-MAY-2001 (first entry)

DE Human IGERB allele specific probe SEQ ID NO: 5.

KW Human; immunoglobulin E receptor beta chain; IGERB; chromosome 11q13;
 KW allergy; asthma; rhinitis; eczema; single nucleotide polymorphism; SNP;
 KW atopy; probe; PCR primer; ss.

XX Homo sapiens.

XX W0200114588-A1.

PD 01-MAR-2001.

PF 11-AUG-2000; 2000WO-US022175.

PR 24-AUG-1999; 99US-0150423P.

PA (GENA-) GENAISANCE PHARM INC.

PA (NAND/) NANDABALAN K.
 XX
 PI Denton RR, Kliehm SE, Stephens JC;
 XX
 DR WPI; 2001-226623/23.
 XX
 PT Novel polynucleotide useful for therapeutic purposes, comprises
 PT nucleotide polymorphisms in immunoglobulin E receptor beta chain gene.
 XX
 PS Claim 15; Page 60; 88pp; English.
 XX
 CC The present invention provides the protein and coding sequences of
 CC several polymorphic variants of the human immunoglobulin E receptor beta
 CC chain (IGERB). These contain single nucleotide polymorphisms (SNPs) which
 CC may be indicative of a predisposition to atopy, allergy, asthma, rhinitis
 CC and eczema. Also provided are the sequences of probes and primers for use
 CC in identifying the genotype of an individual with regards to the IGERB
 CC gene. The IGERB gene is found at human chromosome 11q13. The sequences
 CC are all useful in therapeutics. The present sequence was used to isolate
 CC the IGERB gene
 XX
 SQ Sequence 15 BP; 9 A; 3 C; 1 G; 2 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 Db 76 CTTTATTTCGTA 88
 14 CTTTATTTCGTA 2
 XX
 RESULT 583
 AAH20784
 ID AAH20784 standard; DNA; 15 BP.
 XX
 AC AAH20784;
 XX
 DT 13-AUG-2001 (first entry)
 XX
 DE Complex PCR amplification type 1 primer #29.
 XX
 KM PCR primer; amplification; microarray; genotyping; mutational analysis;
 KM cytosine methylation pattern; ss.
 XX
 OS Unidentified.
 OS
 XX WO200136669-A2.
 XX
 PD 25-MAY-2001.
 XX
 PF 12-NOV-2000; 2000WO-DE003973.
 XX
 PR 12-NOV-1999; 99DE-01056203.
 PR 12-OCT-2000; 2000DE-01051714.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Berlin K;
 XX
 XX WPI; 2001-343834/36.
 XX
 PT Controlling performance of complex polymerase chain reaction
 PT amplification, useful e.g. for genotyping, using a set of many specific
 PT primers and non-specific counter-strand primers.
 XX
 PS Example 2; Page 17; 26pp; German.
 XX
 CC This invention describes a novel controllable performance method of
 CC complex polymerase chain reaction (PCR) amplifications. Firstly, PCR is
 CC carried out with at least 50 different primers (P1) of one type,
 CC complementary to one strand of sample DNA, and with a primer (or library
 CC of primers) of a second type (P2) complementary to the other strand of

CC the DNA, with P2 carrying a marker (M1). Amplicons are hybridized either
 CC to an array of oligonucleotides (ON) that hybridize to the primer used
 CC for the first step or to its complement, or to an array of ON
 CC complementary to the primers used in PCR, and then the lengths of
 CC amplicons bound to the array are determined using a second marker (M2),
 CC different from M1, that is correlated with the length of the relevant DNA
 CC fragments. Signals from M1 and M2 are quantified at relevant positions in
 CC the ON array. The method is used in whole genomic amplification for
 CC genotyping, mutational analysis or related applications, e.g. determining
 CC the cytosine methylation pattern of DNA. The method makes possible
 CC determination of the number and length of many different amplicons,
 CC something that is almost impossible when using two non-specific primers,
 CC as in the conventional method. AAH20756-AAH20823 represent the PCR
 CC primers used to illustrate the method of the invention
 XX
 SQ Sequence 15 BP; 7 A; 0 C; 6 G; 2 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 Db 479 GTAATGACACAG 491
 3 GTAATGACACAG 15
 XX
 RESULT 584
 AAD15970/c
 ID AAD15970 standard; DNA; 15 BP.
 XX
 AC AAD15970;
 XX
 DT 15-NOV-2001 (first entry)
 XX
 DE Papillomavirus modified oligonucleotide PAP #2d.
 XX
 KM Nucleic acid activity modulator; targeting portion; reactive portion;
 KM ss.
 XX
 OS Papillomavirus.
 OS
 XX Synthetic.
 OS
 XX Key Location/Qualifiers
 FH modified_base 14
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-aminopropyl modified adenosine"
 XX
 XX US6262241-B1.
 XX
 PD 17-JUL-2001.
 XX
 PF 03-FEB-1995; 95US-00383666.
 XX
 PR 11-JAN-1990; 90US-00463358.
 PR 13-AUG-1990; 90US-00566977.
 PR 11-JAN-1991; 91WO-US000243.
 PR 01-JUL-1992; 92US-00854634.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Cook PD, Ecker DJ, Guinosso CJ, Acevedo OL, Kawasaki A;
 PI Ramasamy K;
 XX
 DR WPI; 2001-528597/58.
 XX
 PS New heterocycle derivatives, useful for modulating the activity of RNA
 PS and DNA.
 XX
 CC Example 135; Col 65; 54pp; English.
 CC
 CC The present invention relates to compositions and methods for modulating
 CC the activity of RNA and DNA. The compositions comprise a targeting

CC portion specifically hybridisable with a preselected nucleotide sequence
CC of RNA. The composition further provides a reactive portion capable of
CC catalysing, alkylating, or otherwise effecting the cleavage of RNA,
CC especially of its phosphodiester bonds. The compositions are useful for
CC modulating the activity of RNA and DNA. The present sequence is
CC Papillomavirus modified PAP oligonucleotide used in the exemplification
CC of the invention
XX
SQ Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1
XX
RESULT 585
AAD15969/c
ID AAD15969 standard; DNA, 15 BP.
XX
AC AAD15969;
XX
DT 15-NOV-2001 (first entry)
XX
DE Papillomavirus modified oligonucleotide PAP #2c.
XX
KM Nucleic acid activity modulator; targeting portion; reactive portion;
XX ss.
XX Papillomavirus.
XX Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 14
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-t-butylidimethylsilyl modified adenosine"
FT
FT
PN US6262241-B1.
XX
PD 17-JUL-2001.
XX
PF 03-FEB-1995; 95US-00383666.
XX
PR 11-JAN-1990; 90US-00463358.
PR 13-AUG-1990; 90US-00566977.
PR 11-JAN-1991; 91WO-US000243.
PR 01-JUL-1992; 92US-00854634.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Cook PD, Eckert DJ, Guinosso CJ, Acevedo OL, Kawasaki A;
PI Ramasamy K;
XX
DR WPI; 2001-528597/58.
XX
PT New heterocycle derivatives, useful for modulating the activity of RNA
PT and DNA.
XX
PS Example 135; Col 65; 54pp; English.
XX
CC The present invention relates to compositions and methods for modulating
CC the activity of RNA and DNA. The compositions comprise a targeting
CC portion specifically hybridisable with a preselected nucleotide sequence
CC of RNA. The composition further provides a reactive portion capable of
CC catalysing, alkylating, or otherwise effecting the cleavage of RNA,
CC especially of its phosphodiester bonds. The compositions are useful for
CC modulating the activity of RNA and DNA. The present sequence is
CC Papillomavirus modified PAP oligonucleotide used in the exemplification
CC of the invention

XX
SQ.. Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1
XX
RESULT 586
AAD15973/c
ID AAD15973 standard; DNA, 15 BP.
XX
AC AAD15973;
XX
DT 15-NOV-2001 (first entry)
XX
DE Papillomavirus modified oligonucleotide PAP #2g.
XX
KM Nucleic acid activity modulator; targeting portion; reactive portion;
XX ss.
XX Papillomavirus.
XX Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 3
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT
FT modified_base 5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT
FT modified_base 6
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT
FT modified_base 7
FT /*tag= d
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT
FT modified_base 10
FT /*tag= e
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT
FT modified_base 11
FT /*tag= f
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT
FT modified_base 13
FT /*tag= g
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT
FT modified_base 14
FT /*tag= h
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT
PN US6262241-B1.
XX
PD 17-JUL-2001.
XX
PF 03-FEB-1995; 95US-00383666.
XX
PR 11-JAN-1990; 90US-00463358.
PR 13-AUG-1990; 90US-00566977.
PR 11-JAN-1991; 91WO-US000243.
PR 01-JUL-1992; 92US-00854634.
XX

```
PA (ISIS-) ISIS PHARM INC.
XX
XX Cook PD, Ecker DJ, Guinoseo CJ, Acevedo OL, Kawasaki A;
PI Ramasamy K;
XX WPI; 2001-528597/58.
XX
XX New heterocycle derivatives, useful for modulating the activity of RNA
  and DNA.
XX
XX Example 135; Col 69; 54pp; English.
XX
CC The present invention relates to compositions and methods for modulating
CC the activity of RNA and DNA. The compositions comprise a targeting
CC portion specifically hybridisable with a preselected nucleotide sequence
CC of RNA. The composition further provides a reactive portion capable of
CC catalysing, alkylating, or otherwise effecting the cleavage of RNA,
CC especially of its phosphodiester bonds. The compositions are useful for
CC modulating the activity of RNA and DNA. The present sequence is
CC Papillomavirus modified PAP oligonucleotide used in the exemplification
CC of the invention. Note: The specification states that adenosines are
CC modified as 2'-fluoro-2'-deoxy adenosine. However, thymidines are present
CC in the place of adenosines at positions 5, 7 and 13
XX
SQ Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

Query Match          0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 587
AAD15974/C
ID AAD15974 standard; DNA; 15 BP.
XX
XX AAD15974;
AC
XX 15-NOV-2001 (first entry)
DT
XX
XX Papillomavirus modified oligonucleotide PAP #2h.
DE
XX Nucleic acid activity modulator; targeting portion; reactive portion;
KW ss.
XX
XX Papillomavirus.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH 1 Location/Qualifiers
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT 3
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT 4
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT 5
FT /*tag= d
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT 6
FT /*tag= e
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT 7
FT modified_base
FT 7
```

```
FT /*tag= f
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT 9
FT /*tag= g
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT 10
FT /*tag= h
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT 13
FT /*tag= i
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT 14
FT /*tag= j
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
XX
XX US6262241-B1.
XX
XX 17-JUL-2001.
XX
XX 03-FEB-1995; 9SUS-00383666.
XX
XX 11-JAN-1990; 9OUS-00463358.
XX 13-AUG-1990; 9OUS-00566977.
XX 01-JAN-1991; 9IWO-US000243.
XX 01-JUL-1992; 92US-0084634.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cook PD, Ecker DJ, Guinoseo CJ, Acevedo OL, Kawasaki A;
PI Ramasamy K;
XX WPI; 2001-528597/58.
XX
XX New heterocycle derivatives, useful for modulating the activity of RNA
  and DNA.
XX
XX Example 135; Col 69; 54pp; English.
XX
CC The present invention relates to compositions and methods for modulating
CC the activity of RNA and DNA. The compositions comprise a targeting
CC portion specifically hybridisable with a preselected nucleotide sequence
CC of RNA. The composition further provides a reactive portion capable of
CC catalysing, alkylating, or otherwise effecting the cleavage of RNA,
CC especially of its phosphodiester bonds. The compositions are useful for
CC modulating the activity of RNA and DNA. The present sequence is
CC Papillomavirus modified PAP oligonucleotide used in the exemplification
CC of the invention. Note: The specification states that adenosines are
CC modified as 2'-fluoro-2'-deoxy adenosine. However, thymidines are present
CC in the place of adenosines at positions 5, 7 and 13; cytosines are
CC present in the place of adenosines at positions 1, 4 and 9
XX
XX
SQ Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

Query Match          0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 588
AAD15975/C
ID AAD15975 standard; DNA; 15 BP.
XX
XX AAD15975;
AC
XX
```

```

DT 15-NOV-2001 (first entry)
XX Papillomavirus modified capped oligonucleotide PAP #21.
DE Nucleic acid activity modulator; targeting portion; reactive portion;
KM ss.
XX Papillomavirus.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT modified_base 7
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT modified_base 13
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
XX
XX US6262241-B1.
XX 17-JUL-2001.
XX
XX 03-FEB-1995; 95US-00383666.
XX
XX 11-JAN-1990; 90US-00463358.
XX 13-AUG-1990; 90US-00566977.
XX 11-JAN-1991; 91WO-US000243.
XX 01-JUL-1992; 92US-00854634.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cook PD, Ecker DJ, Guinosso CJ, Acevedo OL, Kawasaki A;
XX Ramasamy K;
XX WPI; 2001-528597/58.
XX
XX New heterocycle derivatives, useful for modulating the activity of RNA
XX and DNA.
XX
XX Example 135; Col 70; 54pp; English.
XX
XX The present invention relates to compositions and methods for modulating
XX the activity of RNA and DNA. The compositions comprise a targeting
XX portion specifically hybridizable with a preselected nucleotide sequence
XX of RNA. The composition further provides a reactive portion capable of
XX catalyzing, alkylating, or otherwise effecting the cleavage of RNA,
XX especially of its phosphodiester bonds. The compositions are useful for
XX modulating the activity of RNA and DNA. The present sequence is
XX Papillomavirus modified PAP oligonucleotide used in the exemplification
XX of the invention. Note: The specification states that adenosines are
XX modified as 2'-fluoro-2'-deoxy adenosine. However, thymidines are present
XX in the place of adenosines at positions 5, 7 and 13
XX
XX Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 15;
XX Best Local Similarity 92.3%; Pred. No. 3.6e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 560 ACTGCATAGTCG 572
XX ||| |||||
XX 13 ACTGCATAGTCG 1

```

```

XX AD15972;
XX 15-NOV-2001 (first entry)
XX Papillomavirus modified oligonucleotide PAP #2f.
DE Nucleic acid activity modulator; targeting portion; reactive portion;
KM ss.
XX Papillomavirus.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 3
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT modified_base 6
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT modified_base 10
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT modified_base 11
FT /*tag= d
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
FT modified_base 14
FT /*tag= e
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
XX
XX US6262241-B1.
XX 17-JUL-2001.
XX
XX 03-FEB-1995; 95US-00383666.
XX
XX 11-JAN-1990; 90US-00463358.
XX 13-AUG-1990; 90US-00566977.
XX 11-JAN-1991; 91WO-US000243.
XX 01-JUL-1992; 92US-00854634.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cook PD, Ecker DJ, Guinosso CJ, Acevedo OL, Kawasaki A;
XX Ramasamy K;
XX WPI; 2001-528597/58.
XX
XX New heterocycle derivatives, useful for modulating the activity of RNA
XX and DNA.
XX
XX Example 135; Col 69; 54pp; English.
XX
XX The present invention relates to compositions and methods for modulating
XX the activity of RNA and DNA. The compositions comprise a targeting
XX portion specifically hybridizable with a preselected nucleotide sequence
XX of RNA. The composition further provides a reactive portion capable of
XX catalyzing, alkylating, or otherwise effecting the cleavage of RNA,
XX especially of its phosphodiester bonds. The compositions are useful for
XX modulating the activity of RNA and DNA. The present sequence is
XX Papillomavirus modified PAP oligonucleotide used in the exemplification
XX of the invention.
XX
XX Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11.4; DB 1; Length 15;
XX Best Local Similarity 92.3%; Pred. No. 3.6e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

OY 560 ACTCGCATAGTCG 572
ID AAD15967/c
XX 13 ACTTGCAATAGTCG 1

RESULT 590
AAD15968/c
ID AAD15968 standard; DNA; 15 BP.
XX
AC AAD15968;
XX
DT 15-NOV-2001 (first entry)
XX
DE Papillomavirus modified oligonucleotide PAP #2b.
XX
KW Nucleic acid activity modulator; targeting portion; reactive portion;
KM ss.
XX
OS Papillomavirus.
XX Synthetic.

Key Location/Qualifiers
FT modified_base 14
FT /*tag= a
FT /mod_base= OTHER
FT /note="2'-O-nonyl modified adenosine"

PN US6262241-B1.
PD 17-JUL-2001.
XX
PF 03-FEB-1995; 95US-00383666.
XX
PR 11-JAN-1990; 90US-00463358.
PR 13-AUG-1990; 90US-00566977.
PR 11-JAN-1991; 91WO-US000243.
PR 01-JUL-1992; 92US-00854634.
XX
PA (ISIS-) ISIS PHARM INC.

PI Cook PD, Ecker DJ, Guinasso CJ, Acevedo OL, Kawasaki A;
PI Ramasamy K;
XX WPI; 2001-528597/58.

PT New heterocycle derivatives, useful for modulating the activity of RNA
PT and DNA.
XX
PS Example 135; Col 65; 54pp; English.

CC The present invention relates to compositions and methods for modulating
CC the activity of RNA and DNA. The compositions comprise a targeting
CC portion specifically hybridizable with a preselected nucleotide sequence
CC of RNA. The composition further provides a reactive portion capable of
CC catalyzing, alkylating, or otherwise effecting the cleavage of RNA,
CC especially of its phosphodiester bonds. The compositions are useful for
CC modulating the activity of RNA and DNA. The present sequence is
CC Papillomavirus modified PAP oligonucleotide used in the exemplification
CC of the invention
XX

SO Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 560 ACTCGCATAGTCG 572
ID AAD15976/c
XX 13 ACTTGCAATAGTCG 1

RESULT 591

AAD15967/c
ID AAD15967 standard; DNA; 15 BP.
XX
AC AAD15967;
XX
DT 15-NOV-2001 (first entry)
XX
DE Papillomavirus modified oligonucleotide PAP #2a.
XX
KW Nucleic acid activity modulator; targeting portion; reactive portion;
KM phosphorothioate backbone; ss.
XX
OS Papillomavirus.
XX Synthetic.

Key Location/Qualifiers
FT modified_base 1.15
FT /*tag= a
FT /mod_base= OTHER
FT /note="Phosphorothioate backbone"

PN US6262241-B1.
PD 17-JUL-2001.
XX
PF 03-FEB-1995; 95US-00383666.
XX
PR 11-JAN-1990; 90US-00463358.
PR 13-AUG-1990; 90US-00566977.
PR 11-JAN-1991; 91WO-US000243.
PR 01-JUL-1992; 92US-00854634.
XX

PA (ISIS-) ISIS PHARM INC.
XX
PI Cook PD, Ecker DJ, Guinasso CJ, Acevedo OL, Kawasaki A;
PI Ramasamy K;
XX WPI; 2001-528597/58.

PT New heterocycle derivatives, useful for modulating the activity of RNA
PT and DNA.
XX

PS Example 135; Col 65; 54pp; English.

CC The present invention relates to compositions and methods for modulating
CC the activity of RNA and DNA. The compositions comprise a targeting
CC portion specifically hybridizable with a preselected nucleotide sequence
CC of RNA. The composition further provides a reactive portion capable of
CC catalyzing, alkylating, or otherwise effecting the cleavage of RNA,
CC especially of its phosphodiester bonds. The compositions are useful for
CC modulating the activity of RNA and DNA. The present sequence is
CC Papillomavirus modified PAP oligonucleotide used in the exemplification
CC of the invention
XX

SO Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 560 ACTCGCATAGTCG 572
ID AAD15976/c
XX 13 ACTTGCAATAGTCG 1

RESULT 592
AAD15976/c
ID AAD15976 standard; DNA; 15 BP.
XX
AC AAD15976;
XX
DT 15-NOV-2001 (first entry)
XX

DE	Papillomavirus modified capped oligonucleotide PAP #2j.
XX	
KW	Nucleic acid activity modulator; targeting portion; reactive portion; ss.
XX	
OS	Papillomavirus.
OS	Synthetic.
XX	
FH	Key
FT	modified_base
FT	Location/Qualifiers 3
FT	/tag= a
FT	/mod_base= OTHER
FT	/note= "2'-fluor-2'-deoxy adenosine"
FT	5
FT	/tag= b
FT	/mod_base= OTHER
FT	/note= "2'-fluor-2'-deoxy adenosine"
FT	6
FT	/tag= c
FT	/mod_base= OTHER
FT	/note= "2'-fluor-2'-deoxy adenosine"
FT	7
FT	/tag= d
FT	/mod_base= OTHER
FT	/note= "2'-fluor-2'-deoxy adenosine"
FT	10
FT	/tag= e
FT	/mod_base= OTHER
FT	/note= "2'-fluor-2'-deoxy adenosine"
FT	11
FT	/tag= f
FT	/mod_base= OTHER
FT	/note= "2'-fluor-2'-deoxy adenosine"
FT	13
FT	/tag= g
FT	/mod_base= OTHER
FT	/note= "2'-fluor-2'-deoxy adenosine"
FT	14
FT	/tag= h
FT	/mod_base= OTHER
FT	/note= "2'-fluor-2'-deoxy adenosine"
XX	
PN	US6262241-B1.
XX	
PD	17-JUL-2001.
XX	
PE	03-FEB-1995;
PR	95US-00383566.
XX	
PR	11-JAN-1990;
PR	90US-00463358.
PR	13-AUG-1990;
PR	90US-00566977.
PR	11-JAN-1991;
PR	91WO-US000243.
PR	01-JUL-1992;
XX	92US-00854634.
XX	(ISIS-) ISIS PHARM INC.
XX	
PI	Cook PD, Ecker DJ, Guinoseo CJ, Acevedo OL, Kawasaki A;
PI	Ramassamy K;
XX	
DR	WPI; 2001-528597/58.
XX	
PT	New heterocycle derivatives, useful for modulating the activity of RNA and DNA.
XX	
PS	Example 135; Col 69; 5app; English.
XX	
CC	The present invention relates to compositions and methods for modulating the activity of RNA and DNA. The compositions comprise a targeting portion specifically hybridizable with a preselected nucleotide sequence of RNA. The composition further provides a reactive portion capable of catalyzing, alkylating, or otherwise effecting the cleavage of RNA, especially of its phosphodiester bonds. The compositions are useful for modulating the activity of RNA and DNA. The present sequence is Papillomavirus modified PAP oligonucleotide used in the exemplification
CC	

CC	of the invention. Note: The specification states that adenosines are modified as 2'-fluoro-2'-deoxy adenosine. However, thymidines are present in the place of adenosines at positions 5, 7 and 13					
CC						
XX						
SQ	Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;					
QY	Query Match 0.2%; Score 11.4; DB 1; Length 15; Best Local Similarity 92.3%; Pred. No. 3.6e+02; Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0					
DB	560 ACTGCGATAGTCG 572 13 ACTGCGATAGTCG 1					
RESULT 593						
AAD15908/c						
ID	AAD15908 standard; DNA; 15 BP.					
XX						
AC	AAD15908;					
XX						
DT	15-NOV-2001 (first entry)					
XX						
DE	Papillomavirus oligonucleotide PAP #2.					
XX						
KW	Nucleic acid activity modulator; targeting portion; reactive portion;					
KM	88.					
XX						
OS	Papillomavirus.					
PX						
PN	US6262241-B1.					
PD	17-JUL-2001.					
XX						
PF	03-FEB-1995; 95US-00383666.					
PR	11-JAN-1990; 90US-00463358.					
PR	13-AUG-1990; 90US-00566977.					
BR	11-JAN-1991; 91WO-US0000243.					
RR	01-JUL-1992; 92US-00854634.					
XX						
PA	(ISIS-) ISIS PHARM INC.					
XX						
PI	Cook PD, Ecker DJ, Guinieso CJ, Acevedo OL, Kawasaki A;					
PT	Ramassamy K;					
DR	WPI; 2001-528597/58.					
XX						
PT	New heterocycle derivatives, useful for modulating the activity of RNA					
XX	and DNA.					
PS	Example 135; Col 65; 5app; English.					
XX						
CC	The present invention relates to compositions and methods for modulating					
CC	the activity of RNA and DNA. The compositions comprise a targeting					
CC	portion specifically hybridizable with a preselcted nucleotide sequence					
CC	of RNA. The composition further provides a reactive portion capable of					
CC	catalyzing, alkylating, or otherwise effecting the cleavage of RNA,					
CC	especially of its phosphodiester bonds. The compositions are useful for					
CC	modulating the activity of RNA and DNA. The present sequence is					
CC	Papillomavirus PAP oligonucleotide used in the exemplification of the					
XX	invention					
SQ	Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;					
QY	Query Match 0.2%; Score 11.4; DB 1; Length 15; Best Local Similarity 92.3%; Pred. No. 3.6e+02; Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
DB	560 ACTGCGATAGTCG 572 13 ACTGCGATAGTCG 1					

```
RESULT 594
AAD15971/c
ID AAD15971 standard; DNA; 15 BP.
AC AAD15971;
DT 15-NOV-2001 (first entry)
XX
DE Papillomavirus modified oligonucleotide PAP #2e.
XX
DE Nucleic acid activity modulator; targeting portion; reactive portion;
XX ss.
XX Papillomavirus.
XX OS Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 14 /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-aminobutyl modified adenosine"
XX
XX US6262241-B1.
XX
XX 17-JUL-2001.
XX
XX 03-FEB-1995; 95US-00383666.
XX
XX 11-JAN-1990; 90US-00463358.
XX 13-AUG-1990; 90US-00566977.
XX 11-JAN-1991; 91WO-US000243.
XX 01-JUL-1992; 92US-00854634.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cook PD, Ecker DJ, Guinosso CJ, Acevedo OL, Kawasaki A;
XX Ramasamy K;
XX WPI; 2001-528597/58.
XX
XX New heterocycle derivatives, useful for modulating the activity of RNA
XX and DNA.
XX
XX Example 135; Col 65; 54pp; English.
XX
XX The present invention relates to compositions and methods for modulating
XX the activity of RNA and DNA. The compositions comprise a targeting
XX portion specifically hybridizable with a preselected nucleotide sequence
XX of RNA. The composition further provides a reactive portion capable of
XX catalyzing, alkylating, or otherwise effecting the cleavage of RNA,
XX especially of its phosphodiester bonds. The compositions are useful for
XX modulating the activity of RNA and DNA. The present sequence is useful for
XX Papillomavirus modified PAP oligonucleotide used in the exemplification
XX of the invention.
XX
XX Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 560 ACTGCATAGTCG 572
Db 13 ACTTGCACTAGTCG 1
RESULT 595
AAD15977/c
ID AAD15977 standard; DNA; 15 BP.
XX
AC AAD15977;
XX
```

```
DT 15-NOV-2001 (first entry)
XX
XX Papillomavirus modified capped oligonucleotide PAP #2k.
DE
XX Nucleic acid activity modulator; targeting portion; reactive portion;
XX ss.
XX Papillomavirus.
XX OS Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 12 /*tag= a
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
XX
XX modified_base 13 /*tag= b
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
XX
XX modified_base 14 /*tag= c
FT /mod_base= OTHER
FT /note= "2'-fluor-2'-deoxy adenosine"
XX
XX US6262241-B1.
XX
XX 17-JUL-2001.
XX
XX 03-FEB-1995; 95US-00383666.
XX
XX 11-JAN-1990; 90US-00463358.
XX 13-AUG-1990; 90US-00566977.
XX 11-JAN-1991; 91WO-US000243.
XX 01-JUL-1992; 92US-00854634.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cook PD, Ecker DJ, Guinosso CJ, Acevedo OL, Kawasaki A;
XX Ramasamy K;
XX WPI; 2001-528597/58.
XX
XX New heterocycle derivatives, useful for modulating the activity of RNA
XX and DNA.
XX
XX Example 135; Col 70; 54pp; English.
XX
XX The present invention relates to compositions and methods for modulating
XX the activity of RNA and DNA. The compositions comprise a targeting
XX portion specifically hybridizable with a preselected nucleotide sequence
XX of RNA. The composition further provides a reactive portion capable of
XX catalyzing, alkylating, or otherwise effecting the cleavage of RNA,
XX especially of its phosphodiester bonds. The compositions are useful for
XX modulating the activity of RNA and DNA. The present sequence is
XX Papillomavirus modified PAP oligonucleotide used in the exemplification
XX of the invention. Note: The specification states that adenosines are
XX modified as 2'-fluoro-2'-deoxy adenosine. However, guanosine and
XX thymidine are present in the place of adenosine at positions 12 and 13
XX respectively.
XX
XX Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 560 ACTGCATAGTCG 572
Db 13 ACTTGCACTAGTCG 1
RESULT 596
AAP46986/c
```

ID AAF46986 standard; DNA, 15 BP.
 XX AAF46986;
 AC
 XX
 DT 30-MAR-2001 (first entry)
 XX IGFBP3 oligonucleotide #406.
 DE
 XX
 KM Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KM cytoskeletal; dermatological; cardiant; virucide; ophthalmological; keloid;
 KM skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pteryiasis;
 KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KM growth factor mediated cell proliferation; ichthyosis; serborrhoea; rubra;
 KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KM hyperneovascular condition; hyperplasia; kidney disease;
 KM neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 PI
 XX Wraight CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 DR
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 XX
 PS Example 7; Page 46; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pteryiasis, rubra, pilaris, serborrhoea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 2 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
 QY
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. NO. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Db 379 GCCTCGCGCCTC 391
 14 GCGGTGCGCCTC 2
 RESULT 597
 AAF48776
 ID AAF48776 standard; DNA, 15 BP.
 XX
 AC AAF48776;

DT 30-MAR-2001 (first entry)
 XX
 XX IGFBP3 oligonucleotide #2196.
 DE
 XX
 KM Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KM cytoskeletal; dermatological; cardiant; virucide; ophthalmological; keloid;
 KM skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pteryiasis;
 KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KM growth factor mediated cell proliferation; ichthyosis; serborrhoea; rubra;
 KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KM hyperneovascular condition; hyperplasia; kidney disease;
 KM neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 PI
 XX Wraight CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 DR
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 XX
 PS Example 7; Page 58; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pteryiasis, rubra, pilaris, serborrhoea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 6 A; 1 C; 6 G; 2 T; 0 U; 0 Other;
 QY
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. NO. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Db 441 GACTGACGAAAGG 453
 2 GACTGACGAAAGG 14
 RESULT 598
 AAF50392
 ID AAF50392 standard; DNA, 15 BP.
 XX
 AC AAF50392;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGF-1 oligonucleotide #1352.
 XX

KM Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KM cytosolic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KM skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KM growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
 KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KM hyperneovascular condition; hyperplasia; kidney disease;
 KM neovascular condition of the retina; ss.
 OS Homo sapiens.
 XX
 XX WO200078341-A1.
 XX
 XX 28-DEC-2000.
 XX
 XX 21-JUN-2000; 2000WO-AU000693.
 XX
 XX 21-JUN-1999; 99US-0140345P.
 XX
 XX (MURDOCH CHILDRENS RES INST.
 XX
 XX Wright CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 XX Example 8; Page 69; 201pp; English.
 XX
 XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 CC
 XX
 XX Sequence 15 BP; 5 A; 7 C; 2 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 341 ACTGCAACCTGAC 353
 Db 1 ACCGCAACCTGAC 13
 RESULT 599
 AAF50838/c
 ID AAF50838 standard; DNA; 15 BP.
 XX
 XX AAF50838;
 XX
 XX 30-MAR-2001 (first entry)
 XX
 XX IGF-1 oligonucleotide #1798.
 XX
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KM cytosolic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KM skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KM hyperneovascular condition; hyperplasia; kidney disease;
 KM neovascular condition of the retina; ss.

KM growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
 KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KM hyperneovascular condition; hyperplasia; kidney disease;
 KM neovascular condition of the retina; ss.
 OS Homo sapiens.
 XX
 XX WO200078341-A1.
 XX
 XX 28-DEC-2000.
 XX
 XX 21-JUN-2000; 2000WO-AU000693.
 XX
 XX 21-JUN-1999; 99US-0140345P.
 XX
 XX (MURDOCH CHILDRENS RES INST.
 XX
 XX Wright CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 XX Example 8; Page 72; 201pp; English.
 XX
 XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 CC
 XX
 XX Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 131 ACCATGCTGATGG 143
 Db 14 ACCATGCTGATGG 2
 RESULT 600
 AAF51605
 ID AAF51605 standard; DNA; 15 BP.
 XX
 XX AAF51605;
 XX
 XX 30-MAR-2001 (first entry)
 XX
 XX IGF-1 oligonucleotide #2565.
 XX
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KM cytosolic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KM skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KM growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
 KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KM hyperneovascular condition; hyperplasia; kidney disease;
 KM neovascular condition of the retina; ss.


```

XX OS Homo sapiens.
XX XX MO200078341-A1.
XX PN
XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000MO-AU000693.
XX PR 21-JUN-1999; 99US-0140345P.
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX PI Wright CJ, Werther GA, Edmondson SR;
XX DR WPI; 2001-041421/05.
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX PS Example 8; Page 77; 201pp; English.
XX CC The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisense
XX CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX CC F45161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX SQ Sequence 15 BP; 4 A; 4 C; 6 G; 1 T; 0 U; 0 Other;
QY Query Match 0.2%; Score 11.4; DB 1; Length 15;
Db Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 445 GAGCAAGGCGCTG 457
Db 2 GAGCCAGGCGCTG 14
RESULT 601
AAF48775
ID AAF48775 standard; DNA; 15 BP.
XX AC AAF48775;
XX DE 30-MAR-2001 (first entry)
XX XX IGFBP3 oligonucleotide #2195.
XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX KW cyostatic; dermatological; cardiac; virucide; ophthalmological; keloid;
XX KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX KW hyperneovascular condition; hyperplasia; kidney disease;
XX KM neovascular condition of the retina; ss.
XX OS Homo sapiens.
XX XX MO200078341-A1.
XX PN

```

```

XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000MO-AU000693.
XX PR 21-JUN-1999; 99US-0140345P.
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX PI Wright CJ, Werther GA, Edmondson SR;
XX DR WPI; 2001-041421/05.
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX PS Example 7; Page 58; 201pp; English.
XX CC The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisense
XX CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX CC F45161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX SQ Sequence 15 BP; 6 A; 1 C; 6 G; 2 T; 0 U; 0 Other;
QY Query Match 0.2%; Score 11.4; DB 1; Length 15;
Db Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 441 GACTGAGCAAGG 453
Db 3 GACTGAGCAAGG 15
RESULT 602
AAF53075
ID AAF53075 standard; DNA; 15 BP.
XX AC AAF53075;
XX DE 30-MAR-2001 (first entry)
XX XX IGF-I oligonucleotide #4035.
XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX KW cyostatic; dermatological; cardiac; virucide; ophthalmological; keloid;
XX KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX KW hyperneovascular condition; hyperplasia; kidney disease;
XX KM neovascular condition of the retina; ss.
XX OS Homo sapiens.
XX XX MO200078341-A1.
XX PN
XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000MO-AU000693.

```

```

XX PR 21-JUN-1999; 99US-0140345P.
XX XX
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX PI Wright CJ, Werther GA, Edmondson SR,
XX DR WPI; 2001-041421/05.
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX PS Example 8; Page 87; 201pp; English.
XX XX
XX CC The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisense
XX CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX CC F45161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX SQ Sequence 15 BP; 0 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
XX
QY Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Db 454 CCTGGGCTGCAGG 466
2 CCTGGGCTGCTGG 14
XX
RESULT 603
AAF50544/C
ID AAF50544 standard; DNA; 15 BP.
XX AC AAF50544;
XX XX
XX DT 30-MAR-2001 (first entry)
XX DE IGF-1 oligonucleotide #1504.
XX XX
XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
XX KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX KW hyperneovascular condition; hyperplasia; kidney disease;
XX KW neovascular condition of the retina; ss.
XX OS Homo sapiens.
XX XX
XX PN WO200078341-A1.
XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000WO-AU000693.
XX PR 21-JUN-1999; 99US-0140345P.
XX XX
XX PA (MURD-) MURDOCH CHILDRENS RES INST.

```

```

XX PI Wright CJ, Werther GA, Edmondson SR;
XX XX
XX DR WPI; 2001-041421/05.
XX XX
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX PS Example 8; Page 70; 201pp; English.
XX XX
XX CC The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisense
XX CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX CC F45161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX SQ Sequence 15 BP; 4 A; 3 C; 4 G; 4 T; 0 U; 0 Other;
XX
QY Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Db 171 CACTTGCACAGA 183
13 CACTTGCACAGA 1
XX
RESULT 604
AAF51716/C
ID AAF51716 standard; DNA; 15 BP.
XX AC AAF51716;
XX XX
XX DT 30-MAR-2001 (first entry)
XX DE IGF-1 oligonucleotide #2676.
XX XX
XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
XX KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX KW hyperneovascular condition; hyperplasia; kidney disease;
XX KW neovascular condition of the retina; ss.
XX OS Homo sapiens.
XX XX
XX PN WO200078341-A1.
XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000WO-AU000693.
XX PR 21-JUN-1999; 99US-0140345P.
XX XX
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX PI Wright CJ, Werther GA, Edmondson SR;
XX XX
XX DR WPI; 2001-041421/05.

```

```

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 8; Page 78; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 4 A; 2 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 10 GGACACTTCT 22
Db 13 GGACACACTTCT 1
RESULT 605
AAF53076
ID AAF53076 standard; DNA; 15 BP.
XX
AC AAF53076;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #4036.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytoskeletal; dermatological; cardiant; vitruide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.

```

```

PT inflammation.
XX
XX Example 8; Page 87; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 0 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 454 CCTGGGCGCGGCG 466
Db 1 CCTGGGCGGCTGG 13
RESULT 606
AAF46541
ID AAF46541 standard; DNA; 15 BP.
XX
AC AAF46541;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP2 oligonucleotide #1380.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytoskeletal; dermatological; cardiant; vitruide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 6; Page 43; 201pp; English.

```

CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotide of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia

CC Sequence 15 BP; 3 A; 2 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 77 TTTTATTTCTGAA 89
 Db 1 TTTTATTTTGA 13

RESULT 607
 AAF49445/C
 ID AAF49445 standard; DNA; 15 BP.

AC AAF49445;

DT 30-MAR-2001 (first entry)

DE IGF-1 oligonucleotide #405.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

OS Homo sapiens.

XX WO200078341-A1.

XX 28-DEC-2000.

XX 21-JUN-2000; 2000WO-AU000693.

XX 21-JUN-1999; 99US-0140345P.

XX (MURD-) MURDOCH CHILDRENS RES INST.

PI Wright CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.

XX Example 8, Page 63; 201pp; English.

CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense

CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotide of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia

CC Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 195 AGCTTGTCATCT 207
 Db 15 AGATTGTCATCT 3

RESULT 608
 AAF50543/C
 ID AAF50543 standard; DNA; 15 BP.

AC AAF50543;

DT 30-MAR-2001 (first entry)

DE IGF-1 oligonucleotide #1503.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

OS Homo sapiens.

XX WO200078341-A1.

XX 28-DEC-2000.

XX 21-JUN-2000; 2000WO-AU000693.

XX 21-JUN-1999; 99US-0140345P.

XX (MURD-) MURDOCH CHILDRENS RES INST.

PI Wright CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.

XX Example 8, Page 70; 201pp; English.

CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotide of the present invention (see AAF45151 and AAF45153-

CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
 CC neoplasia, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 4 A; 3 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 171 CACTGTACAGCA 183
 Db 14 CACTTTCACAGCA 2
 RESULT 609
 AAF46539 standard; DNA; 15 BP.
 XX AAF46539;
 AC
 XX 30-MAR-2001 (first entry)
 DT IGFBP2 oligonucleotide #1378.
 DE
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytosaric; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX WO200078341-A1.
 XX 28-DEC-2000.
 PD
 XX 21-JUN-2000; 2000WO-AU000693.
 PF
 XX 21-JUN-1999; 99US-0140345P.
 PR
 XX (MURDOCH CHILDRENS RES INST.
 PA
 XX Wright CJ, Werther GA, Edmondson SR;
 PI WPI; 2001-041421/05.
 DR
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 PT
 XX Example 6; Page 43; 201pp; English.
 PS
 XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
 CC neoplasia, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,

CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels, or any other hyperplasia
 XX
 SQ Sequence 15 BP; 4 A; 0 C; 1 G; 10 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 77 TTTTATTTTCGAA 89
 Db 3 TTTTATTTTCGAA 15
 RESULT 610
 AAF50390 standard; DNA; 15 BP.
 XX AAF50390;
 AC
 XX 30-MAR-2001 (first entry)
 DT IGF-I oligonucleotide #1350.
 DE
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytosaric; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX WO200078341-A1.
 XX 28-DEC-2000.
 PD
 XX 21-JUN-2000; 2000WO-AU000693.
 PF
 XX 21-JUN-1999; 99US-0140345P.
 PR
 XX (MURDOCH CHILDRENS RES INST.
 PA
 XX Wright CJ, Werther GA, Edmondson SR;
 PI WPI; 2001-041421/05.
 DR
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 PT
 XX Example 8; Page 69; 201pp; English.
 PS
 XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
 CC neoplasia, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia

Sequence 15 BP; 4 A; 8 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 3.6e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 341 ACTGCAACTGAC 353
 DB 3 ACCGCAACTGAC 15

RESULT 611
 AAF50391

ID AAF50391 standard, DNA, 15 BP.

AC AAF50391;

DT 30-MAR-2001 (first entry)

DE IGF-I oligonucleotide #1351.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

OS Homo sapiens.

PN WO200078341-A1.

PD 28-DEC-2000.

PF 21-JUN-2000; 2000MO-AU000693.

PR 21-JUN-1999; 99US-0140345P.

PA (MURD-) MURDOCH CHILDRENS RES INST.

PI Wraight CJ, Werther GA, Edmondson SR;

DR WPI; 2001-041421/05.

PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.

PS Example 8; Page 69, 201pp; English.

XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, scleroderma, warts, benign growths, keloids, keratosis,
 CC neoplasias, ptyriasis, ruba, pilaris, serborrhea, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia

SQ Sequence 15 BP; 4 A; 8 C; 2 G; 1 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.2%; Score 11.4; DB 1; Length 15;
 Matches 12; Conservative 92.3%; Pred. No. 3.6e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 341 ACTGCAACTGAC 353
 DB 2 ACCGCAACTGAC 14

RESULT 612
 AAF51606

ID AAF51606 standard, DNA, 15 BP.

AC AAF51606;

DT 30-MAR-2001 (first entry)

DE IGF-I oligonucleotide #2566.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

OS Homo sapiens.

PN WO200078341-A1.

PD 28-DEC-2000.

PF 21-JUN-2000; 2000MO-AU000693.

PR 21-JUN-1999; 99US-0140345P.

PA (MURD-) MURDOCH CHILDRENS RES INST.

PI Wraight CJ, Werther GA, Edmondson SR;

DR WPI; 2001-041421/05.

PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.

PS Example 8; Page 77, 201pp; English.

XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, scleroderma, warts, benign growths, keloids, keratosis,
 CC neoplasias, ptyriasis, ruba, pilaris, serborrhea, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia

SQ Sequence 15 BP; 5 A; 4 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 3.6e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 445 GAGCAAGGCGCTG 457
 ||||| |||||

Db 1 GAGCCAAGCCTG 13

RESULT 613
AAFA9446/C
ID AAF49446 standard; DNA, 15 BP.
XX
AC AAF49446;
XX
XX 30-MAR-2001 (first entry)
XX IGF-1 oligonucleotide #406.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM cytosolic; dermatological; cardiant; virucide; ophthalmological; keloid;
KM skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KM growth factor mediated cell proliferation; ichthyosis; serborrhoea; rubra;
KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM hyperneovascular condition; hyperplasia; kidney disease;
KM neovascular condition of the retina; ss.
XX
XX Homo sapiens.
XX
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX
XX Example 8; Page 63; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, rubra, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
XX Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 195 AGTTGTCATCT 207
|||
14 AGATTGTCATCT 2

RESULT 614

AAF46540
ID AAF46540 standard; DNA, 15 BP.
XX
XX AAF46540;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGFBP2 oligonucleotide #1379.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM cytosolic; dermatological; cardiant; virucide; ophthalmological; keloid;
KM skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KM growth factor mediated cell proliferation; ichthyosis; serborrhoea; rubra;
KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM hyperneovascular condition; hyperplasia; kidney disease;
KM neovascular condition of the retina; ss.
XX
XX Homo sapiens.
XX
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX
XX Example 6; Page 43; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, rubra, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
XX Sequence 15 BP; 3 A; 1 C; 1 G; 10 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 77 TTTTATTTTCGAA 89
|||||
2 TTTTATTTTCGAA 14

RESULT 615
AAF51604
ID AAF51604 standard; DNA, 15 BP.
XX
XX AAF51604;

```

XX 30-MAR-2001 (first entry)
DT
XX
XX IGF-I oligonucleotide #2564.
DE
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborthoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; se.
XX
XX Homo sapiens.
OS
XX
XX WO200078341-A1.
PN
XX
XX 28-DEC-2000.
PD
XX
XX 21-JUN-2000; 2000WO-AU000693.
PF
XX
XX 21-JUN-1999; 99US-0140345P.
PR
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
PA
XX
XX Wraight CJ, Werther GA, Edmondson SR;
PI WPI; 2001-041421/05.
DR
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 8; Page 77; 201pp; English.
PS
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborthoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
CC
XX
XX Sequence 15 BP; 3 A; 4 C; 7 G; 1 T; 0 U; 0 Other;
SQ
XX
XX Query Match
XX Best Local Similarity 0.2%; Score 11.4; DB 1; Length 15;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 445 GAGCAAGGCGCTG 457
Db 3 GAGCCAAAGGCGCTG 15

```

```

RESULT 616
AAF49447/c
ID AAF49447 standard; DNA; 15 BP.
XX
XX AAF49447;
AC
XX
XX 30-MAR-2001 (first entry)
DT
XX
XX IGF-I oligonucleotide #407.
DE

```

```

XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborthoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; se.
XX
XX Homo sapiens.
OS
XX
XX WO200078341-A1.
PN
XX
XX 28-DEC-2000.
PD
XX
XX 21-JUN-2000; 2000WO-AU000693.
PF
XX
XX 21-JUN-1999; 99US-0140345P.
PR
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
PA
XX
XX Wraight CJ, Werther GA, Edmondson SR;
PI WPI; 2001-041421/05.
DR
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 8; Page 63; 201pp; English.
PS
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborthoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
CC
XX
XX Sequence 15 BP; 6 A; 4 C; 2 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match
XX Best Local Similarity 0.2%; Score 11.4; DB 1; Length 15;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 195 AGCTTGCGTCATCT 207
Db 13 AGATTGTCATCT 1

```

```

RESULT 617
AAFS1715/c
ID AAF51715 standard; DNA; 15 BP.
XX
XX AAF51715;
AC
XX
XX 30-MAR-2001 (first entry)
DT
XX
XX IGF-I oligonucleotide #2675.
DE
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cyostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
DE

```


KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KM growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
 KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KM hyperneovascular condition; hyperplasia; kidney disease;
 KM neovascular condition of the retina; ss.
 XX Homo sapiens.
 OS
 XX MO200078341-A1.
 PN
 XX 28-DEC-2000.
 PD
 XX 21-JUN-2000; 2000WO-AU000693.
 PF
 XX 21-JUN-1999; 99US-0140345P.
 PR
 XX 21-JUN-1999; 99US-0140345P.
 XX
 XX (MURDOCH CHILDRENS RES INST.
 PA
 XX Wraight CJ, Werther GA, Edmondson SR;
 PI
 XX WPI; 2001-041421/05.
 DR
 XX
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 PS
 XX Example 8; Page 78; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotide of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 CC
 XX
 SQ Sequence 15 BP; 4 A; 2 C; 5 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 10 GGACACACTTCT 22
 Db 14 GGACACACTTCT 2
 RESULT 618
 AAF46985/c
 ID AAF46985 standard; DNA; 15 BP.
 XX
 XX AAF46985;
 AC
 XX 30-MAR-2001 (first entry)
 DT
 XX
 XX IGFBP3 oligonucleotide #405.
 DE
 XX
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KM cytoskeletal; dermatological; cardiac; viral; ophthalmological; keloid;
 KM skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KM growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
 KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KM hyperneovascular condition; hyperplasia; kidney disease;

KM neovascular condition of the retina; ss.
 XX
 XX Homo sapiens.
 OS
 XX MO200078341-A1.
 PN
 XX 28-DEC-2000.
 PD
 XX 21-JUN-2000; 2000WO-AU000693.
 PF
 XX 21-JUN-1999; 99US-0140345P.
 PR
 XX 21-JUN-1999; 99US-0140345P.
 XX
 XX (MURDOCH CHILDRENS RES INST.
 PA
 XX Wraight CJ, Werther GA, Edmondson SR;
 PI
 XX WPI; 2001-041421/05.
 DR
 XX
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 PS
 XX Example 7; Page 46; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotide of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 CC
 XX
 SQ Sequence 15 BP; 3 A; 6 C; 6 G; 0 T; 0 U; 0 Other;
 SQ
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 379 GCCGTCGCCGCTC 391
 Db 15 GCCGTCGCCGCTC 3
 RESULT 619
 AAF48777
 ID AAF48777 standard; DNA; 15 BP.
 XX
 XX AAF48777;
 AC
 XX 30-MAR-2001 (first entry)
 DT
 XX
 XX IGFBP3 oligonucleotide #2197.
 DE
 XX
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KM cytoskeletal; dermatological; cardiac; viral; ophthalmological; keloid;
 KM skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KM growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
 KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KM hyperneovascular condition; hyperplasia; kidney disease;
 KM neovascular condition of the retina; ss.
 KM
 XX Homo sapiens.
 OS
 XX

PN WO200078341-A1.
 XX 28-DEC-2000.
 XX
 XX 21-JUN-2000; 2000WO-AU000693.
 PF
 XX 21-JUN-1999; 99US-0140345P.
 PR
 XX (MURDOCH CHILDRENS RES INST.
 PA
 XX Wright CJ, Werther GA, Edmondson SR;
 PI WPI; 2001-041421/05.
 DR
 XX
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 PS
 XX Example 7; Page 58; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC P5161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 CC
 SQ Sequence 15 BP; 6 A; 1 C; 7 G; 1 T; 0 U; 0 Other;
 XX
 XX
 XX Query Match 0.2%; Score 11.4; DB 1; Length 15;
 XX Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 441 GACTGACGAAAGG 453
 Db 1 GACTGAGGAAAGG 13
 RESULT 620
 AAF98064/C
 ID AAF98064 standard; DNA; 15 BP.
 XX
 AC AAF98064;
 XX
 DT 19-JUN-2001 (first entry)
 XX
 DE Human IGERA allele specific oligonucleotide probe SEQ ID NO:103.
 XX
 KW Human; polymorphism; immunoglobulin E receptor I alpha subunit; IGERA;
 KW single nucleotide polymorphism; SNP; allele specific oligonucleotide;
 KW immunosassay; detection; PCR primer; probe; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200111010-A2.
 PD
 XX 15-FEB-2001.
 PD
 XX 02-AUG-2000; 2000WO-US021097.
 PF
 XX 09-AUG-1999; 99US-0147860P.
 PR
 XX (GENA-) GENAISSANCE PHARM INC.
 PI
 XX

XX
 PI Chew A, Denton RR, Duda A, Kiem SE, Lanz EM, Nandabalan K;
 PI Stephens JC;
 XX
 XX WPI; 2001-202766/20.
 DR
 XX
 XX New polynucleotide for gene therapy, comprises nucleotide polymorphisms
 PT in the immunoglobulin E receptor I alpha subunit gene.
 PT
 XX Claim 15; Page 23; 99pp; English.
 PS
 XX
 CC The present invention describes an isolated polynucleotide (I) comprising
 CC a nucleotide sequence (S) which is a polymorphic variant of a reference
 CC sequence for the human immunoglobulin E receptor I alpha subunit (IGERA)
 CC gene or its fragment. The polymorphic variant comprises at least one
 CC polymorphism selected from guanine (G) at polymorphic site (PS) 1, PS9,
 CC PS10 or PS21, cytosine (C) at PS2, PS3, PS6, PS12, PS18 or PS20, adenine
 CC (A) at PS5, PS7, PS11, PS14, PS15, PS19, or PS22 and thymine (T) at
 CC PS4, PS8, PS16 or PS17, or (G) at a position corresponding to nucleotide
 CC 251, (A) at a position corresponding to nucleotide 302 or 741, and (T) at
 CC a position corresponding to nucleotide 530. (I) can be used in gene
 CC therapy. (I) is useful for therapeutic purposes. A polypeptide (II)
 CC encoded by (I) is useful in drug screening assays and in assays to
 CC measure the binding affinity of one or more candidate drugs targeting
 CC (II). An antibody (III) to (II) is useful to immunoprecipitate (II) from
 CC solution and also reacts with (II) on Western or immunoblots of
 CC polyacrylamide gels on membrane supports or substrates. (III) is also
 CC useful in immunoassays to detect (II) in biological samples. AAF97965 to
 CC AAF98096 represent IGERA allele specific oligonucleotide probes; AAF98097
 CC to AAF98140 represent IGERA gene polymorphism detection primers; and
 CC AAF98141 to AAF98180 represent IGERA gene PCR primers which are used in
 CC the exemplification of the present invention
 CC
 SQ Sequence 15 BP; 3 A; 4 C; 3 G; 5 T; 0 U; 0 Other;
 XX
 XX
 XX Query Match 0.2%; Score 11.4; DB 1; Length 15;
 XX Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 128 GCTACCATGTGTA 140
 Db 13 GCTACCATGTGTA 1
 RESULT 621
 AAF98062/C
 ID AAF98062 standard; DNA; 15 BP.
 XX
 AC AAF98062;
 XX
 DT 19-JUN-2001 (first entry)
 XX
 DE Human IGERA allele specific oligonucleotide probe SEQ ID NO:101.
 XX
 KW Human; polymorphism; immunoglobulin E receptor I alpha subunit; IGERA;
 KW single nucleotide polymorphism; SNP; allele specific oligonucleotide;
 KW immunosassay; detection; PCR primer; probe; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200111010-A2.
 PD
 XX 15-FEB-2001.
 PD
 XX 02-AUG-2000; 2000WO-US021097.
 PF
 XX 09-AUG-1999; 99US-0147860P.
 PR
 XX (GENA-) GENAISSANCE PHARM INC.
 PA
 XX Chew A, Denton RR, Duda A, Kiem SE, Lanz EM, Nandabalan K;
 PI Stephens JC;
 PI
 XX

DR WPI; 2001-202766/20.
 XX New polynucleotide for gene therapy, comprises nucleotide polymorphisms
 PT in the immunoglobulin E receptor I alpha subunit gene.
 XX
 PS Claim 15; Page 23; 99pp; English.
 CC The present invention describes an isolated polynucleotide (I) comprising
 CC a nucleotide sequence (S) which is a polymorphic variant of a reference
 CC sequence for the human immunoglobulin E receptor I alpha subunit (IGER)
 CC gene or its fragment. The polymorphic variant comprises at least one
 CC polymorphism selected from guanine (G) at polymorphic site (PS) 1, PS9,
 CC PS10 or PS21, cytosine (C) at PS2, PS3, PS6, PS12, PS18 or PS20, adenine
 CC (A) at PS5, PS7, PS11, PS13, PS14, PS15, PS19, or PS22 and thymine (T) at
 CC PS4, PS8, PS16 or PS17, or (G) at a position corresponding to nucleotide
 CC 251, (A) at a position corresponding to nucleotide 302 or 741, and (T) at
 CC a position corresponding to nucleotide 530. (I) can be used in gene
 CC therapy. (I) is useful for therapeutic purposes. A polypeptide (II)
 CC encoded by (I) is useful in drug screening assays and in assays to
 CC measure the binding affinity of one or more candidate drugs targeting
 CC (II). An antibody (III) to (I) is useful to immunoprecipitate (II) from
 CC solution and also reacts with (II) on Western or immunoblots of
 CC polyacrylamide gels on membrane supports or substrates. (III) is also
 CC useful in immunoassays to detect (II) in biological samples. AAF97965 to
 CC AAF98096 represent IGERA allele specific oligonucleotide probes; AAF98097
 CC to AAF98140 represent IGERA gene polymorphism detection primers; and
 CC AAF98141 to AAF98180 represent IGERA gene PCR primers which are used in
 CC the exemplification of the present invention
 XX
 SQ Sequence 15 BP; 3 A; 5 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 128 GCTACCATGCTGA 140
 |||||
 Db 13 GCTACATGCTGA 1
 RESULT 622
 ABA81625/C
 ID ABA81625 standard; DNA; 15 BP.
 XX
 AC ABA81625;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE Human phospholipid transfer protein gene ASO primer SEQ ID NO: 74.
 XX
 KW Human, phospholipid transfer protein, PLTP, SNP, atherosclerosis;
 KW single nucleotide polymorphism; high-density lipoprotein metabolism;
 KW allele-specific oligonucleotide; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200172761-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 15-MAR-2001; 2001WO-US008283.
 XX
 PR 24-MAR-2000; 2000US-0192127P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Chew A, Choi JY, Koshy B;
 XX
 DR WPI; 2001-662922/76.
 XX
 XX Genotyping phospholipid transfer protein gene of individual for
 PT haplotyping individual's gene, comprises determining identity of
 PT nucleotide pair at polymorphic sites for two copies of PLTP gene present

PT in the individual.
 XX
 PS Claim 15; Page 14; 98pp; English.
 XX
 CC The present invention relates to a method for haplotyping the human
 CC phospholipid transfer protein (PLTP) gene, involving determining the
 CC identity of the nucleotide present at one or more of the 25 polymorphic
 CC sites within the gene. This can be used to aid drug development for the
 CC treatment of diseases associated with different haplotypes of the PLTP
 CC gene, possibly including atherosclerosis. The present sequence is an
 CC allele-specific primer used for detecting polymorphisms in the PLTP gene
 XX
 SQ Sequence 15 BP; 2 A; 2 C; 10 G; 0 T; 0 U; 1 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 3.6e+02;
 Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 377 CTGCGTGCAGCCTC 391
 |||||
 Db 15 CYGCCCTGCCCCCTC 1
 RESULT 623
 AAC65562/C
 ID AAC65562 standard; DNA; 15 BP.
 XX
 AC AAC65562;
 XX
 DT 12-FEB-2001 (first entry)
 XX
 DE Human focal adhesion kinase antisense sequence #28.
 XX
 KW Human, focal adhesion kinase, FAK; signal transduction; cancer;
 KW embryonic development disorder; angiogenic disorder; wound healing;
 KW antisense; phosphorothioate; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6133031-A.
 XX
 PD 17-OCT-2000.
 XX
 PF 19-AUG-1999; 99US-00377310.
 XX
 PR 19-AUG-1999; 99US-00377310.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monica BP, Gaarde WA;
 XX
 DR WPI; 2001-006141/01.
 XX
 PT New antisense compounds for inhibiting focal adhesion kinase expression,
 PT especially useful for inhibiting retinal neovascularization, or for
 PT diagnosing and treating e.g. colon cancer.
 XX
 PS Claim 15; Col 25; 30pp; English.
 XX
 CC The present invention describes a number of phosphorothioate antisense
 CC sequences to the human focal adhesion kinase (FAK) protein. This protein
 CC is involved in integrin-mediated signal transduction, and is implicated
 CC in cancer, particularly colon, breast and oral tumours, embryonic
 CC development disorders, angiogenic disorders and wound healing. The
 CC antisense sequences, including the one shown here, can be used in the
 CC treatment of all of these
 XX
 SQ Sequence 15 BP; 4 A; 4 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 293 TGGCAGCTCCTTA 305
 ID |||||
 Db 13 TGGCAGCTCCTTA 1

RESULT 624
 ABRK46589/c
 ID ABRK46589 standard; DNA; 15 BP.
 AC ABRK46589;

XX 05-JUN-2002 (first entry)

DE EDG4 gene, allele specific oligonucleotide primer #12.

XX Endothelial differentiation lysophosphatidic acid GPCR 4; receptor;
 KW G-protein coupled receptor; EDG4; cytosolic; gene therapy;
 KM antisense gene therapy; polymorphism; haplotype; ovarian cancer;
 KW allele specific oligonucleotide; ASO; PCR; primer; ss.

XX Homo sapiens.

OS MO200212342-A2.

PD 14-FEB-2002.

PF 06-AUG-2001; 2001WO-US024649.

PR 04-AUG-2000; 2000US-0223177P.

PA (GENA-) GENAISSANCE PHARM INC.

PI Kazemi A, Koshy B, Sanchis A;

XX WPI; 2002-257470/30.

PT New endothelial differentiation, G-protein coupled receptor-4 gene (EDG4)
 PT polymorphic variants, for studying the expression and function of EDG4
 PT and screening drugs to treat ovarian cancer.

PS Claim 16; Page 13; 66pp; English.

XX The invention describes a polynucleotide (1) which is a polymorphic
 CC variant of a reference sequence for the endothelial differentiation,
 CC lysophosphatidic acid G-protein coupled receptor-4 (EDG4) gene, EDG4 cDNA
 CC (located on chromosome 19p12). (1) is useful for studying the expression
 CC and function of EDG4 and expressing EDG4 protein for use in screening for
 CC candidate drugs to treat diseases related to EDG4 activity. The
 CC polymorphism and haplotype data are useful for validating whether EDG4 is
 CC a suitable target for drugs to treat ovarian cancer. Establishing the
 CC EDG4 haplotype or haplotype pair of an individual is useful for improving
 CC the efficiency and reliability of discovery and development of drugs for
 CC treating diseases associated with EDG4 activity. The haplotyping method
 CC is useful to validate EDG4 as a candidate target for treating a specific
 CC condition or disease predicted to be associated with EDG4 activity and
 CC for screening for compounds targeting EDG4. A polymorphic variant of EDG4
 CC is useful in studying the effect of variation on the biological activity
 CC of EDG4, on the binding affinity of candidate drugs targeting EDG4 for
 CC the treatment of ovarian cancer. This sequence represents an allele
 CC specific oligonucleotide (ASO) primer used for detecting EDG4 gene
 CC polymorphisms

XX Sequence 15 BP; 3 A; 5 C; 3 G; 3 T; 0 U; 1 Other;

Qy Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 3.6e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 444 TGAGCAAGGCTT 456
 ID |||||
 Db 13 TGAGCAAGGCTT 1

RESULT 625
 ABRK1899/c
 ID ABRK1899 standard; DNA; 15 BP.
 AC ABRK1899;

XX 13-AUG-2002 (first entry)

DE Human CYP27A1 gene polymorphism detection ASO probe #11.

XX Human; Cytochrome P450, Subfamily XXVIIA, single nucleotide polymorphism;
 KW Steroid 27-Hydroxylase; Cerebrotendinous xanthomatosis Polypeptide 1;
 KW CYP27A1; SNP; drug screening; cerebrotendinous xanthomatosis;
 KW allele specific oligonucleotide; ASO; probe; ss.

XX Homo sapiens.

OS MO200230952-A2.

PD 18-APR-2002.

PF 15-OCT-2001; 2001WO-US042727.

PR 13-OCT-2000; 2000US-0239942P.

PA (GENA-) GENAISSANCE PHARM INC.

PI Anastasio AE, Chew A, Han J, Sanchis A;

XX WPI; 2002-435436/46.

PT Novel isolated human Cytochrome P450, Subfamily XXVIIA, Steroid 27-
 PT Hydroxylase, Cerebrotendinous xanthomatosis 1 gene, useful for
 PT therapeutic purposes, and for studying expression and function of the
 PT gene.

PS Claim 14; Page 14; 90pp; English.

XX The present invention relates to a new human Cytochrome P450, Subfamily
 CC XXVIIA, (Steroid 27-Hydroxylase, Cerebrotendinous xanthomatosis)
 CC Polypeptide 1 (CYP27A1) polynucleotide. The polynucleotide of the
 CC invention comprises a sequence which is a polymorphic variant for a
 CC reference sequence for the CYP27A1 gene or its fragment, or a polymorphic
 CC variant of a reference sequence for a CYP27A1 cDNA or its fragment. The
 CC invention is useful for screening for drugs by contacting the CYP27A1
 CC polymorphic variant with a candidate agent and assaying for binding
 CC activity. The invention is also useful in studying the expression and
 CC function of CYP27A1, and in expressing CYP27A1 protein for use in
 CC screening for candidate drugs to treat diseases related to CYP27A1
 CC activity, e.g. cerebrotendinous xanthomatosis. Other uses include for
 CC therapeutic purposes and for studying expression of the CYP27A1 isogenes
 CC in vivo, for in vivo screening and testing of drugs targeted against
 CC CYP27A1 protein, and for testing the efficacy of therapeutic agents and
 CC compounds for diseases associated with CYP27A1 activity, e.g.
 CC cerebrotendinous xanthomatosis, in a biological system. The invention is
 CC useful for studying the effect of the variation on the biological
 CC activity of CYP27A1 as well as on the binding affinity of candidate drugs
 CC targeting CYP27A1 for the treatment of cerebrotendinous xanthomatosis.
 CC The present nucleic acid sequence represents one of a collection
 CC (ABK1889-ABK1902) of allele specific oligonucleotide (ASO) probes that
 CC were used in the invention to detect polymorphisms in the human CYP27A1
 CC gene

XX Sequence 15 BP; 2 A; 5 C; 3 G; 4 T; 0 U; 1 Other;

Qy Query Match 0.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 80.0%; Pred. No. 3.6e+02;

Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 103 GAGCAAGCCATGTG 117
 ID |||||
 Db 15 GAGCAAGCCATGTG 1

RESULT 626
AAS95506
ID AAS95506 standard; DNA; 15 BP.
XX
XX AAS95506;
AC
XX
DT 14-FEB-2002 (first entry)
XX
DE Human HSD3B2 gene allele-specific oligonucleotide sequencing primer #10.
XX
XX Human; steroid; dehydrogenase; isomerase; haplotyping; ss; cytostatic;
KW haplotype pair; single nucleotide polymorphism; genotyping; gene therapy;
KW drug screening; congenital adrenal hyperplasia; prostate cancer; HSD3B2;
KW sequencing primer; PCR primer; probe.
XX
XX Homo sapiens.
OS
PN MO200177126-A2.
PD 18-OCT-2001.
XX
PF 10-APR-2001; 2001WO-US011707.
XX
PR 10-APR-2000; 2000US-0195775P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
PI Bentivegna SC, Chew A, Choi JY, Koshy B, Stephens JC;
XX
XX WPI; 2002-041283/05.
DR
XX
PT New haplotypes of the human hydroxy-delta-5-steroid dehydrogenase, 3 beta
PT - and steroid delta-isomerase 2 gene, useful to diagnose and treat
PT congenital adrenal hyperplasia and prostate cancer.
PT
XX
PS Claim 16; Page 13; 60pp; English.
XX
CC The invention relates to single nucleotide polymorphisms in the gene
CC encoding the human hydroxy-delta-5-steroid dehydrogenase, 3 beta- and
CC steroid delta-isomerase 2 gene (HSD3B2). A method for haplotyping the
CC HSD3B2 gene in an individual comprises identifying the nucleotide at one
CC or more polymorphic sites and determining whether one of the copies of
CC the gene is defined by one of the HSD3B2 haplotypes given in the
CC specification or whether both copies are defined by a haplotype pair.
CC This method is useful in genotyping, whereby all possible haplotype pairs
CC can be assigned to specific genotypes. An association between a trait and
CC a haplotype or haplotype pair of the HSD3B2 gene can be identified by
CC comparing the frequency of the haplotype or haplotype pair in a
CC population exhibiting the trait with the frequency of the haplotype or
CC haplotype pair in a reference population, where a higher haplotype
CC frequency in the trait population indicates the trait is associated with
CC the haplotype or haplotype pair. HSD3B2 and its corresponding DNA are
CC used for studying the expression and function of HSD3B2, for use in
CC screening for candidate drugs to treat diseases related to HSD3B2
CC activity, such as congenital adrenal hyperplasia and prostate cancer. The
CC sequences are also useful for studying the effect of variation on the
CC biological activity of HSD3B2, as well as on the binding affinity of
CC candidate drugs targeting HSD3B2. Sequences AAS95490-AAS95524 represent
CC allele-specific oligonucleotide probes, sequencing primers and PCR
CC primers used to detect HSD3B2 gene polymorphisms
XX
XX Sequence 15 BP; 3 A; 5 C; 5 G; 1 T; 0 U; 1 Other;
SO

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

92 CAGCAGCAGCAGC 106
|||||
1 CAGCAGCAGCAGC 15

RESULT 627										
AA14439.1	standard; DNA; 15 BP.									
AC	AA14439.1									
AD	AA14439.1									
AE	AA14439.1									
AF	AA14439.1									
AG	AA14439.1									
AH	AA14439.1									
AI	AA14439.1									
AJ	AA14439.1									
AK	AA14439.1									
AL	AA14439.1									
AM	AA14439.1									
AN	AA14439.1									
AO	AA14439.1									
AP	AA14439.1									
AQ	AA14439.1									
AR	AA14439.1									
AS	AA14439.1									
AT	AA14439.1									
AV	AA14439.1									
AW	AA14439.1									
AX	AA14439.1									
AY	AA14439.1									
AZ	AA14439.1									
BA	AA14439.1									
BB	AA14439.1									
BC	AA14439.1									
BD	AA14439.1									
BE	AA14439.1									
BF	AA14439.1									
BG	AA14439.1									
BH	AA14439.1									
BI	AA14439.1									
BJ	AA14439.1									
BK	AA14439.1									
BL	AA14439.1									
BM	AA14439.1									
BN	AA14439.1									
BO	AA14439.1									
BP	AA14439.1									
BQ	AA14439.1									
BR	AA14439.1									
BS	AA14439.1									
BT	AA14439.1									
BU	AA14439.1									
BV	AA14439.1									
BW	AA14439.1									
BX	AA14439.1									
BY	AA14439.1									
BZ	AA14439.1									
CA	AA14439.1									
CB	AA14439.1									
CC	AA14439.1									
CD	AA14439.1									
CE	AA14439.1									
CF	AA14439.1									
CG	AA14439.1									
CH	AA14439.1									
CI	AA14439.1									
CJ	AA14439.1									
CK	AA14439.1									
CL	AA14439.1									
CM	AA14439.1									
CN	AA14439.1									
CO	AA14439.1									
CP	AA14439.1									
CQ	AA14439.1									
CR	AA14439.1									
CS	AA14439.1									
CT	AA14439.1									
CU	AA14439.1									
CV	AA14439.1									
CW	AA14439.1									
CX	AA14439.1									
CY	AA14439.1									
CA	AA14439.1									
CB	AA14439.1									
CC	AA14439.1									
CD	AA14439.1									
CE	AA14439.1									
CF	AA14439.1									
CG	AA14439.1									
CH	AA14439.1									
CI	AA14439.1									
CJ	AA14439.1									
CK	AA14439.1									
CL	AA14439.1									
CM	AA14439.1									
CN	AA14439.1									
CO	AA14439.1									
CP	AA14439.1									
CQ	AA14439.1									
CR	AA14439.1									
CS	AA14439.1									
CT	AA14439.1									
CU	AA14439.1									
CV	AA14439.1									
CW	AA14439.1									
CX	AA14439.1									
CY	AA14439.1									
CA	AA14439.1									
CB	AA14439.1									
CC	AA14439.1									
CD	AA14439.1									
CE	AA14439.1									
CF	AA14439.1									
CG	AA14439.1									
CH	AA14439.1									
CI	AA14439.1									
CJ	AA14439.1									
CK	AA14439.1									
CL	AA14439.1									
CM	AA14439.1									
CN	AA14439.1									
CO	AA14439.1									
CP	AA14439.1									
CQ	AA14439.1									
CR	AA14439.1									
CS	AA14439.1									
CT	AA14439.1									
CU	AA14439.1									
CV	AA14439.1									
CW	AA14439.1									
CX	AA14439.1									
CY	AA14439.1									
CA	AA14439.1									
CB	AA14439.1									
CC	AA14439.1									
CD	AA14439.1									
CE	AA14439.1									
CF	AA14439.1									
CG	AA14439.1									
CH	AA14439.1									
CI	AA14439.1									
CJ	AA14439.1									
CK	AA14439.1									

```
XX XX WO200208417-A1.
XX PN
XX PD 31-JAN-2002.
XX XX
XX PF 25-JUL-2001; 2001WO-JP006392.
XX PR 25-JUL-2000; 2000JP-00229064.
XX PA (TAKE ) TAKEDA CHEM IND LTD.
XX PI Ito T, Tanaka Y, Kondo M;
XX DR WPI; 2002-179906/23.
XX PT Production of recombinant proteins in prokaryotes or eukaryotes
XX PT particularly with target proteins obtainable through gene recombination
XX PT technique, for use as drugs, reagents, raw materials for industries and
XX PT feeding stuffs.
XX PS Example 6; Page 42; 137pp; Japanese.
XX CC The present invention relates to a method for producing recombinant
XX CC proteins. The method comprises preparing a recombinant vector for
XX CC transforming a host cell before culturing the obtained transformant,
XX CC assaying expression of the reporter gene and confirming high expression
XX CC of the reporter gene. The recombinant proteins are useful as drugs,
XX CC reagents, raw materials for industries and feeding stuffs. Also, the
XX CC proteins are obtainable on large-scale production. The present sequence
XX CC was used to illustrate the invention
XX SQ Sequence 15 BP; 2 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 403 CCGGTTCCAGCC 415
Db 3 CCGGTTCCAGTC 15

RESULT 629
ABL90987/c
ID ABL90987 standard; DNA; 15 BP.
XX AC ABL90987;
XX DT 27-MAY-2002 (first entry)
XX DE Human protein kinase C-related phosphorothioate oligonucleotide 2.
XX KW Human; PKC antisense oligonucleotide; protein kinase C; PKC; PKC-alpha;
XX KW PKC-beta type I; PKC-beta type II; PKC-gamma; PKC-delta; PKC-epsilon;
XX KW PKC-zeta; PKC-eta; PKC expression modulation; ss;
XX KW hyperproliferative condition; tumour; glioblastoma; bladder cancer;
XX KW breast cancer; colon cancer; lung cancer; inflammatory condition;
XX KW psoriasis; phosphorothioate backbone.
XX OS Homo sapiens.
XX PN US6339066-B1.
XX PD 15-JAN-2002.
XX PF 31-MAR-1997; 97US-00829637.
XX PR 11-JAN-1990; 90US-00463358.
XX PR 13-AUG-1990; 90US-00566977.
XX PR 11-JAN-1991; 91WO-US000243.
XX PR 15-OCT-1991; 91US-00777760.
XX PR 16-OCT-1991; 91US-00777007.
XX PR 16-MAR-1992; 92US-00852852.
```

```
PR 05-MAY-1993; 93US-00058023.
PR 09-JUL-1993; 93US-00089996.
PR 29-AUG-1994; 94US-00297703.
PR 07-JUN-1995; 95US-00481066.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett CF, Dean NM, Cook PD, Hoke G,
XX DR WPI; 2002-215022/27.
XX PT New antisense oligonucleotide having nucleoside units which specifically
XX PT binds mRNA encoding human protein kinase C isoform, useful for treating
XX PT hyperproliferative and inflammatory diseases e.g. psoriasis, tumor and
XX PT cancer.
XX PS Example 3; Col 31; 77pp; English.
XX CC The invention comprises antisense oligonucleotides designed to bind mRNA
XX CC encoding a human protein kinase C (PKC) isoform (i.e. PKC-alpha, PKC-beta
XX CC type I, PKC-beta type II, PKC-gamma, PKC-delta, PKC-epsilon, PKC-zeta,
XX CC and PKC-eta). The antisense oligonucleotides of the invention are useful
XX CC for modulating the expression of the PKC isoforms. The antisense
XX CC oligonucleotides are useful for treating hyperproliferative conditions
XX CC (e.g. tumour, glioblastoma, bladder cancer, breast cancer, colon cancer
XX CC and lung cancer), and inflammatory conditions (e.g. psoriasis). The
XX CC antisense oligonucleotides of the invention are also useful for detection
XX CC and diagnosis of PKC expression. The present sequence represents a human
XX CC PKC antisense oligonucleotide of the invention. NOTE: The present
XX CC sequence contains a phosphorothioate backbone
XX SQ Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 560 ACTGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 630
ABN83920/c
ID ABN83920 standard; DNA; 15 BP.
XX AC ABN83920;
XX DT 06-SEP-2002 (first entry)
XX DE Gmdssu 5'UTR sequence.
XX KW Arcelin-5; promoter; plant; transgenic; soybean; agriculture; nutrition;
XX KW pharmaceutical; ds.
XX OS Glycine sp.
XX PN WO200250295-A2.
XX PD 27-JUN-2002.
XX PF 17-DEC-2001; 2001WO-US047495.
XX PR 18-DEC-2000; 2000US-0255879P.
XX PA (RENE-) RENESSEN LLC.
XX PI Wang Q, Dubois P, Liang J, Oulmaseov T;
XX DR WPI; 2002-508809/54.
XX PT New transformed or transgenic soybeans plants or cells with an Arcelin-5
XX PT promoter, for use as an improved dietary source of protein for humans or
```

PT animals, or for producing soybeans with important agricultural or
PT nutritional properties.
PS Example 5; Page 67; 74pp; English.
XX The invention relates to a transformed soybean plant cell and transgenic
CC soybean plant, both of which has a nucleic acid molecule comprising the
CC Phaseolus vulgaris exotic genotype G02771 Arcelin-5 promoter sequence.
CC The transformed soybean plant cell and transgenic soybean plant are
CC useful as an improved source of dietary protein for humans and livestock.
CC These are also useful for producing soybean plants that exhibit important
CC agricultural, nutritional or pharmaceutical properties. The current
CC sequence represents a GmDSU 5'UTR sequence. This sequence was used in
CC the expression of a GUS reporter gene in a soybean cotyledon
XX
SQ Sequence 15 BP; 8 A; 3 C; 3 G; 1 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 63 GGTCTTCTACTT 75
15 GGTCTTCTCTT 3
Db
RESULT 631
ABA96055
ID ABA96055 standard; DNA; 15 BP.
XX
AC ABA96055;
XX
DT 08-APR-2002 (first entry)
XX
DE CYP8B1 allele-specific oligonucleotide probe #7.
XX
KW Probe: CYP8B1; allele-specific oligonucleotide; ASO; cytochrome P450;
KW VIIIb; cardiant; gene therapy; cardiovascular disorder; human; ss.
XX
OS Homo sapiens.
XX
PN WO200179224-A2.
XX
PD 25-OCT-2001.
XX
PF 12-APR-2001; 2001WO-US011946.
XX
PR 12-APR-2000; 2000US-0196408P.
XX
PA (GENA-) GENMAISSANCE PHARM INC.
XX
PI Bentivegna SC, Chew A, Choi JY, Koshy B, Stephens JC;
XX
DR WPI; 2002-075057/10.
XX
PT Novel polymorphic variants of cytochrome P450 subfamily VIIIb gene useful
PT in studying expression and function of the protein, for screening
PT candidate drugs to treat diseases e.g. cardiovascular disorders.
XX
PS Claim 15; Page 13; 63pp; English.
XX
CC The sequence represents an allele-specific oligonucleotide (ASO) probe,
CC used in the invention to detect polymorphisms in the CYP8B1 gene. The
CC invention relates to a novel isolated polynucleotide which is a
CC polymorphic variant of a reference sequence for cytochrome P450 subfamily
CC VIIIb (CYP8B1) gene or their fragment. The polynucleotides of the
CC invention have cardiant activity and may have a use in gene therapy. A
CC polymorphic variant of the CYP8B1 protein is useful for screening drugs
CC targeting CYP8B1. A haplotype or haplotype pair is useful for improving
CC the efficiency and reliability of several steps in the discovery and
CC development of drugs for treating diseases associated with CYP8B1
CC activity e.g., cardiovascular disorders. The invention includes a method
CC for haplotyping CYP8B1 gene in an individual, which can also be used to

CC validate CYP8B1 as a candidate target for, and in design of clinical
CC trials of candidate drugs for, treating a specific condition drugs or
CC disease predicted to be associated with CYP8B1 activity. A method is also
CC included for genotyping CYP8B1 gene of an individual which can also be
CC used in developing diagnostic tests and therapeutic treatments. The
CC advantage to this is that without requiring any a prior knowledge of the
CC phenotypic effect of any particular CYP8B1 haplotype or haplotype pair,
CC the invention provides a method to identify lead compounds that are more
CC likely to show efficacy in clinical trials
XX
SQ Sequence 15 BP; 2 A; 6 C; 3 G; 3 T; 0 U; 1 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
OY 243 CTACCCAAATGCTGG 257
1 CTACCCARGTCCTGG 15
Db
RESULT 632
AAS98470
ID AAS98470 standard; cDNA; 15 BP.
XX
AC AAS98470;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human protective DNA sequence CNI-00738 open reading frame DNA #30.
XX
KW Human; protective sequence; cell death; central nervous system; stroke;
KW ischaemia; open reading frame; ORF; cerebral herniation; septic embolism;
KW cerebral oedema; meningitis; protozoal infection; malaria; CNI-00733; ss;
KW metazoal infection; vascular disease; eye; macular degeneration; trauma;
KW diabetic retinopathy; epidural haematoma; tumour; degenerative disease;
KW nutritional condition; environmental condition; metabolic condition;
KW CNI-00736; CNI-00738; CNI-00742; CNI-00748; cancer; gene therapy.
XX
OS Homo sapiens.
XX
PN WO200181361-A1.
XX
XX
PD 01-NOV-2001.
XX
PF 09-APR-2001; 2001WO-US011501.
XX
PR 11-APR-2000; 2000US-00547938.
XX
PA (COGE-) COGENT NEUROSCIENCE INC.
XX
PI Portbury SD, Puranam K, Katz LC, Lo DC, Barney S, Thomas MB;
XX
DR WPI; 2002-066433/09.
XX
PT P-PSDB; AAU73309.
XX
PT Polypeptides and polynucleotides comprising protective sequences useful
PT for preventing, delaying or rescuing a cell from death in disease,
PT condition or disorders such as Alzheimer's disease, stroke, tumors,
PT trauma.
XX
PS Claim 2; Fig 6AF; 228pp; English.
XX
CC The invention relates to an isolated polypeptide encoded by a protective
CC sequence, which is a polynucleotide comprising sequences which, when
CC introduced into a cell either predisposed to undergo cell death or in the
CC process of undergoing cell death, prevent, delay, or rescue the cell from
CC death, relative to a corresponding cell into which exogenous nucleic
CC acids have been introduced. The sequences of the invention are useful for
CC diagnosing a protective sequence-mediated condition, disorder or disease
CC in an individual. The treatable disorders are preferably of the central
CC nervous system of humans including ischaemia-related conditions such as
CC stroke, cerebral herniation, septic embolism, cerebral oedema, infections

CC	such as meningitis, protozoal infections such as malaria, metazoal
CC	infections such as echinococcosis, vascular diseases such as ischaemic
CC	encephalopathy, conditions involving the eye such as macular
CC	degeneration, diabetic retinopathy, trauma such as epidural haematoma,
CC	tumours such as primary intracranial tumours, degenerative diseases such
CC	as Alzheimer's disease and nutritional, environmental and metabolic
CC	conditions. Sequences AAS98409-AAS98544 represent human protective
CC	sequence DNA and open reading frames of the polynucleotides
SQ	Sequence 15 BP; 7 A; 4 C; 2 G; 2 T; 0 U; 0 Other;
QY	Query Match 0.2%; Score 11.4; DB 1; Length 15;
Db	Best Local Similarity 92.3%; Pred. No. 3.6e+02;
	Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
	550 ATGACACCACT 562
	1 ATGACACCAACT 13
RESULT 633	
ID	AAK98359/c
XX	AAK98359 standard; DNA; 15 BP.
AC	AAK98359;
XX	
DT	09-SEP-2004 (revised)
DT	28-MAY-2002 (first entry)
XX	
DB	Sugar-modified nuclease resistant antisense oligonucleotide 1.
XX	
KW	Sugar-modified oligonucleotide; nuclease resistant oligonucleotide;
KW	antisense oligonucleotide therapy; gene expression modulation; ss; HIV;
KW	human immunodeficiency virus; herpes virus; papillomavirus.
XX	
OS	Synthetic.
XX	
FH	Key
FT	modified_base
FT	Location/Qualifiers
FT	1..15
FT	/*tag= b
FT	/mod_base= OTHER
FT	/note= "Optional phosphorothioate backbone"
FT	1
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note= "Optionally 2'-deoxy-2'-fluoro-cytidine"
FT	2
FT	/*tag= c
FT	/mod_base= OTHER
FT	/note= "Optionally 2'-deoxy-2'-fluoro-guanosine"
FT	3
FT	/*tag= d
FT	/mod_base= OTHER
FT	/note= "2'-deoxy-2'-fluoro-adenosine"
FT	4
FT	/*tag= e
FT	/mod_base= OTHER
FT	/note= "Optionally 2'-deoxy-2'-fluoro-cytidine"
FT	5
FT	/*tag= f
FT	/mod_base= OTHER
FT	/note= "Optionally 2'-deoxy-2'-fluoro-uridine"
FT	6
FT	/*tag= g
FT	/mod_base= OTHER
FT	/note= "2'-deoxy-2'-fluoro-adenosine"
FT	7
FT	/*tag= h
FT	/mod_base= OTHER
FT	/note= "Optionally 2'-deoxy-2'-fluoro-uridine"
FT	8
FT	/*tag= i
FT	/mod_base= OTHER

FT	/note= "Optionally 2'-deoxy-2'-fluoro-guanosine"
FT	9
FT	/*tag= j
FT	/mod_base= OTHER
FT	/note= "Optionally 2'-deoxy-2'-fluoro-cytidine"
FT	10
FT	/*tag= k
FT	/mod_base= OTHER
FT	/note= "2'-deoxy-2'-fluoro-adenosine"
FT	11
FT	/*tag= l
FT	/mod_base= OTHER
FT	/note= "2'-deoxy-2'-fluoro-adenosine"
FT	12
FT	/*tag= m
FT	/mod_base= OTHER
FT	/note= "Optionally 2'-deoxy-2'-fluoro-guanosine"
FT	13
FT	/*tag= n
FT	/mod_base= OTHER
FT	/note= "Optionally 2'-deoxy-2'-fluoro-uridine"
FT	14
FT	/*tag= o
FT	/mod_base= OTHER
FT	/note= "2'-deoxy-2'-fluoro-adenosine"
FT	15
FT	/*tag= p
FT	/mod_base= OTHER
FT	/note= "Optionally 2'-deoxy-2'-fluoro-cytidine"
PN	
XX	US6307040-B1.
PD	
XX	23-OCT-2001.
PX	
PF	23-SEP-1997; 97US-00936166.
XX	
PR	13-AUG-1990; 90US-00566977.
PR	12-AUG-1991; 91WO-US005720.
PR	05-MAR-1992; 92US-00835932.
PR	06-JUN-1995; 95US-00468037.
XX	
PA	(ISIS-) ISIS PHARM INC.
PI	
XX	Cook PD, Kawasaki AM;
DR	WPI: 2002-054477/07.
XX	
PT	New oligonucleotides, useful for detecting and modulating the gene
PT	expression, particularly for treating HIV, herpes virus, papillomavirus
PT	or other infections, comprise at least one modified 2'-deoxyfuranosyl
PT	moleity.
XX	
PS	Disclosure; Page ?; 20pp; English.
XX	
CC	The invention comprises sugar-modified, nuclease resistant
CC	oligonucleotides which modulate the activity of pre-selected DNA/RNA
CC	sequences. Antisense oligonucleotide methodology is a widely used method
CC	of inhibiting gene expression. However any diagnostic, research reagent
CC	or therapeutic application of antisense methodology requires that the
CC	oligonucleotides be taken up by cells hybridise to the target DNA/RNA
CC	and terminate/disrupt the nucleic acid function. It is unlikely that
CC	unmodified oligonucleotides would be effective in this role, as they are
CC	susceptible to nuclease degradation. The oligonucleotides of the
CC	invention are more resistant to nuclease degradation than unmodified
CC	oligonucleotides and are therefore useful in antisense methodology
CC	diagnostics, research reagents or therapeutics (e.g. antisense
CC	oligonucleotide therapy, gene expression modulation). The
CC	oligonucleotides of the invention are particularly useful for detecting
CC	and modulating the gene expression, (e.g. for treating human
CC	immunodeficiency virus (HIV), herpesvirus, papillomavirus or other
CC	infections). The present sequence represents a sugar-modified, nuclease
CC	resistant oligonucleotide of the invention

CC	Revised record issued on 09-SEP-2004 : Correction to feature table key
XX	Sequence 15 BP, 5 A, 4 C, 3 G, 3 T, 0 U, 0 Other;
XX	Query Match 0.2%; Score 11.4; DB 1; Length 15;
XX	Best Local Similarity 92.3%; Pred. No. 3.6e+02;
XX	Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY	560 ACTGCGATAGTCG 572
DB	13 ACTGCGATAGTCG 1
RESULT 634	
AAK98362/c	
ID	AAK98362 standard; RNA; 15 BP.
XX	AAK98362;
AC	
DT	28-MAY-2002 (first entry)
XX	
DE	Sugar-modified nuclease resistant antisense oligonucleotide 4.
XX	
KW	Sugar-modified oligonucleotide; nuclease resistant oligonucleotide;
KW	antisense oligonucleotide therapy; gene expression modulation; ss; HIV;
XX	human immunodeficiency virus; herpes virus; papillomavirus.
OS	Synthetic.
XX	
FT	Key
FT	modified_base
FT	Location/Qualifiers
FT	1
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note= "2'-deoxy-2'-fluoro-cytidine"
FT	4
FT	/*tag= b
FT	/mod_base= OTHER
FT	/note= "2'-deoxy-2'-fluoro-cytidine"
FT	5
FT	/*tag= c
FT	/mod_base= OTHER
FT	/note= "2'-deoxy-2'-fluoro-uridine"
FT	7
FT	/*tag= d
FT	/mod_base= OTHER
FT	/note= "2'-deoxy-2'-fluoro-uridine"
FT	9
FT	/*tag= e
FT	/mod_base= OTHER
FT	/note= "2'-deoxy-2'-fluoro-cytidine"
FT	13
FT	/*tag= f
FT	/mod_base= OTHER
FT	/note= "2'-deoxy-2'-fluoro-uridine"
XX	
PN	US6307040-B1.
XX	
PD	23-OCT-2001.
XX	
XX	23-SEP-1997; 97US-00936166.
XX	
PR	13-AUG-1990; 90US-00566977.
PR	12-AUG-1991; 91WO-US005720.
PR	05-MAR-1992; 92US-00835932.
PR	06-JUN-1995; 95US-00468037.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	
PI	Cook PD, Kawasaki AM;
XX	
DR	WPI: 2002-054477/07.
XX	
XX	New oligonucleotides, useful for detecting and modulating the gene

Pt		expression, particularly for treating HIV, herpes virus, papillomavirus or other infections, comprise at least one modified 2'-deoxyfuranosyl moiety.
P8	XX	Example 13; Col 28; 20pp; English.
CC	XX	The invention comprises sugar-modified, nuclease resistant oligonucleotides which modulate the activity of pre-selected DNA/RNA sequences. Antisense oligonucleotide methodology is a widely used method of inhibiting gene expression. However any diagnostic, research reagent or therapeutic application of antisense methodology requires that the oligonucleotides be taken up by cells, hybridise to the target DNA/RNA and terminate/disrupt the nucleic acid function. It is unlikely that unmodified oligonucleotides would be effective in this role, as they are susceptible to nuclease degradation. The oligonucleotides of the invention are more resistant to nuclease degradation than unmodified oligonucleotides and are therefore useful in antisense methodology diagnostics, research reagents or therapeutics (e.g. antisense oligonucleotide therapy, gene expression modulation). The oligonucleotides of the invention are particularly useful for detecting and modulating the gene expression, (e.g. for treating human immunodeficiency virus (HIV), hepatitisvirus, papillomaviruss or other infections). The present sequence represents a sugar-modified, nuclease resistant oligonucleotide of the invention
SQ	XX	Sequence 15 BP; 5 A; 4 C; 3 G; 0 T; 3 U; 0 Other;
Oy		Query Match 0.2%; Score 11.4; DB 1; Length 15; Best Local Similarity 92.3%; Pred.No. 3.e6+02; Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0,
Dn		560 ACTCGCATAGTCG 572 13 ACTTGCAATAGTGC 1
RESULT 635		
AkK98366/c	ID	AAK98366 standard; DNA; 15 BP.
AC	AK98366;	
DT	09-SEP-2004 (revised)	
DE	28-MAY-2002 (first entry)	
XX		Sugar-modified nuclease resistant antisense oligonucleotide 8.
KW		Sugar-modified oligonucleotide; nuclease resistant oligonucleotide; antisense oligonucleotide therapy; gene expression modulation; ss; HIV; human immunodeficiency virus; herpes virus; papillomavirus.
OS	Synthetic.	
FH	Key	Location/Qualifiers
FT	modified_base	1..15
FT	/tag= a	
FT	/mod_base= OTHER	
FT	/note= "Optional phosphorothioate backbone"	
PN	US6307040-B1.	
PD	23-OCT-2001.	
PF	23-SEP-1997;	97US-00936166.
PR	13-AUG-1990;	90US-00566977.
PR	12-AUG-1991;	91WO-US005720.
PR	05-MAR-1992;	92US-00835932.
PR	06-JUN-1995;	95US-00468037.
PA	(ISIS-) ISIS PHARM INC.	
Cx		
PI	Cook PD, Kawasaki AM;	

XX	DR	WPI; 2002-054477/07.
XX	PT	New oligonucleotides, useful for detecting and modulating the gene
XX	PT	expression, particularly for treating HIV, herpes virus, papillomavirus
XX	PT	or other infections, comprise at least one modified 2'-deoxyfuranosyl
XX	PT	moiety.
XX	PS	
XX	XX	Example 16; Col 29-30; 20pp; English.
CC	CC	The invention comprises sugar-modified, nuclease resistant
CC	CC	oligonucleotides which modulate the activity of pre-selected DNA/RNA
CC	CC	sequences. Antisense oligonucleotide methodology is a widely used method
CC	CC	of inhibiting gene expression. However any diagnostic, research reagent
CC	CC	or therapeutic application of antisense methodology requires that the
CC	CC	oligonucleotides be taken up by cells, hybridise to the target DNA/RNA
CC	CC	and terminate/disrupt the nucleic acid function. It is unlikely that
CC	CC	unmodified oligonucleotides would be effective in this role, as they are
CC	CC	susceptible to nuclease degradation. The oligonucleotides of the
CC	CC	invention are more resistant to nuclease degradation than unmodified
CC	CC	oligonucleotides and are therefore useful in antisense methodology
CC	CC	diagnostics, research reagents or therapeutics (e.g. antisense
CC	CC	oligonucleotide therapy, gene expression modulation). The
CC	CC	oligonucleotides of the invention are particularly useful for detecting
CC	CC	and modulating the gene expression, (e.g. for treating human
CC	CC	immunodeficiency virus (HIV), herpesvirus, papillomavirus or other
CC	CC	infections). The present sequence represents a sugar-modified, nuclease
CC	CC	resistant oligonucleotide of the invention
CC	CC	
XX	SO	Revised record issued on 09-SEP-2004 : Correction to feature table key
XX	XX	Sequence 15 BP; 5 A; 4 C; 3 G; 0 T; 3 U; 0 Other;
XX	XX	
XX	XX	Query Match 0.2%; Score 11.4; DB 1; Length 15;
XX	XX	Best Local Similarity 92.3%; Pred. No. 3.6e+02;
XX	XX	Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY		560 ACTCGCATAGTGC 572
Db		13 ACTTCATAGTGC 1
RESULT 636		
AAS95678/C		
AA95678 standard; DNA; 15 BP.		
AC		AA95678;
XX		
DT		14-FEB-2002 (first entry)
XX		
DE		Superoxide dismutase 1 (SOD1) allele-specific oligonucleotide #19.
XX		
KW		Superoxide dismutase 1; soluble amyotrophic lateral sclerosis 1 (adult);
XX		haplotyping; SOD1; allele-specific oligonucleotide; ss.
XX		
OS		Homo sapiens.
XX		
PN		WO200185741-A2.
XX		
PD		15-NOV-2001.
XX		
PF		07-MAY-2001; 2001WO-US014772.
XX		
PR		05-MAY-2000; 2000US-0202491P.
XX		
PA		(GENA-) GENAISSANCE PHARM INC.
XX		
PI		Choi JY, Bentivegna SC, Kliem SE, Koshy B, Parks KB;
XX		
DR		WPI; 2002-055578/07.
XX		
PT		Isolated human superoxide dismutase 1 (SOD1) soluble polynucleotide;
PT		useful for screening therapeutic compounds, comprises a sequence which is

PT	a polymorphic variant of reference sequence for the SOD1 gene or its fragment.
PS	Claim 15; Page 13; 70pp; English.
XX	The invention relates to an isolated human superoxide dismutase 1,
CC	soluble (amphotrophic lateral sclerosis 1 (adult) (SOD1) polynucleotide
CC	(I) comprising a sequence which is a polymorphic variant of a reference
CC	sequence for the SOD1 gene. Haplotyping the SOD1 gene of an individual,
CC	Involves: (a) determining whether the individual has one of the SOD1
CC	haplotypes or haplotype pairs given in the specification; or (b)
CC	determining for one copy of the SOD1 gene present in the individual, the
CC	identity of the nucleotide at two or more polymorphic sites selected from
CC	PS1-7. The method is useful for determining whether an individual has a
CC	haplotype or haplotype pair defined in the specification. The method is
CC	also useful for improving the efficacy and reliability of several steps
CC	in the discovery and development of drugs for treating diseases
CC	associated with SOD1 activity, e.g., amotrophic lateral sclerosis, and
CC	to validate SOD1 as a candidate agent for treating a specific condition
CC	or disease associated with SOD1 activity. It can further be used in the
CC	design of clinical trials of candidate drugs for treating a specific
CC	condition or disease predicted to be associated with SOD1 activity. (I)
CC	is useful in studying the expression and function of SOD1, and in
CC	expressing SOD1 protein for use in screening for candidate drugs to treat
CC	diseases related to SOD1 activity. AAS95660-AAS95710 represent human
CC	superoxide dismutase 1, soluble (amotrophic lateral sclerosis 1 (adult))
CC	(SOD1) allele-specific oligonucleotides and related PCR primers as
CC	described in the method of the invention
XX	
SQ	Sequence 15 BP; 10 A; 0 C; 3 G; 1 T; 0 U; 1 Other;
Query Match	0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity	80.0%; Pred. No. 3.6e+02;
Matches 12; Conservative	1; Mismatches 2; Indels 0; Gaps 0.
Oy	66 TCTTCACTTCCTTT 80 : Db 15 TTCTCTCTCTAT 1
RESULT 637	
AAS19794	
ID	AAS19794 standard; DNA; 15 BP.
XX	
AC	AAS19794;
DT	08-MAY-2002 (first entry)
XX	
DE	ASO primer #52 to detect human RANGAP1 gene polymorphisms.
XX	
KW	Human; single nucleotide polymorphism; SNP; RANGAP1;
KW	haplotyping chromosome 22q13.2-q13.31; Ran GTPase activating protein 1,
KW	genotyping; cancer; irregular cell cycle associated disorder; ASO;
KW	primer; ss; allele-specific oligonucleotide.
OS	Homo sapiens.
XX	
PX	WO200179240-A2.
XX	
PD	25-OCT-2001.
XX	
PF	17-APR-2001; 2001WO-US012455.
XX	
PR	17-APR-2000; 2000US-0198072P.
XX	
PA	(GENA-) GENAISANCE PHARM INC.
PI	Chew A, Choi JY, Koshy B;
XX	
DR	WPI; 2002-075068/10.
XX	
PT	Genotyping human Ran GTPase activating protein 1 gene of individual for
XX	determining haplotype of individual, involves determining identity of

PT nucleotide pair at specific polymorphic sites for two copies of the gene.
 XX
 PS Claim 15; Page 15; 148pp; English.
 CC The present invention relates to novel single nucleotide polymorphisms
 CC (SNPs) in the human Ran GTPase activating protein 1 (RANGAP1) gene
 CC located on chromosome 22q13.2-q13.31, and methods for haplotyping and/or
 CC genotyping the RANGAP1 gene. The method of the invention make use of
 CC allele-specific oligonucleotides (ASOs) as probes and primers and/or
 CC primer-extension oligonucleotides for detecting the RANGAP1 gene
 CC polymorphisms. The polymorphisms and screened compounds are useful for
 CC treatment of diseases associated with RANGAP1 activity, such as cancer
 CC and other disorders associated with an irregular cell cycle. AAS19743-
 CC AAS19820 represent ASO primers for detecting human RANGAP1 gene
 CC polymorphisms
 XX
 SQ Sequence 15 BP; 3 A; 3 C; 5 G; 3 T; 0 U; 1 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 3.6e+02;
 Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 1 CTGGGATTGGGACAC 15
 Db 1 CTGGGATTGGGACAC 15
 RESULT 638
 AAS19818
 ID AAS19818 standard; DNA; 15 BP.
 XX
 AC AAS19818;
 XX
 DT 08-MAY-2002 (first entry)
 XX
 DE ASO primer #76 to detect human RANGAP1 gene polymorphisms.
 XX
 XX Human; single nucleotide polymorphism; SNP; RANGAP1;
 KM haplotyping; chromosome 22q13.2-q13.31; Ran GTPase activating protein 1;
 KW genotyping; cancer; irregular cell cycle associated disorder; ASO;
 KM primer; ss; allele-specific oligonucleotide.
 XX
 OS Homo sapiens.
 XX
 PN WO200179240-A2.
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012455.
 XX
 PR 17-APR-2000; 2000US-0198072P.
 XX
 PA (GENA-) GENMAISSANCE PHARM INC.
 XX
 PI Chew A, Choi JY, Koehy B;
 XX
 XX WPI; 2002-075068/10.
 DR
 XX Genotyping human Ran GTPase activating protein 1 gene of individual for
 PT determining haplotype of individual, involves determining identity of
 PT nucleotide pair at specific polymorphic sites for two copies of the gene.
 PS Claim 15; Page 15; 148pp; English.
 XX
 CC The present invention relates to novel single nucleotide polymorphisms
 CC (SNPs) in the human Ran GTPase activating protein 1 (RANGAP1) gene
 CC located on chromosome 22q13.2-q13.31, and methods for haplotyping and/or
 CC genotyping the RANGAP1 gene. The method of the invention make use of
 CC allele-specific oligonucleotides (ASOs) as probes and primers and/or
 CC primer-extension oligonucleotides for detecting the RANGAP1 gene
 CC polymorphisms. The polymorphisms and screened compounds are useful for
 CC treatment of diseases associated with RANGAP1 activity, such as cancer
 CC and other disorders associated with an irregular cell cycle. AAS19743-

CC AAS19820 represent ASO primers for detecting human RANGAP1 gene
 CC polymorphisms
 XX
 SQ Sequence 15 BP; 3 A; 1 C; 3 G; 7 T; 0 U; 1 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 3.6e+02;
 Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 78 TTTATTTCGAAATC 92
 Db 1 TTTATTTCGAAATC 15
 RESULT 639
 ABEK3849/C
 ID ABEK3849 standard; DNA; 15 BP.
 XX
 AC ABEK3849;
 XX
 DT 18-JUN-2002 (first entry)
 XX
 DE Neurokinin 1 receptor (NK-1) antisense oligonucleotide #13.
 XX
 XX Human; neurokinin receptor-1; NK-1; dermatological disorder;
 KM immune disorder; autoimmune disorder; cardiovascular disorder; pain;
 KM vascular disorder; airway disorder; neuropathic disorder; pain;
 KM psychiatric disorder; central nervous system disorder; inflammation;
 KM respiratory condition; ophthalmic condition; intestinal condition;
 KM demyelinating disease; small cell lung cancer; depression;
 KM hypersensitivity disorder; allergy; vasospastic disease; alcoholism;
 KM neurodegenerative disorder; acquired immune deficiency syndrome; AIDS;
 KM neuro-pathological disorder; stress; antisense; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200213799-A2.
 PD 21-FEB-2002.
 XX
 PF 17-AUG-2001; 2001WO-IB001510.
 XX
 PR 18-AUG-2000; 2000US-0226086P.
 XX
 PA (UYMC-) UNIV MCGILL.
 XX
 PI Henry JL, Cahill CM, Yashpal K;
 XX
 XX WPI; 2002-241835/29.
 DR
 XX Treating pathological condition involving neurokinin receptor-1, e.g.
 PT pain or inflammation, by administering oligonucleotide or a non-
 PT nucleotide disruptor compound which modulate NK-1 receptor biosynthetic
 PT pathway.
 PS Claim 24; Page 65; 100pp; English.
 XX
 CC The invention relates to a method of treating a pathological condition
 CC characterised partially by involvement of neurokinin receptor-1 (NK-1)
 CC receptor, especially treating, attenuating or preventing pain or
 CC inflammatory condition. The method comprises administering to a mammal, a
 CC compound chosen from an oligonucleotide, its analogue, and a disruptor
 CC which interferes with function or production of NK-1 receptors. The
 CC method is useful for treating a pathological condition characterised by
 CC involvement of NK-1 receptor such as dermatological, immune, autoimmune,
 CC cardiovascular, vascular disorders (e.g. migraine), airway, neuropathic,
 CC psychiatric and central nervous system disorders (e.g. anxiety,
 CC psychosis, schizophrenia), gut inflammation, arthritis, and central or
 CC peripheral aspects of chronic or acute pain, and for treating,
 CC attenuating or preventing pain or inflammation such as peripheral,
 CC chronic, acute pain or inflammation, neuropathic pain, inflammation or
 CC pain relating to psychiatric disorders and central nervous system
 CC disorders, including hyperalgesia, allodynia, neuralgia and dysesthesia

```

RESULT 640
AAD43406/c
ID AAD43406 standard; DNA; 15 BP.
XX
XX AC
XX
AAD43406;
XX
DT 14-NOV-2002 (first entry)
XX
XX Human CYP3A5 gene polymorphism detecting ASO primer #34.
XX
Human: cytochrome P450; subfamily 11A; polypeptide 5 isogene; CYP3A5;
drug screening; polymorphism; haplotype; drug metabolising disorder;
XX gene therapy; primer; ss.

```

WPI; 2002-636448/68.

Novel isolated polynucleotide which is a polymorphic variant of cytochrome P450, subfamily 11A, polypeptide 5 (CYP3A5) gene useful for expressing CYP3A5 protein isoform used in drug screening techniques.

C The invention relates to isolated polynucleotide having cytochrome P450,

CC subfamily IIIA, polypeptide 5 isogene (CYP3A5). The invention is useful
CC for screening drugs. The invention is useful for studying expression and
CC function of CYP3A5 and expressing CYP3A5 protein for use in screening for
CC candidate drugs to treat diseases related to CYP3A5 activity. The
CC polymorphism and haplotype data is useful for validating whether CYP3A5
CC is a suitable target for drugs to treat drug metabolising disorders,
CC screening for such drugs and reducing bias in clinical trials of such
CC drugs. The invention is also useful for therapeutic purposes. The
CC invention is useful in studying the effect of variation on the biological
CC activity of CYP3A5 as well as on the binding affinity of candidate drugs
CC to CYP3A5, or for studying the enzymatic properties of such CYP3A5
CC variants using these candidate drugs as substrate. The invention is
CC useful in gene therapy. The present sequence is human CYP3A5 gene
CC polymorphism detecting ASO (allele-specific oligonucleotide) primer
XX
Sequence 15 BP; 4 A; 5 C; 2 G; 3 T; 0 U; 1 Other;

Query Match	0.2%	Score 11.4	DB 1	Length 15
Best Local Similarity	80.0%	Pred. No. 3.6e+02		
Matches 12	Conservative 1	Mismatches 2	Indels 0	Gaps 0
QY	105 GCAGAGCCATGTGTT 119			
	:			
	:			
Db	15 GCGAAGCCATTTGTT 1			

RESULT 641
AAS94637/C
ID AAS94637 standard; DNA; 15 BP.
XX

DT 14-FEB-2002 (first entry)

human PLIV gene allele-specific oligonucleotide sequencing primer #46.

Human: phospholipid transfer protein; PLTP; haplotyping; haplotype pair; single nucleotide polymorphism; genotyping; gene therapy; drug screening binding affinity; atherosclerosis; ss; sequencing primer; PCR primer; probe.

OS Homo sapiens.

PN WO200172966-A2.

PD 04-OCT-2001

XX 26-MAR-2001 : 2001NO *****
PF

XX
DB

CA WPP 00000

XX
XX

CONSTANCE FARM INC.

CIIEW A, CNOI JY, KOSHY B;
XX
XX

WPI; 2002-010724/01

newly isolated polynucleotide which is polymorphic variant of phospholipid transfer protein (PLTP) gene, having any one of polymorphic sites P31-P35, for studying function of PLTP, and expressing PLTP protein.

Claim 15; Page 80; 99pp; English

The invention relates to single nucleotide polymorphisms in the gene encoding the human phospholipid transfer protein (PLTP). A method for haplotyping the PLTP gene in an individual comprises identifying the nucleotide at one or more polymorphic sites and determining whether one of the copies of the gene is defined by one of the PLTP haplotype given in the specification or whether both copies are defined by haplotype pair. This method is useful in genotyping, whereby all possible haplotype pairs can be assigned to specific genotypes. An association between a trait and a haplotype or haplotype pair of the PLTP gene can be identified by comparing the frequency of the haplotypes.

CC in a population exhibiting the trait with the frequency of the haplotype
 CC or haplotype pair in a reference population, where a higher haplotype
 CC frequency in the trait population indicates the trait is associated with
 CC the haplotype or haplotype pair. PLTP and its corresponding DNA are used
 CC for studying the expression and function of PLTP, for use in screening
 CC for candidate drugs to treat diseases related to PLTP activity. The
 CC sequences are also useful for studying the effect of variation on the
 CC biological activity of PLTP as well as on the binding affinity of
 CC candidate drugs targeting PLTP for treating atherosclerosis. Sequences
 CC MAS94566-MAS94651 represent allele-specific oligonucleotide probes,
 CC sequencing primers and PCR primers used for detecting PLTP gene
 CC polymorphisms
 XX
 SQ Sequence 15 BP; 2 A; 2 C; 10 G; 0 T; 0 U; 1 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 3.6e+02;
 Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 377 CTGCGGTGCGGCGTC 391
 15 CTGCGCTGCCCCCTC 1
 Db
 RESULT 642
 ABX00486/C
 ID ABX00486 standard; RNA; 15 BP.
 AC
 XX ABX00486;
 XX
 DT 23-DEC-2002 (first entry)
 XX
 DE Hepatitis C virus substrate #268 for HCV hammerhead ribozyme #268.
 XX
 KM Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
 KM HCV ribozyme; HCV expression; HCV replication; cirrhosis; virucide;
 KM liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
 KM type I interferon; interferon alpha; interferon beta; cytostatic;
 KM interferon gamma; consensus interferon; hepatotropic; antiinflammatory;
 KM substrate; hammerhead ribozyme; HH ribozyme; ss.
 XX
 OS Hepatitis C virus.
 XX
 PN US2002082225-A1.
 XX
 PD 27-JUN-2002.
 XX
 PF 23-MAR-1999; 99US-00274553.
 XX
 PR 23-MAR-1999; 99US-00274553.
 XX
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGEN J A.
 PA (ROBE/) ROBERTS B.
 PA (PAVC/) PAVCO P A.
 PA (MACE/) MACEJACK D.
 XX
 PI Blatt L, Mcswigen JA, Roberts B, Pavco PA, Macejack D;
 PT WPI; 2002-617759/66.
 XX
 PT New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
 PT replication and are useful to treat hepatitis C virus infections and
 PT cirrhosis; liver failure or hepatocellular carcinoma.
 XX
 PS Claim 1; Page 28; 80pp; English.
 XX
 CC The present invention relates to enzymatic nucleic acids which
 CC specifically cleave RNA derived from Hepatitis C virus (HCV). The
 CC enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin
 CC (HP) motif where the binding arms comprise sequences complementary to one
 CC of the substrate sequences defined in the specification. The HCV
 CC ribozymes are useful for modulating the expression and/or replication of

CC HCV. They can be used to treat cirrhosis, liver failure and/or
 CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating
 CC a condition associated with HCV infection in conjunction with one or more
 CC other drug therapies, particularly type I interferon, especially
 CC interferon alpha, beta or gamma or consensus interferon. The present
 CC sequence represents a substrate for a HCV hammerhead (HH) ribozyme. Note:
 CC Some of the sequence data for this patent did not form part of the
 CC printed specification. The complete sequence data for this patent was
 CC obtained in electronic format directly from the USPTO web site at
 CC seqdata.uspto.gov/patid/patidEntry.html
 XX
 SQ Sequence 15 BP; 3 A; 6 C; 2 G; 0 T; 4 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 137 GTGATGACACAG 149
 14 GTGTTGACACAG 2
 Db
 RESULT 643
 ABX00428/C
 ID ABX00428 standard; RNA; 15 BP.
 XX
 AC ABX00428;
 XX
 DT 23-DEC-2002 (first entry)
 XX
 DE Hepatitis C virus substrate #210 for HCV hammerhead ribozyme #210.
 XX
 KM Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
 KM HCV ribozyme; HCV expression; HCV replication; cirrhosis; virucide;
 KM liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
 KM type I interferon; interferon alpha; interferon beta; cytostatic;
 KM interferon gamma; consensus interferon; hepatotropic; antiinflammatory;
 KM substrate; hammerhead ribozyme; HH ribozyme; ss.
 XX
 OS Hepatitis C virus.
 XX
 PN US2002082225-A1.
 XX
 PD 27-JUN-2002.
 XX
 PF 23-MAR-1999; 99US-00274553.
 XX
 PR 23-MAR-1999; 99US-00274553.
 XX
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGEN J A.
 PA (ROBE/) ROBERTS B.
 PA (PAVC/) PAVCO P A.
 PA (MACE/) MACEJACK D.
 XX
 PI Blatt L, Mcswigen JA, Roberts B, Pavco PA, Macejack D;
 PT WPI; 2002-617759/66.
 XX
 PT New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
 PT replication and are useful to treat hepatitis C virus infections and
 PT cirrhosis; liver failure or hepatocellular carcinoma.
 XX
 PS Claim 1; Page 27; 80pp; English.
 XX
 CC The present invention relates to enzymatic nucleic acids which
 CC specifically cleave RNA derived from Hepatitis C virus (HCV). The
 CC enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin
 CC (HP) motif where the binding arms comprise sequences complementary to one
 CC of the substrate sequences defined in the specification. The HCV
 CC ribozymes are useful for modulating the expression and/or replication of
 CC HCV. They can be used to treat cirrhosis, liver failure and/or
 CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating

CC a condition associated with HCV infection in conjunction with one or more
 CC other drug therapies, particularly type I interferon, especially
 CC interferon alpha, beta or gamma or consensus interferon. The present
 CC sequence represents a substrate for a HCV hammerhead (HH) ribozyme. Note:
 CC Some of the sequence data for this patent did not form part of the
 CC printed specification. The complete sequence data for this patent was
 CC obtained in electronic format directly from the USPTO web site at
 CC seqdata.uspto.gov/psipdsIDentry.html
 CC
 SQ Sequence 15 BP; 3 A; 3 C; 4 G; 0 T; 5 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 36 CAGTCCCAAAATG 48
 Db 15 CAGTCCCAAGATG 3
 RESULT 644
 AAS15410/C
 ID AAS15410 standard; DNA; 15 BP.
 AC AAS15410;
 XX
 DT 29-JAN-2002 (first entry)
 XX
 DE Human focal adhesion kinase (FAK) antisense oligonucleotide ISTS#15406.
 XX
 KM Human, focal adhesion kinase; FAK; melanoma; tumour metastasis; cancer;
 KM angiogenic disorder; retinal neovascularisation; cytosstatic;
 KM ophthalmological; antisense; phosphorothioate; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..15
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate internucleotide linkages,
 FT optionally bases 1-5 and 11-15 are 2'-methoxyethoxy (2'-
 FT MOE) bases, where the 2'-MOE cytosines are also
 FT 5'-methylcytosines"
 XX
 PN US2001034329-A1.
 PD 25-OCT-2001.
 XX
 PF 09-JAN-2001; 2001US-00757100.
 XX
 PR 19-AUG-1999; 99US-00377310.
 PR 13-JUL-2000; 2000WO-US018999.
 XX
 PA (MONI/) MONIA B P.
 PA (GAAR/) GAARDE W A.
 PA (NERO/) NERO P S.
 XX
 PI Monia BP, Gaarde WA, Nero PS;
 XX
 DR WPI; 2002-010103/01.
 XX
 PT Antisense suppression of Focal Adhesion Kinase expression for the
 PT treatment of cancers of the breast, colon, mouth or skin (especially a
 PT melanoma), and angiogenic disorders e.g. retinal neovascularization.
 XX
 PS Claim 3; Page 13; 19pp; English.
 XX
 CC The present invention relates to novel antisense compounds which can be
 CC used for modulating the expression of human focal adhesion kinase (FAK).
 CC The antisense compounds comprise antisense oligonucleotides (8-30
 CC nucleotides in length) targeted to the 5'-untranslated region,
 CC translational termination region or 3' untranslated region of a nucleic

CC acid molecule encoding FAK. The antisense oligonucleotides can be used to
 CC inhibit the expression of FAK mRNA. The antisense oligonucleotides
 CC represent potential chemotherapeutic agents in the treatment of melanoma
 CC and the prevention of tumour metastasis. The antisense compounds and
 CC methods are useful for treating diseases associated with overexpression
 CC or constitutive activation of FAK. Such diseases include angiogenesis
 CC breast, colon, mouth or skin (especially a melanoma), and angiogenic
 CC disorders such as retinal neovascularization. AAS15383-AAS15422 represent
 CC the FAK antisense oligonucleotides of the invention
 CC
 SQ Sequence 15 BP; 4 A; 4 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 293 TGGCAGCTCCTTA 305
 Db 13 TGGCAGCTCCTTA 1
 RESULT 645
 AAS95951
 ID AAS95951 standard; DNA; 15 BP.
 XX
 AC AAS95951;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE Human CALM1 gene allele-specific oligonucleotide #60.
 XX
 KM Calmodulin 1; CALM1; human; single nucleotide polymorphism; SNP;
 KM haplotyping; SCYA3; Alzheimer's disease; drug screening;
 KM calcium-dependent signal transduction; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200179218-A2.
 PD 25-OCT-2001.
 XX
 PF 09-APR-2001; 2001WO-US011509.
 XX
 PR 12-APR-2000; 2000US-0196340P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Bentivegna SC, Chew A, Choi JY, Koshy B, Stephens JC;
 XX
 DR WPI; 2002-049190/06.
 XX
 PT New calmodulin-1 (CALM-1) isogene polymorphic variants, useful in
 PT expressing CALM1 protein for use in screening for candidate drugs to
 PT treat diseases related to CALM1 activity such as Alzheimer's disease.
 XX
 PS Claim 15; Page 13; 82pp; English.
 XX
 CC The invention relates to an isolated polynucleotide comprising a sequence
 CC selected from a polymorphic variant of calmodulin 1 (CALM1). The
 CC polymorphic variant comprises an CALM1 isogene defined by a haplotype
 CC selected from haplotypes 1-21 given in the specification. The
 CC polymorphisms are useful for studying the biological function of CALM1 as
 CC well as in identifying drugs targeting this protein for the treatment of
 CC a disorder related to its abnormal expression or function. The
 CC polymorphic variants may also be used in screening for compounds
 CC targeting CALM1 to treat a specific condition or disease predicted to be
 CC associated with CALM1 activity. Establishing CALM1 haplotype or haplotype
 CC pair of an individual is useful for improving the efficiency and
 CC reliability of several steps in the discovery and development of drugs
 CC for treating diseases associated with SCYA3 activity e.g. Alzheimer's
 CC disease and diseases involving defects in calcium-dependent signal
 CC transduction. Haplotyping the CALM1 gene in an individual is also useful
 CC in the design of clinical trials of candidate drugs for treating a

CC specific condition or disease predicted to be associated with CALM1
CC activity. AAS95892-AAS96018 represent human CALM1 allele- specific
CC oligonucleotides and PCR primers of the invention
XX
SQ Sequence 15 BP; 1 A; 8 C; 4 G; 1 T; 0 U; 1 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
DY 377 CTGCGTCGCGCTC 391
DB 1 CTGCGCGAGCGCCKC 15
RESULT 646
ABSS4516/c
ID ABSS4516 standard; DNA; 15 BP.
XX
AC ABSS4516;
XX
DT 22-NOV-2002 (first entry)
XX
DE HBV1BL1 hepatitis B detector probe.
XX
KM HBV1BL1; hepatitis; probe; ss; HBV1; hepatitis B detection.
XX
OS Hepatitis B virus.
OS Synthetic.
XX
PN EPI227162-A2.
XX
PD 31-JUL-2002.
XX
PF 25-JAN-2002; 2002EP-00001764.
XX
PR 26-JAN-2001; 2001US-00770532.
XX
PA (BECT) BECTON DICKINSON & CO.
XX
PI Berger DM, Nussbaumer WA, Fort TL, Heliyer TJ;
XX
DR WPI; 2002-637852/69.
XX
PT Novel oligonucleotide useful for detecting hepatitis B virus genotypes,
PT has sequence consisting of target binding sequence and optionally, a
PT sequence for selected amplification/detection reaction.
PS Claim 1; Page 4; 10pp; English.
XX
CC This invention relates to oligonucleotide probes and primers having a
CC sequence consisting of the target binding sequence and optionally a
CC sequence required for a selected amplification reaction. The method of
CC the invention is useful for detecting a hepatitis B virus (HBV) target
CC sequence, especially HBV genotypes, by amplifying the target sequence
CC using an oligonucleotide primer of the invention. Detection further
CC comprises a second amplification primer having a sequence consisting of
CC the target binding sequence and optionally a sequence required for a
CC selected amplification reaction. The amplified target sequence is
CC detected using a specific oligonucleotide given in the specification. The
CC oligonucleotide is selected such that a 5' end of the target binding
CC sequence of the oligonucleotide for detection overlaps a 3'-end of the
CC target binding sequence of the first amplification primer. Detection also
CC comprises quantifying the target sequence by co-amplification of a
CC control sequence and the target sequence. The methods and
CC oligonucleotides of the invention allow a real-time, rapid and sensitive
CC detection of all HBV genotypes. The present sequence represents the
CC hepatitis B (HBV) detector probe HBV1BL1 of the invention
XX
SQ Sequence 15 BP; 4 A; 4 C; 3 G; 4 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
DY 1277 AGGAATCCAGATG 289
DB 13 AGGAATCCTGATG 1
RESULT 647
ABX79987/c
ID ABX79987 standard; cDNA; 15 BP.
XX
AC ABX79987;
XX
DT 17-APR-2003 (first entry)
XX
DE EST polymorphic DNA repeat polynucleotide #312.
XX
KM EST; expressed sequence tag; ss; polymorphic repeat; tandem repeat;
KM polymorphic marker prediction of ubiquitous simple sequences; POMF0US;
KM Rep-X; human; genetic disease; drug-treatment; Machado-Joseph;
KM Haw River syndrome; Huntington's disease; fragile-X syndrome;
KM Friedrich's ataxia; myotonic dystrophy; hyperandrogenaemia;
KM spinal atrophy; bulbar atrophy; spinocerebellar ataxia.
XX
OS Homo sapiens.
XX
PN US6472154-B1.
XX
PD 29-OCT-2002.
XX
PF 31-DEC-1999; 99US-00475947.
XX
PR 31-DEC-1999; 99US-00475947.
XX
PA (TEXA) UNIV TEXAS SYSTEM.
XX
PI Garner HR, Wren JD, Minna JD, Fondon JW;
XX
DR WPI; 2003-208818/20.
XX
PT Identifying a candidate polymorphic repeat within a coding sequence, for
PT understanding or treating genetic disease, comprises detecting tandem
PT repeats in a target coding sequence and scoring the repeats for
PT polymorphic probability.
XX
PS Example; Col 1147; 586pp; English.
XX
CC The invention discloses a method for identifying a candidate polymorphic
CC repeat within a coding sequence (expressed sequence tag, EST), which
CC comprises detecting tandem repeats in a target coding sequence, scoring
CC the repeats for polymorphic probability and generating a dataset
CC correlating the repeats with polymorphic probability to identify a
CC candidate polymorphic repeat. The computational methods (polymorphic
CC marker prediction of ubiquitous simple sequences, POMF0US, and Rep-X) are
CC useful for identifying and detecting candidate polymorphic repeats in
CC human genes, which can be used to understand, treat or eliminate genetic
CC diseases, predispositions or adverse drug-treatment reactions. Examples
CC of diseases linked to nucleotide repeats are Machado-Joseph, Haw River
CC syndrome, Huntington's disease, fragile-X syndrome, Friedrich's ataxia,
CC myotonic dystrophy, hyperandrogenaemia, spinal and bulbar atrophy and
CC spinocerebellar ataxia. The sequences presented in ABX79676-ABX80022 are
CC the polymorphic repeats identified for a search of human ESTs
XX
SQ Sequence 15 BP; 9 A; 0 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
DY 66 TCTTCTACTTCTT 78
DB 14 TCTTCTTCTTCTT 2

```

RESULT 648
ABX79986/C
ID ABX79986 standard; cDNA; 15 BP.
XX
AC ABX79986;
XX
DT 17-APR-2003 (first entry)
XX
DE EST polymorphic DNA repeat polynucleotide #311.
XX
KW EST: expressed sequence tag; ss; polymorphic repeat; tandem repeat;
KW polymorphic marker prediction of ubiquitous simple sequences; POMPOUS;
KW Rep-X; human; genetic disease; drug-treatment; Machado-Joseph;
KW Haw River syndrome; Huntington's disease; fragile-X syndrome;
KW Friedrich's ataxia; myotonic dystrophy; hyperandrogenemia;
KW spinal atrophy; bulbar atrophy; spinocerebellar ataxia.
XX
OS Homo sapiens.
XX
PN US6472154-B1.
XX
PD 29-OCT-2002.
XX
PF 31-DEC-1999; 99US-00475947.
XX
PR 31-DEC-1999; 99US-00475947.
XX
PA (TEXA ) UNIV TEXAS SYSTEM.
XX
PI Garner HR, Wren JD, Milna JD, Fondon JW;
XX
DR WPI: 2003-208818/20.
XX
PT Identifying a candidate polymorphic repeat within a coding sequence, for
PT understanding or treating genetic disease, comprises detecting tandem
PT repeats in a target coding sequence and scoring the repeats for
PT polymorphic probability.
XX
PS Example; Col 1147; 588bp; English.
XX
CC The invention discloses a method for identifying a candidate polymorphic
CC repeat within a coding sequence (expressed sequence tag, EST), which
CC comprises detecting tandem repeats in a target coding sequence, scoring
CC the repeats for polymorphic probability and generating a dataset
CC correlating the repeats with polymorphic probability to identify a
CC candidate polymorphic repeat. The computational methods (polymorphic
CC marker prediction of ubiquitous simple sequences, POMPOUS, and Rep-X) are
CC useful for identifying and detecting candidate polymorphic repeats in
CC human genes, which can be used to understand, treat or eliminate genetic
CC diseases, predispositions or adverse drug-treatment reactions. Examples
CC of diseases linked to nucleotide repeats are Machado-Joseph, Haw River
CC syndrome, Huntington's disease, fragile-X syndrome, Friedrich's ataxia,
CC myotonic dystrophy, hyperandrogenemia, spinal and bulbar atrophy and
CC spinocerebellar ataxia. The sequences presented in ABX79676-ABX80022 are
CC the polymorphic repeats identified for a search of human ESTs
XX
SQ Sequence 15 BP; 9 A; 0 C; 6 G; 0 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 66 TCTTCTACTTCTT 78
| | | | | | | | | |
| | | | | | | | | |
14 TCTTCTTCTTCTT 2
XX
RESULT 649
ACD56058
ID ACD56058 standard; RNA; 15 BP.
XX
AC ACD56058;
XX

```

```

XX
DT 23-SEP-2003 (first entry)
XX
DE HBV enzymatic nucleic acid substrate sequence #11.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinczyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW vitruicide; antiinflammatory; substrate; ss.
XX
OS Hepatitis B virus.
XX
PN WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blate L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
DR WPI: 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Example 1; Page 212; 387bp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinczymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC enzymatic nucleic acid sequences disclosed in the present invention
XX
SQ Sequence 15 BP; 3 A; 8 C; 0 G; 0 T; 4 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 3.6e+02;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
XX

```


QY 165 CTCACCACTGTC 177
 Db 1 CUCCACCACTUUC 13

RESULT 650
 ID ACA61367/c
 XX ACA61367 standard; DNA; 15 BP.
 AC ACA61367;
 XX
 DT 11-AUG-2003 (first entry)
 XX
 DE 2'-deoxy-2'-substituted oligonucleotide #1.
 XX
 KM AIDS; ss; nuclease inhibitor; gene therapy; bacterial infection;
 KW viral infection; protozoan infection; abnormal cell proliferation;
 XX tumour formation; atherosclerosis.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..15
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER = 2'-deoxy-2'-fluoro nucleotides"
 XX
 PN US2003004325-A1.
 XX
 PD 02-JAN-2003.
 XX
 PF 28-NOV-2001; 2001US-00996263.
 XX
 PR 11-JAN-1990; 90US-00463358.
 PR 13-AUG-1990; 90US-00566977.
 PR 11-JAN-1991; 91WO-US000243.
 PR 12-AUG-1991; 91WO-US005720.
 PR 24-DEC-1991; 91US-00814961.
 PR 05-MAR-1992; 92US-00835932.
 PR 01-JUL-1992; 92US-00854634.
 PR 23-DEC-1992; 92WO-US011339.
 PR 21-JUN-1994; 94US-00244993.
 PR 06-JUN-1995; 95US-00471973.
 PR 17-AUG-1998; 98US-00135202.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Cook PD, Kawasaki AM;
 XX
 DR WPI; 2003-438873/41.
 XX
 PT New nuclease resistant compounds, useful as therapeutics, diagnostic
 PT agents, or research reagents, or for treating an organism with a disease
 PT associated with the undesired production of a protein, e.g. bacterial
 PT infections or AIDS.
 XX
 PS Example 13; Page 20; 50pp; English.
 XX
 XX The invention relates to a nuclease resistant compound that hybridises
 CC with RNA or DNA, comprising covalently-bound nucleosides that
 CC individually include a ribose of deoxyribose sugar portion and a base
 CC portion. The nuclease resistant compounds are useful as therapeutics,
 CC diagnostic agents, or research reagents. The compounds are also useful
 CC for modulating the activity of an RNA or DNA molecule, or for treating an
 CC organism with a disease associated with the undesired production of a
 CC protein, e.g. bacterial, viral or protozoan infections, AIDS, abnormal
 CC cell proliferation and tumour formation, or atherosclerosis. The present
 CC sequence represents the 2'-deoxy-2'-substituted oligonucleotide #1
 XX
 SQ Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1560 ACTGCATAGTCG 572
 Db 13 ACTGCATAGTCG 1

RESULT 651
 ID ACA61370/c
 XX ACA61370 standard; RNA; 15 BP.
 AC ACA61370;
 XX
 DT 11-AUG-2003 (first entry)
 XX
 DE 2'-deoxy-2'-substituted oligonucleotide #4.
 XX
 KM AIDS; ss; nuclease inhibitor; gene therapy; bacterial infection;
 KW viral infection; protozoan infection; abnormal cell proliferation;
 XX tumour formation; atherosclerosis.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER = 2'-deoxy-2'-methylthio nucleotide"
 FT 4..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER = 2'-deoxy-2'-methylthio nucleotides"
 FT 7
 FT modified_base
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "OTHER = 2'-deoxy-2'-methylthio nucleotide"
 FT 9
 FT modified_base
 FT /*tag= d
 FT /mod_base= OTHER
 FT /note= "OTHER = 2'-deoxy-2'-methylthio nucleotide"
 FT 13
 FT /*tag= e
 FT /mod_base= OTHER
 FT /note= "OTHER = 2'-deoxy-2'-methylthio nucleotide"
 XX
 PN US2003004325-A1.
 XX
 PD 02-JAN-2003.
 XX
 PF 28-NOV-2001; 2001US-00996263.
 XX
 PR 11-JAN-1990; 90US-00463358.
 PR 13-AUG-1990; 90US-00566977.
 PR 11-JAN-1991; 91WO-US000243.
 PR 12-AUG-1991; 91WO-US005720.
 PR 24-DEC-1991; 91US-00814961.
 PR 05-MAR-1992; 92US-00835932.
 PR 01-JUL-1992; 92US-00854634.
 PR 23-DEC-1992; 92WO-US011339.
 PR 21-JUN-1994; 94US-00244993.
 PR 06-JUN-1995; 95US-00471973.
 PR 17-AUG-1998; 98US-00135202.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Cook PD, Kawasaki AM;
 XX
 DR WPI; 2003-438873/41.
 XX
 PT New nuclease resistant compounds, useful as therapeutics, diagnostic
 PT agents, or research reagents, or for treating an organism with a disease
 PT associated with the undesired production of a protein, e.g. bacterial
 PT infections or AIDS.

XX Example 13; Page 20; 50pp; English.

CC The invention relates to a nuclease resistant compound that hybridises
CC with RNA or DNA, comprising covalently-bound nucleosides that
CC individually include a ribose of deoxyribose sugar portion and a base
CC portion. The nuclease resistant compounds are useful as therapeutics,
CC diagnostic agents, or research reagents. The compounds are also useful
CC for modulating the activity of an RNA or DNA molecule, or for treating an
CC organism with a disease associated with the undesired production of a
CC protein, e.g. bacterial, viral or protozoan infections, AIDS, abnormal
CC cell proliferation and tumour formation, or atherosclerosis. The present
CC sequence represents the 2'-deoxy-2'-substituted oligonucleotide #4

XX Sequence 15 BP; 5 A; 4 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 560 ACTCGCATAGTCG 572
Db 13 ACTGCATAGTCG 1

RESULT 652
ADC84280/C
ID ADC84280 standard; DNA; 15 BP.

AC ADC84280;

DT 01-JAN-2004 (first entry)

DE Human papillomavirus type 72 (HPV 72) detection oligonucleotide #3.

XX probe; human papilloma virus; HPV; detection; identification; ss.

OS Human papillomavirus type 72.

PN BP1302550-A1.

PD 16-APR-2003.

XX 10-OCT-2001; 2001EP-00123379.

PR 10-OCT-2001; 2001EP-00123379.

PA (KING-) KING CAR FOOD IND CO LTD.

PI Lin C, Lin R, You C, Huang H, Lee B, Lee H, Lin Y, Fan C;

PI Hsu H, Shih C, Yeh C, Kao Y, Pan C, Chan P;

DR WPI; 2003-432398/41.

PT Detector for identifying human papilloma virus subtypes, comprises
PT carrier having two parts carrying first and second oligonucleotides that
PT respectively hybridize with DNA contained in first and second subtypes of
PT the virus.

XX Claim 4; SEQ ID NO 510; 221pp; English.

CC The invention comprises oligonucleotides for detecting and identifying
CC subtypes of human papilloma virus (HPV) contained in a sample. The
CC oligonucleotides of the invention are useful for simultaneously detecting
CC and identifying subtypes of HPV. The present DNA sequence represents an
CC HPV detection oligonucleotide of the invention.

XX Sequence 15 BP; 2 A; 7 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 286 GATCCTGTGCAG 298
Db 13 GACGCTGTGCAG 1

RESULT 653
ADD44707/C
ID ADD44707 standard; DNA; 15 BP.

AC ADD44707;

DT 15-JAN-2004 (first entry)

DE 2'-Deoxy-2'-fluoro-substituted T7 oligonucleotide #4.

XX T7 RNA polymerase; ss; antisense; virucide; anti-HIV;
XX antiarteriosclerotic; cytosolic; 2'-fluoro substituent; AIDS;
XX atherosclerosis; cancer; DNA-RNA hybrid.

OS Enterobacteria phage T7.

PN US2003187240-A1.

PD 02-OCT-2003.

XX 28-JAN-2003; 2003US-00352586.

PR 11-JAN-1990; 90US-00463358.

PR 13-AUG-1990; 90US-00566977.

PR 05-MAR-1992; 92US-00835932.

PR 06-JUN-1995; 95US-00468037.

PR 02-SEP-1999; 99US-00389283.

PA (ISIS-) ISIS PHARM INC.

PI Cook PD, Kawasaki AM;

DR WPI; 2003-831271/77.

PT Modified oligonucleotides useful as therapeutics, diagnostics and
PT research agents comprises several covalently bound nucleosides joined by
PT internucleoside linkages.

PS Example 13; SEQ ID NO 24; 48pp; English.

XX A modified oligonucleotide comprises several covalently bound nucleosides
XX including a ribose or deoxyribose sugar portion and a base portion. The
XX nucleosides are joined together by internucleoside linkages such that the
XX base portion of the nucleosides form a mixed base sequence. At least one
XX of the nucleosides includes a modified ribofuranosyl moiety bearing a 2'-
XX fluoro substituent. A compound comprises several covalently bound
XX nucleosides including a ribose or deoxyribose sugar portion and a base
XX portion. The nucleosides are joined together by internucleoside linkages
XX such that the base portion of the nucleosides form a mixed base sequence.
XX At least one of the nucleosides includes a modified ribofuranosyl moiety
XX bearing a 2'-fluoro substituent (provided that at least two of the
XX nucleosides are 2-fluoro modified ribofuranosyl nucleosides when the
XX internucleoside linkages are phosphodiester linkages). Preferred
XX compounds: The compound comprises 5 - 50 nucleoside linked nucleosides.
XX At least two of the nucleosides are covalently bound through
XX phosphorothioate, methyl phosphonate or phosphate alkylate
XX internucleoside linkages. Preparation: The 2'-fluoro-substituted
XX nucleosides are prepared by nucleophilic displacement of 2'-leaving group
XX in arabinoside nucleosides by the modification of the general
XX procedure as described in Tetrahedron, 34, 1133 (1978); ibid., 31, 1369
XX (1975). Virucide: Anti-HIV; Antiarteriosclerotic; Cytostatic; DNA or RNA
XX modulator; Protein production modulator; Protein production inhibitor;
XX Viral nucleic acid hybridization inducer. The dosage is 0.01 mg/kg -
XX 100 mg/kg, once daily, weekly, monthly or yearly up to once every 20
XX years. The administration is topically (including ophthalmically,
XX vaginally, rectally, intranasally and transdermally), orally or
XX parenterally (including intravenously by dripping, subcutaneously,
XX intraperitoneally or intramuscularly by injection, intrathecally and

XX 04-MAY-2001; 2001TW-00110785.
 XX
 PR
 PA (KING-) KING CAR FOOD IND CO LTD.
 XX
 DR WPI; 2003-600935/57.

PT A detecting apparatus and a detecting method for identifying the subtypes
 PT of many species of human papilloma viruses at the same time and a
 PT composition for the detection.
 PS
 PS Claim 1; SEQ ID NO 539; 166bp; Japanese.

CC This invention describes a novel detecting apparatus for identifying the
 CC subtypes of human papillomaviruses (HPV) contained in a sample which
 CC comprises a carrier which can load sample, a first oligonucleotide loaded
 CC on first part of the carrier and a second oligonucleotide loaded on
 CC second part of carrier, in which first and second oligonucleotides
 CC hybridize with the DNA of the first and the second HPV subtype and can
 CC identify HPV subtype contained in sample at the same time. ADF43644-
 CC ADF44289 represent oligonucleotide probes used in the method of the
 CC invention.

CC Sequence 15 BP; 2 A; 7 C; 3 G; 3 T; 0 U; 0 Other;

QY Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 DB 286 GATGCTGTGCAG 298
 13 GACGCTGTGCAG 1

RESULT 556
 ADI12097/c
 ID ADI12097 standard; RNA; 15 BP.

AC ADI12097;
 XX
 DT 15-APR-2004 (first entry)
 XX
 DE 2'-modified oligonucleotide #4.

XX ss; nuclease resistant; mixed sequence; 2'-deoxyfuranosyl; antisense.
 OS Synthetic.

XX Key Location/Qualifiers
 FT modified_base 1..15
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-methyl. Optionally 1-7 and 9-14 are
 FT 2'-deoxy-2'-methylthio. Optionally 1-15 are
 FT phosphorothioate"

XX US6531584-B1.
 XX
 PD 11-MAR-2003.

XX 02-SEP-1999; 99US-00389283.

XX 11-JAN-1990; 90US-00463358.
 PR 13-AUG-1990; 90US-00566977.
 PR 05-MAR-1992; 92US-00835932.
 PR 01-JUL-1992; 92US-00854634.
 PR 06-JUN-1995; 95US-00468037.
 PR 05-MAR-1998; 98US-00035357.

XX (ISIS-) ISIS PHARM INC.

XX Cook PD, Kawasaki AM;
 XX
 PI
 XX

DR WPI; 2003-566474/53.

PT Nuclease resistant mixed sequence oligonucleotides useful as
 PT therapeutics, diagnostics, and research agents comprise at least one
 PT modified 2'-deoxyfuranosyl group.
 XX
 XX Example 13; SEQ ID NO 24; 48bp; English.

CC The invention relates to a nuclease resistant mixed sequence
 CC oligonucleotides comprising at least one modified 2'-deoxyfuranosyl
 CC group. The modified oligonucleotides are disclosed as being useful for
 CC modulating the production of a protein by an organism, and especially for
 CC treating a disease in an organism which is characterized by the undesired
 CC production of a protein. The oligonucleotides may be used to treat
 CC diseases caused by viruses or other agents. The oligonucleotides may also
 CC be used for diagnostic methods for detecting the presence or absence of
 CC abnormal RNA molecules, or for detecting the inappropriate expression of
 CC normal RNA molecules in an organism or cell. Oligonucleotides of the
 CC invention that selectively bind RNA may also be useful as research
 CC reagents. The new oligonucleotides are nuclease resistant and hybridise
 CC to RNA or DNA targets with high strength and specificity. The present
 CC sequence represents a 2'-modified oligonucleotide.

CC Sequence 15 BP; 5 A; 4 C; 3 G; 0 T; 3 U; 0 Other;

QY Query Match 0.2%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 DB 560 ACTGCATGTCG 572
 13 ACTTGCAATGTCG 1

RESULT 657
 ADI12094/c
 ID ADI12094 standard; DNA; 15 BP.

AC ADI12094;
 XX
 DT 15-APR-2004 (first entry)
 XX
 DE 2'-modified oligonucleotide #1.

XX ss; nuclease resistant; mixed sequence; 2'-deoxyfuranosyl; antisense.
 OS Synthetic.

XX Key Location/Qualifiers
 FT modified_base 1..15
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER = optionally 2'-deoxy-fluoro nucleotide.
 FT Optionally phosphorothioate"

XX US6531584-B1.
 XX
 PD 11-MAR-2003.

XX 02-SEP-1999; 99US-00389283.

XX 11-JAN-1990; 90US-00463358.
 PR 13-AUG-1990; 90US-00566977.
 PR 05-MAR-1992; 92US-00835932.
 PR 01-JUL-1992; 92US-00854634.
 PR 06-JUN-1995; 95US-00468037.
 PR 05-MAR-1998; 98US-00035357.

XX (ISIS-) ISIS PHARM INC.

XX Cook PD, Kawasaki AM;
 XX
 PI
 XX

DR WPI; 2003-566474/53.

XX Nuclease resistant mixed sequence oligonucleotides useful as
PT therapeutics, diagnostics, and research agents comprise at least one
PT modified 2'-deoxyfuranosyl group.
XX
PS Example 13; SEQ ID NO 21; 48bp; English.
XX
CC The invention relates to a nuclease resistant mixed sequence
CC oligonucleotides comprising at least one modified 2'-deoxyfuranosyl
CC group. The modified oligonucleotides are disclosed as being useful for
CC modulating the production of a protein by an organism, and especially for
CC treating a disease in an organism which is characterised by the undesired
CC production of a protein. The oligonucleotides may be used to treat
CC diseases caused by viruses or other agents. The oligonucleotides may also
CC be used for diagnostic methods for detecting the presence or absence of
CC abnormal RNA molecules, or for detecting the inappropriate expression of
CC normal RNA molecules in an organism or cell. Oligonucleotides of the
CC invention that selectively bind RNA may also be useful as research
CC reagents. The new oligonucleotides are nuclease resistant and hybridise
CC to RNA or DNA targets with high strength and specificity. The present
CC sequence represents a 2'-modified oligonucleotide.
XX
SQ Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 560 ACTGCATAGTCG 572
||| |||||
13 ACTGCATAGTCG 1
DB
RESULT 658
ADL50860
ID ADL50860 standard; RNA; 15 BP.
XX
AC ADL50860;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1974.
XX
XX antiense oligonucleotide; neurite growth inhibitor; NOGO;
KM prostaglandin D2 receptor; PKC α ; IkappaB kinase; IKK;
KM central nervous system injury; CNS injury; spinal cord injury; cancer;
KM melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KM restenosis; asthma; Crohn's disease; diabetes; obesity;
KM autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KM graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KM allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KM substrate; ds.
XX
XX Unidentified.
XX
OS
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeblerli P, Mcswiggen J, Foenbaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 4393; 317bp; English.
XX
XX The invention comprises nucleic acids (e.g. antiense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 15 BP; 7 A; 2 C; 5 G; 0 T; 1 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3.6e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 335 GGGAGTACTGCAA 347
||| |||||
2 GGGAGUACAGCAA 14
DB
RESULT 659
ADM63819
ID ADM63819 standard; RNA; 15 BP.
XX
AC ADM63819;
XX
DT 03-JUN-2004 (first entry)
XX
DE Hepatitis B virus (HBV) RNA target sequence #2553.
XX
XX Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KM Hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KM cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KM virocid; hepatotropic; antiinflammatory; cytostatic.
XX
OS Hepatitis B virus.
XX
PN US2004054156-A1.
XX
PD 18-MAR-2004.
XX
PF 15-JAN-2003; 2003US-00342902.
XX
PR 14-MAY-1992; 92US-00882712.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
XX
XX (DRAP/) DRAPER K.
XX
PA (BLAT/) BLATT L.
XX
PA (MCSW/) MCSWIGGEN J A.
XX
PA (MORR/) MORRISSEY D.
XX
PI Draper K, Blatt L, Mcswiggen JA, Morrissey D;
XX WPI; 2004-247781/23.
XX
XX

PT Novel enzymatic nucleic acid molecule such as DNAzymes and inozymes
PT specifically cleaving RNA derived from hepatitis B virus and comprising
XX one or more binding arms, useful for treating hepatitis and cirrhosis.
PS Disclosure; SEQ ID NO 5953; 122bp; English.
XX
CC The invention relates to an enzymatic nucleic acid molecule that
CC specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC comprising one or more binding arms, without requiring the presence of a
CC 2'-OH group within the molecule for activity. The nucleic acids are
CC useful for treating hepatitis B virus infection, hepatitis,
CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC combination with other therapies such as lamivudine and interferons. The
CC nucleic acids are useful as diagnostic tools to examine genetic drift and
CC mutations within diseased cells, for detecting the presence of HBV RNA in
CC a cell, for the study of RNA and for down-regulating gene expression of
CC target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC sequence represents an HBV RNA target sequence, used in the scope of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 15 BP; 3 A; 8 C; 0 G; 0 T; 4 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 3.6e+02;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
XX
Qy 165 CTCGACGACGATGTC 177
|:|||||:|
Db 1 CUCGACGACGCUUUC 13
XX
RESULT 660
AD049882/C
ID AD049882 standard; DNA; 15 BP.
XX
AC AD049882;
XX
DT 29-JUL-2004 (first entry)
XX
DE H. pylori strain J99 genome fragment SEQ ID NO:505.
XX
KW ds; stroke; phosphodiesterase 4D; PDB4D.
XX
OS Helicobacter pylori.
XX
FN US2004091865-A1.
XX
PD 13-MAY-2004.
XX
PE 25-SEP-2002; 2002US-00255120.
XX
PR 19-MAR-2001; 2001US-00811352.
XX
PR 04-FEB-2002; 2002US-00067514.
XX
PA (DECO-) DECODE GENETICS EHF.
XX
PI Gretsardottir S, Jonadottir S, Reynisdottir ST, Thorleifsson G;
DR WPI; 2004-374932/35.
XX
PT Diagnosing susceptibility to a stroke in an individual comprising
PT screening for an at-risk haplotype in the phosphodiesterase 4D gene.
XX
PS Disclosure; SEQ ID NO 505; 574bp; English.
XX
CC The invention relates to a method of diagnosing susceptibility to a
CC stroke in an individual comprising screening for an at-risk haplotype in
CC the phosphodiesterase 4D (PDB4D) gene that is more frequently present in
CC an individual susceptible to stroke (affected) compared to a healthy
CC individual (control), where the at-risk haplotype increases risk of
CC stroke significantly. The composition, methods and kit are useful for
CC diagnosing, predicting of clinical course and treating stroke using

CC polymorphisms in the PDB4D gene. These may also be used in identifying
CC agents that enhance or inhibit PDB4D polypeptide expression or activity.
CC The present sequence represents a fragment of H. pylori strain J99 genome
CC which is not referred to at all in the main body of the specification.
XX
SQ Sequence 15 BP; 12 A; 1 C; 1 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
Qy 74 TTCTTTATTTCT 86
|:|||||:|
Db 15 TTCTTTATTTCT 3
XX
RESULT 661
AAK89305
ID AAK89305 standard; DNA; 26 BP.
XX
AC AAK89305;
XX
DT 21-SEP-1999 (first entry)
XX
DE Primer used in RT-PCR analysis of transgenic apo(a).
XX
KW Transgenic rabbit; apolipoprotein (a); apolipoprotein B; lipoprotein;
KW atherosclerotic lesion; cholesterol; vascular injury; restenosis; apob;
KW RT-PCR; primer; ss.
XX
OS Synthetic.
XX
PN WO9935241-A1.
XX
PD 15-JUL-1999.
XX
PE 08-JAN-1999; 99WO-US000401.
XX
PR 08-JAN-1998; 98US-0070727P.
XX
PA (RHON) RHONE-POULENC RORER PHARM INC.
XX
PI Rouy D, Duverger N, Emmanuel F, Deneffe P, Houdebine L;
PI Viglietta C, Rubin E, Hughes SD;
XX
DR WPI; 1999-430386/36.
XX
PT A transgenic rabbit that expresses a functional human lipoprotein A.
XX
PS Example 3; Page 46; 73bp; English.
XX
CC The invention provides a transgenic rabbit, which has in its genomic DNA,
CC sequences that encode apolipoprotein (a) and apolipoprotein B
CC polypeptides, which are capable of combining to produce lipoprotein (a).
CC The transgenic rabbit expresses a functional human lipoprotein (a). The
CC rabbit develops human-like atherosclerotic lesions when fed a cholesterol
CC rich diet. The transgenic rabbit is useful as a model for human diseases
CC that are induced and/or exacerbated by lipoprotein (a) expression. The
CC model can be used to identify inhibitors of lipoprotein (a) expression.
CC assembly and inhibitors of lipoprotein (a) associated diseases. The
CC rabbit model is advantageous, when compared to the mouse, due partly to
CC its relatively larger size, enabling facile studies of vascular injury
CC and restenosis. In addition, while rabbits are similar to mice in lacking
CC apo(a) and lipoprotein (a), their lipoprotein profile more closely mimics
CC that of humans, with LDL as the predominant plasma lipoprotein. Sequences
CC AAK89305-308 represent primers used in the analysis of transgenic
CC apo(a) and apob
XX
SQ Sequence 26 BP; 5 A; 7 C; 7 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11.4; DB 1; Length 26;
Best Local Similarity 71.4%; Pred. No. 8.3e+02;
Matches 15; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

```

QY      409 CCAAGCTAGAGGCTCTCC 429
      |||||
      6 CCAAGCTTGGAGGCTCTTCC 26
Db

RESULT 662
AAN30002/c
ID AAN30002 standard; DNA, 14 BP.
XX
AC AAN30002;
XX
DT 25-MAR-2003 (revised)
DT 25-APR-1992 (first entry)
XX
DE Sequence of probe complementary to sequences coding for the sequence
DE WeyCD of tissue plasminogen activator (t-PA).
XX
KM Cardiovascular disorder therapy; pulmonary embolism; thrombolytic agent;
KM ss.
XX
OS Homo sapiens.
XX
PN EP93619-A.
XX
PD 09-NOV-1983.
XX
PF 04-MAY-1983; 83EP-00302501.
XX
PR 05-MAY-1982; 82US-00374860.
PR 14-JUL-1982; 82US-00398003.
PR 07-APR-1983; 83US-00483052.
PR 21-APR-1988; 88US-00184477.
XX
PA (GETH ) GENENTECH INC.
PI Goeddel DVN, Kohr WJ, Pennica D, Vehar GA;
XX
DR WPI; 1983-816270/46.
XX
PT Pure human tissue plasminogen activator - produced by culturing cells
PT with vectors contg. the corresponding DNA sequence.
XX
PS Disclosure; Page 20; 77pp; English.
XX
CC AAN30001 was prepd. from a cDNA library from human melanoma cells
CC screened using DNA probes coding for known sequences in human t-PA. The
CC 35 amino acids preceding the mature sequence is considered a presequence
CC of the mature protein. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ Sequence 14 BP; 3 A; 5 C; 0 G; 3 T; 0 U; 3 Other;
QY
Query Match 0.2%; Score 11.2; DB 1; Length 14;
Best Local Similarity 71.4%; Pred. No. 3.3e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
Db
334 TGGGAGTACTGCAA 347
14 TGGGARTAYTGYGA 1

```

```

XX
XX Homo sapiens.
XX
XX EP117059-A.
XX
XX 29-AUG-1984.
XX
XX 18-JAN-1984; 84EP-00300299.
XX
XX 19-JAN-1983; 83US-00459153.
XX
XX (GETH ) GENENTECH INC.
XX
PI Levinson AD, Simonsen CC, Yelverton EM;
XX
DR WPI; 1984-214788/35.
XX
PT Prodn. of tissue plasminogen activator in eukaryotic host cells - by
PT using gene co-amplified by use of methotrexate.
XX
PS Example; Page 18; 36pp; English.
XX
CC In the example, purified human tissue plasminogen activator was obtained
CC according to the procedure of disclosed references (EPO Publ. 4176).
CC The molecule was scanned in order to locate regions best suited for
CC making synthetic probes. The peptide peaks most likely to contain
CC tryptophan were sequenced first. After sequencing about 25 of the best
CC possible peptide peaks, all the sequence data that could be aligned was
CC pooled. From this data and model, several possible proteases were located.
CC The 32p-labelled probe was prepared (see AAN40060)
XX
SQ Sequence 14 BP; 3 A; 5 C; 0 G; 3 T; 0 U; 3 Other;
QY
Query Match 0.2%; Score 11.2; DB 1; Length 14;
Best Local Similarity 71.4%; Pred. No. 3.3e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
Db
334 TGGGAGTACTGCAA 347
14 TGGGARTAYTGYGA 1

```

```

RESULT 664
AAF95086/c
ID AAF95086 standard; DNA, 16 BP.
XX
AC AAF95086;
XX
DT 23-MAY-2001 (first entry)
XX
DE Wild-type capture oligonucleotide #13.
XX
XX Tubercle bacillus; drug sensitivity; drug resistance; rifampicin;
XX streptomycin; kanamycin; isoniazid; ethambutol; rpoB gene; rrs gene;
XX rplL gene; inhA gene; katG gene; embB gene; probe; PCR primer; ss.
XX
OS Mycobacterium tuberculosis.
XX
PN EP1076099-A2.
XX
PD 14-FEB-2001.
XX
PF 02-AUG-2000; 2000EP-00306563.
XX
PR 03-AUG-1999; 99JP-00220357.
XX
PA (NISN ) NISSHINO IND INC.
PA (SYST-) SYSTEM RES INC.
XX
PI Suzuki Y, Nishida M, Takenishi S;
XX
DR WPI; 2001-246696/26.

```

PT New oligonucleotides, nucleic acid probes and primers are useful for
 PT differentiating drug-resistance and determining infection with tubercle
 XX bacilli.
 PS Claim 21; Page 40; 114pp; English.
 XX
 CC The present invention relates to oligonucleotides based on nucleotide
 CC sequences obtained from both wild-type tubercle bacilli (MTB) that are
 CC susceptible to a drug and mutant-type tubercle bacilli (mTB) that are
 CC resistant to a drug. The drugs used in the present invention are
 CC rifampicin (RFP), streptomycin (SM), kanamycin (KM), isoniazid (INH) and
 CC ethambutol (EB). The ipob gene is responsible for resistance to RFP; the
 CC rrs gene is responsible for resistance to SM and KM; the rpsL gene is
 CC responsible for resistance to SM; the inhA gene is responsible for
 CC resistance to INH; the katG gene is responsible for resistance to INH;
 CC and the embB gene is responsible for resistance to EB. The present
 CC invention also relates to nucleic acid probes having part of a nucleotide
 CC sequence of tubercle bacilli (TB) responsible for drug resistance and
 CC primers used to generate the probes. The present sequence is an
 CC oligonucleotide of the present invention. The oligonucleotides of the
 CC present invention can be used to enable the differentiation of drug
 CC resistance and the determination of infection with tubercle bacilli
 CC simultaneously
 SQ Sequence 16 BP; 3 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.2; DB 1; Length 16;
 Best Local Similarity 81.2%; Pred. No. 4.5e+02;
 Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 156 AGGACGACTGCTCACC 171
 Db 16 AGGACGACTGCTCACC 1
 RESULT 665
 ADO22862/C
 ID ADO22862 standard; DNA; 20 BP.
 XX
 AC ADO22862;
 XX
 DT 12-AUG-2004 (first entry)
 XX
 DE Human interleukin 22 receptor DNA target sequence #6.
 XX
 KW Antisense therapy; human; interleukin 22 receptor; autoimmune disorder;
 KW immunosuppressive; ds.
 XX
 OS Homo sapiens.
 XX
 PN US2004097447-A1.
 XX
 PD 20-MAY-2004.
 XX
 PF 16-NOV-2002; 2002US-00299089.
 XX
 PR 16-NOV-2002; 2002US-00299089.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Double KW;
 XX
 DR WPI; 2004-389188/36.
 XX
 PT New compounds, particularly oligonucleotides targeted to a nucleic acid
 PT encoding interleukin 22 receptor, useful for treating diseases associated
 PT with interleukin 22 receptor, e.g. autoimmune disorders.
 XX
 PS Example 15; SEQ ID NO 96; 58bp; English.
 XX
 CC The present invention relates to antisense compounds targeted to a
 CC nucleic acid encoding human interleukin 22 receptor. The antisense
 CC compound comprises an antisense oligonucleotide that specifically
 CC hybridizes with the nucleic acid and inhibits the expression of
 CC interleukin 22 receptor. The antisense oligonucleotide is a chimeric
 CC oligonucleotide. The antisense oligonucleotide comprises at least one
 CC modified internucleoside linkage, preferably a phosphorothioate linkage.
 CC It also comprises at least one modified sugar moiety, preferably a 2'-O-
 CC methoxyethyl (2'-MOE) sugar moiety. The antisense oligonucleotide further
 CC comprises at least one modified nucleobase, preferably a 5-
 CC methylcytosine. The antisense oligonucleotides are useful for the
 CC treatment of autoimmune disorders. The present sequence represents a
 CC human interleukin 22 receptor DNA target sequence for an antisense
 CC oligonucleotide.
 SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.2; DB 1; Length 20;
 Best Local Similarity 81.2%; Pred. No. 6.9e+02;
 Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 328 GTCAGGTGGAGTACT 343
 Db 17 GTCAGGTGGAGTACT 2

CC hybridizes with the nucleic acid and inhibits the expression of
 CC interleukin 22 receptor. The antisense oligonucleotide is a chimeric
 CC oligonucleotide. The antisense oligonucleotide comprises at least one
 CC modified internucleoside linkage, preferably a phosphorothioate linkage.
 CC It also comprises at least one modified sugar moiety, preferably a 2'-O-
 CC methoxyethyl (2'-MOE) sugar moiety. The antisense oligonucleotide further
 CC comprises at least one modified nucleobase, preferably a 5-
 CC methylcytosine. The antisense oligonucleotides are useful for the
 CC treatment of autoimmune disorders. The present sequence represents a
 CC human interleukin 22 receptor DNA target sequence for an antisense
 CC oligonucleotide.
 SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11.2; DB 1; Length 20;
 Best Local Similarity 81.2%; Pred. No. 6.9e+02;
 Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 328 GTCAGGTGGAGTACT 343
 Db 17 GTCAGGTGGAGTACT 2
 RESULT 666
 ADO22785
 ID ADO22785 standard; DNA; 20 BP.
 XX
 AC ADO22785;
 XX
 DT 12-AUG-2004 (first entry)
 XX
 DE Human interleukin 22 receptor DNA, antisense oligonucleotide #7.
 XX
 KW Antisense therapy; human; interleukin 22 receptor; autoimmune disorder;
 KW immunosuppressive; phosphothioate; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2004097447-A1.
 XX
 PD 20-MAY-2004.
 XX
 PF 16-NOV-2002; 2002US-00299089.
 XX
 PR 16-NOV-2002; 2002US-00299089.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Double KW;
 XX
 DR WPI; 2004-389188/36.
 XX
 PT New compounds, particularly oligonucleotides targeted to a nucleic acid
 PT encoding interleukin 22 receptor, useful for treating diseases associated
 PT with interleukin 22 receptor, e.g. autoimmune disorders.
 XX
 PS Example 15; SEQ ID NO 19; 58bp; English.
 XX
 CC The present invention relates to antisense compounds targeted to a
 CC nucleic acid encoding human interleukin 22 receptor. The antisense
 CC compound comprises an antisense oligonucleotide that specifically
 CC hybridizes with the nucleic acid and inhibits the expression of
 CC interleukin 22 receptor. The antisense oligonucleotide is a chimeric
 CC oligonucleotide. The antisense oligonucleotide comprises at least one


```

XX DE Oligonucleotide primer SEQ ID NO 280888 for detecting SNP TSC0009220.
XX
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX CC Claim 1; SEQ ID NO 280888; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11; DB 1; Length 12;
XX Best Local Similarity 100.0%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 239 AAAACTACCCA 249
XX Db 11 AAAACTACCCA 1
XX
XX RESULT 670
XX ABI08552
XX ID ABI08552 standard; DNA; 12 BP.
XX
XX AC ABI08552;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 308525 for detecting SNP TSC0023067.
XX
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.

```

```

PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX CC Claim 1; SEQ ID NO 308525; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 1 A; 3 C; 0 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11; DB 1; Length 12;
XX Best Local Similarity 100.0%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 73 CTTCTTTTATT 83
XX Db 2 CTTCTTTTATT 12
XX
XX RESULT 671
XX ABI11770/C
XX ID ABI11770 standard; DNA; 12 BP.
XX
XX AC ABI11770;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 311743 for detecting SNP TSC0024663.
XX
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.

```

XX PS Claim 1; SEQ ID NO 311743; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 583 TACTACCCAAA 593
|||
12 TACTACCCAAA 2

Db

RESULT 672
ABI76195/c
ID ABI76195 standard; DNA; 12 BP.
XX
XX ABI76195;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 376168 for detecting SNP TSC0061655.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX
XX Claim 1; SEQ ID NO 376168; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but

CC CC was obtained in electronic format from WIPO at
CC CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 1 A; 0 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 553 ACACACACATC 563
|||
12 ACACACACATC 2

Db

RESULT 673
ABI77608
ID ABI77608 standard; DNA; 12 BP.
XX
XX ABI77608;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 377581 for detecting SNP TSC0062403.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX
XX Claim 1; SEQ ID NO 377581; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 2 A; 2 C; 0 G; 8 T; 0 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 76 CTTTATTCTCT 86
|||
2 CTTTATTCTCT 12

Db

```
RESULT 674
AB123040/c
ID AB123040 standard; DNA; 12 BP.
XX
XX
AC AB123040;
XX
XX
DT 22-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide primer SEQ ID NO 323013 for detecting SNP TSC0031176.
XX
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX
OS Homo sapiens.
XX
XX
WO200177384-A2.
XX
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX
PA (EPIC-) EPIGENOMICS AG.
XX
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX
DR WPI; 2001-657177/75.
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
XX
PS Claim 1; SEQ ID NO 323013; 29pp + Sequence Listing; German.
XX
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligomers are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 12 BP; 2 A; 6 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX
Query Match 0.2%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 55 AAGGAGTGGT 65
Db 11 AAGGAGTGGT 1
XX
XX
RESULT 675
AB148148/c
ID AB148148 standard; DNA; 12 BP.
XX
XX
AC AB148148;
XX
XX
DT 22-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide primer SEQ ID NO 348121 for detecting SNP TSC0045457.
XX
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.
```

```
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX
OS Homo sapiens.
XX
XX
WO200177384-A2.
XX
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX
PA (EPIC-) EPIGENOMICS AG.
XX
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX
DR WPI; 2001-657177/75.
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
XX
PS Claim 1; SEQ ID NO 348121; 29pp + Sequence Listing; German.
XX
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligomers are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 12 BP; 7 A; 0 C; 3 G; 2 T; 0 U; 0 Other;
XX
XX
Query Match 0.2%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 65 TTCTTCTACTT 75
Db 11 TTCTTCTACTT 1
XX
XX
RESULT 676
AB140077/c
ID AB140077 standard; DNA; 12 BP.
XX
XX
AC AB140077;
XX
XX
DT 22-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide primer SEQ ID NO 340050 for detecting SNP TSC0041320.
XX
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX
OS Homo sapiens.
XX
XX
WO200177384-A2.
XX
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX
PA (EPIC-) EPIGENOMICS AG.
```

```

XX Olek A, Piepenbrock C, Berlin K;
XX WPI, 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 340050; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABCG9989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 9 A; 0 C; 2 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11; DB 1; Length 12;
XX Best Local Similarity 100.0%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 76 CTTTATTTCCT 86
XX |||||||
XX 12 CTTTATTTCCT 2
XX
XX RESULT 677
XX AB149928/c
XX ID AB149928 standard; DNA; 12 BP.
XX
XX AC AB149928;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 349901 for detecting SNP TSC0046406.
XX
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI, 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 349901; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

```

```

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABCG9989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11; DB 1; Length 12;
XX Best Local Similarity 100.0%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 219 TCACATATATA 229
XX |||||||
XX 12 TCACATATATA 2
XX
XX RESULT 678
XX ABH86381
XX ID ABH86381 standard; DNA; 12 BP.
XX
XX AC ABH86381;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 286374 for detecting SNP TSC0012697.
XX
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI, 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 286374; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABCG9989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX

```

Query Match 0.2%; Score 11; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 303 TTATTGTTATA 313
 |||||
 DB 2 TTATTGTTATA 12

RESULT 679
 ABH91845/C
 ID ABH91845 standard; DNA; 12 BP.

AC ABH91845;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 291838 for detecting SNP TSC0014967.

DE SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI, 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 291838; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from Wipo at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 71 TACTCTTTTA 81
 |||||
 DB 12 TACTCTTTTA 2

RESULT 680
 ABH72726/C
 ID ABH72726 standard; DNA; 12 BP.

AC ABH72726;
 XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 272711 for detecting SNP TSC0002913.

DE SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI, 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 272711; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from Wipo at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 303 TTATTGTTATA 313
 |||||
 DB 11 TTATTGTTATA 1

RESULT 681
 AB133618/C
 ID AB133618 standard; DNA; 12 BP.

AC AB133618;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 333591 for detecting SNP TSC0037623.

DE SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

```

XX 18-OCT-2001.
PD 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIC-) EPIDENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 33591; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 0 C; 3 G; 2 T; 0 U; 0 Other;
Query Match 0.2%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2,4e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 72 ACTTCTTTTAT 82
Db 11 ACTTCTTTTAT 1
RESULT 682
ABH83544
ID ABH83544 standard; DNA; 12 BP.
XX ABH83544;
XX 22-FEB-2002 (first entry)
DT Oligonucleotide primer SEQ ID NO 283537 for detecting SNP TSC0011367.
XX Oligonucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; 89;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
PD 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIC-) EPIDENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX

```

```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 283537; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 0.2%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2,4e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 239 AAAACTACCCA 249
Db 2 AAAACTACCCA 12
RESULT 683
ABI14477
ID ABI14477 standard; DNA; 12 BP.
XX ABI14477;
XX 22-FEB-2002 (first entry)
DT Oligonucleotide primer SEQ ID NO 314450 for detecting SNP TSC0026369.
XX Oligonucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; 89;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
PD 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIC-) EPIDENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 314450; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC

```

CC -ABCG9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 582 ATACTACCCAA 592
|||
|||
2 ATACTACCCAA 12

RESULT 684

AB177034
ID AB177034 standard; DNA; 12 BP.

XX AB177034;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 377007 for detecting SNP TSC0062098.

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIDENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX

PS Claim 1; SEQ ID NO 377007; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABCG9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

XX Sequence 12 BP; 3 A; 2 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 72 ACTTCTTTAT 82

DB |||
|||
|||
1 ACTTCTTTAT 11

RESULT 685

AB119608
ID AB119608 standard; DNA; 12 BP.

XX AB119608;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 319581 for detecting SNP TSC0029305.

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIDENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX

PS Claim 1; SEQ ID NO 319581; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABCG9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

XX Sequence 12 BP; 5 A; 5 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 238 GAAACTACCC 248
|||
|||
2 GAAACTACCC 12

RESULT 686

AB144428
ID AB144428 standard; DNA; 12 BP.

XX AB144428;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 344401 for detecting SNP TSC0043526.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 344401; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 0 C; 4 G; 4 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 11; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 Db 476 ATGCTAATGA 486
 2 ATGCTAATGA 12
 XX
 RESULT 687
 ABH97425
 ID ABH97425 standard; DNA; 12 BP.
 XX
 AC ABH97425;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 297418 for detecting SNP TSC0017564.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX

PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 297418; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 11; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 Db 219 TCACATATTA 229
 1 TCACATATTA 11
 XX
 RESULT 688
 ABI30266
 ID ABI30266 standard; DNA; 12 BP.
 XX
 AC ABI30266;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 330239 for detecting SNP TSC0035408.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 330239; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 213 ACCACATCAAC 223
|||||
1 ACCACATCAAC 11
XX
Db 1 ACCACATCAAC 11
XX
RESULT 689
ABH96681
ID ABH96681 standard; DNA; 12 BP.
XX
AC ABH96681;
XX
XX 22-FEB-2002 (first entry)
XX
DT Oligonucleotide primer SEQ ID NO 296674 for detecting SNP TSC0017209.
XX
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 296674; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 240 AAATACCACA 250
|||||
1 AAATACCACA 11
XX
Db 1 AAATACCACA 11
XX
RESULT 690
ABI00737/C
ID ABI00737 standard; DNA; 12 BP.
XX
AC ABI00737;
XX
XX 22-FEB-2002 (first entry)
XX
DT Oligonucleotide primer SEQ ID NO 300710 for detecting SNP TSC0019155.
XX
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 300710; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 242 ACTACCAAT 252
|||||
12 ACTACCAAT 2
XX
Db 12 ACTACCAAT 2
XX
RESULT 691

AB102148/c
 ID AB102148 standard; DNA; 12 BP.
 XX
 AC AB102148;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 302121 for detecting SNP TSC0019811.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 302121; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
 XX
 Query Match 0.2%; Score 11; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 239 AAACTACCCA 249
 DB 11 AAACTACCCA 1
 XX
 RESULT 692
 AB105650
 ID AB105650 standard; DNA; 12 BP.
 XX
 AC AB105650;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 305623 for detecting SNP TSC0021534.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX

OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 305623; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 1 A; 3 C; 0 G; 8 T; 0 U; 0 Other;
 XX
 Query Match 0.2%; Score 11; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 76 CTTTATTCT 86
 DB 1 CTTTATTCT 11
 XX
 RESULT 693
 AB180923
 ID AB180923 standard; DNA; 12 BP.
 XX
 AC AB180923;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 308096 for detecting SNP TSC0064034.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX

```

XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX PS Claim 1; SEQ ID NO 380896; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 1 A; 1 C; 0 G; 10 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11; DB 1; Length 12;
XX Best Local Similarity 100.0%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Qy 74 TTCTTTTATT 84
XX 1 TTCTTTTATT 11
XX
XX Db
XX
XX RESULT 694
XX AAT9579
XX ID AAT9579 standard; DNA; 13 BP.
XX
XX AC AAT9579;
XX
XX DT 02-JAN-1998 (first entry)
XX
XX DE Mycobacterium avium complex dnaI targeted capture probe.
XX
XX KM Mycobacterium avium complex; primer; probe; detection; amplification;
XX KM PCR; polymerase chain reaction; diagnosis; dnaI gene; Crohn's disease;
XX KM Jome's ss.
XX
XX OS Mycobacterium avium.
XX
XX PN WO9708340-A1.
XX
XX PD 06-MAR-1997.
XX
XX PF 30-JUL-1996; 96WO-US012492.
XX
XX PR 28-AUG-1995; 95US-00520194.
XX
XX PA (BECT ) BECTON DICKINSON CO.
XX
XX PI Schram JL, Nadeau JG, Dean CH;
XX
XX DR WPI; 1997-179295/16.
XX
XX CC Mycobacterium avium complex amplification primers and probes - for
XX CC detection of M. avium and M. intracellulare dnaI target sequence.
XX
XX PS Claim 4; Page 17; 27pp; English.
XX
XX CC AAT9579-84 are probes used for the detection and capture of an amplified
XX CC target dnaI gene sequence of Mycobacterium avium complex (MAC). Primers
XX CC were used for complex-specific amplification of a target sequence found
XX CC in 26 of 28 serovars comprising MAC. A single pair of primers enabled the
XX CC amplification of 48 bp target sequences from the dnaI gene of both M.

```

```

XX CC avium and M. intracellulare. The primers and probes also allow the
XX CC detection of the dnaI target sequence in M. paratuberculosis, a
XX CC subspecies of M. avium associated with Crohn's disease in humans and
XX CC Jome's disease in livestock
XX
XX SQ Sequence 13 BP; 1 A; 6 C; 4 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.9e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Qy 385 GCGCCTCGAC 395
XX 3 GCGCCTCGAC 13
XX
XX Db
XX
XX RESULT 695
XX AAT91810
XX ID AAT91810 standard; DNA; 13 BP.
XX
XX AC AAT91810;
XX
XX DT 23-MAR-1998 (first entry)
XX
XX DE Mycobacterium capture probe MA133.
XX
XX KM Mycobacterium avium Complex species; DNAI gene; diagnosis; ss.
XX KM Synthetic.
XX
XX OS
XX
XX FH Key Location/Qualifiers
XX FT modified_base 1
XX FT /*tag= a
XX FT /note= "Attached to a 3biotin label"
XX
XX PN EP92937-A2.
XX
XX PD 03-SEP-1997.
XX
XX PF 26-FEB-1997; 97BP-00103099.
XX
XX PR 28-FEB-1996; 96US-00608584.
XX
XX PA (BECT ) BECTON DICKINSON CO.
XX
XX PI Dilly KA, Bustos SA, Roetkowski CA, Berger DM;
XX
XX DR WPI; 1997-427271/40.
XX
XX PT Oligo:nucleotide amplification primers - for the rapid detection and
XX PT identification of Mycobacterium avium Complex species.
XX
XX PS Example 2; Page 5; 19pp; English.
XX
XX CC The present sequence represents a capture probe used in an example of the
XX CC present invention for oligonucleotide amplification primers for the rapid
XX CC detection and identification of Mycobacterium avium Complex species. The
XX CC oligonucleotides of the present invention can be used in methods for
XX CC complex-specific amplification or simultaneous multiplex amplification of
XX CC a target sequence of the DNAI gene present in all the 28 serovars of the
XX CC Mycobacterium avium complex (MAC), allowing the diagnosis of
XX CC Mycobacterium infections in humans and livestock through the detection
XX CC and further identification of MAC species from which the target sequence
XX CC is derived. The oligonucleotides can be used in rapid, highly efficient
XX CC (e.g. PCR and thermoplastic Strand Displacement Amplification (tsDA)) or
XX CC at isothermal conditions (conventional SDA, 3SR or NSBA), reducing the
XX CC time for diagnosis from one week or more, using prior methods to a day or
XX CC less
XX
XX SQ Sequence 13 BP; 1 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

```

Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 385 GCGCCTCCGAC 395
 |||||
 Db 3 GCGCCTCCGAC 13

RESULT 696
 AAV1104/c
 ID AAV1104 standard; RNA; 13 BP.
 XX
 AC AAV1104;
 XX
 DT 25-MAR-2003 (revised)
 DT 14-JUL-1998 (first entry)
 XX
 DE Human ribozyme target sequence from HLA-DRB 11DRB #3.

XX Ribozyme; target; human lymphocyte antigen; HLA-DRB; MHC allele;
 KW major histocompatibility complex; cleavage; suppression; transplant;
 KW incompatibility; autoimmune disease; juvenile diabetes;
 KW rheumatoid arthritis; ss.

OS Homo sapiens.

XX W09704087-A1.

PD 06-FEB-1997.

PF 18-JUL-1996; 96MO-EP003173.

XX 18-JUL-1995; 95EP-00111256.

PR 18-JUL-1995; 95EP-00111256.

PA (KRUPP/) KRUPP G.
 PA (MARG/) MARGET M.
 PA (WEST/) WESTPHAL E.
 PA (MUEBL/) MUELLER-RUCHHOLTZ W.

PI Krupp G, Marget M, Westphal E, Mueller-Ruchholtz W;

DR WPI; 1997-132628/12.

XX Ribozyme that cleaves specific MHC allele(s) - used to inhibit graft
 PT versus host reactions, to overcome blood incompatibility and to treat
 PT auto-immune disease.

XX Claim 5; Fig 1; 76pp; German.

CC AAV10915-V11123 are target sequences for a novel ribozyme which cleaves
 CC specific alleles from the major histocompatibility complex (MHC). This
 CC ribozyme contains a catalytic region and a hybridisation region which is
 CC complementary to all mRNA transcribed from vertebrate genes of a specific
 CC family of closely related MHC alleles or to mRNA from a single MHC
 CC allele, and is able to cleave such mRNA. The mRNA has a target region
 CC which in case is essentially conserved in all genes of the family but
 CC differs from genes of all other MHC alleles to such a degree that no
 CC cleavage of mRNA transcribed from these other alleles occurs. This allows
 CC the selective reduction or inhibition of expression of all genes of a
 CC family or of a single gene. This ribozyme can be used for permanent or
 CC transient suppression of expression of MHC alleles, in vivo or in vitro.
 CC Specific applications are to prevent graft vs. host or host vs. guest
 CC reactions, to prevent blood incompatibilities (partic. of the ABO, Rhesus
 CC and Kell systems) and to treat autoimmune diseases such as juvenile
 CC diabetes and rheumatoid arthritis. The use of this ribozyme avoids the
 CC need for immunosuppressants in transplant patients. It provides very
 CC specific reduction of particular HLA molecules that cause incompatibility
 CC between donor and recipient. (Updated on 25-MAR-2003 to correct PA
 CC field.) (Updated on 25-MAR-2003 to correct PI field.)

XX Sequence 13 BP; 3 A; 2 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 158 GCACGTACTCC 168
 |||||
 Db 12 GCACGTACTCC 2

RESULT 697
 ABC65114/c
 ID ABC65114 standard; DNA; 13 BP.
 XX
 AC ABC65114;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 65131 for detecting SNP TSC0017152.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX W0200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

PR (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 65131; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AEI00010-AEI82073
 CC represent the oligomers described in the invention. NCRS: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 1 Other;

Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.9e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 238 GAAACTACCCAA 250
 :|||
 Db 13 RAACACTACCCAA 1

RESULT 698
 ABF19256/c
 ID ABF19256 standard; DNA; 13 BP.

XX

AC ABF19256;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 119253 for detecting SNP TSC0029783.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 119253; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 164 ACTCCACCACT 174
DB 12 ACTCCACCACT 2
XX
RESULT 699
ID ABH24391 standard; DNA; 13 BP.
XX
AC ABH24391;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 224368 for detecting SNP TSC0054667.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.

XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 224368; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 2 C; 0 G; 9 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 74 TCTTTTATTT 84
DB 1 TCTTTTATTT 11
XX
RESULT 700
ID ABH3536/c
XX
AC ABH3536; standard; DNA; 13 BP.
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 235513 for detecting SNP TSC0004714.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 235513; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 242 ACTACCCAAAT 252
DB 11 ACTACCCAAAT 1
XX
RESULT 701
ABH35537
ID ABH35537 standard; DNA; 13 BP.
XX
AC ABH35537;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 235514 for detecting SNP TSC0004714.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 235514; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 242 ACTACCCAAAT 252
DB 3 ACTACCCAAAT 13
XX
RESULT 702
ABF61273
ID ABF61273 standard; DNA; 13 BP.
XX
AC ABF61273;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 161270 for detecting SNP TSC0340609.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75..
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 161270; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 6 C; 1 G; 1 T; 0 U; 1 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
OY 502 ACATCTCCACCA 514

```

DB      1 RCATACGCCACCA 13
      :|||||
RESULT 703
ABH15668
ID      ABH15668 standard; DNA; 13 BP.
XX
XX      ABH15668;
AC
XX
XX      22-FEB-2002 (first entry)
DT
XX
XX      Oligonucleotide SEQ ID NO 215645 for detecting SNP TSC0052448.
DE
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
OS
XX
XX      WO200177384-A2.
PN
XX
XX      18-OCT-2001.
PD
XX
XX      06-APR-2001; 2001WO-IB000713.
PF
XX
XX      07-APR-2000; 2000DE-01019173.
PR
XX
XX      (EPIC-) EPIDENOMICS AG.
PA
XX
XX      Olek A, Piepenbrock C, Berlin K;
PI
XX
XX      WPI; 2001-657177/75.
DR
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 215645; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 13 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 1 Other;
SQ
XX
XX      Query Match      0.2%; Score 11; DB 1; Length 13;
XX      Best Local Similarity 100.0%; Pred. No. 2.9e+02;
XX      Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      303 TTATTTGTATA 113
DB      1 TTATTTGTATA 11

```

```

XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
OS
XX
XX      WO200177384-A2.
PN
XX
XX      18-OCT-2001.
PD
XX
XX      06-APR-2001; 2001WO-IB000713.
PF
XX
XX      07-APR-2000; 2000DE-01019173.
PR
XX
XX      (EPIC-) EPIDENOMICS AG.
PA
XX
XX      Olek A, Piepenbrock C, Berlin K;
PI
XX
XX      WPI; 2001-657177/75.
DR
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 195913; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 13 BP; 5 A; 0 C; 6 G; 1 T; 0 U; 1 Other;
SQ
XX
XX      Query Match      0.2%; Score 11; DB 1; Length 13;
XX      Best Local Similarity 84.6%; Pred. No. 2.9e+02;
XX      Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY      53 ATACGAAGTGT 65
DB      1 AGAAGGAAGTGT 13

```

```

RESULT 704
ABF95916
ID      ABF95916 standard; DNA; 13 BP.
XX
XX      ABF95916;
AC
XX
XX      22-FEB-2002 (first entry)
DT
XX
XX      Oligonucleotide SEQ ID NO 195913 for detecting SNP TSC0010364.
DE

```



```

PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
PA
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 203107; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 0 C; 3 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.9e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 76 CTTTATTTCCT 86
XX |||||||
XX 11 CTTTATTTCCT 1
XX
XX
XX RESULT 706
XX ABF53491
XX ID ABF53491 standard; DNA; 13 BP.
XX
XX AC ABF53491;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 153488 for detecting SNP TSC0038789.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIC-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 153488; 29pp + Sequence Listing; German.

```

```

XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.2%; Score 11; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.9e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 582 ATACTACCCA 592
XX |||||||
XX 1 ATACTACCCA 11
XX
XX
XX RESULT 707
XX ABC92784/C
XX ID ABC92784 standard; DNA; 13 BP.
XX
XX AC ABC92784;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 92801 for detecting SNP TSC0023209.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIC-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 92801; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

```

```

XX Sequence 13 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 1 Other;
SQ
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 581 AATAGTACCCCAA 593
   :|||||
   13 AATACCCACCCAA 1
Db
RESULT 708
ID ABE03593 standard; DNA; 13 BP.
AC ABE03593;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 103590 for detecting SNP TSC0025910.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 103590; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABE00010-ABF99989, ABH00010-ABH99989 and ABIG0010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 4 C; 0 G; 8 T; 0 U; 0 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 75 TCTTTTATTTTC 85
   :|||||
   2 TCTTTTATTTTC 12
Db
RESULT 709

```

```

ABCS8619
ID ABCS8619 standard; DNA; 13 BP.
XX
XX ABCS8619;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 58636 for detecting SNP TSC0015713.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 58636; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABE00010-ABF99989, ABH00010-ABH99989 and ABIG0010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 1 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 238 GAAAAGTACCCCAA 250
   :|||||
   1 AAAAAATACCCAA 13
Db
RESULT 710
ID ABH21953 standard; DNA; 13 BP.
XX
XX ABH21953;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 221930 for detecting SNP TSC0054003.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

```

XX WP1; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1, SEQ ID NO 224166; 29pp + Sequence Listing; German.

XX

XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_sequences

XX

SQ Sequence 13 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 1 Other;

XX

Query Match 0.2%; Score 11; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. NO. 2.9e+02;

Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 239 AAAACTACCCCAA 251

Db 1 RAAACTACACAA 13

RESULT 712

ABF84426

ID ABF84426 standard; DNA; 13 BP.

XX

AC ABF84426;

XX

DT 22-FEB-2002 (first entry)

XX

DE Oligonucleotide SEQ ID NO 184423 for detecting SNP TSC0045514.

XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

OS Homo sapiens.

XX

PN WO200177384-A2.

XX

PD 18-OCT-2001.

XX

PF 06-APR-2001; 2001MO-IB000713.

XX

PR 07-APR-2000; 2000DE-01019173.

XX

PA (EPIG-) EPIGENOMICS AG.

XX

PI Olek A, Piepenbrock C, Berlin K;

XX

DR WP1; 2001-657177/75.

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1, SEQ ID NO 184423; 29pp + Sequence Listing; German.

XX

XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_sequences

XX

SQ Sequence 13 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 1 Other;

XX

Query Match 0.2%; Score 11; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. NO. 2.9e+02;

Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 239 AAAACTACCCCAA 251

Db 1 RAAACTACACAA 13

RESULT 712

ABF84426

ID ABF84426 standard; DNA; 13 BP.

XX

AC ABF84426;

XX

DT 22-FEB-2002 (first entry)

XX

DE Oligonucleotide SEQ ID NO 184423 for detecting SNP TSC0045514.

XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

OS Homo sapiens.

XX

PN WO200177384-A2.

XX

PD 18-OCT-2001.

XX

PF 06-APR-2001; 2001MO-IB000713.

XX

PR 07-APR-2000; 2000DE-01019173.

XX

PA (EPIG-) EPIGENOMICS AG.

XX

PI Olek A, Piepenbrock C, Berlin K;

XX

DR WP1; 2001-657177/75.

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1, SEQ ID NO 184423; 29pp + Sequence Listing; German.

XX

XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_sequences

XX

SQ Sequence 13 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 1 Other;

XX

Query Match 0.2%; Score 11; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. NO. 2.9e+02;

Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 239 AAAACTACCCCAA 251

Db 1 RAAACTACACAA 13

RESULT 712

ABF84426

ID ABF84426 standard; DNA; 13 BP.

XX

AC ABF84426;

XX

DT 22-FEB-2002 (first entry)

XX

DE Oligonucleotide SEQ ID NO 184423 for detecting SNP TSC0045514.

XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

OS Homo sapiens.

XX

PN WO200177384-A2.

XX

PD 18-OCT-2001.

XX

PF 06-APR-2001; 2001MO-IB000713.

XX

PR 07-APR-2000; 2000DE-01019173.

XX

PA (EPIG-) EPIGENOMICS AG.

XX

PI Olek A, Piepenbrock C, Berlin K;

XX

DR WP1; 2001-657177/75.

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1, SEQ ID NO 184423; 29pp + Sequence Listing; German.

XX

XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_sequences

XX

SQ Sequence 13 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 1 Other;

XX

Query Match 0.2%; Score 11; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. NO. 2.9e+02;

Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 239 AAAACTACCCCAA 251

Db 1 RAAACTACACAA 13

RESULT 712

ABF84426

ID ABF84426 standard; DNA; 13 BP.

XX

AC ABF84426;

XX

DT 22-FEB-2002 (first entry)

XX

DE Oligonucleotide SEQ ID NO 184423 for detecting SNP TSC0045514.

XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

OS Homo sapiens.

XX

PN WO200177384-A2.

XX

PD 18-OCT-2001.

XX

PF 06-APR-2001; 2001MO-IB000713.

XX

PR 07-APR-2000; 2000DE-01019173.

XX

PA (EPIG-) EPIGENOMICS AG.

XX

PI Olek A, Piepenbrock C, Berlin K;

XX

DR WP1; 2001-657177/75.

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1, SEQ ID NO 184423; 29pp + Sequence Listing; German.

XX

XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 3 A; 0 C; 1 G; 9 T; 0 U; 0 Other;
 XX
 Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 303 TTATGCTATA 313
 DB 2 TTATGCTATA 12
 RESULT 713
 ID ABF00155 standard; DNA; 13 BP.
 AC ABF00155;
 XX
 DT 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 100152 for detecting SNP TSC0024888.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 100152; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers of peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 4 A; 4 C; 1 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 425 CTTCCGAACAA 435
 DB 2 CTTCCGAACAA 12
 RESULT 714
 ID ABF00301 standard; DNA; 13 BP.
 AC ABF00301;
 XX
 DT 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 100298 for detecting SNP TSC0024929.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 100298; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 7 A; 5 C; 0 G; 0 T; 0 U; 1 Other;
 XX
 Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.9e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 210 GACACCAATATA 222
 DB 1 GACACCAATATA 13
 RESULT 715
 ID ABF34783 standard; DNA; 13 BP.
 AC ABF34783;
 XX
 DT 21-FEB-2002 (first entry)

```

DT 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 134780 for detecting SNP TSC0033586.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 134780; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 5 C; 0 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 12 ACACACTTCT 22
DB 2 ACACACTTCT 12

```

```

XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 145847; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 331 AGGTGGAGTA 341
DB 2 AGGTGGAGTA 12

```



```
RESULT 720
ABC67328/C
ID ABC67328 standard; DNA; 13 BP.
XX
AC ABC67328;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 67345 for detecting SNP TSC0017613.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 67345; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 553 ACACCACTC 563
Db 13 ACACCACTC 3
RESULT 721
ABC23767/C
ID ABC23767 standard; DNA; 13 BP.
XX
AC ABC23767;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 23784 for detecting SNP TSC0005311.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
```

```
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 23784; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 53 ATAGGAAGTG 63
Db 12 ATAGGAAGTG 2
RESULT 722
ABF00154/C
ID ABF00154 standard; DNA; 13 BP.
XX
AC ABF00154;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 100151 for detecting SNP TSC0024888.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
```

PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 100151; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 1 C; 4 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 425 CTTCCGAAACAA 435
DB 12 CTTCCGAAACAA 2
XX
RESULT 723
ABC04986
ID ABC04986 standard; DNA; 13 BP.
XX
AC ABC04986;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 4977 for detecting SNP TSC0001735.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 4977; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 1 G; 9 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 303 TTATTTGTTAA 313
DB 1 TTATTTGTTAA 11
XX
RESULT 724
ABC06058/c
ID ABC06058 standard; DNA; 13 BP.
XX
AC ABC06058;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 6049 for detecting SNP TSC0001919.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 6049; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 10 A; 0 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 76 CTTTATTCT 86
 |||||
 13 CTTTATTCT 3

RESULT 725

ABC39811/c
 ID ABC39811 standard; DNA; 13 BP.

XX ABC39811;

XX 20-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 39828 for detecting SNP TSC0012155.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX W02001.77384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 39828; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 303 TTATGTATA 313
 |||||
 11 TTATGTATA 1

RESULT 726

ABF33617
 ID ABF33617 standard; DNA; 13 BP.

XX ABF33617;
 AC
 XX 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 133614 for detecting SNP TSC0033320.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX W02001.77384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 133614; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 241 AACTACCCAAA 251
 |||||
 2 AACTACCCAAA 12

RESULT 727

ABF94893
 ID ABF94893 standard; DNA; 13 BP.

XX ABF94893;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 194890 for detecting SNP TSC0047945.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.

PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 194890; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 240 AACCTACCCCA 250
 DB 3 AACCTACCCCA 13
 XX
 RESULT 728
 ABH21823/c
 ID ABH21823 standard; DNA, 13 BP.
 XX
 AC ABH21823;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 221800 for detecting SNP TSC0053983.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.

XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 221800; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 5 C; 0 G; 4 T; 0 U; 1 Other;
 XX
 Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.9e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 OY 142 GCACAGAGTTATC 154
 DB 13 GCACAGAGTTATY 1
 XX
 RESULT 729
 ABF77847
 ID ABF77847 standard; DNA, 13 BP.
 XX
 AC ABF77847;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 177844 for detecting SNP TSC0044079.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 177844; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 581 AATACCTACCCA 591
DB 2 AATACCTACCCA 12
RESULT 730
ABF78839/C
ID ABF78839 standard; DNA, 13 BP.
AC ABF78839;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 178836 for detecting SNP TSC0044292.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGNOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 178836; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 3 A; 6 C; 0 G; 3 T; 0 U; 1 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 134 ATGCTGATGGA 144
DB 13 ATGCTGATGGA 3
RESULT 731
ABF81199
ID ABF81199 standard; DNA, 13 BP.
AC ABF81199;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 181196 for detecting SNP TSC0044828.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGNOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 181196; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 1 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 573 GACCCAGAAATAC 585
DB 1 RACCCCAATAC 13
RESULT 732
ABC48974/C
ID ABC48974 standard; DNA, 13 BP.
AC ABC48974;
XX
DT 21-FEB-2002 (first entry)
XX

```
DE Oligonucleotide SEQ ID NO 48991 for detecting SNP TSC0013902.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 48991; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 8 A; 0 C; 4 G; 1 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.2%; Score 11; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.9e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 69 TCTACTTCTTT 79
DB 11 TCTACTTCTTT 1
XX
XX RESULT 733
XX ABF07269
XX ID ABF07269 standard; DNA; 13 BP.
XX
XX ABR07269;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 107266 for detecting SNP TSC0026858.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX
```

```
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 107266; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 1 Other;
SQ
XX
XX Query Match 0.2%; Score 11; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.9e+02;
XX Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 238 GAAACTACCCAA 250
DB 1 RAAACTACTTA 13
XX
XX RESULT 734
XX ABC58618/c
XX ID ABC58618 standard; DNA; 13 BP.
XX
XX ABC58618;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 58635 for detecting SNP TSC0015713.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
```

BS Claim 1, SEQ ID NO 58635; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 1 Other;

XX Query Match 0.2%; Score 11; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.9e+02;
XX Matches 11; Conservative 1; Mismatches 0; Indels 0; Gaps 0

Oy 238 GAAACTACCCCA 250
Db :|||||
13 RAAAAATACCCTA 1

RESULT 735
ABC90248/C
ID ABC90248 standard; DNA; 13 BP.
XX AC ABC90248;
XX DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 90265 for detecting SNP TSC0022617.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PE 07-APR-2000; 2000DE-01019173.
XX PR (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PM

XX Claim 1; SEQ ID NO 90265; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at

```
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 1 Other;
        Query Match          0.2%; Score 11; DB 1; Length 13;
        Best Local Similarity 84.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0
QY      580 GAATCTACTCCCA 592
       :||||| |||||
Db      13 RAATACAAACCAG 1

RESULT 736
ABF16919/C
ID      ABF16919 standard; DNA; 13 BP.
XX
XX      ABF16919;
AC
XX
DT      21-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 116916 for detecting SNP TSC0029264.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PE      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPIG-) EPIGENOMICS AG.
PI      Olek A, Piepenbrock C, Berlin K;
XX      WPI. 2001-657177/75.
DR
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, its
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX
PS      Claim 1; SEQ ID NO 116916; 2ppp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABH00010-ABH99989, ABH00010-ABH99989 and AEI00010-AEI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 1 Other;
Query Match          0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0
QY      56 AGGAAGTGCGT 66
       :||||| |||||
Db      13 AGGAAGTGCGT 3
```

```
RESULT 737
ID ABF20913 standard; DNA; 13 BP.
XX
XX
AC ABF20913;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 120910 for detecting SNP TSC0030169.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 120910; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 5 C; 0 G; 6 T; 0 U; 1 Other;
XX
XX Query Match 0.2%; Score 11; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.9e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 67 CTTCTACTTCT 77
XX |||||
XX 2 CTTCTACTTCT 12
XX
RESULT 738
ID ABF78838 standard; DNA; 13 BP.
XX
XX ABF78838;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 178835 for detecting SNP TSC0044292.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
```

```
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 178835; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 0 C; 6 G; 3 T; 0 U; 1 Other;
XX
XX Query Match 0.2%; Score 11; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.9e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 134 ATGCTGATGGA 144
XX |||||
XX 1 ATGCTGATGGA 11
XX
RESULT 739
ID ABF61271 standard; DNA; 13 BP.
XX
XX ABF61271;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 161268 for detecting SNP TSC0040609.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
```

PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 161268; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 1 Other;
 Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.9e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 502 ACATACCTCCACCA 514
 :|||||
 Db 1 RCATACGCACCA 13
 RESULT 740
 ABF87218/c
 ID ABF87218 standard; DNA; 13 BP.
 XX
 XX ABF87218;
 AC
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 187215 for detecting SNP TSC0046146.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 OS
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 187215; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 1 A; 1 C; 6 G; 4 T; 0 U; 1 Other;
 Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.9e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 160 ACGTACTCCACCA 172
 :|||||
 Db 13 RCGTACGCACCA 1
 RESULT 741
 ABH15669/c
 ID ABH15669 standard; DNA; 13 BP.
 XX
 XX ABH15669;
 AC
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 215646 for detecting SNP TSC0052448.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 OS
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 215646; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 1 Other;
 Query Match 0.2%; Score 11; DB 1; Length 13;

Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 303 TTATTGTTATA 313
Db 13 TTATTGTTATA 3

RESULT 742

ABH47434/C

ID ABH47434 standard; DNA; 13 BP.

AC ABH47434;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 247411 for detecting SNP TSC0060458.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIC-) EPIGENOMICS AG.

PI Olek A, Piegenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 247411; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 1 Other;

Query Match 0.2%; Score 11; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. No. 2.9e+02;

Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 160 ACCTACTCCACCA 172

Db 13 RCTCTACTCCACCA 1

RESULT 743

ABH54670

ID ABH54670 standard; DNA; 13 BP.

AC ABH54670;

XX 22-FEB-2002 (first entry)
DT Oligonucleotide SEQ ID NO 254647 for detecting SNP TSC0008823.
DE
XX
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIC-) EPIGENOMICS AG.

PI Olek A, Piegenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 254647; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 3 A; 1 C; 2 G; 6 T; 0 U; 1 Other;

Query Match

Best Local Similarity 0.2%; Score 11; DB 1; Length 13;

Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 302 CTTATTGTTATAC 314

Db 1 CGTATTGTTATAY 13

RESULT 744

ABF07268/C

ID ABF07268 standard; DNA; 13 BP.

AC ABF07268;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 107265 for detecting SNP TSC0026858.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIC-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 CC
 PS Claim 1; SEQ ID NO 107265; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pcr_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 1 Other;
 XX
 QY Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.9e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 Db 238 GAAACCTACCCAA 250
 13 RAACACTACCTAA 1
 RESULT 745
 ABC99810
 ID ABC99810 standard; DNA; 13 BP.
 AC ABC99810;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 39827 for detecting SNP TSC0012155.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 39827; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pcr_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 303 TTATGTTATA 313
 3 TTATGTTATA 13
 RESULT 746
 ABF19257
 ID ABF19257 standard; DNA; 13 BP.
 AC ABF19257;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 119254 for detecting SNP TSC0029783.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 CC
 PS Claim 1; SEQ ID NO 119254; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 164 ACTCCACCACT 174
 |||||
 Db 2 ACTCCACCACT 12

RESULT 747
 ABF27940/C
 ID ABF27940 standard; DNA; 13 BP.

AC ABF27940;
 XX
 DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 127937 for detecting SNP TSC0032024.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 127937; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 1 Other;

Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.9e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 582 ATACTCCCAAT 594
 :|||||

Db 13 RTACTACTTAAT 1

RESULT 748
 ABF33616/C
 ID ABF33616 standard; DNA; 13 BP.

XX ABF33616;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 133613 for detecting SNP TSC0033320.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 133613; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 241 AACTACCAAA 251
 |||||
 Db 12 AACTACCAAA 2

RESULT 749
 ABH22817/C

ID ABH22817 standard; DNA; 13 BP.

XX ABH22817;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 222794 for detecting SNP TSC0054239.

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 222794; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 303 TTATTGTTATA 313
Db 12 TTATTGTTATA 2
RESULT 750
ABF98627
ID ABF98627 standard; DNA; 13 BP.
XX
AC ABF98627;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 198624 for detecting SNP TSC0048875.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 187218; 29pp + Sequence Listing; German.

XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 198624; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 5 C; 1 G; 0 T; 0 U; 1 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 231 GACCACGAAAC 243
Db 1 RACCACGAAAC 13
RESULT 751
ABF87221
ID ABF87221 standard; DNA; 13 BP.
XX
AC ABF87221;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 187218 for detecting SNP TSC0046146.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 187218; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 6 C; 2 G; 1 T; 0 U; 1 Other;

Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 160 ACGTACTCCACCA 172
DB 1 RCGTACCGCACCA 13

RESULT 752
ABH39496
ID ABH39496 standard; DNA; 13 BP.
XX ABH39496;
AC
XX
XX 22-FEB-2002 (first entry)
XX
XX

DE Oligonucleotide SEQ ID NO 239473 for detecting SNP TSC0058414.
XX
XX

KM SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 239473; 29bp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 303 TTATGTTATA 313
DB 2 TTATGTTATA 12

RESULT 753
ABH54671/C
ID ABH54671 standard; DNA; 13 BP.
XX ABH54671;
AC
XX
XX 22-FEB-2002 (first entry)
XX
XX

DE Oligonucleotide SEQ ID NO 254648 for detecting SNP TSC0008823.
XX
XX

KM SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 254648; 29bp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 2 C; 1 G; 3 T; 0 U; 1 Other;

Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 302 CTTATGTTATAC 314
DB 13 CTTATGTTATAT 1

RESULT 754
ABC23766

```

ID ABC23766 standard; DNA; 13 BP.
XX
XX ABC23766;
AC
XX
XX 20-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 23783 for detecting SNP TSC005311.
DE
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX
XX Claim 1; SEQ ID NO 23783; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
XX
XX Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
SQ
XX
XX
XX Query Match 0.2%; Score 11; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.9e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX
XX 53 ATAAGGAAGTG 63
QY |||||
XX 2 ATAGGAAGTG 12
DB
XX
XX
XX RESULT 755
XX ABC53350
XX ID ABC53350 standard; DNA; 13 BP.
XX
XX ABC53350;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 53367 for detecting SNP TSC004732.
DE
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX

```

```

XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 53367; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 13 BP; 4 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
SQ
XX
XX
XX Query Match 0.2%; Score 11; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.9e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX
XX 303 TTATGTTATA 313
QY |||||
XX 2 TTATGTTATA 12
DB
XX
XX
XX RESULT 756
XX ABC04987/C
XX ID ABC04987 standard; DNA; 13 BP.
XX
XX ABC04987;
AC
XX
XX 20-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 4978 for detecting SNP TSC001735.
DE
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX

```

DR WPI: 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 4978; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
XX Sequence 13 BP; 9 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 303 TTATTGTTATA 313
DB 13 TTATTGTTATA 3
RESULT 757
ID ABC15694/c
XX ABC15694 standard; DNA; 13 BP.
XX
XX ABC15694;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 15701 for detecting SNP TSC0003474.
DE
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI: 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 15701; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
XX Sequence 13 BP; 9 A; 1 C; 0 G; 3 T; 0 U; 0 Other;

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
XX Sequence 13 BP; 7 A; 0 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 65 TTCTTACTT 75
DB 11 TTCTTACTT 1
RESULT 758
ID ABF45851/c
XX ABF45851 standard; DNA; 13 BP.
XX
XX ABF45851;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 145848 for detecting SNP TSC0036744.
DE
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI: 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 145848; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
XX Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 331 AGGTGGAGTA 341
 DB 12 AGGTGGAGTA 2

RESULT 759
 ID ABF53490/C
 XX ABF53490 standard; DNA; 13 BP.
 AC ABF53490;
 DT 21-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 153487 for detecting SNP TSC0038789.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 153487; 29pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SO Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 582 ATACTACCCAA 592
 DB 13 ATACTACCCAA 3

RESULT 760
 ABF38289
 XX ABF38289 standard; DNA; 13 BP.
 AC ABF38289;
 XX
 DT 21-FEB-2002 (first entry)
 XX

XX Oligonucleotide SEQ ID NO 138286 for detecting SNP TSC0034609.
 DE
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 138286; 29pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SO Sequence 13 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 1 Other;
 Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.9e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 239 AAACCTACCCAA 251
 DB 1 AAACCTACCCAA 13

RESULT 761
 ABH21822
 ID ABH21822 standard; DNA; 13 BP.
 AC ABH21822;
 DT 22-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 221799 for detecting SNP TSC0053983.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX

PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 221799; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 4 A; 0 C; 5 G; 3 T; 0 U; 1 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Oy 142 GACACAGAGTATC 154
Db 1 GGACGAGTATY 13
XX
RESULT 762
ABF98626/C
ID ABR98626 standard; DNA; 13 BP.
XX
AC ABR98626;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 198623 for detecting SNP TSC0048875.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX
PS Claim 1; SEQ ID NO 198623; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 0 A; 1 C; 5 G; 6 T; 0 U; 1 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Oy 231 GACACAGAAAC 243
Db 13 RACCACGAAAC 1
XX
RESULT 763
ABF75923
ID ABF75923 standard; DNA; 13 BP.
XX
AC ABF75923;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 175920 for detecting SNP TSC0043683.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 175920; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 241 AACTACCCCAA 251
DB 1 AACTACCCCAA 11
RESULT 764
ABH03131
ID ABH03131 standard; DNA; 13 BP.
XX
AC ABH03131;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 203108 for detecting SNP TSC0049883.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN W0200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 203108; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 3 C; 0 G; 8 T; 0 U; 0 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 76 CTTTATTCT 86
DB 3 CTTTATTCT 13

RESULT 765
ABF67220/C
ID ABF67220 standard; DNA; 13 BP.
XX
AC ABF67220;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 187217 for detecting SNP TSC0046146.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN W0200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 187217; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 2 C; 6 G; 3 T; 0 U; 1 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 160 ACGTCTCCACA 172
DB 13 RCGTACGCCACA 1
RESULT 766
ABF6755
ID ABF6755 standard; DNA; 13 BP.
XX
AC ABF6755;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 166752 for detecting SNP TSC0041756.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PM WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 166752; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. The
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 219 TCAACATATATA 229
DB 1 TCAACATATATA 11
XX
RESULT 767
ABC80114/c
ID ABC80114 standard; DNA; 13 BP.
XX
AC ABC80114;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 80131 for detecting SNP TSC0020340.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.

XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 80131; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. The
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 219 TCAACATATATA 229
DB 13 TCAACATATATA 3
XX
RESULT 768
ABF28018/c
ID ABF28018 standard; DNA; 13 BP.
XX
AC ABF28018;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 128015 for detecting SNP TSC0032053.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 128015; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
XX
SQ Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 241 AACTACCCAAA 251
13 AACTACCCAAA 3
Db
RESULT 769
ABF89098
ID ABR89098 standard; DNA; 13 BP.
XX
AC ABR89098;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 189095 for detecting SNP TSC0046542.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WC00177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 189095; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
XX
SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 303 TTATGTTAAT 313
3 TTATGTTAAT 13
Db
RESULT 770
ABF6754/c
ID ABR6754 standard; DNA; 13 BP.
XX
AC ABR6754;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 166751 for detecting SNP TSC0041756.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WC00177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 166751; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
XX
SQ Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 219 TCAACATATA 229
13 TCAACATATA 3
Db
RESULT 771
ABC42847
ID ABC42847 standard; DNA; 13 BP.
XX

AC ABC42847;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 42864 for detecting SNP TSC0012740.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 42864; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 12 ACACACTTTCT 22
DB 3 ACACACTTTCT 13
XX
RESULT 772
ABC48975
ID ABC48975 standard; DNA; 13 BP.
XX
AC ABC48975;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 48992 for detecting SNP TSC0013902.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.

XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 48992; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 4 C; 0 G; 8 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 69 TCTACTCTTT 79
DB 3 TCTACTCTTT 13
XX
RESULT 773
ABC11055/C
ID ABC11055 standard; DNA; 13 BP.
XX
AC ABC11055;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 11046 for detecting SNP TSC0002721.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 11046; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 1 Other;
 QY
 .Query Match 0.2%; Score 11; DB 1; Length 13;
 .Best Local Similarity 84.6%; Pred. No. 2.9e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 Db 80 TATTTCGAAATC 92
 13 TATTTTGAATY 1
 RESULT 774
 ABC15695
 ID ABC15695 standard; DNA; 13 BP.
 XX
 AC ABC15695;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 15702 for detecting SNP TSC0003474.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 15702; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 3 C; 0 G; 7 T; 0 U; 0 Other;
 QY
 .Query Match 0.2%; Score 11; DB 1; Length 13;
 .Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 65 TTCTTCTACTT 75
 3 TTCTTCTACTT 13
 RESULT 775
 ABF77846/C
 ID ABF77846 standard; DNA; 13 BP.
 XX
 AC ABF77846;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 177843 for detecting SNP TSC0044079.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 177843; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
 QY
 .Query Match 0.2%; Score 11; DB 1; Length 13;
 .Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 581 AATCTACCA 591

```

Db          12 AATACTACCA 2
|||||
RESULT 776
ABF89099/C
ID   ABF89099 standard; DNA; 13 BP.
XX
XX   ABF89099;
AC
XX
XX   22-FEB-2002 (first entry)
DT
XX
DE   Oligonucleotide SEQ ID NO 189096 for detecting SNP TSC0046542.
XX
XX   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX   Homo sapiens.
OS
XX
XX   WO200177384-A2.
XX
XX   18-OCT-2001.
PD
XX
XX   06-APR-2001; 2001WO-IB000713.
XX
XX   07-APR-2000; 2000DE-01019173.
PR
XX
XX   (EPIC-) EPIGENOMICS AG.
PA
XX   Olek A, Piepenbrock C, Berlin K;
PI
XX   WPI; 2001-657177/75.
DR
XX
XX   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
XX   Claim 1; SEQ ID NO 189096; 29pp + Sequence Listing; German.
XX
XX   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
XX   Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
SQ
XX
Query Match          0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      303 TTATGTTATA 313
      |||||
      11 TTATGTTATA 1
Db
XX
RESULT 777
ABC67333
ID   ABC67333 standard; DNA; 13 BP.
XX
XX   ABC67333;
AC
XX
XX   21-FEB-2002 (first entry)
DT
XX
XX   Oligonucleotide SEQ ID NO 67350 for detecting SNP TSC0017613.
DE

```

```

XX
XX   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX   Homo sapiens.
OS
XX
XX   WO200177384-A2.
XX
XX   18-OCT-2001.
PD
XX
XX   06-APR-2001; 2001WO-IB000713.
XX
XX   07-APR-2000; 2000DE-01019173.
PR
XX
XX   (EPIC-) EPIGENOMICS AG.
PA
XX   Olek A, Piepenbrock C, Berlin K;
PI
XX   WPI; 2001-657177/75.
DR
XX
XX   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
XX   Claim 1; SEQ ID NO 67350; 29pp + Sequence Listing; German.
XX
XX   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
XX   Sequence 13 BP; 4 A; 7 C; 1 G; 1 T; 0 U; 0 Other;
SQ
XX
Query Match          0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      553 ACACGACACTC 563
      |||||
      1 ACACGACACTC 11
Db
XX
RESULT 778
ABF27941
ID   ABF27941 standard; DNA; 13 BP.
XX
XX   ABF27941;
AC
XX
XX   21-FEB-2002 (first entry)
DT
XX
XX   Oligonucleotide SEQ ID NO 127938 for detecting SNP TSC0032024.
DE
XX
XX   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX   Homo sapiens.
OS
XX
XX   WO200177384-A2.
XX
XX   18-OCT-2001.
PD
XX
XX   06-APR-2001; 2001WO-IB000713.
PF
XX
XX

```

PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 127938; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 3 C; 0 G; 4 T; 0 U; 1 Other;
 XX
 Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.9e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 582 ATACTACCCCAAT 594
 :|||||
 1 R TACTACTCAAT 13
 DB
 RESULT 779
 ABF28019
 ID ABF28019 standard; DNA; 13 BP.
 XX
 AC ABF28019;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 128016 for detecting SNP TSC0032053.
 XX
 SN: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 128016; 29pp + Sequence Listing; German.

XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
 XX
 Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 241 AACTACCCCAA 251
 :|||||
 1 AACTACCCCAA 11
 DB
 RESULT 780
 ABC53351/C
 ID ABC53351 standard; DNA; 13 BP.
 XX
 AC ABC53351;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 53368 for detecting SNP TSC0014732.
 XX
 SN: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 53368; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

```
XX SQ Sequence 13 BP; 8 A; 1 C; 0 G; 4 T; 0 U; 0 Other;
XX Query Match 0.2%; Score 11; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.9e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 303 TTATTGTTATA 313
DB 12 TTATTGTTATA 2

RESULT 781
ABF10742
ID ABF10742 standard; DNA; 13 BP.
XX AC ABF10742;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 110739 for detecting SNP TSC0027631.
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PS Claim 1; SEQ ID NO 110739; 29bp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABG00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB102073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
QY Query Match 0.2%; Score 11; DB 1; Length 13;
DB Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 303 TTATTGTTATA 313
DB 3 TTATTGTTATA 13

RESULT 782
```

```
ABF30954
ID ABF30954 standard; DNA; 13 BP.
XX AC ABF30954;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 130951 for detecting SNP TSC0032682.
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PS Claim 1; SEQ ID NO 130951; 29bp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABG00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB102073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 4 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
QY Query Match 0.2%; Score 11; DB 1; Length 13;
DB Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 303 TTATTGTTATA 313
DB 2 TTATTGTTATA 12

RESULT 783
ABF30955/C
ID ABF30955 standard; DNA; 13 BP.
XX AC ABF30955;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 130952 for detecting SNP TSC0032682.
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
```


OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 130952; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 1 C; 0 G; 4 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 11; DB 1; Length 13;
 Db Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 303 TTATTGTTATA 313
 Db 12 TTATTGTTATA 2
 XX
 RESULT 784
 ABF34782/c
 ID ABF34782 standard; DNA; 13 BP.
 XX
 AC ABF34782;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 134779 for detecting SNP TSC0033586.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX

XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 134779; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 0 C; 5 G; 3 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 11; DB 1; Length 13;
 Db Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 12 ACACACTTCT 22
 Db 12 ACACACTTCT 2
 XX
 RESULT 785
 ABF94892/c
 ID ABF94892 standard; DNA; 13 BP.
 XX
 AC ABF94892;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 194889 for detecting SNP TSC0047945.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 194889; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 240 AAACCTACCCAA 250
 DB 11 AAACCTACCCAA 1
 RESULT 786
 ABH24390/C
 ID ABH24390 standard; DNA; 13 BP.
 AC ABH24390;
 XX
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 224367 for detecting SNP TSC0054667.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DX WPI; 2001-657177/75.
 XX
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 224367; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 9 A; 0 C; 2 G; 2 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 XX

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 74 TTCTTTATTT 84
 DB 13 TTCTTTATTT 3
 RESULT 787
 ABF00300/C
 ID ABF00300 standard; DNA; 13 BP.
 AC ABF00300;
 XX
 XX
 DT 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 100297 for detecting SNP TSC024929.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DX WPI; 2001-657177/75.
 XX
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 100297; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 0 A; 0 C; 5 G; 7 T; 0 U; 1 Other;
 Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.9e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 210 GACACACATCAA 222
 DB 13 RACACACACAA 1
 RESULT 788
 ABF38288/C
 ID ABF38288 standard; DNA; 13 BP.
 AC ABF38288;
 XX

DT 21-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 138285 for detecting SNP TSC0034609.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 CC
 PS Claim 1; SEQ ID NO 138285; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 1 Other;
 XX
 XX Query Match 0.2%; Score 11; DB 1; Length 13;
 XX Best Local Similarity 84.6%; Pred. No. 2.9e+02;
 XX Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 239 AAAACTACCCAAA 251
 DB 13 RAAACTACCCAAA 1
 XX
 XX RESULT 789
 XX ABF75922/c
 XX ID ABF75922 standard; DNA; 13 BP.
 XX
 XX AC ABF75922;
 XX
 XX DT 22-FEB-2002 (first entry)
 XX
 XX DE Oligonucleotide SEQ ID NO 175919 for detecting SNP TSC0043663.
 XX
 XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX

XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 CC
 PS Claim 1; SEQ ID NO 175919; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
 XX
 XX Query Match 0.2%; Score 11; DB 1; Length 13;
 XX Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 241 AACTACCCAAA 251
 DB 13 AACTACCCAAA 3
 XX
 XX RESULT 790
 XX ABF61270/c
 XX ID ABF61270 standard; DNA; 13 BP.
 XX
 XX AC ABF61270;
 XX
 XX DT 22-FEB-2002 (first entry)
 XX
 XX DE Oligonucleotide SEQ ID NO 161267 for detecting SNP TSC0040609.
 XX
 XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX PR 07-APR-2000; 2000DE-01019173.
 XX
 XX PA (EPIG-) EPIGENOMICS AG.
 XX
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine

methylation status.

Claim 1; SEQ ID NO 161267; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABG9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 1 A; 0 C; 6 G; 5 T; 0 U; 1 Other;

Query Match
Best Local Similarity 84.6%; Score 11; DB 1; Length 13;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

502 ACATCTCCACCA 514
:|||||
13 RCTATACACCA 1

RESULT 791
ABF87219
XX ABF87219 standard; DNA; 13 BP.
XX
XX ABF87219;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 187216 for detecting SNP TSC0046146.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K,
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 187216; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 4 A; 6 C; 1 G; 1 T; 0 U; 1 Other;

Query Match
Best Local Similarity 84.6%; Score 11; DB 1; Length 13;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

160 ACATCTCCACCA 172
:|||||
1 RCTATACACCA 13

RESULT 792
ABH39497/c
ID ABH39497 standard; DNA; 13 BP.
XX
XX AC ABH39497;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 239474 for detecting SNP TSC0058414.
XX
XX DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K,
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 239474; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match
Best Local Similarity 100.0%; Score 11; DB 1; Length 13;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

303 TTATGTTATA 313
:|||||
12 TTATGTTATA 2

```

RESULT 793
ABC67329
ID ABC67329 standard; DNA; 13 BP.
XX
AC ABC67329;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 67346 for detecting SNP TSC0017613.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 67346; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 553 ACACCACACTC 563
Db 1 ACACCACACTC 11

```

```

KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 92802; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 1 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
OY 581 AATACTACCCAAA 593
Db 1 AATACCAACCCAAA 13

```

```

RESULT 794
ABC92785
ID ABC92785 standard; DNA; 13 BP.
XX
AC ABC92785;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 92802 for detecting SNP TSC0023209.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX

```

```

RESULT 795
ABC42846/C
ID ABC42846 standard; DNA; 13 BP.
XX
AC ABC42846;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 42863 for detecting SNP TSC0012740.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX

```

PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 42863; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 11; DB 1; Length 13;
 XX Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 DB 12 ACACACTTCT 22
 XX 11 ACACACTTCT 1
 XX
 RESULT 796
 ABF03592/c
 ID ABF03592 standard; DNA; 13 BP.
 XX
 AC ABF03592;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 103589 for detecting SNP TSC0025910.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 103589; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 0 C; 4 G; 1 T; 0 U; 0 Other;
 XX
 QY Query Match 0.2%; Score 11; DB 1; Length 13;
 XX Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 DB 75 TCTTTTATTC 85
 XX 12 TCTTTTATTC 2
 XX
 RESULT 797
 ABC80115
 ID ABC80115 standard; DNA; 13 BP.
 XX
 AC ABC80115;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 80132 for detecting SNP TSC0020340.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 80132; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 219 TCACATATA 229
 |||||
 1 TCACATATA 11

Db 1 TCACATATA 11

RESULT 798
 ABF10743/C
 ID ABF10743 standard; DNA; 13 BP.
 XX
 AC ABF10743;
 XX
 XX 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 110740 for detecting SNP TSC0027631.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPIC-) EPIGENOMICS AG.
 PA
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX
 PS Claim 1; SEQ ID NO 110740; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX
 SQ Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 303 TTATGTTATA 313
 |||||
 1 TTATGTTATA 1

Db 1 TTATGTTATA 1

RESULT 799
 ABC90250/C
 ID ABC90250 standard; DNA; 13 BP.

XX
 AC ABC90250;
 XX
 XX 21-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 90267 for detecting SNP TSC0022617.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPIC-) EPIGENOMICS AG.
 PA
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX
 PS Claim 1; SEQ ID NO 90267; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX
 SQ Sequence 13 BP; 2 A; 1 C; 4 G; 5 T; 0 U; 1 Other;

Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.9e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 580 GAATCTACCCAA 592
 :|||||
 13 GAATCTACCCGA 1

Db 13 GAATCTACCCGA 1

RESULT 800
 ABC90251
 ID ABC90251 standard; DNA; 13 BP.
 XX
 AC ABC90251;
 XX
 XX 21-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 90268 for detecting SNP TSC0022617.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX

PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 90268; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 4 C; 1 G; 2 T; 0 U; 1 Other;
 XX
 Query Match
 Best Local Similarity 0.2%; Score 11; DB 1; Length 13;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 580 GAATACTACCCCA 592
 DB :|||||||
 1 RAATACTACCCCA 13
 XX
 RESULT 801
 ID ABF20912/C
 AC ABF20912 standard; DNA; 13 BP.
 XX
 AC ABF20912;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 120909 for detecting SNP TSC0030169.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX

XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 120909; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 0 C; 5 G; 1 T; 0 U; 1 Other;
 XX
 Query Match
 Best Local Similarity 0.2%; Score 11; DB 1; Length 13;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 67 CTCTACTCTCT 77
 DB :|||||||
 12 CTCTACTCTCT 2
 XX
 RESULT 802
 ID ABC67332/C
 AC ABC67332 standard; DNA; 13 BP.
 XX
 AC ABC67332;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 67349 for detecting SNP TSC0017613.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 67349; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 1 A; 1 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 553 ACACCACCTC 563
 DB 13 ACACCACCTC 3
 RESULT 803
 ABC06059
 ID ABC06059 standard; DNA; 13 BP.
 XX
 AC ABC06059;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 6050 for detecting SNP TSC0001919.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 6050; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 1 A; 2 C; 0 G; 10 T; 0 U; 0 Other;
 Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 76 CTTTATTTC 86
 DB 1 CTTTATTTC 11
 RESULT 804
 ABC11054
 ID ABC11054 standard; DNA; 13 BP.
 XX
 AC ABC11054;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 11045 for detecting SNP TSC0002731.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 11045; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 1 Other;
 Query Match 0.2%; Score 11; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.9e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 OY 80 TATTTCTGAATC 92
 DB 1 TATTTCTGAATY 13
 RESULT 805
 ABC90249
 ID ABC90249 standard; DNA; 13 BP.
 XX
 AC ABC90249;
 XX
 DT 21-FEB-2002 (first entry)
 XX

PS Claim 1; SEQ ID NO 116915; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 5 G; 4 T; 0 U; 1 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 56 AGGAAGTGGTT 66
DB 1 AGGAAGTGGTT 11
RESULT 808
ABH21952/c
ID ABH21952 standard; DNA; 13 BP.
XX
AC ABH21952;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 221929 for detecting SNP TSC0054003.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
PS Claim 1; SEQ ID NO 221929; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ .Sequence 13 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 1 Other;
XX
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
OY 582 ATACTACCAAT 594
DB 13 RTACTACCAAT 1
RESULT 809
ABH24188/c
ID ABH24188 standard; DNA; 13 BP.
XX
AC ABH24188;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 224165 for detecting SNP TSC0054619.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
PS Claim 1; SEQ ID NO 224165; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 1 Other;
Query Match 0.2%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
OY 239 AAAACTACCAAA 251
DB 13 RAAACTACCAAA 1

```
RESULT 810
ABF84427/c
ID ABF84427 standard; DNA; 13 BP.
XX
AC ABF84427;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 184424 for detecting SNP TSC0045514.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PE 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 184424; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match
Best Local Similarity 0.2%; Score 11; DB 1; Length 13;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 303 TTATTGTTATA 313
DB 12 TTATTGTTATA 2
XX
RESULT 811
ABF61272/c
ID ABF61272 standard; DNA; 13 BP.
XX
AC ABF61272;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 161269 for detecting SNP TSC0040609.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
```

```
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PE 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 161269; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 1 C; 6 G; 4 T; 0 U; 1 Other;
XX
Query Match
Best Local Similarity 0.2%; Score 11; DB 1; Length 13;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
OY 502 ACATACCTCCACCA 514
DB 13 RCATACGCCACCA 1
XX
RESULT 812
ABH47435
ID ABH47435 standard; DNA; 13 BP.
XX
AC ABH47435;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 247412 for detecting SNP TSC0060458.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PE 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIG-) EPIGENOMICS AG.
XX
```

PI	Olek A., Piepenbrock C., Berlin K;
DR	WPI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
PS	Claim 1; SEQ ID NO 247412; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligonucleotides are also used for detecting cell type differentiation. ABC00010
CC	-ABC9989, ABH00010-ABF9989, ABH00010-ABH9989 and ABH00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from Wipo at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
SQ	Sequence 13 BP; 3 A; 7 C; 0 G; 2 T; 0 U; 1 Other;
XX	
Query Match	0.2%; Score 11; DB 1; Length 13;
Best Local Similarity	84.6%; Pred. No. 2.9e+02;
Matches 11, Conservative 1; Mismatches 1; Indels 0; Gaps 0;	
OY	160 ACGTACTCCACCA 172
Db	1 RCTACTCCACCA 13
XX	
RESULT 813	
AAV11056/C	
ID	AAV11056 standard; RNA; 14 BP.
XX	
AC	AAV11056;
XX	
DT	25-MAR-2003 (revised)
DT	14-JUL-1998 (first entry)
XX	
DE	Human ribozyme target sequence from HLA-DQB 06DOB #1.
XX	
KW	Ribozyme; target; human lymphocyte antigen; HLA-DQB; MHC allele;
KW	major histocompatibility complex; cleavage; suppression; transplant;
KW	incompatibility; autoimmune disease; juvenile diabetes;
KW	rheumatoid arthritis; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO9704087-A1.
XX	
PD	06-FEB-1997.
XX	
PF	18-JUL-1996; 96WO-EP003173.
XX	
PR	18-JUL-1995; 95EP-0011256.
XX	
PA	(KRUPP/) KRUPP G.
PA	(MARG/) MARGET M.
PA	(WEST/) WESTPHAL E.
PA	(MUEL/) MUELLER-RUCHNOLTZ W.
XX	
PI	Krupp G, Marget M, Westphal E, Mueller-Ruchnoltz W;
XX	
WPI; 1997-132628/12.	
XX	
PT	Ribozyme that cleaves specific MHC allele(s) - used to inhibit graft
PT	versus host reactions, to overcome blood incompatibility and to treat
PT	auto-immune disease.
XX	

PS Claim 5; Fig 1; 76pp; German.

XX AAVY0915-VII123 are target sequences for a novel ribozyme which cleaves
CC specific alleles from the major histocompatibility complex (MHC). This
CC ribozyme contains a catalytic region and a hybridisation region which is
CC complementary to all mRNA transcribed from vertebrate genes of a specific
CC family of closely related MHC alleles or to mRNA from a single MHC
CC allele, and is able to cleave such mRNA. The mRNA has a target region
CC which in case is essentially conserved in all genes of the family but
CC differs from genes of all other MHC alleles to such a degree that no
CC cleavage of mRNA transcribed from these other alleles occurs. This allows
CC the selective reduction or inhibition of expression of all genes of a
CC family or of a single gene. This ribozyme can be used for permanent or
CC transient suppression of expression of MHC alleles, in vivo or in vitro.
CC Specific applications are to prevent guest vs. host or host vs. guest
CC reactions, to prevent blood incompatibilities (partic. of the ABO, rhesus
CC and Kell systems) and to treat autoimmune diseases such as juvenile
CC diabetes and rheumatoid arthritis. The use of this ribozyme avoids the
CC need for immunosuppressants in transplant patients. It provides very
CC specific reduction of particular HLA molecules that cause incompatibility
CC between donor and recipient. (Updated on 25-MAR-2003 to correct PA
CC field.) (Updated on 25-MAR-2003 to correct PI field.)
XX SQ Sequence 14 BP; 3 A; 3 C; 6 G; 0 T; 2 U; 0 Other;

OY 158 GCAGCTACTC 168
|||
DB 12 GCAGCTACTC 2

RESULT 814
AAV48474
ID AAV48474 standard; DNA; 14 BP.
AC AAV48474;
XX
DT 15-OCT-1998 (first entry)
DE TGF-beta-1 antisense oligonucleotide TGF-beta1-23.
XX
XX TGF-beta-1 transforming growth factor beta-1; TGF beta-1; antisense oligonucleotide;
KW modulate; gene expression; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN EP856579-A1.
PD 05-AUG-1998.
XX
PF 31-JAN-1997; 97EP-00101531.
XX
PR 31-JAN-1997; 97EP-00101531.
XX
PA (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI Schlingensiefen K, Brysch W;
DR WPI; 1998-400910/35.
XX
PT Preparation of antisense oligo:nucleotide(s) which lack long runs of
FT consecutive guanosine or inosine - and have specific ratio of residues
FT able to form two or three hydrogen bonds, have greater activity and
PT reduced toxicity, used therapeutically or to modulate growth of cells in
culture.
XX
PS Claim 10; Fig 3b; 286pp; English.
XX
CC AAV48412-84 represent antisense oligonucleotides directed against

CC transforming growth factor beta-1 (TGF beta-1). The oligonucleotides
 CC exemplify the invention. The specification describes oligonucleotides
 CC that contain 8-30 nucleotides, which contain at most 8 nucleotides that
 CC can each form three hydrogen bonds to cytosine; do not contain four
 CC consecutive nucleotides able to form three H-bonds each to four
 CC consecutive cytosines; do not contain two sequences of three consecutive
 CC nucleotides each able to form three H-bonds to three consecutive
 CC cytosines; and the ratio between residues able to form two H-bonds each
 CC (2R) or three such bonds (3R) is given by 2R/3R = 0.33-0.72. The
 CC oligonucleotides are used to modulate expression of genes, particularly
 CC the genes for p53, ErbB-2, JunB, JunD, TGF-beta 1 or beta 2 to control
 CC proliferation of primary cell cultures (e.g. bone marrow stem, liver or
 CC kidney cells, osteoclasts, osteoblasts and/or keratinocytes). The
 CC oligonucleotides can also be used to analyse function of proteins (by
 CC altering their expression or activity) and therapeutically, e.g. in cases
 CC of cancer or (targeting TGF) for stimulating the immune system
 CC

SQ Sequence 14 BP; 3 A; 4 C; 5 G; 2 T; 0 U; 0 Other;

Query Match Best Local Similarity 100.0%; Score 11; DB 1; Length 14;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 173 CTGTCAACGGA 183
 DB 2 CTGTCAACGGA 12

RESULT 815

ID AAA21657/c
 AC AAA21657 standard; RNA; 14 BP.

XX AAA21657;

DT 19-JUN-2000 (first entry)

DE Integrin alpha 6 subunit target site SEQ ID NO:4883.

XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 XX Integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 XX hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 XX ophthalmologic; antiinflammatory; anticholesteric; antidiabetic;
 XX dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 XX age related macular degeneration; inflammation; neovascular glaucoma;
 XX myopic degeneration; psoriasis; verruca vulgaris; angiodioma;
 XX tuberos scleriosis; pot-wine stain; Sturge Weber syndrome;
 XX Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.

OS Homo sapiens.

XX W09950403-A2.

XX 07-OCT-1999.

XX 24-MAR-1999; 99WO-US006507.

XX 27-MAR-1998; 98US-0079678P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswigen JA;

XX WPI; 1999-591315/50.

XX Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.

XX Claim 55; Page 219; 305pp; English.

XX The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to

CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequences
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (AMD), inflammation, psoriasis, verruca vulgaris,
 CC neovascular glaucoma, myopic degeneration, and arthritis, as well as
 CC angiodioma of tuberos scleriosis, pot-wine stain, Sturge Weber
 CC syndrome, Kippel-Trenauay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 CC

SQ Sequence 14 BP; 4 A; 2 C; 4 G; 0 T; 4 U; 0 Other;

Query Match Best Local Similarity 100.0%; Score 11; DB 1; Length 14;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 84 TCTGAATCAG 94
 DB 14 TCTGAATCAG 4

Search completed: October 26, 2004, 16:14:14
 Job time : 54 secs